

10-2-03

Vol. 68 No. 191

Thursday Oct. 2, 2003

Pages 56765-57318

1



The **FEDERAL REGISTER** (ISSN 0097–6326) is published daily, Monday through Friday, except official holidays, by the Office of the Federal Register, National Archives and Records Administration, Washington, DC 20408, under the Federal Register Act (44 U.S.C. Ch. 15) and the regulations of the Administrative Committee of the Federal Register (1 CFR Ch. I). The Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 is the exclusive distributor of the official edition. Periodicals postage is paid at Washington, DC.

The **FEDERAL REGISTER** provides a uniform system for making available to the public regulations and legal notices issued by Federal agencies. These include Presidential proclamations and Executive Orders, Federal agency documents having general applicability and legal effect, documents required to be published by act of Congress, and other Federal agency documents of public interest.

Documents are on file for public inspection in the Office of the Federal Register the day before they are published, unless the issuing agency requests earlier filing. For a list of documents currently on file for public inspection, see http://www.nara.gov/fedreg.

The seal of the National Archives and Records Administration authenticates the Federal Register as the official serial publication established under the Federal Register Act. Under 44 U.S.C. 1507, the contents of the Federal Register shall be judicially noticed.

The **Federal Register** is published in paper and on 24x microfiche. It is also available online at no charge as one of the databases on GPO Access, a service of the U.S. Government Printing Office.

The online edition of the **Federal Register** www.access.gpo.gov/nara, available through GPO Access, is issued under the authority of the Administrative Committee of the Federal Register as the official legal equivalent of the paper and microfiche editions (44 U.S.C. 4101 and 1 CFR 5.10). It is updated by 6 a.m. each day the **Federal Register** is published and includes both text and graphics from Volume 59, Number 1 (January 2, 1994) forward.

For more information about GPO Access, contact the GPO Access User Support Team, call toll free 1-888-293-6498; DC area 202-512-1530; fax at 202-512-1262; or via email at <code>gpoaccess@gpo.gov</code>. The Support Team is available between 7:00 a.m. and 5:30 p.m. Eastern Time, Monday–Friday, except official holidays.

The annual subscription price for the Federal Register paper edition is \$699, or \$764 for a combined Federal Register, Federal Register Index and List of CFR Sections Affected (LSA) subscription; the microfiche edition of the Federal Register including the Federal Register Index and LSA is \$264. Six month subscriptions are available for one-half the annual rate. The charge for individual copies in paper form is \$10.00 for each issue, or \$10.00 for each group of pages as actually bound; or \$2.00 for each issue in microfiche form. All prices include regular domestic postage and handling. International customers please add 40% for foreign handling. Remit check or money order, made payable to the Superintendent of Documents, or charge to your GPO Deposit Account, VISA, MasterCard, American Express, or Discover. Mail to: New Orders, Superintendent of Documents, P.O. Box 371954, Pittsburgh, PA 15250-7954; or call toll free 1-866-512-1800, DC area 202-512-1800; or go to the U.S. Government Online Bookstore site, bookstore@gpo.gov.

There are no restrictions on the republication of material appearing in the **Federal Register**.

How To Cite This Publication: Use the volume number and the page number. Example: 68 FR 12345.

Postmaster: Send address changes to the Superintendent of Documents, Federal Register, U.S. Government Printing Office, Washington DC 20402, along with the entire mailing label from the last issue received.

SUBSCRIPTIONS AND COPIES

PUBLIC

Subscriptions:

Paper or fiche 202–512–1800
Assistance with public subscriptions 202–512–1806

General online information 202–512–1530; 1–888–293–6498

Single copies/back copies:

Paper or fiche
Assistance with public single copies
202–512–1800
1–866–512–1800
(Toll-Free)

FEDERAL AGENCIES

Subscriptions:

Paper or fiche 202–741–6005 Assistance with Federal agency subscriptions 202–741–6005

What's NEW!

Federal Register Table of Contents via e-mail

Subscribe to FEDREGTOC, to receive the **Federal Register** Table of Contents in your e-mail every day.

If you get the HTML version, you can click directly to any document in the issue.

To subscribe, go to http://listserv.access.gpo.gov and select:

Online mailing list archives FEDREGTOC-L Join or leave the list

Then follow the instructions.



Contents

Federal Register

Vol. 68, No. No. 191

Thursday, October 2, 2003

Agency for Healthcare Research and Quality NOTICES

Meetings:

Healthcare Research and Quality Technical Review Committee, 56841

Agriculture Department

See Forest Service

See Grain Inspection, Packers and Stockyards Administration

Census Bureau

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 56813–56814

Centers for Disease Control and Prevention NOTICES

Agency information collection activities; proposals, submissions, and approvals, 56841–56844

Citizenship and Immigration Services Bureau NOTICES

Agency information collection activities; proposals, submissions, and approvals, 56847–56848

Commerce Department

See Census Bureau

See Economic Development Administration

See International Trade Administration

See National Institute of Standards and Technology

See National Oceanic and Atmospheric Administration

Committee for the Implementation of Textile Agreements NOTICES

Cotton, wool, and man-made textiles:

Vietnam, 56818-56819

Customs and Border Protection Bureau PROPOSED RULES

Drawback:

Merchandise processing fees; claim eligibility based on substitution of finished petroleum derivatives, 56804–56805

Defense Department

See Navy Department

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 56819–56820

Dependents' Education Advisory Council, 56820 Science Board task forces, 56820–56821

Drug Enforcement Administration NOTICES

Applications, hearings, determinations, etc.: Organix, Inc., 56852

Economic Development Administration

NOTICES

Trade adjustment assistance eligibility determination petitions.:

Precix, Inc., et al., 56814-56815

Education Department

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 56821–56822
Grants and cooperative agreements; availability, etc.:
Special education and rehabilitative services—

Rehabilitation Long-Term Training Program; correction, 56822–56823

Energy Department

See Energy Efficiency and Renewable Energy Office See Federal Energy Regulatory Commission NOTICES

Electricity export and import authorizations, permits, etc.: Manitoba Hydro, 56823–56824

Meetings:

Basic Energy Sciences Advisory Committee, 56824 Environmental Management Site-Specific Advisory Board—

Fernald Site, OH, 56824

Nuclear Energy Research Advisory Committee, 56824–56825

Presidential permit applications:

Sharyland Utilities, L.P., 56825-56826

Energy Efficiency and Renewable Energy Office NOTICES

Meetings:

Biomass Research and Development Technical Advisory Committee, 56826

Environmental Protection Agency

RULES

Air programs:

Fuels and fuel additives-

Gasoline and diesel fuel test method update, 56776–56781

PROPOSED RULES

Air programs:

Fuel and fuel additives—

Gasoline and diesel fuel test method update, 56805–56809

Stratospheric ozone protection—

Ozone-depleting substances; substitutes list; correction, 56809–56810

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 56834–56835

Superfund; response and remedial actions, proposed settlements, etc.:

Mercury Refining Site, NY, 56835-56836

Federal Aviation Administration

PROPOSED RULES

Airworthiness directives:

Airbus, 56792-56794, 56799-56801

Empresa Brasileira de Aeronautica, S.A. (EMBRAER), 56801-56804

McDonnell Douglas, 56794-56799

Federal Communications Commission

RULES

Common carrier services:

Numbering resource optimization, 56781-56783 PROPOSED RULES

Radio stations; table of assignments:

Illinois, 56811

Indiana, 56810-56811

Agency information collection activities; proposals, submissions, and approvals, 56836

Meetings:

Technological Advisory Council, 56840-56841 Applications, hearings, determinations, etc.:

Alvarez, Oscar, 56836–56837 Angelides, John, 56837-56839 Maynard, Duane, 56839-56840

Federal Energy Regulatory Commission NOTICES

Electric rate and corporate regulation filings:

Virginia Electric & Power Co. et al. [Editorial Note: The page number for this document, 56628, published in the Federal Register of October 1, 2003, was inadvertently omitted in that issue's table of contents.]

Environmental statements; availability, etc.: Wisconsin Public Service Co., 56830

Hydroelectric applications, 56830-56834

Meetings:

North American Hydro, Inc.; Park Mill Project early relicensing, 56834

Applications, hearings, determinations, etc.:

ÅNR Pipeline Co., 56826–56827

CenterPoint Energy-Mississippi River Transmission Corp.,

Columbia Gas Transmission Corp., 56827-56828 Columbia Gas Transmission Corp. et al., 56828 LSP-Cottage Grove, L.P., et al., 56828-56829 Old Dominion Electric Cooperative, 56829 Questar Pipeline Co., 56829-56830 SCG Pipeline, Inc., 56830

Federal Highway Administration

NOTICES

Environmental statements; notice of intent: Montgomery and Grimes Counties, TX, 56862-56863

Federal Motor Carrier Safety Administration NOTICES

Environmental statements; availability, etc.: Safety auditors, investigators, and inspectors; certification, 56863-56865

Federal Reserve System

NOTICES

Banks and bank holding companies: Formations, acquisitions, and mergers, 56841 Meetings; Sunshine Act, 56841

Federal Transit Administration

NOTICES

Grants and cooperative agreement awards: Over-the-Road Bus Accessibility Program, 57303-57305

Fish and Wildlife Service

RULES

Hunting and fishing:

Refuge-specific regulations, 57307-57318

NOTICES

Endangered and threatened species:

Incidental take permits—

West Virginia flying squirrel, 56849-56850

Food and Drug Administration

RULES

Animal drugs, feeds, and related products: Dexamethasone injection, 56765

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 56844-56845 Meetings:

Anti-Infective Drugs Advisory Committee, 56845 Drug Safety and Risk Management Advisory Committee, 56845-56846

Pharmaceutical Science Advisory Committee, 56846

Forest Service

NOTICES

Environmental statements; notice of intent: Medicine Bow-Routt National Forests and Thunder Basin National Grassland, WY, 56813

Grain Inspection, Packers and Stockyards Administration NOTICES

Committees; establishment, renewal, termination, etc.: Grain Inspection Advisory Committee, 56813

Health and Human Services Department

See Agency for Healthcare Research and Quality See Centers for Disease Control and Prevention See Food and Drug Administration See National Institutes of Health

Homeland Security Department

See Citizenship and Immigration Services Bureau See Customs and Border Protection Bureau See Immigration and Customs Enforcement Bureau

Housing and Urban Development Department

Agency information collection activities; proposals, submissions, and approvals, 56849

Immigration and Customs Enforcement Bureau NOTICES

Agency information collection activities; proposals, submissions, and approvals, 56848-56849

Interior Department

See Fish and Wildlife Service See Surface Mining Reclamation and Enforcement Office

Internal Revenue Service

Agency information collection activities; proposals, submissions, and approvals, 56870-56872

International Trade Administration NOTICES

Agency information collection activities; proposals, submissions, and approvals, 56815-56816

International Trade Commission

Import investigations:
Polyvinyl alcohol from—
China and Korea, 56850

Justice Department

See Drug Enforcement Administration NOTICES

Pollution control; consent judgments: Harding Township, NJ, 56850–56851 Mallinckrodt Baker, Inc., et al., 56851 Phelps Dodge Corp., 56851–56852

Maritime Administration

NOTICES

Coastwise trade laws; administrative waivers: BON ALIZE, 56865 GATO VERDE, 56865–56866 LADYHAWKE, 56866 PRINCESS MARIA, 56866–56867 SEASONS, 56867 SILVER SEA, 56867–56868

National Institute of Standards and Technology NOTICES

Agency information collection activities; proposals, submissions, and approvals, 56816

National Institutes of Health

NOTICES

Inventions, Government-owned; availability for licensing, 56846–56847

National Oceanic and Atmospheric Administration RULES

Fishery conservation and management:

Alaska; fisheries of Exclusive Economic Zone— Gulf of Alaska groundfish, 56788

Atlantic coastal fisheries cooperative management— Weakfish, 56789–56791

Atlantic highly migratory species— Atlantic bluefin tuna, 56783–56788

PROPOSED RULES

Fishery conservation and management:

Northeastern United States fisheries—

New England Fishery Management Council; meeting, 56811–56812

NOTICES

Meetings:

Western Pacific Fishery Management Council, 56816–56818

National Science Foundation

NOTICES

Antarctic Conservation Act of 1978; permit applications, etc., 56852

Navy Department

NOTICES

Environmental statements; availability, etc.: F/A-18 E/F Super Hornet aircraft introduction to U.S. East Coast; correction, 56821

Nuclear Regulatory Commission NOTICES

Environmental statements; availability, etc.: Plateau Resources Ltd., 56852–56853

Railroad Retirement Board

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 56853

Research and Special Programs Administration NOTICES

Hazardous materials:

Applications; exemptions, renewals, etc., 56868–56869 Meetings:

International standards on transportation of dangerous goods, 56869–56870

Securities and Exchange Commission

NOTICES

Investment Company Act of 1940:

Deregistration applications—

Credit Suisse Municipal Bond Fund, Inc., et al., 56853–56856

Self-regulatory organizations; proposed rule changes: Chicago Board Options Exchange, Inc., 56856–56858 Pacific Exchange, Inc., 56858–56859

Small Business Administration

NOTICES

Disaster loan areas:
Delaware, 56859
Oregon, 56859
Virginia, 56859–56860
West Virginia, 56860

State Department

NOTICES

Agency information collection activities; proposals, submissions, and approvals, 56860

Foreign terrorists and terrorist organizations; determinations:

Abu Nidal Organization et al., 56860–56862 Organization, functions, and authority delegations: Administrator of U.S. Agency for International

Development, 56862

Surface Mining Reclamation and Enforcement Office RULES

Permanent program and abandoned mine land reclamation plan submissions:

Pennsylvania, 56765-56776

Textile Agreements Implementation Committee

See Committee for the İmplementation of Textile
Agreements

Transportation Department

See Federal Aviation Administration

See Federal Highway Administration

See Federal Motor Carrier Safety Administration

See Federal Transit Administration

See Maritime Administration

See Research and Special Programs Administration

Treasury Department

See Internal Revenue Service

NOTICES

Meetings:

Community Development Advisory Board, 56870

Veterans Affairs Department

PROPOSED RULES

Medical benefits:

Medical care or services, reasonable charges; 2003 methodology changes, 56875–56891

NOTICES

Inventions, Government-owned; availability for licensing, 56872

Medical benefits:

Medical care or services, reasonable charges; 2003 methology changes; charge tables, data sources, and list of VA health care facilities, 56891–57302

Meetings:

Professional Certification and Licensure Advisory Committee, 56872

Voluntary Service National Advisory Committee, 56873

Separate Parts In This Issue

Part II

Veterans Affairs Department, 56875-57302

Part III

Transportation Department, Federal Transit Administration, 57303–57305

Part IV

Interior Department, Fish and Wildlife Service, 57307–57318

Reader Aids

Consult the Reader Aids section at the end of this issue for phone numbers, online resources, finding aids, reminders, and notice of recently enacted public laws.

To subscribe to the Federal Register Table of Contents LISTSERV electronic mailing list, go to http://listserv.access.gpo.gov and select Online mailing list archives, FEDREGTOC-L, Join or leave the list (or change settings); then follow the instructions.

CFR PARTS AFFECTED IN THIS ISSUE

A cumulative list of the parts affected this month can be found in the Reader Aids section at the end of this issue.

14 CFR

14 CFR
Proposed Rules: 39 (5 documents)56792, 56794, 56796, 56799, 56801
19 CFR
Proposed Rules: 19156804
21 CFR 52256765
30 CFR 93856765
38 CFR
Proposed Rules: 1756876
40 CFR 8056776
Proposed Rules: 80
47 CFR
5256781
Proposed Rules:
73 (2 documents)56810,
56811
50 CFR
3257308
63556783 67956788
69756789
Proposed Rules:
64856811

Rules and Regulations

Federal Register

Vol. 68, No. 191

Thursday, October 2, 2003

This section of the FEDERAL REGISTER contains regulatory documents having general applicability and legal effect, most of which are keyed to and codified in the Code of Federal Regulations, which is published under 50 titles pursuant to 44 U.S.C. 1510.

The Code of Federal Regulations is sold by the Superintendent of Documents. Prices of new books are listed in the first FEDERAL REGISTER issue of each week.

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

21 CFR Part 522

Implantation or Injectable Dosage Form New Animal Drugs; Dexamethasone Injection

AGENCY: Food and Drug Administration, HHS.

ACTION: Final rule.

SUMMARY: The Food and Drug Administration (FDA) is amending the animal drug regulations to reflect approval of an abbreviated new animal drug application (ANADA) filed by Veterinary Laboratories, Inc. The ANADA provides for the use of dexamethasone injectable solution for the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses.

DATES: This rule is effective October 2, 2003

FOR FURTHER INFORMATION CONTACT:

Lonnie W. Luther, Center for Veterinary Medicine (HFV 104), Food and Drug Administration, 7519 Standish Pl., Rockville, MD 20855, 301–827–8549, email: *lluther@cvm.fda.gov*.

SUPPLEMENTARY INFORMATION: Veterinary Laboratories, Inc., 12340 Santa Fe Dr., Lenexa, KS 66215, filed ANADA 200-324 that provides for use of Dexamethasone Injection for the treatment of primary bovine ketosis and as an anti-inflammatory agent in cattle and horses. Veterinary Laboratories' Dexamethasone Injection is approved as a generic copy of Schering-Plough Animal Health's AZIUM (dexamethasone) Solution 2 Mg., approved under NADA 012-559. The ANADA is approved as of August 19, 2003, and the regulations are amended in § 522.540 to reflect the approval. The

basis of approval is discussed in the freedom of information summary.

In accordance with the freedom of information provisions of 21 CFR part 20 and 21 CFR 514.11(e)(2)(ii), a summary of safety and effectiveness data and information submitted to support approval of this application may be seen in the Division of Dockets Management (HFA–305), Food and Drug Administration, 5630 Fishers Lane, rm. 1061, Rockville, MD 20852, between 9 a.m. and 4 p.m., Monday through Friday.

The agency has determined under 21 CFR 25.33(a)(1) that this action is of a type that does not individually or cumulatively have a significant effect on the human environment. Therefore, neither an environmental assessment nor an environmental impact statement is required.

This rule does not meet the definition of "rule" in 5 U.S.C. 804(3)(A) because it is a rule of "particular applicability." Therefore, it is not subject to the congressional review requirements in 5 U.S.C. 801–808.

List of Subjects in 21 CFR Part 522

Animal drugs.

■ Therefore, under the Federal Food, Drug, and Cosmetic Act and under authority delegated to the Commissioner of Food and Drugs and redelegated to the Center for Veterinary Medicine, 21 CFR part 522 is amended as follows:

PART 522—IMPLANTATION OR INJECTABLE DOSAGE FORM NEW ANIMAL DRUGS

■ 1. The authority citation for 21 CFR part 522 continues to read as follows:

Authority: 21 U.S.C. 360b.

■ 2. Section 522.540 is amended by revising paragraph (a) to read as follows:

§ 522.540 Dexamethasone injection.

- (a)(1) Specifications. Each milliliter of solution contains 2 milligrams (mg) dexamethasone.
- (2) *Sponsors*. See sponsors in § 510.600(c) of this chapter:
- (i) Nos. 000061 and 059130 for use as in paragraph (a)(3) of this section.
- (ii) No. 000857 for use as in paragraphs (a)(3)(i)(C), (a)(3)(i)(D), (a)(3)(ii)(A), and (a)(3)(iii) of this section.
- (3) Conditions of use—(i) Amount. The drug is administered intravenously

or intramuscularly and dosage may be repeated if necessary, as follows:

- (A) *Dogs*. 0.25 to 1 mg.
- (B) Cats. 0.125 to 0.5 mg.
- (C) Horses. 2.5 to 5 mg.
- (D) *Cattle*. 5 to 20 mg, depending on the severity of the condition.
- (ii) *Indications for use*. The drug is indicated:
- (A) For the treatment of primary bovine ketosis and as an antiinflammatory agent in cattle and horses;
- (B) As an anti-inflammatory agent in dogs and cats.
- (iii) *Limitations*. Federal law restricts this drug to use by or on the order of a licensed veterinarian.

Dated: September 11, 2003.

Linda Tollefson,

Deputy Director, Center for Veterinary Medicine.

[FR Doc. 03–24928 Filed 10–1–03; 8:45 am] BILLING CODE 4160–01–S

DEPARTMENT OF THE INTERIOR

Office of Surface Mining Reclamation and Enforcement

30 CFR Part 938

[PA-135-FOR]

Pennsylvania Regulatory Program

AGENCY: Office of Surface Mining Reclamation and Enforcement (OSM), Interior.

ACTION: Final rule; approval of amendment.

SUMMARY: We are approving a proposed amendment to the Pennsylvania regulatory program (the "Pennsylvania program") under the Surface Mining Control and Reclamation Act of 1977 (SMCRA or the Act). Pennsylvania proposed revisions to its rules about surface and ground water monitoring and coal refuse disposal to satisfy required program amendments. Additionally, Pennsylvania submitted new rules concerning coal refuse disposal operations. Pennsylvania intended to revise its program to be consistent with the corresponding Federal regulations and SMCRA, clarify ambiguities, and provide additional safeguards. Finally, we are removing a regulatory program amendment where we required Pennsylvania to correct

cross-section references within the Pennsylvania Surface Mining Conservation and Reclamation Act (PA SMCRA).

EFFECTIVE DATE: October 2, 2003. **FOR FURTHER INFORMATION CONTACT:** George Rieger, Acting Field Office Director, Harrisburg Field Office, Telephone: 717–782–4036, Internet address: *grieger@osmre.gov.*

SUPPLEMENTARY INFORMATION:

I. Background on the Pennsylvania Program II. Submission of the Proposed Amendment III. OSM's Findings

IV. Summary and Disposition of Comments V. OSM's Decision

VI. Procedural Determinations

I. Background on the Pennsylvania Program

Section 503(a) of the Act permits a State to assume primacy for the regulation of surface coal mining and reclamation operations on non-Federal and non-Indian lands within its borders by demonstrating that its State program includes, among other things, "a State law which provides for the regulation of surface coal mining and reclamation operations in accordance with the requirements of the Act * * *; and rules and regulations consistent with regulations issued by the Secretary pursuant to the Act." See 30 U.S.C. 1253(a)(1) and (7). On the basis of these criteria, the Secretary of the Interior conditionally approved the Pennsylvania program on July 30, 1982. You can find background information on the Pennsylvania program, including the Secretary's findings, the disposition of comments, and conditions of approval of the Pennsylvania program in the July 30, 1982, Federal Register (47 FR 33050). You can also find later actions concerning Pennsylvania program and program amendments at 30 CFR 938.11, 938.12, 938.15 and 938.16.

II. Submission of the Proposed Amendment

By two letters, both dated December 20, 2001, Pennsylvania sent us proposed

amendments to its program (Administrative Record Nos. PA 837.101 and 881.00) under SMCRA (30 U.S.C. 1201 et seq.). In PA 837.101, Pennsylvania revised and added regulations at 25 Pennsylvania Code (Pa. Code) Chapters 88 and 90 regarding coal refuse disposal operations to implement statutory changes made to its Coal Refuse Disposal Control Act (CRDCA). Through these revised and added regulations, Pennsylvania was also responding to required amendments codified at 30 CFR 938.16(vvv), (www), (xxx), (yyy), (zzz), (aaaa), and (bbbb). We required these amendments to the Pennsylvania program as a result of our review of Pennsylvania's amendment to the CRDCA as found in the April 22, 1998, Federal Register (63 FR 19802). In a May 22, 1998, letter (Administrative Record No. PA 837.72) to OSM, Pennsylvania provided clarifications in response to the required amendments. In the February 2, 2000, Federal Register (65 FR 4882), we responded to Pennsylvania's clarifications by indicating that we would remove the required program amendments when Pennsylvania's clarifications were incorporated into regulations and those regulations were approved by OSM. In the amendment submitted under PA 837.101, Pennsylvania has provided those regulations.

In PA 881.00, Pennsylvania submitted changes made to its regulations at 25 Pa. Code 89.59(a)(2), (3) and (b) regarding ground water monitoring. These changes were made in response to the required amendment at 30 CFR 938.16(hh) in which we required Pennsylvania to amend its program to be no less effective than 30 CFR 784.14(h)(1) regarding ground water monitoring plans. At a minimum, the plans are to contain the total dissolved solids or specific conductance, pH, total iron, total manganese, and water levels shall be monitored and data submitted to Pennsylvania at least every three months for each monitoring location.

In a third letter dated November 16, 2001 (Administrative Record No. PA 880.00), Pennsylvania sent us an explanation regarding citation of cross-references in PA SMCRA required by the program amendment at 30 CFR 938.16(kk).

We announced receipt of the proposed amendments in the January 25, 2002, Federal Register (67 FR 3633). In the same document, we opened the public comment period and provided an opportunity for a public hearing or meeting on the amendment's adequacy. We did not hold a public hearing or meeting because no one requested one. The public comment period ended on February 25, 2002. We received comments on PA 837.101 from four Federal agencies, on PA 881.00 we received comments from two Federal agencies, and on PA 880.00 we received comments from one Federal agency.

III. OSM's Findings

Following are the findings we made concerning the amendment under SMCRA and the Federal regulations at 30 CFR 732.15 and 732.17. We are approving the amendment. Any revisions that we do not specifically discuss below concern nonsubstantive wording or editorial changes.

In the proposed amendment, Pennsylvania submitted regulations that implement provisions of the CRDCA. Many of these regulations are substantively the same, or have the same meaning, as portions of the CRDCA that are already in the approved Pennsylvania program. We announced our approval of these portions of the CRDCA in the April 22, 1998, Federal Register (63 FR 19802). The following regulations, listed in the first column of the table below, are approved because they are substantively identical to, or have the same meaning as, the corresponding State statutory provisions (shown in the second column) that we approved on April 22, 1998:

Regulation	Corresponding CRDCA sections that were previously approved		
25 Pa. Code 88.332	Section 30.56a(i).		
25 Pa. Code 90.1 definition of "operator"	Section 30.53 Definitions (8): "operator".		
25 Pa. Code 90.1 definition of "public recreational impoundment"	Section 30.53 Definitions (10.1): "public recreational impoundment"		
25 Pa. Code 90.167(d)	Section 30.56a(i).		
25 Pa. Code 90.201 definition of "preferred site"	Section 30.54a(a)(1)–(5).		
25 Pa. Code 90.202(a)	Section 30.54a(a).		
25 Pa. Code 90.202(b)(1)	Section 30.54a(c).		
25 Pa. Code 90.202(b)(2)	Section 30.54a(d).		
25 Pa. Code 90.202(c)	Section 30.54a(c), (d).		
25 Pa. Code 90.202(d)	Section 30.54a(c), (d).		
25 Pa. Code 90.202(e)(1)–(7)	Section 30.54a(b).		
25 Pa. Code 90.204(a)(1)–(3)	Section 30.54a(c), (d).		
25 Pa. Code 90.204(b)(1)–(3)	Section 30.54a(c), (d).		
25 Pa. Code 90.205	Section 30.54a(e).		

•	Section 30.53 Definitions (1): "abatement plan".
25 Pa. Code 90.302 definition of "best technology"	Section 30.53 Definitions (1.1) "actual improvement". Section 30.53 Definitions (1.4) "best technology". Section 30.53 Definitions (9.1) "pollution abatement area". Section 30.56b(b)(1). Section 30.56b(c)(1)(i)—(v). Section 30.56b(c)(2)—(4). Section 30.56b(c)(5). Section 30.56b(c)(7). Section 30.56b(d).

The following section contains our evaluation of regulations that do not have substantively identical corresponding sections to those in the CRDCA. Pennsylvania has made changes to its regulations at Chapter 88 covering coal refuse disposal operations in the anthracite region as well as regulations at Chapter 90 covering operations in the bituminous region.

Chapter 88 Anthracite Coal

25 Pa. Code 88.281 Requirements. This section formerly required anthracite coal operators who conduct coal refuse disposal activities to comply with the performance standards and design requirements of this subchapter. Pennsylvania added references to the new coal refuse disposal regulations to insure that anthracite operators comply with these new standards. Although these references have no direct Federal counterparts, the Director is approving them because they do not render the Pennsylvania program inconsistent with SMCRA or the Federal regulations.

25 Pa. Code 88.310 Coal refuse disposal: general requirements. Pennsylvania added subsections (j) and (k) to this section. Subsection (j) requires that the system to prevent adverse impacts to the surface and groundwater shall be constructed in accordance with design schematics, test results, descriptions, plans, maps, profiles or cross-sections approved in the permit and shall function to prevent adverse impacts to surface water and groundwater. This section is essentially the same as 25 Pa. Code 90.122(g) that the Director is approving below. This section will assure that anthracite refuse disposal operations are conducted in conjunction with the same safeguards as those in the bituminous region. Although these subsections have no direct Federal counterparts, the Director is approving them because they do not render the Pennsylvania program inconsistent with SMCRA or the Federal regulations.

Subsection (k) provides the design and installation requirements of a system designed to prevent precipitation from coming in contact with the coal refuse. These requirements are essentially the same as those that the Director is approving at 25 Pa. Code 90.122(h) (see the discussion under 25 Pa. Code 90.122(h) below for more information). The addition of these requirements to Pennsylvania's anthracite regulations will insure that anthracite coal refuse disposal operations will be carried out with the same safeguards in place as those in the bituminous region. Although this subsection has no direct Federal counterpart, the Director is approving it because it does not render the Pennsylvania program inconsistent with SMCRA or the Federal regulations.

Chapter 90 Coal Refuse Disposal

25 Pa. Code 90.1 Definition of "coal refuse disposal". Pennsylvania defines 'coal refuse disposal" in section 90.1 as "the storage, placement, or disposal of coal refuse." The term includes engineered features integral to the placement of the coal refuse including relocation or diversions of stream segments contained within the proposed fill area and the construction of required systems to prevent adverse impacts to surface water and groundwater and to prevent precipitation from contacting the coal refuse." While the term "coal refuse disposal" is not defined in the Federal regulations, Pennsylvania's definition is used in its regulations for meeting the requirements of 30 CFR 816.81(a)(1) which requires waste disposal areas to minimize effects of leachate and surface water runoff on surface and ground water quality and quantity. The Director finds that the definition of "coal refuse disposal" is not inconsistent with SMCRA or the Federal regulations.

25 Pa. Code 90.5 Site selection and permitting. Subsection (a) provides that an applicant for a permit to conduct coal refuse disposal activities shall

comply with Subchapter E (relating to site selection) and shall use Pennsylvania's Technical Guidance Document number 563-2113-660, titled "Coal Refuse Disposal—Site Selection" as guidance for selecting a coal refuse disposal site. Subsection (b) provides that after Pennsylvania has approved a site in accordance with Subchapter E, the applicant may apply for a permit for coal refuse disposal activities. There is no direct Federal counterpart for this regulation. However, this section merely describes the sequence of events that an applicant must go through to secure a permit for coal refuse disposal. Because this section is not inconsistent with SMCRA or the Federal regulations, the Director is approving it.

25 Pa. Code 90.12 Geology. Pennsylvania rearranged this section and also added and deleted some language. This section describes the geologic information that an application for coal refuse disposal must include. Former subsection (a)(1) was combined into subsection (a). Pennsylvania also deleted language from former subsection (a)(1) that described the information on the specific geologic stratum that operators are required to put in their permit applications. The deleted information required stratum information that was tied to the lowest coal seam to be mined. This information was replaced with the phrase, "The description shall include the strata down to and including any aquifer that may be affected." Pennsylvania made these changes because coal refuse disposal operations typically do not require the mining of coal. If coal mining does occur in conjunction with the refuse disposal operations, it will be regulated under Pennsylvania's surface coal mining regulations.

The Federal regulation most comparable to this section is found at 30 CFR 780.22(b)(1). This section requires geologic information in applications to include the deeper of either the stratum immediately below the lowest coal seam to be mined or any aquifer below the

lowest coal seam to be mined which may be adversely impacted by mining. Since no coal mining will occur in a refuse disposal operation, Pennsylvania's revised language requiring a description of the stratum down to and including the lowest aquifer that could be affected is as effective as the Federal regulations in requiring the application to contain geologic information about strata that could be affected in a coal refuse disposal operation. The Director finds that this change is no less effective than the Federal regulations and is approving the change.

Former subsection (a)(1)(i) was moved in its entirety to (a)(1). Former subsection (a)(1)(ii) is now (a)(2) and was changed from "Depth, lithology and structure of overburden or underlying strata," to "Depth, lithology and structure of near-surface bedrock." As noted earlier, coal refuse disposal operations in Pennsylvania generally are fills that do not involve the mining of coal. Therefore, the requirement to provide the depth, lithology and structure of overburden or underlying strata, is not applicable since this requirement is tied to a coal seam to be mined. The Director finds that a description of the lithology and structure of the near-surface bedrock is no less effective than the Federal regulations requiring descriptions of the strata to be affected by refuse operations. Accordingly, the Director is approving this change.

Former subsection (a)(2) has been deleted. This section provided the geologic information to be included in an application for any portion of a permit area in which the strata will be removed. As noted earlier, this provision is not applicable to refuse disposal operations because coal mining (unless otherwise authorized under Pennsylvania's surface mining regulations) does not occur on such operations. The Director is approving this change.

Former subsection (b) has been deleted. This section provided that an applicant may request that the requirements for a statement of the results of the test borings or core samplings required under subsection (a)(2) may be waived in part or in its entirety by the Department. Since former subsection (a)(2) has been deleted there is no reason to get a waiver from its requirements, therefore, the Director is approving deletion of this section.

Pennsylvania added requirements (4) through (9) to subsection (a). These sections provide the application requirements for describing the soils,

geologic strata characteristics, aquifers, and mine workings below proposed refuse disposal areas. These additions do not correspond directly to any Federal regulations. However, they require operators to inform Pennsylvania of the conditions beneath and adjacent to the proposed coal refuse disposal area. Because they require additional descriptions of site conditions, they are not inconsistent with the Federal regulations, and the Director is approving them.

Pennsylvania added a new subsection (b) that provides that maps, cross-sections, and geologic descriptions required by this section shall be prepared and certified by a qualified registered professional geologist. The Director finds that this section is no less effective than the Federal regulations at 30 CFR 779/783.25(b), which provides that a professional geologist is among the professionals authorized to submit maps and cross-sections for permit information.

25 Pa. Code 90.13 Groundwater information. In subsection (2), Pennsylvania proposed to add the following sentence to the end of the subsection: "The application shall include a description of the groundwater flow system as it relates to the design and operation of the proposed groundwater and surface water protection system as described in § 90.50 (relating to Design criteria: groundwater and surface water protection system)." This section does not have a direct Federal counterpart. However, it is useful to provide a description of the groundwater flow system as it relates to design and operation of the groundwater and surface water protection system in the application so that Pennsylvania may evaluate the effectiveness of such systems. The information required by 25 Pa. Code 90.13(2) assists operators in meeting the requirements of, and is therefore consistent with, 30 CFR 816.81(a)(1), which requires operators to minimize adverse effects of leachate and surface water runoff on surface and ground water quality and quantity. As a result, the Director is approving this

25 Pa. Code 90.45 Prime farmland
The only change to this section was the addition of a reference to Subchapter E which now requires that a person who conducts or intends to conduct coal refuse disposal activities on prime farmlands historically used for cropland, in accordance with Subchapter E (relating to site selection), to submit a plan as part of the permit application for the disposal and restoration of the land. The addition of

this language clarifies that an operator must take into account the requirements of subchapter E when proposing to conduct refuse disposal on prime farmland sites. In Subchapter E, section 90.202(e)(1) provides that Pennsylvania will not approve coal refuse disposal on, or within, prime farmlands except on preferred sites. The Director finds that because this section provides protections for prime farmlands in addition to those found in 30 CFR 785.17, it is consistent with that Federal regulation and is hereby approved.

25 Pa. Code 90.49 Štream buffer zone variance This is a new section added to define the conditions when Pennsylvania will allow coal refuse disposal operations to occur within 100 feet of a stream. As such, it expands upon and clarifies the statutory provisions partially approved on April 22, 1998 (63 FR 19806). Subsection (a) provides that coal refuse disposal may not occur within 100 feet of a stream, however, the Department may grant a variance under subsection (c) if the application is consistent with Subchapter E (relating to site selection). Subsection (b) provides that surface mining operations supporting coal refuse disposal must comply with 25 Pa. Code 86.102(12) relating to areas where mining is prohibited or limited. Subsection (c) provides the procedures an operator must follow to obtain a variance for disposal of coal refuse within the 100-foot stream buffer zone (SBZ) and the circumstances under which the Department will grant such a variance.

This amendment responds to the required amendment codified at 30 CFR 938.16(www). This required amendment concerns application of the SBZ rule at 30 CFR 816/817.57. The required amendment stated:

By July 1, 1998, Pennsylvania shall amend the Pennsylvania program to authorize stream buffer zone variances for coal refuse disposal activities only where such activities will not cause or contribute to the violation of applicable State or Federal water quality standards, and will not adversely affect water quality and quantity, or other environmental resources of the stream.

Pennsylvania's submission of regulations at 25 Pa. Code 90.49(a), (b) and (c)(1), regarding coal refuse disposal activities within a SBZ, are substantially the same as the Federal regulations regarding surface mining activities within a SBZ found at 30 CFR 816/817.57. Those sections provide assurance that the activities will not cause or contribute to the violation of applicable State or Federal water quality standards, and will not adversely affect the water quantity and quality or other

environmental resources of the stream. In addition, at 25 Pa. Code 90.49(c)(2), Pennsylvania contains regulations regarding public notice of a potential variance and a method by which the public can file an exception to the proposed variance with the aim of receiving a public hearing. These sections are no less effective than the Federal regulations and we are approving them. As a result, we will remove the required amendment at 30 CFR 938.16(www).

In 25 Pa. Code 90.49(c)(3), Pennsylvania has indicated that variances to SBZs will be issued as written orders specifying the methods and techniques to be employed to prevent or mitigate adverse impacts. Mitigation can include, but is not limited to, compensatory restoration and enhancements of nearby streams or stream segments. The first sentence of this provision is essentially identical to the statutory language previously approved on April 22, 1998, which states "The variance shall be issued as a written order specifying the methods and techniques that must be employed to prevent or mitigate adverse impacts." Therefore, there is no issue in approving that language in regulation here. The second sentence merely elaborates on the scope of that mitigation concept we have previously accepted by indicating that it may include off-site restoration or enhancement. Therefore, it is also approved.

25 Pa. Code 90.50 Design criteria: groundwater and surface water protection system. This entire section was added by the amendment and provides the application requirements for the performance standards of section 30.56a(i) of the CRDCA. Subsection (a) provides that the application must include a description of the system that will be installed to prevent adverse impacts to groundwater and surface water, while subsection (b) requires the application to include a description of the system that will be installed to prevent precipitation from coming in contact with the coal refuse. Subsection (c) provides that the Department's Technical Guidance Document number 563-2112-656, titled, "Liners-Impoundments, Stockpiles and Coal Refuse Disposal Areas" shall be used as guidance for designing coal refuse disposal sites incorporating earthen, admixed, or synthetic liners or caps for preventing adverse impact to groundwater and surface water and for preventing precipitation from contacting coal refuse. Subsection (d) requires the application to include a description of the measures to be taken to ensure the long-term functionality of the systems

described in subsections (a) and (b). The description must address the site's susceptibility to mine subsidence and deterioration due to physical or chemical processes.

We approved Pennsylvania's use of a system to prevent adverse impacts to surface and ground water and to prevent precipitation from contacting the coal refuse, as described in section 30.56a(i) of the CRDCA, in the April 22, 1998, Federal Register (63 FR 19807). The requirements, as presented in the amendment, to describe such systems in the permit application including when and how the systems will be used and how they will be maintained are a logical extension of the requirements of their use. These permit application requirements, in conjunction with the requirements of previously approved sections 25 Pa. Code 90.35 concerning protection of the hydrologic balance, and 25 Pa. Code 90.101 concerning general requirements of the hydrologic balance, are consistent with the requirements of SMCRA section 515(b)(10) concerning protection of the hydrologic balance and 30 CFR 816.81(a) concerning coal mine waste, protection of surface and groundwater from leachate and surface water runoff. As a result, the Director is approving this section.

25 Pa. Code 90.101 Hydrologic balance: general requirements. Pennsylvania proposed only a minor change to this section. Subsection (b) previously required coal refuse disposal activities to be planned and conducted to prevent pollution of the water. In this amendment, Pennsylvania clarified that the water referred to in this section is groundwater and surface water. This clarification is consistent with the requirements of SMCRA section 515(b)(10) regarding minimizing disturbances to surface and ground water systems. As a result, the Director is approving this section.

25 Pa. Code 90.116a Hydrologic

balance: water rights and replacement.

This new section provides that an operator who conducts coal refuse disposal and adversely affects a water supply shall comply with 25 Pa. Code 87.119 (relating to water rights and replacement). Section 87.119 requires restoration or replacement of an affected water supply with an alternate source adequate in quantity and quality for the purpose served by the supply. While we are reviewing changes to 25 Pa. Code 87.119 as part of a different program

87.119 as part of a different program amendment, the Director finds that the reference in 25 Pa. Code 90.116a to 25 Pa. Code 87.119 will insure that water supplies adversely affected by coal refuse disposal operation will be

restored or replaced. Therefore, the Director is approving this section.

25 Pa. Code 90.122 Coal refuse disposal. In this section, Pennsylvania deleted former subsections (e) and (g), and redesignated former subsection (f) as (e) and former subsection (h) as (f). Pennsylvania then added new subsections (g) and (h). In the former subsection (e) Pennsylvania required coal refuse disposal areas to be located on the most moderately sloping and naturally stable areas available. The section further provided that fill materials suitable for disposal are to be placed on or above a natural terrace, bench or berm to provide additional stability and prevent mass movement. Former subsection (g) required coal refuse disposal areas to be located in areas where groundwater discharge and surface water flows are minimal. These sections, which have no direct Federal counterparts, were designed to provide stability to refuse disposal fills and prevent pollution to surface and groundwater, both of which are provided for under the remaining and new subsections of 25 Pa. Code 90.122. Therefore, the Director is approving the deletion of these sections.

The new subsection (g) requires refuse disposal areas to be provided with a system to prevent adverse impacts to surface water and groundwater. New subsection (h) specifies how and when the system for preventing precipitation from coming into contact with coal refuse is to be installed. These sections are derived from, and are consistent with, section 30.56a(i) of the CRDCA that we approved in the April 22, 1998, Federal Register notice (63 FR 19807). Therefore, the Director is approving them.

Subchapter E. Site selection.
Pennsylvania is proposing to add a new Subchapter E titled, "Site Selection" to the Chapter 90 regulations. Subchapter E will contain 25 Pa. Code 90.201
Definitions, 25 Pa. Code 90.202 General requirements, 25 Pa. Code 90.203
Proposing a preferred site, 25 Pa. Code 90.204 Proposing an alternate site, 25 Pa. Code 90.205 Alternatives analysis, 25 Pa. Code 90.206 Disapproval of a proposed site, and 25 Pa. Code 90.207
Approval of a selected site.

25 Pa. Code 90.201 Definitions. This section contains definitions of the terms "search area," and "selected site." These definitions are used to implement Pennsylvania's regulations for the selection of sites for coal refuse disposal operations.

Pennsylvania has defined the term "search area" to mean the geographic area within a 1-mile radius of an existing coal preparation facility or the 25 square mile geographic area encompassing a proposed coal preparation facility. Although these terms were not specifically used in the CRDCA, the definitions were used in section 30.54a(c) and (d) regarding criteria for selecting sites for coal refuse disposal operations. We approved the use of the 1-mile radius in identifying alternative sites for new refuse disposal areas to support an existing coal mining activity and the use of the 25 square mile geographic area for alternative sites for a proposed coal preparation facility (63 FR 19806). Accordingly, the Director is approving the definition of the term

"search area" in 25 Pa. Code 90.202.

The term "selected site" is defined as a location selected by the applicant and approved by the Department for which the applicant can then apply for a permit to conduct coal refuse disposal activities. This term is not used in the CRDCA and there is no comparable term in the Federal regulations. We are approving the term because we have already approved the concept of coal refuse disposal site selection set forth in the CRDCA at 52 P.S. 30.54a(a) (63 FR 19806), and because the term is not inconsistent with SMCRA or the Federal regulations.

25 Pa. Code 90.202 General requirements. Subsection (f) provides that as part of the site selection process, an applicant may request approval for more than one site. The applicant will have the option of choosing a selected site from those approved by the Department to be used as the site for submitting an application on which to conduct coal refuse disposal operations. While there is no comparable Federal regulation for this section, there is nothing in SMCRA or the Federal regulations to prevent an operator from examining any number of sites to conduct refuse disposal operations. Any of the sites chosen must undergo the permitting process and be approved by the Department in accordance with the counterparts to SMCRA and the Federal regulations. Accordingly, the Director is approving subsection (f) of 25 Pa. Code 90.202.

25 Pa. Code 90.203 Proposing a preferred site. This section provides that if an applicant proposes to use a preferred site, the Department will approve the proposed site subject to 25 Pa. Code 90.202(c) (relating to general requirements) provided the applicant demonstrates that the attendant adverse environmental impacts will not clearly outweigh the public benefits. This section relates to section 30.54a(a) of the CRDCA, which provides that preferred sites shall be used for coal refuse disposal unless the applicant

demonstrates another site is more suitable; and that where the adverse environmental impacts of the preferred site clearly outweigh the public benefits, the site shall not be considered a preferred site. We approved section 30.54a(a) in the April 22, 1998, Federal Register (63 FR 19804). Because 25 Pa. Code 90.203 is consistent with the approved State statutory provision, the Director is approving it.

25 Pa. Code 90.206 Disapproval of a proposed site This section provides that if the Department disapproves the applicant's proposed site, the applicant may submit a new proposal supporting the selection of another site located within or outside the search area. There is no similar language in the CRDCA or SMCRA or the Federal regulations. However, there is no provision in SMCRA or the Federal regulations that prohibits an applicant from submitting alternative proposals if one is turned down. The Director finds this section is not inconsistent with the Federal regulations or SMCRA and is approving

25 Pa. Code 90.207 Approval of a selected site. This section provides that Pennsylvania's approval of a selected site does not indicate it will approve an application for coal refuse disposal activities on the selected site. The Director finds that this provision is consistent with Pennsylvania's permitting responsibilities under State counterparts to permitting requirements contained in SMCRA and the Federal regulations, and is therefore approving it

Subchapter F. Coal Refuse Disposal Activities on Areas with Preexisting Pollutional Discharges. This is a new section added by Pennsylvania. These regulations are modeled on existing regulations regarding remining areas with preexisting pollutional discharges found in 25 Pa. Code Chapter 87, Subchapter F and approved by OSM in the February 19, 1986 Federal Register (51 FR 5997).

25 Pa. Code 90.301 Scope. This section gives a general overview of the sections that follow and notes that Chapter 86 (relating to surface and underground coal mining: General) and Subchapters A-D apply to authorizations to mine areas with preexisting pollutional discharges except as specifically modified by this chapter. The Director has approved, with some conditions, the concept of establishing coal refuse disposal areas on sites with preexisting pollutional discharges in the analysis of the amendment of the CRDCA in the April 22, 1998 Federal Register (63 FR 19802). Section 25 Pa. Code 90.301

introduces the concept in regulation; therefore the Director is approving this section.

25 Pa. Code 90.302 Definitions, Baseline Pollution Load. Pennsylvania added the definition of the term "baseline pollution load" to 25 Pa. Code 90.302. This term is defined as, "The characterization of the pollutional material being discharged from or on the pollution abatement area, described in terms of mass discharge for each parameter deemed relevant by the Department, including seasonal variations and variations in response to precipitation events. The Department will establish in each authorization the specific parameters it deems relevant for the baseline pollution load, including, at a minimum, iron and acid loadings. This term was similarly defined in the CRDCA except for the last sentence. The term, including the last sentence, was also defined in 25 Pa. Code 87.202 regarding remining on surface mining sites with pollutional discharges. We approved the definition in our evaluation of the Chapter 87 regulations in the February 19, 1986 Federal Register (51 FR 5997). We are approving the definition for use in coal refuse disposal operations for the same reasons.

25 Pa. Code 90.302 Definitions, Best Professional Judgment. Pennsylvania added the definition of the term "best professional judgment" to 25 Pa. Code 90.302. The term is defined to mean, "the highest quality technical opinion forming the basis for the terms and conditions of the treatment level required after consideration of all reasonably available and pertinent data. The treatment levels shall be established by the Department under sections 301 and 402 of the Federal Water Pollution Control Act (33 U.S.C.A. §§ 1311 and 1342)." This definition is identical in substance to the definition of "best professional judgment" found at 25 Pa. Code sections 87.202 and 88.502, which was approved by OSM as part of Pennsylvania's standards for treatment of preexisting discharges on remined areas in the February 19, 1986, Federal Register (51 FR 5997). As a result, the Director is approving the definition at 25 Pa. Code 90.302.

25 Pa. Code 90.302 Definitions, Coal Refuse Disposal Activities. The term "coal refuse disposal activities" was similarly defined in the CRDCA and in this section to mean the storage, dumping or disposal of any waste coal, rock, shale, slurry, culm, gob, boney, slate, clay, underground development wastes, coal processing wastes, excess soil and related materials, associated with or near a coal seam, that are either

brought above ground or otherwise removed from a coal mine in the process of mining coal or are separated from coal during the cleaning or preparation operations. The term does not include the removal or storage of overburden from surface mining activities. In our analysis of the term in the April 22, 1998, Federal Register (63 FR 19803), we required Pennsylvania to amend its program to clarify the meaning of the term "excess soil and related materials" as used in the definition. This requirement was codified at 30 CFR 938.16(vvv).

In the February 2, 2000, Federal Register (65 FR 4882), we noted that Pennsylvania submitted information in response to the required amendment at 30 CFR 938.16(vvv). As part of that response, Pennsylvania defined the term "excess soil and related material to mean rock, clay or other material located immediately above or below a coal seam and which are extracted from a coal mine during the process of mining coal. The term does not include topsoil or subsoil." In that Federal Register notice, we indicated that we would remove the required program amendment when the clarification is incorporated in Pennsylvania's regulations and those regulations are approved by OSM. Pennsylvania incorporated the definition of "excess soil and related materials" verbatim into its regulations at 25 Pa. Code 90.302. Therefore, the Director is approving the definition and removing the required amendment at 30 CFR 938.16(vvv). 25 Pa. Code 90.303 Applicability.

Notwithstanding subsection (a), authorization will not be granted under this subchapter for repermitting under § § 86.12 and 86.14 (relating to continued operation under interim permits; and permit application filing deadlines), permit renewals under § 86.55 (relating to permit renewals: general requirements) or permit transfers under § 86.56 (relating to transfer of permit).

Subsection (b) provides that:

There is no direct Federal counterpart to this provision but the Director is approving it because it acts to limit permits where coal refuse disposal activities can occur. This section does not make Pennsylvania's coal refuse disposal regulations less effective than Federal regulations.

25 Pa. Code 90.304 Application for authorization. This section provides the permit application requirements for operators seeking to obtain authorization to conduct refuse disposal operations on areas with preexisting pollutional discharges. Parts of section 6.2(e) (52 P.S. 30.56b(e)) of the CRDCA are repeated in this section. Additionally, this section copies 25 Pa.

Code 87.204, which contains the surface coal mining requirements for remining areas with pollutional discharges. As noted above, OSM approved 25 Pa. Code 87.204 in the February 19, 1986, **Federal Register** (51 FR 5997). The Director is approving this section for the same reasons.

25 Pa. Code 90.305 Application approval or denial. Subsection (a)(5) provides standards for success of revegetation on areas approved under this section. For areas previously reclaimed to the standards of Chapters 87, 88 and 90, the revegetation success standards of 25 Pa. Code 90.159 apply. OSM previously approved the revegetation standards in 25 Pa. Code 90.159. Therefore, the Director is approving this portion of the amendment.

Subsection (a)(5) also provides that for those sites not previously reclaimed to the standards of Chapters 87, 88, and 90 the standards of subsection (a)(5)(i)–(iii) apply providing the site is not a bond forfeiture. These standards are the same as those OSM approved for previously affected sites in 25 Pa. 87.205(a)(5)(i)–(iii). Therefore, the Director is approving this section.

The submission of this portion of the amendment satisfies the required amendment codified at 30 CFR 938.16(zzz). This required amendment indicates that Pennsylvania must amend its program to be no less effective than 30 CFR 816.116(b)(5), by limiting the application of the revegetation standards under subsection 6.2(k) of the CRDCA to areas that were previously disturbed by mining and that were not reclaimed to the State reclamation standards.

The submission of this portion of the amendment also allows us to remove the required amendment codified at 30 CFR 938.16(aaaa). This section required Pennsylvania to amend its program to clarify that under Subsection 6.2(1) of its Coal Refuse Disposal Act, a special authorization for coal refuse disposal operations will not be granted, when such an authorization would result in the site being reclaimed to lesser standards than could be achieved if the moneys paid into the Fund, as a result of a prior forfeiture on the area, were used to reclaim the site to the standards approved in the original permit under which the bond moneys were forfeited. Pennsylvania responded to this required amendment by including language in 25 Pa. Code 90.305(a)(5) that provides an exception to the revegetation standards for special authorization projects. The revegetation standards of that section are not applicable when such projects are conducted on bond forfeiture sites

not previously reclaimed to the standards of Chapters 87, 88 and 90, where the money paid into the fund is sufficient to reclaim the forfeited site to the applicable standards. Additionally, we find that the Pennsylvania program prohibits the issuance of a special authorization where preexisting pollutional discharges would not be adequately treated where proceeds paid into the Surface Mining Conservation and Reclamation Fund as a result of a bond forfeiture on the proposed special authorization site are sufficient to pay for such treatment. In other words, treatment of pollutional discharges will not be compromised by special authorizations. Our finding is based upon two premises. First, according to PADEP, there are no currently existing sites for which the forfeited bond would be sufficient to pay for adequate discharge treatment. Second, discharge treatment costs for any future sites will be covered either by conventional bonds, or by treatment trust funds. In the event of operator default on such sites, proceeds from the conventional bonds or treatment trust funds must be expended to accomplish discharge treatment on the sites to which they are dedicated. Thus, where those proceeds are adequate to pay for discharge treatment, they must be used to that end. For these reasons, the remaining concerns that led to the imposition of 30 CFR 938.16(aaaa) have been satisfied, and we are hereby removing this required amendment.

30 CFR 816.116(b)(5) requires that vegetative cover, for areas previously disturbed by mining that were not reclaimed to the standards of Subchapter K, shall not be less than the ground cover existing before redisturbance and shall be adequate to control erosion. In Pennsylvania's amendment, 25 Pa. Code 90.305(a)(5)(ii) and (iii) contains these requirements. As a result, Pennsylvania has satisfied the conditions of the required amendment and we are removing it.

Subsection (d) provides that the authorization allowed under this subsection is only for the pollution abatement area and does not apply to other areas of the permit. The Director is approving this portion of the regulations because it limits the areas of the permit on which coal refuse disposal activities can occur. While there is no direct Federal counterpart to this provision, it does not make this portion of the regulations less effective than the Federal regulations regarding coal refuse disposal.

25 Pa. Code 90.306 Operational requirements. This section provides that operators must comply with Chapter 86

requirements, implement the approved water monitoring program, implement the approved abatement plan and notify the Department prior to the completion of each step of the abatement plan. In addition, this section requires a progress report be sent to the Department within 30 days of completion of each step of the abatement program. We approved the statutory authority for these regulations, contained in 52 P.S. 30.56b(f)(1)–(4), on April 22, 1998 (63 FR 19808). Section 90.306 contains the same requirements as 25 Pa. Code 87.206 that OSM approved in the February 19, 1986, Federal Register (51 FR 5997) except that the reporting statement signed by the operator in section (a)(4) need not be notarized in 25 Pa. Code 90.306(a). The lack of a notarized seal on the operator's statement does not lessen the reporting requirements of this section. There is no comparable Federal requirement to this section so Pennsylvania's reporting requirements are more stringent than any Federal provisions. The Director is approving this section.

25 Pa. Code 90.307 Treatment of discharges. This section provides that operators shall comply with the effluent standards of 25 Pa. Code 90.102 for treating discharges, except for preexisting discharges that are not encountered during coal refuse activities or implementation of the abatement plan. For preexisting discharges that are not encountered during coal refuse activities or implementation of the abatement plan, the operator must treat the discharge to comply with the effluent limits established by best professional judgment. The effluent limitations established by best professional judgment may not be less than the baseline pollution load.

This section is the same as 25 Pa. Code 87.207. OSM approved 25 Pa. Code 87.207 in the February 19, 1986, Federal Register (51 FR 5997). However, both 25 Pa. Code 87.207 and 90.307 contain language that Pennsylvania added after the 1986 approval. In 1989, Pennsylvania amended 25 Pa. Code 87.207(b) by adding the following language:

If the baseline pollution load when expressed as a concentration for a specific parameter satisfies the effluent limitations at § 87.102 (relating to hydrologic balance: Effluent standards) for that parameter, the operator shall treat the preexisting discharge for that parameter to comply with either effluent limitations established by best professional judgment or the effluent limitations at § 87.102.

In our evaluation of this revision, as published in the May 31, 1991, **Federal**

Register (56 FR 24657,) we noted that while the United States Environmental Protection Agency (EPA) generally concurred with the amendment package that included the above-quoted change, we asked for a specific determination by EPA as to whether the new language in section 87.207(b) is consistent with section 301(p) of the Federal Water Pollution Act, 33 U.S.C. 1311(p). Section 301(p) authorizes the issuance of National Pollutant Discharge Elimination System permits with modified effluent limitations for pH, iron and manganese on previously mined sites with preexisting discharges. We decided to defer a decision on this provision, pending specific EPA concurrence.

While we did not receive specific concurrence from EPA on revised 25 Pa. Code 87.207(b), EPA did publish a final rule on January 23, 2002 (67 FR 3370), that addresses our questions concerning the revision. Appendix B, part I d, indicates that:

In the event that a pollutant concentration in the data used to determine baseline is lower than the daily maximum limitation established in subpart C of this part for active mine wastewater, the statistical procedures should not establish a baseline more stringent than the BPT and BAT effluent standards established in subpart C of this part.

This language, plus EPA's concurrence received for this amendment, makes 25 Pa. Code 90.307 no less effective than the Federal regulation at 30 CFR 816.42 which provides that discharges of water from areas disturbed by surface mining activities must be made in compliance with effluent limitations for coal mining promulgated by EPA.

The submission of this section also satisfies required amendments codified at 30 CFR 938.16(xxx) and (yyy) that we put into place as a result of our review of the CRDCA (63 FR 19802). The required amendment at 30 CFR 938.16(xxx) indicates that Pennsylvania shall amend its program to clarify, in regulations developed to implement the provisions of section 6.2 of the CRDCA, that preexisting discharges that are encountered must be treated to the effluent standards at 25 Pa. Code 90.102.

In the February 2, 2000, Federal Register (65 FR 4883), we indicated that we would remove the required amendment at 30 CFR 938.16(xxx) if Pennsylvania submitted regulations that clarified that under section 6.2 of the CRDCA, preexisting discharges that are encountered must be treated to the State effluent standards at 25 Pa. Code 90.102. In its amendment, Pennsylvania submitted section 25 Pa. Code 90.307

which indicates that in subsection (a) that all discharges, except for preexisting discharges that are not encountered during coal refuse disposal activities or the implementation of the abatement plan, must comply with 25 Pa. Code 90.102. In this regulation, Pennsylvania has satisfied the conditions of the required amendment and, as a result, we are removing it.

The required amendment at 30 CFR 938.16(yyy) indicates that Pennsylvania shall amend its program to clarify that subsection 6.2(h) of the CRDCA pertains to preexisting discharges that are not encountered. In the Federal Register of April 22, 1998 (63 FR 19810), we approved section 6.2(h) of the CRDCA to the extent that it provides that an operator may only discontinue treating preexisting discharges that are not encountered when the operator demonstrates that the "baseline" pollution load is no longer being exceeded. Preexisting discharges must be treated to the water quality standards of 25 Pa. Code 90.102.

In this amendment, Pennsylvania submitted 25 Pa. Code 90.307(b) which provides that preexisting discharges that are not encountered must comply with effluent limitations established by best professional judgment. The best professional judgment limitations cannot be less than the baseline pollution load. Subsection (d) in describing when an operator may discontinue treating the discharges under subsection (b), indicates that treatment may be discontinued when the preexisting discharges are meeting the effluent limits established in subsection (b). Taken together, subsections (b) and (d) satisfy the conditions of the required amendment at 30 CFR 938.16(yyy) and as a result, we are removing it.

25 Pa. Code 90.308 Request for bond release. This section is the same as 25 Pa. Code 87.208 that OSM approved on February 19, 1986. The Director is approving this section for the same reason. We note that section 90.308 states that 25 Pa. Code subsection 86.172(d) shall not apply to the release of bonds for pollution abatement areas. Subsection 86.172(d) no longer exists; however, since the now deleted provision would not have applied to bond releases under section 90.308 anyway, the cross-reference to it is a nullity.

25 Pa. Code 90.309 Criteria and schedule for release of bonds on pollution abatement areas. For the most part, this section is the same as 25 Pa. Code 87.209 that OSM approved on February 19, 1986, except for two areas. In the first, the percentage of bond

release is different. In 25 Pa. Code 87.209(a), the initial bond release can be up to 60% of the bond and the percentage of the phase II bond release in 25 Pa. Code 87.209(b) is not specified (subsection (b) specifies only that the Department will release an additional bond while retaining an amount sufficient to cover the cost of reestablishing vegetation if completed by a third party). In the regulations covering coal refuse disposal at 25 Pa. Code 90.309(a), the initial bond release is up to 50% of the bond and the phase II bond release specified in 25 Pa. Code 90.309(b) can be up to an additional 35% of the bond while retaining an amount sufficient to cover the cost of reestablishing vegetation if completed by a third party. The regulations at 25 Pa. Code 90.309(a) could result in retention of more of the bond after phase I release than the counterpart regulations at 25 Pa. Code Chapter 87. This would provide more funds available to complete reclamation if an operator defaults after phase I release. Therefore, the Director is approving this portion of the amendment.

The second area of difference is at 25 Pa. Code 90.309(b)(3)(ii)(A)(I). This section deals with one of the standards the operator must achieve to receive a bond release of up to 35%. The section provides that this portion of the bond can be released if the operator, among other things, has not caused degradation of the baseline pollution load for a period of twelve months from the date of the initial bond release under subsection (a), if backfilling, final grading, drainage control, placement of impermeable cover, topsoiling and establishment of revegetation to achieve the standard of success for revegetation in 25 Pa. Code 90.305(a)(5) have been completed. The similar section approved by OSM on February 19, 1986, for surface mines at 25 Pa. Code 87.209(b)(3)(ii)(A)(I) indicated that up to 35% of bonds could be released if the operator, among other things, had not caused degradation of the baseline pollution load for the twelve months prior to the date of application for bond release and until the bond release is approved under subsection (b), if final grading, drainage control, topsoiling and establishment of revegetation to achieve the standard of success for revegetation in 25 Pa. Code 87.205(a)(5) have been completed. The difference in the two sections amounts to the period of time for demonstrating that the site did not degrade the baseline pollution load. The proposed rules at 25 Pa. Code 90.309(b)(3)(ii)(A)(I) provide for a demonstration period of twelve months

from the date of the initial bond release, while in the previously approved regulation at 87.209(b)(3)(ii)(A)(I) the demonstration period is for twelve months prior to the date of application for bond release and until the bond release is approved. Pennsylvania indicated that the demonstration period for the bond release on coal refuse disposal sites was set by the CRDCA which is why it is different than the surface mining regulations in Chapter 87. There is no comparable Federal regulation for this provision. However, the demonstration period is not inconsistent with the Federal regulations at 30 CFR 800.40(c)(2) regarding the release of Phase II bonds. As a result, the Director is approving it.

The remaining sections of 25 Pa. Čode 90.309 are the same as the sections of 25 Pa. Code 87.209 that OSM previously approved on February 19, 1986. Therefore the Director is approving them.

Subchapter G. Experimental Practices.

25 Pa. Code 90.401 General. This section provides the standards that coal refuse disposal practices must attain to be considered experimental practices. Subsection (a) is approved because it is substantively identical to, and therefore no less stringent than, the corresponding portions of section 711 of SMCRA. In addition, subsection (b) requires experimental practice permits to meet all the provisions, standards, and information requirements of 30 CFR 785.13. The Director finds that this provision will make Pennsylvania's regulations no less effective than 30 CFR 785.13 and is therefore approving it.

Submission of this portion of the amendment also satisfies the required amendment codified at 30 CFR 938.16(bbbb). This required amendment indicates that Pennsylvania must amend its program by adding implementation rules no less effective than 30 CFR 785.13 and no less stringent than SMCRA section 711. Further, Pennsylvania must clarify that experimental practices are only approved as part of the normal permit approval process and only for departures from the environmental protection performance standards, and that each experimental practice receive the approval of the Secretary. This required amendment is satisfied by subsection 90.401(a), which is substantively identical to most of section 711 of SMCRA, and by subsection (b), which requires compliance with 30 CFR 785.13, which contains the remaining applicable requirements of section 711 of SMCRA not covered by 90.401(a). Those

remaining requirements are that experimental practices be approved only as departures from the performance standards in individual cases, and that such practices must also receive the approval of the Secretary of the United States Department of the Interior, as delegated to the OSM Director.

Therefore, we are removing 30 CFR 938.16(bbbb).

Removal of Required Amendments at 30 CFR 938.16(hh) and (kk)

In the required amendment codified at 938.16(hh), we required Pennsylvania to amend 25 Pa. Code 89.59(a)(1) and (2) or otherwise amend its program to be no less effective than 30 CFR 784.14(h)(1) to require the monitoring plan to specify that, at a minimum, the total dissolved solids or specific conductance, pH, total iron, total manganese, and water levels shall be monitored and data submitted to Pennsylvania at least every 3 months for each monitoring location.

In response to this required amendment, Pennsylvania submitted changes to 25 Pa. Code 89.59(a)(3). The changes include deleting the last sentence from the section that reads, "The Department will approve the nature of data, frequency of collection, reporting requirements and the duration of the monitoring programs," and adding the following two sentences to the end of the section:

Surface water shall be monitored for parameters that relate to the suitability of the surface water for current and approved postmining land uses and to the objectives for protection of the hydrologic balance as set forth in § 89.36 (relating to protection of hydrologic balance). At a minimum, total dissolved solids or specific conductance corrected to 250C, total suspended solids, total iron, total manganese, acidity, alkalinity, pH, sulfates and flow shall be monitored and reported to the Department at least every 3 months for each monitoring location.

Pennsylvania is also proposing to change 25 Pa. Code 89.59(b) by adding a sentence to the end of the section that reads, "The Department may also require the operator to conduct monitoring and reporting more frequently than every 3 months and to monitor additional parameters beyond the minimum specified in this section."

We find that Pennsylvania's regulatory language regarding surface and groundwater monitoring is substantively identical to the corresponding portions of the Federal requirements at 30 CFR 784.14(h)(1) and therefore satisfies the required amendment at 30 CFR 938.16(hh). We are removing the required amendment at 30 CFR 938.16(hh).

The required amendment codified at 30 CFR 938.16(kk) requires Pennsylvania to correct cross-references in two sections of PA SMCRA. In section 3.1(c), the cross-reference to section 4.2(f) was to be changed to 4(b)(f). In section 3.1(d), the cross-reference to 18.6 was to be replaced with Section 24.

In response to the required amendment, Pennsylvania submitted a letter dated November 16, 2001 (Administrative Record No. PA 880.00). Pennsylvania explained that sections 3.1(c) and 3.1(d) of PA SMCRA are part of a numbering system used by the Pennsylvania Legislative Reference Bureau. Likewise the cross-referenced Sections 4.2(f) and 18.6 are also Legislative Reference Bureau numbering. Section 4b(f) is part of a numbering system used in Purdon's Pennsylvania Statutes Annotated (Purdon's). The complete number for Section 4(b)(f) in Purdon's is 52 P.S. 1396.4b(f). Purdon's 52 P.S. 1396.4b(f) is the Legislative Reference Bureau's Section 4.2(f). Section 24 was formerly a Purdon's number. The complete number for Section 24 in Purdon's was 52 P.S. 1396.24. Section 1396.24 was renumbered to 1396.18f in 1993 as a result of amendments to PA SMCRA. Purdon's section 1396.18f is the Legislative Reference Bureau's Section 18.6. Pennsylvania believes that since the cross-references in Sections 3.1(c) and 3.1(d) of SMCRA are the appropriate Legislative Reference Bureau Numbers that should be referenced, 30 CFR 938.16(kk) should be removed.

We agree with Pennsylvania's explanation regarding the cross-references and therefore, we are removing the required amendment codified at 30 CFR 938.16(kk).

IV. Summary and Disposition of Comments

Public Comments

No public comments were received.

Federal Agency Comments

Four responses were received from Federal agencies in response to Pennsylvania's submission under Administrative Record No. PA 837.101. One response was received from the United States Department of the Interior, Fish and Wildlife Service (FWS), two responses were received from the U.S. Department of Labor, Mine Safety and Health Administration's (MSHA), and one response was from the United States Department of Agriculture, Natural Resources Conservation Service (NRCS).

FWS submitted comments dated February 25, 2002 (Administrative Record No. PA 837.108). FWS indicated that 25 Pa. Code 90.49, Stream Buffer Zone Variance is inconsistent with Federal regulations. FWS indicated that the Federal regulations at 30 CFR 816.57 would prevent disturbance of a stream channel in the ephemeral portion of streams, 100 feet upstream of the intermittent zone and is therefore more protective of water quality and the stream's other environmental resources than PADEP's language. Our review of this section finds that it is similar to the stream buffer zone requirements of 25 Pa. Code 86.102(12) regarding areas not suitable for mining that we previously approved. Additionally, it appears that Pennsylvania's stream buffer zone may protect more area around streams, including the ephemeral zone upstream from an intermittent portion of a stream, because it includes areas 100 feet from an intermittent or perennial stream bank, and not just the stream itself. As a result, we have found that Pennsylvania's regulations regarding buffer zones are no less effective than the Federal regulations.

FWS further indicated that language at 25 Pa. Code 90.49(c)(1) that states that a stream buffer zone variance will only be granted if the operator demonstrates to the satisfaction of PADEP that coal refuse disposal will not adversely affect water quality or other environmental resources of the stream and will not cause or contribute to the violation of water quality standards is not as effective as the requirement of 30 CFR 816.57. FWS indicated that the Federal regulation requires that the regulatory authority must make a finding that the stream will be protected. We find that Pennsylvania's regulation does require it to make a finding that the stream will be protected because it requires that any demonstration by the operator be made to the Department's satisfaction. The Department will not be satisfied with substandard demonstrations and therefore will not allow a variance in those circumstances. We have found Pennsylvania's regulation to be no less effective than the Federal regulation.

Finally, regarding the stream buffer zone regulation at 25 Pa. Code 90.49(c)(1), FWS indicated that the words, "as a result of the variance" are also inconsistent with 30 CFR 816.57(a)(1) which states "[s]urface mining activities will not cause or contribute to * * *" We find that because both 30 CFR 816.57(a)(1) and 90.49(c)(1) are specifically written for stream buffer zones, there is no significant difference between the language of these two sections. In other

words, implicit in the language of the Federal regulation is the required finding that, as a result of the variance, there will be no adverse effects on water quality or quantity or other environmental resources of the stream nor violations of the State or Federal water quality standards. Both 25 Pa. Code 90.49(c)(1) and 30 CFR 816.57(a)(1) indicate the conditions under which a buffer zone variance will be issued and Pennsylvania's language is no less effective than the Federal regulation in communicating those conditions.

FWS's other concern was with threatened and endangered species. FWS indicated that language to ensure the protection of Federally listed threatened or endangered species was removed from the on-line version of PADEP's Technical Guidance Document 563-2113-660 titled, "Coal Refuse Disposal—Site Selection." PADEP indicated that a footnote containing the referenced language was inadvertently removed from the on-line version of the Technical Guidance Document. The footnote has subsequently been restored to the on-line version of the document. The footnote, as it now appears on page 4, reads:

PADEP's Section 4.1 (b) of CRDCA prohibits coal refuse disposal on nonpreferred sites that contain federally listed threatened or endangered species. With respect to preferred sites, the Department will not approve (via the site selection process) or permit (via the permitting process) a site that is known or likely to contain Federally listed threatened or endangered species, unless the Department concludes and the U.S. Fish and Wildlife Service concurs that the proposed activity is not likely to adversely affect Federally listed threatened or endangered species or result in the "take" of federally listed threatened or endangered species in violation of Section 9 of the Endangered Species Act.

In our final rule of April 22, 1998 (63 FR 19802), we indicated that the proposed site selection provision at subsection 4.1(b) of the CRDCA was approved to the extent of the provisions contained in the above language. Consequently, we find that FWS's concern has been answered.

MSHA's Wilkes-Barre Office replied on January 14, 2002, (Administrative Record No. PA 837.104) that the amendment did not conflict with existing MSHA regulations. On January 23, 2002, MSHA's New Stanton Office (Administrative Record No. PA 837.105) replied that the amendment did not conflict with its refuse pile regulations.

NRCS replied on January 29, 2002, (Administrative Record No. PA 837.106) that it found no inadequacies with the proposed amendment.

In regard to Pennsylvania's submission under Administrative Record No. PA 881.00, there were three responses from Federal agencies: two from MSHA and one from NRCS. MSHA's New Stanton Office replied on January 11, 2002, (Administrative Record No. PA 881.03) that the amendment did not conflict with any of MSHA's regulations under 30 CFR parts 75 and 77. MSHA's Wilkes-Barre Office replied on January 14, 2002, (Administrative Record No. PA 881.04) that nothing in the amendment conflicted with existing MSHA regulations. NRCS replied on January 29, 2002, (Administrative Record No. PA 881.05) that it found no inadequacies with the proposed change.

In regard to Pennsylvania's submission under Administrative Record No. PA 880.00, we received a response from MSHA's Wilkes-Barre office on September 6, 2002 (Administrative Record No. PA 880.04), indicating that it had no comments on the amendment.

Environmental Protection Agency (EPA) Concurrence and Comments

Under 30 CFR 732.17(h)(11)(ii), we are required to get a written concurrence from EPA for those provisions of the program amendment that relate to air or water quality standards issued under the authority of the Clean Water Act (33 U.S.C. 1251 et seq.) or the Clean Air Act (42 U.S.C. 7401 et seq.). On February 25, 2002 (Administrative Record No. PA 837.107), EPA informed us that there are no apparent inconsistencies with the Clean Water Act or other statutes or regulations under EPA's jurisdiction regarding Pennsylvania's submission under Administrative Record No. PA 837.101. EPA had three additional comments:

(1) EPA commended the portion of the amendment requiring the use of previously impacted areas for refuse disposal because of the environmental benefits of reclamation of previously impacted areas and because it would spare non-impacted areas that would otherwise be designated as refuse disposal sites.

OSM accepts the comments and also recognizes the environmental benefits of Pennsylvania's refuse disposal regulations.

(2) EPA indicated that it is apparent that some refuse disposal fills will be in headwater areas and pointed out that filling of waters of the United States requires proper authorization under Section 404 of the Clean Water Act, administered by the U.S. Army Corps of Engineers.

This comment is similar to one EPA made during its review of the changes to the CRDCA that precipitated this amendment. For a detailed discussion of OSM's response to the comment, see the final rule of April 22, 1998 (63 FR 19816–19819).

(3) Discharges from refuse disposal sites into waters of the United States require National Pollutant Discharge Elimination System (NPDES) permits from the Pennsylvania Department of Environmental Protection. NPDES permits for refuse disposal discharges must meet the more stringent of effluent guideline regulations under 40 CFR part 434 or those effluent limits necessary to comply with Pennsylvania's water quality standards for the receiving stream.

We note that one of the conditions of EPA's concurrence with the CRDCA involved the relationship between discharges and NPDES permits. For a full discussion of the Director's concurrence with this condition, see the final rule of April 22, 1998 (63 FR 19818–19819).

On September 5, 2002 (Administrative Record No. PA 880.05), EPA also responded to our request for comments on Pennsylvania's submission under Administrative Record No. PA 880.00. After reviewing Pennsylvania's submission, EPA determined that there were no apparent inconsistencies with the Clean Water Act or other statutes and regulations under its jurisdiction.

V. OSM's Decision

Based on the above findings, we approve the amendment Pennsylvania sent us on December 20, 2001. In addition, we are removing the required amendments codified at 30 CFR 938.16(hh), (kk), (vvv), (www), (xxx), (yyy), (zzz), (aaaa), and (bbbb).

To implement this decision, we are amending the Federal regulations at 30 CFR Part 938, which codify decisions concerning the Pennsylvania program. We find that good cause exists under 5 U.S.C. 553(d)(3) to make this final rule effective immediately. Section 503(a) of SMCRA requires that the State's program demonstrate that the State has the capability of carrying out the provisions of the Act and meeting its purposes. Making this regulation effective immediately will expedite that process. SMCRA requires consistency of State and Federal standards.

VI. Procedural Determinations

Executive Order 12630—Takings

This rule does not have takings implications. This determination is

based on the analysis performed for the counterpart Federal regulation.

Executive Order 12866—Regulatory Planning and Review

This rule is exempted from review by the Office of Management and Budget under Executive Order 12866.

Executive Order 12988—Civil Justice Reform

The Department of the Interior has conducted the reviews required by section 3 of Executive Order 12988 and has determined that this rule meets the applicable standards of subsections (a) and (b) of that section. However, these standards are not applicable to the actual language of State regulatory programs and program amendments because each program is drafted and promulgated by a specific State, not by OSM. Under sections 503 and 505 of SMCRA (30 U.S.C. 1253 and 1255) and the Federal regulations at 30 CFR 730.11, 732.15, and 732.17(h)(10), decisions on proposed State regulatory programs and program amendments submitted by the States must be based solely on a determination of whether the submittal is consistent with SMCRA and its implementing Federal regulations and whether the other requirements of 30 CFR Parts 730, 731, and 732 have been met.

Executive Order 13132—Federalism

This rule does not have Federalism implications. SMCRA delineates the roles of the Federal and State governments with regard to the regulation of surface coal mining and reclamation operations. One of the purposes of SMCRA is to "establish a nationwide program to protect society and the environment from the adverse effects of surface coal mining operations." Section 503(a)(1) of SMCRA requires that State laws regulating surface coal mining and reclamation operations be "in accordance with" the requirements of SMCRA, and section 503(a)(7) requires that State programs contain rules and regulations "consistent with" regulations issued by the Secretary pursuant to SMCRA.

Executive Order 13175—Consultation and Coordination With Indian Tribal Governments

In accordance with Executive Order 13175, we have evaluated the potential effects of this rule on Federally recognized Indian tribes and have determined that the rule does not have substantial direct effects on one or more Indian tribes, on the relationship between the Federal Government and

Indian tribes, or on the distribution of power and responsibilities between the Federal Government and Indian Tribes. The basis for this determination is that our decision is on a State regulatory program and does not involve a Federal program involving Indian lands.

Executive Order 13211—Regulations That Significantly Affect the Supply, Distribution, or Use of Energy

On May 18, 2001, the President issued Executive Order 13211 which requires agencies to prepare a Statement of Energy Effects for a rule that is (1) considered significant under Executive Order 12866, and (2) likely to have a significant adverse effect on the supply, distribution, or use of energy. Because this rule is exempt from review under Executive Order 12866 and is not expected to have a significant adverse effect on the supply, distribution, or use of energy, a Statement of Energy Effects is not required.

National Environmental Policy Act

This rule does not require an environmental impact statement because section 702(d) of SMCRA (30 U.S.C. 1292(d)) provides that agency decisions on proposed State regulatory program provisions do not constitute major Federal actions within the meaning of section 102(2)(C) of the National Environmental Policy Act (42 U.S.C. 4332(2)(C)).

Paperwork Reduction Act

This rule does not contain information collection requirements that require approval by OMB under the Paperwork Reduction Act (44 U.S.C. 3507 *et seq.*).

Regulatory Flexibility Act

The Department of the Interior certifies that this rule will not have a significant economic impact on a substantial number of small entities under the Regulatory Flexibility Act (5 U.S.C. 601 et seq.). The State submittal, which is the subject of this rule, is based upon counterpart Federal regulations for which an economic analysis was prepared and certification made that such regulations would not have a significant economic effect upon a substantial number of small entities. In making the determination as to whether this rule would have a significant economic impact, the Department relied upon the data and assumptions for the counterpart Federal regulations.

Small Business Regulatory Enforcement Fairness Act

This rule is not a major rule under 5 U.S.C. 804(2), the Small Business Regulatory Enforcement Fairness Act. This rule: (a) Does not have an annual effect on the economy of \$100 million; (b) will not cause a major increase in costs or prices for consumers, individual industries, Federal, State, or local government agencies, or geographic regions; and (c) Does not have significant adverse effects on competition, employment, investment, productivity, innovation, or the ability of U.S.-based enterprises to compete with foreign-based enterprises. This determination is based upon the fact that the State submittal which is the subject of this rule is based upon counterpart Federal regulations for which an analysis was prepared and a determination made that the Federal

regulation was not considered a major rule

Unfunded Mandates

This rule will not impose an unfunded mandate on State, local, or tribal governments or the private sector of \$100 million or more in any given year. This determination is based upon the fact that the State submittal, which is the subject of this rule, is based upon counterpart Federal regulations for which an analysis was prepared and a determination made that the Federal regulation did not impose an unfunded mandate.

List of Subjects in 30 CFR Part 938

Intergovernmental relations, Surface mining, Underground mining.

Dated: September 8, 2003.

Brent Wahlquist,

Regional Director, Appalachian Regional Coordinating Center.

■ For the reasons set out in the preamble, 30 CFR part 938 is amended as set forth below:

PART 938—PENNSYLVANIA

■ 1. The authority citation for part 938 continues to read as follows:

Authority: 30 U.S.C. 1201 et seq.

■ 2. Section 938.15 is amended in the table by adding a new entry in chronological order by "Date of final publication" to read as follows:

§ 938.15 Approval of Pennsylvania regulatory program amendments.

* * * *

Original amendment submission date

Date of final publication

Citation/description

date

December 20, 2001 October 2, 2003

25 Pa. Code 88.281, 88.310, 88.332, 89.59, 90.1, 90.5, 90.12, 90.13, 90.34, 90.45, 90.49, 90.50, 90.101, 90.116a, 90.122, 90.167, 90.201–207, 90.301–309, and 90.401.

§ 938.16 [Amended]

■ 3. Section 938.16 is amended by removing and reserving paragraphs (hh), (kk), (vvv), (www), (xxx), (yyy), (zzz), (aaaa), and (bbbb).

[FR Doc. 03–24945 Filed 10–1–03; 8:45 am] **BILLING CODE 4310–05–P**

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 80

[FRL-7566-3]

Regulation of Fuel and Fuel Additives: Gasoline and Diesel Fuel Test Method Update

AGENCY: Environmental Protection Agency (EPA).

ACTION: Direct final rule.

SUMMARY: The Environmental Protection Agency (EPA) is taking action to make certain fuel testing requirements more consistent and up-to-date by having refiners and laboratories use the most current version of an American Society of Testing and Materials (ASTM) analytical test method.

Specifically, we are updating an ASTM designated analytical test method, ASTM D 1319 to the most recent 2002a version which when adopted will supersede earlier versions of this method in EPA's motor vehicle

fuel regulations. This method is designated in EPA regulations for measuring chemical compositions in reformulated gasoline (RFG), conventional gasoline (CG), and diesel fuel, specifically aromatics and olefins in CG and RFG and aromatics in diesel fuel. These updates allow for more consistent use of the same methodology across EPA motor vehicle fuel regulations and incorporate improvements in the test method procedures that will ensure better operation.

DATES: This direct final rule is effective December 1, 2003, unless we receive adverse comments or a request for public hearing by November 3, 2003. If the Agency receives adverse comment or a request for public hearing, we will withdraw this direct final rule by publishing a timely withdrawal notice in the Federal Register.

The incorporation by reference of certain publications in this rule is approved by the Director of the Office of the Federal Register as of December 1, 2003.

ADDRESSES: If you wish to submit comments or request a public hearing, you should send any written materials to the docket address listed and to Joe Sopata, Chemist, Transportation & Regional Programs Division, U.S. Environmental Protection Agency, 1200 Pennsylvania Avenue, NW. (6406J),

Washington, DC 20460 or by e-mail to sopata.joe@epa.gov. Materials relevant to this direct final rule have been placed in docket A-2002-15 and docket A-2001-21 located at the following address: EPA Docket Center (EPA/DC), Public Reading Room, Room B102, EPA West Building, 1301 Constitution Avenue, NW., Washington, DC. Dockets may be inspected from 8:30 a.m. to 4:30 p.m., Monday through Friday, except on government holidays. You may reach the Air Docket by telephone at (202) 566-1742 and by facsimile at (202) 566-1741. You may be charged a reasonable fee for photocopying docket materials, as provided in 40 CFR Part 2. Comments and data may be submitted by email to: a-and-r-docket@epa.gov. All comments and data submitted in electronic form must note the docket number, A-2002-15. No confidential business information (CBI) should be submitted by e-mail.

FOR FURTHER INFORMATION CONTACT: If you would like further information about this rule or to request a hearing, contact Joe Sopata, Chemist, Transportation & Regional Programs Division, (202) 564–9034.

SUPPLEMENTARY INFORMATION: The contents of today's preamble are listed in the following outline.

I. Regulated Entities II. Rule Changes

- A. Updating ASTM D 1319 Test Method to 2002a Year Version
- III. Statutory and Executive Order Reviews A. Executive Order 12866: Regulatory
 - Planning and Review B. Paperwork Reduction Act
 - C. Regulatory Flexibility Act (RFA)
 - D. Unfunded Mandates Reform Act
- E. Executive Order 13132: Federalism F. Executive Order 13175: Consultation and Coordination With Indian Tribal
- Governments
 G. Executive Order 13045: Protection of
 Children from Environmental Health &
 Safety Risks
- H. Executive Order 13211: Actions that Significantly Affect Energy Supply, Distribution, or Use
- I. National Technology Transfer Advancement Act
- J. Congressional Review Act
- VÍ. Statutory Provisions and Legal Authority

I. Regulated Entities

Entities potentially affected by this action include those involved with the production, importation, distribution, sale and storage of gasoline motor fuel and diesel motor fuel.

The table below gives some examples of entities that may have to comply with the regulations. However, since these are only examples, you should carefully examine these and other existing regulations in 40 CFR part 80. If you have any questions, please call the person listed in the FOR FURTHER INFORMATION CONTACT section above.

Category	NAICSs codes a	SIC codes b	Examples of potentially regulated parties
Industry	32411 54138	2911 8734	Petroleum refiners. Testing Laboratories.

^a North American Industry Classification System (NAICS).

II. Rule Changes

A. Updating ASTM D 1319 Test Method to 2002a Year Version

Refiners, importers and oxygenate blenders producing gasoline and diesel motor vehicle fuel are required to test Reformulated Gasoline (RFG), Conventional Gasoline (CG) and diesel fuel for various fuel parameters including olefins, and aromatics. ASTM test method D1319 is currently a designated test method for measuring olefins ¹ in gasoline and aromatics ² in diesel fuel and is also allowed as an alternative test method for measuring aromatics ³ in gasoline. Because rules were adopted at different points in time, the regulations currently cite three

different versions of D 1319 (published in three different years) for these applications.

On February 26, 2002, the Agency published a final rule entitled "Regulation of Fuel and Fuel Additives: Reformulated Gasoline Transition".4 Among other things, this final rule updated certain ASTM test methods for RFG and CG, designated in EPA regulations, to their most recent ASTM version. Several designated test methods were updated to their most recent version including methods covering oxygen content, distillation properties, RVP, and aromatics. The designated test method for olefins, ASTM D 1319, was updated by EPA only to its 1998 version and not to the most recent version. This was because the 1999 version of ASTM D 1319 (the most recent version at that

time) had mistakenly left out an important reference to use of another ASTM method. ASTM D 5599-00, the missing test method, measures oxygenate concentration when present in the gasoline sample. Measurement of oxygenate content when oxygenates are present is a required procedure when determining olefin content. Therefore, since ASTM D 5599-00 is EPA's designated method for oxygenate determination, omission of this procedure in the 1999 version of ASTM 1319 meant that it would not be appropriate for EPA to adopt that version of ASTM 1319. We explained in our response to comments that "unless a determination is made that ASTM D 5599-00 can be appropriately included as a method for measuring oxygen and oxygen content with ASTM D 1319-99, EPA will retain the 1998 version of D

^b Standard Industrial Classification (SIC) system code.

^{1 40} CFR 80.46(b).

² 40 CFR 80.2(z).

^{3 40} CFR 80.46(f)(3).

⁴ February 26, 2002, (67 FR 8729).

1319 as the designated test method for olefins".⁵

Recently, David Bradley, the ASTM Director of Committee D02 for Petroleum Products and Lubricants, said in a letter to EPA that ASTM has updated test method D1319 to a 2002 year version.⁶ Mr. Bradley also pointed out that this most recent version of ASTM D 1319 now includes the reference to ASTM D 5599 thus resolving the problem associated with omission of EPA's designated test method for oxygen and oxygen content. The American Petroleum Institute (API) also submitted comments to EPA in support of this test method update of ASTM D 1319 to the 2002 year version.7 Thus, both ASTM and API support revising our motor vehicle fuels

regulations to allow the use of D1319–02a for testing of olefins.

In addition to updating our regulations to allow for the use of ASTM D 1319–02a for determining olefins in gasoline (discussed above), we are also today taking action to allow use of the newest version of D1319 for determination of aromatics content in RFG and CG (as an alternative method) and in determining aromatics content in diesel motor fuel. Previous versions of ASTM D1319 were allowed for determining aromatic content under previous rulemakings.

Table 1 lists the designated analytical test methods and alternative analytical test methods which are being updated for parameters measured under RFG, CG, and diesel fuels program in today's

action. We have reviewed the 2002a version of ASTM test method D 1319 and we are in agreement with its revisions. We believe that the revisions in ASTM D 1319-02a are not significant changes that would cause a user of an older version of the same method to incur significant costs. All of the revisions were deemed necessary by ASTM so that improvements in the test method's procedures would ensure better operation for the user of the test method. By updating ASTM D 1319 to the 2002a version for all three of these applications, the required analytical methodologies will be more consistent, making it easier for manufacturers of gasoline and diesel fuel to utilize the ASTM technique for all fuels and properties being tested.

TABLE 1.—DESIGNATED & ALTERNATIVE ANALYTICAL TEST METHODS UNDER RFG, CG & DIESEL FUEL PROGRAMS

Fuel parameter	Analytical test method
Olefins	ASTM D 1319–02a, entitled, "Standard Test Method for Hydrocarbon Types in Liquid Petroleum Products by Fluorescent Indicator Absorption."
Aromatics (gasoline and diesel)	ASTM D 1319–02a, entitled, "Standard Test Method for Hydrocarbon Types in Liquid Petroleum Products by Fluorescent Indicator Absorption", for diesel fuel, this method is the designated test method, for gasoline, this method is an alternative test method and if used as an alternative method, its results must be correlated to ASTM D 5769–98.

In the "Proposed Rules" section of today's Federal Register, we are publishing a proposed rule that matches the substance of this direct final rule. If the Agency receives adverse comment or a request for public hearing by November 3, 2003, we will withdraw the direct final rule by publishing a timely withdrawal notice in the Federal **Register.** If the Agency receives no adverse comment or a request for public hearing by November 3, 2003, these test method changes will be effective sixty (60) days after publication of this direct final rule in the Federal Register. We are confident that sixty(60) days is sufficient lead time for industry to become familiar and implement this most recent ASTM test method for the applications mentioned above.

III. Statutory and Executive Order Reviews

A. Executive Order 12866: Regulatory Planning and Review

Under Executive Order 12866, (58 FR 51735 (October 4, 1993)) the Agency must determine whether the regulatory action is "significant" and therefore subject to OMB review and the

requirements of the Executive Order. The Order defines "significant regulatory action" as one that is likely to result in a rule that may:

(1) Have an annual effect on the economy of \$100 million or more or adversely affect in a material way the economy, a sector of the economy, productivity, competition, jobs, the environment, public health or safety, or State, local, or tribal governments or communities:

(2) Create a serious inconsistency or otherwise interfere with an action taken or planned by another agency;

(3) Materially alter the budgetary impact of entitlements, grants, user fees, or loan programs or the rights and obligations of recipients thereof; or

(4) Raise novel legal or policy issues arising out of legal mandates, the President's priorities, or the principles set forth in the Executive Order.

Pursuant to the terms of Executive Order 12866, we have determined that this direct final rule is not a significant regulatory action.

B. Paperwork Reduction Act

This action does not add any new requirements involving the collection of

information as defined by the Paperwork Reduction Act, 44 U.S.C. 3501 et seq. The Office of Management and Budget (OMB) has approved the information collection requirements contained in the final RFG/antidumping rulemaking (See 59 FR 7716, February 16, 1994) and has assigned OMB control number 2060-0277 (EPA ICR No. 1591.14). The OMB has approved the information collection requirements contained in the final Tax Exempt (Dyed) Highway Diesel Fuel rulemaking (See 66 FR 64817, December 14, 2001) and has assigned OMB control number 2060-0308 (EPA ICR No. 1718.03).

Burden means the total time, effort, or financial resources expended by persons to generate, maintain, retain, or disclose or provide information to or for a Federal agency. This includes the time needed to review instructions; develop, acquire, install, and utilize technology and systems for the purposes of collecting, validating, and verifying information, processing and maintaining information, and disclosing and providing information; adjust the existing ways to comply with any

 $^{^5\,\}mathrm{See}$ Air Docket # A–2001–21, Document # V–C–01.

 $^{^{6}}$ See Air Docket # A–2002–15, Document # II–D– $_{01}$

 $^{^7}$ See Air Docket # A=2002=15, Document # II=D= 02

previously applicable instructions and requirements; train personnel to be able to respond to a collection of information; search data sources; complete and review the collection of information; and transmit or otherwise disclose the information. An Agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The OMB control numbers for EPA's regulations are listed in 40 CFR Part 9 and 48 CFR Chapter 15.

C. Regulatory Flexibility Act

The Regulatory Flexibility Act (RFA) generally requires an agency to prepare a regulatory flexibility analysis of any rule subject to notice and comment rulemaking requirements under the Administrative Procedure Act or any other statute unless the agency certifies that the rule will not have a significant economic impact on a substantial number of small entities. Small entities include small businesses, small organizations, and small governmental jurisdictions.

For purposes of assessing the impacts of today's direct final rule on small entities, small entity is defined as: (1) A small business that has not more than 1,500 employees (13 CFR 121.201); (2) a small governmental jurisdiction that is a government of a city, county, town, school district or special district with a population of less than 50,000; and (3) a small organization that is any not-forprofit enterprise which is independently owned and operated and is not dominant in its field.

After considering the economic impacts of today's direct final rule on small entities, we believe that this action will not have a significant economic impact on a substantial number of small entities. We have determined that no small entities will experience an impact from this direct final rule. ASTM test method D 1319 is currently a designated test method for measuring olefins in gasoline and aromatics in diesel fuel and is also allowed as an alternative test method for measuring aromatics in gasoline (see citations above in Section II.A). Because rules were adopted at different points in time, the regulations currently cite three different versions of ASTM D 1319 (published in three different years) for these applications. Currently, if a small entity produces both gasoline and diesel fuel, and it relies on ASTM D 1319 for determining compliance with the fuel parameters mentioned above, it must maintain three different versions of ASTM D 1319. These updates allow for more consistent use of the same

methodology across EPA motor vehicle fuel regulations, thus increasing flexibility for small entities who manufacture gasoline or diesel fuel. Thus this direct final rule is expected to reduce operating costs for all parties, including small entities.

Although this direct final rule will not have a significant impact on a substantial number of small entities, EPA has nonetheless tried to reduce the impact of this rule on small entities. If the Agency receives no adverse comment or request for public hearing on the corresponding proposed rule to this direct final rule, these test method changes will be effective sixty (60) days after publication of this direct final rule in the Federal Register. We are confident that sixty (60) days is sufficient lead time for small entities to become familiar and implement this ASTM test method for its applications.

D. Unfunded Mandates Reform Act

Title II of the Unfunded Mandates Reform Act of 1995 (UMRA), Public Law 104–4, establishes requirements for Federal agencies to assess the effects of their regulatory actions on State, local, and tribal governments and the private sector. Under section 202 of the UMRA, EPA generally must prepare a written statement, including a cost-benefit analysis, for proposed and final rules with "Federal mandates" that may result in expenditures to State, local, and tribal governments, in the aggregate, or to the private sector, of \$100 million or more in any one year. Before promulgating an EPA rule for which a written statement is needed, section 205 of the UMRA generally requires EPA to identify and consider a reasonable number of regulatory alternatives and adopt the least costly, most costeffective or least burdensome alternative that achieves the objectives of the rule. The provisions of section 205 do not apply when they are inconsistent with applicable law. Moreover, section 205 allows EPA to adopt an alternative other than the least costly, most cost-effective or least burdensome alternative if the Administrator publishes with the final rule an explanation why that alternative was not adopted. Before EPA establishes any regulatory requirements that may significantly or uniquely affect small governments, including tribal governments, it must have developed under section 203 of the UMRA a small government agency plan. The plan must provide for notifying potentially affected small governments, enabling officials of affected small governments to have meaningful and timely input in the development of EPA regulatory proposals with significant Federal

intergovernmental mandates, and informing, educating, and advising small governments on compliance with the regulatory requirements.

Today's direct final rule contains no Federal mandates (under the regulatory provisions of Title II of the UMRA) for State, local or tribal governments or the private sector. The rule would impose no enforceable duty on any State, local or tribal governments or the private sector. This rule applies to gasoline refiners, blenders and importers that supply gasoline or diesel fuel.

E. Executive Order 13132: Federalism

Executive Order 13132, entitled "Federalism" (64 FR 43255, August 10, 1999), requires EPA to develop an accountable process to ensure "meaningful and timely input by State and local officials in the development of regulatory policies that have federalism implications." "Policies that have federalism implications" is defined in the Executive Order to include regulations that have "substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government."

This direct final rule does not have federalism implications. It will not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132. This direct final rule updates an ASTM test method to its most recent version. Thus, Executive Order 13132 does not apply to this direct final rule.

In the spirit of Executive Order 13132, and consistent with EPA policy to promote communications between EPA and State and local governments, EPA specifically solicits comment on this direct final rule's corresponding proposed rule from State and local officials.

F. Executive Order 13175: Consultation and Coordination With Indian Tribal Governments

Executive Order 13175, entitled "Consultation and Coordination with Indian Tribal Governments" (65 FR 67249, November 6, 2000), requires EPA to develop an accountable process to ensure "meaningful and timely input by tribal officials in the development of regulatory policies that have tribal implications." "Policies that have tribal implications" is defined in the Executive Order to include regulations that have "substantial direct effects on

one or more Indian tribes, on the relationship between the Federal government and the Indian tribes, or on the distribution of power and responsibilities between the Federal government and Indian tribes."

This direct final rule does not have tribal implications. It will not have substantial direct effects on tribal governments, on the relationship between the Federal government and Indian tribes, or on the distribution of power and responsibilities between the Federal government and Indian tribes, as specified in Executive Order 13175. This direct final rule applies to gasoline refiners, blenders and importers that supply gasoline or diesel fuel. Today's action updates an ASTM test method to its most recent version, and does not impose any enforceable duties on communities of Indian tribal governments. Thus, Executive Order 13175 does not apply to this direct final

G. Executive Order 13045: Protection of Children From Environmental Health & Safety Risks

Executive Order 13045: "Protection of Children from Environmental Health Risks and Safety Risks" (62 FR 19885, April 23, 1997) applies to any rule that: (1) is determined to be "economically significant" as defined under Executive Order 12866, and (2) concerns an environmental health or safety risk that EPA has reason to believe may have a disproportionate effect on children. If the regulatory action meets both criteria, the Agency must evaluate the environmental health or safety effects of the planned rule on children, and explain why the planned regulation is preferable to other potentially effective and reasonably feasible alternatives considered by the Agency.

EPA interprets Executive Order 13045 as applying only to those regulatory actions that are based on health or safety risks, such that the analysis required under section 5–501 of the Order has the potential to influence the regulation. This rule is not subject to Executive Order 13045 because it does not establish an environmental standard intended to mitigate health or safety risks.

H. Executive Order 13211: Actions That Significantly Affect Energy Supply, Distribution, or Use

This direct final rule is not an economically "significant energy action" as defined in Executive Order 13211, "Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use" (66 FR 28355 (May 22, 2001)) because it does not have a

significant adverse effect on the supply, distribution, or use of energy. EPA is allowing additional flexibility and streamlining the regulations by updating an ASTM test method to its most current version for three applications under its motor vehicle programs.

I. National Technology Transfer Advancement Act

Section 12(d) of the National Technology Transfer and Advancement Act of 1995 ("NTTAA"), Public Law No. 104-113, section 12(d) (15 U.S.C. 272 note) directs EPA to use voluntary consensus standards in its regulatory activities unless to do so would be inconsistent with applicable law or otherwise impractical. Voluntary consensus standards are technical standards (e.g., materials specifications, test methods, sampling procedures, and business practices) that are developed or adopted by voluntary consensus standards bodies. The NTTAA directs EPA to provide Congress, through OMB, explanations when the Agency decides not to use available and applicable voluntary consensus standards.

This rule will update an ASTM test method which is a designated analytical test method for two applications and an alternative test method for one application to its most recent ASTM version. Today's action does not establish new technical standards or analytical test methods, although it does update an ASTM test method to its most current version. To the extent that this action would allow the use of standards developed by voluntary consensus bodies (such as ASTM) this action would further the objectives of the NTTAA.

J. Congressional Review Act

The Congressional Review Act, 5 U.S.C. 801 et seq., as added by the Small **Business Regulatory Enforcement** Fairness Act of 1996, generally provides that before a rule may take effect, the agency promulgating the rule must submit a rule report, which includes a copy of the rule, to each House of the Congress and to the Comptroller General of the United States. EPA will submit a report containing this rule and other required information to the U.S. Senate, the U.S. House of Representatives, and the Comptroller General of the United States prior to publication of the rule in the Federal Register. A "major rule" cannot take effect until 60 days after it is published in the Federal Register. This action is not a "major rule" as defined by 5 U.S.C. 804(a).

VI. Statutory Provisions and Legal Authority

Statutory authority for today's direct final rule comes from sections 211(c), 211(i) and 211(k) of the CAA (42 U.S.C. 7545(c) and (k)). Section 211(c) and 211(i) allows EPA to regulate fuels that contribute to air pollution which endangers public health or welfare, or which impairs emission control equipment. Section 211(k) prescribes requirements for RFG and conventional gasoline and requires EPA to promulgate regulations establishing these requirements. Additional support for the fuels controls in today's rule comes from sections 114(a) and 301(a) of the CAA.

List of Subjects in 40 CFR Part 80

Environmental protection, Air pollution control, Fuel additives, Gasoline, Diesel, Imports, Incorporation by reference, Motor vehicle pollution, Reporting and recordkeeping requirements.

Dated: September 24, 2003.

Marianne Lamont Horinko,

Acting Administrator.

■ For the reasons set forth in the preamble, part 80 of title 40, chapter I of the Code of Federal Regulations is amended as follows:

PART 80—REGULATION OF FUELS AND FUEL ADDITIVES

■ 1. The authority citation for part 80 continues to read as follows:

Authority: 42 U.S.C. 7414, 7545 and 7601(a).

■ 2. Section 80.2 is amended by revising paragraphs (z) to read as follows:

§ 80.2 Definitions.

* * * * *

(z) Aromatic content is the aromatic hydrocarbon content in volume percent as determined by ASTM standard test method D 1319–02a, entitled, "Standard Test Method for Hydrocarbon Types in Liquid Petroleum Products by Fluorescent Indicator Adsorption". ASTM test method D 1319-02a is incorporated by reference. This incorporation by reference was approved by the Director of the Federal Register in accordance 5 U.S.C. 552(a) and 1 CFR part 51. Copies may be obtained from the American Society for Testing and Materials, 100 Barr Harbor Dr., West Conshohocken, PA 19428-2959. Copies may be inspected at the Air Docket Center, room B-108, U.S. Environmental Protection Agency, Docket No. A-2202-15, 1200 Pennsylvania Avenue, NW.,

Washington, DC 20460, or at the Office of the Federal Register, National Archives and Records Administration, 800 North Capitol Street, NW., Suite 700, Washington, DC.

* * * * *

■ 3. Section 80.46 is amended by revising paragraphs (b), (f)(3)(i), and (h) to read as follows:

§ 80.46 Measurement of reformulated gasoline fuel parameters.

* * * * *

(b) Olefins. Olefin content shall be determined using ASTM standard method D 1319–02a, entitled "Standard Test Method for Hydrocarbon Types in Liquid Petroleum Products by Fluorescent Indicator Adsorption."

* * * * * * (f) * * *

(3) (i) Prior to September 1, 2004, any refiner or importer may determine aromatics content using ASTM standard method D 1319–02a, entitled "Standard Test Method for Hydrocarbon Types in Liquid Petroleum Products by Flourescent Indicator Adsorption," for purposes of meeting any testing requirement involving aromatics content; provided that

* * * * *

(h) Incorporations by reference. ASTM standard methods D 3606-99, entitled "Standard Test Method for Determination of Benzene and Toluene in Finished Motor and Aviation Gasoline by Gas Chromatography;" D 1319-02a, entitled "Standard Test Method for Hydrocarbon Types in Liquid Petroleum Products by Fluorescent Indicator Adsorption;" D 4815-99, entitled "Standard Test Method for Determination of MTBE, ETBE, TAME, DIPE, tertiary-Amyl Alcohol and C₁ to C₄ Alcohols in Gasoline by Gas Chromatography;" D 2622-98, entitled "Standard Test Method for Sulfur in Petroleum Products by Wavelength Dispersive X-Ray Fluorescence Spectrometry;" D 3246-96, entitled "Standard Test Method for Sulfur in Petroleum Gas by Oxidative Microcoulometry;" D 5191-01, entitled, "Standard Test Method for Vapor Pressure of Petroleum Products (Mini Method);" D 5599-00, entitled, "Standard Test Method for Determination of Oxygenates in Gasoline by Gas Chromatography and Oxygen Selective Flame Ionization Detection;" D 5769–98, entitled, "Standard Test Method for Determination of Benzene, Toluene, and **Total Aromatics in Finished Gasolines** by Gas Chromatography/Mass Spectrometry," and D 86-01, entitled, "Standard Test Method for Distillation

of Petroleum Products at Atmospheric Pressure;" are incorporated by reference in this section. These incorporations by reference were approved by the Director of the Federal Register in accordance with 5 U.S.C. 552(a) and 1 CFR part 51. Copies may be obtained from the American Society for Testing and Materials, 100 Barr Harbor Dr., West Conshohocken, PA 19428-2959. Copies may be inspected at the Air Docket Center, room B-108, U.S. Environmental Protection Agency, Docket No. A-2202-15, 1200 Pennsylvania Avenue, NW., Washington, DC 20460, or at the Office of the Federal Register, National Archives and Records Administration, 800 North Capitol Street, NW., Suite 700, Washington, DC.

[FR Doc. 03–24907 Filed 10–1–03; 8:45 am] BILLING CODE 6560–50–P

FEDERAL COMMUNICATIONS COMMISSION

47 CFR Part 52

[CC Docket 99-200; FCC 03-140]

Numbering Resource Optimization

AGENCY: Federal Communications Commission.

ACTION: Final rule.

SUMMARY: In this document, the Commission denied the petition for forbearance filed by the Cellular Telecommunications and Internet Association (CTIA) and found that forbearance was not warranted.

FOR FURTHER INFORMATION CONTACT: Cara Voth, Attorney, Wireline Competition Bureau, Telecommunications Access Policy Division, (202) 418–7400, TTY (202) 418–0484.

SUPPLEMENTARY INFORMATION: This is a summary of the Commission's Memorandum Opinion and Order in CC Docket No. 99–200, FCC 03–140 released on June 26, 2003. The full text of this document is available for public inspection during regular business hours in the FCC Reference Center, Room CY–A257, 445 Twelfth Street SW., Washington, DC 20554.

I. Introduction

In this Order, the Commission denied the petition for forbearance filed by the Cellular Telecommunications and Internet Association (CTIA) on June 28, 2002. CTIA sought forbearance from further scheduled increases to the numbering resources utilization threshold. CTIA argued that forbearance should be granted because the projected life of the North American Numbering Plan (NANP) has been extended, and increases to the current utilization threshold will raise the cost of providing service and increase the risk that numbering resources will not be available to carriers when needed. All commenters opposed CTIA's forbearance request. The Commission denied CTIA's Petition and found that forbearance was not warranted.

II. Discussion

1. We find that CTIA's forbearance petition does not satisfy the forbearance criteria set forth in section 10(a) of the Act. Specifically, we find that the numbering resources utilization threshold, and the scheduled increases up to the 75% cap, are necessary to ensure that carriers will obtain numbering resources in a just and reasonable manner, i.e., only when and where they are needed to provide services. We further find that requiring carriers to manage their numbering inventories at increasing thresholds is a preventative measure that is necessary to protect consumers from premature area code changes and exhaust of the NANP. We also find that it is consistent with the public interest to increase the threshold because it will continue to require carriers to use numbering resources more efficiently, which will benefit carriers and consumers.

Charges, Practices, Classifications and Regulations

2. The scheduled increases to the threshold ensure that carriers will obtain additional numbering resources only when they are needed and utilize their numbering inventories on an increasingly efficient basis. Such efficiency is necessary to avoid the waste of finite numbering resources that are essential to providing telecommunications service. Conversely, freezing the threshold at its current level could accelerate NANP exhaust and burden customers with premature area code changes, contrary to the public interest.

3. As the Commission first concluded in the Numbering Resource Optimization First Report and Order, 65 FR 43251, July 13, 2000, the utilization threshold requirement, coupled with the MTE requirement, deters carriers from stockpiling excessive inventories and helps ensure that carriers optimize the use of existing numbering resources. Due in part to these measures, the projected life of the NANP has been significantly extended. Even CTIA lauds the success of these measures. Furthermore, the Pennsylvania Commission submits that forbearance

from increasing the utilization threshold could result in the unnecessary stranding of over 1.3 million individual telephone numbers in Pennsylvania's NPAs. Thus, we find that the Commission's numbering resources utilization threshold and its scheduled increases are necessary to ensure that carrier practices with regard to numbering resources are not unjust or unreasonable.

4. We also disagree with CTIA's suggestion that scheduled increases are rendered unnecessary by the Commission's already existing authority under sections 201 and 202 of the Act to address unjust or unreasonable carrier practices. While we agree that we have authority pursuant to these sections to address matters regarding carriers' access to numbering resources, the existence of such authority does not, by itself, negate the necessity of retaining scheduled increases to the utilization threshold. Targeted rules, such as the utilization threshold and its scheduled increases, provide an additional measure to ensure that carriers optimize the use of existing numbering resources on an ongoing basis to prevent premature NANP exhaust. As mentioned above, telephone numbers are a finite resource. Therefore, we must maintain proactive and predictable measures that preserve the NANP in addition to depending on our authority to initiate case-by-case enforcement investigations. We find that because of the concerns described above, we would not be justified in forbearing now, even if we were to "revisit the issue at a later date if necessary to preserve the NANP" as CTIA suggests.

Consumer Protection

5. We conclude that retaining the scheduled increases to the numbering resource utilization threshold is necessary for the protection of consumers, and we disagree with CTIA that forbearance in this instance would benefit consumers. One of the overarching goals of the Commission's numbering optimization orders is to protect consumers from the expense and inconvenience resulting from frequent area code changes, and to prevent what would be a costly premature expansion of the NANP. We agree with the Pennsylvania, California and Michigan commissions that freezing the utilization threshold could burden customers with premature area code changes as a result of earlier NANP exhaust. We find that by increasing the threshold, we are minimizing the opportunity for carriers to stockpile unused numbers when other carriers are

in need of such resources to serve their customers. Higher utilization levels will help to maximize the use of all available numbers which, in turn, will delay the exhaust of individual area codes.

6. Furthermore, we agree with the states that maintain that evolving technologies, as well as expanding services, could cause the demand for numbers to spike past the previous levels. For example, as voice over Internet protocol (VoIP) providers continue to penetrate the telecommunications market, the demand for numbers may increase. Such demand could burden existing numbering resources. Therefore, we find that requiring carriers to manage their numbering inventories at higher thresholds is a preventative measure that is necessary to ensure that consumers will not have to bear the burden of premature area code changes and NANP expansion.

7. We disagree with CTIA's claim that we should forbear from further increases because they will lead to increased carrier and consumer costs. CTIA has not presented any data or detailed costbenefit analysis to support this assertion. In fact, CTIA readily concedes that it is "impossible to quantify the administrative costs carriers will incur from managing numbers at higher utilization levels." Moreover, the New York and California commissions have maintained utilization thresholds at 75% without any indication that there have been adverse effects on consumers. We are not convinced that increases to the utilization threshold would result in significantly more costs because the scheduled increases to the threshold are limited to 5% annually and are capped at 75%. We note that previously CTIA proposed and supported 5% annual increases to the utilization threshold. Moreover, in a recent ex parte filing, CTIA appears to depart from its position that the Commission should freeze the threshold at 65% by indicating that a 70% threshold would be an acceptable utilization level. Thus, it appears that CTIA now claims only that the difference between a 70% and 75% utilization threshold would be unnecessarily burdensome, in which case carriers would be required to use only 50 more numbers per thousandsblock. We reject CTIA's claim that scheduled increases to the utilization threshold will raise costs while providing little benefit.

8. We also disagree with CTIA's claim that forbearance is warranted as a consumer benefit because it will allow carriers more time to "age" telephone numbers. We find that the numbering utilization threshold has little or no

affect on the aging process. Because carriers have the flexibility to age numbers up to 90 days regardless of the utilization threshold, carriers will be able to replenish their inventories of unused numbers with numbers that have been aged on an ongoing basis. Carriers, therefore, must make a business decision as to how long to age their numbering resources. In the Numbering Resource Optimization First Report and Order, the Commission stated that it believes that carriers can reuse numbers in significantly less than 90 days. Certain states have maintained utilization thresholds higher than the current threshold without any indication that there have been adverse effects on the aging process or on consumers. Therefore, we find that carriers' ability to age numbers within the Commission's prescribed limits will not be negatively affected by further increases in the numbering resources utilization threshold.

9. Moreover, we believe that CTIA's claim regarding the aging process is merely another attempt at arguing that increases to the utilization threshold are burdensome because they require carriers to use numbers more efficiently. Requiring carriers to use numbering resources more efficiently, however, is the goal that increases to the utilization threshold were designed to achieve. We find that freezing the utilization threshold at its current level would have a detrimental effect on numbering resource optimization and, in turn, on consumers because it would provide opportunity for carriers to stockpile unused numbers that could be assigned to other requesting customers.

Public Interest

10. We conclude that it is in the public interest to retain scheduled increases to the utilization threshold because it will continue to result in more efficient use of numbering resources, further extend the life of the NANP, and facilitate impartial numbering administration by encouraging all carriers to use numbers in their existing inventory before requesting new ones. In the Numbering Resource Optimization Second Report and Order, the Commission adopted 60% only as an "initial" utilization threshold. The Commission chose this initial threshold because it was demonstrably achievable and it would give carriers the opportunity to transition to the 75% ceiling without compromising their ability to obtain numbering resources to serve customers. The Commission found, as we do here, that a utilization threshold ceiling of 75% was appropriate because it

balanced the Commission's goals of encouraging carriers to use numbers currently in their inventories before applying for additional resources with carriers' need to retain flexibility in managing their inventories. The Commission was concerned that many carriers were not doing enough to groom their numbering inventories to minimize waste of the NANP's finite numbering resources. Today, many areas continue to face a heightened demand for numbering resources and, therefore, a utilization threshold of 75% remains in the public interest to ensure that carriers continue to use their numbering resources more efficiently.

11. We disagree with CTIA's claim that we should forbear because doing so will bring about reduced regulatory costs that will promote competitive market conditions. As stated above, any reductions in regulatory costs that would result from forbearance are speculative, and would relate to relatively few numbers in a carrier's inventory. Thus any cost savings would only be minimal, at best. Even if we granted forbearance from further increases, carriers would still have to continue to bear the costs associated with complying with the current utilization level. We have not been shown, nor are we convinced, that the marginal costs related to compliance with increases to the utilization threshold have any effect on competitive market conditions. In fact, we find that forbearance would result in lost efficiencies in numbering resource optimization. When such costly inefficiencies are balanced against the minimal regulatory costs that may be saved by carriers as a result of freezing the current utilization threshold, it is clear that forbearance is not consistent with the public interest.

12. Finally, we find unsupportable CTIA's alternative claim that increases to the utilization threshold will result in certain carriers not having enough numbers available to them to meet customer demand. Once the utilization threshold reaches 75%, carriers will have 25% of their resources available to assign to new customers. Moreover, sufficient mechanisms, such as the safety valve, are in place to ensure that carriers with a verifiable need for additional numbers can get them even if they do not meet the utilization threshold requirements. For example, if, as CTIA suggests is the case for some carriers, a carrier has to use a large amount of numbers for E911 routing purposes, and as a result does not have a sufficient amount of telephone numbers to meet customer demand, that carrier can apply for relief via the safety

valve. In addition, the state commissions note that no carriers have complained that the utilization thresholds are technically or otherwise infeasible, and that no customers have complained about being unable to obtain service because a carrier did not have enough numbers. Therefore, we reject CTIA's contention that forbearance is in the public interest, or will promote or enhance competitive market conditions among providers of telecommunications services.

III. Ordering Clause

13. Pursuant to sections 10 and 251(e) of the Communications Act of 1934, as amended, 47 U.S.C. 160 and 251(e), that the Cellular Telecommunications and Internet Association's Petition for Forbearance From Further Increases in the Numbering Utilization Threshold, filed on June 28, 2002, is denied.

Federal Communications Commission.

Marlene H. Dortch,

Secretary.

[FR Doc. 03–24941 Filed 10–1–03; 8:45 am] BILLING CODE 6712–01–P

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

50 CFR Part 635

[Docket No. 030613152-3235-02; I.D. 051903B]

RIN 0648-AQ38

Atlantic Highly Migratory Species; Atlantic Bluefin Tuna Quota Specification, General Category Effort Controls, and Permit Revisions

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Final initial 2003 quota specifications, General category effort controls, permit revisions, and definition of the management boundary area.

SUMMARY: NMFS announces the final initial 2003 fishing year specifications for the Atlantic bluefin tuna (BFT) fishery to set BFT quotas for each of the established fishing categories, to set General category effort controls, to allocate 25 metric tons (mt) of BFT to account for incidental catch of BFT by pelagic longline vessels "in the vicinity of the management boundary area," to define the management boundary area and applicable restrictions, and to revise permit requirements to allow General

category vessels to participate in registered recreational Highly Migratory Species (HMS) fishing tournaments and to allow permit applicants a 10calendar day period to make permit category changes to correct potential errors. The final initial quota specifications, including the quota allocation to account for incidental catch of BFT by pelagic longline vessels in the vicinity of the management boundary area and the General category effort controls, are necessary to implement recommendations of the International Commission for the Conservation of Atlantic Tunas (ICCAT), pursuant to the Atlantic Tunas Convention Act (ATCA), and to achieve domestic management objectives under the Magnuson-Stevens Fishery Conservation and Management Act (Magnuson-Stevens Act). The definition of the management boundary area is to assist management, monitoring, and enforcement of the 25 mt allocated to the Longline category. The permit revisions to allow General category permitted vessels to participate in registered recreational HMS fishing tournaments and to allow a time period for permit category changes are intended to relieve restrictions and help achieve domestic management objectives.

DATES: The final initial quota specifications and General category effort controls are effective November 3, 2003 through May 31, 2004. The definition of the management boundary area and applicable restrictions and the revisions to the permit requirements are effective November 3, 2003.

ADDRESSES: Copies of the supporting documents including the Environmental Assessment/Regulatory Impact Review/ Final Regulatory Flexibility Analysis (EA/RIR/FRFA) and the Fishery Management Plan for Atlantic Tunas, Swordfish, and Sharks (HMS FMP) may be obtained from Brad McHale, Highly Migratory Species Management Division, NMFS, Northeast Regional Office, One Blackburn Drive, Gloucester, MA 01930. These documents are also available from the Highly Migratory Species Division website at www.nmfs.noaa.gov/sfa/ hmspg.html.

FOR FURTHER INFORMATION CONTACT: Brad McHale at (978) 281–9260.

SUPPLEMENTARY INFORMATION: Atlantic tunas are managed under the dual authority of the Magnuson-Stevens Act and ATCA. ATCA authorizes the Secretary of Commerce (Secretary) to implement binding recommendations of ICCAT. The authority to issue

regulations under the Magnuson-Stevens Act and ATCA has been delegated from the Secretary to the Assistant Administrator for Fisheries, NOAA (AA).

Background

Background information about the need for the final initial BFT quota specifications, General category effort controls, and revisions to the HMS permit regulations was provided in the preamble to the proposed rule (68 FR 41103, July 10, 2003), and is not repeated here. By this final rule, NMFS announces the final initial BFT quota specifications, announces the General category effort controls, including timeperiod subquotas and restricted fishing days (RFDs), allocates 25 mt of BFT to account for incidental catch of BFT by pelagic longline vessels in the vicinity of the management boundary area. defines the management boundary area and applicable restrictions, revises permit requirements to allow General category vessels to participate in registered recreational HMS fishing tournaments, and revises permit requirements to allow permit applicants a 10-calendar day period to make permit category changes to correct potential errors.

Changes From the Proposed Rule

2002 Underharvest / Overharvest

The current ICCAT BFT quota recommendation allows, and U.S. regulations require, the addition or subtraction, as appropriate, of any underharvest or overharvest in a fishing year to the following fishing year, provided that such carryover does not result in overharvest of the total annual BFT quota and is consistent with all applicable ICCAT Recommendations, including restrictions on landings of school BFT. At the time of publication of the proposed initial specifications, 2002 fishing year landings had not yet been fully accounted. Therefore, NMFS adjusts these final initial 2003 fishing year quota specifications for the BFT fishery to account for underharvest and/ or overharvest in the 2002 fishing year and recently available data on dead

For the 2002 fishing year, NMFS has determined that General category landings were higher than the adjusted General category quota by 15.7 mt. The Reserve category contains 10.3 mt of BFT quota, and will be used to address partially the General category overharvest. Purse Seine category landings were less than the adjusted Purse Seine category quota by 110.0 mt. Regulations at 50 CFR 635.27(a)(9)(i)

require that Purse Seine category underharvests or overharvests be subtracted from or added to each individual vessel's quota allocation, as appropriate. Harpoon category landings are less than the adjusted Harpoon category quota by approximately 20.4 mt. Angling category under/over harvests vary by size class for the 2002 fishing year: School BFT - 133.8 mt underharvest, large school/small medium BFT — 76.1 mt underharvest, large medium/giant BFT — 1.5 mt overharvest, and school reserve - 20.5 mt underharvest. Overharvest in the large medium/giant size class is addressed by a transfer from the large school/small medium size category underharvest. Longline category landings are less than the adjusted quota by 5.2 mt. In 2002, no landings were recorded in the Trap category, leaving

For all categories with underharvests from the 2002 fishing year, these final initial specifications include provisions to carry forward remaining quota to the same category for the 2003 fishing year. However, the unused school reserve (approximately 20.5 mt) is allocated to the Reserve category.

Dead Discards

As part of the BFT rebuilding program, ICCAT recommends an allowance for dead discards. The U.S. dead discard allowance is 68 mt. The 2002 calendar vear preliminary estimate of U.S. dead discards, as reported in pelagic longline vessel logbooks, totaled 38.0 mt (U.S. TASK I data submitted to ICCAT in 2003). As estimates of BFT dead discards for the 2002 fishing year are not yet available, the estimate for the 2002 calendar year was used to calculate the amount to be added to, or subtracted from, the U.S. BFT landings quota for 2003 as a result of dead discards. Estimates of dead discards from other gear types and fishing sectors that do not use the pelagic longline vessel logbook are unavailable at this time and thus are not included in this calculation. As U.S. fishing activity is estimated to have resulted in less dead discards than its allowance, the ICCAT Recommendation and U.S. regulations state that the United States may add one half of the difference between the amount of dead discards and the allowance (i.e., 68.0 mt - 38.0 mt = 30.0 mt, 30.0 mt/2 = 15.0 mt) to its total allowed landings for the following fishing year, or to individual fishing categories, or to the Reserve. NMFS allocates the 15.0 mt to the Reserve category quota.

BFT to Atlantic Tunas in General Category Tournament Exception

When General category vessels fish in tournaments, it is NMFS' intent that HMS Angling category regulations for sharks, swordfish, and/or billfish, as well as any specific tournament rules, would apply to the General category vessels. However, when fishing for, or landing Atlantic tunas in a tournament, the General category regulations would apply, including RFDs and General category retention limits. Thus, this would not allow General category vessels to fish for or retain BFT less than 73 inches (1.85 m). This is intended to provide some relief from the current restrictions and allow General category vessels the same access to tournaments where they may have participated in the past. It is incumbent upon the General category fishermen to verify that a tournament is registered.

2003 Final Initial Quota Specifications

In accordance with the 2002 ICCAT Recommendation, the ICCAT Recommendation regarding the dead discard allowance, the HMS FMP percentage shares for each of the domestic categories, and regulations regarding annual adjustments at § 635.27(a)(9)(ii), NMFS announces final initial quota specifications for the 2003 fishing year as follows: General category — 684.4 mt; Harpoon category — 77.5 mt; Purse Seine category — 382.4 mt; Angling category — 497.0 mt; Longline category — 148.8 mt; and Trap category — 3.8 mt. Additionally, 72.1 mt will be allocated to the Reserve category for inseason allocations, including providing for a late season General category fishery, or to cover scientific research collection and potential overharvest in any category except the Purse Seine category. The overall final initial BFT quota for the 2003 fishing vear equals 1,866.0 mt.

Based on the above final initial specifications, the Angling category quota of 497.0 mt will be further subdivided as follows: School BFT — 230.9 mt, with 130 mt to the northern area (north of 39° 18′ N. latitude), 100.9 mt to the southern area (south of 39° 18′ N. latitude), plus 22.1 mt held in reserve; large school/small medium BFT — 237.4 mt, with 127.6 mt to the northern area and 109.8 mt to the southern area; and large medium/giant BFT — 6.6 mt, with 2.2 mt to the northern area and 4.4 mt to the southern area.

The 2002 ICCAT Recommendation includes a 25 mt set-aside quota to account for bycatch of BFT related to directed longline fisheries in the

vicinity of the management area boundary. This set-aside quota is in addition to the overall incidental longline quota to be subdivided in accordance to the North/South allocation percentages mentioned below. NMFS recently adjusted the boundary line between the northern and southern areas to 31°00' N. latitude, near Jekyll Island, Georgia (an area with little longline fishing activity nearby), and adjusted the Longline quota distribution to allocate 40 percent to the northern area and 60 percent to the southern area (68 FR 32414, May 30, 2003). Thus, the Longline category quota of 148.8 mt will be subdivided as follows: 49.8 mt to longline vessels landing BFT north of 31° N. latitude and 74.0 mt to longline vessels landing BFT south of 31° N. latitude. The 25 mt allocated by ICCAT for longline vessels in the vicinity of the management boundary area will be allocated to the Longline north subcategory for a total of 74.8 mt. Accounting for landings under this additional quota will be maintained separately from other landings under the Longline north subcategory.

General Category Effort Controls

For the last several years, NMFS has implemented General category time-period subquotas to increase the likelihood that fishing would continue throughout the entire General category season. The subquotas are consistent with the objectives of the HMS FMP and are designed to address concerns regarding allocation of fishing opportunities, to assist with distribution and achievement of optimum yield, to allow for a late season fishery, and to improve market conditions and scientific monitoring.

The HMS FMP divides the annual General category quota into three timeperiod subquotas as follows: 60 percent for June-August, 30 percent for September, and 10 percent for October-December. These percentages will be applied to the adjusted 2003 coastwide quota for the General category of 684.4 mt, minus 10.0 mt reserved for the New York Bight fishery. Therefore, of the available 674.4 mt coastwide quota, 404.6 mt will be available in the period beginning June 1 and ending August 31; 202.4 mt will be available in the period beginning September 1 and ending September 30; and 67.4 mt will be available in the period beginning October 1 and ending December 31,

In addition to time-period subquotas, NMFS also implements General category RFDs to extend the General category fishing season. The RFDs are designed to address the same issues

addressed by time-period subquotas and provide additional fine-scale inseason flexibility. For the 2003 fishing year, NMFS implements a schedule of RFDs that would assist in extending the General category BFT fishery into the late season to provide southern Atlantic General category participants commercial fishing opportunities on large medium and giant BFT. Therefore, NMFS announces that persons aboard vessels permitted in the General category are prohibited from fishing for BFT of all sizes on the following days: November 15 through November 30 inclusive. These RFDs will improve distribution of fishing opportunities without increasing BFT mortality.

Comments and Response

Comment 1: Comments expressed support for the new RFDs of November 15–30 to assist in extending the General category fishery into the late winter season. Comments also stated that implementing this block of RFDs should also provide NMFS with adequate time to account for all BFT harvests made prior to any winter fishery.

Response: NMFS' final action maintains the proposed block of RFDs in the final initial specifications for the Fall, from November 15 through November 31, inclusive, where no General category BFT fishing would take place. This is due primarily to the experience of the past several years when low catch rates have resulted in NMFS having to waive all previously announced RFDs mid-season, which can cause confusion and disrupt fishermen's activities. This action will allow for BFT to migrate off southern Atlantic States, assist the availability of quota late in the season, and partially address economic and social concerns from south Atlantic area fishermen.

Comment 2: Comments regarding the General category permit revision to allow General category vessels to participate in registered HMS recreational fishing tournaments were generally supportive. One commentor stated that General category vessels should also be allowed to land BFT in the recreational size classes while participating in a tournament. One comment received stated that the catching of shark, swordfish, and/or billfish recreationally or retaining any by catch for personal consumption, has been a traditional component of the General category. The same comment stated that this action sets a precedent which could mean that a commercial permit holder for one species may not fish recreationally for another species.

Response: The final action maintains the preferred alternative that will allow

General category vessels to participate in recreational HMS fisheries provided they are participating in a registered recreational HMS fishing tournament (according to HMS tournament registration and participation regulations), as well as abiding by the regulations of the tournament. NMFS' intent is to allow General category vessels to land sharks, swordfish, and/ or billfish recreationally while actively participating in a tournament. However, when fishing for, or landing, Atlantic tunas in a tournament the General category regulations would apply, including RFDs and General category retention/size limits. This action is intended to provide some relief from the current restriction and allow General category vessels the same access to tournaments where they may have participated in the past. As the tournament must be registered, NMFS will also be able to collect data on catch, effort, and participants.

Recent rulemaking established a new recreational permit category for all HMS which, among other matters, means General category permit holders must choose whether to retain their commercial General category permit and forgo recreational HMS fishing opportunities or, switch permit categories to the new Atlantic HMS Angling permit and forgo their ability to sell tunas. The HMS Angling category permit completes a process that NMFS initiated several years ago to separate commercial and recreational HMS fishing activities to enhance both monitoring and management of all domestic HMS fishing categories.

Comment 3: Comments regarding the 10-calendar day window of opportunity to correct any errors in permit categories were generally positive. Some comments stated that the 10 calendar days should be business days to provide a more adequate time frame for permit applicants to receive and check their permit. One commentor stated that permit category changes should be allowed up until NMFS finalizes the BFT Quota Specifications for each fishing year.

Response: The final action establishes a 10–calendar day window of opportunity to correct any errors in permit categories (e.g., if a permit is issued on July 1, then corrections to the permit category must be made by July 10). This action is intended to address the situation where permit applicants received a permit in the wrong category, due to applicant or administrative error, and are unable to change to the intended permit category. Ten calendar days provide enough time for permit applicants to obtain their permit, check

that it is the correct permit, and contact the NMFS permit contractor to affect a change. Extending the time period may begin to undermine the original intent of the regulation (i.e., restricting multiple permit category changes) if permit applicants are motivated to actively participate in more than one category per season.

Comment 4: Some comments stated that based on the system NMFS has in place for rapid curtailment of effort in the BFT fisheries, and due to the large amounts of inseason transfers made in the past, a large portion of the Reserve category quota for this season should be earmarked for the late season fishery off the south Atlantic states. The comments also stated this could be accomplished by changing the description of the Reserve category for this season to assure that a portion of the Reserve category quota is transferred to the General category in the late fall-early winter months.

Response: The final action will maintain the Reserve category description as stated in § 635.27 (a)(8). NMFS maintains the authority to transfer quota among categories or, as appropriate, subcategories throughout the fishing year. Prior to making any such transfers, NMFS has established a set of criteria that must be considered before performing an inseason transfer. The criteria are listed at § 635.27 (a)(7)(iii)(A)–(F).

Classification

These final initial BFT quota specifications, General category effort controls, and revisions to the HMS regulations are published under the authority of the Magnuson-Stevens Act and ATCA. The Assistant Administrator for Fisheries (AA) has determined that the regulations contained in this final rule are necessary to implement the recommendations of ICCAT and to manage the domestic Atlantic HMS fisheries.

NMFS prepared an Initial Regulatory Flexibility Analysis (IRFA) for the proposed rule and submitted it to the Chief Counsel for Advocacy of the Small Business Administration. No comments were received on the IRFA concerning the economic impact of this final rule. A summary of the Final Regulatory Flexibility Analysis (FRFA) is provided below.

The analysis for the FRFA assesses the impacts of the various alternatives on the vessels that participate in the BFT fisheries, all of which are considered small entities. In order to do this, NMFS has estimated the average impact that the alternative to establish the 2003 BFT quota for all domestic

fishing categories would have on individual categories and the vessels within those categories. As mentioned above, the 2002 ICCAT Recommendation increased the BFT quota allocation to 1,489.6 mt. This increase includes 77.6 mt to be redistributed to the domestic fishing categories based on the allocation percentages established in the HMS FMP, as well as a set-aside quota of 25 mt to account for incidental catch of BFT related to directed longline swordfish and BAYS (bigeve, albacore, yellowfin, skipjack) fisheries in the vicinity of the management area boundary. In 2002, the annual gross revenues from the commercial BFT fishery were approximately \$18 million. There are approximately 11,091 vessels that are permitted to land and sell BFT under four BFT quota categories. The four quota categories and their 2002 gross revenues are General (\$13,948,190), Harpoon (\$588,884), Purse Seine (\$3,066,034), and Incidental Longline (\$588,352). The analysis for the FRFA assumes that all category vessels have similar catch and gross revenues. While this may not be true, the analyses are sufficient to show the relative impact of the various final actions on vessels.

For the allocation of BFT quota among domestic fishing categories, two alternatives were considered: The final action that will allocate the ICCATrecommended quota to domestic categories in accordance with the 2002 ICCAT Recommendation and HMS FMP and the No Action alternative. Under ATCA, the United States is authorized to promulgate regulations as necessary and appropriate to implement ICCATapproved recommendations, except that no regulations may have the effect of increasing or decreasing any allocation or quota agreed to pursuant to an ICCAT Recommendation. The final action will increase the quota by 77.6 mt and will have positive impacts for fishermen. The No Action alternative was rejected because it was not consistent with the purpose and need for this action and the HMS FMP. The No Action alternative would maintain economic impacts to the United States and to local economies at a distribution and scale similar to 2002, but would deny fishermen additional fishing opportunities as recommended by the 2002 ICCAT Recommendation, inconsistent with ATCA. No other alternatives would meet the purpose and need for this action.

For the General category effort controls, three alternatives were considered: The final action to establish RFDs late in the season to provide a late

Fall, southern Atlantic fishery, designate RFDs according to a published schedule, and the No Action (no initial RFDs and publish a schedule during the season). The final action would have positive economic impacts to those south Atlantic fishermen, but could have potentially negative economic impacts to those northern area fishermen who would have otherwise caught and sold fish earlier in the season. These negative impacts will be slightly mitigated if northern area fishermen are willing to travel south late in the season. NMFS has selected this final action because extending the season as late as possible enhances the likelihood of increasing participation by southern area fishermen and increasing overall access to the fishery over a greater range of the fish migration. The impacts of designating RFDs according to a published schedule may vary according to the pace of the fishery. If catch rates are slow as in recent years, as is expected, scheduled RFDs may need to be waived which causes confusion and disrupts fishermen's activities, thus having negative economic impacts. Therefore, this alternative is rejected. The No Action alternative could have positive economic consequences if another season of low catch rates occurs. However, even with low catch rates and no RFDs, it is unlikely that there will be enough quota in the General category to sustain a late season commercial handgear fishery off south Atlantic states, thus negatively impacting south Atlantic fishermen. Therefore, this alternative is rejected.

For the permit revision issue, four alternatives were considered: The final action which allows General category vessels to participate in registered recreational HMS fishing tournaments, a final action which allows 10 calendar days from the date of issuance of the permit to change categories, No Action General category vessels cannot participate in recreational HMS fisheries and no permit changes are allowed once a permit has been issued), and allow dual permits and require declarations by General category vessels prior to every trip regarding which permit is to be used. The final action, which allows General category vessels to participate in registered recreational HMS tournaments, will have positive economic and social impacts by relieving a restriction on General category vessels. The final action also provides a 10-calendar day time period for permit changes due to errors which would have positive social and economic impacts. The No Action

alternative would have negative social and economic impacts because General category vessels would not be able to participate fully in recreational fishing tournaments, and because it would not allow permit category changes to correct errors. Therefore, this alternative is rejected. The alternative to allow dual permits would further liberalize the restriction and alleviate any negative economic impacts by allowing General category vessels to choose on any given day whether they wish to fish commercially or recreationally. However, there would be some administrative impacts to vessel owners/operators as they would have to declare with NMFS their intent before making a trip, and difficulties in monitoring and enforcing the declarations in real-time and providing multiple permits for the same vessel may end up causing more confusion within the fishery than alleviating any perceived negative economic impacts, thus this alternative is rejected. The final action that provides a 10-calendar day time period for permit changes due to errors would have positive economic impacts by allowing permit holders to fish in the manner intended.

For the definition of the management boundary area, four alternatives were considered: the final action which defines the area as the Northeast Distant (NED) area and will allow retention of the 25 mt quota of BFT with no target catch requirements, the No Action (no definition of the area and operational procedures would account for quota allocated to the area), defining the area as 5 degrees on both sides of the management boundary line, and defining the area as east of the management boundary line. All but the No Action alternative would restrict the quota to vessels participating in the NED experimental fishery. The final action will provide slight positive economic impacts by allowing more retention of incidentally caught BFT relative to the other alternatives because no target requirements will apply. Under the No Action alternative and the other two rejected alternatives, more BFT would likely be discarded than under the final action and negative economic impacts may occur due to lost revenues from discarded BFT.

None of the final actions in this document will result in additional reporting, record keeping, compliance, or monitoring requirements for the public.

NMFS prepared an EA for this final rule, and the AA has concluded that there would be no significant impact on the human environment. The EA presents analyses of the anticipated

impacts of these final actions and the alternatives considered. A copy of the EA and other analytical documents prepared for this rule, are available from NMFS (see ADDRESSES).

This final rule has been determined to be not significant for purposes of Executive Order 12866.

A Biological Opinion (BiOp) issued June 14, 2001, concluded that continued operation of the Atlantic pelagic longline fishery is likely to jeopardize the continued existence of endangered and threatened sea turtle species under NMFS jurisdiction. On July 9, 2002 (67 FR 45393), NMFS implemented the reasonable and prudent alternative required by the BiOp. None of the actions in this final rule would have any additional impact on sea turtles as these actions would not likely increase or decrease pelagic longline effort, nor are they expected to shift effort into other fishing areas. A memo concluding that no adverse effect would result from this action if implemented was submitted to the Office of Protected Resources on July 18, 2003. No comments were received that would alter that conclusion. No impacts are expected from this final action that would adversely affect the implementation of the requirements of the BiOp.

NMFS has determined that the final regulations would be implemented in a manner consistent to the maximum extent practicable with the enforceable policies of those Atlantic, Gulf of Mexico, and Caribbean coastal states that have approved coastal zone management programs. On July 15, 2003, the proposed regulations were submitted to the responsible state agencies for their review under Section 307 of the Coastal Zone Management Act. As of September 25, 2003, NOAA Fisheries has received six responses, all concurring with NOAA Fisheries consistency determination. Because no responses were received from other states, their concurrence is presumed.

The area in which this final action is planned has been identified as Essential Fish Habitat (EFH) for species managed by the New England Fishery
Management Council, the Mid-Atlantic Fishery Management Council, the South Atlantic Fishery Management Council, the Gulf of Mexico Fishery Management Council, the Caribbean Fishery
Management Council, and the HMS
Management Division of the Office of Sustainable Fisheries at NMFS. It is not anticipated that this action will have any adverse impacts to EFH and, therefore, no consultation is required.

List of Subjects in 50 CFR Part 635

Fisheries, Fishing, Fishing vessels, Foreign relations, Intergovernmental relations, Penalties, Reporting and recordkeeping requirements, Statistics, Treaties.

Dated: September 25, 2003.

John Oliver,

Deputy Assistant Administrator for Operations, National Marine Fisheries Service.

■ For the reasons set out in the preamble, 50 CFR part 635 is amended as follows:

PART 635—ATLANTIC HIGHLY MIGRATORY SPECIES

■ 1. The authority citation for part 635 continues to read as follows:

Authority: 16 U.S.C. 971 *et seq.*; 16 U.S.C. 1801 *et seq.*

■ 2. In § 635.4, paragraphs (c) and (j)(3) are revised to read as follows:

§ 635.4 Permits and fees.

k * * * *

(c) HMS Angling permits. (1) The owner of any vessel used to fish recreationally for Atlantic HMS or on which Atlantic HMS are retained or possessed recreationally, must obtain an HMS Angling permit, except as provided in § 635.4(c)(2). Atlantic HMS caught, retained, possessed, or landed by persons on board vessels with an HMS Angling permit may not be sold or transferred to any person for a commercial purpose. A vessel issued an HMS Angling permit for a fishing year shall not be issued an HMS Charter/ Headboat permit or an Atlantic Tunas permit in any category for that same fishing year, regardless of a change in the vessel's ownership.

(2) A vessel issued an Atlantic Tunas General category permit under paragraph (d) of this section may fish in a recreational HMS fishing tournament if the vessel has registered for, paid an entry fee to, and is fishing under the rules of a tournament that has notified NMFS as required under § 635.5(d). When a vessel issued an Atlantic Tunas General category permit is fishing in such a tournament, such vessel must comply with HMS Angling category regulations, except as provided in 635.4(c)(3).

(3) A vessel issued an Atlantic Tunas General category permit fishing in a tournament, as authorized under § 635.4(c)(2), shall comply with Atlantic Tunas General category regulations when fishing for, retaining, possessing, or landing Atlantic tunas.

(j) * * *

- (3) Except for Atlantic Tunas Longline and Purse Seine category permits, a vessel owner issued a permit under paragraphs (b), (c), or (d) of this section may change the category of the vessel's permit within 10–calendar days of the date of issuance of the permit. Beyond 10 calendar days after the date of issuance of the permit, no permit category changes may be made.
- 3. In § 635.23, paragraph (f)(3) is added to read as follows:

§ 635.23 Retention limits for BFT.

* * * * * * (f) * * *

(3) For pelagic longline vessels participating in an experimental fishery in the Northeast distant area, as defined under § 635.2 of this part, under exempted fishing permits issued under § 635.32 of this part, all BFT taken incidental to fishing for other species while in the Northeast distant area may be retained up to a maximum of 25 mt for all vessels so authorized, notwithstanding the retention limits and target catch requirements specified in paragraph (f)(1) of this section. Once the 25 mt limit is attained, the retention limits and target catch requirements specified in paragraph (f)(1) of this section or as adjusted pursuant to paragraph (f)(2) of this section will apply to such vessels. * * *

■ 4. In \S 635.27, paragraph (a)(3) is revised to read as follows:

§ 635.27 Quotas.

(a) * * *

(3) Longline category quota. The total amount of large medium and giant BFT that may be caught incidentally and retained, possessed, or landed by vessels for which Longline category Atlantic tunas permits have been issued is 8.1 percent of the overall U.S. BFT quota. In the initial quota specifications issued under paragraph (a) of this section, no more than 60.0 percent of the Longline category quota may be allocated for landing in the area south of 31° 00': N. lat. In addition, 25 mt shall be allocated for incidental catch by pelagic longline vessels participating in an experimental fishery in the Northeast distant area, as defined under § 635.2 of this part, under exempted fishing permits issued under § 635.32.

■ 5. In § 635.71, new paragraph (b)(29) is added to read as follows:

§ 635.71 Prohibitions.

* * * * *

(b) * * *

(29) Participate in any HMS recreational fishing activity aboard a vessel issued an Atlantic Tunas General category permit unless, as specified at § 635.4(c)(2) and (3), the vessel has registered and paid an entry fee to, and is fishing under the rules of, a recreational HMS fishing tournament registered as required under § 635.5(d).

[FR Doc. 03–24930 Filed 10–1–03; 8:45 am]

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

50 CFR Part 679

[Docket No. 021122286-3036-02; I.D. 092403G]

Fisheries of the Economic Exclusive Zone Off Alaska; Groundfish Fisheries by Vessels using Hook-and-Line Gear in the Gulf of Alaska

AGENCY: National Marine Fisheries Service (NMFS), NationalOceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Closure.

SUMMARY: NMFS is prohibiting directed fishing for groundfish by vessels using hook-and-line gear in the Gulf of Alaska (GOA), except for demersal shelf rockfish in the Southeast Outside District or sablefish. This action is necessary because the 2003 bycatch mortality allowance of Pacific halibut apportioned to hook-and-line gear targeting groundfish other than demersal shelf rockfish in the Southeast Outside District or sablefish has been reached.

DATES: Effective 1200 hrs, Alaska local time (A.l.t.), September 28, 2003, until 2400 hrs, A.l.t., December 31, 2003.

FOR FURTHER INFORMATION CONTACT: Mary Furuness, 907–586–7228.

SUPPLEMENTARY INFORMATION: NMFS manages the groundfish fishery in the GOA exclusive economic zone according to the Fishery Management Plan for Groundfish of the Gulf of Alaska (FMP) prepared by the North Pacific Fishery Management Council under authority of the Magnuson-Stevens Fishery Conservation and Management Act. Regulations governing fishing by U.S. vessels in accordance with the FMP appear at subpart H of 50 CFR part 600 and 50 CFR part 679.

The Pacific halibut bycatch mortality allowance for groundfish included in the other hook-and-line fishery, defined at § 679.21(d)(4)(iii)(C), was established by the final 2003 harvest specifications for groundfish of the GOA (68 FR 9924, March 3, 2003) as 290 metric tons. The other hook-and-line fishery includes all groundfish except for demersal shelf rockfish in the Southeast Outside District or sablefish.

In accordance with § 679.21(d)(7)(ii), the Administrator, Alaska Region, NMFS, has determined that the 2003 Pacific halibut bycatch mortality allowance specified for the other hookand-line fishery has been reached. Consequently, NMFS is prohibiting directed fishing for groundfish other than demersal shelf rockfish in the Southeast Outside District or sablefish by vessels using hook-and-line gear.

Maximum retainable amounts may be found in the regulations at § 679.20(e) and (f).

Classification

This action responds to the best available information recently obtained from the fishery. The Assistant Administrator for Fisheries, NOAA (AA), finds good cause to waive the requirement to provide prior notice and opportunity for public comment pursuant to the authority set forth at 5 U.S.C. 553(b)(B) as such requirement is contrary to the public interest. This requirement is contrary to the public interest as it would delay the closure of the fishery, lead to exceeding the 2003 bycatch mortality allowance of Pacific halibut apportioned to hook-and-line gear, and therefore reduce the public's ability to use and enjoy the fishery resource.

The AA also finds good cause to waive the 30–day delay in the effective date of this action under 5 U.S.C. 553(d)(3). This finding is based upon the reasons provided above for waiver of prior notice and opportunity for public comment.

This action is required by § 679.21 and is exempt from review under Executive Order 12866.

Authority: 16 U.S.C. 1801 et seq.

Dated: September 25, 2003.

Bruce C. Morehead,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service. [FR Doc. 03–24922 Filed 9–26–03; 3:54 pm]

BILLING CODE 3510-22-S

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

50 CFR Part 697

[Docket No. 030617155-3232-02; I.D. 051903D]

RIN 0648-AR11

Atlantic Coastal Fisheries Cooperative Management Act Provisions; Weakfish Fishery

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Final rule.

SUMMARY: NMFS issues this final rule to increase the incidental catch allowance for weakfish caught in the Exclusive Economic Zone (EEZ) from 150 lb (67 kg) to no more than 300 lb (135 kg) per day or trip, whichever is longer in duration; to remove Connecticut from the list of states where commercially caught weakfish from the EEZ can be landed; and to add to NMFS' regulations the Director, Office of Sustainable Fisheries, as an official who can grant Exempted Fishing Permits. The intent of this final rule is to modify regulations for the Atlantic coast stock of weakfish to promote the effectiveness of the Atlantic States Marine Fisheries Commission's (Commission) Interstate Fishery Management Plan (ISFMP) for weakfish.

DATES: Effective November 3, 2003. Copies of supporting documents, including an Environmental Assessment/Regulatory Impact Review/Final Regulatory Flexibility Analysis (EA/RIR/FRFA).

ADDRESSES: are available from Anne Lange, Chief, State-Federal Fisheries Division (SF8), Office of Sustainable Fisheries, National Marine Fisheries Service, 1315 East-West Highway, Suite 13317, Silver Spring, MD 20910.

FOR FURTHER INFORMATION CONTACT: Tom Meyer, 301–713–2334.

SUPPLEMENTARY INFORMATION:

Background

The background and rationale for this final rule were contained in the preamble to the proposed rule, published in the **Federal Register** on July 1, 2003 (68 FR 39048), and are not repeated here. Additional background for this final rule is available and contained in a EA/RIR/FRFA prepared by NMFS. (See **ADDRESSES**).

This final rule allows vessels using a mesh size less than 3 1/4-inch (8.3 cm)

square stretch mesh or 3 3/4-inch (9.5 cm) diamond stretch mesh for trawls and 2 7/8-inch (7.3 cm) stretch mesh for gillnets to possess no more than 300 lb (135 kg) of weakfish during any one day or trip, whichever is longer in duration (an increase of 150 lb (67 kg)) per day or trip over the current Federal EEZ regulation)(§ 697.7(a)(4)); removes the State of Connecticut from the list of states where weakfish caught in the EEZ for commercial purposes can be landed (§ 697.7(a)(7)); adds to NMFS' regulations the Director, Office of Sustainable Fisheries, as an official who can grant Exempted Fishing Permits (§ 697.22); and adds Atlantic Coastal Act and Director to the definition section (§697.2).

Comments and Responses

There was one comment submitted by a state agency during the comment period.

1. Comment: One state agency that is currently a de minimis state under Amendment 4 to the weakfish plan commented that the regulation (§ 697.7(a)(7)) that does not allow landings of weakfish from the EEZ in a de minimis state is not enforceable and should be re-considered, because it is impossible to determine where the fish were harvested when a vessel comes to port. As an alternative to this unnecessary rule, the state suggested that it could easily adopt trip limits (300 lb) to ensure that the state does not become a destination for unlawful catches of weakfish.

Response: Although enforcement of the regulation pertaining to a de minimis state does create certain challenges, NMFS declines to categorize the regulation as unenforceable. This regulation was implemented in 1997, after the Commission specifically requested that the de minimis language be included in the EEZ rule in order to support Commission efforts in state waters. The Commission also requested in 1997 that any enforcement problems raised by this regulation be forwarded to the Commission's Weakfish Management Board (Weakfish Board); none have been. The Commission recommended in 2003 that this regulation remain in place. The present restrictions on commercial landings in a de minimis state, therefore, remain the Commission's stated regulatory preference. Given the Commission's stated preference, the lack of information and debate suggesting that an alternative approach is necessary, and NMFS's mandate under the Atlantic Coastal Act to support the Commission's interstate fishery management efforts, NMFS remains committed to the present

Commission approach. However, NMFS notes the state agency may request that the Weakfish Board reconsider the enforcement concerns associated with this regulation. The adoption by any *de minimis* state of a trip limit of 300 lbs (135 kg) could be part of the discussion. NMFS would consider any additional recommendations from the Commission that may arise from such discussions.

Changes from the Proposed Rule

In its comment letter dated July 9, 2003, the Commonwealth of Massachusetts indicated its intention to withdraw itself from *de minimis* status under the current management regime due to the difficulty that state would have in codifying and enforcing its de minimis status. The process of withdrawal from de minimis status is far less complicated than inclusion into such a category. The state would upon approval of the withdrawal be expected to comply with all regulatory responsibilities of the plan, whereas it would be exempted from some responsibilities as a de minimis state. On July 16, 2003, the Commonwealth of Massachusetts requested that the Commission remove them from de mininis state status. On August 29, 2003, the Weakfish Board recommended and the Commission agreed to withdraw their finding that Massachusetts be given de minimis status. Under either status — that is, as a de minimis state or not — the actions of Massachusetts are not expected to contribute significantly to the Commission's coastwide conservation program for the species. Accordingly, NMFS is able to support the Commission's change on this matter and add the Commonwealth of Massachusetts to the list of states where commercially caught weakfish from the EEZ can be landed in the final rule at 50 CFR 697.7(a)(7) because it is no longer considered de minimis.

In the proposed rule, the term Director was added as an official who can grant Exempted Fishing Permits, but the term Director was not defined. This final rule adds the term Director to the definition section (§ 697.2), and defines it as the Director, Office of Sustainable Fisheries, 1315 East-West Highway, Silver Spring, MD 20910.

Classification

This final rule is published under the authority of the Atlantic Coastal Act. Paragraphs (A) and (B) of section 804(b)(1) authorizes the Secretary to implement regulations in the EEZ in the absence of a Magnuson-Stevens Act FMP. Such regulations must be compatible with the effective implementation of a Commission's

ISFMP, and consistent with the national standards set forth in section 301 of the Magnuson-Stevens Act.

The Assistant Administrator for Fisheries, NOAA (AA) has determined that these actions are compatible with the effective implementation of the Commission's ISFMP for Weakfish and consistent with the national standards of the Magnuson-Stevens Fishery Conservation and Management Act.

NMFS did not receive any comments on the economic impacts of the rule. NMFS prepared a final regulatory flexibility analysis (FRFA) that describes the impact of this final rule on small entities. A summary of the FRFA follows:

This final rule is published under the authority of section 803 of the Atlantic Coastal Act. The purpose of the rule is to improve cooperative management of the Atlantic coast weakfish fishery by supporting the Commission's Amendment 4 to the Interstate Fishery Management Plan for Weakfish, as required under the Atlantic Coastal Act. This rule will increase the permitted non-directed incidental catch of the species from 150 lb (67 kg) to no more than 300 lb (135 kg) per day or trip. Analysis of the best available data in the EA/RIR/FRFA suggests that the increase would not alter current fishing practices or effort, or increase the number of weakfish caught. The 150-lb (67 kg) increase would simply convert 150 lb (67 kg) of weakfish, which would be caught and discarded at sea as dead bycatch, into 150 lb (67 kg) of weakfish caught as incidental catch and landed. The need for the action was explained in the preamble to the proposed rule and is not repeated here.

Two alternatives were considered for this action. They were: Alternative 1: No Action; and Alternative 2 (Preferred Alternative): Allow vessels in nondirected fisheries, using mesh sizes less than 3 1/4-inch (8.3 cm) square stretch mesh or 3 3/4-inch (9.5 cm) diamond stretch mesh for trawls and 2 7/8-inch (7.3 cm) stretch mesh for gillnets to possess no more than 300 lb (135 kg) of weakfish during any one day or trip, whichever is longer in duration. Although a third alternative was identified in the environmental assessment, it would not meet the goals and objectives of the Commission's recommendation. Because the Secretary is required to develop and implement a program to support the Commission's action, analysis of this additional alternative would not meet the purpose and need for this action, or objectives of the Atlantic Coastal Act.

The preferred alternative would allow vessels in non-directed fisheries, using

a mesh size less than 3 1/4-inch (8.3 cm) square stretch mesh or 3 3/4-inch (9.5 cm) diamond stretch mesh for trawls and 2 7/8-inch (7.3 cm) stretch mesh for gillnets, to possess no more than 300 lb (135 kg) of weakfish during any one day or trip, whichever is longer in duration (an increase of 150 lb (67 kg)).

NMFS is not able to estimate the number of small entities to which the action would apply because vessels most likely to be impacted are not required to hold a permit to fish for weakfish in the EEZ. In the proposed rule, NMFS requested specifically that the public comment on the number of small entities likely to be affected. However, NMFS did not receive any information pertaining to the number of small entities and is therefore not able to estimate further the number of entities to which this rule will apply. Although the number of small entities cannot be estimated, NMFS believes the action would only apply to those fishermen who capture weakfish incidentally while fishing for other species using a smaller mesh size than is allowed in the directed weakfish fishery. In addition, under Alternative 1, status quo, no additional small entities would be impacted; while implementation of Alternative 2 would apply to fishermen who use nets with smaller mesh sizes and catch over 150 lb (67 kg) of weakfish on a given day or trip. During 1998 - 2002, vessel trip reports indicated that only 1,116 small mesh otter trawl trips and 4 small mesh gillnet trips landed weakfish caught while fishing in the EEZ. The average price received by fishermen reporting weakfish catch in the EEZ in 2001 was \$0.614 per lb. If an affected vessel were to land 150 lb (67 kg) of weakfish, as currently permitted (Alternative 1), \$92 in revenue could be realized, per trip. If Alternative 2 were implemented, an additional \$92 in revenue, for a weakfish total of \$184 per trip (double the current amount) would be possible. For a more accurate picture of the expected economic impacts for the two alternatives, actual catches from individual vessel trip records, from 1998 - 2002, were multiplied by average price-per-pound of weakfish from the EEZ to determine estimated revenues per trip. Since vessels may not catch the full 150 lb (67 kg) or 300 lb (135 kg) allowed in Alternative 1 and 2, revenues for each Alternative were projected as the average for those trips that reported from 1 to 150 lb (67 kg) (Alternative 1) and from 151 to 300 lb (135 kg) (Alternative 2). Catches from trips that

reported over 300 lb (135 kg) were

capped at the 300 lb (135 kg) proposed limit (Alternative 2) for these calculations. Calculated revenues for sale of allowed weakfish landings under Alternative 1 averaged \$22; potential revenues for Alternative 2 were estimated at \$160 per trip. Based on 1998 - 2002 vessel trip data, total annual revenues for all non-directed weakfish trips, coastwide are projected to be about \$6,200 under Alternative 1, and about \$7,800, if Alternative 2 were to be implemented. A copy of the FRFA is available from NMFS (see ADDRESSES).

There will be no reporting and recordkeeping requirements resulting from this action.

This final rule has been determined to be not significant for purposes of Executive Order 12866.

List of Subjects in 50 CFR Part 697

Fisheries, Fishing.

Dated: September 24, 2003.

Rebecca Lent,

Deputy Assistant Administrator for Regulatory Programs, National Marine Fisheries Service.

■ For the reasons set out in the preamble, 50 CFR chapter VI, part 697, is amended as follows:

PART 697—ATLANTIC COASTAL FISHERIES COOPERATIVE MANAGEMENT

■ 1. The authority citation for part 697 is revised to read as follows:

Authority: 16 U.S.C. 5101 et seq.

■ 2. In § 697.2, the definitions for "Atlantic Coastal Act" and "Director" are added in alphabetical order to read as follows:

§ 697.2 Definitions.

Atlantic Coastal Act means the Atlantic Coastal Fisheries Cooperative Management Act, as amended (16 U.S.C. 5101 et seq.).

Director means the Director of the Office of Sustainable Fisheries, 1315 East-West Highway, Silver Spring, MD

■ 3. Section 697.7, paragraph (a)(4) and (a)(7) are revised to read as follows:

§ 697.7 Prohibitions.

(a) * * *

20910

(4) Possess more than 300 lb (135 kg) of weakfish during any one day or trip, whichever is longer, in the EEZ when using a mesh size less than 3 1/4—inch (8.3 cm) square stretch mesh (as measured between the centers of opposite knots when stretched taut) or

- 3 3/4–inch (9.5 cm) diamond stretch mesh for finfish trawls and 2 7/8–inch (7.3 cm) stretch mesh for gillnets.
- (7) Land weakfish for commercial purposes caught in the EEZ in any state other than Massachusetts, Rhode Island, New York, New Jersey, Delaware, Maryland, Virginia, or North Carolina.
- 4. Section 697.22 is revised to read as follows:

§ 697.22 Exempted fishing.

The Regional Administrator or Director may exempt any person or vessel from the requirements of this part for the conduct of exempted fishing beneficial to the management of the American lobster, weakfish, Atlantic striped bass, Atlantic sturgeon, or horseshoe crab resource or fishery, pursuant to the provisions of '600.745 of this chapter.

(a) The Regional Administrator or Director may not grant such exemption unless it is determined that the purpose, design, and administration of the exemption is consistent with the objectives of any applicable stock rebuilding program, the provisions of the Atlantic Coastal Act, the Magnuson-Stevens Act, and other applicable law, and that granting the exemption will not:

(1) Have a detrimental effect on the American lobster, Atlantic striped bass, weakfish, Atlantic sturgeon, or horseshoe crab resource or fishery; or

- (2) Create significant enforcement problems.
- (b) Each vessel participating in any exempted fishing activity is subject to all provisions of this part, except those explicitly relating to the purpose and nature of the exemption. The exemption will be specified in a letter issued by the Regional Administrator or Director to each vessel participating in the exempted activity. This letter must be carried aboard the vessel seeking the benefit of such exemption. Exempted fishing activity shall be authorized pursuant to and consistent with § 600.745 of this chapter.

[FR Doc. 03-25025 Filed 10-1-03; 8:45 am]

BILLING CODE 3510-22-S

Proposed Rules

Federal Register

Vol. 68, No. 191

Thursday, October 2, 2003

This section of the FEDERAL REGISTER contains notices to the public of the proposed issuance of rules and regulations. The purpose of these notices is to give interested persons an opportunity to participate in the rule making prior to the adoption of the final rules.

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. 2002-NM-61-AD]

RIN 2120-AA64

Airworthiness Directives; Airbus Model A319–113 and –114; and A320–111, –211, and –212 Series Airplanes

AGENCY: Federal Aviation Administration, DOT.

ACTION: Notice of proposed rulemaking

(NPRM).

SUMMARY: This document proposes the adoption of a new airworthiness directive (AD) that is applicable to all Airbus Model A319-113 and -114; and A320–111, –211, and –212 series airplanes. This proposal would require either a review of airplane maintenance or delivery records, or one-time inspection of the hydraulic actuators located in the pivot doors of both thrust reversers to identify the part number, and eventual replacement of certain actuators with modified or new actuators. This action is necessary to prevent jamming of a thrust reverser door during operation, or inadvertent deployment of a thrust reverser door inflight, which could result in reduced controllability of the airplane. This action is intended to address the identified unsafe condition.

DATES: Comments must be received by November 3, 2003.

ADDRESSES: Submit comments in triplicate to the Federal Aviation Administration (FAA), Transport Airplane Directorate, ANM–114, Attention: Rules Docket No. 2002–NM–61–AD, 1601 Lind Avenue, SW., Renton, Washington 98055–4056. Comments may be inspected at this location between 9 a.m. and 3 p.m., Monday through Friday, except Federal holidays. Comments may be submitted via fax to (425) 227–1232. Comments may also be sent via the Internet using the following address: 9–anm–

nprmcomment@faa.gov. Comments sent via fax or the Internet must contain "Docket No. 2002–NM–61–AD" in the subject line and need not be submitted in triplicate. Comments sent via the Internet as attached electronic files must be formatted in Microsoft Word 97 or 2000 or ASCII text.

The service information referenced in the proposed rule may be obtained from Airbus Industrie, 1 Rond Point Maurice Bellonte, 31707 Blagnac Cedex, France. This information may be examined at the FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington.

FOR FURTHER INFORMATION CONTACT: Tim Dulin, Aerospace Engineer, International Branch, ANM-116, FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington 98055-4056; telephone (425) 227-2141; fax (425) 227-1149.

SUPPLEMENTARY INFORMATION:

Comments Invited

Interested persons are invited to participate in the making of the proposed rule by submitting such written data, views, or arguments as they may desire. Communications shall identify the Rules Docket number and be submitted in triplicate to the address specified above. All communications received on or before the closing date for comments, specified above, will be considered before taking action on the proposed rule. The proposals contained in this action may be changed in light of the comments received.

Submit comments using the following format:

- Organize comments issue-by-issue. For example, discuss a request to change the compliance time and a request to change the service bulletin reference as two separate issues.
- For each issue, state what specific change to the proposed AD is being requested.
- Include justification (e.g., reasons or data) for each request.

Comments are specifically invited on the overall regulatory, economic, environmental, and energy aspects of the proposed rule. All comments submitted will be available, both before and after the closing date for comments, in the Rules Docket for examination by interested persons. A report summarizing each FAA-public contact concerned with the substance of this

proposal will be filed in the Rules Docket.

Commenters wishing the FAA to acknowledge receipt of their comments submitted in response to this action must submit a self-addressed, stamped postcard on which the following statement is made: "Comments to Docket Number 2002–NM–61–AD." The postcard will be date stamped and returned to the commenter.

Availability of NPRMs

Any person may obtain a copy of this NPRM by submitting a request to the FAA, Transport Airplane Directorate, ANM–114, Attention: Rules Docket No. 2002–NM–61–AD, 1601 Lind Avenue, SW., Renton, Washington 98055–4056.

Discussion

The Direction Générale de l'Aviation Civile (DGAC), which is the airworthiness authority for France, notified the FAA that an unsafe condition may exist on certain Airbus Model A319-113 and -114; and A320-111, -211, and -212 series airplanes. The DGAC advises that certain hydraulic actuators of the thrust reverser system failed endurance testing. Some of these actuators are inservice and may be approaching or may have already exceeded the life limits established during qualification. The use of actuators that have exceeded the established life limits, if not corrected, could result in jamming of the thrust reverser door during operation, or inadvertent deployment of a thrust reverser door in-flight, which could result in reduced controllability of the

Explanation of Relevant Service Information

Airbus has issued Service Bulletin A320-78-1020, including Appendix 01, dated March 28, 2001, which describes procedures for inspecting actuators located in the pivot doors of both thrust reversers to determine the part number, and replacing certain actuators with new or modified actuators. This service bulletin references Rohr CFM56-5A Service Bulletin RA32078-106, dated November 16, 2000, as an additional source of service information for accomplishment of the actuator modification. Accomplishment of the actions specified in the Airbus service bulletin is intended to adequately address the identified unsafe condition.

The DGAC classified the Airbus service bulletin as mandatory and issued French airworthiness directive 2001–361(B) R1, dated September 3, 2003, to ensure the continued airworthiness of these airplanes in France.

FAA's Conclusions

These airplane models are manufactured in France and are type certificated for operation in the United States under the provisions of § 21.29 of the Federal Aviation Regulations (14 CFR 21.29) and the applicable bilateral airworthiness agreement. Pursuant to this bilateral airworthiness agreement, the DGAC has kept the FAA informed of the situation described above. The FAA has examined the findings of the DGAC, reviewed all available information, and determined that AD action is necessary for products of this type design that are certificated for operation in the United States.

Explanation of Requirements of Proposed AD

Since an unsafe condition has been identified that is likely to exist or develop on other airplanes of the same type design registered in the United States, the proposed AD would require accomplishment of the actions specified in the Airbus service bulletin described previously, except as discussed below.

Differences Between the Proposed AD and the French Airworthiness Directive

Operators should note that the parallel French airworthiness directive requires replacement of certain actuators within either 250 airplane flight cycles or 500 airplane flight cycles after the part number identification, depending on whether the actuator has accumulated more than 20,000 total flight cycles or fewer than 20,000 total flight cycles, respectively. However, after consultation with Airbus and the DGAC, the FAA has determined that these actuators can be safely operated up to 20,000 total flight cycles. Therefore, we find that accomplishment of the actuator replacement prior to the accumulation of 20,000 flight cycles, or within 250 flight cycles after identification of the part number, whichever occurs later, represents an appropriate interval of time allowable for affected airplanes to continue to operate without compromising safety. The DGAC has been notified of this difference.

Also, the French airworthiness directive specifies the replacement times for the actuators in terms of actuator flight cycles. Operators might not track actuator flight cycles;

therefore, for the purposes of this proposed AD, if operators do not have a means of obtaining information regarding actuator flight cycles, engine flight cycles must be used.

Clarification of Applicability

Because operators can remove and install thrust reversers and engines on various airplanes in their fleet, this proposed AD would require either a review of airplane maintenance or delivery records, or a detailed inspection of the hydraulic actuators located in the pivot doors of the thrust reversers on all Airbus Model A319–113 and 114; and A320–111, -211, and -212 series airplanes, to ensure that all actuators are identified.

Cost Impact

The FAA estimates that 108 airplanes of U.S. registry would be affected by this proposed AD, that it would take approximately 8 work hours per airplane to accomplish the proposed inspection (1 hour per actuator × 4 actuators per thrust reverser × 2 thrust reversers per airplane), and that the average labor rate is \$65 per work hour. Based on these figures, the cost impact of the proposed AD on U.S. operators is estimated to be \$56,160, or \$520 per airplane.

The cost impact figure discussed above is based on assumptions that no operator has yet accomplished any of the proposed requirements of this AD action, and that no operator would accomplish those actions in the future if this AD were not adopted. The cost impact figures discussed in AD rulemaking actions represent only the time necessary to perform the specific actions actually required by the AD. These figures typically do not include incidental costs, such as the time required to gain access and close up, planning time, or time necessitated by other administrative actions.

Regulatory Impact

The regulations proposed herein would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, it is determined that this proposal would not have federalism implications under Executive Order 13132.

For the reasons discussed above, I certify that this proposed regulation (1) is not a "significant regulatory action" under Executive Order 12866; (2) is not a "significant rule" under the DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and (3) if

promulgated, will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act. A copy of the draft regulatory evaluation prepared for this action is contained in the Rules Docket. A copy of it may be obtained by contacting the Rules Docket at the location provided under the caption ADDRESSES.

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Proposed Amendment

Accordingly, pursuant to the authority delegated to me by the Administrator, the Federal Aviation Administration proposes to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. Section 39.13 is amended by adding the following new airworthiness directive:

Airbus: Docket 2002-NM-61-AD.

Applicability: All Model A319–113 and -114; and A320–111, -211, and -212 series airplanes; certificated in any category.

Compliance: Required as indicated, unless accomplished previously.

To prevent jamming of the thrust reverser door during operation or inadvertent deployment of a thrust reverser door inflight, which could result in reduced controllability of the airplane, accomplish the following:

Inspection and Follow-on Actions

(a) Within 500 airplane flight cycles after the effective date of this AD: Do a detailed inspection of the eight hydraulic actuators located in the pivot doors of the thrust reversers (one actuator per pivot door, four pivot doors per thrust reverser, two thrust reversers per airplane) to identify the part number (P/N) of each actuator, in accordance with Airbus Service Bulletin A320-78-1020, excluding Appendix 01, dated March 28, 2001. Instead of a detailed inspection of the hydraulic actuators, a review of airplane maintenance and delivery records is acceptable if the P/N of each actuator installed on the airplane can be positively determined from that review.

Note 1: For the purposes of this AD, a detailed inspection is defined as: "An intensive visual examination of a specific structural area, system, installation, or assembly to detect damage, failure, or irregularity. Available lighting is normally supplemented with a direct source of good

lighting at intensity deemed appropriate by the inspector. Inspection aids such as mirror, magnifying lenses, etc., may be used. Surface cleaning and elaborate access procedures may be required."

- (1) For any actuator having P/Ns D23090000-1, D23090000-2, D23090000-3, or D23090000-4: Prior to the accumulation of 20,000 total actuator flight cycles, or within 250 airplane flight cycles after accomplishment of the detailed inspection or airplane records review required by paragraph (a) of this AD, whichever occurs later, replace the actuator with a modified or new actuator having part number D23090000-5 or D23090000-6, in accordance with the service bulletin.
- (2) For any actuator having P/N D23090000–5: Prior to the accumulation of 30,000 total actuator flight cycles, or within 250 airplane flight cycles after the detailed inspection or airplane records review required by paragraph (a) of this AD, whichever occurs later, replace the actuator with a modified or new actuator having P/N D23090000–6, in accordance with the service bulletin.
- (3) For any actuator having P/N D23090000–6: No further action is required by this paragraph.

Note 2: Airbus Service Bulletin A320–78–1020 references Rohr CFM56–5A Service Bulletin RA32078–106, dated November 16, 2000, as an additional source of service information for modification of the actuators.

- (b) Once all of the actuators located in the pivot doors of the thrust reversers have P/N D23090000–6, no further action is required by paragraph (a) of this AD.
- (c) For operators that do not track actuator flight cycles, or do not have a means of obtaining information regarding actuator flight cycles, engine flight cycles must be used instead of actuator flight cycles.

Parts Installation

(d) As of the effective date of this AD, no person shall install an actuator having P/N D23090000–1, D23090000–2, D23090000–3, or D23090000–4 on any airplane.

Submission of Inspection Results to Manufacturer Not Required

(e) Although the service bulletin referenced in this AD specifies to submit information to the manufacturer, this AD does not include such a requirement.

Alternative Methods of Compliance

(f) In accordance with 14 CFR 39.19, the Manager, International Branch, ANM–116, FAA, Transport Airplane Directorate, is authorized to approve alternative methods of compliance for this AD.

Note 3: The subject of this AD is addressed in French airworthiness directive 2001–361(B) R1, dated September 3, 2003.

Issued in Renton, Washington, on September 26, 2003.

Ali Bahrami,

Acting Manager, Transport Airplane Directorate, Aircraft Certification Service. [FR Doc. 03–24973 Filed 10–1–03; 8:45 am] BILLING CODE 4910–13–P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. 2003-NM-31-AD]

RIN 2120-AA64

Airworthiness Directives; McDonnell Douglas Model DC9–15 Airplane

AGENCY: Federal Aviation Administration, DOT.

ACTION: Notice of proposed rulemaking (NPRM).

SUMMARY: This document proposes the adoption of a new airworthiness directive (AD) that is applicable to a McDonnell Douglas Model DC9-15 airplane. This proposal would require an inspection to detect chafing or overheat damage of the electrical wires located at fuselage station Y=110.000 bulkhead of the lower nose left tunnel; and corrective actions, if necessary. This AD also requires replacing the external power ground stud with a new ground stud using new attaching parts, torquing new attachments, and installing a nameplate. This action is necessary to prevent loose external power ground wires, which could cause arcing and overheated wire insulation and consequent smoke/fire in the cockpit. This action is intended to address the identified unsafe condition.

DATES: Comments must be received by November 17, 2003.

ADDRESSES: Submit comments in triplicate to the Federal Aviation Administration (FAA), Transport Airplane Directorate, ANM-114, Attention: Rules Docket No. 2003-NM-31-AD, 1601 Lind Avenue, SW., Renton, Washington 98055-4056. Comments may be inspected at this location between 9 a.m. and 3 p.m., Monday through Friday, except Federal holidays. Comments may be submitted via fax to (425) 227-1232. Comments may also be sent via the Internet using the following address: 9-anmnprmcomment@faa.gov. Comments sent via fax or the Internet must contain "Docket No. 2003-NM-31-AD" in the subject line and need not be submitted in triplicate. Comments sent via the Internet as attached electronic files must be formatted in Microsoft Word 97 or 2000 or ASCII text.

The service information referenced in the proposed rule may be obtained from Boeing Commercial Aircraft Group, Long Beach Division, 3855 Lakewood Boulevard, Long Beach, California 90846, Attention: Data and Service Management, Dept. C1–L5A (D800– 0024). This information may be examined at the FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington; or at the FAA, Los Angeles Aircraft Certification Office, 3960 Paramount Boulevard, Lakewood, California.

FOR FURTHER INFORMATION CONTACT: Elvin Wheeler, Aerospace Engineer, Systems and Equipment Branch, ANM– 130L, FAA, Los Angeles Aircraft Certification Office, 3960 Paramount Boulevard, Lakewood, California 90712–4137; telephone (562) 627–5344; fax (562) 627–5210.

SUPPLEMENTARY INFORMATION:

Comments Invited

Interested persons are invited to participate in the making of the proposed rule by submitting such written data, views, or arguments as they may desire. Communications shall identify the Rules Docket number and be submitted in triplicate to the address specified above. All communications received on or before the closing date for comments, specified above, will be considered before taking action on the proposed rule. The proposals contained in this action may be changed in light of the comments received.

Submit comments using the following format:

- Organize comments issue-by-issue. For example, discuss a request to change the compliance time and a request to change the service bulletin reference as two separate issues.
- For each issue, state what specific change to the proposed AD is being requested.
- Include justification (*e.g.*, reasons or data) for each request.

Comments are specifically invited on the overall regulatory, economic, environmental, and energy aspects of the proposed rule. All comments submitted will be available, both before and after the closing date for comments, in the Rules Docket for examination by interested persons. A report summarizing each FAA-public contact concerned with the substance of this proposal will be filed in the Rules Docket.

Commenters wishing the FAA to acknowledge receipt of their comments submitted in response to this action must submit a self-addressed, stamped postcard on which the following statement is made: "Comments to Docket Number 2003–NM–31–AD." The postcard will be date stamped and returned to the commenter.

Availability of NPRMs

Any person may obtain a copy of this NPRM by submitting a request to the

FAA, Transport Airplane Directorate, ANM-114, Attention: Rules Docket No. 2003-NM-31-AD, 1601 Lind Avenue, SW., Renton, Washington 98055-4056.

Discussion

The FAA has received reports of loose external power ground wires at the ground stud located in the lower nose left tunnel at fuselage station Y=110.00 bulkhead on certain McDonnell Douglas Model DC-9–82 airplanes. The cause of such loose wires has been attributed to ground stud buildup loosening due to normal airplane vibration. This condition, if not corrected, could result in arcing and overheated wire insulation and consequent smoke/fire in the cockpit.

Other Relevant Rulemaking

We have previously issued AD 2001–24–19, amendment 39–12536 (66 FR 64125, December 12, 2001), applicable to certain McDonnell Douglas airplane models, as follows:

McDonnell Douglas Models DC-9-10, DC-9-20, DC-9-30, DC-9-40, and DC-9-50 series airplanes C-9 airplanes DC-9-81, DC-9-82, DC-9-83, and DC-9-87 airplanes MD-88 airplanes

That AD requires an inspection to detect chafing or overheat damage of the electrical wires located at fuselage station Y=110.000 bulkhead of the lower nose left tunnel; and corrective actions, if necessary. That AD also requires replacing the external power ground stud with a new ground stud using new attaching parts, torquing new attachments, and installing a nameplate. That AD was prompted by reports of loose external power ground wires at the ground stud located in the lower nose left tunnel at fuselage station Y=110.00 bulkhead on McDonnell Douglas Model DC-9-82 series airplanes. The actions specified by that AD are intended to prevent loose external power ground wires, which could cause arcing and overheated wire insulation and consequent smoke/fire in the cockpit.

Actions Since Issuance of Previous Rule

Since issuance of that AD, the FAA was advised that one Model DC9–15 airplane (fuselage number 0097) was omitted inadvertently from the applicability of AD 2001–24–19 because the airplane had been excluded inadvertently from the effectivity of Section I.A. of McDonnell Douglas Alert Service Bulletin DC9–24A135, Revision 01, dated May 1, 2000, as cited in AD 2001–24–19. Therefore, the additional airplane is also subject to the same

unsafe condition addressed in AD 2001–24–19.

Explanation of Relevant Service Information

The FAA has reviewed and approved Boeing Alert Service Bulletin DC9-24A135, Revision 02, dated January 7, 2003, which describes procedures that are essentially the same as those procedures included in McDonnell Douglas Alert Service Bulletin DC9-24A135, Revision 01, dated May 1, 2000. This revision also adds an additional airplane fuselage number to the effectivity. No more work is necessary on airplanes changed as shown in Revision 01 of the service bulletin. Accomplishment of the actions specified in the service bulletin is intended to adequately address the identified unsafe condition.

Accomplishment of the actions specified in AD 2001–24–19 is acceptable for compliance with the requirements of this proposed AD.

Explanation of Requirements of Proposed Rule

Since an unsafe condition has been identified that is likely to exist or develop on other products of this same type design, the proposed AD would require accomplishment of the actions specified in the service bulletin described previously.

Since this proposed AD expands the applicability of AD 2001-24-19, the FAA has considered a number of factors in determining whether to issue a new AD or to supersede the existing AD. The FAA has considered the entire fleet size that would be affected by superseding AD 2001-24-19 and the consequent workload associated with revising maintenance record entries. In light of this, the FAA has determined that a less burdensome approach is to issue a separate AD applicable only to the additional airplane. This proposed AD would not supersede AD 2001-24-19; airplanes listed in the applicability of AD 2001-24-19 are required to continue to comply with the requirements of that AD. This proposed AD is a separate AD action, and is applicable to only one McDonnell Douglas Model DC9-15 airplane (fuselage number 0097), certificated in any category.

Changes to 14 CFR Part 39/Effect on the Proposed AD

On July 10, 2002, the FAA issued a new version of 14 CFR part 39 (67 FR 47997, July 22, 2002), which governs the FAA's airworthiness directives system. The regulation now includes material that relates to altered products, special flight permits, and alternative methods

of compliance (AMOCs). Because we have now included this material in part 39, only the office authorized to approve AMOCs is identified in each individual AD.

Change to Labor Rate Estimate

We have reviewed the figures we have used over the past several years to calculate AD costs to operators. To account for various inflationary costs in the airline industry, we find it necessary to increase the labor rate used in these calculations from \$60 per work hour to \$65 per work hour. The cost impact information, below, reflects this increase in the specified hourly labor rate.

Cost Impact

The FAA estimates that 1 Model DC–9–15 airplane, having fuselage number 0097, of U.S. registry would be affected by this proposed AD, that it would take approximately 2 work hours to accomplish the proposed actions, and that the average labor rate is \$65 per work hour. Required parts would cost approximately \$35. Based on these figures, the cost impact of the proposed AD on the U.S. operator is estimated to be \$165.

The cost impact figure discussed above is based on assumptions that no operator has yet accomplished any of the proposed requirements of this AD action, and that no operator would accomplish those actions in the future if this proposed AD were not adopted. The cost impact figures discussed in AD rulemaking actions represent only the time necessary to perform the specific actions actually required by the AD. These figures typically do not include incidental costs, such as the time required to gain access and close up, planning time, or time necessitated by other administrative actions.

Regulatory Impact

The regulations proposed herein would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, it is determined that this proposal would not have federalism implications under Executive Order 13132.

For the reasons discussed above, I certify that this proposed regulation (1) is not a "significant regulatory action" under Executive Order 12866; (2) is not a "significant rule" under the DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and (3) if promulgated, will not have a significant economic impact, positive or negative,

on a substantial number of small entities under the criteria of the Regulatory Flexibility Act. A copy of the draft regulatory evaluation prepared for this action is contained in the Rules Docket. A copy of it may be obtained by contacting the Rules Docket at the location provided under the caption ADDRESSES.

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Proposed Amendment

Accordingly, pursuant to the authority delegated to me by the Administrator, the Federal Aviation Administration proposes to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. Section 39.13 is amended by adding the following new airworthiness directive:

McDonnell Douglas: Docket 2003–NM–31–

Applicability: Model DC-9-15 airplane, fuselage number 0097; certificated in any category.

Compliance: Required as indicated, unless accomplished previously.

To prevent loose external power ground wires, which could cause arcing and overheated wire insulation and consequent smoke/fire in the cockpit, accomplish the following:

Inspection

(a) Within 18 months after the effective date of this AD, do a general visual inspection to detect chafing or overheat damage of the electrical wires located at fuselage station Y=110.000 bulkhead of the lower nose left tunnel, per Boeing Alert Service Bulletin DC9–24A135, Revision 02, dated January 7, 2003.

Note 1: For the purposes of this AD, a general visual inspection is defined as "A visual examination of an interior or exterior area, installation, or assembly to detect obvious damage, failure, or irregularity. This level of inspection is made under normally available lighting conditions such as daylight, hangar lighting, flashlight, or droplight, and may require removal or opening of access panels or doors. Stands, ladders, or platforms may be required to gain proximity to the area being checked."

Condition 1 (No Chafing or Damage)

(b) If no chafing or overheat damage is detected during the inspection required by paragraph (a) of this AD, within 18 months after the effective date of this AD, do the actions specified in paragraphs (b)(1), (b)(2), and (b)(3) of this AD per Boeing Alert Service Bulletin DC9–24A135, Revision 02, dated January 7, 2003.

- (1) Replace the external power ground stud with a new ground stud using new attaching parts.
 - (2) Torque the new attachments.
- (3) Install nameplate (includes applying silicone primer and adhesive/sealant).

Condition 2 (Chafing or Damage Within Limits)

(c) If, during the inspection required by paragraph (a) of this AD, any chafing or damage is detected within the limits referenced in Boeing Alert Service Bulletin DC9–24A135, Revision 02, dated January 7, 2003, before further flight, repair damage; perform a continuity test to check the integrity of the wiring, and repair as applicable; and do the actions required by paragraphs (b)(1), (b)(2), and (b)(3) of this AD; per the alert service bulletin.

Condition 3 (Chafing or Damage Beyond Limits)

(d) If, during the inspection required by paragraph (a) of this AD, any chafing or damage is detected beyond the limits referenced in Boeing Alert Service Bulletin DC9–24A135, Revision 02, dated January 7, 2003, before further flight, replace any damaged wire with a new wire; perform a continuity test to check the integrity of the wiring, and repair as applicable; and do the actions required by paragraphs (b)(1), (b)(2), and (b)(3) of this AD; per the alert service bulletin.

Accomplishment of the Actions

(e) Accomplishment of the actions specified in AD 2001–24–19, amendment 39–12536, is acceptable for compliance with the requirements of this proposed AD.

Alternative Methods of Compliance

(f) In accordance with 14 CFR 39.19, the Manager, Los Angeles Aircraft Certification Office, FAA, is authorized to approve alternative methods of compliance for this AD.

Issued in Renton, Washington, on September 26, 2003.

Ali Bahrami,

Acting Manager, Transport Airplane
Directorate, Aircraft Certification Service.
[FR Doc. 03–24974 Filed 10–1–03; 8:45 am]

BILLING CODE 4910-13-U

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. 2002-NM-283-AD]

RIN 2120-AA64

Airworthiness Directives; McDonnell Douglas Model DC-10-10, DC-10-10F, DC-10-15, DC-10-30, DC-10-30F, DC-10-30F (KC10A and KDC-10), DC-10-40, DC-10-40F, MD-10-10F, and MD-10-30F Airplanes

AGENCY: Federal Aviation Administration, DOT.

ACTION: Notice of proposed rulemaking (NPRM).

SUMMARY: This document proposes the supersedure of an existing airworthiness directive (AD), applicable to McDonnell Douglas transport category airplanes listed above, that currently requires a one-time detailed inspection to determine if wire segments of the wire bundle routed through the feed-through on the aft side of the flight engineer's station are damaged or chafed, and corrective actions if necessary. That AD also requires revising the wire bundle support clamp installation at the flight engineer's station. For certain airplanes, this action would require a new revision of the wire bundle support clamp installation, and modification of a certain wire bundle. This action also would reduce the applicability in the existing AD. The actions specified by the proposed AD are intended to prevent chafing of the wire bundle located behind the flight engineer's panel caused by the wire bundle coming in contact with the lower edge of the feed-through, and consequent electrical arcing, which could result in smoke and fire in the cockpit. This action is intended to address the identified unsafe condition.

DATES: Comments must be received by November 17, 2003.

ADDRESSES: Submit comments in triplicate to the Federal Aviation Administration (FAA), Transport Airplane Directorate, ANM-114, Attention: Rules Docket No. 2002-NM-283-AD, 1601 Lind Avenue, SW., Renton, Washington 98055-4056. Comments may be inspected at this location between 9 a.m. and 3 p.m., Monday through Friday, except Federal holidays. Comments may be submitted via fax to (425) 227–1232. Comments may also be sent via the Internet using the following address: 9-anmnprmcomment@faa.gov. Comments sent via fax or the Internet must contain

"Docket No. 2002–NM–283–AD" in the subject line and need not be submitted in triplicate. Comments sent via the Internet as attached electronic files must be formatted in Microsoft Word 97 or 2000 or ASCII text.

The service information referenced in the proposed rule may be obtained from Boeing Commercial Aircraft Group, Long Beach Division, 3855 Lakewood Boulevard, Long Beach, California 90846, Attention: Data and Service Management, Dept. C1–L5A (D800–0024). This information may be examined at the FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington.

FOR FURTHER INFORMATION CONTACT:

Natalie Phan-Tran, Aerospace Engineer, Systems and Equipment Branch, ANM–130L, FAA, Los Angeles Aircraft Certification Office, 3960 Paramount Boulevard, Lakewood, California 90712–4137; telephone (562) 627–5343; fax (562) 627–5210.

SUPPLEMENTARY INFORMATION:

Comments Invited

Interested persons are invited to participate in the making of the proposed rule by submitting such written data, views, or arguments as they may desire. Communications shall identify the Rules Docket number and be submitted in triplicate to the address specified above. All communications received on or before the closing date for comments, specified above, will be considered before taking action on the proposed rule. The proposals contained in this action may be changed in light of the comments received.

Submit comments using the following format:

- Organize comments issue-by-issue. For example, discuss a request to change the compliance time and a request to change the service bulletin reference as two separate issues.
- For each issue, state what specific change to the proposed AD is being requested.
- Include justification (e.g., reasons or data) for each request.

Comments are specifically invited on the overall regulatory, economic, environmental, and energy aspects of the proposed rule. All comments submitted will be available, both before and after the closing date for comments, in the Rules Docket for examination by interested persons. A report summarizing each FAA-public contact concerned with the substance of this proposal will be filed in the Rules Docket.

Commenters wishing the FAA to acknowledge receipt of their comments

submitted in response to this action must submit a self-addressed, stamped postcard on which the following statement is made: "Comments to Docket Number 2002–NM–283–AD." The postcard will be date stamped and returned to the commenter.

Availability of NPRMs

Any person may obtain a copy of this NPRM by submitting a request to the FAA, Transport Airplane Directorate, ANM-114, Attention: Rules Docket No. 2002–NM-283–AD, 1601 Lind Avenue, SW., Renton, Washington 98055–4056.

Discussion

On November 8, 2001, the FAA issued AD 2001-24-21, amendment 39-12538 (66 FR 64121, December 12, 2001), applicable to all McDonnell Douglas Model DC-10 series airplanes and Model MD-10-10F and -30F series airplanes, to continue to require a onetime detailed inspection to determine if wire segments of the wire bundle routed through the feed-through on the aft side of the flight engineer's station are damaged or chafed, and corrective actions if necessary. That AD also requires revising the wire bundle support clamp installation at the flight engineer's station. The requirements of that AD are intended to prevent chafing of the wire bundle located behind the flight engineer's panel caused by the wire bundle coming in contact with the lower edge of the feed-through and consequent electrical arcing, which could result in smoke and fire in the cockpit.

Actions Since Issuance of Previous Rule

Since the issuance of AD 2001-24-21. the FAA has reviewed and approved Boeing Alert Service Bulletins DC10-24A149, Revision 03, dated September 19, 2002; and Revision 04, dated March 26, 2003. The inspection and repair procedures described in these revisions are identical to those described in Revisions 01 and 02 of the service bulletin (which were referenced in the existing AD as the appropriate sources of service information for accomplishment of the specified actions). The procedures for revising the wire bundle support clamp installation at the flight engineer's station described in Revision 02 have been changed to add procedures for installation and relocation of a new bracket when revising the wire bundle support clamp installation, and to add the revision of the wire bundle support clamp installation at the first observer's station for Group 3 airplanes, as specified in Revision 03. Revision 04 adds procedures for modification of Groups 1

and 2 airplanes on which wire bundle run (RDZ) is installed and was changed as specified in Revision 03 of the service bulletin.

The effectivity listing of Revisions 03 and 04 of the service bulletin have also been revised to remove inactive airplanes and to identify a new Group 3 (which includes the MD-10-10F and MD-10-30F airplanes), and a new Group 4, respectively.

Accomplishment of the actions specified in the service bulletins is intended to adequately address the identified unsafe condition.

Other Related Rulemaking

The FAA, in conjunction with Boeing and operators of Model DC–10 airplanes, has reviewed all aspects of the service history of those airplanes to identify potential unsafe conditions and to take appropriate corrective actions. This proposed AD is one of a series of corrective actions identified during that process. We have previously issued several other ADs and may consider further rulemaking actions to address the remaining identified unsafe conditions.

Explanation of Requirements of Proposed Rule

Since an unsafe condition has been identified that is likely to exist or develop on other products of this same type design, the proposed AD would supersede AD 2001-24-21 to continue to require a one-time detailed inspection to determine if wire segments of the wire bundle routed through the feedthrough on the aft side of the flight engineer's station are damaged or chafed, and corrective actions if necessary. The proposed AD also would continue to require revising the wire bundle support clamp installation at the flight engineer's station. For certain airplanes, this action would require a new revision of the wire bundle support clamp installation, and modification of a certain wire bundle. This action also would reduce the applicability in the existing AD. The actions would be required to be accomplished in accordance with the service bulletins described previously.

Explanation of Change to Applicability

We have revised the applicability of the existing AD to identify model designations as published in the most recent type certificate data sheet for the affected models.

Explanation of Change Made To Existing Requirements

The FAA has changed all references to a "detailed visual inspection" in the

existing AD to "detailed inspection" in this action.

Changes to 14 CFR Part 39/Effect on the AD

On July 10, 2002, the FAA issued a new version of 14 CFR part 39 (67 FR 47997, July 22, 2002), which governs the FAA's airworthiness directives system. The regulation now includes material that relates to altered products, special flight permits, and alternative methods of compliance (AMOCs). Because we have now included this material in part 39, only the office authorized to approve AMOCs is identified in each individual AD.

Change in Labor Rate

We have reviewed the figures we have used over the past several years to calculate AD costs to operators. To account for various inflationary costs in the airline industry, we find it necessary to increase the labor rate used in these calculations from \$60 per work hour to \$65 per work hour. The cost impact information, below, reflects this increase in the specified hourly labor rate.

Cost Impact

There are approximately 412 airplanes of the affected design in the worldwide fleet. The FAA estimates that 298 airplanes of U.S. registry would be affected by this proposed AD.

The inspection that is currently required by AD 2001–24–21, takes approximately 1 work hour per airplane to accomplish, at an average labor rate of \$65 per work hour. Based on these figures, the cost impact of the currently required actions on U.S. operators is estimated to be \$65 per airplane.

The revision of the wire bundle support clamp installation that is currently required by AD 2001–24–21 takes approximately 2 work hours per airplane to accomplish, at an average labor rate of \$65 per work hour. Based on these figures, the cost impact of the currently required actions on U.S. operators is estimated to be \$130 per airplane.

For Groups 1, 2, and 3 airplanes: It would take approximately 2 work hours per airplane to do the new revision of the wire bundle support clamp installation, at an average labor rate of \$65 per work hour. Required parts cost would be minimal. Based on these figures, the cost impact of the proposed installation is estimated to be \$38,740, or \$130 per airplane.

For Group 4 airplanes: It would take approximately 1 work hour per airplane to do the new modification of the wire bundle, at an average labor rate of \$65 per work hour. Required parts cost would be minimal. Based on these figures, the cost impact of the proposed modification is estimated to be \$19,370, or \$65 per airplane.

The cost impact figures discussed above are based on assumptions that no operator has yet accomplished any of the current or proposed requirements of this AD action, and that no operator would accomplish those actions in the future if this AD were not adopted. The cost impact figures discussed in AD rulemaking actions represent only the time necessary to perform the specific actions actually required by the AD. These figures typically do not include incidental costs, such as the time required to gain access and close up, planning time, or time necessitated by other administrative actions.

Regulatory Impact

The regulations proposed herein would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, it is determined that this proposal would not have federalism implications under Executive Order 13132.

For the reasons discussed above, I certify that this proposed regulation (1) is not a "significant regulatory action" under Executive Order 12866; (2) is not a "significant rule" under the DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and (3) if promulgated, will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act. A copy of the draft regulatory evaluation prepared for this action is contained in the Rules Docket. A copy of it may be obtained by contacting the Rules Docket at the location provided under the caption ADDRESSES.

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Proposed Amendment

Accordingly, pursuant to the authority delegated to me by the Administrator, the Federal Aviation Administration proposes to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. Section 39.13 is amended by removing amendment 39–12538 (66 FR 64121, December 12, 2001), and by adding a new airworthiness directive (AD), to read as follows:

McDonnell Douglas: Docket 2002–NM–283– AD. Supersedes AD 2001–24–21, Amendment 39–12538.

 $Applicability: \ Model \ DC-10-10, \ DC-10-10F, \ DC-10-15, \ DC-10-30, \ DC-10-30F, \ DC-10-30F \ (KC10A \ and \ KDC-10), \ DC-10-40, \ DC-10-40F, \ MD-10-10F, \ and \ MD-10-30F \ airplanes; \ as listed in Boeing Alert Service Bulletin \ DC10-24A149, \ Revision \ 04, \ dated \ March \ 26, \ 2003; \ certificated \ in \ any \ category.$

Compliance: Required as indicated, unless accomplished previously.

To prevent chafing of the wire bundle located behind the flight engineer's panel caused by the wire bundle coming in contact with the lower edge of the feed-through, and consequent electrical arcing, which could result in smoke and fire in the cockpit, accomplish the following:

Restatement of Requirements of AD 2001–24–21

Inspection and Repair, If Necessary

(a) Within 1 year after June 21, 2000 (the effective date of AD 2000-10-03, amendment 39-11727), perform a one-time detailed inspection to determine if the wire segments of the wire bundle routed through the feedthrough on the aft side of the flight engineer's station are damaged or chafed, in accordance with McDonnell Douglas Alert Service Bulletin DC10-24A149, Revision 01, dated July 28, 1999; or Boeing Alert Service Bulletin DC10-24A149, Revision 02, dated April 5, 2001; Revision 03, dated September 19, 2002; or Revision 04, dated March 26, 2003. If any damaged or chafed wire is found, prior to further flight, repair in accordance with the alert service bulletin.

Note 1: For the purposes of this AD, a detailed inspection is defined as: "An intensive visual examination of a specific structural area, system, installation, or assembly to detect damage, failure, or irregularity. Available lighting is normally supplemented with a direct source of good lighting at intensity deemed appropriate by the inspector. Inspection aids such as mirror, magnifying lenses, etc. may be used. Surface cleaning and elaborate access procedures may be required."

Revision of Wire Bundle Support Clamp Installation

(b) Within 1 year after January 16, 2002 (the effective date of AD 2001–24–21, amendment 39–12538), revise the wire bundle support clamp installation at the flight engineer's station, per Boeing Alert Service Bulletin DC10–24A149, Revision 02, dated April 5, 2001.

New Requirements of This AD

New Revision of Wire Bundle Support Clamp Installation

- (c) Within 1 year after the effective date of this AD, do the applicable actions specified in paragraph (c)(1), (c)(2), or (c)(3) of this AD, per Boeing Alert Service Bulletin DC10—24A149, Revision 04, dated March 26, 2003.
- (1) For Group 1 airplanes, as defined in Boeing Alert Service Bulletin DC10–24A149, Revision 04, dated March 26, 2003: Revise the wire bundle support clamp installation at the flight engineer's station.
- (2) For Group 2 airplanes, as defined in Boeing Alert Service Bulletin DC10–24A149, Revision 04, dated March 26, 2003: Revise the wire bundle support clamp installation at the flight engineer's station.
- (3) For Group 3 airplanes, as defined in Boeing Alert Service Bulletin DC10–24A149, Revision 04, dated March 26, 2003: Revise the wire bundle support clamp installation at the first observer's station.

Modification

(d) For Group 4 airplanes, as defined in Boeing Alert Service Bulletin DC10–24A149, Revision 04, dated March 26, 2003: Within 1 year after the effective date of this AD, modify the wire bundle per the Accomplishment Instructions of Boeing Alert Service Bulletin DC10–24A149, Revision 04, dated March 26, 2003.

Alternative Methods of Compliance

(e) In accordance with 14 CFR 39.19, the Manager, Los Angeles Aircraft Certification Office, FAA, is authorized to approve alternative methods of compliance for this AD.

Issued in Renton, Washington, on September 26, 2003.

Ali Bahrami,

Acting Manager, Transport Airplane Directorate, Aircraft Certification Service. [FR Doc. 03–24975 Filed 10–1–03; 8:45 am] BILLING CODE 4910–13–U

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. 2002-NM-113-AD]

RIN 2120-AA64

Airworthiness Directives; Airbus Model A300 B2–1C, B2–203, B2K–3C, B4–2C, B4–103, and B4–203 Series Airplanes; Model A300 B4–600, B4–600R, and F4–600R (collectively called A300–600); and Model A310 Series Airplanes

AGENCY: Federal Aviation Administration, DOT.

ACTION: Notice of proposed rulemaking (NPRM).

SUMMARY: This document proposes the supersedure of an existing airworthiness

directive (AD), applicable to all Airbus Model A300 B2-1C, B2-203, B2K-3C, B4-2C, B4-103, and B4-203 series airplanes, that currently requires a onetime inspection of the space between the fuel quantity indication (FQI) probes and any adjacent structures for minimum clearance, and corrective action if necessary. This action would expand the applicability in the existing AD and would require the subject onetime inspection on the additional airplanes. The actions specified by the proposed AD are intended to prevent the possibility of electrical arcing to the fuel tank if the airplane should be struck by lightning. Such arcing could create a potential ignition source within the fuel tank and an increased risk of a fuel tank explosion and fire. This action is intended to address the identified unsafe condition.

DATES: Comments must be received by November 3, 2003.

ADDRESSES: Submit comments in triplicate to the Federal Aviation Administration (FAA), Transport Airplane Directorate, ANM-114, Attention: Rules Docket No. 2002-NM-113-AD, 1601 Lind Avenue, SW., Renton, Washington 98055-4056. Comments may be inspected at this location between 9 a.m. and 3 p.m., Monday through Friday, except Federal holidays. Comments may be submitted via fax to (425) 227–1232. Comments may also be sent via the Internet using the following address: 9-anmnprmcomment@faa.gov. Comments sent via fax or the Internet must contain "Docket No. 2002-NM-113-AD" in the subject line and need not be submitted in triplicate. Comments sent via the Internet as attached electronic files must be formatted in Microsoft Word 97 or 2000 or ASCII text.

The service information referenced in the proposed rule may be obtained from Airbus Industrie, 1 Rond Point Maurice Bellonte, 31707 Blagnac Cedex, France. This information may be examined at the FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington.

FOR FURTHER INFORMATION CONTACT: Dan Rodina, Aerospace Engineer, International Branch, ANM-116, FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington 98055-4056; telephone (425) 227-2125; fax (425) 227-1149.

SUPPLEMENTARY INFORMATION:

Comments Invited

Interested persons are invited to participate in the making of the proposed rule by submitting such written data, views, or arguments as they may desire. Communications shall identify the Rules Docket number and be submitted in triplicate to the address specified above. All communications received on or before the closing date for comments, specified above, will be considered before taking action on the proposed rule. The proposals contained in this action may be changed in light of the comments received.

Submit comments using the following format:

- Organize comments issue-by-issue. For example, discuss a request to change the compliance time and a request to change the service bulletin reference as two separate issues.
- For each issue, state what specific change to the proposed AD is being requested.
- Include justification (*e.g.*, reasons or data) for each request.

Comments are specifically invited on the overall regulatory, economic, environmental, and energy aspects of the proposed rule. All comments submitted will be available, both before and after the closing date for comments, in the Rules Docket for examination by interested persons. A report summarizing each FAA-public contact concerned with the substance of this proposal will be filed in the Rules Docket.

Commenters wishing the FAA to acknowledge receipt of their comments submitted in response to this action must submit a self-addressed, stamped postcard on which the following statement is made: "Comments to Docket Number 2002–NM–113–AD." The postcard will be date stamped and returned to the commenter.

Availability of NPRMs

Any person may obtain a copy of this NPRM by submitting a request to the FAA, Transport Airplane Directorate, ANM-114, Attention: Rules Docket No. 2002–NM-113–AD, 1601 Lind Avenue, SW., Renton, Washington 98055–4056.

Discussion

On June 19, 2001, the FAA issued AD 2001–13–09, amendment 39–12289 (66 FR 34088, June 27, 2001), applicable to all Airbus Model A300 B2-1C, B2-203, B2K-3C, B4-2C, B4-103, and B4-203 series airplanes, to require a one-time inspection of the space between the fuel quantity indication (FQI) probes and any adjacent structures for minimum clearance, and corrective action if necessary. That action was prompted by the issuance of mandatory continuing airworthiness information by a foreign civil airworthiness authority. The requirements of that AD are intended to prevent the possibility of electrical

arcing to the fuel tank if the airplane should be struck by lightning.

Actions Since Issuance of Previous Rule

Since the issuance of AD 2001–13–09, the Direction Générale de l'Aviation Civile (DGAC), which is the airworthiness authority for France, has mandated the one-time inspection required by the existing AD (which is applicable to Model A300 B2–1C, B2–203, B2K–3C, and A300 B4 series airplanes) for Model A310 and Model A300 B4–600, B4–600R, and F4–600R (collectively called A300–600) series airplanes, and expanded the applicability to include those airplanes.

Explanation of Relevant Service Information

Airbus has issued Service Bulletin A300–28–0080, Revision 01, dated September 3, 2001 (the original issue of the service bulletin was referenced in the existing AD for accomplishment of the referenced actions). Revision 01 has no substantial changes from the original issue.

Airbus also has issued Service Bulletins A300–28–6065, dated March 29, 2001; Revision 01, dated August 31, 2001; and Revision 02, dated August 1, 2002 (for Model A300–600 series airplanes); and A310–28–2145, dated August 21, 2001 (for Model A310 series airplanes). The service bulletins describe procedures for inspecting the FQI probes to make sure that there is a minimum clearance of 3.0 mm (0.118 in.) between each FQI probe and any adjacent structure and/or component in the wing fuel tanks, and adjustment of the clearance space if necessary.

The DGAC classified these service bulletins as mandatory and issued French airworthiness directive 2002– 170(B), dated April 3, 2002, in order to ensure the continued airworthiness of these airplanes in France.

FAA's Conclusions

These airplane models are manufactured in France and are type certificated for operation in the United States under the provisions of section 21.29 of the Federal Aviation Regulations (14 CFR 21.29) and the applicable bilateral airworthiness agreement. Pursuant to this bilateral airworthiness agreement, the DGAC has kept us informed of the situation described above. We have examined the findings of the DGAC, reviewed all available information, and determined that AD action is necessary for products of this type design that are certificated for operation in the United States.

Explanation of Requirements of Proposed Rule

Since an unsafe condition has been identified that is likely to exist or develop on other airplanes of the same type design registered in the United States, the proposed AD would supersede AD 2001-13-09 to continue to require a one-time inspection of the space between the fuel quantity indication (FQI) probes and any adjacent structures for minimum clearance, and corrective action if necessary. The proposed AD also would expand the applicability in the existing AD and would require the subject onetime inspection on the additional airplanes. The actions would be required to be accomplished in accordance with the service bulletins described previously.

Changes to 14 CFR Part 39/Effect on the AD

On July 10, 2002, we issued a new version of 14 CFR part 39 (67 FR 47997, July 22, 2002), which governs the FAA's airworthiness directives system. The regulation now includes material that relates to altered products, special flight permits, and alternative methods of compliance (AMOCs). Because we have now included this material in part 39, only the office authorized to approve AMOCs is identified in each individual AD.

Change to Labor Rate Estimate

We have reviewed the figures we have used over the past several years to calculate AD costs to operators. To account for various inflationary costs in the airline industry, we find it necessary to increase the labor rate used in these calculations from \$60 per work hour to \$65 per work hour. The cost impact information, below, reflects this increase in the specified hourly labor rate.

Cost Impact

There are approximately 115 airplanes of U.S. registry that would be affected by this proposed AD.

The inspection that is currently required by AD 2001–13–09 takes approximately 7 work hours per airplane to accomplish, at an average labor rate of \$65 per work hour. Based on these figures, the cost impact of the currently required inspection is estimated to be \$455 per airplane.

It would take approximately 5 work hours per airplane to accomplish the new inspection, specified in Airbus Service Bulletin A310–28–2145, at an average labor rate of \$65 per work hour. Based on these figures, the cost impact of this proposed inspection is estimated to be \$325 per airplane.

It would take approximately 10 work hours per airplane to accomplish the new inspection of the wing fuel tank, and approximately 5 work hours per airplane to accomplish the new inspection of the trim fuel tank, specified in Airbus Service Bulletin A300–28–6065, at an average labor rate of \$65 per work hour. Based on these figures, the cost impact of these proposed inspections is estimated to be \$650 per wing fuel tank, and \$325 per trim fuel tank, per airplane.

The cost impact figures discussed above are based on assumptions that no operator has yet accomplished any of the proposed requirements of this AD action, and that no operator would accomplish those actions in the future if this AD were not adopted. The cost impact figures discussed in AD rulemaking actions represent only the time necessary to perform the specific actions actually required by the AD. These figures typically do not include incidental costs, such as the time required to gain access and close up, planning time, or time necessitated by other administrative actions.

Regulatory Impact

The regulations proposed herein would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, it is determined that this proposal would not have federalism implications under Executive Order 13132.

For the reasons discussed above, I certify that this proposed regulation (1) is not a "significant regulatory action" under Executive Order 12866; (2) is not a "significant rule" under the DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and (3) if promulgated, will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act. A copy of the draft regulatory evaluation prepared for this action is contained in the Rules Docket. A copy of it may be obtained by contacting the Rules Docket at the location provided under the caption ADDRESSES.

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Proposed Amendment

Accordingly, pursuant to the authority delegated to me by the

Administrator, the Federal Aviation Administration proposes to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. Section 39.13 is amended by removing amendment 39-12289 (66 FR 34088, June 27, 2001), and by adding a new airworthiness directive (AD), to read as follows:

Airbus: Docket 2002-NM-113-AD. Supersedes AD 2001-13-09, Amendment 39–12289.

Applicability: All Model A300 B2-1C, B2-203, B2K-3C, B4-2C, B4-103, and B4-203 series airplanes; Model A300 B4-600, B4-600R, and F4-600R (collectively called A300-600) series airplanes except those on which Airbus Modification 12278 has been accomplished in production; and Model A310 series airplanes except those on which Airbus Modification 12248 has been accomplished in production; certificated in any category.

Compliance: Required as indicated, unless accomplished previously.

To prevent the possibility of electrical arcing to the fuel tank if the airplane should be struck by lightning, which could create a potential ignition source within the fuel tank and an increased risk of a fuel tank explosion and fire, accomplish the following:

Restatement of Requirements of AD 2001-13-09

Inspection

(a) For Model A300 B2-1C, B2-203, B2K-3C, and A300 B4 series airplanes: Within 4,000 flight hours after August 1, 2001 (the effective date of AD 2001-13-09, amendment 39-12289), inspect the clearance space from each fuel quantity indication (FQI) probe to any adjacent structure or metallic component, in accordance with Airbus Service Bulletin A300-28-0080, dated September 28, 2000; or Revision 01, dated September 3, 2001.

New Requirements of This AD

Detailed Inspection

(b) For Model A300-600 and A310 series airplanes: Within 4,000 flight hours after the effective date of this AD; do a detailed inspection of the clearance space from each FQI probe to any adjacent structure or metallic component, in accordance with Airbus Service Bulletin A300-28-6065, dated March 29, 2001; Revision 01, dated August 31, 2001; or Revision 02, dated August 1, 2002; or Airbus Service Bulletin A310-28-2145, dated August 21, 2001; as

Note 1: For the purposes of this AD, a detailed inspection is defined as: "An intensive visual examination of a specific

structural area, system, installation, or assembly to detect damage, failure, or irregularity. Available lighting is normally supplemented with a direct source of good lighting at intensity deemed appropriate by the inspector. Inspection aids such as mirror, magnifying lenses, etc., may be used. Surface cleaning and elaborate access procedures may be required."

Clearance Adjustment

(c) If, during any inspection required by this AD, the clearance between any probe and its adjacent parts is less than 3.0 mm (0.118 in.), as described in Airbus Service Bulletin A300-28-0080, dated September 28, 2000; or Revision 01, dated September 3, 2001; or A300-28-6065, dated March 29, 2001; Revision 01, dated August 31, 2001; or Revision 02, dated August 1, 2002; or A310-28-2145, dated August 21, 2001: Before further flight, adjust the position of the FQI probe in accordance with paragraph 3.C. of the Accomplishment Instructions of the applicable service bulletin.

Alternative Methods of Compliance

(d)(1) In accordance with 14 CFR 39.19, the Manager, International Branch, ANM-116, FAA, is authorized to approve alternative methods of compliance for this AD.

(2) Alternative methods of compliance, approved previously per AD 2001-13-09, amendment 39-12289, are approved as alternative methods of compliance with paragraph (a) of this AD.

Note 2: The subject of this AD is addressed in French airworthiness directive 2002-170(B), dated April 3, 2002.

Issued in Renton, Washington, on September 26, 2003.

Acting Manager, Transport Airplane Directorate, Aircraft Certification Service. [FR Doc. 03-24977 Filed 10-1-03; 8:45 am] BILLING CODE 4910-13-P

DEPARTMENT OF TRANSPORTATION

Federal Aviation Administration

14 CFR Part 39

[Docket No. 2002-NM-87-AD] RIN 2120-AA64

Airworthiness Directives; Empresa Brasileira de Aeronautica S.A. (EMBRAER) Model EMB-120 Series **Airplanes**

AGENCY: Federal Aviation Administration, DOT.

ACTION: Notice of proposed rulemaking

(NPRM).

SUMMARY: This document proposes the supersedure of an existing airworthiness directive (AD), applicable to certain EMBRAER Model EMB-120 series airplanes, that currently requires revising the airplane flight manual

(AFM), and either installing hydraulic tube assemblies incorporating a check valve, or visually inspecting the check valve if already installed and performing corrective actions if necessary. This action would add airplanes to the applicability of the existing AD. The actions specified by the proposed AD are intended to prevent the landing gear doors from becoming blocked from opening during application of emergency procedures in the event of a loss of hydraulics. This action is intended to address the identified unsafe condition.

DATES: Comments must be received by November 3, 2003.

ADDRESSES: Submit comments in triplicate to the Federal Aviation Administration (FAA), Transport Airplane Directorate, ANM-114, Attention: Rules Docket No. 2002-NM-87-AD, 1601 Lind Avenue, SW., Renton, Washington 98055-4056. Comments may be inspected at this location between 9 a.m. and 3 p.m., Monday through Friday, except Federal holidays. Comments may be submitted via fax to (425) 227–1232. Comments may also be sent via the Internet using the following address: 9-anmnprmcomment@faa.gov. Comments sent via fax or the Internet must contain "Docket No. 2002-NM-87-AD" in the subject line and need not be submitted in triplicate. Comments sent via the Internet as attached electronic files must be formatted in Microsoft Word 97 or 2000 or ASCII text.

The service information referenced in the proposed rule may be obtained from Empresa Brasileira de Aeronautica S.A. (EMBRAER), P.O. Box 343—CEP 12.225, Sao Jose dos Campos—SP, Brazil. This information may be examined at the FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington.

FOR FURTHER INFORMATION CONTACT:

Todd Thompson, Aerospace Engineer, International Branch, ANM-116, FAA, Transport Airplane Directorate, 1601 Lind Avenue, SW., Renton, Washington 98055-4056; telephone (425) 227-1175; fax (425) 227-1149.

SUPPLEMENTARY INFORMATION:

Comments Invited

Interested persons are invited to participate in the making of the proposed rule by submitting such written data, views, or arguments as they may desire. Communications shall identify the Rules Docket number and be submitted in triplicate to the address specified above. All communications received on or before the closing date for comments, specified above, will be

considered before taking action on the proposed rule. The proposals contained in this action may be changed in light of the comments received.

Submit comments using the following format:

- Organize comments issue-by-issue. For example, discuss a request to change the compliance time and a request to change the service bulletin reference as two separate issues.
- For each issue, state what specific change to the proposed AD is being requested.
- Include justification (e.g., reasons or data) for each request.

Comments are specifically invited on the overall regulatory, economic, environmental, and energy aspects of the proposed rule. All comments submitted will be available, both before and after the closing date for comments, in the Rules Docket for examination by interested persons. A report summarizing each FAA-public contact concerned with the substance of this proposal will be filed in the Rules Docket.

Commenters wishing the FAA to acknowledge receipt of their comments submitted in response to this action must submit a self-addressed, stamped postcard on which the following statement is made: "Comments to Docket Number 2002–NM–87–AD." The postcard will be date stamped and returned to the commenter.

Availability of NPRMs

Any person may obtain a copy of this NPRM by submitting a request to the FAA, Transport Airplane Directorate, ANM–114, Attention: Rules Docket No. 2002–NM–87–AD, 1601 Lind Avenue, SW., Renton, Washington 98055–4056.

Discussion

On September 26, 2000, the FAA issued AD 2000-20-05, amendment 39-11916 (65 FR 59708, October 6, 2000), applicable to certain EMBRAER Model EMB-120 series airplanes. That AD requires revising the airplane flight manual (AFM), and either installing hydraulic tube assemblies incorporating a check valve, or visually inspecting the check valve if already installed and performing corrective actions if necessary. That action was prompted by a report indicating that, in the event of the loss of pressure in the green hydraulic system, if the present AFM "free-fall" operational procedure was not followed, there was a possibility that the landing gear doors may not open. The requirements of that AD are intended to prevent the landing gear doors from becoming blocked from opening during application of

emergency procedures in the event of a loss of hydraulics.

Actions Since Issuance of Previous AD

Since the issuance of that AD, the Departmento de Aviacao Civil (DAC), which is the airworthiness authority for Brazil, advised the FAA that additional airplanes are subject to the same unsafe condition.

Explanation of Relevant Service Information

Since the issuance of AD 2000–20–05. Empresa Brasileira de Aeronautica S.A. (EMBRAER) has issued Service Bulletin 120-32-0077, Change 03, dated August 3, 2001, which describes the same inspection and installation procedures as those specified in Service Bulletin 120–32–0077, Change 02, dated December 23, 1997. Change 02 of the service bulletin was cited in AD 2000-20-05 as the appropriate source of service information. The relevant change in Change 03 of the service bulletin is that the effectivity listing has been changed to include new serial numbers. Accomplishment of the actions specified in the service bulletin is intended to adequately address the identified unsafe condition.

The DAC classified this service bulletin as mandatory and issued Brazilian airworthiness directive 97–05–03R3, effective date October 2, 2001, to ensure the continued airworthiness of these airplanes in Brazil. The Brazilian AD also mandates incorporation of an AFM revision of abnormal landing gear extension procedures.

FAA's Conclusions

This airplane model is manufactured in Brazil and is type certificated for operation in the United States under the provisions of section 21.29 of the Federal Aviation Regulations (14 CFR 21.29) and the applicable bilateral airworthiness agreement. Pursuant to this bilateral airworthiness agreement, the DAC has kept the FAA informed of the situation described above. The FAA has examined the findings of the DAC, reviewed all available information, and determined that AD action is necessary for products of this type design that are certificated for operation in the United States.

Explanation of Requirements of Proposed AD

Since an unsafe condition has been identified that is likely to exist or develop on other airplanes of the same type design registered in the United States, the proposed AD would supersede AD 2000–20–05 to continue to require revising the airplane flight

manual (AFM), and either installing hydraulic tube assemblies incorporating a check valve, or visually inspecting the check valve if already installed and performing corrective actions if necessary. The actions would be required to be accomplished in accordance with the service bulletin described previously. This action would also add airplanes to the applicability of the existing AD.

Changes to the Applicability of the Existing AD

This proposed AD would expand the applicability from affected airplanes as listed in EMBRAER Service Bulletin 120–32–0077, Change 02, dated December 23, 1997, to include affected airplanes as listed in EMBRAER Service Bulletin 120–32–0077, Change 03, dated August 3, 2003.

Explanation of Change Made to Existing Requirements

The FAA has changed all references to a "visual inspection" in the existing AD to "general visual inspection" in this action. Also, the definition of a "general visual inspection" has been included in this action.

Cost Impact

There are approximately 219 airplanes of U.S. registry that would be affected by this proposed AD. This proposed AD adds no new requirements, but only adds airplanes to the applicability of the existing AD. This proposed AD adds no new economic burden on affected operators, but since issuance of AD 2000-20-05, the estimated labor rate has increased from \$60 to \$65 per work hour, and the estimated cost for required parts has increased from \$2,021 to \$2,129. The current costs associated with this proposed AD are otherwise reiterated in their entirety as follows for the convenience of affected operators:

The AFM revision that is currently required by AD 2000–20–05, and retained in this proposed AD, takes approximately 1 work hour per airplane to accomplish, at an average labor rate of \$65 per work hour. Based on these figures, the cost impact of the currently required AFM revision on U.S. operators is estimated to be \$14,235, or \$65 per airplane.

The general visual inspection that is currently required by AD 2000–20–05, and retained in this proposed AD, takes approximately 1 work hour per airplane to accomplish, at an average labor rate of \$65 per work hour. Based on these figures, the cost impact of the currently required general visual inspection on

U.S. operators is estimated to be \$14,235, or \$65 per airplane.

The installation of hydraulic tube assemblies that include check valves that is currently required by AD 2000–20–05, and retained in this proposed AD, takes approximately 2 work hours per airplane to accomplish, at an average labor rate of \$65 per work hour. Required parts cost approximately \$2,129 per airplane. Based on these figures, the cost impact of the currently required actions on U.S. operators is estimated to be \$494,921, or \$2,259 per airplane.

The cost impact figures discussed above are based on assumptions that no operator has yet accomplished any of the current or proposed requirements of this AD action, and that no operator would accomplish those actions in the future if this AD were not adopted. The cost impact figures discussed in AD rulemaking actions represent only the time necessary to perform the specific actions actually required by the AD. These figures typically do not include incidental costs, such as the time required to gain access and close up, planning time, or time necessitated by other administrative actions.

Regulatory Impact

The regulations proposed herein would not have a substantial direct effect on the States, on the relationship between the national Government and the States, or on the distribution of power and responsibilities among the various levels of government. Therefore, it is determined that this proposal would not have federalism implications under Executive Order 13132.

For the reasons discussed above, I certify that this proposed regulation (1) is not a "significant regulatory action" under Executive Order 12866; (2) is not a "significant rule" under the DOT Regulatory Policies and Procedures (44 FR 11034, February 26, 1979); and (3) if promulgated, will not have a significant economic impact, positive or negative, on a substantial number of small entities under the criteria of the Regulatory Flexibility Act. A copy of the draft regulatory evaluation prepared for this action is contained in the Rules Docket. A copy of it may be obtained by contacting the Rules Docket at the location provided under the caption ADDRESSES.

List of Subjects in 14 CFR Part 39

Air transportation, Aircraft, Aviation safety, Safety.

The Proposed Amendment

Accordingly, pursuant to the authority delegated to me by the

Administrator, the Federal Aviation Administration proposes to amend part 39 of the Federal Aviation Regulations (14 CFR part 39) as follows:

PART 39—AIRWORTHINESS DIRECTIVES

1. The authority citation for part 39 continues to read as follows:

Authority: 49 U.S.C. 106(g), 40113, 44701.

§ 39.13 [Amended]

2. Section 39.13 is amended by removing amendment 39–11916 (65 FR 59708, October 6, 2000), and by adding a new airworthiness directive (AD), to read as follows:

Empresa Brasileira De Aeronautica S.A. (EMBRAER): Docket 2002–NM–87–AD. Supersedes AD 2000–20–05, Amendment 39–11916.

Applicability: Model EMB–120 series airplanes as listed in EMBRAER Service Bulletin 120–32–0077, Change 03, dated August 3, 2001; certificated in any category. Compliance: Required as indicated, unless

accomplished previously.

To prevent the landing gear doors from becoming blocked from opening during application of emergency procedures in the event of a loss of hydraulics, accomplish the following:

Restatement of Requirements of AD 2000– 20–05

Airplane Flight Manual (AFM) Revision

(a) For airplanes subject to AD 2000–20–05: Within 10 flight hours after November 13, 2000 (the effective date of AD 2000–20–05, amendment 39–11916), revise the "Emergency Procedures" and "Abnormal Procedures" sections of the airplane flight manual (AFM) by inserting into the AFM a copy of EMB–120 AFM 120/794, Revision 45, dated October 14, 1996.

Note 1: Airplanes subject to AD 2000–20–05 are those listed in EMBRAER Service Bulletin 120–32–0077, Change 02, dated December 23, 1997.

Inspection and Corrective Actions

(b) For airplanes subject to AD 2000–20–05, on which the check valve has been installed in accordance with EMBRAER Service Bulletin 120–32–0077, dated February 7, 1997: Within 100 flight hours after November 13, 2000, conduct a general visual inspection to detect the check valve flow direction in accordance with EMBRAER Service Bulletin 120–32–0077, Change 02, dated December 23, 1997; or Change 03, dated August 3, 2001. If the check valve is installed incorrectly, prior to further flight, reinstall the check valve in the proper position in accordance with Change 02 or Change 03 of the service bulletin.

Note 2: For the purposes of this AD, a general visual inspection is defined as: "A visual examination of an interior or exterior area, installation, or assembly to detect obvious damage, failure, or irregularity. This level of inspection is made from within

touching distance unless otherwise specified. A mirror may be necessary to enhance visual access to all exposed surfaces in the inspection area. This level of inspection is made under normally available lighting conditions such as daylight, hangar lighting, flashlight, or droplight and may require removal or opening of access panels or doors. Stands, ladders, or platforms may be required to gain proximity to the area being checked."

(c) For airplanes subject to AD 2000–20–05, that are not equipped with the check valve installed in accordance with EMBRAER Service Bulletin 120–32–0077, dated February 7, 1997; or Change 01, dated September 25, 1997; or Change 02, dated December 23, 1997; or Change 03, dated August 3, 2003: Within 2,000 flight hours after November 13, 2000, install hydraulic tube assemblies incorporating a check valve in accordance with Service Bulletin 120–32–0077, Change 01, dated September 25, 1997; Change 02, dated December 23, 1997; or Change 03, dated August 3, 2001.

New Requirements of This AD

Note 3: Airplanes not subject to AD 2000–20–05 are those airplanes added by Change 03 of EMBRAER Service Bulletin 120–32–0077, dated August 3, 2001.

Airplane Flight Manual (AFM) Revision

(d) For airplanes not subject to AD 2000–20–05: Within 10 flight hours after the effective date of this AD, revise the "Emergency Procedures" and "Abnormal Procedures" sections of the airplane flight manual (AFM) by inserting into the AFM a copy of EMB–120 AFM 120/794, Revision 45, dated October 14, 1996.

Inspection and Corrective Actions

(e) For airplanes that are not subject to AD 2000–20–05, and on which the check valve has been installed in accordance with EMBRAER Service Bulletin 120–32–0077, dated February 7, 1997: Within 100 flight hours after the effective date of this AD, accomplish all of the applicable actions in accordance with the Accomplishment Instructions of EMBRAER Service Bulletin 120–32–0077, Change 03, dated August 3, 2001.

(f) For airplanes not subject to AD 2000–20–05, on which the check valve has not been installed in accordance with EMBRAER Service Bulletin 120–32–0077, dated February 7, 1997; or Change 01, dated September 25, 1997; or Change 02, dated December 23, 1997: Within 2,000 flight hours after the effective date of this AD, accomplish all of the applicable actions in accordance with the Accomplishment Instructions of EMBRAER Service Bulletin 120–32–0077, Change 03, dated August 3, 2001.

(g) Accomplishment of the specified actions before the effective date of this AD per EMBRAER Service Bulletin 120–32–0077, Change 01, dated September 25, 1997; or Change 02, dated December 23, 1997; is considered acceptable for compliance with the applicable requirements of paragraphs (e) and (f) of this AD.

Alternative Methods of Compliance

(h) In accordance with 14 CFR 39.19, the Manager, International Branch, ANM–116,

Transport Airplane Directorate, FAA, is authorized to approve alternative methods of compliance for this AD.

Note 4: The subject of this AD is addressed in Brazilian airworthiness directive 97–05–03R3, dated October 2, 2001.

Issued in Renton, Washington, on September 26, 2003.

Ali Bahrami,

Acting Manager, Transport Airplane Directorate, Aircraft Certification Service. [FR Doc. 03–24978] Filed 10–1–03; 8:45 am]

BILLING CODE 4910-13-P

DEPARTMENT OF HOMELAND SECURITY

Bureau of Customs and Border Protection

DEPARTMENT OF THE TREASURY

19 CFR Part 191

RIN 1515-AD32

Merchandise Processing Fees Eligible To Be Claimed as Certain Types of Drawback Based on Substitution of Finished Petroleum Derivatives

AGENCY: Customs and Border Protection, Homeland Security; Treasury. **ACTION:** Notice of proposed rulemaking.

SUMMARY: This document proposes to amend the Customs Regulations to provide that merchandise processing fees are eligible to be claimed, in limited circumstances, as drawback based on substitution of finished petroleum derivatives. The proposed amendments are consistent with a court decision in which merchandise processing fees were found to be eligible to be claimed as unused merchandise drawback. As drawback based on substitution of finished petroleum derivatives is, in limited circumstances, treated in the same manner as unused merchandise drawback, the amendments to the Customs Regulations proposed in this document reflect that merchandise processing fees are also eligible to be claimed as drawback in these circumstances.

DATES: Comments must be received on or before December 1, 2003.

ADDRESSES: Written comments may be submitted to Bureau of Customs and Border Protection, Office of Regulations & Rulings, Attention: Regulations Branch, 1300 Pennsylvania Avenue NW., Washington, DC 20229. Submitted comments may be inspected at Bureau of Customs and Border Protection, 799 9th Street, NW., Washington, DC, during regular business hours. Arrangements to

inspect submitted comments should be made in advance by calling Mr. Joseph Clark at (202) 572–8768.

FOR FURTHER INFORMATION CONTACT:

William G. Rosoff, Chief, Duty and Refund Determinations Branch, Office of Regulations and Rulings, Bureau of Customs and Border Protection, Tel. (202) 572–8807.

SUPPLEMENTARY INFORMATION:

Background

Merchandise Processing Fees

Merchandise processing fees are fees charged and collected for the processing of merchandise that is formally entered or released into the United States. See 19 U.S.C. 58c(a)(9)(A). Merchandise processing fees are assessed as a percentage of the value of the imported merchandise, as determined under 19 U.S.C. 1401a.

Merchandise Processing Fees Eligible To Be Claimed as Drawback

Section 313 of the Tariff Act of 1930, as amended, (19 U.S.C. 1313), concerns drawback and refunds. Drawback is a refund of certain duties, taxes and fees paid by the importer of record and granted to a drawback claimant under specific conditions.

In Texport Oil v. United States, 185 F.3d 1291 (Fed. Cir. 1999), the Court of Appeals for the Federal Circuit (CAFC) held that merchandise processing fees were assessed under Federal law and imposed by reason of importation and therefore eligible to be claimed as unused merchandise drawback pursuant to 19 U.S.C. 1313(j).

Subsection (p) of 19 U.S.C. 1313 authorizes drawback that is based on "substitution of finished petroleum derivatives." Subsection (p)(4)(B) of 19 U.S.C. 1313, in pertinent part, limits the amount of drawback payable under this subsection to the amount of drawback that would be attributable to the article "if imported under [subsection 1313(p)(2)(A)(iii) or (iv)] had the claim qualified for drawback under subsection (j)." [emphasis added]

Subsection 1313(p)(2)(A)(iii) requires that the exporter of the exported article had imported the qualified article in a quantity equal to or greater than the quantity of the exported article. Subsection 1313(p)(2)(A)(iv) requires that the exporter of the exported article had purchased or had exchanged, directly or indirectly, an imported qualified article from an importer in a quantity equal to or greater than the quantity of the exported article.

The language "had the claim qualified for drawback under subsection (j)" reflects that drawback is payable under

1313(p)(2)(A)(iii) or (iv) pursuant to the same formula set forth in subsection 1313(j), *i.e.*, the amount of drawback payable under 19 U.S.C. 1313(j) is not to exceed 99 percent of any duty, tax, or fee imposed under Federal law because of the imported article's importation. It is noted that "drawback payable" pursuant to 19 U.S.C. 1313(p)(2)(A)(iii) or (iv) includes merchandise processing fees.

merchandise processing fees.

It follows, therefore, that as the CAFC has determined that merchandise processing fees are eligible to be claimed as drawback pursuant to 19 U.S.C. 1313(j), such fees are also eligible to be claimed as drawback when drawback is based on substitution of finished petroleum derivatives pursuant to 19 U.S.C. 1313(p)(2)(A)(iii) or (iv).

Proposed Amendments to the Customs Regulations

The Texport Oil decision is reflected in the Customs Regulations at §§ 191.3 and 191.51. See 67 FR 48547 (July 25, 2002), in which a final rule was published amending the Customs Regulations to reflect that merchandise processing fees are eligible to be claimed as unused merchandise drawback pursuant to 19 U.S.C. 1313(j).

In order to reflect that the court's holding is applicable, in limited circumstances, to drawback based on substitution of finished petroleum derivatives, this document proposes to further amend the Customs Regulations.

Explanation of Amendments

It is proposed to amend §§ 191.3(a)(4), 191.3(b)(2), 191.51(b)(2) and 191.171 of the Customs Regulations (19 CFR 191.3, 191.51 and 191.171) to provide that merchandise processing fees are eligible to be claimed as drawback when the basis for drawback is the substitution of finished petroleum derivatives pursuant to 19 U.S.C. 1313(p)(2)(A)(iii) or (iv). A more detailed explanation of the proposed amendments is set forth below.

Amendment to § 191.3 of the Customs Regulations

Section 191.3(a)(4) of the Customs Regulations provides that merchandise processing fees for unused merchandise drawback pursuant to 19 U.S.C. 1313(j) are subject to drawback. As merchandise processing fees are eligible to be claimed as drawback for substitution of finished petroleum derivatives pursuant to 19 U.S.C. 1313(p)(2)(A)(iii) or (iv), it is proposed to amend § 191.3(a)(4) accordingly.

Conversely, § 191.3(b)(2) of the Customs Regulations lists the types of duties and fees that are not subject to drawback, and specifically excepts merchandise processing fees where unused merchandise drawback is claimed.

For the reasons stated above, it is proposed that this provision be amended to include an exception for merchandise processing fees where drawback is claimed for substitution of finished petroleum derivatives pursuant to 19 U.S.C. 1313(p)(2)(A)(iii) or (iv).

Amendment to § 191.51

Section § 191.51(b)(2) of the Customs Regulations sets forth the apportionment calculation to be used when determining the amount of merchandise processing fee eligible for drawback. It is proposed to amend § 191.51(b)(2) to include reference to drawback for substitution of finished petroleum derivatives pursuant to 19 U.S.C. 1313(p)(2)(A)(iii) or (iv).

Amendment to § 191.171

Finally, it is proposed to amend § 191.171 of the Customs Regulations, which describes the drawback allowance for substitution of finished petroleum derivatives, to add a new subsection (c) which sets forth the conditions when merchandise processing fees will be eligible for drawback pursuant to 19 U.S.C. 1313(p)(2)(A)(iii) or (iv).

Comments

Before adopting this proposal as a final rule, consideration will be given to any written comments timely submitted to CBP, including comments on the clarity of this proposed rule and how it may be made easier to understand. Comments submitted will be available for public inspection in accordance with the Freedom of Information Act (5 U.S.C. 552) and § 103.11(b) of the Customs Regulations (19 CFR § 103.11(b)), on regular business days between the hours of 9 a.m. and 4:30 p.m. at the Regulations Branch, Office of Regulations and Rulings, Bureau of Customs and Border Protection, 799 9th St., NW., Washington, DC. Arrangements to inspect submitted comments should be made in advance by calling Mr. Joseph Clark at (202) 572-

The Regulatory Flexibility Act and Executive Order 12866

Because these proposed regulatory changes conform the Customs
Regulations to reflect the full scope of a recent decision by the Court of
Appeals for the Federal Circuit,
pursuant to the provisions of the
Regulatory Flexibility Act, 5 U.S.C. 601
et seq., it is certified that, if adopted, the

proposed amendments will not have a significant impact on a substantial number of small entities. Further, these proposed amendments do not meet the criteria for a "significant regulatory action" as specified in Executive Order 12866.

Drafting Information

The principal author of this document was Ms. Suzanne Kingsbury, Office of Regulations and Rulings, Bureau of Customs and Border Protection. However, personnel from other offices participated in its development.

List of Subjects in 19 CFR Part 191

Claims, Commerce, Customs duties and inspection, Drawback.

Proposed Amendments to the Regulations

For the reasons stated above, it is proposed to amend part 191 of the Customs Regulations (19 CFR part 191) as follows:

PART 191—DRAWBACK

1. The general authority citation for part 191 continues to read as follows:

Authority: 5 U.S.C. 301; 19 U.S.C. 66, 1202 (General Note 23, Harmonized Tariff Schedule of the United States), 1313, 1624.

2. Section 191.3(a)(4) and (b)(2) are revised, and the introductory texts of paragraphs (a) and (b) are republished to read as follows:

§191.3 Duties and fees subject or not subject to drawback.

(a) Duties and fees subject to drawback include:

* *

(4) Merchandise processing fees (see § 24.23 of this chapter) for merchandise subject to unused merchandise drawback pursuant to 19 U.S.C. 1313(j), or merchandise subject to drawback for substitution of finished petroleum derivatives pursuant to 19 U.S.C. 1313(p)(2)(A)(iii) or (iv).

(b) Duties and fees not subject to drawback include:

(2) Merchandise processing fees (see § 24.23 of this chapter), except where unused merchandise drawback pursuant to 19 U.S.C. 1313(j) or drawback for substitution of finished petroleum derivatives pursuant to 19 U.S.C. 1313(p)(2)(A)(iii) or (iv) is claimed; and

3. In § 191.51, paragraph (b)(2) is revised to read as follows:

§191.51 Completion of drawback claims.

* * * * *

(b) Drawback due.

(2) Merchandise processing fee apportionment calculation. Where a drawback claimant seeks unused merchandise drawback pursuant to 19 U.S.C. 1313(j), or drawback for substitution of finished petroleum derivatives pursuant to 19 U.S.C. 1313(p)(2)(A)(iii) or (iv), for a merchandise processing fee paid pursuant to 19 U.S.C. 58c(a)(9)(A), the claimant is required to correctly apportion the fee to that merchandise that provides the basis for drawback when calculating the amount of drawback requested on the drawback entry. This is determined as follows:

4. In § 191.171, a new paragraph (c) is added to read as follows:

§ 191.171 General; Drawback allowance.

(c) Merchandise processing fees. In cases where the requirements of paragraph (b)(1) of this section have been met, merchandise processing fees will be eligible for drawback.

Robert C. Bonner,

Commissioner, Customs and Border Protection.

Approved: September 26, 2003.

Timothy E. Skud,

Deputy Assistant Secretary of the Treasury. [FR Doc. 03–24856 Filed 10–1–03; 8:45 am] BILLING CODE 4820–02–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 80

[FRL-7566-4]

Regulation of Fuel and Fuel Additives: Gasoline and Diesel Fuel Test Method Update

AGENCY: Environmental Protection Agency (EPA).

ACTION: Proposed rule.

SUMMARY: The Environmental Protection Agency (EPA) is proposing to take action to make certain fuel testing requirements more consistent and up-to-date by having refiners and laboratories use the most current version of an American Society of Testing and Materials (ASTM) analytical test method.

Specifically, we are proposing to update an ASTM designated analytical test method, ASTM D 1319 to the most recent 2002a version which if adopted will supersede earlier versions of this method in EPA's motor vehicle fuel

regulations. This method is designated in EPA regulations for measuring chemical compositions in reformulated gasoline (RFG), conventional gasoline (CG), and diesel fuel, specifically aromatics and olefins in CG and RFG and aromatics in diesel fuel. These updates allow for more consistent use of the same methodology across EPA motor vehicle fuel regulations and incoporate improvements in the test method procedures that will ensure better operation.

DATES: The Agency must receive comments or a request for public hearing by November 3, 2003.

ADDRESSES: If you wish to submit comments or request a public hearing, you should send any written materials to the docket address listed and to Joe Sopata, Chemist, Transportation & Regional Programs Division, U.S. Environmental Protection Agency, 1200 Pennsylvania Avenue, NW. (6406J), Washington, DC 20460; or by e-mail to sopata.joe@epa.gov. All comments and materials relevant to today's action are contained in Public Docket No. A–2002–15 and docket A–2001–21 located

at the following address: EPA Docket Center (EPA/DC), Public Reading Room, Room B102, EPA West Building, 1301 Constitution Avenue, NW., Washington, DC. Dockets may be inspected from 8:30 a.m. to 4:30 p.m., Monday through Friday, except on government holidays. You may reach the Air Docket by telephone at (202) 566–1742 and by facsimile at (202) 566–1741. You may be charged a reasonable fee for photocopying docket materials, as provided in 40 CFR part 2.

FOR FURTHER INFORMATION CONTACT: If you would like further information about this rule or to request a hearing, contact Joe Sopata, Chemist, Transportation & Regional Programs Division, (202) 564–9034.

SUPPLEMENTARY INFORMATION: The contents of today's preamble are listed in the following outline.

- I. Regulated Entities
- II. Rule Changes
 - A. Updating ASTM D 1319 Test Method to 2002a Year Version
- III. Statutory and Executive Order Reviews
- A. Executive Order 12866: Regulatory Planning and Review
- B. Paperwork Reduction Act

- C. Regulatory Flexibility Act
- D. Unfunded Mandates Reform Act
- E. Executive Order 13132: Federalism
- F. Executive Order 13175: Consultation and Coordination with Indian Tribal Governments
- G. Executive Order 13045: Protection of Children from Environmental Health & Safety Risks
- H. Executive Order 13211: Actions that Significantly Affect Energy Supply, Distribution, or Use
- I. National Technology Transfer Advancement Act
- IV. Statutory Provisions and Legal Authority

I. Regulated Entities

Entities potentially affected by this action include those involved with the production, importation, distribution, sale and storage of gasoline motor fuel and diesel motor fuel.

The table below gives some examples of entities that may have to comply with the regulations. However, since these are only examples, you should carefully examine these and other existing regulations in 40 CFR part 80. If you have any questions, please call the person listed in the FOR FURTHER INFORMATION CONTACT section above.

Category	NAICSs codes	SIC codes	Examples of potentially regulated parties
Industry	32411	2911	Petroleum refiners.
	54138	8734	Testing Laboratories.

^a North American Industry Classification System (NAICS).

II. Rule Changes

A. Updating ASTM D 1319 Test Method to 2002a Year Version

Refiners, importers and oxygenate blenders producing gasoline and diesel motor vehicle fuel are required to test Reformulated Gasoline (RFG), Conventional Gasoline (CG) and diesel fuel for various fuel parameters including olefins, and aromatics. ASTM test method D1319 is currently a designated test method for measuring olefins 1 in gasoline and aromatics 2 in diesel fuel and is also allowed as an alternative test method for measuring aromatics 3 in gasoline. Because rules were adopted at different points in time, the regulations currently cite three different versions of D 1319 (published in three different years) for these applications.

On February 26, 2002, the Agency published a final rule entitled "Regulation of Fuel and Fuel Additives:

Reformulated Gasoline Transition." 4 Among other things, this final rule updated certain ASTM test methods for RFG and CG, designated in EPA regulations, to their most recent ASTM version. Several designated test methods were updated to their most recent version including methods covering oxygen content, distillation properties, RVP, and aromatics. The designated test method for olefins, ASTM D 1319, was updated by EPA only to its 1998 version and not to the most recent version. This was because the 1999 version of ASTM D 1319 (the most recent version at that time) had mistakenly left out an important reference to use of another ASTM method. ASTM D 5599-00, the missing test method, measures oxygenate concentration when present in the gasoline sample. Measurement of oxygenate content when oxygenates are present is a required procedure when determining olefin content. Therefore, since ASTM D 5599-00 is EPA's designated method for oxygenate determination, omission of this

procedure in the 1999 version of ASTM 1319 meant that it would not be appropriate for EPA to adopt that version of ASTM 1319. We explained in our response to comments that "unless a determination is made that ASTM D 5599–00 can be appropriately included as a method for measuring oxygen and oxygen content with ASTM D 1319–99, EPA will retain the 1998 version of D 1319 as the designated test method for olefins." ⁵

Recently, David Bradley, the ASTM Director of Committee D02 for Petroleum Products and Lubricants, said in a letter to EPA that ASTM has updated test method D1319 to a 2002 year version. Mr. Bradley also pointed out that this most recent version of ASTM D 1319 now includes the reference to ASTM D 5599 thus resolving the problem associated with omission of EPA's designated test method for oxygen and oxygen content. The American Petroleum Institute (API)

^b Standard Industrial Classification (SIC) system code.

¹⁴⁰ CFR 80.46(b).

² 40 CFR 80.2(z).

^{3 40} CFR 80.46(f)(3).

⁴ February 26, 2002, (67 FR 8729).

 $^{^5}$ See Air Docket #A–2001–21, Document #V–C–01.

⁶ See Air Docket #A–2002–15, Document #II–D–

also submitted comments to EPA in support of this test method update of ASTM D 1319 to the 2002 year version.⁷ Thus, both ASTM and API support revising our motor vehicle fuels regulations to allow the use of D1319–02a for testing of olefins.

In addition to updating our regulations to allow for the use of ASTM D 1319–02a for determining olefins in gasoline (discussed above), we are also today proposing to allow use of the newest version of D1319 for determination of aromatics content in RFG and CG (as an alternative method)

and in determining aromatics content in diesel motor fuel. Previous versions of ASTM D1319 were allowed for determining aromatic content under previous rulemakings.

Table 1 lists the designated analytical test methods and alternative analytical test methods which are being updated for parameters measured under RFG, CG, and diesel fuels program in today's action. We have reviewed the 2002a version of ASTM test method D 1319 and we are in agreement with its revisions. We believe that the revisions in ASTM D 1319–02a are not significant

changes that would cause a user of an older version of the same method to incur significant costs. All of the revisions were deemed necessary by ASTM so that improvements in the test method's procedures would ensure better operation for the user of the test method. By updating ASTM D 1319 to the 2002a version for all three of these applications, the required analytical methodologies will be more consistent, making it easier for manufacturers of gasoline and diesel fuel to utilize the ASTM technique for all fuels and properties being tested.

TABLE 1.—DESIGNATED & ALTERNATIVE ANALYTICAL TEST METHODS UNDER RFG, CG & DIESEL FUEL PROGRAMS

Fuel parameter	Analytical test method
Olefins	ASTM D 1319–02a, entitled, "Standard Test Method for Hydrocarbon Types in Liquid Petroleum Products by Fluorescent Indicator Absorption."
Aromatics (gasoline and diesel)	ASTM D 1319–02a, entitled, "Standard Test Method for Hydrocarbon Types in Liquid Petroleum Products by Fluorescent Indicator Absorption", for diesel fuel, this method is the designated test method, for gasoline, this method is an alternative test method and if used as an alternative method, its results, must be correlated to ASTM D 5769–98.

In the "Final Rules" section of today's Federal Register, we are publishing a direct final rule that matches the substance of this proposed rule. If the Agency receives adverse comment or a request for public hearing by November 3, 2003, we will withdraw the direct final rule by publishing a timely withdrawal notice in the Federal Register. If the Agency receives no adverse comment or a request for public hearing by November 3, 2003, these test method changes will be effective sixty (60) days after publication of the final rule in the Federal Register. We are confident that sixty(60) days is sufficient lead time for industry to become familiar and implement this most recent ASTM test method for the applications mentioned above.

III. Statutory and Executive Order Reviews

A. Executive Order 12866: Regulatory Planning and Review

Under Executive Order 12866, (58 FR 51735 (October 4, 1993)) the Agency must determine whether the regulatory action is "significant" and therefore subject to OMB review and the requirements of the Executive Order. The Order defines "significant regulatory action" as one that is likely to result in a rule that may:

(1) Have an annual effect on the economy of \$100 million or more or adversely affect in a material way the economy, a sector of the economy, productivity, competition, jobs, the environment, public health or safety, or State, local, or tribal governments or communities;

(2) Create a serious inconsistency or otherwise interfere with an action taken or planned by another agency;

(3) Materially alter the budgetary impact of entitlements, grants, user fees, or loan programs or the rights and obligations of recipients thereof; or

(4) Raise novel legal or policy issues arising out of legal mandates, the President's priorities, or the principles set forth in the Executive Order."

Pursuant to the terms of Executive Order 12866, we have determined that this proposed rule is not a significant regulatory action.

B. Paperwork Reduction Act

This action does not add any new requirements involving the collection of information as defined by the Paperwork Reduction Act, 44 U.S.C. 3501 et seq. The Office of Management and Budget (OMB) has approved the information collection requirements contained in the final RFG/antidumping rulemaking (See 59 FR 7716, February 16, 1994) and has assigned OMB control number 2060–0277 (EPA

ICR No. 1591.14). The OMB has approved the information collection requirements contained in the final Tax Exempt (Dyed) Highway Diesel Fuel rulemaking (See 66 FR 64817, December 14, 2001) and has assigned OMB control number 2060–0308 (EPA ICR No. 1718.03).

Burden means the total time, effort, or financial resources expended by persons to generate, maintain, retain, or disclose or provide information to or for a Federal agency. This includes the time needed to review instructions; develop, acquire, install, and utilize technology and systems for the purposes of collecting, validating, and verifying information, processing and maintaining information, and disclosing and providing information; adjust the existing ways to comply with any previously applicable instructions and requirements; train personnel to be able to respond to a collection of information; search data sources; complete and review the collection of information; and transmit or otherwise disclose the information. An Agency may not conduct or sponsor, and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number. The OMB control numbers for EPA's regulations are listed in 40 CFR part 9 and 48 CFR chapter 15.

 $^{^{7}\,}See$ Air Docket #A=2002=15, Document #II=D=02.

C. Regulatory Flexibility Act

The Regulatory Flexibility Act (RFA) generally requires an agency to prepare a regulatory flexibility analysis of any rule subject to notice and comment rulemaking requirements under the Administrative Procedure Act or any other statute unless the agency certifies that the rule will not have a significant economic impact on a substantial number of small entities. Small entities include small businesses, small organizations, and small governmental jurisdictions.

For purposes of assessing the impacts of today's proposed rule on small entities, small entity is defined as: (1) A small business that has not more than 1,500 employees (13 CFR 121.201); (2) a small governmental jurisdiction that is a government of a city, county, town, school district or special district with a population of less than 50,000; and (3) a small organization that is any not-forprofit enterprise which is independently owned and operated and is not dominant in its field.

After considering the economic impacts of today's proposed rule on small entities, we believe that this action will not have a significant economic impact on a substantial number of small entities. We have determined that no small entities will experience an impact from this proposal. ASTM test method D 1319 is currently a designated test method for measuring olefins in gasoline and aromatics in diesel fuel and is also allowed as an alternative test method for measuring aromatics in gasoline (see citations above in Section II.A). Because rules were adopted at different points in time, the regulations currently cite three different versions of ASTM D 1319 (published in three different years) for these applications. Currently, if a small entity produces both gasoline and diesel fuel, and it relies on ASTM D 1319 for determining compliance with the fuel parameters mentioned above, it must maintain three different versions of ASTM D 1319. These proposed updates allow for more consistent use of the same methodology across EPA motor vehicle fuel regulations, thus increasing flexibility for small entities who manufacture gasoline or diesel fuel. Thus this proposed rule is expected to reduce operating costs for all parties, including small entities.

Although this proposed rule will not have a significant impact on a substantial number of small entities, EPA has nonetheless tried to reduce the impact of this rule on small entities. If the Agency receives no adverse comment or request for public hearing on this proposed rule, these test method changes will be effective sixty (60) days after publication of this proposed rules corresponding direct final rule in the **Federal Register**. We are confident that sixty (60) days is sufficient lead time for small entities to become familiar and implement this ASTM test method for its applications. We continue to be interested in the potential impacts of the rule on small entities and welcome comments on issues related to such impacts.

D. Unfunded Mandates Reform Act

Title II of the Unfunded Mandates Reform Act of 1995 (UMRA), Public Law 104-4, establishes requirements for Federal agencies to assess the effects of their regulatory actions on State, local, and tribal governments and the private sector. Under section 202 of the UMRA, EPA generally must prepare a written statement, including a cost-benefit analysis, for proposed and final rules with "Federal mandates" that may result in expenditures to State, local, and tribal governments, in the aggregate, or to the private sector, of \$100 million or more in any one year. Before promulgating an EPA rule for which a written statement is needed, section 205 of the UMRA generally requires EPA to identify and consider a reasonable number of regulatory alternatives and adopt the least costly, most costeffective or least burdensome alternative that achieves the objectives of the rule. The provisions of section 205 do not apply when they are inconsistent with applicable law. Moreover, section 205 allows EPA to adopt an alternative other than the least costly, most cost-effective or least burdensome alternative if the Administrator publishes with the final rule an explanation why that alternative was not adopted. Before EPA establishes any regulatory requirements that may significantly or uniquely affect small governments, including tribal governments, it must have developed under section 203 of the UMRA a small government agency plan. The plan must provide for notifying potentially affected small governments, enabling officials of affected small governments to have meaningful and timely input in the development of EPA regulatory proposals with significant Federal intergovernmental mandates, and informing, educating, and advising small governments on compliance with the regulatory requirements.

Today's proposed rule contains no Federal mandates (under the regulatory provisions of Title II of the UMRA) for State, local or tribal governments or the private sector. The rule would impose no enforceable duty on any State, local or tribal governments or the private sector. This rule applies to gasoline refiners, blenders and importers that supply gasoline or diesel fuel.

E. Executive Order 13132: Federalism

Executive Order 13132, entitled "Federalism" (64 FR 43255, August 10, 1999), requires EPA to develop an accountable process to ensure "meaningful and timely input by State and local officials in the development of regulatory policies that have federalism implications." "Policies that have federalism implications" is defined in the Executive Order to include regulations that have "substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government."

This proposed rule does not have federalism implications. It will not have substantial direct effects on the States, on the relationship between the national government and the States, or on the distribution of power and responsibilities among the various levels of government, as specified in Executive Order 13132. This proposed rule updates an ASTM test method to its most recent version. Thus, Executive Order 13132 does not apply to this proposed rule.

In the spirit of Executive Order 13132, and consistent with EPA policy to promote communications between EPA and State and local governments, EPA specifically solicits comment on this proposed rule from State and local officials.

F. Executive Order 13175: Consultation and Coordination With Indian Tribal Governments

Executive Order 13175, entitled "Consultation and Coordination with Indian Tribal Governments" (65 FR 67249, November 6, 2000), requires EPA to develop an accountable process to ensure "meaningful and timely input by tribal officials in the development of regulatory policies that have tribal implications." "Policies that have tribal implications" is defined in the Executive Order to include regulations that have "substantial direct effects on one or more Indian tribes, on the relationship between the Federal government and the Indian tribes, or on the distribution of power and responsibilities between the Federal government and Indian tribes.'

This proposed rule does not have tribal implications. It will not have substantial direct effects on tribal governments, on the relationship between the Federal government and Indian tribes, or on the distribution of power and responsibilities between the Federal government and Indian tribes, as specified in Executive Order 13175. This proposed rule applies to gasoline refiners, blenders and importers that supply gasoline or diesel fuel. Today's action updates an ASTM test method to its most recent version, and does not impose any enforceable duties on communities of Indian tribal governments. Thus, Executive Order 13175 does not apply to this proposed rule.

G. Executive Order 13045: Protection of Children From Environmental Health and Safety Risks

Executive Order 13045: "Protection of Children from Environmental Health Risks and Safety Risks" (62 FR 19885, April 23, 1997) applies to any rule that: (1) is determined to be "economically significant" as defined under Executive Order 12866, and (2) concerns an environmental health or safety risk that EPA has reason to believe may have a disproportionate effect on children. If the regulatory action meets both criteria, the Agency must evaluate the environmental health or safety effects of the planned rule on children, and explain why the planned regulation is preferable to other potentially effective and reasonably feasible alternatives considered by the Agency.

EPA interprets Executive Order 13045 as applying only to those regulatory actions that are based on health or safety risks, such that the analysis required under section 5–501 of the Order has the potential to influence the regulation. This rule is not subject to Executive Order 13045 because it does not establish an environmental standard intended to mitigate health or safety risks.

H. Executive Order 13211: Actions That Significantly Affect Energy Supply, Distribution, or Use

This proposed rule is not an economically "significant energy action" as defined in Executive Order 13211, "Actions Concerning Regulations That Significantly Affect Energy Supply, Distribution, or Use" (66 FR 28355 (May 22, 2001)) because it does not have a significant adverse effect on the supply, distribution, or use of energy. EPA is allowing additional flexibility and streamlining the regulations by updating an ASTM test method to its most current version for three applications under its motor vehicle programs.

I. National Technology Transfer Advancement Act

Section 12(d) of the National Technology Transfer and Advancement Act of 1995 ("NTTAA"), Public Law 104-113, section 12(d) (15 U.S.C. 272 note) directs EPA to use voluntary consensus standards in its regulatory activities unless to do so would be inconsistent with applicable law or otherwise impractical. Voluntary consensus standards are technical standards (e.g., materials specifications, test methods, sampling procedures, and business practices) that are developed or adopted by voluntary consensus standards bodies. The NTTAA directs EPA to provide Congress, through OMB, explanations when the Agency decides not to use available and applicable voluntary consensus standards.

This rule will update an ASTM test method which is a designated analytical test method for two applications and an alternative test method for one application to its most recent ASTM version. Today's action does not establish new technical standards or analytical test methods, although it does update an ASTM test method to its most current version. To the extent that this action would allow the use of standards developed by voluntary consensus bodies (such as ASTM) this action would further the objectives of the NTTAA.

IV. Statutory Provisions and Legal Authority

Statutory authority for today's proposed rule comes from sections 211(c), 211(i) and 211(k) of the CAA (42 U.S.C. 7545(c) and (k)). Sections 211(c) and 211(i) allow EPA to regulate fuels that contribute to air pollution which endangers public health or welfare, or which impairs emission control equipment. Section 211(k) prescribes requirements for RFG and conventional gasoline and requires EPA to promulgate regulations establishing these requirements. Additional support for the fuels controls in today's rule comes from sections 114(a) and 301(a) of the CAA.

List of Subjects in 40 CFR Part 80

Environmental protection, Air pollution control, Fuel additives, Gasoline, Diesel, Imports, Incorporation by reference, Motor vehicle pollution, Reporting and recordkeeping requirements.

Dated: September 24, 2003.

Marianne Lamont Horinko,

Administrator.

[FR Doc. 03–24908 Filed 10–1–03; 8:45 am] BILLING CODE 6560–50–P

ENVIRONMENTAL PROTECTION AGENCY

40 CFR Part 82

[FRL-7567-4]

RIN 2060-AK28

Protection of Stratospheric Ozone: Listing of Substitutes for Ozone-Depleting Substances-n-Propyl Bromide; Correction

AGENCY: Environmental Protection Agency.

ACTION: Notice of proposed rulemaking; correction.

SUMMARY: The Environmental Protection Agency (EPA) published in the Federal Register of June 3, 2003, a Notice of Proposed Rulemaking related to the Significant New Alternatives Policy (SNAP) program's review of n-propyl bromide. During the public comment period, members of the public requested clarification or correction of a number of statements in the preamble to the proposed rule. This document identifies, corrects, and clarifies these portions of the preamble.

FOR FURTHER INFORMATION CONTACT:

Margaret Sheppard. Before October 16, 2003, contact Ms. Sheppard by telephone at (202) 564-9163, by fax at (202) 565-2141, by e-mail at sheppard.margaret@epa.gov, or by mail at U.S. Environmental Protection Agency, Mail Code 6205J, Washington, DC 20460. Overnight or courier deliveries should be sent to the office location at 501 3rd Street, NW., Washington, DC 20001. Further information can be found by calling the Stratospheric Protection Hotline at (800) 296-1996, or by viewing EPA's Ozone Depletion World Wide Web site at http:/ /www.epa.gov/ozone/snap/. On and after October 16, 2003, contact Ms. Sheppard by telephone at (202) 343-9163, by e-mail at sheppard.margaret@epa.gov, or by mail at U.S. Environmental Protection Agency, Mail Code 6205J, Washington, DC 20460. Overnight or courier deliveries on and after October 16, 2003 should be sent to the new office location at 1310 L Street, NW., Washington, DC 20005.

SUPPLEMENTARY INFORMATION: The Environmental Protection Agency published in the Federal Register of June 3, 2003 (68 FR 33284), a Notice of Proposed Rulemaking related to the Significant New Alternatives Policy (SNAP) program's review of n-propyl bromide. During the public comment period, members of the public requested clarification or correction of certain

statements in the proposal, FR Doc. 03–75043, published on June 3, 2003.

In the proposed rule, FR Doc. 03–75043, published on June 3, 2003, in the "Supplementary Information" section make the following corrections:

- 1. On page 33286 at the top of the third column, the chemical name for HCFC–141b is corrected to read "1,1-dichloro-1-fluoroethane."
- 2. On page 33286 on the 8th line down from the top of the third column, the chemical name for HCFC–225cb is corrected to read "1,3-dichloro-1,1,2,2,3-pentafluoropropane."
- 3. On page 33286, on the 21st line down from the top of the third column, the chemical name for HFC–365mfc is corrected to read "1,1,1,3,3-pentafluorobutane."
- 4. On page 33304, at the bottom of the third column, footnote 15 is corrected to read as follows:

"The recommended AEL for nPB is lower than that for many acceptable solvents (HFEs, ketones, HFCs, HCFC–225ca/cb, hydrocarbons), but is higher or comparable to the AEL for some acceptable solvents (d-limonene, VMSs, dichlorobenzotrifluoride, HCFC–123, methylene chloride, PCBTF). However, a direct comparison between two compounds with different AELs does not necessarily mean that using a compound with a lower AEL is more risky. Actual exposure levels will vary based upon factors other than the AEL, such as emission controls in place, work practices, ventilation, rate of spraying, and vapor pressure of the solvent."

5. On page 33311, in the first column under the first bullet point, the following sentence appears beginning in the 51st line: "Recent regulations for hazardous air pollutants disallow use of methylene chloride in foam fabrication facilities." This sentence is corrected to read as follows: "Recent regulations for flexible polyurethane foam fabrication facilities that are major sources of hazardous air pollutants disallow use of methylene chloride-based adhesives at loop slitters and associated equipment used to apply adhesives to bond foam."

The National Emissions Standard for Hazardous Air Pollutants (NESHAP) for new and existing sources at flexible polyurethane foam fabrication facilities, published in the Federal Register of April 14, 2003 (68 FR 18062), does not generally disallow use of methylene chloride in all foam fabrication facilities. The NESHAP disallows the use of HAP-based adhesives at loopslitter affected sources at plants that are major source of hazardous air pollutants (HAPs), in accordance with the compliance dates set forth in the NESHAP. Stationary sources emitting, or having the potential to emit, less than 10 tons per year of a particular HAP, such as methylene chloride, and less than 25 tons per year of any combination of HAPs are not regulated as major sources under the NESHAP and are thus considered "area sources." EPA has listed flexible foam fabrication operations as an area source category for further scrutiny and may address HAP emissions from area sources under section 112(k) of the Clean Air Act in the future.

Users of adhesives containing methylene chloride must comply with applicable requirements of the Methylene Chloride Standard issued by the Occupational Safety and Health Administration (29 CFR 1910.1052).

Dated: September 17, 2003.

Jeanne Briskin,

Acting Director, Global Programs Division. [FR Doc. 03–25011 Filed 10–1–03; 8:45 am] BILLING CODE 6560–50–P

FEDERAL COMMUNICATIONS COMMISSION

47 CFR Part 73

[DA 03-2753; MB Docket No. 03-192; RM-10763]

Radio Broadcasting Services; Brazil and Spencer, IN

AGENCY: Federal Communications Commission.

ACTION: Proposed rule.

SUMMARY: This document requests comments on a petition for rulemaking filed jointly by Crossroads Investments, Inc., licensee of Station WSDM-FM, Channel 249A, Brazil, Indiana, and Mid-America Radio of Indiana, Inc., licensee of Station WSKT(FM), Channel 224A, Spencer, Indiana. Parties request the substitution of Channel 224A for Channel 249A at Brazil and modification of the license for Station WSDM-FM accordingly, and the substitution of Channel 249A for Channel 224A at Spencer and modification of the license of Station WSKT(FM) accordingly. Channel 249A can be allotted to Spencer in compliance with the Commission's minimum distance separation requirements with a site restriction of 9.5 kilometers (5.9 miles) west of the community at Station WSKT(FM)'s requested site at coordinates 39-15-18 North Latitude and 86-51-51 West Longitude. Additionally, Channel 224A can be allotted to Brazil with a site restriction of 1.8 kilometers (1.1 miles) southwest of the community at Station WSDM-FM's requested site at

coordinates 39–30–43 NL and 87–08–19 WL. In accordance with Section 1.420(g)(3) of the Commission's Rules, any party expressing an interest in the respective channels should demonstrate why these proposals are not "incompatible channel swaps" such that their expressions of interest are foreclosed.

DATES: Comments must be filed on or before October 27, 2003, and reply comments on or before November 12, 2003.

ADDRESSES: Federal Communications Commission, 445 Twelfth Street, SW., Washington, DC 20554. In addition to filing comments with the FCC, interested parties should serve the petitioner's counsel, as follows: Frank R. Jazzo, Anne Goodwin Crump, Fletcher, Heald and Hildreth, PLC, 1300 North 17th Street, Eleventh Floor, Arlington, Virginia 22209.

FOR FURTHER INFORMATION CONTACT: Victoria McCauley, Media Bureau, (202) 418–2180.

SUPPLEMENTARY INFORMATION: This is a synopsis of the Commission's Notice of Proposed Rule Making, MB Docket No. 03-192 adopted September 3, 2003, and released September 5, 2003. The full text of this Commission decision is available for inspection and copying during normal business hours in the FCC's Reference Information Center at Portals II, CY-A257, 445 Twelfth Street. SW., Washington, DC. This document may also be purchased from the Commission's duplicating contractors, Qualex International, Portals II, 445 12th Street, SW., Room CY-B402, Washington, DC 20554, telephone (202) 863-2893, or via e-mail qualexint@aol.com.

Provisions of the Regulatory Flexibility Act of 1980 do not apply to this proceeding.

Members of the public should note that from the time a Notice of Proposed Rule Making is issued until the matter is no longer subject to Commission consideration or court review, all *ex parte* contacts are prohibited in Commission proceedings, such as this one, which involve channel allotments. *See* 47 CFR 1.1204(b) for rules governing permissible *ex parte* contacts.

For information regarding proper filing procedures for comments, *see* 47 CFR 1.415 and 1.420.

List of Subjects in 47 CFR Part 73

Radio, Radio broadcasting.

For the reasons discussed in the preamble, the Federal Communications Commission proposes to amend 47 CFR part 73 as follows:

PART 73—RADIO BROADCAST SERVICES

1. The authority citation for part 73 continues to read as follows:

Authority: 47 U.S.C. 154, 303, 334 and 336.

§73.202 [Amended]

2. Section 73.202(b), the Table of FM Allotments under Indiana, is amended by removing Channel 249A and adding Channel 224A at Brazil and by removing Channel 224A and adding Channel 249A at Spencer.

Federal Communications Commission.

John A. Karousos,

Assistant Chief, Audio Division, Media Bureau.

[FR Doc. 03–24939 Filed 10–1–03; 8:45 am] **BILLING CODE 6712–01–P**

FEDERAL COMMUNICATIONS COMMISSION

47 CFR Part 73

[DA 03-2829; MB Docket No. 03-196; RM-10626]

Radio Broadcasting Services; Mt. Vernon and Okawville, IL

AGENCY: Federal Communications

Commission.

ACTION: Proposed rule.

SUMMARY: This document requests comments on a petition for rulemaking filed by Benjamin Stratemeyer, licensee of Station WIBV(FM), Mount Vernon, Illinois, requesting the reallotment of Channel 271B1 from Mount Vernon to Okawville, Illinois, as the community's first local aural transmission service, and modification of the license of Station WIBV(FM) to reflect the change of community. The proposal also requires the reclassification of Station KEZK-FM, St. Louis, Missouri, Channel 273C to specify operation on Channel 273C0 pursuant to the reclassification procedures adopted by the Commission. See Second Report and Order in MM Docket 98–93 (1998 Biennial Regulatory Review—Streamlining of Radio Technical Rules in Parts 73 and 74 of the Commission's Rules) 65 FR 79773 (2000). An Order to Show Cause was issued to Infinity Radio Subsidiary Operations, Inc., licensee of Station KEZK(FM) (RM-10626). Channel 271B1 can be allotted at Okawville, Illinois, at Petitioner's requested site 19.0 kilometers (11.8 miles) southeast of the community. Coordinates for Channel 271B1 at Okawville are 38-21-56NL and 89-21-2 WL.

DATES: Comments must be filed on or before October 30, 2003, and reply

comments on or before November 14, 2003. Any counterproposal filed in this proceeding need only protect Station KEZK(FM), St. Louis, Missouri, as a Class C0 allotment.

ADDRESSES: Federal Communications Commission, 445 Twelfth Street, SW., Washington, DC 20554. In addition to filing comments with the FCC, interested parties should serve the petitioner's counsel, and Station KEZK(FM) as follows: Clifford M. Harrington, Esq., Dawn M. Scarrino, Esq., Collette M. Capretz, Esq., Shaw Pittman, LLP, 2300 N Street NW., Washington, DC 20037–1128; Infinity Radio Subsidiary Operations Inc., 2000 K Street NW., Suite 725, Washington, DC 20006.

FOR FURTHER INFORMATION CONTACT:

Victoria McCauley, Media Bureau, (202) 418–2180.

SUPPLEMENTARY INFORMATION: This is a synopsis of the Commission's Notice of Proposed Rule Making, MB Docket No. 03-196 adopted September 3, 2003, and released September 8, 2003. The full text of this Commission decision is available for inspection and copying during normal business hours in the FCC's Reference Information Center at Portals II, CY-A257, 445 Twelfth Street SW., Washington, DC. This document may also be purchased from the Commission's duplicating contractors, Qualex International, Portals II, 445 12th Street, SW., Room CY-B402, Washington, DC 20554, telephone (202) 863-2893, or via e-mail qualexint@aol.com.

Provisions of the Regulatory Flexibility Act of 1980 do not apply to

this proceeding.

Members of the public should note that from the time a Notice of Proposed Rule Making is issued until the matter is no longer subject to Commission consideration or court review, all *ex parte* contacts are prohibited in Commission proceedings, such as this one, which involve channel allotments. *See* 47 CFR 1.1204(b) for rules governing permissible *ex parte* contacts.

For information regarding proper filing procedures for comments, see 47 CFR 1.415 and 1.420.

List of Subjects in 47 CFR Part 73

Radio, Radio broadcasting.

For the reasons discussed in the preamble, the Federal Communications Commission proposes to amend 47 CFR part 73 as follows:

PART 73—RADIO BROADCAST SERVICES

1. The authority citation for part 73 continues to read as follows:

Authority: 47 U.S.C. 154, 303, 334 and 336.

§73.202 [Amended]

- 2. Section 73.202(b), the Table of FM Allotments under Illinois is amended by removing Channel 271B1 at Mount Vernon and adding Okawville, Channel 271B1.
- 3. Section 73.202(b), the Table of FM Allotments under Missouri is amended by removing Channel 273C and adding Channel 273C0 at St. Louis.

Federal Communications Commission.

John A. Karousos,

Assistant Chief, Audio Division, Media Bureau.

[FR Doc. 03–24940 Filed 10–1–03; 8:45 am]

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

50 CFR Part 648

[I.D. 092903A]

New England Fishery Management Council; Public Meeting

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Public meeting.

SUMMARY: The New England Fishery Management Council (Council) will hold a special one-day Council meeting on October 21, 2003, to consider actions affecting New England fisheries in the exclusive economic zone (EEZ).

DATES: The meeting will be held on Tuesday, October 21, 2003, and will begin at 9 a.m.

ADDRESSES: The meeting will be held at the Holiday Inn, One Newbury Street, Peabody, MA 01960; telephone (978) 535–4600. Requests for special accommodations should be addressed to the New England Fishery Management Council, 50 Water Street, Mill 2, Newburyport, MA 01950; telephone (978) 465–0492.

FOR FURTHER INFORMATION CONTACT: Paul J. Howard, Executive Director, New England Fishery Management Council, (978) 465–0492.

Tuesday, October 21, 2003

Following introductions, the Council will review, consider and respond to comments submitted in response to Draft Amendment 13 to the Northeast Multispecies Fishery Management Plan and its Draft Supplemental Environmental Impact Statement. Final

decisions on the Amendment 13 alternatives are scheduled to occur on November 4–6, 2003. In addition, the Council will consider and approve recommendations for Spiny Dogfish specifications for the 2004–2005 fishing year.

Although other non-emergency issues not contained in this agenda may come before this Council for discussion, those issues may not be the subject of formal action during this meeting. Council action will be restricted to those issues specifically listed in this notice and any issues arising after publication of this notice that require emergency action under section 305(c) of the Magnuson-Stevens Act, provided that the public has been notified of the Council's intent to take final action to address the emergency.

Special Accommodations

This meeting is physically accessible to people with disabilities. Requests for

sign language interpretation or other auxiliary aids should be directed to Paul J. Howard (see **ADDRESSES**) at least 5 days prior to the meeting date.

Dated: September 29, 2003.

Bruce C. Morehead,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service. [FR Doc. 03–25027 Filed 10–1–03; 8:45 am] BILLING CODE 3510–22–S

Notices

Federal Register

Vol. 68, No. 191

Thursday, October 2, 2003

This section of the FEDERAL REGISTER contains documents other than rules or proposed rules that are applicable to the public. Notices of hearings and investigations, committee meetings, agency decisions and rulings, delegations of authority, filing of petitions and applications and agency statements of organization and functions are examples of documents appearing in this section.

DEPARTMENT OF AGRICULTURE

Forest Service

Medicine Bow-Routt National Forests and Thunder Basin National Grassland Carbon County, WY; Blackhall-McAnulty Timber Sale, Prescribed Burn and Travel Management; Correction

AGENCY: Forest Service, USDA.

ACTION: Notice of intent to prepare an environmental impact statement; correction.

SUMMARY: The Forest Service published a notice of intent to prepare an environmental impact statement for the Blackhall-McAnulty Timber Sale, Prescribed Burn and Travel Management Analysis in the **Federal Register** of June 11, 2003. The original notice designated the Forest Supervisor as the Responsible Official. This correction will designate the District Ranger as the Responsible Official.

FOR FURTHER INFORMATION CONTACT: Terry DeLay, Brush Creek/Hayden

Ranger District, P.O. Box 249, Saratoga, WY 82331, 307–326–2518.

Correction

In the **Federal Register** of June 11, 2003, in FR Doc. 03–14672, on page 34902, in the third column, correct the "Responsible Official" caption to read:

Responsible Official

Scott G. Armentrout, District Ranger, Brush Creek/Hayden Ranger District, Medicine Bow-Routt National Forests and Thunder Basin National Grassland, South Highway 130, Saratoga, Wyoming 82331, is the official responsible for making the decision on this action. He will document his decision and rationale in a Record of Decision.

Dated: September 25, 2003.

Scott G. Armentrout,

District Ranger.

[FR Doc. 03–24981 Filed 10–1–03; 8:45 am] BILLING CODE 3410–11–M

DEPARTMENT OF AGRICULTURE

Grain Inspection, Packers and Stockyards Administration

Solicitation of Nominations for Members of the Grain Inspection Advisory Committee

AGENCY: Grain Inspection, Packers and Stockyards Administration, USDA. **ACTION:** Notice to solicit nominees.

SUMMARY: The Grain Inspection, Packers and Stockyards Administration (GIPSA) is announcing that nominations are being sought for persons to serve on GIPSA's Grain Inspection Advisory Committee.

DATES: Form AD–755 must be received not later than December 1, 2003.

ADDRESSES: Completed AD–755 forms should be submitted to GIPSA at 1400 Independence Avenue, SW., STOP 3601, Washington, DC 20250–3601. The completed form may also be faxed to GIPSA.

supplementary information: Under authority of section 21 of the United States Grain Standards Act (Act), as amended, the Secretary of Agriculture established the Grain Inspection Advisory Committee (Advisory Committee) on September 29, 1981, to provide advice to the Administrator on implementation of the Act. Section 109 of the Grain Standards and Warehouse Improvement Act of 2000, Pub. L. 106–472, extended the authority for the Advisory Committee through September 30, 2005.

The Advisory Committee presently consists of 15 members, appointed by the Secretary, who represent the interests of grain producers, processors, handlers, merchandisers, consumers, and exporters, and includes scientists with expertise in research related to the policies in section 2 of the Act. Members of the Advisory Committee serve without compensation. They are reimbursed for travel expenses, including per diem in lieu of subsistence, for travel away from their homes or regular places of business in

performance of Advisory Committee service, as authorized under section 5703 of Title 5, United States Code. Alternatively, travel expenses may be paid by Committee members.

Nominations are being sought for persons to serve on the Advisory Committee to replace the five members and the five alternate members whose terms will expire March 2004.

Persons interested in serving on the Advisory Committee, or in nominating individuals to serve, should contact: GIPSA, by telephone (tel: 202–205–8281), fax (fax: 202–205–4714), or electronic mail (e-mail: Terri.L.Henry@usda.gov) and request Form AD–755. Form AD–755 may also be obtained via the Internet through GIPSA's Home page at: http://www.usda.gov/gipsa/advcommittee/ad755.pdf. The completed form should be sent to the address above or faxed to GIPSA.

Nominations are open to all individuals without regard to race, color, religion, sex, national origin, age, disability, marital status, or sexual orientation. To ensure that recommendations of the Committee take into account the needs of the diverse groups served by the Department, membership shall include, to the extent practicable, individuals with demonstrated ability to represent minorities, women, and persons with disabilities.

The final selection of Advisory Committee members and alternates will be made by the Secretary.

Donna Reifschneider,

Administrator.

[FR Doc. 03–24946 Filed 10–1–03; 8:45 am]

DEPARTMENT OF COMMERCE

Census Bureau

Title: Report of Privately-Owned Residential Building or Zoning Permits Issued (Building Permits Survey)

ACTION: Proposed collection; comment request.

SUMMARY: The Department of Commerce, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to

take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Pub. L. 104–13 (44 U.S.C. 3506(c)(2)(A)). DATES: Written comments must be submitted on or before December 1, 2003.

ADDRESSES: Direct all written comments to Diana Hynek, Departmental Paperwork Clearance Officer, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW, Washington, DC 20230 (or via the Internet at dhynek@doc.gov).

FOR FURTHER INFORMATION CONTACT:

Requests for additional information or copies of the information collection instrument(s) and instructions should be directed to Erica Filipek, Census Bureau, Room 2105, FOB 4, Washington, DC 20233–6900, (301) 763–5161 (or via the Internet at erica.mary.filipek@census.gov).

SUPPLEMENTARY INFORMATION:

I. Abstract

The Census Bureau plans to request a three year extension of a currently approved collection of the Form C-404, Building Permits Survey. The Census Bureau produces statistics used to monitor activity in the large and dynamic construction industry. Given the importance of this industry, several of the statistical series are key economic indicators. Two such series are (a) Housing Units Authorized by Building Permits and (b) Housing Starts. Both are based on data from samples of permitissuing places. These statistics help state and local governments and the Federal Government, as well as private industry, to analyze this important sector of the economy.

The Census Bureau uses Form C–404 to collect data to provide estimates of the number and valuation of new residential housing units authorized by building permits. We use the data, a component of the index of leading economic indicators, to estimate the number of housing units started, completed, and sold, if single-family, and to select samples for the Census Bureau's demographic surveys. Policymakers, planners, businessmen/

women, and others use the detailed geographic data collected from state and local officials on new residential construction authorized by building permits to monitor growth and plan for local services and to develop production and marketing plans. The Building Permits Survey is the only source of statistics on residential construction for states and smaller geographic areas. Building permits are public records so the information is not subject to disclosure restrictions.

II. Method of Collection

The Census Bureau collects this information by mail and electronically through files we download or receive on diskettes or via e-mail.

Monthly, we currently collect this information by mail for about 8,170 permit-issuing jurisdictions and electronically for 550 jurisdictions. Annually, we collect this information by mail for about 10,180 jurisdictions. The universe for the survey will be updated in January 2004 from about 18,900 jurisdictions to 19,600 jurisdictions. A new monthly sample will also be introduced. Monthly data for 2004 will be collected for both the old and the new monthly samples. For 2004, we plan to collect monthly data for about 10,600 permit-issuing jurisdictions (at least 560 electronically), and to collect annual data for about 9,000 jurisdictions. The sample overlap will end in January 2005, thereafter, we will collect monthly data for about 8,600 jurisdictions (at least 560 electronically) and annual data for about 11.000 jurisdictions.

III. Data

OMB Number: 0607–0094. *Form Number:* C–404.

Type of Review: Regular submission.
Affected Public: State and local
governments.

Estimated Number of Respondents: 19,600.

Estimated Time Per Response: 10 minutes for monthly respondents who report by mail, 3 minutes for monthly respondents who report electronically, and 25 minutes for annual respondents who report by mail.

Estimated Total Annual Burden Hours: 24,166 for 2004, 20,999 thereafter.

Estimated Total Annual Cost: \$323,596.

Respondent's Obligation: Voluntary. Legal Authority: Title 13, United States Code, Section 182.

IV. Request for Comments

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection; they also will become a matter of public record.

Dated: September 26, 2003.

Madeleine Clayton,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. 03–24960 Filed 10–1–03; 8:45 am] BILLING CODE 3510–07–P

DEPARTMENT OF COMMERCE

Economic Development Administration

Notice of Petitions by Producing Firms for Determination of Eligibility To Apply for Trade Adjustment Assistance

AGENCY: Economic Development Administration (EDA).

ACTION: To give all interested parties an opportunity to comment.

Petitions have been accepted for filing on the dates indicated from the firms listed below.

LIST OF PETITION ACTION BY TRADE ADJUSTMENT ASSISTANCE FOR PERIOD AUGUST 20, 2003-SEPTEMBER 26, 2003

Firm name	Address	Date petition accepted	Product
Acushnet Rubber Co., Inc. dba Precix, Inc.	744 Belleville Avenue, New Bedford, MA 02742.	09/26/03	Copier rolls and blades and windshield wiper blades.
Beadles Lumber Company Bobs Candies, Inc	900 6th Street, N.E., Moultrie, GA 31776 1315 West Oakridge Drive, Albany, GA		Southern yellow pine lumber. Candy canes.
·	31707.		

LIST OF PETITION ACTION BY TRADE ADJUSTMENT ASSISTANCE FOR PERIOD AUGUST 20, 2003—SEPTEMBER 26, 2003—Continued

Firm name	Address	Date petition accepted	Product
Calhoun Bend Mill, Inc	3615 Fourth Street, Jonesville, LA 71343.	09/04/03	Dry flour-based mixes.
Dan River, Inc	P.O. Box 261, Danville, VA 24543	09/11/03	Fabric for home fashions and automotive industries.
Delta Brands, Inc	2204 Century Center Blvd., Irving, TX 75062.	09/04/03	Steel milling machines.
Eagle Stud Mill, Inc	1620 Rogers Street, Unit 7, Missoula, MT 599802.	09/04/03	Coniferous lumber studs.
Fields & Sons, Inc	P.O. Box 25, Kodiak, AK 99615	09/17/03	Salmon.
Henkel, Inc	211 East Church Street, Hammond, LA 70401.	09/04/03	Electrode ovens.
IndTool, Inc	412 Bradley Street, Burlington, NC 27215.	09/05/03	Gear boxes and parts and other speed changers.
Janssen Engineering, Inc	6920 Route 7, North Dover, AR 72837	09/04/03	Camshafts and repair parts for tractors and implements.
National Magnetic Group, Inc	1210 Win Drive, Bethlehem, PA 18017	09/03/03	Soft ferrites and dielective resonators.
Northcutt Woodworks, L. P	101 South 4th Street, Crockett, TX 75835.	09/17/03	Pine moldings.
Polar Ware Company	2806 North 15th Street, Sheboygan, WI 53082.	08/29/03	Stainless steel kitchen ware.
Scott Powr-Ply Company dba Scott Fly Rods and The Scott Fly Rod Company.	2355 Air Park Way, Montrose, CO 81401.	08/26/03	Fishing rods.
Silverton Victorian Millworks, Inc. dba The Millworks, Inc.	466 S. Sky Lane, Durango, CO 81303	08/26/03	Wood moldings.
Williamson Corporation	70 Dominion Drive, Concord, MA 01742	09/26/03	Non-contact infrared temperature sensors for used in process control systems.

The petitions were submitted pursuant to Section 251 of the Trade Act of 1974 (19 U.S.C. 2341). Consequently, the United States Department of Commerce has initiated separate investigations to determine whether increased imports into the United States of articles like or directly competitive with those produced by each firm contributed importantly to total or partial separation of the firm's workers, or threat thereof, and to a decrease in sales or production of each petitioning firm. Any party having a substantial interest in the proceedings may request a public hearing on the matter. A request for a hearing must be received by Trade Adjustment Assistance, Room 7315, Economic Development Administration, U.S. Department of Commerce, Washington, DC 20230, no later than the close of business of the tenth calendar day following the publication of this notice.

The Catalog of Federal Domestic Assistance official program number and title of the program under which these petitions are submitted is 11.313, Trade Adjustment Assistance.

Dated: September 26, 2003.

Brenda A. Johnson,

Acting Director, Planning and Development Assistance Division.

[FR Doc. 03–24971 Filed 10–1–03; 8:45 am] BILLING CODE 3510–24–P

DEPARTMENT OF COMMERCE

International Trade Administration

Format for Petition Requesting Relief Under U.S. Countervailing Duty Law

ACTION: Proposed collection; comment request.

SUMMARY: The Department of Commerce, as part of its continuing effort to reduce paperwork and respondent burdens, invites the general public and other Federal agencies to take this opportunity to comment on the continuing information collections, as required by the Paperwork Reduction Act of 1995, Pub. L. 104–13 (44 U.S.C. 3506(c)(2)(A)).

DATES: Written comments must be submitted on or before December 1, 2003.

ADDRESSES: Direct all written comments to Diana Hynek, Departmental Paperwork Clearance Officer, Department of Commerce, Room 6625, 14th and Constitution Avenue, NW., Washington, DC 20230 or via the Internet at dHynek@doc.gov.

FOR FURTHER INFORMATION CONTACT:

Request for additional information or copies of the information collection instrument and instructions should be directed to: Nicole Bankhead, Import Administration, Office of Policy, Room 3713, 14th & Constitution Avenue, NW., Washington, DC 20230; Phone number: (202) 482–8221, and fax number: (202) 501–7952.

SUPPLEMENTARY INFORMATION:

I. Abstract

The International Trade Administration, Import Administration, AD/CVD Enforcement, implements the U.S. antidumping and countervailing duty law. Import Administration investigates allegations of unfair trade practices by foreign governments and producers and, in conjunction with the U.S. International Trade Commission, can impose duties on the product in question to offset the unfair practices. Form ITA-366P—Format for Petition Requesting Relief Under the U.S. Countervailing Duty Law—is designed for U.S. companies or industries that are unfamiliar with the Countervailing law and the petition process. The Form is designed for potential petitioners that believe a foreign competitor is being subsidized unfairly. Since a variety of detailed information is required under the law before initiation of a countervailing duty investigation, the Form is designed to extract such information in the least burdensome manner possible.

II. Method of Data Collection

Form ITA-366P is sent by request to potential U.S. petitioners.

III. Data

OMB Number: 0625–0148. *Form Number:* ITA–366P.

Type of Review: Regular Submission. Affected Public: U.S. companies or industries that suspect the presence of unfair competition from subsidized foreign enterprises.

Estimated Number of Respondents: 5. Estimated Time Per Response: 40 hours.

Estimated Total Annual Burden Hours: 200 hours.

Estimated Total Annual Costs: Assuming the number of petitioners remains the same, the estimated annual cost for this collection is \$27,500 (\$14,000 for respondents and \$13,500 for federal government).

IV. Request for Comments

Comments are invited on (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden (including hours and costs) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or forms of information technology.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection; they also will become a matter of public record.

Dated: September 26, 2003.

Madeleine Clayton,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. 03–24961 Filed 10–1–03; 8:45 am] **BILLING CODE 3510–DS-P**

DEPARTMENT OF COMMERCE

National Institute of Standards and Technology

Proposed Information Collection; Comment Request; Malcolm Baldrige National Quality Award Application

ACTION: Notice.

SUMMARY: The Department of Commerce, as part of its continuing effort to reduce paperwork and

respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Public Law 104–13 (44 U.S.C. 3506(c)(2)(A).

DATES: Written comments must be submitted on or before December 1, 2003

ADDRESSES: Direct all written comments to Diana Hynek, Departmental Paperwork Clearance Officer, Department of Commerce, Room 6625, Herbert Hoover Building, 1401 Constitution Avenue, NW., Washington, DC 20230 (or via the Internet at dHynek@doc.gov).

FOR FURTHER INFORMATION CONTACT:

Requests for additional information or copies of the information collection instrument(s) and instruction should be directed to JoAnne M. Surette, Baldrige National Quality Program,
Administration Building, Room 621,
100 Bureau Drive, Stop 1020, National Institute of Standards and Technology,
Gaithersburg, MD 20899–1020;
telephone (301) 975–5267, fax (301)
948–3716, e-mail
joanne.surette@nist.gov.

SUPPLEMENTARY INFORMATION:

I. Abstract

The Department of Commerce is responsible for the Baldrige National Quality Program and the Malcolm Baldrige National Quality Award. The National Institute of Standards and Technology (NIST), an agency of the Department's Technology Administration, manages the Baldrige Program. Applicants for the Malcolm Baldrige National Quality Award are required to perform two steps: (1) The applicant organization certifies that it meets eligibility requirements; (2) the applicant organization prepares and completes an application form and the application process. The Malcolm Baldrige National Quality Award Program Office will assist with or offer advice on any questions or issues that the applicant may have concerning the eligibility process or in completing the self-certification forms. NIST will use the application package to assess and provide feedback on the applicant's quality and performance practices.

II. Method of Collection

Applicants must comply in writing according to the Baldrige Award Application Forms booklet.

III. Data

OMB Number: 0693-0006.

Form Number: None.

Type of Review: Regular submission. Affected Public: Business or other forprofit organizations.

Estimated Number of Respondents: 100.

Estimated Time Per Response: 74 hours.

Estimated Total Annual Burden Hours: 7.400.

Estimated Total Annual Cost: \$0

IV. Request for Comments

Comments are invited on: (a) Whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden (including hours and cost) of the proposed collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology.

Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval of this information collection; they will also become a matter of public record.

Dated: September 26, 2003.

Gwellnar Banks,

Management Analyst, Office of the Chief Information Officer.

[FR Doc. 03–24959 Filed 10–1–03; 8:45 am] **BILLING CODE 3510–13–P**

DEPARTMENT OF COMMERCE

National Oceanic and Atmospheric Administration

[I.D. 092503B]

Western Pacific Fishery Management Council; Public Meetings

AGENCY: National Marine Fisheries Service (NMFS), National Oceanic and Atmospheric Administration (NOAA), Commerce.

ACTION: Notice of public meetings and hearings.

SUMMARY: The Western Pacific Fishery Management Council's (Council) Scientific and Statistical Committee (SSC) will meet on Tuesday, October 14, 2003, through Wednesday October 16, 2003; and the Council will hold its 120th meeting from Monday October 20, 2003 through Thursday October 23, 2003, in Honolulu, HI. (see **SUPPLEMENTARY INFORMATION** for specific times, dates, and agenda items).

ADDRESSES: The SSC meeting will be held at the Council Office Conference Room, 1164 Bishop St., Suite 1400, Honolulu, HI; telephone: (808) 522–8220. The Council meeting will be held at Pagoda Hotel, Cest'Si Bon Room, 1525 Rycroft Street, Honolulu, HI 96814; telephone (808) 941–6611.

FOR FURTHER INFORMATION CONTACT:

Kitty M. Simonds, Executive Director; telephone: 808–522–8220.

SUPPLEMENTARY INFORMATION:

Dates and Times

The SSC meeting will be held from 9 a.m. to 5 p.m. on October 14, 2003, and from 8:30 a.m. to 5 p.m. on October 15–16, 2003.

- 1. Introductions
- 2. Approval of draft agenda and assignment of rapporteur
- 3. Approval of the minutes of the 83rd meeting
 - 4. Bottomfish
 - A. Stock assessment workshop
- B. Main Hawaiian Islands (MHI) catch data project
 - C. Genetic research proposal
 - D. Status of MHI area closure review
 - E. Report on MHI scoping meeting
 - F. Seamount groundfish moratorium
 - 5. Protected species
- A. Status of Sea Turtle Recovery Team and Recovery Plans
- B. Observer programs: objectives and design
 - 6. Crustaceans fisheries
- A. Report on Northwestern Hawaiian Islands (NWHI) 2003 lobster research cruise
- B. Results of September lobster tagging charter
- C. Application of lobster research in stock assessment model
 - 7. Precious Corals
 - A. Report on MHI black coral meeting

8:30 a.m. Wednesday, October 15, 2003

- 8. Pelagic Fisheries
- A. American Samoa and Hawaii Longline Quarterly Reports
 - B. Tuna and billfish stock assessments
- C. Final Report on phase two of chute trials for seabird conservation
- D. Turtle conservation and management
- a. Update on Judge Kotelly's ruling vacating the June 2002 regulations and 2002 Biological Opinion
- b. Movement and survivorship of turtles released from Longline fisheries
- c. Status of Environmental Impact Statements (EIS)
 - i. Supplemental Pelagic EIS
 - ii. MHI Turtle EIS
 - iii. Longline Experimental Permit EIS

- 1. Preferred alternative
- 2. Atlantic mitigation experiments
- d. Turtle Advisory Committee & Database meetings
 - e. Council turtle conservation actions f. Measures to manage Hawaii's
- Longline fishery
 - E. Marlin management
 - a. Report on public scoping meetings
 - b. Marlin tagging project
 - F. Private fish aggregation devices
 - G. Shark management
- H. Report on international meetings and issues
- a. Standing Committee on Tuna and Billfish
- b. Predatory conference
- c. People and the Sea Conference
- d. Inter-American Convention on Sea Turtles

8:30 a.m. Thursday, October 16, 2003

Ecosystem and Habitat

- A. Northwestern Hawaiian Islands/ Mariana Islands Archipelagic Ecological Assessments
- B. NWHI Sanctuary designation progress report
- C. Report on the State of Hawaii papio and ulua tagging project
 - 10. Other business
- A. Draft Pacific Islands Region Strategic Plan - Research
 - B. 85th SSC meeting
 - 11. Summary of SSC

Recommendations to the Council

Council Standing Committee Meetings

The following Standing Committees of the Council will meet on Monday, October 20, 2003. Enforcement/Vessel Monitoring System (VMS) from 7:30 a.m. to 9 a.m.; Fishery Rights of Indigenous People from 7:30 a.m. to 9 a.m.; International Fisheries/Pelagics from 9 a.m. to 12 noon; Bottomfish from 9 a.m. to 12 noon; Ecosystem and Habitat from 1:30 p.m. to 3 p.m.; Crustaceans and Precious Corals from 3 p.m. to 4:30 p.m.; and Executive/Budget and Program from 4:30 p.m. to 6 p.m.

In addition, the Council will hear recommendations from its scientific and statistical committee, and other ad hoc groups. Public comment periods will be provided throughout the agenda. The order in which agenda items are addressed may change. The Council will meet as late as necessary to complete scheduled business.

Public Hearing

Public hearing will be held to solicit comments on long-term management measures for the region's pelagic fishery on October 22, 2003 at 4:30 p.m. at the Pagoda Hotel, Honolulu HI. The agenda during the full Council meeting will include the items listed here.

9 a.m. Tuesday, October 21, 2003

- 1. Introductions
- 2. Approval of agenda
- 3. Approval of 118th and 119th meeting minutes
 - 4. Island reports
 - A. American Samoa
 - B. Guam
 - C. Hawaii
- D. Commonwealth of the Northern Mariana Islands (CNMI)
- 5. Reports from fishery agencies and organizations
 - A. Department of Commerce
 - a. NMFS
 - i. Pacific Islands Regional Office
- ii. Pacific Islands Fisheries Science Center
- b. NOAA General Counsel Southwest Region
 - c. National Ocean Service
- B. Department of the Interior, U.S.
- Fish and Wildlife Service
- 6. Enforcement/vessel monitoring system (VMS)
 - A. U.S. Coast Guard activities
 - B. NMFS activities
- C. Enforcement activities of local agencies
 - D. Status of violations
- E. Report on national VMS program and policies
- F. Options for using electronic logbooks for Hawaii longline fishery

Guest Speaker: Ueta Fa'asili Strategic plan for fisheries management and sustainable coastal fisheries in Pacific islands

- 7. Observer programs
- A. Objectives and design
- B. Monitoring and compliance policy
- C. Native observer program
- 8. Precious coral fisheries
- A. Report on precious coral industry meeting black coral minimum size
 - 9. Crustaceans fisheries
 - A. Status of lobster research
- a. Report on the 2003 Annual Lobster Resource Cruise
- b. Report on the 2003 Lobster Tagging Charter
- B. Progress on NWHI lobster population model
- 10. Fishery Rights of indigenous peoples
- A. Revision of CNMI marine conservation plan
- B. Status and prognosis of community demonstration projects program
- C. Community Development Program (CDP)
 - a. Status of Mau Zone CDP regulations
 - b. Indigenous database
- c. Guam community monitoring program options
- D. Saltonstall-Kennedy solicitation, June 30, 2003, Omnibus solicitation

Wednesday, October 22, 2003

11. Pelagic/international fisheries

- A. American Samoa & Hawaii longline quarterly reports
- B. Standing Committee on Tuna and Billfish stock assessments
- C. Report on Hawaii longline observer program
- D. Final report on phase two of chute trials for seabird conservation
- E. Turtle conservation and management
- a. Update on Judge Kollar-Kotelly's ruling vacating the June 2002 regulations and 2002 Biological Opinion
- b. Movement and survivorship of turtles released from longline fisheries
- c. Status of Environmental Impact Statements (EISs)
 - i. Supplemental Pelagic EIS
 - ii. MHI Turtle EIS
 - iii. Longline experimental permit EIS
 - 1. Preferred alternative
 - 2. Atlantic mitigation experiments
- d. Turtle Advisory Committee & Database meetings
 - e. Council turtle conservation actions
- f. Measures to manage Hawaii's longline fishery
- F. Marlin management Report on public scoping meeting
- G. Private fish aggregation devices -Report on public scoping meetings
 - H. Shark management (Action Item)
 - I. International meetings
- a. Standing Committee on Tuna and Billfish
 - b. Preparatory Conference
 - c. People and the Sea Conference
- d. Inter-American Convention on Sea
- J. Public hearing on measures to manage the Hawaii longline fishery

A public hearing will be held to receive comments on long-term management of the pelagic fishery of the Western Pacific Region, especially the Hawaii-based longline fishery. The Council is developing an amendment to the regulations under the Fishery Management Plan for the Pelagics Fisheries of the Western Pacific Region that would address the fact that an August 31, 2003, Court order vacated NMFS' 2002 Biological Opinion and related regulations, removing any authorization of incidental takes of sea turtles by the fishery that had been provided by the Biological Opinion. At its 119th meeting, the Council took final action to recommend an emergency rule for the short-term management of the longline fishery to conserve sea turtles, and also directed its staff to analyze and document the impacts of a range of alternatives for the long-term management of the fishery. At its 120th meeting, the Council may take final action to recommend a preferred longterm alternative, or it may defer that decision to a later date.

Thursday, October 23, 2003

- 12. Ecosystems and Habitat
- A. NWHĬ/CNMI Archipelago Ecological Assessments
- B. Status of NWHI Reserve Operations Plan
- C. NWHI Sanctuary designation process report
- D. Pacific National Wildlife Refuge expansion
- a. Midway Atoll National Wildlife Refuge expansion
- b. Hawaiian Island National Wildlife Refuge expansion proposal
- E. Report on the U.S. Coral Reef Task Force meeting
- a. Pacific regional/local action strategies
- b. Guam/Hawaii coral reef fisheries management workshops
 - 13. Bottomfish fisheries
- A. Report on MHI management program review
- B. Report on Hawaii public scoping meetings
- C. Report on CNMI public scoping meetings
- D. Seamount groundfish moratorium (expires 8/04)
 - 1. Status of fishery
- 2. Management options: continue moratorium, closure, other
 - 14. Program planning
 - A. Legislation
- B. Pacific Islands Region Strategic Plan
 - C. CNMI fishery development project
 - D. Report on programmatic grants
 - 15. Administrative matters
 - A. Financial reports
 - B. Administrative report
 - C. Meetings and workshops
 - D. Advisory Group changes
 - 16. Election of officers
 - 17. Other business

Although non-emergency issues not contained in this agenda may come before the Council for discussion, those issues may not be the subject of formal Council action during this meeting. Council action will be restricted to those issues specifically listed in this document and any issue arising after publication of this document that requires emergency action under section 305(c) of the Magnuson-Stevens Fishery Conservation and Management Act, provided the public has been notified of the Council's intent to take final action to address the emergency.

Special Accommodations

These meetings are physically accessible to people with disabilities. Requests for sign language interpretation or other auxiliary aids should be directed to Kitty M. Simonds, 808–522–8220 (voice) or (808)522–8226

(fax), at least 5 days prior to the meeting date.

Authority: 1801 et seq.

Dated: September 29, 2003.

Bruce C. Morehead,

Acting Director, Office of Sustainable Fisheries, National Marine Fisheries Service. [FR Doc. 03–25026 Filed 10–1–03; 8:45 am]

BILLING CODE 3510-22-S

COMMITTEE FOR THE IMPLEMENTATION OF TEXTILE AGREEMENTS

Adjustment of Import Limits for Certain Cotton and Man-Made Fiber Textile Products Produced or Manufactured in the Socialist Republic of Vietnam

September 26, 2003.

AGENCY: Committee for the Implementation of Textile Agreements (CITA).

ACTION: Issuing a directive to the Commissioner, Bureau of Customs and Border Protection.

EFFECTIVE DATE: October 2, 2003.

FOR FURTHER INFORMATION CONTACT:

Naomi Freeman, International Trade Specialist, Office of Textiles and Apparel, U.S. Department of Commerce, (202) 482–4212. For information on the quota status of these limits, refer to the Quota Status Reports posted on the bulletin boards of each Customs port, call (202) 927–5850, or refer to the Bureau of Customs and Border Protection Web site at http://www.customs.gov. For information on embargoes and quota re-openings, refer to the Office of Textiles and Apparel Web site at http://otexa.ita.doc.gov.

SUPPLEMENTARY INFORMATION:

Authority: Section 204 of the Agricultural Act of 1956, as amended (7 U.S.C. 1854); Executive Order 11651 of March 3, 1972, as amended.

The current limits for certain categories are being adjusted for swing.

A description of the textile and apparel categories in terms of HTS numbers is available in the CORRELATION: Textile and Apparel Categories with the Harmonized Tariff Schedule of the United States (see **Federal Register** notice 68 FR 1599, published on January 13, 2003). Also

see 68 FR 26575, published on May 16, 2003.

D. Michael Hutchinson,

Acting Chairman, Committee for the Implementation of Textile Agreements.

Committee for the Implementation of Textile Agreements

September 26, 2003.

Commissioner,

Bureau of Customs and Border Protection, Washington, DC 20229

Dear Commissioner: This directive amends, but does not cancel, the directive issued to you on May 12, 2003, by the Chairman, Committee for the Implementation of Textile Agreements. That directive concerns imports of certain cotton, wool and man—made fiber textiles and textile products, produced or manufactured in Vietnam and exported during the twelve-month period which began on May 1, 2003 and extends through December 31, 2003.

Effective on October 2, 2003, you are directed to adjust the limits for the following categories, as provided for under the terms of the current bilateral textile agreement between the Governments of the United States and Vietnam:

Category	Restraint limit 1
332 347/348 352/652 632 647/648	6,667 dozen pairs. 5,320,000 dozen. 1,179,794 dozen. 13,333 dozen pairs. 1,473,411 dozen.

¹The limits have not been adjusted to account for any imports exported after April 30, 2003.

The Committee for the Implementation of Textile Agreements has determined that these actions fall within the foreign affairs exception to the rulemaking provisions of 5 U.S.C. 553(a)(1).

Sincerely,

D. Michael Hutchinson,

Acting Chairman, Committee for the Implementation of Textile Agreements.

[FR Doc. 03-24989 Filed 10-1-03; 8:45 am]

BILLING CODE 3510-DR-S

COMMITTEE FOR THE IMPLEMENTATION OF TEXTILE AGREEMENTS

Adjustment of Import Limits for Certain Cotton, Wool and Man-Made Fiber Textiles and Textile Products Produced or Manufactured in the Socialist Republic of Vietnam

September 26, 2003.

AGENCY: Committee for the Implementation of Textile Agreements (CITA)

ACTION: Issuing a directive to the Commissioner, Bureau of Customs and Border Protection.

EFFECTIVE DATE: October 2, 2003.

FOR FURTHER INFORMATION CONTACT:

Naomi Freeman, International Trade Specialist, Office of Textiles and Apparel, U.S. Department of Commerce, (202) 482–4212. For information on the quota status of these limits, refer to the Quota Status Reports posted on the bulletin boards of each Customs port, call (202) 927–5850, or refer to the Bureau of Customs and Border Protection website at http://www.customs.gov. For information on embargoes and quota re-openings, refer to the Office of Textiles and Apparel website at http://otexa.ita.doc.gov.

SUPPLEMENTARY INFORMATION:

Authority: Section 204 of the Agricultural Act of 1956, as amended (7 U.S.C. 1854); Executive Order 11651 of March 3, 1972, as amended.

The current limits for certain categories are being adjusted for swing.

A description of the textile and apparel categories in terms of HTS numbers is available in the CORRELATION: Textile and Apparel Categories with the Harmonized Tariff Schedule of the United States (see Federal Register notice 68 FR 1599, published on January 13, 2003). Also see 68 FR 26575, published on May 16, 2003.

D. Michael Hutchinson,

Acting Chairman, Committee for the Implementation of Textile Agreements.

Committee for the Implementation of Textile Agreements

September 26, 2003.

Commissioner,

Bureau of Customs and Border Protection, Washington, DC 20229

Dear Commissioner: This directive amends, but does not cancel, the directive issued to you on May 12, 2003, by the Chairman, Committee for the Implementation of Textile Agreements. That directive concerns imports of certain cotton, wool and man—made fiber textiles and textile products, produced or manufactured in Vietnam and exported during the twelve-month period which began on May 1, 2003 and extends through December 31, 2003.

Effective on October 2, 2003, you are directed to adjust the limits for the following categories, as provided for under the terms of the current bilateral textile agreement between the Governments of the United States and Vietnam:

Category	Restraint limit 1
340/640	1,383,333 dozen.
345	224,000 dozen.
448	21,713 dozen.
645/646	149,333 dozen.

¹The limits have not been adjusted to account for any imports exported after April 30, 2003.

The Committee for the Implementation of Textile Agreements has determined that

these actions fall within the foreign affairs exception to the rulemaking provisions of 5 U.S.C. 553(a)(1).

Sincerely.

D. Michael Hutchinson,

Acting Chairman, Committee for the Implementation of Textile Agreements.

[FR Doc. 03-24990 Filed 10-1-03; 8:45 am]

BILLING CODE 3510-DR-S

DEPARTMENT OF DEFENSE

Office of the Secretary

Proposed Collection; Comment Request

AGENCY: Office of the Assistant Secretary of Defense for Health Affairs.

ACTION: Notice.

In accordance with Section 3506(c)(2)(A) of the Paperwork Reduction Act of 1995, the Office of the Assistant Secretary of Defense for Health Affairs announced the proposed extension of a currently approved collection and seeks public comment on the provisions thereof. Comments are invited on: (a) Whether the proposed extension of collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the information collection; (c) ways to enhance the quality, utility, and clarity of the information to be collected; and (d) ways to minimize the burden of the information collection on respondents, including through the use of automated collection techniques or other forms of information technology.

DATES: Consideration will be given to all comments received on or before December 1, 2003.

ADDRESSES: Written comments and recommendations on the information collection should be sent to TRICARE Management Activity—Aurora, Office of Program Requirements Division, 16401 E. Centretech Parkway, ATTN: Graham Kolb, Aurora, CO 80011–9043.

FOR FURTHER INFORMATION CONTACT: To request more information on this proposed information collection, please write to the above address or call TRICARE Management Activity, Office of Program Requirements Division at (303) 676–3580.

Title, Associated Form, and OMB Number: Health Insurance Claim Form, HCFA–1500, OMB Number 0720–0001

Needs and Uses: This information collection requirement is used by TRICARE to determine reimbursement for health care services or supplies rendered by individual professional providers to TRICARE beneficiaries. The requested information is used to determine beneficiary eligibility, appropriations and costs of care, other health insurance liability and whether services received are benefits. Use of this form continues TRICARE commitments to use the national standard claim form for reimbursement of services/supplies provided by individual professional providers.

Affected Public: Business or other form profit, State, local or tribal government, Federal government and not for profit institutions.

Annual Burden Hours: 5,600,000. Number of Respondents: 22,400,000. Responses per Respondent: 1. Average Burden per Response: 15 minutes.

Frequency: On occasion.

SUPPLEMENTARY INFORMATION:

Summary of Information Collection

This collection instrument is for is for use by health care providers under the TRICARE Program. TRICARE is a health benefits entitlement program for the dependents of active duty Uniformed Services member and deceased sponsors, retirees and their dependents, dependents of Department of Transportation (Coast Guard) sponsors, and certain North Atlantic Treaty Organizations, National Oceanic and Atmospheric Administration, and Public Health Service eligible beneficiaries. The Form HCFA 1500 is used by individual professional health care or health care related providers to file for reimbursement of civilian health care services or supplies provided to TRICARE beneficiaries. This is the national standard claim from accepted by all major commercial and government payers.

Dated: September 22, 2003.

Patricia L. Toppings,

Alternate OSD Federal Register, Liaison Officer, Department of Defense.

[FR Doc. 03–24985 Filed 10–1–03; 8:45 am] BILLING CODE 5001–08–M

DEPARTMENT OF DEFENSE

Office of the Secretary

Meeting of the Advisory Council on Dependents' Education

AGENCY: Department of Defense Education Activity (DoDEA). **ACTION:** Open meeting notice.

SUMMARY: Pursuant to the Federal Advisory Committee Act, Appendix 2 of title 5, United States Code, Public Law

92-463, notice is hereby given that a meeting of the Advisory Council on Dependents' Education (ACDE) is scheduled to be held on October 3,2003, from 8 a.m. to 5 p.m. The meeting will be held at the Hotel Oranien Wiesbaden, Platter Strasse 2, Wiesbaden, Germany. The purpose of the ACDE is to recommend to the Director, DoDEA, general policies for the operation of the Department of Defense Dependents Schools (DoDDS); to provide the Director with information about effective educational programs and practices that should be considered by DoDDS; and to perform other tasks as may be required by the Secretary of Defense. The meeting emphases will be on the current operational qualities of 15 schools in DoDDS, the institutionalized school improvement processes in DoDDS and other educational matters. For further information contact Mr. Jim Jarrard, at 703-696-4471, extension 1964.

Dated: September 24, 2003.

Patricia L. Toppings,

Alternate OSD Federal Register Liaison Officer, Department of Defense.

[FR Doc. 03–24986 Filed 10–1–03; 8:45 am]

BILLING CODE 5001-08-M

DEPARTMENT OF DEFENSE

Office of the Secretary

Defense Science Board

AGENCY: Department of Defense. **ACTION:** Notice of advisory committee meetings.

SUMMARY: The Defense Science Board Task Force on Enabling Joint Force Capabilities will tentatively meet in closed session October 24, 2003, at IDA, 4850 Mark Center Drive, Alexandria, VA: and October 30, 2003, at Joint Forces Command, Norfolk, VA. This Task Force will review the current state of assigned responsibilities and accountability for joint capabilities to quickly bring combat forces together and focus them on joint objectives across a wide spectrum of possible contingencies and will help identify unfilled needs and areas where assigned responsibility and accountability calls for further clarification and/or organizational arrangements.

The mission of the Defense Science Board is to advise the Secretary of Defense and the Under Secretary of Defense for Acquisition, Technology & Logistics on scientific and technical matters as they affect the perceived needs of the Department of Defense. At these meetings, the Defense Science Board Task Force will identify specific characteristics and examples of organizations that could be capable of accepting responsibility and accountability for delivering the capability with needed responsiveness, and will recommend further steps to strengthen the joint structure ability to quickly integrate service-provided force capabilities into effective joint forces.

În accordance with Section 10(d) of the Federal Advisory Committee Act, P.L. No. 92–463, as amended (5 U.S.C. App. II), it has been determined that the Defense Science Board Task Force meetings concern matters listed in 5 U.S.C. § 552b(c)(1) and that, accordingly, the meetings will be closed to the public.

Dated: September 25, 2003.

Patricia L. Toppings,

Alternate OSD Federal Register Liaison Officer, Department of Defense.

[FR Doc. 03–24987 Filed 10–1–03; 8:45 am]

BILLING CODE 5001-08-M

DEPARTMENT OF DEFENSE

Office of the Secretary

Defense Science Board

ACTION: Notice of advisory committee meeting.

SUMMARY: The Defense Science Board Task Force on Quarantining Guidance for the Severe Acute Respiratory Syndrome (SARS) Epidemic will meet in open session October 27, 2003, from 0930-1200 and from 1300-1500. The Task Force will meet at SAIC, 4001 N. Fairfax Drive, Suite 500, Arlington, VA. The Task Force will review the impact quarantining may have on DoD planning and operations by preventing the flow of personnel and material to areas of concern, eroding relationships with host countries, and impacting our forces through anxieties about family members.

The mission of the Defense Science Board is to advise the Secretary of Defense and the Under Secretary of Defense for Acquisition, Technology & Logistics on scientific and technical matters as they affect the perceived needs of the Department of Defense. At this meeting, the Defense Science Board Task Force will review and evaluate the Department's ability to provide information to integrate public health needs, on behalf of national security. Specifically, the Task Force will review: Existing doctrine and processes by which quarantine policy is generated; required cooperation with non-DoD

agencies and non-U.S. government entities, including other countries; the capacity of local commanders to rapidly survey disease status, and establish need, ways and means for quarantine in relation to their assigned missions; methods, technologies and doctrine to allow safe transport of personnel through quarantined areas, and restriction of movement where needed; sample scenarios; coordination and allocation of DoD and non DoD resources to combat SARS; identification and tracking of individuals potentially exposed to SARS; and features of the SARS guidance which may be applicable to future infectious disease outbreaks.

FOR FURTHER INFORMATION CONTACT: CDR David Waugh, USN, Defense Science Board, 3140 Defense Pentagon, Room 3D865, Washington, DC 20301–3140, via email at *david.waugh@osd.mil*, or via phone at (703) 695–4158.

SUPPLEMENTARY INFORMATION: Members of the public who wish to attend the meeting must contact CDR Waugh no later than October 20, 2003, for further information about admission as seating is limited. Additionally, those who wish to make oral comments or deliver written comments should also request to be scheduled, and submit a written text of the comments by October 20, 2003, to allow time for distribution to Task Force members prior to the meeting. Individual oral comments will be limited to five minutes, with the total oral comment period not exceeding 30 minutes.

Dated: September 25, 2003.

Patricia L. Toppings,

Alternate OSD Federal Register Liaison Officer, Department of Defense.

[FR Doc. 03–24988 Filed 10–1–03; 8:45 am]

BILLING CODE 5001-08-M

DEPARTMENT OF DEFENSE

Department of the Navy

Record of Decision for Introduction of F/A-18 E/F (Super Hornet) Aircraft to the East Coast of the United States

AGENCY: Department of the Navy, DOD. **ACTION:** Notice of record of decision, correction.

SUMMARY: The Department of the Navy published a Notice in the Federal Register of September 10, 2003, concerning the Record of Decision for Introduction of F/A–18 E/F (Super Hornet) Aircraft to the East Coast of the United States. The document contained an incorrect statement and needs additional clarification.

FOR FURTHER INFORMATION CONTACT: Mr. Fred Pierson, Atlantic Division Naval Facilities Engineering Command (Code BD32FP), 6506 Hampton Blvd., Norfolk, VA 23508–1278, telephone (757) 322–4935.

Correction

In the **Federal Register** of September 10, 2003, in FR Doc. 03–53353, on page 53355, in the third column, second paragraph, delete the third sentence, "Aircraft will not be able to utilize visual flight rules (VFR) when transiting airspace in the area of Site C." The statement is not correct and is now deleted from the decision.

On page 53355, in the third column, fourth paragraph, add the following statements for additional clarification to the end of the paragraph:

The Class D airspace will extend approximately five miles laterally from the OLF from the surface up to and including 2,500 feet above ground level. Establishment of Class D airspace is contingent upon results of an FAA Airspace Study. No military Special Use Airspace (SUA) will be established.

The revised version of the Record of Decision will also appear in the administrative record.

Dated: September 29, 2003.

E.F. McDonnell,

Major, Marine Corps, Federal Register Liaison Officer.

[FR Doc. 03–25024 Filed 10–1–03; 8:45 am] **BILLING CODE 3810-FF-P**

DEPARTMENT OF EDUCATION

Submission for OMB Review; Comment Request

AGENCY: Department of Education.

SUMMARY: The Leader, Regulatory
Information Management Group, Office
of the Chief Information Officer invites
comments on the submission for OMB
review as required by the Paperwork
Reduction Act of 1995.

DATES: Interested persons are invited to submit comments on or before November 3, 2003.

ADDRESSES: Written comments should be addressed to the Office of Information and Regulatory Affairs, Attention: Karen Lee, Desk Officer, Department of Education, Office of Management and Budget, 725 17th Street, NW., Room 10235, New Executive Office Building, Washington, DC 20503 or should be electronically mailed to the internet address Karen_F._Lee@omb.eop.gov.

SUPPLEMENTARY INFORMATION: Section 3506 of the Paperwork Reduction Act of

1995 (44 U.S.C. Chapter 35) requires that the Office of Management and Budget (OMB) provide interested Federal agencies and the public an early opportunity to comment on information collection requests. OMB may amend or waive the requirement for public consultation to the extent that public participation in the approval process would defeat the purpose of the information collection, violate State or Federal law, or substantially interfere with any agency's ability to perform its statutory obligations. The Leader, Regulatory Information Management Group, Office of the Chief Information Officer, publishes that notice containing proposed information collection requests prior to submission of these requests to OMB. Each proposed information collection, grouped by office, contains the following: (1) Type of review requested, e.g. new, revision, extension, existing or reinstatement; (2) Title; (3) Summary of the collection; (4) Description of the need for, and proposed use of, the information; (5) Respondents and frequency of collection; and (6) Reporting and/or Recordkeeping burden. OMB invites public comment.

Dated: September 29, 2003.

Angela C. Arrington,

Leader, Regulatory Information Management Group, Office of the Chief Information Officer.

Office of Vocational and Adult Education

Type of Review: Extension.
Title: Application for Vocational and
Technical Education and Adult
Education Direct Grants.

Frequency: Semi-Annually.

Affected Public: State, Local, or Tribal
Gov't, SEAs or LEAs.

Reporting and Recordkeeping Hour Burden:

Responses: 569.

Burden Hours: 73,970.

Abstract: This form will be used to apply for funding authorized by the Carl D. Perkins Vocational and Technical Education Act of 1998 and the Adult Education and Family Literacy Act, administered by the Office of Vocational and Adult Education. The information will be used to award discretionary grants and cooperative agreeements.

This information collection is being submitted under the Streamlined Clearance Process for Discretionary Grant Information Collections (1890–0001). Therefore, the 30-day public comment period notice will be the only public comment notice published for this information collection.

Requests for copies of the submission for OMB review; comment request may

be accessed from http:// edicsweb.ed.gov, by selecting the "Browse Pending Collections" link and by clicking on link number 2351. When you access the information collection, click on "Download Attachments "to view. Written requests for information should be addressed to Vivian Reese, Department of Education, 400 Maryland Avenue, SW, Room 4050, Regional Office Building 3, Washington, DC 20202-4651 or to the e-mail address vivan.reese@ed.gov. Requests may also be electronically mailed to the internet address OCIO RIMG@ed.gov or faxed to 202-708-9346. Please specify the complete title of the information collection when making your request.

Comments regarding burden and/or the collection activity requirements should be directed to Sheila Carey at her e-mail address *Sheila.Carey@ed.gov*. Individuals who use a telecommunications device for the deaf (TDD) may call the Federal Information Relay Service (FIRS) at 1–800–877–8339.

[FR Doc. 03–25014 Filed 10–1–03; 8:45 am]

DEPARTMENT OF EDUCATION

Submission for OMB Review; Comment Request

AGENCY: Department of Education.
SUMMARY: The Leader, Regulatory
Information Management Group, Office
of the Chief Information Officer invites
comments on the submission for OMB
review as required by the Paperwork
Reduction Act of 1995.

DATES: Interested persons are invited to submit comments on or before November 3, 2003.

ADDRESSES: Written comments should be addressed to the Office of Information and Regulatory Affairs, Attention: Karen Lee, Desk Officer, Department of Education, Office of Management and Budget, 725 17th Street, NW., Room 10235, New Executive Office Building, Washington, DC 20503 or should be electronically mailed to the Internet address Karen F. Lee@omb.eop.gov.

SUPPLEMENTARY INFORMATION: Section 3506 of the Paperwork Reduction Act of 1995 (44 U.S.C. Chapter 35) requires that the Office of Management and Budget (OMB) provide interested Federal agencies and the public an early opportunity to comment on information collection requests. OMB may amend or waive the requirement for public consultation to the extent that public participation in the approval process

would defeat the purpose of the information collection, violate State or Federal law, or substantially interfere with any agency's ability to perform its statutory obligations. The Leader, Regulatory Information Management Group, Office of the Chief Information Officer, publishes that notice containing proposed information collection requests prior to submission of these requests to OMB. Each proposed information collection, grouped by office, contains the following: (1) Type of review requested, e.g. new, revision, extension, existing or reinstatement; (2) Title; (3) Summary of the collection; (4) Description of the need for, and proposed use of, the information; (5) Respondents and frequency of collection; and (6) Reporting and/or Recordkeeping burden. OMB invites public comment.

Dated: September 29, 2003.

Angela C. Arrington,

 $\label{lem:lemma$

Office of Vocational and Adult Education

Type of Review: Reinstatement. Title: Carl D. Perkins Vocational and Technical Education Act (Pub. L. 105– 332)—State Plan-Perkins Annual Levels of Performance.

Frequency: Annually.

Affected Public: State, local or Tribal Gov't, SEAs or LEAs.

Reporting and Recordkeeping Hour Burden:

Responses: 25.

Burden Hours: 1,700.

Abstract: Pub. 105–332 requires eligible State agencies to submit a 5-year State plan, with annual revisions as the agency deems necessary, in order to receive Federal funds. Program staff review the plans for compliance and quality. This collection also solicits proposed annual levels of performance from States and outlying areas in accordance with section 113(b)(3)(A)(v) of the Carl D. Perkins Vocational and Technical Education Act (Pub. L 105–332).

Requests for copies of the submission for OMB review; comment request may be accessed from http://edicsweb.ed.gov, by selecting the "Browse Pending Collections" link and by clicking on link number 2313. When you access the information collection, click on "Download Attachments" to view. Written requests for information should be addressed to Vivian Reese, Department of Education, 400 Maryland Avenue, SW., Room 4050, Regional Office Building 3, Washington, DC 20202–4651 or to the e-mail address

Vivan.Reese@ed.gov. Requests may also be electronically mailed to the internet address OCIO_RIMG@ed.gov or faxed to 202–708–9346. Please specify the complete title of the information collection when making your request.

Comments regarding burden and/or the collection activity requirements should be directed to Sheila Carey at her e-mail address *Sheila.Carey@ed.gov*. Individuals who use a telecommunications device for the deaf (TDD) may call the Federal Information Relay Service (FIRS) at 1–800–877–8339.

[FR Doc. 03–25015 Filed 10–1–03; 8:45 am] BILLING CODE 4000–01–P

DEPARTMENT OF EDUCATION

[CFDA Nos.: 84.129C, 84.129E, 84.129F, 84.129P, 84.129Q, 84.129R]

Rehabilitation Training: Rehabilitation Long-Term Training; Notice Inviting Applications for New Awards for Fiscal Year (FY) 2004; Correction

SUMMARY: On August 26, 2003, a notice inviting applications for new awards for the Rehabilitation Training: Rehabilitation Long-Term Training program for FY 2004 was published in the **Federal Register** (68 FR 51263).

On page 51263, in column two, 2nd line, in the list after CFDA No:, add "84.129P," after "84.129F,".

On page 51263 in the chart after 84.129F, add the following: "84.129P", "Specialized personnel for rehabilitation of individuals who are blind or have vision impairment (4)", and "\$100,000" under the headings CFDA number, Priority area (maximum number of awards in parentheses), and Maximum award, respectively.

On page 51263, in column three, the *Estimated Total Number of Awards* reads "11". This figure is corrected to read "14".

On page 51264, in column one, under the heading *Pilot Project for Electronic Submission of Applications*, in line eight, add "84.129P," after "84.129F,".

On page 51264, in column three, under the heading For Applications Contact, in the 4th paragraph in line four, add "P," after "F,".

For Applications Contact: Education

For Applications Contact: Education Publications Center (ED Pubs), P.O. Box 1398, Jessup, MD 20794–1398.
Telephone (toll free): 1–877–433–7827.
FAX: (301) 470–1244. If you use a telecommunications device for the deaf (TDD), you may call (toll free): 1–877–576–7734.

You may also contact ED Pubs at its Web site: http://www.ed.gov/pubs/edpubs.html.

Or you may contact ED Pubs at its email address: edpubs@inet.ed.gov.

If you request an application from ED Pubs, be sure to identify this competition as follows: CFDA number 84.129C, E, F, P, Q, or R.

FOR FURTHER INFORMATION CONTACT:

Marilyn Fountain, U.S. Department of Education, 400 Maryland Avenue, SW., room 3332, Switzer Building, Washington, DC 20202–2649. Telephone: (202) 205–8294 or via Internet: Marilyn.Fountain@ed.gov.

If you use a telecommunications device for the deaf (TDD), you may call the Federal Information Relay Service (FIRS) at 1–800–877–8339.

Individuals with disabilities may obtain this document in an alternative format (e.g., Braille, large print, audiotape, or computer diskette) on request to the program contact person listed under FOR FURTHER INFORMATION CONTACT.

Individuals with disabilities may obtain a copy of the application package in an alternative format by contacting the Grants and Contracts Services Team, U.S. Department of Education, 400 Maryland Avenue, SW., room 3317, Switzer Building, Washington, DC 20202-2550. Telephone: (202) 205-8207. If you use a telecommunications device for the deaf (TDD), you may call the Federal Information Relay Service (FIRS) at 1-800-877-8339. However, the Department is not able to reproduce in an alternative format the standard forms included in the application package.

Electronic Access to This Document

You may view this document, as well as all other Department of Education documents published in the **Federal Register**, in text or Adobe Portable Document Format (PDF) on the Internet at the following site: www.ed.gov/news/fedregister.

To use PDF you must have Adobe Acrobat Reader, which is available free at this site. If you have questions about using PDF, call the U.S. Government Printing Office (GPO), toll free, at 1–888–293–6498; or in the Washington, DC, area at (202) 512–1530.

Note: The official version of this document is the document published in the Federal Register. Free Internet access to the official edition of the Federal Register and the Code of Federal Regulations is available on GPO Access at: http://www.gpoaccess.gov/nara/index.html.

Program Authority: 29 U.S.C. 772.

Dated: September 26, 2003.

Robert H. Pasternack,

Assistant Secretary for Special Education and Rehabilitative Services.

[FR Doc. 03–24947 Filed 10–1–03; 8:45 am] BILLING CODE 4000–01–P

DEPARTMENT OF ENERGY

[Docket Nos. EA-281]

Application To Export Electric Energy; Manitoba Hydro

AGENCY: Office of Fossil Energy, DOE. **ACTION:** Notice of application.

SUMMARY: Manitoba Hydro has applied for authority to export electric energy from the United States to Canada, pursuant to section 202(e) of the Federal Power Act.

DATES: Comments, protests or requests to intervene must be submitted on or before November 3, 2003.

ADDRESSES: Comments, protests or requests to intervene should be addressed as follows: Office of Coal & Power Import/Export (FE–27), Office of Fossil Energy, U.S. Department of Energy, 1000 Independence Avenue, SW., Washington, DC 20585–0350 (FAX 202–287–5736).

FOR FURTHER INFORMATION CONTACT:

Rosalind Carter (Program Office) 202–586–7983 or Michael Skinker (Program Attorney) 202–586–2793.

SUPPLEMENTARY INFORMATION: Exports of electricity from the United States to a foreign country are regulated and require authorization under section 202(e) of the Federal Power Act (FPA) (16 U.S.C. 824a(e)).

On September 2, 2003, Manitoba Hydro, a Canadian Crown Corporation, applied to the Office of Fossil Energy, of the Department of Energy (DOE) for authority to export electric energy from the Unites States to Canada, Manitoba Hydro engages in the generation, transmission and distribution of electricity primarily in the Province of Manitoba, Canada. Manitoba Hydro does not own, control, or operate any generation, transmission or other facilities in the United States and does not sell power at wholesale within the United States. Manitoba Hydro is not a public utility subject to the jurisdiction of the Federal Energy Regulatory Commission (FERC).

The type of export transactions that Manitoba Hydro proposes in FE Docket No. EA–281 include: (1) Purchasing electric energy in Canada and wheeling the energy through facilities located in the U.S. and exporting the energy back to Canada to itself or to third parties in

Canada and/or (2) purchasing electric energy in the United States, exporting that energy through facilities within the U.S. and then exporting the energy to itself or third parties in Canada. Manitoba Hydro will arrange for the delivery of exports to Canada over the international transmission facilities owned by Basin Electric Power Cooperative, Bonneville Power Administration, Citizens Utilities, Eastern Maine Electric Cooperative, International Transmission Co., Joint Owners of the Highgate Project, Long Sault, Inc., Maine Electric Power Company, Maine Public Service Company, Minnesota Power, Inc., Minnkota Power Cooperative, Inc., New York Power Authority, Niagara Mohawk Power Corp., Northern States Power Company and Vermont Electric Transmission.

The construction of each of the international transmission facilities to be utilized by Manitoba Hydro has previously been authorized by a Presidential permit issued pursuant to Executive Order 10485, as amended.

Procedural Matters: Any person desiring to become a party to this proceeding or to be heard by filing comments or protests to this application should file a petition to intervene, comment or protest at the address provided above in accordance with §§ 385.211 or 385.214 of the FERC's Rules of Practice and Procedures (18 CFR 385.211, 385.214). Fifteen copies of each petition and protest should be filed with the DOE on or before the date listed above.

Comments on the Manitoba Hydro application to export electric energy to Canada should be clearly marked with Docket EA–281. Additional copies are to be filed directly with K. Jennifer Moroz, Barrister & Solicitor, Legal Department, Manitoba Hydro, 820 Taylor Avenue, Winnipeg, Manitoba Canada R3M 3T1 and David Martin Connelly, Bruder, Gentile & Marcoux, L.L.P., 1701 Pennsylvania Avenue, NW., Suite 900, Washington, DC 20006–5805.

A final decision will be made on this application after the environmental impact has been evaluated pursuant to the National Environmental Policy Act of 1969, and a determination is made by the DOE that the proposed action will not adversely impact on the reliability of the U.S. electric power supply system.

Copies of this application will be made available, upon request, for public inspection and copying at the address provided above or by accessing the Fossil Energy Home Page at http://www.fe.doe.gov. Upon reaching the Fossil Energy Home page, select

"Electricity Regulation," and then "Pending Proceedings" from the options

Issued in Washington, DC, on September 24, 2003.

Anthony Como,

Deputy Director, Electric Power Regulation, Office of Coal & Power Import/Export, Office of Coal & Power Systems, Office of Fossil Energy.

[FR Doc. 03-25005 Filed 10-1-03; 8:45 am] BILLING CODE 6450-01-P

DEPARTMENT OF ENERGY

Office of Science

Basic Energy Sciences Advisory Committee

AGENCY: Department of Energy. **ACTION:** Notice of open meeting.

SUMMARY: This notice announces a meeting of the Basic Energy Sciences Advisory Committee (BESAC). Federal Advisory Committee Act (Pub. L. 92– 463, 86 Stat. 770) requires that public notice of these meetings be announced in the Federal Register.

DATES: Monday, October 20, 2003, 8:30 a.m. to 5 p.m., and Tuesday, October 21, 2003, 8:30 a.m. to 12 p.m.

ADDRESSES: Doubletree Hotel and Executive Meeting Center, 1750 Rockville Pike, Rockville, MD 20852.

FOR FURTHER INFORMATION CONTACT:

Sharon Long; Office of Basic Energy Sciences; U.S. Department of Energy; 19901 Germantown Road; Germantown, MD 20874-1290; Telephone: (301) 903-

SUPPLEMENTARY INFORMATION:

Purpose of the Meeting: The purpose of this meeting is to provide advice and guidance with respect to the basic energy sciences research program.

Tentative Agenda: Agenda will include discussions of the following: Monday, October 20, 2003.

- News from the Office of Science.
- News from the Office of Basic Energy Sciences.
- Basic Energy Sciences Hydrogen Workshop Follow-up and Related Activities.
- Summary of the Chemical Sciences, Geosciences, and Biosciences Division.
- Update of the Linac Coherent Light Source.
- Update and Status of the Spallation Neutron Source.
- BESAC Charges and Directions, Tuesday, October 21, 2003.
- Review of Recent DOE and National Studies on High-end Computing.
- BESAC Discussion.

Public Participation: The meeting is open to the public. If you would like to

file a written statement with the Committee, you may do so either before or after the meeting. If you would like to make oral statements regarding any of the items on the agenda, you should contact Sharon Long at 301-903-6594 (fax) or sharon.long@science.doe.gov (email). You must make your request for an oral statement at least 5 business days prior to the meeting. Reasonable provision will be made to include the scheduled oral statements on the agenda. The Chairperson of the Committee will conduct the meeting to facilitate the orderly conduct of business. Public comment will follow the 10-minute rule.

Minutes: The minutes of this meeting will be available for public review and copying within 30 days at the Freedom of Information Public Reading Room; 1E-190, Forrestal Building; 1000 Independence Avenue, SW., Washington, DC 20585; between 9 a.m. and 4 p.m., Monday through Friday, except holidays.

Issued in Washington, DC on September 26, 2003.

Rachel M. Samuel,

Deputy Advisory Committee Management Officer.

[FR Doc. 03–25003 Filed 10–1–03; 8:45 am] BILLING CODE 6450-01-P

DEPARTMENT OF ENERGY

Environmental Management Site-Specific Advisory Board, Fernald

AGENCY: Department of Energy. **ACTION:** Notice of open meeting.

SUMMARY: This notice announces a meeting of the Environmental Management Site-Specific Advisory Board (EM SSAB), Fernald. The Federal Advisory Committee Act (Pub. L. No. 92-463, 86 Stat. 770) requires that public notice of these meetings be announced in the Federal Register.

DATES: Thursday, October 21, 2003, 7 p.m.-9 p.m.

ADDRESSES: Fernald Closure Project Site, 7400 Willey Road, Trailer 214, Hamilton, OH 45013-9402.

FOR FURTHER INFORMATION CONTACT:

Doug Sarno, The Perspectives Group, Inc., 1055 North Fairfax Street, Suite 204, Alexandria, VA 22314, at (703) 837-1197, or e-mail:

djsarno@theperspectivesgroup.com.

SUPPLEMENTARY INFORMATION: Purpose of the Board: The Board is to make recommendations to DOE in areas of environmental restoration, waste management, and related activities.

Tentative Agenda:

7 p.m. Call to Order. 7-7:15 p.m. Chair's Remarks, Ex Officio Announcements. 7:15–7:30 p.m Report from the EM

SSAB Chairs Meeting.

7:30-8 p.m. Discussion and Proposed Action on Risk Based End States. 8-8:45 p.m. Results of Retreat and

Actions for 2004. 8:45-9 p.m. Public Comment.

9 p.m. Adjourn.

Public Participation: The meeting is open to the public. Written statements may be filed with the Board chair either before or after the meeting. Individuals who wish to make oral statements pertaining to agenda items should contact the Board chair at the address or telephone number listed below. Requests must be received five days prior to the meeting and reasonable provision will be made to include the presentation in the agenda. The Deputy Designated Federal Officer, Gary Stegner, Public Affairs Office, Ohio Field Office, U.S. Department of Energy, is empowered to conduct the meeting in a fashion that will facilitate the orderly conduct of business. Each individual wishing to make public comment will be provided a maximum of five minutes to present their comments.

Minutes: The minutes of this meeting will be available for public review and copying at the Freedom of Information Public Reading Room, 1E–190, Forrestal Building, 1000 Independence Avenue, SW., Washington, DC, 20585 between 9 a.m. and 4 p.m., Monday-Friday, except Federal holidays. Minutes will also be available by writing to the Fernald Citizens' Advisory Board, c/o Phoenix Environmental Corporation, MS-76, Post Office Box 538704, Cincinnati, OH 43253–8704, or by calling the Advisory Board at (513) 648-6478.

Issued at Washington, DC on September 29, 2003.

Rachel Samuel,

 $Deputy\ Advisory\ Committee\ Management$ Officer.

[FR Doc. 03-25001 Filed 10-1-03; 8:45 am] BILLING CODE 6450-01-P

DEPARTMENT OF ENERGY

Nuclear Energy Research Advisory Committee

AGENCY: Department of Energy. **ACTION:** Notice of open meeting.

SUMMARY: This notice announces a meeting of the Nuclear Energy Research Advisory Committee. The Federal Advisory Committee Act (Pub. L. No.

92–463, 86 Stat. 770), requires that public notice of the meetings be announced in the **Federal Register**.

DATES: Monday, November 3, 2003, 9:15 a.m. to 6 p.m.; Tuesday, November 4, 2003, 9 a.m. to 1 p.m.

ADDRESSES: Crowne Plaza Hotel, 1489 Jefferson Davis Highway, Arlington, VA 22202.

FOR FURTHER INFORMATION CONTACT: Mr. Mark Roth, Designated Federal Officer, Nuclear Energy Research Advisory Committee, U.S. Department of Energy, NE–20, 1000 Independence Avenue, SW., Washington DC 20585, Telephone Number 301–903–5501, E-mail: mark.roth@hq.doe.gov.

SUPPLEMENTARY INFORMATION:

Purpose of the Meeting: To provide advice to the Director of the Office of Nuclear Energy, Science and Technology (NE) of the Department of Energy on the many complex planning, scientific and technical issues that arise in the development and implementation of the Nuclear Energy research program.

Tentative Agenda

Monday, November 3, 2003

Welcome Remarks. Status of Nuclear Energy's FY 2004 Budget Request.

Role of Nuclear Power Under the Administration's Climate Change Initiative.

Subcommittee Reports and Organizational Issues.

Tuesday, November 4, 2003

Subcommittee Reports and Organization Issues (continued).

Open Discussion.

Public Comment Period.

Public Participation: The day and a half meeting is open to the public on a first-come, first-serve basis because of limited seating. Written statements may be filed with the committee before or after the meeting. Members of the public who wish to make oral statements pertaining to agenda items should contact Mark Roth at the address or telephone listed above. Requests to make oral statements must be made and received five days prior to the meeting; reasonable provision will be made to include the statement in the agenda. The Chair of the committee is empowered to conduct the meeting in a fashion that will facilitate the orderly conduct of business.

Minutes: The minutes of this meeting will be available for public review and copying at the Freedom of Information Reading Room 1E–190, Forrestal Building, 1000 Independence Avenue, SW., Washington, DC, between 9 a.m.

and 4 p.m., Monday through Friday, except holidays.

Issued in Washington, DC on September 29, 2003.

Rachel M. Samuel,

Deputy Advisory Committee Management Officer.

[FR Doc. 03–25006 Filed 10–1–03; 8:45 am] BILLING CODE 6450–01–P

DEPARTMENT OF ENERGY

[FE Docket No. PP-285]

Application for Presidential Permit; Sharyland Utilities, L.P.

AGENCY: Office of Fossil Energy, DOE. **ACTION:** Notice of application.

SUMMARY: Sharyland Utilities, L.P. (Sharyland) has applied for a Presidential permit to construct, connect, operate, and maintain a single-circuit, 138,000-volt (138-kV) alternating current electric transmission line across the U.S. border with Mexico. DATES: Comments, protests, or requests

to intervene must be submitted on or before November 3, 2003. **ADDRESSES:** Comments, protests, or requests to intervene should be addressed as follows: Office of Coal &

addressed as follows: Office of Coal & Power Import and Export (FE–27), Office of Fossil Energy, U.S. Department of Energy, 1000 Independence Avenue, SW., Washington, DC 20585–0350.

FOR FURTHER INFORMATION CONTACT:

Ellen Russell (Program Office) 202–586–9624 or Michael T. Skinker (Program Attorney) 202–586–6667.

SUPPLEMENTARY INFORMATION: The construction, operation, maintenance, and connection of facilities at the international border of the United States for the transmission of electric energy between the United States and a foreign country is prohibited in the absence of a Presidential permit issued pursuant to Executive Order (EO) 10485, as amended by EO 12038.

On September 11, 2003, Sharyland filed an application with the Office of Fossil Energy(FE) of the Department of Energy (DOE) for a Presidential permit. Sharyland is a transmission and distribution service provider operating within a 6,000-acre master-planned community called Sharyland Plantation, situated between the cities of McAllen and Mission, Texas, along the border between the United States and Mexico.

Sharyland proposes to develop a single-circuit 138-kV transmission line in two phases. In the first phase Sharyland would tap an existing 138-kV transmission facility also owned by Sharyland, construct a 150-megawatt

(MW) back-to-back alternating current/ direct current/alternating current converter station in the immediate vicinity of the tap, and construct approximately one mile of 138-kV transmission line to the Mexico-U.S. border near the southern boundary of the City of Mission, Texas. At the border the facilities would interconnect with similar facilities owned by Comision Federal de Electricidad (ČFE), the national electric utility of Mexico, and continue an additional five miles to CFE's Cumbres substation located approximately 6 miles from the City of Reynosa, Tamaulipas, Mexico. In the second phase, Sharyland would expand the converter facility to a capacity of 300 MW. Sharyland proposes to operate the transmission line as an "open access" facility available for use by other parties to transfer electric power between the United States and Mexico. Sharyland does not intend to seek an electricity export authorization from

Since the restructuring of the electric power industry began, resulting in the introduction of different types of competitive entities into the marketplace, DOE has consistently expressed its policy that cross-border trade in electric energy should be subject to the same principles of comparable open access and nondiscrimination that apply to transmission in interstate commerce. DOE has stated that policy in export authorization granted to entities requesting authority to export over international transmission facilities. Specifically, DOE expects transmitting utilities owning border facilities constructed pursuant to Presidential permits to provide access across the border in accordance with the principles of comparable open access and non-discrimination contained in the FPA and articulated in Federal Energy Regulation Commission Order No. 888, as amended (Promoting Wholesale Competition Through Open Access Non-Discriminatory Transmission Services by Public Utilities). In furtherance of this policy, DOE intends to condition any Presidential permit issued in this proceeding on compliance with these open access principles.

Procedural Matters: Any person desiring to become a party to this proceeding or to be heard by filing comments or protests to this application should file a petition to intervene, comment or protest at the address provided above in accordance with §§ 385.211 or 385.214 of FERC's Rules of Practice and Procedures (18 CFR 385.211, 385.214). Fifteen copies of each

petition and protest should be filed with DOE on or before the date listed above.

Additional copies of such petitions to intervene or protest also should be filed directly with Mark E. Caskey P.E., General Manager, Sharyland Utilities, L.P., 4403 West Military Highway, Suite 700, McAllen, TX 78503 AND Richard P. Noland, James M. Bushee, Sutherland Asbill & Brennan LLP, 1275 Pennsylvania Avenue, NW., Washington, DC 20004–2415.

Before a Presidential permit may be issued or amended, the DOE must determine that the proposed action will not adversely impact on the reliability of the U.S. electric power supply system. In addition, DOE must consider the environmental impacts of the proposed action (*i.e.*, granting the presidential permit, with any conditions and limitations, or denying the permit) pursuant to NEPA. DOE also must obtain the concurrence of the Secretary of State and the Secretary of Defense before taking final action on a Presidential permit application.

The NEPA compliance process is a cooperative, non-adversarial process involving members of the public, state governments and the Federal government. The process affords all persons interested in or potentially affected by the environmental consequences of a proposed action an opportunity to present their views, which will be considered in the preparation of the environmental documentation for the proposed action. Intervening and becoming a party to this proceeding will not create any special status for the petitioner with regard to the NEPA process. To apply for the NEPA mailing list now, contact Mrs. Ellen Russell at the address above.

Copies of this application will be made available, upon request, for public inspection and copying at the address provided above. In addition, the application may be viewed or downloaded from the Office of Fossil Energy Web site at http://www.fe.doe.gov. Upon reaching the Fossil Energy home page, select "Electricity Regulation" and then "Pending Proceedings" from the options menu.

Issued in Washington, DC, on September 24, 2003.

Anthony J. Como,

Deputy Director, Electric Power Regulation, Office of Coal & Power Import/Export, Office of Coal & Power Systems, Office of Fossil Energy.

[FR Doc. 03–25004 Filed 10–1–03; 8:45 am] BILLING CODE 6450–01–P

DEPARTMENT OF ENERGY

Office of Energy Efficiency and Renewable Energy

Biomass Research and Development Technical Advisory Committee

AGENCY: Department of Energy. **ACTION:** Notice of Open Meeting.

SUMMARY: This notice announces an open meeting of the Biomass Research and Development Technical Advisory Committee under the Biomass Research and Development Act of 2000. The Federal Advisory Committee Act (Pub. L. No. 92–463, 86 Stat. 770) requires that agencies publish these notices in the **Federal Register** to allow for public participation.

DATES: October 23–24, 2003, 8:30 a.m. ADDRESSES: Hilton Crystal City Hotel at National Airport, Crystal Room, 2399 Jefferson Davis Highway, Arlington, VA 22202.

FOR FURTHER INFORMATION CONTACT: John Ferrell, Designated Federal Officer for the Committee, Office of Energy Efficiency and Renewable Energy, U.S. Department of Energy, 1000 Independence Avenue, SW., Washington, DC 20585; (202) 586–7766.

SUPPLEMENTARY INFORMATION:

Purpose of Meeting: To finalize recommendations concerning the federal biomass R&D portfolio and the direction of the Biomass Initiative, to report on these recommendations to the Biomass R&D Board, and to plan Committee activities for FY 2004.

Tentative Agenda: Agenda will include discussions on the following:

• Finalizing recommendations concerning the federal biomass R&D portfolio, reviewing the process and results of the FY 2003 USDA/DOE joint solicitation and providing input on the FY 2004 solicitation, finalizing recommendations to the Secretaries of Agriculture and Energy, providing recommendations to the Biomass R&D Board on the direction of the Biomass Initiative, and developing a committee work plan for FY 2004.

Public Participation: In keeping with procedures, members of the public are welcome to observe the business of the Biomass Research and Development Technical Advisory Committee. To attend the meeting and/or to make oral statements regarding any of the items on the agenda, contact John Ferrell at (202) 586–7766 or Sara Mitcho via e-mail at sara.mitcho@ee.doe.gov. You must make your request for an oral statement at least 5 business days before the meeting. Members of the public will be heard in the order in which they sign up at the beginning of the meeting.

Reasonable provision will be made to include the scheduled oral statements on the agenda. The Co-Chairs of the Committee will make every effort to hear the views of all interested parties. If you would like to file a written statement with the Committee, you may do so either before or after the meeting. The Co-Chairs will conduct the meeting to facilitate the orderly conduct of business.

Minutes: The minutes of the meeting will be available for public review and copying within 60 days of the meeting at the Freedom of Information Public Reading Room; Room 1E–190; Forrestal Building; 1000 Independence Avenue, SW, Washington, DC, between 9 a.m. and 4 p.m., Monday through Friday, except Federal holidays.

Issued at Washington, DC on September 29, 2003.

Rachel M. Samuel,

Deputy Advisory Committee Management Officer.

[FR Doc. 03-25002 Filed 10-1-03; 8:45 am] BILLING CODE 6450-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP99-301-083]

ANR Pipeline Company; Notice of Compliance Filing

September 24, 2003.

Take notice that on September 15, 2003 subject ANR Pipeline Company (ANR), tendered for filing a service agreement (Agreement) between ANR and Interstate Gas Supply, Inc. pursuant to ANR's Rate Schedule FTS-1.

ANR requests the Commission find that the Agreement contains acceptable material deviations from ANR's Form of Service Agreement and accept the attached tariff sheet which references the Agreement as a non-conforming agreement.

Any person desiring to protest said filing should file a protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with § 385.211 of the Commission's Rules and Regulations. All such protests must be filed on or before the protest date as shown below. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. This filing is available for review at the Commission in the Public Reference Room or may be viewed on the

Commission's Web site at http://www.ferc.gov using the "eLibrary" (FERRIS) link. Enter the docket number excluding the last three digits in the docket number field to access the document. Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. For assistance, please contact FERC Online Support at

FERCOnlineSupport@ferc.gov or toll-free at (866) 208–3676, or TTY, contact (202) 502–8659. The Commission strongly encourages electronic filings. See18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the "e-Filing" link.

Protest Date: September 30, 2003.

Magalie R. Salas,

Secretary.

[FR Doc. 03–24893 Filed 10–1–03; 8:45 am] BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP03-610-000]

CenterPoint Energy-Mississippi River Transmission Corporation; Notice of Tariff Filing

September 24, 2003.

Take notice that on September 22, 2003, CenterPoint Energy-Mississippi River Transmission Corporation (MRT) tendered for filing has part of its FERC Gas Tariff, Third Revised Volume No. 1, Fiftieth Revised Sheet No. 5; Fiftieth Revised Sheet No. 6; Forty-Eighth Revised Sheet No. 7; and Twentieth Revised Sheet No. 8, effective November 1, 2003.

MRT states that the purpose of this filing is to adjust the Fuel Use and Loss Percentages under its Rate Schedules FTS, SCT, ITS, FSS and ISS.

MRT further states that a copy of this filing is being mailed to each of MRT's customers and to the state Commissions of Arkansas, Illinois, Louisiana, Missouri and Texas.

Any person desiring to be heard or to protest said filing should file a motion to intervene or a protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Sections 385.214 or 385.211 of the Commission's Rules and Regulations. All such motions or protests must be filed in accordance with § 154.210 of the Commission's Regulations. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to

the proceedings. Any person wishing to become a party must file a motion to intervene. This filing is available for review at the Commission in the Public Reference Room or may be viewed on the Commission's Web site at http://www.ferc.gov using the "eLibrary". Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, please contact FERC Online Support at

FERCOnlineSupport@ferc.gov or toll-free at (866) 208–3676, or TTY, contact (202) 502–8659. The Commission strongly encourages electronic filings. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the "e-Filing" link.

Comment Date: October 6, 2003.

Magalie R. Salas,

Secretary.

[FR Doc. 03–24891 Filed 10–1–03; 8:45 am] BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. CP03-351-000]

Columbia Gas Transmission Corporation; Notice of Request Under Blanket Authorization

September 25, 2003.

Take notice that on September 12, 2003, Columbia Gas Transmission Corporation (Columbia), 12801 Fair Lakes Parkway, Fairfax, Virginia 22030-0146, filed in Docket No. CP03-351-000, a request pursuant to Sections 157.205 and 157.208 of the Commission's Regulations under the Natural Gas Act (18 CFR Sections 157.205 and 157.208) for authorization to increase the maximum allowable operating pressure (MAOP) of portions of its existing transmission pipeline designated as Line 1655 and Line 136 located in Adams and York Counties, Pennsylvania, under Columbia's blanket certificate issued in Docket No. CP83-76–000 pursuant to Section 7(C) of the Natural Gas Act, all as more fully set forth in the request.

Copies of this request are on file with the Commission and are available for public inspection. The application may also be viewed on the Web at http://www.ferc.gov using the "eLibrary" link. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, please contact FERC Online Support at

FERCOnlineSupport@ferc.gov or toll-

free at (866) 208–3676, or for TTY, contact (202) 502–8659.

Columbia states that the increased MAOPs are necessary in order to meet its existing contractual obligations. Columbia states further, that to the extent uncommitted capacity becomes available as a result of the uprate, Columbia would post such available capacity in accordance with the applicable provisions of its tariff.

Any questions regarding the application should be directed to Fredric J. George, Senior Attorney, Columbia Gas Transmission Corporation, P.O. Box 1273, Charleston, West Virginia 22030–0146 at (304) 357–2359, fax (304) 357–3206.

There are two ways to become involved in the Commission's review of this project. First, any person wishing to obtain legal status by becoming a party to the proceedings for this project should, on or before the comment date below, file with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, a motion to intervene in accordance with the requirements of the Commission's Rules of Practice and Procedure (18 CFR 385.214) and the Regulations under the NGA (18 CFR 157.205). A person obtaining party status will be placed on the service list maintained by the Secretary of the Commission and will receive copies of all documents filed by the applicant and by all other parties. A party must submit 14 copies of filings made with the Commission and must mail a copy to the applicant and to every other party in the proceeding. Only parties to the proceeding can ask for court review of Commission orders in the proceeding.

However, a person does not have to intervene in order to have comments considered. The second way to participate is by filing with the Secretary of the Commission, as soon as possible, an original and two copies of comments in support of or in opposition to this project. The Commission will consider these comments in determining the appropriate action to be taken, but the filing of a comment alone will not serve to make the filer a party to the proceeding. The Commission's rules require that persons filing comments in opposition to the project provide copies of their protests only to the party or parties directly involved in the protest.

Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the "e-Filing" link.

If no protest is filed within the time allowed, therefore, the proposed activity shall be deemed to be authorized effective the day after the time allowed for filing a protest. If a protest is filed and not withdrawn within 30 days after the time allowed for filing a protest, the instant request shall be treated as an application for authorization pursuant to Section 7 of the Natural Gas Act.

Comment Date: October 16, 2003.

Linda Mitry,

Acting Secretary.
[FR Doc. 03–24882 Filed 10–1–03; 8:45 am]
BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket Nos. CP03-353-000 & CP03-355-000]

Columbia Gas Transmission, Energy Corporation of America & Eastern American Energy Corporation; Notice of Application

September 25, 2003.

On September 16, 2003, Columbia Gas Transmission Corporation (Columbia), Energy Corporation of America (ECA), and Eastern American Energy Corporation (EAEC), filed a joint application pursuant to Section 7(b) of the Natural Gas Act (NGA), as amended, and the Federal Energy Regulatory Commission's (Commission) Rules and Regulations. Columbia requests authorization to abandon by sale to ECA certain facilities located in West Virginia as well as the services currently provided by the facilities. Columbia requests that the facilities be determined to be non-jurisdictional gathering facilities and exempt from the Commission's jurisdiction pursuant to NGA § 7(b). EAEC, a wholly owned subsidiary of ECA and an explorer, developer and producer of oil and natural gas would own and operated the facilities to provide current services, as more fully set forth in the application. This filing is available for review at the Commission or may be viewed on the Commission's Web site at http:// www.ferc.gov, using the "eLibrary" link. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, please contact FERC Online Support at

FERCOnlineSupport@ferc.gov or toll-free at (866) 208–3676, or for TTY, contact (202) 502–8659.

The facilities proposed for abandonment by sale are Columbia's

8000 system which consists of some 87.8 miles of jurisdictional pipeline and appurtenances. The proposed sale would also include about 10 miles of non-jurisdictional pipeline. The facilities were constructed by Columbia's predecessor in the early 1900's as part of a low-pressure transmission system to support Columbia's merchant role. However the facilities currently transmit local production from various points along the facilities, providing service to local markets along the facilities. Columbia states that the facilities are no longer pertinent to its transporter role. EAEC\ECA the owner and operator of the facilities following the sale requests that it be issued a limited jurisdiction certificate pursuant to NGA § 7(c), so on the rare occasion that local supply is insufficient to supply all service needs, they may utilize interstate natural gas. The sale price for both the jurisdictional and non-jurisdictional facilities is \$1.2

Questions regarding the application may be directed to V. J. Hamilton, Senior Certificate Coordinator, or Frederic J. George, Senior Attorney, both at Columbia Gas Transmission Corporation, P.O. Box 1273, Charleston, West Virginia 25325–1273 or by calling respectively, 304–357–2297 (304–357–2926 Fax) or 304–357–2359 (304–357–3206 Fax).

There are two ways to become involved in the Commission's review of this project. First, any person wishing to obtain legal status by becoming a party to the proceedings for this project should, on or before the comment date below, file with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, a motion to intervene in accordance with the requirements of the Commission's Rules of Practice and Procedure (18 CFR 385.214 or 385.211) and the Regulations under the NGA (18 CFR 157.10). A person obtaining party status will be placed on the service list maintained by the Secretary of the Commission and will receive copies of all documents filed by the applicant and by all other parties. A party must submit 14 copies of filings made with the Commission and must mail a copy to the applicant and to every other party in the proceeding. Only parties to the proceeding can ask for court review of Commission orders in the proceeding.

However, a person does not have to intervene in order to have comments considered. The second way to participate is by filing with the Secretary of the Commission, as soon as possible, an original and two copies of comments in support of or in opposition

to this project. The Commission will consider these comments in determining the appropriate action to be taken, but the filing of a comment alone will not serve to make the filer a party to the proceeding. The Commission's rules require that persons filing comments in opposition to the project provide copies of their protests only to the party or parties directly involved in the protest.

Persons who wish to comment only on the environmental review of this project should submit an original and two copies of their comments to the Secretary of the Commission. Environmental commenters will be placed on the Commission's environmental mailing list, will receive copies of the environmental documents, and will be notified of meetings associated with the Commission's environmental review process. Environmental commenters will not be required to serve copies of filed documents on all other parties. However, the nonparty commenters will not receive copies of all documents filed by other parties or issued by the Commission (except for the mailing of environmental documents issued by the Commission) and will not have the right to seek court review of the Commission's final order.

Comments, protests and interventions may be filed electronically via the Internet in lieu of paper. The Commission strongly encourages electronic filings. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the "e-Filing" link.

Comment Date: October 16, 2003.

Linda Mitry,

Acting Secretary.
[FR Doc. 03–24883 Filed 10–2–03; 8:45 am]
BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP03-604-000]

LSP—Cottage Grove, L.P., LSP— Whitewater, Limited Partnership v. Northern Natural Gas Company; Notice of Complaint

September 25, 2003.

Take notice that on September 12, 2003, LSP—Cottage Grove, L.P. (Cottage Grove) and LSP—Whitewater, Limited Partnership (Whitewater) filed with the Federal Energy Regulatory Commission (Commission) a Compliant Requesting Fast-Track Processing pursuant to Rule 206 of the Commission's Rules of Practice and Procedure, 18 CFR 385.206. The Complaint requests that the Commission grant relief in a billing dispute with Northern Natural Gas Company. Cottage Grove and Whitewater request confidential treatment of certain information in the complaint and the supporting appendices and attachment.

Any person desiring to be heard or to protest this filing should file with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214). Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a motion to intervene. The answer to the complaint and all comments, interventions or protests must be filed on or before the comment date. This filing is available for review at the Commission in the Public Reference Room or may be viewed on the Commission's Web site at http:// www.ferc.gov using the "eLibrary" link. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, please contact FERC Online Support at

FERCOnlineSupport@ferc.gov or toll-free at (866)208–3676, or for TTY, contact (202) 502–8659. The answer to the complaint, comments, protests and interventions may be filed electronically via the Internet in lieu of paper; see 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the "e-Filing" link. The Commission strongly encourages electronic filings.

Comment Date: October 15, 2003.

Linda Mitry,

Acting Secretary.

[FR Doc. 03–24890 Filed 10–1–03; 8:45 am] BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. AD03-53-001]

Old Dominion Electric Cooperative; Notice of Filing

September 24, 2003.

Take notice that on September 12, 2003, Old Dominion Electric Cooperative made a compliance filing pursuant to the accounting and reporting requirements set forth by the Commission in Order 631, Accounting, Financial reporting, and Rate Filing Requirements for Asset Retirement Obligations. The Commission directed jurisdictional entities to file journal entries and supporting information for any adjustments made that affect net income as a result of implementing the accounting rules contained in Order 631.

Any person desiring to intervene or to protest this filing should file with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Rules 211 and 214 of the Commission's Rules of Practice and Procedure (18 CFR 385.211 and 385.214). Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceeding. Any person wishing to become a party must file a motion to intervene. All such motions or protests should be filed on or before the comment date, and, to the extent applicable, must be served on the applicant and on any other person designated on the official service list. This filing is available for review at the Commission or may be viewed on the Commission's Web site at http:// www.ferc.gov, using the eLibrary (FERRIS) link. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, please contact FERC Online Support at FERCOnlineSupport@ferc.gov or tollfree at (866) 208-3676, or for TTY, contact (202) 502-8659. Protests and interventions may be filed electronically via the Internet in lieu of paper; see 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the "e-Filing" link. The Commission strongly encourages electronic filings.

Comment Date: October 3, 2003.

Magalie R. Salas,

Secretary.

[FR Doc. 03–24881 Filed 10–1–03; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP03-342-003]

Questar Pipeline Company; Notice of Tariff Filing

September 24, 2003.

Take notice that on September 22, 2003, Questar Pipeline Company (Questar) tendered for filing as part of its FERC Gas Tariff, First Revised Volume No. 1, Substitute Second Revised Sheet No. 86, to be effective May 12, 2003.

Questar states that this filing is being made to make a minor administrative correction relating to Questar's two tariff filings dated April 14, 2003, and April 29, 2003, filed in Docket Nos. RP03–342–000 and –001, respectively, that modified Questar's measurement section of its tariff. This filing deletes language that was intended to be deleted in Docket No. RP03–342–001 upon discovery that the North American Energy Standards Board (NAESB) Standard 2.3.9 was inadvertently deleted in Docket No. RP03–342–000 and replaced by a new paragraph.

Questar states that it filed an amendment to reverse this replacement, but only half of the incorrect paragraph was deleted. Questar states that this filing continues that correction by deleting the remaining part of the paragraph that is redundant in purpose to NAESB Standard 2.3.9.

Questar states that a copy of this filing has been served upon its customers, the Public Service Commission of Utah and the Public Service Commission of Wyoming.

Any person desiring to protest said filing should file a protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with § 385.211 of the Commission's Rules and Regulations. All such protests must be filed in accordance with § 154.210 of the Commission's Regulations. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. This filing is available for review at the Commission in the Public Reference Room or may be viewed on the Commission's Web site at http:// www.ferc.gov using the eLibrary link. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, please contact FERC Online Support at FERCOnlineSupport@ferc.gov or tollfree at (866) 208–3676, or TTY, contact (202) 502–8659. The Commission strongly encourages electronic filings. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the "eFiling" link.

Protest Date: October 6, 2003.

Magalie R. Salas,

Secretary.

[FR Doc. 03–24889 Filed 10–1–03; 8:45 am] BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. RP03-611-000]

SCG Pipeline, Inc.; Notice of Tariff Filing

September 24, 2003.

Take notice that on September 22, 2003, SCG Pipeline, Inc. (SCG) tendered for filing as part of its FERC Gas Tariff, Original Volume No. 1, the tariff sheets attached to Appendix A, with an effective date of November 1, 2003.

SCG states that the filing is being made in compliance with ordering paragraph A of the Commission's July 29, 2003 "Order on Pro Forma Tariff" (Tariff Order) 104 FERC ¶ 61,159.

SCG states that these actual tariff sheets reflect modifications to SCG's originally filed Pro Forma FERC Gas Tariff to bring it into compliance with the Tariff Order, current NAESB standards, all the requirements in Order Nos. 637, 637–A, and 637–B and subsequent orders, and any other tariff regulations currently in effect. Additional tariff modifications have been made as indicated in SCG's filing.

SCG states that a copy of this filing has been served upon the official service list in this proceeding and upon its customers.

Any person desiring to be heard or to protest said filing should file a motion to intervene or a protest with the Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426, in accordance with Sections 385.214 or 385.211 of the Commission's Rules and Regulations. All such motions or protests must be filed in accordance with § 154.210 of the Commission's Regulations. Protests will be considered by the Commission in determining the appropriate action to be taken, but will not serve to make protestants parties to the proceedings. Any person wishing to become a party must file a motion to intervene. This filing is available for review at the Commission in the Public Reference Room or may be viewed on

the Commission's Web site at http://www.ferc.gov using the "eLibrary". Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, please contact FERC Online Support at

FERCOnlineSupport@ferc.gov or toll-free at (866) 208–3676, or TTY, contact (202) 502–8659. The Commission strongly encourages electronic filings. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the "e-Filing" link.

Comment Date: October 6, 2003.

Magalie R. Salas,

Secretary.

[FR Doc. 03–24892 Filed 10–1–03; 8:45 am] BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project Nos. 2525-051, 2546-068, 2560-047, 2522-074 & 2595-065]

Wisconsin Public Service Company; Notice of Availability of Environmental Assessment

September 25, 2003.

In accordance with the National Environmental Policy Act of 1969 and the Federal Energy Regulatory Commission's (Commission) regulations, 18 CFR part 380 (Order No. 486, 52 FR 47897), the Office of Energy Projects' staff has prepared an Environmental Assessment (EA) for Wisconsin Public Service Company's application requesting Commission approval to amend the application regarding project boundaries of five of its projects to remove 9,738 acres of land, of which it proposes to convey approximately 9,349 acres to the Wisconsin Department of Natural Resources and to use 389 acres for development. The five projects are the Caldron Falls Project No. 2525, the Sandstone Rapids Project No. 2546, the Potato Rapids Project No. 2560, the Johnson Falls Project No. 2522, and the High Falls Project No. 2595 all located on the Peshtigo River in the counties of Marinette and Oconto, Wisconsin. The U.S. Bureau of Land Management owns and manages approximately 10 acres of federal lands (consisting of islands in the Peshtigo River) within the boundaries of the High Falls, Sandstone Rapids, and Potato Rapids projects.

The EA contains the staff's analysis of the potential environmental impacts of the proposal and concludes that approval of the proposal would not constitute a major federal action significantly affecting the quality of the human environment.

A copy of the EA is attached to a Commission Order titled "Order Granting Motions To Intervene, Reinstating Request for Rehearing, Granting Rehearing In Part, And Granting With Conditions Application To Amend Project Boundaries" issued on September 15, 2003 (See 104 FERC & 61,295) which is available for review at the Commission in the Public Reference Room, or it may be viewed on the Commission's Web site at http:// www.ferc.gov using the "AeLibrary" link. Enter the docket number (prefaced by P-) and excluding the last three digits, in the docket number field to access the document. For assistance, please contact FERC Online Support at FERCOnlineSupport@ferc.gov or tollfree (866) 208-3676, or for TTY, contact (202) 502-8659.

For further information, contact Jean Potvin at 202–502–8928.

Linda Mitry,

Acting Secretary.

[FR Doc. 03–24886 Filed 10–1–03; 8:45 am] **BILLING CODE 6717–01–P**

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No. 2232-457]

Notice of Application Accepted for Filing and Soliciting Comments, Motions To Intervene, and Protests

September 25, 2003.

Take notice that the following hydroelectric application has been filed with the Commission and is available for public inspection:

a. Type of Application: Increase in existing water withdrawal from licensed project waters.

- b. Project No: 2232-457.
- c. Date Filed: August 28, 2003.
- d. Applicant: Duke Power Company.
- e. Name of Project: Catawba-Wateree.
- f. Location: The Catawba-Wateree Project is located in Alexander, Burke, Caldwell, Catawba, Gaston, Iredell, Lincoln, McDowell and Mecklenburg Counties, North Carolina and Chester, Fairfield, Kershaw, Lancaster, and York Counties, South Carolina. This project does not occupy any federal lands.

g. *Filed Pursuant to:* Federal Power Act, 16 U.S.C.791a–825r.

Applicant Contact: Mr. Joe Hall, Lake Management Representative, Duke Power, Division of Duke Energy Corp., P.O. Box 1006, Charlotte, North Carolina 28201–1006, (704) 382–8576.

- i. FERC Contact: Any questions regarding this notice should be addressed to B. Peter Yarrington at (202) 502–6129.
- j. Description of Request: Duke Power proposes to grant an updated Water Withdrawal Easement to the City of Mount Holly, North Carolina for project property within Mountain Island Lake that will supercede an existing easement. The updated easement will provide for the placement and maintenance of new intake screens on existing water intake pipes, allowing Mount Holly to increase water withdrawal using the existing Raw Water Intake Pump Station. Mount Holly has requested an increase in water withdrawal from Mount Island Lake from the currently-permitted withdrawal of 3.0 million gallons per day (MGD) to 13.5 MGD.

k. Deadline for filing comments or motions: October 27, 2003.

- l. Locations of the application: A copy of the application is available for inspection and reproduction at the Commission's Public Reference Room, located at 888 First Street, NE., Room 2A, Washington, DC 20426 or may be viewed on the Commission's Web site at http://www.ferc.gov using the "eLibrary" link. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, call toll-free 1-866-208-3676 or e-mail FERCOnlineSupport@ferc.gov. For TTY, call (202) 502-8659. A copy is also available for inspection and reproduction at the address in item "h" above.
- m. Filing and Service of Responsive Documents: Any filings must bear in all capital letters the title "COMMENTS", "RECOMMENDATIONS FOR TERMS AND CONDITIONS", "PROTEST", OR "MOTION TO INTERVENE", as applicable, and the project number (P-2232–457) to which the filing refers. All documents (original and eight copies) should be filed with: The Secretary, Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426. A copy of any motion to intervene must also be served upon each representative of the Applicant specified in the particular application. Comments, protests, and interventions may be filed electronically via the internet in lieu of paper. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site under the "e-Filing" link. The Commission strongly encourages e-filings.

Anyone may submit responses in accordance with the requirements of Rules of Practice and Procedure, 18 CFR 385.210, .211, .214. In determining the

appropriate action to take, the Commission will consider all protests or other comments filed, but only those who file a motion to intervene in accordance with the Commission's Rules may become a party to the proceeding. Any responses must be received on or before the specified comment date for the particular application.

n. Agency Comments: Federal, state, and local agencies are invited to file comments on the described applications. A copy of the applications may be obtained by agencies directly from the Applicant. If an agency does not file comments within the time specified for filing comments, that agency will be presumed to have no comments. One copy of an agency's comments must also be sent to the Applicant's representatives.

Linda Mitry,

Acting Secretary.

FR Doc. 03–24885 Filed 10–1–03; 8:45 am]

BILLING CODE 6717-01-P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[P-516-379]

Notice of Application for Amendment of License and Soliciting Comments, Motions To Intervene, and Protests

September 25, 2003.

Take notice that the following application has been filed with the Commission and is available for public inspection:

- a. *Application Type:* Application for Non-Project Use of Project Lands and Waters.
 - b. Project No: 516-379.
 - c. Date Filed: August 27, 2003.
- d. *Applicant:* South Carolina Electric & Gas Company (SCE&G).
 - e. Name of Project: Saluda Project.
- f. Location: The project is located on the Saluda River in Lexington, Newberry, Richland, and Saluda Counties, South Carolina. The project does not utilize federal or tribal lands.
- g. Filed Pursuant to: Federal Power Act, 16 U.S.C. 791(a)–825(r) and 799 and 801.
- h. Applicant Contact: Randolph R. Mahan, Manager, Environmental Programs and Special Projects, SCANA Services, Inc., Columbia, SC 29218. Telephone Number (803) 217–8538.
- i. FERC Contact: Any questions on this notice should be addressed to Mrs. Jean Potvin at (202) 502–8928, or e-mail address: jean.potvin@ferc.gov.

j. Deadline for filing comments and or motions: October 27, 2003.

All documents (original and eight copies) should be filed with: Ms. Magalie R. Salas, Secretary, Federal Energy Regulatory Commission, 888 First Street, NE., Washington DC 20426. Please include the project number (P–516–379) on any comments or motions filed. Comments, protests, and interventions may be filed electronically via the internet in lieu of paper. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site at http://www.ferc.gov under the "efiling" link. The Commission strongly encourages e-filings.

k. Description of Request: SCE&G is requesting Commission approval to issue a permit to Boulevard Partners, Inc. for the use of project lands and waters to accommodate the installation of a concrete boat ramp and a multi-boat docking facility designed to berth 32 boats in association with the development of a residential community to be known as Lakeside at Ballentine.

- 1. Location of the Applications: This filing is available for review at the Commission in the Public Reference Room 888 First Street, NE., Room 2A, Washington, DC 20426 or may be viewed on the Commission's Web site at http://www.ferc.gov using the "eLibrary" link. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, call toll-free 1-866-208-3676 or e-mail FERCOnlineSupport@ferc.gov. For TTY, call (202) 502-8659. A copy is also available for inspection and reproduction at the address in item h above
- m. Individuals desiring to be included on the Commission's mailing list should so indicate by writing to the Secretary of the Commission.
- n. Comments, Protests, or Motions to Intervene—Anyone may submit comments, a protest, or a motion to intervene in accordance with the requirements of Rules of Practice and Procedure, 18 CFR 385.210, .211, .214. In determining the appropriate action to take, the Commission will consider all protests or other comments filed, but only those who file a motion to intervene in accordance with the Commission's Rules may become a party to the proceeding. Any comments, protests, or motions to intervene must be received on or before the specified comment date for the particular application.
- o. Filing and Service of Responsive Documents—Any filings must bear in all capital letters the title "COMMENTS",

"RECOMMENDATIONS FOR TERMS AND CONDITIONS", "PROTEST", OR "MOTION TO INTERVENE", as applicable, and the Project Number of the particular application to which the filing refers. A copy of any motion to intervene must also be served upon each representative of the Applicant specified in the particular application.

p. Agency Comments: Federal, state, and local agencies are invited to file comments on the described applications. A copy of the application may be obtained by agencies directly from the Applicant. If an agency does not file comments within the time specified for filing comments, it will be presumed to have no comments. One copy of an agency's comments must also be sent to the Applicant's representatives.

Linda Mitry,

Acting Secretary.

[FR Doc. 03–24894 Filed 10–1–03; 8:45 am] **BILLING CODE 6717–01–P**

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

Notice of Application for Land Conveyance and Change in Project Boundary and Soliciting Comments, Motions To Intervene, and Protests

September 25, 2003.

Take notice that the following application has been filed with the Commission and is available for public inspection:

- a. *Application Type:* Amendment to remove project lands from the project boundary.
 - b. *Project No.:* 1953–069.
 - c. Date Filed: September 9, 2003.
- d. *Applicant:* Consolidated Water Power Company
- e. *Name of Project:* DuBay Hydroelectric Project
- f. Location: The project is located on the Wisconsin River, in Portage, Marathon, and Wood Counties, Wisconsin. According to the license the project does not utilize federal or tribal lands.
- g. Filed Pursuant to: Federal Power Act, 16 U.S.C. 791(a)–825(r) and 799 and 801.
- h. Applicant Contact: Mr. Mark Anderson, Consolidated Water Power Company, P.O. Box 8050, Wisconsin Rapids, Wisconsin 54495–8050. (715) 422–3927.
- i. FERC Contact: Any questions on this notice should be addressed to Jean Potvin, jean.potvin@ferc.gov, or (202) 502–8928.

j. Deadline for filing comments and or motions: October 27, 2003.

All documents (original and eight copies) should be filed with: Ms.
Magalie R. Salas, Secretary, Federal
Energy Regulatory Commission, 888
First Street, NE., Washington, DC 20426.
Please include the project number (P–
1953–069) on any comments or motions filed. Comments, protests and interventions may be filed electronically via the internet in lieu of paper. See 18
CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site at http://www.ferc.gov under the "e-Filing" link. The Commission strongly encourages e-filings.

k. Description of Proposal: This proposal includes the conveyance of 2,804 acres of DuBay Project lands to the Wisconsin Department of Natural Resources and removal of the lands from the project boundary. The lands removed from the project boundary would be added to the existing Mead Wildlife Area.

I. Locations of the Application: The filing is available for review at the Commission's Public Reference Room, at 888 First Street, NE., Room 2A, Washington, DC 20426, or may be viewed on the Commission's Web site at http://www.ferc.gov using the "eLibrary" link. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, please call the Helpline at (866) 208–3676 or contact FERCOnlineSupport@ferc.gov. For TTY, contact (202) 502–8659.

m. Individuals desiring to be included on the Commission's mailing list should so indicate by writing to the Secretary of the Commission.

n. Comments, Protests, or Motions to Intervene—Anyone may submit comments, a protest, or a motion to intervene in accordance with the requirements of Rules of Practice and Procedure, 18 CFR 385.210, .211, .214. In determining the appropriate action to take, the Commission will consider all protests or other comments filed, but only those who file a motion to intervene in accordance with the Commission's Rules may become a party to the proceeding. Any comments, protests, or motions to intervene must be received on or before the specified comment date for the particular application.

o. Filing and Service of Responsive Documents—Any filings must bear in all capital letters the title "COMMENTS",

"RECOMMENDATIONS FOR TERMS AND CONDITIONS", "PROTEST", OR "MOTION TO INTERVENE", as applicable, and the Project Number of the particular application to which the filing refers. A copy of any motion to intervene must also be served upon each representative of the Applicant specified in the particular application.

p. Agency Comments: Federal, state, and local agencies are invited to file comments on the described application. A copy of the application may be obtained by agencies directly from the Applicant. If an agency does not file comments within the time specified for filing comments, it will be presumed to have no comments. One copy of an agency's comments must also be sent to the Applicant's representatives.

Linda Mitry,

Acting Secretary.

[FR Doc. 03–24884 Filed 10–1–03; 8:45 am]

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Docket No. P-12187-000]

Notice of Application Accepted for Filing and Soliciting Motions To Intervene and Protest

September 24, 2003.

Take notice that the following hydroelectric application has been filed with the Commission and is available for public inspection.

- a. *Type of Application:* Original Major License.
 - b. *Project No.:* P–12187–000.
 - c. Date Filed: June 03, 2002.
- d. *Applicant:* Price Dam Partnership, Limited.
- e. *Name of Project:* Price Dam Hydroelectric Project.
- f. Location: Located on the Mississippi River in city of Alton, Wood River Township, Madison County, Illinois. The proposed project would be constructed on the U.S. Corps of Engineers (Corps) Melvin Price Locks & Dam and the nearby Illinois shoreline of the Mississippi River and would affect a portion of the 7.8 acres of federal lands (including six of the nine existing gate bays in the dam and a portion of the Illinois shoreline for the construction of a proposed transmission line and a proposed Control/Storage building).
- g. *Filed Pursuant to:* Federal Power Act 16 U.S.C. 791(a)–825(r).
- h. Applicant Contact: Mr. James B. Price, WV Hydro, Inc., P.O. Box 903, Gatlinburg, TN 37738 (865) 436–0402.
- i. FERC Contact: Lee Emery, (202) 502–8379 or e-mail lee.emery@ferc.gov.

j. Deadline for filing motions to intervene and protest: 60 days from the issuance date of this notice.

All documents (original and eight copies) should be filed with: Magalie R. Salas, Secretary, Federal Energy Regulatory Commission, 888 First Street, NE., Washington, DC 20426.

The Commission's Rules of Practice and Procedure require all intervenors filing documents with the Commission to serve a copy of that document on each person on the official service list for the project. Further, if an intervenor files comments or documents with the Commission relating to the merits of an issue that may affect the responsibilities of a particular resource agency, they must also serve a copy of the document on that resource agency.

Motions to intervene and protests may be filed electronically via the Internet in lieu of paper. The Commission strongly encourages electronic filings. See 18 CFR 385.2001(a)(1)(iii) and the instructions on the Commission's Web site (http://www.ferc.gov) under the "e-

Filing" link.

k. This application has been accepted for filing, but is not ready for environmental analysis at this time.

l. Description of Project: The proposed Price Dam Project would use the U.S. Corps of Engineers' Melvin Price Locks & Dam and Reservoir, and would consist of the following facilities: (1) 192 individual, turbine/generator units grouped in six moveable steel modules 108.9-feet-long by 26.2-feet-wide by 44.0-feet-high, (a) each module contains 32 turbine/generator sets (two horizontal rows of 16 units each) that will be installed in stoplog slots on adjacent piers upstream from the Taintor gates, and (b) each turbine/ generator unit includes a 550 kilowatt bulb-type generator, a fixed-blade propeller turbine, and a single draft tube for each two turbine/generating units; (2) flexible power cables, each connecting the six 32-turbine/generatorsets to six 7.2 kilovolt (kV) transformer and breaker sets on an adjacent pier; (3) lifting/access columns at the end of each module; (4) six air-operated spillway gates, 7-feet-high by 96-feet-long, installed on top of each module with each gate containing an inflatable rubber bladder; (5) a hallway housing the station service transformer, motor control center, and control system; (6) a slave terminal at the lockmaster's office and a control station located on the dam superstructure; (7) a 6.9-kV/138-kV stepup transformer located on a platform on the dam axis at elevation 479 feet National Geodetic Vertical Datum; (8) a mobile, 1,000 metric ton crane with an auxiliary crane riding on top of the

module cranes' lifting beam; these cranes would lower and raise the power modules and operate the trash rake; (9) a fish bypass on each module; (10) a trashrack assembly with a two-inch clear spacing between the bars, and a crane-operated trash rake; (11) a 500kilowatt generator; (12) a 0.8-mile-long, 138-kV transmission line connecting the project power to the Mississippi Substation of Ameren, Incorporated; (13) an auxiliary Control/Storage building; and (14) appurtenant facilities. The average annual generation is estimated to be 319,000 megawatt-hours and have an installed generating capacity of 92 megawatts (MW). All generated power would be sold to a local utility connected to the grid.

m. A copy of the application is available for review at the Commission in the Public Reference Room or may be viewed on the Commission's Web site at http://www.ferc.gov using the "eLibrary" link. Enter the docket number excluding the last three digits in the docket number field to access the document. For assistance, contact FERC Online Support at FERCOnlineSupport@ferc.gov or toll-free at 1–866–208–3676, or for TTY, (202) 502–8659. A copy is also available for inspection and reproduction at the

address in item h. above.
You may also register online at http://www.ferc.gov /docs-filing/esubscription.asp to be notified via email of new filings and issuances related to this or other pending projects. For assistance, contact FERC Online Support.

n. Any qualified applicant desiring to file a competing application must submit to the Commission, on or before the specified deadline date for the particular application, a competing development application, or a notice of intent to file such an application. Submission of a timely notice of intent allows an interested person to file the competing development application no later than 120 days after the specified deadline date for the particular application. Applications for preliminary permits will not be accepted in response to this notice.

A notice of intent must specify the exact name, business address, and telephone number of the prospective applicant, and must include an unequivocal statement of intent to submit, if such an application may be filed, either a preliminary permit application or a development application (specify which type of application). A notice of intent must be served on the applicant(s) named in this public notice.

Anyone may submit a protest or a motion to intervene in accordance with the requirements of Rules of Practice and Procedure, 18 CFR 385.210, 385.211, and 385.214. In determining the appropriate action to take, the Commission will consider all protests filed, but only those who file a motion to intervene in accordance with the Commission's Rules may become a party to the proceeding. Any protests or motions to intervene must be received on or before the specified deadline date for the particular application.

When the application is ready for environmental analysis, the Commission will issue a public notice requesting comments, recommendations, terms and conditions, or prescriptions.

All filings must (1) Bear in all capital letters the title "PROTEST" or "MOTION TO INTERVENE," "NOTICEOF INTENT TO FILE COMPETING APPLICATION.'or "COMPETING APPLICATION;" (2) set forth in the heading the name of the applicant and the project number of the application to which the filing responds; (3) furnish the name, address, and telephone number of the person protesting or intervening; and (4) otherwise comply with the requirements of 18 CFR 385.2001 through 385.2005. Agencies may obtain copies of the application directly from the applicant. A copy of any protest or motion to intervene must be served upon each representative of the applicant specified in the particular application.

o. *Procedural schedule:* The application will be processed according to the following Hydro Licensing Schedule. Revisions to the schedule will be made as appropriate.

Notice of Application Accepted For Filing and Soliciting: September 2003.

Motions To Intervene And Protests
Issue Scoping Document: January 2004.
Notice Application Beady For FA

Notice Application Ready For EA (REA) and Soliciting: April 2004.

Comments and Recommendations

Notice Of The Availability Of The EA: October 2004.

Order Issuing The Commission's Decision on the Application: January 2005

Unless substantial comments are received in response to the EA, staff intends to prepare a single EA in this case. If substantial comments are received in response to the EA, a final EA will be prepared with the following modifications to the schedule.

Notice of the Availability of the EA: December 2004.

Order issuing the Commission's decision on the application: February

Magalie R. Salas

Secretary.

[FR Doc. 03–24888 Filed 10–1–03; 8:45 am] BILLING CODE 6717–01–P

DEPARTMENT OF ENERGY

Federal Energy Regulatory Commission

[Project No. 2744-000]

North American Hydro, Inc.; Notice of Meeting To Address the Potential for Early Relicensing of the Park Mill Project

September 25, 2003.

On July 5, 2002, the Commission's Dispute Resolution Service (DRS) issued a notice to convene interested parties on unresolved issues related to fish entrainment and mortality resulting from the outcome of a two-year feasibility study on fish protection required by a Commission order issued in June 24, 1997. The Menominee-Park Mill Project is located on the Menominee River in Marinette County, Wisconsin and Menominee County, Michigan. At the convening session on July 25, 2002, the DRS explored whether the parties would agree to an Alternative Dispute Resolution (ADR) process to resolve the fishery-related issues through assisted negotiations. North American Hydro, Inc. (licensee), federal and state agencies and nongovernmental organizations (NGOs) who attended the July meeting agreed to an ADR process to try to resolve the fishery-related issues. Between July 25, 2002 and the present, the parties have been working toward a settlement on the fishery-related issues in mediated discussions under the Administrative Dispute Resolution Act (Pub. L. 104-320, as amended).

The existing license expires in 2015. The parties in the ADR process are exploring the option of accelerating the relicensing of the Park Mill project. An application for an accelerated license has not been filed at this time. The purpose of the up-coming meeting is to explore the concerns and interests of the stakeholders not involved in the ADR process. Formal scoping meetings would be held should the licensee file an application to relicense the project and the Commission issues a formal notice to accelerate the license.

FERC staff will conduct one daytime meeting and one evening meeting. The daytime meeting will focus on resource agency and NGO's concerns and interests. The evening meeting will be held primarily for input from the public on its concerns and interests. All interested individuals, organizations, and agencies are invited to attend one or both of the meetings to assist the staff in addressing the option noted above. The time and locations of these meetings are as follows:

Daytime Scoping Meeting—Agency-Related

Date: Monday, October 27, 2003.

Time: 2 p.m.

Place: Wisconsin Department of

Natural Resources.

Address: 101 North Ogden Street, Peshtigo, WI.

Evening Public Scoping Meeting

Date: Monday, October 27, 2003.

Time: 7 p.m.-9 p.m.

Place: Same location noted above. If you have further questions, please contact Deborah Osborne at 202–502–8831.

Linda Mitry,

Acting Secretary.

[FR Doc. 03-24887 Filed 10-1-03; 8:45 am]

BILLING CODE 6717-01-P

ENVIRONMENTAL PROTECTION AGENCY

[OAR-2003-0087; FRL-7567-6]

Agency Information Collection Activities; Submission to OMB for Review and Approval; Comment Request; National Volatile Organic Compound Emission Standards for Consumer Products, EPA ICR Number 1764.03, OMB Control Number 2060– 0348

AGENCY: Environmental Protection Agency (EPA).

ACTION: Notice.

SUMMARY: In compliance with the Paperwork Reduction Act (44 U.S.C. 3501 et seq.), this document announces that an Information Collection Request (ICR) has been forwarded to the Office of Management and Budget (OMB) for review and approval. This is a request to renew an existing approved collection. This ICR is scheduled to expire on September 30, 2003. Under OMB regulations, the Agency may continue to conduct or sponsor the collection of information while this submission is pending at OMB. This ICR describes the nature of the information collection and its estimated burden and cost.

DATES: Additional comments may be submitted on or before November 3, 2003

ADDRESSES: Submit your comments, referencing docket ID number OAR—2003—0087, to (1) EPA online using EDOCKET (our preferred method), by email to a-and-r-Docket@epa.gov, or by mail to: EPA Docket Center, Environmental Protection Agency, Air and Radiation Docket and Information Center, Mail Code 6102T, 1200 Pennsylvania Ave., NW., Washington, DC 20460, and (2) OMB at: Office of Information and Regulatory Affairs, Office of Management and Budget (OMB), Attention: Desk Officer for EPA, 725 17th Street, NW., Washington, DC 20503.

FOR FURTHER INFORMATION CONTACT: Mr. Bruce Moore, Emission Standards Division, Mail Code C504–03, Environmental Protection Agency, Research Triangle Park, North Carolina 27711; telephone number: (919) 541–5460; fax number: (919) 541–0072; email address: moore.bruce@epa.gov.

SUPPLEMENTARY INFORMATION: EPA has submitted the following ICR to OMB for review and approval according to the procedures prescribed in 5 CFR 1320.12. On June 5, 2003 (68 FR 33688), EPA sought comments on this ICR pursuant to 5 CFR 1320.8(d). EPA received no comments.

EPA has established a public docket for this ICR under Docket ID No. OAR-2003–0087, which is available for public viewing at the Air and Radiation Docket and Information Center in the EPA Docket Center (EPA/DC), EPA West, Room B102, 1301 Constitution Ave., NW., Washington, DC. The EPA Docket Center Public Reading Room is open from 8:30 a.m. to 4:30 p.m., Monday through Friday, excluding legal holidays. The telephone number for the Reading Room is (202) 566-1744, and the telephone number for the Air and Radiation Docket and Information Center is (202) 566-1742. An electronic version of the public docket is available through EPA Dockets (EDOCKET) at http://www.epa.gov/edocket. Use EDOCKET to submit or view public comments, access the index listing of the contents of the public docket, and to access those documents in the public docket that are available electronically. Once in the system, select "search," then key in the docket ID number identified above.

Any comments related to this ICR should be submitted to EPA and OMB within 30 days of this notice. EPA's policy is that public comments, whether submitted electronically or in paper, will be made available for public

viewing in EDOCKET as EPA receives them and without change, unless the comment contains copyrighted material, CBI, or other information whose public disclosure is restricted by statute. When EPA identifies a comment containing copyrighted material, EPA will provide a reference to that material in the version of the comment that is placed in EDOCKET. The entire printed comment, including the copyrighted material, will be available in the public docket. Although identified as an item in the official docket, information claimed as CBI, or whose disclosure is otherwise restricted by statute, is not included in the official public docket, and will not be available for public viewing in EDOCKET. For further information about the electronic docket, see EPA's **Federal Register** notice describing the electronic docket at 67 FR 38102 (May 31, 2002), or go to http://www.epa.gov/

Title: National Volatile Organic Compound Emission Standards for Consumer Products.

Abstract: The information collection includes initial reports and periodic recordkeeping necessary for EPA to ensure compliance with Federal standards for volatile organic compounds in consumer products. Respondents are manufacturers, distributors, and importers of consumer products. Responses to the collection are mandatory under 40 CFR part 59, subpart C—National Volatile Organic Compound Emission Standards for Consumer Products. All information submitted to EPA for which a claim of confidentiality is made will be safeguarded according to Agency policies set forth in 40 CFR part 2, subpart B—Confidentiality of Business Information.

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless it displays a currently valid OMB control number. The OMB control numbers for EPA's regulations in 40 CFR are listed in 40 CFR part 9 and are identified on the form and/or instrument, if applicable.

Burden Statement: The annual public reporting and recordkeeping burden for this collection of information is estimated to average 81 hours per respondent. Burden means the total time, effort, or financial resources expended by persons to generate, maintain, retain, or disclose or provide information to or for a Federal agency. This includes the time needed to review instructions; develop, acquire, install, and utilize technology and systems for the purposes of collecting, validating, and verifying information, processing

and maintaining information, and disclosing and providing information; adjust the existing ways to comply with any previously applicable instructions and requirements; train personnel to be able to respond to a collection of information; search data sources; complete and review the collection of information; and transmit or otherwise disclose the information.

Respondents/Affected Entities:
Entities potentially affected by this action are those which manufacture, distribute, or import consumer products for sale or distribution in the United States, including the District of Columbia and all United States territories.

Estimated Number of Respondents: 367.

Frequency of Response: occasional recordkeeping and reporting.

Estimated Total Annual Hour Burden: 29,613.

Estimated Total Annual Cost: \$1,104,057, includes \$0 annualized capital or O&M costs and \$1,104,057 labor costs.

Changes in the Estimates: There is a decrease of 82 hours in the total estimated burden currently identified in the OMB Inventory of Approved ICR Burdens. This decrease reflects an updated estimate calculation and is not due to any change in program requirements.

Dated: September 23, 2003.

Sara Hisel McCoy,

Acting Director, Collection Strategies Division.

[FR Doc. 03–25009 Filed 10–1–03; 8:45 am]

ENVIRONMENTAL PROTECTION AGENCY

[FRL-7567-5]

Proposed CERCLA Section 122(h) Administrative Agreement for Recovery of Past Costs for the Mercury Refining Superfund Site, Towns of Guilderland and Colonie, Albany County, NY

AGENCY: Environmental Protection Agency.

ACTION: Notice; request for public comment.

SUMMARY: In accordance with section 122(i) of the Comprehensive Environmental Response, Compensation, and Liability Act of 1980, as amended ("CERCLA"), 42 U.S.C. 9622(i), notice is hereby given by the U.S. Environmental Protection Agency ("EPA"), Region II, of a

proposed administrative agreement pursuant to section 122(h) of CERCLA, 42 U.S.C. 9622(h), with the settling parties, Mercury Refining Company, Inc. ("Mereco"), and Leo Cohen, for recovery of past and future response costs concerning the Mercury Refining Superfund Site ("Site") located in the Towns of Guilderland and Colonie, Albany County, New York. The settlement requires that EPA be paid a total of approximately \$524,000: the total remaining funds in an escrow account established by Mereco (estimated to be approximately \$494,000) and \$30,000 from Leo Cohen, Mereco's founder, sole shareholder and former president. The settlement includes a covenant not to sue the settling parties pursuant to sections 106 and 107(a) of CERCLA, 42 U.S.C. 9606 and 9607(a), and section 7003 of the Resource Conservation and Recovery Act ("RCRA"), 42 U.S.C. 6973, in exchange for their payment of monies.

For thirty (30) days following the date of publication of this notice, EPA will receive written comments relating to the settlement. EPA will consider all comments received and may modify or withdraw its consent to the settlement if comments received disclose facts or considerations that indicate that the proposed settlement is inappropriate, improper or inadequate.EPA's response to any comments received will be available for public inspection at EPA Region II, 290 Broadway, New York, New York 10007-1866. Commenters may request an opportunity for a public meeting in the affected area in accordance with section 7003(d) of RCRA, 42 U.S.C. 6973(d).

DATES: Comments must be submitted on or before November 3, 2003.

ADDRESSES: The proposed settlement is available for public inspection at EPA Region II offices at 290 Broadway, New York, New York 10007–1866. Comments should reference the Mercury Refining Superfund Site, Towns of Guilderland and Colonie, Albany County, New York, Index No. CERCLA–02–2003–2009. To request a copy of the proposed settlement agreement, please contact the individual identified below.

FOR FURTHER INFORMATION CONTACT:

Sharon E. Kivowitz, Assistant Regional Counsel, New York/Caribbean Superfund Branch, Office of Regional Counsel, U.S. Environmental Protection Agency, 290 Broadway—17th Floor, New York, New York 10007–1866. Telephone: 212–637–3183. Dated: September 16, 2003.

William J. Muszynski,

Deputy Regional Administrator, Region 2. [FR Doc. 03–25010 Filed 10–1–03; 8:45 am]

BILLING CODE 6560-50-P

FEDERAL COMMUNICATIONS COMMISSION

Public Information Collection Approved by Office of Management and Budget

AGENCY: Federal Communications

Commission. **ACTION:** Notice.

SUMMARY: The Federal Communications Commission (FCC) has received Office of Management and Budget (OMB) approval for the following public information collection pursuant to the Paperwork Reduction Act of 1995, Public Law 104–13.

DATES: Written comments should be submitted on or before November 3, 2003. If you anticipate that you will be submitting comments, but find it difficult to do so within the period of time allowed by this notice, you should advise the contacts listed below as soon as possible.

ADDRESSES: Kim A. Johnson, Office of Management and Budget, Room 10236 NEOB, Washington, DC 20503, (202) 395–7232 or

Kim_A. Johnson@omb.eop.gov; or Les Smith, Federal Communications Commission, 445 12th Street, Room 1–A804, Washington DC, 20554, (202) 418–0217 or Leslie.Smith@fcc.gov.

Paperwork Reduction Act

OMB Control No.: 3060–1033. *Expiration Date:*

Title: Multi-channel Video Program Distributor EEO Program Annual Report, FCC Form 396–C.

Form No.: 396-C.

Respondents: 10 minutes to 2.5 hours. Number of Respondents: 2,200. Total Annual Burden: 3188 hours. Total Annual Cost: None.

Description: FCC Form 396—C collects information on the EEO program of multi-channel video program distributors during the last year prior to filing once every five years, each employment unit is also required to submit as an attachment a copy of the units most recent EEO public file report, and is also required to answer additional questions about its hiring program on a Supplemental Investigation Sheet.

Federal Communications Commission.

Marlene H. Dortch,

Secretary.

[FR Doc. 03-24935 Filed 10-1-03; 8:45 am]

BILLING CODE 6712-01-P

FEDERAL COMMUNICATIONS COMMISSION

[DA 03-2706]

Notice of Suspension and of Proposed Debarment Proceedings; Schools and Libraries Universal Service Support Mechanism

AGENCY: Federal Communications Commission.

ACTION: Notice.

SUMMARY: The Enforcement Bureau ("Bureau") gives notice of Mr. Oscar Alvarez's suspension from the schools and libraries universal service support mechanism. In addition, the Bureau gives notice that debarment proceedings are commencing against him. Mr. Alvarez, or any person who has an existing contract with or intends to contract with him to provide or receive services in matters arising out of activities associated with or related to the schools and libraries support, may respond by filing an opposition request, supported by documentation.

DATES: Opposition requests must be received by November 3, 2003. However, an opposition request by the party to be suspended must be received 30 days from the receipt of the suspension letter or November 3, 2003, whichever comes first. The Bureau will decide any opposition request for reversal or modification of suspension or debarment within 90 days of its receipt of such requests.

FOR FURTHER INFORMATION CONTACT:

Diana Lee, Federal Communications Commission, Enforcement Bureau, Investigations and Hearings Division, Room 6–C326, 445 12th Street, SW., Washington, DC 20554. Diana Lee may be contacted by phone at (202) 418– 1420 or e-mail at diana.lee@fcc.gov.

SUPPLEMENTARY INFORMATION: The Bureau has suspension and debarment authority under 47 CFR 54.521 and 47 CFR 0.111(a)(14). Suspension will help to ensure that the party to be suspended cannot continue to benefit from the schools and libraries mechanism pending resolution of the debarment process. Attached is the suspension letter, Notice of Suspension and of Proposed Debarment Proceedings, DA 03–2706, which was mailed to Mr. Alvarez and released on August 21, 2003. The letter (1) gives notice of the

suspension and proposed debarment; (2) gives the reasons for the proposed debarment; (3) explains the debarment procedures, and (4) describes the potential effect of debarment. The complete text of the suspension letter is available for public inspection and copying during regular business hours at the FCC Reference Information Center, Portals II, 445 12th Street, SW., Room CY-A257, Washington, DC 20554. In addition, the complete text of this letter may be retrieved from the FCC's Web site at http://www.fcc.gov. The text may also be purchased from the Commission's duplicating contractor, Qualex International, Portals II, 445 12th Street, SW., Room CY-B402, Washington, DC 20554, telephone (202) 863-2893, facsimile (202) 863-2898, or via e-mail qualexint@aol.com.

Federal Communications Commission.

Maureen F. Del Duca,

Chief, Investigations and Hearings Division, Enforcement Bureau.

The suspension letter follows:

Federal Communications Commission

Washington, DC 20554

[DA 03-2706]

August 21, 2003.

Via Certified Mail

Return Receipt Requested

Mr. Oscar Alvarez

Connect2 Internet Networks, Inc.

26 Bay Street

Staten Island, NY 10301

Re: Notice of Suspension and of Proposed Debarment, File No. EB-03-IHD-0377.

Dear Mr. Alvarez: The Federal Communications Commission ("FCC" or "Commission") has received notice of your May 20, 2003 conviction pursuant to 18 U.S.C. 1512 for misleading conduct toward another person: (1) to influence, delay, or prevent the testimony of any person in an official proceeding; and (2) with the intent to cause and induce another person to alter, destroy, mutilate and conceal objects with the intent to impair the objects' integrity and availability for use in an official proceeding.1 Consequently, pursuant to 47 CFR 54.521, this letter constitutes official notice of your suspension from the schools and libraries universal service support mechanism. In addition, the Enforcement Bureau ("Bureau")

¹ Any further reference in this letter to "your conviction" refers to your May 20, 2003 guilty plea and conviction of this count based on your attempt to persuade two school administrators not to reveal evidence to FCC auditors conducting an official investigation into violations by your employer, Connect2 Internet Networks, Inc. ("Connect2") of the FCC rules governing the E-Rate schools and libraries internet funding program ("E-Rate program"). See United States v. Alvarez, Criminal Docket No. 1:03cr634, Felony Information at 1–2 (S.D.N.Y. filed May 20, 2003) ("Alvarez Felony Information").

hereby notifies you that we are commencing debarment proceedings against you.²

I. Notice of Suspension

Pursuant to section 54.521(a)(4) of the Commission's rules,³ your conviction requires the Bureau to suspend you from participating in any activities associated with or related to the schools and libraries fund mechanism, including the receipt of funds or discounted services through the schools and libraries fund mechanism, or consulting with, assisting, or advising applicants or service providers regarding the schools and libraries support mechanism.⁴ Your suspension becomes effective upon the earlier of your receipt of this letter or publication of notice in the Federal Register.⁵

Suspension is immediate pending the Bureau's final debarment determination. You may contest this suspension or the scope of this suspension by filing arguments in opposition to the suspension, with any relevant documentation. Your request must be received within 30 days after you receive this letter or after notice is published in the Federal Register, whichever comes first.6 Such requests, however, will not ordinarily be granted.7 The Bureau may reverse or limit the scope of suspension only upon a finding of extraordinary circumstances.8 Absent extraordinary circumstances, the Bureau will decide any request for reversal or modification of suspension within 90 days of its receipt of such request.9

II. Notice of Proposed Debarment

A. Reasons for and Cause of Debarment

The Commission's rules establish procedures to prevent persons who have "defrauded the government or engaged in similar acts through activities associated with or related to the schools and libraries support mechanism" from receiving the benefits associated with that program. ¹⁰ On May 20, 2003, you pleaded guilty to attempting to persuade two school administrators not to show to FCC auditors a letter signed by your employer that falsely represented that the school could participate in the E-Rate program at "absolutely no cost to the

school.''¹¹ These actions constitute the conduct or transactions upon which this debarment proceeding is based.¹² Moreover, your conviction on the basis of these acts falls within the categories of causes for debarment defined in section 54.521(c) of the Commission's rules.¹³ Therefore, pursuant to section 54.521(a)(4) of the Commission's rules, your conviction requires the Bureau to commence debarment proceedings against you.

B. Debarment Procedures

You may contest debarment or the scope of the proposed debarment by filing arguments and any relevant documentation within 30 calendar days of the earlier of the receipt of this letter or of publication in the Federal Register. 14 Absent extraordinary circumstances, the Bureau will debar you.¹⁵ Within 90 days of receipt of any opposition to your suspension and proposed debarment, the Bureau, in the absence of extraordinary circumstances, will provide you with notice of its decision to debar. 16 If the Bureau decides to debar you, its decision will become effective upon the earlier of your receipt of a debarment notice or publication of its decision in the Federal Register. 17

C. Effect of Debarment

If and when your debarment becomes effective, you will be prohibited from participating in activities associated with or related to the schools and libraries support mechanism for at least three years from the date of debarment.¹⁸ The Bureau may, if

necessary to protect the public interest, extend the debarment period.¹⁹

Please direct any responses to the following address:

Diana Lee,

Federal Communications Commission, Enforcement Bureau.

Investigations and Hearings Division, Room 6–C326,

445 12th Street, SW., Washington, DC 20554.

If you submit your response via handdelivery or non-United States Postal Service delivery (e.g., Federal Express, DHL, etc.), please send your response to Ms. Lee at the following address:

Federal Communications Commission, 9300 East Hampton Drive, Capitol Heights, MD 20743.

If you have any questions, please contact Ms. Lee via mail, by telephone at (202) 418–1420 or by e-mail at diana.lee@fcc.gov. If Ms. Lee is unavailable, you may contact William Davenport by telephone at (202) 418–1420 and by e-mail at william.davenport@fcc.gov.

Sincerely yours,

Maureen F. Del Duca,

Chief, Investigations and Hearings Division, Enforcement Bureau.

cc: Joel M. Cohen, Greenberg Traurig, LLP Kristy Carroll, USAC

[FR Doc. 03–24938 Filed 10–1–03; 8:45 am] **BILLING CODE 6712–01–P**

FEDERAL COMMUNICATIONS COMMISSION

[DA 03-2707]

Notice of Suspension and of Proposed Debarment Proceedings; Schools and Libraries Universal Service Support Mechanism

AGENCY: Federal Communications Commission.

ACTION: Notice.

SUMMARY: The Enforcement Bureau ("Bureau") gives notice of Mr. John Angelides" suspension from the schools and libraries universal service support mechanism. In addition, the Bureau gives notice that debarment proceedings are commencing against him. Mr. Angelides, or any person who has an existing contract with or intends to contract with him to provide or receive services in matters arising out of activities associated with or related to the schools and libraries support, may respond by filing an opposition request, supported by documentation.

DATES: Opposition requests must be received by November 3, 2003. However, an opposition request by the party to be suspended must be received 30 days from the receipt of the

² 47 CFR 54.521; 47 CFR 0.111(a)(14) (delegating to the Enforcement Bureau authority to resolve universal service suspension and debarment proceedings pursuant to 47 CFR 54.521).

³ 47 CFR 54.521(a)(4). See Schools and Libraries Universal Service Support Mechanism, Second Report and Order and Further Notice of Proposed Rulemaking, 18 FCC Rcd 9202, 9225–9227, ¶¶ 67– 74 (2003) ("Second Report and Order").

⁴ Second Report and Order, 18 FCC Rcd at 9225, ¶ 67; 47 U.S.C. 254; 47 CFR 54.502–54.503; 47 CFR 54.521(a)(4).

⁵ Second Report and Order, 18 FCC Rcd at 9226, ¶ 69; 47 CFR 54.521(e)(1).

⁶ Second Report and Order, 18 FCC Rcd at 9226, ¶ 70: 47 CFR 54.521(e)(4).

 $^{^{7}\,}Second$ Report and Order, 18 FCC Rcd at 9226, \P 70.

^{8 47} CFR 54.521(f).

 $^{^9}$ See Second Report and Order, 18 FCC Rcd at 9226, § 70; 47 CFR 54.521(e)(5), 54.521(f).

 $^{^{10}\,}Second$ Report and Order, 18 FCC Rcd at 9225, \P 66.

¹¹ See United States v. John Angelides, John Dotson, Oscar Alvarez, and Gary Blum, U.S. District Court, Southern District of New York, Complaint at 29 (S.D.N.Y. filed Dec. 17, 2003). The incriminating letter was signed by John Angelides, owner and CEO of Connect2. Id. Further, the conduct for which you were convicted served to conceal and further a fraudulent scheme unlawfully to obtain E-Rate program funds. See generally id.

 $^{^{12}}$ Second Report and Order, 18 FCC Rcd at 9226, \P 70; 47 CFR 54.521(e)(2)(i).

^{13 &}quot;Causes for suspension and debarment are the conviction of or civil judgment for attempt or commission of criminal fraud, theft, embezzlement, forgery, bribery, falsification or destruction of records, making false statements, receiving stolen property, making false claims, obstruction of justice and other fraud or criminal offense arising out of activities associated with or related to the schools and libraries support mechanism." 47 CFR 54.521(c). Such activities "include the receipt of funds or discounted services through the schools and libraries support mechanism, or consulting with, assisting, or advising applicants or service providers regarding schools and libraries support mechanism described in this section (47 CFR 54.500 et seq.)." 47 CFR 54.521(a)(1).

¹⁴ See Second Report and Order, 18 FCC Rcd at 9226, ¶ 70; 47 CFR 54.521(e)(2(i), 54.521(e)(3).

 $^{^{15}}$ Second Report and Order, 18 FCC Rcd at 9227, \P 74.

 $^{^{16}}$ See Second Report and Order, 18 FCC Rcd at 9226, \P 70; 47 CFR 54.521(e)(5).

¹⁷ *Id.* The Commission may reverse a debarment, or may limit the scope or period of debarment upon a finding of extraordinary circumstances, following the filing of a petition by you or an interested party or upon motion by the Commission. 47 CFR 54.521(f).

 $^{^{18}}$ Second Report and Order, 18 FCC Rcd at 9225, \P 67; 47 CFR 54.521(d), 54.521(g).

¹⁹ *Id*.

suspension letter or November 3, 2003, whichever comes first. The Bureau will decide any opposition request for reversal or modification of suspension or debarment within 90 days of its receipt of such requests.

FOR FURTHER INFORMATION CONTACT:

Diana Lee, Federal Communications Commission, Enforcement Bureau, Investigations and Hearings Division, Room 6–C326, 445 12th Street, SW., Washington, DC 20554. Diana Lee may be contacted by phone at (202) 418–1420 or e-mail at diana.lee@fcc.gov.

SUPPLEMENTARY INFORMATION: The Bureau has suspension and debarment authority under 47 CFR 54.521 and 47 CFR 0.111(a)(14). Suspension will help to ensure that the party to be suspended cannot continue to benefit from the schools and libraries mechanism pending resolution of the debarment process. Attached is the suspension letter, Notice of Suspension and of Proposed Debarment Proceedings, DA 03-2707, which was mailed to Mr. Angelides and released on August 21, 2003. The letter (1) gives notice of the suspension and proposed debarment; (2) gives the reasons for the proposed debarment; (3) explains the debarment procedures, and (4) describes the potential effect of debarment. The complete text of the suspension letter is available for public inspection and copying during regular business hours at the FCC Reference Information Center, Portals II, 445 12th Street, SW., Room CY-A257, Washington, DC, 20554. In addition, the complete text of this letter may be retrieved from the FCC's Web site at http://www.fcc.gov. The text may also be purchased from the Commission's duplicating contractor, Qualex International, Portals II, 445 12th Street, SW., Room CY-B402, Washington, DC, 20554, telephone (202) 863-2893, facsimile (202) 863-2898, or via e-mail qualexint@aol.com.

Federal Communications Commission.

Maureen F. Del Duca,

Chief, Investigations and Hearings Division, Enforcement Bureau.

The suspension letter follows:

Federal Communications Commission, Washington, DC 20554

[DA 03-2707]

August 21, 2003.

Via Certified Mail, Return Receipt Requested

Mr. John Angelides,

Chief Executive Officer, Connect2 Internet Networks, Inc., 26 Bay Street, Staten Island, NY 10301

Re: Notice of Suspension and of Proposed Debarment, File No. EB-03-IHD-0376

Dear Mr. Angelides: The Federal Communications Commission ("FCC" or "Commission") has received notice of your May 22, 2003 conviction under 18 U.S.C. 371 for conspiracy to commit an offense against or to defraud the United States. Specifically, you were convicted of conspiracy to violate the following laws of the United States: (1) 18 U.S.C. 287 (false, fictitious, and fraudulent claims); (2) 18 U.S.C. 1001 (false statements and entries generally); and (3) 18 U.S.C. 1343 (fraud by wire, radio, or television).1 Consequently, pursuant to 47 CFR 54.521, this letter constitutes official notice of your suspension from the schools and libraries universal service support mechanism. In addition, the Enforcement Bureau ("Bureau") hereby notifies you that we are commencing debarment proceedings against you.2

I. Notice of Suspension

Pursuant to section 54.521(a)(4) of the Commission's rules,³ your conviction requires the Bureau to suspend you from participating in any activities associated with or related to the schools and libraries fund mechanism, including the receipt of funds or discounted services through the schools and libraries fund mechanism, or consulting with, assisting, or advising applicants or service providers regarding the schools and libraries support mechanism.⁴ Your suspension becomes effective upon the earlier of your receipt of this letter or publication of notice in the Federal Register.⁵

Suspension is immediate pending the Bureau's final debarment determination. You may contest this suspension or the scope of this suspension by filing arguments in opposition to the suspension, with any relevant documentation. Your request must be received within 30 days after you receive this letter or after notice is published in the Federal Register, whichever comes first. Such requests, however, will not ordinarily be granted. The Bureau may reverse or limit the scope of suspension only upon a finding of extraordinary circumstances. Absent extraordinary circumstances, the Bureau will

decide any request for reversal or modification of suspension within 90 days of its receipt of such request.⁹

II. Notice of Proposed Debarment

A. Reasons for and Cause of Debarment

The Commission's rules establish procedures to prevent persons who have 'defrauded the government or engaged in similar acts through activities associated with or related to the schools and libraries support mechanism" from receiving the benefits associated with that program. 10 On May 22, 2003, you admitted, among other things, to selling eligible services to certain participating schools through your company Connect2, imposing 100 percent of the cost on the E-Rate program. You admitted to each of the following acts: (1) Falsely representing to the schools that they could participate in the program at no cost to them; (2) falsely representing to fund administrators and Government investigators that the schools would pay or had paid their unsubsidized share; and (3) falsifying documents, as well as attempting to persuade school administrators not to reveal evidence to Government investigators, in order to conceal the scheme.¹¹ These actions constitute the conduct or transactions upon which this debarment proceeding is based.12

Moreover, your conviction on the basis of these acts falls within the categories of causes for debarment defined in section 54.521(c) of the Commission's rules. ¹³ Therefore, pursuant to section 54.521(a)(4) of the Commission's rules, your conviction requires the Bureau to commence debarment proceedings against you.

B. Debarment Procedures

You may contest debarment or the scope of the proposed debarment by filing arguments and any relevant documentation within 30 calendar days of the earlier of the receipt of this letter or of publication in the Federal Register. 14 Absent extraordinary circumstances, the Bureau will debar you. 15 Within 90 days of receipt of any opposition to your suspension and proposed debarment,

¹Any further reference in this letter to "your conviction" refers to your May 22, 2003 guilty plea and conviction on this count based on your fraudulent scheme to obtain schools and libraries E-Rate program funds. See United States v. Angelides, Docket No. 1:03cr635, Felony Information (S.D.N.Y. filed May 20, 2003) ("Angelides Felony Information").

² 47 CFR 54.521; 47 CFR 0.111(a)(14) (delegating to the Enforcement Bureau authority to resolve universal service suspension and debarment proceedings pursuant to 47 CFR 54.521).

³ 47 CFR 54.521(a)(4) See Schools and Libraries Universal Service Support Mechanism, Second Report and Order and Further Notice of Proposed Rulemaking, 18 FCC Rcd 9202, 9225—9227, ¶¶ 67−74 (2003) ("Second Report and Order").

⁴ Second Report and Order, 18 FCC Rcd at 9225, ¶ 67; 47 U.S.C. 254; 47 CFR 54.502–54.503; 47 CFR 54.521(a)(4).

 $^{^5}$ Second Report and Order, 18 FCC Rcd at 9226, \P 69 47 CFR 54.521(e)(1).

 $^{^6}$ Second Report and Order, 18 FCC Rcd at 9226, ¶ 70; 247 CFR 54.521–54.521(e)(4).

 $^{^7\}operatorname{Second}$ Report and Order, 18 FCC Rcd at 9226, \P 70.

^{8 47} CFR 54.521(f).

⁹ Second Report and Order, 18 FCC Rcd at 9226, ¶ 70; 47 CFR 54.521(e)(5), 54.521(f).

 $^{^{10}\}operatorname{Second}$ Report and Order, 18 FCC Rcd at 9225, \P 66.

¹¹ See Angelides Felony Information at 3–11.

¹² Second Report and Order, 18 FCC Rcd at 9226, ¶ 70; 47 CFR 54.521(e)(2)(i).

^{13 &}quot;Causes for suspension and debarment are the conviction of or civil judgment for attempt or commission of criminal fraud, theft, embezzlement, forgery, bribery, falsification ordestruction of records, making false statements, receiving stolen property, making false claims, obstruction of justice and other fraud or criminal offense arising out of activities associated with or related to the schools and libraries support mechanism." 47 CFR 54.521(c). Such activities "include the receipt of funds or discounted services through the schools and libraries support mechanism, or consulting with, assisting, or advising applicants or service providers regarding schools and libraries support mechanism described in this section 47 CFR 54.500 et seq.)." 47 CFR 54.521(a)(1).

 $^{^{14}\,}Second\,Report\,and\,Order,\,18$ FCC Rcd at 9226, ¶ 70; 47 CFR 54.521(e)(2)(i), 47 CFR 54.521(e)(3).

¹⁵ Second Report and Order, 18 FCC Rcd at 9227,

the Bureau, in the absence of extraordinary circumstances, will provide you with notice of its decision to debar. ¹⁶ If the Bureau decides to debar you, its decision will become effective upon the earlier of your receipt of a debarment notice or the publication of its decision in the **Federal Register.** ¹⁷

C. Effect of Debarment

If and when your debarment becomes effective, you will be prohibited from participating in activities associated with or related to the schools and libraries support mechanism for at least three years from the date of debarment. ¹⁸ The Bureau may, if necessary to protect the public interest, extend the debarment period. ¹⁹

Please direct any responses to the following address: Diana Lee, Federal Communications Commission, Enforcement Bureau, Investigations and Hearings Division, Room 6–C326, 445 12th Street, SW., Washington, DC 20554.

If you submit your response via hand-delivery or non-United States Postal Service delivery (e.g., Federal Express, DHL, etc.), please send your response to Ms. Lee at the following address: Federal Communications Commission, 9300 East Hampton Drive, Capitol Heights, MD 20743.

If you have any questions, please contact Ms. Lee via mail, by telephone at (202) 418–1420 or by e-mail at diana.lee@fcc.gov. If Ms. Lee is unavailable, you may contact William Davenport by telephone at (202) 418–1420 and by e-mail at william.davenport@fcc.gov.

Sincerely yours,

Maureen F. Del Duca,

Chief, Investigations and Hearings Division, Enforcement Bureau.

cc: Mark S. Cohen, Cohen & Gressler, LLP Kristy Carroll, USAC

[FR Doc. 03–24937 Filed 10–1–03; 8:45 am] BILLING CODE 6712–01–P

FEDERAL COMMUNICATIONS COMMISSION

[DA 03-2882]

Notice of Suspension and of Proposed Debarment Proceedings; Schools and Libraries Universal Service Support Mechanism

AGENCY: Federal Communications

Commission.

ACTION: Notice.

SUMMARY: The Enforcement Bureau ("Bureau") gives notice of Mr. Duane

¹⁶ Second Report and Order, 18 FCC Rcd at 9226, ¶ 70; 47 CFR 54.521(e)(5).

Maynard's suspension from the schools and libraries universal service support mechanism. In addition, the Bureau gives notice that debarment proceedings are commencing against him. Mr. Maynard, or any person who has an existing contract with or intends to contract with him to provide or receive services in matters arising out of activities associated with or related to the schools and libraries support, may respond by filing an opposition request, supported by documentation.

DATES: Opposition requests must be received by November 3, 2003. However, an opposition request by the party to be suspended must be received 30 days from the receipt of the suspension letter or November 3, 2003, whichever comes first. The Bureau will decide any opposition request for reversal or modification of suspension or debarment within 90 days of its receipt of such requests.

FOR FURTHER INFORMATION CONTACT:

Diana Lee, Federal Communications Commission, Enforcement Bureau, Investigations and Hearings Division, Room 6–C326, 445 12th Street, SW., Washington, DC 20554. Diana Lee may be contacted by phone at (202) 418–1420 or e-mail at diana.lee@fcc.gov.

SUPPLEMENTARY INFORMATION: The Bureau has suspension and debarment authority under 47 CFR 54.521 and 47 CFR 0.111(a)(14). Suspension will help to ensure that the party to be suspended cannot continue to benefit from the schools and libraries mechanism pending resolution of the debarment process. Attached is the suspension letter, Notice of Suspension and of Proposed Debarment Proceedings, DA 03-2882, which was mailed to Mr. Maynard and released on August 21, 2003. The letter (1) gives notice of the suspension and proposed debarment; (2) gives the reasons for the proposed debarment; (3) explains the debarment procedures, and (4) describes the potential effect of debarment. The complete text of the suspension letter is available for public inspection and copying during regular business hours at the FCC Reference Information Center, Portals II, 445 12th Street, SW., Room CY-A257, Washington, DC 20554. In addition, the complete text of this letter may be retrieved from the FCC's Web site at http://www.fcc.gov. The text may also be purchased from the Commission's duplicating contractor, Qualex International, Portals II, 445 12th Street, SW., Room CY-B402, Washington, DC 20554, telephone (202) 863-2893, facsimile (202) 863-2898, or via e-mail qualexint@aol.com.

Federal Communications Commission.

Maureen F. Del Duca,

Chief, Investigations and Hearings Division, Enforcement Bureau.

The suspension letter follows:

Federal Communications Commission, Washington, DC 20554

[DA 03-2882]

September 11, 2003.

Via Certified Mail Return Receipt Requested

Mr. Duane Maynard

Howe Electric, Inc., 4682 E. Olive Ave., Fresno, CA 93702

Re: Notice of Suspension and of Proposed Debarment, File No. EB–03–IHD–0387.

Dear Mr. Maynard: The Federal Communications Commission ("FCC" or "Commission") has received notice of your August 26, 2003 conviction pursuant to 15 U.S.C. 1 for bid rigging.¹ Consequently, pursuant to 47 CFR 54.521, this letter constitutes official notice of your suspension from the schools and libraries universal service support mechanism. In addition, the Enforcement Bureau ("Bureau") hereby notifies you that we are commencing debarment proceedings against you.²

I. Notice of Suspension

Pursuant to section 54.521(a)(4) of the Commission's rules,³ your conviction requires the Bureau to suspend you from participating in any activities associated with or related to the schools and libraries fund mechanism, including the receipt of funds or discounted services through the schools and libraries fund mechanism, or consulting with, assisting, or advising applicants or service providers regarding the schools and libraries support mechanism.⁴ Your suspension becomes effective upon the earlier of your receipt of this letter or publication of notice in the Federal Register.⁵

Suspension is immediate pending the Bureau's final debarment determination. You

¹⁷ *Id.* The Commission may reverse a dabarment, or may limit the scope or period of debarment upon a finding f extraordinary circumstances,, following the filing of a petition by you or an interested party or upon motion by the Commission. 47 CFR 54.521(f).

¹⁸ Second Report and Order, 18 FCC Rcd at 9225, ¶ 67. 47 CFR 54.521(d), 47 CFR 54.521(g).

¹⁹ Id.

¹Any further reference in this letter to "your conviction" refers to your August 26, 2003 guilty plea and conviction of this count based on your participation, on behalf of your employer, Howe Electric, Inc., in a "combination and conspiracy to suppress bidding for the West Fresno Elementary School District E-Rate project and to allocate among conspirators the responsibility for supplying goods and services for that project." See United States v. Maynard, Criminal Docket No. 1:03cr5325, Information at 2–3 (E.D.Cal. filed August 19, 2003) ("Maynard Felony Information"); United States v. Maynard, Criminal Docket No. 1:03cr5325, Plea Agreement at 6–7 (E.D.Cal. filed August 26, 2003) ("Maynard Plea Agreement").

² 47 CFR 54.521; 47 CFR 0.111(a)(14) (delegating to the Enforcement Bureau authority to resolve universal service suspension and debarment proceedings pursuant to 47 CFR 54.521).

³⁴⁷ CFR 54.521(a)(4); Schools and Libraries Universal Service Support Mechanism, Second Report and Order and Further Notice of Proposed Rulemaking, 18 FCC Rcd 9202, 9225−27, ¶¶67−74 (2003) ("Second Report and Order"); id. at Appendix B, 18 FCC Rcd at 9263−65.

⁴ Second Report and Order, 18 FCC Rcd at 9225, ¶ 67; 47 U.S.C. 254; 47 CFR 54.502–54.503; 47 CFR 54.521(a)(4).

⁵ Second Report and Order, 18 FCC Rcd at 9226, ¶ 69; 47 CFR 54.521(e)(1).

may contest this suspension or the scope of this suspension by filing arguments in opposition to the suspension, with any relevant documentation. Your request must be received within 30 days after you receive this letter or after notice is published in the **Federal Register**, whichever comes first.⁶ Such requests, however, will not ordinarily be granted.⁷ The Bureau may reverse or limit the scope of suspension only upon a finding of extraordinary circumstances.⁸ Absent extraordinary circumstances, the Bureau will decide any request for reversal or modification of suspension within 90 days of its receipt of such request.⁹

II. Notice of Proposed Debarment

A. Reasons for and Cause of Debarment

The Commission's rules establish procedures to prevent persons who have 'defrauded the government or engaged in similar acts through activities associated with or related to the schools and libraries support mechanism" from receiving the benefits associated with that program. 10 On August 26, 2003, you admitted to participating in a combination and conspiracy with West Fresno Elementary School District representatives, a consultant and others representing potential competitors, on behalf of your employer, Howe Electric, Inc. 11 Specifically, you admitted that you and the other co-conspirators combined, conspired, and agreed that: (1) Howe Electric, Inc. would be the successful bidder to provide goods and services for the schools and libraries E-Rate project in the district, while no other co-conspirator companies would bid for the project; (2) certain co-conspirator companies would be Howe Electric's subcontractors; and (3) any competing bids would be disqualified as nonresponsive. 12

These actions constitute the conduct or transactions upon which this debarment proceeding is based. ¹³ Moreover, your conviction on the basis of these acts falls within the categories of causes for debarment defined in section 54.521(c) of the Commission's rules. ¹⁴ Therefore, pursuant to

section 54.521(a)(4) of the Commission's rules, your conviction requires the Bureau to commence debarment proceedings against you.

B. Debarment Procedures

You may contest debarment or the scope of the proposed debarment by filing arguments and any relevant documentation within 30 calendar days of the earlier of the receipt of this letter or of publication in the Federal Register. 15 Absent extraordinary circumstances, the Bureau will debar you.16 Within 90 days of receipt of any opposition to your suspension and proposed debarment, the Bureau, in the absence of extraordinary circumstances, will provide you with notice of its decision to debar. 17 If the Bureau decides to debar you, its decision will become effective upon the earlier of your receipt of a debarment notice or publication of its decision in the Federal Register. 18

C. Effect of Debarment

If and when your debarment becomes effective, you will be prohibited from participating in activities associated with or related to the schools and libraries support mechanism for at least three years from the date of debarment. ¹⁹ The Bureau may, if necessary to protect the public interest, extend the debarment period. ²⁰

Please direct any responses to the following address: Diana Lee, Federal Communications Commission, Enforcement Bureau, Investigations and Hearings Division, Room 6–C326, 445 12th Street, SW., Washington, DC 20554.

If you submit your response via hand-delivery or non-United States Postal Service delivery (e.g., Federal Express, DHL, etc.), please send your response to Ms. Lee at the following address: Federal Communications Commission, 9300 East Hampton Drive, Capitol Heights, MD 20743.

If you have any questions, please contact Ms. Lee via mail, by telephone at (202) 418–1420 or by e-mail at *diana.lee@fcc.gov*. If Ms. Lee is unavailable, you may contact William Davenport by telephone at (202) 418–1420 and by e-mail at *william.davenport@fcc.gov*. Sincerely yours,

Maureen F. Del Duca,

and libraries support mechanism." 47 CFR 54.521(c). Such activities "include the receipt of funds or discounted services through the schools and libraries support mechanism, or consulting with, assisting, or advising applicants or service providers regarding schools and libraries support mechanism described in this section ([47 C.F. R.] 54.500 et seq.)." 47 CFR 54.521(a)(1).

Chief, Investigations and Hearings Division, Enforcement Bureau.

cc: Kenneth Alan Reed, Law Office of Kenneth Alan Reed Kristy Carroll, USAC.

[FR Doc. 03–24936 Filed 10–1–03; 8:45 am] BILLING CODE 6712–01–P

FEDERAL COMMUNICATIONS COMMISSION

Technological Advisory Council

AGENCY: Federal Communications Commission.

ACTION: Notice of public meeting.

SUMMARY: In accordance with the Federal Advisory Committee Act, Public Law 92–463, as amended, this notice advises interested persons of the first of the Technological Advisory Council ("Council") under its new charter.

DATES: October 20, 2003 beginning at 10 a.m. and concluding at 3 p.m.

ADDRESSES: Federal Communications Commission, 445 12th St. SW., Room TW–C305, Washington, DC 20554.

FOR FURTHER INFORMATION CONTACT: Jeffery Goldthorp, (202) 418–1096.

SUPPLEMENTARY INFORMATION:

Continuously accelerating technological changes in telecommunications design, manufacturing, and deployment require that the Commission be promptly informed of those changes to fulfill its statutory mandate effectively. The Council was established by the Federal Communications Commission to provide a means by which a diverse array of recognized technical experts from different areas such as manufacturing, academia, communications services providers, the research community, etc., can provide advice to the FCC on innovation in the communications industry. At this third meeting under the Council's new charter, the Council will focus on Voice services over IP. Members of the public may attend the meeting. The Federal Communications Commission will attempt to accommodate as many persons as possible. Admittance, however, will be limited to the seating available. Unless so requested by the Council's Chair, there will be no public oral participation, but the public may submit written comments to Jeffery Goldthorp, the Federal Communications Commission's Designated Federal Officer for the Technological Advisory Council, before the meeting. Mr. Goldthorp's e-mail address is Jeffery.Goldthorp@fcc.gov. Mail delivery address is: Federal Communications Commission, 445 12th Street, SW., Room 7-A325, Washington, DC 20554.

 $^{^6}$ Second Report and Order, 18 FCC Rcd at 9226, \P 70; 47 CFR 54.521(e)(4).

 $^{^{7}\,}Second$ Report and Order, 18 FCC Rcd at 9226, \P 70.

^{8 47} CFR 54.521(f).

⁹ See Second Report and Order, 18 FCC Rcd at 9226, ¶ 70; 47 CFR 54.521(e)(5), 54.521(f).

 $^{^{10}}$ Second Report and Order, 18 FCC Rcd at 9225, \P 66.

¹¹ See United States v. Maynard, Criminal Docket No. 1:03cr5325, Docket Proceedings (E.D.Cal. filed August 26, 2003).

¹² See Maynard Felony Information at 3; Maynard Plea Agreement at 6–7. The conspiracy violated the Commission's competitive bid requirements for telecommunications services supported by the schools and libraries E-Rate program. 47 CFR 54.504.

 $^{^{13}}$ Second Report and Order, 18 FCC Rcd at 9226, \P 70; 47 CFR 54.521(e)(2)(i).

^{14 &}quot;Causes for suspension and debarment are the conviction of or civil judgment for attempt or commission of criminal fraud, theft, embezzlement, forgery, bribery, falsification or destruction of records, making false statements, receiving stolen property, making false claims, obstruction of justice and other fraud or criminal offense arising out of activities associated with or related to the schools

¹⁵ See Second Report and Order, 18 FCC Rcd at 9226, ¶ 70; 47 CFR 54.521(e)(2(i), 54.521(e)(3).

 $^{^{16}}$ Second Report and Order, 18 FCC Rcd at 9227, \P 74.

 $^{^{17}}$ See Second Report and Order, 18 FCC Rcd at 9226, \P 70; 47 CFR 54.521(e)(5).

¹⁸ Id. The Commission may reverse a debarment, or may limit the scope or period of debarment upon a finding of extraordinary circumstances, following the filing of a petition by you or an interested party or upon motion by the Commission. 47 CFR 54.521(f).

 $^{^{19}}$ Second Report and Order, 18 FCC Rcd at 9225, \P 67; 47 CFR 54.521(d), 54.521(g).

²⁰ Id.

Federal Communications Commission.

Marlene H. Dortch,

Secretary.

[FR Doc. 03–24991 Filed 10–1–03; 8:45 am] BILLING CODE 6712–01–P

FEDERAL RESERVE SYSTEM

Formations of, Acquisitions by, and Mergers of Bank Holding Companies

The companies listed in this notice have applied to the Board for approval, pursuant to the Bank Holding Company Act of 1956 (12 U.S.C. 1841 et seq.) (BHC Act), Regulation Y (12 CFR Part 225), and all other applicable statutes and regulations to become a bank holding company and/or to acquire the assets or the ownership of, control of, or the power to vote shares of a bank or bank holding company and all of the banks and nonbanking companies owned by the bank holding company, including the companies listed below.

The applications listed below, as well as other related filings required by the Board, are available for immediate inspection at the Federal Reserve Bank indicated. The application also will be available for inspection at the offices of the Board of Governors. Interested persons may express their views in writing on the standards enumerated in the BHC Act (12 U.S.C. 1842(c)). If the proposal also involves the acquisition of a nonbanking company, the review also includes whether the acquisition of the nonbanking company complies with the standards in section 4 of the BHC Act (12 U.S.C. 1843). Unless otherwise noted, nonbanking activities will be conducted throughout the United States. Additional information on all bank holding companies may be obtained from the National Information Center website at www.ffiec.gov/nic/.

Unless otherwise noted, comments regarding each of these applications must be received at the Reserve Bank indicated or the offices of the Board of Governors not later than October 27, 2003.

A. Federal Reserve Bank of Philadelphia (Michael E. Collins, Senior Vice President) 100 North 6th Street, Philadelphia, Pennsylvania 19105-1521:

1. National Penn Bancshares, Inc., Boyertown, Pennsylvania; to acquire 21 percent of the voting shares of The Pennsylvania State Banking Company, Camp Hill, Pennsylvania, and thereby indirectly acquire voting shares of Pennsylvania State Bank, Camp Hill, Pennsylvania.

B. Federal Reserve Bank of Chicago (Phillip Jackson, Applications Officer)

230 South LaSalle Street, Chicago, Illinois 60690-1414:

1. First Midwest Bancorp, Inc., Itasca, Illinois; to merge with Covest Bancshares, Inc., Des Plaines, Illinois, and thereby indirectly acquire voting shares of Covest Banc, National Association, Des Plaines, Illinois.

Board of Governors of the Federal Reserve System, September 26, 2003.

Robert deV. Frierson,

Deputy Secretary of the Board. [FR Doc. 03–24955 Filed 10–1–03; 8:45 am] BILLING CODE 6210–01–S

FEDERAL RESERVE SYSTEM

Government in the Sunshine Meeting Notice

AGENCY: Board of Governors of the Federal Reserve System.

FEDERAL REGISTER CITATION OF PREVIOUS ANNOUNCEMENT: 68, FR 56294, September 30, 2003.

PREVIOUSLY ANNOUNCED TIME AND DATE OF THE MEETING: 11:30 a.m., Monday, October 6, 2003.

CHANGES IN THE MEETING: Change in the time and date of the *closed* meeting to 11:30 a.m., Tuesday, October 7, 2003.

FOR FURTHER INFORMATION CONTACT:

Michelle A. Smith, Director, Office of Board Members; (202) 452–2955.

SUPPLEMENTARY INFORMATION: You may call (202) 452–3206 beginning at approximately 5 p.m., two business days before the meeting for a recorded announcement of bank and bank holding company applications scheduled for the meeting; or you may contact the Board's Web site at http://www.federalreserve.gov for an electronic announcement that not only lists applications, but also indicates procedural and other information about the meeting.

Dated: September 30, 2003.

Jennifer J. Johnson,

Secretary of the Board.
[FR Doc. 03–25166 Filed 9–30–03; 2:31 pm]
BILLING CODE 6210–01–M

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Agency for Healthcare Research and Quality

Contract Review Meeting

In accordance with section 10(a) of the Federal Advisory Committee Act as amended (5 U.S.C., Appendix 2), announcement is made of an Agency for Healthcare Research and Quality (AHRQ) Technical Review Committee (TRC) meeting. This TRC's charge is to review contract proposals and provide recommendations to the Director, AHRQ, with respect to the technical merit of proposals submitted in response to a Request for Proposals (RFP) regarding "Knowledge Transfer and Application Support." The RFP was published in the Federal Business Opportunities on July 17, 2003.

The upcoming TRC meeting will be closed to the public in accordance with the Federal Advisory Committee Act (FACA), section 10(d) of 5 U.S.C., Appendix 2, implementing regulations, and procurement regulations, 41 CFR 101-6.1023 and 48 CFR 315.604(d). The discussions at this meeting of contract proposals submitted in response to the above-referenced RFP are likely to reveal proprietary information and personal information concerning individuals associated with the proposals. Such information is exempt from disclosure under the above-cited FACA provision and procurement rules that protect the free exchange of candid views and facilitate Department and Committee operations.

Name of TRC: The Agency for Healthcare Research and Quality—"Knowledge Transfer and Application Support."

Date: October 8 and 9, 2003 (Closed to the public).

Place: Agency for Healthcare Research & Quality, 540 Gaither Road, Rock Creek Room, Rockville, Maryland 20850.

Contact Person: Anyone wishing to obtain information regarding this meeting should contact Steve Seitz, Office of Communications and Knowledge Transfer, Agency for Healthcare Research and Quality, 540 Gaither Road, Rockville, Maryland 20850, 301–427–1257.

Dated: September 24, 2003.

Carolyn M. Clancy,

Director.

[FR Doc. 03-24968 Filed 10-1-03; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-80-03]

Proposed Data Collections Submitted for Public Comment and Recommendations

The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Officer at (404) 498–1210. Send written comments to CDC, Desk Officer, Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503 or by fax to (202) 395–6974. Written comments should be received within 30 days of this notice.

Proposed Project: Evaluating the Effectiveness of the Asthma Intervention Program, Power Breathing—New—National Center for Environmental Health (NCEH), Centers for Disease Control and Prevention (CDC).

The Centers for Disease Control and Prevention (CDC) seeks to conduct an evaluation of the effectiveness of the asthma intervention program, Power Breathing, in two school districts in Kansas City, KS and Fredericksburg, VA. The overall aim of this program, developed by the Asthma and Allergy Foundation of America, is to provide adolescents with a basic understanding of asthma and its management in a peerfriendly environment and to empower them to take control of their asthma on a personal level.

The proposed data collection for the evaluation will provide feedback to CDC about the usefulness and cost-effectiveness of this teen asthma intervention program. Sample participants will come from students, parents, program facilitators, and school personnel (school nurses and teachers) in the selected two school districts. Self-administered questionnaires will be given to students at baseline (pre-intervention program), immediately post-program, and at six-months post-program, while parents receive baseline and six-months post-program surveys.

The student survey will focus on: knowledge, attitudes, and behaviors regarding their asthma; perception of their health status and quality of life; assessment of the program; and impact of the program on their asthma management skills. Parents will be asked about their child's asthma condition, assessment of the program, and cost-related issues for their child's asthma.

Individual, one-time interviews will be conducted with program facilitators and school personnel regarding their perceptions of the intervention program and its impact on the students. Two focus groups will be conducted with students post-program to obtain additional, in-depth information about their perceptions of the program. The annualized burden is estimated to be 1029 hours.

Respondents	Number of respondents	Number of re- sponses/re- spondent	Average bur- den/response (in hrs.)
Students:			
Baseline	524	1	30/60
Post-program	524	1	15/60
6-month follow-up Focus group	524	1	30/60
Focus group	16	1	1
Parents:			
Baseline	524	1	10/60
6-month follow-up	524	1	15/60
Program facilitators:			
Interview	6	1	40/60
Program sessions	6	12	30/60
School nurses:			
School profile	6	1	10/60
Record abstraction	6	87	10/60
Interview	6	1	40/60
Teachers:			
Interview	12	1	40/60

Dated: September 25, 2003.

Nancy E Cheal,

Acting Associate Director for Policy, Planning and Evaluation, Centers for Disease Control and Prevention.

[FR Doc. 03–24972 Filed 10–1–03; 8:45 am]

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-71-03]

Proposed Data Collections Submitted for Public Comment and Recommendations

The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance Officer at (404) 498–1210. Send written comments to CDC, Desk Officer, Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503 or by fax to (202) 395–6974. Written comments should be received within 30 days of this notice.

Proposed Project: Work-related
Assaults Treated In Hospital Emergency
Departments (OMB Control No. 0920–
0575)—Reinstatement without change—
The National Institute for Occupational
Safety and Health (NIOSH), Centers for
Disease Control and Prevention (CDC).
Workplace violence, both fatal and
nonfatal, is recognized as an important
occupational safety and health issue.
Various data systems have provided
fairly detailed information on fatal
workplace violence, but much less is
known about the circumstances and risk

factors for nonfatal workplace violence. A number of strategies have been suggested for reducing the incidence and severity of workplace violence in various settings (e.g., taxicabs, health care, law enforcement, social services), yet, little empirical knowledge exists about what has been implemented and what impact such strategies may have. The report, Workplace Violence: A Report to the Nation, published by the University of Iowa based on recommendations from a workshop of experts states, "* * research focused on a much broader understanding of the scope and impact of workplace violence is urgently needed to reduce the human and financial burden of this significant public health problem." In 2000, there were 677 workplace homicides in the U.S. From 1993–1999, there were an estimated 1.7 million non-fatal victimizations "while at work or on duty" every year, accounting for 18

percent of all violent crime during the seven-year period.

The Consumer Product Safety Commission (CPSC) maintains a database of injuries treated in a nationally-representative sample of U.S. hospital emergency departments (ED) called the National Electronic Injury Surveillance System (NEISS). Data routinely collected through NEISS include a brief narrative description of the injury event as well as basic demographic information, intent and mechanism of injury, work-relatedness, principal diagnosis, part of body affected, location where the injury occurred, involvement of consumer products, and disposition at ED discharge. For assaults, summary data are also being collected on the relationship of the perpetrator to the injured person and the context (e.g., altercation, robbery, sexual assault, etc.). For work-related cases, occupation and industry information is collected. The data system does not include any information on issues such as the specific workplace circumstances and risk factors for workplace violence, security measures in place in the workplace and whether they were utilized/worked appropriately, training in workplace violence risk factors and

prevention strategies, previous incidents of workplace violence, return to work after assault, and other specific workplace violence information.

In December 2001, Congress directed NIOSH to develop an intramural and extramural prevention research program that will target all aspects of workplace violence. For the last ten years, NIOSH has been collaborating with CPSC to collect surveillance data on workrelated injuries treated in the NEISS EDs. In addition, NIOSH has utilized the capacity of NEISS to incorporate followback surveys. Follow-back surveys allow collection of first-hand, detailed knowledge that does not exist in administrative or other records. CPSC routinely uses this mechanism to collect information on various types of injuries (e.g., fireworks-related injuries, injuries to children in baby walkers, etc.). NIOSH has used this mechanism to collect information on the circumstances of injury, training, protective equipment (if appropriate), and other issues important to more fully understanding the risk factors for workrelated injuries and to make appropriate recommendations for preventing other such injuries in the future.

The current proposed study will consist of a telephone interview survey

of workers treated in NEISS hospital emergency departments for injuries sustained during a work-related assault over a one-year period. CPSC will hire a contractor to conduct the actual telephone interviews. NIOSH will review potential cases to identify those cases that should be forwarded to the contractor for interview. The survey includes an extended narrative description of the injury incident as well as items regarding general workplace organization; personal characteristics of the worker; work tasks at the time of the assault; training on workplace violence risk factors and prevention strategies; security measures in place and how they impacted the outcome of the incident; medical care received for injuries: time away from work; and return to work after the assault. This study will provide critical information for understanding the nature and impact of nonfatal assault among U.S. workers. In combination with data collected from other sources, this information will ultimately contribute to the prevention of violence in the workplace. The annualized burden for this data collection is 227 hours.

Survey	Number of respondents	Number of re- sponses/re- spondent	Avg. burden/ response (hours)
Work-related assaults treated in hospital emergency departments		1	20/60

Dated: September 26, 2003.

Nancy Cheal,

Acting Associate Director for Policy, Planning and Evaluation, Centers for Disease Control and Prevention.

[FR Doc. 03–24998 Filed 10–1–03; 8:45 am] BILLING CODE 4163–18–P

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Centers for Disease Control and Prevention

[30Day-79-03]

Proposed Data Collections Submitted for Public Comment and Recommendations

The Centers for Disease Control and Prevention (CDC) publishes a list of information collection requests under review by the Office of Management and Budget (OMB) in compliance with the Paperwork Reduction Act (44 U.S.C. Chapter 35). To request a copy of these requests, call the CDC Reports Clearance

Officer at (404) 498–1210. Send written comments to NCHS/CDC, Desk Officer, Human Resources and Housing Branch, New Executive Office Building, Room 10235, Washington, DC 20503 or by fax to (202) 395–7245. Written comments should be received within 30 days of this notice.

Proposed Project: NCHS 2003-2004 National Ambulatory Medical Care Survey (NAMCS) (OMB Control No. 0920-0234)—Extension—National Center for Health Statics (NCHS), Centers for Disease Control and Prevention (CDC). The National Ambulatory Medical Care Survey (NAMCS) was conducted annually from 1973 to 1981, again in 1985, and resumed as an annual survey in 1989. It is directed by the Division of Health Care Statistics, National Center for Health Statistics, CDC. The purpose of NAMCS is to meet the needs and demands for statistical information about the provision of ambulatory medical care services in the United States. Ambulatory services are rendered in a wide variety of settings,

including physicians' offices and hospital outpatient and emergency departments. The NAMCS target population consists of all office visits within the United States made by ambulatory patients to non-Federal office-based physicians (excluding those in the specialties of anesthesiology, radiology, and pathology) who are engaged in direct patient care. Since more than 80 percent of all direct ambulatory medical care visits occur in physicians' offices, the NAMCS provides data on the majority of ambulatory medical care services. To complement these data, in 1992 NCHS initiated the National Hospital Ambulatory Medical Care Survey (NHAMCS, OMB No. 0920-0278) to provide data concerning patient visits to hospital outpatient and emergency departments. The NAMCS, together with the NHAMCS constitute the ambulatory component of the National Health Care Survey (NHCS), and will provide coverage of more than 90 percent of ambulatory medical care.

The NAMCS provides a range of baseline data on the characteristics of the users and providers of ambulatory medical care. Data collected include the patients' demographic characteristics and reason(s) for visit, and the physicians' diagnosis(es) and diagnostic services, medications and disposition. These data, together with trend data, may be used to monitor the effects of change in the health care system,

provide new insights into ambulatory medical care, and stimulate further research on the use, organization, and delivery of ambulatory care.

Users of NAMCS data include, but are not limited to, congressional and other federal government agencies such as NIH and FDA, state and local governments, medical schools, schools of public health, colleges and universities, private businesses,

nonprofit foundations and corporations, professional associations, as well as individual practitioners, researchers, administrators and health planners. Uses vary from the inclusion of a few selected statistics in a large research effort, to an in-depth analysis of the entire NAMCS data set covering several years. The annual burden for this data collection is 6,175 burden hours.

Form	Number of respondents	Number of responses per respondent	Hours per response
Induction—eligible	2,250	1	35/60
Induction—ineligible	750	1	5/60
Patient Record	2,250	30	4/60
Nonresponse Studies	300	1	60/60

Dated: September 26, 2003.

Nancy E. Cheal,

Acting Associate Director for Policy, Planning and Evaluation, Centers for Disease Control and Prevention.

[FR Doc. 03–24999 Filed 10–1–03; 8:45 am] **BILLING CODE 4163–18–P**

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

[Docket No. 2003N-0136]

Agency Information Collection Activities: Submission for Office of Management and Budget Review; Comment Request; Adoption of the Food and Drug Administration Food Code By Local, State, and Tribal Governments

AGENCY: Food and Drug Administration, HHS.

ннъ.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is announcing that the proposed collection of information has been submitted to the Office of Management and Budget (OMB) for review and clearance under the Paperwork Reduction Act of 1995.

DATES: Fax written comments on the collection of information by November 3, 2003.

ADDRESSES: OMB is still experiencing significant delays in the regular mail, including first class and express mail, and messenger deliveries are not being accepted. To ensure that comments on the information collection are received, OMB recommends that written comments be faxed to the Office of Information and Regulatory Affairs,

OMB, Attn: Fumie Yokota, Desk Officer for FDA, FAX: 202–395–6974.

FOR FURTHER INFORMATION CONTACT:

Denver Presley, Office of Management Programs (HFA–250), Food and Drug Administration, 5600 Fishers Lane, Rockville, MD 20857, 301–827–1472.

SUPPLEMENTARY INFORMATION: In compliance (44 U.S.C. 3507), FDA has submitted the following proposed collection of information to OMB for review and clearance.

Adoption of the FDA Food Code By Local, State, and Tribal Governments (OMB Control Number 0910–0448)— Extension

FDA has developed its model Food Code to assist and promote consistent implementation of national food safety regulatory policy among the local, State, and tribal jurisdictions that have primary responsibility for the regulation or oversight of retail level food operations. The FDA Food Code provides a scientifically sound technical and legal basis for regulating the retail segment of the food industry. Authority for providing such assistance is derived from section 311(a) of the Public Health Service Act (42 U.S.C. 243(a)) and delegation of authority from the Public Health Service to the Commissioner of Food and Drugs relative to food protection is contained in 21 CFR 5.10(a)(2) and (a)(4). Under 31 U.S.C. 1535, FDA provides assistance to other Federal agencies such as the Indian Health Service (IHS).

Nationwide adoption of the model FDA Food Code is an important step towards the agency's goal for consistent, scientifically sound, and risk-based food safety standards and practices. A current, comprehensive and accurate inventory of Food Code adoptions by States and U.S. Territories, local, and

tribal governments is necessary to determine the status of up-to-date protection of the U.S. population and to identify areas where assistance to these governments may promote the adoption of regulations based on the FDA Food Code.

This collection effort, which began in 2001, has had remarkable success with 97-percent participation from State and Territorial agencies. FDA contracted with the Association of Food and Drug Officials (AFDO) to conduct the initial survey using the OMB approved survey form. Contacts were made by telephone and e-mail to determine the Food Code status in their jurisdiction(s). Follow up contacts by telephone and e-mail to minimize the burden on respondents were made to clarify responses.

The rulemaking process that local, State, Territorial, and tribal governments must follow to adopt the Food Code often is a long and complicated process that can extend 2 or more years. For this reason, many agencies reported in the initial survey that they were still in the rulemaking process to adopt or update their food codes for the years 2004, 2005, or beyond. Thus, FDA believes that further implementation of the initial survey is needed to cover this additional rulemaking in order to keep the current database accurate and up-to-date. Based on experience gained in the past 3 years from the initial survey, FDA has developed a more condensed followup survey, to further minimize the burden requirements on respondent agencies. For example, FDA now knows if responding agencies have adopted a new code since 1993, the types of establishments regulated by those codes, the populations of the jurisdiction covered, and the status of local health agencies in the states. This information

will not be collected again. We have reduced the number of questions from 16 to 5. Collection(s) of information will be electronically and/or telephonically obtained thus, providing respondents with data already in the database to further the ease of response and lower the burden.

In the **Federal Register** of April 17, 2003 (68 FR 18989), FDA published a 60-day notice requesting public

comment on the information collection provisions. No comments were received in response to that notice.

FDA estimates the burden of this collection of information as follows:

TABLE 1.—ESTIMATED ANNUAL REPORTING BURDEN¹

	No. of Respondents	Annual Frequency per Response	Total Annual Responses	Hours per Response	Total Hours
Food Code Survey	150	4	600	1	600

¹There are no capital costs or operating and maintenance costs associated with this collection of information.

Experience in the initial survey has more clearly identified the respondents for updating the information in the database. For example, FDA will obtain information from the IHS, relative to the tribal nations' adoption of the Food Code that IHS maintains, using the information categories in the revised followup survey form for which this extension is requested. Seventy-three State and Territorial agencies were identified as respondents for Food Code adoption, and it appears that initially, only 30 local agencies in cities of 500,000 or more will need to be contacted because most local iurisdictions are under State requirements. This further reduces the total burden on respondents. Quarterly updates from respondents under active rulemaking, will be requested by AFDO to keep the database current and accurate. Respondents that have concluded rulemaking will likely need only annual contact. Estimated response time is about 1 hour or less because most reporting will be done telephonically or electronically.

Dated: September 24, 2003.

Jeffrey Shuren,

Assistant Commissioner for Policy.
[FR Doc. 03–24929 Filed 10–1–03; 8:45 am]
BILLING CODE 4160–0–8

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Anti-Infective Drugs Advisory Committee; Notice of Meeting

AGENCY: Food and Drug Administration, HHS

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). At least one portion of the meeting will be closed to the public. Name of Committee: Anti-Infective Drugs Advisory Committee.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on October 28, 2003, from 8 a.m. to 5:30 p.m., and on October 29, 2003, from 8:30 a.m. to 4:30 p.m.

Location: Holiday Inn, The Ballrooms, 2 Montgomery Village Ave., Gaithersburg, MD. Contact Person: Tara P. Turner, Center for

Contact Person: Tara P. Turner, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093) Rockville, MD 20857, 301–827–7001, e-mail: TurnerT@cder.fda.gov, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12530. Please call the Information Line for up to date information on this meeting.

Agenda: On October 28, 2003, the committee will begin with a closed session from 8 a.m. to 12 noon. Following the closed session, from 1 p.m. to 5:30 p.m., the committee will discuss clinical trial design issues for demonstrating the safety and efficacy of antimicrobials in the treatment of diabetic foot infections. On October 29, 2003, the committee will discuss clinical trial design issues for demonstrating the safety and efficacy of antimicrobials in the treatment of acute bacterial sinusitis.

Procedure: On October 28, 2003, from 1 p.m. to 5:30 p.m., and on October 29, 2003, from 8:30 a.m. to 4:30 p.m., the meeting is open to the public. Interested persons may present data, information, or views, orally or in writing, on issues pending before the committee. Written submissions may be made to the contact person by October 21, 2003. Oral presentations from the public will be scheduled between approximately 3:15 p.m. and 3:45 p.m. on October 28, 2003, and between approximately 1 p.m. and 1:30 p.m. on October 29, 2003. Ťime allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before October 21, 2003, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Closed Committee Deliberations: On October 28, 2003, from 8 a.m. to 12 noon, the meeting will be closed to permit discussion and review of trade secret and/or confidential information (5 U.S.C. 552b(c)(4)).

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Tara Turner at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: September 25, 2003.

Peter J. Pitts,

Associate Commissioner for External Relations.

[FR Doc. 03–24926 Filed 10–1–03; 8:45 am] BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Drug Safety and Risk Management Advisory Committee; Notice of Postponement

AGENCY: Food and Drug Administration, HHS.

ACTION: Notice.

SUMMARY: The Food and Drug Administration (FDA) is postponing the meeting of the Drug Safety and Risk Management Advisory Committee scheduled for September 18, 2003, due to Hurricane Isabel. This meeting was announced in the Federal Register of June 30, 2003 (68 FR 38713). An amendment to the notice of meeting was announced in the Federal Register of July 23, 2003 (68 FR 43534). The future date for this meeting is to be determined.

FOR FURTHER INFORMATION CONTACT:

Shalini Jain, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301–827–7001, FAX: 301–827–6776, e-mail: *JAINS@CDER.FDA.GOV*, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12535. Please call the Information Line for upto-date information on this meeting.

Dated: September 26, 2003.

Peter J. Pitts,

Associate Commissioner for External Relations.

[FR Doc. 03–24925 Filed 10–1–03; 8:45 am] BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

Food and Drug Administration

Advisory Committee for Pharmaceutical Science; Notice of Meeting

AGENCY: Food and Drug Administration,

ACTION: Notice.

This notice announces a forthcoming meeting of a public advisory committee of the Food and Drug Administration (FDA). The meeting will be open to the public.

Name of Committee: Advisory Committee for Pharmaceutical Science.

General Function of the Committee: To provide advice and recommendations to the agency on FDA's regulatory issues.

Date and Time: The meeting will be held on October 21, 2003, from 8:30 a.m. to 4:30 p.m., and October 22, 2003, from 8:30 a.m. to 5 p.m.

Location: Best Western Washington Gateway Hotel, 1251 West Montgomery Ave., Rockville, MD.

Contact Person: Hilda Scharen, Center for Drug Evaluation and Research (HFD–21), Food and Drug Administration, 5600 Fishers Lane (for express delivery, 5630 Fishers Lane, rm. 1093), Rockville, MD 20857, 301–827–7001, or FDA Advisory Committee Information Line, 1–800–741–8138 (301–443–0572 in the Washington, DC area), code 12539. Please call the Information Line for up-to-date information on this meeting.

Agenda: On October 21, 2003, the committee will do the following: (1) Receive updates from the Manufacturing, Clinical Pharmacology, and Pharmacology/
Toxicology Subcommittees, (2) discuss and provide comments on the FDA draft guidance for industry entitled "Process Analytical Technologies (PAT), a Framework for Innovative Pharmaceutical Manufacturing and Quality Assurance," (see the FDA Internet Web address https://www.fda.gov/

cder/guidance/5815dft.htm), and (3) discuss and provide comments on parametric tolerance interval test for dose content uniformity. On October 22, 2003, the committee will do the following: (1) Discuss and provide comments on risk based Chemistry Manufacturing and Control (CMC) review proposals, (2) discuss and provide comments on nomenclature, and (3) discuss and provide direction to the research plan for generics.

Procedure: Interested persons may present data, information, or views, orally or in writing, on issues pending before the subcommittee. Written submissions may be made to the contact person by October 10, 2003. Oral presentations from the public will be scheduled between approximately 11:30 a.m. and 12:30 p.m. on October 21, 2003, and between approximately 1 p.m. and 2 p.m. on October 22, 2003. Time allotted for each presentation may be limited. Those desiring to make formal oral presentations should notify the contact person before October 10, 2003, and submit a brief statement of the general nature of the evidence or arguments they wish to present, the names and addresses of proposed participants, and an indication of the approximate time requested to make their presentation.

Persons attending FDA's advisory committee meetings are advised that the agency is not responsible for providing access to electrical outlets.

FDA welcomes the attendance of the public at its advisory committee meetings and will make every effort to accommodate persons with physical disabilities or special needs. If you require special accommodations due to a disability, please contact Hilda Scharen at least 7 days in advance of the meeting.

Notice of this meeting is given under the Federal Advisory Committee Act (5 U.S.C. app. 2).

Dated: September 25, 2003.

Peter J. Pitts,

Associate Commissioner for External Relations.

[FR Doc. 03–24927 Filed 10–1–03; 8:45 am] BILLING CODE 4160–01–S

DEPARTMENT OF HEALTH AND HUMAN SERVICES

National Institutes of Health

Government-Owned Inventions; Availability for Licensing

AGENCY: National Institutes of Health, Public Health Service, DHHS

ACTION: Notice.

SUMMARY: The inventions listed below are owned by agencies of the U.S. Government and are available for licensing in the U.S. in accordance with 35 U.S.C. 207 to achieve expeditious commercialization of results of federally-funded research and development. Foreign patent

applications are filed on selected inventions to extend market coverage for companies and may also be available for licensing.

ADDRESSES: Licensing information and copies of the U.S. patent applications listed below may be obtained by writing to the indicated licensing contact at the Office of Technology Transfer, National Institutes of Health, 6011 Executive Boulevard, Suite 325, Rockville, Maryland 20852–3804; telephone: 301/496–7057; fax: 301/402–0220. A signed Confidential Disclosure Agreement will be required to receive copies of the patent applications.

HLtat Cell Line

Barbara K. Felber and George Pavlakis (NCI).

DHHS Reference No. E-273-2003/0 (NIH AIDS Research & Reference Reagent Program catalog number 1293).

Licensing Contact: Susan Ano; 301/435–5515; anos@mail.nih.gov.

This cell line contains stably integrated copies of the HIV-1 LTR promoter linked to a synthetic one-exon tat gene. HLtat was generated by cotransfection of HeLa cells with pSV2neo and with pL3tat, which contains the HIV-1 LTR promoter, synthetic first tat exon, and the SV40 polyadenylation signal. Clone HLtat was selected in G418 on the basis of highlevel production of the one-exon Tat. The cell line is stable and does not need to be routinely maintained under G418 selection. When transfected with HIV DNA or with any plasmid expressing the gene of interest driven by the HIV LTR promoter, high-level of gene expression is achieved. This cell line is further described in J. Virol 64:3734, 1990; AIDS Res. Ref. Reagent Program Courier 91-01:8, 1991; and J. Virol 64:2519, 1990. This cell line is available for licensing through a Biological Materials License Agreement.

Novel Anti-Tumor and Anti-Fungal Compounds Isolated From Plants of the Genus

Aniba

R. Shoemaker, E. Sausville, G. Cragg, D. Newman, M. Currens, T. McCloud, P. Klausmeyer, K. Tucker, M. Baseler, G. Chnurny, and W. Bancroft (NCI).

U.S. Provisional Application No. 60/ 433,489 filed 28 Jan 2003 (DHHS Reference No. E–224–2002/0–US–01). Licensing Contact: Brenda Hefti; 301/ 435–4632; heftib@mail.nih.gov.

The invention describes separate and combined extracts from two plants of the genus Aniba, and a specific compound possessing and indolizinium core. Both the purified extracts and the pure substituted inolizinium compound were found to inhibit the growth of the azone-resistant fungi C. albicans, certain bacteria, as well as demonstrating a differential response across the NCI human tumor cell line panel with a special sensitivity observed in several leukemia cell lines.

Cloning and Characterization of VIAF in Several Organisms

Colin S. Duckett, Bettina M. Richter (NCI).

U.S. Provisional Application No. 60/ 163,748 filed 05 Nov 1999 (DHHS Reference No. E-016-2000/0-US-01), PCT/US00/20576 filed 28 Jul 2000 (DHHS Reference No. E-016-2000/0-PCT-02), U.S. Patent Application No. 10/129,424 filed 03 May 2002 (DHHS Reference No. E-016-2000/0-US-03).

Licensing Contact: Matthew Kiser; 301/435–5236; e-mail: kiserm@mail.nih.gov.

The process of apoptosis, or programmed cell death, can be utilized to eliminate unwanted cells, and it can occur during embryogenesis, turnover of senescent cells or metamorphosis. It can also be part of a defense mechanism against pathogens, e.g., viruses, by allowing the host organism to eliminate infected cells. In an attempt to circumvent this defense mechanism, pathogens can produce gene products that block these apoptotic pathways. For example, O. pseudotsugata expresses a family of inhibitors of apoptosis proteins (IAP), and experimental data suggests that these IAPs can play a role in the protection from cellular apoptosis. This application claims nucleic acid and amino acid sequences corresponding to a viral IAP-associated factor, or VIAF. The gene and its product may enhance the anti-apoptotic properties of IAPs although the exact mechanism of this interaction is not clear. This technology could be used to treat disease states where VIAF is under-expressed, e.g., breast adenocarcinomas, where there is an over-expression of VIAF, e.g., neurodegenerative diseases and where apoptosis is undesired, e.g., AIDS and autoimmune diseases. Additional information may be found in Duckett, CS, "Novel modulators of the apoptotic cell death pathway," Mol. Biol. Cell 12: 732 Suppl. S Nov 2001.

Dated: September 26, 2003.

Richard U. Rodriguez,

Acting Director, Division of Technology Development and Transfer, Office of Technology Transfer, National Institutes of Health.

[FR Doc. 03–24969 Filed 10–1–03; 8:45 am] BILLING CODE 4140–01–P

DEPARTMENT OF HOMELAND SECURITY

Bureau of Citizenship and Immigration Services

Agency Information Collection Activities: Extension of Existing Collection; Comment Request

ACTION: 60-Day notice of information collection under review; The Student and Exchange Visitor Information System (SEVIS); OMB–30.

The Department of Homeland Security, Bureau of Citizenship and Immigration Services (BCIS), has submitted the following information collection request for review and clearance in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. Commenters are encouraged and will be accepted for sixty days until December 1, 2003.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information should address one or more of the following four points:

- (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- (2) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- (3) Enhance the quality, utility, and clarity of the information to be collected; and
- (4) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

Overview of this information collection:

- (1) Type of Information Collection: Extension of and existing information collection.
- (2) *Title of the Form/Collection:* The Student and Exchange Visitor Information System (SEVIS).
- (3) Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection: No Agency Form Number (File No. 0MB–30). Bureau of Citizenship and Immigration Services, Department of Homeland Security.
- (4) Affected public who will be asked or required to respond, as well as a brief abstract: Primary: Individuals or households. This system is used by institutions and sponsors to provide notification, reports, updates and data required by regulations and the institutions and programs, as well as on student and exchange visitors. Additionally, the BCIS and the Department of State will use SEVIS to adjudicate benefits and services, track student and exchange visitor data, and to monitor institution and program sponsor compliance with current regulations.
- (5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: 625,135 applicant and 5 responses at 20 minutes (.333 hours) per response.
- (6) An estimate of the total public burden (in hours) associated with the collection: 1,040,850 annual burden hours:

If you have additional comments, suggestions, or need a cov of the proposed information collection instrument with instructions, or additional information, please contact Richard A. Sloan 202-514-3291, Director, Regulations and Forms Services Division, Bureau of Citizenship and Immigration Services, Department of Homeland Security, 425 I Street, NW., Room 4034, Washington, DC 20536. Additionally, comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time may also be directed to Mr. Richard A. Sloan.

If additional information is required contact: Mr. Theresa O'Malley, Chief Information Officer, Department of Homeland Security, Regional Office Building 3, 7th and D Streets, SW., Suite 4636–26, Washington, DC 20202.

Dated: September 26, 2003.

Richard A. Sloan,

Department Clearance Officer, Department of Homeland Security, Bureau of Citizenship and Immigration Services.

[FR Doc. 03–24942 Filed 10–1–03; 8:45 am] BILLING CODE 4410–10–M

DEPARTMENT OF HOMELAND SECURITY

Bureau of Citizenship and Immigration Services

Agency Information Collection Activities: Proposed Collection; Comment Request

ACTION: 30-Day notice of information collection under review: Application for Authorization to Issue Health Care Certificates; Form I–905.

The Department of Homeland Security, Bureau of Citizenship and Immigration Services (BCIS) has submitted the following information collection request to the Office of Management and Budget (OMB) for review and clearance in accordance with the Paperwork Reduction Act of 1995. The information collection was previously published in the Federal Register on September 17, 2002, at 67 FR 58634, and again on February 25, 2003, at 68 FR 8784, allowing for a 30day public review and comment period on the proposed revised form. No comments were received on this information collection. However, the proposed form was withdrawn and continued by OMB until submission of accompanying final regulation. The information collection was submitted to OMB on June 20, 2003, for review and was granted temporary approval until December 31, 2003.

The purpose of this notice is to allow an additional 30 days for public comments. Comments are encouraged and will be accepted until November 3, 2003. This process is conducted in accordance with 5 CFR 1320.10.

Written comments and/or suggestions regarding the items contained in this notice, especially regarding the estimated public burden and associated response time, should be directed to the Office of Management and Budget, Office of Information and Regulatory Affairs, 725–17th Street, NW., Suite 10102, Washington, DC 20530; Attention: Department of Justice Desk Officer, Room 10235.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information should address one or more of the following four points:

- (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- (2) Evaluate the accuracy of the agency's estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- (3) Enhance the quality, utility, and clarity of the information to be collected; and
- (4) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

Överview of this information

- (1) Type of Information Collection: Extension of a currently approved information collection.
- (2) *Title of the Form/Collection:*Application for Authorization to Issue Health Care Certificates.
- (3) Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection: Form I–905, Business and Trade Services, Bureau of Citizenship and Immigration Services, Department of Homeland Security.
- (4) Affected public who will be asked or required to respond, as well as a brief abstract: Primary: Not-for-profit institutions. The data collected on this form is used by the BCIS to determine eligibility of an organization to issue certificates to foreign health care workers.
- (5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: 10 responses at 4 hours per response.
- (6) An estimate of the total public burden (in hours) associated with the collection: 40 annual burden hours.

If you have additional comments, suggestions, or need a copy of the proposed information collection instrument with instructions, or additional information, please contact Richard A. Sloan 202–514–3291, Director, Regulations and Forms Services Division Bureau of Citizenship and Immigration Services, Department of Homeland Security, Room 4034, 425 I Street, NW., Washington, DC 20536. Additionally, comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden

and associated response time may also be directed to Mr. Richard A. Sloan.

If additional information is required contact: Ms. Theresa O'Malley, Chief Information Officer, Department of Homeland Security, Regional Office Building 3, 7th and D Streets, SW., Suite 4636–26, Washington, DC 20202.

Dated: September 26, 2003.

Richard A. Sloan,

SECURITY

Department Clearance Officer, Department of Homeland Security, Bureau of Citizenship and Immigration Services.

[FR Doc. 03–24944 Filed 10–1–03; 8:45 am] **BILLING CODE 4410–10–M**

DEPARTMENT OF HOMELAND

Bureau of Immigration and Customs Enforcement

Agency Information Collection Activities: Comment Request

ACTION: 60-Day notice of information collection under review; Application—Alternative Inspection Services and FAST Commercial Driver Application; Forms I–823 and 823F.

The Department of Homeland Security (DHS), Bureau of Immigration and Customs Enforcement, has submitted the following information collection request for review and clearance in accordance with the Paperwork Reduction Act of 1995. The proposed information collection is published to obtain comments from the public and affected agencies. Comments are encouraged and will be accepted for sixty days until December 1, 2003.

Written comments and suggestions from the public and affected agencies concerning the proposed collection of information should address one or more of the following four points:

- (1) Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility;
- (2) Evaluate the accuracy of the agencies estimate of the burden of the proposed collection of information, including the validity of the methodology and assumptions used;
- (3) Enhance the quality, utility, and clarity of the information to be collected; and
- (4) Minimize the burden of the collection of information on those who are to respond, including through the use of appropriate automated, electronic, mechanical, or other technological collection techniques or

other forms of information technology, e.g., permitting electronic submission of responses.

Overview of this information collection:

- (1) Type of Information Collection: Extension of a currently approved collection.
- (2) Title of the Form/Collection: Application—Alternative Inspection Services and FAST Commercial Driver Application.
- (3) Agency form number, if any, and the applicable component of the Department of Justice sponsoring the collection: Forms I–823 and 823F. Bureau of Immigration and Customs Enforcement, Department of Homeland Security.
- (4) Affected public who will be asked or required to respond, as well as a brief abstract: Primary: Individuals or Households. The information collected on this form will be used by the DHS to determine eligibility for automated inspections programs and to secure those data elements necessary to confirm enrollment at the time of application for admission to the United States.
- (5) An estimate of the total number of respondents and the amount of time estimated for an average respondent to respond: 250,000 Form I–823 responses at 70 minutes (1.166 hours) per response; 25,000 CBP Form 823F responses at 30 minutes (.50 hours) per response.
- (6) An estimate of the total public burden (in hours) associated with the collection: 304,000 annual burden hours.

If you have additional comments, suggestions, or need a cov of the proposed information collection instrument with instructions, or additional information, please contact Richard A. Sloan 202-514-3291, Director, Regulations and Forms Services Division, Bureau of Immigration and Customs Enforcement, Department of Homeland Security, Room 4304, 425 I Street, NW., Washington, DC 20536. Additionally, comments and/or suggestions regarding the item(s) contained in this notice, especially regarding the estimated public burden and associated response time may also be directed to Mr. Richard A. Sloan.

If additional information is required contact: Ms. Theresa O'Malley, Chief Information Officer, Department of Homeland Security, Regional Office Building 3, 7th and D Streets, SW., Suite 4636–26, Washington, DC 20202.

Dated: September 26, 2003.

Richard A. Sloan,

Department Clearance Officer, U.S. Department of Homeland Security, Bureau of Immigration and Customs Enforcement. [FR Doc. 03–24943 Filed 10–1–03; 8:45 am]

DEPARTMENT OF HOUSING AND URBAN DEVELOPMENT

[Docket No. FR-4820-N-37]

Notice of Proposed Information Collection: Comment Request; Comprehensive Needs Assessment

AGENCY: Office of the Assistant Secretary for Housing—Federal Housing Commissioner, HUD.

ACTION: Notice.

SUMMARY: The proposed information collection requirement described below will be submitted to the Office of Management and Budget (OMB) for review, as required by the Paperwork Reduction Act. The Department is soliciting public comments on the subject proposal.

DATES: Comments Due Date: December 1, 2003.

ADDRESSES: Interested persons are invited to submit comments regarding this proposal. Comments should refer to the proposal by name and/or OMB Control Number and should be sent to: Wayne Eddins, Reports Management Officer, Department of Housing and Urban Development, 451 7th Street, SW., L'Enfant Building, Room 8003, Washington, DC 20410 or Wayne Eddins@hud.gov.

FOR FURTHER INFORMATION CONTACT:

Beverly J. Miller, Director, Office of Multifamily Asset Management, Department of Housing and Urban Development, 451 7th Street, SW., Washington, DC 20410, telephone (202) 708–3730 (this is not a toll free number) for copies of the proposed forms and other available information.

SUPPLEMENTARY INFORMATION: The Department is submitting the proposed information collection to OMB for review, as required by the Paperwork Reduction Act of 1995 (44 U.S.C. chapter 35, as amended).

This Notice is soliciting comments from members of the public and affected agencies concerning the proposed collection of information to: (1) Evlauate whether the proposed collection is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility; (2) Evaluate the

accuracy of the agency's estimate of the burden of the proposed collection of information; (3) Enhance the quality, utility, and clarity of the information to be collected; and (4) Minimize the burden of the collection of information on those who are to respond; including the use of appropriate automated collection techniques or other forms of information technology, e.g., permitting electronic submission of responses.

This Notice also lists the following information:

Title of Proposal: Comprehensive Needs Assessment.

OMB Control Number, if applicable: 2502–0505.

Description of the need for the information and proposed use: This information is necessary for HUD to review and assess the current and future resources and needs of multifamily housing projects. Owners and non-profit entities submit this information.

Agency form numbers, if applicable: HUD-96001, HUD-96002, HUD-96003.

Estimation of the total numbers of hours needed to prepare the information collection including number of respondents, frequency of response, and hours of response: The estimated total number of burden hours needed to prepare the information collection is 1,105,000; the number of respondents is 26,000 generating approximately 78,000 annual responses; the frequency of response is annually and every 5 years; and the estimated number of time needed to prepare the response varies from 1.25 hours to 40 hours.

Status of the proposed information collection: Extension of a currently approved collection.

Authority: The Paperwork Reduction Act of 1995, 44 U.S.C., chapter 35, as amended.

Dated: September 24, 2003.

Sean G. Cassidy,

General Deputy Assistant Secretary for Housing Deputy Federal Housing Commissioner.

[FR Doc. 03–24963 Filed 10–1–03; 8:45 am] BILLING CODE 4210–27–M

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

Endangered and Threatened Wildlife and Plants: Notice of Issuance of Permits for Incidental Take of Endangered (or Threatened) Species for Fiscal Year 2003 in the Northeast Region

AGENCY: Fish and Wildlife Service, Interior.

ACTION: Notice of issuance of incidental take permit for endangered species.

SUMMARY: On November 29, 2002, a notice was published in the Federal Register (67 FR 71192), that an application had been filed with the U.S. Fish and Wildlife Service (Service) by Snowshoe Mountain Resort, for a permit to incidentally take, pursuant to section 10(a)(1)(B) of the Endangered Species Act (Act) of 1973 (16 U.S.C. 1539), as amended, the West Virginia Northern Flying Squirrel (Glaucomys sabrinus fuscus) on the proposed 51-acre Camp Wilderness Development pursuant to the terms of the Habitat Conservation Plan for the West Virginia Northern Flying Squirrel at the Proposed Camp Wilderness Development, Snowshoe Mountain, Pocahontas County, West Virginia.

Notice is hereby given that on February 24, 2003, after a 60-day public comment period as authorized by the provisions of the Act, the Service issued a permit (PRT–065121–0) to the abovenamed party subject to certain conditions set forth therein. The permit was granted only after the Service determined that it was applied for in good faith, that granting the permit will not be to the disadvantage of the threatened species, and that it will be consistent with the purpose and policy set forth in the Act, as amended.

Additional information on this permit action may be requested by contacting the West Virginia Field Office, 694
Beverly Pike, Elkins, West Virginia 26241, telephone number 304–636–6586, during normal business hours of 8 a.m. to 4:30 p.m.

No other Incidental Take Permits were issued in the Northeast Region in Fiscal Year 2003.

Dated: September 17, 2003.

Richard O. Bennett,

Acting Regional Director, Region 5. [FR Doc. 03–24970 Filed 10–1–03; 8:45 am] BILLING CODE 4310–55–P

INTERNATIONAL TRADE COMMISSION

[Investigations Nos. 731–TA–1014 and 1017 (Final)]

Polyvinyl Alcohol From China and Korea

Determinations

On the basis of the record ¹ developed in the subject investigations, the United States International Trade Commission (Commission) determines, pursuant to section 735(b) of the Tariff Act of 1930 (19 U.S.C. § 1673d(b)) (the Act), that an industry in the United States is materially injured by reason of imports from China and Korea of polyvinyl alcohol ("PVA"),² provided for in subheading 3905.30.00 of the Harmonized Tariff Schedule of the United States, that have been found by the Department of Commerce (Commerce) to be sold in the United States at less than fair value (LTFV).³

- ² For purposes of these investigations, PVA is defined as all polyvinyl alcohol hydrolyzed in excess of 80 percent, whether or not mixed or diluted with commercial levels of defoamer or boric acid, except as excluded from the definition. The following forms of polyvinyl alcohol are excluded from the definition of PVA:
 - (1) PVA in fiber form:
- (2) PVA with hydrolysis less than 83 mole percent and certified not for use in the production of textiles:
- (3) PVA with hydrolysis greater than 85 percent and viscosity greater than or equal to 90 cps;
- (4) PVA with a hydrolysis greater than 85 percent, viscosity greater than or equal to 80 cps but less than 90 cps, certified for use in an ink jet application;
- (5) PVA for use in the manufacture of an excipient or as an excipient in the manufacture of film coating systems which are components of a drug or dietary supplement, and accompanied by an end-use certification;
- (6) PVA covalently bonded with cationic monomer uniformly present on all polymer chains in a concentration equal to or greater than one mole percent;
- (7) PVA covalently bonded with carboxylic acid uniformly present on all polymer chains in a concentration equal to or greater than two mole percent, certified for use in a paper application;
- (8) PVA covalently bonded with thiol uniformly present on all polymer chains, certified for use in emulsion polymerization of non-vinyl acetic material;
- (9) PVA covalently bonded with paraffin uniformly present on all polymer chains in a concentration equal to or greater than one mole percent:
- (10) PVA covalently bonded with silan uniformly present on all polymer chains certified for use in paper coating applications;
- (11) PVA covalently bonded with sulfonic acid uniformly present on all polymer chains in a concentration level equal to or greater than one mole percent;
- (12) PVA covalently bonded with acetoacetylate uniformly present on all polymer chains in a concentration level equal to or greater than one mole percent;
- (13) PVA covalently bonded with polyethylene oxide uniformly present on all polymer chains in a concentration level equal to or greater than one mole percent;
- (14) PVA covalently bonded with quaternary amine uniformly present on all polymer chains in a concentration level equal to or greater than one mole percent; and
- (15) PVA covalently bonded with diacetoneacrylamide uniformly present on all polymer chains in a concentration level greater than three mole percent certified for use in a paper application.
- ³ Commissioner Charlotte R. Lane did not participate in these investigations.

Background

The Commission instituted these investigations effective September 5, 2002, following receipt of a petition filed with the Commission and Commerce by Celanese, Ltd. of Dallas, TX and E.I. du Pont de Nemours & Co. of Wilmington, DE. The final phases of the investigations were scheduled by the Commission following notification of preliminary determinations by Commerce that imports of polyvinyl alcohol from China and Korea were being sold at LTFV within the meaning of section 733(b) of the Act (19 U.S.C. 1673b(b)). Notices of the scheduling of the final phases of the Commission's investigations and of a public hearing to be held in connection therewith were given by posting copies of the notices in the Office of the Secretary, U.S. International Trade Commission, Washington, DC, and by publishing the notices in the **Federal Register** of April 14, 2003 (68 FR 17964), as amended by the Federal Register of August 19, 2003 (68 FR 49792). The hearing was held in Washington, DC, on May 8, 2003, and all persons who requested the opportunity were permitted to appear in person or by counsel.

The Commission transmitted its determinations in these investigations to the Secretary of Commerce on September 24, 2003. The views of the Commission are contained in USITC Publication 3634 (September 2003), entitled *Polyvinyl Alcohol from China and Korea: Investigations Nos. 1014 and 1017 (Final).*

By order of the Commission. Issued: September 29, 2003.

Marilyn R. Abbott,

Secretary.

[FR Doc. 03–25012 Filed 10–1–03; 8:45 am] BILLING CODE 7020–02–P

DEPARTMENT OF JUSTICE

Notice of Lodging of Consent Decree Under the Comprehensive Environmental Response, Compensation and Liability Act

In accordance with 28 U.S.C. 50.7 and section 122 of the Comprehensive Environmental Response, Compensation and Liability Act ("CERCLA"), 42 U.S.C. 9622, notice is hereby given that on September 18, 2003, a proposed Consent Decree in *United States* v. *Harding Township, New Jersey*, Civil Action No. 03–4445 (FSH), was lodged with the United States District Court for the District of New Jersey.

In this action the United States, on behalf of the United States Department

¹ The record is defined in sec. 207.2(f) of the Commission's Rules of Practice and Procedure (19 CFR 207.2(f)).

of the Interior ("DOI"), seeks reimbursement of response costs incurred and to be incurred in connection with response actions at the former Harding Landfill (the "Site"), located within the Great Swamp National Wildlife Refuge in Harding Township, Morris County, New Jersey. The Complaint alleges that the defendant is liable under sections 107(a) and 113(f) of CERCLA, 42 U.S.C. 9607(a) and 9613(f). Pursuant to the Consent Decree, the defendant will transfer title to and interest in a 65 acre parcel of real property (the "Parcel") adjacent to the Great Swamp National Wildlife Refuge to DOI's Central Hazardous Materials Fund as reimbursement for costs incurred and to be incurred by DOI at the Site. The Parcel will be managed by Fish & Wildlife Service as part of the Great Swamp National Wildlife Refuge for use by and enjoyment of the public.

The Department of Justice will receive for a period of thirty (30) days from the date of this publication comments relating to the Consent Decree.

Comments should be addressed to the Assistant Attorney General,
Environment and Natural Resources Division, P.O. Box 7611, U.S.

Department of Justice, Washington, DC 20044–7611, and should refer to *United States v. Harding Township, New Jersey*, D.J. Ref. 90–11–3–07117.

The Consent Decree may be examined at the Office of the United States Attorney for the District of New Jersey, 970 Broad Street, Room 400, Newark, New Jersey 07102, and at U.S. Department of the Interior, Office of the Solicitor, 1849 C Street, NW., Washington, DC 20240. During the public comment period, the Consent Decree may also be examined on the following Department of Justice Web site: http://www.usdoj.gov/enrd/ open.html. A copy of the Consent Decree may also be obtained by mail from the Consent Decree Library, P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044–7611 or by faxing or e-mailing a request to Tonia Fleetwood (tonia.fleetwood@usdoj.gov), fax no. (202) 514-0097, phone confirmation number (202) 514-1547. In requesting a copy from the Consent Decree Library, please enclose a check in the amount of \$8.00 (25 cents per page reproduction cost), payable to the U.S. Treasury.

Ronald Gluck,

Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 03–24932 Filed 10–1–03; 8:45 am]

BILLING CODE 4410-15-M

DEPARTMENT OF JUSTICE

Notice of Lodging of Consent Decree Under the Comprehensive Environmental Response, Compensation and Liability Act ("CERCLA")

Consistent with Departmental policy, 28 CFR 50.7, 38 FR 19029, and 42 U.S.C. 9622(d), notice is hereby given that on September 15, 2003, a proposed consent decree in *United States* v. *Mallinckrodt Baker, Inc., et al.,* Civil Action No. 03–417S, was lodged with the United States District Court for the District of Rhode Island.

In this action the United States sought recovery of response costs pursuant to Section 107(a) of CERCLA, for costs incurred related to the Davis Liquid Waste Site in Smithfield, Rhode Island. The consent decree requires three generator defendants to pay \$1,400,00, of which the United States will receive \$660,000. The remaining portion will go to the State of Rhode Island and National Starch and Chemical Co. ("National Starch"), a contribution plaintiff.

The Department of Justice will receive for a period of thirty (30) days from the date of this publication comments relating to the consent decree.

Comments should be addressed to the Assistant Attorney General,
Environment and Natural Resources Division, P.O. Box 7611, U.S.

Department of Justice, Washington, DC 20044–7611, and should refer to *United States v. Mallinckrodt Baker, Inc., et al.,* D.J. Ref. #90–11–2–137/1.

The consent decree may be examined at the Office of the United States Attorney, Fleet Center, 50 Kennedy Plaza, 8th Floor, Providence, Rhode Island 02903 (contact AUSA Michael Iannotti), and at U.S. EPA Region I, One Congress Street, Suite 1100, Mail Code SES, Boston, MA 02114 (contact Ruthann Sherman). During the public comment period the consent decree may also be examined on the following Department of Justice Web site, http:// www.usdoj.gov/enrd/open.html. A copy of the consent decree may also be obtained by mail from the Consent Decree Library, P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044-7611 or by faxing or e-mailing a request to Tonia Fleetwood (tonia.fleetwood@usdoj.gov), fax no. (202) 514-0097, phone confirmation number (202) 514-1547. In requesting a copy from the Consent Decree Library, please enclose a check in the amount of

\$10.50 (25 cents per page reproduction cost) payable to the U.S. Treasury.

Ronald G. Gluck,

Assistant Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 03–24933 Filed 10–1–03; 8:45 am] BILLING CODE 4410–35–M

DEPARTMENT OF JUSTICE

Notice of Lodging of Consent Decree Under the Clean Water Act

Notice is hereby given that on September 16, 2003, a proposed Consent Decree in *United States* v. *Phelps Dodge Corporation*, Civil Action No. CIV–03– 1804–PHX–SMM, was lodged with the United States District Court for the District of Arizona.

In this action the United States sought injunctive relief and civil penalties for violations of section 301(a) of the Clean Water Act, 33 U.S.C. 1311(a), at the United Verde mine near Jerome, Arizona. The defendant is Phelps Dodge Corporation, the owner of the United Verde mine.

Under the terms of the proposed settlement, Phelps Dodge will pay a civil penalty of \$220,142. In addition, Phelps Dodge will carry out three projects at the United Verde mine designed to address the violations alleged in the complaint.

The Department of Justice will receive for a period of thirty (30) days from the date of this publication, comments relating to the Consent Decree.

Comments should be addressed to the Assistant Attorney General,
Environment and Natural Resources Division, P.O. Box 7611, U.S.

Department of Justice, Washington, DC 20044–7611, and should refer to *United States* v. *Phelps Dodge Corporation*, D.J.

Ref. 90–5–1–1–07311.

The Consent Decree may be examined at the Office of the United States Attorney, Sue A. Klein, Assistant U.S. Attorney, Two Renaissance Square, 40 North Central Ave., Suite 1200, Phoenix, AZ 8500. During the public comment period, the Consent Decree may also be examined on the following Department of Justice Web site, http:// www.usdoj.gov/enrd/open.html. A copy of the Consent Decree may also be obtained by mail from the Consent Decree Library, P.O. Box 7611, U.S. Department of Justice, Washington, DC 20044-7611, or by faxing or e-mailing a request to Tonia Fleetwood (tonia.fleetwood@usdoj.gov), fax no. (202) 616-6584, phone confirmation number (202) 514-1547. In requesting a copy, please enclose a check in the

amount of \$9.25 (37 pages at 25 cents per page reproduction cost) payable to the U.S. Treasury.

Ellen Mahan,

Assistant Section Chief, Environmental Enforcement Section, Environment and Natural Resources Division.

[FR Doc. 03-24934 Filed 10-1-03; 8:45 am]

BILLING CODE 4410-15-M

DEPARTMENT OF JUSTICE

Drug Enforcement Administration

Manufacturer of Controlled Substances; Notice of Registration

By Notice dated May 7, 2003, and published in the **Federal Register** on May 29, 2003 (68 FR 32089), Organix, Inc., 240 Salem Street, Woburn, Massachusetts 01810, made application by renewal to the Drug Enforcement Administration to be registered as a bulk manufacturer of the basic class of Cocaine (9041), a Schedule II controlled substance.

The firm plans to manufacture small quantities of a cocaine derivative for distribution for research purposes.

No comments or objections have been received. DEA has considered the factors in Title 21, United States Code, Section 823(a) and determined that the registration of Organix, Inc. to manufacture the listed controlled substances is consistent with the public interest at this time. DEA has investigated Organix, Inc. to ensure that the company's registration is consistent with the public interest. This investigation has included inspection and testing of the company's physical security systems, verification of the company's compliance with state and local laws, and a review of the company's background and history. Therefore, pursuant to 21 U.S.C. 823 and 28 CFR 0.100 and 0.104, the Deputy Assistant Administrator, Office of Diversion Control, hereby orders that the application submitted by the above firm for registration as a bulk manufacturer of the basic class of controlled substance listed is granted.

Dated: August 27, 2003.

Laura M. Nagel,

Deputy Assistant Administrator, Office of Diversion Control, Drug Enforcement Administration.

[FR Doc. 03-24983 Filed 10-1-03; 8:45 am]

BILLING CODE 4410-09-M

NATIONAL SCIENCE FOUNDATION

Notice of Permits Issued Under the Antarctic Conservation Act of 1978

AGENCY: National Science Foundation **ACTION:** Notice of permits issued under the Antarctic Conservation of 1978, Pub. L. 95–541.

SUMMARY: The National Science Foundation (NSF) is required to publish notice of permits under the Antarctic Conservation Act of 1978. This is the required notice.

FOR FURTHER INFORMATION CONTACT:

Nadene G. Kennedy, Permit Office, Office of Polar Programs, Rm. 755, National Science Foundation, 4201 Wilson Boulevard, Arlington, VA 22230. SUPPLEMENTARY INFORMATION: On August 13, 2003 and August 19, 2003, the National Science Foundation published notices in the Federal Register of a permit applications received. Permits were issued on September 16, 2003, and September 24, 2003, to Paul J. Ponganis (2004–010) and David Caron (2004–012) respectively.

Nadene G. Kennedy,

Permit Officer.

[FR Doc. 03–24948 Filed 10–1–03; 8:45 am] BILLING CODE 7555–01–M

NUCLEAR REGULATORY COMMISSION

[Docket No. 40-8698]

Finding of No Significant Impact and Notice of Availability of the Environmental Assessment Concerning the License Amendment Request for Consideration of the Proposed Reclamation Plan for the Plateau Resources Limited Shootaring Canyon Uranium Project

AGENCY: Nuclear Regulatory Commission.

ACTION: Notice of availability; environmental assessment and finding of no significant impact.

FOR FURTHER INFORMATION CONTACT: Rick

Weller, Fuel Cycle Facilities Branch, Division of Fuel Cycle Safety and Safeguards, Office of Nuclear Material Safety and Safeguards, U.S. Nuclear Regulatory Commission, Mail Stop T8–A33, Washington DC 20555–0001, telephone (301) 415–7287 and e-mail rmw2@nrc.gov.

SUPPLEMENTARY INFORMATION:

I. Introduction

The U.S. Nuclear Regulatory Commission (NRC) has received, by letter dated October 24, 2002, a request from Plateau Resources Limited (PRL) to (1) amend Source Materials License SUA-1371 for the Shootaring Canyon Uranium Project to change its status from "operational" to "reclamation;" and (2) review and approve PRL's proposed reclamation plan for this facility.

Pursuant to the requirements of 10 CFR part 51 (Environmental Protection Regulations for Domestic Licensing and Related Regulatory Functions), the NRC has prepared an environmental assessment (EA) to evaluate the environmental impacts associated with decommissioning and reclamation of the Shootaring Canyon facility. Based on this evaluation, the NRC has concluded that a Finding of No Significant Impact (FONSI) is appropriate for the proposed licensing action.

II. Summary of the Environmental Assessment

The EA was prepared to evaluate the environmental impacts associated with PRL's decommissioning and reclamation plan. In the conduct of its evaluation, the NRC considered the following: (1) PRL's reclamation plan, as supplemented and revised, (2) information contained in prior environmental evaluations of the Shootaring Canyon facility, (3) information in Shootaring Canyon environmental monitoring reports, and (4) information derived from NRC site visits and inspections of the Shootaring Canyon site and from communications with PRL, the Utah Department of Environmental Quality, the Utah State Historic Preservation Office, the U.S. Fish and Wildlife Service, the U.S. Bureau of Land Management (Henry Mountains Field Station), and the U.S. National Park Service (Glen Canyon National Recreational Area). In preparing the EA, the NRC evaluated the potential impacts to cultural resources, threatened and endangered species, surface waters, and groundwater at the Shootaring Canyon site. Additionally, the NRC evaluated the potential impacts to members of the public from construction activities associated with decommissioning and reclamation. Lastly, the NRC evaluated the potential radiological impacts to members of the public from the cleanup and disposal of the radioactive wastes generated during uranium recovery operations. The results of the staff's evaluation are documented in an EA which is available for public inspection and/or copying in the NRC's Public Document Room or from the Publicly Available Records (PARS) component of NRC's document

system (ADAMS). The safety aspects of the decommissioning and reclamation plan are discussed separately in a Technical Evaluation Report that will accompany the agency's final licensing action on PRL's request to amend Source Materials License SUA–1371.

III Finding of No Significant Impact

Pursuant to 10 CFR part 51, the NRC has prepared the EA, summarized above, concerning the decommissioning and reclamation of the Shootaring Canyon Uranium Project located in Garfield County, Utah. On the basis of the EA, the NRC has concluded that this licensing action would not have any significant effect on the quality of the environment, and, therefore, an environmental impact statement is not required. The NRC has concluded that the approval of PRL's decommissioning and reclamation plan will not cause any significant impacts on the environment and is protective of human health. The NRC has concluded that decommissioning and reclamation of the Shootaring Canyon facility will not result in any adverse impacts to regional surface and groundwater. A groundwater monitoring program will be maintained throughout site reclamation and following site closure to ensure that groundwater is adequately protected during long-term custody of the site. The NRC has also concluded that the waste impoundment at the site will be designed in accordance with the requirements of 10 CFR part 40, appendix A, to provide reasonable assurance of effective control of radiological hazards for 1,000 years, to the extent reasonably achievable, and, in any case, for at least 200 years.

IV. Further Information

The EA for this proposed action, as well as the licensee's request, as supplemented and revised, are available electronically for public inspection in the NRC's Public Document Room or from the Publicly Available Records (PARS) component of NRC's document system (ADAMS). ADAMS is accessible from the NRC Web site at http://www.nrc.gov/reading-rm/adams.html. The ADAMS Accession Numbers for the licensee's request, as supplemented and revised, are:

ML023050449, ML023050465, ML023080393, ML023090051, ML023090054, ML023090059, ML023090062, ML023090067, ML023090070, (October 24, 2002); ML030640211 (February 24, 2003); ML031200325 (April 24, 2003); and ML032541114, ML032541131 (September 5, 2003). The ADAMS Accession Number for the EA is: ML032530553. Documents can also be examined and/or copied for a fee, at the NRC's Public Document Room, located at One White Flint North, 11555 Rockville Pike, Rockville, MD 20852.

Dated at Rockville, Maryland, this 25th day of September, 2003.

For the Nuclear Regulatory Commission. Rick Weller,

Senior Project Manager, Fuel Cycle Facilities Branch, Division of Fuel Cycle Safety and Safeguards, Office of Nuclear Material Safety and Safeguards.

[FR Doc. 03–24982 Filed 10–1–03; 8:45 am] BILLING CODE 7590–01–P

RAILROAD RETIREMENT BOARD

Agency Forms Submitted for OMB Review

SUMMARY: In accordance with the Paperwork Reduction Act of 1995 (44 U.S.C. chapter 35), the Railroad Retirement Board (RRB) has submitted the following proposal(s) for the collection of information to the Office of Management and Budget for review and approval.

Summary of Proposal(s)

- (1) *Collection title:* Job Information Report.
- (2) Form(s) submitted: G–251a, G–251b.
 - (3) OMB Number: 3220-0193.
- (4) Expiration date of current OMB clearance: 11/30/2003.
- (5) *Type of request:* Extension of a currently approved collection.
- (6) Respondents: Business or other for-profit.
- (7) Estimated annual number of respondents: 430.
 - (8) Total annual responses: 430.
 - (9) Total annual reporting hours: 144.
- (10) Collection description: The collection obtains information used by the Railroad Retirement Board (RRB) to assist in determining whether a railroad employee is disabled from his or her regular occupation. It provides, under certain conditions, railroad employers with the opportunity to provide information to the RRB regarding the employee applicant's job duties.

Additional Information or Comments: Copies of the forms and supporting documents can be obtained from Chuck Mierzwa, the agency clearance officer (312–751–3363).

Comments regarding the information collection should be addressed to Ronald J. Hodapp, Railroad Retirement Board, 844 North Rush Street, Chicago, Illinois, 60611–2092 and to the OMB Desk Officer for the RRB, at the Office of Management and Budget, Room

10230, New Executive Office Building, Washington, DC 20503.

Chuck Mierzwa,

Clearance Officer.

[FR Doc. 03–24958 Filed 10–1–03; 8:45 am] BILLING CODE 7905–01–M

SECURITIES AND EXCHANGE COMMISSION

[Release No. IC-26193]

Notice of Applications for Deregistration Under Section 8(f) of the Investment Company Act of 1940

September 26, 2003.

The following is a notice of applications for deregistration under section 8(f) of the Investment Company Act of 1940 for the month of September, 2003. A copy of each application may be obtained for a fee at the SEC's Public Reference Branch, 450 Fifth St., NW., Washington, DC 20549-0102 (tel. 202-942-8090). An order granting each application will be issued unless the SEC orders a hearing. Interested persons may request a hearing on any application by writing to the SEC's Secretary at the address below and serving the relevant applicant with a copy of the request, personally or by mail. Hearing requests should be received by the SEC by 5:30 p.m. on October 21, 2003, and should be accompanied by proof of service on the applicant, in the form of an affidavit or, for lawyers, a certificate of service. Hearing requests should state the nature of the writer's interest, the reason for the request, and the issues contested. Persons who wish to be notified of a hearing may request notification by writing to the Secretary, SEC, 450 Fifth Street, NW., Washington, DC 20549-0609. For Further Information Contact: Diane L. Titus at (202) 942-0564, SEC, Division of Investment Management, Office of Investment Company Regulation, 450 Fifth Street, NW., Washington, DC 20549-0504.

Credit Suisse Municipal Bond Fund, Inc. [File No. 811–8923]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On August 20, 2003, applicant made a liquidating distribution to its shareholders, based on net asset value. Expenses of \$65,000 incurred in connection with the liquidation were paid by Credit Suisse Asset Management, LLC, applicant's investment adviser, and/or its affiliates.

Filing Date: The application was filed on September 16, 2003.

Applicant's Address: 466 Lexington Ave., New York, NY 10017.

Prudential International Bond Fund, Inc. [File No. 811–5123]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On May 4, 2001, applicant transferred its assets to Dryden Global Total Return Fund, Inc. (formerly Prudential Global Total Return Fund, Inc.), based on net asset value. Expenses of \$135,925 incurred in connection with the reorganization were paid by the surviving fund.

Filing Date: The application was filed

on August 21, 2003.

Applicant's Address: Gateway Center Three, 100 Mulberry St., Newark, NJ 07102–4077.

Morgan Stanley Africa Investment Fund, Inc. [File No. 811–8218]

Summary: Applicant, a closed-end investment company, seeks an order declaring that it has ceased to be an investment company. On July 18, 2003, applicant made a final liquidating distribution to its shareholders, based on net asset value. Expenses of \$81,599 incurred in connection with the liquidation were paid by applicant.

Filing Date: The application was filed

on September 5, 2003.

Applicant's Address: c/o Morgan Stanley Investment Management Inc., 1221 Avenue of the Americas, New York, NY 10020.

Mercury Global Holdings, Inc. [File No. 811–4351]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On July 21, 2003, applicant transferred its assets to Merrill Lynch Global Growth Fund, Inc., based on net asset value. Expenses of \$139,612 incurred in connection with the reorganization were paid by the acquiring fund.

Filing Date: The application was filed

on August 27, 2003.

Applicant's Address: 800 Scudders Mill Rd., Plainsboro, NJ 08536.

Camelot Funds [File No. 811-3139]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On December 13, 2002, applicant made a liquidating distribution to its shareholders, based on net asset value. Expenses of \$515 incurred in connection with the liquidation were paid by The Sachs Company, applicant's investment adviser.

Filing Date: The application was filed on August 27, 2003.

Applicant's Address: 1346 South Third St., Louisville, KY 40208.

Prudential Intermediate Global Income Fund, Inc. [File No. 811–5510]

Prudential Global Limited Maturity Fund, Inc. [File No. 811–6048]

Summary: Each applicant seeks an order declaring that it has ceased to be an investment company. On October 22, 1999, applicants transferred their assets to Dryden Global Total Return Fund, Inc. (formerly Prudential Global Total Return Fund, Inc.), based on net asset value. Expenses of \$181,061 and \$108,034, respectively, incurred in connection with the reorganizations were paid by the surviving fund.

Filing Date: The applications were filed on August 21, 2003.

Applicants' Address: Gateway Center Three, 100 Mulberry St., Newark, NJ 07102–4077.

Prudential Balanced Fund [File No. 811–5055]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On November 10, 2000, applicant transferred its assets to Prudential Active Balanced Fund, a series of The Prudential Investment Portfolios, Inc., based on net asset value. Expenses of \$307,095 incurred in connection with the reorganization were paid by the surviving fund.

Filing Date: The application was filed

on August 21, 2003.

Applicant's Address: Gateway Center Three, 100 Mulberry St., Newark, NJ 07102–4077.

General American Capital Company [File No. 811–4900]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. Shareholders approved the merger of applicant's series on April 25, 2003 and applicant distributed its assets on April 28, 2003. The funds surviving the merger are portfolios of the Metropolitan Series Fund, Inc. MetLife Advisers, LLC and its affiliates, including General American Life Insurance Company, paid expenses of approximately \$660,000 incurred in connection with the merger.

Filing Date: The application was filed on September 5, 2003.

Applicant's Address: 700 Market Street, St. Louis, Missouri 63101.

Lincoln National Bond Fund, Inc. [File No. 811-3210]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On April 30, 2003, applicant distributed all of its assets to its shareholders based on net asset value pursuant to an agreement approved by the applicant's

shareholders to reorganize Applicant, along with certain other Lincoln National funds, from a Maryland corporation into a series of a Delaware business trust. Aggregate expenses of approximately \$42,901.00 were incurred in connection with the reorganization and merger, and were allocated to applicant prior to May 1, 2003, and to the Bond Fund (acquiring fund), a series of the Lincoln Variable Insurance Products Trust, as of May 1, 2003, and thereafter.

Filing Dates: The application was filed on May 23, 2003, and amended on August 1, 2003.

Applicant's Address: 1300 South Clinton Street, Fort Wayne, IN 46802.

Lincoln National Capital Appreciation Fund, Inc. [File No. 811–8074]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On April 30, 2003, applicant distributed all of its assets to its shareholders based on net asset value pursuant to an agreement approved by the applicant's shareholders to reorganize applicant, along with certain other Lincoln National funds, from a Maryland corporation into a series of a Delaware business trust. Aggregate expenses of approximately \$42,901.00 were incurred in connection with the reorganization and merger, and were allocated to applicant prior to May 1, 2003, and to the Capital Appreciation Fund (acquiring fund), a series of the Lincoln Variable Insurance Products Trust, as of May 1, 2003, and thereafter.

Filing Dates: The application was filed on May 23, 2003, and amended on August 1, 2003.

Applicant's Address: 1300 South Clinton Street, Fort Wayne, IN 46802.

Lincoln National Global Asset Allocation Fund, Inc. [File No. 811– 5115]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On April 30, 2003, applicant distributed all of its assets to its shareholders based on net asset value pursuant to an agreement approved by the applicant's shareholders to reorganize applicant, along with certain other Lincoln National funds, from a Maryland corporation into a series of a Delaware business trust. Aggregate expenses of approximately \$42,901.00 were incurred in connection with the reorganization and merger, and were allocated to applicant prior to May 1, 2003, and to the Global Asset Allocation Fund (acquiring fund), a series of the Lincoln

Variable Insurance Products Trust, as of May 1, 2003, and thereafter.

Filing Dates: The application was filed on May 23, 2003, and amended on August 1, 2003.

Applicant's Address: 1300 South Clinton Street, Fort Wayne, IN 46802.

Lincoln National Social Awareness Fund, Inc. [File No. 811–5464]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On April 30, 2003, applicant distributed all of its assets to its shareholders based on net asset value pursuant to an agreement approved by the applicant's shareholders to reorganize applicant, along with certain other Lincoln National funds, from a Maryland corporation into a series of a Delaware business trust. Aggregate expenses of approximately \$42,901.00 were incurred in connection with the reorganization and merger, and were allocated to applicant prior to May 1, 2003, and to the Social Awareness Fund (acquiring fund), a series of the Lincoln Variable Insurance Products Trust, as of May 1, 2003, and thereafter.

Filing Dates: The application was filed on May 23, 2003, and amended on August 1, 2003.

Applicant's Address: 1300 South Clinton Street, Fort Wayne, IN 46802.

Lincoln National Growth and Income Fund, Inc. [File No. 811–3211]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On April 30, 2003, applicant distributed all of its assets to its shareholders based on net asset value pursuant to an agreement approved by the applicant's shareholders to reorganize applicant, along with certain other Lincoln National funds, from a Maryland corporation into a series of a Delaware business trust. Aggregate expenses of approximately \$42,901.00 were incurred in connection with the reorganization and merger, and were allocated to applicant prior to May 1, 2003, and to the Growth and Income Fund (acquiring fund), a series of the Lincoln Variable Insurance Products Trust, as of May 1, 2003, and thereafter.

Filing Dates: The application was filed on May 23, 2003, and amended on August 1, 2003.

Applicant's Address: 1300 South Clinton Street, Fort Wayne, IN 46802.

Lincoln National Money Market Fund, Inc. [File No. 811–3212]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On April 30,

2003, applicant distributed all of its assets to its shareholders based on net asset value pursuant to an agreement approved by the applicant's shareholders to reorganize applicant, along with certain other Lincoln National funds, from a Maryland corporation into a series of a Delaware business trust. Aggregate expenses of approximately \$42,901.00 were incurred in connection with the reorganization and merger, and were allocated to applicant prior to May 1, 2003, and to the Money Market Fund (acquiring fund), a series of the Lincoln Variable Insurance Products Trust, as of May 1, 2003, and thereafter.

Filing Dates: The application was filed on May 23, 2003, and amended on August 1, 2003.

Applicant's Address: 1300 South Clinton Street, Fort Wayne, IN 46802.

Lincoln National Special Opportunities Fund, Inc. [File No. 811–3291]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On April 30, 2003, applicant distributed all of its assets to its shareholders based on net asset value pursuant to an agreement approved by the applicant's shareholders to reorganize applicant, along with certain other Lincoln National funds, from a Maryland corporation into a series of a Delaware business trust. Aggregate expenses of approximately \$42,901.00 were incurred in connection with the reorganization and merger, and were allocated to applicant prior to May 1, 2003, and to the Special Opportunities Fund (acquiring fund), a series of the Lincoln Variable Insurance Products Trust, as of May 1, 2003, and thereafter.

Filing Dates: The application was filed on May 23, 2003, and amended on August 1, 2003.

Applicant's Address: 1300 South Clinton Street, Fort Wayne, IN 46802.

Lincoln National Managed Fund, Inc. [File No. 811–3683]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On April 30, 2003, applicant distributed all of its assets to its shareholders based on net asset value pursuant to an agreement approved by the applicant's shareholders to reorganize applicant, along with certain other Lincoln National funds, from a Maryland corporation into a series of a Delaware business trust. Aggregate expenses of approximately \$42,901.00 were incurred in connection with the reorganization and merger, and were allocated to applicant prior to May 1, 2003, and to

the Managed Fund (acquiring fund), a series of the Lincoln Variable Insurance Products Trust, as of May 1, 2003, and thereafter.

Filing Dates: The application was filed on May 23, 2003, and amended on August 1, 2003.

Applicant's Address: 1300 South Clinton Street, Fort Wayne, IN 46802.

Lincoln National International Fund, Inc. [File No. 811–6233]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On April 30, 2003, applicant distributed all of its assets to its shareholders based on net asset value pursuant to an agreement approved by the applicant's shareholders to reorganize applicant, along with certain other Lincoln National funds, from a Maryland corporation into a series of a Delaware business trust. Aggregate expenses of approximately \$42,901.00 were incurred in connection with the reorganization and merger, and were allocated to applicant prior to May 1, 2003, and to the International Fund (acquiring fund), a series of the Lincoln Variable Insurance Products Trust, as of May 1, 2003, and thereafter.

Filing Dates: The application was filed on May 23, 2003, and amended on August 1, 2003.

Applicant's Address: 1300 South Clinton Street, Fort Wayne, IN 46802.

Lincoln National Equity-Income Fund, Inc. [File No. 811–8126]

Summary: Applicant seeks an order declaring that it has ceased to be an investment company. On April 30, 2003, applicant distributed all of its assets to its shareholders based on net asset value pursuant to an agreement approved by the applicant's shareholders to reorganize applicant, along with certain other Lincoln National funds, from a Maryland corporation into a series of a Delaware business trust. Aggregate expenses of approximately \$42,901.00 were incurred in connection with the reorganization and merger, and were allocated to applicant prior to May 1, 2003, and to the Equity-Income Fund (acquiring fund), a series of the Lincoln Variable Insurance Products Trust, as of May 1, 2003, and thereafter.

Filing Dates: The application was filed on May 23, 2003, and amended on August 1, 2003.

Applicant's Address: 1300 South Clinton Street, Fort Wayne, IN 46802.

For the Commission, by the Division of Investment Management, pursuant to delegated authority.

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 03–24950 Filed 10–1–03; 8:45 am]

BILLING CODE 8010-01-P

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–48540; File No. SR–CBOE– 2003–31]

Self-Regulatory Organizations; Notice of Filing and Proposed Rule Change by the Chicago Board Options Exchange, Inc. Relating to Audit Committee Requirements Applicable to Companies Listing Non-Option Securities

September 25, 2003.

Pursuant to section 19(b)(1) of the Securities Exchange Act of 1934 ("Exchange Act"),¹ and Rule 19b–4 thereunder,² notice is hereby given that on July 11, 2002, the Chicago Board Options Exchange, Inc. ("CBOE" or "Exchange") filed with the Securities and Exchange Commission ("Commission") the proposed rule change as described in Items I, II, and III below, which Items have been prepared by CBOE. The Commission is publishing this notice to solicit comments on the proposed rule change from interested persons.

I. Self-Regulatory Organization's Statement of the Terms of Substance of the Proposed Rule Change

CBOE proposes to amend certain nonoption listing rules of the Exchange in response to the adoption of Rule 10A— 3 of the Exchange Act.³ Below is the text of the proposed rule change. Proposed new language is italicized; deletions are in brackets.

Rule 31.7 Securities of Foreign Issuers

(1) No change.

(2) The Exchange will consider the law, and commercial and business practice of the applicant's domicile in evaluating (A) the election and composition of its Board of Directors, to the extent such law, and commercial and business practice with respect to the election and composition of its Board of Directors is consistent with the federal securities laws, including, but not limited to, Rule 10A-3 of the Securities Exchange Act of 1934, as

amended, (B) shareholder approval and quorum requirements for meetings, and (C) the issuance of quarterly earnings statements.

(3)–(5) No change.

Rule 31.10 Independent Directors

The Exchange requires an issuer to

have at least two independent directors. For purposes of this section, "independent director" shall mean a person other than an officer or employee of the company or its subsidiaries or any other individual having a relationship which, in the opinion of the board of directors, would interfere with the exercise of independent judgment in carrying out the responsibilities of a director. The issuer shall maintain an audit committee (i) composed of such independent directors[.] and (ii) that complies with the listing standards set forth in Rule 10A–3 of the Securities Exchange Act of 1934, as amended ("Exchange Act"). If a member of the audit committee ceases to be independent in accordance with the requirements of Exchange Act Rule 10A-3 for reasons outside the member's reasonable control, that person, with written notice to the Exchange, may remain an audit committee member of the listed issuer until the earlier of the next annual shareholders meeting of the listed issuer or one year from the occurrence of the event that caused the member to be no longer independent.

Rule 31.94 Suspension and Delisting Policies

(A)–(I) No change.

* * * Interpretations and Policies

.01 With respect to an issuer that does not comply with the requirements of Rule 10A–3 of the Securities Exchange Act of 1934, as amended, as set forth in Rule 31.10, the Exchange shall remove from listing the securities of such issuer.

Rule 31.96 Notices to Exchange

(A) No change.

(B) Changes in Officers or Directors.

A listed company is required to notify the Exchange promptly (and confirm in writing) (i) of any changes of officers or directors and (ii) after an executive officer of the listed company becomes aware of any material noncompliance by the listed company with the requirements of Rule 10A–3 of the Securities Exchange Act of 1934, as amended.

(C)–(G) No change.

Rule 31.97 [Reserved for additional original listing standards.]

Forms for Listing

* * * * * *

Form 1

*

Listing Agreement

_____(the "Company"), in consideration of the listing of its securities, hereby agrees with the Chicago Board Options Exchange, Incorporated (the "Exchange"), that it will:

1. Promptly notify the Exchange of the following:

(a) changes in the general character or nature of its business, its principal executive officers, directors, its independent public accountants, its transfer agent or registrar and material noncompliance by the listed company with Rule 10A–3 of the Securities Exchange Act of 1934, as amended ("Exchange Act"), after an executive officer becomes aware of such noncompliance:

(b)–(k) No change. (2)–(27) No change.

(28) Comply with Exchange rules, policies and procedures as in effect and as they may be amended from time to time and with the requirements of Exchange Act Rule 10A-3.

II. Self-Regulatory Organization's Statement of the Purpose of, and the Statutory Basis for, the Proposed Rule Change

In its filing with the Commission, CBOE included statements concerning the purpose of, and basis for, the proposed rule change and discussed any comments it received on the proposed rule change. The text of these statements may be examined at the places specified in Item IV below. CBOE has prepared summaries, set forth in Sections A, B, and C below, of the most significant aspects of such statements.

A. Self-Regulatory Organization's Statement of the Purpose of, and Statutory Basis for, the Proposed Rule Change

1. Purpose

Exchange Act Rule 10A–3(a)(1) provides that the "rules of each national securities exchange registered pursuant to section 6 of the [Exchange] Act (15 U.S.C. 78f) must, in accordance with the provisions of [Exchange Act Rule 10A–3], prohibit the initial or continued listing of any security of an issuer that

¹ 15 U.S.C. 78s(b)(1).

² 17 CFR 240.19b-4.

³ 17 CFR 240.10A–3. *See* Securities Exchange Act Release No. 47137 (January 8, 2003) 68 FR (date).

is not in compliance with the requirements of any portion of paragraph (b) or (c) of [Exchange Act Rule 10A–3]." Exchange Act Rule 10A–3(b) contains new requirements for an issuer's audit committee and Exchange Act Rule 10A–3(c) provides general exemptions from the requirements of Exchange Act Rule 10A–3. Exchange Act Rule 10A–3(a)(5)(ii) requires CBOE to propose new rules or rule amendments that comply with Exchange Act Rule 10A–3 no later than July 15, 2003.

ČBOE Rules 31.5—31.16 contain the criteria for the original listing of an applicant's non-option securities on CBOE. In particular, CBOE Rule 31.7 provides that with respect to foreign issuers, CBOE will consider the law, and commercial and business practice of the foreign issuer's domicile in evaluating the election and composition of the foreign issuer's Board of Directors. CBOE proposes to add a proviso that makes clear CBOE's intention to consider the law, and commercial and business practice of the foreign issuer's domicile only if such law and practices are consistent with federal securities laws, including Exchange Act Rule 10A-3. CBOE also proposes to amend another original listing criterion, CBOE Rule 31.10, which currently provides in part that "the issuer shall maintain an audit committee composed of * independent directors." To comply with Exchange Act Rule 10A-3, CBOE proposes to amend the quoted language above in CBOE Rule 31.10 by incorporating by reference the listing standards set forth in Exchange Act Rule 10A-3. Specifically, the proposed language in CBOE Rule 31.10 provides in part that "the issuer shall maintain an audit committee (i) composed of such independent directors and (ii) that complies with the listing standards set forth in Rule 10A-3 of the Securities Exchange Act of 1934, as amended." CBOE proposes to amend the listing agreement on CBOE Form 1 so that it conforms to the proposed language set forth above in CBOE Rule 31.10. Proposed CBOE Rule 31.10 also incorporates the language set forth in Exchange Act Rule 10A-3(a)(3) to satisfy the requirement that CBOE provides appropriate procedures for an issuer to have an opportunity to cure any defects that would be the basis for the prohibition of listing the securities of such issuer under Exchange Act Rule 10A - 3(a).

CBOE proposes to add an interpretation to CBOE Rule 31.94 that revises one of CBOE's delisting policies in order to comply with Exchange Act

Rule 10A–3. The revision is required because CBOE Rule 31.94(B)(d) currently permits CBOE's Board of Directors to use its discretion in deciding whether to delist an issuer's non-option securities from trading when, in the opinion of CBOE, "the issuer has failed to comply with its listing agreements" with CBOE. Exchange Act Rule 10A–3(a)(1) makes clear that an exchange may not use discretion in deciding whether to delist a non-option security of an issuer that does not comply with Exchange Act Rule 10A–3.

Exchange Act Rule 10A–3(a)(4) provides that the rules required by Exchange Act Rule 10A–3(a)(1) and (2) must include a requirement that a listed issuer must notify CBOE promptly after an executive officer of the listed issuer becomes aware of any material noncompliance by the listed issuer with the requirements of Exchange Act Rule 10A–3. Proposed Rule 31.96(B) and the listing agreement on CBOE Form 1 are amended to reflect this requirement.

The proposed rule change reserves a new rule, proposed CBOE Rule 31.97, to incorporate additional and enhanced original listing standards for the listing of non-option securities on the Exchange. CBOE understands that the National Association of Securities Dealers, Inc. ("NASD") and the New York Stock Exchange, Inc. ("NYSE") have filed rule proposals with the Commission that strengthen their listing standards by enhancing corporate governance requirements for listed entities.4 Following the Commission's approval of these rule proposals, CBOE intends to submit a rule proposal to the Commission to adopt substantially similar changes to CBOE's original listing rules. For example, consistent with the listing standards that are adopted by NYSE and/or NASD, CBOE intends to revise its original listing rules to, among other things, further address (i) independent director representation on the issuer's Board of Directors; (ii) independent director representation on the issuer's nominating and compensation committees; (iii) shareholder approval requirements of equity-compensation plans, (iv) corporate governance guidelines of issuers; (v) issuer codes of business conduct and ethics; and (vi) the definition of "independent" that is

currently provided for in CBOE Rule 31.10.

2. Statutory Basis

The Exchange believes that the proposed rule change is consistent with Section 6(b) of the Exchange Act,⁵ in general, and furthers the objectives of Sections 6(b)(5) of the Exchange Act, ⁶ in particular, in that it should promote just and equitable principles of trade, serve to remove impediments to and perfect the mechanism of a free and open market and a national market system, and protect investors and the public interest.

B. Self-Regulatory Organization's Statement on Burden on Competition

CBOE does not believe that the proposed rule change will impose any burden on competition not necessary or appropriate in furtherance of the purposes of the Exchange Act.

C. Self-Regulatory Organization's Statement on Comments on the Proposed Rule Change Received From Members, Participants or Others

No written comments were solicited or received with respect to the proposed rule change.

III. Date of Effectiveness of the Proposed Rule Change and Timing for Commission Action

Within 35 days of the date of publication of this notice in the **Federal Register** or within such longer period (i) as the Commission may designate up to 90 days of such date if it finds such longer period to be appropriate and publishes its reasons for so finding or (ii) as to which the self-regulatory organization consents, the Commission will:

(A) By order approve such rule change, or

(B) Institute proceedings to determine whether the proposed rule change should be disapproved.

IV. Solicitation of Comments

Interested persons are invited to submit written data, views and arguments concerning the foregoing, including whether the proposed rule change is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposed rule

⁴ See Securities Exchange Act Release No. 34–47516 (March 17, 2003), 68 FR 14451 (March 25, 2003) (noticing SR–NASD–2002–141) and Securities Exchange Act Release No. 34–47672 (April 11, 2003), 68 FR 19051 (April 17, 2003) (noticing SR–NYSE–2002–33).

⁵ 15 U.S.C. 78f(b).

^{6 15} U.S.C. 78f(b)(5).

change that are filed with the Commission, and all written communications relating to the proposed rule change between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying in the Commission's Public Reference Room. Copies of such filing will also be available for inspection and copying at the principal office of CBOE. All submissions should refer to File No. SR-CBOE-2003-31 and should be submitted by October 23, 2003.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority. 7

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 03-25013 Filed 10-1-03; 8:45 am] BILLING CODE 8010-01-P

SECURITIES AND EXCHANGE COMMISSION

[Release No. 34–48538; File No. SR–PCX–2002–01]

Self Regulatory Organizations; Order Approving Proposed Rule Change and Notice of Filing and Order Granting Accelerated Approval to Amendment No. 3 to the Proposed Rule Change by the Pacific Exchange, Inc., Relating to Procedures for Obvious Errors in Options Transactions

September 25, 2003.

I. Introduction

On January 3, 2002, the Pacific Exchange, Inc. ("PCX" or "Exchange") filed with the Securities and Exchange Commission ("SEC" or "Commission"), pursuant to section 19(b)(1) of the Securities Exchange Act of 1934 ("Act"),¹ and Rule 19b-4 thereunder,² a proposed rule change to adopt an obvious error rule for options transactions. On July 28, 2003, the Exchange submitted Amendment No. 1 to the proposed rule change.³ On August 8, 2003, the Exchange submitted Amendment No. 2 to the proposed rule change, as

amended, was published for comment in the **Federal Register** on August 22, 2003.⁵ The Commission did not receive any comments on the proposed rule change. On September 16, 2003, the PCX filed Amendment No. 3 to the proposed rule change.⁶ This order approves the proposed rule change, as amended, grants accelerated approval to Amendment No. 3, and solicits comments from interested persons on that amendment.

II. Discussion and Commission Findings

The Commission has reviewed carefully the proposed rule change and finds that the proposed rule change is consistent with the requirements of the Act and the rules and regulations thereunder applicable to a national securities exchange.7 In particular, the Commission finds that the proposed rule change is consistent with section 6(b)(5)⁸ of the Act, which requires that the rules of an exchange be designed to prevent fraudulent and manipulative acts and practices, to promote just and equitable principles of trade, to remove impediments to and perfect the mechanism for a free and open market and a national market system, and, in general, to protect investors and the public interest.9

The Commission considers that in most circumstances trades that are executed between parties should be honored. On rare occasions, the price of the executed trade indicates an "obvious error" may exist, suggesting that it is unrealistic to expect that the parties to the trade had come to a meeting of the minds regarding the terms of the transaction. In the Commission's view, the determination of whether such an "obvious error" has occurred should be based on specific and objective criteria and subject to

specific and objective procedures. The Commission believes that the PCX's proposed obvious error rule establishes specific and objective criteria for determining when a trade is an "obvious error." The Commission also believes that the proposal establishes specific and objective procedures governing the adjustment or nullification of such trade. In addition, the Commission notes that several provisions of the PCX obvious error rule proposal, as amended, are substantially similar to proposed rule changes submitted by the Chicago Board Options Exchange, Inc. and International Securities Exchange, Inc., which the Commission has approved. 10

The Commission finds good cause for approving Amendment No. 3 to the proposed rule change prior to the thirtieth day after the date of publication of notice thereof in the Federal Register. Amendment No. 3 does not make any substantive changes to the proposed rule text. It simply clarifies the determination of an obvious price error and the definition of a transaction executed below parity. Therefore, the Commission believes that granting accelerated approval of Amendment No. 3 is appropriate and consistent with section 6(b)(5)11 and section 19(b)12 of the Act.

III. Solicitation of Comments

Interested persons are invited to submit written data, views, and arguments concerning Amendment No. 3, including whether Amendment No. 3 is consistent with the Act. Persons making written submissions should file six copies thereof with the Secretary, Securities and Exchange Commission, 450 Fifth Street, NW., Washington, DC 20549–0609. Copies of the submission, all subsequent amendments, all written statements with respect to the proposal that are filed with the Commission, and all written communications relating to the proposal between the Commission and any person, other than those that may be withheld from the public in accordance with the provisions of 5 U.S.C. 552, will be available for inspection and copying at the Commission's Public Reference Room. Copies of such filing will also be available for inspection and copying at the principal office of the Exchange. All submissions should refer to File No.

^{7 17} CFR 200.30-3(a)(12).

¹ 15 U.S.C. 78s(b)(1).

² 17 CFR 240.19b-4.

³ See Letter from Mai S. Shiver, Senior Attorney, Regulatory Policy, Exchange, to Nancy J. Sanow, Assistant Director, Division of Market Regulation ("Division"), Commission, dated July 25, 2003 ("Amendment No. 1"). Amendment No. 1 supersedes and replaces the proposed rule change in its entirety.

⁴ See Letter from Mai S. Shiver, Senior Attorney, Regulatory Policy, Exchange, to Nancy J. Sanow,

Assistant Director, Division, Commission, dated August 7, 2003 ("Amendment No. 2"). Amendment No. 2 supersedes and replaces the proposed rule change and Amendment No. 1 in their entirety.

⁵ See Securities Exchange Act Release No. 48342 (August 14, 2003), 68 FR 50820 (August 22, 2003) ("Notice").

⁶ See Letter from Mai S. Shiver, Senior Attorney, Regulatory Policy, Exchange, to Nancy J. Sanow, Assistant Director, Division, Commission, dated September 15, 2003 ("Amendment No. 3"). In Amendment No. 3, the Exchange amended proposed PCX Rule 6.87(g)(2)(E) to clarify a provision relating to the determination of an obvious price error and amended proposed PCX Rule 6.87(g)(2)(G) to clarify the definition of "parity."

⁷ For a description of the proposed rule change, see Notice, supra, n.4.

^{8 15} U.S.C. 78f(b)(5).

⁹ In approving this proposed rule change, the Commission notes that it has considered the proposed rule's impact on efficiency, competition, and capital formation. 15 U.S.C. 78c(f).

¹⁰ See Securities Exchange Act Release No. 47628 (April 3, 2003), 68 FR 17697 (April 10, 2003) (SR–CBOE–00–55); Securities Exchange Act Release No. 48097 (June 26, 2003), 68 FR 39604 (July 2, 2003) (SR–ISE–2003–10).

^{11 15} U.S.C. 78f(b)(5).

^{12 15} U.S.C. 78s(b).

SR-PCX-2002-01 and should be submitted by October 23, 2003.

IV. Conclusion

For the reasons discussed above, the Commission finds that the proposal, as amended, is consistent with the Act and the rules and regulations thereunder.

It is therefore ordered, pursuant to section 19(b)(2) of the Act,13 that the proposed rule change (SR-PCX-2002-01), as amended, be, and hereby is, approved, and that Amendment No. 3 to the proposed rule change be, and hereby is, approved on an accelerated basis.

For the Commission, by the Division of Market Regulation, pursuant to delegated authority.14

Margaret H. McFarland,

Deputy Secretary.

[FR Doc. 03-24951 Filed 10-1-03; 8:45 am] BILLING CODE 8010-01-P

SMALL BUSINESS ADMINISTRATION [Declaration of Disaster #3551]

State of Delaware

As a result of the President's major disaster declaration on September 23, 2003, I find that New Castle County in the State of Delaware constitutes a disaster area due to damages caused by Tropical Storm Henri occurring on September 15, 2003. Applications for loans for physical damage as a result of this disaster may be filed until the close of business on November 24, 2003 and for economic injury until the close of business on June 23, 2004 at the address listed below or other locally announced locations: U.S. Small Business Administration, Disaster Area 1 Office. 360 Rainbow Blvd., South 3rd Fl., Niagara Falls, NY 14303-1192.

In addition, applications for economic injury loans from small businesses located in the following contiguous counties may be filed until the specified date at the above location: Kent County in the State of Delaware; Cecil and Kent Counties in the State of Maryland: Gloucester and Salem Counties in the State of New Jersey; and Chester and Delaware Counties in the Commonwealth of Pennsylvania.

The interest rates are:

	Percent
For Physical Damage: Homeowners with Credit Available Elsewhere Homeowners without Credit Available Elsewhere	5.125 2.562

^{13 15} U.S.C. 78s(b)(2).

	Percent
Businesses with Credit Available Elsewhere	6.199
ganizations without Credit Available Elsewhere Others (Including Non-Profit Or-	3.100
ganizations) with Credit Avail- able Elsewhere	5.500
Businesses and Small Agricul- tural Cooperatives without Credit Available Elsewhere	3.100

The number assigned to this disaster for physical damage is 355108. For economic injury the number is 9X1300 for Delaware; 9X1400 for Maryland; 9X1500 for New Jersey; and 9X1600 for Pennsylvania.

(Catalog of Federal Domestic Assistance Program Nos. 59002 and 59008).

Dated: September 24, 2003.

Cheri L. Cannon,

Acting Associate Administrator for Disaster Assistance.

[FR Doc. 03–25033 Filed 10–1–03; 8:45 am] BILLING CODE 8025-01-P

SMALL BUSINESS ADMINISTRATION

[Declaration of Economic Injury Disaster #9X061

State of Oregon

Deschutes and Jefferson Counties and the contiguous counties of Crook, Harney, Klamath, Lake, Lane, Linn, Marion, Wasco and Wheeler in the State of Oregon constitute an economic injury disaster area as a result of a wildfire known as the B & B Complex wildfire that began on August 19, 2003 and continues to burn. The wildfire caused the closure of Highway 20/126 for approximately two weeks and has caused several businesses to suffer substantial economic losses. Eligible small businesses and small agricultural cooperatives without credit available elsewhere may file applications for economic injury assistance for this disaster until the close of business on June 28, 2004 at the address listed below or other locally announced locations: U.S. Small Business Administration, Disaster Area 4 Office, P.O. Box 13795, Sacramento, CA 95853-4795.

The interest rate for eligible small businesses and small agricultural cooperatives is 3.100 percent.

The number assigned for economic injury for this disaster is 9X0600.

(Catalog of Federal Domestic Assistance Program No. 59002.)

Dated: September 26, 2003.

Hector V. Barreto,

Administrator. [FR Doc. 03-25031 Filed 10-1-03; 8:45 am] BILLING CODE 8025-01-P

SMALL BUSINESS ADMINISTRATION

[Declaration of Disaster #3546]

Commonwealth of Virginia (Amendment #2)

In accordance with a notice received from the Department of Homeland Security—Federal Emergency Management Agency, effective September 22, 2003, the above numbered declaration is hereby amended to include the Independent Cities of Bedford, Buena Vista, Charlottesville, Fredericksburg, Harrisonburg, Lynchburg, Manassas, Manassas Park, and Winchester, and the counties of Albemarle, Amelia, Amherst, Appomattox, Bedford, Buckingham, Campbell, Charlotte, Clarke, Culpeper, Cumberland, Dinwiddie, Fauquier, Frederick, Greene, Halifax, Hanover, King George, King William, King and Queen, Louisa, Loudoun, Lunenburg, Madison, Nelson, New Kent, Nottoway, Pittsylvania, Powhatan, Prince Edward, Rappahannock, Rockingham, Shenandoah, and Warren in the Commonwealth of Virginia as disaster areas due to damages caused by Hurricane Isabel occurring on September 18, 2003 and continuing.

In addition, applications for economic injury loans from small businesses located in the contiguous counties of Franklin, Henry, and Roanoke in the Commonwealth of Virginia; Berkeley, Hampshire, Hardy, Jefferson, and Morgan Counties in the State of West Virginia; Frederick and Washington Counties in the State of Maryland; and Caswell, Person, and Rockingham Counties in the State of North Carolina may be filed until the specified date at the previously designated location. All other counties contiguous to the above named independent cities and primary counties have been previously declared.

All other information remains the same, *i.e.*, the deadline for filing applications for physical damage is November 17, 2003, and for economic injury the deadline is June 18, 2004. (Catalog of Federal Domestic Assistance Program Nos. 59002 and 59008).

^{14 17} CFR 200.30-3(a)(12).

Dated: September 25, 2003.

Cheri L. Cannon,

Acting Associate Administrator for Disaster Assistance.

[FR Doc. 03–25032 Filed 10–1–03; 8:45 am] BILLING CODE 8025–01–P

SMALL BUSINESS ADMINISTRATION

[Declaration of Disaster #P017]

State of West Virginia

As a result of the President's major disaster declaration for Public Assistance on September 23, 2003 the U.S. Small Business Administration is activating its disaster loan program only for private non-profit organizations that provide essential services of a governmental nature. I find that Berkeley, Grant, Hampshire, Hardy, Jefferson, Mineral, Morgan, Pendleton, Randolph and Tucker Counties in the State of West Virginia constitute a disaster area due to damages caused by Hurricane Isabel occurring on September 18, 2003 and continuing. Applications for loans for physical damage as a result of this disaster may be filed until the close of business on November 24, 2003 at the address listed below or other locally announced locations: U.S. Small Business Administration, Disaster Area 1 Office. 360 Rainbow Blvd., South, 3rd Floor, Niagara Falls, NY 14303.

The interest rates are:

	Percent
For Physical Damage:	
Non-Profit Organizations with-	
out Credit Available Else-	
where	3.100
Non-Profit Organizations with	
Credit Available Elsewhere	5.500

The number assigned to this disaster for physical damage is P01708.

(Catalog of Federal Domestic Assistance Program Nos. 59008)

Dated: September 25, 2003.

Cheri L. Cannon,

Acting Associate Administrator for Disaster Assistance.

[FR Doc. 03–25034 Filed 10–1–03; 8:45 am] BILLING CODE 8025–01–P

DEPARTMENT OF STATE

[Public Notice 4502]

Bureau of Political-Military Affairs; 30-Day Notice of Proposed Information Collection: Form DS-4028, Request for Approval of Technical Assistance Agreement Cover Letter; Form DS-4029, Request for Approval of Technical Assistance Agreement; OMB Control Number 1405-0148

AGENCY: Department of State.

ACTION: Notice.

SUMMARY: The Department of State has submitted the following information collection request to the Office of Management and Budget (OMB) for approval in accordance with the Paperwork Reduction Act of 1995. Comments should be submitted to OMB within 30 days of the publication of this notice.

The following summarizes the information collection proposal submitted to OMB:

Type of Request: Extension of a Currently Approved Collection.

Originating Office: Bureau of Political-Military Affairs, Directorate of Defense Trade Controls, PM/DDTC.

Title of Information Collection: Request for Approval of Technical Assistance Agreement Cover Letter and Request for Approval of Technical Assistance Agreement.

Frequency: On occasion.
Form Number: DS-4028 and DS-

Form Number: DS-4028 and DS-4029.

Respondents: Businesses.

Estimated Number of Respondents: 13.

Average Hours Per Response: 2 hours. Total Estimated Burden: 2,000 hours, (Total Estimated Burden based on number of forms received per year.)

Public comments are being solicited to permit the agency to:

- Evaluate whether the proposed collection of information is necessary for the proper performance of the functions of the agency, including whether the information will have practical utility.
- Evaluate the accuracy of the agency's estimate of the burden of the collection, including the validity of the methodology and assumptions used.
- Enhance the quality, utility, and clarity of the information to be collected.
- Minimize the reporting burden on those who are to respond, including through the use of automated collection techniques or other forms of technology.

FOR FURTHER INFORMATION CONTACT:

Copies of the proposed information

collection and supporting documents may be obtained from Michael T. Dixon, Director, Office of Defense Trade Controls Management, Directorate of Defense Trade Controls, Bureau of Political-Military Affairs, SA-1, Room H1200, 2401 E Street, NW., Washington, DC 20522-0112; (202) 663-2700. Public comments and questions should be directed to State Department Desk Officer, Office of Information and Regulatory Affairs, Office of Management and Budget (OMB), Washington, DC 20530, who may be reached on (202) 395-3897.

Dated: September 16, 2003.

Gregory M. Suchan,

Deputy Assistant Secretary for Defense Trade Controls, Bureau of Political-Military Affairs, Department of State.

[FR Doc. 03–25022 Filed 10–1–03; 8:45 am] BILLING CODE 4710–25–P

DEPARTMENT OF STATE

[Public Notice 4501]

Redesignation of Foreign Terrorist Organizations

Pursuant to section 219 of the Immigration and Nationality Act, as amended, 8 U.S.C. 1189, the Secretary of State or the Deputy Secretary of State, in consultation with the Secretary of the Treasury and the Attorney General, hereby redesignates, effective October 2, 2003, the following organizations as foreign terrorist organizations:

Abu Nidal Organization

Also known as ANO

Also known as Black September Also known as the Fatah Revolutionary Council

Also known as the Arab Revolutionary Council

Also known as the Arab Revolutionary Brigades

Also known as the Revolutionary Organization of Socialist Muslims

Abu Sayyaf Group

Also known as Al Harakat Al Islamiyya

Armed Islamic Group

Also known as GIA

Also known as Groupement Islamique Arme

Also known as Al-Jama'ah al-Islamiyah al-Musallah

Aum Shinrikyo

Also known as Aleph Also known as Aum Supreme Truth Also known as A.I.C. Sogo Kenkyusho Also known as A.I.C. Comprehensive Research Institute

Basque Fatherland and Liberty

Also known as Euzkadi Ta Askatasuna

Also known as ETA

Also known as Batasuna

Also known as Euskal Herritarrok

Also known as Herri Batasuna

Also known as Ekin

Also known as K.A.S.

Also known as Xaki

Also known as Jarrai-Haika-Segi

Also known as Askatasuna

Gama'a al-Islamiyya

Also known as the Islamic Group

Also known as IG

Also known as al-Gama'at

Also known as Islamic Gama'at

Also known as Egyptian al-Gama'at al-Islamivva

Also known as GI

HAMAS

Also known as the Islamic Resistance Movement

Also known as Harakat al-Muqawama al-Islamiva

Also known as Students of Avvash

Also known as Students of the Engineer

Also known as Yahya Ayyash Units

Also known as Izz Al-Din Al-Qassim Brigades

Also known as Izz Al-Din Al-Qassim Forces

Also known as Izz Al-Din Al-Qassim **Battalions**

Also known as Izz al-Din Al-Qassam

Brigades Also known as Izz al-Din Al-Qassam

Also known as Izz al-Din Al-Qassam **Battalions**

Harakat ul-Muiahideen

Also known as HUM

Also known as Harakat ul-Ansar

Also known as HUA

Also known as Jamiat ul-Ansar

Hizballah

Also known as the Party of God

Also known as Islamic Jihad

Also known as Islamic Jihad

Organization

Also known as Revolutionary Justice Organization

Also known as Organization of the Oppressed on Earth

Also known as Islamic Jihad for the

Liberation of Palestine Also known as Organization of Right

Against Wrong Also known as Ansar Allah

Also known as Followers of the Prophet Muhammed

al-Jihad

Also known as Egyptian al-Jihad

Also known as New Jihad

Also known as Egyptian Islamic Jihad

Also known as Jihad Group

Kahane Chai

Also known as Kach

Also known as Kahane Lives

Also known as the Kfar Tapuah Fund

Also known as The Judean Voice

Also known as The Judean Legion Also known as The Way of the Torah

Also known as The Yeshiva of the

Iewish Idea

Also known as the Repression of Traitors

Also known as Dikuy Bogdim

Also known as DOV

Also known as the State of Judea

Also known as the Committee for the Safety of the Roads

Also known as the Sword of David

Also known as Iudea Police

Also known as Forefront of the Idea

Also known as The Qomemiyut Movement

Also known as KOACH

Also known as New Kach Movement

Also known as newkach.org

Also known as Kahane

Also known as Yeshivat HaRav Meir

Also known as the International Kahane Movement

Also known as Kahane.org

Also known as Kahane.net

Also known as Kahanetzadak.com

Also known as Kahane Tzadak

Also known as the Hatikva Jewish **Identity Center**

Also known as the Rabbi Meir David Kahane Memorial Fund

Also known as Friends of the Jewish Idea Yeshiva

Also known as Iudean Congress Also known as Jewish Legion

Also known as The Voice of Judea

Also known as No'ar Meir

Also known as Meir's Youth

Also known as American Friends of Yeshivat Rav Meir

Also known as American Friends of the United Yeshiva Movement

Also known as The Committee Against Racism and Discrimination (CARD)

Kurdistan Workers' Party

Also known as Partiya Karkeran Kurdistan

Also known as the PKK

Also known as the Kurdistan Freedom and Democracy Congress

Also known as KADEK

Also known as Freedom and Democracy Congress of Kurdistan

Also known as the People's Defense Force

Also known as Halu Mesru Savunma Kuvveti (HSK)

Liberation Tigers of Tamil Eelam

Also known as the LTTE

Also known as the Tamil Tigers

Also known as the Ellalan Force

Mujahedin-e Khalq Organization

Also known as Mujahedin-e Khalq

Also known as MEK

Also known as MKO

Also known as People's Mujahedin Organization of Iran (including its U.S. representative office and all other offices worldwide)

Also known as PMOI

Also known as Organization of the People's Holy Warriors of Iran

Also known as Sazeman-e Mujahedin-e Khalq-e Iran

Also known as National Council of Resistance (including its U.S. representative office and all other offices worldwide)

Also known as NCR

Also known as National Council of Resistance of Iran (including its U.S. representative office and all other offices worldwide)

Also known as NCRI

Also known as the National Liberation Army of Iran

Also known as NLA

Also known as Muslim Iranian Student's Society

National Liberation Army

Also known as the ELN Also known as Ejercito de Liberacion

Palestine Islamic Jihad—Shaqaqi **Faction**

Also known as PIJ-Shaqaqi Faction

Also known as PIJ-Shallah Faction

Also known as Palestinian Islamic Jihad

Nacional

Also known as PIJ Also known as Islamic Jihad of Palestine

Also known as Islamic Jihad in Palestine

Also known as Abu Ghunaym Squad of the Hizballah Bayt Al-Maqdis

Also known as the Al-Quds Squads

Also known as Al-Awdah Brigades

Also known as the Al-Quds Brigades Also known as Saraya Al-Quds

Palestine Liberation Front—Abu Abbas **Faction**

Also known as the Palestine Liberation Front

Also known as the PLF

Also known as PLF-Abu Abbas

Popular Front for the Liberation of **Palestine**

Also known as the PFLP

Also known as the Red Eagles

Also known as the Red Eagle Group

Also known as the Red Eagle Gang

Also known as the Halhul Gang Also known as the Halhul Squad

Also known as Palestinian Popular Resistance Forces

Also known as PPRF Also known as Martyr Abu-Ali Mustafa Battalion

Popular Front for the Liberation of Palestine—General Command

Also known as PFLP-GC

al-Qa'ida

Also known as al Qaeda Also known as "the Base" Also known as the Islamic Army Also known as the World Islamic Front for Jihad Against Jews and Crusaders Also known as the Islamic Army for the Liberation of the Holy Places Also known as the Usama Bin Laden Network

Also known as the Usama Bin Laden Organization

Also known as Islamic Salvation Foundation

Also known as The Group for the
Preservation of the Holy Sites
Also known as Egyptian Islamic Jihad
Also known as al-Jihad
Also known as the Jihad Group
Also known as Egyptian al-Jihad
Also known as New Jihad

Revolutionary Armed Forces of Colombia

Also known as FARC Also known as Fuerzas Armadas Revolucionarias de Colombia

Revolutionary Nuclei

Also known as Epanastatiki Pirines Also known as Revolutionary People's Struggle

Also known as Epanastatikos Laikos Agonas

Also known as ELA

Also known as Revolutionary Popular Struggle

Also known as Popular Revolutionary Struggle

Also known as June 78

Also known as Organization of Revolutionary Internationalist Solidarity

Also known as Revolutionary Cells Also known as Liberation Struggle

Revolutionary Organization 17 November

Also known as 17 November Also known as Epanastatiki Organosi 17 Noemvri

Revolutionary People's Liberation Party/Front

Also known as the Devrimci Halk Kurtulus Partisi-Cephesi Also known as the DHKP/C Also known as Devrimci Sol Also known as Revolutionary Left Also known as Dev Sol Also known as Dev Sol Silahli Devrimci

Birlikleri

Also known as Dev Sol SDB Also known as Dev Sol Armed Revolutionary Units

Shining Path

Also known in Spanish as Sendero Luminoso

Also known as SL

Also known as Partido Comunista del Peru en el Sendero Luminoso de Jose Carlos Mariategui (Communist Party of Peru on the Shining Path of Jose Carlos Mariategui)

Also known as Partido Comunista del Peru (Communist Party of Peru)

Also known as PCP

Also known as Socorro Popular del Peru (People's Aid of Peru)

Also known as SPP

Also known as Ejercito Guerrillero Popular (People's Guerrilla Army) Also known as EGP

Also known as Ejercito Popular de Liberacion (People's Liberation Army) Also known as the EPL

Dated: September 26, 2003.

Cofer Black,

Ambassador, Coordinator for Counterterrorism, Department of State. [FR Doc. 03–25017 Filed 10–1–03; 5 pm] BILLING CODE 4710–10–P

DEPARTMENT OF STATE

[Delegation of Authority 262]

Office of the Deputy Secretary; Redelegation of Authorities by the Deputy Secretary of State, to the Administrator of the United States Agency for International Development

By the authority vested in me as Deputy Secretary of State, including the authority delegated to me by the Secretary of State in Delegation of Authority No. 245 of April 23, 2001, and by Section 1 of the State Department Basic Authorities Act (22 U.S.C. 2651A), I hereby delegate to the Administrator of the U.S Agency for International Development, to the extent authorized by law, the functions conferred upon the Secretary of State by the President relating to loan guarantees to Israel under chapter 5 of title I of the Emergency Wartime Supplemental Appropriations Act, 2003 (Public Law 108-11).

Notwithstanding this delegation of authority, the Secretary of State or Deputy Secretary of State may exercise any function delegated hereby. The Administrator may, to the extent consistent with law, redelegate such functions and authorize their successive redelegation.

This memorandum shall be published in the **Federal Register**.

Dated: September 13, 2003.

Richard L. Armitage,

Deputy Secretary of State, Department of State.

[FR Doc. 03–25021 Filed 10–1–03; 8:45 am] BILLING CODE 4710–10–P

DEPARTMENT OF TRANSPORTATION

Federal Highway Administration

Environmental Impact Statement: Montgomery and Grimes Counties, TX

AGENCY: Federal Highway Administration (FHWA), DOT.

ACTION: Notice of intent.

SUMMARY: The FHWA is issuing this notice to advise the public that an environmental impact statement will be prepared for a proposed transportation project in Montgomery and Grimes Counties, Texas.

FOR FURTHER INFORMATION CONTACT: Mr. John Mack, P.E., Federal Highway Administration, Texas Division, 826 Federal Building, 300 East 8th Street, Austin, Texas 78701, Telephone (512) 536–5960.

SUPPLEMENTARY INFORMATION: The FHWA, in cooperation with the Texas Department of Transportation (TxDOT) will prepare an environmental impact statement (EIS) for improvements in the SH 249 corridor within Montgomery and Grimes Counties, Texas. The project study area is approximately 15 miles in length from FM 149 in Montgomery County to FM 1774 in Grimes County. Cities within the study area include Pinehurst, Magnolia, and Todd Mission.

A Major Investment Study (MIS) for the project was completed in 2002. The MIS evaluated modal, configuration, and route corridor alternatives within the overall study area and recommended an alternative which was the most feasible modal, configuration, and route corridor that met the regions transportation needs, while minimizing impacts to the surrounding environment. The most feasible corridor alternative studied in the MIS was selected based on the detailed evaluation of the viable alternatives, as well as public input. This alternative encompasses two (2) general-purpose lanes in each direction, including auxiliary lanes between on-ramps and off-ramps where appropriate. The EIS will study in detail the preferred route corridor that was selected in the MIS and recommend a preferred alternative alignment within this corridor. The EIS is authorized pursuant to the Texas Transportation Commission Minute

Order No. 104908 issued January 26, 1995.

A public scoping meeting will be held in the fall of 2003. The purpose of the public scoping meeting is to request comments and identify issues that will be considered during the evaluation of alignment alternatives and preparation of the EIS. All interested citizens are encouraged to attend these meetings. Large-scale maps of the project area will be displayed at the meeting. This will be the first in a series of meetings to solicit public comments on the proposed action. In addition, a public hearing will be held.

The EIS will evaluate potential impacts from construction and operation of the proposed roadway including, but not limited to, the following: transportation impacts (construction detours, construction traffic, mobility improvement and evacuation improvement), air, and noise impacts from construction equipment and operation of the facilities, water quality impacts from construction area and roadway storm water runoff, impacts to water of the United States including wetlands from right-of-way encroachment, impacts to historic and archaeological resources, impacts to floodplains, and impacts and/or potential displacements to residents and businesses.

Letters describing the proposed action and soliciting comments will be sent to appropriate Federal, State and Local agencies, and private organizations and citizens who have previously expressed or are known to have interest in this proposal. To ensure that the full range of issues related to this proposed action are addressed and all significant issues identified, comments and suggestions are invited from all interested parties. Comments or questions concerning this proposed action and the EIS should be directed to FHWA at the address above.

(Catalog of Federal Domestic Assistance Program Number 20.205 Highway Planning and Construction. The regulations implementing Executive Order 12372 regarding governmental consultation on Federal programs and activities apply to this program.)

John R. Mack,

District Engineer.

[FR Doc. 03–25008 Filed 10–1–03; 8:45 am] **BILLING CODE 4910–22–M**

DEPARTMENT OF TRANSPORTATION

Federal Motor Carrier Safety Administration

[Docket No. FMCSA-2001-11060]

Availability of an Environmental Assessment for the Certification of Safety Auditors, Safety Investigators, and Safety Inspectors Interim Final Rule

AGENCY: Federal Motor Carrier Safety Administration (FMCSA), DOT.

ACTION: Notice of availability; request for comments.

SUMMARY: The Federal Motor Carrier Safety Administration (FMCSA) announces the availability of the Environmental Assessment for the Certification of Safety Auditors, Safety Investigators, and Safety Inspectors interim final rule (67 FR 12776, Mar. 19, 2002) (commonly referred to as the "Certification" rule). This announcement is pursuant to the National Environmental Policy Act of 1969 (NEPA), as amended; the Council on Environmental Quality Regulations implementing NEPA (40 CFR parts 1500-1508); and U.S. Department of Transportation (DOT) Order 5610.1C, Procedures for Considering Environmental Impacts, dated September 18, 1979, as amended July 13, 1982, and July 30, 1985. The Certification rule was one of three interim final rules set aside by the U.S. Court of Appeals for the Ninth Circuit on January 16, 2003. The court concluded that FMCSA failed to comply with statutory environmental impact analysis requirements in developing these rules. Accordingly, FMCSA has analyzed the potential environmental impacts from implementation of the Certification rule. The agency has concluded that implementing the rule's requirements would have no adverse environmental consequences and in fact would be likely to have a positive, if minimal, impact on the affected environment.

DATES: Submit comments on or before November 3, 2003.

ADDRESSES: You may submit comments identified by DOT DMS Docket Number FMCSA-2001-11060 by any of the following methods:

- Web site: http://dms.dot.gov. Follow the instructions for submitting comments on the DOT electronic docket site.
 - Fax: 1-202-493-2251.
- Mail: Docket Management Facility,
 U.S. Department of Transportation, 400
 Seventh Street, SW, Nassif Building,

Room PL-401, Washington, DC 20590-0001.

- Hand Delivery: Room PL-401 on the plaza level of the Nassif Building, 400 Seventh Street, SW, Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.
- Federal eRulemaking Portal: Go to http://www.regulations.gov. Follow the online instructions for submitting comments.

Instructions: All submissions must include the agency name and docket number for this notice. Note that all comments received will be posted without change to http://dms.dot.gov including any personal information provided. Please see the Privacy Act heading for further information.

Docket: For access to the docket to read background documents or comments received, go to http://dms.dot.gov and/or Room PL-401 on the plaza level of the Nassif Building, 400 Seventh Street, SW, Washington, DC, between 9 a.m. and 5 p.m., Monday through Friday, except Federal holidays.

Privacy Act: Anyone may search the electronic form of all comments received into any of DOT's dockets by the name of the individual submitting the comment (or of the person signing the comment, if submitted on behalf of an association, business, labor union, or other entity). You may review DOT's complete Privacy Act Statement in the Federal Register (65 FR 19477, Apr. 11, 2000). This statement is also available at http://dms.dot.gov.

FOR FURTHER INFORMATION CONTACT:

Mary Pat Woodman, Chief of the Enforcement and Compliance Division (MC–ECE), (202) 366–9699, FMCSA, 400 Seventh Street, SW., Washington, DC 20590.

SUPPLEMENTARY INFORMATION:

Background

Sec. 210 of the Motor Carrier Safety Improvement Act (MCSIA) of 1999 (Pub. L. 106-159, 113 Stat. 1748) directs that all motor carriers (both foreign and domestic) granted new operating authority must undergo a safety audit within 18 months of commencing operations in interstate commerce in the United States [49 U.S.C. 31144(b)]. Sec. 211 of the MCSIA requires that any safety audit conducted after December 31, 2002, be performed by a certified motor carrier safety auditor [49 U.S.C. 31148(b)]. The legislation also gives the Secretary of Transportation (Secretary) authority to decertify a safety auditor and extend the December 31, 2002, compliance deadline [49 U.S.C. 31148 (e) and (c)]. On July 17, 2003, the Secretary notified the Senate Committee

on Commerce, Science, and Transportation and the House of Representatives Committee on Transportation and Infrastructure that he had extended the compliance deadline to December 31, 2003. FMCSA notified the public of this extension (68 FR 44378, Jul. 28, 2003).

As required by Sec. 211, the agency published an interim final rule, Certification of Safety Auditors, Safety Investigators, and Safety Inspectors, establishing procedures to certify and maintain certification for safety auditors, inspectors, and investigators (67 FR 12776, Mar. 19, 2002). This rule amends 49 CFR parts 350 and 385 to provide for three types of certification: (1) Certification to conduct safety audits, (2) certification to conduct compliance reviews, and (3) certification to conduct roadside vehicle and driver inspections. FMCSA determined the Certification rule was not subject to environmental analysis due to a categorical exclusion from statutory requirements. The rule took effect on July 17, 2002.

The 2002 DOT Appropriations Act (Pub. L. 107-87) stipulated that FMCSA could not begin processing applications to allow Mexico-domiciled motor carriers to operate in the United States beyond the border commercial zones in accordance with the North American Free Trade Agreement (NAFTA) until FMCSA published, among other things, a number of regulations including the Certification rule (a condition again imposed in the 2003 Appropriations Act). Another precondition for processing such applications was publication of a rule implementing Sec. 210 of the MCSIA. An interim final rule, New Entrant Safety Assurance Process (New Entrant rule) establishing procedures to heighten the agency's safety scrutiny of new entrant motor carriers, including standards and procedures regarding the safety audits mandated by Sec. 210, was published on May 13, 2002 (67 FR 31978, May 13, 2002) and became effective on January

On January 16, 2003, the U.S. Court of Appeals for the Ninth Circuit set aside the Certification rule and two other FMCSA rules that established application and safety monitoring procedures for Mexico-domiciled motor carriers seeking authority to operate in the United States. The court concluded that FMCSA failed to comply with statutory environmental impact analysis requirements in developing these regulations. *Public Citizen* v. *DOT*, 316 F.3d 1002 (9th Cir. 2003). Specifically with respect to the Certification rule, the court determined that because the rule

did not fall within any of the existing DOT categorical exclusions, FMCSA acted arbitrarily and capriciously by failing to at least conduct an Environmental Assessment (EA) of the rule. DOT's petition for rehearing was denied on April 10, 2003. Consequently, the court's mandate setting aside the three rules took effect on April 18, 2003. On September 8, 2003, the United States sought Supreme Court review of the Ninth Circuit decision as to the application and safety monitoring rules, but not the Certification rule.

On August 26, 2003, FMCSA issued a notice to advise the public that a Programmatic Environmental Impact Statement (PEIS) will be prepared pursuant to NEPA and a General Conformity Evaluation will be made pursuant to the Clean Air Act before promulgating the regulations establishing the application and safety monitoring procedures for Mexicodomiciled carriers (68 FR 51322). The Notice stated that FMCSA was preparing an EA for the Certification rule and that a supplemental Notice of Intent would be issued if, based on the EA, FMCSA determined that preparation of a PEIS is required.

Summary of Environmental Assessment

FMCSA limited its analysis to those environmental resources—land use, traffic and congestion, air quality, noise, and public safety and health-that could be affected by implementation of the safety auditor certification procedures. The certification process preserves and formalizes training requirements and practices that have been in effect within the DOT system for more than 20 years. Implementing the proposed procedures would not require FMCSA to engage in any new activities. Although the New Entrant rule created a new kind of review—the "safety audit" of new entrant carriers—the training required for safety auditor certification is merely a simplified, less comprehensive version of that required to conduct compliance reviews and roadside vehicle and driver inspections.

For each type of certification, initial and refresher training would take place at existing classroom facilities. Audits, inspections and compliance reviews necessary to obtain and maintain certification would be conducted at carrier facilities, weigh stations and other inspection facilities, or by use of existing mobile equipment. No additional facilities or roadways would need to be built. Further, as the certification program would not, in and of itself, increase the number of inspections performed, commercial vehicular traffic congestion and

associated air emissions would not increase. Because the Certification rule would not affect construction activity or commercial vehicular traffic, it would not have an adverse impact on air quality and noise levels or increase existing land use.

Generally, an action that involves operational changes or construction of facilities would have potential impacts on a range of environmental characteristics, including visual, cultural, and aesthetic resources, geology and soils, water resources and hydrology, biological and ecological resources, energy consumption, socioeconomics, and environmental justice. However, because the employee certification process would not increase commercial vehicular traffic, alter established safety oversight activities, or require construction of new facilities, it would have no measurable impact in these conventional analysis areas.

As required by DOT Order 5610.1C and the Council on Environmental Quality's regulations implementing NEPA, FMCSA also analyzed the potential environmental impact of failure to implement the proposed certification procedures (the No Action Alternative). Under this scenario, the agency would withdraw the Certification rule and make no changes to the safety fitness regulations at 49 CFR part 385. In addition, we considered two alternative actions: (1) restricting the grandfather period for the certification program to those safety employees who were fully trained before December 9, 1999, and (2) codifying the training requirements. We judged all three alternatives to be inadequate.

Under the No Action Alternative, the inability to hire certified safety employees could diminish the government's ability to identify unsafe motor carriers, vehicles, and drivers. This would adversely impact public safety and be likely to hinder FMCSA's achievement of continued reductions in commercial vehicle-related accidents and fatalities. Limiting the grandfather period would impose significant costs and burdens on FMCSA as well as on State and local governments, while producing little if any safety benefit. Codification of the training requirements would make the certification program less flexible by hampering the agency's ability to quickly modify course content in response to regulatory or circumstantial changes.

The certification alternative is intended to promote more accurate compliance reviews, safety audits, and inspections by ensuring that these activities are conducted by highly trained personnel certified by FMCSA or by State or local governments. To the extent that implementation of the certification process increases the government's ability to identify potentially unsafe carriers and vehicles and remove them from the Nation's roads, it would have positive, if minimal, effects on air quality, noise levels, and public safety. Accordingly, FMCSA anticipates that implementation of the Certification rule would produce a net positive impact on the quality of the human environment. The agency's full Environmental Assessment is available in this docket.

As noted in the Background section of this document, the 2002 and 2003 DOT Appropriations Acts made issuance of the Certification rule a precondition to FMCSA's expenditure of funds on the processing of Mexico-domiciled motor carrier applications for authority to operate beyond the border commercial zones. Nevertheless, the EA does not attempt to analyze the prospective environmental impacts of Mexicodomiciled carriers operating in the United States. This is because the environmental analysis of such operations, in the form of a PEIS and General Conformity Evaluation required by the Ninth Circuit decision, is already being undertaken with respect to two other rules discussed above (establishing application and safety monitoring procedures for Mexicodomiciled carriers) that are preconditions to the processing of applications of Mexican carriers for beyond-the-border-commercial-zones operating authority. Unless the Ninth Circuit decision is reversed or the relevant terms of the DOT Appropriations Acts are not extended, FMCSA cannot process applications of Mexico-domiciled motor carriers seeking authority to operate beyond the border commercial zones until the PEIS and General Conformity Evaluation have been completed and considered by FMCSA. Thus, no operations of Mexican-domiciled carriers could take place beyond the border commercial zones as a result of issuance of the Certification rule.

Additionally, given the nature of the Certification rule, the rule standing alone would have no impact on Mexican truck and bus operations beyond the border commercial zones. For example, implementation of the rule would not affect either the number of Mexico-domiciled vehicles entering the United States or the number and duration of safety inspections of these vehicles. Indeed, unlike the application and safety monitoring rules, which

apply solely to Mexico-domiciled motor carriers, the only connection between the Certification rule and the operation of Mexican carriers beyond the border commercial zones is the contingency Congress created when it made issuance of the rule one of the preconditions to the processing of these carriers' applications for operating authority. For these reasons, FMCSA believes that the scope of the Environmental Assessment for the Certification rule is appropriate.

Issued on: September 26, 2003.

John H. Hill,

Assistant Administrator/Chief Safety Officer. [FR Doc. 03–24979 Filed 10–1–03; 8:45 am]
BILLING CODE 4910–EX-P

DEPARTMENT OF TRANSPORTATION

Maritime Administration

[Docket Number MARAD 2003 16229]

Requested Administrative Waiver of the Coastwise Trade Laws

AGENCY: Maritime Administration, Department of Transportation.

ACTION: Invitation for public comments on a requested administrative waiver of the Coastwise Trade Laws for the vessel BON ALIZE.

SUMMARY: As authorized by Public Law 105-383 and Public Law 107-295, the Secretary of Transportation, as represented by the Maritime Administration (MARAD), is authorized to grant waivers of the U.S.-build requirement of the coastwise laws under certain circumstances. A request for such a waiver has been received by MARAD. The vessel, and a brief description of the proposed service, is listed below. The complete application is given in DOT docket 2003-16229 at http://dms.dot.gov. Interested parties may comment on the effect this action may have on U.S. vessel builders or businesses in the U.S. that use U.S.-flag vessels. If MARAD determines, in accordance with Public Law 105-383 and MARAD's regulations at 46 CFR part 388 (68 FR 23084; April 30, 2003), that the issuance of the waiver will have an unduly adverse effect on a U.S.vessel builder or a business that uses U.S.-flag vessels in that business, a waiver will not be granted. Comments should refer to the docket number of this notice and the vessel name in order for MARAD to properly consider the comments. Comments should also state the commenter's interest in the waiver application, and address the waiver criteria given in § 388.4 of MARAD's regulations at 46 CFR part 388.

DATES: Submit comments on or before November 3, 2003.

ADDRESSES: Comments should refer to docket number MARAD-2003 16229. Written comments may be submitted by hand or by mail to the Docket Clerk, U.S. DOT Dockets, Room PL-401, Department of Transportation, 400 7th St., SW., Washington, DC 20590-0001. You may also send comments electronically via the Internet at http:// dmses.dot.gov/submit/. All comments will become part of this docket and will be available for inspection and copying at the above address between 10 a.m. and 5 p.m., e.t., Monday through Friday, except Federal holidays. An electronic version of this document and all documents entered into this docket is available on the World Wide Web at http://dms.dot.gov.

FOR FURTHER INFORMATION CONTACT:

Michael Hokana, U.S. Department of Transportation, Maritime Administration, MAR–830 Room 7201, 400 Seventh Street, SW., Washington, DC 20590. Telephone 202–366–0760.

SUPPLEMENTARY INFORMATION: As described by the applicant the intended service of the vessel BON ALIZE is:

Intended Use: "Sailing charter, private sailing lessons, passage making, and funeral services scattering ashes."

Geographic Region: "California and Hawaii."

Dated: September 29, 2003.

By order of the Maritime Administrator.

Joel C. Richard,

Secretary, Maritime Administration. [FR Doc. 03–24997 Filed 10–1–03; 8:45 am] BILLING CODE 4910–81–P

DEPARTMENT OF TRANSPORTATION

Maritime Administration

[Docket Number MARAD 16230]

Requested Administrative Waiver of the Coastwise Trade Laws

AGENCY: Maritime Administration, Department of Transportation.

ACTION: Invitation for public comments on a requested administrative waiver of the Coastwise Trade Laws for the vessel GATO VERDE.

SUMMARY: As authorized by Pub. L. 105–383 and Pub. L. 107–295, the Secretary of Transportation, as represented by the Maritime Administration (MARAD), is authorized to grant waivers of the U.S.-build requirement of the coastwise laws under certain circumstances. A request for such a waiver has been received by MARAD. The vessel, and a brief description of the proposed service, is

listed below. The complete application is given in DOT docket 2003-16230 at http://dms.dot.gov. Interested parties may comment on the effect this action may have on U.S. vessel builders or businesses in the U.S. that use U.S.-flag vessels. If MARAD determines, in accordance with Pub. L. 105-383 and MARAD's regulations at 46 CFR part 388 (68 FR 23084; April 30, 2003), that the issuance of the waiver will have an unduly adverse effect on a U.S.-vessel builder or a business that uses U.S.-flag vessels in that business, a waiver will not be granted. Comments should refer to the docket number of this notice and the vessel name in order for MARAD to properly consider the comments. Comments should also state the commenter's interest in the waiver application, and address the waiver criteria given in § 388.4 of MARAD's regulations at 46 CFR part 388.

DATES: Submit comments on or before November 3, 2003.

ADDRESSES: Comments should refer to docket number MARAD-2003 16230. Written comments may be submitted by hand or by mail to the Docket Clerk, U.S. DOT Dockets, Room PL-401, Department of Transportation, 400 7th St., SW., Washington, DC 20590-0001. You may also send comments electronically via the Internet at http:// dmses.dot.gov/submit/. All comments will become part of this docket and will be available for inspection and copying at the above address between 10 a.m. and 5 p.m., E.T., Monday through Friday, except federal holidays. An electronic version of this document and all documents entered into this docket is available on the World Wide Web at http://dms.dot.gov.

FOR FURTHER INFORMATION CONTACT:

Michael Hokana, U.S. Department of Transportation, Maritime Administration, MAR–830 Room 7201, 400 Seventh Street, SW., Washington, DC 20590. Telephone 202–366–0760.

SUPPLEMENTARY INFORMATION: As described by the applicant the intended service of the vessel GATO VERDE is:

Intended Use: "It is intended for use as an uninspected vessel used for sail training, outdoor education, and charters. Day trips and overnight expeditions."

Geographic Region: "Washington State."

Dated: September 29, 2003.

By order of the Maritime Administrator.

Joel C. Richard,

Secretary, Maritime Administration. [FR Doc. 03–24995 Filed 10–1–03; 8:45 am] BILLING CODE 4910–81–P

DEPARTMENT OF TRANSPORTATION

Maritime Administration

[Docket Number 2003 16232]

Requested Administrative Waiver of the Coastwise Trade Laws

AGENCY: Maritime Administration, Department of Transportation.

ACTION: Invitation for public comments on a requested administrative waiver of the Coastwise Trade Laws for the vessel LADYHAWKE.

SUMMARY: As authorized by Pub. L. 105-383 and Pub. L. 107-295, the Secretary of Transportation, as represented by the Maritime Administration (MARAD), is authorized to grant waivers of the U.S.build requirement of the coastwise laws under certain circumstances. A request for such a waiver has been received by MARAD. The vessel, and a brief description of the proposed service, is listed below. The complete application is given in DOT docket 2003-16232 at http://dms.dot.gov. Interested parties may comment on the effect this action may have on U.S. vessel builders or businesses in the U.S. that use U.S.-flag vessels. If MARAD determines, in accordance with Pub. L. 105-383 and MARAD's regulations at 46 CFR part 388 (68 FR 23084; April 30, 2003), that the issuance of the waiver will have an unduly adverse effect on a U.S.-vessel builder or a business that uses U.S.-flag vessels in that business, a waiver will not be granted. Comments should refer to the docket number of this notice and the vessel name in order for MARAD to properly consider the comments. Comments should also state the commenter's interest in the waiver application, and address the waiver criteria given in § 388.4 of MARAD's regulations at 46 CFR part 388.

DATES: Submit comments on or before November 3, 2003.

ADDRESSES: Comments should refer to docket number MARAD-2003 16232. Written comments may be submitted by hand or by mail to the Docket Clerk, U.S. DOT Dockets, Room PL-401, Department of Transportation, 400 7th St., SW., Washington, DC 20590-0001. You may also send comments electronically via the Internet at http:// dmses.dot.gov/submit/. All comments will become part of this docket and will be available for inspection and copying at the above address between 10 a.m. and 5 p.m., E.T., Monday through Friday, except federal holidays. An electronic version of this document and all documents entered into this docket is available on the World Wide Web at http://dms.dot.gov.

FOR FURTHER INFORMATION CONTACT:

Michael Hokana, U.S. Department of Transportation, Maritime Administration, MAR–830 Room 7201, 400 Seventh Street, SW., Washington, DC 20590. Telephone 202–366–0760.

SUPPLEMENTARY INFORMATION: As described by the applicant the intended service of the vessel SOWELU is:

Intended Use: "Excursion tours." Geographic Region: "Mississippi, Alabama, Florida."

Dated: September 25, 2003.

By order of the Maritime Administrator.

Joel C. Richard,

Secretary, Maritime Administration. [FR Doc. 03–24994 Filed 10–1–03; 8:45 am] BILLING CODE 4910–81–P

DEPARTMENT OF TRANSPORTATION

Maritime Administration

[Docket Number MARAD 2003 16228]

Requested Administrative Waiver of the Coastwise Trade Laws

AGENCY: Maritime Administration, Department of Transportation.

ACTION: Invitation for public comments on a requested administrative waiver of the Coastwise Trade Laws for the vessel PRINCESS MARIA.

SUMMARY: As authorized by Pub. L. 105-383 and Pub. L. 107-295, the Secretary of Transportation, as represented by the Maritime Administration (MARAD), is authorized to grant waivers of the U.S.build requirement of the coastwise laws under certain circumstances. A request for such a waiver has been received by MARAD. The vessel, and a brief description of the proposed service, is listed below. The complete application is given in DOT docket 2003-16228 at http://dms.dot.gov. Interested parties may comment on the effect this action may have on U.S. vessel builders or businesses in the U.S. that use U.S.-flag vessels. If MARAD determines, in accordance with Pub. L. 105-383 and MARAD's regulations at 46 CFR part 388 (68 FR 23084; April 30, 2003), that the issuance of the waiver will have an unduly adverse effect on a U.S.-vessel builder or a business that uses U.S.-flag vessels in that business, a waiver will not be granted. Comments should refer to the docket number of this notice and the vessel name in order for MARAD to properly consider the comments. Comments should also state the commenter's interest in the waiver application, and address the waiver criteria given in § 388.4 of MARAD's regulations at 46 CFR part 388.

DATES: Submit comments on or before November 3, 2003.

ADDRESSES: Comments should refer to docket number MARAD-2003 16228. Written comments may be submitted by hand or by mail to the Docket Clerk, U.S. DOT Dockets, Room PL-401, Department of Transportation, 400 7th St., SW., Washington, DC 20590-0001. You may also send comments electronically via the Internet at http:// dmses.dot.gov/submit/. All comments will become part of this docket and will be available for inspection and copying at the above address between 10 a.m. and 5 p.m., e.t., Monday through Friday, except federal holidays. An electronic version of this document and all documents entered into this docket is available on the World Wide Web at http://dms.dot.gov.

FOR FURTHER INFORMATION CONTACT:

Michael Hokana, U.S. Department of Transportation, Maritime Administration, MAR–830 Room 7201, 400 Seventh Street, SW., Washington, DC 20590. Telephone 202–366–0760.

SUPPLEMENTARY INFORMATION: As described by the applicant the intended service of the vessel PRINCESS MARIA is:

Intended Use: "Pleasure charters".

Geographic Region: "Gulf Coast of the USA".

Dated: September 29, 2003.

By order of the Maritime Administrator.

Joel C. Richard,

Secretary, Maritime Administration.
[FR Doc. 03–24993 Filed 10–1–03; 8:45 am]
BILLING CODE 4910–81–P

DEPARTMENT OF TRANSPORTATION

Maritime Administration

[Docket Number 2003 16231]

Requested Administrative Waiver of the Coastwise Trade Laws

AGENCY: Maritime Administration, Department of Transportation.

ACTION: Invitation for public comments on a requested administrative waiver of the Coastwise Trade Laws for the vessel SEASONS.

SUMMARY: As authorized by Pub. L. 105–383 and Pub. L. 107–295, the Secretary of Transportation, as represented by the Maritime Administration (MARAD), is authorized to grant waivers of the U.S.-build requirement of the coastwise laws under certain circumstances. A request for such a waiver has been received by MARAD. The vessel, and a brief description of the proposed service, is listed below. The complete application

is given in DOT docket 2003-16231 at http://dms.dot.gov. Interested parties may comment on the effect this action may have on U.S. vessel builders or businesses in the U.S. that use U.S.-flag vessels. If MARAD determines, in accordance with Pub. L. 105-383 and MARAD's regulations at 46 CFR part 388 (68 FR 23084; April 30, 2003), that the issuance of the waiver will have an unduly adverse effect on a U.S.-vessel builder or a business that uses U.S.-flag vessels in that business, a waiver will not be granted. Comments should refer to the docket number of this notice and the vessel name in order for MARAD to properly consider the comments. Comments should also state the commenter's interest in the waiver application, and address the waiver criteria given in § 388.4 of MARAD's regulations at 46 CFR part 388.

DATES: Submit comments on or before November 3, 2003.

ADDRESSES: Comments should refer to docket number MARAD-2003 16321. Written comments may be submitted by hand or by mail to the Docket Clerk, U.S. DOT Dockets, Room PL-401, Department of Transportation, 400 7th St., SW., Washington, DC 20590-0001. You may also send comments electronically via the Internet at http:// dmses.dot.gov/submit/. All comments will become part of this docket and will be available for inspection and copying at the above address between 10 a.m. and 5 p.m., E.T., Monday through Friday, except federal holidays. An electronic version of this document and all documents entered into this docket is available on the World Wide Web at http://dms.dot.gov.

FOR FURTHER INFORMATION CONTACT:

Michael Hokana, U.S. Department of Transportation, Maritime Administration, MAR–830 Room 7201, 400 Seventh Street, SW., Washington, DC 20590. Telephone 202–366–0760.

SUPPLEMENTARY INFORMATION: As described by the applicant the intended service of the vessel SEASONS is:

Intended Use: "Charter."

Geographic Region: "East Coast of the United States and the U.S. Virgin Islands."

Dated: September 25, 2003.

By order of the Maritime Administrator.

Joel C. Richard,

Secretary, Maritime Administration. [FR Doc. 03–24992 Filed 10–1–03; 8:45 am] BILLING CODE 4910–81–P

DEPARTMENT OF TRANSPORTATION

Maritime Administration

[Docket Number 2003 16233]

Requested Administrative Waiver of the Coastwise Trade Laws

AGENCY: Maritime Administration, Department of Transportation.

ACTION: Invitation for public comments on a requested administrative waiver of the Coastwise Trade Laws for the vessel SILVER SEA.

SUMMARY: As authorized by Public Law 105-383 and Public Law 107-295, the Secretary of Transportation, as represented by the Maritime Administration (MARAD), is authorized to grant waivers of the U.S.-build requirement of the coastwise laws under certain circumstances. A request for such a waiver has been received by MARAD. The vessel, and a brief description of the proposed service, is listed below. The complete application is given in DOT docket 2003-16233 at http://dms.dot.gov. Interested parties may comment on the effect this action may have on U.S. vessel builders or businesses in the U.S. that use U.S.-flag vessels. If MARAD determines, in accordance with Public Law 105-383 and MARAD's regulations at 46 CFR part 388 (68 FR 23084; April 30, 2003), that the issuance of the waiver will have an unduly adverse effect on a U.S.vessel builder or a business that uses U.S.-flag vessels in that business, a waiver will not be granted. Comments should refer to the docket number of this notice and the vessel name in order for MARAD to properly consider the comments. Comments should also state the commenter's interest in the waiver application, and address the waiver criteria given in § 388.4 of MARAD's regulations at 46 CFR part 388.

DATES: Submit comments on or before November 3, 2003.

ADDRESSES: Comments should refer to docket number MARAD-2003 16233. Written comments may be submitted by hand or by mail to the Docket Clerk, U.S. DOT Dockets, Room PL-401, Department of Transportation, 400 7th St., SW., Washington, DC 20590-0001. You may also send comments electronically via the Internet at http:// dmses.dot.gov/submit/. All comments will become part of this docket and will be available for inspection and copying at the above address between 10 a.m. and 5 p.m., e.t., Monday through Friday, except Federal holidays. An electronic version of this document and all documents entered into this docket is

available on the World Wide Web at http://dms.dot.gov.

FOR FURTHER INFORMATION CONTACT:

Michael Hokana, U.S. Department of Transportation, Maritime Administration, MAR–830 Room 7201, 400 Seventh Street, SW., Washington, DC 20590. Telephone 202–366–0760.

SUPPLEMENTARY INFORMATION: As described by the applicant the intended

service of the vessel SILVER SEA is:

Intended Use: "Charter—Recreational fishing, Dinner Cruises."

Geographic Region: "Local, State & Federal waters within a 100 mile radius of Cape Cod, Massachusetts."

Dated: September 25,2003.

By order of the Maritime Administrator.

Joel C. Richard,

Secretary, Maritime Administration.
[FR Doc. 03–24996 Filed 10–1–03; 8:45 am]
BILLING CODE 4910–81–P

DEPARTMENT OF TRANSPORTATION

Research and Special Programs Administration

Office of Hazardous Materials Safety; Notice of Applications for Exemptions

AGENCY: Research and Special Programs Administration, DOT.

ACTION: List of Applicants for Exemptions.

SUMMARY: In accordance with the procedures governing the applications for, and the processing of, exemptions from the Department of Transportation's Hazardous Materials Regulations (49 CFR part 107, subpart B), notice is hereby given that the Office of Hazardous Materials Safety has received the applications described herein. Each mode of transportation for which a particular exemption is requested is indicated by a number in the "Nature of Application" portion of the table below as follows: 1—Motor vehicle, 2—Rail freight, 3—Cargo vessel, 4—Cargo aircraft only, 5—Passenger-carrying aircraft.

DATES: Comments must be received on or before November 3, 2003.

ADDRESS COMMENTS TO: Records Center, Research and Special Programs Administration, U.S. Department of Transportation, Washington, DC 20590.

Comments should refer to the application number and be submitted in triplicate. If confirmation of receipt of comments is desired, include a self-addressed stamped postcard showing the exemption application number.

FOR FURTHER INFORMATION CONTACT:

Copies of the applications (See Docket Number) are available for inspection at the New Docket Management Facility, PL–401, at the U.S. Department of Transportation, Nassif Building, 400 7th Street, SW., Washington, DC 20590 or at http://dms.dot.gov.

This notice of receipt of application for new exemptions is published in accordance with Part 107 of the Federal hazardous materials transportation law (49 U.S.C. 5117(b); 49 CFR 1.53(b)).

Issued in Washington, DC, on September 26, 2003.

R. Ryan Posten,

Exemptions Program Officer, Office of Hazardous Materials, Exemptions and Approvals.

NEW EXEMPTIONS

Application number	Docket number	Applicant	Regulation(s) affected	Nature of exemption thereof
13289–N		TITEQ Corporation Palmdale, CA	49 CFR 173.302(a)(3), 175.3;178.65.	To authorize the manufacture, marking, sale and use of a limited life, non-refillable non-DOT specification steel cylinder similar to DOT Specification 39 for use in transporting certain Division 2.2 hazardous materials. (modes 1, 2, 4)
13290-N		Teris, L.L.C. Camarillo, CA	49 CFR 173.188	To authorize the transportation in commerce of waste white phosphorus, Division 4.2, in 30 gallon 1H2 plastic drums further packaged in 1A2 steel 55 gallon drums banded together and palletized. (mode 1)
13292–N		Seaquist Perfect Dispensing Cary, IL	49 CFR 173.306(h)	To authorize the manufacture, mark, sale and use of plastic containers of not more than 20 fluid ounces pressurized with a non-flammable, non-toxic gas to a maximum pressure of 150 psi for transportation of consumer commodities. (modes 1, 2)
13293–N		Penox Tech- nologies, LLC Pitts, PA	49 CFR 173.316	To authorize the transportation in commerce of a non- DOT specification cylinder equipped with an alter- native heat transfer design pressure for use in trans- porting oxygen, refrigerated liquid, Division 2.2. (mode 1)
13294–N		BOC Edwards San Marcos, CA	49 CFR 173.211, 173.242	To authorize the transportation in commerce of electro- lyte cells to be shipped in bulk in alternative pack- aging. (mode 1)
13295–N		Taylor-Wharton Harrisburg, PA	49 CFR 172.203(a), 172.203(a), 172.301, 173.302.	To authorize the manufacture, marking, sale and use of non-DOT specification seamless steel cylinders for use in transporting certain compressed gases. (modes 1, 2, 3, 4)

[FR Doc. 03–24966 Filed 10–1–03; 8:45 am] BILLING CODE 4910–60-M

DEPARTMENT OF TRANSPORTATION

Research and Special Programs Administration

Office of Hazardous Materials Safety; Notice of Applications for Modification of Exemption

AGENCY: Research and Special Programs Administration, DOT.

ACTION: List of applications for modification of exemptions.

SUMMARY: In accordance with the procedures governing the application for, and the processing of, exemptions from the Department of Transportation's Hazardous Materials Regulations (49 CFR Part 107, Subpart B), notice is hereby given that the Office of Hazardous Materials Safety has received

the applications described herein. This notice is abbreviated to expedite docketing and public notice. Because the sections affected, modes of transportation, and the nature of application have been shown in earlier **Federal Register** publications, they are not repeated here. Requests for modifications of exemptions (e.g. to provide for additional hazardous materials, packaging design changes, additional mode of transportation, etc.) are described in footnote to the application number. Application numbers with the suffix "M" denote a modification request. These applications have been separated from the new applications for exemptions to facilitate processing.

DATES: Comments must be received on or before (15 days after publication). **ADDRESSES:** Records Center, Research

and Special Programs Administration, U.S. Department of Transportation, Washington, DC 20590. Comments should refer to the application number and be submitted in triplicate. If confirmation of receipt of comments is desired, include a self-addressed stamped postcard showing the exemption number.

FOR FURTHER INFORMATION CONTACT:

Copies of the applications are available for inspection in the Records Center, Nassif Building, 400 7th Street, SW., Washington, DC or at http://dms.dot.gov.

This notice of receipt of applications for modification of exemptions is published in accordance with Part 107 of the Federal hazardous materials transportation law (49 U.S.C. 5117(b); 49 CFR 1.53(b)).

Issued in Washington, DC, on September 26, 2003.

R. Ryan Posten,

Exemptions Program Officer, Office of Hazardous Materials Exemptions and Approvals.

Application No.	Docket No.	Applicant	Modification of exemption
9266–M		Eurotainer SA Paris, FR (See Footnote 1)	9266
11494–M		Atlantic Research Corp. (Auto. Products Group) Knoxville, TN (See Footnote 2).	11494
11947–M	RSPA-97-2901	Patts Fabrication and Services Odessa, TX (See Footnote 3)	11947
12122–M	RSPA-98-4313	Atlantic Research Corp. (Auto. Products Group) Knoxville, TN (See Footnote 4).	12122
12468–M	RSPA-00-7421	Connecticut Yankee Atomic Power Company East Hampton, CT (See Footnote 5).	12468
13282–M	RSPA-03-16054	ConocoPhillips Alaska, Inc. Anchorage, AK (See Footnote 6)	13282

⁽¹⁾ To modify the exemption to authorize the transportation of an additional Division 2.2 material in non-DOT specification IMO Type 5 portable tanks.

(3) To modify the exemption to authorize the transportation of a Class 8 material in non-DOT specification containers.

(5) To modify the exemption to authorize a change to the configuration, project management, transport-related responsibilities and shipment date of the reactor pressure vessel containing a Class 7 material within a Reactor Vessel Transport System.

(6) To reissue the exemption originally issued on an emergency basis for the transportation of a Class 8 material in a DOT Specification 1A1 steel drum which exceeds the quantity limitation when shipped by air.

[FR Doc. 03–24967 Filed 10–1–03; 8:45 am] **BILLING CODE 4910–60–M**

DEPARTMENT OF TRANSPORTATION

Research and Special Programs Administration

International Standards on the Transport of Dangerous Goods; Public Meetings

AGENCY: Research and Special Programs Administration (RSPA), Department of Transportation.

ACTION: Notice of public meeting.

SUMMARY: This notice is to advise interested persons that RSPA will conduct a public meeting in preparation

for the nineteenth meeting of the International Civil Aviation Organization's Dangerous Goods Panel (ICAO DGP) to be held October 27– November 7, 2003 in Montreal, Canada.

DATES: October 15, 10 a.m.–12:30 p.m., Room 8440.

ADDRESSES: The meeting will be held at DOT Headquarters, Nassif Building, 400 Seventh Street SW., Washington, DC 20590.

FOR FURTHER INFORMATION CONTACT: Bob Richard, International Standards Coordinator, Office of Hazardous Materials Safety, Department of Transportation, Washington, DC 20590; (202) 366–0656.

SUPPLEMENTARY INFORMATION: The purpose of the meeting will be to

prepare and discuss draft positions for the nineteenth meeting of the Dangerous Goods Panel. Topics to be covered during the public meeting will include: (1) Amendments for the 2005-2006 edition of the ICAO Technical Instructions; (2) Harmonization of the ICAO TI with the 13th revised edition of the UN Model Regulations on the Transport of Dangerous Goods; (3) Requirements for infectious substances; (4) Training; (5) Dangerous goods security requirements; (6) revision of the packing instructions; (7) the air eligibility marking requirement; and (8) Dangerous goods carried by passengers and crew members.

The public is invited to attend without prior notification.

⁽²⁾ To modify the exemption to authorize passenger-carrying aircraft as an additional mode of transportation for Class 9 and Division 2.2 materials in non-DOT specification cylinders.

⁽⁴⁾ To modify the exemption to authorize passenger-carrying aircraft as an additional mode of transportation for Division 2.1, 2.2 and Class 9 materials in non-DOT specification cylinders.

Issued in Washington, DC, on September 26, 2003.

Robert A. McGuire,

Associate Administrator for Hazardous Materials Safety.

[FR Doc. 03–24964 Filed 9–1–03; 8:45 am]

BILLING CODE 4910-60-M

DEPARTMENT OF THE TREASURY

Community Development Financial Institutions Fund: Open Meeting of the Community Development Advisory Board

AGENCY: Community Development Financial Institutions Fund, Department of the Treasury.

ACTION: Notice of open meeting.

SUMMARY: This notice announces the next meeting of the Community Development Advisory Board, which provides advice to the Director of the Community Development Financial Institutions Fund.

DATES: The next meeting of the Community Development Advisory Board will be held on Thursday, October 23, 2003, beginning at 10 a.m.

ADDRESSES: The Community Development Advisory Board meeting will be held at The American Institute of Architects Boardroom, located at 1735 New York Avenue, NW., Washington, DC.

FOR FURTHER INFORMATION CONTACT: The Office of External Affairs of the Community Development Financial Institutions Fund (the "Fund"), U.S. Department of the Treasury, 601 13th Street, NW., Suite 200 South, Washington, DC 20005, (202) 622–9046 (this is not a toll free number). Other information regarding the Fund and its programs may be obtained through the Fund's Web site at http://www.cdfifund.gov.

SUPPLEMENTARY INFORMATION: Section 104(d) of the Community Development Banking and Financial Institutions Act of 1994 (12 U.S.C. 4703(d)) established the Community Development Advisory Board (the "Advisory Board"). The charter for the Advisory Board has been filed in accordance with the Federal Advisory Committee Act, as amended (5 U.S.C. App.), and with the approval of the Secretary of the Treasury.

The function of the Advisory Board is to advise the Director of the Fund (who has been delegated the authority to administer the Fund) on the policies regarding the activities of the Fund. The Fund is a wholly owned corporation within the Department of the Treasury. The Advisory Board shall not advise the

Fund on the granting or denial of any particular application for monetary or non-monetary awards. The Advisory Board shall meet at least annually.

It has been determined that this document is not a major rule as defined in Executive Order 12291 and therefore regulatory impact analysis is not required. In addition, this document does not constitute a rule subject to the Regulatory Flexibility Act (5 U.S.C. Chapter 6).

The next meeting of the Advisory Board, all of which will be open to the public, will be held at The American Institute of Architects Boardroom, located at 1735 New York Avenue, NW., Washington, DC, on Thursday, October 23, 2003, beginning at 10 a.m. The room will accommodate 50 members of the public. Seats are available on a firstcome, first-served basis, Participation in the discussions at the meeting will be limited to Advisory Board members and Department of the Treasury staff. Anyone who would like to have the Advisory Board consider a written statement must submit it to the Fund, at the address of the Fund specified above in the FOR FURTHER INFORMATION CONTACT section, by 4 p.m., Monday, October 13, 2003.

The meeting will include a report from the Director on the activities of the CDFI Fund since the last Advisory Board meeting, including programmatic, fiscal and legislative initiatives for the years 2003 and 2004.

Authority: 12 U.S.C. 4703; Chapter X, Pub. L. 104–19, 109 Stat. 237.

Tony T. Brown,

 ${\it Director, Community Development Financial} \\ {\it Institutions Fund}.$

[FR Doc. 03–25007 Filed 10–1–03; 8:45 am] BILLING CODE 4810–70–M

DEPARTMENT OF THE TREASURY

Internal Revenue Service

Proposed Collection; Comment Request for Form 8816

AGENCY: Internal Revenue Service (IRS), Treasury.

ACTION: Notice and request for comments.

SUMMARY: The Department of the Treasury, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Public Law 104–13 (44 U.S.C.

3506(c)(2)(A)). Currently, the IRS is soliciting comments concerning Form 8816, Special Loss Discount Account and Special Estimated Tax Payments for Insurance Companies.

DATES: Written comments should be received on or before December 1, 2003, to be assured of consideration.

ADDRESSES: Direct all written comments to Glenn Kirkland, Internal Revenue Service, room 6411, 1111 Constitution Avenue, NW., Washington, DC 20224.

FOR FURTHER INFORMATION CONTACT:

Requests for additional information or copies of the form and instructions should be directed to Larnice Mack at Internal Revenue Service, room 6407, 1111 Constitution Avenue, NW., Washington, DC 20224, or at (202) 622–3179, or through the Internet at Larnice.Mack@irs.gov.

SUPPLEMENTARY INFORMATION:

Title: Special Loss Discount Account and Special Estimated Tax Payments for Insurance Companies.

OMB Number: 1545–1130. *Form Number:* 8816.

Abstract: Form 8816 is used by insurance companies claiming an additional deduction under Internal Revenue Code section 847 to reconcile estimated tax payments and to determine their tax benefit associated with the deduction. The information is needed by the IRS to determine that the proper additional deduction was claimed and to insure the proper amount of special estimated tax was computed and deposited.

Current Actions: The following changes are being made to Form 8816: The line items in Part I are being separated into two parts. Part I will be Unpaid Losses—Undiscounted and Discounted, and Part II will be Special Loss Discount Account. Part III will be Special Estimated Tax Payments (previously Part II). The old Part III, Tax Benefit Associated with the Additional Deduction under Section 847, is being eliminated because it is no longer needed. Also, a new line is being added to Part III to request information on prior section 847 payments transferred to the current year. This will enable both taxpayers and the Service Centers to properly identify payments that are transferred between accident years.

Type of Review: Revision of a currently approved collection.

Affected Public: Business or other forprofit organizations.

Estimated Number of Respondents: 3,000.

Estimated Time Per Respondent: 6 hr., 24 minutes.

Estimated Total Annual Burden Hours: 19,200.

The following paragraph applies to all of the collections of information covered by this notice:

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless the collection of information displays a valid OMB control number. Books or records relating to a collection of information must be retained as long as their contents may become material in the administration of any internal revenue law. Generally, tax returns and tax return information are confidential, as required by 26 U.S.C. 6103.

Request for Comments: Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval. All comments will become a matter of public record. Comments are invited on: (a) Whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology; and (e) estimates of capital or start-up costs and costs of operation, maintenance, and purchase of services to provide information.

Approved: September 23, 2003.

Glenn Kirkland,

IRS Reports Clearance Officer.
[FR Doc. 03–25028 Filed 10–1–03; 8:45 am]
BILLING CODE 4830–01–P

DEPARTMENT OF THE TREASURY

Internal Revenue Service

Proposed Collection; Comment Request for Notice 2003–67

AGENCY: Internal Revenue Service (IRS), Treasury.

ACTION: Notice and request for comments.

SUMMARY: The Department of the Treasury, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Public Law 104–13 (44 U.S.C. 3506(c)(2)(A)). Currently, the IRS is

soliciting comments concerning Notice 2003–67, Notice on Information Reporting for Payments in Lieu of Dividends.

DATES: Written comments should be received on or before December 1, 2003, to be assured of consideration.

ADDRESSES: Direct all written comments to Glenn P. Kirkland, Internal Revenue Service, room 6411, 1111 Constitution Avenue, NW., Washington, DC 20224.

FOR FURTHER INFORMATION CONTACT:

Requests for additional information or copies of notice should be directed to Carol Savage at Internal Revenue Service, room 6407, 1111 Constitution Avenue, NW., Washington, DC 20224, or at (202) 622–3945, or through the Internet at *CAROL.A.SAVAGE@irs.gov*.

SUPPLEMENTARY INFORMATION:

Title: Notice on Information Reporting for Payments in Lieu of Dividends.

OMB Number: 1545–1858.

Notice Number: Notice 2003–67. Abstract: Notice 2003–67 provides guidance to brokers and individuals regarding provisions in the Jobs and

Growth Tax Relief Reconciliation Act of 2003. The notice provides rules for brokers to use in determining loanable shares and rules for allocating transferred shares for purposes of determining payments in lieu of dividend reportable to individuals. These rules require brokers to comply with certain recordkeeping requirements to use the favorable rules for determining loanable shares and for allocating transferred shares that may give rise to payments in lieu of dividends.

Current Actions: There are no changes being made to the notice at this time.

Type of Review: Extension of a currently approved collection.

Affected Public: Business or other forprofit organizations.

Estimated Number of Respondents: 600.

Estimated Average Time Per Respondent: 100 hours.

Estimated Total Annual Burden Hours: 60,000.

The following paragraph applies to all of the collections of information covered by this notice:

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless the collection of information displays a valid OMB control number. Books or records relating to a collection of information must be retained as long as their contents may become material in the administration of any internal revenue law. Generally, tax returns and tax return information are confidential, as required by 26 U.S.C. 6103.

Request for Comments: Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval. All comments will become a matter of public record. Comments are invited on: (a) Whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection techniques or other forms of information technology; and (e) estimates of capital or start-up costs and costs of operation, maintenance, and purchase of services to provide information.

Approved: September 26, 2003.

Glenn P. Kirkland,

IRS Reports Clearance Officer. [FR Doc. 03–25029 Filed 10–1–03; 8:45 am] BILLING CODE 4830–01–P

DEPARTMENT OF THE TREASURY

Internal Revenue Service

Proposed Collection; Comment Request for Form 8818

AGENCY: Internal Revenue Service (IRS), Treasury.

ACTION: Notice and request for comments.

SUMMARY: The Department of the Treasury, as part of its continuing effort to reduce paperwork and respondent burden, invites the general public and other Federal agencies to take this opportunity to comment on proposed and/or continuing information collections, as required by the Paperwork Reduction Act of 1995, Public Law 104–13 (44 U.S.C. 3506(c)(2)(A)). Currently, the IRS is soliciting comments concerning Form 8818, Optional Form To Record Redemption of Series EE and I U.S. Savings Bonds Issued After 1989.

DATES: Written comments should be received on or before December 1, 2003, to be assured of consideration.

ADDRESSES: Direct all written comments to Glenn Kirkland, Internal Revenue Service, room 6411, 1111 Constitution Avenue, NW., Washington, DC 20224.

FOR FURTHER INFORMATION CONTACT: Requests for additional information or

copies of the form and instructions

should be directed to Larnice Mack at Internal Revenue Service, room 6407, 1111 Constitution Avenue, NW., Washington, DC 20224, or at (202) 622–3179, or through the Internet at Larnice.Mack@irs.gov.

SUPPLEMENTARY INFORMATION:

Title: Optional Form To Record Redemption of Series EE and I U.S. Savings Bonds Issued After 1989.

OMB Number: 1545–1151. *Form Number:* 8818.

Abstract: Under Internal Revenue Code section 135, if an individual redeems U.S. savings bonds issued after 1989 and pays qualified higher education expenses during the year, the interest on the bonds is excludable from income. Form 8818 can be used to keep a record of the bonds cashed so that the taxpayer can claim the proper interest exclusion.

Current Actions: There are no changes being made to the form at this time.

Type of Review: Extension of a currently approved collection.

Affected Public: Individuals or

households.

Estimated Number of Respondents:

Estimated Number of Respondents: 50,000.

Estimated Time Per Respondent: 38 minutes.

Estimated Total Annual Burden Hours: 32,000.

The following paragraph applies to all of the collections of information covered by this notice:

An agency may not conduct or sponsor, and a person is not required to respond to, a collection of information unless the collection of information displays a valid OMB control number. Books or records relating to a collection of information must be retained as long as their contents may become material in the administration of any internal revenue law. Generally, tax returns and tax return information are confidential, as required by 26 U.S.C. 6103.

Request for Comments: Comments submitted in response to this notice will be summarized and/or included in the request for OMB approval. All comments will become a matter of public record. Comments are invited on: (a) Whether the collection of information is necessary for the proper performance of the functions of the agency, including whether the information shall have practical utility; (b) the accuracy of the agency's estimate of the burden of the collection of information; (c) ways to enhance the quality, utility, and clarity of the information to be collected; (d) ways to minimize the burden of the collection of information on respondents, including through the use of automated collection

techniques or other forms of information technology; and (e) estimates of capital or start-up costs and costs of operation, maintenance, and purchase of services to provide information.

Approved: September 24, 2003.

Glenn Kirkland,

IRS Reports Clearance Officer.
[FR Doc. 03–25030 Filed 10–1–03; 8:45 am]
BILLING CODE 4830–01–P

DEPARTMENT OF VETERANS AFFAIRS

Research and Development Office; Government Owned Invention Available for Licensing

AGENCY: Research and Development Office, Veterans Affairs.

ACTION: Notice of Government owned invention available for licensing.

SUMMARY: The invention listed below is owned by the U.S. Government as represented by the Department of Veterans Affairs, and is available for licensing in accordance with 35 U.S.C. 207 and 37 CFR part 404 to achieve expeditious commercialization of results of federally funded research and development. Foreign patents are filed on selected inventions to extend market coverage for U.S. companies and may also be available for licensing.

FOR FURTHER INFORMATION CONTACT:

Technical and licensing information on the invention may be obtained by writing to: Robert W. Potts, Department of Veterans Affairs, Director Technology Transfer Program, Research and Development Office, 810 Vermont Avenue, NW., Washington, DC 20420; fax: 202-254-0473; e-mail at bob.potts@hq.med.va.gov. Any request for information should include the Number and Title for the relevant invention as indicated below. Issued patents may be obtained from the Commissioner of Patents, U.S. Patent and Trademark Office, Washington, DC 20231.

SUPPLEMENTARY INFORMATION: The invention available for licensing is:

US Patent Application No. 08/956,518; Australian Patent No. 752331: "Alpha–7 Nicotinic Receptor"

Dated: September 24, 2003.

Anthony J. Principi,

Secretary, Department of Veterans Affairs. [FR Doc. 03–24957 Filed 10–1–03; 8:45 am]

BILLING CODE 8320-01-P

DEPARTMENT OF VETERANS AFFAIRS

Professional Certification and Licensure Advisory Committee; Notice of Meeting

The Department of Veterans Affairs (VA) gives notice under Public Law 92–463 (Federal Advisory Committee Act) that the Professional Certification and Licensure Advisory Committee has scheduled a meeting on Wednesday, October 15, 2003, at the Department of Veterans Affairs, Veterans Benefits Administration Education Conference Room 601V, 1800 G Street, NW., Washington, DC, from 8:30 a.m. to 4 p.m. The meeting is open to the public.

The purpose of the Committee is to advise the Secretary of Veterans Affairs on the requirements of organizations or entities offering licensing and certification tests to individuals for which payment for such tests may be made under chapters 30, 32, 34, or 35 of Title 38, United States Code.

The meeting will begin with opening remarks and introduction of new members by Ms. Sandra Winborne, Committee Chair. During the morning session, the Committee will receive a report on outreach activities, and a presentation on licensure and certification usage. The afternoon session will include a progress report on improvements to the Licensing and Certification Approval System (LACAS), and discussion of any old or new business.

Interested persons may file written statements to the committee before the meeting, or within 10 days after the meeting, with Mr. Giles Larrabee, Designated Federal Official, Department of Veterans Affairs, Veterans Benefits Administration (225B), 810 Vermont Avenue, NW., Washington, DC 20420. Oral statements from the public will be heard at 1 p.m. Any member of the public wishing to attend the meeting should contact Mr. Giles Larrabee or Mr. Michael Yunker at (202) 273–7187.

Dated: September 17, 2003. By Direction of the Secretary:

E. Philip Riggin,

Committee Management Officer. [FR Doc. 03–24923 Filed 9–30–03; 8:45 am] BILLING CODE 8320–01–M

DEPARTMENT OF VETERANS AFFAIRS

Executive Committee to the Voluntary Service National Advisory Committee, Notice of Meeting

The Department of Veterans Affairs gives notice under Public Law 92–463 (Federal Advisory Committee Act) that the Executive Committee to the Department of Veterans Affairs Voluntary Service (VAVS) National Advisory Committee (NAC) will meet October 20–21, 2003, at the Rosen Plaza Hotel, Orlando, Florida. The meetings are scheduled from 8:30 a.m. until 4:30 p.m. on October 20, 2003, and from 8:30 a.m. until 12 noon on October 21, 2003. The meeting is open to the public.

The NAC consists of sixty-two national organizations and advises the Secretary, through the Under Secretary for Health, on the coordination and promotion of volunteer activities within VA health care facilities. The Executive Committee consists of nineteen representatives from the NAC member organizations and acts as the NAC governing body in the interim period between NAC Annual Meetings.

Business topics for the October 20 morning session include: review goals and objectives, VHA update and a VAVS update of the Voluntary Service program's progress since the 2003 NAC Annual Meeting, Parke Board update, review of the 2003 annual meeting evaluations and the VAVS Partner's Treasurer report. The October 20 afternoon business session topics include: the 58th annual meeting plans, workshop and plenary sessions/ suggestions. The October 21 morning business session topics include: 2006 NAC annual meeting planning, membership report review, recommendations, subcommittee reports, standard operating procedure

revisions, new business and Executive Committee appointments.

No time will be allocated at this meeting for receiving oral presentations from the public. However, interested persons may either attend or file statements with the Committee. Written statements may be filed either before the meeting or within 10 days after the meeting and addressed to: Ms. Laura Balun, Administrative Officer, Voluntary Service Office (10C2), Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420. Individuals interested in attending are encouraged to contact Ms. Balun at (202) 273–8952.

Dated: September 25, 2003. By Direction of the Secretary.

E. Philip Riggin,

Committee Management Officer. [FR Doc. 03–24924 Filed 10–1–03; 8:45 am] BILLING CODE 8320–01–M



Thursday, October 2, 2003

Part II

Department of Veterans Affairs

38 CFR Part 17

Reasonable Charges for Medical Care or Services; 2003 Methodology Changes; Proposed Rule and Notice

DEPARTMENT OF VETERANS AFFAIRS

38 CFR Part 17

RIN 2900-AL06

Reasonable Charges for Medical Care or Services; 2003 Methodology Changes

AGENCY: Department of Veterans Affairs. **ACTION:** Proposed rule.

SUMMARY: This document proposes to amend the Department of Veterans Affairs (VA) medical regulations concerning "reasonable charges" for medical care or services provided or furnished by VA to a veteran:

- —For a nonservice-connected disability for which the veteran is entitled to care (or the payment of expenses of care) under a health plan contract;
- —For a nonservice-connected disability incurred incident to the veteran's employment and covered under a worker's compensation law or plan that provides reimbursement or indemnification for such care and services; or
- —For a nonservice-connected disability incurred as a result of a motor vehicle accident in a State that requires automobile accident reparations insurance.

The regulations contain methodologies designed to establish VA charges that replicate, insofar as possible, the 80th percentile of community charges, adjusted to the market areas in which VA facilities are located, and trended forward to the time period during which the charges will be used. This document proposes to amend the regulations regarding VA's reasonable charges methodologies for the following purposes: to establish charges for medical care, procedures, services, durable medical equipment (DME), drugs, injectables, medical items, and supplies for which we currently do not have charges; to replace certain charges currently based on VA costs with charges based on community charges; to establish separate charges for medical care, procedures, services, DME, drugs, injectables, medical items, and supplies whose charges are presently combined with other charges; to bring our charge structures and associated billing practices closer to industry standard charge structures and billing practices; and to provide certain clarifications.

DATES: Comments must be received on or before November 3, 2003.

ADDRESSES: Mail or hand-deliver written comments to: Director,

Regulations Management (00REG1), Department of Veterans Affairs, 810 Vermont Avenue, NW, Room 1068, Washington, DC 20420; or fax comments to (202) 273–9026; or e-mail comments to OGCRegulations@mail.va.gov.

Comments should indicate that they are submitted in response to "RIN 2900–AL06." All written comments received will be available for public inspection in the Office of Regulations Policy and Management, Room 1063B, between the hours of 8 a.m. and 4:30 p.m., Monday through Friday (except holidays). Please call (202) 273–9515 for an appointment.

FOR FURTHER INFORMATION CONTACT:

David Cleaver, Chief Business Office (168), Veterans Health Administration, Department of Veterans Affairs, 810 Vermont Avenue, NW, Washington, DC 20420, (202) 254–0361. (This is not a toll free number.)

SUPPLEMENTARY INFORMATION: This document proposes to amend VA's medical regulations that are set forth in 38 CFR part 17. More specifically, we are proposing to amend the regulations that establish methodologies for determining reasonable charges for medical care or services provided or furnished by VA to a veteran:

(i) For a nonservice-connected disability for which the veteran is entitled to care (or the payment of expenses of care) under a health plan contract:

(ii) For a nonservice-connected disability incurred incident to the veteran's employment and covered under a worker's compensation law or plan that provides reimbursement or indemnification for such care and services; or

(iii) For a nonservice-connected disability incurred as a result of a motor vehicle accident in a State that requires automobile accident reparations insurance.

Under the provisions of 38 U.S.C. 1729, VA has the right to recover or collect reasonable charges for such medical care and services from a third party to the extent that the veteran or a provider of the care or services would be eligible to receive payment therefor from that third party if the care or services had been furnished by a provider other than a department or agency of the United States. However, consistent with that statutory authority, a third-party payer liable for such medical care and services under a health plan contract has the option of paying, to the extent of its coverage, either the billed charges or the amount the third-party payer demonstrates it would pay for care or services furnished by providers other than entities of the

United States for the same care or services in the same geographic area.

The methodologies for establishing reasonable charges are designed to replicate, insofar as possible, the 80th percentile of community charges, adjusted to the market areas in which VA facilities are located, and trended forward to the time period during which the charges will be used. An exception is that charges for prescription drugs are based on VA costs in accordance with the methodology set forth in § 17.102.

This document proposes to amend VA's reasonable charges regulations to make significant changes to our charge development methodologies and charge structures, to provide charges for 2003 Current Procedural Terminology (CPT) codes, and to provide certain clarifications. These proposed changes are described in more detail in the following paragraphs.

Data for Calculating Actual Charge Amounts

As we have done in the past, we are publishing data for calculating actual charge amounts based on the methodologies set forth in this proposed rule in an accompanying notice in this same edition of the Federal Register. However, this document proposes that in the future this information will either be published in a notice in the **Federal Register** or will be posted on the Internet site of the Veterans Health Administration Chief Business Office at http://www.va.gov/revenue, under "Charge Data." We are proposing this change because we believe posting this information on the Internet will make it more readily available to the public, while at the same time greatly reducing the volume of information and associated taxpayer expense of publishing it in the Federal Register.

Data Sources

Presently, the regulations identify data sources used to calculate charges by name and edition (for example, 2001 Medicare MedPAR file). In addition, the regulations give specific information on where various databases can be obtained (for example, the Internet site where the Medicare Clinical Diagnostic Laboratory Fee Schedule can be found). This document proposes that data sources will hereafter be identified in these regulations only by name, and that the editions used and information on where these data sources may be obtained will be presented along with the data for calculating actual charge amounts, either in notices in the Federal Register or on the Internet site of the Veterans Health Administration Chief Business Office at http://www.va.gov/revenue,

under "Charge Data." We are proposing this change so that a change in the edition of a data source or in the information on where a database may be obtained will not, by itself, require any change to the regulations.

Definitions—Additions, Changes, and Deletions

This document proposes to add definitions for APC (Ambulatory Payment Classification), CMS (Centers for Medicare and Medicaid Services), DME, HCPCS (Healthcare Common Procedure Coding System) code, ICU (Intensive Care Unit), non-provider-based, provider-based, and RBRVS (Resource-Based Relative Value Scale). We are proposing to amend the definition of the term "CPT procedure code" to indicate that the same definition applies equally to the term "CPT code."

Presently, geographic area is defined, for acute inpatient facility charges and skilled nursing facility/sub-acute inpatient facility charges, as Metropolitan Statistical Area (MSA) or the local market, if the VA facility is not located in an MSA; and is defined, for outpatient facility charges and physician charges, as three-digit ZIP Code locality. We are proposing to amend the definition of geographic area to mean simply a three-digit ZIP Code area. This change reflects the fact that we are proposing to use three-digit ZIP Code areas as the geographic areas for all of our charge types. We are proposing this change for acute inpatient facility charges and skilled nursing facility/sub-acute inpatient facility charges because, due to the variability of charges within MSA and non-MSA areas, changing to three-digit ZIP Code areas will produce charges that are more accurate for the location in which the care was provided.

We are proposing to delete the definition for CPI–W (Consumer Price Index—Urban Wage Earners and Clerical Workers) because we have not used CPI–W information anywhere in the regulations, and have no plans to do so. We are also proposing to delete the separate definition for CPI (Consumer Price Index), because that term appears in the regulations only as part of the defined term CPI–U (Consumer Price Index—All Urban Consumers).

Provider-Based and Non-Provider-Based Entities and Charges

For a specific item of medical care or service provided on an outpatient basis, we may have a professional charge, or an outpatient facility charge, or both. Presently, for all outpatient services for which we have both a professional

charge and an outpatient facility charge, these charges are developed so as to be mutually exclusive, with the expectation that both charges will be billed for the same occasion of service. In addition, most of our outpatient facility charges are expected to be billed by all VA facilities that perform the applicable service, regardless of the type of facility. In other words, these charges are equally available to be billed by the outpatient departments of VA medical centers (VAMCs), by VA communitybased outpatient clinics (CBOCs) operating similar to private-sector ambulatory surgery centers, by VA CBOCs operating like private-sector doctors' offices, etc. Presently, the only outpatient facility charges not available to be billed by all VA facilities are those for office or other outpatient evaluation and management (E&M) services CPT codes 99201 through 99215. Billing of the outpatient facility charges for the ten services covered by these codes is presently restricted to the outpatient departments of 169 VAMCs.

This document proposes to amend the regulations to provide that each VA healthcare entity will be designated as either provider-based (entitled to bill outpatient facility charges) or nonprovider-based (not entitled to bill outpatient facility charges), based on CMS criteria for provider-based and non-provider-based entities. Further, application of the proposed methodologies presented in this document will provide two sets of charges for outpatient care, one set for use by provider-based entities and one for use by non-provider-based entities. For those outpatient services that have both a professional charge and an outpatient facility charge, the professional charge for use by providerbased entities will be lower, based on Medicare's lower facility practice expense Relative Value Units (RVUs), in consideration of the fact that both the professional charge and the outpatient facility charge will be billed. For the same services, the professional charge for use by non-provider-based entities will be higher, based on Medicare's higher non-facility practice expense RVUs, in consideration of the fact that only the professional charge will be billed. We are proposing these changes because they will result in VA charge structures and billing practices that more closely approximate industry standard charge structures and billing practices.

Charges for Medical Care or Services Provided by Non-VA Providers at VA Expense

Presently, the phrase in the regulations, "medical care or services provided or furnished by VA," is understood to include medical care or services provided by non-VA providers at VA expense, and the charges billed for such care are those determined according to this section. This document proposes to amend the regulations by adding language to confirm this understanding.

Charges for Medical Care or Services for Which VA Does Not Have an Established Charge

Presently, the regulations do not address the issue of charges for medical care or services for which VA does not have an established charge or does not specifically make other provision for charges. The result has been that VA has not been charging for such care or services. This document proposes to amend the regulations by adding language to provide for charges, under specified circumstances, when we do not have established charges.

Under the proposed change, when VA provides or furnishes medical care or services and VA does not have an established charge for such care or services, then the charges billed for such care or services will be determined according to the provisions of the proposed new paragraph (a)(8) of the regulations, which sets forth four criteria for establishing a charge and provides that, if none apply, then no charge will be made. We believe that these proposed changes provide a fair and reasonable basis for such charges. We are proposing these changes to provide appropriate charges, under these specified circumstances, where presently we have no charges.

Unlisted and Unspecified Procedures, Services, and Supplies

Both the American Medical Association and CMS, in compiling CPT and HCPCS Level II, respectively, recognize that there may be procedures, services, or supplies provided by physicians and other healthcare professionals which have not yet been defined. Accordingly, both CPT and HCPCS Level II provide specific codes for reporting unlisted and unspecified procedures, services, and supplies. Presently, the regulations do not provide charges for unlisted CPT codes or for any HCPCS Level II codes. This document proposes methodologies that will enable us to provide charges for unlisted and unspecified procedures,

services, and supplies. We are proposing this change so that we will be able to bill for these procedures, services, and supplies when we provide or furnish them to our patients, and so that our charge structures and billing practices will more closely approximate industry standard charge structures and billing practices.

Charge Types

Presently, the reasonable charges regulations set forth methodologies for four basic types of charges, as follows:

- —Acute inpatient facility charges;—Skilled nursing facility/sub-acute
- inpatient facility charges;
 —Outpatient facility charges; and
- —Outpatient facility charges; an —Physician charges.

Under the above organization of charge types, facility charges for observation care are included under outpatient facility charges, and charges for pathology/laboratory and anesthesia services are included under physician charges. This document proposes to amend the regulations to describe separate charge types for observation care, pathology/laboratory, and anesthesia.

Presently, we do not have partial hospitalization facility charges. This document proposes to amend the regulations to establish partial hospitalization facility charges.

Presently, we do not have separate charges for HCPCS Level II codes. This document proposes to amend the regulations to establish charges for HCPCS Level II codes.

Presently, our charges for prosthetic devices and DME provided on an outpatient basis are VA's actual cost, and our charges for outpatient dental care are based on VA costs in accordance with the methodology set forth in § 17.102. In place of these costrelated charges, this document proposes to amend the regulations to establish reasonable charges for prosthetic devices, DME, and outpatient dental care by establishing charges for the associated HCPCS Level II codes.

Presently, we do not have charges for ambulance or other emergency transportation services. This document proposes to amend the regulations to establish reasonable charges for ambulance and other emergency transportation services by establishing charges for the associated HCPCS Level II codes.

Associated with these changes, we are proposing to amend the regulations to organize reasonable charges into the following eleven charge types:

—Acute inpatient facility charges;
 —Skilled nursing facility/sub-acute inpatient facility charges;

- —Partial hospitalization facility charges;
- —Outpatient facility charges;
- —Physician and other professional charges except for anesthesia services and certain dental services;
- —Professional charges for anesthesia services;
- Professional charges for dental services identified by HCPCS Level II codes;
- —Pathology and laboratory charges;—Observation care facility charges;
- Ambulance and other emergency transportation charges; and
- —Charges for durable medical equipment, drugs, injectables, and other medical services, items, and supplies identified by HCPCS Level II codes.

The reasons we are proposing these changes are (1) to enable us to bill for medical care, procedures, services, DME, drugs, injectables, medical items, and supplies for which we currently do not have charges; (2) to replace certain charges currently based on VA costs with charges based on community charges; (3) to enable us to bill separately for medical care, procedures, services, DME, drugs, injectables, medical items, and supplies whose charges are presently combined with other charges; and (4) to bring our charge structures and billing practices closer to industry standard charge structures and billing practices.

Additional information regarding each of the above charge types is provided in the following paragraphs.

Acute Inpatient Facility Charges

Presently, the regulations provide methodologies for calculating two per diem charges for each diagnosis related group (DRG), one for room and board and one for ancillary services. These same per diem charges are used for both ICU days and non-ICU days. This document proposes to amend the regulations by providing methodologies for calculating different room and board per diem charges for ICU days and non-ICU days. With these changes, each DRG will have three per diem charges: a room and board per diem charge for ICU days, a different room and board per diem charge for non-ICU days, and an ancillary services per diem charge that applies to both ICU and non-ICU days. We are proposing these changes because they will result in charges for each patient that will be more specific to the care and services the patient received, and will result in VA charge structures and billing practices that more closely approximate industry standard charge structures and billing practices.

As noted earlier, we are proposing to change from MSAs to three-digit ZIP

Codes for geographic areas for acute inpatient facility charges. Presently, we calculate 80th percentile factors and geographic area adjustment factors for acute inpatient facility charges by MSA, based on charge data from the Medicare Standard Analytical File 5% Sample. Associated with the change to threedigit ZIP Codes, we are proposing to amend the regulations to base the calculation of these factors on the MedPAR file, which provides a complete record of all Medicare hospital admissions. This change from 5% to 100% of Medicare hospital admissions will produce more accurate 80th percentile factors and geographic area adjustment factors for the smaller threedigit ZIP Code areas.

Skilled Nursing Facility/Sub-Acute Inpatient Facility Charges

Presently, we calculate skilled nursing facility/sub-acute inpatient facility all-inclusive per diem charges based on the nationwide average per diem charge presented in annual releases of the Milliman USA, Inc., Health Cost Guidelines. We are proposing to change the regulations to base these charges on the actual average per diem billed charge derived from the MedPAR skilled nursing facility file. This will more directly and accurately measure the nationwide baseline charge. and enable calculation of a more accurate nationwide 80th percentile charge. We are also proposing to change the trending methodology from one based on trends in Medicare reimbursement rates, as presented in the Annual Report of the Boards of Trustees of the Federal Supplementary Medical Insurance Trust Funds, to trends based on the inpatient hospital services component of the CPI-U. This change will result in trending that more accurately reflects changes in billed charge levels.

Presently, we calculate 80th percentile adjustment factors and geographic area adjustment factors based on the Medicare Standard Analytical File 5% Sample and the Milliman USA, Inc., Health Cost Guidelines, respectively. We are proposing to amend the regulations to base calculation of these factors on the MedPAR skilled nursing facility file. These changes will produce more accurate 80th percentile adjustment factors and geographic area adjustment factors.

Partial Hospitalization Facility Charges

Presently, we do not have a per diem facility charge that is specific to partial hospitalization, nor do we have charges for any of the HCPCS Level II codes, including those associated with partial hospitalization. We are proposing to amend the regulations to provide a methodology for establishing partial hospitalization facility charges. We are proposing this change so that we will be able to bill for these services when we provide or furnish them to our patients.

Outpatient Facility Charges

Presently, we calculate outpatient facility charges utilizing a statistical method based on 1998 Medicare practice expense RVUs, which we adopted as a proxy weighting system for the calculation of outpatient facility charges. We are proposing to amend the methodology to base nationwide average outpatient facility charges on Medicare Ambulatory Payment Classification (APC) groups, using data from the Medicare Standard Analytical File 5% Sample. This will provide the basis for a more accurate calculation, because APC payment groups are based on actual outpatient facility charge data, whereas the 1998 Medicare practice expense RVUs were based on physician charge data for overhead expenses.

One consequence of adopting APC groups for this purpose is that the statistical methodology we presently use to bundle CPT codes into CPT code groups will no longer be needed, because APCs provide appropriate groupings of codes. We are also proposing to amend the regulations to adjust APC charges, which represent Medicare average reimbursement levels, to nationwide 80th percentile billed charge levels. This adjustment will result in charges that more accurately reflect market-level charges.

For outpatient facility services which do not have APC assignments, we propose to calculate outpatient facility charges using data from the MDR database, the MedStat claims database, and the Medicare Standard Analytical File 5% Sample.

These changes to the regulations will result in VA charge structures and billing practices that more closely approximate industry standard charge structures and billing practices.

Physician and Other Professional Charges Except for Anesthesia Services and Certain Dental Services

Presently, the regulations incorporate the methodologies for charges for pathology/laboratory and anesthesia services in the methodology for physician charges. We are proposing to restructure the regulations so that pathology/laboratory charges and professional charges for anesthesia services are identified as separate charge types. We are also proposing to specify

in the regulations that charges for professional dental services identified by CPT code are determined in accordance with the same methodology as for physician charges, while professional dental services identified by HCPCS Level II code are treated as a separate charge type, with charges determined using a different methodology as discussed below. We are proposing these changes so that different charge types and different charge development methodologies will be separately identified and described in the regulations.

Presently, our charges are not influenced by the presence or absence of CPT code modifiers. This document proposes to amend the regulations to add methodology for developing charge adjustment factors for specified CPT/ HCPCS code modifiers, using data from the Medicare Standard Analytical File 5% Sample. Some charge adjustment factors will act to increase the charge (for example, modifier 22, Unusual Procedural Services). Other charge adjustment factors will act to decrease the charge (for example, modifier 52, Reduced Services). This change will result in VA charge structures and billing practices that more closely approximate industry standard charge structures and billing practices.

Presently, language in the regulations is interpreted to mean that we do not have professional charges for categories of providers other than physicians unless the provider category is specifically named in the regulations. This document proposes to amend the regulations to set forth charge methodologies for physicians and other professionals that apply to all professional provider categories. This change will result in VA charge structures and billing practices that more closely approximate industry standard charge structures and billing practices.

Professional Charges for Anesthesia Services

Presently, professional charges for anesthesia services are based in part on average time units compiled from a Health Care Financing Administration study. Applying this methodology, the professional charge for a given anesthesia procedure is the same, regardless of the length of time the patient received anesthesia. This document proposes to amend the methodology so that professional charges for anesthesia services will vary according to the length of time the patient received anesthesia. This change will result in VA charge structures and billing practices that more closely

approximate industry standard charge structures and billing practices.

Professional Charges for Dental Services Identified by HCPCS Level II Codes

Presently, charges for outpatient dental care are based on VA costs in accordance with the methodology set forth in § 17.102. This document proposes to amend the methodology to establish reasonable charges for dental services identified by HCPCS Level II codes, using data from the Prevailing Healthcare Charges System, the National Dental Advisory Service nationwide pricing index, the Dental UCR (Usual, Customary, or Reasonable) Module of the Ingenix Comprehensive Healthcare Payment System, the Milliman USA, Inc., Dental Health Cost Guidelines, and the dental services component of the CPI-U. This change will result in VA charge structures and billing practices that more closely approximate industry standard charge structures and billing practices.

Pathology and Laboratory Charges

Presently, the regulations provide that for each pathology and laboratory CPT code, the technical component RVUs are added to the professional component RVUs, if any, resulting in only one charge for each pathology and laboratory CPT code. This document proposes to amend the methodology so that those pathology and laboratory procedures which require a professional interpretation will have two separate charges: a professional component charge determined according to the methodology set forth in the Physician and Other Professional Charges paragraph in the regulations, and a technical component charge determined according to the methodology set forth in the Pathology and Laboratory Charges paragraph in the regulations. This change will result in VA charge structures and billing practices that more closely approximate industry standard charge structures and billing practices.

Observation Care Facility Charges

Presently, our facility charges for observation care consist of outpatient facility charges for three observation care CPT codes, 99218, 99219, and 99220. These charges are per occurrence, regardless of the number of hours the patient received observation care. This document proposes to amend the regulations to provide a methodology for establishing observation care facility charges that will vary according to the number of hours the patient receives observation

care. For this purpose, we propose to use data from the outpatient facility component of the Medicare Standard Analytical File 5% Sample, trend the charges forward using the outpatient hospital services component of the CPI-U, and use the geographic area adjustment factors computed for outpatient facility charges. This change will result in VA charge structures and billing practices that more closely approximate industry standard charge structures and billing practices.

Ambulance and Other Emergency Transportation Charges

Ambulance and other emergency transportation services are identified by HCPCS Level II codes. Presently, we do not have charges for any HCPCS Level II codes. This document proposes to amend the regulations to provide a methodology for establishing charges for ambulance and other emergency transportation services by HCPCS Level II code. For this purpose, we propose to use data from the outpatient facility component of the Medicare Standard Analytical File 5% Sample, trend the charges forward using the outpatient hospital services component of the CPI-U, and use the geographic area adjustment factors computed for outpatient facility charges. We are proposing this change so that we will be able to bill and be reimbursed for these services when we provide or furnish them to our patients.

Charges for Durable Medical Equipment, Drugs, Injectables, and Other Medical Services, Items, and Supplies Identified By HCPCS Level II Codes

Presently, we do not have charges for any HCPCS Level II codes. This document proposes to amend the regulations to provide a methodology for establishing charges for DME, drugs, injectables, and other medical services, items, and supplies identified by HCPCS Level II code. For this purpose, we propose to use the following data sources: Ingenix/St. Anthony's RBRVS; Medicare DME Fee Schedule; Medicare Parenteral and Enteral Nutrition Fee Schedule; Part B and DME components of the Medicare Standard Analytical File 5% Sample; MDR database; Milliman USA, Inc., Optimized HMO (Health Maintenance Organization) Data Sets; Milliman USA, Inc., Health Cost Guidelines; and a VA nationwide distribution of procedures, services, items, and supplies. We propose to trend these charges forward using the medical care commodities component of the CPI-U. We are proposing this change so that we will be able to bill

and be reimbursed for these services, items, and supplies when we provide or furnish them to our patients.

Responses to Comments

In response to our interim final rule published in the **Federal Register** on May 8, 2001 (66 FR 23326, RIN 2900–AK73), we received two comments, both from the same commenter, that we have not previously resolved.

The commenter stated that we should add charges for codes G0193 through G0201 (HCPCS Level II codes). In this document, we are proposing to add charges for nearly all HCPCS Level II codes, including codes G0193 through G0201

The same commenter also stated that we have identified audiology services furnished in conjunction with a hearing aid, CPT codes 92590 through 92595, as physician services, when in fact these services are performed solely by audiologists and should not be designated as physician services.

With respect to our charge development methodology, our charge for a given service reflects the actual amounts billed by the providers of that service. Therefore, our charge for a service performed solely by audiologists will reflect the actual amounts billed by audiologists, not by physicians. However, we agree that including these and other services not performed by physicians under the general category of 'physician charges'' may be confusing. Therefore, in this document, we are proposing to change from the term 'physician services'' to the term "physician and other professional services" so as to allow for the fact that many professional medical services are performed by audiologists and other healthcare professionals instead of, or in addition to, physicians.

Unfunded Mandates

The Unfunded Mandates Reform Act requires, at 2 U.S.C. 1532, that agencies prepare an assessment of anticipated costs and benefits before developing any rule that may result in an expenditure by State, local, or tribal governments, in the aggregate, or by the private sector, of \$100 million or more in any given year. This proposed rule would have no such effect on State, local, or tribal governments, or the private sector.

Paperwork Reduction Act

This document contains provisions at 38 CFR 17.101(a)(4) constituting a collection of information under the Paperwork Reduction Act (44 U.S.C. 3501–3521). The Office of Management and Budget (OMB) has approved the information collection requirements for

§ 17.101(a)(4) under OMB control number 2900–0606.

Executive Order 12866

This document has been reviewed by the Office of Management and Budget under Executive Order 12866.

Regulatory Flexibility Act

The Secretary hereby certifies that this proposed rule will not have a significant economic impact on a substantial number of small entities as they are defined in the Regulatory Flexibility Act, 5 U.S.C. 601-612. This proposed rule would affect mainly large insurance companies, and where small entities are involved, they would not be impacted significantly since most of their business is not with VA. Accordingly, pursuant to 5 U.S.C. 605(b), this proposed rule is exempt from the initial and final regulatory flexibility analysis requirements of sections 603 and 604.

Catalog of Federal Domestic Assistance Numbers

The Catalog of Federal Domestic Assistance numbers for the programs affected by this rule are 64.005, 64.007, 64.008, 64.009, 64.010, 64.011, 64.012, 64.013, 64.014, 64.015, 64.016, 64.018, 64.019, 64.022, and 64.025.

List of Subjects in 38 CFR Part 17

Administrative practice and procedure, Alcohol abuse, Alcoholism, Claims, Day care, Dental health, Drug abuse, Foreign relations, Government contracts, Grant programs-health, Grant programs-veterans, Health care, Health facilities, Health professions, Health records, Homeless, Medical and dental schools, Medical devices, Medical research, Mental health programs, Nursing homes, Philippines, Reporting and recordkeeping requirements, Scholarships and fellowships, Travel and transportation expenses, Veterans.

Approved: August 8, 2003.

Anthony J. Principi,

Secretary of Veterans Affairs.

For the reasons set out in the preamble, 38 CFR part 17 is proposed to be amended as set forth below:

PART 17—MEDICAL

1. The authority citation for part 17 continues to read as follows:

Authority: 38 U.S.C. 501, 1721, unless otherwise noted.

2. Section 17.101 is revised to read as follows:

§ 17.101 Collection or recovery by VA for medical care or services provided or furnished to a veteran for a nonservice-connected disability.

(a)(1) General. This section covers collection or recovery by VA, under 38 U.S.C. 1729, for medical care or services provided or furnished to a veteran:

(i) For a nonservice-connected disability for which the veteran is entitled to care (or the payment of expenses of care) under a health plan contract;

(ii) For a nonservice-connected disability incurred incident to the veteran's employment and covered under a worker's compensation law or plan that provides reimbursement or indemnification for such care and services; or

(iii) For a nonservice-connected disability incurred as a result of a motor vehicle accident in a State that requires automobile accident reparations insurance.

(2) Methodologies. Based on the methodologies set forth in this section, the charges billed will include the following types of charges, as appropriate: acute inpatient facility charges; skilled nursing facility/subacute inpatient facility charges; partial hospitalization facility charges; outpatient facility charges; physician and other professional charges, including professional charges for anesthesia services and dental services; pathology and laboratory charges; observation care facility charges; ambulance and other emergency transportation charges; and charges for durable medical equipment, drugs, injectables, and other medical services, items, and supplies identified by HCPCS Level II codes. In addition, the charges billed for prescription drugs not administered during treatment will be based on VA costs in accordance with the methodology set forth in § 17.102. Data for calculating actual charge amounts based on the methodologies set forth in this section will either be published in a notice in the Federal Register or will be posted on the Internet site of the Veterans Health Administration Chief Business Office at http://www.va.gov/revenue, under "Charge Data." For care for which VA has established a charge, VA will bill using its most recent published or posted charge. For care for which VA has not established a charge, VA will bill according to the methodology set forth in paragraph (a)(8) of this section.

(3) Data sources. In this section, data sources are identified by name. The specific editions of these data sources used to calculate actual charge amounts, and information on where these data

sources may be obtained, will be presented along with the data for calculating actual charge amounts, either in notices in the **Federal Register** or on the Internet site of the Veterans Health Administration Chief Business Office at http://www.va.gov/revenue, under "Charge Data."

(4) Amount of recovery or collection third party liability. A third-party payer liable under a health plan contract has the option of paying either the billed charges described in this section or the amount the health plan demonstrates is the amount it would pay for care or services furnished by providers other than entities of the United States for the same care or services in the same geographic area. If the amount submitted by the health plan for payment is less than the amount billed, VA will accept the submission as payment, subject to verification at VA's discretion in accordance with this section. A VA employee having responsibility for collection of such charges may request that the third party health plan submit evidence or information to substantiate the appropriateness of the payment amount (e.g., health plan or insurance policies, provider agreements, medical evidence, proof of payment to other providers in the same geographic area for the same care and services VA provided).

(5) *Definitions*. For purposes of this section:

APC means Medicare Ambulatory Payment Classification.

CMS means the Centers for Medicare and Medicaid Services.

CPI–U means Consumer Price Index—All Urban Consumers.

CPT code and CPT procedure code mean Current Procedural Terminology code, a five-digit identifier defined by the American Medical Association for a specified physician service or procedure.

DME means Durable Medical Equipment.

DRG means Diagnosis Related Group. Geographic area means a three-digit ZIP Code area.

HCPCS code means a Healthcare Common Procedure Coding System Level II identifier, consisting of a letter followed by four digits, defined by CMS for a specified physician service, procedure, test, supply, or other medical service.

ICU means Intensive Care Unit, including coronary care units.

MDR means Medical Data Research, a medical charge database published by Ingenix, Inc.

MedPAR means the Medicare Provider Analysis and Review file. Non-provider-based means a VA healthcare entity (such as a small VA community-based outpatient clinic) that functions as the equivalent of a doctor's office or for other reasons does not meet CMS provider-based criteria, and, therefore, is not entitled to bill outpatient facility charges.

Provider-based means the outpatient department of a VA hospital or any other VA healthcare entity that meets CMS provider-based criteria. Provider-based entities are entitled to bill outpatient facility charges.

RBRVS means Resource-Based Relative Value Scale.

procedures, services, items, and

RVU means Relative Value Unit.
Unlisted procedures mean
procedures, services, items, and
supplies that have not been defined or
specified by the American Medical
Association or CMS, and the CPT and
HCPCS codes used to report such

supplies.

(6) Provider-based and non-providerbased entities and charges. Each VA healthcare entity (medical center, hospital, community-based outpatient clinic, independent outpatient clinic, etc) is designated as either providerbased or non-provider-based. Providerbased entities are entitled to bill outpatient facility charges; nonprovider-based entities are not. The charges for physician and other professional services provided at nonprovider-based entities will be billed as professional charges only. Professional charges for both provider-based entities and non-provider-based entities are produced by the methodologies set forth in this section, with professional charges for provider-based entities based on facility practice expense RVUs, and professional charges for nonprovider-based entities based on nonfacility practice expense RVUs.

(7) Charges for medical care or services provided by non-VA providers at VA expense. When medical care or services are furnished at the expense of the VA by non-VA providers, the charges billed for such care or services will be the higher of the charges determined according to this section, or the amount VA paid to the non-VA

provider.

(8) Charges for medical care or services for which VA does not have an established charge. When medical care or services are provided or furnished at VA expense by either VA or non-VA providers, and VA does not have an established charge for such care or services, then the charges billed for such care or services will be according to the first of the following subparagraphs that applies:

(i) In the event that a new identifier (DRG, CPT code, or HCPCS code) is assigned to a particular type or item of medical care or service, then until such time as VA establishes a charge for the new identifier, VA's charge for such care or service will be VA's most recent established charge for the identifier previously assigned to that type or item of medical care or service; otherwise,

(ii) In the event that the medical care or service is provided or furnished at VA expense by a non-VA provider, then VA's charge for such care or service will be the amount VA paid to the non-VA

provider; otherwise,

(iii) VA's charges for prosthetic devices and durable medical equipment will be VA's actual cost; otherwise.

(iv) If a Medicare allowed charge amount can be determined for the care or service, then VA's charge will be the Medicare participating provider allowed charge amount geographically adjusted using the applicable geographic area adjustment factors determined pursuant to this section; otherwise,

(v) If a charge cannot be established under paragraphs (a)(8)(i) through (iv) of this section, then VA will not charge for the care or service under this section.

(b) Acute inpatient facility charges. When VA provides or furnishes acute inpatient services within the scope of care referred to in paragraph (a)(1) of this section, acute inpatient facility charges billed for such services will be determined in accordance with the provisions of this paragraph. Acute inpatient facility charges consist of per diem charges for room and board and for ancillary services that vary by geographic area and by DRG. These charges are calculated as follows:

(1) Formula. For each acute inpatient stay, or portion thereof, for which a particular DRG assignment applies, the total acute inpatient facility charge is the sum of the applicable charges determined pursuant to paragraphs (b)(1)(i), (ii), and (iii) of this section. For purposes of this section, standard room and board days and ICU room and board days are mutually exclusive: VA will bill either a standard room and board per diem charge or an ICU room and board per diem charge, as applicable, for each day of a given acute inpatient stay.

(i) Standard room and board charges. Multiply the nationwide standard room and board per diem charge determined pursuant to paragraph (b)(2) of this section by the appropriate geographic area adjustment factor determined pursuant to paragraph (b)(3) of this section. The result constitutes the areaspecific standard room and board per diem charge. Multiply this amount by the number of days for which standard

room and board charges apply to obtain the total acute inpatient facility standard room and board charge.

(ii) ICU room and board charges. Multiply the nationwide ICU room and board per diem charge determined pursuant to paragraph (b)(2) of this section by the appropriate geographic area adjustment factor determined pursuant to paragraph (b)(3) of this section. The result constitutes the areaspecific ICU room and board per diem charge. Multiply this amount by the number of days for which ICU room and board per diem charges apply to obtain the total acute inpatient facility ICU room and board charge.

(iii) Ancillary charges. Multiply the nationwide ancillary per diem charge determined pursuant to paragraph (b)(2) of this section by the appropriate geographic area adjustment factor determined pursuant to paragraph (b)(3) of this section. The result constitutes the area-specific ancillary per diem charge. Multiply this amount by the number of days of acute inpatient care to obtain the total acute inpatient facility ancillary charge.

Note to paragraph (b)(1): If there is a change in a patient's condition and/or treatment during a single acute inpatient stay such that the DRG assignment changes (for example, a psychiatric patient who develops a medical or surgical problem), then calculations of acute inpatient facility charges will be made separately for each DRG, according to the number of days of care applicable for each DRG, and the total acute inpatient facility charge will be the sum of the total acute inpatient facility charges for the different DRGs.

(2) Per diem charges. To establish a baseline, two nationwide average per diem amounts for each DRG are calculated, one from the MedPAR file and one from the MedStat claims database, a database of nationwide commercial insurance claims. Average per diem charges are calculated based on all available charges, except for care reported for emergency room, ambulance, professional, and observation care. These two data sources may report charges for two differing periods of time; when this occurs, the data source charges with the earlier center date are trended forward to the center date of the other data source, based on changes to the inpatient hospital services component of the CPI-U. Results obtained from these two data sources are then combined into a single weighted average per diem charge for each DRG. The resulting charge for each DRG is then separated into its two components, a room and board component and an ancillary component, with the per diem

charge for each component calculated by multiplying the weighted average per diem charge by the corresponding percentage determined pursuant to paragraph (b)(2)(i) of this section. The room and board per diem charge is further differentiated into a standard room and board per diem charge and an ICU room and board per diem charge by multiplying the average room and board charge by the corresponding DRGspecific ratios determined pursuant to paragraph (b)(2)(ii) of this section. The resulting per diem charges for standard room and board, ICU room and board, and ancillary services for each DRG are then each multiplied by the final ratio determined pursuant to paragraph (b)(2)(iii) of this section to reflect the nationwide 80th percentile charges. Finally, the resulting amounts are each trended forward from the center date of the trended data sources to the effective time period for the charges, as set forth in paragraph (b)(2)(iv) of this section. The results constitute the nationwide 80th percentile standard room and board, ICU room and board, and ancillary per diem charges.

(i) Room and board charge and ancillary charge component percentages. Using only those cases from the MedPAR file for which a distinction between room and board charges and ancillary charges can be determined, the percentage of the total charges for room and board compared to the combined total charges for room and board and ancillary services, and the percentage of the total charges for ancillary services compared to the combined total charges for room and board and ancillary services, are calculated by DRG.

(ii) Standard room and board per diem charge and ICU room and board per diem charge ratios. Using only those cases from the MedPAR file for which a distinction between room and board and ancillary charges can be determined, overall average per diem room and board charges are calculated by DRG. Then, using the same cases, an average standard room and board per diem charge is calculated by dividing total non-ICU room and board charges by total non-ICU room and board days. Similarly, an average ICU room and board per diem charge is calculated by dividing total ICU room and board charges by total ICU room and board days. Finally, ratios of standard room and board per diem charges to average overall room and board per diem charges are calculated by DRG, as are ratios of ICU room and board per diem charges to average overall room and board per diem charges.

(iii) 80th percentile. Using cases from the MedPAR file with separately identifiable semi-private room rates, the ratio of the day-weighted 80th percentile semi-private room and board per diem charge to the average semi-private room and board per diem charge is obtained for each geographic area. The geographic area-based ratios are averaged to obtain a final 80th

percentile ratio. (iv) Trending forward. 80th percentile charges for each DRG, obtained as described in paragraph (b)(2) of this section, are trended forward based on changes to the inpatient hospital services component of the CPI-U. Actual CPI–U changes are used from the center date of the trended data sources through the latest available month as of the time the calculations are performed. The three-month average annual trend rate as of the latest available month is then held constant to the midpoint of the calendar year in which the charges are primarily expected to be used. The projected total CPI–U change so obtained is then applied to the 80th

percentile charges.

(3) Geographic area adjustment factors. For each geographic area, the average per diem room and board charges and ancillary charges from the MedPAR file are calculated for each DRG. The DRGs are separated into two groups, surgical and non-surgical. For each of these groups of DRGs, for each geographic area, average room and board per diem charges and ancillary per diem charges are calculated, weighted by nationwide VA discharges and by average lengths of stay from the combined MedPAR file and MedStat claims database. This results in four average per diem charges for each geographic area: room and board for surgical DRGs, ancillary for surgical DRGs, room and board for non-surgical DRGs, and ancillary for non-surgical DRGs. Four corresponding national average per diem charges are obtained from the MedPAR file, weighted by nationwide VA discharges and by average lengths of stay from the combined MedPAR file and MedStat claims database. Four geographic area adjustment factors are then calculated for each geographic area by dividing each geographic area average per diem charge by the corresponding national average per diem charge.

(c) Skilled nursing facility/sub-acute inpatient facility charges. When VA provides or furnishes skilled nursing/sub-acute inpatient services within the scope of care referred to in paragraph (a)(1) of this section, skilled nursing facility/sub-acute inpatient facility charges billed for such services will be

determined in accordance with the provisions of this paragraph. The skilled nursing facility/sub-acute inpatient facility charges are per diem charges that vary by geographic area. The facility charges cover care, including room and board, nursing care, pharmaceuticals, supplies, and skilled rehabilitation services (e.g., physical therapy, inhalation therapy, occupational therapy, and speechlanguage pathology), that is provided in a nursing home or hospital inpatient setting, is provided under a physician's orders, and is performed by or under the general supervision of professional personnel such as registered nurses, licensed practical nurses, physical therapists, occupational therapists, speech-language pathologists, and audiologists. These charges are calculated as follows:

(1) Formula. For each stay, multiply the nationwide per diem charge determined pursuant to paragraph (c)(2) of this section by the appropriate geographic area adjustment factor determined pursuant to paragraph (c)(3) of this section. The result constitutes the area-specific per diem charge. Finally, multiply the area-specific per diem charge by the number of days of care to obtain the total skilled nursing facility/sub-acute inpatient facility charge.

(2) Per diem charge. To establish a baseline, a nationwide average per diem billed charge is calculated based on charges reported in the MedPAR skilled nursing facility file. For this purpose, the following MedPAR charge categories are included: room and board (private, semi-private, and ward), physical therapy, occupational therapy, inhalation therapy, speech-language pathology, pharmacy, medical/surgical supplies, and "other" services. The following MedPAR charge categories are excluded from the calculation of the per diem charge and will be billed separately, using the charges determined as set forth in other applicable paragraphs of this section, when these services are provided to skilled nursing patients or sub-acute inpatients: ICU and CCU room and board, laboratory, radiology, cardiology, dialysis, operating room, blood and blood administration, ambulance, MRI, anesthesia, durable medical equipment, emergency room, clinic, outpatient, professional, lithotripsy, and organ acquisition services. The resulting average per diem billed charge is then multiplied by the 80th percentile adjustment factor determined pursuant to paragraph (c)(2)(i) of this section to obtain a nationwide 80th percentile charge level. Finally, the resulting amount is trended forward to the

effective time period for the charges, as set forth in paragraph (c)(2)(ii) of this section.

(i) 80th percentile adjustment factor. Using the MedPAR skilled nursing facility file, the ratio of the day-weighted 80th percentile room and board per diem charge to the day-weighted average room and board per diem charge is obtained for each geographic area. The geographic areabased ratios are averaged to obtain the 80th percentile adjustment factor.

(ii) Trending forward. The 80th percentile charge is trended forward based on changes to the inpatient hospital services component of the CPI-U. Actual CPI-U changes are used from the time period of the source data through the latest available month as of the time the calculations are performed. The three-month average annual trend rate as of the latest available month is then held constant to the midpoint of the calendar year in which the charges are primarily expected to be used. The projected total CPI-U change so obtained is then applied to the 80th percentile charge.

(3) Geographic area adjustment factors. The average billed per diem charge for each geographic area is calculated from the MedPAR skilled nursing facility file. This amount is divided by the nationwide average billed charge calculated in paragraph (c)(2) of this section. The geographic area adjustment factor for charges for each VA facility is the ratio for the geographic area in which the facility is

located.

(d) Partial hospitalization facility charges. When VA provides or furnishes partial hospitalization services that are within the scope of care referred to in paragraph (a)(1) of this section, the facility charges billed for such services will be determined in accordance with the provisions of this paragraph. Partial hospitalization facility charges are per diem charges that vary by geographic area. These charges are calculated as follows:

(1) Formula. For each partial hospitalization stay, multiply the nationwide per diem charge determined pursuant to paragraph (d)(2) of this section by the appropriate geographic area adjustment factor determined pursuant to paragraph (d)(3) of this section. The result constitutes the areaspecific per diem charge. Finally, multiply the area-specific per diem charge by the number of days of care to obtain the total partial hospitalization facility charge.

(2) Per diem charge. To establish a baseline, a nationwide median per diem billed charge is calculated based on

charges associated with partial hospitalization from the outpatient facility component of the Medicare Standard Analytical File 5% Sample. That median per diem billed charge is then multiplied by the 80th percentile adjustment factor determined pursuant to paragraph (d)(2)(i) of this section to obtain a nationwide 80th percentile charge level. Finally, the resulting amount is trended forward to the effective time period for the charges, as set forth in paragraph (d)(2)(ii) of this section.

(i) 80th percentile adjustment factor. The 80th percentile adjustment factor for partial hospitalization facility charges is the same as that computed for skilled nursing facility/sub-acute inpatient facility charges under paragraph (c)(2)(i) of this section.

(ii) *Trending forward*. The 80th percentile charge is trended forward based on changes to the outpatient hospital services component of the CPI-U. Actual CPI-U changes are used from the time period of the source data through the latest available month as of the time the calculations are performed. The three-month average annual trend rate as of the latest available month is then held constant to the midpoint of the calendar year in which the charges are primarily expected to be used. The projected total CPI-U change so obtained is then applied to the 80th percentile charges, as described in paragraph (d)(2) of this section.

(3) Geographic area adjustment factors. The geographic area adjustment factors for partial hospitalization facility charges are the same as those computed for outpatient facility charges under paragraph (e)(4) of this section.

(e) Outpatient facility charges. When VA provides or furnishes outpatient facility services that are within the scope of care referred to in paragraph (a)(1) of this section, the charges billed for such services will be determined in accordance with the provisions of this paragraph. Charges for outpatient facility services vary by geographic area and by CPT/HCPCS code. These charges apply in the situations set forth in paragraph (e)(1) of this section and are calculated as set forth in paragraph (e)(2) of this section.

(1) Settings and circumstances in which outpatient facility charges apply. Outpatient facility charges consist of facility charges for procedures, diagnostic tests, evaluation and management services, and other medical services, items, and supplies provided in the following settings and circumstances:

(i) Outpatient departments and clinics at VA medical centers;

(ii) Other VA provider-based entities; and

(iii) VA non-provider-based entities, for procedures and tests for which no corresponding professional charge is established under the provisions of paragraph (f) of this section.

(2) Formula. For each outpatient facility charge CPT/HCPCS code, multiply the nationwide 80th percentile charge determined pursuant to paragraph (e)(3) of this section by the appropriate geographic area adjustment factor determined pursuant to paragraph (e)(4) of this section. The result constitutes the area-specific outpatient facility charge. When multiple surgical procedures are performed during the same outpatient encounter by a provider or provider team, the outpatient facility charges for such procedures will be reduced as set forth in paragraph (e)(5) of this section.

(3) Nationwide 80th percentile charges by CPT/HCPCS code. For each CPT/HCPCS code for which outpatient facility charges apply, the nationwide 80th percentile charge is calculated as set forth in either paragraph (e)(3)(i) or (e)(3)(ii) of this section. The resulting amount is trended forward to the effective time period for the charges, as set forth in paragraph (e)(3)(iii) of this section. The results constitute the nationwide 80th percentile outpatient facility charges by CPT/HCPCS code.

(i) Nationwide 80th percentile charges for CPT/HCPCS codes which have APC assignments. Using the outpatient facility charges reported in the outpatient facility component of the Medicare Standard Analytical File 5% Sample, claim records are selected for which all charges can be assigned to an APC. Using this subset of the 5% Sample data, nationwide median charge to Medicare APC payment amount ratios, by APC, and nationwide 80th percentile to median charge ratios, by APC, are computed according to the methodology set forth in paragraphs (e)(3)(i)(A) and (e)(3)(i)(B) of this section, respectively. The product of these two ratios by APC is then computed, resulting in a composite nationwide 80th percentile charge to Medicare APC payment amount ratio. This ratio is then compared to the alternate nationwide 80th percentile charge to Medicare APC payment amount ratio computed in paragraph (e)(3)(i)(C) of this section, and the lesser amount is selected and multiplied by the current Medicare APC payment amount. The resulting product is the APC-specific nationwide 80th percentile charge amount for each applicable CPT/ HCPCS code.

(A) Nationwide median charge to Medicare APC payment amount ratios. For each CPT/HCPCS code, the ratio of median billed charge to Medicare APC payment amount is determined. The weighted average of these ratios for each APC is then obtained, using the reported 5% Sample frequencies as weights. In addition, corresponding ratios are calculated for each of the APC categories set forth in paragraph (e)(3)(i)(D) of this section, again using the reported 5% Sample frequencies as weights. For APCs where the 5% Sample frequencies provide a statistically credible result, the APCspecific weighted average nationwide median charge to Medicare APC payment amount ratio so obtained is accepted without further adjustment. However, if the 5% Sample data do not produce statistically credible results for any specific APC, then the APC category-specific ratio is applied for that APC.

(B) Nationwide 80th percentile to median charge ratios. For each CPT/ HCPCS code, a geographically normalized nationwide 80th percentile billed charge amount is divided by a similarly normalized nationwide median billed charge amount. The weighted average of these ratios for each APC is then obtained, using the reported 5% Sample frequencies as weights. In addition, corresponding ratios are calculated for each of the APC categories set forth in paragraph (e)(3)(i)(D) of this section, again using the reported 5% Sample frequencies as weights. For APCs where the 5% Sample frequencies provide a statistically credible result, the APCspecific weighted average nationwide 80th percentile to median charge ratio so obtained is accepted without further adjustment. However, if the 5% Sample data do not produce statistically credible results for any specific APC, then the APC category-specific ratio is applied for that APC.

(C) Alternate nationwide 80th percentile charge to Medicare APC payment amount ratios. A minimum 80th percentile charge to Medicare APC payment amount ratio is set at 2.0 for APCs with Medicare APC payment amounts of \$25 or less. A maximum 80th percentile charge to Medicare APC payment amount ratio is set at 6.5 for APCs with Medicare APC payment amounts of \$10,000 or more. Using linear interpolation with these endpoints, the alternate APC-specific nationwide 80th percentile charge to Medicare APC payment amount ratio is then computed, based on the Medicare APC payment amount.

- (D) APC categories for the purpose of establishing 80th percentile to median factors. For the purpose of the statistical methodology set forth in paragraph (e)(3)(i) of this section, APCs are assigned to the following APC categories:
 - (1) Radiology.
 - (2) Drugs.
- (3) Office, Home, and Urgent Care Visits.
 - (4) Cardiovascular.
 - (5) Emergency Room Visits.
- (6) Outpatient Psychiatry, Alcohol and Drug Abuse.
 - (7) Pathology.
 - (8) Surgery.
- (9) Allergy Immunotherapy, Allergy Testing, Immunizations, and Therapeutic Injections.
- (10) All APCs not assigned to any of the above groups.
- (ii) Nationwide 80th percentile charges for CPT/HCPCS codes which do not have APC assignments. Nationwide 80th percentile billed charge levels by CPT/HCPCS code are computed from the outpatient facility component of the MDR database, from the MedStat claims database, and from the outpatient facility component of the Medicare Standard Analytical File 5% Sample. If the MDR database contains sufficient data to provide a statistically credible 80th percentile charge, then that result is retained for this purpose. If the MDR database does not provide a statistically credible 80th percentile charge, then the result from the MedStat database is retained for this purpose, provided it is statistically credible. If neither the MDR nor the MedStat databases provide statistically credible results, then the nationwide 80th percentile billed charge computed from the 5% Sample data is retained for this purpose. The nationwide 80th percentile charges retained from each of these data sources are trended forward to the effective time period for the charges, as set forth in paragraph (e)(3)(iii) of this section.
- (iii) Trending forward. The charges for each CPT/HCPCS code, obtained as described in paragraph (e)(3) of this section, are trended forward based on changes to the outpatient hospital services component of the CPI-U. Actual CPI-U changes are used from the time period of the source data through the latest available month as of the time the calculations are performed. The three-month average annual trend rate as of the latest available month is then held constant to the midpoint of the calendar year in which the charges are primarily expected to be used. The projected total CPI-U change so obtained is then applied to the 80th

- percentile charges, as described in paragraph (e)(3) of this section.
- (4) Geographic area adjustment factors. For each geographic area, a single adjustment factor is calculated as the arithmetic average of the outpatient geographic area adjustment factor published in the Milliman USA, Inc., Health Cost Guidelines (this factor constitutes the ratio of the level of charges for each geographic area to the nationwide level of charges), and a geographic area adjustment factor developed from the MDR database. See paragraph (a)(3) of this section for data sources. The MDR-based geographic area adjustment factors are calculated as the ratio of the CPT/HCPCS code weighted average charge level for each geographic area to the nationwide CPT/ HCPCS code weighted average charge level.
- (5) Multiple surgical procedures. When multiple surgical procedures are performed during the same outpatient encounter by a provider or provider team as indicated by multiple surgical CPT/HCPCS procedure codes, then the CPT/HCPCS procedure code with the highest facility charge will be billed at 100% of the charges established under this section; the CPT/HCPCS procedure code with the second highest facility charge will be billed at 25% of the charges established under this section; the CPT/HCPCS procedure code with the third highest facility charge will be billed at 15% of the charges established under this section; and no outpatient facility charges will be billed for any additional surgical procedures.
- (f) Physician and other professional charges except for anesthesia services and certain dental services. When VA provides or furnishes physician and other professional services, other than professional anesthesia services and certain professional dental services, within the scope of care referred to in paragraph (a)(1) of this section, physician and other professional charges billed for such services will be determined in accordance with the provisions of this paragraph. Charges for professional dental services identified by CPT code are determined in accordance with the provisions of this paragraph; charges for professional dental services identified by HCPCS Level II code are determined in accordance with the provisions of paragraph (h) of this section. Physician and other professional charges consist of charges for professional services that vary by geographic area, by CPT/HCPCS code, by site of service, and by modifier, where applicable. These charges are calculated as follows:

- (1) Formula. For each CPT/HCPCS code or, where applicable, each CPT/ HCPCS code and modifier combination, multiply the total geographicallyadjusted RVUs determined pursuant to paragraph (f)(2) of this section by the applicable geographically-adjusted conversion factor (a monetary amount) determined pursuant to paragraph (f)(3) of this section to obtain the physician charge for each CPT/HCPCS code in a particular geographic area. Then, multiply this charge by the appropriate factors for any charge-significant modifiers, determined pursuant to paragraph (f)(4) of this section.
- (2)(i) Total geographically-adjusted RVUs for physician services that have Medicare RVUs. The work expense and practice expense RVUs for CPT/HCPCS codes, other than the codes described in paragraphs (f)(2)(ii) and (f)(2)(iii) of this section, are compiled using Medicare Physician Fee Schedule RVUs. The sum of the geographically-adjusted work expense RVUs determined pursuant to paragraph (f)(2)(i)(A) of this section and the geographically-adjusted practice expense RVUs determined pursuant to paragraph (f)(2)(i)(B) of this section equals the total geographically-adjusted RVUs.
- (A) Geographically-adjusted work expense RVUs. For each CPT/HCPCS code for each geographic area, the Medicare Physician Fee Schedule work expense RVUs are multiplied by the work expense Medicare Geographic Practice Cost Index. The result constitutes the geographically-adjusted work expense RVUs.
- (B) Geographically-adjusted practice expense RVUs. For each CPT/HCPCS code for each geographic area, the Medicare Physician Fee Schedule practice expense RVUs are multiplied by the practice expense Medicare Geographic Practice Cost Index. The result constitutes the geographicallyadjusted practice expense RVUs. In these calculations, facility practice expense RVUs are used to obtain geographically-adjusted practice expense RVUs for use by provider-based entities, and non-facility practice expense RVUs are used to obtain geographically-adjusted practice expense RVUs for use by non-providerbased entities.
- (ii) RVUs for CPT/HCPCS codes that do not have Medicare RVUs and are not designated as unlisted procedures. For CPT/HCPCS codes that are not assigned RVUs in paragraphs (f)(2)(i) or (f)(2)(iii) of this section, total RVUs are developed based on various charge data sources. For these CPT/HCPCS codes, the nationwide 80th percentile billed charges are obtained, where statistically

credible, from the MDR database. For any remaining CPT/HCPCS codes, the nationwide 80th percentile billed charges are obtained, where statistically credible, from the Part B component of the Medicare Standard Analytical File 5% Sample. For any remaining CPT/ HCPCS codes, the nationwide 80th percentile billed charges are obtained, where statistically credible, from the Prevailing Healthcare Charges System nationwide commercial insurance database. For each of these CPT/HCPCS codes, nationwide total RVUs are obtained by taking the nationwide 80th percentile billed charges obtained using the preceding three databases and dividing by the untrended nationwide conversion factor for the corresponding CPT/HCPCS code group determined pursuant to paragraphs (f)(3) and (f)(3)(i) of this section. For any remaining CPT/ HCPCS codes that have not been assigned RVUs using the preceding data sources, the nationwide total RVUs are calculated by summing the work expense and non-facility practice expense RVUs found in Ingenix/St. Anthony's RBRVS. The resulting nationwide total RVUs obtained using these four data sources are multiplied by the geographic area adjustment factors determined pursuant to paragraph (f)(2)(iv) of this section to obtain the area-specific total RVUs.

(iii) RVUs for CPT/HCPCS codes designated as unlisted procedures. For CPT/HCPCS codes designated as unlisted procedures, total RVUs are developed based on the weighted median of the total RVUs of CPT/HCPCS codes within the series in which the unlisted procedure code occurs. A nationwide VA distribution of procedures and services is used for the purpose of computing the weighted median. The resulting nationwide total RVUs are multiplied by the geographic area adjustment factors determined pursuant to paragraph (f)(2)(iv) of this section to obtain the area-specific total RVUs.

(iv) RVU geographic area adjustment factors for CPT/HCPCS codes that do not have Medicare RVUs, including codes that are designated as unlisted procedures. The adjustment factor for each geographic area consists of the weighted average of the work expense and practice expense Medicare Geographic Practice Cost Indices for each geographic area using charge data for representative CPT/HCPCS codes statistically selected and weighted for work expense and practice expense.

(3) Geographically-adjusted 80th percentile conversion factors. CPT/HCPCS codes are separated into the following 23 CPT/HCPCS code groups:

allergy immunotherapy, allergy testing, cardiovascular, chiropractor, consults, emergency room visits and observation care, hearing/speech exams, immunizations, inpatient visits, maternity/cesarean deliveries, maternity/non-deliveries, maternity/ normal deliveries, miscellaneous medical, office/home/urgent care visits, outpatient psychiatry/alcohol and drug abuse, pathology, physical exams, physical medicine, radiology, surgery, therapeutic injections, vision exams, and well baby exams. For each of the 23 CPT/HCPCS code groups, representative CPT/HCPCS codes are statistically selected and weighted so as to give a weighted average RVU comparable to the weighted average RVU of the entire CPT/HCPCS code group (the selected CPT/HCPCS codes are set forth in the Milliman USA, Inc., Health Cost Guidelines fee survey; see paragraph (a)(3) of this section for data sources). The 80th percentile charge for each selected CPT/HCPCS code is obtained from the MDR database. A nationwide conversion factor (a monetary amount) is calculated for each CPT/HCPCS code group as set forth in paragraph (f)(3)(i) of this section. The nationwide conversion factors for each of the 23 CPT/HCPCS code groups are trended forward to the effective time period for the charges, as set forth in paragraph (f)(3)(ii) of this section. The resulting amounts for each of the 23 groups are multiplied by geographic area adjustment factors determined pursuant to paragraph (f)(3)(iii) of this section, resulting in geographically-adjusted 80th percentile conversion factors for each geographic area for the 23 CPT/ HCPCS code groups for the effective charge period.

(i) Nationwide conversion factors. Using the nationwide 80th percentile charges for the selected CPT/HCPCS codes from paragraph (f)(3) of this section, a nationwide conversion factor is calculated for each of the 23 CPT/HCPCS code groups by dividing the weighted average charge by the

weighted average RVU.

(ii) Trending forward. The nationwide conversion factors for each of the 23 CPT/HCPCS code groups, obtained as described in paragraph (f)(3)(i) of this section, are trended forward based on changes to the physicians' services component of the CPI-U. Actual CPI-U changes are used from the time period of the source data through the latest available month as of the time the calculations are performed. The three-month average annual trend rate as of the latest available month is then held constant to the midpoint of the calendar year in which the charges are primarily

expected to be used. The projected total CPI-U change so obtained is then applied to the 23 conversion factors.

(iii) Geographic area adjustment factors. Using the 80th percentile charges for the selected CPT/HCPCS codes from paragraph (f)(3) of this section for each geographic area, a geographic area-specific conversion factor is calculated for each of the 23 CPT/HCPCS code groups by dividing the weighted average charge by the weighted average geographicallyadjusted RVU. The resulting conversion factor for each geographic area for each of the 23 CPT/HCPCS code groups is divided by the corresponding nationwide conversion factor determined pursuant to paragraph (f)(3)(i) of this section. The resulting ratios are the geographic area adjustment factors for the conversion factors for each of the 23 CPT/HCPCS code groups for each geographic area.

(4) Charge adjustment factors for specified CPT/HCPCS code modifiers. Surcharges or charge discounts are calculated in the following manner: from the Part B component of the Medicare Standard Analytical File 5% Sample, the ratio of weighted average billed charges for CPT/HCPCS codes with the specified modifier to the weighted average billed charge for CPT/ HCPCS codes with no charge modifier is calculated, using the frequency of procedure codes with the modifier as weights in both weighted average calculations. The resulting ratios constitute the surcharge or discount factors for specified charge-significant CPT/HCPCS code modifiers.

(5) Certain charges for providers other

than physicians. When services for which charges are established according to the preceding provisions of this paragraph (f) are performed by providers

paragraph (t) are performed by providers other than physicians, the charges for those services will be as determined by the preceding provisions of this

paragraph, except as follows:

(i) Outpatient facility charges. When the services of providers other than physicians are furnished in outpatient facility settings or in other facilities designated as provider-based, and outpatient facility charges for those services have been established under paragraph (e) of this section, then the outpatient facility charges established under paragraph (e) will apply instead of the charges established under this paragraph (f).

(ii) Discounted charges. Charges for the professional services of the following providers will be the indicated percentages of the amount that would be charged if the care had

been provided by a physician:

- (A) Nurse practitioner: 85%.
- (B) Clinical nurse specialist: 85%.
- (C) Physician assistant: 85%. (D) Clinical psychologist: 80%.
- (E) Clinical social worker: 75%.
- (F) Dietitian: 75%.
- (G) Clinical pharmacist: 80%.
- (g) Professional charges for anesthesia services. When VA provides or furnishes professional anesthesia services within the scope of care referred to in paragraph (a)(1) of this section, professional anesthesia charges billed for such services will be determined in accordance with the provisions of this paragraph. Charges for professional anesthesia services provided by physicians or by certified registered nurse anesthetists when not medically directed by an anesthesiologist will be 100% of the charges determined as set forth in this paragraph. Charges for professional anesthesia services provided by a certified registered nurse anesthetist when medically directed by an anesthesiologist will be 50% of the charges otherwise determined as set forth in this paragraph, and shall be in addition to the charges for the anesthesiologist. Professional anesthesia charges consist of charges for professional services that vary by geographic area, by CPT/HCPCS code base units, and by number of time units. These charges are calculated as follows:
- (1) Formula. For each anesthesia CPT/HCPCS code, multiply the total anesthesia RVUs determined pursuant to paragraph (g)(2) of this section by the applicable geographically-adjusted conversion factor (a monetary amount) determined pursuant to paragraph (g)(3) of this section to obtain the professional anesthesia charge for each CPT/HCPCS code in a particular geographic area.
- (2) Total RVUs for professional anesthesia services. The total anesthesia RVUs for each anesthesia CPT/HCPCS code are the sum of the base units (as compiled by CMS) for that CPT/HCPCS code and the number of time units reported for the anesthesia service, where one time unit equals 15 minutes. For anesthesia CPT/HCPCS codes designated as unlisted procedures, base units are developed based on the weighted median base units for anesthesia CPT/HCPCS codes within the series in which the unlisted procedure code occurs. A nationwide VA distribution of procedures and services is used for the purpose of computing the weighted median base units.
- (3) Geographically-adjusted 80th percentile conversion factors. A nationwide 80th percentile conversion factor is calculated according to the methodology set forth in paragraph

- (g)(3)(i) of this section. The nationwide conversion factor is then trended forward to the effective time period for the charges, as set forth in paragraph (g)(3)(ii) of this section. The resulting amount is multiplied by geographic area adjustment factors determined pursuant to paragraph (g)(3)(iii) of this section, resulting in geographically-adjusted 80th percentile conversion factors for each geographic area for the effective charge period.
- (i) Nationwide conversion factor. Preliminary 80th percentile conversion factors for each area are compiled from the MDR database. Then, a preliminary nationwide weighted-average 80th percentile conversion factor is calculated, using as weights the population (census) frequencies for each geographic area as presented in the Milliman USA, Inc., Health Cost Guidelines (see paragraph (a)(3) of this section for data sources). A nationwide 80th percentile fee by CPT/HCPCS code is then computed by multiplying this conversion factor by the MDR base units for each CPT/HCPCS code. An adjusted 80th percentile conversion factor by CPT/HCPCS code is then calculated by dividing the nationwide 80th percentile fee for each procedure code by the anesthesia base units (as compiled by CMS) for that CPT/HCPCS code. Finally, a nationwide weighted average 80th percentile conversion factor is calculated using combined frequencies for billed base units and time units from the Part B component of the Medicare Standard Analytical File 5% Sample as weights.
- (ii) Trending forward. The nationwide conversion factor, obtained as described in paragraph (g)(3)(i) of this section, is trended forward based on changes to the physicians' services component of the CPI-U. Actual CPI-U changes are used from the time period of the source data through the latest available month as of the time the calculations are performed. The three-month average annual trend rate as of the latest available month is then held constant to the midpoint of the calendar year in which the charges are primarily expected to be used. The projected total CPI-U change so obtained is then applied to the conversion factor.
- (iii) Geographic area adjustment factors. The preliminary 80th percentile conversion factors for each geographic area described in paragraph (g)(3)(i) of this section are divided by the corresponding preliminary nationwide 80th percentile conversion factor also described in paragraph (g)(3)(i). The resulting ratios are the adjustment factors for each geographic area.

- (h) Professional charges for dental services identified by HCPCS Level II codes. When VA provides or furnishes outpatient dental professional services within the scope of care referred to in paragraph (a)(1) of this section, and such services are identified by HCPCS code rather than CPT code, the charges billed for such services will be determined in accordance with the provisions of this paragraph. The charges for dental services vary by geographic area and by HCPCS code. These charges are calculated as follows:
- (1) Formula. For each HCPCS dental code, multiply the nationwide 80th percentile charge determined pursuant to paragraph (h)(2) of this section by the appropriate geographic area adjustment factor determined pursuant to paragraph (h)(3) of this section. The result constitutes the area-specific dental charge.
- (2) Nationwide 80th percentile charges by HCPCS code. For each HCPCS dental code, 80th percentile charges are extracted from three independent data sources: Prevailing Healthcare Charges System database; National Dental Advisory Service nationwide pricing index; and the Dental UCR Module of the Comprehensive Healthcare Payment System, a release from Ingenix from a nationwide database of dental charges (see paragraph (a)(3) of this section for data sources). Charges for each database are then trended forward to a common date, based on actual changes to the dental services component of the CPI-U. Charges for each HCPCS dental code from each data source are combined into an average 80th percentile charge by means of the methodology set forth in paragraph (h)(2)(i) of this section. HCPCS dental codes designated as unlisted are assigned 80th percentile charges by means of the methodology set forth in paragraph (h)(2)(ii) of this section. Finally, the resulting amounts are each trended forward to the effective time period for the charges, as set forth in paragraph (h)(2)(iii) of this section. The results constitute the nationwide 80th percentile charge for each HCPCS dental code.
- (i) Averaging methodology. The average charge for any particular HCPCS dental code is calculated by first computing a preliminary mean average of the three charges for each code. Statistical outliers are identified and removed by testing whether any charge differs from the preliminary mean charge by more than 50% of the preliminary mean charge. In such cases, the charge most distant from the preliminary mean is removed as an outlier, and the average charge is

calculated as a mean of the two remaining charges. In cases where none of the charges differ from the preliminary mean charge by more than 50% of the preliminary mean charge, the average charge is calculated as a mean of all three reported charges.

(ii) Nationwide 80th percentile charges for HCPCS dental codes designated as unlisted procedures. For HCPCS dental codes designated as unlisted procedures, 80th percentile charges are developed based on the weighted median 80th percentile charge of HCPCS dental codes within the series in which the unlisted procedure code occurs. The distribution of procedures and services from the Prevailing Healthcare Charges System nationwide commercial insurance database is used for the purpose of computing the weighted median.

(iii) Trending forward. 80th percentile charges for each dental procedure code, obtained as described in paragraph (h)(2) of this section, are trended forward based on the dental services component of the CPI-U. Actual CPI-U changes are used from the time period of the source data through the latest available month as of the time the calculations are performed. The threemonth average annual trend rate as of the latest available month is then held constant to the midpoint of the calendar vear in which the charges are primarily expected to be used. The projected total CPI-U change so obtained is then applied to the 80th percentile charges.

(3) Geographic area adjustment factors. A geographic adjustment factor (consisting of the ratio of the level of charges in a given geographic area to the nationwide level of charges) for each geographic area and dental class of service is obtained from Milliman USA, Inc., Dental Health Cost Guidelines, a database of nationwide commercial insurance charges and relative costs; and a normalized geographic adjustment factor computed from the Dental UCR Module of the Comprehensive Healthcare Payment System compiled by Ingenix, as follows: Using local and nationwide average charges reported in the Ingenix data, a local weighted average charge for each dental class of procedure codes is calculated using utilization frequencies from the Milliman USA, Inc., Dental Health Cost Guidelines as weights (see paragraph (a)(3) of this section for data sources). Similarly, using nationwide average charge levels, a nationwide average charge by dental class of procedure codes is calculated. The normalized geographic adjustment factor for each dental class of procedure codes and for each geographic area is the ratio of the

local average charge divided by the corresponding nationwide average charge. Finally, the geographic area adjustment factor is the arithmetic average of the corresponding factors from the data sources mentioned in the first sentence of this paragraph (h)(3).

(i) Pathology and laboratory charges. When VA provides or furnishes pathology and laboratory services within the scope of care referred to in paragraph (a)(1) of this section, charges billed for such services will be determined in accordance with the provisions of this paragraph. Pathology and laboratory charges consist of charges for services that vary by geographic area and by CPT/HCPCS code. These charges are calculated as follows:

(1) Formula. For each CPT/HCPCS code, multiply the total geographically-adjusted RVUs determined pursuant to paragraph (i)(2) of this section by the applicable geographically-adjusted conversion factor (a monetary amount) determined pursuant to paragraph (i)(3) of this section to obtain the pathology/laboratory charge for each CPT/HCPCS code in a particular geographic area.

(2)(i) Total geographically-adjusted RVUs for pathology and laboratory services that have Medicare-based RVUs. Total RVUs are developed based on the Medicare Clinical Diagnostic Laboratory Fee Schedule (CLAB). The CLAB payment amounts are upwardly adjusted such that the adjusted payment amounts are, on average, equivalent to Medicare Physician Fee Schedule payment levels, using statistical comparisons to the 80th percentile derived from the MDR database. These adjusted payment amounts are then divided by the corresponding Medicare conversion factor to derive RVUs for each CPT/HCPCS code. The resulting nationwide total RVUs are multiplied by the geographic adjustment factors determined pursuant to paragraph (i)(2)(iv) of this section to obtain the

area-specific total RVUs. (ii) RVUs for CPT/HCPCS codes that do not have Medicare-based RVUs and are not designated as unlisted procedures. For CPT/HCPCS codes that are not assigned RVUs in paragraphs (i)(2)(i) or (i)(2)(iii) of this section, total RVUs are developed based on various charge data sources. For these CPT/ HCPCS codes, the nationwide 80th percentile billed charges are obtained, where statistically credible, from the MDR database. For any remaining CPT/ HCPCS codes, the nationwide 80th percentile billed charges are obtained, where statistically credible, from the Part B component of the Medicare Standard Analytical File 5% Sample.

For any remaining CPT/HCPCS codes, the nationwide 80th percentile billed charges are obtained, where statistically credible, from the Prevailing Healthcare Charges System nationwide commercial insurance database. For each of these CPT/HCPCS codes, nationwide total RVUs are obtained by taking the nationwide 80th percentile billed charges obtained using the preceding three databases and dividing by the untrended nationwide conversion factor determined pursuant to paragraphs (i)(3) and (i)(3)(i) of this section. For any remaining CPT/HCPCS codes that have not been assigned RVUs using the preceding data sources, the nationwide total RVUs are calculated by summing the work expense and non-facility practice expense RVUs found in Ingenix/St. Anthony's RBRVS. The resulting nationwide total RVUs obtained using these four data sources are multiplied by the geographic area adjustment factors determined pursuant to paragraph (i)(2)(iv) of this section to obtain the area-specific total RVUs.

(iii) RVUs for CPT/HCPCS codes designated as unlisted procedures. For CPT/HCPCS codes designated as unlisted procedures, total RVUs are developed based on the weighted median of the total RVUs of CPT/HCPCS codes within the series in which the unlisted procedure code occurs. A nationwide VA distribution of procedures and services is used for the purpose of computing the weighted median. The resulting nationwide total RVUs are multiplied by the geographic area adjustment factors determined pursuant to paragraph (i)(2)(iv) of this section to obtain the area-specific total RVUs.

(iv) RVU geographic area adjustment factors for CPT/HCPCS codes that do not have Medicare RVUs, including codes that are designated as unlisted procedures. The adjustment factor for each geographic area consists of the weighted average of the work expense and practice expense Medicare Geographic Practice Cost Indices for each geographic area using charge data for representative CPT/HCPCS codes statistically selected and weighted for work expense and practice expense.

(3) Geographically-adjusted 80th percentile conversion factors.
Representative CPT/HCPCS codes are statistically selected and weighted so as to give a weighted average RVU comparable to the weighted average RVU of the entire pathology/laboratory CPT/HCPCS code group (the selected CPT/HCPCS codes are set forth in the Milliman USA, Inc., Health Cost Guidelines fee survey). The 80th percentile charge for each selected CPT/

HCPCS code is obtained from the MDR database. A nationwide conversion factor (a monetary amount) is calculated as set forth in paragraph (i)(3)(i) of this section. The nationwide conversion factor is trended forward to the effective time period for the charges, as set forth in paragraph (i)(3)(ii) of this section. The resulting amount is multiplied by a geographic area adjustment factor determined pursuant to paragraph (i)(3)(iv) of this section, resulting in the geographically-adjusted 80th percentile conversion factor for the effective charge period.

(i) Nationwide conversion factors. Using the nationwide 80th percentile charges for the selected CPT/HCPCS codes from paragraph (i)(3) of this section, a nationwide conversion factor is calculated by dividing the weighted average charge by the weighted average RVU.

(ii) Trending forward. The nationwide conversion factor, obtained as described in paragraph (i)(3) of this section, is trended forward based on changes to the physicians' services component of the CPI-U. Actual CPI-U changes are used from the time period of the source data through the latest available month as of the time the calculations are performed. The three-month average annual trend rate as of the latest available month is then held constant to the midpoint of the calendar year in which the charges are primarily expected to be used. The projected total CPI-U change so obtained is then applied to the pathology/laboratory conversion factor.

(iii) Geographic area adjustment factor. Using the 80th percentile charges for the selected CPT/HCPCS codes from paragraph (i)(3) of this section for each geographic area, a geographic areaspecific conversion factor is calculated by dividing the weighted average charge by the weighted average geographicallyadjusted RVU. The resulting geographic area conversion factor is divided by the corresponding nationwide conversion factor determined pursuant to paragraph (i)(3)(i) of this section. The resulting ratios are the geographic area adjustment factors for pathology and laboratory services for each geographic

(j) Observation care facility charges. When VA provides observation care within the scope of care referred to in paragraph (a)(1) of this section, the facility charges billed for such care will be determined in accordance with the provisions of this paragraph. The charges for this care vary by geographic area and number of hours of care. These charges are calculated as follows:

(1) Formula. For each occurrence of observation care, add the nationwide

base charge determined pursuant to paragraph (j)(2) of this section to the product of the number of hours in observation care and the hourly charge also determined pursuant to paragraph (j)(2) of this section. Then multiply this amount by the appropriate geographic area adjustment factor determined pursuant to paragraph (j)(3) of this section. The result constitutes the areaspecific observation care facility charge.

(2)(i) Nationwide 80th percentile observation care facility charges. To calculate nationwide base and hourly facility charges, all claims with observation care line items are selected from the outpatient facility component of the Medicare Standard Analytical File 5% Sample. Then, using the 80th percentile observation line item charges for each unique hourly length of stay, a standard linear regression technique is used to calculate the nationwide 80th percentile base charge and 80th percentile hourly charge. Finally, the resulting amounts are each trended forward to the effective time period for the charges, as set forth in paragraph (j)(2)(ii) of this section. The results constitute the nationwide 80th percentile base and hourly facility charges for observation care.

(ii) Trending forward. The nationwide 80th percentile base and hourly facility charges for observation care, obtained as described in paragraph (j)(2)(i) of this section, are trended forward based on changes to the outpatient hospital services component of the CPI–U. Actual CPI–U changes are used from the time period of the source data through the latest available month as of the time the calculations are performed. The three-month average annual trend rate as of the latest available month is then held constant to the midpoint of the calendar year in which the charges are primarily expected to be used. The projected total CPI-U change so obtained is then applied to the 80th percentile charges.

(3) Geographic area adjustment factors. The geographic area adjustment factors for observation care facility charges are the same as those computed for outpatient facility charges under paragraph (e)(4) of this section.

(k) Ambulance and other emergency transportation charges. When VA provides ambulance and other emergency transportation services that are within the scope of care referred to in paragraph (a)(1) of this section, the charges billed for such services will be determined in accordance with the provisions of this paragraph. The charges for these services vary by HCPCS code, length of trip, and

geographic area. These charges are calculated as follows:

(1) Formula. For each occasion of ambulance or other emergency transportation service, add the nationwide base charge for the appropriate HCPCS code determined pursuant to paragraph (k)(2)(i) of this section to the product of the number of miles traveled and the appropriate HCPCS code mileage charge determined pursuant to paragraph (k)(2)(ii) of this section. Then multiply this amount by the appropriate geographic area adjustment factor determined pursuant to paragraph (k)(3) of this section. The result constitutes the area-specific ambulance or other emergency transportation service charge.

(2)(i) Nationwide 80th percentile allinclusive base charge. To calculate a nationwide all-inclusive base charge, all ambulance and other emergency transportation claims are selected from the outpatient facility component of the Medicare Standard Analytical File 5% Sample. Excluding professional and mileage charges, as well as all-inclusive charges which are reported on such claims, the total charge per claim, including incidental supplies, is computed. Then, the 80th percentile amount for each HCPCS code is computed. Finally, the resulting amounts are each trended forward to the effective time period for the charges, as set forth in paragraph (k)(2)(iii) of this section. The results constitute the nationwide 80th percentile all-inclusive base charge for each HCPCS base charge

(ii) Nationwide 80th percentile mileage charge. To calculate a nationwide mileage charge, all ambulance and other emergency transportation claims are selected from the outpatient facility component of the Medicare Standard Analytical File 5% Sample. Excluding professional, incidental, and base charges, as well as claims with all-inclusive charges, the total mileage charge per claim is computed. This amount is divided by the number of miles reported on the claim. Then, the 80th percentile amount for each HCPCS code, using miles as weights, is computed. Finally, the resulting amounts are each trended forward to the effective time period for the charges, as set forth in paragraph (k)(2)(iii) of this section. The results constitute the nationwide 80th percentile mileage charge for each HCPCS mileage code.

(iii) Trending forward. The nationwide 80th percentile charge for each HCPCS code, obtained as described in paragraphs (k)(2)(i) and (k)(2)(ii) of this section, is trended forward based on

changes to the outpatient hospital services component of the CPI–U. Actual CPI–U changes are used from the time period of the source data through the latest available month as of the time the calculations are performed. The three-month average annual trend rate as of the latest available month is then held constant to the midpoint of the calendar year in which the charges are primarily expected to be used. The projected total CPI–U change so obtained is then applied to the 80th percentile charges.

(3) Geographic area adjustment factors. The geographic area adjustment factors for ambulance and other emergency transportation charges are the same as those computed for outpatient facility charges under paragraph (e)(4) of this section.

- (1) Charges for durable medical equipment, drugs, injectables, and other medical services, items, and supplies identified by HCPCS Level II codes. When VA provides DME, drugs, injectables, or other medical services, items, or supplies that are identified by HCPCS Level II codes and that are within the scope of care referred to in paragraph (a)($\bar{1}$) of this section, the charges billed for such services, items, and supplies will be determined in accordance with the provisions of this paragraph. The charges for these services, items, and supplies vary by geographic area, by HCPCS code, and by modifier, when applicable. These charges are calculated as follows:
- (1) Formula. For each HCPCS code, multiply the nationwide charge determined pursuant to paragraphs (l)(2), (l)(3), and (l)(4) of this section by the appropriate geographic area adjustment factor determined pursuant to paragraph (l)(5) of this section. The result constitutes the area-specific charge.
- (2) Nationwide 80th percentile charges for HCPCS codes with RVUs. For each applicable HCPCS code, RVUs are compiled from the data sources set forth in paragraph (l)(2)(i) of this section. The RVUs are multiplied by the charge amount for each incremental RVU determined pursuant to paragraph (l)(2)(ii) of this section, and this amount is added to the fixed charge amount also determined pursuant to paragraph (l)(2)(ii) of this section. Then, for each HCPCS code, this charge is multiplied by the appropriate 80th percentile to median charge ratio determined pursuant to paragraph (l)(2)(iii) of this section. Finally, the resulting amount is trended forward to the effective time period for the charges, as set forth in paragraph (l)(2)(iv) of this section to

obtain the nationwide 80th percentile charge.

- (i) RVUs for DME, drugs, injectables, and other medical services, items, and supplies. For the purpose of the statistical methodology set forth in paragraph (l)(2)(ii) of this section, HCPCS codes are assigned to the following HCPCS code groups. For the HCPCS codes in each group, the RVUs or amounts indicated constitute the RVUs:
- (A) Chemotherapy Drugs: Ingenix/St. Anthony's RBRVS Practice Expense RVIIs
- (B) Other Drugs: Ingenix/St. Anthony's RBRVS Practice Expense RVUs.
- (C) DME—Hospital Beds: Medicare DME Fee Schedule amounts.
- (D) DME—Medical/Surgical Supplies: Medicare DME Fee Schedule amounts.
- (E) DME—Orthotic Devices: Medicare DME Fee Schedule amounts.
- (F) DME—Oxygen and Supplies: Medicare DME Fee Schedule amounts.
- (G) DME—Wheelchairs: Medicare DME Fee Schedule amounts.
- (H) Other DME: Medicare DME Fee Schedule amounts.
- (I) Enteral/Parenteral Supplies: Medicare Parenteral and Enteral Nutrition Fee Schedule amounts.
- (J) Surgical Dressings and Supplies: Medicare DME Fee Schedule amounts.
- (K) Vision Items—Other Than Lenses: Medicare DME Fee Schedule amounts.
- (L) Vision Items—Lenses: Medicare DME Fee Schedule amounts.
- (M) Hearing Items: Ingenix/St. Anthony's RBRVS Practice Expense RVUs.
- (ii) Charge amounts. Using combined Part B and DME components of the Medicare Standard Analytical File 5% Sample, the median billed charge is calculated for each HCPCS code. A mathematical approximation methodology based on least squares techniques is applied to the RVUs specified for each of the groups set forth in paragraph (1)(2)(i) of this section, yielding two charge amounts for each HCPCS code group: a charge amount per incremental RVU, and a fixed charge amount.
- (iii) 80th Percentile to median charge ratios. Two ratios are obtained for each HCPCS code group set forth in paragraph (l)(2)(i) of this section by dividing the weighted average 80th percentile charge by the weighted average median charge derived from two data sources: Medicare data, as represented by the combined Part B and DME components of the Medicare Standard Analytical File 5% Sample; and the MDR database. Charge frequencies from the Medicare data are

- used as weights when calculating all weighted averages. For each HCPCS code group, the smaller of the two ratios is selected as the adjustment from median to 80th percentile charges.
- (iv) Trending forward. The charges for each HCPCS code, obtained as described in paragraph (1)(2)(iii) of this section, are trended forward based on changes to the medical care commodities component of the CPI-U. Actual CPI-U changes are used from the time period of the source data through the latest available month as of the time the calculations are performed. The three-month average annual trend rate as of the latest available month is then held constant to the midpoint of the calendar year in which the charges are primarily expected to be used. The projected total CPI-U change so obtained is then applied to the 80th percentile charges, as described in paragraph (l)(2)(iii) of this section.
- (3) Nationwide 80th percentile charges for HCPCS codes without RVUs. For each applicable HCPCS code, 80th percentile charges are extracted from three independent data sources: the MDR database; Medicare, as represented by the combined Part B and DME components of the Medicare Standard Analytical File 5% Sample; and Milliman USA, Inc., Optimized HMO (Health Maintenance Organization) Data Sets (see paragraph (a)(3) of this section for data sources). Charges from each database are then trended forward to the effective time period for the charges, as set forth in paragraph (l)(3)(i) of this section. Charges for each HCPCS code from each data source are combined into an average 80th percentile charge by means of the methodology set forth in paragraph (l)(3)(ii) of this section. The results constitute the nationwide 80th percentile charge for each applicable HCPCS code.
- (i) Trending forward. The charges from each database for each HCPCS code, obtained as described in paragraph (l)(3) of this section, are trended forward based on changes to the medical care commodities component of the CPI-U. Actual CPI-U changes are used from the time period of each source database through the latest available month as of the time the calculations are performed. The threemonth average annual trend rate as of the latest available month is then held constant to the midpoint of the calendar year in which the charges are primarily expected to be used. The projected total CPI-U change so obtained is then applied to the 80th percentile charges, as described in paragraph (1)(3) of this section.

(ii) Averaging methodology. The average 80th percentile trended charge for any particular HCPCS code is calculated by first computing a preliminary mean average of the three charges for each HCPCS code. Statistical outliers are identified and removed by testing whether any charge differs from the preliminary mean charge by more than 5 times the preliminary mean charge, or by less than 0.2 times the preliminary mean charge. In such cases, the charge most distant from the preliminary mean is removed as an outlier, and the average charge is calculated as a mean of the two remaining charges. In cases where none of the charges differ from the preliminary mean charge by more than 5 times the preliminary mean charge, or less than 0.2 times the preliminary mean charge, the average charge is calculated as a mean of all three reported charges.

(4) Nationwide 80th percentile charges for HCPCS codes designated as unlisted or unspecified. For HCPCS codes designated as unlisted or unspecified procedures, services, items, or supplies, 80th percentile charges are developed based on the weighted median 80th percentile charges of HCPCS codes within the series in which the unlisted or unspecified code occurs. A nationwide VA distribution of procedures, services, items, and supplies is used for the purpose of computing the weighted median.

(5) Geographic area adjustment factors. For the purpose of geographic adjustment, HCPCS codes are combined into two groups: drugs and DME/supplies, as set forth in paragraph

(l)(5)(i) of this section. The geographic area adjustment factor for each of these groups is calculated as the ratio of the area-specific weighted average charge determined pursuant to paragraph (l)(5)(ii) of this section divided by the nationwide weighted average charge determined pursuant to paragraph (l)(5)(iii) of this section.

(i) Combined HCPCS code groups for geographic area adjustment factors for DME, drugs, injectables, and other medical services, items, and supplies. For the purpose of the statistical methodology set forth in paragraph (1)(5) of this section, each of the HCPCS code groups set forth in paragraph (1)(2)(i) of this section is assigned to one of two combined HCPCS code groups, as follows:

(A) Chemotherapy Drugs: Drugs.

(B) Other Drugs: Drugs. (C) DME—Hospital Beds: DME/supplies.

(D) DME—Medical/Surgical Supplies: DME/supplies.

(E) DME—Orthotic Devices: DME/supplies.

(F) DME—Oxygen and Supplies: DME/supplies.

(G) DME—Wheelchairs: DME/supplies.

(Ĥ) Other DME: DME/supplies. (I) Enteral/Parenteral Supplies: DME/supplies.

(J) Surgical Dressings and Supplies: DME/supplies.

(K) Vision Items—Other Than Lenses: DME/supplies.

(L) Vision Items—Lenses: DME/supplies.

(M) Hearing Items: DME/supplies. (ii) Area-specific weighted average charges. Using the median charges by HCPCS code from the MDR database for each geographic area and utilization frequencies by HCPCS code from the combined Part B and DME components of the Medicare Standard Analytical File 5% Sample, an area-specific weighted average charge is calculated for each combined HCPCS code group.

(iii) Nationwide weighted average charges. Using the area-specific weighted average charges determined pursuant to paragraph (1)(5)(ii) of this section, a nationwide weighted average charge is calculated for each combined HCPCS code group, using as weights the population (census) frequencies for each geographic area as presented in the Milliman USA, Inc., Health Cost Guidelines (see paragraph (a)(3) of this section for data sources).

(m) Charges for prescription drugs not administered during treatment. Notwithstanding other provisions of this section, when VA provides or furnishes prescription drugs not administered during treatment, within the scope of care referred to in paragraph (a)(1) of this section, charges billed separately for such prescription drugs will be based on VA costs in accordance with the methodology set forth in § 17.102 of this part.

(The Office of Management and Budget has approved the information collection requirements in this section under control number 2900–0606.)

(Authority: 38 U.S.C. 101, 501, 1701, 1705, 1710, 1721, 1722, 1729)

[FR Doc. 03–24102 Filed 10–1–03; 8:45 am]

DEPARTMENT OF VETERANS AFFAIRS

Reasonable Charges For Medical Care Or Services; 2003 Methodology Changes

AGENCY: Department of Veterans Affairs. **ACTION:** Notice.

SUMMARY: In a companion document published as a proposed rule in this issue of the **Federal Register**, we are proposing to amend VA's medical regulations concerning "reasonable charges" for medical care or services provided or furnished by VA to a veteran:

—For a nonservice-connected disability for which the veteran is entitled to care (or the payment of expenses of care) under a health plan contract;

—For a nonservice-connected disability incurred incident to the veteran's employment and covered under a worker's compensation law or plan that provides reimbursement or indemnification for such care and services; or

—For a nonservice-connected disability incurred as a result of a motor vehicle accident in a State that requires automobile accident reparations insurance.

If the methodology changes presented in the proposed rule are subsequently adopted as a final rule, then the information set forth in this document for calculating actual charge amounts at individual VA facilities will be used from the effective date of the final rule until changed by a subsequent **Federal Register** notice. Accordingly, interested

parties may wish to retain this document for future reference.

This document also identifies the editions of the data sources used to develop the accompanying charge tables, provides information on where the various data sources may be obtained, and provides a list of VA health care facilities.

FOR FURTHER INFORMATION CONTACT: David Cleaver, Chief Business Office (168), Veterans Health Administration, Department of Veterans Affairs, 810 Vermont Avenue, NW., Washington, DC 20420, (202) 254–0361. (This is not a toll free number.)

SUPPLEMENTARY INFORMATION: A proposed rule published as a companion document in this issue of the Federal Register proposes to amend VA's "reasonable charges" regulations for medical care and services (38 CFR 17.101) to revise the methodology for establishing acute inpatient facility charges; skilled nursing facility/subacute inpatient facility charges; partial hospitalization facility charges; outpatient facility charges; physician and other professional charges, including professional charges for anesthesia services and dental services; pathology and laboratory charges; observation care facility charges; ambulance and other emergency transportation charges; and charges for durable medical equipment, drugs, injectables, and other medical services, items, and supplies identified by HCPCS Level II codes. If the changes presented in the proposed rule are subsequently adopted as a final rule, then information for calculating actual

charge amounts at individual VA facilities using the amended methodologies will be as set forth in Tables A through S in this document and will be effective until changed by a subsequent **Federal Register** notice.

The proposed rule also proposes to amend the existing regulations to provide authority to charge for medical care and services under specified circumstances when VA does not have an established charge.

Previously, information on the editions of the data sources used to establish reasonable charges and where the various data sources could be obtained was included in the regulations. We are now proposing to present this information in the applicable Federal Register notice. Accordingly, Supplementary Table 1 lists the data sources and editions used for compiling the data in Tables A through S in this document. Supplementary Table 2 provides information on where the various data sources may be obtained.

Previously, the tables of geographic area adjustment factors (GAAFs) listed VA facility locations by city and state. Consistent with the proposal to use three-digit ZIP Code areas as the geographic areas for all charge types, the GAAFs presented in this document are listed by three-digit ZIP Code. Supplementary Table 3 provides a list of VA facilities that links them to their three-digit ZIP Codes.

Anthony J. Principi, Secretary of Veterans Affairs. BILLING CODE 8320-01-P

PAGE 1 OF 8

		Surgical/	Po	er Diem Charg	ge
DRG	Description	Non- Surgical Indicator	Standard Room and Board	ICU Room and Board	Ancillary
001	Craniotomy age >17 w cc	s	\$1,166.51	\$2,499.20	\$4,591.91
002	Craniotomy age >17 w/o cc	š	\$1,133.18	\$2,447.46	\$5,683.42
003	Craniotomy age 0-17	s	\$1,175.33	\$2,527.44	\$4,872.17
004	Spinal procedures	S	\$1,034.21	\$2,184.06	\$4,454.33
005	Extracranial vascular procedures	S	\$893.55	\$1,771.88	\$5,669.96
006	Carpal tunnel release	S	\$1,094.44	\$1,558.78	\$3,714.81
007	Periph & cranial nerve & other nerv syst proc w cc	S	\$1,083.26	\$1,979.25	\$3,223.00
800	Periph & cranial nerve & other nerv syst proc w/o cc	S N	\$895.38 \$895.88	\$1,639.09 \$2,102.85	\$7,069.63 \$1,378.66
009 010	Spinal disorders & injuries Nervous system neoplasms w cc	N	\$1,115.84	\$2,007.43	\$2,001.86
010	Nervous system neoplasms w/o cc	N	\$841.72	\$1,712.33	\$1,562.88
012	Degenerative nervous system disorders	N	\$897.26	\$1,421.96	\$812.08
013	Multiple sclerosis & cerebellar ataxia	N	\$740.03	\$1,350.96	\$1,026.67
014	Intracranial hemorrhage & stroke w infarct	N	\$906.40	\$1,754.78	\$1,931.30
015	Nonspecific cva & precerebral occlusion w/o infarct	N	\$760.94	\$1,462.70	\$1,681.37
016	Nonspecific cerebrovascular disorders w cc	N	\$989.76	\$1,826.20	\$2,107.43
017	Nonspecific cerebrovascular disorders w/o cc Cranial & peripheral nerve disorders w cc	N N	\$809.67 \$844.15	\$1,320.12 \$1,537.12	\$1,586.09 \$1,711.10
018 019	Cranial & peripheral nerve disorders w cc	N	\$937.65	\$1,569.88	\$1,863.70
020	Nervous system infection except viral meningitis	N	\$972.95	\$1,888.67	\$2,662.45
021	Viral meningitis	N	\$1,005.94	\$1,972.71	\$2,674.78
022	Hypertensive encephalopathy	N	\$849.92	\$1,658,63	\$2,049.26
023	Nontraumatic stupor & coma	N	\$1,077.63	\$1,881.63	\$2,109.49
024	Seizure & headache age >17 w cc	N	\$962.80	\$1,750.09	\$1,998.97
025	Seizure & headache age >17 w/o cc	N N	\$960.38 \$1,291.96	\$1,720.89 \$2,342.71	\$1,811.09 \$2,621.82
026 027	Seizure & headache age 0-17 Traumatic stupor & coma, coma >1 hr	N	\$1,291.90	\$2,342.71	\$2,645.80
028	Traumatic stupor & coma, coma > 1 hr age > 17 w cc	N	\$965.43	\$2,064.56	\$1,933.15
029	Traumatic stuper & coma, coma <1 hr age >17 w/o cc	l N	\$963.13	\$2,186.93	\$1,448.54
030	Traumatic stupor & coma, coma <1 hr age 0-17	N	\$858.08	\$1,862.81	\$1,617.19
031	Concussion age >17 w cc	N	\$1,359.87	\$2,702.66	\$2,942.84
032	Concussion age >17 w/o cc	N	\$1,096.58	\$2,355.33	\$2,473.20
033	Concussion age 0-17	N	\$1,199.55	\$2,425.30	\$2,622.45
034 035	Other disorders of nervous system w cc Other disorders of nervous system w/o cc	N N	\$848.01 \$754.40	\$1,591.64 \$1,465.97	\$1,603.46 \$1,196.43
036	Retinal procedures	S	\$1,025.67	\$2,252.96	\$7,235.50
037	Orbital procedures	\$ \$ \$ \$ \$ \$	\$1,117.48	\$2,122.96	\$3,937.33
038	Primary iris procedures	(s	\$1,388.99	\$1,872.02	\$2,969.74
039	Lens procedures with or without vitrectomy	S	\$1,010.64	\$2,201.77	\$4,160.29
040	Extraocular procedures except orbit age >17	S	\$996.11	\$2,494.26	\$3,144.26
041	Extraocular procedures except orbit age 0-17	S	\$996.11 \$1,022.03	\$2,494.26 \$1,878.05	\$3,144.26 \$3,949.83
042 043	Intraocular procedures except retina, iris & lens Hyphema	S	\$861.95	\$1,070.03	\$1,502.45
043	Acute major eye infections	l N	\$1,045.99	\$1,551.72	\$1,233.80
045	Neurological eye disorders	N	\$887.43	\$1,494.87	\$2,256.56
046	Other disorders of the eye age >17 w cc	N	\$960.46	\$1,676.72	\$1,620.26
047	Other disorders of the eye age >17 w/o cc	N	\$1,074.35	\$1,484.03	\$1,513.63
048	Other disorders of the eye age 0-17	N	\$983.74	\$1,654.00	\$1,593.02
049	Major head & neck procedures	S	\$1,005.82 \$1,029.62	\$1,951.66 \$2,152.91	\$5,364.64 \$6,790.30
050 051	Sialoadenectomy Salivary gland procedures except sialoadenectomy	S	\$1,130.50	\$1,871.59	\$4,316.28
052	Cleft lip & palate repair	š	\$888.87	\$1,904.81	\$5,282.24
053	Sinus & mastoid procedures age >17	S	\$911.10	\$1,874.58	\$4,364.36
054	Sinus & mastoid procedures age 0-17	S	\$911.10	\$1,874.58	\$4,364.36
055	Miscellaneous ear, nose, mouth & throat procedures	S	\$1,034.65	\$1,907.77	\$3,968.24
056	Rhinoplasty T&a proc. except tonsillectomy &/or adenoidectomy only, age >17	S	\$1,115.79 \$878.78	\$2,074.45 \$1,907.45	\$5,871.38 \$3,278.15
057 058	T&a proc, except tonsillectomy &/or adenoidectomy only, age >17	S	\$878.78	\$1,907.45	\$3,278.15
059	Tonsillectomy &/or adenoidectomy only, age >17	Š	\$816.95	\$1,670.48	\$3,496.87
060	Tonsillectomy &/or adenoidectomy only, age 0-17	S	\$647.71	\$1,324.42	\$2,772.44
061	Myringotomy w tube insertion age >17	9999999992	\$1,082.88	\$1,964.67	\$3,649.88
062	Myringotomy w tube insertion age 0-17	S	\$1,082.88	\$1,964.67	\$3,649.88
063 064	Other ear, nose, mouth & throat or procedures Ear, nose, mouth & throat malignancy) N	\$1,160.06 \$1,119.92	\$2,223.62 \$2,160.66	\$4,740.29 \$2,099.41
065	Dysequilibrium	N	\$976.77	\$1,685.09	\$2,022.20
066	Epistaxis	N	\$1,023.73	\$1,957.37	\$1,884.60
067	Epiglottitis	N	\$933.87	\$1,942.70	\$2,246.66
068	Otitis media & uri age >17 w cc	l N	\$845.51	\$1,585.00	\$1,801.42

PAGE 2 OF 8

		Surgical/	P	er Diem Char	ge
DRG	Description	Non- Surgical Indicator	Standard Room and Board	ICU Room and Board	Ancillary
069	Otitis media & uri age >17 w/o cc	N	\$700 A2	\$1.524.01	\$1,541.06
070	Otitis media & un age 2-17 w/o cc	N	\$788.42 \$765.06	\$1,524.91 \$1,443.14	\$1,600.80
071	Laryngotracheitis	l N	\$787.23	\$1,775.98	\$1,801.85
072	Nasal trauma & deformity	N	\$1,504.19	\$2,899.86	\$2,862.53
073	Other ear, nose, mouth & throat diagnoses age >17	N	\$1,015.54	\$2,003.33	\$1,986.87
074	Other ear, nose, mouth & throat diagnoses age 0-17	, N	\$1,395.39	\$2,752.63	\$2,730.01
075	Major chest procedures	S	\$1,007.10	\$1,899.96	\$3,802.03
076	Other resp system or procedures w cc	s	\$1,103.30	\$2,007.27	\$3,101.15
077	Other resp system or procedures w/o cc	S	\$966.84	\$1,534.21	\$3,047.30
078	Pulmonary embolism	N	\$868.61	\$1,526.64 \$1,696.98	\$1,982.43
079 080	Respiratory infections & inflammations age >17 w cc Respiratory infections & inflammations age >17 w/o cc	N N	\$957.37 \$927.26	\$1,751.23	\$2,098.74 \$1,644.59
081	Respiratory infections & inflammations age 217 w/o cc	N	\$1,230.52	\$2,186.51	\$2,681.20
082	Respiratory neoplasms	l N	\$895.41	\$1,534.82	\$1,954.50
083	Major chest trauma w cc	l N	\$901.05	\$1,739.21	\$1,752.23
084	Major chest trauma w/o cc	l N	\$947.40	\$2,102.84	\$1,635.93
085	Pleural effusion w cc	N	\$952.87	\$1,575.87	\$2,088.41
086	Pleural effusion w/o cc	N	\$972.60	\$1,715.74	\$2,078.08
087	Pulmonary edema & respiratory failure	. N	\$978.32	\$1,804.65	\$2,540.94
088	Chronic obstructive pulmonary disease	N	\$817.88	\$1,466.21	\$1,732.37
089 090	Simple pneumonia & pleurisy age >17 w cc	N N	\$882.57 \$824.86	\$1,582.64 \$1,452.82	\$1,835.86 \$1,503.88
090	Simple pneumonia & pleurisy age >17 w/o cc Simple pneumonia & pleurisy age 0-17	N	\$1,034.86	\$1,858.91	\$2,137.34
092	Interstitial lung disease w cc	Ň	\$902.04	\$1,589.60	\$1,996.62
093	Interstitial lung disease w/o cc	N	\$933.22	\$1,669.64	\$1,842.06
094	Pneumothorax w cc	N	\$818.21	\$1,487.12	\$1,773.21
095	Pneumothorax w/o cc	l N	\$769.37	\$1,608.02	\$1,422.36
096	Bronchitis & asthma age >17 w cc	N N	\$808.64	\$1,504.23	\$1,658.14
097	Bronchitis & asthma age >17 w/o cc	N N	\$791.21 \$961.41	\$1,457.05 \$1,783.58	\$1,513.60 \$1,932.77
098 099	Bronchitis & asthma age 0-17 Respiratory signs & symptoms w cc	l N	\$943.46	\$1,600.08	\$2,509.73
100	Respiratory signs & symptoms w/o cc	N N	\$839.35	\$1,383.98	\$2,430.68
101	Other respiratory system diagnoses w cc	N	\$1,005.82	\$1,790.75	\$2,259.80
102	Other respiratory system diagnoses w/o cc	N	\$1,054.03	\$1,846.39	\$2,380.03
103	Heart transplant	S	\$1,041.93	\$2,237.60	\$6,646.03
104	Cardiac valve & oth major cardiothoracic proc w card cath	S S S	\$1,314.32	\$2,298.70 \$2,181.78	\$8,048.76 \$8,365.85
105 106	Cardiac valve & oth major cardiothoracic proc w/o card cath	0	\$1,204.48 \$1,110.15	\$2,001.26	\$9,584.07
100	Coronary bypass w ptca Coronary bypass w cardiac cath	l š	\$1,064.69	\$1,847.48	\$6,922.52
108	Other cardiothoracic procedures	S S	\$1,246.65	\$2,264.68	\$7,976.36
109	Coronary bypass w/o ptca or cardiac cath	S S	\$1,095.81	\$1,947.85	\$7,112.59
110	Major cardiovascular procedures w cc	S	\$1,010.35	\$1,952.53	\$5,758.52
111	Major cardiovascular procedures w/o cc	S	\$882.68	\$1,662.88	\$6,827.14
112	No longer valid	S	\$0.00	\$0.00	\$0.00
113	Amputation for circ system disorders except upper limb & toe	\$ \$ \$ \$ \$ \$ \$ \$ \$ \$	\$996.02 \$925.09	\$1,922.64 \$1,687.87	\$2,638.93 \$1,996.75
114 115	Upper limb & toe amputation for circ system disorders Prm card pacem impl w ami, hrt fail or shk, or aicd lead or gn	l s	\$1,370.30	\$2,201.40	\$6,674.27
116	Other permanent cardiac pacemaker implant	Š	\$1,107.65	\$1,732.80	\$7,241.45
117	Cardiac pacemaker revision except device replacement	S	\$1,235.97	\$2,207.21	\$4,593.82
118	Cardiac pacemaker device replacement	s	\$1,342.15		
119	Vein ligation & stripping	S	\$1,017.96	\$1,814.25	\$3,360.63
120	Other circulatory system or procedures	S	\$1,066.75	\$1,922.50	\$3,055.77
121	Circulatory disorders w ami & major comp, discharged alive	l N	\$1,201.09 \$1,303.82	\$2,145.20 \$2,326.83	\$2,960.00 \$4,070.69
122	Circulatory disorders w ami w/o major comp, discharged alive Circulatory disorders w ami, expired	N N	\$1,039.28	\$1,971.43	\$3,646.50
123 124	Circulatory disorders warm, expired Circulatory disorders except ami, w card cath & complex diag	N	\$1,162.78	\$1,932.41	\$4,635.92
125	Circulatory disorders except ami, w card cath w/o complex diag	N	\$1,089.56	\$1,748.38	\$5,831.27
126	Acute & subacute endocarditis	N	\$1,282.18	\$2,169.29	\$2,700.09
127	Heart failure & shock	l N	\$897.65	\$1,556.84	\$1,773.08
128	Deep vein thrombophlebitis	N N	\$869.24 \$592.80	\$1,689.65	\$1,210.99 \$2,795.63
129 130	Cardiac arrest, unexplained Peripheral vascular disorders w cc	N N	\$893.51	\$1,324.17 \$1,679.22	\$1,544.53
130	Peripheral vascular disorders w/o cc	N	\$904.94	\$1,780.59	\$1,310.37
132	Atherosclerosis w cc	N N	\$1,386.62	\$2,406.43	\$3,115.91
133	Atherosclerosis w/o cc	N	\$1,859.09	\$3,224.45	\$3,434.41
134	Hypertension	N	\$880.46	\$1,473.82	\$1,713.56
135	Cardiac congenital & valvular disorders age >17 w cc	l N	\$1,036.16 \$928.43		\$1,902.81 \$1,513.08
136	Cardiac congenital & valvular disorders age >17 w/o cc	l in	μ φ σ 2 0.43	\$1,669.74	ψ1,515.00

PAGE 3 OF 8

		Surgical/	Pi	er Diem Char	ge
DRG	Description	Non- Surgical Indicator	Standard Room and Board	ICU Room and Board	Ancillary
137	Cardiac congenital & valvular disorders age 0-17	. N	\$2,934.48	\$5,058.79	\$5,317.30
138	Cardiac arrhythmia & conduction disorders w cc	N	\$1,040.06	\$1,675.93	\$2,143.64
139	Cardiac arrhythmia & conduction disorders w/o cc	N N	\$1,052.38 \$931.40	\$1,649.00 \$1,662.77	\$2,130.42 \$2,363.80
140 141	Angina pectoris Syncope & collapse w cc	N	\$1,118.18	\$1,753.62	\$2,188.68
142	Syncope & collapse w/o cc	l N	\$1,002.11	\$1,534.45	\$2,056.66
143	Chest pain	N	\$1,023.10	\$1,614.53	\$3,027.09
144	Other circulatory system diagnoses w cc	N	\$1,017.78	\$1,790.72	\$2,516.30
145	Other circulatory system diagnoses w/o cc	N N	\$1,074.54	\$1,933.75	\$2,471.51
146	Rectal resection w.cc	S S	\$1,065.65 \$954.51	\$2,136.26 \$1,871.23	\$3,562.81 \$3,055.80
147 148	Rectal resection w/o cc Major small & large bowel procedures w cc	Š	\$902.04	\$1,860.13	\$3,256.93
149	Major small & large bowel procedures w/o cc	lš	\$937.34	\$1,860.03	\$2,965.89
150	Peritoneal adhesiolysis w cc	S	\$884.86	\$1,811.57	\$2,901.99
151	Peritoneal adhesiolysis w/o cc	S	\$817.02	\$1,742.25	\$2,591.97
152	Minor small & large bowel procedures w cc	\ S	\$882.35 \$961.45	\$1,768.25 \$2,387.17	\$2,653.45 \$2,670.53
153 154	Minor small & large bowel procedures w/o cc Stomach, esophageal & duodenal procedures age >17 w cc	800000	\$1,031.15	\$2,367.17	\$4,134.11
155	Stomach, esophageal & duodenal procedures age >17 w/o cc	S	\$972.87	\$2,241.71	\$4,934.25
156	Stomach, esophageal & duodenal procedures age 0-17	s	\$872.09	\$1,842.41	\$3,564.28
157	Anal & stomal procedures w cc	8888888	\$1,111.49	\$2,095.62	\$3,217.29
158	Anal & stomal procedures w/o cc	8	\$873.31 \$902.07	\$1,574.86 \$1,849.86	\$3,208.68 \$3,305.80
159 160	Hernia procedures except inguinal & femoral age >17 w cc Hernia procedures except inguinal & femoral age >17 w/o cc	S	\$878.56	\$1,720.44	\$3,918.21
161	Inguinal & femoral hernia procedures age >17 w cc	Š	\$1,150.35	\$2,076.88	\$3,859.22
162	Inguinal & femoral hernia procedures age >17 w/o cc	S	\$952.74	\$1,839.83	\$4,388.95
163	Hernia procedures age 0-17	S	\$976.92	\$1,927.96	\$3,706.85
164	Appendectomy w complicated principal diag w cc	8	\$896.45 \$898.27	\$1,910.25 \$1,811.52	\$3,306.24 \$3,308.63
165 166	Appendectomy w complicated principal diag w/o cc Appendectomy w/o complicated principal diag w cc	S	\$899.42	\$1,810.19	\$3,845.38
167	Appendectomy w/o complicated principal diag w/o cc	50050	\$926.31	\$2,355.65	\$4,779.32
168	Mouth procedures w cc	S	\$1,067.04	\$2,368.11	\$3,810.49
169	Mouth procedures w/o cc	S S S	\$932.34	\$2,855.54	\$4,573.45
170 171	Other digestive system or procedures w cc Other digestive system or procedures w/o cc	8	\$1,016.79 \$907.96	\$1,976.33 \$1,854.75	\$3,171.14 \$3,642.45
172	Digestive malignancy w cc	Ň	\$1,044.98	\$1,907.59	\$2,075.35
173	Digestive matignancy w/o cc	N	\$867.81	\$1,386.90	\$1,522.93
174	Gi hemorrhage w cc	l N	\$977.96	\$1,874.70	\$2,268.23
175 176	Gi hemorrhage w/o cc Complicated peptic ulcer	N	\$928.46 \$934.32	\$1,712.03 \$1,687.11	\$1,926.80 \$2,200.33
177	Uncomplicated peptic dicer w cc	N	\$875.60	\$1,605.17	\$2,254.59
178	Uncomplicated peptic ulcer w/o cc	N	\$890.23	\$1,518.86	\$2,329.30
179	Inflammatory bowel disease	N	\$994.64	\$1,770.74	\$1,885.55
180	Gi obstruction w cc	N	\$919.68	\$1,695.99	\$1,822.50
181 182	Gi obstruction w/o cc Esophagitis, gastroent & misc digest disorders age >17 w cc	N N	\$944.21 \$893.14	\$1,534.19 \$1,575.25	\$1,606.52 \$1,915.09
183	Esophagitis, gastroent & misc digest disorders age >17 w/cc	N	\$866.74	\$1,484.51	\$2,079.62
184	Esophagitis, gastroent & misc digest disorders age 0-17	N	\$923.06	\$1,619.57	\$2,023.13
185	Dental & oral dis except extractions & restorations, age >17	l N	\$954.60	\$1,722.80	\$2,085.57
186	Dental & oral dis except extractions & restorations, age 0-17	N N	\$1,027.49 \$1,128.41	\$1,854.35 \$1,838.32	\$2,244.82 \$2,797.68
187 188	Dental extractions & restorations Other digestive system diagnoses age >17 w cc	N	\$948.70	\$1,727.03	\$2,063.56
189	Other digestive system diagnoses age >17 w/o cc	N	\$1,125.09	\$1,893.78	\$2,186.96
190	Other digestive system diagnoses age 0-17	N	\$1,028.34	\$1,864.00	\$2,215.20
191	Pancreas, liver & shunt procedures w cc	S	\$1,196.06	\$2,569.64	\$4,726.12
192 193	Pancreas, liver & shunt procedures w/o cc Biliary tract proc except only cholecyst w or w/o cde w cc	S S	\$946.52 \$1,124.96	\$2,046.15 \$2,276.64	\$3,729.14 \$3,691.43
194	Biliary tract proc except only cholecyst w or w/o cde w/o cc	88888888888	\$891.08	\$1,585.34	\$2,909.29
195	Cholecystectomy w cde w cc	S	\$932.18	\$1,867.84	\$3,707.46
196	Cholecystectomy w cde w/o cc	S	\$887.91	\$1,793.22	\$3,940.18
197 198	Cholecystectomy except by laparoscope w/o cde w cc Cholecystectomy except by laparoscope w/o cde w/o cc	5 9	\$939.05 \$876.47	\$1,918.70 \$1,766.82	\$3,446.11 \$3,344.96
198	Hepatobiliary diagnostic procedure for malignancy	l s	\$1,013.84	\$2,013.65	\$3,220.31
200	Hepatobiliary diagnostic procedure for non-malignancy	s	\$1,019.50	\$2,129.91	\$3,719.26
201	Other hepatobiliary or pancreas or procedures	S	\$1,115.91	\$2,313.60	\$3,251.94
202	Cirrhosis & alcoholic hepatitis Malignancy of hepatobiliary system or pancreas	N N	\$977.84 \$990.31	\$1,915.07 \$1,821.93	\$2,196.14 \$2,088.55
203 204	Disorders of pancreas except malignancy	N N	\$867.40		
	• • • • • • • • • • • • • • • • • • • •	•			

PAGE 4 OF 8

		Surgical/	Pe	er Diem Charç	je
DRG	Description	Non- Surgical Indicator	Standard Room and Board	ICU Room and Board	Ancillary
205	Disorders of liver except malig, cirr, alc hepa w cc	N	\$1,053.74	\$2,136.19	\$2.388.50
206	Disorders of liver except malig, cirr, alc hepa w/o cc	N	\$841.07	\$1,503.99	\$1,811.37
207	Disorders of the biliary tract w cc	N	\$1,025.17	\$1,876.46	\$2,640.14
208	Disorders of the biliary tract w/o cc	N	\$1,032.37	\$1,633.46	\$2,890.54
209	Major joint & limb reattachment procedures of lower extremity	S	\$951.66	\$1,878.80	\$5,957.64
210	Hip & femur procedures except major joint age >17 w cc	S	\$959.49 \$1,079.70	\$1,850.43 \$1,960.96	\$3,312.94 \$3,791.71
211 212	Hip & femur procedures except major joint age >17 w/o cc Hip & femur procedures except major joint age 0-17	0 0	\$1,079.70	\$2,154.20	\$3,791,71
213	Amputation for musculoskeletal system & conn tissue disorders	Š	\$1,051.65	\$1,999.60	\$2,657.61
214	No longer valid	S	\$0.00	\$0.00	\$0.00
215	No longer valid	000000000000000000000000000000000000000	\$0.00	\$0.00	\$0.00
216	Biopsies of musculoskeletal system & connective tissue	S	\$1,018.88	\$1,862.79	\$2,826.09
217	Wnd debrid & skn grft except hand, for muscskelet & conn tiss dis	S	\$1,245.08	\$2,638.13	\$3,330.54
218 219	Lower extrem & humer proc except hip, foot, femur age >17 w cc Lower extrem & humer proc except hip, foot, femur age >17 w/o cc	٥	\$926.41 \$987.18	\$1,815.31 \$1,879.57	\$3,600.61 \$4,482.57
220	Lower extrem & humer proc except hip, foot, femur age 0-17 w/o cc	Š	\$1,186.26	\$2,321.09	\$4,882.91
221	No longer valid	Š	\$0.00	\$0.00	\$0.00
222	No longer valid	S	\$0.00	\$0.00	\$0.00
223	Major shoulder/elbow proc, or other upper extremity proc w cc	S	\$1,005.49	\$1,853.81	\$5,187.87
224	Shoulder, elbow or forearm proc, exc major joint proc, w/o cc	S	\$928.79	\$1,567.69	\$5,992.02
225 226	Foot procedures	5	\$1,126.50 \$943.91	\$1,952.50 \$1,837.20	\$3,349.09 \$2,693.26
220	Soft tissue procedures w cc Soft tissue procedures w/o cc	0	\$990.79	\$1,593.79	\$4,158.00
228	Major thumb or joint proc, or oth hand or wrist proc w cc	Š	\$994.58	\$2,159.89	\$3,909.47
229	Hand or wrist proc, except major joint proc, w/o cc	S	\$998.54	\$1,565.22	\$4,632.84
230	Local excision & removal of int fix devices of hip & femur	S	\$938.31	\$1,933.59	\$3,308.95
231	Local excision & removal of int fix devices except hip & femur	S	\$992.04	\$2,104.08	\$3,939.92
232 233	Arthroscopy Other museuleskelet ava 8 conn ties or preserves	5	\$1,078.70	\$1,445.17	\$5,558.94
233	Other musculoskelet sys & conn tiss or proc w cc Other musculoskelet sys & conn tiss or proc w/o cc	3	\$1,040.58 \$911.11	\$2,371.58 \$1,911.05	\$3,802.73 \$5,397.84
235	Fractures of femur	N	\$770.85	\$1,548.00	\$1,065.58
236	Fractures of hip & pelvis	N	\$697.08	\$1,479.58	\$904.53
237	Sprains, strains. & dislocations of hip, pelvis & thigh	N	\$1,019.21	\$1,952.30	\$1,549.44
238	Osteomyelitis	N	\$895.38	\$1,522.78	\$1,401.33
239 240	Pathological fractures & musculoskeletal & conn tiss malignancy Connective tissue disorders w cc	N N	\$1,037.23 \$950.71	\$1,840.23	\$1,633,66 \$2,127,39
240	Connective tissue disorders w cc	N	\$1,100.68	\$1,772.07 \$2,219.87	\$1,447.80
242	Septic arthritis	N	\$950.83	\$1,775.98	\$1,541.89
243	Medical back problems	N	\$936.60	\$1,797.66	\$1,490.67
244	Bone diseases & specific arthropathies w cc	N	\$817.06	\$1,512.55	\$1,065.91
245	Bone diseases & specific arthropathies w/o cc	N	\$925.71	\$1,806.38	\$1,058.00
246 247	Non-specific arthropathies Signs & symptoms of musculoskeletal system & conn tissue	N N	\$831.37 \$952.30	\$1,500.81 \$1,655.80	\$1,060.57 \$1,434.41
248	Tendonitis, myositis & bursitis	N	\$1,015.28	\$1,873.73	\$1,483.84
249	Aftercare, musculoskeletal system & connective tissue	Ň	\$1,055.88	\$2,100.23	\$1,780.98
250	Fx, sprn, strn & disl of forearm, hand, foot age >17 w cc	N	\$922.26	\$1,858.73	\$1,449.29
251	Fx, sprn, strn & disl of forearm, hand, foot age >17 w/o cc	N	\$997.16	\$1,915.87	\$1,386.65
252 253	Fx, sprn, strn & disl of forearm, hand, foot age 0-17	N N	\$947.22 \$865.67	\$1,907.04 \$1,715.48	\$1,426.20 \$1,275.48
253 254	Fx, sprn, strn & disl of uparm, lowleg ex foot age >17 w cc Fx, sprn, strn & disl of uparm, lowleg ex foot age >17 w/o cc	N	\$1,015.36		
255	Fx, sprn, strn & disl of uparm, lowleg ex foot age 0-17	N	\$910.82	\$1,831.64	\$1,252.89
256	Other musculoskeletal system & connective tissue diagnoses	N	\$801.66	\$1,543.19	\$1,142.52
257	Total mastectomy for malignancy w cc	S	\$966.31	\$1,885.99	\$4,675.25
258	Total mastectomy for malignancy w/o cc Subtotal mastectomy for malignancy w cc	SS	\$892.57	\$1,625.03	\$5,448.71
259 260	Subtotal mastectomy for malignancy w cc Subtotal mastectomy for malignancy w/o cc	3	\$1,106.09 \$991.23	\$1,875.06 \$1,710.89	\$4,606.07 \$7,183.82
261	Breast proc for non-malignancy except biopsy & local excision	SS	\$966.40	\$1,779.34	\$6,376.78
262	Breast biopsy & local excision for non-malignancy	S	\$994.17	\$1,491.01	\$2,728.78
263	Skin graft &/or debrid for skn ulcer or cellulitis w cc	S	\$879.68	\$1,655.07	\$1,728.41
264	Skin graft &/or debrid for skn ulcer or cellulitis w/o cc	500000000	\$865.22	\$1,307.73	\$1,602.49
265 266	Skin graft &/or debrid except for skin ulcer or cellulitis w cc Skin graft &/or debrid except for skin ulcer or cellulitis w/o cc	0 0	\$1,352.67 \$1,089.89	\$2,740.28 \$2,188.48	\$4,031.28 \$4,071.39
267	Perianal & pilonidal procedures	l s	\$834.60	\$2,721.14	\$2,828.25
268	Skin, subcutaneous tissue & breast plastic procedures	S	\$1,097.85	\$2,608.58	\$4,956.57
269	Other skin, subcut tiss & breast proc w cc	S	\$900.96	\$1,730.04	\$2,290.35
270	Other skin, subcut tiss & breast proc w/o cc	S	\$902.52	\$1,667.33	\$2,666.17
271 272	Skin ulcers Major skin disorders w cc	N N	\$795.67 \$1,036.06	\$1,277.40 \$2,321.94	\$1,207.72 \$1,710.03
212	1 Major Gilli disordoro trico	1 14	, 41,500.00	, 42,021.04	. 4.,. 10.00

PAGE 5 OF 8

Major skin disorders w/o c				Surgical/	P:	er Diem Char	ge
274 Maiignant breast disorders wo c N \$1,126.17 \$1,122.98 \$1,226.276 \$1,222.98 \$1,226.276 \$1,222.98 \$1,227 \$2,025.62 \$2,025.6	DRG	Description		Surgical	Room and	1	Ancillary
Maiignant breast disorders w cc N \$1,126.17 \$1,122.98 \$1,226.77 \$1,122.98 \$1,226.77 \$1,122.98 \$1,226.77 \$1,122.98 \$1,227 \$2,025.62 \$2,0	273	Major skin disorders w/o co		N	\$975.97	\$1.511.89	\$1,417.53
275			-				\$1,746.68
276							\$1,322.24
278 Cellulitis age >17 w/o cc 279 Cellulitis age >17 w/o cc 279 Cellulitis age >17 w/o cc 279 Cellulitis age >17 w/o cc 270 N \$892.02 \$1.525.24 \$1.52 280 Trauma to the skin, subcut tiss & breast age >17 w/o cc 281 Trauma to the skin, subcut tiss & breast age >17 w/o cc 381 Minor skin disorders w cc 382 Trauma to the skin, subcut tiss & breast age >17 w/o cc 383 Minor skin disorders w cc 384 Minor skin disorders w cc 385 Amputat of lower limb for endocrine, nutrit, & metabol disorders 386 Adrenal & pitulary procedures 387 Solkin grafts & wound debrid for endoc, nutrit & metab disorders 387 Solkin grafts & wound debrid for endoc, nutrit & metab disorders 389 Parathyroid procedures 390 Parathyroid procedures 391 Thyroid procedures 391 Cher endocrine, nutrit & metab or proc w cc 391 Thyroid procedures 392 Other endocrine, nutrit & metab or proc w cc 393 Other endocrine, nutrit & metab or proc w cc 394 Diabetes age >35 N Solkin So				N	\$1,172.91		\$1,714.26
279 Cellutitis age 0-17 N \$892.02 \$1,552.34 \$1 281 Trauma to the skin, subcut tiss & breast age >17 w/o c N \$983.70 \$1,738.95 \$1 282 Trauma to the skin, subcut tiss & breast age 0-17 N \$348.92 \$1,745.28 \$1 283 Minor skin disorders w c N \$394.92 \$1,745.28 \$1 284 Minor skin disorders w c N \$394.92 \$1,745.28 \$1 284 Minor skin disorders w c N \$394.92 \$1,745.28 \$1 285 Amputat of lower limb for endocrine, nutrit, & metab disorders \$348.64 \$1.854.43 \$2 286 Ardreal & pitutary procedures \$349.92 \$2,045.66 \$3 287 Parathyroid procedures \$35,000.00 \$2,127.78 \$3 289 Trivorid procedures \$35,000.00 \$2,127.78 \$3 289 Trivorid procedures \$35,000.00 \$2,127.78 \$3 290 Trivorid procedures \$35,000.00 \$2,127.18 \$3			ł	N		\$1,624.89	\$1,386.17
Trauma to the skin, subcut tiss & breast age >17 w cc			i i				\$1,056.31
281 Trauma to the skin, subcut its & breast age >17 w/o cc							\$1,272.57
282							\$1,669.71
283							\$1,461.71
Minor skin disorders w/o cc			1				\$1,548.06 \$1,488.93
285 Amputat of lower limb for endocrine, nutrit, & metabol disorders S 5944.64 \$1,854.43 \$2,28 287 Skin grafts & wound debrid for endoc, nutrit & metab disorders S \$1,178.35 \$2,045.66 \$3 288 Or procedures for obesity S \$981.42 \$1,997.36 \$4 290 Thyroid procedures S \$981.42 \$1,997.36 \$4 291 Thyroid procedures S \$981.42 \$1,997.36 \$4 292 Other endocrine, nutrit & metab or proc w/o c S \$1,049.99 \$1,934.04 \$2 293 Other endocrine, nutrit & metab or proc w/o c S \$1,059.93 \$2,601.34 \$3 294 Diabetes age > 35 N \$905.24 \$1,1668.28 \$1,709.82 \$1 295 Diabetes age > 35 N \$359.89 \$1,709.82 \$1 296 Nutritional & misc metabolic disorders age > 17 w c N \$891.31 \$1,506.09 \$1 297 Nutritional & misc metabolic disorders age > 17 w c N \$891.31							\$1,325.62
286 Adrenal & pituitary procedures 287 Skin grafts & wound debrid for endoc, nutrit & metab disorders 3 Sin grafts & wound debrid for endoc, nutrit & metab disorders 3 Sin grafts & wound debrid for endoc, nutrit & metab disorders 3 Sin grafts & wound debrid for endoc, nutrit & metab disorders 3 Sin grafts & Sin graft & Sin grafts & Sin graft & Sin							\$2,101.17
287 Skin grafts & wound debrid for endoc, nutrit & metab disorders S \$1,178.35 \$2,165.27 \$28 289 Parathryroid procedures \$ \$980.00 \$2,132.73 \$5 290 Thyroid procedures \$ \$984.18 \$2,000.77 \$5 291 Thyroid procedures \$ \$1,040.99 \$1,884.67 \$5 292 Other endocrine, nutrit & metab or proc w/o c \$ \$1,040.99 \$1,884.67 \$5 293 Other endocrine, nutrit & metab or proc w/o c \$1,069.99 \$1,984.04 \$2 294 Diabetes age ≥ 35 \$1,069.95 \$1,089.35 \$2,601.34 \$3 295 Diabetes age ≥ 35 \$1,089.89 \$1,709.82 \$1,709.82 \$1 296 Nutritional & misc metabolic disorders age > 17 w/o cc \$389.147 \$1,508.79 \$1,508.79 \$1,508.79 297 Nutritional & misc metabolic disorders age > 17 w/o cc \$3891.47 \$1,017.95 \$1,168.67 \$2,133.16 \$2 298 Inborn errors of metabolism \$1,017.95 \$1,017.95 <			1	S			\$4,595.81
289				S			\$2,015.05
290		Or procedures for obesity	l				\$6,085.54
291 Thyroglossal procedures 292 Other endocrine, nutrit & metab or proc w cc 293 Other endocrine, nutrit & metab or proc w cc 294 Other endocrine, nutrit & metab or proc w cc 295 Diabetes age 2-35 296 Nutritional & misc metabolic disorders age >17 w cc 397 Nutritional & misc metabolic disorders age >17 w cc 398 Nutritional & misc metabolic disorders age >17 w cc 399 Nutritional & misc metabolic disorders age >17 w cc 390 Nutritional & misc metabolic disorders age >17 w cc 391 Nutritional & misc metabolic disorders age >17 w cc 392 Nutritional & misc metabolic disorders age >17 w cc 393 Nutritional & misc metabolic disorders age >17 w cc 394 Nutritional & misc metabolic disorders age >17 w cc 395 Nutritional & misc metabolic disorders age >17 w cc 396 Nutritional & misc metabolic disorders age >17 w cc 397 Nutritional & misc metabolic disorders age >17 w cc 398 Nutritional & misc metabolic disorders age >17 w cc 399 Inbom errors of metabolism 300 Endocrine disorders w cc 301 Endocrine disorders w cc 302 Kidney transplant 303 Kidney, ureter & major bladder procedures for neoplasm 304 Kidney, ureter & major bladder proc for non-neopl w cc 305 Kidney, ureter & major bladder proc for non-neopl w cc 306 Prostatectomy w cc 307 Prostatectomy w cc 308 Minor bladder procedures w cc 309 Minor bladder procedures w cc 3100 Minor bladder procedures w cc 3100 Minor bladder procedures w cc 3100 Signey and self w cc 311 Transurethral procedures w cc 311 Cretinal procedures, age >17 w cc 312 Cretinal procedures, age >17 w cc 313 Urethral procedures, age >17 w cc 314 Urethral procedures, age >17 w cc 315 Nutritional & self y cc 316 Nutritional & self y cc 317 Admit for renal dialysis 318 Kidney & urinary tract infections age >17 w cc 319 Nutritional & self y cc 310 Nutritional & self y cc 310 Nutritional & self y cc 311 Nutritional & self y cc 312 Victorial y ccd 313 Victorial y ccd 314 Victorial y ccd 315 Nutritional & self y ccd 316 Nutritional & self y ccd 317 Nutritional & se			·				\$4,786.42
292 Other endocrine, nutrit & metab or proc w oc S \$1,040,90 \$1,934,04 \$2 294 Diabetes age >35 N \$905,24 \$1,668,28 \$1 295 Diabetes age >35 N \$858,98 \$1,709,82 \$1,709,82 296 Nutritional & misc metabolic disorders age >17 w oc N \$893,81 \$1,508,79 \$1 297 Nutritional & misc metabolic disorders age >17 w oc N \$891,47 \$1,506,79 \$1 298 Nutritional & misc metabolic disorders age >17 w oc N \$891,31 \$1,506,79 \$1 299 Inborn errors of metabolism N \$947,76 \$2,133,18 \$2 300 Endocrine disorders w oc N \$1,017,95 \$1,845,35 \$3 301 Endocrine disorders wo cc N \$1,017,95 \$1,845,35 \$3 302 Kidney transplant \$3,997,23 \$2,013,45 \$3 303 Kidney trater & major bladder procedures for non-neopl w cc \$1,128,87 \$3,201,45 \$3 304 Ki				S			\$5,617.23
293 Other endocrine, nutrit & metab or proc w/o cc S \$1,059.35 \$2,601.34 \$3 295 Diabetes age >35 N \$905.24 \$1,668.28 \$1,709.82 \$1 296 Nutritional & misc metabolic disorders age >17 w cc N \$392.81 \$1,508.79 \$1 297 Nutritional & misc metabolic disorders age >17 w/o cc N \$891.47 \$1,508.79 \$1 298 Inhorm errors of metabolism N \$947.76 \$2,133.18 \$2 300 Endocrine disorders w cc N \$1,017.95 \$1,845.35 \$3 301 Endocrine disorders w/o cc N \$1,014.26 \$1,816.97 \$1 302 Kidney transplant S \$1,239.72 \$2,501.78 \$1 303 Kidney, ureter & major bladder proc for non-neopl w cc \$1,126.87 \$2,333.11 \$3 304 Kidney, ureter & major bladder proc for non-neopl w/o cc \$1,126.87 \$2,333.11 \$3 305 Kidney, ureter & major bladder proc edures w cc \$1,126.87 \$2,233.11 \$3				5			\$5,969.60
294 Diabetes age >35 N \$905.24 \$1,668.28 \$1 296 Nutritional & misc metabolic disorders age >17 w cc N \$889.89 \$1,709.82 \$1 297 Nutritional & misc metabolic disorders age >17 w cc N \$891.47 \$1,506.79 \$1 298 Nutritional & misc metabolic disorders age 0-17 N \$913.31 \$1,590.08 \$1 299 Inborn errors of metabolism N \$947.76 \$2,133.18 \$2 300 Endocrine disorders w cc N \$1,017.95 \$1,845.35 \$3 301 Endocrine disorders w cc N \$1,043.26 \$1,818.97 \$1 302 Kidney transplant S \$1,239.72 \$2,017.45 \$3 304 Kidney, urster & major bladder proc for non-neopl w cc \$1,126.87 \$2,333.11 \$3 305 Kidney, urster & major bladder proc for non-neopl w/o cc \$1,004.91 \$1,845.32 \$3 306 Prostatectomy w/o cc \$3,981.09 \$1,881.26 \$4 307 Prostatectomy w/o cc				8			\$2,977.60 \$3,764.96
295 Diabetes are 0-35 N \$859.89 \$1,709.82 \$1,209.82 297 Nutritional & misc metabolic disorders age >17 w/o cc N \$932.81 \$1,506.79 \$1 298 Nutritional & misc metabolic disorders age 0-17 N \$891.47 \$1,506.79 \$1 299 Inborn errors of metabolic disorders age 0-17 N \$913.31 \$1,506.79 \$1 300 Inborn errors of metabolic disorders age 0-17 N \$947.76 \$2,133.18 \$2 300 Endocrine disorders wicc N \$1,017.95 \$1,845.35 \$1 301 Endocrine disorders wicc N \$1,017.95 \$1,846.35 \$1 302 Kidney transplant S \$2,332.13 \$3 \$2,333.11 \$3 303 Kidney, ureter & major bladder procedures for non-neopl w/c c \$1,218.72 \$2,333.11 \$3 304 Kidney, ureter & major bladder proce for non-neopl w/c c \$1,028.22 \$1,881.26 \$4 305 Fixed term major bladder procedures w/c \$5,100.21 \$1,815.67 \$1,81.65 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td>\$1,504.78</td>							\$1,504.78
296 Nutritional & misc metabolic disorders age >17 w cc N			Į.				\$1,969.69
Nutritional & misc metabolic disorders age 0-17 N						\$1,626.09	\$1,635.55
Inborn errors of metabolism S 347.76 \$2,133.18 \$3 \$3 \$3 \$3 \$3 \$3 \$3 \$							\$1,353.70
Endocrine disorders w cc		1					\$1,577.43
Signature Sign			į.				\$2,029.07
Signature Sign							\$1,867.25 \$1,762.05
Signature Sign							\$1,762.05
Kidney, ureter & major bladder proc for non-neopl w cc				Š			\$3,751.10
Minor bladder procedures w/o cc S \$772.91 \$1,242.11 \$5 \$106.75 \$1,066.75 \$1,877.51 \$3 \$311 Transurethral procedures w/o cc S \$959.78 \$1,712.33 \$4 \$312 Urethral procedures, age >17 w cc S \$1,009.62 \$1,456.02 \$2 \$313 Urethral procedures, age >17 w/o cc S \$1,009.62 \$1,456.02 \$2 \$314 Urethral procedures, age 0-17 S \$1,060.91 \$1,724.06 \$3 \$314 Urethral procedures, age 0-17 S \$1,060.91 \$1,724.06 \$3 \$316 Urethral procedures \$1,062.01 \$1,894.59 \$3 \$316 Renal failure N \$871.34 \$1,565.80 \$1 \$317 Admit for renal dialysis N \$883.60 \$1,468.92 \$2 \$317 Admit for renal dialysis N \$883.60 \$1,468.92 \$2 \$319 Kidney & urinary tract neoplasms w/o cc N \$692.22 \$984.72 \$3 \$320 Kidney & urinary tract infections age >17 w/o cc N \$895.63 \$1,551.93 \$1 \$323 Urinary stones w/o cc N \$919.06 \$1,660.34 \$1 \$323 Urinary stones w/o cc N \$997.92 \$1,819.50 \$3 \$324 Urinary stones w/o cc N \$895.63 \$1,561.71 \$1 \$1,778.99 \$1 \$1,010.93 \$1,661.34 \$1 \$1,778.99 \$1 \$1,010.93 \$1,661.30 \$1 \$1,778.99 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.9				Š			\$3,851.12
Minor bladder procedures w/o cc S \$772.91 \$1,242.11 \$5 \$106.75 \$1,066.75 \$1,877.51 \$3 \$311 Transurethral procedures w/o cc S \$959.78 \$1,712.33 \$4 \$312 Urethral procedures, age >17 w cc S \$1,009.62 \$1,456.02 \$2 \$313 Urethral procedures, age >17 w/o cc S \$1,009.62 \$1,456.02 \$2 \$314 Urethral procedures, age 0-17 S \$1,060.91 \$1,724.06 \$3 \$314 Urethral procedures, age 0-17 S \$1,060.91 \$1,724.06 \$3 \$316 Urethral procedures \$1,062.01 \$1,894.59 \$3 \$316 Renal failure N \$871.34 \$1,565.80 \$1 \$317 Admit for renal dialysis N \$883.60 \$1,468.92 \$2 \$317 Admit for renal dialysis N \$883.60 \$1,468.92 \$2 \$319 Kidney & urinary tract neoplasms w/o cc N \$692.22 \$984.72 \$3 \$320 Kidney & urinary tract infections age >17 w/o cc N \$895.63 \$1,551.93 \$1 \$323 Urinary stones w/o cc N \$919.06 \$1,660.34 \$1 \$323 Urinary stones w/o cc N \$997.92 \$1,819.50 \$3 \$324 Urinary stones w/o cc N \$895.63 \$1,561.71 \$1 \$1,778.99 \$1 \$1,010.93 \$1,661.34 \$1 \$1,778.99 \$1 \$1,010.93 \$1,661.30 \$1 \$1,778.99 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.9				S	\$961.22		\$4,676.03
Minor bladder procedures w/o cc S \$772.91 \$1,242.11 \$5 \$106.75 \$1,066.75 \$1,877.51 \$3 \$311 Transurethral procedures w/o cc S \$959.78 \$1,712.33 \$4 \$312 Urethral procedures, age >17 w cc S \$1,009.62 \$1,456.02 \$2 \$313 Urethral procedures, age >17 w/o cc S \$1,009.62 \$1,456.02 \$2 \$314 Urethral procedures, age 0-17 S \$1,060.91 \$1,724.06 \$3 \$314 Urethral procedures, age 0-17 S \$1,060.91 \$1,724.06 \$3 \$316 Urethral procedures \$1,062.01 \$1,894.59 \$3 \$316 Renal failure N \$871.34 \$1,565.80 \$1 \$317 Admit for renal dialysis N \$883.60 \$1,468.92 \$2 \$317 Admit for renal dialysis N \$883.60 \$1,468.92 \$2 \$319 Kidney & urinary tract neoplasms w/o cc N \$692.22 \$984.72 \$3 \$320 Kidney & urinary tract infections age >17 w/o cc N \$895.63 \$1,551.93 \$1 \$323 Urinary stones w/o cc N \$919.06 \$1,660.34 \$1 \$323 Urinary stones w/o cc N \$997.92 \$1,819.50 \$3 \$324 Urinary stones w/o cc N \$895.63 \$1,561.71 \$1 \$1,778.99 \$1 \$1,010.93 \$1,661.34 \$1 \$1,778.99 \$1 \$1,010.93 \$1,661.30 \$1 \$1,778.99 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.9				S			\$2,753.48
Minor bladder procedures w/o cc S \$772.91 \$1,242.11 \$5 \$106.75 \$1,066.75 \$1,877.51 \$3 \$311 Transurethral procedures w/o cc S \$959.78 \$1,712.33 \$4 \$312 Urethral procedures, age >17 w cc S \$1,009.62 \$1,456.02 \$2 \$313 Urethral procedures, age >17 w/o cc S \$1,009.62 \$1,456.02 \$2 \$314 Urethral procedures, age 0-17 S \$1,060.91 \$1,724.06 \$3 \$314 Urethral procedures, age 0-17 S \$1,060.91 \$1,724.06 \$3 \$316 Urethral procedures \$1,062.01 \$1,894.59 \$3 \$316 Renal failure N \$871.34 \$1,565.80 \$1 \$317 Admit for renal dialysis N \$883.60 \$1,468.92 \$2 \$317 Admit for renal dialysis N \$883.60 \$1,468.92 \$2 \$319 Kidney & urinary tract neoplasms w/o cc N \$692.22 \$984.72 \$3 \$320 Kidney & urinary tract infections age >17 w/o cc N \$895.63 \$1,551.93 \$1 \$323 Urinary stones w/o cc N \$919.06 \$1,660.34 \$1 \$323 Urinary stones w/o cc N \$997.92 \$1,819.50 \$3 \$324 Urinary stones w/o cc N \$895.63 \$1,561.71 \$1 \$1,778.99 \$1 \$1,010.93 \$1,661.34 \$1 \$1,778.99 \$1 \$1,010.93 \$1,661.30 \$1 \$1,778.99 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,681.08 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.9				S			\$3,345.13
310 Transurethral procedures w cc S \$1,066.75 \$1,877.51 \$3 \$311 Transurethral procedures w/o cc S \$959.78 \$1,712.33 \$4 Urethral procedures, age >17 w/o cc S \$1,009.62 \$1,456.02 \$2 \$313 Urethral procedures, age >17 w/o cc S \$1,006.91 \$1,724.06 \$3 \$314 Urethral procedures, age 0-17 S \$1,074.84 \$1,554.66 \$3 \$316 Cher kidney & urinary tract or procedures S \$1,060.91 \$1,724.06 \$3 \$316 Cher kidney & urinary tract or procedures S \$1,062.01 \$1,894.59 \$3 \$316 Renal failure N \$871.34 \$1,565.80 \$1 \$317 Admit for renal dialysis N \$883.60 \$1,468.92 \$2 \$318 Kidney & urinary tract neoplasms w cc N \$883.60 \$1,468.92 \$2 \$318 Kidney & urinary tract infections age >17 w cc N \$863.36 \$1,561.71 \$1 \$319 Kidney & urinary tract infections age >17 w cc N \$863.36 \$1,561.71 \$1 \$319 \$320 Kidney & urinary tract infections age >17 w cc N \$895.63 \$1,561.71 \$1 \$319 \$320 Urinary stones w cc, &/or esw lithotripsy N \$947.92 \$1,819.50 \$3 \$322 Urinary stones w/o cc N \$832.82 \$1,643.20 \$2 \$325 Kidney & urinary tract signs & symptoms age >17 w/o cc N \$879.15 \$1,343.07 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1 \$1,010.93 \$1,681.08 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010.93 \$1,010			Į.	5			\$3,168.23 \$5,019.25
Transurethral procedures w/o cc			i	Š			\$3,362.73
312 Urethral procedures, age >17 w cc S \$1,009.62 \$1,456.02 \$2 \$313 Urethral procedures, age >17 w/o cc S \$1,000.91 \$1,724.06 \$3 \$314 Urethral procedures, age 0-17 S \$1,074.84 \$1,554.66 \$3 \$315 Other kidney & urinary tract or procedures S \$1,062.01 \$1,894.59 \$3 \$316 Renal failure N \$871.34 \$1,565.80 \$1 \$317 Admit for renal dialysis N \$883.60 \$1,469.20 \$2 \$2 \$318 Kidney & urinary tract neoplasms w cc N \$1,057.07 \$1,944.76 \$2 \$319 Kidney & urinary tract infections age >17 w cc N \$863.36 \$1,561.71 \$1 \$1 \$1 \$1 \$1 \$1 \$1				š			\$4,582.58
Standard				s			\$2,879.36
Standard		Urethral procedures, age >17 w/o cc	l	S			\$3,951.85
Renal failure			1	S			\$3,243.57
Admit for renal dialysis N \$883.60 \$1,468.92 \$2 \$318 Kidney & urinary tract neoplasms w cc N \$1,057.07 \$1,944.76 \$2 \$2 \$320 Kidney & urinary tract neoplasms w/o cc N \$692.22 \$984.72 \$321 Kidney & urinary tract infections age >17 w cc N \$863.36 \$1,551.71 \$1 \$321 Kidney & urinary tract infections age >17 w/o cc N \$895.63 \$1,551.93 \$1 \$322 Kidney & urinary tract infections age 0-17 N \$919.06 \$1,660.34 \$1 \$1 \$1 \$1 \$1 \$1 \$1 \$			[\$3,704.92
Signature Sign							\$1,864.33
Signature Sign							\$2,763.47 \$2,202.46
Xidney & urinary tract infections age >17 w cc			1				\$1,220.11
Signature Sign							\$1,572.19
323 Urinary stones w cc, &/or esw lithotripsy N \$947.92 \$1,819.50 \$3 324 Urinary stones w/o cc N \$832.82 \$1,643.20 \$2 325 Kidney & urinary tract signs & symptoms age >17 w cc N \$1,064.21 \$1,778.99 \$1 326 Kidney & urinary tract signs & symptoms age >17 w/o cc N \$879.15 \$1,343.07 \$1 327 Kidney & urinary tract signs & symptoms age 0-17 N \$1,010.93 \$1,681.08 \$1 328 Urethral stricture age >17 w cc N \$1,115.88 \$1,694.39 \$2 329 Urethral stricture age >17 w/o cc N \$1,065.40 \$1,526.98 \$2 330 Urethral stricture age 0-17 N \$1,138.71 \$1,727.40 \$2 331 Other kidney & urinary tract diagnoses age >17 w/o cc N \$804.64 \$1,320.02 \$1 332 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2 333 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2 334 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2 335 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2 336 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2 337 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2 338 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2 339 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2 340 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2 341 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2 341 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2 341 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2 342 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2 343 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2 343 Other kidney & urinary tract diagnoses age 0-17 Other kidney		Kidney & urinary tract infections age >17 w/o cc		N	\$895.63	\$1,551.93	\$1,458.92
324 Urinary stones w/o cc N \$832.82 \$1,643.20 \$2 \$25 \$25 \$25 \$25 \$26 \$25 \$26							
Signature Sign			1				\$3,167.77
326 Kidney & urinary tract signs & symptoms age >17 w/o cc N \$879.15 \$1.343.07 \$1 \$1.343.07 \$1 \$1.343.07 \$1 \$1.343.07 \$1 \$1.343.07 \$1 \$1.343.07 \$1 \$1.343.07 \$1 \$1.343.07 \$1 \$1.343.07 \$1 \$1.343.07 \$1 \$1.343.07 \$1 \$1.343.07 \$1 \$1.010.09 \$1.010.09 \$1.010.09 \$1.010.09 \$1.010.09 \$1.010.09 \$1.010.09 \$1.010.09 \$1.010.09 \$1.000.09			1				\$2,862.30
327 Kidney & urinary tract signs & symptoms age 0-17 N \$1,010.93 \$1,681.08 \$1 328 Urethral stricture age >17 w cc N \$1,115.88 \$1,694.39 \$2 329 Urethral stricture age >17 w/o cc N \$1,065.40 \$1,526.98 \$2 330 Urethral stricture age 0-17 N \$1,727.40 \$1,727.40 331 Other kidney & urinary tract diagnoses age >17 w/o cc N \$965.65 \$1,746.74 \$2 332 Other kidney & urinary tract diagnoses age >17 w/o cc N \$804.64 \$1,320.02 \$1 333 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2			1				\$1,781.63 \$1,463.75
328 Urethral stricture age >17 w cc N \$1,115.88 \$1,694.39 \$2 329 Urethral stricture age >17 w/o cc N \$1,065.40 \$1,526.98 \$2 330 Urethral stricture age 0-17 N \$1,138.71 \$1,727.40 \$1,727.40 \$1,727.40 \$1,727.40 \$1,727.40 \$1,727.40 \$2 332 Other kidney & urinary tract diagnoses age >17 w/o cc N \$804.64 \$1,320.02 \$1 333 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2							\$1,690.93
329 Urethral stricture age >17 w/o cc N \$1,065.40 \$1,526.98 \$2 330 Urethral stricture age 0-17 N \$1,138.71 \$1,727.40 \$2 331 Other kidney & urinary tract diagnoses age >17 w cc N \$965.65 \$1,746.74 \$2 332 Other kidney & urinary tract diagnoses age >17 w/o cc N \$804.64 \$1,320.02 \$1 333 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2			1				\$2,450.61
331 Other kidney & urinary tract diagnoses age >17 w cc N \$965.65 \$1,746.74 \$2 332 Other kidney & urinary tract diagnoses age >17 w/o cc N \$804.64 \$1,320.02 \$1 333 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2		Urethral stricture age >17 w/o cc					\$2,961.12
332 Other kidney & urinary tract diagnoses age >17 w/o cc N \$804.64 \$1,320.02 \$1 333 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2			I				\$2,554.78
333 Other kidney & urinary tract diagnoses age 0-17 N \$1,188.09 \$2,142.08 \$2			1				\$2,113.28
334 Major male pelvic procedures w cc S \$991.33 \$1,829.53 \$4 335 Major male pelvic procedures w/o cc S \$882.84 \$1,783.98 \$4 336 Transurethral prostatectomy w cc S \$905.16 \$1,707.70 \$3 337 Transurethral prostatectomy w/o cc S \$862.09 \$1.587.79 \$3						\$2 142 08	\$1,746.81 \$2,598.78
335 Major male pelvic procedures w/o cc S \$882.84 \$1,783.98 \$4 336 Transurethral prostatectomy w cc S \$905.16 \$1,707.70 \$3 337 Transurethral prostatectomy w/o cc S \$862.09 \$1,587.79 \$3						\$1,829.53	\$4,175.79
336 Transurethral prostatectomy w cc S \$905.16 \$1,707.70 \$3 337 Transurethral prostatectomy w/o cc S \$862.09 \$1.587.79 \$3				š			\$4,752.34
337 Transurethral prostatectomy w/o cc S \$862.09 \$1.587.79 \$3	336		1	S	\$905.16	\$1,707.70	\$3,071.49
	337	Transurethral prostatectomy w/o cc		S			\$3,737.15
338 Testes procedures, for malignancy S \$882.25 \$1,668.97 \$2				S			\$2,935.28
339 Testes procedures, non-malignancy age >17 S \$806.43 \$1,757.94 \$2 340 Testes procedures, non-malignancy age 0-17 S \$818.52 \$1,682.58 \$2	339		. 1	S			\$2,781.17 \$2,778.53

PAGE 6 OF 8

		Surgical/	P	er Diem Char	ge
DRG	Description	Non- Surgical Indicator	Standard Room and Board	ICU Room and Board	Ancillary
341	Penis procedures	S S	\$1,169.69	\$2,596.18	\$6,270.96
342	Circumcision age >17	S	\$861.78	\$1,546.73	\$2,971.69
343 344	Circumcision age 0-17 Other male reproductive system or procedures for malignancy	S	\$861.78	\$1,546.73	\$2,971.69
345	Other male reproductive system or procedures for malignancy	S S S	\$977.19 \$1,024.39	\$1,431.15 \$2,087.99	\$6,956.84 \$3,102.84
346	Malignancy, male reproductive system, w cc	Ň	\$994.49	\$1,652.62	\$1,744.07
347	Malignancy, male reproductive system, w/o cc	N	\$727.57	\$1,014.32	\$1,545.17
348	Benign prostatic hypertrophy w cc	N	\$1,088.89	\$1,819.18	\$1,883.52
349 350	Benign prostatic hypertrophy w/o cc Inflammation of the male reproductive system	N N	\$1,142.04 \$910.99	\$1,968.50	\$1,914.07
351	Sterilization, male	N	\$806.74	\$1,726.49 \$1,539.10	\$1,649.32 \$2,198.30
352	Other male reproductive system diagnoses	l N	\$1,073.97	\$2,493.79	\$1,971.18
353	Pelvic evisceration, radical hysterectomy & radical vulvectomy	S	\$1,240.36	\$3,107.75	\$4,772.07
354	Uterine, adnexa proc for non-ovarian/adnexal malig w cc	S	\$1,031.45	\$2,081.74	\$3,435.33
355 356	Uterine, adnexa proc for non-ovarian/adnexal malig w/o cc Female reproductive system reconstructive procedures	0 0	\$1,022.51 \$780.14	\$1,981.69 \$1,658.85	\$3,822.53 \$4,598.89
357	Uterine & adnexa proc for ovarian or adnexal malignancy	s	\$1,093.70	\$2,296.47	\$3,901.50
358	Uterine & adnexa proc for non-malignancy w cc	S	\$889.06	\$1,835.41	\$3,692.13
359	Uterine & adnexa proc for non-malignancy w/o cc	S	\$828.45	\$1,610.78	\$4,065.99
360 361	Vagina, cervix & vulva procedures Laparoscopy & incisional tubal interruption	S	\$860.70 \$710.75	\$1,983.53	\$4,155.65
362	Endoscopic tubal interruption	00000000000000	\$719.67	\$807.79 \$1,452.60	\$3,621.16 \$3,399.54
363	D&c, conization & radio-implant, for malignancy	Š	\$1,105.70	\$2,266.71	\$3,335.72
364	D&c, conization except for malignancy	S	\$1,247.32	\$1,996.17	\$2,999.28
365	Other female reproductive system or procedures	S	\$987.34	\$1,894.57	\$3,322.42
366 367	Malignancy, female reproductive system w cc Malignancy, female reproductive system w/o cc	N N	\$926.88 \$1,049.25	\$1,686.51 \$1,416.19	\$1,685.61 \$1,341.59
368	Infections, female reproductive system	N	\$909.63	\$1,969.95	\$1,752.12
369	Menstrual & other female reproductive system disorders	N	\$1,430.27	\$2,086.21	\$2,443.78
370	Cesarean section w cc	S	\$929.27	\$1,893.55	\$2,135.97
371	Cesarean section w/o cc	S	\$905.90	\$1,944.98	\$2,238.63
372 373	Vaginal delivery w complicating diagnoses Vaginal delivery w/o complicating diagnoses	N	\$1,001.39 \$894.61	\$2,042.05 \$1,465.55	\$2,049.16 \$2,026.66
374	Vaginal delivery was complicating diagnoses Vaginal delivery was terilization &/or d&c	l s	\$941.93	\$7,930.86	\$3,301.37
375	Vaginal delivery w or proc except steril &/or d&c	S	\$506.82	\$1,725.30	\$2,307.19
376	Postpartum & post abortion diagnoses w/o or procedure	N	\$1,106.71	\$1,784.87	\$1,350.58
377 378	Postpartum & post abortion diagnoses w or procedure Ectopic pregnancy	S	\$607.59 \$819.75	\$773.42 \$1,256.11	\$4,369.56 \$4,606.12
379	Threatened abortion	N	\$906.56	\$1.879.59	\$1,226.35
380	Abortion w/o d&c	N	\$815.29	\$1,754.39	\$2,852.56
381	Abortion w d&c, aspiration curettage or hysterotomy	S	\$1,168.70	\$2,372.78	\$3,798.49
382 383	False labor Other antepartum diagnoses w medical complications	N N	\$1,325.67 \$988.48	\$1,399.98 \$1,780.67	\$1,088.89 \$1,253.41
384	Other antepartum diagnoses w/nedical complications Other antepartum diagnoses w/o medical complications	l n	\$1,042.59	\$2,111.34	\$1,738.80
385	Neonates, died or transferred to another acute care facility	N	\$871.48	\$1,758.99	\$4,112.02
386	Extreme immaturity	N	\$701.84	\$1,416.60	\$3,311.60
387	Prematurity w major problems Prematurity w/o major problems	N N	\$621.24 \$397.61	\$1,253.93 \$802.54	\$2,931.34 \$1,876.13
388 389	Full term neonate w major problems	N N	\$354.69	\$715.90	\$1,673.55
390	Neonate w other significant problems	N N	\$216.75	\$437.49	
391	Normal newborn	N	\$134.68	\$271.85	\$635.50
392	Splenectomy age >17	S	\$910.66 \$910.66	\$1,759.39 \$1,759.39	\$4,001.80
393 394	Splenectomy age 0-17 Other or procedures of the blood and blood forming organs	SS	\$1,019.69	\$1,756.20	\$4,001.80 \$3,855.35
395	Red blood cell disorders age >17	Ň	\$952.62	\$1,653.74	\$2,066.19
396	Red blood cell disorders age 0-17	N	\$1,165.76	\$2,023.74	\$2,528.48
397	Coagulation disorders	l N	\$986.31	\$1,801.53	\$3,276.91
398 399	Reticuloendothelial & immunity disorders w cc Reticuloendothelial & immunity disorders w/o cc	N N	\$1,011.70 \$962.45	\$1,883.56 \$1,758.73	\$2,604.00 \$2,214.47
400	Lymphoma & leukemia w major or procedure	l s	\$1,060.40	\$2,083.56	\$3,912.53
401	Lymphoma & non-acute leukemia w other or proc w cc	l S	\$1,058.00	\$2,069.68	\$3,140.25
402	Lymphoma & non-acute leukemia w other or proc w/o cc	S	\$920.66	\$1,597.43	\$3,576.95
403 404	Lymphoma & non-acute leukemia w cc Lymphoma & non-acute leukemia w/o cc	N N	\$1,149.69 \$1,092.66	\$2,061.41 \$1,763.98	\$2,811.16 \$2,421.64
405	Acute leukemia w/o major or procedure age 0-17	N	\$1,277.36	\$2,548.40	\$4,139.45
406	Myeloprolif disord or poorly diff neopl w major proc w cc	S	\$1,307.40	\$2,585.97	\$4,485.38
407	Myeloprolif disord or poorly diff neopl w major proc w/o cc	S	\$926.08	\$1,881.93	\$4,150.89
408	Myeloprolif disord or poorly diff neopl w other or proc	1 3	\$1,501.54	\$2,802.72	\$4,632.74

PAGE 7 OF 8

411 History of	Description	Non- Surgical	Standard		
410 Chemoth 411 History of		Indicator	Room and Board	ICU Room and Board	Ancillary
411 History of		N	\$1,222.12	\$2,647.14	\$2,164.36
	erapy w/o acute leukemia as secondary diagnosis	N	\$1,128.59	\$1,742.65	\$3,441.58
	f malignancy w/o endoscopy	N N	\$813.86	\$2,106.73	\$1,743.40
	f malignancy w endoscopy eloprolif dis or poorly diff neopl diag w cc	N N	\$1,086.08 \$1,012.11	\$0.00 \$1,937.86	\$1,631.90 \$2,120.79
	reloprolif dis or poorly diff neopl diag w/o cc	N	\$923.95	\$2,668.51	\$1,387.54
	dure for infectious & parasitic diseases	s	\$1,140.40	\$2,170.22	\$3,147.27
	nia age >17	N	\$1,017.26	\$1,908.58	\$2,155.49
	nia age 0-17	N	\$1,410.90	\$2,647.11	\$2,989.57
	rative & post-traumatic infections	N	\$967.99	\$1,717.73	\$1,716.87
	unknown origin age >17 w cc unknown origin age >17 w/o cc	N	\$997.33 \$904.17	\$1,658.52 \$1,442.84	\$2,084.28 \$1,737.41
	ess age >17	N	\$949.46	\$1,586.06	\$1,737.41
	ess & fever of unknown origin age 0-17	Ň	\$897.85	\$1,491.87	\$1,855.55
	ectious & parasitic diseases diagnoses	N	\$933.48	\$1,838.48	\$2,427.98
	dure w principal diagnoses of mental illness	S	\$1,006.06	\$1,369.58	\$1,150.12
	justment reaction & psychosocial dysfunction ve neuroses	N	\$1,042.84	\$1,612.57	\$1,184.44
	s except depressive	N N	\$1,022.01 \$945.17	\$1,211.66 \$1,317.52	\$403.16 \$354.02
	s of personality & impulse control	l n	\$1,005.98	\$1,537.57	\$319.81
1 .	disturbances & mental retardation	N	\$1,255.92	\$1,720.04	\$622.80
430 Psychos		N	\$1,051.27	\$1,278.61	\$337.26
	d mental disorders	N	\$917.72	\$1,207.78	\$277.76
	ental disorder diagnoses	N N	\$915.71 \$1,078.88	\$1,461.81	\$327.50 \$647.78
434 No longe	trug abuse or dependence, left ama er valid	l N	\$0.00	\$1,693.80 \$0.00	\$0.00
435 No longe		l N	\$0.00	\$0.00	\$0.00
436 No longe		N	\$0.00	\$0.00	\$0.00
437 No longe		N	\$0.00	\$0.00	\$0.00
438 No longe		N	\$0.00	\$0.00	\$0.00
	ts for injuries	S	\$921.40 \$944.90	\$1,742.47 \$1,991.91	\$2,238.01 \$2,535.37
	lebridements for injuries occurred for injuries	S S S	\$856.81	\$2,169.12	\$2,555.57 \$3,844.49
	procedures for injuries w cc	Š	\$955.81	\$1,930.72	\$3,474.53
	procedures for injuries w/o cc	S	\$992.11	\$1,954,76	\$3,990.46
	c injury age >17 w cc	N	\$807.69	\$1,620.07	\$1,528.17
	c injury age >17 w/o cc c injury age 0-17	N	\$1,047.09 \$721.06	\$2,164.53 \$1,462.49	\$1,442.99 \$1,239.56
	eactions age >17	N	\$926.93	\$1,811.72	\$1,985.64
	eactions age 0-17	N	\$926.93	\$1,811.72	\$1,985.64
449 Poisonin	g & toxic effects of drugs age >17 w cc	N	\$1,059.07	\$2,027.14	\$2,402.52
	g & toxic effects of drugs age >17 w/o cc	N	\$989.79	\$1,804.68	\$1,877.43
	g & toxic effects of drugs age 0-17	N N	\$1,005.67	\$1,913.67	\$2,236.99 \$2,174.28
	ations of treatment w cc ations of treatment w/o cc	l N	\$905.26 \$952.17	\$1,724.13 \$1,821.34	\$1,853.20
	ury, poisoning & toxic effect diag w cc	l n	\$1,706.04	\$3,192.04	\$3,156.07
455 Other in	ury, poisoning & toxic effect diag w/o cc	N	\$986.75	\$1,841.38	\$1,867.20
456 No longe		N	\$0.00	\$0.00	\$0.00
457 No longe		N S	\$0.00 \$0.00	\$0.00 \$0.00	\$0.00
458 No longe 459 No longe		s	\$0.00	\$0.00	\$0.00 \$0.00
460 No longe		Ň	\$0.00	\$0.00	\$0.00
461 Or proc	v diagnoses of other contact w health services	s	\$1,124.56	\$2,024.38	\$2,488.23
462 Rehabili		N	\$908.51	\$1,188.19	\$1,111.11
	symptoms w cc	N N	\$843.64	\$1,471.96	\$1,357.45 \$891.37
	symptoms w/o cc w history of malignancy as secondary diagnosis	N	\$660.32 \$1,037.75	\$1,181.02 \$2,221.82	\$1,082.94
	w/o history of malignancy as secondary diagnosis	N	\$1,099.89	\$1,754.19	\$1,126.24
	ctors influencing health status	N	\$628.18	\$1,683.79	\$763.92
	e or procedure unrelated to principal diagnosis	S	\$1,068.47	\$1,998.79	\$3,592.24
	diagnosis invalid as discharge diagnosis	N N	\$358.38 \$424.41	\$683.70 \$4,658.89	\$976.55 \$875.54
470 Ungroup 471 Bilateral	or multiple major joint procs of lower extremity	S	\$852.66	\$1,726.96	\$7,008.39
472 No longe		S	\$0.00	\$0.00	\$0.00
473 Acute le	ukemia w/o major or procedure age >17	S	\$1,105.18	\$2,204.90	\$3,585.48
474 No longe		S	\$0.00	\$0.00 \$1,999.96	\$0.00 \$3,475.10
	ory system diagnosis with ventilator support or procedure unrelated to principal diagnosis	N S	\$1,036.49 \$1,115.69		

PAGE 8 OF 8

		Surgical/	P	er Diem Char	ge
DRG	Description	Non- Surgical	Standard Room and	ICU Room	Ancillary
		Indicator	Board	and Board	
477	Non-extensive or procedure unrelated to principal diagnosis	s	\$1,078.97	\$1,918.49	\$2,802.98
478	Other vascular procedures w cc	S	\$1,092.57	\$1,968.45	\$4,254.70
479 480	Other vascular procedures w/o cc Liver transplant	S	\$994.93	\$1,785.08	\$6,053.03
481	Bone marrow transplant	S S	\$1,154.82 \$1,755.55	\$2,894.63 \$2,368.29	\$9,659.58 \$4,341.88
482	Tracheostomy for face, mouth & neck diagnoses	3	\$1,755.55	\$2,300.29	\$3,413.51
483	Trac w mech vent 96+hrs or pdx except face, mouth & neck dx	S S S S S	\$1,484.30	\$2,407.90	\$4,944.24
484	Craniotomy for multiple significant trauma	S	\$1,165,46	\$2,643.72	\$6,114.97
485	Limb reattachment, hip and femur proc for multiple significant trauma	Š	\$999.93	\$2,178.80	\$4,488.78
486	Other or procedures for multiple significant trauma	Š	\$1,094,48	\$2,307.88	\$5,661.86
487	Other multiple significant trauma	Ň	\$943.97	\$2,161.62	\$2,610.34
488	Hiv w extensive or procedure	S	\$1,329.35	\$2,690.75	\$4,292.63
489	Hiv w major related condition	N	\$1,261.07	\$2,287.66	\$2,477.20
490	Hiv w or w/o other related condition	N	\$1,019.81	\$1,623.87	\$1,852.08
491	Major joint & limb reattachment procedures of upper extremity	S	\$944.50	\$1,878.77	\$7,199.50
492	Chemotherapy w acute leukemia as secondary diagnosis	N	\$1,035.24	\$1,782.67	\$3,350.8
493	Laparoscopic cholecystectomy w/o cde w cc	S	\$932.14	\$1,739.80	\$4,164.36
494	Laparoscopic cholecystectomy w/o cde w/o cc	88888	\$870.74	\$1,553.42	\$5,444.4
495	Lung transplant	S	\$1,708.36	\$2,813.75	\$12,316.8
496	Combined anterior/posterior spinal fusion	S	\$1,053.93	\$2,232.99	\$8,592.1
497	Spinal fusion except cervical w cc	S	\$980.48	\$2,180.78	\$7,827.3
498	Spinal fusion except cervical w/o cc	S	\$900.37	\$2,127.35	\$8,992.0
499	Back & neck procedures except spinal fusion w cc	l S	\$984.47	\$2,042.61	\$4,315.3
500	Back & neck procedures except spinal fusion w/o cc	S	\$912.62	\$1,955.87	\$5,487.8
501	Knee procedures w pdx of infection w cc	S S S S	\$1,021.34	\$1,888.32	\$3,247.2
502	Knee procedures w pdx of infection w/o cc) 8	\$887.72	\$1,582.23	\$3,039.5
503 504	Knee procedures w/o pdx of infection	S S	\$1,149.19 \$1,782.37	\$2,326.56 \$3,945.97	\$4,942.8 \$7,476.6
504 505	Extensive 3rd degree burns w skin graft Extensive 3rd degree burns w/o skin graft	N	\$779.40	\$3,184.88	\$5,932.1
506	Full thickness burn w skin graft or inhal inj w cc or sig trauma	S	\$1,593,61	\$3,938.86	\$4,344.8
507	Full thickness burn w skin grit or inhal inj w/o cc or sig trauma	S	\$1,266.73	\$3,461.66	\$2,713.5
508	Full thickness burn w/o skin grft or inhal inj w/o cc or sig trauma	Ň	\$851.59	\$2,461.11	\$1,747.1
509	Full thickness burn w/o skin grft or inh inj w/o cc or sig trauma	N N	\$810.37	\$3,324.63	\$1,520.1
510	Non-extensive burns w cc or significant trauma	N	\$984.76	\$3,314.38	\$2,065.0
511	Non-extensive burns w/o cc or significant trauma	N	\$670.98	\$2,415.12	\$1,174.8
512	Simultaneous pancreas/kidney transplant		\$1,112.89	\$2,760.57	\$12,956.6
513	Pancreas transplant	000000000	\$1,394.98	\$2,314.81	\$10,927.2
514	Cardiac defibrillator implant w cardiac cath	S	\$1,176.14	\$2,001.25	\$13,497.1
515	Cardiac defibrillator implant w/o cardiac cath	S	\$1,074.59	\$1,821.48	\$13,889.8
516	Percutaneous cardiovascular proc w ami	S	\$1,151.11	\$1,953.40	\$8,426.8
517	Perc cardio proc w non-drug eluting stent w/o ami	S	\$1,093.60	\$1,818.50	\$12,898.6
518	Perc cardio proc w/o coronary artery stent or ami	S	\$1,314.56	\$2,022.61	\$8,024.8
519	Cervical spinal fusion w cc	S	\$1,049.47	\$2,384.89	\$7,008.8
520	Cervical spinal fusion w/o cc	S	\$880.67	\$1,993.61	\$10,718.7
521	Alcohol/drug abuse or dependence w cc	l N	\$958.32	\$1,706.78	\$919.4
522	Alc/drug abuse or depend w rehabilitation therapy w/o cc	N	\$841.07	\$1,403.51	\$242.8
523	Alc/drug abuse or depend w/o rehabilitation therapy w/o cc	N	\$850.18	\$1,203.67	\$290.8
524	Transient ischemia	N S	\$925.81	\$1,547.49	\$2,133.1
525 526	Heart assist system implant	٥	\$1,234.41 \$1,314.56	\$2,518.32 \$2,022.61	\$11,095.1 \$8,024.8
526 527	Percutaneous cardiovascular proc w drug eluting stent w ami Percutaneous cardiovascular proc w drug eluting stent w/o ami	SSS	\$1,314.56	\$2,022.61	\$8,024.8
321	i ereataneous cardiovascular proc w drug ending sterit w/o anii	,	Ψ1,314.30	WE, UZZ.U1	ψυ,υ24.0

TABLE B. — SKILLED NURSING FACILITY/SUB-ACUTE INPATIENT FACILITY NATIONWIDE PER DIEM CHARGE

Description	All-Inclusive Per Diem Charge
Skilled Nursing Facility/Sub-Acute Inpatient Facility	\$655.39

TABLE C. — OBSERVATION CARE FACILITY NATIONWIDE BASE AND HOURLY CHARGES

Description	Base Charge	Hourly Charge
Observation Facility Care	\$200.91	\$35.22

TABLE D. — PARTIAL HOSPITALIZATION FACILITY NATIONWIDE PER DIEM CHARGE

Description	All-Inclusive Per Diem Charge
Partial Hospitalization Facility	\$449.76

TABLE E. — AMBULANCE AND OTHER EMERGENCY TRANSPORTATION CHARGES BY HCPCS CODE

HCPCS Code	Description	
A0380 A0390 A0425 A0426 A0427 A0428 A0429 A0430 A0431 A0435 A0436	Basic Life Support Mileage (Per Mile) Advanced Life Support Mileage (Per Mile) Ground Mileage, Per Statute Mile Ambulance Service, Advanced Life Support, Non-Emergency Transport, Level 1 (ALS 1) Ambulance Service, Advanced Life Support, Emergency Transport, Level 1 (ALS1-Emergency) Ambulance Service, Basic Life Support, Non-Emergency Transport, (BLS) Ambulance Service, Basic Life Support, Emergency Transport (BLS-Emergency) Ambulance Service, Conventional Air Services, Transport, One Way (Fixed Wing) Ambulance Service, Conventional Air Services, Transport, One Way (Rotary Wing) Fixed Wing Air Mileage, Per Statute Mile Rotary Wing Air Mileage, Per Statute Mile	\$10.92 \$10.06 \$13.07 \$597.60 \$690.98 \$4435.75 \$464.39 \$3.486.00 \$5,727.00 \$42.33 \$68.48

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 1 OF 78

	PAGE 1 OF	10			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
0003T 0012T 0013T 0014T 0018T 0025T 0027T 10021 10022 10040 10060 10061 10081 10120 10121 10140 10160 11001 11010 11011 11012 11040 11041 11042 11043 11055 11056 11057 11100 11201 11301 11401	Cervicography Endometrial cryoablation Osteochondral knee autograft Osteochondral knee autograft Meniscal transplant, knee Transcranial magnetic stimul Ultrasonic pachymetry Endoscopic epidural lysis Fna w/o image Fna w/image Acne surgery Drainage of skin abscess Drainage of skin abscess Drainage of pilonidal cyst Drainage of pilonidal cyst Drainage of pilonidal cyst Drainage of pilonidal cyst Remove foreign body Remove foreign body Prainage of hematoma/fluid Puncture drainage of lesion Complex drainage, wound Debride infected skin Debride skin/muscle, fx Debride skin/muscle, fx Debride skin/muscle/bone, fx Debride skin, partial Debride skin, full Debride skin, full Debride tissue/muscle Debride tissue/muscle Debride tissue/muscle Debride tissue/muscle Debride tissue/muscle Debride skin lesion Trim skin lesions, 2 to 4 Trim skin lesions, 2 to 4 Trim skin lesions, over 4 Biopsy of skin tags Remove skin tags Remove skin tags Remove skin tags add-on Shave skin lesion		+ + + + + + + + + + + + + + + + + + +	\$129.26 \$9,694.54 \$7,043.98 \$7,043.98 \$139.60 \$199.00 \$4,534.03 \$159.39 \$159.39 \$177.67 \$483.36 \$483.36 \$483.36 \$2,701.58 \$415.44 \$290.03 \$4,689.89 \$4,698.89 \$4,698.8	
11423 11424 11426 11440	Exc h-f-nk-sp b9+marg 2.1-3 Exc h-f-nk-sp b9+marg 3.1-4 Exc h-f-nk-sp b9+marg > 4 cm Exc face-mm b9+marg 0.5 < cm		+ + + +	\$1,938.68 \$3,757.15 \$4,689.89 \$1,016.36	
11441 11442 11443 11444	Exc face-mm b9+marg 0.6-1 cm Exc face-mm b9+marg 1.1-2 cm Exc face-mm b9+marg 2.1-3 cm Exc face-mm b9+marg 3.1-4 cm		+ + + +	\$1,016.36 \$1,938.68 \$1,938.68 \$1,938.68	

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. CDT-4 Codes copyright American Dental Association. All rights reserved.

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 2 OF 78

	PAGE 2 OF	10			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
11446 11450 11451 11462 11463 11470 11601 11602 11603 11604 11602 11621 11622 11623 11624 11626 11640 11641 11642 11643 11644 11644 11719 11720 11721 11730 11750 11755 11760 11752 11755 11760 11752 11770 11771 11772 11900 11911 11921 11921 11921 11950 11951 11950 11971 11980 11981 11983	Exc face-mm b9+marg > 4 cm Removal, sweat gland lesion Exc tr-ext mig+marg 0.5 < cm Exc tr-ext mig+marg 0.6-1 cm Exc tr-ext mig+marg 2.1-3 cm Exc tr-ext mig+marg 2.1-3 cm Exc tr-ext mig+marg 3.1-4 cm Exc tr-ext mig+marg 3.1-4 cm Exc tr-ext mig+marg 0.5 < Exc h-f-nk-sp mlg+marg 0.6-1 Exc h-f-nk-sp mlg+marg 0.6-1 Exc h-f-nk-sp mlg+marg 1.1-2 Exc h-f-nk-sp mlg+marg 3.1-4 Exc h-f-nk-sp mlg+marg 3.1-4 Exc h-f-nk-sp mlg+marg 0.5 < Exc face-mm malig+marg 0.5-1 Exc face-mm malig+marg 0.5-1 Exc face-mm malig+marg 0.6-1 Exc face-mm malig+marg 1.1-2 Exc face-mm malig+marg 3.1-4 Exc face-mm malig+marg 3.1-4 Exc face-mm malig+marg 3.1-4 Exc face-mm malig+marg 1.1-2 Exc face-mm mig+marg 2.1-3 Exc face-mm mig+marg 1.1-2 Exc face-mm mig+marg 1		+++++++++++++++++++++++++++++++++++++++	\$4,689.89 \$4,689.89 \$4,689.89 \$4,689.89 \$4,689.89 \$4,689.89 \$4,689.89 \$1,016.36 \$1,016.36 \$1,938.68 \$1,938.68 \$1,938.68 \$1,938.68 \$1,938.68 \$1,938.68 \$1,938.68 \$1,938.68 \$1,1938.68 \$1,938.68	
12002 12004 12005 12006 12007	Repair superficial wound(s)		+ + + +	\$499.03 \$499.03 \$499.03 \$499.03 \$499.03	
12017 12011 12013 12014	Repair superficial wound(s) Repair superficial wound(s) Repair superficial wound(s) Repair superficial wound(s)		+ + +	\$499.03 \$499.03 \$499.03	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 3 OF 78

	PAGE 3 OF	10			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
12015 12016	Repair superficial wound(s) Repair superficial wound(s)		+ +	\$499.03 \$499.03	
12017 12018	Repair superficial wound(s) Repair superficial wound(s)		++	\$499.03 \$499.03	
12020	Closure of split wound		+	\$499.03	
12021	Closure of split wound		+	\$499.03	
12031	Layer closure of wound(s)		+	\$499.03	
12032 12034	Layer closure of wound(s) Layer closure of wound(s)		+	\$499.03 \$499.03	
12035	Layer closure of wound(s)		+	\$499.03	
12036	Layer closure of wound(s)		+	\$499.03	
12037	Layer closure of wound(s)		+	\$1,580.73	
12041 12042	Layer closure of wound(s) Layer closure of wound(s)		+	\$499.03 \$499.03	
12044	Layer closure of wound(s)		+	\$499.03	
12045	Layer closure of wound(s)		+	\$499.03	
12046	Layer closure of wound(s)		+	\$499.03 \$1,580.73	
12047 12051	Layer closure of wound(s) Layer closure of wound(s)		+	\$499.03	
12052	Layer closure of wound(s)		+	\$499.03	
12053	Layer closure of wound(s)		+	\$499.03	
12054	Layer closure of wound(s) Layer closure of wound(s)		++	\$499.03 \$499.03	
12055 12056	Layer closure of wound(s) Layer closure of wound(s)		+ +	\$499.03	
12057	Layer closure of wound(s)		+	\$1,580.73	
13100	Repair of wound or lesion		+	\$1,580.73	
13101	Repair of wound or lesion Repair wound/lesion add-on		+	\$1,580.73 \$499.03	
13102 13120	Repair of wound or lesion		+	\$499.03	
13121	Repair of wound or lesion		+	\$499.03	
13122	Repair wound/lesion add-on		+	\$499.03	
13131 13132	Repair of wound or lesion Repair of wound or lesion		+	\$499.03 \$499.03	
13133	Repair wound/lesion add-on		+	\$499.03	
13150	Repair of wound or lesion	*	+	\$1,580.73	
13151	Repair of wound or lesion		+	\$499.03	
13152 13153	Repair of wound or lesion Repair wound/lesion add-on		+	\$1,580.73 \$499.03	
13160	Late closure of wound		+	\$4,104.63	
14000	Skin tissue rearrangement		+	\$4,104.63	
14001	Skin tissue rearrangement		+	\$4,104.63 \$4,104.63	
14020 14021	Skin tissue rearrangement Skin tissue rearrangement		+	\$4,104.63	
14040	Skin tissue rearrangement		+	\$4,104.63	
14041	Skin tissue rearrangement		+	\$4,104.63	
14060 14061	Skin tissue rearrangement Skin tissue rearrangement		+	\$4,104.63 \$4,104.63	
14300	Skin tissue rearrangement		+	\$4,104.63	
14350	Skin tissue rearrangement		+	\$4,104.63	
15000	Skin graft		++	\$1,580.73	
15001 15050	Skin graft add-on Skin pinch graft		+	\$1,580.73 \$1,580.73	
15100	Skin split graft		+	\$4,104.63	
15101	Skin split graft add-on	1	+	\$4,104.63	
15120 15121	Skin split graft Skin split graft add-on		+ +	\$4,104.63 \$4,104.63	
15200	Skin spiit graft add-oil Skin full graft		+	\$4,104.63	
15201	Skin full graft add-on		+	\$1,580.73	1
15220	Skin full graft	1	+ +	\$4,104.63 \$1,580.73	
15221 15240	Skin full graft add-on Skin full graft		+	\$1,580.73	
15241	Skin full graft add-on		+	\$1,580.73	
15260	Skin full graft		†	\$4,104.63	
15261 15342	Skin full graft add-on Cultured skin graft, 25 cm	1	+ +	\$1,580.73 \$1,580.73	
15343	Culture skin graft addl 25 cm		+	\$499.03	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 4 OF 78

	PAGE 4 OF	/0			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
15350 15351 15400	Skin homograft Skin homograft add-on Skin heterograft		+ + +	\$3,840.76 \$4,104.63 \$1,580.73	
15401	Skin heterograft add-on		+	\$1,580.73	
15570 15572	Form skin pedicle flap Form skin pedicle flap		++	\$4,104.63 \$4,104.63	
15574	Form skin pedicle flap		+	\$4,104.63	
15576	Form skin pedicle flap		+	\$4,104.63	
15600 15610	Skin graft Skin graft		+	\$4,104.63 \$4,104.63	
15620	Skin graft		+	\$4,104.63	
15630	Skin graft		+	\$4,104.63	
15650	Transfer skin pedicle flap		+	\$4,104.63	
15732 15734	Muscle-skin graft, head/neck Muscle-skin graft, trunk		+	\$4,104.63 \$4,104.63	
15736	Muscle-skin graft, arm		+	\$4,104.63	
15738	Muscle-skin graft, leg		+	\$4,104.63	
15740 15750	Island pedicle flap graft Neurovascular pedicle graft		+	\$4,104.63 \$4,104.63	
15760	Composite skin graft		+	\$4,104.63	
15770	Derma-fat-fascia graft		+	\$4,104.63	
15775	Hair transplant punch grafts		+	\$1,580.73	
15776 15780	Hair transplant punch grafts Abrasion treatment of skin		+	\$1,580.73 \$4,689.89	
15781	Abrasion treatment of skin		+	\$4,689.89	
15782	Abrasion treatment of skin		+	\$4,689.89	
15783	Abrasion treatment of skin		+	\$705.44 \$290.03	
15786 15787	Abrasion, lesion, single Abrasion, lesions, add-on		, , , , , , , , , , , , , , , , , , ,	\$290.03	
15788	Chemical peel, face, epiderm		+	\$211.64	
15789	Chemical peel, face, dermal		+	\$415.44	
15792 15793	Chemical peel, nonfacial Chemical peel, nonfacial		+	\$211.64 \$290.03	
15810	Salabrasion		+	\$705.44	
15811	Salabrasion		+	\$705.44	
15819	Plastic surgery, neck		+	\$1,580.73 \$4,104.63	
15820 15821	Revision of lower eyelid Revision of lower eyelid		+	\$4,104.63	
15822	Revision of upper eyelid		+	\$4,104.63	
15823	Revision of upper eyelid		+	\$4,104.63	
15824 15825	Removal of forehead wrinkles Removal of neck wrinkles		+ +	\$4,104.63 \$4,104.63	
15826	Removal of brow wrinkles		+	\$4,104.63	
15828	Removal of face wrinkles		+	\$4,104.63	
15829	Removal of skin wrinkles Excise excessive skin tissue		++	\$4,104.63 \$4,689.89	
15831 15832	Excise excessive skin tissue		+	\$4,689.89	
15833	Excise excessive skin tissue		+	\$4,689.89	
15834	Excise excessive skin tissue		+	\$4,689.89	
15835 15836	Excise excessive skin tissue Excise excessive skin tissue		+ +	\$1,580.73 \$1,938.68	
15837	Excise excessive skin tissue		+	\$1,938.68	
15838	Excise excessive skin tissue		+	\$1,938.68	
15839	Excise excessive skin tissue		+ +	\$1,938.68 \$4,104.63	
15840 15841	Graft for face nerve palsy Graft for face nerve palsy		+	\$4,104.63	
15842	Flap for face nerve palsy		+	\$4,104.63	
15845	Skin and muscle repair, face		+ +	\$4,104.63 \$705.44	
15850 15851	Removal of sutures Removal of sutures		+ +	\$290.03	
15852	Dressing change,not for burn		1	\$175.05	
15860	Test for blood flow in graft			\$129.26	
15876 15877	Suction assisted lipectomy Suction assisted lipectomy	1	+ +	\$4,104.63 \$4,104.63	
15878	Suction assisted lipectomy		+	\$4,104.63	
15879	Suction assisted lipectomy	1	+	\$4,104.63	1

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 5 OF 78

	PAGE 5 OF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
15920	Removal of tail bone ulcer		+	\$4,689,89	
15922	Removal of tail bone ulcer		+	\$4,104.63	
15931	Remove sacrum pressure sore		+	\$4,689.89	
15933	Remove sacrum pressure sore		+	\$4,689.89	
15934	Remove sacrum pressure sore		+	\$4,104.63	
15935 15936	Remove sacrum pressure sore Remove sacrum pressure sore		+	\$4,104.63 \$4,104.63	
15937	Remove sacrum pressure sore		+	\$4,104.63	
15940	Remove hip pressure sore		+	\$4,689.89	
15941	Remove hip pressure sore		+	\$4,689.89	
15944	Remove hip pressure sore		+	\$4,104.63	
15945	Remove hip pressure sore		+	\$4,104.63	
15946 15950	Remove hip pressure sore Remove thigh pressure sore		+	\$4,104.63 \$4,689.89	
15951	Remove thigh pressure sore		+	\$4,689.89	
15952	Remove thigh pressure sore		+	\$4,104.63	
15953	Remove thigh pressure sore		+	\$4,104.63	
15956	Remove thigh pressure sore		+	\$4,104.63	
15958	Remove thigh pressure sore		+	\$4,104.63	
15999 16000	Removal of pressure sore Initial treatment of burn(s)		+	\$4,689.89 \$290.03	
16010	Treatment of burn(s)		+	\$705.44	
16015	Treatment of burn(s)		+	\$4,266.63	
16020	Treatment of burn(s)		+	\$290.03	
16025	Treatment of burn(s)		+	\$290.03	
16030	Treatment of burn(s)		+	\$415.44	
17000 17003	Destroy benign/premig lesion Destroy lesions, 2-14		++	\$177.67 \$177.67	
17003	Destroy lesions, 2-14 Destroy lesions, 15 or more		+	\$499.03	
17106	Destruction of skin lesions		+	\$499.03	
17107	Destruction of skin lesions		+	\$499.03	
17108	Destruction of skin lesions		+	\$499.03	
17110	Destruct lesion, 1-14		+ +	\$177.67 \$499.03	
17111 17250	Destruct lesion, 15 or more Chemical cautery, tissue		+	\$290.03	
17260	Destruction of skin lesions		+	\$415.44	
17261	Destruction of skin lesions		+	\$415.44	
17262	Destruction of skin lesions		+	\$415.44	
17263	Destruction of skin lesions		+	\$415.44	
17264	Destruction of skin lesions Destruction of skin lesions		+ +	\$415.44 \$705.44	1
17266 17270	Destruction of skin lesions		+	\$415.44	
17271	Destruction of skin lesions		+	\$290.03	
17272	Destruction of skin lesions		+	\$415.44	
17273	Destruction of skin lesions		+	\$415.44	
17274	Destruction of skin lesions		+ +	\$705.44 \$705.44	
17276 17280	Destruction of skin lesions Destruction of skin lesions		;	\$415.44	
17281	Destruction of skin lesions		+	\$415.44	
17282	Destruction of skin lesions		+	\$415.44	
17283	Destruction of skin lesions		+	\$415.44	
17284	Destruction of skin lesions		<u> </u>	\$705.44	
17286 17304	Destruction of skin lesions 1 stage mohs, up to 5 spec		+ +	\$415.44 \$935.36	
17304	2 stage mons, up to 5 spec		-	\$935.36	
17306	3 stage mohs, up to 5 spec	1	+	\$935.36	1
17307	Mohs addl stage up to 5 spec		+	\$935.36	
17310	Mohs any stage > 5 spec each		+	\$935.36	
17340	Cryotherapy of skin	1	+ +	\$211.64 \$211.64	
17360 17380	Skin peel therapy Hair removal by electrolysis		+	\$211.64	
17999	Skin tissue procedure		+	\$483.36	1
19000	Drainage of breast lesion		+	\$470.28	
19001	Drain breast lesion add-on		+ +	\$470.28 \$4,352.84	
19020 19100	Incision of breast lesion Bx breast percut w/o image		+	\$841.31	
, 5 , 60	1 baraat	•	•		•

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 6 OF 78

	PAGE 0 OF	10			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
19101	Biopsy of breast, open	·	+	\$4,548.82	
19102	Bx breast percut w/image		+	\$841.31	
19103	Bx breast percut w/device		+	\$1,421.34	
19110	Nipple exploration		+	\$4,548.82	
19112 19120	Excise breast duct fistula Removal of breast lesion		+	\$4,548.82 \$4,548.82	
19125	Excision, breast lesion		+	\$4,548.82	
19126	Excision, addl breast lesion		+	\$4,548.82	
19140	Removal of breast tissue		+	\$4,548.82	
19160	Removal of breast tissue		+	\$4,548.82	
19162 19180	Remove breast tissue, nodes Removal of breast		++	\$10,134.87 \$7,762.50	
19182	Removal of breast		+	\$7,762.50	
19240	Removal of breast		+	\$10,116.58	
19260	Removal of chest wall lesion		+	\$3,757.15	
19295	Place breast clip, percut			\$389.31	
19316	Suspension of breast		+	\$7,762.50	
19318 19324	Reduction of large breast Enlarge breast		+	\$10,134.87 \$10,134.87	
19325	Enlarge breast with implant		+	\$12,078.77	
19328	Removal of breast implant		+	\$7,762.50	
19330	Removal of implant material		+	\$7,762.50	
19340	Immediate breast prosthesis		+	\$10,116.58	
19342 19350	Delayed breast prosthesis		++	\$12,078.77	
19355	Breast reconstruction Correct inverted nipple(s)		+	\$7,762.50 \$7,762.50	
19357	Breast reconstruction		+	\$12,078.77	
19366	Breast reconstruction		+	\$7,762.50	
19370	Surgery of breast capsule		+	\$7,762.50	
19371	Removal of breast capsule		+	\$7,762.50	
19380 19396	Revise breast reconstruction Design custom breast implant		+	\$10,116.58 \$7,762.50	
19499	Breast surgery procedure		,	\$4,548.82	
20000	Incision of abscess		+	\$483.36	
20005	Incision of deep abscess		+	\$5,016.48	
20100	Explore wound, neck		+	\$679.31	
20101 20102	Explore wound, chest Explore wound, abdomen		+	\$4,104.63 \$4,104.63	
20102	Explore wound, abdoment Explore wound, extremity		+	\$679.31	
20150	Excise epiphyseal bar		+	\$8,872.91	
20200	Muscle biopsy		+	\$3,757.15	
20205	Deep muscle biopsy		+	\$3,757.15	
20206	Needle biopsy, muscle		+	\$841.31	
20220 20225	Bone biopsy, trocar/needle Bone biopsy, trocar/needle		, , , , , , , , , , , , , , , , , , ,	\$1,016.36 \$1,016.36	
20240	Bone biopsy, excisional		+	\$4,689.89	
20245	Bone biopsy, excisional		+	\$4,689.89	
20250	Open bone biopsy		+	\$5,016.48	
20251	Open bone biopsy		+	\$5,016.48 \$514.72	
20500 20520	Injection of sinus tract Removal of foreign body		+	\$514.72 \$1,016.36	
20525	Removal of foreign body		+	\$4,689.89	
20526	Ther injection, carp tunnel		+	\$546.05	
20550	Ini tendon sheath/ligament		+	\$546.05	
20551	Inject tendon origin/insert		+	\$546.05	
20552 20553	Inject trigger point, 1 or 2 Inject trigger points, =/> 3		++	\$546.05 \$546.05	
20600	Drain/inject, joint/bursa		+	\$546.05 \$546.05	
20605	Drain/inject, joint/bursa		+	\$546.05	
20610	Drain/inject, joint/bursa		+	\$546.05	
20612	Aspirate/ini ganglion cyst		+	\$546.05	
20615	Treatment of bone cyst Insert and remove bone pin	1	+	\$470.28 \$5,016.48	
20650 20660	Apply, rem fixation device		T	\$451,48	MDR
20665	Removal of fixation device			\$175.05	
20670	Removal of support implant	1	+	\$3,757.15	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 7 OF 78

	PAGE / OF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
20680 20690 20692 20693 20693 20694 20900 20902 20910 20912 20924 20926 20950 20975 20999 21010 21015 21025 21026 21029 21030 21031 21032 21034 21040 21044 21046 21047 21048 21049 21050 21060 21077 21077 21077 21077 21077 21078 21080 21081 21082 21083 21084 21085 21086 21087 21088 21088 21089 21100 211100 211120 21121 21122 21123 21125 21127 21137 21138 21139	Removal of support implant Apply bone fixation device Apply bone fixation device Adiust bone fixation device Remove bone fixation device Removal of bone for graft Removal of bone for graft Remove cartilage for graft Remove cartilage for graft Removal of fascia for graft Removal of tendon for graft Removal of tendon for graft Removal of tissue for graft Removal of jaw joint Resection of facial tumor Excision of bone, lower jaw Excision of facial bone(s) Contour of face bone lesion Excise max/zygoma by tumor Remove exostosis, mandible Remove mandible lesion Removal of jaw bone lesion Removal of jaw bone lesion Remove mandible cyst complex Excise lwr jaw cyst w/repair Remove maxilla cyst complex Excise lwr jaw cyst w/repair Remove maxilla cyst complex Excis uppr jaw cyst w/repair Remove ojaw joint cartilage Remove coronoid process Prepare face/oral prosthesis Pre		i e	\$4,689.89 \$6,283.67 \$5,016.48 \$5,016.48 \$5,016.48 \$5,016.48 \$6,283.67 \$4,104.63 \$4,104.63 \$4,104.63 \$4,104.63 \$5,016.48 \$5,016.48 \$5,016.48 \$5,016.48 \$5,016.48 \$5,424.08 \$3,895.61 \$9,175.99 \$1,565.03 \$5,424.08 \$5,424.08 \$5,424.08 \$5,424.08 \$5,424.08 \$5,424.08 \$5,424.08 \$5,424.08	1
21181 21198 21199 21206 21208 21209	Contour cranial bone lesion Reconstr lwr jaw segment Reconstr lwr jaw w/advance Reconstruct upper jaw bone Augmentation of facial bones Reduction of facial bones		+ + + +	\$9,175.99 \$9,175.99 \$9,175.99 \$9,175.99 \$9,175.99	1
21210 21215	Face bone graft Lower jaw bone graft		+ +	\$9,175.99 \$9,175.99	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 8 OF 78

	FAGE 8 OF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
21230 21235 21240 21242 21243 21244 21245 21246 21248 21249 21260 21261 21263 21267 21275 21280 21275 21280 21295 21296 21295 21300 21315 21320 21315 21320 21335 21336 21337 21338 21339 21340 21345 21355 21356 21365 21390 21400 21401 21406 21407 21421 21440 21445 21450 21451 21452 21453 21454 21461 21465 21470 21480 21493 21490 21493 21499 21501 21502 21555 21556	Rib cartilage graft Ear cartilage graft Reconstruction of jaw joint Reconstruction of jaw joint Reconstruction of jaw joint Reconstruction of lower jaw Reconstruction of jaw Revise eye sockets Revision of jaw muscle/bone Revision, orbitofacial bones Revision of jaw muscle/bone Revision of jaw muscle/bone Revision of jaw muscle/bone Revision of jaw muscle/bone Cranio/maxillofacial surgery Treatment of swill fracture Treatment of nose fracture Treat nasal septal fracture Treat nasal septal fracture Treat nasoethmoid fracture Treat nasoethmoid fracture Treat nasoethmoid fracture Treat nasoethmoid fracture Treat cheek bone fracture Treat cheek bone fracture Treat eye socket fracture Treat ower jaw fracture Treat lower jaw fracture Trea		+++++++++++++++++++++++++++++++++++++++	\$9,175.99 \$9,175.99 \$9,175.99 \$9,175.99 \$9,175.99 \$9,175.99 \$9,175.99 \$9,175.99 \$9,175.99 \$9,175.99 \$9,175.99 \$9,175.99 \$9,175.99 \$9,175.99 \$1,175.99 \$1,175.99 \$1,175.95 \$1,175.09 \$1,175.99	MDR MDR

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 9 OF 78

	PAGE 9 OF	70 -			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
21600 21610 21700 21725 21742 21743 21800 21805 21820 21899 21920 21925 21930 21935 22100 22101 22102 22103 22305 22521 22522 22614 22522 22614 22899 22900 22999 23000 23030 23031 23035 23030 23105 23100 23105 23100 23110 23110 23110 23115 23110 23115 23110 23115 23110 23115 23110 23115 23110 23115 23110 23115 23110 23115 23110 23115 23110 23115 23110 23115 23110 23115 23110 23115 23110 23115 23110 23115 23116 23115 23116 23115 23116 23117 23115 23117	Partial removal of rib Partial removal of rib Revision of neck muscle Revision of neck muscle Revision of neck muscle Repair stern/unss w/o scope Repair sternum/nuss w/scope Treatment of rib fracture Treatment of rib fracture Treats sternum fracture Neck/chest surgery procedure Biopsy soft tissue of back Biopsy soft tissue of back Remove lesion, back or flank Remove lesion, back or flank Remove part, lumbar vertebra Remove part, lumbar vertebra Remove part, lumbar vertebra Remove extra spine segment Treat spine fracture Treat spine fracture Treat spine fracture Manipulation of spine Percut vertebroplasty thor Percut vertebroplasty lumb Percut vertebroplasty addl Lumbar spine fusion Spine fusion, extra segment Spine surgery procedure Remova abdominal wall lesion Abdomen surgery procedure Removal of calcium deposits Release shoulder joint Drain shoulder bursa Drain shoulder bursa Drain shoulder bursa Drain shoulder lesion Exploratory shoulder surgery Exploratory shoulder surgery Biopsy shoulder tissues Removal of shoulder lesion Removal of shoulder lesion Removal of shoulder lesion Removal of shoulder lesion Removal of collarbone joint Shoulder joint surgery Remove shoulder joint lining Incision of collarbone joint Explore treat shoulder joint Partial removal, collar bone Removal of bone lesion Removal of bone lesion Removal of humerus lesion Remova eshoulder blade lesion Remove humerus lesion		+++++++++++++++++++++++++++++++++++++++	\$6,283.67 \$5,016.48 \$5,016.48 \$483.36 \$8,872.91 \$6,74.08 \$7,898.37 \$674.08 \$1,565.03 \$1,938.68 \$4,689.89 \$4,689.89 \$4,689.89 \$10,367.41 \$10,367.41 \$10,367.41 \$10,367.41 \$10,367.41 \$10,367.41 \$10,367.41 \$10,367.41 \$674.08 \$674.08 \$674.08 \$3,488.02 \$6,283.67 \$10,367.41 \$10,367	
23180 23182 23184 23190 23195 23330	Remove collar bone lesion Remove shoulder blade lesion Remove humerus lesion Partial removal of scapula Removal of head of humerus Remove shoulder foreign body		+ + + + +	\$6,283.67 \$6,283.67 \$6,283.67 \$6,283.67 \$6,283.67 \$1,938.68	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 10 OF 78

	PAGE 10 OF	10			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
23331	Remove shoulder foreign body		+	\$4,689.89	
23395	Muscle transfer, shoulder/arm		+	\$8,872.91	
23397	Muscle transfers		+	\$10,991.87	
23400	Fixation of shoulder blade		+	\$6,283.67	
23405	Incision of tendon & muscle		+	\$6,283.67	
23406 23410	Incise tendon(s) & muscle(s) Repair rotator cuff, acute		+	\$6,283.67	
23412	Repair rotator cuff, acute Repair rotator cuff, chronic		+	\$10,991.87 \$10,991.87	
23415	Release of shoulder ligament		+	\$8,872.91	
23420	Repair of shoulder		+	\$10,991.87	
23430	Repair biceps tendon		+	\$10,991.87	
23440	Remove/transplant tendon		+	\$10,991.87	
23450 23455	Repair shoulder capsule Repair shoulder capsule		+	\$10,991.87 \$10,991.87	
23460	Repair shoulder capsule		+	\$10,991.87	
23462	Repair shoulder capsule		+	\$10,991.87	
23465	Repair shoulder capsule		+	\$10,991.87	
23466	Repair shoulder capsule		+	\$10,991.87	
23470	Reconstruct shoulder joint		+	\$10,955.28	
23480 23485	Revision of collar bone Revision of collar bone		+	\$8,872.91 \$8,872.91	
23490	Reinforce clavicle		+	\$8,872.91	
23491	Reinforce shoulder bones		+	\$8,872.91	
23500	Treat clavicle fracture		+	\$674.08	
23505	Treat clavicle fracture		+	\$674.08	
23515	Treat clavicle fracture		+	\$7,898.37	
23520 23525	Treat clavicle dislocation Treat clavicle dislocation		++	\$674.08 \$674.08	
23530	Treat clavicle dislocation		+	\$7.898.37	
23532	Treat clavicle dislocation		+	\$7,898.37	
23540	Treat clavicle dislocation	,	+	\$674.08	
23545	Treat clavicle dislocation		+	\$674.08	
23550	Treat clavicle dislocation		++	\$7,898.37	
23552 23570	Treat clavicle dislocation Treat shoulder blade fx		+	\$7,898.37 \$674.08	
23575	Treat shoulder blade fx		+	\$674.08	
23585	Treat scapula fracture		+	\$7,898.37	
23600	Treat humerus fracture		+	\$674.08	
23605	Treat humerus fracture		+	\$674.08	
23615 23616	Treat humerus fracture Treat humerus fracture		++	\$7,898.37 \$7,898.37	
23620	Treat humerus fracture		+	\$674.08	
23625	Treat humerus fracture		+	\$674.08	
23630	Treat humerus fracture		+	\$7,898.37	
23650	Treat shoulder dislocation		+	\$674.08	
23655 23660	Treat shoulder dislocation		++	\$3,488.02 \$7,898.37	
23665	Treat shoulder dislocation Treat dislocation/fracture		+	\$674.08	
23670	Treat dislocation/fracture		+	\$7,898.37	
23675	Treat dislocation/fracture		· +	\$674.08	
23680	Treat dislocation/fracture		+	\$7,898.37	
23700	Fixation of shoulder		+	\$3,488.02	
23800 23802	Fusion of shoulder joint Fusion of shoulder joint		++	\$8,872.91 \$8,872.91	
23921	Amputation follow-up surgery		+	\$1,580.73	
23929	Shoulder surgery procedure		+	\$674.08	
23930	Drainage of arm lesion		+	\$4,352.84	
23931	Drainage of arm bursa		+	\$483.36	
23935 24000	Drain arm/elbow bone lesion Exploratory elbow surgery	1	+ +	\$5,016.48 \$6,283.67	
24000	Release elbow joint		+	\$6,283.67	
24065	Biopsy arm/elbow soft tissue		+	\$3,757.15	
24066	Biopsy arm/elbow soft tissue		+	\$3,757.15	
24075	Remove arm/elbow lesion		+ +	\$3,757.15 \$4,689.89	
24076 24077	Remove arm/elbow lesion Remove tumor of arm/elbow		+	\$4,689.89	
_ (0) /		•	•		•

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 11 OF 78

	FAGETIOF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
24100 24101 24102 24105 24110 24115 24116 24120 24125 24126 24130 24130	Biopsy elbow joint lining Explore/treat elbow joint Remove elbow joint lining Removal of elbow bursa Remove/graft bone lesion Remove/graft bone lesion Remove elbow lesion Remove/graft bone lesion Removal of head of radius Removal of arm bone lesion		+ + + + + + + + +	\$5,016.48 \$6,283.67 \$5,016.48 \$5,016.48 \$6,283.67 \$6,283.67 \$6,283.67 \$6,283.67 \$6,283.67 \$6,283.67	
24136 24138 24140 24145 24147 24150 24151 24152 24153 24153	Remove radius bone lesion Remove elbow bone lesion Partial removal of arm bone Partial removal of radius Partial removal of elbow Extensive humerus surgery Extensive radius surgery Extensive radius surgery Extensive radius surgery Removal of elbow joint		+ + + + + + + + + +	\$6,283.67 \$6,283.67 \$6,283.67 \$6,283.67 \$10,991.87 \$10,991.87 \$10,991.87 \$10,991.87 \$10,991.87	
24160 24164 24200 24201 24300 24301 24305 24310 24320 24330 24331	Remove elbow joint implant Remove radius head implant Removal of arm foreign body Removal of arm foreign body Manipulate elbow w/anesth Muscle/tendon transfer Arm tendon lengthening Revision of arm tendon Repair of arm tendon Revision of arm muscles Revision of arm muscles		+ + + + + + + + +	\$6,283.67 \$6,283.67 \$1,016.36 \$3,757.15 \$3,488.02 \$6,283.67 \$5,016.48 \$8,872.91 \$8,872.91	
24332 24340 24341 24342 24343 24344 24345 24346 24350 24351	Tenolysis, triceps Repair of biceps tendon Repair arm tendon/muscle Repair of ruptured tendon Repr elbow lat ligmnt w/tiss Reconstruct elbow lat ligmnt Repr elbw med ligmnt w/tissu Reconstruct elbow med ligmnt Repair of tennis elbow Repair of tennis elbow		+ + + + + + + + + + + + + + + + + + + +	\$5,016.48 \$8,872.91 \$8,872.91 \$6,283.67 \$8,872.91 \$6,283.67 \$8,872.91 \$6,283.67 \$8,872.91 \$6,283.67	
24351 24352 24354 24356 24361 24361 24362 24363 24365 24366 24400	Repair of tennis elbow Repair of tennis elbow Revision of tennis elbow Reconstruct elbow joint Reconstruct elbow joint Replace elbow joint Reconstruct head of radius Reconstruct head of radius Revision of humerus		+ + + + + + + + + + + + + + + + + + + +	\$6,283.67 \$6,283.67 \$6,283.67 \$7,626.62 \$10,955.28 \$10,955.28 \$7,626.62 \$10,955.28 \$6,283.67	
24410 24420 24430 24435 24470 24495 24498 24500 24505 24515	Revision of humerus Revision of humerus Repair of humerus Repair humerus with graft Revision of elbow joint Decompression of forearm Reinforce humerus Treat humerus fracture Treat humerus fracture Treat humerus fracture		+ + + + + + + + + + + + + + + + + + + +	\$6,283.67 \$8,872.91 \$8,872.91 \$8,872.91 \$6,283.67 \$8,872.91 \$674.08 \$674.08 \$77,898.37	
24516 24530 24535	Treat humerus fracture Treat humerus fracture Treat humerus fracture		+++	\$674.08 \$674.08	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 12 OF 78

	PAGE 12 OF	10			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
24538 24545 24546 24560 24565 24566 24575	Treat humerus fracture		+ + + + + +	\$7,898.37 \$7,898.37 \$7,898.37 \$674.08 \$674.08 \$7,898.37 \$7,898.37	
24576 24577 24579 24582 24586 24587 24600	Treat humerus fracture Treat humerus fracture Treat humerus fracture Treat humerus fracture Treat elbow fracture Treat elbow fracture Treat elbow dislocation		+ + + + + +	\$674.08 \$674.08 \$7,898.37 \$7,898.37 \$7,898.37 \$7,898.37 \$674.08	
24605 24615 24620 24635 24640 24650 24655	Treat elbow dislocation Treat elbow dislocation Treat elbow fracture Treat elbow fracture Treat elbow dislocation Treat radius fracture Treat radius fracture Treat radius fracture		+ + + + + +	\$3,488.02 \$7,898.37 \$674.08 \$7,898.37 \$674.08 \$674.08 \$674.08	
24665 24666 24670 24675 24685 24800 24802	Treat radius fracture Treat radius fracture Treat ulnar fracture Treat ulnar fracture Treat ulnar fracture Treat ulnar fracture Fusion of elbow joint Fusion/graft of elbow joint		+ + + + + +	\$7,898.37 \$7,898.37 \$674.08 \$674.08 \$7,898.37 \$8,872.91 \$8,872.91	
24925 24935 24999 25000 25001 25020 25023	Amputation follow-up surgery Revision of amputation Upper arm/elbow surgery Incision of tendon sheath Incise flexor carpi radialis Decompress forearm 1 space Decompress forearm 1 space		+ + + + + +	\$5,016.48 \$10,991.87 \$674.08 \$5,016.48 \$5,016.48 \$5,016.48 \$6,283.67	
25024 25025 25028 25031 25035 25040 25065	Decompress forearm 2 spaces Decompress forarm 2 spaces Drainage of forearm lesion Drainage of forearm bursa Treat forearm bone lesion Explore/treat wrist joint Biopsy forearm soft tissues		+ + + + + +	\$6,283.67 \$6,283.67 \$5,016.48 \$5,016.48 \$5,016.48 \$6,283.67 \$3,757.15	
25066 25075 25076 25077 25085 25100 25101	Biopsy forearm soft tissues Removel forearm lesion subcu Removel forearm lesion deep Remove tumor, forearm/wrist Incision of wrist capsule Biopsy of wrist joint Explore/treat wrist joint		+ + + + + +	\$4,689.89 \$3,757.15 \$4,689.89 \$4,689.89 \$5,016.48 \$5,016.48 \$6,283.67	
25107 25105 25107 25110 25111 25112 25115 25116	Remove wrist joint lining Remove wrist joint cartilage Remove wrist tendon lesion Remove wrist tendon lesion Reremove wrist tendon lesion Remove wrist fendon lesion Remove wrist/forearm lesion Remove wrist/forearm lesion		+ + + + + + +	\$6,283.67 \$6,283.67 \$5,016.48 \$3,822.45 \$3,822.45 \$5,016.48	
25118 25119 25120 25125 25126 25130	Excise wrist tendon sheath Partial removal of ulna Removal of forearm lesion Remove/graft forearm lesion Remove/graft forearm lesion Removal of wrist lesion		+ + + + + +	\$6,283.67 \$6,283.67 \$6,283.67 \$6,283.67 \$6,283.67 \$6,283.67 \$6,283.67	
25135 25136 25145 25150	Remove & graft wrist lesion Remove & graft wrist lesion Remove forearm bone lesion Partial removal of ulna		+ + +	\$6,283.67 \$6,283.67 \$6,283.67	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 13 OF 78

	PAGE 13 OF	76			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
25151 25170 25210 25215 25230 25240	Partial removal of radius Extensive forearm surgery Removal of wrist bone Removal of wrist bones Partial removal of radius Partial removal of ulna		+ + + + +	\$6,283.67 \$10,991.87 \$6,126.90 \$6,126.90 \$6,283.67 \$6,283.67	
25248 25250 25251 25259 25260	Remove forearm foreign body Removal of wrist prosthesis Removal of wrist prosthesis Manipulate wrist w/anesthes Repair forearm tendon/muscle		+ + + +	\$5,016.48 \$6,283.67 \$6,283.67 \$674.08 \$6,283.67	
25263 25265 25270 25272 25274	Repair forearm tendon/muscle Repair forearm tendon/muscle Repair forearm tendon/muscle Repair forearm tendon/muscle Repair forearm tendon/muscle		+ + + + + + + + + + + + + + + + + + + +	\$6,283.67 \$6,283.67 \$6,283.67 \$6,283.67 \$6,283.67	
25275 25280 25290 25295 25300 25301	Repair forearm tendon sheath Revise wrist/forearm tendon Incise wrist/forearm tendon Release wrist/forearm tendon Fusion of tendons at wrist Fusion of tendons at wrist		+ + + + +	\$6,283.67 \$6,283.67 \$6,283.67 \$5,016.48 \$6,283.67 \$6,283.67	
25301 25310 25312 25315 25316 25320	Transplant forearm tendon Transplant forearm tendon Revise palsy hand tendon(s) Revise palsy hand tendon(s) Repair/revise wrist joint		+ + + +	\$8,872.91 \$8,872.91 \$8,872.91 \$8,872.91 \$8,872.91	
25332 25335 25337 25350 25355	Revise wrist joint Realignment of hand Reconstruct ulna/radioulnar Revision of radius Revision of radius		+ + + +	\$7,626.62 \$8,872.91 \$8,872.91 \$8,872.91 \$8,872.91	
25360 25365 25370 25375 25390	Revision of ulna Revise radius & ulna Revise radius or ulna Revise radius & ulna Shorten radius or ulna		+ + + +	\$6,283.67 \$6,283.67 \$8,872.91 \$8,872.91 \$6,283.67	
25391 25392 25393 25394 25400	Lengthen radius or ulna Shorten radius & ulna Lengthen radius & ulna Repair carpal bone, shorten Repair radius or ulna		+ + + +	\$8,872.91 \$6,283.67 \$8,872.91 \$3,822.45 \$6,283.67	
25405 25415 25420 25425 25426	Repair/graft radius or ulna Repair radius & ulna Repair/graft radius & ulna Repair/graft radius or ulna Repair/graft radius & ulna		+ + + + + + + + + + + + + + + + + + + +	\$6,283.67 \$6,283.67 \$8,872.91 \$8,872.91 \$8,872.91	
25430 25431 25440 25441 25442 25443	Vasc graft into carpal bone Repair nonunion carpal bone Repair/graft wrist bone Reconstruct wrist joint Reconstruct wrist joint Reconstruct wrist joint	·	+ + + + +	\$6,126.90 \$6,126.90 \$8,872.91 \$10,955.28 \$10,955.28 \$10,955.28	
25444 25445 25446 25447 25449	Reconstruct wist joint Reconstruct wrist joint Reconstruct wrist joint Wrist replacement Repair wrist joint(s) Remove wrist joint implant	,	+ + + +	\$10,955.28 \$10,955.28 \$10,955.28 \$10,955.28 \$7,626.62 \$7,626.62	
25450 25455 25490 25491 25492	Revision of wrist joint Revision of wrist joint Reinforce radius Reinforce ulna Reinforce radius and ulna	-	+ + + +	\$8,872.91 \$8,872.91 \$8,872.91 \$8,872.91 \$8,872.91	
25500 25505 25515	Treat fracture of radius Treat fracture of radius Treat fracture of radius		+ + +	\$674.08 \$674.08 \$7,898.37	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 14 OF 78

	PAGE 14 OF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
25520	Treat fracture of radius		+	\$674.08	
25525	Treat fracture of radius		+	\$7,898.37	
25526	Treat fracture of radius		+	\$7,898.37	
25530	Treat fracture of ulna		+	\$674.08	
25535	Treat fracture of ulna		+	\$674.08	
25545	Treat fracture of ulna		+	\$7,898.37	
25560	Treat fracture radius & ulna		+	\$674.08	
25565	Treat fracture radius & ulna		+	\$674.08	
25574	Treat fracture radius & ulna		+	\$7,898.37	
25575	Treat fracture radius/ulna		+	\$7,898.37	
25600	Treat fracture radius/ulna	1	+	\$674.08	
25605	Treat fracture radius/ulna		+	\$674.08	
25611	Treat fracture radius/ulna		+	\$7,898.37	
25620	Treat fracture radius/ulna		++	\$7,898.37	
25622	Treat wrist bone fracture Treat wrist bone fracture		+	\$674.08 \$674.08	
25624 25628	Treat wrist bone fracture Treat wrist bone fracture		+	\$7,898.37	
25630	Treat wrist bone fracture		+	\$674.08	
25635	Treat wrist bone fracture]	1	\$674.08	
25645	Treat wrist bone fracture		+	\$7,898.37	
25650	Treat wrist bone fracture		+	\$674.08	
25651	Pin ulnar styloid fracture		+	\$7,898.37	
25652	Treat fracture ulnar styloid		+	\$7,898.37	
25660	Treat wrist dislocation		+	\$674.08	
25670	Treat wrist dislocation		+	\$7,898.37	
25671	Pin radioulnar dislocation		+	\$7,898.37	
25675	Treat wrist dislocation	1	+	\$674.08	
25676	Treat wrist dislocation		+	\$7,898.37	
25680	Treat wrist fracture		+ +	\$674.08	
25685	Treat wrist fracture		‡	\$7,898.37 \$674.08	
25690 25695	Treat wrist dislocation Treat wrist dislocation	l	+	\$7,898.37	
25893 25800	Fusion of wrist joint	1	+	\$8,872.91	
25805	Fusion/graft of wrist joint		+	\$8,872.91	}
25810	Fusion/graft of wrist joint		+	\$8,872.91	1
25820	Fusion of hand bones		+	\$3,822.45	
25825	Fuse hand bones with graft	l	+	\$6,126.90	l .
25830	Fusion, radioulnar int/ulna		+	\$8,872.91	
25907	Amputation follow-up surgery		+	\$5,016.48	
25922	Amputate hand at wrist		+	\$5,016.48	
25929	Amputation follow-up surgery	1	+ +	\$4,104.63 \$674.08	
25999	Forearm or wrist surgery Drainage of finger abscess		+	\$483.36	l
26010 26011	Drainage of finger abscess		+	\$2,701.58	
26020	Drain hand tendon sheath		+	\$3,822.45	l
26025	Drainage of palm bursa		+	\$3,822.45	
26030	Drainage of palm bursa(s)		+	\$3,822.45	l
26034	Treat hand bone lesion		+	\$3,822.45	
26035	Decompress fingers/hand		+	\$3,822.45	
26037	Decompress fingers/hand		+	\$3,822.45	
26040	Release palm contracture	l	+	\$6,126.90	
26045	Release palm contracture		+	\$6,126.90	
26055	Incise finger tendon sheath		+	\$3,822.45	
26060	Incision of finger tendon		+ +	\$3,822.45 \$3,822.45	
26070	Explore/treat hand joint		+	\$3,822.45	
26075 26080	Explore/treat finger joint Explore/treat finger joint		+	\$3,822.45	1
26100	Biopsy hand joint lining		+	\$3,822.45	1
26105	Biopsy finger joint lining		+	\$3,822.45	l
26110	Biopsy finger joint lining		+	\$3,822.45	
26115	Removel hand lesion subcut		+	\$4,689.89	
26116	Removel hand lesion, deep		+	\$4,689.89	1
26117	Remove tumor, hand/finger	1	+	\$4,689.89	
26121	Release palm contracture		+ +	\$6,126.90 \$6,126.90	
26123	Release palm contracture	1		\$6,126.90	
26125	Release palm contracture	ı		ψ0,120.80	'

See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 15 OF 78

PAGE 15 OF 76					
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
	Remove wrist joint lining Revise finger joint, each Revise finger joint, each Tendon excision, palm/finger Remove tendon sheath lesion Removal of palm tendon, each Removal of finger tendon Remove finger bone Remove hand bone lesion Remove/graft bone lesion Remove/graft finger lesion Remove/graft finger lesion Remove/graft finger lesion Partial removal, finger bone Partial removal, finger bone Partial removal, finger bone Extensive hand surgery Extensive hand surgery Extensive finger surgery Partial removal of finger Removal of implant from hand Manipulate finger w/anesth Repair finger/hand tendon Repair/graft hand tendon Repair/graft finger tendon Repair/finger tendon Repair/graft finger tendon Release palm/finger tendon Release palm/finger tendon Release palm/finger tendon Release palm/finger tendon Release forearm/hand tendon Incision of finger tendons Fusion of finger tendons Fusion of finger tendons Fusion of finger tendons Fusion of finger tendon Fusion of finger		1	\$3,822.45 \$3,822.45	1
26485 26489 26490 26492 26494 26496	Transplant palm tendon Transplant/graft palm tendon Revise thumb tendon Tendon transfer with graft Hand tendon/muscle transfer Revise thumb tendon		+ + + + +	\$6,126.90 \$6,126.90 \$6,126.90 \$6,126.90 \$6,126.90 \$6,126.90	
26497	Finger tendon transfer	i	+	\$6,126.90	I

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 16 OF 78

CP77	PAGE 10 OF 78					
26499	HCPCS	Description	Usage	Surgery Reduction	Charge	Method-
28500 Hand tendon reconstruction		Finger tendon transfer		+	\$6,126.90	
26502 Hand tendon reconstruction		Revision of finger		+		
26504 Hand tendon reconstruction				+		
26508 Release thumb contracture + \$3,822,45 26510 Thumb tendon transfer + \$6,126,90 26516 Fusion of knuckle joints + \$6,126,90 26517 Susion of knuckle joints + \$6,126,90 26526 Release knuckle contracture + \$3,822,45 26527 Release finger contracture + \$3,822,45 26528 Revise knuckle joint + \$7,626,62 26531 Revise knuckle with implant + \$10,955,28 26536 Revise knuckle with implant + \$10,955,28 26536 Revise knuckle with implant + \$10,955,28 26536 Revise finger joint + \$30,256,50 26536 Revise finger joint + \$30,256,50 26537 Revise finger joint + \$30,256,50 26542 Repair hand joint with graft + \$3,362,45 26543 Reconstruct finger joint + \$6,126,90 26544 Repair hand joint with graft + \$3,382,45 26545 Reconstruct finger joint + \$6,126,90 26546 Repair norminon hand + \$6,126,90 26547 Repair diversity finger joint + \$6,126,90 26548 Reconstruct finger joint + \$6,126,90 26559 Construct thumb replacement + \$6,126,90 26550 Construct thumb replacement + \$6,126,90 26550 Repair of web finger + \$6,126,90 26560 Repair of web finger + \$6,126,90 26561 Repair of web finger + \$6,126,90 26562 Repair of web finger + \$6,126,90 26563 Repair of web finger + \$6,126,90 26564 Repair of web finger + \$6,126,90 26567 Repair of web finger + \$6,126,90 26568 Repair of web finger + \$6,126,90 26569 Repair of web finger + \$6,126,90 26560 Repair of web finger + \$6,126,90 26561 Repair of web finger + \$6,126,90 26562 Repair of web finger + \$6,126,90 26563 Repair of web finger + \$6,126,90 26564 Repair of web finger + \$6,126,90 26567 Repair of web finger + \$6,126,90 26568 Repair of web finger + \$6,126,90 26569 Repair of web finger + \$6,126,90 26560 Repair of web finger + \$6,126,90 26561 Repair of web finger + \$6,126,90 26562 Repair						
26510 Thumb tendon transfer				l		
26516				i		
26517			1	l .		
Release knuckle contracture	26517	Fusion of knuckle joints		+		
26525 Release finger contracture						
26530 Revise knuckle joint						
26531 Revise finger joint + \$10,955.28 26536 Revise/implant finger joint + \$10,955.28 26541 Repair hand joint with graft + \$3,822.45 26542 Repair hand joint with graft + \$6,126.90 26543 Repair hand joint with graft + \$6,126.90 26544 Repair nonunion hand + \$6,126.90 26548 Reconstruct finger joint + \$6,126.90 26549 Repair on onunion hand + \$6,126.90 26549 Reconstruct thumb replacement + \$6,126.90 26550 Positional change of finger + \$6,126.90 26551 Repair of web finger + \$6,126.90 26552 Repair of web finger + \$6,126.90 26553 Repair of web finger + \$6,126.90 26554 Repair of web finger + \$6,126.90 26555 Correct finger deformity + \$6,126.90 26561 Repair finger deformity + \$6,126.90 26565 Correct metacarpal flav + \$6,126.90 26576 Correct finger deformity + \$6,126.90				l .		
26535 Revise finger joint + \$7,026,62 82540 26540 Repair hand joint with graft + \$3,822,45 82541 Repair hand joint with graft + \$3,822,45 82,129,90 82,129,90 82,129,90 82,129,90 82,129,90 82,129,90 82,129,90 82,129,90 82,129,90 82,129,90 82,129,90 82,128,90 <t< td=""><td></td><td></td><td></td><td>l .</td><td></td><td></td></t<>				l .		
26536 Revise/implant finger joint + \$10,955,28 26541 Repair hand joint with graft + \$3,822,45 26542 Repair hand joint with graft + \$6,126,90 26543 Repair nonunion hand + \$6,126,90 26546 Reconstruct finger joint + \$6,126,90 26547 Repair on nonunion hand + \$6,126,90 26548 Reconstruct finger joint + \$6,126,90 26549 Repair of web finger + \$6,126,90 26550 Repair of web finger + \$6,126,90 26561 Repair of web finger + \$3,822,45 26562 Repair of web finger + \$3,128,90 26563 Repair of web finger + \$3,128,90 26560 Correct finger deformity + \$5,126,90 26561 Repair metacarpal/finger + \$5,126,90 26590 Repair finger deformity + \$5,126,90 26593 Repair muscles of hand + \$3,82				l		
26541 Repair hand joint with graft + \$6,126,90 26545 Repoir hand joint with graft + \$3,822,45 26546 Repoir norunion hand + \$6,126,90 26548 Repair norunion hand + \$6,126,90 26548 Reconstruct finger joint + \$6,126,90 26555 Construct thumb replacement + \$6,126,90 26550 Repair of web finger + \$6,126,90 26561 Repair of web finger + \$6,128,90 26562 Repair of web finger + \$6,128,90 26563 Repair of web finger + \$6,128,90 26564 Repair of web finger + \$6,128,90 26565 Correct metacarpal flaw + \$6,128,90 26566 Correct finger deformity + \$6,128,90 26567 Correct finger deformity + \$6,128,90 26580 Repair finder deformity + \$6,126,90 26591 Repair muscles of hand + \$6,126,90 26593 Release muscles of hand + \$3,822,45 26594 Repair muscles of facture + \$6,126,90 26600	26536			+		
26542 Repair hand joint with graft + \$3,822,45 26546 Reconstruct finger joint + \$6,128,90 26548 Reconstruct funder joint + \$6,128,90 26550 Construct thumb replacement + \$6,128,90 26550 Positional change of finger + \$6,128,90 26550 Positional change of finger + \$3,822,45 26561 Repair of web finger + \$3,822,45 26562 Repair of web finger + \$6,126,90 26565 Correct finger deformity + \$6,126,90 26565 Correct finger deformity + \$6,126,90 26568 Lengthen metacarpal/finger + \$6,126,90 26569 Repair finger deformity + \$6,126,90 26591 Repair finger deformity + \$6,126,90 26591 Repair finger deformity + \$6,126,90 26591 Repair muscles of hand + \$6,126,90 26591 Repair finger finger deformity				l		
26545 Reconstruct finger joint + \$6,126,90 26548 Repair nonunion hand + \$6,128,90 26550 Construct thumb replacement + \$6,128,90 26550 Positional change of finger + \$6,128,90 26550 Repair of web finger + \$6,128,90 26561 Repair of web finger + \$6,126,90 26562 Repair of web finger + \$6,126,90 26563 Correct finger deformity + \$6,126,90 26564 Correct finger deformity + \$6,126,90 26565 Lengthen metacarpal/finger + \$6,126,90 26566 Repair hand deformity + \$6,126,90 26567 Repair hand deformity + \$6,126,90 26580 Repair muscles of hand + \$6,126,90 26591 Repair muscles of hand + \$6,126,90 26592 Repair muscles of hand + \$6,126,90 26593 Release muscles of hand + \$6,126,90 26596 Texture the accurate the accurate of				l		
26546 Repair nonunion hand + \$6,126,90 26550 Construct thumb replacement + \$6,126,90 26550 Construct thumb replacement + \$6,126,90 26550 Positional change of finger + \$6,126,90 26560 Repair of web finger + 38,22,45 26561 Repair of web finger + \$6,126,90 26562 Repair of web finger + \$6,126,90 26563 Repair for deformity + \$6,126,90 26565 Correct finger deformity + \$6,126,90 26568 Repair hand deformity + \$6,126,90 26587 Reconstruct extra finger + \$3,822,45 26591 Repair muscles of hand + \$6,126,90 26593 Repair muscles of hand + \$6,126,90 26594 Repair metacarpal fracture + \$6,126,90 26605 Treat metacarpal fracture + \$6,126,90 26606 Treat metacarpal fracture + \$6,1				ł		
26548 Reconstruct fumbre replacement + \$6,126.90 26550 Construct thumb replacement + \$6,126.90 26551 Positional change of finger + \$6,126.90 26560 Repair of web finger + \$6,126.90 26561 Repair of web finger + \$6,126.90 26562 Repair of web finger + \$6,126.90 26565 Correct finger deformity + \$6,126.90 26567 Correct finger deformity + \$6,126.90 26580 Repair hand deformity + \$6,126.90 26581 Repair maceles of hand + \$6,126.90 26590 Repair finger deformity + \$6,126.90 26591 Repair muscles of hand + \$6,126.90 26593 Release muscles of hand + \$6,126.90 26593 Release muscles of hand + \$6,126.90 26605 Treat metacarpal fracture + \$6,126.90 26607 Treat metacarpal fracture + \$6,126.90 26608 Treat metacarpal fracture + \$6,126.90 26615 Treat humb fracture + \$6,126.90 2						
26550 Positional change of finger + \$3,822,45 26561 Repair of web finger + \$3,822,45 26562 Repair of web finger + \$6,126,90 26565 Repair of web finger + \$6,126,90 26565 Correct metacarpal flaw + \$6,126,90 26567 Correct finger deformity + \$6,126,90 26580 Repair hand deformity + \$6,126,90 26581 Reconstruct extra finger + \$3,822,45 26591 Repair finger deformity + \$6,126,90 26592 Repair muscles of hand + \$3,822,45 26593 Release muscles of hand + \$3,822,45 26594 Repair finger deformity + \$6,126,90 26595 Repair muscles of hand + \$3,822,45 26596 Excision constricting tissue + \$6,126,90 26601 Treat metacarpal fracture + \$6,126,90 26605 Treat metacarpal fracture + \$6,126,90 26606 Treat metacarpal fracture + \$6,126,90 26607 Treat metacarpal fracture + \$6,126,90 2				t e		
265601 Repair of web finger + \$3,822,45 26561 Repair of web finger + \$6,126,90 26562 Repair of web finger + \$6,126,90 26565 Correct metecarpal flaw + \$6,126,90 26568 Lengthen metecarpal/finger + \$6,126,90 26580 Repair hand deformity + \$6,126,90 26587 Reconstruct extra finger + \$3,822,45 26589 Repair finger deformity + \$6,126,90 26591 Repair muscles of hand + \$6,126,90 26593 Repair muscles of hand + \$6,126,90 26594 Repair muscles of hand + \$6,126,90 26505 Treat metacarpal fracture + \$6,126,90 26591 Repair muscles of hand + \$6,126,90 26592 Repair muscles of hand + \$6,126,90 26593 Repair finger ffecture + \$6,126,90 26590 Treat metacarpal fracture + \$674,08	26550	Construct thumb replacement		1		
26561 Repair of web finger + \$6,126.90 26562 Repair of web finger + \$6,126.90 26567 Correct finger deformity + \$6,126.90 26568 Lengthen metacarpal/finger + \$6,126.90 26580 Repair hand deformity + \$6,126.90 26581 Repair finger deformity + \$6,126.90 26591 Repair finger deformity + \$6,126.90 26591 Repair muscles of hand + \$6,126.90 26593 Release muscles of hand + \$6,126.90 26596 Excision constricting tissue + \$6,126.90 26600 Treat metacarpal fracture + \$6,126.90 26601 Treat metacarpal fracture + \$674.08 26605 Treat metacarpal fracture + \$674.08 26607 Treat metacarpal fracture + \$7,898.37 26615 Treat thumb facture + \$7,898.37 26645 Treat thumb facture + \$7,898.37				1		
26562 Repair of web finger + \$6,128.90 26567 Correct finger deformity + \$6,128.90 26568 Lengthen metacarpal/finger + \$6,126.90 26580 Repair hand deformity + \$6,126.90 26587 Reconstruct extra finger + \$3,822.45 26590 Repair finger deformity + \$3,126.90 26591 Repair muscles of hand + \$6,126.90 26593 Release muscles of hand + \$3,822.45 26596 Excision constricting tissue + \$6,126.90 26509 Treat metacarpal fracture + \$674.08 26600 Treat metacarpal fracture + \$674.08 26600 Treat metacarpal fracture + \$674.08 26601 Treat metacarpal fracture + \$674.08 26607 Treat thetacarpal fracture + \$7,898.37 26611 Treat thetacarpal fracture + \$7,898.37 26611 Treat thunb fracture + <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td></t<>						
28565 Correct metacarpai flaw + \$6,126,90 28568 Lengthen metacarpal/finger + \$6,126,90 28580 Repair hand deformity + \$6,126,90 28587 Reconstruct extra finger + \$3,822,45 28590 Repair finger deformity + \$6,126,90 28593 Repair finger deformity + \$6,126,90 28593 Release muscles of hand + \$6,126,90 28593 Release muscles of hand + \$6,126,90 28690 Treat metacarpal fracture + \$6,126,90 28690 Treat metacarpal fracture + \$6,126,90 28600 Treat metacarpal fracture + \$6,126,90 28600 Treat metacarpal fracture + \$6,126,90 28600 Treat metacarpal fracture + \$674,08 28600 Treat metacarpal fracture + \$74,08 28601 Treat metacarpal fracture + \$7,898,37 28604 Treat thumb fracture + <				ł		
26567 Correct finger deformity + \$6,126.90 26588 Lengthen metacarpal/finger + \$6,126.90 26580 Repair hand deformity + \$3,822.45 26597 Reconstruct extra finger + \$3,822.45 26591 Repair muscles of hand + \$6,126.90 26593 Release muscles of hand + \$6,126.90 26596 Excision constricting tissue + \$6,126.90 26596 Treat metacarpal fracture + \$6,126.90 26600 Treat metacarpal fracture + \$6,126.90 26600 Treat metacarpal fracture + \$674.08 26601 Treat metacarpal fracture + \$674.08 26607 Treat metacarpal fracture + \$7,898.37 26615 Treat thumb dislocation + \$7,898.37 26641 Treat thumb fracture + \$674.08 26650 Treat thumb fracture + \$7,898.37 26661 Treat hand dislocation + \$				ŧ		
26588 Lengthen metacarpal/finger + \$6,126,90 26580 Repair hand deformity + \$6,126,90 26587 Reconstruct extra finger + \$3,822,45 26591 Repair finger deformity + \$6,126,90 26593 Release muscles of hand + \$6,126,90 26596 Excision constricting tissue + \$6,126,90 26590 Treat metacarpal fracture + \$674,08 26600 Treat metacarpal fracture + \$674,08 26607 Treat metacarpal fracture + \$674,08 26608 Treat metacarpal fracture + \$7,898,37 26615 Treat thumb flocation + \$674,08 26650 Treat thumb fracture + \$7,898,37 26651 Treat thumb fracture + \$7,898,37 26652 Treat thumb fracture + \$7,898,37 26653 Treat hand dislocation + \$674,08 26676 Treat hand dislocation + \$674,08		• • • • • • • • • • • • • • • • • • • •		ł		
26587 Reconstruct extra finger + \$3,822,45 26590 Repair finger deformity + \$6,126,90 26591 Repair muscles of hand + \$5,126,90 26596 Release muscles of hand + \$3,822,45 26596 Excision constricting tissue + \$6,126,90 26600 Treat metacarpal fracture + \$674,08 26600 Treat metacarpal fracture + \$674,08 26607 Treat metacarpal fracture + \$7,898,37 26615 Treat metacarpal fracture + \$7,898,37 26615 Treat thumb dislocation + \$7,898,37 26615 Treat thumb fracture + \$7,898,37 26651 Treat thumb fracture + \$7,898,37 26652 Treat thumb fracture + \$7,898,37 26653 Treat thumb fracture + \$7,898,37 26665 Treat thumb fracture + \$7,898,37 26670 Treat hand dislocation + \$7,988,37 <td></td> <td></td> <td></td> <td>+</td> <td></td> <td></td>				+		
Repair finger deformity				1		
26591 Repair muscles of hand + \$6,126.90 26596 Release muscles of hand + \$3,822.45 26596 Excision constricting tissue + \$6,126.90 26600 Treat metacarpal fracture + \$674.08 26607 Treat metacarpal fracture + \$674.08 26608 Treat metacarpal fracture + \$7,898.37 26615 Treat metacarpal fracture + \$7,898.37 26641 Treat thumb dislocation + \$674.08 26645 Treat thumb fracture + \$674.08 26650 Treat thumb fracture + \$7,898.37 26665 Treat thumb fracture + \$7,898.37 26670 Treat hand dislocation + \$674.08 26675 Treat hand dislocation + \$674.08 26676 Treat hand dislocation + \$7,898.37 26685 Treat hand dislocation + \$7,898.37 26700 Treat knuckle dislocation + \$7,898.37				1		
Release muscles of hand + \$3,822.45 26596						
26596 Excision constricting tissue + \$6,126.90 26600 Treat metacarpal fracture + \$674.08 26607 Treat metacarpal fracture + \$674.08 26608 Treat metacarpal fracture + \$7,898.37 26615 Treat metacarpal fracture + \$7,898.37 26641 Treat thumb dislocation + \$674.08 26650 Treat thumb fracture + \$674.08 26650 Treat thumb fracture + \$7,898.37 26665 Treat thumb fracture + \$7,898.37 26665 Treat thand dislocation + \$674.08 26675 Treat hand dislocation + \$674.08 26676 Pin hand dislocation + \$7,898.37 26686 Treat hand dislocation + \$7,898.37 26700 Treat knuckle dislocation + \$7,898.37 26700 Treat knuckle dislocation + \$674.08 26706 Pin knuckle dislocation + \$674.08						
Treat metacarpal fracture				+		
Treat metacarpal fracture				3		
26608 Treat metacarpal fracture + \$7,898.37 26615 Treat metacarpal fracture + \$7,898.37 26641 Treat thumb dislocation + \$674.08 26645 Treat thumb fracture + \$674.08 26650 Treat thumb fracture + \$7,898.37 26660 Treat thumb fracture + \$7,898.37 26670 Treat hand dislocation + \$674.08 26675 Treat hand dislocation + \$674.08 26676 Pin hand dislocation + \$7,898.37 26686 Treat hand dislocation + \$7,898.37 26700 Treat knuckle dislocation + \$7,898.37 26701 Treat knuckle dislocation + \$674.08 26705 Treat knuckle dislocation + \$674.08 26706 Pin knuckle dislocation + \$674.08 26705 Treat finger fracture, each + \$674.08 26705 Treat finger fracture, each + \$674.08 <						
Treat metacarpal fracture						
26641 Treat thumb dislocation + \$674.08 26650 Treat thumb fracture + \$674.08 26650 Treat thumb fracture + \$7,898.37 26665 Treat thumb fracture + \$7,898.37 26670 Treat hand dislocation + \$674.08 26675 Treat hand dislocation + \$7,898.37 26685 Treat hand dislocation + \$7,898.37 26686 Treat hand dislocation + \$7,898.37 26700 Treat knuckle dislocation + \$7,898.37 26700 Treat knuckle dislocation + \$674.08 26705 Treat knuckle dislocation + \$674.08 26706 Pin knuckle dislocation + \$674.08 26715 Treat finger fracture, each + \$7,898.37 26720 Treat finger fracture, each + \$674.08 26725 Treat finger fracture, each + \$7,898.37 26735 Treat finger fracture, each + \$7,898.37<				1		
26645 Treat thumb fracture + \$674.08 26650 Treat thumb fracture + \$7,898.37 26665 Treat thumb fracture + \$7,898.37 26670 Treat hand dislocation + \$674.08 26675 Treat hand dislocation + \$674.08 26676 Pin hand dislocation + \$7,898.37 26685 Treat hand dislocation + \$7,898.37 26686 Treat hand dislocation + \$7,898.37 26700 Treat knuckle dislocation + \$674.08 26705 Treat knuckle dislocation + \$674.08 26706 Pin knuckle dislocation + \$674.08 26705 Treat finger fracture, each + \$7,898.37 26720 Treat finger fracture, each + \$674.08 26725 Treat finger fracture, each + \$7,898.37 26726 Treat finger fracture, each + \$7,898.37 26740 Treat finger fracture, each + \$7,898.37 </td <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>						
26665 Treat thumb fracture + \$7,898.37 26670 Treat hand dislocation + \$674.08 26675 Treat hand dislocation + \$7,898.37 26676 Pin hand dislocation + \$7,898.37 26685 Treat hand dislocation + \$7,898.37 26700 Treat knuckle dislocation + \$674.08 26705 Treat knuckle dislocation + \$674.08 26706 Pin knuckle dislocation + \$674.08 26715 Treat knuckle dislocation + \$674.08 26715 Treat finger fracture, each + \$674.08 26720 Treat finger fracture, each + \$674.08 26725 Treat finger fracture, each + \$7,898.37 26735 Treat finger fracture, each + \$7,898.37 26740 Treat finger fracture, each + \$7,898.37 26740 Treat finger fracture, each + \$7,898.37 26750 Treat finger fracture, each +				+	\$674.08	
26670 Treat hand dislocation + \$674.08 26675 Treat hand dislocation + \$7,898.37 26685 Pin hand dislocation + \$7,898.37 26686 Treat hand dislocation + \$7,898.37 26700 Treat knuckle dislocation + \$674.08 26705 Treat knuckle dislocation + \$674.08 26706 Pin knuckle dislocation + \$674.08 26715 Treat knuckle dislocation + \$674.08 26720 Treat finger fracture, each + \$674.08 26725 Treat finger fracture, each + \$674.08 26727 Treat finger fracture, each + \$7,898.37 26735 Treat finger fracture, each + \$7,898.37 26740 Treat finger fracture, each + \$674.08 26742 Treat finger fracture, each + \$674.08 26750 Treat finger fracture, each + \$674.08 26750 Treat finger fracture, each + \$7,898.37 26756 Pin finger fracture, each + \$7,898.37 26756 Pin finger fracture, each + \$7,898.37				ı		
26675 Treat hand dislocation + \$674.08 26676 Pin hand dislocation + \$7,898.37 26685 Treat hand dislocation + \$7,898.37 26686 Treat hand dislocation + \$7,898.37 26700 Treat knuckle dislocation + \$674.08 26705 Treat knuckle dislocation + \$674.08 26706 Pin knuckle dislocation + \$674.08 26715 Treat knuckle dislocation + \$7,898.37 26720 Treat finger fracture, each + \$674.08 26725 Treat finger fracture, each + \$674.08 26727 Treat finger fracture, each + \$7,898.37 26735 Treat finger fracture, each + \$7,898.37 26740 Treat finger fracture, each + \$674.08 26742 Treat finger fracture, each + \$7,898.37 26750 Treat finger fracture, each + \$7,898.37 26756 Pin finger fracture, each +				1		
26676 Pin hand dislocation + \$7,898.37 26685 Treat hand dislocation + \$7,898.37 26686 Treat hand dislocation + \$7,898.37 26700 Treat knuckle dislocation + \$674.08 26705 Treat knuckle dislocation + \$674.08 26706 Pin knuckle dislocation + \$674.08 26715 Treat finger fracture, each + \$674.08 26720 Treat finger fracture, each + \$674.08 26725 Treat finger fracture, each + \$674.08 26727 Treat finger fracture, each + \$7,898.37 26735 Treat finger fracture, each + \$674.08 26740 Treat finger fracture, each + \$674.08 26740 Treat finger fracture, each + \$7,898.37 26750 Treat finger fracture, each + \$7,898.37 26750 Treat finger fracture, each + \$7,898.37 26756 Pin finger fracture, each + </td <td></td> <td></td> <td></td> <td>1</td> <td></td> <td></td>				1		
26685 Treat hand dislocation + \$7,898.37 26686 Treat hand dislocation + \$7,898.37 26700 Treat knuckle dislocation + \$674.08 26705 Treat knuckle dislocation + \$674.08 26706 Pin knuckle dislocation + \$674.08 26715 Treat knuckle dislocation + \$7,898.37 26720 Treat finger fracture, each + \$674.08 26725 Treat finger fracture, each + \$674.08 26727 Treat finger fracture, each + \$7,898.37 26735 Treat finger fracture, each + \$7,898.37 26740 Treat finger fracture, each + \$674.08 26742 Treat finger fracture, each + \$7,898.37 26750 Treat finger fracture, each + \$674.08 26755 Treat finger fracture, each + \$7,898.37 26756 Pin finger fracture, each + \$7,898.37 7reat finger fracture, each +				ŧ		
26686 Treat hand dislocation + \$7,898.37 26700 Treat knuckle dislocation + \$674.08 26705 Treat knuckle dislocation + \$674.08 26706 Pin knuckle dislocation + \$674.08 26715 Treat knuckle dislocation + \$7,898.37 26720 Treat finger fracture, each + \$674.08 26725 Treat finger fracture, each + \$674.08 26727 Treat finger fracture, each + \$7,898.37 26735 Treat finger fracture, each + \$674.08 26740 Treat finger fracture, each + \$674.08 26742 Treat finger fracture, each + \$7,898.37 26750 Treat finger fracture, each + \$674.08 26755 Treat finger fracture, each + \$674.08 26756 Pin finger fracture, each + \$7,898.37 26765 Treat finger fracture, each + \$7,898.37 7reat finger fracture, each + <td< td=""><td></td><td></td><td></td><td></td><td></td><td></td></td<>						
26705 Treat knuckle dislocation + \$674.08 26706 Pin knuckle dislocation + \$674.08 26715 Treat knuckle dislocation + \$7,898.37 26720 Treat finger fracture, each + \$674.08 26725 Treat finger fracture, each + \$674.08 26727 Treat finger fracture, each + \$7,898.37 26735 Treat finger fracture, each + \$674.08 26740 Treat finger fracture, each + \$674.08 26742 Treat finger fracture, each + \$674.08 26746 Treat finger fracture, each + \$7,898.37 26750 Treat finger fracture, each + \$674.08 26756 Treat finger fracture, each + \$7,898.37 26756 Treat finger fracture, each + \$7,898.37 26765 Treat finger fracture, each + \$7,898.37 26765 Treat finger fracture, each + \$7,898.37	26686	Treat hand dislocation		ł	,	
26706 Pin knuckle dislocation + \$674.08 26715 Treat knuckle dislocation + \$7,898.37 26720 Treat finger fracture, each + \$674.08 26725 Treat finger fracture, each + \$674.08 26727 Treat finger fracture, each + \$7,898.37 26735 Treat finger fracture, each + \$674.08 26740 Treat finger fracture, each + \$674.08 26742 Treat finger fracture, each + \$674.08 26750 Treat finger fracture, each + \$674.08 26755 Treat finger fracture, each + \$674.08 26756 Pin finger fracture, each + \$7,898.37 26765 Pin finger fracture, each + \$7,898.37 7 Treat finger fracture, each + \$7,898.37				I		
26715 Treat knuckle dislocation + \$7,898.37 26720 Treat finger fracture, each + \$674.08 26725 Treat finger fracture, each + \$674.08 26727 Treat finger fracture, each + \$7,898.37 26735 Treat finger fracture, each + \$7,898.37 26740 Treat finger fracture, each + \$674.08 26742 Treat finger fracture, each + \$7,898.37 26750 Treat finger fracture, each + \$674.08 26755 Treat finger fracture, each + \$674.08 26756 Pin finger fracture, each + \$7,898.37 26765 Treat finger fracture, each + \$7,898.37 26765 Treat finger fracture, each + \$7,898.37				1		
26720 Treat finger fracture, each + \$674.08 26725 Treat finger fracture, each + \$674.08 26727 Treat finger fracture, each + \$7,898.37 26735 Treat finger fracture, each + \$7,898.37 26740 Treat finger fracture, each + \$674.08 26742 Treat finger fracture, each + \$674.08 26746 Treat finger fracture, each + \$7,898.37 26750 Treat finger fracture, each + \$674.08 26755 Treat finger fracture, each + \$7,898.37 26765 Treat finger fracture, each + \$7,898.37 26765 Treat finger fracture, each + \$7,898.37				1		
26725 Treat finger fracture, each + \$674.08 26727 Treat finger fracture, each + \$7,898.37 26735 Treat finger fracture, each + \$7,898.37 26740 Treat finger fracture, each + \$674.08 26742 Treat finger fracture, each + \$674.08 26746 Treat finger fracture, each + \$7,898.37 26750 Treat finger fracture, each + \$674.08 26756 Teat finger fracture, each + \$7,898.37 26765 Treat finger fracture, each + \$7,898.37 26765 Treat finger fracture, each + \$7,898.37				1		
26735 Treat finger fracture, each + \$7,898.37 26740 Treat finger fracture, each + \$674.08 26742 Treat finger fracture, each + \$674.08 26746 Treat finger fracture, each + \$7,898.37 26750 Treat finger fracture, each + \$674.08 26755 Treat finger fracture, each + \$674.08 26756 Pin finger fracture, each + \$7,898.37 26765 Treat finger fracture, each + \$7,898.37		Treat finger fracture, each		+	\$674.08	
26740 Treat finger fracture, each + \$674.08 26742 Treat finger fracture, each + \$674.08 26746 Treat finger fracture, each + \$7,898.37 26750 Treat finger fracture, each + \$674.08 26755 Treat finger fracture, each + \$674.08 26756 Pin finger fracture, each + \$7,898.37 26765 Treat finger fracture, each + \$7,898.37						
26742 Treat finger fracture, each + \$674.08 26746 Treat finger fracture, each + \$7,898.37 26750 Treat finger fracture, each + \$674.08 26755 Treat finger fracture, each + \$674.08 26756 Pin finger fracture, each + \$7,898.37 26765 Treat finger fracture, each + \$7,898.37				1		
26746 Treat finger fracture, each + \$7,898.37 26750 Treat finger fracture, each + \$674.08 26755 Treat finger fracture, each + \$674.08 26756 Pin finger fracture, each + \$7,898.37 26765 Treat finger fracture, each + \$7,898.37			1			
26750 Treat finger fracture, each + \$674.08 26755 Treat finger fracture, each + \$674.08 26756 Pin finger fracture, each + \$7,898.37 26765 Treat finger fracture, each + \$7,898.37			1			
26756 Pin finger fracture, each + \$7,898.37 26765 Treat finger fracture, each + \$7,898.37	26750	Treat finger fracture, each				
26765 Treat finger fracture, each + \$7,898.37						
				1		
			1	ł		

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 17 OF 78

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
26775	Treat finger dislocation		+	\$3,488.02	
26776	Pin finger dislocation		+	\$7,898.37	
26785	Treat finger dislocation		+	\$7,898.37	
26820	Thumb fusion with graft		+	\$6,126.90	
26841	Fusion of thumb		+	\$6,126.90	
26842	Thumb fusion with graft		+	\$6,126.90	
26843 26844	Fusion of hand joint Fusion/graft of hand joint		+	\$6,126.90 \$6,126.90	
26850	Fusion of knuckle		+	\$6,126.90	
26852	Fusion of knuckle with graft		+	\$6,126.90	
26860	Fusion of finger joint		+	\$6,126.90	
26861	Fusion of finger int, add-on		+	\$6,126.90	
26862	Fusion/graft of finger joint		+	\$6,126.90 \$6,126.90	
26863 26910	Fuse/graft added joint Amputate metacarpal bone		+	\$6,126.90	
26951	Amputation of finger/thumb	l	+	\$3,822.45	
26952	Amputation of finger/thumb		+	\$3,822.45	
26989	Hand/finger surgery		+	\$674.08	
26990	Drainage of pelvis lesion	1	+	\$5,016.48	
26991 27000	Drainage of pelvis bursa Incision of hip tendon	1	+ +	\$5,016.48 \$5,016.48	
27000	Incision of hip tendon		+	\$6,283.67	
27003	Incision of hip tendon		+	\$6,283.67	
27033	Exploration of hip joint	·	+	\$8,872.91	
27035	Denervation of hip joint		+	\$10,991.87	
27040	Biopsy of soft tissues		+	\$3,757.15	
27041 27047	Biopsy of soft tissues Remove hip/pelvis lesion		+ +	\$4,689.89 \$4,689.89	
27047	Remove hip/pelvis lesion		, +	\$4,689.89	
27049	Remove tumor, hip/pelvis		+	\$4,689.89	
27050	Biopsy of sacroiliac joint		+	\$5,016.48	
27052	Biopsy of hip joint		+	\$5,016.48	
27060	Removal of ischial bursa		+ +	\$5,016.48 \$5,016.48	
27062 27065	Remove femur lesion/bursa Removal of hip bone lesion] ;	\$5,016.48	
27066	Removal of hip bone lesion		+	\$6,283.67	
27067	Remove/graft hip bone lesion	, i	+	\$6,283.67	
27080	Removal of tail bone		+	\$6,283.67	
27086	Remove hip foreign body		+ +	\$1,938.68 \$5,016.48	
27087 27097	Remove hip foreign body Revision of hip tendon		-	\$6,283.67	
27098	Transfer tendon to pelvis		+	\$6,283.67	
27100	Transfer of abdominal muscle	1	+	\$8,872.91	
27105	Transfer of spinal muscle		+	\$8,872.91	
27110	Transfer of iliopsoas muscle		†	\$8,872.91	
27111 27193	Transfer of iliopsoas muscle Treat pelvic ring fracture		+ +	\$8,872.91 \$674.08	
27193	Treat pelvic ring fracture		;	\$3,488.02	
27200	Treat tail bone fracture		+	\$674.08	
27202	Treat tail bone fracture		+	\$7,898.37	
27216	Treat pelvic ring fracture		+	\$6,283.67	
27220	Treat hip socket fracture		+ +	\$674.08 \$674.08	
27230 27235	Treat thigh fracture Treat thigh fracture		1 7	\$6,283,67	
27238	Treat thigh fracture		+	\$674.08	
27246	Treat thigh fracture		+	\$674.08	
27250	Treat hip dislocation		+	\$674.08	
27252	Treat hip dislocation		+ +	\$3,488.02 \$674.08	
27256 27257	Treat hip dislocation Treat hip dislocation		+	\$3,488.02	1
27265	Treat hip dislocation	1	+	\$674.08	
27266	Treat hip dislocation		+	\$3,488.02	
27275	Manipulation of hip joint	1	+	\$3,488.02	
27299	Pelvis/hip joint surgery		+ +	\$674.08 \$4,352.84	
27301 27305	Drain thigh/knee lesion Incise thigh tendon & fascia	1	+	\$5,016.48	1
21300	I meise migh teridon or idsold	•		, +=,0.0.10	•

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 18 OF 78

	17102 19 01				
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
27306	Incision of thigh tendon		+	\$5,016.48	
27307	Incision of thigh tendons		+	\$5,016.48	
27310	Exploration of knee joint		+	\$6,283.67	
27315 27320	Partial removal, thigh nerve Partial removal, thigh nerve		+	\$4,264.02 \$4,264.02	
27323	Biopsy, thigh soft tissues		+	\$3,757.15	
27324	Biopsy, thigh soft tissues		+	\$4,689.89	
27327	Removal of thigh lesion		+	\$4,689.89	
27328	Removal of thigh lesion		+	\$4,689.89	
27329 27330	Remove tumor, thigh/knee Biopsy, knee joint lining		+	\$4,689.89 \$6,283.67	
27331	Explore/treat knee joint		+	\$6,283.67	
27332	Removal of knee cartilage		+	\$6,283.67	
27333	Removal of knee cartilage		+	\$6,283.67	
27334	Remove knee joint lining		+	\$6,283.67	
27335 27340	Remove knee joint lining		++	\$6,283.67 \$5,016.48	
27345 27345	Removal of kneecap bursa Removal of knee cyst		+	\$5,016,48	
27347	Remove knee cyst		+	\$5,016.48	
27350	Removal of kneecap	1	+	\$6,283.67	
27355	Remove femur lesion		+	\$6,283.67	
27356 27357	Remove femur lesion/graft Remove femur lesion/graft	-	+ +	\$6,283.67 \$6,283.67	
27358 27358	Remove femur lesion/fixation		+	\$6,283.67	
27360	Partial removal, leg bone(s)		+	\$6,283.67	
27372	Removal of foreign body		+	\$4,689.89	
27380	Repair of kneecap tendon	1	+	\$5,016.48	
27381 27385	Repair/graft kneecap tendon Repair of thigh muscle	l	+ +	\$5,016.48 \$5,016.48	
27386	Repair/graft of thigh muscle		+	\$5,016.48	
27390	Incision of thigh tendon		+	\$5,016.48	
27391	Incision of thigh tendons		+	\$5,016.48	
27392 27393	Incision of thigh tendons Lengthening of thigh tendon		+ +	\$5,016.48 \$6,283.67	
27393 27394	Lengthening of thigh tendons		<u> </u>	\$6,283.67	
27395	Lengthening of thigh tendons		+	\$8,872.91	1
27396	Transplant of thigh tendon		+	\$6,283.67	
27397	Transplants of thigh tendons		+ +	\$8,872.91	
27400 27403	Revise thigh muscles/tendons Repair of knee cartilage		+	\$8,872.91 \$6,283.67	
27405	Repair of knee ligament		+	\$8,872.91	
27407	Repair of knee ligament		+	\$8,872.91	
27409	Repair of knee ligaments		+	\$8,872.91	
27418	Repair degenerated kneecap		+ +	\$8,872.91 \$8,872.91	l
27420 27422	Revision of unstable kneecap Revision of unstable kneecap		+	\$8,872.91	
27424	Revision/removal of kneecap		+	\$8,872.91	
27425	Lat retinacular release open		+	\$6,283.67	
27427	Reconstruction, knee		+ +	\$10,991.87 \$10,991.87	
27428 27429	Reconstruction, knee Reconstruction, knee		+	\$10,991.87	
27430	Revision of thigh muscles		+	\$8,872.91	
27435	Incision of knee joint		+	\$8,872.91	
27437	Revise kneecap		+	\$7,626.62	
27438 27440	Revise kneecap with implant Revision of knee joint		+ +	\$10,955.28 \$7,626.62	
27440 27441	Revision of knee joint Revision of knee joint		+	\$7,626.62	
27442	Revision of knee joint		+	\$7,626.62	j
27443	Revision of knee joint		+	\$7,626.62	
27446	Revision of knee joint		+	\$23,385.84 \$11,544.36	
27447 27496	Total knee arthroplasty Decompression of thigh/knee		+	\$5,016.48	
27497	Decompression of thigh/knee		+	\$5,016.48	
27498	Decompression of thigh/knee		+	\$5,016.48	
27499	Decompression of thigh/knee		+ +	\$5,016.48 \$674.08	
27500	Treatment of thigh fracture	I	, ,	1 4014.00	1

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 19 OF 78

PAGE 19 UP 70					
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
27501	Treatment of thigh fracture		+	\$674.08	
27502	Treatment of thigh fracture		+	\$674.08	
27503	Treatment of thigh fracture		+	\$674.08	
27508 27509	Treatment of thigh fracture Treatment of thigh fracture		++	\$674.08 \$7,898.37	
27510	Treatment of thigh fracture		+	\$674.08	
27516	Treat thigh fx growth plate		+	\$674.08	
27517	Treat thigh fx growth plate		+	\$674.08	
27520	Treat kneecap fracture		+	\$674.08	
27524 27530	Treat kneecap fracture Treat knee fracture		+ +	\$7,898.37 \$674.08	
27532	Treat knee fracture		+	\$674.08	
27538	Treat knee fracture(s)		+	\$674.08	
27550	Treat knee dislocation		+	\$674.08	
27552	Treat knee dislocation		+	\$3,488.02	
27560 27562	Treat kneecap dislocation Treat kneecap dislocation		++	\$674.08 \$3,488.02	
27566	Treat kneecap dislocation		ļ ;	\$7,898.37	
27570	Fixation of knee joint		+	\$3,488.02	
27594	Amputation follow-up surgery		+	\$5,016.48	
27599	Leg surgery procedure		+	\$674.08	
27600 27601	Decompression of lower leg		+ +	\$5,016.48	
27602	Decompression of lower leg Decompression of lower leg		+	\$5,016.48 \$5,016.48	
27603	Drain lower leg lesion		+	\$4,352.84	
27604	Drain lower leg bursa		+	\$5,016.48	
27605	Incision of achilles tendon		+	\$4,765.66	
27606	Incision of achilles tendon		+ +	\$5,016.48	
27607 27610	Treat lower leg bone lesion Explore/treat ankle joint		+	\$5,016.48 \$6,283.67	
27612	Exploration of ankle joint		+	\$6,283.67	
27613	Biopsy lower leg soft tissue		+	\$1,938.68	
27614	Biopsy lower leg soft tissue		+	\$4,689.89	
27615	Remove tumor, lower leg		+ +	\$7,898.37 \$3,757.15	
27618 27619	Remove lower leg lesion Remove lower leg lesion		+	\$4,689.89	
27620	Explore/treat ankle joint		+	\$6,283.67	
27625	Remove ankle joint lining		+	\$6,283.67	
27626	Remove ankle joint lining		+	\$6,283.67	
27630 27635	Removal of tendon lesion		+ +	\$5,016.48	
27637	Remove lower leg bone lesion Remove/graft leg bone lesion		+	\$6,283.67 \$6,283.67	
27638	Remove/graft leg bone lesion		+	\$6,283.67	
27640	Partial removal of tibia		+	\$8,872.91	
27641	Partial removal of fibula		+	\$6,283.67	
27647 27650	Extensive ankle/heel surgery Repair achilles tendon	1	+ +	\$8,872.91 \$8,872.91	
27650 27652	Repair achilles tendon Repair/graft achilles tendon		+	\$8,872.91	
27654	Repair of achilles tendon		+	\$8,872.91	
27656	Repair leg fascia defect		+	\$5,016.48	
27658	Repair of leg tendon, each		+	\$5,016.48	
27659	Repair of leg tendon, each		+ +	\$5,016.48 \$5,016.48	
27664 27665	Repair of leg tendon, each Repair of leg tendon, each		+	\$6,283.67	
27675	Repair lower leg tendons		+	\$5,016.48	
27676	Repair lower leg tendons		+	\$6,283.67	
27680	Release of lower leg tendon	1	+	\$6,283.67	1
27681 27685	Release of lower leg tendons Revision of lower leg tendon		+ +	\$6,283.67 \$6,283.67	
27686	Revise lower leg tendons	l	+	\$6,283.67	
27687	Revision of calf tendon	1	+	\$6,283.67	
27690	Revise lower leg tendon		+	\$8,872.91	
27691	Revise lower leg tendon	-	+ +	\$8,872.91 \$8,872.91	
27692 27695	Revise additional leg tendon Repair of ankle ligament		+	\$6,283.67	
27696	Repair of ankle ligaments		+	\$6,283.67	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 20 OF 78

PAGE 20 OF 78					
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
27698 27700 27704 27705 27707 27709 27730 27732 27734 27745 27756 27755 27756 27758 27756 27758 27758 27758 27758 27758 27758 27758 27760 27762 27766 27780 27762 27766 27781 27784 27784 27788 27782 27808 27811 2784 27888 27810 27814 27816 27818 27827 27828 27829 27831 27831 27832 27840 27844 27889 27831 27832 27840 27848 27860 27871 27884 27889 27893 27894 27899 28001 28002 28003 28005 28008	Repair of ankle ligament Revision of ankle implant Incision of tibia Incision of tibia & fibula Incision of tibia & fibula Repair of tibia epiphysis Repair of tibia epiphysis Repair lower leg epiphyses Repair of leg epiphyses Reinforce tibia Treatment of tibia fracture Treatment of ankle fracture Treatment of ankle fracture Treatment of ankle fracture Treatment of fibula fracture Treatment of fibula fracture Treatment of fibula fracture Treatment of ankle fracture Treat lower leg dislocation Treat ankle dislocation Treat of tibia fracture Treatment of foot infection Treatment of foot infection Treatment of foot infection Tr		+++++++++++++++++++++++++++++++++++++++	\$6,283.67 \$7,626.62 \$5,016.48 \$8,872.91 \$5,016.48 \$6,283.67 \$6,283.67 \$6,283.67 \$6,283.67 \$6,283.67 \$6,283.67 \$6,283.67 \$8,872.91 \$6,74.08 \$7,898.37 \$7,898.37 \$674.08 \$7,898.37 \$674.08 \$7,898.37 \$674.08 \$7,898.37 \$674.08 \$7,898.37 \$674.08 \$7,898.37 \$674.08 \$7,898.37 \$674.08 \$7,898.37 \$674.08 \$7,898.37 \$674.08 \$7,898.37 \$674.08 \$7,898.37 \$674.08 \$7,898.37 \$674.08 \$7,898.37 \$674.08 \$7,898.37 \$674.08 \$7,898.37 \$674.08 \$7,898.37 \$674.08 \$5,016.48	
28008 28010 28011 28020 28022 28024 28030	Incision of toe tascia Incision of toe tendon Incision of toe tendons Exploration of foot joint Exploration of foot joint Exploration of toe joint Removal of foot nerve		+ + + + + + +	\$4,765.66 \$4,765.66 \$4,765.66 \$4,765.66 \$4,765.66 \$4,264.02	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 21 OF 78

	PAGE 21 OF	10			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
28035 28043 28045 28045 28046 28050 28052 28054 28060 28062 28070 28072 28080 28086 28088 28090 28100 28102 28100 28102 28101 28110 28111 28113 28114 28116 28118 28119 28122 28120 28120 28120 28120 28140 28150 28140 28153 28160 28171 28173 28160 28171 28173 28160 28171 28173 28160 28171 28173 28160 28173 28160 28179 28122 28222 28226 28200 28202	Decompression of tibia nerve Excision of foot lesion Excision of foot lesion Resection of tumor, foot Biopsy of foot joint lining Biopsy of foot joint lining Biopsy of toe joint lining Partial removal, foot fascia Removal of foot fascia Removal of foot joint lining Removal of foot joint lining Removal of foot lesion Excise foot tendon sheath Removal of foot lesion Removal of foot lesion Removal of soot lesion Remove/graft foot lesion Removal of metatarsal Part removal of heel bone Removal of heel bone Removal of heel bone Removal of heel bone Removal of ankle/heel Partial removal of toe Parti		+ + + + + + + + + + + + + + + + + + + +	\$4,264.02 \$3,757.15 \$4,765.66 \$4,765.66 \$4,765.66 \$4,765.66 \$5,977.98 \$5,977.98 \$5,977.98 \$5,977.98 \$4,765.66 \$5,977.98 \$4,765.66 \$4,765.66 \$5,977.98	
28250 28260 28261 28262 28264 28270 28272	Revision of foot fascia Release of midfoot joint Revision of foot tendon Revision of foot and ankle Release of midfoot joint Release of foot contracture Release of toe joint, each	-	+ + + + + +	\$5,977.98 \$5,977.98 \$5,977.98 \$5,977.98 \$5,977.98 \$4,765.66 \$4,765.66	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 22 OF 78

PAGE 22 OF 78					
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
28280 28285 28286 28288 28289 28290 28292 28293 28294 28296 28297 28300 28302 28300 28305 28307 28308 28307 28309 28310 28311 28313 28315 28315 28315 28315 28320 28320 28320 28341 28345 28345 28345 28345 28345 28345 28345 28345 28345 28345 28345 28345 28346 28345 2835 2835 2835 2835 2835 2835 2855 285	Fusion of toes Repair of hammertoe Repair of hammertoe Partial removal of foot bone Repair hallux rigidus Correction of bunion Incision of heel bone Incision of midfoot bones Incision of midfoot bones Incision of metatarsal Revision of toe Repair deformity of toe Repair deformity of toe Repair of foot bones Repair		+++++++++++++++++++++++++++++++++++++++	\$4,765.66 \$4,765.66 \$5,977.98	
28531 28540 28545 28546	Treat sesamoid bone fracture Treat foot dislocation Treat foot dislocation Treat foot dislocation		+ + + +	\$7,898.37 \$674.08 \$3,488.02 \$7,898.37	
28555 28570 28575 28576	Repair foot dislocation Treat foot dislocation Treat foot dislocation Treat foot dislocation		+ + + +	\$7,898.37 \$674.08 \$674.08 \$7,898.37	
28585	Repair foot dislocation		+	\$7,898.37	1

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 23 OF 78

PAGE 23 OF 76					
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
28600 28605 28606 28615 28606 28615 28636 28635 28636 28635 28636 28665 28666 28675 28705 28715 28725 28730 28740 28755 28737 28740 28755 28760 28810 28820 28825 28939 29000 29010 29015 29025 29035 29044 29046 29049 29049 29048 29049 29055 29058 29065 29075 29085 29086 29105 29125 29126 29130 29131 29200 29240 29240 29260 29280 29305 29355 29355 29355 29358 29365 29355 29358 29365 29355 29358 29365 29355 29358 29365 29355 29358	Treat foot dislocation Treat foot dislocation Repair foot dislocation Treat toe dislocation Fusion of foot bones Fusion of big toe joint Amputation fo be Ametatarsal Amputation of toe Partial amputation of toe Foot/toes surgery procedure Application of body cast Application of forearm cast Application of forearm cast Application of forearm cast Apply hand/wrist cast Apply hand/wrist cast Apply forearm splint Strapping of chest Strapping of chest Strapping of hand or finger Strapping of bow or wrist Strapping of how back Strapping of soluder Strapping of how or wrist Strapping of low back Strapping of soluder	Indicator 1	\$	\$674.08 \$77.898.37 \$7.898.37 \$7.898.37 \$7.898.37 \$7.898.37 \$674.08 \$3.488.02 \$7.898.37 \$5.977.98 \$5.977.98 \$5.977.98 \$5.977.98 \$5.977.98 \$4.765.66 \$4.765.66 \$4.765.66 \$4.765.66 \$4.765.66 \$4.765.66 \$4.765.66 \$4.765.66 \$4.765.67 \$279.57	
29435 29440 29445 29450 29505 29515	Apply short leg cast Addition of walker to cast Apply rigid leg cast Application of leg cast Application, long leg splint Application lower leg splint			\$279.57 \$279.57 \$279.57 \$279.57 \$279.57 \$279.57 \$279.57	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 24 OF 78

FAGE 24 OF 76					
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
29520 29530 29540 29550 29580 29580 29590 29700 29705 29711 29715 29720 29730 29740 29750 29799 29804 29805 29806 29807 29819 29820 29821 29823 29824 29825 29826 29827 29830 29834 29835 29844 29835 29844 29845 29846 29847 29838 29840 29844 29845 29856 29851 29856 29860 29861 29860 29861 29860 29861 29860 29861 29862 29863 29870 29871	Strapping of hip Strapping of knee Strapping of loes Application of paste boot Application of foot splint Removal/revision of cast Repair of body cast Windowing of cast Wedging of cast Wedging of clubfoot cast Casting/strapping procedure Jaw arthroscopy/surgery Jaw arthroscopy/surgery Shoulder arthroscopy/surgery Elbow arthroscopy/surgery Elbow arthroscopy/surgery Elbow arthroscopy/surgery Elbow arthroscopy/surgery Elbow arthroscopy/surgery Wrist arthroscopy/surgery Tibial arthroscopy/surgery Hip arthroscopy/surge	Indicator	B .	\$279.57 \$270.43.98 \$7,043.98	ology
29875 29876 29877 29879 29880 29881 29882 29883 29884 29885	Knee arthroscopy/surgery		+ + + + + + + + + + + + + + + + + + + +	\$7,043,98 \$7,043,98 \$7,043,98 \$7,043,98 \$7,043,98 \$7,043,98 \$7,043,98 \$7,043,98 \$7,043,98 \$7,043,98	
29886 29887	Knee arthroscopy/surgery Knee arthroscopy/surgery		+	\$7,043.98	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 25 OF 78

PAGE 23 OF 76					
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
29888	Knee arthroscopy/surgery		+	\$11,046.72	
29889	Knee arthroscopy/surgery		+	\$11,046.72	
29891	Ankle arthroscopy/surgery		+	\$7,043.98	
29892 29893	Ankle arthroscopy/surgery		+	\$7,043.98 \$4,765.66	
29894	Scope, plantar fasciotomy Ankle arthroscopy/surgery		+	\$7,043.98	
29895	Ankle arthroscopy/surgery		+	\$7,043.98	
29897	Ankle arthroscopy/surgery		+	\$7,043.98	
29898	Ankle arthroscopy/surgery		+	\$7,043.98	
29899 29900	Ankle arthroscopy/surgery Mcp joint arthroscopy, dx		+	\$7,043.98 \$3,822.45	
29900	Mcp joint arthroscopy, dx Mcp joint arthroscopy, surg		+	\$3,822.45	
29902	Mcp joint arthroscopy, surg	•	+	\$3,822.45	
29999	Arthroscopy of joint		+	\$7,043.98	
30000	Drainage of nose lesion		+ +	\$514.72 \$514.72	
30020 30100	Drainage of nose lesion Intranasal biopsy		+	\$1,565.03	
30110	Removal of nose polyp(s)		+	\$3,895.61	
30115	Removal of nose polyp(s)		+	\$3,895.61	
30117	Removal of intranasal lesion		+	\$3,895.61	
30118	Removal of intranasal lesion		++	\$5,424.08 \$3,895.61	
30120 30124	Revision of nose Removal of nose lesion	<u> </u>	, ,	\$1,565.03	
30125	Removal of nose lesion		+	\$9,175.99	
30130	Removal of turbinate bones		+	\$3,895.61	
30140	Removal of turbinate bones		+	\$5,424.08	
30150 30160	Partial removal of nose Removal of nose		++	\$9,175.99 \$9,175.99	
30200	Injection treatment of nose		+	\$3,895.61	
30210	Nasal sinus therapy		+	\$1,565.03	
30220	Insert nasal septal button		+	\$1,565.03	
30300 30310	Remove nasal foreign body Remove nasal foreign body		+	\$175.05 \$3,895.61	
30320	Remove nasal foreign body		+	\$3,895.61	}
30400	Reconstruction of nose	1	+	\$9,175.99	
30410	Reconstruction of nose		+	\$9,175.99	
30420	Reconstruction of nose		+ +	\$9,175.99 \$5,424.08	
30430 30435	Revision of nose Revision of nose]] ;	\$9,175.99	,
30450	Revision of nose		+	\$9,175.99	
30460	Revision of nose		+	\$9,175.99	
30462	Revision of nose		+	\$9,175.99 \$9,175.99	1
30465 30520	Repair nasal stenosis Repair of nasal septum		+ +	\$5,424.08	
30540	Repair nasal defect		+	\$9,175.99	1
30545	Repair nasal defect		+	\$9,175.99	
30560	Release of nasal adhesions		+	\$514.72 \$9,175.99	l
30580 30600	Repair upper jaw fistula Repair mouth/nose fistula		† +	\$9,175.99	
30620	Intranasal reconstruction		+	\$9,175.99	1
30630	Repair nasal septum defect		+	\$5,424.08	
30801	Cauterization, inner nose		+	\$1,565.03	
30802 30901	Cauterization, inner nose Control of nosebleed		+ +	\$3,895.61 \$441.57	
30903	Control of nosebleed		+	\$441.57	j
30905	Control of nosebleed		+	\$441.57	
30906	Repeat control of nosebleed		+	\$441.57	
30915 30920	Ligation, nasal sinus artery Ligation, upper jaw artery		+ +	\$7,200.75 \$6,414.31	
30930	Therapy, fracture of nose	1	+	\$3,895.61	
30999	Nasal surgery procedure		+	\$514.72	
31000	Irrigation, maxillary sinus	1	+	\$514.72 \$1,565.03	
31002 31020	Irrigation, sphenoid sinus Exploration, maxillary sinus		+ +	\$5,424.08	1
31020	Exploration, maxillary sinus		+	\$9,175.99	
31032	Explore sinus, remove polyps	l	+	\$9,175.99	1

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 26 OF 78

	FAGE 20 OF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
31040 31050 31051 31075 31075 31080 31081 31084 31085 31086 31087 31200 31201 31205 31231 31235 31237 31238 31237 31238 31237 31238 31237 31238 31237 31255 31256 31257 31258 31250 31500 31500 31500 31501 31511 31512 31513 31512 31513 31525 31526 31527 31528 31529 31530 31520 31521 31522 31531 31535 31536 31536 31540 31541 31535 31536 31536 31540 31536 31536 31536 31536 31536 31536 31536 31540 31551 31536 31536 31536 31540 31557 31571	Exploration behind upper jaw Exploration, sphenoid sinus Sphenoid sinus surgery Exploration of frontal sinus Removal of frontal sinus Exploration of sinuses Removal of ethmoid sinus Removal of ethmoid sinus Removal of ethmoid sinus Removal of ethmoid sinus Removal of upper jaw Nasal endoscopy, dx Nasal/sinus endoscopy, dx Nasal/sinus endoscopy, surg Nasal/sinus endoscopy, surg Nasal/sinus endoscopy, surg Rasal/sinus endoscopy, surg Revision of ethmoid sinus Exploration maxillary sinus Endoscopy, maxillary sinus Endoscopy, maxillary sinus Sinus endoscopy, surg Nasal/sinus endoscopy Nasal/sinus en	indicator .	Applies + + + + + + + + + + + + + + + + + + +	\$5,424.08 \$9,175.99 \$5,424.08 \$9,175.99 \$9,175.99 \$9,175.99 \$9,175.99 \$9,175.99 \$9,175.99 \$9,175.99 \$9,175.99 \$7,296.14 \$248.21 \$862.21 \$3,467.12 \$5,301.28	MDR
31575 31576 31577	Diagnostic laryngoscopy Laryngoscopy with biopsy Remove foreign body, larynx		+ + +	\$248.21 \$5,301.28 \$862.21	
31578 31579 31580 31582	Removal of larynx lesion Diagnostic laryngoscopy Revision of larynx Revision of larynx		+ + + +	\$5,301.28 \$862.21 \$9,175.99 \$9,175.99	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 27 OF 78

	PAGE 27 OF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
31585 31586 31588 31590 31595 31600 31601 31601 31605 31610 31611 31613 31614 31615 31622 31623 31624 31625 31629 31630 31631 31631 31631 31643 31644 31645 31640 31700 31717 31720 31730 31755 31825 31825 31825 31825 31825 31829 32002 32201 32400 32405 32602 32601 32602 32603 32604 32605 32606	Treat larynx fracture Treat larynx fracture Revision of larynx Reinnervate larynx Larynx nerve surgery Larynx surgery procedure Incision of windpipe Repair windpipe opening Repair windpipe opening Visualization of windpipe Ox bronchoscope/wash Dx bronchoscope/lavage Bronchoscopy w/biopsy(s) Bronchoscopy w/biopsy(s) Bronchoscopy dilate/fx repr Bronchoscopy dilate w/stent Bronchoscopy w/biore excise Bronchoscopy w/brore excise Bronchoscopy w/brore excise Bronchoscopy, reat blockage Diag bronchoscope/catheter Bronchoscopy, reclear airway Bronchoscopy win for x-ray Insertion of airway catheter Bronchial brush biopsy Clearance of airways Intro, windpipe wire/tube Repair of windpipe defect Revise windpipe scar Airways surgical procedure Drainage of chest Treatment of collapsed lung Treat lung lining chemically Insertion of chest tube Drain, percut, lung lesion Needle biopsy chest lining Biopsy, lung or mediastinum Puncture/clear lung Thoracoscopy, diagnostic Thoracoscopy		Reduction Applies + + + + + + + + + + + + + + + + + +	\$3,895.61 \$9,175.99 \$9,175.99 \$9,175.99 \$5,424.08 \$5,424.08 \$5,424.08 \$5,424.08 \$5,424.08 \$5,424.08 \$5,424.08 \$5,424.08 \$5,424.08 \$5,424.08 \$5,424.19 \$2,414.19 \$313.54 \$862.21 \$313.54 \$313.5	1
33010 33011 33206 33207 33208	Drainage of heart sac Repeat drainage of heart sac Insertion of heart pacemaker Insertion of heart pacemaker Insertion of heart pacemaker		+ + + +	\$906.62 \$906.62 \$22,676.59 \$22,676.59 \$23,199.52	
33210 33211 33212	Insertion of heart electrode Insertion of heart electrode Insertion of pulse generator		+ + +	\$14,782.96 \$14,782.96 \$20,376.10	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 28 OF 78

	PAGE 28 OF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
33213	Insertion of pulse generator		+	\$20,839.40	
33214	Upgrade of pacemaker system		+	\$23,199.52	
33215	Reposition pacing-defib lead		+	\$5,013.87	
33216	Insert lead pace-defib, one		+	\$14,782.96	
33217	Insert lead pace-defib, dual		+	\$14,782.96	
33218 33220	Repair lead pace-defib, one		+ +	\$14,782.96	
33220 33222	Repair lead pace-defib, dual Revise pocket, pacemaker		+	\$14,782.96 \$4,104.63	
33223	Revise pocket, pacernaker Revise pocket, pacing-defib		 	\$4,104.63	
33224	Insert pacing lead & connect		+	\$4,534.03	
33225	L ventric pacing lead add-on		+	\$5,816.72	
33226	Reposition I ventric lead	1	+	\$5,013.87	
33233	Removal of pacemaker system		+ +	\$5,013.87 \$5,013.87	
33234 33235	Removal of pacemaker system Removal pacemaker electrode		+	\$5,013.87	
33240	Insert pulse generator		+	\$34,025.72	
33241	Remove pulse generator		+	\$5,013.87	
33244	Remove eltrd, transven	1	+	\$5,013.87	
33249	Eltrd/insert pace-defib		+	\$46,262.73	
33282 33284	Implant pat-active ht record		+	\$15,135.68 \$2,014.45	
33999	Remove pat-active ht record Cardiac surgery procedure		+	\$906.62	
34101	Removal of artery clot		+	\$8,784.09	
34111	Removal of arm artery clot		+	\$8,784.09	
34201	Removal of artery clot		+	\$8,784.09	
34203	Removal of leg artery clot		+	\$8,784.09	
34421 34471	Removal of vein clot Removal of vein clot		+ +	\$8,784.09 \$8,784.09	
34490	Removal of vein clot		+	\$8,784.09	
34501	Repair valve, femoral vein		+	\$8,784.09	
34510	Transposition of vein valve		+	\$8,784.09	
34520	Cross-over vein graft		+	\$8,784.09	
34530	Leg vein fusion		+ +	\$8,784.09	
35011 35180	Repair defect of artery Repair blood vessel lesion		+	\$8,096.93 \$5,562.56	
35184	Repair blood vessel lesion	`	+	\$5,562.56	
35188	Repair blood vessel lesion		+	\$8,784.09	
35190	Repair blood vessel lesion		+	\$5,562.56	
35201	Repair blood vessel lesion		+	\$5,562.56	
35206 35207	Repair blood vessel lesion Repair blood vessel lesion		+ +	\$5,562.56 \$8,784.09	
35226	Repair blood vessel lesion		;	\$5,562.56	
35231	Repair blood vessel lesion		+	\$5,562.56	
35236	Repair blood vessel lesion		+	\$5,562.56	
35256	Repair blood vessel lesion		+	\$5,562.56	
35261	Repair blood vessel lesion		+	\$8,096.93	
35266 35286	Repair blood vessel lesion Repair blood vessel lesion		+ +	\$8,096.93 \$8,096.93	
35321	Rechanneling of artery		1 +	\$5,562.56	
35458	Repair arterial blockage		+	\$11,731.26	
35459	Repair arterial blockage		+	\$11,731.26	
35460	Repair venous blockage		+	\$11,731.26	
35470 35471	Repair arterial blockage Repair arterial blockage	1	+ +	\$11,731.26 \$11,731.26	
35471	Repair arterial blockage		-	\$11,731.26	
35473	Repair arterial blockage	1	+	\$11,731.26	
35474	Repair arterial blockage	1	+	\$11,731.26	
35475	Repair arterial blockage		+	\$11,731.26	
35476 35484	Repair venous blockage		+ +	\$11,731.26 \$11,731.26	
35485	Atherectomy, open Atherectomy, open		1 7	\$11,731.26	
35490	Atherectomy, percutaneous		+	\$11,731.26	
35491	Atherectomy, percutaneous		+	\$11,731.26	
35492	Atherectomy, percutaneous		+	\$11,731.26	
35493 35494	Atherectomy, percutaneous Atherectomy, percutaneous		+ +	\$11,731.26 \$11,731.26	
35484	/ Amereciany, perculaneous	ŀ	1 '	, Ψ, 1,1 31.20	,

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 29 OF 78

	PAGE 29 OF	78			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
35495	Atherectomy, percutaneous		+	\$11,731.26	
35500	Harvest vein for bypass		+	\$11,731.26	
35685	Bypass graft patency/patch		+	\$5,562.56	
35686	Bypass graft/av fist patency		+	\$5,562.56	
35761 35860	Exploration of artery/vein Explore limb vessels		+	\$6,558.00 \$5,562.56	
35875	Removal of clot in graft		+	\$8,784.09	
35876	Removal of clot in graft		+	\$8,784.09	
35879	Revise graft w/vein		+	\$8,784.09	
35881 35903	Revise graft w/vein Excision, graft, extremity		+	\$8,784.09 \$6,558.00	
36002	Pseudoaneurysm injection trt		ŕ	\$740.18	
36260	Insertion of infusion pump		+	\$20,540.52	
36261	Revision of infusion pump		+	\$13,505.34	
36262 36420	Removal of infusion pump Vein access cutdown < 1 yr		+	\$2,014.45 \$60.10	
36425	Vein access cutdown > 1 vr		+	\$60,10	
36430	Blood transfusion service	l		\$1,086.90	
36440	Bl push transfuse, 2 yr or <			\$1,086.90	
36450 36455	Bl exchange/transfuse, nb Bl exchange/transfuse non-nb			\$1,086.90 \$1,086.90	
36460	Transfusion service, fetal			\$1,086.90	
36468	Injection(s), spider veins		+	\$449.39	
36469	Injection(s), spider veins		+	\$449.39	
36470 36471	Injection therapy of vein Injection therapy of veins		+	\$449.39 \$449.39	
36488	Insertion of catheter, vein		+	\$3,093.50	
36489	Insertion of catheter, vein		+	\$3,093.50	
36490	Insertion of catheter, vein		+	\$3,093.50	
36491 36493	Insertion of catheter, vein Repositioning of cvc		+	\$3,093.50 \$1,104.86	
36511	Apheresis wbc			\$4,039.33	
36512	Apheresis rbc			\$4,039.33	
36513	Apheresis platelets			\$4,039.33	
36514 36515	Apheresis plasma Apheresis, adsorp/reinfuse			\$4,039.33 \$9,821.35	
36516	Apheresis, selective			\$9,821.35	
36522	Photopheresis			\$9,821.35	
36530 36531	Insertion of infusion pump Revision of infusion pump		+ +	\$20,540.52 \$13,505.34	
36532	Removal of infusion pump		+	\$2,014.45	
36533	Insertion of access device		+	\$6,558.00	
36534	Revision of access device		+	\$2,014.45	
36535 36536	Removal of access device Remove cva device obstruct		++	\$2,014.45 \$1,295.44	
36537	Remove cva lumen obstruct		+	\$1,295.44	
36550	Declot vascular device		+	\$713.29	
36640	Insertion catheter, artery		+	\$3,093.50	
36680 36800	Insert needle, bone cavity Insertion of cannula		+	\$734.50 \$6,558.00	
36810	Insertion of cannula		+	\$6,558.00	
36815	Insertion of cannula		+	\$6,558.00	
36819	Av fusion/uppr arm vein		+	\$8,784.09	
36820 36821	Av fusion/forearm vein Av fusion direct any site		+ +	\$8,784.09 \$8,784.09	
36825	Artery-vein autograft		+	\$8,784.09	
36830	Artery-vein nonautograft		+	\$8,784.09	
36831	Open thrombect av fistula		+	\$8,784.09	
36832 36833	Av fistula revision, open Av fistula revision		+ +	\$8,784.09 \$8,784.09	
36834	Repair A-V aneurysm		+	\$8,784.09	
36835	Artery to vein shunt		+	\$6,558.00	
36860	External cannula declotting		+ +	\$3,192.78 \$6,558.00	
36861 36870	Cannula declotting Percut thrombect av fistula		+	\$8,096.93	
37200	Transcatheter biopsy		+	\$1,614.67	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 30 OF 78

	PAGE 30 OF	78			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
37201	Transcatheter therapy infuse		+	\$1,113.03	
37202	Transcatheter therapy infuse		+	\$713.29	
37203	Transcatheter retrieval		+	\$3,192.78	
37204	Transcatheter occlusion		+	\$6,558.00	
37205	Transcatheter stent Transcatheter stent add-on		++	\$15,460.71	
37206 37207	Transcatheter stent add-on Transcatheter stent		+	\$15,460.71 \$15,460.71	
37208	Transcatheter stent add-on		+	\$15,460.71	
37209	Exchange arterial catheter		+	\$3,192.78	
37250	lv us first vessel add-on	-		\$9,147.02	
37251	Iv us each add vessel add-on			\$9,147.02	
37500 37501	Endoscopy ligate perf veins Vascular endoscopy procedure		+	\$6,414.31 \$6,414.31	
37565	Ligation of neck vein		<u>,</u>	\$5,562.56	
37600	Ligation of neck artery		+	\$5,562.56	
37605	Ligation of neck artery		+	\$7,200.75	
37606	Ligation of neck artery		+	\$7,200.75	
3760 7 37609	Ligation of a-v fistula Temporal artery procedure		+ +	\$6,414.31 \$3,757.15	
37615	Ligation of neck artery		+	\$7,200.75	l
37620	Revision of major vein		+	\$7,200.75	
37650	Revision of major vein		+	\$7,200.75	-
37700	Revise leg vein		+	\$7,200.75	
37720	Removal of leg vein		+	\$6,414.31	
37730 37735	Removal of leg veins Removal of leg veins/lesion		++	\$6,414.31 \$6,414.31	
37760	Ligation, leg veins, open		+	\$7,200.75	
37780	Revision of leg vein		+	\$7,200.75	
37785	Revise secondary varicosity		+	\$7,200.75	
37790	Penile venous occlusion		+	\$7,885.29	***************************************
37799	Vascular surgery procedure		+ +	\$60.10 \$10,840.33	
38120 38129	Laparoscopy, splenectomy Laparoscope proc, spleen		+	\$8,214.50	
38205	Harvest allogenic stem cells		-	\$4,039.33	
38206	Harvest auto stem cells			\$4,039.33	
38220	Bone marrow aspiration		+	\$331.82	
38221 38230	Bone marrow biopsy Bone marrow collection		+	\$331.82 \$1,727.03	
38240	Bone marrow/stem transplant			\$1,727.03	
38241	Bone marrow/stem transplant			\$1,727.03	
38242	Lymphocyte infuse transplant			\$4,039.33	
38300	Drainage, lymph node lesion		+	\$4,352.84	
38305 38308	Drainage, lymph node lesion		++	\$4,352.84	
38500	Incision of lymph channels Biopsy/removal, lymph nodes		+	\$5,055.69 \$5,055.69	
38505	Needle biopsy, lymph nodes		+	\$841.31	
38510	Biopsy/removal, lymph nodes		+	\$5,055.69	
38520	Biopsy/removal, lymph nodes		+	\$5,055.69	
38525	Biopsy/removal, lymph nodes		+	\$5,055.69	
38530 38542	Biopsy/removal, lymph nodes Explore deep node(s), neck		\	\$5,055.69 \$9,737.74	
38550	Removal, neck/armpit lesion		+	\$5,055.69	ł
38555	Removal, neck/armpit lesion		+	\$5,055.69	
38570	Laparoscopy, lymph node biop		+	\$10,840.33	
38571	Laparoscopy, lymphadenectomy		+	\$15,368.09	
38572 38589	Laparoscopy, lymphadenectomy Laparoscope proc, lymphatic		+ +	\$10,840.33 \$8,214.50	
38700	Removal of lymph nodes, neck	1	+	\$5,055.69	1
38720	Removal of lymph nodes, neck		+	\$5,055.69	
38740	Remove armpit lymph nodes		+	\$9,737.74	
38745	Remove armpit lymph nodes		+	\$9,737.74	1
38760 38999	Remove groin lymph nodes		+	\$5,055.69 \$1,086.90	
38999 39400	Blood/lymph system procedure Visualization of chest		+	\$7,430.67	
40490	Biopsy of lip		+	\$514.72	
40500	Partial excision of lip	1	+	\$3,895.61	I

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 31 OF 78

	PAGE 31 OF	10			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
40510 40520 40525 40527 40530 40650 40652 40654 40700 40701 40702 40761 40799 40800 40801 40805 40806 40808 40810 40812 40814 40816 40818 40819 40820 40831 40842 40844 40845 40840 40840 40840 40840 40841 40840 40841 40840 40841 40840 40841 40840 40841 40841 40840 40841 40840 40841 40840 40841	Partial excision of lip Partial excision of lip Reconstruct lip with flap Reconstruct lip with flap Partial removal of lip Repair lip Repair lip Repair lip Repair cleft lip/nasal Lip surgery procedure Drainage of mouth lesion Drainage of mouth lesion Drainage of mouth lesion Removal, foreign body, mouth Removal, foreign body, mouth Incision of lip fold Biopsy of mouth lesion Excise/repair mouth lesion Excise/repair mouth lesion Excise/repair mouth lesion Excise oral mucosa for graft Excise lip or cheek fold Treatment of mouth lesion Repair mouth laceration Repair mouth laceration Repair mouth laceration Reconstruction of mouth Nouth surgery procedure Drainage of mouth lesion		+++++++++++++++++++++++++++++++++++++++	\$5,424.08 \$3,895.61 \$5,424.08 \$5,424.08 \$5,424.08 \$5,424.08 \$1,565.03 \$1,565.03 \$1,565.03 \$1,565.03 \$1,75.99 \$9,175.99 \$9,175.99 \$9,175.99 \$3,895.61 \$514.72 \$3,895.61 \$3,895.61 \$5,424.08	
41510 41520 41599 41800 41805 41806	Tongue to lip surgery Reconstruction, tongue fold Tongue and mouth surgery Drainage of gum lesion Removal foreign body, gum Removal foreign body, jawbone		+ + + + +	\$3,895.61 \$1,565.03 \$514.72 \$514.72 \$5,424.08 \$3,895.61	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 32 OF 78

CPT/ HCPCS Description Usage Indicator 1 House Surgery Reduction Applies 41820 Excision, gum, each quadrant + \$1,56 41821 Excision of gum lesion + \$3,89	ology .03 .03 .61 .08 .61 .61
41821 Excision of gum flap + \$1,56 41822 Excision of gum lesion + \$3,89	5.03 5.61 5.68 5.61 5.61
41823 Excision of gum lesion + \$5.42	i.61 i.08
41825 Excision of gum lesion + \$3.89 41826 Excision of gum lesion + \$3.89	
41827 Excision of gum lesion + \$5,42 41828 Excision of gum lesion + \$3,89 41830 Removal of gum tissue + \$3,89	
41850 Treatment of gum lesion + \$3,89	5.61
41872 Repair gum + \$3,89	6.61
41874 Repair tooth socket + \$5,42 41899 Dental surgery procedure + \$3,89 42000 Drainage mouth roof lesion + \$51	5.61
42100 Brainage floutiff for institution 1	5.03
42106 Excision lesion, mouth roof + \$3,89 42107 Excision lesion, mouth roof + \$5,42	5.61
42120 Remove palate/lesion + \$9,17 42140 Excision of uvula + \$1,56	5.99
42145 Repair palate, pharynx/uvula + \$5,42 42160 Treatment mouth roof lesion + \$3,89	.08
42180 Repair palate + \$51 42182 Repair palate + \$9,17	1.72
42200 Reconstruct cleft palate + \$9,17 42205 Reconstruct cleft palate + \$9,17	
42210 Reconstruct cleft palate + \$9,17 42215 Reconstruct cleft palate + \$9,17	5.99
42220 Reconstruct cleft palate + \$9,17 42225 Reconstruct cleft palate + \$9,17	5.99
42226 Lengthening of palate + \$9,17 42227 Lengthening of palate + \$9,17	5.99
42235 Repair palate + \$3,89 42260 Repair nose to lip fistula + \$5,42 42280 Preparation, palate mold + \$51	1.08
42280 Preparation, palate mold + \$51 42281 Insertion, palate prosthesis + \$3,89 42299 Palate/uvula surgery + \$51	5.61
42300 Drainage of salivary gland + \$3,89 42305 Drainage of salivary gland + \$3,89	5.61
Table Standard Standard Table	1.72
42325	1.72
42330 Removal of salivary stone + \$3.89 42335 Removal of salivary stone + \$3.89	5.61
42340 Removal of salivary stone + \$3,89 42400 Biopsy of salivary gland + \$84	1.31
42405 Biopsy of salivary gland + \$3,89 42408 Excision of salivary cyst + \$3,89	5.61
42409 Drainage of salivary cyst + \$3,89 42410 Excise parotid gland/lesion + \$9,17 42415 Excise parotid gland/lesion + \$9.17	5.99
42415 Excise parotid gland/lesion + \$9,17 42420 Excise parotid gland/lesion + \$9,17 42425 Excise parotid gland/lesion + \$9,17	5.99
42440 Excise submaxillary gland + \$9,17 42450 Excise sublingual gland + \$5,42	5.99
42500 Repair salivary duct + \$5.42 42505 Repair salivary duct + \$9.17	1.08
42507 Parotid duct diversion + \$9,17 42508 Parotid duct diversion + \$9,17	5.99 5.99
42509 Parotid duct diversion + \$9,17 42510 Parotid duct diversion + \$9,17	5.99
42600 Closure of salivary fistula + \$3,89 42650 Dilation of salivary duct + \$1,56 42660 Dilation of salivary duct + \$1,56	5.03

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 33 OF 78

	PAGE 33 OF	78			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
42665 42699 42700 42720 42725 42800 42802 42804 42806 42808 42809 42815 42821 42825 42826 42830 42831 42835 42836 42842 42844 42860 42870 42890 42950 42950 42955 42960 42952 42970 42972 42999 43020 43030 43130 43130 43130 43130 43202 43205 43215 43216 43217 43219 43220 43226 43227 43228 43231 43232 43234 43235 43236 43239 43240 43241	Ligation of salivary duct Salivary surgery procedure Drainage of tonsil abscess Drainage of throat abscess Biopsy of throat Biopsy of upper nose/throat Biopsy of upper nose/throat Biopsy of upper nose/throat Biopsy of upper nose/throat Excise pharynx foreign body Excision of neck cyst Excision of neck cyst Excision of neck cyst Remove tonsils and adenoids Remove tonsils and adenoids Removal of tonsils Removal of tonsils Removal of adenoids Extensive surgery of throat Extensive surgery of throat Extensive surgery of throat Excision of tonsil tags Excision of lingual tonsil Partial removal of obarrynx Revision of pharyngeal walls Repair throat wound Reconstruction of throat Surgical opening of throat Control throat bleeding Control nose/throat bleeding Control nose/throat bleeding Throat surgery procedure Incision of esophagus Throat muscle surgery Removal of esophagus pouch Esophagus endoscopy Esoph scope w/submucous inj Esophagus endoscopy Esophendoscopy, dilation Esoph endoscopy, biopsy Esoph endoscopy, dilation Esoph endoscopy, biopsy		+++++++++++++++++++++++++++++++++++++++	\$5,424.08 \$3,895.61 \$514.72 \$3,895.61 \$9,175.99 \$1,565.03 \$3,895.61 \$3,895.61 \$3,895.61 \$3,895.61 \$3,895.61 \$3,895.61 \$5,424.08 \$9,175.99 \$5,358.77 \$5,358.7	
43242 43243 43244 43245 43246 43247 43248	Uppr gi endoscopy w/us fn bx Upper gi endoscopy & inject Upper Gl endoscopy/ligation Uppr gi scope dilate strictr Place gastrostomy tube Operative upper Gl endoscopy Uppr gi endoscopy/guide wire		+ + + + + +	\$2,097.86 \$2,097.86 \$2,097.86 \$2,097.86 \$2,097.86 \$2,097.86 \$2,097.86	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 34 OF 78

	FAGE 34 OF				
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
43249 43250 43251 43255 43256 43258 43259 43260 43261 43262 43263 43264 43265 43267 43268 43269 43271 43272 43280 43289 43450 43453 43650 43458 43499 43651 43652 43659 43750 43752 43760 43761 43830 43831 43870 43899 44100 44201 44206 44207 44208 44208 44207 44208 44360 44361 44360 44361 44363 44368 44368 44368 44370 44370 44378 44378 44378 44378 44378 44388 44388	Esoph endoscopy, dilation Upper Gl endoscopy Operative upper Gl endoscopy Uppr gi endoscopy w stent Operative upper Gl endoscopy Uppr gi endoscopy w stent Operative upper Gl endoscopy Endoscopic ultrasound exam Endo cholangiopancreatograph Endo cho		+++++++++++++++++++++++++++++++++++++++	\$2,097.86 \$2,097.86 \$2,097.86 \$2,097.86 \$2,097.86 \$2,097.86 \$2,097.86 \$2,097.86 \$2,097.86 \$4,721.25 \$4,721.25 \$4,721.25 \$4,721.25 \$4,721.25 \$4,721.25 \$4,721.25 \$4,721.25 \$4,721.25 \$4,721.25 \$4,721.25 \$4,721.25 \$15,368.09 \$8,214.50 \$1,643.42 \$1,947.0 \$2,097.86	MedStat

³ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 35 OF 78

	PAGE 35 OF				
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
44386 44388 44389 44390 44391 44392 44393 44394 44397 44500 44799 44970 44979 45005 45005 45005 45100 45108 45150 45160 45170 45190 45303 45305 45307 45308 45307 45308 45307 45308 45307 45308 45317 45320 45327 45330 45331 45337 45338 45337 45338 45337 45338 45337 45338 45337 45338 45337 45338 45337 45338 45337 45338 45337 45338 45337 45338 45340 45341 45342 45345 45355 45379 45380 45381 45382 45380 45381 45382 45381 45382 45383 45380 45381 45382 45383 45380 45381 45382 45386 45387 45386 45387 45386	Endoscopy, bowel pouch/biop Colon endoscopy Colonoscopy with biopsy Colonoscopy for foreign body Colonoscopy for bleeding Colonoscopy, lesion removal Colonoscopy, lesion removal Colonoscopy wistent Intro, gastrointestinal tube Intestine surgery procedure Laparoscopy, appendectomy Laparoscope proc, app Drainage of pelvic abscess Drainage of rectal abscess Drainage of rectal abscess Drainage of rectal abscess Drainage of rectal lesion Excision of rectal lesion Excision of rectal lesion Destruction, rectal tumor Proctosigmoidoscopy wibx Proctosigmoidoscopy wibx Proctosigmoidoscopy removal Proctosigmoidoscopy removal Proctosigmoidoscopy removal Proctosigmoidoscopy removal Proctosigmoidoscopy wistent Diagnostic sigmoidoscopy wistent Diagnostic sigmoidoscopy Sigmoidoscopy and biopsy Sigmoidoscopy wild proctosigmoidoscopy wistent Diagnostic sigmoidoscopy Sigmoidoscopy wild proctosigmoidoscopy Sigmoidoscopy wild biopsy Sigmoidoscopy wild biopsy Sigmoidoscopy wild removal Sigmoidoscopy wild biopsy Sigmoidoscopy wild biopsy Sigmoidoscopy wild biopsy Sigmoidoscopy wild biopsy Colonoscopy Colonoscopy Colonoscopy Colonoscopy Colonoscopy Lesion removal colonoscopy Colonoscope dilat stricture Colonoscopy wistent Repair of rectum Repair of rectum		+++++++++++++++++++++++++++++++++++++++	\$2,067.65 \$2,067.65 \$2,067.65 \$2,067.65 \$2,067.65 \$2,067.65 \$2,067.65 \$2,067.65 \$2,1067.65 \$2,1067.65 \$2,1067.65 \$3,11.55 \$3,11.55 \$3,11.55 \$5,727.15 \$5,727.15 \$5,727.15 \$5,727.15 \$5,727.15 \$5,727.15 \$5,727.15 \$1,891.62 \$1,891	
45520 45560 45900 45905 45910 45915 45999	Treatment of rectal prolapse Repair of rectocele Reduction of rectal prolapse Dilation of anal sphincter Dilation of rectal narrowing Remove rectal obstruction Rectum surgery procedure		+ + + + + +	\$449.39 \$5,727.15 \$922.31 \$4,415.56 \$4,415.56 \$922.31 \$922.31	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 36 OF 78

	'	PAGE 36 OF 76			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
46020	Placement of seton		+	\$922.31	
46030	Removal of rectal marker	1	+	\$922.31	
46040	Incision of rectal abscess		+	\$2,748.63	
46045	Incision of rectal abscess	1	+	\$5,727.15	
46050	Incision of anal abscess	l	+	\$922.31	
46060	Incision of rectal abscess	ł	+	\$5,727.15	
46070	Incision of anal septum	1	++	\$2,748.63 \$4,415.56	
46080 46083	Incision of anal sphincter Incise external hemorrhoid	1	+	\$922.31	
46200	Removal of anal fissure		+	\$5,727.15	
46210	Removal of anal crypt	į	+	\$4,415.56	
46211	Removal of anal crypts	1 ·	+	\$5,727.15	
46220	Removal of anal tag	ĺ	+	\$4,415.56	
46221	Ligation of hemorrhoid(s)		+	\$922.31	
46230	Removal of anal tags	1	+	\$4,415.56	
46250	Hemorrhoidectomy		+	\$5,727.15	
46255	Hemorrhoidectomy	1	<u> </u>	\$5,727.15	
46257	Remove hemorrhoids & fissure	1	++	\$5,727.15	
46258 46260	Remove hemorrhoids & fistula Hemorrhoidectomy		+	\$5,727.15 \$5,727.15	
46261	Remove hemorrhoids & fissure	1	1 +	\$5,727.15	
46262	Remove hemorrhoids & fistula	1	+	\$5,727.15	
46270	Removal of anal fistula	1	+	\$5,727.15	
46275	Removal of anal fistula	1	+	\$5,727.15	
46280	Removal of anal fistula	1 '	+	\$5,727.15	
46285	Removal of anal fistula		+	\$5,727.15	
46288	Repair anal fistula		+	\$5,727.15	
46320	Removal of hemorrhoid clot	ļ	<u> </u>	\$922.31	
46500	Injection into hemorrhoid(s)	1	+	\$2,748.63 \$175.05	
46600	Diagnostic anoscopy		+	\$1,891.62	
46604 46606	Anoscopy and dilation Anoscopy and biopsy		+	\$1,891.62	
46608	Anoscopy, remove for body		+	\$1,891.62	
46610	Anoscopy, remove lesion	1	+	\$1,891.62	
46611	Anoscopy	İ	+	\$1,891.62	
46612	Anoscopy, remove lesions	l l	+	\$1,891.62	
46614	Anoscopy, control bleeding	-	+	\$1,891.62	
46615	Anoscopy		+	\$1,891.62	
46700	Repair of anal stricture	1	+	\$5,727.15	
46706	Repr of anal fistula w/glue	1	+ +	\$922.31 \$5,727.15	
46750 46753	Repair of anal sphincter Reconstruction of anus		1 +	\$5,727.15	
46754	Removal of suture from anus		1	\$4,415.56	
46760	Repair of anal sphincter	•	+	\$5,727.15	
46761	Repair of anal sphincter		+	\$5,727.15	
46762	Implant artificial sphincter		+	\$5,727.15	
46900	Destruction, anal lesion(s)		+	\$705.44	
46910	Destruction, anal lesion(s)		+	\$4,266.63	
46916	Cryosurgery, anal lesion(s)		+	\$290.03	
46917	Laser surgery, anal lesions	1 .	+	\$5,037.38 \$5,037.38	
46922 46924	Excision of anal lesion(s) Destruction, anal lesion(s)		+	\$5,037.38	
46934	Destruction of hemorrhoids		+	\$2,748.63	
46935	Destruction of hemorrhoids		+	\$2,748.63	
46936	Destruction of hemorrhoids		+	\$4,415.56	
46937	Cryotherapy of rectal lesion		+	\$4,415.56	
46938	Cryotherapy of rectal lesion		+	\$5,727.15	
46940	Treatment of anal fissure		+	\$4,415.56	
46942	Treatment of anal fissure		+ +	\$922.31 \$2,748.63	
46945 46046	Ligation of hemorrhoids		1 ‡	\$2,748.63	
46946 46999	Ligation of hemorrhoids Anus surgery procedure		+	\$922.31	
47000	Needle biopsy of liver	ļ ·	+	\$1,614.67	
47011	Percut drain, liver lesion		+	\$841.31	
47100	Wedge biopsy of liver	1		\$1,727.22	MedStat
47370	Laparo ablate liver tumor rf		+	\$8,214.50	l

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 37 OF 78

HCPCS Description	Status/ Usage	Multiple		-
Code	ndicator 1	Surgery Reduction Applies	Charge	Charge Method- ology
47371 Laparo ablate liver cryosurg 47382 Percut ablate liver rf 47382 Liver surgery procedure Incision of galibladder Insert Catheter, bile duct Insert bile duct drain 47510 Linsert bile duct drain 47525 Change bile duct catheter Reviser/enisert bile tube Billary endoscopy thru skin Billary endoscopy thru skin Billary endoscopy thru skin Billary endoscopy thru skin Billary endoscopy thru skin Billary endoscopy thru skin 47554 Billary endoscopy thru skin Billary endoscopy thru skin 47556 Billary endoscopy thru skin 47561 Laparoscopic whololangio Laparoscopic cholecystectomy 47562 Laparoscopic cholecystectomy/graph Laparo cholecystectomy/graph Laparo cholecystectomy/graph Laparoscope proc, billary 47660 Remova bile duct stone Bile tract surgery procedure Remova bile duct stone Bile tract surgery procedure Needle biopsy, pancreas Drain pancreatic pseudocyst Pancreas surgery procedure Exploration of abdomen Drain abdominal abscess Drain abdominal abscess Drain abdominal abscess Drain abdominal abscess Drain abdominal mass Removal of adolominal fluid Removal of adolominal fluid Removal of adolominal fluid Removal of adolominal fluid Removal of abdominal fluid Removal o		+ + + + + + + + + + + + + + + + + + +	\$8,214.50 \$9,694.54 \$841.31 \$2,704.19 \$2,704.19 \$2,704.19 \$2,704.19 \$2,704.19 \$2,704.19 \$2,704.19 \$2,704.19 \$2,704.19 \$2,704.19 \$2,704.19 \$2,704.19 \$2,704.19 \$2,704.19 \$3,14.50 \$10,840.33 \$10,940.19 \$2,704.19 \$2,	MedStat MDR MDR MDR

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 38 OF 78

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
49565 49568 49568 49570 49572 49580 49582 49585 49587 49590 49650 49651 49659 49900 49651 50080 50081 50200 50392 50393 50395 50396 50398 50541 50543	Rerepair ventrl hern, reduce Rerepair ventrl hern, block Hernia repair w/mesh Rpr epigastric hern, reduce Rpr epigastric hern, blocked Rpr umbil hern, reduc < 5 yr Rpr umbil hern, reduc < 5 yr Rpr umbil hern, plock < 5 yr Rpr umbil hern, block > 5 yr Rpr umbil hern, block > 5 yr Rpr umbil hern, block > 5 yr Repair spigilian hernia Repair umbilical lesion Laparo hernia repair initial Laparo hernia repair recur Laparo proc, hernia repair Repair of abdominal wall Abdomen surgery procedure Renal abscess, percut drain Removal of kidney stone Biopsy of kidney Drainage of kidney lesion Insert kidney drain Insert ureteral tube Create passage to kidney Measure kidney ressure Change kidney tube Laparo ablate renal cyst Laparo ablate renal mass Laparo partial nephrectomy		+ + + + + + + + + + + + + + + + + + +	\$6,936.88 \$6,936.88 \$6,936.88 \$6,936.88 \$6,936.88 \$6,936.88 \$6,936.88 \$6,936.88 \$6,936.88 \$10,840.33 \$10,840.33 \$10,840.33 \$10,840.33 \$10,840.33 \$10,840.33 \$10,840.33 \$10,840.33 \$10,840.33 \$10,840.33 \$10,840.33 \$10,840.33	MDR
50544 50549 50551 50553 50555 50557 50559 50561 50562 50575 50590 50686 50945 50947 50948 50949 50951 50953 50957 50959 50961 50970 50970 50972 50974 50976 50978 50980 51000 51000 51020 51030 51040 51045 51050	Laparoscopy, pyeloplasty Laparoscope proc, renal Kidney endoscopy Kidney endoscopy & biopsy Kidney endoscopy & biopsy Kidney endoscopy & treatment Renal endoscopy & treatment Renal scope w/tumor resect Kidney endoscopy & treatment Renal scope w/tumor resect Kidney endoscopy Fragmenting of kidney stone Measure ureter pressure Change of ureter tube Laparoscopy ureterolithotomy Laparo new ureter/bladder Laparoscope proc, ureter Endoscopy of ureter Ureter endoscopy & treatment Ur		+++++++++++++++++++++++++++++++++++++++	\$8,214.50 \$8,214.50 \$1,700.91 \$4,235.28 \$1,700.91 \$5,604.37 \$1,700.91 \$4,235.28 \$1,700.91 \$10,840.33 \$10,840.33 \$10,840.33 \$10,840.33 \$11,700.91 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$5,604.37 \$5,604.37 \$5,604.37 \$5,604.37	MDR

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 39 OF 78

	FAGE 39 OF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
51065 51080 51500 51520 51705 51705 51710 51715 51725 51726 51726 51736 51741 51772 51784 51785 51797 51798 51890 51990 52001 52005 52007 52010 52005 52007 52010 52204 52214 52234 52234 52234 52234 52235 52260 52265 52270 52265 52277 52281 52283 52285 52290 52300 52301 52315 52317 52318 52327 52330 52317 52318 52327 52332 52334 52341 52341	Remove ureter calculus Drainage of bladder abscess Removal of bladder cyst Removal of bladder cyst Removal of bladder lube Change of bladder tube Endoscopic injection/implant Treatment of bladder lesion Simple cystometrogram Complex cystometrogram Urine flow measurement Electro-uroflowmetry, first Urethra pressure profile Anal/urinary muscle study Urinary reflex study Urinary reflex study Urine voiding pressure study Intraabdominal pressure test Us urine capacity measure Repair of bladder opening Laparo urethral suspension Laparo sling operation Cystoscopy, removal of clots Cystoscopy & ureter catheter Cystoscopy & duct catheter Cystoscopy and biopsy Cystoscopy and treatment Cystoscopy a	0000000000	+++++++++++++++++++++++++++++++++++++++	\$5,604.37 \$2,701.58 \$6,936.88 \$5,604.37 \$303.08 \$561.75 \$7,637.09 \$802.11 \$802.11 \$802.11 \$303.08 \$303.08 \$303.08 \$303.08 \$303.08 \$303.08 \$303.08 \$303.08 \$175.05 \$5,604.37 \$1,700.91 \$1,700.91 \$1,700.91 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$4,235.28 \$5,604.37	
52342 52343 52344 52345 52346 52347	Cysto w/up stricture tx Cysto w/renal stricture tx Cysto/uretero, stone remove Cysto/uretero w/up stricture Cystouretero w/renal strict Cystoscopy, resect ducts		+ + + + +	\$5,604.37 \$5,604.37 \$5,604.37 \$5,604.37 \$1,700.91	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 40 OF 78

FAGE 40 OF 76						
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology	
52351	Cystouretero & or pyeloscope		+	\$1,700.91		
52352	Cystouretero w/stone remove		+	\$5,604.37		
52353	Cystouretero w/lithotripsy		+	\$8,705.69		
52354	Cystouretero w/biopsy		+	\$5,604.37		
52355	Cystouretero w/excise tumor		+	\$5,604.37		
52400	Cystouretero w/congen repr		+	\$5,604.37		
52450	Incision of prostate		+	\$5,604.37		
52500 52510	Revision of bladder neck Dilation prostatic urethra		+	\$5,604.37 \$4,235.28		
52601	Prostatectomy (TURP)		+	\$8,705.69		
52606	Control postop bleeding		<u>;</u>	\$5,604.37		
52612	Prostatectomy, first stage		+	\$8,705.69		
52614	Prostatectomy, second stage		+	\$8,705.69		
52620	Remove residual prostate		+	\$8,705.69		
52630	Remove prostate regrowth		+	\$8,705.69		
52640	Relieve bladder contracture		+	\$5,604.37		
52647	Laser surgery of prostate		+	\$8,705.69		
52648	Laser surgery of prostate		+ +	\$8,705.69 \$5,604.37		
52700 53000	Drainage of prostate abscess Incision of urethra		+	\$4,156.89		
53010	Incision of urethra		+	\$4,156.89		
53020	Incision of urethra		+	\$4,156.89		
53025	Incision of urethra		+	\$4,156.89		
53040	Drainage of urethra abscess		+	\$4,156.89		
53060	Drainage of urethra abscess		+	\$4,156.89		
53080	Drainage of urinary leakage		+	\$4,156.89		
53200	Biopsy of urethra		+	\$4,156.89	1	
53210	Removal of urethra		+	\$6,597.21		
53215	Removal of urethra		+	\$6,597.21		
53220 53230	Treatment of urethra lesion Removal of urethra lesion		++	\$6,597.21 \$6,597.21		
53235	Removal of urethra lesion		+	\$6,597.21		
53240	Surgery for urethra pouch		+	\$6,597.21		
53250	Removal of urethra gland		+	\$4,156.89	l	
53260	Treatment of urethra lesion		+	\$4,156.89		
53265	Treatment of urethra lesion		+	\$4,156.89		
53270	Removal of urethra gland		+	\$7,637.09		
53275	Repair of urethra defect		+	\$4,156.89		
53400	Revise urethra, stage 1		++	\$6,597.21	l	
53405 53410	Revise urethra, stage 2 Reconstruction of urethra		+	\$6,597.21 \$6,597.21		
53420	Reconstruct urethra, stage 1			\$6,597.21		
53425	Reconstruct urethra, stage 2		+	\$6,597.21		
53430	Reconstruction of urethra		+	\$6,597.21	l	
53431	Reconstruct urethra/bladder		+	\$6,597.21	1	
53440	Male sling procedure		+	\$22,074.67		
53442	Remove/revise male sling		+	\$4,156.89		
53444	Insert tandem cuff	l .	+	\$22,074.67		
53445	Insert uro/ves nck sphincter	1	+	\$22,074.67 \$6,597.21		
53446 53447	Remove uro sphincter Remove/replace ur sphincter	·	+	\$22,074.67		
53449	Repair uro sphincter		+	\$6,597.21		
53450	Revision of urethra		+	\$6,597.21		
53460	Revision of urethra	İ	+	\$6,597.21	1	
53502	Repair of urethra injury	I	+	\$4,156.89]	
53505	Repair of urethra injury		+	\$7,637.09	l	
53510	Repair of urethra injury	1	+	\$4,156.89		
53515	Repair of urethra injury	1	+	\$6,597.21		
53520 53600	Repair of urethra defect Dilate urethra stricture	I	+ +	\$6,597.21 \$802.11	1	
53601	Dilate urethra stricture	1	+	\$303.08		
53605	Dilate urethra stricture		+	\$4,235.28	1	
53620	Dilate urethra stricture		+	\$3,307.76		
53621	Dilate urethra stricture		+	\$303.08	1	
53660	Dilation of urethra		+	\$303.08	1	
53661	Dilation of urethra	1	, +	\$303.08	1	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 41 OF 78

PAGE 41 OF 78					
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
53665 53850 53852 53852 53853 53899 54000 54001 54055 54056 54055 54066 54065 54100 54110 54111 541112 541150 54163 54163 54163 54163 54163 54164 54200 54205 54200 54205 54200 54205 54200 54205 54200 54205 54200 54205 54200 54205 54200 54205 54200 54300 54400	Dilation of urethra Prostatic microwave thermotx Prostatic f thermotx Prostatic water thermother Urology surgery procedure Slitting of prepuce Drain penis lesion Destruction, penis lesion(s) Destruction, penis lesion(s) Cryosurgery, penis lesion(s) Laser surg, penis lesion(s) Excision of penis lesion(s) Excision of penis lesion(s) Excision of penis lesion(s) Biopsy of penis Biopsy of penis Biopsy of penis Treatment of penis lesion Treat penis lesion, graft Treat penis lesion, graft Treat penis lesion, graft Treat penis lesion, graft Treatrent of penis lesion Partial removal of penis Circumcision Circumcision Circumcision Circumcision Circumcision Circumcision Treatment of penis lesion Repair of circumic lesion Repair of circumic lesion Treatment of penis lesion Treatment of penis lesion Treatment of penis lesion Treatment of penis lesion Dynamic cavernosometry Penile injection Penis study Penis study Revision of penis Reconstruction of urethra Reconstruction of uret	b b	+++++++++++++++++++++++++++++++++++++++	\$4,156.89 \$13,095.14 \$13,095.14 \$13,095.14 \$5,816.72 \$303.08 \$4,156.89 \$4,156.89 \$4,156.89 \$2,701.58 \$290.03 \$4,266.63 \$211.64 \$4,266.63 \$5,037.38 \$3,757.15 \$4,689.89 \$7,885.29 \$7,885.29 \$4,880.64 \$4,880.64 \$4,880.64 \$4,880.64 \$4,880.64 \$4,880.64 \$4,880.64 \$4,880.64 \$4,880.64 \$4,880.64 \$5,037.38 \$3,307.76 \$7,885.29	
54505	Biopsy of testis		+	\$5,732.38	l

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 42 OF 78

FAGE 42 OF 70						
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology	
54512 54522 54522 54530 54650 54660 54660 546670 54680 54699 54692 54699 54700 54800 54820 54830 54840 54861 54900 55100 55100 55110 55110 551120 55150 551120 55150 551120 55150 551120 55150 55550 55550 55550 55550 55550 55550 55570 55705 55700 55705 55705 55700 55705 55705 55705 55700 55870 55840 56840 56840 56840 568440 568441	Excise lesion testis Removal of testis Orchiectomy, partial Removal of testis Exploration for testis Reduce testis torsion Suspension of testis Revision of testis Revision of testis Repair testis injury Relocation of testis(es) Laparoscopy, orchiectomy Laparoscopy, orchiectomy Laparoscope proc, testis Drainage of scrotum Biopsy of epididymis Exploration of epididymis Remove epididymis lesion Remove epididymis lesion Removal of epididymis Fusion of spermatic ducts Fusion of spermatic ducts Fusion of spermatic ducts Drainage of hydrocele Removal of hydrocele Removal of hydrocele Removal of scrotum abscess Explore scrotum Removal of scrotum lesion Removal of scrotum Revision of scrotum Revision of sperm duct Removal of sperm cord lesion Revise spermatic cord veins Revise spermatic cord veins Revise spermatic cord veins Revise spermatic cord lesion Biopsy of prostate Biopsy of prostate Biopsy of prostate Biopsy of prostate Biopsy of prostate Biopsy of prostate Biopsy of prostate Drainage of prostate abscess Drainage of prostate abscess Drainage of prostate abscess Drainage of prostate Biopsy of prostate Cryoablate prostate Genital surgery procedure I & D of vulva/perineum Drainage of gland abscess Surgery for vulva lesion Lysis of labial lesion(s)	Thursday of the state of the st	+ + + + + + + + + + + + + + + + + + + +	\$5,732.38 \$5,732.38 \$6,936.88 \$6,936.88 \$5,732.38		
56501 56515 56605 56606 56620 56625 56700	Destroy, vulva lesions, sim Destroy vulva lesion/s compl Biopsy of vulva/perineum Biopsy of vulva/perineum Partial removal of vulva Complete removal of vulva Partial removal of hymen		+ + + + + +	\$4,266.63 \$5,037.38 \$1,016.36 \$1,016.36 \$6,398.64 \$6,398.64 \$4,859.71		
56720	Incision of hymen	I	+	\$3,903.45	ł	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 43 OF 78

	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,				
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
56740	Remove vagina gland lesion		+	\$4,859.71	
56800	Repair of vagina		+	\$4,859.71	
56805	Repair clitoris		+	\$4,859.71	
56810	Repair of perineum		+	\$4,859.71	
56820	Exam of vulva w/scope		+	\$282.18	
56821	Exam/biopsy of vulva w/scope		+	\$412.82	
57000	Exploration of vagina		+	\$4,859.71	
57010	Drainage of pelvic abscess		+	\$4,859.71	
57020	Drainage of pelvic fluid		+	\$734.18	
57022	I & d vaginal hematoma, pp		+	\$2,701.58	
57023	I & d vag hematoma, non-ob		+ +	\$2,701.58 \$4,859.71	
57061 57065	Destroy vag lesions, simple Destroy vag lesions, complex		+	\$4,859.71	
57100 57100	Biopsy of vagina		ļ ;	\$734.18	
57105	Biopsy of vagina		+	\$4,859.71	
57106	Remove vagina wall, partial		+	\$4,859.71	
57107	Remove vagina tissue, part		+	\$6,398.64	
57109	Vaginectomy partial w/nodes		+	\$12,285.18	
57120	Closure of vagina		+	\$4,859.71	
57130	Remove vagina lesion		+	\$4,859.71	
57135	Remove vagina lesion		+	\$4,859.71	
57150	Treat vagina infection		+ +	\$54.87	
57155 57160	Insert uteri tandems/ovoids Insert pessary/other device		+ +	\$734.18 \$282.18	
57170	Fitting of diaphragm/cap		+	\$54.87	
57180	Treat vaginal bleeding		+	\$734.18	
57200	Repair of vagina		+	\$4,859.71	
57210	Repair vagina/perineum		+	\$4,859.71	
57220	Revision of urethra		+	\$6,398.64	
57230	Repair of urethral lesion		+	\$4,859.71	
57240	Repair bladder & vagina		+	\$6,398.64	
57250	Repair rectum & vagina		!	\$6,398.64	•
57260 57265	Repair of vagina Extensive repair of vagina		+ +	\$6,398.64 \$6,398.64	
57268	Repair of bowel bulge		-	\$6,398.64	
57284	Repair paravaginal defect		+	\$6.398.64	
57287	Revise/remove sling repair		+	\$12,285.18	
57288	Repair bladder defect		+	\$12,285.18	
57289	Repair bladder & vagina		+	\$6,398.64	
57291	Construction of vagina		+	\$6,398.64	
57300	Repair rectum-vagina fistula		+	\$6,398.64	
57310	Repair urethrovaginal lesion	1	+ +	\$6,398.64	
57320	Repair bladder-vagina lesion Repair bladder-vagina lesion	1	1 7	\$6,398.64 \$6,398.64	}
57330 57400	Dilation of vagina	1	+	\$4,859.71	
57410	Pelvic examination		+	\$4,859.71	
57415	Remove vaginal foreign body	-	+	\$4,859.71	
57420	Exam of vagina w/scope		+	\$734.18	١
57421	Exam/biopsy of vag w/scope		+	\$734.18	
57452	Exam of cervix w/scope		+	\$412.82	
57454	Bx/curett of cervix w/scope	1	+ +	\$734.18 \$734.18	
57455 57456	Biopsy of cervix w/scope Endocerv curettage w/scope		+	\$734.18	
57460	Bx of cervix w/scope, leep		+	\$3,903.45	
57461	Conz of cervix w/scope, leep		+	\$4,859.71	
57500	Biopsy of cervix		+	\$734.18	1
57505	Endocervical curettage		+	\$734.18	į
57510	Cauterization of cervix		+	\$3,903.45	
57511	Cryocautery of cervix		+	\$412.82	1
57513	Laser surgery of cervix	1	+ +	\$3,903.45 \$4,859.71	1
57520 57522	Conization of cervix Conization of cervix		+	\$6,398.64	1
57522 57530	Removal of cervix	1	+	\$6,398.64	
57550	Removal of residual cervix	1	+	\$6,398.64	
57555	Remove cervix/repair vagina		+	\$6,398.64	
57556	Remove cervix, repair bowel	1	+	\$6,398.64	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 44 OF 78

PAGE 44 OF 70						
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology	
57700 57720 57800	Revision of cervix Revision of cervix Dilation of cervical canal	-	+ + +	\$4,859.71 \$4,859.71 \$3,903.45		
57820	D & c of residual cervix		+	\$4,180.40		
58100 58120	Biopsy of uterus lining Dilation and curettage		+	\$282.18 \$4,180.40		
58145	Myomectomy vag method		+	\$6,398.64		
58301	Remove intrauterine device		+	\$412.82		
58321 58322	Artificial insemination Artificial insemination		+	\$423.26 \$423.26		
58323	Sperm washing		+	\$423.26 \$423.26		
58345	Reopen fallopian tube		+	\$4,859.71		
58346	Insert heyman uteri capsule		+	\$734.18		
58350 58353	Reopen fallopian tube Endometr ablate, thermal		+	\$4,859.71 \$3,903.45		
58545	Laparoscopic myomectomy		+	\$8,214.50		
58546	Laparo-myomectomy, complex		+	\$10,840.33		
58550	Laparo-asst vag hysterectomy		+	\$15,368.09		
58552 58553	Laparo-vag hyst incl t/o Laparo-vag hyst, complex		+	\$10,840.33 \$10,840.33		
58554	Laparo-vag hyst w/t/o, compl		+	\$10,840.33		
58555	Hysteroscopy, dx, sep proc		+	\$4,859.71		
58558 58559	Hysteroscopy, biopsy		+	\$5,139.28		
58560	Hysteroscopy, lysis Hysteroscopy, resect septum		+	\$5,139.28 \$5,139.28		
58561	Hysteroscopy, remove myoma		+	\$5,139.28		
58562	Hysteroscopy, remove fb		+	\$5,139.28		
58563 58578	Hysteroscopy, ablation Laparo proc, uterus		+	\$5,139.28 \$5,139.28		
58579	Hysteroscope procedure		+	\$5,139.28		
58600	Division of fallopian tube		+	\$4,859.71		
58615 58660	Occlude fallopian tube(s)		+	\$4,859.71		
58661	Laparoscopy, lysis Laparoscopy, remove adnexa		+	\$10,840.33 \$10,840.33		
58662	Laparoscopy, excise lesions		+	\$10,840.33		
58670	Laparoscopy, tubal cautery		+	\$10,840.33		
58671 58672	Laparoscopy, tubal block Laparoscopy, fimbrioplasty		+	\$10,840.33 \$10,840.33		
58673	Laparoscopy, amonopiasty Laparoscopy, salpingostomy		+	\$10,840.33		
58679	Laparo proc, oviduct-ovary		+	\$8,214.50		
58720	Removal of ovary/tube(s)			\$9,019.84	MedStat	
58800 58820	Drainage of ovarian cyst(s) Drain ovary abscess, open		+	\$6,398.64 \$6,398.64		
58823	Drain pelvic abscess, percut		+	\$3,903.45		
58900	Biopsy of ovary(s)		+	\$6,398.64		
58920 58925	Partial removal of ovary(s) Removal of ovarian cyst(s)		+	\$12,285.18 \$12,285.18		
58970	Retrieval of oocyte		+	\$4,859.71		
58974	Transfer of embryo		+	\$423.26		
58976	Transfer of embryo		+	\$423.26		
58999 59000	Genital surgery procedure Amniocentesis, diagnostic		++	\$54.87 \$340.41		
59001	Amniocentesis, therapeutic		+	\$340.41		
59012	Fetal cord puncture prenatal	,	+	\$340.41		
59015 59020	Chorion biopsy Fetal contract stress test	b	+ +	\$340.41 \$340.41		
59025	Fetal non-stress test	b	+	\$340.41		
59030	Fetal scalp blood sample	-	+	\$340.41		
59150 59151	Treat ectopic pregnancy Treat ectopic pregnancy		+ +	\$10,840.33 \$10.840.33		
59160	D & c after delivery		+	\$4,180.40		
59200	Insert cervical dilator		+	\$412.82		
59300	Episiotomy or vaginal repair		+ +	\$3,903.45 \$4,859.71		
59320 59409	Revision of cervix Obstetrical care	ļ	+	\$1,057.86		
59412	Antepartum manipulation]	+	\$1,057.86		

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 45 OF 78

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
59414 59612 59812 59820 59821 59840 59841 59866 59870 59871 59898 60000 60001 60210 60210 60212 60220 60225 60240 60252 60240 60252 60252 60260 60281 60500 60512 60659 61000 61001 61020 61001 61020 61070 61071 61070 61071 61070 61215 61330 61623 61624 61626 61790 61791 61793 61793 61793 61795 61886	Deliver placenta Vbac delivery only Treatment of miscarriage Care of miscarriage Treatment of miscarriage Abortion Abortion Abortion (mpr) Evacuate mole of uterus Remove cerclage suture Laparo proc, ob care/deliver Maternity care procedure Drain thyroid/tongue cyst Aspirate/inject thyriod cyst Biopsy of thyroid Remove thyroid lesion Partial thyroid excision Partial thyroid excision Partial removal of thyroid Removal of thyroid Removal of thyroid Removal of thyroid Removal of thyroid Removal of thyroid Removal of thyroid Repeat thyroid surgery Remove thyroid duct lesion Remove thyroid duct lesion Explore parathyroid glands Autotransplant parathyroid Laparo proc, endocrine Endocrine surgery procedure Remove cranial cavity fluid Remove brain cavity fluid Remove brain cavity fluid Remove brain canal Brain canal shunt procedure Insert brain-fluid device Decompress eve socket Endovasc tempory vessel occl Transcath occlusion, cns Treat trigeminal nerve Treat trigeminal rerve Replace/irrigate catheter Replace/irrigate spinal cord Spinal fluid tap, diagnostic Drain cerebro spinal fluid Treat epidural lysis on single day Drain spinal cord lesion Treat spinal cord lesion Treat spinal cord lesion Treat spinal cord lesion Treat spinal cord lesion Treat spinal cord lesion Treat spinal cord lesion Treat spinal cord lesion Treat spinal cord lesion Treat spinal cord lesion Treat spinal cord lesion	. в	+++++++++++++++++++++++++++++++++++++++	\$1,057.86 \$1,057.86 \$1,057.86 \$4,137.19 \$4,137.19 \$4,137.19 \$4,103.17 \$4,103.17 \$4,103.17 \$4,103.17 \$340.41 \$4,137.19 \$4,859.71 \$8,214.50 \$340.41 \$1,565.03 \$470.28 \$9,737.74 \$9,737.74 \$9,737.74 \$9,737.74 \$9,737.74 \$9,737.74 \$9,737.74 \$9,737.74 \$9,737.74 \$9,737.74 \$9,737.74 \$9,737.74 \$9,737.74 \$9,737.74 \$9,737.74 \$9,737.74 \$9,737.74 \$9,175.99 \$9,175.99 \$4,689.89 \$8,214.50 \$9,175.99 \$4,689.89 \$8,214.50 \$9,175.99 \$4,189.357 \$893.57	MDR

See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 46 OF 78

PAGE 40 OF 70						
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology	
62310 62311 62318 62319 62350 62351 62355 62360 62361 62362 62365 62367 62368 63001 63003 63005 63011 63012 63015 63016 63017 63020 63030 63035 63040 63042 63042 63045 63040 63045 63040 63045 63040 63047 63048 63047 63048 63047 63048 63047 63048 63047 63048 63047 63048 63047 63048 63047 63048 63047 63048 63047 63048 63047 63048 63047 63048 63047 63048 63047 63048 63047 63048 63049 63049 63049 63040 63040 63041 63441 63441 63441 63441 63441 63441 63441 63441 63441 63441 63441 64411 64411 64411 64411 64411 64411 64411 64411 64411	Inject spine c/t Inject spine w/cath, c/t Inject spine w/cath l/s (cd) Inject spine w/cath l/s (cd) Implant spinal canal cath Implant spinal canal cath Implant spinal canal cath Remove spinal canal catheter Insert spine infusion device Implant spine infusion pump Implant spine infusion pump Implant spine infusion pump Remove spine infusion pump Remove spine infusion pump Analyze spine infusion pump Removal of spinal lamina Removal of spinal lord Decompress spinal cord Remove lesion of spinal cord Implant neuroelectrodes Implant neuroelectrodes Implant neuroelectrodes Implant neuroelectrodes Revise/remove neuroelectrode Implant neuroelectrodes Revise/remove neuroeceiver Revise/remove neuroeceiver Revise/remove neuroeceiver Revise/remove neuroeceiver Revise/remove neuroeceiver Install spinal shunt Removal of spinal shunt Removal of spinal shunt Removal of spinal shunt Revision of spinal shunt Revision of spinal shunt Revision of spinal shunt Revision of spinal shunt Revision of spinal shunt Revision of spinal shunt Revision of spinal shunt Revision of spinal shunt Revision of spinal shunt Revision of spinal shunt Revision of spinal shunt Revision of spinal shunt Revision of spinal shunt Revision of spinal shunt Revision of spinal shunt Revision of spinal shunt Revision of spinal shunt Removal of spinal shunt Removal of spinal shunt Removal of spinal shunt Removal of spinal shunt Removal	b b	+++++++++++++++++++++++++++++++++++++++	\$1,127.73 \$1,127.73 \$1,127.73 \$1,127.73 \$1,127.73 \$1,127.73 \$11,082.41 \$10,367.41 \$10,36		
64418 64420 64421 64425 64425 64435 64445 64446	N block ini, suprascapular N block ini, intercost, sng N block ini, intercost, mlt N block ini, ilio-ing/hypogi N block ini, pudendal N block ini, paracervical N block ini, sciatic, sng N blk ini, sciatic, sng N blk ini, sciatic, cont inf		+ + + + + + +	\$546.05 \$1,554.60 \$1,554.60 \$546.05 \$546.05 \$546.05 \$546.05 \$546.05		
64447 64448	N block inj fem, single N block inj fem, cont inf		++	\$546.05 \$546.05		

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 47 OF 78

	PAGE 47 OF	10			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
64450 64470 64472 64475 64476 64479 64480 64483 64484 64505 64505 64510 64520 64553 64550 64553 64555 64560 64561 64565 64577 64580 64585 64577 64580 64585 64577 64580 64581 64585 64577 64580 64581 64585 64590 64605 64612 64612 64613 64614 64613 64614 64620 64627 64626 64627 64627 64620 64627 64620 64627 64630 64640 64702 64702 64704 64718 64718 64718 64718 64718 64718 64718 64718 64719 64727 64732 64734 64736 64736 64736 64736 64736 64737 64738 64740 64742	N block, other peripheral Ini paravertebral c/t Ini paravertebral c/t Ini paravertebral l/s Ini paravertebral l/s Ini paravertebral l/s Ini paravertebral l/s Ini paravertebral l/s Ini foramen epidural c/t Ini foramen epidural add-on Ini foramen epidural add-on N block, spenopalatine gangl N block, spenopalatine gangl N block, carotid sinus s/p N block, stellate ganglion N block, iumbar/thoracic N block ini, celiac pelus Apply neurostimulator Implant neuroelectrodes Implant neuroele		+++++++++++++++++++++++++++++++++++++++	\$546.05 \$1,554.60 \$1,554.60 \$1,554.60 \$1,554.60 \$1,554.60 \$1,554.60 \$1,554.60 \$1,554.60 \$546.05 \$546.05 \$546.05 \$546.05 \$1,554.60 \$1,554.60 \$1,554.60 \$1,554.60 \$1,554.60 \$1,554.60 \$23,493.74 \$23,493.74 \$23,493.74 \$23,493.74 \$23,493.74 \$23,493.74 \$23,493.73 \$3,179.73	MDR
64744 64746 64761 64771 64772	Incise diaphragm nerve Incision of pelvis nerve Sever cranial nerve Incision of spinal nerve		+ + + +	\$4,264.02 \$4,264.02 \$4,264.02 \$4,264.02	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 48 OF 78

PAGE 40 OF 76						
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology	
64774	Remove skin nerve lesion		+	\$4,264.02		
64776	Remove digit nerve lesion		+	\$4,264.02		
64778	Digit nerve surgery add-on		+	\$4,264.02		
64782	Remove limb nerve lesion		+	\$4,264.02		
64783	Limb nerve surgery add-on		+	\$4,264.02		
64784	Remove nerve lesion		+	\$4,264.02		
64786	Remove sciatic nerve lesion		+	\$5,802.92		
64787	Implant nerve end		+	\$4,264.02		
64788 64790	Remove skin nerve lesion Removal of nerve lesion		+ +	\$4,264.02		
64792	Removal of nerve lesion		+	\$4,264.02 \$5,802.92		
64795	Biopsy of nerve		+	\$4,264.02		
64802	Remove sympathetic nerves		+	\$4,264.02		
64820	Remove sympathetic nerves		+	\$4,264.02		
64821	Remove sympathestic nerves		+	\$6,126.90		
64822	Remove sympathetic nerves		+	\$6,126.90		
64823	Remove sympathetic nerves		+	\$6,126.90		
64831	Repair of digit nerve		+	\$5,802.92		
64832	Repair nerve add-on		+	\$5,802.92		
64834 64835	Repair of hand or foot nerve		++	\$5,802.92 \$5,802.92		
64836	Repair of hand or foot nerve Repair of hand or foot nerve		+	\$5,802.92		
64837	Repair nerve add-on	1	+	\$5,802.92		
64840	Repair of leg nerve		+	\$5,802.92		
64856	Repair/transpose nerve		+	\$5,802.92		
64857	Repair arm/leg nerve		+	\$5,802.92		
64858	Repair sciatic nerve		+	\$5,802.92		
64859	Nerve surgery	l	+	\$5,802.92		
64861	Repair of arm nerves		+	\$5,802.92		
64862	Repair of low back nerves	1	+	\$5,802.92		
64864 64865	Repair of facial nerve Repair of facial nerve		++	\$5,802.92 \$5,802.92		
64870	Fusion of facial/other nerve		+	\$5,802.92		
64872	Subsequent repair of nerve]	+	\$5,802.92		
64874	Repair & revise nerve add-on		+	\$5,802.92		
64876	Repair nerve/shorten bone	1	+	\$5,802.92		
64885	Nerve graft, head or neck		+	\$5,802.92		
64886	Nerve graft, head or neck	1	+	\$5,802.92		
64890	Nerve graft, hand or foot		+	\$5,802.92		
64891 64892	Nerve graft, hand or foot Nerve graft, arm or leg		+ +	\$5,802.92 \$5,802.92		
64893	Nerve graft, arm or leg		+	\$5,802.92		
64895	Nerve graft, hand or foot		+	\$5,802.92		
64896	Nerve graft, hand or foot		+	\$5,802.92		
64897	Nerve graft, arm or leg		+	\$5,802.92		
64898	Nerve graft, arm or leg	1	+	\$5,802.92		
64901	Nerve graft add-on	'	+	\$5,802.92		
64902	Nerve graft add-on		+	\$5,802.92		
64905	Nerve pedicle transfer	1	+ +	\$5,802.92		
64907 64999	Nerve pedicle transfer Nervous system surgery	1	+	\$5,802.92 \$546.05		
65091	Revise eye	1	+	\$7,563.93		
65093	Revise eye with implant		+	\$5,562.56		
65101	Removal of eye	1	+	\$7,563.93		
65103	Remove eye/insert implant		+	\$7,563.93		
65105	Remove eye/attach implant		+	\$7,563.93		
65110	Removal of eye	1	+	\$7,563.93		
65112 65114	Remove eye/revise socket	1	+ +	\$7,563.93 \$7,563.93		
65114 65125	Remove eye/revise socket Revise ocular implant			\$4,397.28		
65130	Insert ocular implant	Į	1	\$5,562.56		
65135	Insert ocular implant	1	+	\$5,562.56		
65140	Attach ocular implant		+	\$7,563.93		
65150	Revise ocular implant	l .	+	\$5,562.56		
65155 65175	Reinsert ocular implant	1	+	\$7,563.93 \$4,397.28		
65175	Removal of ocular implant	ı	1 *	1 94,381.28	l	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 49 OF 78

PAGE 49 OF 78						
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology	
65205 65210 65222 65235 65265 65270 65272 65275 65286 65286 65280 65410 65420 65410 65420 65430 65430 65436 65436 65530 656385 65436 65530 65755 65760 65775 65800 65765 65767 65775 65800 65765 65767 65772 65775 65800 65810 65815 65820 65855 65810 65815 65880 65865 65870 65875 65800 65810 65815 65800 65810 65815 65800 65810 65815 65800 65810	Remove foreign body from eye Remove foreign body from eye Remove foreign body from eye Remove foreign body from eye Remove foreign body from eye Remove foreign body from eye Remove foreign body from eye Remove foreign body from eye Repair of eye wound Repair of eye wound Repair of eye wound Repair of eye wound Repair of eye wound Repair of eye wound Repair of eye socket wound Repair of eye lesion Removal of eye lesion Removal of eye lesion Removal of eye lesion Removal of eye lesion Removal of eye lesion Removal of eye lesion Removal of cornea Curette/treat cornea Curette/treat cornea Curette/treat cornea Corneal transplant Corneal transplant Corneal transplant Revision of cornea Revision of cornea Revision of cornea Revision of cornea Revision of cornea Revision of cornea Revision of cornea Revision of cornea Revision of cornea Revision of cornea Revision of cornea Revision of cornea Revision of cornea Revision of cornea Revision of cornea Revise cornea with implant Correction of astigmatism Drainage of eye Drainage of eye Drainage of eye Drainage of eye Relieve inner eye adhesions Incise inner eye adhesions Incise inner eye adhesions Incise inner eye adhesions Incise inner eye adhesions Incise inner eye adhesions Remove eye lesion Remove implant of eye Remove blood clot from eye Injection treatment of eye Injection treatment of eye Remove blood clot from eye Injection treatment of eye Remove aurgery Glaucoma surgery Glaucoma surgery Glaucoma surgery Glaucoma surgery Glaucoma surgery Incision of iris		+++++++++++++++++++++++++++++++++++++++	\$248.75 \$585.26 \$585.26 \$585.26 \$585.23.56 \$5,238.56 \$5,238.56 \$5,238.56 \$3,618.66 \$5,507.69 \$3,618.66 \$3,618.66 \$3,618.66 \$3,618.66 \$5,507.69 \$1,836.78 \$3,618.66 \$5,507.69 \$1,836.78 \$3,618.66 \$5,507.69 \$1,836.78 \$3,618.66 \$5,507.69 \$1,607.09 \$1,209.80 \$1,	MDR MDR MDR	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 50 OF 78

	PAGE 50 OF	10			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
66625	Removal of iris		+	\$3,618.66	
66630	Removal of iris		+	\$3,618.66	
66635	Removal of iris		+	\$5,507.69	
66680	Repair iris & ciliary body		+	\$5,507.69	
66682	Repair iris & ciliary body		+	\$5,507.69	
66700	Destruction, ciliary body Destruction, ciliary body		+	\$3,618.66	
66710 66720	Destruction, ciliary body Destruction, ciliary body		+	\$3,618.66 \$3,618.66	
66740	Destruction, ciliary body Destruction, ciliary body		+	\$3,618.66	
66761	Revision of iris		+	\$1,269.80	
66762	Revision of iris		+	\$1,269.80	
66770	Removal of inner eye lesion		+	\$1,269.80	
66820	Incision, secondary cataract		+	\$1,212.31	
66821 66825	After cataract laser surgery		+	\$1,269.80 \$5,507.69	
66830	Reposition intraocular lens Removal of lens lesion		+	\$1,212.31	
66840	Removal of lens material		+	\$3,921.74	
66850	Removal of lens material		+	\$7,205.98	
66852	Removal of lens material	·	+	\$7,205.98	
66920	Extraction of lens		+	\$7,205.98	
66930	Extraction of lens		+	\$7,205.98	
66940 66982	Extraction of lens Cataract surgery, complex		+ +	\$3,921.74 \$5,352.68	
66983	Cataract surgery, complex Cataract surg w/iol, 1 stage		+	\$5,352.68	İ
66984	Cataract surg w/iol, 1 stage		+	\$5,352.68	
66985	Insert lens prosthesis		+	\$5,352.68	
66986	Exchange lens prosthesis		+	\$5,352.68	
66999 67005	Eye surgery procedure		++	\$1,212.31	
67010	Partial removal of eye fluid Partial removal of eye fluid		+	\$8,969.58 \$8,969.58	
67015	Release of eye fluid		+	\$8,969.58	
67025	Replace eye fluid		+	\$5,238.56	
67027	Implant eye drug system		+	\$8,969.58	1
67028	Injection eye drug		+	\$1,345.55	
67030 67031	Incise inner eye strands Laser surgery, eye strands		+ +	\$5,238.56 \$1,269.80	
67036	Removal of inner eye fluid		+	\$8,969.58	
67038	Strip retinal membrane		+	\$8,969.58	
67039	Laser treatment of retina		+	\$8,969.58]
67040	Laser treatment of retina		+	\$10,221.10	
67101	Repair detached retina		+	\$1,345.55	
67105 67107	Repair detached retina Repair detached retina		+	\$1,157.44 \$10,221.10	
67108	Repair detached retina	1	+	\$10,221.10	
67110	Repair detached retina	1	+	\$1,345.55	
67112	Rerepair detached retina		+	\$10,221.10	
67115	Release encircling material		+	\$5,238.56	•
67120	Remove eye implant material	1	++	\$5,238.56	
67121 67141	Remove eye implant material Treatment of retina			\$8,969.58 \$1,345.55	
67145	Treatment of retina		+	\$1,157.44	
67208	Treatment of retinal lesion		+	\$1,345.55	
67210	Treatment of retinal lesion		+	\$1,157.44	
67218	Treatment of retinal lesion		+	\$5,238.56	
67220 67221	Treatment of choroid lesion Ocular photodynamic ther	1	+ +	\$1,345.55 \$1,345.55	
67221 67225	Eye photodynamic ther add-on	1	+	\$1,345.55	
67227	Treatment of retinal lesion		+	\$1,345.55	
67228	Treatment of retinal lesion	1	+	\$1,157.44	
67250	Reinforce eye wall		+	\$4,397.28	
67255	Reinforce/graft eye wall	1	† †	\$8,969.58 \$1,345.55	1
67299 67311	Eye surgery procedure Revise eye muscle		+ +	\$1,345.55	
67312	Revise eye muscles Revise two eye muscles		+	\$5,384.90	
67314	Revise eye muscle		+	\$5,384.90	
67316	Revise two eye muscles	ł	+	\$5,384.90	1

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 51 OF 78

	PAGE 51 OF	78			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
67318 67320 67331 67332 67334 67335 67340 67345 67350 67399 67400 67405 67412 67413 67414 67415 67420 67430 67440 67450 67500 67500 67500 67500 67500 67500 67500 67505 67515 67550 67560 67570 67580 67580 67580 67580 67580 67580 67599 67700 67710 67710 67710 67800 67800 67800 67800 67800 67800 67800 67800 67800 67800 67800 67800 67800 67800 67800 67800 67800 67800 67810 67800 67810 67820 67820 67830 67830 67830 67840 67850 67900 67901 67901 67901 67901 67901 67901 67901 67901 67901 67901 67901 67901 67901 67901 67901 67902 67901 67901 67901 67901 67901 67901 67901 67901 67901 67901 67901 67901 67901 67901 67901 67901 67902 67901 67902 67901 67902 67901 67902 67901 67902 67902 67902 67903 67904 67904 67905 67905 67902	Revise eye muscle(s) Revise eye muscle(s) add-on Eye surgery follow-up add-on Rerevise eye muscles add-on Revise eye muscles w/suture Eye suture during surgery Revise eye muscle add-on Release eye tissue Destroy nerve of eye muscle Biopsy eye muscle Eye muscle surgery procedure Explore/biopsy eye socket Explore/drain eye socket Explore/treat eye socket Explore/treat eye socket Explore/treat eye socket Explore/treat eye socket Explore/treat eye socket Explore/treat eye socket Explore/treat eye socket Explore/treat eye socket Explore/treat eye socket Explore/treat eye socket Inject/treat eyelid abscess Incision of eyellid Incision of eyellid Incision of eyellid Incision of eyellid Incision of eyellid lesions Remove eyellid lesions Remove eyellid lesions Remove eyellid lesion Treat eyellid defect Repair eyel		+++++++++++++++++++++++++++++++++++++++	\$5,384.90 \$5,384.90 \$5,384.90 \$5,384.90 \$5,384.90 \$5,384.90 \$5,384.90 \$5,384.90 \$5,384.90 \$5,384.90 \$5,562.56 \$5,562.56 \$5,562.56 \$5,562.56 \$7,563.93 \$7,563	
67923 67924 67930 67935 67938	Repair eyelid defect Repair eyelid defect Repair eyelid wound Repair eyelid wound Repair eyelid foreign body		+ + +	\$4,397.28 \$4,397.28 \$4,397.28 \$4,397.28 \$248.75	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 52 OF 78

	17102 02 07	· -			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
67950 67961 67966 67971 67973 67974 67975 67999 68020 68040	Revision of eyelid Revision of eyelid Revision of eyelid Reconstruction of eyelid Revision of eyelid Incise/drain eyelid lining Treatment of eyelid lesions		+ + + + + + + + +	\$4,397,28 \$4,397,28 \$4,397,28 \$5,562,56 \$5,562,56 \$5,562,56 \$4,397,28 \$4,397,28 \$4,397,28	
68100 68110 68115 68135 68135 68200 68320 68325 68326	Remove eyelid lining Remove eyelid lining lesion Remove eyelid lining lesion Remove eyelid lining lesion Remove eyelid lining lesion Remove eyelid lining lesion Treat eyelid by injection Revise/graft eyelid lining Revise/graft eyelid lining Revise/graft eyelid lining		+ + + + + + + + + + + + + + + + + + + +	\$1,212.31 \$1,013.75 \$1,836.78 \$3,618.66 \$1,836.78 \$248.75 \$4,397.28 \$7,563.93 \$5,562.56	
68328 68330 68335 68340 68360 68362 68399 68400 68420	Revise/graft eyelid lining Revise/graft eyelid lining Revise/graft eyelid lining Separate eyelid adhesions Revise eyelid lining Revise eyelid lining Eyelid lining surgery Incise/drain tear gland Incise/drain tear sac		+ + + + + + +	\$5,562.56 \$3,618.66 \$5,562.56 \$4,397.28 \$5,507.69 \$5,507.69 \$1,836.78 \$802.11 \$4,397.28	
68440 68500 68505 68510 68520 68525 68530 68540	Incise tear duct opening Removal of tear gland Partial removal, tear gland Biopsy of tear gland Removal of tear sac Biopsy of tear sac Clearance of tear duct Remove tear gland		+ + + + + + +	\$802.11 \$5,562.56 \$5,562.56 \$4,397.28 \$5,562.56 \$4,397.28 \$4,397.28 \$4,397.28	
68550 68700 68705 68720 68745 68750 68760 68761 68770	Remove tear gland lesion Repair tear ducts Revise tear duct opening Create tear sac drain Create tear duct drain Create tear duct drain Close tear duct opening Close tear duct opening Close tear system fistula		+ + + + + +	\$7,563.93 \$5,562.56 \$802.11 \$7,563.93 \$5,562.56 \$7,563.93 \$248.75 \$585.26 \$4,397.28	
68801 68810 68811 68815 68840 68899 69000 69005 69020	Dilate tear duct opening Probe nasolacrimal duct Probe nasolacrimal duct Probe nasolacrimal duct Explore/irrigate tear ducts Tear duct system surgery Drain external ear lesion Drain outer ear canal lesion		+ + + + + + +	\$585.26 \$1,013.75 \$4,397.28 \$4,397.28 \$1,013.75 \$1,013.75 \$483.36 \$2,701.58 \$483.36	
69100 69105 69110 69120 69140 69145 69150 69200	Biopsy of external ear Biopsy of external ear canal Remove external ear, partial Removal of external ear Remove ear canal lesion(s) Remove ear canal lesion(s) Extensive ear canal surgery Clear outer ear canal		+ + + + + +	\$1,016.36 \$3,895.61 \$3,757.15 \$5,424.08 \$5,424.08 \$3,757.15 \$1,565.03 \$175.05	
69205 69210 69220 69222	Clear outer ear canal Remove impacted ear wax Clean out mastoid cavity Clean out mastoid cavity	-	+ + +	\$4,689.89 \$175.05 \$211.64 \$3,895.61	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 53 OF 78

	PAGE 33 OF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
69300	Revise external ear		+	\$5,424.08	
69310	Rebuild outer ear canal		+	\$9,175.99	
69320	Rebuild outer ear canal		+	\$9,175.99	
69399	Outer ear surgery procedure		+	\$514.72	
69400	Inflate middle ear canal Inflate middle ear canal		+ +	\$514.72 \$514.72	
69401 69405	Catheterize middle ear canal		+	\$1,565.03	
69410	Inset middle ear (baffle)		+	\$1,565.03	
69420	Incision of eardrum		+	\$514.72	
69421	Incision of eardrum		+	\$3,895.61	
69424 69433	Remove ventilating tube		+ +	\$1,565.03	
69436	Create eardrum opening Create eardrum opening		+	\$1,565.03 \$3,895.61	
69440	Exploration of middle ear		+	\$5,424.08	
69450	Eardrum revision		+	\$9,175.99	
69501	Mastoidectomy		+	\$9,175.99	
69502 69505	Mastoidectomy Remove mastoid structures		+	\$5,424.08 \$9,175.99	
69511	Extensive mastoid surgery		+	\$9,175.99 \$9,175.99	
69530	Extensive mastoid surgery		+	\$9,175.99	
69540	Remove ear lesion		+	\$3,895.61	
69550	Remove ear lesion		+	\$9,175.99	
69552 69601	Remove ear lesion Mastoid surgery revision		++	\$9,175.99	
69602	Mastoid surgery revision		+	\$9,175.99 \$9,175.99	
69603	Mastoid surgery revision		+	\$9,175.99	
69604	Mastoid surgery revision		+	\$9,175.99	
69605	Mastoid surgery revision		+	\$9,175.99	
69610 69620	Repair of eardrum Repair of eardrum		++	\$5,424.08	
69631	Repair of eardrum Repair eardrum structures		+	\$5,424.08 \$9,175.99	
69632	Rebuild eardrum structures		+	\$9,175.99	
69633	Rebuild eardrum structures		+	\$9,175.99	
69635	Repair eardrum structures		+	\$9,175.99	
69636 69637	Rebuild eardrum structures Rebuild eardrum structures		+ +	\$9,175.99 \$9,175.99	
69641	Revise middle ear & mastoid		· +	\$9,175.99	
69642	Revise middle ear & mastoid		+	\$9,175.99	
69643	Revise middle ear & mastoid		+	\$9,175.99	
69644 69645	Revise middle ear & mastoid Revise middle ear & mastoid		++	\$9,175.99	
69646	Revise middle ear & mastoid Revise middle ear & mastoid		+	\$9,175.99 \$9,175.99	
69650	Release middle ear bone		+	\$5,424.08	
69660	Revise middle ear bone		+	\$9,175.99	
69661	Revise middle ear bone		+	\$9,175.99	
69662 69666	Revise middle ear bone Repair middle ear structures		+ +	\$9,175.99 \$9,175.99	
69667	Repair middle ear structures		+	\$9,175.99	
69670	Remove mastoid air cells		+	\$9,175.99	
69676	Remove middle ear nerve		+	\$9,175.99	
69700	Close mastoid fistula		+	\$9,175.99 \$8,109.16	
69710 69711	Implant/replace hearing aid Remove/repair hearing aid		+	\$9,175.99	
69714	Implant temple bone w/stimul		+	\$9,175.99	
69715	Temple bne implnt w/stimulat		+	\$9,175.99	
69717	Temple bone implant revision		+	\$9,175.99	
69718 69720	Revise temple bone implant Release facial nerve		+ +	\$9,175.99 \$9,175.99	
69725	Release facial nerve		+	\$9,175.99	
69740	Repair facial nerve		+	\$9,175.99	
69745	Repair facial nerve	1	+	\$9,175.99	
69799 69801	Middle ear surgery procedure		+ +	\$3,895.61 \$9,175.99	
69801 69802	Incise inner ear Incise inner ear		+	\$9,175.99	
69805	Explore inner ear		+	\$9,175.99	
69806	Explore inner ear	1	+	\$9,175.99	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 54 OF 78

	F 10			
CPT/ HCPCS Description Code	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
69820 69840 Revise inner ear window 69905 Remove inner ear and 69915 Remove inner ear and 69916 Remove inner ear and 69917 Remove inner ear and 69918 Remove inner ear and 69919 Implant cochlear device Inner ear surgery procedure 69955 Release facial nerve 69960 Release facial nerve Release inner ear canal 69979 Temporal bone surgery 70010 Contrast x-ray of brain 70030 X-ray evam of iaw 70110 X-ray evam of jaw 70110 X-ray exam of mastoids 70134 X-ray exam of mastoids 70134 X-ray exam of mastoids 70134 X-ray exam of facial bones 70150 X-ray exam of facial bones 70160 X-ray exam of facial bones 70170 X-ray exam of eye sockets 70210 X-ray exam of eye sockets 70210 X-ray exam of sinuses 70240 X-ray exam of sinuses 70240 X-ray exam of skull 70300 X-ray exam of skull 70300 X-ray exam of jaw 10311 X-ray exam of jaw 10311 X-ray exam of jaw 10311 X-ray exam of jaw 10311 X-ray exam of jaw 10311 X-ray exam of jaw 10311 X-ray exam of jaw 10311 X-ray exam of jaw 10311 X-ray exam of jaw 10311 X-ray exam of jaw 10311 X-ray exam of jaw 10311 X-ray exam of jaw 10311 X-ray exam of jaw 10311 X-ray exam of jaw 10311 X-ray exam of jaw 10311 X-ray exam of jaw 10311 X-ray exam of jaw 10311 X-ray exam of jaw 10311 X-ray exam of jaw 10311 X-ray exam of jaw 10311 X-ray exam 10311 X-ray exam 10311 X-ray exam 10311 X-ray exam 10311 X-ray exam 10311 X-ray exam 10311 X-ray exam 10311 X-ray exam 10311 X-ray exam 10311 X-ray exam 10311 X-ray exam 10311 X-ray exam 10311 X-ray exam 10311 X-ray exam 10311 X-ray exam 10311 X-ray exam 10311 X-ray exam 10311 X-ray exam 10311 X-r		+ + + + + + + + + + + + + + + + + + + +	\$9,175,99 \$9,175,99 \$9,175,99 \$9,175,99 \$3,175,99 \$3,189,61 \$9,175,99 \$3,175,99 \$5,14,72 \$1,083,21 \$1,083,21 \$2,17,31	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 55 OF 78

	PAGE 55 C	DF 78			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
70549 70551 70552 70553 71010 71015 71020 71021 71022 71023 71030 71034 71035 71040 71060 71090 71100 71111 71110 71111 71120 71130 71250 71250 71250 71250 71250 71275 71551 71552 72010 72020 72040 72052 72069 72070 72072 72074 72080 72090 72110 72114 72126 72127 72128 72129 72130 72131 72132 72131 72132 72141 72142 72148 72149 72158 72170 72158 72170 72190 72191	Mr angiograph neck w/o&w dye Mri brain w/o dye Mri brain w/o dye Mri brain w/o&w dye Chest x-ray Chest			\$2,849.72 \$1,975.57 \$2,022.87 \$2,17.31 \$217.31 \$217.31 \$217.31 \$217.31 \$217.31 \$373.71 \$217.31 \$373.71 \$217.31 \$530.77 \$788.03 \$373.71 \$217.31 \$217.31 \$217.31 \$1,505.09 \$1,787.49 \$1,524.60 \$1,975.57 \$2,022.87 \$2,849.72 \$386.95 \$217.31 \$217.31 \$31.505.09 \$1,787.49 \$1,524.60 \$1,975.57 \$2,022.87 \$2,849.72 \$386.95 \$217.31 \$217.31 \$31.505.09 \$1,787.49 \$1,153.53 \$1,505.09 \$1,787.49 \$1,787.	
72192	Ct pelvis w/o dye	b	l	\$1,153.53	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 56 OF 78

	PAGE 30 OF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
TCPCS Code 72193 72194 72195 72196 72197 72200 72202 72200 72240 72255 72265 72275 72285 73000 73010 73020 73030 73040 73050 73060 73070 73080 73080 73080 73080 73090 73110 73115 73120 73130 73140 73201 73218 73219 73220 73206 73218 73219 73220 73550 73550 73550 73550 73550	Ct pelvis w/dye Ct pelvis w/o&w/dye Mri pelvis w/o dye Mri pelvis w/o & w/dye X-ray exam sacroiliac joints X-ray exam sacroiliac joints X-ray exam of tailbone Contrast x-ray, florax spine Contrast x-ray, lower spine Contrast x-ray of spine Epidurography X-ray c/t spine disk X-ray exam of collar bone X-ray exam of shoulder blade X-ray exam of shoulder Contrast x-ray of shoulder Contrast x-ray of shoulder X-ray exam of shoulder X-ray exam of shoulder Contrast x-ray of elbow X-ray exam of elbow Contrast x-ray of elbow X-ray exam of forearm X-ray exam of forearm X-ray exam of wrist X-ray exam of wrist X-ray exam of hand X-ray exam of hand X-ray exam of finger(s) Ct upper extremity w/o dye Ct upper extremity w/o dye Ct upper extremity w/o&w/dye Mri upper extremity w/o&w/dye Mri upper extremity w/odw/dye Mri ipint upr extrem w/odw/dye Mri ipint upr extrem w/odw/dye Mri ipint upr extrem w/odw/dye Mri ipint upr extrem w/odw/dye Mri ipint upr extremity w/odw/dye Mri ipint upr extremity w/odw/dye Mri ipint upr extremity w/odw/dye Mri ipint upr extremity w/odw/dye Mri ipint upr extrem w/odw/dye Mri ipin	Usage	Surgery Reduction	\$1,505.09 \$1,787.49 \$1,975.57 \$2,022.87 \$2,849.72 \$217.31 \$1,083.21 \$1,083.21 \$1,083.21 \$1,083.21 \$1,083.21 \$1,083.21 \$1,083.21 \$1,083.21 \$217.31	Method-
73562 73564 73565 73580 73590 73592 73600 73610 73615 73620 73630 73650 73660 73700	X-ray exam of knee, 3 X-ray exam, knee, 4 or more X-ray exam of knees Contrast x-ray of knee joint X-ray exam of lower leg X-ray exam of leg, infant X-ray exam of ankle X-ray exam of ankle Contrast x-ray of ankle X-ray exam of foot X-ray exam of foot X-ray exam of heel X-ray exam of toe(s) Ct lower extremity w/o dye	6 6 6 6 6 6 6 6 6 6 6		\$217.31 \$217.31 \$217.31 \$831.35 \$217.31 \$217.31 \$217.31 \$217.31 \$217.31 \$217.31 \$217.31 \$217.31 \$1,153.53	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 57 OF 78

_	PAGE 57 OF	78			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
	Ct lower extremity w/dye Ct lwr extremity w/o&w/dye Ct angio lwr extr w/o&w/dye Mri lower extremity w/o dye Mri lower extremity w/o dye Mri lwr extremity w/o&w/dye Mri joint of lwr extre w/o dye Mri joint lwr extr w/o&w/dye Mri joint lwr extr w/o&w/dye Mri joint lwr extr w/o&w/dye X-ray exam of abdomen X-ray exam of abdomen X-ray exam of abdomen X-ray exam of abdomen Ct abdomen w/o dye Ct abdomen w/o dye Ct abdomen w/o dye Ct angio abdom w/o&w/dye Mri abdomen w/o dye X-ray exam of peritoneum Contrst x-ray exam of throat Contrst x-ray, esophagus Cine/vid x-ray, throat/esoph Remove esophagus obstruction X-ray exam, upper gi tract X-ray exam, upper gi tract X-ray exam, upper gi tract Contrst x-ray uppr gi tract Contrst x-ray uppr gi tract Contrst x-ray uppr gi tract		•	\$1,505.09 \$1,787.49 \$1,524.60 \$1,975.57 \$2,022.87 \$2,849.72 \$217.31 \$217.31 \$217.31 \$386.95 \$1,1505.09 \$1,787.49 \$1,505.09 \$1,787.49 \$1,505.09 \$1,787.45 \$475.45	1
74250 74250 74251 74260 74270 74280 74280 74280 74280 74291 74300 74301 74305 74305 74327 74340 74355 74360 74363 74460 74415 74425 74425 74440 74445 74455 74450 74455 74470 74475 74485 74470 74476 74740 74742	X-ray exam of small bowel X-ray exam of small bowel X-ray exam of small bowel Contrast x-ray exam of colon Contrast x-ray exam of colon Contrast x-ray exam of colon Contrast x-ray, gallbladder Contrast x-rays, gallbladder X-ray bile ducts/pancreas X-ray sat surgery add-on X-ray bile ducts/pancreas Contrast x-ray of bile ducts X-ray bile stone removal X-ray guide for GI tube X-ray guide, stomach tube X-ray guide, stomach tube X-ray guide, GI dilation X-ray, bile duct dilation Contrst x-ray, urinary tract Contrst x-ray, urinary tract Contrst x-ray, urinary tract Contrst x-ray, urinary tract Contrst x-ray, urinary tract Contrst x-ray, urinary tract Contrst x-ray, urinary tract Contrst x-ray, urinary tract Contrast x-ray			\$475.45 \$658.04 \$658.04 \$475.45 \$475.45 \$475.45 \$475.45 \$475.45 \$530.77 \$530.77 \$530.77 \$530.77 \$530.77 \$530.77 \$530.77 \$530.77 \$530.77 \$674.28 \$2,147.43 \$706.78 \$706	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 58 OF 78

	PAGE 56 OF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
74775 75552 75553 75554 75555 75556 75600 75605 75635 75635 75635 75658 75660 75662 75662 75666 75660 75662 75668 75671 75676 75680 75685 75705 75710 75710 75710 75714 75726 75724 75726 75731 75733 75746 75741 75746 75774 75790 75801 75801 75803 75805 75807 75809 75807 75809 75807 75809 75827 75831 75827 75831 75827 75831 75827 75831 75840 75827 75831 75840 75842 75860 75872 75887	X-ray exam of perineum Heart mri for morph w/o dye Heart mri for morph w/o dye Heart mri for morph w/o dye Cardiac MRI/function Cardiac MRI/function Cardiac MRI/function mapping Contrast x-ray exam of aorta Contrast x-ray exam of aorta Contrast x-ray exam of aorta Contrast x-ray exam of aorta X-ray aorta, leg arteries Ct angio abdominal arteries Artery x-rays, head & neck Artery x-rays, head & neck Artery x-rays, head & neck Artery x-rays, head & neck Artery x-rays, head & neck Artery x-rays, neck Artery x-rays, neck Artery x-rays, arms/legs Artery x-rays, arms/legs Artery x-rays, atms/legs Artery x-rays, addomen Artery x-rays, addomen Artery x-rays, addomen Artery x-rays, addenals Artery x-rays, lung Artery x-rays, lung Artery x-rays, lung Artery x-rays, chest Artery x-rays, chest Artery x-rays, chest Artery x-ray, chest Artery x-ray, chest Artery x-ray, spelvis Artery x-ray, chest Artery x-ray, chest Visualize A-V shunt Lymph vessel x-ray, trunk Nonvascular shunt, x-ray Vein x-ray, spleen/liver Vein x-ray, arms/legs Vein x-ray, arms/legs Vein x-ray, trunk Vein x-ray, drest Vein x-ray, drenal gland Vein x-ray, trunk Vein x-ray, drenal gland Vein x-ray, arms/legs Vein x-ray, arms/legs Vein x-ray, arms/legs Vein x-ray, arms/legs Vein x-ray, shidneys Vein x-ray, adrenal gland Vein x-ray, skull Vein x-ray, skull Vein x-ray, skull Vein x-ray, liver Vein x-ray, liver Vein x-ray, liver Vein x-ray, liver Vein x-ray, liver Vein x-ray, liver Vein x-ray, liver Vein x-ray, liver Vein x-ray, liver Vein x-ray, liver Vein x-ray, liver Vein x-ray, liver Vein x-ray, liver Vein x-ray, liver Vein x-ray, liver Vein x-ray, liver Vein x-ray, liver Vein x-ray, liver			\$706.78 \$1,975.57 \$2,022.87 \$1,760.20 \$2,653.79 \$4,251.55 \$2,415.53 \$2,415.53 \$2,415.53 \$2,415.53 \$1,952.47	
75894 75898 75898 75900 75901 75902 75940 75945 75946	X-rays, transcath therapy X-rays, transcath therapy Follow-up angiography Arterial catheter exchange Remove cva device obstruct Remove cva lumen obstruct X-ray placement, vein filter Intravascular us Intravascular us add-on	b b b b b b b		\$2,147.43 \$2,147.43 \$788.03 \$1,157.61 \$788.03 \$530.77 \$1,104.86 \$740.18	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 59 OF 78

	PAGE 59 OF	· 78			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
75960 75961 75962 75964 75966 75968 75970 75978 75980 75982 75984 75992 75993 75994 75995 75996 76000 76010 76010 76012 76013 76020 76040 76061 76061 76071 76076 76076 76076 76076 76076 76076 76076 76078 76088 76078 76088 76090 76091 76091 76091 76092 76093 76090 76091 76093 76090 76091 76090 76091 76090	Transcatheter intro, stent Retrieval, broken catheter Repair arterial blockage Repair arterial blockage Repair artery blockage, each Repair artery blockage, each Vascular biopsy Repair venous blockage Contrast xray exam bile duct Contrast xray exam bile duct Xray control catheter change Atherectomy, x-ray exam Atherectomy, x-ray		Applies	\$4,251.55 \$386.95 \$386.95 \$386.95 \$386.95 \$386.95 \$217.31 \$468.48 \$362.42 \$230.17 \$530.77 \$530	
76700	Us exam, abdom, complete	j b	•	\$536.72	1

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 60 OF 78

	17.62.00 01				
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
76705 76770 76775 76778 76800 76801	Echo exam of abdomen Us exam abdo back wall, comp Us eam abdo back wall, lim Us exam kidney transplant Us exam, spinal canal Ob us < 14 wks, single fetus	b b b b		\$536.72 \$536.72 \$536.72 \$536.72 \$536.72 \$331.16	
76802 76805 76810	Ob us < 14 wks, addl fetus Ob us >/= 14 wks, sngl fetus Ob us >/= 14 wks, addl fetus	b b		\$331.16 \$536.72 \$331.16	
76811 76812 76815	Ob us, detailed, sngl fetus Ob us, detailed, addl fetus Ob us, limited, fetus(s)	b b b		\$740.18 \$536.72 \$331.16	
76816 76817 76818 76819	Ob us, follow-up, per fetus Transvaginal us, obstetric Fetal biophys profile w/nst Fetal biophys profil w/o nst	b b b		\$331.16 \$331.16 \$536.72 \$536.72	
76825 76826 76827	Echo exam of fetal heart Echo exam of fetal heart Echo exam of fetal heart Echo exam of fetal heart	b b b		\$426.95 \$376.50 \$426.95	
76828 76830 76831 76856	Echo exam of fetal heart Transvaginal us, non-ob Echo exam, uterus Us exam, pelvic, complete	b b b		\$376.50 \$536.72 \$536.72 \$536.72	
76857 76870 76872	Us exam, pelvic, limited Us exam, scrotum Echo exam, transrectal	. p		\$331.16 \$536.72 \$536.72	
76873 76880 76885 76886	Echograp trans r, pros study Us exam, extremity Us exam infant hips, dynamic Us exam infant hips, static	b b b		\$536.72 \$536.72 \$536.72 \$536.72	
76930 76932 76936	Echo guide, cardiocentesis Echo guide for heart biopsy Echo guide for artery repair	b b b		\$387.24 \$387.24 \$387.24	
76941 76942 76945 76946	Echo guide for transfusion Echo guide for biopsy Echo guide, villus sampling Echo guide for amniocentesis	b b b		\$387.24 \$387.24 \$387.24 \$387.24	
76948 76950 76965	Echo guide, ova aspiration Echo guidance radiotherapy Echo guidance radiotherapy	b b b		\$387.24 \$387.24 \$387.24	
76970 76975 76977 76986	Ultrasound exam follow-up Gl endoscopic ultrasound Us bone density measure Ultrasound guide intraoper	b b b		\$331.16 \$536.72 \$331.16 \$536.72	
76999 77280 77285	Echo examination procedure Set radiation therapy field Set radiation therapy field	b b b		\$331.16 \$402.15 \$983.60 \$983.60	
77290 77295 77300 77301	Set radiation therapy field Set radiation therapy field Radiation therapy dose plan Radiotherapy dose plan, imrt	b b		\$3,818.29 \$402.15 \$4,534.03	
77305 77310 77315 77321	Teletx isodose plan simple Teletx isodose plan intermed Teletx isodose plan complex Special teletx port plan	b b b		\$402.15 \$402.15 \$983.60 \$983.60	
77326 77327 77328	Brachytx isodose calc simp Brachytx isodose calc interm Brachytx isodose plan compl	b b		\$983.60 \$983.60 \$983.60	
77331 77332 77333 77334	Special radiation dosimetry Radiation treatment aid(s) Radiation treatment aid(s) Radiation treatment aid(s)	b b b		\$402.15 \$764.74 \$764.74 \$764.74	
77336 77370 77399 77401	Radiation physics consult Radiation physics consult External radiation dosimetry Radiation treatment delivery	b		\$402.15 \$983.60 \$402.15 \$382.70	
,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	1 Magazion double donvery	•	f		•

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 61 OF 78

	PAGE 61 OF 78			
CPT/ HCPCS Description Code	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
77402 77403 77404 77406 77406 77406 77407 77407 77407 77407 77408 77408 77408 77407 77408 77408 77407 77408 77408 77409 77409 77409 77409 77411 77410 77411 77411 77411 77412 77412 77413 77414 77414 77416 77416 77416 77417 77418 77418 77418 77418 77418 77410 77418 77410 77410 77410 77410 77410 77411 77410 77411 77410 77411 77410 77411 77410 77411 77410 77411 77410 77411 77410 77410 77411 77410 77411 77410 77411 77410 77410 77410 77410 77410 77411 77410 77410 77410 77410 77411 77410			\$382.70 \$382.70 \$382.70 \$382.70 \$382.70 \$382.70 \$382.70 \$382.70 \$382.70 \$382.70 \$382.70 \$528.07 \$538.1,67.16 \$1,167.16 \$	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 62 OF 78

	FAGE 02 OF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
78185 78190 78191 78191 78199 78201 78202 78205 78206 78215 78216 78215 78217 78222 78230 78231 78232 78230 78231 78232 78258 78261 78262 78264 78270 78271 78272 78278 78278 78279 78271 78272 78278 78282 78290 78291 78299 78300 78305 78305 78305 78305 78305 783456 78357 78458 78455 78456 78457 78458 78455 78456 78457 78458 78459 78460 78461 78468 78468 78468 78468 78468 78468 78468 78468 78473 78478 78478 78478 78478 78478 78480 78481 78480 78481 78480 78481 78480 78481 78480 78481	Spleen imaging Platelet survival, kinetics Platelet survival Lymph system imaging Blood/lymph nuclear exam Liver imaging with flow Liver imaging (3D) Liver imaging (3D) Liver imaging (3D) Liver imaging (3D) Liver imaging (3D) Liver imaging (3D) Liver systeen image/flow Liver function study Hepatobiliary imaging Salivary gland imaging Salivary gland imaging Salivary gland function exam Esophageal motility study Gastric mucosa imaging Gastroesophageal reflux exam Gastric emptying study Vit B-12 absorption exam Vit b-12 absorp combined Acute GI blood loss imaging GI protein loss exam Meckel's divert exam Leveen/shunt patency exam GI nuclear procedure Bone imaging, milited area Bone imaging, multiple areas Bone imaging, whole body Bone imaging, shole body Bone imaging (3D) Bone mineral, single photon Musculoskeletal nuclear exam Non-imaging heart function Cardiac shunt imaging Vanous thrombosis image Venous thrombosis image Venous thrombosis imaging Venous thrombosis imaging Venous thrombosis imaging Venous thrombosis imaging Heart muscle blood, multiple Heart muscle blood, multiple Heart infarct image Heart image, spect			\$1,083,42 \$565.96 \$1,199.63 \$1,083,42 \$1,083,42 \$1,083,42 \$1,083,42 \$1,083,42 \$1,083,42 \$1,199.63 \$1,199.63 \$1,199.63 \$1,199.63 \$1,199.63 \$1,199.63 \$1,199.63 \$1,199.63 \$1,199.63 \$1,199.63 \$565.96 \$565.96 \$1,199.63 \$1,083,42 \$1,877,82	
78496 78499 78580 78584 78585 78586 78587 78588	Heart first pass add-on Cardiovascular nuclear exam Lung perfusion imaging Lung V/Q image single breath Lung V/Q imaging Aerosol lung image, single Aerosol lung image, multiple Perfusion lung image	b b b b b b b b b		\$489.66 \$1,083.42 \$1,083.42 \$1,199.63 \$1,199.63 \$1,083.42 \$1,083.42 \$1,083.42	
78591	Vent image, 1 breath, 1 proj	b	I	\$1,083.42	1

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 63 OF 78

PAGE 63 OF 78					
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
78593 78594 78596 78599 78600 78601 78605 78606 78606 78607 78610 78615 78635 78645 78645 78645 78645 78660 78699 78700 78701 78704 78708 78707 78708 78707 78708 78709 78710 78715 78725 78730 78740 78761 78799 78800 78761 78799 78800 78761 78799 78800 78761 78799 78900 79001 79020 79035 78805 78806 78807 78999 79000 79001 79020 79035 79100 79200 79035 79100 79200 79400 79400 79400 79420 79440 79499 80500 80502 85060 85097 86078 86078 86078 86077 86078 86078 86078 86078 86490 86510 86580 86580	Vent image, 1 proj, gas Vent image, mult proj, gas Lung differential function Respiratory nuclear exam Brain imaging, ltd static Brain imaging, complete Brain imaging, complete Brain imaging, complete Brain imaging, complete Brain imaging (3D) Brain flow imaging only Cerebral vascular flow image Cerebrospinal fluid scan CSF ventriculography CSF shunt evaluation Cerebrospinal fluid scan CSF leakage imaging Nuclear exam of tear flow Nervous system nuclear exam Kidney imaging, static Kidney imaging, static Kidney imaging with flow Imaging renogram Kidney flow/function image Kidney flow/function image Kidney flow/function image Kidney flow/function image Kidney flow/function image Kidney flow/function image Kidney imaging (3D) Renal vascular flow exam Kidney function study Urinary bladder retention Ureteral reflux study Testicular imaging Testicular imaging, limited area Tumor imaging, imilt areas Tumor imaging, mult areas Tumor imaging, whole body Tumor imaging (3D) Abscess imaging, tld area Abscess imaging, tld area Abscess imaging, whole body Nuclear localization/abscess Nuclear diagnostic exam Init hyperthyroid therapy Repeat hyperthyroid therapy Hematopoetic nuclear therapy Intracavitary nuclear trerapy Intracavitary nuclear trerapy Intracavitary nuclear therapy Intracavitary nuclear therapy Intracavitary nuclear therapy Intravascular nuclear therapy Intravascula			\$1,083.42 \$1,083.42 \$1,083.42 \$1,083.42 \$1,083.42 \$1,083.42 \$1,083.42 \$1,083.42 \$1,199.63 \$1,199.63 \$1,199.63 \$1,199.63 \$1,199.63 \$1,083.42 \$1,083.42 \$1,083.42 \$1,083.42 \$1,083.42 \$1,083.42 \$1,083.42 \$1,083.42 \$1,199.63 \$1,140.08 \$1,140	
86586 86850	Skin test, unlisted RBC antibody screen			\$46.81 \$62.84	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 64 OF 78

	FAGE 04 OF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
86860 86870 86880 86885 86886 86890 86891 86900 86901 86903 86904 86905 86920 86921 86922 86927 86931 86932 86945 86950 86971 86972 86975 86976 86977 86978 86978 86977 86978 86978 86977 86978	RBC antibody elution RBC antibody identification Coombs test, idrect Coombs test, indirect, qual Coombs test, indirect, qual Coombs test, indirect, qual Coombs test, indirect, titer Autologous blood, op salvage Blood typing, ABO Blood typing, ABO Blood typing, RBC Blood typing, RBC Blood typing, patient serum Blood typing, RBC antigens Blood typing, RBC antigens Blood typing, RP phenotype Compatibility test Compatibility test Compatibility test Plasma, fresh frozen Frozen blood prep Frozen blood prep Frozen blood freeze/thaw Blood product/irradiation Leukacyte transfusion Pooling blood platelets RBC pretreatment RBC pretreatment RBC pretreatment RBC pretreatment, serum RBC pretreatment, serum RBC pretreatment, serum RBC pretreatment, serum RBC pretreatment, serum RBC pretreatment, serum RBC pretreatment, serum RBC pretreatment, serum RBC pretreatment, serum Cytopathology, fluids Cytopathology, fluids Cytopathology, fluids Cytopath smear, other source Cytopath smear, other source Cytopath smear, other source Cytopath smear, other source Cytopath ser, other ser, other source Cytopath se			\$121.67 \$121.67 \$46.81 \$46.81 \$46.81 \$362.13 \$62.84 \$62.84 \$62.84 \$62.84 \$62.84 \$121.67 \$121.67 \$121.67 \$121.67 \$362.13 \$362.13 \$362.13 \$362.13 \$362.13 \$362.13 \$362.13 \$362.13 \$121.67 \$62.84 \$62.84 \$62.84 \$62.84 \$62.84 \$62.84 \$62.84 \$62.84 \$62.84 \$62.84 \$62.84 \$62.84 \$62.84 \$145.86 \$14	
88346 88347 88348	Immunofluorescent study Immunofluorescent study Electron microscopy	b b		\$145.86 \$199.79 \$1,130.12	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 65 OF 78

	FAGE 05 OF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
88349 88355 88356 88356 88362 88365 89100 89105 89132 89135 89136 89140 89141 89250 89251 89253 89254 89255 89256 89257 89256 89257 89258 89259 89260 89261 89260 89261 89260 89261 89263 89264 89350 89360 90375 90376 90379 90581 90636 90657 90658 90659 90693 90723 90784 90788 90788 90788 90788 90789 90780 90801 90801 90804 90805 90806 90807 90806 90807 90806 90807 90806 90807 90808 90809 90810 90811 90813 90814 90815 90815 90817 90816 90817 90816 90817 90816 90817 90816 90817 90816 90817 90816 90817 90816 90817 90816 90817 90816 90817 90816 90817 90816 90817 90816 90817 90818 90819 90819 90821 90821 90821	Scanning electron microscopy Analysis, skeletal muscle Analysis, nerve Analysis, tumor Nerve teasing preparations Tissue hybridization Sample intestinal contents Sample intestinal contents Sample stomach contents Sample stomach contents Sample stomach contents Sample stomach contents Sample stomach contents Sample stomach contents Sample stomach contents Sample stomach contents Fertilization of oocyte Culture oocyte w/embryos Assist oocyte fertilization Embryo hatching Oocyte identification Prepare embryo for transfer Prepare cryopreserved embryo Sperm identification Cryopreservation, embryo Cryopreservation, sperm Sperm isolation, simple Sperm isolation, simple Sperm isolation, simple Sperm isolation, simple Sperm isolation, complex Identify sperm tissue Sputum specimen collection Collect sweat for test Diphtheria antitoxin Rabies ig, im/sc Rabies ig, im/sc Rabies ig, im/sc Rabies ig, im/sc Rabies ig, iw/sc Ra	b b b b b		\$1,130.12 \$199.79 \$199.79 \$199.79 \$145.86 \$199.79 \$439.91 \$439.91 \$439.91 \$439.91 \$439.91 \$177.94 \$177	SAF SAF SAF

See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 66 OF 78

	FAGE 60 OF	10			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
90823 90824 90826 90827 90828 90829 90845 90846 90847 90849 90853 90857 90862 90865 90870 90871 90880 90899 90901 90911 90935 90947 90989 91000 91010 91011 91012 91020 91030 91033 91052 91033 91052 91055 91066 91100 911129 91033 91052 91033 91052 91055 91065 91100 911129 92020 92061 92014 92012 92014 92014 92018 92019 92020 92065 92081 92083 92130 92135 92136 92140 92225 92230 92235	Intac psytx, hosp, 20-30 w/e&m Intac psytx, hosp, 45-50 min Intac psytx, hosp, 45-50 min Intac psytx, hosp, 75-80 min Intac psytx, hosp, 75-80 min Intac psytx, hosp, 75-80 w/e&m Psychoanalysis Family psytx w/o patient Family psytx w/o patient Family psytx w/o patient Multiple family group psytx Group psychotherapy Intac group psytx Medication management Narcosynthesis Electroconvulsive therapy Electroconvulsive therapy Hypnotherapy Psychiatric service/therapy Biofeedback train, any meth Biofeedback peri/uro/rectal Hemodialysis, one evaluation Hemodialysis, repeated eval Dialysis, one evaluation Dialysis, repeated eval Dialysis, repeated eval Dialysis training, complete Dialysis training, incompl Dialysis procedure Esophagus motility study Esophagus motility study Esophagus motility study Esophagus motility study Gastric motility Acid perfusion of esophagus Esophagus, acid reflux test Prolonged acid reflux test Gastric intubation for smear Gastric saline load test Breath hydrogen test Pass intestine bleeding tube Gastric intubation treatment Anal pressure record Electrogastrography Electrogastrography Electrogastrography Electrogastrography Electrogastrography Witest Gastroenterology procedure Eye exam new patient Eye exam stablished pat Eye exam streatment New eye evaluation Orthoptic/pleoptic training Visual field examination(s)	999999999999999999999999999999999999999	+ + +	\$220.26 \$220.26 \$189.44 \$189.44 \$189.44 \$189.44 \$189.44 \$189.45 \$192.54 \$192.54 \$192.54 \$192.54 \$120.03 \$189.44 \$566.43 \$566.43 \$566.43 \$566.43 \$189.44 \$220.26 \$1,306.63 \$73.53 \$202.14 \$419.49 \$171.56 \$916.47	SAF SAF SAF SAF

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 67 OF 78

	FAGE OF OF	10			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
92240 92250 92260 92265 92270 92275 92283 92284 92285 92286 92287 92311 92312 92313 92315 92316 92330 92352 92353 92354 92355 92358 92371 92499 92502 92511 92512 92512 92514 92542 92543 92545 92546 92547 92548 92545 92548 92557 92561 92557 92561 92562 92557 92563 92564 92567 92568 92567 92568 92567 92568 92567 92568 92567 92568 92567 92568 92567 92568 92567 92568 92567 92568 92567 92568 92567 92568 92567 92568 92567	lcg angiography Eye exam with photos Ophthalmoscopy/dynamometry Eye muscle evaluation Electro-oculography Electroretinography Color vision examination Dark adaptation eye exam Eye photography Internal eye photography Internal eye photography Internal eye photography Contact lens fitting Contact lens fitting Contact lens fitting Prescription of contact lens Prescription of contact lens Prescription of contact lens Replacement of contact lens Fitting of artificial eye Special spectacles fitting Special spectacles fitting Special spectacles fitting Special spectacles fitting Special spectacles fitting Special spectacles fitting Eye prosthesis service Repair & adjust spectacles Eye service or procedure Ear and throat examination Nasopharyngoscopy Nasal function studies Facial nerve function test Laryngeal function studies Spontaneous nystagmus test Optokinetic nystagmus test Optokinetic nystagmus test Optokinetic nystagmus test Optokinetic nystagmus test Sinusoidal rotational test Supplemental electrical test Posturography Pure tone audiometry, air Audiometry, air & bone Speech threshold audiometry Speech audiometry, complete Comprehensive hearing test Bekesy audiometry, diagnosis Loudness balance test Tone decay hearing test Senger test, pure tone Tympanometry Acoustic reflex decay test Filtered speech hearing test Stanger test, speech Visual audiometry (vra) Conditioning play audiometry Select picture audiometry Select picture audiometry Select picture audiometry Select picture audiometry Select picture audiometry Select picture audiometry Select picture audiometry Select picture audiometry Select picture audiometry Select picture audiometry	b b b b b b b b b b b b b b b b b b b		\$585.26 \$199.00 \$199.00 \$585.26 \$248.75 \$585.26 \$199.00 \$248.75 \$585.26 \$767.22 \$767.23 \$767.24 \$767.25 \$767.25 \$767.26 \$199.00 \$767.26 \$199.00 \$767.27 \$199.00 \$110.0	ology
92584 92585 92586 92587	Electrocochleography Auditor evoke potent, compre Auditor evoke potent, limit Evoked auditory test	b b		\$429.43 \$782.92 \$208.14 \$293.26	

See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 68 OF 78

	PAGE 00 OF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
92588 92589 92596 92700 92950 92953 92960 92973 92974 92977 92978 92979 92980 92981 92982 92984 92986 92987 92995 92995 92995 92995 93005 93017 93024 93025 93041 93025 93041 93226 93231 93232 93230 93231 93232 93350 93311 93315 93311 93315 93311 93316 93311 93315 93311 93321 93322 93321 93322 93321 93322 93350 93501 93503 93501 93501 93501 93501 93511 93524 93526 93527 93528	Evoked auditory test Auditory function test(s) Ear protector evaluation Ent procedure/service Heart/lung resuscitation cpr Temporary external pacing Cardioversion electric, int Percut coronary thrombectomy Cath place, cardio brachytx Dissolve clot, heart vessel Intravasc us, heart add-on Intravasc us, heart add-on Insert intracoronary stent Coronary artery dilation Coronary artery dilation Coronary artery dilation Revision of aortic valve Revision of pulmonary valve Coronary atherectomy Coronary atherectomy Coronary atherectomy add-on Pul art balloon repr, percut Pul art balloon repr, percut Electrocardiogram, tracing Cardiovascular stress test Cardiac drug stress test Microvolt t-wave assess Rhythm ECG, tracing ECG monitor/report, 24 hrs ECG monitor/report, 24 hrs ECG monitor/report, 24 hrs ECG monitor/report, 24 hrs ECG monitor/report, 24 hrs ECG monitor/report, 24 hrs ECG recording Ecg/monitoring and analysis ECG/signal-averaged Echo transthoracic Echo transstophageal Echo transesophageal	b bb eebbeeee bbbbbb b bbbbbbbbbbbbbbb	+ + + + + + + + + + + + + + + + + + + +	\$429.43 \$120.44 \$327.31 \$120.44 \$1,227.40 \$1,227.40 \$1,227.40 \$1,729.54 \$1,729.54 \$1,113.03 \$9,147.02 \$18,804.07 \$18,804.07 \$18,804.07 \$14,014.81 \$14,014.81 \$14,014.81 \$14,014.81 \$14,014.83 \$11,731.26 \$12,81 \$14,014.81 \$	
93529 93530 93531 93532 93533	Rt, It heart catheterization Rt heart cath, congenital R & I heart cath, congenital R & I heart cath, congenital R & I heart cath, congenital	b b b b	+ + + + +	\$9,518.27 \$9,518.27 \$9,518.27 \$9,518.27 \$9,518.27	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 69 OF 78

	PAGE 09 OF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
93580 93581 93602 93603 93602 93603 93610 93612 93613 93615 93616 93618 93619 93622 93623 93622 93623 93641 93641 93640 93641 93652 93660 93651 93701 93727 93731 93727 93731 93727 93731 93735 93736 93740 93741 93742 93744 93742 93744 93745 93749 93744 93749 93749 93786 93886 93886 93888 93922 93826 93886 93888 93922 93923 93924 93925 93930 93931 93975 93976 93978	Transcath closure of asd Transcath closure of vsd Bundle of His recording Intra-atrial recording Right ventricular recording Map tachycardia, add-on Intra-atrial pacing Electrophys map 3d, add-on Esophageal recording Esophageal recording Esophageal recording Heart rhythm pacing Electrophysiology evaluation Electrophysiology evaluation Electrophysiology evaluation Electrophysiology evaluation Electrophysiologic study Heart pacing, mapping Evaluation heart device Electrophysiology evaluation Electrophysiology evaluation Stimulation, pacing heart Electrophysiology evaluation Electrophysiology evaluation Ablate heart dysrhythm focus Ablate heart dysrhythm focus Ablate heart dysrhythm focus Ablate heart dysrhythm focus Ablate heart dysrhythm focus Ablate heart dysrhythm focus Tilt table evaluation Intracardiac ecg (ice) Bioimpedance, thoracic Plethysmography tracing Analyze pacemaker system Analyze pacemaker system Analyze pacemaker system Analyze pacemaker system Analyze pacemaker system Analyze pacemaker system Analyze pacemaker system Telephone analy, pacemaker Analyze pacemaker system Telephone analy, pacemaker Temperature gradient studies Analyze ht pace device sngl Analyze ht pace device dual Analyze ht pace device dual Analyze ht pace device dual Analyze ht pace device dual Analyze ht pace device dual Analyze ht pace device dual Analyze ht pace device dual Analyze ht pace device dual Analyze ht pace device dual Analyze ht pace device dual Analyze ht pace device dual Analyze ht pace device dual Analyze ht pace device buse Extracranial study Extremity study Extremity study Extremity study Extremity study Extremity study Extremity study Extremity study Extremity study Extremity study Extremity study Vascular study Vascular study Vascular study Vascular study Vascular study Vascular study		+ + + + + + + + + + + + + + + + + + +	\$12,366.54 \$12,366.54 \$11,473.97 \$11,473.97 \$11,473.97 \$11,473.97 \$11,473.97 \$11,473.97 \$11,473.97 \$11,473.97 \$11,473.97 \$12,032.18 \$12,032.18 \$12,032.18 \$12,032.18 \$12,032.18 \$12,032.18 \$12,032.18 \$12,032.18 \$12,032.18 \$12,032.18 \$12,032.18 \$12,032.18 \$12,032.18 \$12,032.18 \$12,032.18 \$12,032.18 \$13,351.39 \$2,984.84 \$2,984.84 \$2,984.84 \$1,351.39 \$1,35	
93979 93980	Vascular study Penile vascular study	b		\$740.18 \$740.18	1

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 70 OF 78

	FAGE 70 OF	10			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
93981	Penile vascular study	b		\$740.18	
93990	Doppler flow testing	b		\$740.18	
94010	Breathing capacity test	b	1	\$285.97	
94014	Patient recorded spirometry			\$182.18	
94015	Patient recorded spirometry		1	\$182.18	
94060	Evaluation of wheezing	b		\$285.97	
94070	Evaluation of wheezing	b	1	\$699.12	
94150	Vital capacity test	b	1	\$182.18	
94200	Lung function test (MBC/MVV)	b	l	\$182.18	
94240 94250	Residual lung capacity	b b		\$285.97 \$182.18	
94260	Expired gas collection Thoracic gas volume	b	ļ	\$285.97	
94350	Lung nitrogen washout curve	b	1	\$285.97	
94360	Measure airflow resistance	b	}	\$182.18	į
94370	Breath airway closing volume	b		\$182.18	
94375	Respiratory flow volume loop	b]	\$182.18	•
94400	CO2 breathing response curve	b	1	\$182.18	
94450	Hypoxia response curve	b	1	\$182.18	1
94620	Pulmonary stress test/simple	b		\$285.97	
94621	Pulm stress test/complex	b		\$699.12 \$78.56	
94640 94642	Airway inhalation treatment Aerosol inhalation treatment			\$175.44	
94656	Initial ventilator mgmt			\$442.53	
94657	Continued ventilator mgmt		[\$442.53	
94660	Pos airway pressure, CPAP			\$560.36	
94662	Neg press ventilation, cnp			\$442.53	1
94664	Evaluate pt use of inhaler			\$78.56	
94667	Chest wall manipulation			\$78.56	l
94668	Chest wall manipulation	l .		\$78.56	
94680	Exhaled air analysis, o2	b		\$182.18	
94681 94690	Exhaled air analysis, o2/co2 Exhaled air analysis	b b		\$285.97 \$182.18	
94720	Monoxide diffusing capacity	Ь	1	\$285.97	1
94725	Membrane diffusion capacity	Ď		\$285.97	
94750	Pulmonary compliance study	b		\$182.18	
94770	Exhaled carbon dioxide test	b		\$182.18	1
94772	Breath recording, infant			\$699.12	l
94799	Pulmonary service/procedure	b		\$182.18	
95004	Percut allergy skin tests	1		\$166.99	
95010	Percut allergy titrate test			\$166.99 \$166.99	
95015 95024	ld allergy titrate-drug/bug Id allergy test, drug/bug			\$166.99	1
95027	Id allergy titrate-airborne			\$166.99	
95028	Id allergy test-delayed type			\$166.99	
95044	Allergy patch tests			\$166.99	
95052	Photo patch test		1	\$166.99	1
95056	Photosensitivity tests			\$166.99	
95060	Eye allergy tests	1	1	\$166.99	
95065	Nose allergy test			\$166.99 \$699.12	
95070 95071	Bronchial allergy tests Bronchial allergy tests			\$699.12	
95075	Ingestion challenge test			\$916.47	1
95078	Provocative testing	1	1	\$166.99	1
95115	Immunotherapy, one injection		-	\$48.02	
95117	Immunotherapy injections)		\$88.14	
95144	Antigen therapy services	1		\$108.55	
95145	Antigen therapy services		}	\$108.55 \$108.55	
95146 95147	Antigen therapy services Antigen therapy services		·	\$108.55	
95147 95148	Antigen therapy services Antigen therapy services	1	1	\$108.55	
95149	Antigen therapy services	-	1	\$108.55	
95165	Antigen therapy services		1	\$108.55	ļ
95170	Antigen therapy services			\$108.55	
95180	Rapid desensitization		1	\$166.99	
95199	Allergy immunology services		[+	\$166.99 \$777.26	
95250	Glucose monitoring, cont	ı	1 7	1 9111.20	ı

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 71 OF 78

		. •			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
95805	Multiple sleep latency test	b		\$3,063.61	
95806	Sleep study, unattended	b		\$879.80	
95807	Sleep study, attended	b	ĺ	\$3,063.61	
95808	Polysomnography, 1-3	b		\$3,063.61	
95810	Polysomnography, 4 or more	b	l	\$3,063.61	
95811	Polysomnography w/cpap	b		\$3,063.61	
95812	Eeg, 41-60 minutes	b	l	\$879.80	
95813	Eeg, over 1 hour	b		\$879.80	
95816	Eeg, awake and drowsy	b	l	\$602.24 \$602.24	
95819 95822	Eeg, awake and asleep Eeg, coma or sleep only) b	1	\$602.24	
95824	Eeg, cerebral death only	b	·	\$602.24	
95827	Eeg, all night recording	b		\$3,063.61	
95829	Surgery electrocorticogram	b	}	\$602.24	
95857	Tensilon test			\$208.14	
95858	Tensilon test & myogram	b	1	\$208.14	
95860	Muscle test, one limb	b	l .	\$208.14	
95861	Muscle test, 2 limbs	b	1	\$208.14)
95863	Muscle test, 3 limbs	b	1	\$208.14 \$208.14	
95864 95867	Muscle test, 4 limbs Muscle test cran nerv unilat	b	1	\$208.14]
95868	Muscle test cran nerve bilat) b	1	\$208.14	
95869	Muscle test that herve bliat	b		\$139.60	
95870	Muscle test, nonparaspinal	Ь		\$208.14	
95872	Muscle test, one fiber	b		\$208.14	
95875	Limb exercise test	b		\$139.60	
95900	Motor nerve conduction test	b	1	\$208.14	
95903	Motor nerve conduction test	b	ĺ	\$208.14	
95904	Sense nerve conduction test	b		\$139.60	1
95920	Intraop nerve test add-on	b	1	\$782.92 \$208.14	
95921 95922	Autonomic nerv function test Autonomic nerv function test	b		\$208.14	
95923	Autonomic nerv function test	b		\$139.60	1
95925	Somatosensory testing	b		\$782.92	
95926	Somatosensory testing	b		\$782.92	
95927	Somatosensory testing	b		\$782.92	
95930	Visual evoked potential test	b		\$208.14	l
95933	Blink reflex test	b		\$139.60	
95934	H-reflex test H-reflex test	b	l	\$139.60 \$139.60	1
95936 95937	Neuromuscular junction test	Ь		\$208.14	
95950	Ambulatory eeg monitoring	Ь		\$879.80	l
95951	EEG monitoring/videorecord	b		\$3,063.61	
95953	EEG monitoring/computer	b		\$3,063.61	1
95954	EEG monitoring/giving drugs	b		\$602.24	
95955	EEG during surgery	b	1	\$602.24	1
95956	Eeg monitoring, cable/radio	b		\$602.24	1
95957	EEG digital analysis	b		\$602.24 \$879.80	l
95958 95961	EEG monitoring/function test Electrode stimulation, brain	Ь Б		\$782.92	
95962	Electrode stim brain add-on	b		\$782.92	l
95965	Meg, spontaneous	ь		\$11,658.94	
95966	Meg, evoked, single	b		\$7,124.91	1
95967	Meg, evoked, each addl	b	1	\$4,534.03	1
95970	Analyze neurostim, no prog			\$1,691.53	1
95971	Analyze neurostim, simple			\$1,691.53 \$1,691.53	1
95972	Analyze neurostim, complex Analyze neurostim, complex	1		\$1,691.53	
95973 95974	Cranial neurostim, complex			\$1,691.53	
95975	Cranial neurostim, complex			\$1,691.53	1
95990	Spin/brain pump refil & main		+	\$557.74	
95999	Neurological procedure	1	1	\$139.60	1
96000	Motion analysis, video/3d	1		\$777.26	1
96001	Motion test w/ft press meas	1		\$777.26 \$777.26	1
96002	Dynamic surface emg Dynamic fine wire emg	1	1	\$777.26	
96003	I Dynamic mic wire emg	1	ī	, 4111.20	•

See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 72 OF 78

	FAGE 12 OF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
96100 96105 96110 96111 96111 96115 96117 96150 96151 96151 96155 96520 96553 96154 96155 96570 96571 96900 96910 96912 96912 96913 96922 96999 98925 98927 98928 98927 98928 98929 99211 99201 99202 99203 99204 99205 99211 99212 99213 99214 99215 99211 99215 99211 99215 99211 99215 99211 99215 99211 99215 99211 99215 99211 99215 99211 99215 99211 99215 99211 99215 99211 99215 99215 99211 99215 99211 99215 99211 99215 99211 99215 99211 99215 99211 99215 99211 99215 99211 99215 99211 99215 99211 99215 99211 99215 99211 99215 99215 99211 99215 99215 99211 99215 99215 99215 99215 99211	Psychological testing Assessment of aphasia Developmental test, lim Developmental test, extend Neuropsych test battery Assess lth/behave, init Assess lth/behave, indiv Intervene hlth/behave, group Intervene hlth/behave, indiv Intervene hlth/behave, indiv Intervene hlth/behave, group Intervene hlth/behave, indiv Intervene hlth/behave, indiv Intervene hlth/behave, group Intervene hlth/behave, indiv Intervene hlth/behave, indiv Intervene hlth/behave, indiv Intervene hlth/behave, group Intervene hlth/behave, indiv Intervene hlth/behave, intervene hlth/behave, intervene hlth/behave, intervene hlth/behave, intervene hlth/behave, intervene hlth/behave, intervene hlth/behave, intervene hlth/behave, intervene hlth/behave, intervene hlth/behave, intervene hlth/behave, intervene hlth/behave, intervene hlth/behave, intervene hlth/behave, intervene hlth/beha	aaaaaaaaafffff	+ + + + + + + + + + + + + + + + + + + +	\$610.11 \$610.11 \$610.11 \$610.11 \$610.11 \$6220.26 \$220.26 \$220.26 \$220.26 \$220.26 \$220.26 \$220.26 \$220.26 \$1.295.44 \$1.295.44 \$1.295.44 \$1.295.44 \$1.295.45 \$1.295.40 \$1.295.40 \$1.295.40 \$1.295.40 \$1.295.40 \$1.295.40 \$1.295.40 \$1.295.40 \$1.295.40 \$1.295.40 \$1.295.40 \$1.295.40 \$211.64 \$290.03 \$177.6 \$89.01 \$95.20 \$100.98 \$146.92 \$14	

See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 73 OF 78

	PAGE 73 OF	78			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
A9518 A9521 A9600 A9605 A9700 C1010 C1011 C1012 C1013 C1014 C1015 C1016 C1017	I-131 sodium iodide solution Technetiumtc-99m exametazine Strontium-89 chloride Samarium sm153 lexidronamm Echocardiography Contrast Blood, L/R, Cmv-Neg Platelets, HLA-m, L/R, unit Platelet Conc, L/R, Irrad Platelet Conc, L/R, Unit Platelet, Aph/Pher, L/R, unit Plt, pher, L/R, CMV, irrad Blood, L/R, Froz/Degly/Washed Plt, Aph/Pher, L/R, Cmv-Neg			\$253.99 \$1,199.27 \$2,429.94 \$3,951.30 \$615.33 \$631.05 \$2,589.68 \$617.97 \$256.61 \$2,118.36 \$2,326.32 \$1,563.25 \$2,037.18	
C1018 C1020 C1021 C1022 C1088 C1091 C1092 C1096 C1122 C1167 C1178 C1207	Blood, L/R, Irradiated Rbc, Frz/Deg/Wsh, L/R, Irrad Rbc, L/R, Cmv Neg, Irrad Plasma, frz within 24 hour Laser Optic Tr Sys IN111 oxyquinoline,per0.5mCi IN 111 pentetate per 0.5 mCi Tc 99M Exametazime, Per Dose Tc 99M ARCITUMOMAB PER VIAL Epirubicin Hcl, 2 Mg Busulfan Iv, 6 Mg Octreotide Acetate Depot 1Mg		+	\$686.04 \$1,578.56 \$944.77 \$492.28 \$9,694.54 \$1,272.58 \$1,199.27 \$1,199.27 \$3,100.28 \$89.01 \$130.93	
C1300 C1305 C1348 C1716 C1718 C1719 C1720 C1774 C1775 C2616 C8900	Hyperbaric Oxygen Apligraf I-131 sol, per 1-6 mCi Brachytx seed, Gold 198 Brachytx seed, Iodine 125 Brachytx seed, Non-HDR Ir-192 Brachytx seed, Palladium 103 Darbepoetin alfa, non-esrd FDG, per dose (4-40 mCi/ml) Brachytx seed, Yttrium-90 MRA w/cont, abd			\$874.58 \$3,527.09 \$253.99 \$117.82 \$162.36 \$141.39 \$227.81 \$12.28 \$2,034.56 \$23,253.60 \$2,022.87 \$1,975.57	
C8901 C8902 C8903 C8904 C8905 C8906 C8907 C8908 C8909 C8910 C8911	MRA w/o cont, abd MRA w/o fol w/cont, abd MRI w/cont, breast, uni MRI w/o cont, breast, uni MRI w/o fol w/cont, brst, un MRI w/cont, breast, bi MRI w/o cont, breast, bi MRI w/o fol w/cont, breast, MRA w/cont, chest MRA w/o fol w/cont, chest			\$2,849.72 \$2,022.87 \$1,975.57 \$2,849.72 \$2,022.87 \$1,975.57 \$2,849.72 \$2,022.87 \$1,975.57 \$2,849.72 \$2,022.87	
C8912 C8913 C8914 C9000 C9003 C9009 C9010 C9019 C9020 C9105 C9108	MRA w/cont, lwr ext MRA w/o cont, lwr ext MRA w/o fol w/cont, lwr ext Na chromateCr51, per 0.25mCi Palivizumab, per 50 mg Baclofen Refill Kit-2000mcg Baclofen Refill Kit-4000mcg Caspofungin acetate, 5 mg Sirolimus tablet, 1 mg Hep B imm glob, per 1 ml Thyrotropin alfa, 1.1 mg			\$1,975.57 \$2,849.72 \$460.50 \$2,314.74 \$196.38 \$248.75 \$160.66 \$14.23 \$370.31	
C9109 C9110 C9111 C9112 C9113 C9114 C9115	Tirofiban hcl, 6.25 mg Alemtuzumab, per 10mg/ml Inj, bivalirudin, 250mg vial Perflutren lipid micro, 2ml Inj pantoprazole sodium, via Nesiritide, per 1.5 mg vial Inj, zoledronic acid, 2 mg Ertapenem sodium, per 1 gm			\$538.85 \$2,401.47 \$1,868.73 \$696.17 \$107.10 \$678.32 \$955.43 \$212.85	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 74 OF 78

	PAGE 14 OF				
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
C9119 C9120 C9121 C9200 C9121 C9503 C9701 C9503 C9708 C9711 D0150 D0240 D0250 D0260 D0272 D0274 D0277 D0460 D0472 D0473 D0473 D0474 D0480 D0502 D0999 D1510 D1515 D1550 D1555 D1550 D2970 D2999 D3460 D3999 D3460 D3999 D3460 D3999 D3460 D3991 D4263 D4264 D4268 D4271 D4273 D4355 D4361 D5911 D5912 D5983 D5984 D5985 D5987 D6920 D7111 D7140 D7210 D7220 D7230	Injection, pegfilgrastim Injection, fulvestrant Injection, argatroban Orcel, per 36 cm2 Dermagraft, per 37.5 sq cm Fresh frozen plasma, ea unit Stretta System Bard Endoscopic Suturing Sys Preview Tx Planning Software H.E.L.P. Apheresis System Comprehensve oral evaluation Intraoral occlusal film Extraoral first film Extraoral ea additional film Dental bitewings stwo films Dental bitewings four films Vert bitewings-sev to eight Pulp vitality test Gross exam, prep & report Micro exam, prep & report Micro exam, prep & report Other oral pathology procedu Unspecified diagnostic proce Space maintainer fxd unilat Fixed bilat space maintain Remove unilat space maintain Remove bilat space maintain Recement space maintain Recement space maintain Recoment space maintain Recement space maintain Recement space maintain Fixed bilat space maintain Recement space maintain Re	indicator	+ + + + + + + + + + + + + + + + + + +	\$13,164.84 \$822.82 \$66.94 \$5,332.88 \$2,713.30 \$361.36 \$9,694.54 \$8,420.35 \$3,238.60 \$7,124.91 \$1,290.91	Ology
D7230 D7240 D7241 D7250 D7260 D7261 D7291 D7940 D9630 D9930 D9940 D9950	Impact tooth remov part bony Impact tooth remov comp bony Impact tooth rem bony w/comp Tooth root removal Oral antral fistula closure Primary closure sinus perf Transseptal fiberotomy Reshaping bone orthognathic Other drugs/medicaments Treatment of complications Dental occlusal guard Occlusion analysis			\$1,290.91 \$1,290.91 \$1,290.91 \$1,290.91 \$1,290.91 \$1,290.91 \$1,290.91 \$1,290.91 \$1,290.91 \$1,290.91	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 75 OF 78

	PAGE 75 OF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
D9951 D9952 G0008 G0009 G0010 G0030 G0031 G0032 G0035 G0036 G0037 G0038 G0039 G0040 G0041 G0042 G0043 G0045 G0046 G0047 G0101 G0104 G0105 G0106 G0107 G0118 G0121 G0125 G0127 G0138 G0127 G0138 G0127 G0138 G0127 G0138 G0127 G0138 G0127 G0138 G0127 G0138 G0177 G0118 G0121 G0125 G0127 G0130 G0166 G0177 G0118 G0121 G0125 G0127 G0130 G0168 G0177 G0118 G0121 G0125 G0127 G0130 G0168 G0177 G0118 G0121 G0125 G0127 G0130 G0168 G0177 G0186 G0177 G0186 G0177 G0186 G0177 G0186 G0186 G0177 G0186 G0187 G0186 G0187 G0186 G0187 G0188 G0177 G0188 G0188 G0177 G0188 G0188 G0177 G0188 G0188 G0177 G0188 G0188 G0177 G0188 G0188 G0177 G0188 G0188 G0177 G0188 G0188 G0177 G0188 G0188 G0177 G0188 G0188 G0177 G0188 G0188 G0177 G0188 G0188 G0177 G0188 G0188 G0188 G0188 G0177 G0188	Limited occlusal adjustment Complete occlusal adjustment Admin influenza virus vac Admin pneumococcal vaccine PET imaging prev PET single PET imaging prev PET multple PET follow SPECT 78464 singl PET follow SPECT 78465 singl PET follow SPECT 78465 mult PET follow SPECT 78465 mult PET follow SPECT 78465 mult PET follow cornry angio sing PET follow cornry angio sing PET follow myocard perf sing PET follow myocard perf sing PET follow stress echo singl PET follow stress echo mult PET follow ventriculogm sing PET follow ventriculogm mult PET follow ventriculogm mult PET follow stress ECG singl PET following rest ECG mult CA screen;pelvic/breast exam CA screen;flexi sigmoidscope Colorectal scrn; hi risk ind Colon CA screen;barium enema Glaucoma scrn hgh risk direc Colon ca scrn not hi rsk ind PET image pulmonary nodule Trim nail(s) Single energy x-ray study Extrnl counterpulse, per tx Wound closure by adhesive Stereo radoisurgery,complete OPPS Service, sched team conf Dstry eye lesn,fdr vssl tech Diagnostic mammography digital Diagnostic mammography digital Diagnostic mammography digital PET img wholebod ydxlung PET img wholebod restag lung PET img wholebod restag lung PET img wholebod restag pea PET img wholebod restag mela PET img wholebod restag mela PET img wholebod restag mela PET img wholebod restag mela PET img wholebod restag lung PET img wholebod restag heaf pet imag wholbod reg dx head PET imag wholbod reg dx head PET imag wholbod reg dx head PET imag wholbod restag lymph PET imag wholbod restag lymph PET imag wholbod restag lymph PET imag wholbod restag pea PET imag wholbod restag pea PET imag wholbod restag pea PET imag wholbod restag pea PET imag wholbod restag pea PET imag wholbod restag head PET imag wholbod restag pea PET imag wholbod restag pea PET imag wholbod restag pea PET imag wholbod restag pea PET imag wholbod restag pea PET imag wholbod restag pea PET imag wholbod restag pea PET imag wholbod restag pea PET imag wholbod restag pea PET imag wholbod restag pea PET imag wholbod restag pea PET ima		+ + + + +	\$1,290.91 \$1,290.91 \$12,45 \$15.56 \$45.93 \$5,066.66 \$5,06	SAF
G0229 G0230 G0231 G0232	PET img metaboloc brain pres PET myocard viability post PET WhBD colorec; gamma cam PET whbd lymphoma; gamma cam	C C C		\$7,124.91 \$7,124.91 \$7,124.91 \$7,124.91	
G0233 G0234 G0236	PET whbd melanoma; gamma cam PET WhBD pulm nod; gamma cam Digital film convert diag ma	c c b		\$7,124.91 \$7,124.91 \$129.26	

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 76 OF 78

	PAGE 76	OF 78			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
G0237 G0238 G0239 G0242 G0243 G0244 G0245 G0246 G0247 G0248 G0251 G0252 G0253 G0256 G0257 G0258 G0261 G0262 G0264 G0268 G0262 G0268 G0272 G0273 G0274 G0288 G0292 G0293 G0293 G0294 J0130 J0151 J0287 J0587 J0587 J0587 J0587 J0587 J0587 J0587 J0587 J0587 J0585 J0587 J1565	Therapeutic procd strg endur Oth resp proc, indiv Oth resp proc, group Multisource photon ster plan Multisour photon stero treat Observ care by facility topt Initial foot exam pt lops Followup eval of foot pt lop Routine footcare pt w lops Demonstrate use home inr mon Provide test material, equipm Linear acc based stero radio PET imaging initial dx PET image brst dection recur PET image brst eval to tx Prostate brachy w palladium Unsched dialysis ESRD pt hos IV infusion during obs stay Ini for sacrolliac it anesth Prostate brachy w iodine see Sm intestinal image capsule Assmt otr CHF, CP, asthma Removal of impacted wax md Naso/oro gastric tube pl MD Pretx planning, non-Hodgkins Radiopharm tx, non-Hodgkins Radiopharm tx, non-Hodgkins Raeon, CTA for surg plan Adm exp drugs, clinical trial Non-cov surg proc, clin trial Non-cov proc, clinical trial Non-cov proc, clinical trial Abciximab injection Adenosine injection Amifostine Amphotericin b lipid complex Botulinum toxin type B Caspofungin acetate Cytomegalovirus imm IV /vial Dexrazoxane HCI injection Eptifibatide injection Filgrastim 300 mcg injection Filgrastim 480 mcg injection Filgrastim 480 mcg injection Infilkimab injection Interferon beta-1a Interferon beta-1a Interferon beta-1a Interferon beta-1a Interferon beta-1a Interferon beta-1a Interferon beta-1a Interferon beta-1a Interferon beta-1a Interferon beta-1b / .25 MG Leuprolide acetate /3.75 MG Nesiritide Octreotide acetate injection Oprelvekin injection Pamidronate disodium /30 MG Rho d immune globulin 50 mcg Rho(D) immune globulin 50 mcg Rho(D) immune globulin 50 mcg Rho(D) immune globulin 50 mcg Rho(D) immune globulin 50 mcg Rho(D) immune globulin 50 mcg Rho(D) immune globulin 50 mcg Rho(D) immune globulin 60 mcg Reteplase injection Trecteplase injection Trecteplase injection Tirofiban hydrochloride Inj trimetrexate glucoronate Verteporfin injection Tirofiban hydrochloride Inj trimetrexate glucoronate Verteporfin injection Eactor VIII (porcine)	c c c	+ + + +	\$129.26 \$129.26 \$129.26 \$129.26 \$7,124.91 \$22,165.41 \$1,950.76 \$95.20 \$169.82 \$777.26 \$5,829.47 \$7,124.91 \$7,124.91 \$7,124.91 \$7,124.91 \$22,825.13 \$1,306.63 \$175.05 \$546.05 \$21,576.13 \$3,238.60 \$95.20 \$175.05 \$341,506.37 \$14,249.82 \$40,000.00 \$3,238.60 \$9777.26 \$2,143.56 \$388.60 \$777.26 \$2,143.56 \$388.60 \$1,103.81 \$102.08 \$9.95 \$41.29 \$160.66 \$1,160.66 \$1,160.67 \$1,160.79 \$5553.09 \$35.61 \$515.12 \$790.48 \$179.51 \$2.38 \$144.81 \$180.40 \$683.64 \$486.63 \$930.54 \$678.32 \$310.98 \$669.41 \$799.96 \$11.86 \$3310.98 \$669.41 \$799.96 \$11.86 \$54.61 \$175.65 \$3,100.16 \$6,760.57 \$1,858.67 \$1,210.62 \$320.43 \$955.43 \$955.43 \$97.93 \$7.13	
J7192	Factor viii recombinant	1	1	1 94.70	3

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 77 OF 78

	PAGE 17 OF	70			
CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
J7193	Factor IX non-recombinant			\$2.38	
J7194	Factor ix complex			\$2.14	
J7195	Factor IX recombinant			\$4.75	
J7197	Antithrombin iii injection			\$4.75	
J7198	Anti-inhibitor			\$1.88	
J7320	Hylan G-F 20 injection			\$579.21	
J7330	Cultured chondrocytes implnt		,	\$22,781.67	
J7502	Cyclosporine oral 100 mg			\$8.53	
J7504	Lymphocyte immune globulin			\$818.95	
J7505	Monoclonal antibodies			\$1,704.38	
J7507	Tacrolimus oral per 1 MG			\$4.77	
J7511	Antithymocyte globuln rabbit			\$645.68	
J7513	Daclizumab, parenteral			\$1,077.70	
J7517	Mycophenolate mofetil oral			\$3.51 \$14.23	
J7520 J8520	Sirolimus, oral Capecitabine, oral, 150 mg			\$7.13	
J8560	Etoposide oral 50 MG	}	l	\$135.30	
J8700	Temozolmide		1	\$14.23	
J9001	Doxorubicin hcl liposome inj	1		\$1,075.32	
J9010	Alemtuzumab injection	ļ		\$2,401.47	
J9015	Aldesleukin/single use vial			\$1,785.10	
J9017	Arsenic trioxide	1	1	\$147.27	1
J9040	Bleomycin sulfate injection	!		\$780.98	
J9045	Carboplatin injection	(•	\$365.56	
J9050	Carmus bischl nitro ini			\$375.07	
J9060	Cisplatin 10 MG injection			\$104.44 \$194.66	
J9065	Inj cladribine per 1 MG			\$474.75	
J9150 J9151	Daunorubicin Daunorubicin citrate liposom			\$712.14	1
J9151 J9160	Denileukin diffitox, 300 mcg			\$2,971.99	
J9165	Diethylstilbestrol injection	į.	,	\$496.11]
J9170	Docetaxel			\$954.28	1
J9185	Fludarabine phosphate inj		l	\$804.71	1
J9200	Floxuridine injection]	\$543.59	•
J9201	Gemcitabine HCI			\$318.08	(
J9202	Goserelin acetate implant		1	\$1,362.56 \$429.65	1
J9206 J9208	Irinotecan injection Ifosfomide injection		1	\$470.02	
J9209	Mesna injection			\$123.45	l
J9205 J9211	Idarubicin hcl injection) .		\$1,191.64	1
J9216	Interferon gamma 1-b inj			\$745.38	!
J9217	Leuprolide acetate suspnsion	1	1	\$1,609.42	ł
J9218	Leuprolide acetate injection	1		\$189.91	Į.
J9219	Leuprolide acetate implant			\$22,005.69	l
J9245	Inj melphalan hydrochl 50 MG	l		\$1,110.94	1
J9265	Paclitaxel injection			\$567.33	1
J9266	Pegaspargase/singl dose vial			\$2,157.77 \$4,871.03	1
J9268	Pentostatin injection	1		\$277.74	1
J9280	Mitomycin 5 MG inj Mitoxantrone hydrochl / 5 MG		1	\$716.89	1
J9293 J9310	Rituximab cancer treatment		1	\$1,345.95	1
J9350	Topotecan			\$1,889.54	
J9355	Trastuzumab			\$154.29	1
J9357	Valrubicin, 200 mg)	\$873.55	
J9390	Vinorelbine tartrate/10 mg		1	\$263.50	[
J9600	Porfimer sodium	1		\$7,254.31	
M0064	Visit for drug monitoring			\$120.03 \$455.61	1
P9010	Whole blood for transfusion	1		\$151.87	
P9012 P9016	Cryoprecipitate each unit RBC leukocytes reduced	1	1	\$617.97	
P9017	One donor fresh frozn plasma		1	\$492.28	
P9019	Platelets, each unit		1	\$214.73	
P9020	Plaelet rich plasma unit	Į	1	\$277.56	
P9021	Red blood cells unit	Į.	1	\$447.75	
P9022	Washed red blood cells unit	1	1	\$832.67 \$644.16	
P9023	Frozen plasma, pooled, sd	I	I	1 4044,10	1

¹ See end of table.

TABLE F. — OUTPATIENT FACILITY NATIONWIDE CHARGES BY CPT/HCPCS CODE PAGE 78 OF 78

CPT/ HCPCS Code	Description	Status/ Usage Indicator ¹	Multiple Surgery Reduction Applies	Charge	Charge Method- ology
P9031 P9032 P9033 P9034 P9035 P9036 P9037 P9038 P9039 P9040 P9041 P9044 P9045 P9046 P9047 P9048 P9050 Q0035 Q0081 Q0083 Q0084 Q0085 Q0091 Q0136 Q0187 Q2005 Q2006 Q2011 Q2017 Q2019 Q2022 Q3003 Q3008 Q3011 Q3022 Q3023 Q3025	Platelets leukocytes reduced Platelets, irradiated Platelets, pheresis Platelet pheres leukoreduced Platelet pheres leukoreduced Platelet pheres leukoreduced Platelet pheres leukoredu irrad RBC irradiated RBC deglycerolized RBC leukoreduced irradiated Albumin (human), 5%, 50ml Plasma protein fract,5%,50ml Cryoprecipitatereducedplasma Albumin (human), 25%, 20 ml Albumin (human), 25%, 20 ml Albumin (human), 25%, 50ml Plasmaprotein fract,5%,250ml Granulocytes, pheresis unit Cardiokymography Infusion ther other than che Chemo by other than infusion Chemotherapy by infu	b d d d	+	\$256.61 \$387.54 \$617.97 \$2,118.36 \$2,118.36 \$2,299.04 \$2,105.25 \$562.98 \$950.52 \$269.69 \$481.80 \$193.76 \$1,343.28 \$290.66 \$725.31 \$2,409.00 \$6,470.26 \$543.02 \$734.50 \$1343.28 \$57.80 \$5,091.79 \$66.470.26 \$543.02 \$734.50 \$1,343.57 \$54.87 \$57.80 \$5,091.79 \$62.60 \$1,220.13 \$2,38 \$479.50 \$3,273.46 \$3,273.46 \$4,75 \$949.52 \$2,012.99 \$389.30 \$45.93 \$164.90 \$164.90 \$227.88	

Key to Status/Usage Indicators:

- a Cannot be billed by VA non-provider-based clinics, because the charge is included in the associated professional charge.
- b Cannot be billed by VA non-provider-based clinics, because a technical component charge from the professional charge table applies.
- c Can be billed by VA non-provider-based clinics.
- d Cannot be billed by VA non-provider-based clinics, because a different code is used for professional billing.
- e Cannot be billed by VA non-provider-based clinics, because a stand-alone charge from the professional charge table applies.
- f Can be billed for patients who are subsequently admitted to the hospital.

All other procedures: Cannot be billed by VA non-provider-based clinics, because the service is generally considered facility only, or else the facility charge is included in the professional non-facility practice expense units.

Charge Methodology:

No entry: Charge derived using the methodology based on Medicare Ambulatory Payment Classifications. All other entries: See Supplementary Table 1, Reasonable Charges Data Sources - V2.0.

¹ See end of table.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 1 OF 173

	Charge Method- ology	
	Total Expense RVUs	
	Non- Facility Practice Expense RVUs	0.002 0.033
	Facility Practice Expense RVUs	7.22.23 7.23.43 7.2
	Work Expense RVUs	0.00 1.127 1.1
	Status/ Usage Indicator	
221212122	Conversion Factor/GAAF Category	Miscellaneous Medical Surgery
	CPT/HCPCS Code Description	Extracorp shock wave tx, ft Fna wo image Acne surgery Drainage of skin abscess Drainage of skin abscess Drainage of skin abscess Drainage of pilonidal cyst Drainage of pilonidal cyst Remove foreign body Remove foreign body Remove foreign body Drainage of hematomar/fluid Puncture drainage, wound Debride skin add-on Debride skin, fx Debride skin/muscle/bone, fx Debride skin/muscle/bone Tim skin lesion Tim skin lesion Tim skin lesion Biopsy, skin add-on Remova of skin lesion Biopsy, skin lesion Shave skin lesion
	Modifier	
	CPT/ HCPCS Code	00207 10020 10020 10060 10060 10080 10080 10120 10120 10140 11000

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 2 OF 173

Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense	Total Expense RVUs	Charge Method- ology
						RVUs		
		Surgery		2.06	2.84	1.42		
	Exc tr-ext b9+marg > 4.0 cm Exc h-f-nk-sp b9+marg 0.5 <	Surgery		0.98	1.81	. 6.		
	Exc h-f-nk-sp b9+marg 0.6-1	Surgery		1.42	2.12	1.18		
		Surgery		1.63	2.30	1.38		
		Surgery		2.01	2.66	1.49		
	Exc h-f-nk-sp b9+marg 3.1-4	Surgery		2.43	2.93	1.64		
	Exc h-f-nk-sp b9+marg > 4 cm	Surgery		3.78	3.75	2.15		
	Exc face-mm b9+marg 0.5 < cm	Surgery		00.1	2.27	14.		
		Surgery		1.40	2.40	2.03		
	Excrace-mm by+marg 1.1-z cm	Surgery		27.7	3.00	8.6		
		Singer		3.14	3.64	2.28		
	Exclade mm b9+marg > 1 + cm	Surgery		4.49		2.88		
	Removal, sweat gland lesion	Surgery		2.73		0.98		
	Removal, sweat gland lesion	Surgery		3.95		1.43		
	Removal, sweat gland lesion	Surgery		2.51		0.95		
	Removal, sweat gland lesion	Surgery		3.95		1.57		
	Removal, sweat gland lesion	Surgery		3.25		1.23		
	Removal, sweat gland lesion	Surgery	···	4.41	5.69	1.72		
	Exc tr-ext mig+marg 0.5 < cm	Surgery		1.31	2.53	0.99		
	Exc tr-ext mig+maig 0.0-1 cm	Alacino		90.1	2,73	1 20		
	Exc tr-ext mig+marg 1.1-z cm Exc tr-ext mig+marg 2.1-3 cm	Surgery		2.19	2.73	1.35		
	Exc treat mid+marg 2.1 o cm	Surger		2.40	3.27	1,41		
	Exc tr-ext mla+marg > 4 cm	Surgery		3.43	3.96	1.76		
	Exc h-f-nk-sp mlg+marg 0.5 <	Surgery		1.19	2.49	0.97		
		Surgery		1.76	2.60	1.27		
	Exc h-f-nk-sp mig+marg 1.1-2	Surgery	****	2.03	70.0	74.1		
	Exc n-r-nk-sp mig+marg 2.1-3	Suiderly		90.7	3.62	184		
	Exc h-f-nk-sp mig-marg 5: 1-4 Exc h-f-nk-sp mig+mar > 4 cm	Security	•	4.30	4.56	2.44		
	Exc face-mm malio+marg 0.5 <	Surgery	***************************************	1.35	2.54	1.14		
	Exc face-mm malig+marg 0.6-1	Surgery		2.16	2.92	1.57		
	Exc face-mm malig+marg 1.1-2	Surgery		2.59	3.30	1.77		
	Exc face-mm malig+marg 2.1-3	Surgery		3.10	3.70	2.01		
	Ď,	Surgery		4.03	4.63	2.56		
	Exc face-mm mlg+marg > 4 cm	Surgery		5.95	5.73	3.60		
	Trim nail(s)	Surgery		0.17	0.25	0.07		
	Debride nail, 1-5	Surgery		0.32	0.34	0.13		
	Debride nail, 6 or more	Surgery		0.54	44.0	0.21		
	Removal of nail plate	Surgery		0.13	0.0	0.44		
	Remove nail plate, add-on	Surgery		0.37	0.30	0.23		
	Digiti plood north mider right Removal of nail bed	Surgery		1.86	1.72	0.77		
			_					

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 3 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	0.55 0.00
Facility Practice Expense RVUs	12.22 12.22 12.23 12.23 12.23 12.23 12.23 12.23 12.23 12.23 13.23 13.33
Work Expense RVUs	1. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2.
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Andens Anders An
CPT/HCPCS Code Description	Biopsy, nail unit Repair of nail bed Reconstruction of nail bed Reconstruction of nail bed Removal of pilonidal lesion Removal of pilonidal lesion Removal of pilonidal lesion Removal of pilonidal lesion Injection into skin lesions Added skin lesions injection Correct skin color defects Correct skin color defects Correct skin color defects Therapy for contour defec
Modifier	
CPT/ HCPCS Code	1755 1766 1766 1777 1770 1771 1770 11900 11900 11920 11920 11920 11920 11920 11920 11920 11930 12004 12005 12005 12015 12016 12017 12018 1

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 4 OF 173

	,								
CPT/	<u>!</u>		Conversion	Status/	Work	Facility Practice	Non- Facility	Total	Charge
HCPCS Code	Modifier	CP1/HCPCS Code Description	ractof/sAAr Category	Usage Indicator	RVUs	Expense RVUs	Fractice Expense RVUs	Expense RVUs	ology
12037		Layer closure of wound(s)	Surgery		4.67	5.62	2.80		
12041		Layer closure of wound(s)	Surgery		2.3/	3.17	1.41		
12044		Layer closure of wound(s)	Surgery		3.14	3.26	1.60		
12045		Layer closure of wound(s)	Surgery		3.64	3.58	1.87		
12046		Layer closure of wound(s)	Surgery		4.25	5.53	2.55		
12051		Layer closure of wound(s) Layer closure of wound(s)	Surgery		2.47	3.16	1.41		
12052		Layer closure of wound(s)	Surgery		2.77	3.12	1.38		
12053		Layer closure of wound(s)	Surgery		3.12	3.26	4. 2. 4. 2.		
12054		Layer closure of wound(s)	Surgery		4,43	4.60	2.19		
12056		Layer closure of wound(s)	Surgery		5.24	6.62	3.05		
12057		Layer closure of wound(s)	Surgery		5.96	6.14	3.73		
13100		Repair of wound or lesion	Surgery		3 65	3.76	4 6		
13102		Repair wound/lesion add-on	Surgery		1.24	0.76	0.58		
13120		Repair of wound or lesion	Surgery		3.30	3.60	1.88		
13121		Repair of wound or lesion	Surgery		4.33	3.99	2.39		
13122		Repair wound/lesion add-on	Surgery		3.79	3 88	0.65		
13132		Repair of wound or lesion	Surgery		5.95	4.72	3.25		
13133		Repair wound/lesion add-on	Surgery	-	2.19	1.22	1.05		
13150		Repair of wound or lesion	Surgery		3.81	5.29	2.64		
13151		Repair of wound or lesion	Surgery		6.33	6.01	3.98		
13153		Repair wound/lesion add-on	Surgery		2.38	1.37	1.16		
13160		Late closure of wound	Surgery		10.48	6.33	6.33		
14000		Skin tissue rearrangement Skin tissue rearrangement	Surgery		8 47	20.00	96.00		
14020		Skin tissue rearrangement	Surgery		6.59	8.10	5.35		
14021		Skin tissue rearrangement	Surgery		10.06	9.53	7.12		
14040		Skin tissue rearrangement	Surgery		11.40	11.01	7.03 8 94		
14041		Skin tissue rearrangement	Surgery		8.50	9.48	7.84		
14061		Skin tissue rearrangement	Surgery		12.29	12.05	9.77		
14300		Skin tissue rearrangement	Surgery		11.76	11.44	9.36		
14350		Skin tissue rearrangement	Surgery		9.61	6.36	6.36		
15000		Skin graft Skin graft add-on	Surgery		9.4	1.00	0.42		
15050		Skin pinch graft	Surgery		4.30	5.12	3.99		
15100		Skin split graft	Surgery		9.05	11.70	8.09		
15101		Skin split graft add-on	Surgery		1.72	3.27	1.48		
15120		Skin split grant	Surgery		2.67	4.19	1.85		
15200		Skin full graft	Surgery		8.03	09.6	5.54	_	

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 5 OF 173

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
15201 15220 15240 15241 15240 15342 15343 15343 15343 15572 15574 15600 15600 15600 15610 15732 15734 15734 15736 15736 15756 15760 15760 15760 15760 15770 15781 15782 15783		Skin full graft add-on Skin full graft add-on Skin full graft add-on Skin full graft add-on Skin full graft add-on Skin full graft add-on Skin full graft add-on Skin full graft add-on Skin full graft add 25 cm Culture skin graft add 25 cm Skin homograft add-on Skin heterograft add-on Skin heterograft add-on Skin heterograft add-on Form skin pedicle flap Form skin pedicle flap Form skin pedicle flap Form skin pedicle flap Form skin pedicle flap Form skin pedicle flap Skin graft Skin graft Skin graft Transfer skin pedicle flap Skin graft Skin graft Transfer skin pedicle flap Skin graft Form skin pedicle flap Skin graft Skin graft Transfer skin graft, trunk Muscle-skin graft, trunk Auscle-skin graft, trunk Muscle-skin graft, trunk Muscle-skin graft, trunk Muscle-skin graft, trunk Auscle-skin graft, trunk Muscle-skin graft, trunk Muscle-skin graft, trunk Auscle-skin graft, trunk Muscle-skin graft, trunk Auscle-skin graft, trunk Muscle-skin graft, trunk Muscle-skin graft, trunk Ausclo-skin graft, trunk Ausclo-skin graft, trunk Muscle-skin graft, trunk Muscle-skin graft, trunk Muscle-skin graft, trunk Auscle-skin graft, trunk Muscle-skin urgery Surger		1.877 1.877 1.877 1.877 1.877 1.877 1.878	20093 2019	0.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0			

NOTES: OPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 6 OF 173

Charge Method- ology	M M DR M M DR M DR M DR	PHCS PHCS PHCS PHCS	
Total Expense RVUs	18.73 2141 18.73 49.50 54.85	12.05 20.08 13.17 24.10	<u></u>
Non- Facility Practice Expense RVUs	7.68 7.68 7.68 7.68 7.68 7.68 7.68 6.93 6.93 6.93	6.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00	6.62 9.80 9.59 13.95 1.55 1.55
Facility Practice Expense RVUs	6.09 6.607 7.12 7.12 7.69 8.06 7.68 7.68 6.93 6.93 6.93 6.93 6.93	86.0. 0. 4.2.5. 8. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4. 4.	5.92 9.80 9.51 13.95 5.15
Work Expense RVUs	55.38 57.25 57.25 50.77 50.75 60	23.26 23.26 23.26 23.26 23.26 20.00	9.34 11.46 12.69 21.57 7.54
Status/ Usage Indicator			
Conversion Factor/GAAF Category	Surgery Surger	Surgery Surgery	Surgery Surgery Surgery Surgery Surgery
CPT/HCPCS Code Description	Salabrasion Plastic surgery, neck Revision of lower eyelid Revision of upper eyelid Revision of upper eyelid Revision of upper eyelid Removal of forehead wrinkles Removal of forehead wrinkles Removal of face wrinkles Removal of show wrinkles Removal of skin wrinkles Removal of skin wrinkles Removal of skin wrinkles Removal of skin wrinkles Excise excessive skin tissue Excise excessive skin tissue Excise excessive skin tissue Excise excessive skin tissue Excise excessive skin tissue Excise excessive skin tissue Excise excessive skin tissue Excise excessive skin tissue Excise excessive skin tissue Excise excessive skin tissue Excise excessive skin tissue	Excise excessive skin tissue Excise excessive skin tissue Graft for face nerve palsy Graft for face nerve palsy Graft for face nerve palsy Graft for face nerve palsy Graft for face nerve palsy Flap for face nerve palsy Skin and muscle repair, face Removal of sutures Dressing change, not for burn Test for blood flow in graft Suction assisted lipectomy Suction assisted lipectomy Suction assisted lipectomy Suction assisted lipectomy Suction assisted lipectomy Suction assisted lipectomy Removal of tail bone ulcer Removal of tail bone ulcer Remove sacrum pressure sore Remove sacrum pressure sore Remove sacrum pressure sore Remove sacrum pressure sore Remove sacrum pressure sore Remove sacrum pressure sore Remove sacrum pressure sore Remove sacrum pressure sore	Kemove hip pressure sore Remove thigh pressure sore
Modifier			
CPT/ HCPCS Code	15811 15820 15821 15821 15823 15825 15826 15828 15838 15833 15833 15833 15833 15835	15839 15840 15840 15845 15845 15845 15850 15873 15878 15933 15933 15933 15934 15935 15936	15940 15941 15944 15945 15946

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 7 OF 173

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 8 OF 173

Charge Method- ology	MDR Misc
Total Expense RVUs	0.0 4.6
Non- Facility Practice Expense RVUs	0.00 0.00
Facility Practice Expense RVUs	0.38 0.38 0.39
Work Expense RVUs	2.7.
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Cryotherapy of skin Skin peel therapy Hair removal by electrolysis Skin tissue procedure Drainage of breast lesion Drainage of breast lesion add-on Indision of breast lesion add-on Indision of breast lesion of breast percut win mage Bx breast percut win mage Bx breast percut win mage Bx breast percut win mage Bx breast percut win mage Bx breast percut win mage Bx breast percut win mage Bx breast percut win mage Bx breast percut win mage Bx breast percut win mage Bx breast percut win mage Bx breast percut win mage Bx breast percut fissue Excision, add breast lesion Excision, add breast lesion Excision, add breast lesion Excision, add breast lesion Excision, add breast lesion Excision, add breast lesion Removal of breast Removal of breast Removal of breast Femoval of breast Place needle wire, breast Place needle wire, breast Place needle wire, breast Place needle wire, breast Place needle wire, breast Enlarge breast clip, percut Suspension of breast Enlarge breast with implant Removal of breast prosthesis Breast reconstruction Breast reconstruction Breast reconstruction Breast reconstruction
Modifier	
CPT/ HCPCS Code	17340 17340 17380 17380 19000 19000 19000 19100 19110 19110 19110 19110 19110 19120 19182 19182 19182 1920 1920 1920 1920 19318 19324 19325 19355 19355 19355 19366

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 9 OF 173

Charge Method- ology	Wisc
Total Expense RVUs	25.83
Non- Facility Practice Expense RVUs	20.08 6.08
Facility Practice Expense RVUs	22.08 20.05 20
Work Expense RVUs	29.22 29.28 29.38 29.38 20.38 20.21 2.12 2.12 3.32 2.23 3.32 2.23 3.32 2.23 3.32 2.23 3.32 2.23 3.32 2.23 3.23 3.23 3 3.2
Status/ Usage Indicator	*
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Breast reconstruction Breast reconstruction Surgery of breast capsule Removal of breast capsule Removal of breast capsule Removal of breast reconstruction Design custom breast implant Breast surgery procedure Incision of abscess Incision of abscess Explore wound, abdomen Explore wound, abdomen Explore wound, abdomen Explore wound, abdomen Explore wound, extremity Excise epiphyseal bar Muscle biopsy Deep muscle biopsy Needle biopsy, muscle Bone biopsy, trocar/needle Bone biopsy, trocar/needle Bone biopsy, trocar/needle Bone biopsy, trocar/needle Bone biopsy, trocar/needle Bone biopsy, trocar/needle Bone biopsy, trocar/needle Bone biopsy, trocar/needle Bone biopsy, trocar/needle Bone biopsy, trocar/needle Bone biopsy, trocar/needle Bone biopsy, trocar/needle Bone biopsy, trocar/needle Bone biopsy, trocar/needle Bone biopsy in trocar/needle Bone biopsy, trocar/needle Bone bio
Modifier	
CPT/ HCPCS Code	19368 19379 19379 19379 19379 19380 19380 19499 20102 20102 20102 20102 20102 20102 20220

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 10 OF 173

Charge Method- ology		MDR	MDR	Misc
Total Expense RVUs		3.37	5.12	2.18
Non- Facility Practice Expense RVUs	1.82 6.56 6.56 6.56 6.56 6.56 6.56 6.56 6.5	6.42	1.59 2.24 29.76	28.28 28.28 28.28 28.28 28.39 28.39 28.39 28.39 29.35 20.35 20.05 20.35 20.05
Facility Practice Expense RVUs	1.8.20 1.3.20 1.	0.42	1.49 1.59 2.24 29.76	28.13 28.149 28.149 39.2148 39.2148 39.24 28.24 39.24 39.24 39.35 39.35 39.35
Work Expense RVUs	255 644 746 644 746 746 746 746 746 746 746	5.53 18	2.79 3.02 1.26 39.21	39.05 40
Status/ Usage Indicator				
Conversion Factor/GAAF Category	Surgery Surger	Surgery	Surgery Surgery Surgery Surgery Surgery	Surgery Surgery
CPT/HCPCS Code Description	ce ce ce ce ce co co co co co co co co co co co co co		t t t sle scovasc	E
Modifier				
CPT/ HCPCS Code	20690 20692 20693 20694 20892 20805 20816 20827 20827 20827 20900 20910 20910 20920 20920 20920 20920 20920 20920	20926 20930 20931	20936 20937 20938 20950 20955	20956 20957 20962 20962 20970 20973 20974 20978 20979 21010 21015 21025 21026 21026 21030 21030

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 11 OF 173

Charge Method- ology	PHCS
Total Expense RVUs	10.04
Non- Facility Practice Expense RVUs	0.22.00 0.26.00 0.2
Facility Practice Expense RVUs	0.8.7.00 0.9.00
Work Expense RVUs	6.17 6.17
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surgery
CPT/HCPCS Code Description	Excise max/zygoma mlg tumor Excise mandible lesion Removal of law bone lesion Atenoval of law bone lesion Removal of law bone lesion Remove mandible cyst complex Excise lwr law cyst wirepair Remove mandible cyst complex Excise lwr law cyst wirepair Remove law joint artilage Remove law joint cartilage Remove law joint cartilage Remove coronoid process Prepare face/oral prosthesis Prepare fac
Modifier	
CPT/ HCPCS Code	21034 21046 21046 21046 21046 21046 21047 21048 21060 21080 21080 21080 21080 21080 21120 21120 21121 21121 21121 21121 21122 21122 21123 21124 21125 21125 21125 21126 21127

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 12 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	88 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
Facility Practice Expense RVUs	25.59 26.69 26.69 27.20
Work Expense RVUs	28.28 28.28 28.28 29.99 39.90 39.90 39.90 39.90 39.90 39.90 39.90 39.90 39.90 39.90 39.90 39.90 39.90 39.90 39.90 39.90 39.90 39.90
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Reconstruct midface, lefort Reconstruct midface, lefort Reconstruct orbit/forehead Reconstruct entire forehead Reconstruct entire forehead Reconstruct cranial bone lesion Reconstruct cranial bone Reconstruct cranial bone Reconstruct cranial bone Reconstruct cranial bone Reconstruct cranial bone Reconstruct cranial bone Reconstruct or amid bone Reconstruct paw w/graft Reconst lwr jaw w/graft Reconst lwr jaw w/graft Reconst lwr jaw w/graft Reconst lwr jaw w/graft Reconstruct upper jaw bone Augmentation of facial bones Reconstruct upper jaw bone Reconstruct or facial bones Reconstruct of graft Ear cartilage graft Ear cartilage graft Ear cartilage graft Reconstruction of jaw joint Reconstruction of jaw joint Reconstruction of jaw joint Reconstruction of jaw Reconstruction of jaw Reconstruction of jaw Reconstruction of jaw Reconstruction of jaw Reconstruction of jaw Reconstruction of jaw Reconstruction of jaw Reconstruction of jaw Reconstruction of jaw Reconstruction of jaw Reconstruction of jaw Reconstruction of jaw Reconstruction of jaw Reconstruction of jaw Reconstruction of jaw Reconstruction of jaw Reconstruction of jaw Revise eye sockets Revise eye sockets Revise eye sockets Revise eye sockets Revise eye sockets Revise eye sockets Revision of eyelid Revision of eyelid Revision of jaw muscle/bone Revision of jaw muscle/bone
Modifier	
CPT/ HCPCS Code	21159 21175 21175 21176 21177 21188 21188 21188 21188 21188 21188 21208

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 13 OF 173

Charge Method- ology	Misc
Total Expense RVUs	14.84
Non- Facility Practice Expense RVUs	000 600 600 600 600 600 600 600 600 600
Facility Practice Expense RVUs	2228.4 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
Work Expense RVUs	2001 2011 2011 2012 2013 2014 2015 2016 2016 2016 2016 2016 2016 2016 2016
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Cranio/maxillofacial surgery Treatment of nose fracture Treatment of nose fracture Treatment of nose fracture Treatment of nose fracture Treatment of nose fracture Treat nasal septal fracture Treat nasal septal fracture Treat nasoethmoid fracture Treat nasoethmoid fracture Treat nasoethmoid fracture Treat nasoethmoid fracture Treat nose/jaw fracture Treat nose/jaw fracture Treat nose/jaw fracture Treat nose/jaw fracture Treat nose/jaw fracture Treat nose/jaw fracture Treat nose/jaw fracture Treat nose/jaw fracture Treat nose/jaw fracture Treat nose/jaw fracture Treat nose/jaw fracture Treat seek bone fracture Treat cheek bone fracture Treat seek bone fracture Treat cheek bone fracture Treat see socket fracture Treat see socket fracture Treat eye socket fracture Treat eye socket fracture Treat eye socket fracture Treat eye socket fracture Treat eye socket fracture Treat eye socket fracture Treat eye socket fracture Treat eye socket fracture Treat anouth noof fracture Treat craniofacial fracture Treat craniofacial fracture Treat craniofacial fracture Treat craniofacial fracture Treat craniofacial fracture Treat craniofacial fracture Treat dental ridge fracture Treat dental ridge fracture Treat lead and raidge fracture
Modifier	
CPT/ HCPCS Code	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 14 OF 173

Charge Method- ology	Misc	S A A	Misc
Total Expense RVUs	30.71	29.64	31.97
Non- Facility Practice Expense RVUs	4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	7.01 7.45 12.48 9.85 1.08 4.71 7.06	10.26
Facility Practice Expense RVUs	9.39 9.30	7.95 7.95 12.48 9.85 2.38 7.06 2.92	10.26
Work Expense RVUs	86.50 8 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	5.68 16.50 7.77 2.25 6.86 6.86 6.86	7.41
Status/ Usage Indicator			
Conversion Factor/GAAF Category	Surgery Surger	Surgery Surgery Surgery Surgery Surgery Surgery Surgery	Surgery Surgery Surgery Surgery
CPT/HCPCS Code Description	Treat lower jaw fracture Treat lower jaw fracture Treat lower jaw fracture Treat lower jaw fracture Treat lower jaw fracture Treat lower jaw fracture Treat lower jaw fracture Treat lower jaw fracture Treat lower jaw fracture Reset dislocated jaw Repair dislocated jaw Repair dislocated jaw Repair dislocated jaw Repair dislocated jaw Treat hyoid bone fracture Treat hyoid bone fracture Treat hyoid bone fracture Interdental wiring Head surgery procedure Drain neck/chest lesion Drain neck/chest lesion Drain chest lesion Drain chest lesion Drain chest lesion Remove lesion, neck/chest Remove lesion, neck/chest Remove lesion, neck/chest Removal of rib Partial removal of rib Removal of rib		cedure ck ck
Modifier			
CPT/ HCPCS Code	21452 21453 21454 21461 21461 21465 21465 21465 21489 21489 21489 21489 21489 21500 21500 21500 21550	21720 21725 21740 21740 21743 21750 21800 21805 21805	21825 21899 21920 21925

NOTES. CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 15 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	262.88 262.86 262.66 262.66 263.66 26
Facility Practice Expense RVUs	4 £ £ 8 8 8 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Work Expense RVUs	2.152 2.152
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Remove lesion, back or flank Remove tumor, back Remove part of neck vertebra Remove part, thorax vertebra Remove part, thorax vertebra Remove part, thorax vertebra Remove part, thorax vertebra Remove part, thorax vertebra Remove part, thorax vertebra Remove part, thorax vertebra Remove part, thorax vertebra Remove part, thorax vertebra Revision of neck spine Revision of thorax spine Revision of thorax spine Revision of thorax spine Revision of thorax spine Revision of thorax spine Revision of thorax spine Revision of thorax spine Revision of thorax spine Revision of thorax spine Revision of thorax spine Revision of thorax spine fracture Treat spine fusion Neck spine fusion Neck spine fusion Spine & skull spinal fusion Neck spine fusion Spine & skull spinal fusion Neck spine fusion Spine fusion Spine fusion Spine fusion Spine fusion Spine fusion Spine fusion of spine Fusion of spine
Modifier	
CPT/ HCPCS Code	21933 22100 22100 22100 22100 22110 22210 22222 22222 22222 22222 22222 22222 2222

NOTES. CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 16 OF 173

Charge Method- ology	M MDR Misc	
Total Expense RVUs	9.74	
Non- Facility Practice Expense RVUs	23.15 16.75 18.75 20.27 20.27 20.58 8.32 8.32 8.32 8.32 8.32 8.32 8.32 8.3	4 2 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
Facility Practice Expense RVUs	23.15 16.75 20.27 18.75 20.27 20.58 8.32 8.32 6.78 8.99 6.24 6.24 6.51 7.21 7.21 7.21 7.21 8.35 8.35 8.35 8.35 8.35 8.35 8.35 8.35	85.4 80.6 10.6
Work Expense RVUs	36.27 26.27 30.27 30.27 31.83 31.83 36.48 36.48 36.48 36.69 37.49	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
Status/ Usage Indicator		
Conversion Factor/GAAF Category	Surgery Surger	Aubūns Au
CPT/HCPCS Code Description	Fusion of spine Fusion of spine Fusion of spine Fusion of spine Fusion of spine Kyphectomy, 1-2 segments Kyphectomy, 3 or more Exploration of spinal fusion Insert spine fixation device Insert spine fixation device Insert spine fixation device Insert spine fixation device Insert spine fixation device Insert spine fixation device Insert spine fixation device Insert spine fixation device Insert spine fixation device Remove spine fixation device Remove spine fixation device Remove spine fixation device Remove spine fixation device Remove spine fixation device Remove spine fixation device Remove spine fixation device Spine surgery procedure	Remove abdominal wall lesion Removal of calcium deposits Release shoulder joint Drain shoulder lesion Drain shoulder bursa Drain shoulder bursa Drain shoulder bursa Drain shoulder surgery Exploratory shoulder surgery Biopsy shoulder tissues Biopsy shoulder tissues Removal of shoulder lesion Removal of shoulder lesion Remove turnor of shoulder Biopsy of shoulder joint Shoulder joint surgery Remove shoulder joint surgery Remove shoulder joint Partial removal, collar bone Removal of collarbone joint Removal of bone lesion Removal of bone lesion Removal of bone lesion Removal of bone lesion
Modifier		
CPT/ HCPCS Code	22804 22808 22810 22810 22811 22811 22813 22843 22844 22844 22844 22844 22844 22846 22846 22846 22846 22846 22846 22846 22846 22846 22865 22865 22865	22900 23000 23000 23030 23030 23030 23040 23040 23040 23066 23066 23066 23075 23075 23100 23100 23110 23140 23140 23144 23144

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 17 OF 173

			***		Facility	Non-		
Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	' Status/ Usage Indicator	Work Expense RVUs	Practice Expense RVUs	Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
 	Removal of humerus lesion Removal of humerus lesion	Surgery		8.48	10.37	10.37		
	Removal of humerus lesion	Surgery		8.68	10.74	10.74	-	
	Remove collar bone lesion	Surgery		98.9	11.17	11.17		
	Remove humerus lesion	Surgery		9.51	12.19	12.19		
	Remove collar bone lesion	Surgery		8.53	16.82	16.82		
	Remove shoulder blade lesion	Surgery		8.15	16.90	16.90		
	Remove humerus lesion	Surgery		9.38	17.08	17.08		
	Partial removal of scapula	Surgery		7.24	8.72	8.72		
*******	Removal of head of humerus	Surgery		20.01	11.11	11.1		
	Removal of collar bone	Surgery		12.49	14 47	14 47		
	Partial removal of humerus	Surgery		14.56	15.73	15.73		
	Partial removal of humerus	Surgery		17.74	17.13	17.13		
	Partial removal of humerus	Surgery		23.92	21.02	21.02		
	Remove shoulder foreign body	Surgery		1.85	5.75	3.77		
	Remove shoulder foreign body	Surgery		7.38	10.06	10.06		
	Remove shoulder foreign body	Surgery		11.62	12.40	12.40		
	Injection for shoulder x-ray	Surgery		1.00	7.30	0.34		
	Muscle transfer, shoulder/arm	Surgery		16.85	14.27	14.27		
	Muscle transfers	Surgery		13.54	14.58	14 58		
	Incision of tendon & muscle	Surgery		8.37	9.69	9.69		
	Incise tendon(s) & muscle(s)	Surgery		10.79	11.89	11.89		
	Repair rotator cuff, acute	Surgery		12.45	12.81	12.81		
	Repair rotator cuff, chronic	Surgery		13.31	13.32	13.32		
	Release of shoulder ligament	Surgery		13.30	14.31	14.34		
	Repair bicens tendon	Sugar		86.6	11.50	11.50		
	Remove/transplant tendon	Surgery		10.48	11.82	11.82		
	Repair shoulder capsule	Surgery		13.40	13.30	13.30		
	Repair shoulder capsule	Surgery		14.37	13.88	13.88		
	Repair shoulder capsule	Surgery		15.37	14.46	14.46		
	Repair shoulder capsule	Surgery		15.30	14.13	14.13		
_	Repair shoulder capsule	Surgery		15.85	14.31	14.31		
	Repair shoulder capsule	Surgery		14.22	13.84	13.84		
	Reconstruct shoulder joint	Surgery		17.15	12.42	12.42		
	Reconstruct shoulder joint	Surgery		21.10	40.4	40.4		
	Revision of collar bone	Surgery		10.10	2 7 0	12.10		
	Revision of collar bone	Surgery		11.45	10.00	10.00		
	Reinforce clavicle	Surgery	m4+4+4+4	2.50	12.24	12.24		
	Reinforce shoulder bones Troot cloudele fracture	Surgery		2.4	4 08	2.7		
	Treat claviole fracture	Singer		3.69	6.20	4 12		
_	וימשו כושאוכום וושכוחים	i Sino		2	9			

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 18 OF 173

Charge Method- ology	SAFE CONTRACTOR OF THE CONTRAC
Total Expense RVUs	1.98
Non- Facility Practice Expense RVUs	22.888.00.00.00.00.00.00.00.00.00.00.00.00
Facility Practice Expense RVUs	4.088.84.08.94.09.08.60.00.00.00.44.00.00.00.00.00.00.00.00.00
Work Expense RVUs	22.8.7.8.8.8.2.8.8.8.8.8.8.8.8.8.8.8.8.8
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Andens Anders An
CPT/HCPCS Code Description	Treat clavicle dislocation Treat clavicle dislocation Treat clavicle dislocation Treat clavicle dislocation Treat clavicle dislocation Treat clavicle dislocation Treat clavicle dislocation Treat clavicle dislocation Treat clavicle dislocation Treat shoulder blade fx Treat shoulder blade fx Treat shoulder blade fx Treat humerus fracture Treat humerus fracture Treat humerus fracture Treat humerus fracture Treat humerus fracture Treat humerus fracture Treat humerus fracture Treat shoulder dislocation Treat shoulder dislocation Treat shoulder dislocation Treat shoulder dislocation Treat shoulder dislocation Treat shoulder dislocation Treat shoulder dislocation Treat shoulder dislocation Treat dislocation/fracture Trea
Modifier	
CPT/ HCPCS Code	23520 23525 23525 23525 23526

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 19 OF 173

Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
	Remove fumerus lesion Removegraft bone lesion Removegraft bone lesion Removegraft bone lesion Removegraft bone lesion Removegraft bone lesion Removegraft bone lesion Removegraft bone lesion Remove radius bone lesion Remove adius bone lesion Remove lebow bone lesion Partial removal of arm bone Partial removal of radius Partial removal of radius Remove lebow bone lesion Partial removal of arm bone Partial removal of radius Remove lebow loint implant Remove lebow joint implant Remove lebow joint implant Removal of arm foreign body Remove lebow joint implant Removal of arm foreign body Removal of arm foreign body Removal of arm foreign body Removal of arm foreign body Removal of arm foreign body Removal of arm foreign body Removal of arm fendon Removal of arm fendon Repair of arm muscles Tenolysis, triceps Repair of arm muscles Tenolysis, triceps Repair of arm muscles Repair of fremis elbow Repair of fremis elbow Repair of tennis elbow Repair of tennis elbow Repair of tennis elbow Repair of tennis elbow Repair of tennis elbow Repair of tennis elbow Repair of fennis elbow	Surgery Surger		26.00 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	0.00 0.00	0.00 0.00		·
	Modifier	A S S S S S S S S S S S S S S S S S S S	Remove/graft bone lesion Remove/graft bone lesion Remove/graft bone lesion Remove/graft bone lesion Remove/graft bone lesion Remove/graft bone lesion Remove/graft bone lesion Remove elbow lesion Remove graft bone lesion Remove adults bone lesion Remove of new bone lesion Remove elbow bone lesion Remove elbow bone lesion Remove elbow bone lesion Partial removal of arm bone Partial removal of arm bone Partial removal of arm bone Partial removal of elbow Remove radius surgery Removel of elbow Surgery Stansive humerus surgery Stansive radius surgery Extensive radius surgery Removal of elbow joint implant Removal of elbow joint implant Removal of amm foreign body Removal of amm foreign body Removal of arm foreign body Revision of arm muscles Repair of farmit elbow and ligmnt witissu Repair of tennis elbow Repair of tennis elb	Remove fractive lesion Repair of numbractive lesion Repair of numbractive lesion Repair of femnis elbow Repair of	Remove humens leakin Repair of mendinent wiles Repair of mendinent wiles Repair of tensie lebow Repair of tensie lebow Repair of tensie lebow Repair of tensie lebow Repair of tensie lebow Repair of tensie lebow Repair of tensie lebow Repair of tensie lebow Repair of tensie lebow Repair of tensie lebow Repair of tensie lebow Repair of tensie lebow Repair of tensie lebow Repair of tensie lebow Reconstruct elbow hout Repair of tensie lebow Repair of tensie lebow Repair of tensie lebow Repair of tensie lebow Repair of tensie lebow Repair of tensie lebow Reconstruct elbow hout Repair of tensie lebow Repair of tensie lebow Repair of tensie lebow Repair of tensie lebow Reconstruct lebow hout Repair of tensie lebow Repair of tensie lebow Repair of tensie lebow Reconstruct lebow hout Reconstruct lebow hout Repair of tensie lebow	Remove furnerus lesion Surgery Careversion Status/ Practor/GAAF Usager Practor/GAAF Patents Remove furnerus lesion Surgery Category Indicator RYUVIs Practor Category Surgery Partial removed and the lesion Surgery S	Permove furnitive fesion Surgery Catego	CPT/HCPCS Code Description Factor(CAAF Usage Expense Feature Practice Practice

NOTES. CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 20 OF 173

CPT/			Conversion	Status/	Work	Facility	Non- Facility	Total	Charge
HCPCS	Modifier	CPT/HCPCS Code Description	Factor/GAAF	Usage	Expense	Practice	Practice	Expense	Method-
Code			Category	Indicator	RVUs	RVUs	Expense RVUs	RVUs	ology
24362		Reconstruct elbow joint	Surgery		14.99	12.41	12.41		
24363		Replace elbow joint	Surgery		18.49	11.53	11.53		
24365		Reconstruct head of radius	Surgery		8.39	7.31	7.31		
24366		Reconstruct head of radius	Surgery		9.13	7.69	7.69		
24400		Revision of humens	Surgery		2,00	14.83	14.33		
24410		Revision of humens	Vienes.		13.44	17.27	17.27		
24430		Repair of humerus	Surgery		12.81	13.18	13.18		
24435		Repair humerus with graff	Surgery		13.17	14.37	14.37		
24470		Revision of elbow joint	Surgery		8.74	8.50	8.50		
24495		Decompression of forearm	Surgery		8.12	10.28	10.28		
24490		Treat humerus fracture	Surgery		3.21	5.34	3 38		
24505		Treat humerus fracture	Surgery		5.17	933	7.10		
24515		Treat humerus fracture	Surgery		11.65	11.58	11.58		
24516		Treat humerus fracture	Surgery		11.65	12.14	12.14	•	
24530		Treat humerus fracture	Surgery		3.50	6.52	4.97		
24535		Treat humerus fracture	Surgery		6.87	9.14	6.89		
24538		reat humerus tracture	Surgery		9.43	10.85	10.85		
24545		Tract humorus fracture	Surgery		10.40	10.37	10.37		
24540		Treat humerus fracture	Simple		2.03	5.05	3.03		
24565		Treat humerus fracture	Surgery		5,56	8.24	6.05		
24566		Treat humerus fracture	Surgery		7.79	10.34	10.34		
24575		Treat humerus fracture	Surgery		10.66	8.43	8.43		
24576		Treat humerus fracture	Surgery		2.86	4.85	3.31		
24577		Freat humerus fracture	Surgery		5.79	14.24	6.32		
24573		Treat humerus fracture	Surgery		8.55	10.77	10.77		
24586		Treat elbow fracture	Surgery		15.21	11.05	11.05		
24587		Treat elbow fracture	Surgery		15.16	10.88	10.88		
24600		Treat elbow dislocation	Surgery		4.23	7.12	5.11		
24605		reat elbow dislocation	Surgery		5.42	5.09	5.09		
24615		Treat elbow disconding	Surgery Surgery		80.8	6.3	1.37		
24635		Treat elbow fracture	Surgery		13.19	16.64	16.64		
24640		Treat elbow dislocation	Surgery		1,20	3.54	1,84		
24650		Treat radius fracture	Surgery		2.16	4.81	2.92		
24655		Treat radius fracture	Surgery		4.40	2.66	5.41		
24665		Treat radius fracture	Surgery		8.14	9.72	9.72		
24666		Treat radius fracture	Surgery		9.49	10.48	10.48		
24670		Treat ulnar fracture	Surgery		2.54	4.71	3.13		
24675		Treat ulnar fracture	Surgery		4.72	98.0	20.00		
24800		Fision of Albow joint	Surgery		11.20	0.00	0.00		
24802		Fusion/graft of elbow joint	Surgery		13.69	11.56	11.56		

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 21 OF 173

	Charge Method- ology	MDR Misc
	Total Expense RVUs	9.76
	Non- Facility Practice Expense RVUs	12.22 12.23 12.23 12.23 12.23 12.23 13.86 14.15 15.23 16
	Facility Practice Expense RVUs	12.22 12.22 13.86 14.38 14
	Work Expense RVUs	9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9
	Status/ Usage Indicator	·
211212121	Conversion Factor/GAAF Category	Surgery Surger
	CPT/HCPCS Code Description	Amputation of upper arm Amputation of upper arm Amputation follow-up surgery Amputation follow-up surgery Amputation follow-up surgery Amputation of low-up surgery Amputation of amputation Revision of upper arm & implant Revision of tendon sheath Incise flexor carp radialis Decompress forearm 1 space Decompress forearm 1 space Decompress forearm 2 spaces Decompress forearm 2 spaces Decompress forearm 2 spaces Decompress forearm 4 space Decompress forearm 2 spaces Decompress forearm 2 spaces Decompress forearm bone lesion Explore/treat wrist joint Biopsy forearm soft tissues Biopsy forearm soft tissues Remove forearm lesion abcurdency forearm lesion deep Remove wrist joint artitiage Remove wrist joint cartitage Remove wrist joint cartitage Remove wrist tendon lesion Remove wrist tendon lesion Remove wrist tendon sheath Partial removal of forearm lesion Removelgraft forearm bone lesion Removelgraft forearm lesion Removelgraft forearm lesion Removelgraft forearm lesion Removelgraft forearm lesion Removelgraft forearm lesion Removelgraft forearm lesion Removelgraft forearm lesion Removelgraft forearm lesion Removelgraft forearm lesion Removelgraft forearm lesion
	Modifier	
	CPT/ HCPCS Code	24900 24920 24930 24933 24933 24933 24930 25020 25020 25020 25020 25020 25020 25020 25020 25020 25020 25031

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 22 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	25.8 6.10
Facility Practice Expense RVUs	25.8 10.00 10.
Work Expense RVUs	7.828.888.8888.8888.8888.88888888888888
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Removal of wrist bones Partial removal of radius Partial removal of radius Partial removal of ulna Injection for wrist x-ray Remove forearm foreign body Removal of wrist prosthesis Removal of wrist prosthesis Repair forearm tendon/muscle Repair forearm tendon/muscle Repair forearm tendon/muscle Repair forearm tendon/muscle Repair forearm tendon/muscle Repair forearm tendon/muscle Repair forearm tendon/muscle Repair forearm tendon/muscle Repair forearm tendon/muscle Repair forearm tendon sheath Revise wrist/forearm tendon Incise wrist/forearm tendon Incise wrist/forearm tendon Release wrist/forearm tendon Fusion of tendons at wrist Transplant forearm tendon Revise palsy hand tendon(s) Revise palsy hand tendon(s) Revise palsy hand tendon(s) Revise palsy hand tendon(s) Revise palsy hand tendon(s) Revise palsy hand tendon(s) Revise palsy hand tendon(s) Revise palsy hand tendon(s) Revise ardius & ulna Revise radius & ulna Revise radius & ulna Revise radius & ulna Repair carpal bone, shorten Repair radius & ulna Repair radius & ulna Repair radius & ulna Repair radius & ulna Repair/graft radius & ulna
Modifier	
CPT/ HCPCS Code	25215 25230 25240 25246 25246 25248 25250 25251 25250 25251 25272 25272 25274 25274 25275 25275 25276 25276 25276 25276 25276 25277 25276 25276 25276 25276 25277 25276 25276 25276 25276 25277 25276 25276 25276 25276 25276 25276 25276 25276 25276 25276 25277 25276 25277 25276 252776 252776 2527

NOTES. CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 23 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	8 1 2 2 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
Facility Practice Expense RVUs	85.7.1.00.00.00.00.00.00.00.00.00.00.00.00.0
Work Expense RVUs	00000000000000000000000000000000000000
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Repair nonunion carpal bone Repairgraft wrist bone Reconstruct wrist joint Reconstruct wrist joint Reconstruct wrist joint Reconstruct wrist joint Reconstruct wrist joint Reconstruct wrist joint Reconstruct wrist joint Reconstruct wrist joint Repair wrist joint implant Revision of wrist joint Revision of wrist joint Revision of wrist joint Revision of wrist joint Revision of wrist joint Revision of wrist joint Revision of wrist joint Revision of wrist joint Revision of wrist joint Revision of wrist joint Revision of wrist joint Revision of wrist joint Revision of wrist joint Revision of wrist joint Revision of wrist joint Revision of wrist joint Revision of wrist joint Revision of wrist joint Revision of wrist ioint Treat fracture of radius Treat fracture radius/ulna Treat fracture radius/ulna Treat fracture radius/ulna Treat fracture radius/ulna Treat fracture radius/ulna Treat fracture radius/ulna Treat fracture radius/ulna Treat wrist bone fracture Treat wrist bone fracture Treat wrist bone fracture Treat wrist bone fracture Treat wrist bone fracture Treat wrist bone fracture Treat wrist bone fracture Treat wrist bone fracture Treat wrist bone fracture Treat wrist bone fracture Treat wrist bone fracture Treat wrist bone fracture Treat wrist bone fracture Treat wrist bone fracture Treat wrist bone fracture Treat wrist bone fracture Treat wrist bone fracture Treat wrist dislocation Pin radioulnar dislocation Treat wrist dislocation Treat wrist dislocation
Modifier	
CPT/ HCPCS Code	25431 25440 25440 25441 25442 25443 25444 25444 25444 25444 25444 25446 25446 25446 25446 25491 25491 25491 25491 25491 25491 25500

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 24 OF 173

- 1
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
Surgery
ิดี

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 25 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	2000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Facility Practice Expense RVUs	2004 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Work Expense RVUs	2 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surgery
CPT/HCPCS Code Description	Remove wrist joint lining Revise finger joint, each Revise finger joint, each Revise finger joint, each Removal of palm tendon, each Removal of finger tendon Removal of finger tendon Removal of finger tendon Removal of finger lesion Removal of finger lesion Removal of finger lesion Removal of finger lesion Removal of finger lesion Removal of finger lesion Removal of finger lesion Removal of finger lesion Removal of finger lesion Removal of finger lesion Removal of finger lesion Removal of finger lesion Removal of finger lesion Removal of finger lesion Removal of finger lesion Repair finger lesion Repair finger wanesth Repair finger/hand tendon Repair finger/hand tendon Repair finger/hand tendon Repair finger/hand tendon Repair finger/hand tendon Repair finger lendon Repair finger tendon
Modifier	
CPT/ HCPCS Code	26130 26130 26145 26145 26145 26146 26146 26146 262000 26200

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 26 OF 173

Modifier					T. a. a. illih.	-LoN		
	CPT/HCPCS Code Description	Conversion Factor/GAAF	Status/ Usage	Work Expense	Facility Practice Expense	Facility Practice	Total Expense	Charge Method-
		y Description	0000	Ŝ	RVUs	RVUs		6800
	Release hand/finger tendon	Surgery		4.31	18.71	18.71		
	Incision of palm tendon	Surgery		3.67	8.57	8.57		
	Incision of finger tendon	Surgery		3.64	8.45	8.45		
	Incise hand/finger tendon	Surgery		3.46	8.20	8.20		
	Fusion of finger tendons	Surgery		5.73	14.00	14.00		
	Tendon lengthening	Surgery		5.18	13.80	13.80		
	Tendon shortening	Surger		5.15	14.01	14.01		
	Lengthening of hand tendon	Surgery		5.80	14.65	14.65		
	Shortening of hand tendon	Surgery		5.74	14.65	14.65		
	Transplant hand tendon	Surgery		69.9	19.94	19.94		
	Transplant/oraft hand tendon	Surgery		8.29	20.43	20.43		
	Transplant palm tendon	Surgery		7.70	20.34	20.34		
	Transplant/graft palm tendon	Surgery		9.55	17.04	17.04		
	Revise thumb tendon	Surgery		8.41	15.54	15.54		
_	Tendon transfer with graft	Surgery		9.62	16.15	16.15		
	Hand tendon/muscle transfer	Surgery		8.47	16.14	16.14		
	Revise thumb tendon	Surgery	-	9.59	15.87	15.87		
	Finger tendon transfer	Surgery		9.57	16.32	16.32		
	Finger tendon transfer	Surgery		14.00	18.71	18.71		
	Revision of finger	Surgery		8.98	17.02	17.02		
	Hand tendon reconstruction	Surgery		5.96	14.98	14.98		
	Hand tendon reconstruction	Surgery		7.14	15.27	15.27		
	Hand tendon reconstruction	Surgery		7.47	15.08	15.08		
	Release thumb contracture	Surgery		5.01	96.41	14.59		
	Thumb tendon transfer	Surgery		54.0	14.30	05.47		
	Fusion of knuckie joint	Surgery		0.10	70.04	10.07		
	Fusion of knuckie joints	Surgery		300	16.4	15.45		
	Release knickle contractine	Singer		5.30	18.85	18.85		
	Release finder contracture	Surgery		5.33	19.02	19.02		
	Revise knuckle joint	Surgery		69.9	6.04	6.04		
	Revise knuckle with implant	Surgery		7.91	6.95	6.95		
	Revise finger joint	Surgery		5.24	3.69	3.69		
	Revise/implant finger joint	Surgery		6.37	10.32	10.32		
	Repair hand joint	Surgery		6.43	14.89	14.89		
	Repair hand joint with graft	Surgery		8.62	16.25	16.25		
	Repair hand joint with graft	Surgery		6.78	14.78	14.78		
	Reconstruct finger joint	Surgery		6.92	15.52	15.52		
	Repair nonunion hand	Surgery		8.92	16.15	16.15		
	Reconstruct finger joint	Surgery		8.03	16.02	16.02		
	Construct thumb replacement	Surgery		21.24	23.47	23.47		
	Great toe-hand transfer	Surgery		46.58	36.90	36.90		
	Single transfer, toe-hand	Surgery		46.27	28.16	28.16		

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 27 OF 173

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 28 OF 173

	Charge Method- ology	SAF
	Total Expense RVUs	7.32
	Non- Facility Practice Expense RVUs	7.66.00 7.6
	Facility Practice Expense RVUs	7.61 7.61
	Work Expense RVUs	4 2 8 8 8 8 9 7 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3
	Status/ Usage Indicator	
> -	_ LL	
, , , , , , , , , , , , , , , , , , , ,	Conversion Factor/GAAF Category	
		Anderson Sunderson
	CPT/HCPCS Code Description	Treat finger dislocation Thumb fusion with graft Fusion of thumb Thumb fusion with graft Fusion of hand joint Fusion of hand joint Fusion of knuckle with graft Fusion of finger joint Fusion of finger joint Fusion of finger joint Fusion of finger joint Amputation of finger joint Fusion/graft of finger joint Fusion/graft of finger joint Fusion/graft of finger joint Fusion/graft of finger/thumb Amputation of finger/thumb Handfinger surgery Drainage of pelvis lesion Drainage of pelvis bursa Drainage of pelvis bursa Drainage of pelvis bursa Drainage of pelvis bursa Drainage of pelvis bursa Drainage of pelvis bursa Drainage of pip into thendon Incision of hip tendon Incision of hip tendon Incision of hip tendon Incision of hip joint Exploration of hip joint Denewation of hip joint Exploration of hip joint Exploration of hip joint Exploration of hip joint Benove for hip joint Remove hip/pelvis lesion Removal of hip joint lining Removal of hip bone lesion Removal of hip bone lesion Removal of hip bone lesion Partial removal of hip bone Extensive hip surgery Extensive hip surgery
	Modifier	
	CPT/ HCPCS Code	26735 26820 26841 26842 26842 26843 26844 26850 26850 26850 26850 26850 26850 26850 26850 26850 26850 26850 26850 26850 26850 26850 26850 27000 27000 27000 27005

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 29 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	29 46 46 46 46 46 46 46 46 46 46
Facility Practice Expense RVUs	82 8 4 4 5 1 1 5 1 5 1 5 1 5 1 5 1 5 1 5 1 5
Work Expense RVUs	0.00 0.00
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Extensive hip surgery Extensive hip surgery Extensive hip surgery Extensive hip surgery Removal of tail bone Removal of hip prosthesis Removal of hip prosthesis Removal of hip prosthesis Removal of hip prosthesis Removal of hip prosthesis Injection for hip x-ray Injection for hip x-ray Injection for hip x-ray Injection for hip x-ray Injection of hip prodon in predict Revision of hip prost in transfer of spinal muscle Transfer of spinal muscle Transfer of spinal muscle Transfer of litopsoas muscle Reconstruction of hip socket Reconstruction of hip socket Reconstruction of hip socket Reconstruction of hip socket Reconstruction of hip socket Revise hip joint replacement Total hip arthroplasty Total hip arthroplasty Total hip arthroplasty Revise hip joint replacement Revise hip joint replacement Revise hip joint replacement Revise hip joint replacement Revise hip joint replacement Transplant femur ridge Revision of hip bone Revision of hip bones Revision of hip bones Revision of neck of femur Incision of pelvysis Treat slipped epiphysis Revise nead/neck of femur Treat tail bone fracture Treat tail bone fracture Treat tail bone fracture
Modifier	
CPT/ HCPCS Code	27077 27078 27078 27079 27080 27080 27080 27081 27090 27091 27091 27091 27091 27105 27110 27110 27113 27132 27134 27144 27146 27147 27161 27161 27177 27181 27181 27181 27181 27181 27181 27181 27183 27176 27177 27181 27181 27183 27176 27177 27181 27181 27183 27176 27177 27181 27181 27183 27176

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 30 OF 173

	Charge Method- ology	Misc
	Total Expense RVUs	42.42
	Non- Facility Practice Expense RVUs	0.44 £ £ £ 6.00 £ £ £ £ £ £ £ £ £ £ £ £ £ £ £ £ £ £
	Facility Practice Expense RVUs	0.44 t 4
	Work Expense RVUs	0.051456 0.051456 0.051456 0.05146
	Status/ Usage Indicator	
2	Conversion Factor/GAAF Category	Surgery Surger
	CPT/HCPCS Code Description	Treat pelvic fracture(s) Treat pelvic ring fracture Treat pelvic ring fracture Treat hip socket fracture Treat hip socket fracture Treat hip socket fracture Treat hip fracture(s) Treat hip fracture Treat high fracture Fusion of high joint Fusion of high joint Fusion of high joint Fusion of high piont Treat high fracture Trea
	Modifier	
	CPT/ HCPCS Code	27215 27216 27217 27220 2720 27220 2

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 31 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	7.00 7.00 7.00 7.00 8.00
Facility Practice Expense RVUs	7.88
Work Expense RVUs	4 4 6 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Biopsy, thigh soft tissues Removal of thigh lesion Removal of thigh lesion Removal of thigh lesion Removal unor, thigh/knee Biopsy, knee joint lining Explore/treat knee joint Removal of knee cartilage Removal of knee cartilage Removal of knee cyst Removal of knee cyst Removal of knee cyst Removal of knee cyst Removal of knee cyst Removal of kneecap Removal of kneecap Removal of kneecap Removal of kneecap Remove femur lesion/graft Repair of thigh tendons Injection of thigh tendons Incision of thigh tendons Repair of knee ligament
Modifier	
CPT/ HCPCS Code	27324 27323 27323 27323 27333 27333 27333 27334 27335 27335 27335 27336 27336 27336 27336 27336 27337 27338 27338 27339 27339 27336 27337 27338 27338 27338 27338 27338 27338 27338 27338 27338 27338 27338 27338 2738 27

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 32 OF 173

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
27429 27435 27436 27440 27444 27444 27444 27446 27466		Reconstruction, knee Revision of thigh muscles Incision of knee joint Revise kneecap with implant Revise kneecap with implant Revision of knee joint Revision of knee joint Revision of knee joint Revision of knee joint Revision of knee joint Revision of thigh Incision of thigh Incision of thigh Realignment of thee Realignment of thigh bone Realignment of thigh bone Realignment of thigh bone Realignment of thigh bone Realignment of thigh bone Realignment of thigh bone Realignment of thigh bone Shortening of thigh bone Lengthening of thigh bone Shortening of thigh bone Shortening of thigh bone Lengthening of thigh bone Shortening of thigh bone Shortening of thigh bone Caugery to stop leg growth Surgery to stop leg gr	Surgery Surger		55 9 9 9 9 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2	\$50 8 8 8 5 1 1 4 2 4 5 6 6 6 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	£50 £50 £50 £50 £50 £50 £50 £50		

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 33 OF 173

				***************************************		***************************************		
Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
	Treat thigh fx growth plate Treat thigh fx growth plate Treat therecap fracture Treat kneecap fracture Treat knee fracture Treat knee fracture Treat knee fracture Treat knee fracture Treat knee fracture Treat knee fracture Treat knee fracture Treat knee dislocation Treat knee dislocation Treat knee dislocation Treat knee dislocation Treat knee dislocation Treat knee dislocation Treat kneecap dislocation Fresion of knee Amputate leg at thigh Amputate leg at thigh Amputate leg at thigh Amputate leg at thigh Amputate of lower leg Decompression of lower leg Decompression of lower leg Decompression of achilles tendon Incision of achilles tendon Splore/Ireat ankle joint Biopsy lower leg soft tissue Remove lower leg lesion Explore/Ireat ankle joint Remove lower leg lesion Explore/Ireat ankle joint lining Remove ankle joint lining	Audens Ruders Ru		688 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	88.25 89.26 80	6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	21.	Misc
	Modifier	A A A A A A T T T T T T T T T T T T T T	Treat thigh fx growth plate Treat thigh fx growth plate Treat thigh fx growth plate Treat thigh fx growth plate Treat wherecap fracture Treat where dislocation Treat where dislocation Treat where dislocation Treat where dislocation Treat where dislocation Treat where dislocation Treat where dislocation Treat where dislocation Treat where dislocation Treat where fracture Biopsy lower leg bursa Biopsy lower leg besion Treat lower leg lesion Biopsy lower leg lesion Treat lower leg lesion Biopsy lower leg lesion Biopsy lower leg lesion Treat lower leg lesion Biopsy lower leg lesi	CPTHCPCS Code Description Treat thigh fx growth plate Treat thigh fx growth plate Treat were fracture Treat were fracture Treat were fracture Treat were fracture Treat were fracture Treat were fracture Treat were fracture Treat were fracture Treat were fracture Treat were fracture Treat were fracture Treat were fracture Treat were fracture Treat were dislocation Surgery	Centrection Conversion Status With Conversion Conversion Status With Conversion Conversion Conversion Category Indicator Factor/GAF Disage Ext. Category Treat there are fracture Surgery Surgery Treat there are fracture Surgery Treat there are fracture Surgery Surgery Treat where fracture Surgery Surgery Treat where fracture Surgery Surgery Treat where fracture Surgery Surgery Surgery Treat where fracture Surgery Surgery Surgery Treat where fracture Surgery S	Treat tries for growth plate Treat tries for growth plate Treat tries for growth plate Treat tries for growth plate Treat tries for growth plate Treat tries for growth plate Treat tries for growth plate Treat tries for growth plate Treat tries for growth plate Treat tries for growth plate Treat tries fracture Treat tries fracture Treat tries fracture Treat tries fracture Treat tries fracture Surgery Treat tries fracture Treat tries fracture Surgery Treat tries fracture Surgery Treat tries discoalion Treat tries discoalion Treat tries discoalion Treat tries discoalion Treat tries discoalion Treat tries discoalion Treat tries discoalion Treat tries discoalion Treat tries discoalion Treat tries discoalion Treat tries discoalion Surgery Treat tries discoalion Treat tries discoalion Surgery Surgery Surgery Tries discoalion Surgery Tries discoalion Surgery	Treat think k growth plate Surgery Treat think k growth plate Surgery Treat think k growth plate Surgery Treat think k growth plate Surgery Treat think k growth plate Surgery Treat think k growth plate Surgery Surgery Treat think k growth plate Surgery Surgery Treat think k growth plate Surgery Surgery Treat think k growth plate Surgery Surgery Treat think k growth plate Surgery Surgery Treat think k growth plate Surgery Surgery Treat there be facture Surgery Surgery Treat k thereball fracture Surgery Surger	Comparison Comparison Category Facility Facil

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 34 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	7.1.1.2.1.2.1.2.1.2.1.2.1.2.1.2.1.2.1.2.
Facility Practice Expense RVUs	11121212121212121212121212121212121212
Work Expense RVUs	4 × × × × × × × × × × × × × × × × × × ×
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Removal of tendon lesion Removelgraft leg bone lesion Remove/graft leg bone lesion Remove/graft leg bone lesion Partial removal of tibia Partial removal of tibia Partial removal of tibia Partial removal of tibia Partial removal of tibia Extensive lower leg surgery Extensive lower leg surgery Extensive lower leg surgery Injection for ankle x-ray Repair of achilles tendon Repair of achilles tendon Repair of leg tendon, each Repair of leg tendon, each Repair of leg tendon, each Repair of leg tendon, each Repair of leg tendon, each Repair of leg tendon, each Repair of leg tendons Repair of leg tendon each Repair of leg tendon each Repair of leg tendon each Repair of leg tendon each Repair of leg tendon each Repair of leg tendon each Repair of leg tendon each Repair of leg tendon each Repair of leg tendon each Repair of onwer leg tendon Revise lower leg tendon Revise of ankle ligament Repair of ankle ligament Reconstruct ankle joint Reconstruction, ankle joint Reconstruction, ankle joint Reconstruction of fibula Incision of fibula Incision of fibula Incision of fibia Incision of fibia Repair of lower leg Repair of lower leg Repair of lower leg Repair of lower leg Repair of lower leg Repair of lower leg Repair of lower leg Repair of lower leg Repair of lower leg Repair of lower leg
Modifier	
CPT/ HCPCS Code	27630 27635 27635 27635 27635 27636 27646 27646 27646 27656 27702 27703 27703 27704 27705 27704 27705 27705 27705 27707

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 35 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	8 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
Facility Practice Expense RVUs	4 9 2 9 9 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Work Expense RVUs	28 8 8 6 5 5 5 6 6 6 7 6 7 8 8 7 4 7 7 2 4 7 8 8 8 8 8 8 8 8 9 8 9 8 9 8 9 8 9 8 9
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Repair of fbula epiphysis Repair of the epiphyses Repair of leg epiphyses Repair of leg epiphyses Repair of leg epiphyses Repair of leg epiphyses Repair of leg epiphyses Repair of leg epiphyses Remortoe tibia Treatment of tibia fracture Treatment of tibia fracture Treatment of tibia fracture Treatment of ankle fracture Treatment of ankle fracture Treatment of ankle fracture Treatment of fibula fracture Treatment of ankle fracture Treatment of ankle fracture Treatment of ankle fracture Treatment of ankle fracture Treatment of ankle fracture Treatment of ankle fracture Treatment of ankle fracture Treatment of ankle fracture Treatment of ankle fracture Treatment of ankle fracture Treatment of ankle fracture Treatment of ankle fracture Treat lower leg fracture Treat lower leg fracture Treat lower leg fracture Treat lower leg fracture Treat lower leg fracture Treat lower leg fracture Treat lower leg fracture Treat lower leg fracture Treat ankle dislocation
Modifier	
CPT/ HCPCS Code	27732 27742 27742 27742 27745 27756 27756 27756 27762 27762 27784 27784 27784 27784 27787 27787 27787 27787 27787 27787 27787 27787 27787 27787 27787 27787 27787 27787 27787 27787 27787 27787 2787 2787 2787 2787 2787 2788

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 36 OF 173

Charge Method- ology	Misc.
Total Expense RVUs	35.61
Non- Facility Practice Expense RVUs	11.33 88.30 86.30 10.88
Facility Practice Expense RVUs	11.23 10.58 8.26 8.26 9.56 11.29 11.29 11.29 12.35 12.
Work Expense RVUs	9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9
Status/ Usage Indicator	
Conversion Factor/GAAF Category	6.7 6.8 6.9 6.1 6.2 6.2 6.3 6.4 6.5 6.6 6.7 6.7 6.2 6.3 6.4 6.2 6.2 6.3 6.4 6.2 6.2 6
	Surgery Surger
CPT/HCPCS Code Description	Amputation follow-up surgery Amputation of foot at ankle Decompression of leg Decompression of leg Decompression of leg Decompression of leg Decompression of leg Decompression of leg Leg/ankle surgery procedure Drainage of bursa of foot Treatment of foot infection Treat foot bone lesion Incision of foot infection Treat foot bone lesion Incision of foot fascia Incision of foot fascia Incision of foot legion Exploration of foot joint Exploration of foot joint Exploration of foot lesion Excision of foot lesion Biopsy of foot joint lining Biopsy of foot joint lining Biopsy of foot joint lining Removal of foot joint lining Removal of foot joint lining Removal of foot joint lining Removal of foot lesion Removal of foot lesion Removal of foot lesion Removal of foot lesion Removal of foot lesion Removal of foot lesion Removal of foot lesion Removal of foot lesion Removal of foot lesion Removal of foot lesion Removal of foot lesion Removal of foot lesion Removal of foot lesion Removal of metatarsal Part removal of metatarsal
Modifier	
CPT/ HCPCS Code	27886 27889 278892 27893 27893 278994 28000 2800

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 37 OF 173

Charge Method- ology	
Total Expense RVUs	·
Non- Facility Practice Expense RVUs	683 683 683 683 683 683 683 683
Facility Practice Expense RVUs	8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9
Work Expense RVUs	7.7.7.7.4.8.8.8.8.8.8.9.4.8.8.8.4.4.8.8.8.7.4.8.8.9.9.8.8.9.4.8.8.8.4.8.8.8.7.4.8.8.7.4.8.8.7.4.8.8.7.4.8.8.7.4.8.8.7.4.8.8.7.8.8.8.7.4.8.8.7.4.8.8.7.4.8.8.7.4.8.8.7.4.8.8.7.4.8.8.7.4.8.8.7.8.8.8.7.8.8.8.7.8.8.8.7.8.8.8.8
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Revision of foot Removal of heel bone Removal of heel bone Removal of ankle/heel Partial removal of too Partial removal of too Partial removal of too Removal of ankle bone Removal of ankle bone Removal of ankle bone Removal of too Removal of too Partial removal of too Extensive foot surgery Extensive foot surgery Extensive foot surgery Removal of foot foreign body Removal of foot foreign body Removal of foot foreign body Removal of foot tendon Repair of foot tendon Repair of foot tendon Repair of foot tendon Repair of foot tendon Release of foot tendon
Modifier	·
CPT/ HCPCS Code	281146 281118 281118 281120 281120 281120 281120 281120 281120 281120 281120 281120 281130 28

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 38 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	7.80 6.80
Facility Practice Expense RVUs	0.0011.001.001.001.001.001.001.001.001.
Work Expense RVUs	8 6 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surgery
CPT/HCPCS Code Description	Correction of bunion Correction of bunion Correction of bunion Correction of bunion Correction of bunion Correction of bunion Correction of bunion Correction of bunion Correction of beel bone Incision of metatarsal Incision of metatarsal Incision of metatarsal Incision of metatarsal Incision of metatarsal Incision of metatarsal Incision of metatarsal Revision of metatarsal Revision of metatarsal Revision of toe Repair deformity of toe Repair of toot bones Repair of foot bones Repair of foot bones Repair of foot bones Repair of netatarsals Resect enlarged toe tissue Resect enlarged toe tissue Resect enlarged toe tissue Resect enlarged toe fecture Treatment of heel fracture Treatment of heel fracture Treatment of heel fracture Treatment of ankle fracture Treatment of ankle fracture Treatment of ankle fracture Treat midfoot fracture, each Treat midfoot fracture Treat midfoot fracture Treat midfoot fracture Treat metatarsal fracture Treat metatarsal fracture Treat metatarsal fracture Treat metatarsal fracture Treat big toe fracture Treat big toe fracture Treat big toe fracture Treat big toe fracture Treat big toe fracture Treat big toe fracture Treat big toe fracture Treat big toe fracture Treat big toe fracture Treat big toe fracture Treat big toe fracture Treat big toe fracture Treat big toe fracture
Modifier	
CPT/ HCPCS Code	28294 28296 28296 28296 28296 28300 28400

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 39 OF 173

Charge Method- ology		MISC
Total Expense RVUs		46.
Non- Facility Practice Expense RVUs	2.00	1.72 1.60 1.44 1.86 1.53
Facility Practice Expense RVUs	24. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8.	3.08 3.07 2.97 3.27 3.16
Work Expense RVUs	23.46 4.22 4.22 4.23 5.22 5.22 5.23	2.25 2.06 2.41 2.40
Status/ Usage Indicator		
Conversion Factor/GAAF Category	Surgery Surgery	Surgery Surgery Surgery Surgery Surgery
CPT/HCPCS Code Description	0.0	Application of body cast Application of body cast Application of body cast Application of body cast Application of body cast Application of body cast Application of body cast Shppication of body cast
Modifier		
CPT/ HCPCS Code	28515 28525 28530 28531 28531 28535 28530 28535 28536 28536 28600	28889 28000 29010 29020 29025 29035

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 40 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	7.44 7.60
Facility Practice Expense RVUs	22.2.1.1.1.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0
Work Expense RVUs	22222 222222 2426 252
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Application of body cast Application of body cast Application of ode cast Application of shoulder cast Application of shoulder cast Application of shoulder cast Application of forearm cast Apply finger cast Apply long arm splint Application of forearm solint Apply orearm splint Application of finger splint Application of finger splint Application of finger splint Application of finger splint Application of finger splint Application of finger splint Application of hip cast Apply long leg cast Apply short leg cast Apply rigid leg cast Apply rigid leg cast Application of hip leg cast Application of paste boot Application of paste boot Application of paste boot Application of paste boot Application of paste boot Application of od cast Removal/revision of cast Removal/revision of cast Removal/revision of cast Removal/revision of cast Removal/revision of cast Removal/revision of cast Removal/revision of cast Removal/revision of cast
Modifier	
CPT/ HCPCS Code	29040 29040 29040 29040 29040 29040 29102 29102 29102 29102 29102 29102 29102 29102 29102 29103

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 41 OF 173

Charge Method- ology	Misc
Total Expense RVUs	1.52
Non- Facility Practice Expense RVUs	0.50 0.50
Facility Practice Expense RVUs	400. 100.
Work Expense RVUs	48.8.8.4.5.6.6.6.6.6.6.6.6.6.6.6.6.6.6.6.6.6.6
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Wedging of cast Wedging of cast Wedging of clubfoot cast Casting/strapping procedure Jaw arthroscopy/surgery Shoulder arthroscopy/surgery Shoulder arthroscopy/surgery Shoulder arthroscopy/surgery Shoulder arthroscopy/surgery Shoulder arthroscopy/surgery Shoulder arthroscopy/surgery Shoulder arthroscopy/surgery Shoulder arthroscopy/surgery Shoulder arthroscopy/surgery Shoulder arthroscopy/surgery Shoulder arthroscopy/surgery Shoulder arthroscopy/surgery Shoulder arthroscopy/surgery Shoulder arthroscopy/surgery Shoulder arthroscopy/surgery Elbow arthroscopy/surgery Elbow arthroscopy/surgery Elbow arthroscopy/surgery Elbow arthroscopy/surgery Wrist arthroscopy/surgery Wrist arthroscopy/surgery Wrist arthroscopy/surgery Wrist arthroscopy/surgery Wrist arthroscopy/surgery Wrist arthroscopy/surgery Wrist arthroscopy/surgery Hip arthroscopy/surgery Hip arthroscopy/surgery Hip arthroscopy/surgery Hip arthroscopy/surgery Knee arthroscopy/surgery
Modifier	
CPT/ HCPCS Code	29740 29750 29750 29750 29750 298004 298005 29807

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 42 OF 173

Charge Method- ology	Misc
Total Expense RVUs	16.82
Non- Facility Practice Expense RVUs	7. 7. 7. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8. 8.
Facility Practice Expense RVUs	7.7.7.9.9.6.7.7.7.8.8.8.8.9.9.9.9.9.9.9.9.9.9.9.9.9
Work Expense RVUs	8.7.8.1. 6.7.8.2. 6.7.8.
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Knee arthroscopy/surgery Knee arthroscopy/surgery Knee arthroscopy/surgery Knee arthroscopy/surgery Knee arthroscopy/surgery Knee arthroscopy/surgery Knee arthroscopy/surgery Knee arthroscopy/surgery Knee arthroscopy/surgery Knee arthroscopy/surgery Ankle arthroscopy/surgery An
Modifier	
CPT/ HCPCS Code	29880 29881 29882 29883 29884 29886 29886 29887 29889 29895 29899 29899 29899 29899 29899 30100 30100 30110 30110 30120

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 43 OF 173

	Charge Method- ology	Misc
	Total Expense RVUs	. 2.94
	Non- Facility Practice Expense RVUs	0.55 0.55
	Facility Practice Expense RVUs	00000000000000000000000000000000000000
	Work Expense RVUs	17.88 17.75 17
	Status/ Usage Indicator	
	Conversion Factor/GAAF Category	Surgery Surger
	CPT/HCPCS Code Description	Revision of nose Revision of nose Revision of nose Revision of nose Repair on asal septum Repair nasal septum Repair nasal defect Repair nasal defect Repair nasal defect Repair nasal defect Repair nasal defect Repair nasal defect Repair nasal defect Repair nasal septum defect Cauterization, inner nose Control of nosebleed Control of nosebleed Control of nosebleed Control of nosebleed Control of nosebleed Control of nosebleed Control of nosebleed Ingation, nasal sinus artery Ligation, upper jaw artery Therapy, fracture of nose Nasal surgery procedure Irrigation, maxillary sinus Exploration, maxillary sinus Exploration, maxillary sinus Exploration, sphenoid sinus Exploration of frontal sinus Removal of frontal sinus Removal of frontal sinus Removal of frontal sinus Removal of frontal sinus Removal of frontal sinus Removal of frontal sinus Removal of frontal sinus Removal of frontal sinus Removal of frontal sinus Removal of sinus dethmoid sinus Removal of sinus dethmoid sinus Removal of upper jaw Removal of upper jaw Removal of upper jaw Removal of upper jaw Removal of upper jaw Removal of upper jaw Removal of upper jaw Removal of upper jaw Removal of upper jaw Removal of upper jaw Removal of upper jaw Removal of upper jaw
	Modifier	
	CPT/ HCPCS Code	30435 30450 30465 30465 30465 30540 30540 30560 30560 30560 306000 306000 306000 306

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 44 OF 173

Charge Method- ology	Misc
Total Expense RVUs	3.68
Non- Facility Practice Expense RVUs	2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.
Facility Practice Expense RVUs	2.63 2.63 2.71 2.71 2.71 2.71 2.71 2.71 2.71 2.71
Work Expense RVUs	2.18 2.18 3.28 3.28 3.28 3.28 3.28 3.28 3.28 3.2
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Nasal/sinus endoscopy, dx Nasal/sinus endoscopy, surg Nasal/sinus endoscopy, surg Nasal/sinus endoscopy, surg Nasal/sinus endoscopy, surg Revision of ethmoid sinus Removal of ethmoid sinus Exploration maxillary sinus Endoscopy, maxillary sinus Endoscopy, surgical Nasal/sinus endoscopy, surg Nasal/sinus endoscopy, surg Parail removal of larynx Removal of larynx Partial removal of larynx Partial removal of larynx Partial removal of larynx Removal of la
Modifier	
CPT/ HCPCS Code	31233 31233 31235 31235 31236 31236 31236 31236 31236 31236 31236 31236 31236 31236 31236 31320 31520

NOTES. CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 45 OF 173

Charge Method- ology	Misc
Total Expense RVUs	3.74
Non- Facility Practice Expense RVUs	2.1.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2
Facility Practice Expense RVUs	2.1.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2
Work Expense RVUs	2 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surgery
CPT/HCPCS Code Description	Laryngoscopy and dilation Operative laryngoscopy Operative laryngoscopy Operative laryngoscopy Operative laryngoscopy Operative laryngoscopy Operative laryngoscopy Operative laryngoscopy Operative laryngoscopy Laryngoscopy with injection Laryngoscopy with injection Laryngoscopy with linjection Laryngoscopy with linjection Diagnostic laryngoscopy Removal of larynx Revision of larynx Revision of larynx Revision of larynx Revision of larynx Revision of larynx Revision of larynx Revision of larynx Revision of larynx Revision of larynx Revision of larynx Larynx nerve surgery Larynx surgery procedure Incision of windpipe Incision of wind
Modifier	
CPT/ HCPCS Code	31529 31529 31535 31536 31536 31536 31540 31576 31576 31578

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 46 OF 173

Charge Method- ology	Misc
Total Expense RVUs	6.91
Non- Facility Practice Expense RVUs	22221 22221
Facility Practice Expense RVUs	22211222222222222222222222222222222222
Work Expense RVUs	6.8.8.2.2.4.4.4.6.1.2.2.8.8.2.8.2.8.2.8.2.8.2.8.2.8.2.8.2
Status/ Usage Indicator	· ·
Conversion Factor/GAAF Category	Surgery Surgery
CPT/HCPCS Code Description	Bronchoscopy, treat blockage Diag bronchoscope/catheter Bronchoscopy, lecar ainway Bronchoscopy, lecar ainway Bronchoscopy, in for x-ray Insertion of ainway catheter Insertion of ainway catheter Insertion of ainway catheter Insertion of ainway catheter Insertion of ainway catheter Insertion of ainway catheter Insertion of ainway catheter Insertion of ainway catheter Insertion for bronchus x-ray Bronchal brush biopsy Clearance of ainways Intro, windpipe wire/fube Repair of windpipe Repair of windpipe Repair of windpipe Repair of windpipe Reconstruct bronchus Repair of windpipe lesion Reporation of chest Exploration of chest Expl
Modifier	
CPT/ HCPCS Code	31641 31645 31646 31646 31646 31700 31710 31717 31720

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 47 OF 173

Non- Facility Total Charge Practice Expense Method- Expense RVUs ology RVUs	2.54 2.44 2.45 2.45 2.65
Facility Practice Expense RVUs	2.00.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Work Expense RVUs	4 1 2 4 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Drain, percut, lung lesion Treat chest lining Release of lung Removal of chest lining Removal of chest lining Removal of chest lining Removal of chest lining Removal of lung Needle biopsy chest lining Den biopsy chest lining Removal of lung Removal of lung Removal of lung Removal of lung Removal of lung Removal of lung Removal of lung Removal of lung Removal of lung Removal of lung Removal of lung Removal of lung Removal of lung Removal of lung Removal of lung and removal of lung Remove lung & revise chest Remove lung & revise chest Remove lung & revise chest Remove lung & revise chest Remove lung & revise chest Remove lung & revise chest Remove lung & revise chest Remove lung & revise chest Remove lung & revise chest Remove lung de revise chest Re
Modifier	·
CPT/ HCPCS Code	32201 32201 32201 32202 32202 32202 32202 32202 32202 32402 32402 32402 32442 32445 32444 32445 32446 32446 32446 32460 32600

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 48 OF 173

Charge Method- ology	Misc
Total Expense RVUs	44.67
Non- Facility Practice Expense RVUs	8 9 0 0 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Facility Practice Expense RVUs	8 6 0 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Work Expense RVUs	223.15 2
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surgery
CPT/HCPCS Code Description	Thoracoscopy, surgical Repair lung hermia Close chest after drainage Close bronchial fistula Reconstruct injured chest Lung transplant, single Lung transplant with bypass Lung transplant with bypass Lung transplant with bypass Removal of rib(s) Revise & repair chest wall Revise & repair chest wall Revise & repair chest wall Revise of lung Therapeutic pneumothorax Total lung lavage Chest surgery procedure Drainage of heart sac Chest surgery procedure Chest surgery procedure Drainage of heart sac Repeat drainage of heart sac Repeat drainage of heart sac Chest surgery procedure Drainage of heart sac Repeat drainage of heart sac Repeat drainage of heart sac Repeat drainage of heart sac Removal of heart sac Removal of heart sac Removal of heart sac Removal of heart sac Removal of heart sac Removal of heart sac Incision of heart sac Removal of heart sac Removal of heart sac Removal of heart sac Insertion of heart dacemaker Insertion of heart pacemaker Insertion of heart pacemaker Insertion of heart pacemaker Insertion of pulse generator Insertion of heart pacemaker Insertion of pulse generator Insertion of pulse generator Uggrade of pacemaker system Reposition pacing-defib lead Insert lead pace-defib, one Repair lead pace-defib, dual Repair lead pace-defib, dual Repair lead pace-defib, dual Repair lead pace-defib, dual Repair lead pace-defib, dual Repair lead pace-defib, dual Repair lead pace-defib, dual Revise pocket, pacing-defib Insertion gead & connect
Modifier	
CPT/ HCPCS Code	32665 328665 328800 32810 32810 32810 32810 32852 32853 32854 32864 32864 32900 32900 32900 33010

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 49 OF 173

	Charge Method- ology	
	Total Expense RVUs	
	Non- Facility Practice Expense RVUs	86.69 8 114 9 4 4 4 4 215 125 125 125 125 125 125 125 125 125
	Facility Practice Expense RVUs	8 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
	Work Expense RVUs	8 8 8 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
	Status/ Usage Indicator	
2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	Conversion Factor/GAAF Category	Surgery Surger
	CPT/HCPCS Code Description	L ventric pacing lead add-on Reposition I ventric lead Removal of pacemaker system Removal of pacemaker system Removal pacemaker system Removal pacemaker system Remova leactrode/thoracotomy Remove electrode/thoracotomy Remove electrode/thoracotomy Remove electrode/thoracotomy Remove electrode/thoracotomy Remove eltrd/thoracotomy Remove eltrd/thoracotomy Remove eltrd/thoracotomy Remove eltrd/thoracotomy Remove eltrd/thoracotomy Remove eltrd/generator Eltrd/insert pace-defib Insert epic eltrd/generator Eltrd/insert pace-defib Insert epic eltrd/generator Eltrd/insert pace-defib Insert epic eltrd/generator Eltrd/insert pace-defib Insert epic eltrd/generator Reconstruct atria Ablate heart dysrhythm focus Repair of heart wound Repair of heart wound Repair of heart wound Exploratory heart surgery Exploratory heart surgery Exploratory heart surgery Repair major vessel graft Insert major vessel graft Insert major vessel graft Insert major vessel graft Insert major vessel graft Insert major vessel graft Repair major vessel graft Repair major vessel graft Repair major vessel graft Repair major vessel graft Repair major vessel graft Repair major vessel graft Repair major vessel graft Repair major vessel graft Repair major vessel graft Repair of aortic valve Replacement of aortic va
	Modifier	
	CPT/ HCPCS Code	33225 33225 33233 33234 33234 33234 33237 33237 33240 33241 33244 33244 33244 33246 33246 33360 33311 3331 33311 33311 33311 33311 33311 33311 33311 33311 33311 33311 3

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 50 OF 173

Conversion Factor/GAAF Category	CPT/HCPCS Code Description
. 1	
	Surgery

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 51 OF 173

	Conversion Status/ Work Practice Expense Expense CPT/HCPCS Code Description Category Category Category CPT/HCPCS Code Description Code Descrip	Surgery 29.51 16.89 Surgery 28.54 16.43		Surgery 30.61 18.66	Surgery 34.00 19.21	Surgery 35.00 19.97	Surgery 34.00 18.80	Surgery 37.00	Surgery 27.24	riect Surgery 11.95	Surgery 24.87	76.71	Surgery 2500 1757	Surgery 3500 1619	Surgery 30.61 18.02	Surgery 29.65 16.93	Surgery	tery Surgery 13.65	16.47	298730	Surgery 26.54 16.85	Surgery 29.71 18.23	Surgery 26.56 16.34	Surgery 1.91	28.16 17.20	Surgery 12.25	7.20 CC	Surgery 23.52 15.56 Surgery 24.4 & R	Namber Surgery 23.52 15.56 Namber Surgery 21.76 14.86 Surgery 21.41 13.38	Surgery 23.52 15.56 Surgery 21.76 14.86 Surgery 21.41 13.38 Surgery 21.79 12.25	Surgery Surgery 23.52 15.56 14.86 Surgery 13.40	Agricol Surgery Surger	Agringery Surgery graft Surgery	Agrant Surgery	Agriculture Surgery Su	Agricol Surgery Surger	Agringery Surgery gringery Surgery -----	--	--	------------	---------------------	---------------------	---------------------	---------------------	---------------	---------------	---------------------	---------------	-------	-------------------	-------------------	---------------------	---------------------	---------	--------------------	-------	--------	---------------------	---------------------	---------------------	--------------	-------------	---------------	---------	--------------------------------------	---	---	---	--	--	--	--	--	--	--	--
														-													_		amber	amber	namber	namber namber & graft	ramber amber & graft	amber 8 graft	A graff	& graft stefec	& graft S defect S defect S defect	& graft S defect S defect S defect S defect S defect S defect S defect S defect	& graft s defect s defect s defect s defect s defect s defect s defect s defect																																					
- 1	O	1 2 2	nas	Repa	Repa	Repa	Repa	Repa	Yeba	Kepa	Yevi	Z con	מלים מ	Repa	Repa	Repa	Repa	Rein	Kepa	Repa	Repa	Repa	Repa	Kepa	Repa	Revie	Yes (2	X evis	Majo Majo Majo	Kevis Majo Majo	M M M A S S S S S S S S S S S S S S S S	Majo o o o o o o o o o o o o o o o o o o	Majo O	M Majo o o o o o o o o o o o o o o o o o o	M M M M M M M M M M M M M M M M M M M	M M M M M M M M M M M M M M M M M M M	Majo o o o o o o o o o o o o o o o o o o	Najori Majori Majori Majori Repa																																					
	Modifier	88	~ □																									_																																																

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 52 OF 173

	Charge Method- ology	PHCS
	Total Expense RVUs	46.59
	Non- Facility Practice Expense RVUs	22 22 25:15
	Facility Practice Expense RVUs	22 24 25 25 25 25 25 25 25 25 25 25 25 25 25
	Work Expense RVUs	45.50 45
	Status/ Usage Indicator	
1,705.05.01	Conversion Factor/GAAF Category	Surgery Surger
	CPT/HCPCS Code Description	Repair great vessels defect Repair arterial trunk Revision of pulmonary artery Adric suspension Repair vessel defect Repair vessel defect Repair vessel defect Repair vessel defect Repair septal defect Repair septal defect Revise major vessel Revise major vessel Revise major vessel Revise major vessel Revise major vessel Revise major vessel Revise major vessel Revise major vessel Repair septal defect St. Repair septal defect St. Repair septal defect St. Repair septal defect St. Repair septal defect St. Repair septal defect St. Repair septal defect St. Repair septal defect St. Repair septal defect St. Repair septal defect St. Repair septal defect St. Repair septal defect St. Repair septal defect St. Repair septal defect St. Repair septal defect St. Repair septal defect St. Repair pulmonary artery Repair pulmonary artery Repair pulmonary artery Repair pulmonary artery Repair pulmonary artery Repair pulmonary artery Repair pulmonary artery Repair pulmonary artery Remove luminary shunt Transplantation of heart External circulation assist Insert ia percut device St. Remove ortic assist device St. Remove ortic assist device St. Remove ortic assist device St. Remove ortic assist device St. Remove ortic assist device St. Remove ortic assist device St. Remove ortic device St. Remove intra-aortic balloon Implant ventricular device St. Remove ventricular device
	Modifier	
	CPT/ HCPCS Code	33780 33786 33786 33803 33803 33813 33814 33824 33824 33825 33825 33826 33826 33846 33861 33861 33861 33861 33861 33861 33861 33861 33861 33862 33863 33876 33916 33916 33916 33916 33917 33917 33961 3397 3397 3397 3397 3397 3397 3397 339

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 53 OF 173

Charge Method- ology	Wisc
Total Expense RVUs	50.99
Non- Facility Practice Expense RVUs	11.7.7.4.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0
Facility Practice Expense RVUs	75. 17. 17. 17. 17. 17. 17. 17. 17. 17. 17
Work Expense RVUs	22.64.00.00.00.00.00.00.00.00.00.00.00.00.00
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Remove ventricular device Insert intracorporeal device Cardiac surgery procedure Remova of a fartery clot Removal of antery clot Removal of vein clot Repair valve, femoral Leg vein fusion Endovasc abdo repr w/device Endovasc abdo repr w/device Endovasc abdo repr w/device Endovasc abdo repr w/device Endovasc extend prosth, init Endovasc extend prosth, init Endovasc extend prosth, init Endovasc extend prosth, repr Open aortofemor prosth repr Repair defect of artery Repair defect of artery Repair defect of artery Repair defect of artery Repair defect of artery Repair defect of artery Repair defect of artery Repair defect of artery Repair defect of artery Repair defect of artery Repair defect of artery Repair defect of artery Repair defect of artery Repair defect of artery Repair defect of artery Repair defect of artery Repair defect of artery Repair defect of artery Acres artery pr
Modifier	
CPT/ HCPCS Code	33978 33978 33999 33999 33999 33999 34001 34101 34101 34101 34401 34401 34401 34500 34500 34808 34833 3483 358 3483 3483

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 54 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	£65256556666666666666666666666666666666
Facility Practice Expense RVUs	£6612450 6612460 661240
Work Expense RVUs	3.8.4.2.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Repair defect of artery Repair antery rupture, aorta Repair antery rupture, aorta Repair antery rupture, groin Repair antery rupture, groin Repair antery rupture, spleen Repair antery rupture spleen Repair antery rupture, spleen Repair antery rupture, and Repair antery rupture, and Repair antery rupture, thigh Repair antery rupture, thigh Repair antery rupture, knee Repair antery rupture, knee Repair antery rupture, knee Repair antery rupture, knee Repair antery rupture, knee Repair antery rupture Repair antery rupture Repair antery rupture Repair antery rupture Repair antery rupture Repair antery rupture Repair antery rupture Repair antery rupture Repair blood vessel lesion
Modifier	
CPT/ HCPCS Code	35091 35092 35092 35103 35111 35111 35112 35122 35131 35132 35131 35142 35142 35182 35184 35184 3520 3520 3520 3520 3520 3520 3520 3520

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 55 OF 173

	Charge Method- ology	
	Total Expense RVUs	
	Non- Facility Practice Expense RVUs	9 8 11 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
	Facility Practice Expense RVUs	9 8 111 7 12 12 12 12 12 12 12 12 12 12 12 12 12
	Work Expense RVUs	23.00 28.20 28.20 28.20 28.20 28.20 28.20 29.20 20.20
	Status/ Usage Indicator	
	Conversion Factor/GAAF Category	Surgery Surger
	CPT/HCPCS Code Description	Rechanneling of artery Rechanneling of artery Rechanneling of artery Rechanneling of artery Rechanneling of artery Rechanneling of artery Rechanneling of artery Rechanneling of artery Rechanneling of artery Rechanneling of artery Rechanneling of artery Repair arterial blockage Repair venous blockage Repair venous blockage Atherectomy, open Atherectomy, open Atherectomy, open Atherectomy, percutaneous
	Modifier	
	CPT/ HCPCS Code	35351 35351 35351 35363 35363 35363 35381 35381 35450 35450 35456 35456 35470 35570

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 56 OF 173

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
35526 35533 35533 35533 35536 35549 35549 35549 35560 35560 35560 35560 35560 35561 35601 35647 35642 35644 35644 35644 35645 35646 35646 35646 35647 35646 35646 35647 35646 35646 35647 35646 35667 35666 36666		Artery bypass graff Artery bypass graff Artery bypass graft	Surgery Surger		88888888888888888888888888888888888888	244-15-15-15-15-15-15-15-15-15-15-15-15-15-	24 1 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2		

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 57 OF 173

Charge	Method- ology																																											
Total	Expense RVUs																																											
Non- Facility	Practice Expense	RVUs	2.44	1.00	1.26	7.54	6.59	7.83	7.78	1.03	4.59	5.13	45.0	24.4	4 19	2,0	3.54	9.95	6.30	8.80	7.61	8.46	5.85	8.08	15.12	14.57	0.05	00.0	0.81	1.05	1.18	29.0	1.02	1.18	1.12	29.0	99.0	0.68	0.86	1.04	1.62	1.81	2.21	0.35
Facility Practice	Expense	SO VC	2.44	1.52	1.26	7.54	6.59	7.83	7.78	1.03	4.59	5.13	45.0	24.6	00.7	2,5	3.54	9.95	6.30	8.80	7.61	8.46	5.82	8.08	15.12	14.5/	0.00	7. 2. 7. 2.	0.81	1.05	1.18	19.0	1.02	1.18	1.12	0.67	99.0	0.68	0.86	104	1.62	1.81	2.21	0.35
Work	Expense RVUs		7.20	4.05	3,35	18.05	15.36	19.16	19.16	3.08	05.50	7.18	8.00	10.07	12.88	22.5	5.55	22.17	10.13	17.00	16.00	18.00	8.19	9.39	31.25	35.00	O. 1	0.90	2.43	3.14	3.52	2.52	3.02	3.52	3.02	2.01	2.01	2.01	2.52	3.02	4.68	5.28	6.30	1,0,1
Status/	Usage Indicator																						-					•							****									
Conversion	Factor/GAAF Category		Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery
	CPT/HCPCS Code Description		Composite bypass graft	Bypass graft patency/patch	Bypass graft/av fist patency	Arterial transposition	Arterial transposition			Reoperation, bypass graft	Exploration, carotid arrery	Exploration, remoral arrery	Exploration populeal afterly	Exploration of afterly/veill	-	sels		efect								Excision, graff, abdomen	Prace needle in veill						Place catheter in artery	Place catheter in artery	Establish access to artery				ta .					Place catheter in arreny
:	Modifier																																											
CPT/	HCPCS Code		35682	35685	35686	35691	35693	35694	35695	35700	35/01	12/58	35761	35800	35820	35840	35860	35870	35875	35876	35879	35881	35901	35903	35905	32907	36000	36005	36010	36011	36012	36013	36014	36015	36100	36120	36140	36145	36160	36200	36215	36216	36217	36218

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 58 OF 173

Charge Method- ology	Misc SAF SAF PHCS
Total Expense RVUs	5.10 0.18 0.18 2.16 2.16
Non- Facility Practice Expense RVUs	1.85
Facility Practice Expense RVUs	2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.
Work Expense RVUs	6.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Status/ Usage Indicator	م
Conversion Factor/GAAF Category	Surgery Surgery
CPT/HCPCS Code Description	Place catheter in artery Place catheter in artery Place catheter in artery Place catheter in artery Place catheter in artery Place catheter in artery Revision of infusion pump Rewoval of infusion pump Vessel injection procedure Bl draw < 3 yrs scalp vein Bl draw < 3 yrs scalp vein Bl draw < 3 yrs other vein Non-routine bl draw > 3 yrs Routine venipuncture Capillary blood draw Vein access cutdown < 1 yr Ven access cutdown < 1 yr Ven access cutdown < 1 yr Ven access cutdown < 1 yr Ven access cutdown < 1 yr Ven access cutdown < 1 yr Ven access cutdown < 1 yr Ven access cutdown < 1 yr Ven access cutdown < 1 yr Ven access cutdown < 1 yr Ven access cutdown < 1 yr Nen access cutdown < 1 yr Nen access cutdown < 1 yr Ven access cutdown < 1 yr Ven access cutdown < 1 yr Ven access cutdown < 1 yr Ven access cutdown < 1 yr Ven access cutdown < 1 yr Ven access cutdown < 1 yr Ven access cutdown < 1 yr Ven access cutdown < 1 yr Ven access cutdown < 1 yr Nerange/transfuse non-nb Irransfusion of catheter, vein Insertion of catheter, vein Apheresis plasma Apheresis plasm
Modifier	
CPT/ HCPCS Code	36246 36247 36247 36247 36247 36260 36260 36400 36415 36416 36416 36416 36416 36416 36416 36416 36416 36416 36416 36410 36610

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 59 OF 173

Charge Method- ology	MD BB
Total Expense RVUs	0.51
Non- Facility Practice Expense RVUs	0.49 0.038 0.029 0.029 0.024 0.027 0.0
Facility Practice Expense RVUs	7.69 0.038 0.024 0.025 0.0
Work Expense RVUs	0.75 0.30 0.30 0.32 1.15 0.32 1.15 0.32 1.15 0.32 1.15 0.32 1.15 0.32 1.15 0.32 1.15 0.32 1.15 0.32 1.15 0.32 1.15 0.32 1.15 0.32 1.15 0.32 1.15 0.32 1.15 0.32 1.15 0.32 1.15 0.32 1.15 0.32 1.15 0.32 1.15 0.33 1.15
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Remove cva lumen obstruct Collect blood venous device Declot vascular device Withdrawal of arterial blood Insertion catheter, artery Insertion catheter, artery Insertion catheter, artery Insertion catheter, artery Insertion of cannula Insertion of cannula Insertion of cannula Insertion of cannula Av fusion/forearm vein Av fusion/forearm vein Av fusion/forearm vein Av fusion/forearm vein Av fusion direct any site Insertion of cannula(s) Insertion of cannula(s) Artery-vein autograft Avtery-vein autograft Avtery-vein nonautograft Artery-vein nonautograft Artery-vein nonautograft Artery-vein autograft Artery-vein autograft Artery-vein nonautograft Artery-vein nonautograft Artery to vein shunt External cannula declotting Cannula d
Modifier	
CPT/ HCPCS Code	36537 36540 36550 36600 36620 36620 36620 36635 36640 36620 36640 36620 36640 36640 36640 36640 36819 36819 36819 36823 36823 36823 36823 36823 36823 36833 36833 36835 36835 36836 37140 37141 37141 37202 37203

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 60 OF 173

	Charge Method- ology		Micr		Misc		S S S	X & &	S, A	S &	S,A	
	Total Expense RVUs		1 63	3	27.62		1.65	1.73	1.73	1.43	1.73	
	Non- Facility Practice Expense RVUs	0 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8	6.11	6.56 6.94 7.04	200	0.61					0.43	0.54
	Facility Practice Expense RVUs	0.88 0.08 0.00 0.00 0.00 0.00 0.00 0.00	6.11	6.56 6.94 1.68 7.04	5 6	0.61				•	4.64	2.42
	Work Expense RVUs	1.60 1.155 1.125 1	8.34	14.50 15.31 4.80 15.82	78.0	200	3				1.08	4.54
	Status/ Usage Indicator											
	Conversion Factor/GAAF Category	Surgery Surgery	Surgery	Surgery Surgery Surgery Surgery	Surgery Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery	Surgery Surgery
	CPT/HCPCS Code Description			Removal of spleen, total Removal of spleen, total Removal of spleen, total Repair of ruptured spleen			sils				Harvest stem cell concentre Bone marrow aspiration	
	Modifier											
	CPT/ HCPCS Code	37251 37565 37565 37606 37606 37605 37615 37615 37615 37616 37700 37700 37730 37730 37730 37730 37730 37730 37730	37790	38100 38101 38102 38115	38129	38205 38205 38206	38207 38208	38210 38211	38212	38214	38215 38220	38221 38230

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 61 OF 173

	Charge Method- ology	Misc	Misc	Misc
	Total Expense RVUs	26.88	8.09	14.79
	Non- Facility Practice Expense RVUs	0.00 0.00	7.58 7.19 7.30 9.05	7.73
	Facility Practice Expense RVUs	0.84 0.070 0.088 0.0	7.58 7.19 7.30 9.05	7.73
	Work Expense RVUs	2.22 4.22 6.00	6.10 11.79 13.62 17.42	13.19
	Status/ Usage Indicator			
	Conversion Factor/GAAF Category	Surgery Surger	Surgery Surgery Surgery Surgery Surgery	Surgery
	CPT/HCPCS Code Description	Bone marrow/stem transplant Bone marrow/stem transplant Cymphocyte infuse transplant Drainage, lymph node lesion Drainage, lymph node lesion Incision of lymph channels Thoracic duct procedure Thoracic duct procedure Thoracic duct procedure Thoracic duct procedure Biopsy/removal, lymph nodes Biopsy/removal, lymph nodes Biopsy/removal, lymph nodes Biopsy/removal, lymph nodes Biopsy/removal, lymph nodes Biopsy/removal, lymph nodes Biopsy/removal, lymph nodes Biopsy/removal, lymph nodes Biopsy/removal, lymph nodes Explore deep node(s), neck Removal, neck/armpit lesion Removal, neck/armpit lesion Removal, abdomen lymph nodes Laparoscopy, lymphadenectomy Laparoscopy, lymphadenectomy Laparoscope, lymphadenectomy Laparoscope proc, lymphadenectomy Laparoscope proc, lymphadenectomy Laparoscope proc, lymphadenectomy Removal of lymph nodes, neck Removal of lymph nodes Remove armpit lymph nodes Remove armpit lymph nodes Remove armpit lymph nodes Remove aptoin lymph nodes Remove aptoin lymph nodes Remove aptoin lymph nodes Remove aptoin lymph nodes Remove aptoin lymph nodes Remove aptoin lymph nodes Remove aptoin lymph nodes Remove aptoin lymph nodes		Chest procedure Repair diaphragm laceration
	Modifier			
	CPT/ HCPCS Code	38240 38241 38242 38242 38306 38306 38380 38381 38500 38500 38500 38500 38525 38526 38526 38526 38526 38570 38570 38570 38746 38746 38746 38746 38770 38770 38770 38770 38770 38770 38770 38770 38770 38770 38770	38999 38999 39000 39200 39220 39220	39400 39499 39501

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 62 OF 173

Charge Method- ology	Misc
Total Expense RVUs	32.77
Non- Facility Practice Expense RVUs	84.688867778686868686868686868686868686868
Facility Practice Expense RVUs	8.48 8.88
Work Expense RVUs	688 66 66 66 66 66 66 66 66 66 66 66 66
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Repair paraesophageal hernia Repair of diaphragm hernia Repair of diaphragm hernia Repair of diaphragm hernia Repair of diaphragm hernia Repair of diaphragm hernia Repair of diaphragm hernia Repair of diaphragm hernia Repair of diaphragm hernia Resect diaphragm hernia Resect diaphragm hernia Resect diaphragm complex Diaphragm surgery procedure Biopsy of lip Partial excision of lip Partial excision of lip Partial excision of lip Reconstruct lip with flap Reconstruct lip with flap Repair lip Repair lip Repair lip Repair cleft lip/nasal Repair mouth lesion Recise/repair mouth lesion Reconstruction of mouth Reconstruction of mouth Reconstruction of mouth Reconstruction of mouth Reconstruction of mouth Reconstruction of mouth Reconstruction of mouth Reconstruction of mouth
Modifier	
CPT/ HCPCS Code	39502 39503 39503 39503 39530 39540 39540 39540 39560 39560 40490 40500 40500 40500 40500 40500 40500 40500 40500 40500 40500 40500 40654 40701 40701 40701 40800 40800 40810 40810 40810 40811 40810 40811 40810 408110 40810

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 63 OF 173

Charge Method- ology	Misc	Misc	MDR
Total Expense RVUs	3.92	5.39	5.28 1.19
Non- Facility Practice Expense RVUs	0.00 0.00	1.37	2.45 2.36 2.36 2.64
Facility Practice Expense RVUs	0.092	1.97	2.83 3.58 2.40 2.64
Work Expense RVUs	8.55 1.30	1.17	2.31 3.30 1.31 2.31
Status/ Usage Indicator			
Conversion Factor/GAAF Category	Surgery Surgery	Surgery Surgery Surgery Surgery	Surgery Surgery Surgery Surgery Surgery
CPT/HCPCS Code Description	Reconstruction of mouth Mouth surgery procedure Drainage of mouth lesion Drainage of mouth lesion Drainage of mouth lesion Drainage of mouth lesion Drainage of mouth lesion Drainage of mouth lesion Drainage of mouth lesion Drainage of mouth lesion Drainage of mouth lesion Drainage of mouth lesion Drainage of mouth lesion Drainage of mouth lesion Drainage of mouth lesion Drainage of mouth lesion Drainage of mouth lesion Drainage of mouth lesion Drainage of mouth lesion Drainage of mouth lesion Drainage of mouth lesion Excision of tongue lesion Excision of tongue lesion Excision of tongue lesion Excision of tongue lesion Excision of tongue lesion Excision of tongue lesion Excision of tongue lesion Excision of tongue lesion Excision of tongue lesion Fartial removal of tongue excision of tongue lacer surgery Tongue, mouth, iaw surgery Tongue, mouth, iaw surgery Tongue, mouth, iaw surgery Tongue, mouth, iaw surgery Tongue, in lips vurgery Repair tongue laceration Repair tongue laceration Fixation of tongue	Tongue and mouth surgery Drainage of gum lesion Removal foreign body, gum	Kemoval foreign body, lawbone Excision, gum, each quadrant Excision of gum lesion Excision of gum lesion Excision of gum lesion Excision of gum lesion Excision of gum lesion Excision of gum lesion
Modifier			
CPT/ HCPCS Code	40894 408995 410006 410006 410006 410009 411009 41110 411	41800 41800 41805	4 1 1 8 2 6 1 8 2 9 1 8 2 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 64 OF 173

Charge Method- ology	MDR Misc
Total Expense RVUs	2.64 6.60 8.37 6.32
Non- Facility Practice Expense RVUs	23.58 24.00 25.00 26.00 26.00 27
Facility Practice Expense RVUs	3.5.8 3.0.0 8.0.0 1.
Work Expense RVUs	25.8 26.8 27.6
Status/ Usage Indicator	
Conversion Factor/GAAF Category	aeny aeny aeny aeny aeny aeny aeny aeny
	Surgery Surger
CPT/HCPCS Code Description	Excision of gum lesion Excision of gum lesion Removal of gum tissue Treatment of gum tissue Treatment of gum tissue Treatment of gum tissue Repair gum Repair gum Repair gum Repair gum Repair gum Repair palore fesion Biopsy roof of mouth Excision lesion, mouth roof Excision lesion, mouth roof Excision lesion, mouth roof Excision lesion, mouth roof Excision lesion, mouth roof Excision lesion, mouth roof Excision lesion, mouth roof Excision lesion, mouth roof Repair palate Repair palate Reconstruct cleft palate Respair palate Respair palate Respair palate Repair palate Removal of salivary gland Create salivary gland Create salivary gland Salivary gland Excision of salivary cyst Removal of salivary cyst Drainage of salivary cyst Drainage of salivary cyst Drainage of salivary cyst Drainage of salivary cyst Drainage of salivary cyst Drainage of salivary cyst Drainage of salivary cyst Drainage of salivary cyst Drainage of salivary cyst Drainage of salivary cyst
Modifier	
CPT/ HCPCS Code	41828 41828 41830 41830 41870 41872 42104 42104 42104 42104 42106 42206 42206 42206 42227 42280 4280 4

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 65 OF 173

	Charge Method- ology	Misc
	Total Expense RVUs	14.42
	Non- Facility Practice Expense RVUs	24404484488888484848880400448888848484888888
	Facility Practice Expense RVUs	24404 6444 6444 6444 6444 6444 6444 6444
	Work Expense RVUs	1958 1958 1958 1958 1958 1958 1958 1958
	Status/ Usage Indicator	
	Conversion Factor/GAAF Category	Andens An
	CPT/HCPCS Code Description	Excise parotid gland/lesion Excise parotid gland/lesion Excise parotid gland/lesion Excise parotid gland/lesion Excise submaxillary gland Excise sublingual gland Excise sublingual gland Excise sublingual gland Excise sublingual gland Excise sublingual gland Repair salivary duct Parotid duct diversion Parotid duct diversion Parotid duct diversion Parotid duct diversion Parotid duct diversion Parotid duct diversion Darotid duct diversion Parotid duct diversion Parotid duct diversion Parotid duct diversion Darotid duct diversion Parotid duct diversion Darotid duct diversion Darotid duct diversion Darotid duct diversion Dilation of salivary varay Closure of salivary varay Closure of salivary duct Ligation of salivary duct Dilation of salivary duct Dilation of salivary duct Dilation of salivary duct Cisalivary surgery procedure Drainage of throat abscess Biopsy of throat Biopsy of throat Biopsy of upper nose/throat Excision of neck cyst Remove tonsils and adenoids Removal of donsils Removal of daenoids Removal of daenoids Removal of daenoids Removal of daenoids Extensive surgery of throat Excision of fonsil tags Excision of fonsil tags Excision of fonsil tags Excision of fonsil tags Excision of fonsil tags Excision of pharyngeal walls Revision of pharyngeal walls Repair throat wound
	Modifier	
	CPT/ HCPCS Code	42415 42426 42426 42426 42426 42440 42508 42508 42508 42508 42508 42508 42508 42680 42680 42802 42802 42802 42808

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 66 OF 173

	Charge Method- ology	Misc National Control of the Control
	Total Expense RVUs	7.10
	Non- Facility Practice Expense RVUs	7.8.8.8.2.2.2.2.8.8.2.2.2.2.2.2.2.2.2.2.
	Facility Practice Expense RVUs	7.52 8.65 9.65 1.65
	Work Expense RVUs	8 8 10 2 23 3 20 2 2 2 2 3 3 2 2 2 2 3 3 2 2 2 3 3 2 2 2 3 3 2 2 2 3 3 2 2 2 3 3 2 3 2 3 2 3 3 2 3 3 2 3
	Status/ Usage Indicator	
	Conversion Factor/GAAF Category	### ### #### #### #### ###############
		Surgery Surger
	CPT/HCPCS Code Description	Reconstruction of throat Repair throat, esophagus Surgical opening of throat Control throat bleeding Control throat bleeding Control nose/throat bleeding Throat surgery procedure Incision of esophagus Excision of esophagus Excision of esophagus Excision of esophagus Removal of esophagus Removal of esophagus Removal of esophagus Partial removal of esophagus Parti
	Modifier	
	CPT/ HCPCS Code	42950 42955 42955 42960 42960 42960 42970 42971 42971 42971 42971 42971 42970 43030 43030 43112 43112 43112 43124 43124 43202 43202 43202 43202 43202 43203 43203 43204 43215 43215 43226 43226 43233 4323 4323 4323 4323 4

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 67 OF 173

Charge Method- ology	Misc
Total Expense RVUs	29.47
Non- Facility Practice Expense RVUs	2.2703 2.
Facility Practice Expense RVUs	0.20 0.20
Work Expense RVUs	2.86 6.86 6.86 7.35 7.35 8.30 8.30 8.30 8.30 8.30 8.30 8.30 8.30
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surgery
CPT/HCPCS Code Description	Upper GI endoscopy, biopsy Esoph endoscope w/drain cyst Upper GI endoscopy w/lus fin bx Upper gi endoscopy w/lus fin bx Upper gi endoscopy w/lus fin bx Upper gi endoscopy w/lus fin bx Upper gi endoscopy/ligation Uppr gi scope dilate strictr Place gastrostomy tube Operative upper GI endoscopy Uppr gi endoscopy/quide wire Esoph endoscopy/quide wire Esoph endoscopy/quide wire Uppr gi endoscopy/quide wire Esoph endoscopy wistent Operative upper GI endoscopy Uppr gi endoscopy wistent Operative upper GI endoscopy Operative upper GI endoscopy Operative upper GI endoscopy Operative upper GI endoscopy Operative upper GI endoscopy Coperative upper GI endoscopy Uppr gi endoscopy ultrasound exam Endo cholangiopancreatograph Endo cholangiopancr
Modifier	
CPT/ HCPCS Code	43239 43240 43241 43241 43243 43243 43244 43246 43246 43250 43250 43250 43250 43262 43262 43262 43263 43263 43263 43263 43263 43263 43263 43263 43263 43263 43263 43263 43263 43310 43320 43330 43330 43330 43330 43331 43331 43331 43331 43331 43331 43331 43331 43331 43331 43331 43331 43331 43331 43331 43331 43331 43331

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 68 OF 173

Charge Method- ology	PHCS Misc	Misc
Total Expense RVUs	65.67 33.65	16.19
Non- Facility Practice Expense RVUs	6 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	2.52 2.62 0.80
Facility Practice Expense RVUs	6 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	2.62 1.42 0.80
Work Expense RVUs	22.20 22.20 22.20 22.20 20.20	4.49 1.10 2.01
Status/ Usage Indicator		
Conversion Factor/GAAF Category	Surgery Surger	Surgery Surgery Surgery Surgery Surgery Surgery
CPT/HCPCS Code Description	Surgical opening, esophagus Gastrointestinal repair Gastrointestinal repair Ligate esophagus veins Esophagus surgery for veins Ligatefstaple esophagus Repair esophagus wound Repair esophagus opening Dilate esophagus Dilate esophagus Dilate esophagus Dilate esophagus Dilate esophagus Dilate esophagus Dilate esophagus Surgical repair of stomach Surgical repair of stomach Surgical repair of stomach Surgical repair of stomach Surgical repair of stomach Surgical repair of stomach Surgical opening of stomach Surgical repair of stomach Surgical opening of stomach Surgical opening of stomach Excision of stomach lesion Excision of stomach lesion Excision of stomach lesion Excision of stomach Removal of stomach Removal of stomach Removal of stomach Removal of stomach Removal of stomach, partial	Laparoscopy, vagus nerve Laparoscopy, gastrostomy Laparoscope proc, stom Place gastrostomy tube Nasal/orogastric w/stent Change gastrostomy tube Reposition gastrostomy tube
Modifier		
CPT/ HCPCS Code	43352 43360 43360 43361 4340 43415 43420 43420 43420 43420 43420 43456 43456 43456 43450 43500 43500 43500 43500 43520 43631 43621 43632 43633	43652 43653 43659 43750 43760 43761

NOTES: OPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 69 OF 173

Charge Method- ology	Wisc Wisc
Total Expense RVUs	29.29
Non- Facility Practice Expense RVUs	44.6 44.6 44.6 44.6 44.6 44.6 44.6 46.6
Facility Practice Expense RVUs	44.6.6.6.4.4.7.7.1.0.2.0.0.2.0.0.2.0.0.2.0.0.2.0.0.0.0.0
Work Expense RVUs	\$25.50 \$2.50
Status/ Usage Indicator	-
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Reconstruction of pylorus Fusion of stomach and bowel Fusion of stomach and bowel Fusion of stomach and bowel Place gastrostomy tube Place gastrostomy tube Place gastrostomy tube Place gastrostomy tube Place gastrostomy tube Place gastrostomy tube Place gastrostomy tube Place gastrostomy tube Place gastrostomy tube Place gastrostomy tube Repair of stomach-bowel fusion Revise stomach-bowel fusion Revise stomach-bowel fusion Revise stomach-bowel fusion Revise stomach-bowel fusion Revise stomach-bowel fusion Revise stomach-bowel fusion Revise stomach-bowel fusion Repair stomach-bowel fusion Revise stomach-bowel fusion Repair stomach-bowel fusion Repair stomach-bowel fusion Repair stomach-bowel fusion Revise stomach-bowel fusion Revise stomach-bowel fusion Revise stomach-bowel fusion Incision of small bowel Insert needle cath bowel Explore small intestine Decompress small bowel Incision of large bowel Reduce bowel obstruction Correct malrotation of bowel Biopsy of bowel Excise intestine lesion(s) Excision of small intestine Removal of small intestine Removal of small intestine Removal of small intestine Removal of small intestine Removal of small intestine Removal of small intestine Removal of small intestine Removal of small intestine Removal of small intestine Removal of small intestine Removal of small intestine Partial removal of colon Partial removal of colon Partial removal of colon Partial removal of colon Partial removal of colon Partial removal of colon Partial removal of colon Partial removal of colon Partial removal of colon Partial removal of colon Partial removal of colon
Modifier	
CPT/ HCPCS Code	438810 438810 438810 438810 438810 438810 438810 438810 438810 438810 438810 438810 438810 438810 438810 438810 44010 44010 44010 441111 441111 44112 44113 44113 44113 44113 44113 44113 44113 44113 44114

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 70 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	22.55. 44.44. 44.44. 44.44. 44.45. 44.66. 44.66. 44.66. 44.66. 46
Facility Practice Expense RVUs	22.21 44.44.45 66.83 66.
Work Expense RVUs	23.28.38.38.38.38.38.38.38.38.38.38.38.38.38
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Removal of colon Removal of colon/lieostomy Removal of colon/lieostomy Removal of colon/lieostomy Removal of colon/lieostomy Removal of colon/lieostomy Removal of colon/lieostomy Removal of colon/lieostomy Removal of colon Laparoscopy, eliterolysis Laparoscopy, jejunostomy Lap resect s/intestine singl Lap resect s/intestine, addl Lap resect s/intestine, addl Lap resect s/intestine, addl Lap resect s/intestine singl Lap and colectomy Lap and colectomy Lap and colectomy Lap and colectomy Lap and tolectomy Laparo total proctocolectomy Colectomy Colostomy Revision of ileostomy Revision of ileostomy Revision of colostomy Revision of colostomy Small bowel endoscopy
Modifier	
CPT/ HCPCS Code	44152 44152 44153 44155 44155 44200

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 71 OF 173

Charge Method- ology		Misc Misc
Total Expense RVUs		19.00
Non- Facility Practice Expense RVUs	0.096 1.51 1.73 1.73 1.73 1.73 1.73 1.73 1.73 1.7	6.5.0 6.0 6.0 6.0 6.0 6.0 6.0 6.0 6
Facility Practice Expense RVUs	4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5	6.50 6.50 6.50 6.50 6.50 6.50 6.50 6.50
Work Expense RVUs	22.132 2.822 2.823 2.833 2.833 2.835	10.00 10.00
Status/ Usage Indicator		
Conversion Factor/GAAF Category	Surgery Surgery	Surgery Surgery
CPT/HCPCS Code Description	Endoscopy of bowel pouch Endoscopy, bowel pouch/biop Colon endoscopy Colonoscopy with biopsy Colonoscopy with biopsy Colonoscopy of pleeding Colonoscopy of pleeding Colonoscopy & polypectomy Colonoscopy & polypectomy Colonoscopy wisnare Colonoscopy wisnare Colonoscopy wisnare Colonoscopy wisnare Colonoscopy wisnare Colonoscopy wisnare Colonoscopy wisnare Colonoscopy wisnare Colonoscopy wisnare Colonoscopy wisnare Colonoscopy wisnare Colonoscopy wisnare Colonoscopy wisnare Colonoscopy wisnare Intro- Surfure, small intestine Suture, small intestine Suture is mall intestine Colonoscopy wisnare intestine Repair bowel opening Repair bowel opening Repair bowel opening Repair bowel-bladder fistula Repair bowel-bladder fistula Repair bowel-bladder fistula Surgical revision, intestine Colonoscopy, in the colonoscopy with the	Sus bower wiprosthesis Intraop colon lavage add-on Intestine surgery procedure Excision of bowel pouch Excision of mesentery lesion Repair of mesentery Bowel surgery procedure Drain app abscess, open Drain app abscess, percut Apectomy Apectomy Laparoscopy, apectomy Laparoscope proc, app Crainage of rectal abscess Drainage of rectal abscess Drainage of rectal abscess Biopsy of rectum Removal of anorectal lesion Removal of rectum Partial removal of rectum Removal of rectum
Modifier		
CPT/ HCPCS Code	44385 444386 44386 44389 44390 44390 44603 44603 44603 44604 44606 44606 44660 44660 44660 44660	44700 44701 44800 44800 44850 44850 44900 44950 44970 44970 44970 45000 45000 45111 45111

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 72 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	2110111
Facility Practice Expense RVUs	21-01-01-01-01-01-01-01-01-01-01-01-01-01
Work Expense RVUs	8,7428,4726,454,667,746,746,746,746,746,746,746,746,74
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Partial proctectomy Partial removal of rectum Partial removal of rectum Removal of fectum Removal of fectum Removal of fectum Removal of fectum Removal of rectum and colon Partial proctectomy Pelvic exenteration Excision of rectal prolapse Excision of rectal prolapse Excision of rectal prolapse Excision of rectal lesion Excision of rectal lesion Destruction, rectal tumor Proctosigmoidoscopy wibx Proctosigmoidoscopy removal Proctosigmoidoscopy removal Proctosigmoidoscopy removal Proctosigmoidoscopy removal Proctosigmoidoscopy wilten Proctosigmoidoscopy wilten Proctosigmoidoscopy wilten Proctosigmoidoscopy wilten Proctosigmoidoscopy wilten Proctosigmoidoscopy wilten Diagnostic sigmoidoscopy wilten Diagnostic sigmoidoscopy wilten Diagnostic sigmoidoscopy wilten Sigmoidoscopy wil
Modifier	
CPT/ HCPCS Code	45113 45114 45119 45119 45120 45120 45120 45130 45300 45300 45300 45300 45300 45300 45317 45332 45333 4533 453 45

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 73 OF 173

Charge Method- ology	Misc
Total Expense RVUs	3.30
Non- Facility Practice Expense RVUs	22244.8.00 20244.
Facility Practice Expense RVUs	6.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Work Expense RVUs	7.6.4.6.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Lesion remove colonoscopy Lesion removal colonoscopy Colonoscopy wistent Repair of rectum Repair of rectum Repair of rectum Treatment of rectal prolapse Correct rectal prolapse Correct rectal prolapse Correct rectal prolapse Correct rectal prolapse Correct rectal prolapse Correct rectal prolapse Correct rectal prolapse Correct rectal prolapse Correct rectal prolapse Correct rectal prolapse Correct rectal prolapse Repair rectum/remove sigmoid Repair rectum/remove sigmoid Repair rectum/remove sigmoid Repair rectum/remove sigmoid Repair rectum/remove sigmoid Repair rectum/remove sigmoid Repair rectum/remove sigmoid Repair rectum/remove Repair rectum/remove Repair rectum/remove Repair fistula w/colostomy Reduction of rectal anarrowing Rectum surgery procedure Placement of seton Rectum surgery procedure Placement of seton Rectum surgery procedure Placement of seton Rectum surgery procedure Placement of seton Removal of nextal abscess Incision of nextal abscess Incision of anal septum Incision of anal sep
Modifier	·
CPT/ HCPCS Code	45384 45385 45387 45500 45500 45500 45500 45500 45500 45500 45500 45500 45800

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 74 OF 173

Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
	Removal of anal fistula Removal of anal fistula Repair anal fistula Removal of hemorrhoid clot Injection into hemorrhoid clot Injection into hemorrhoid clot Injection into hemorrhoid clot Injection into hemorrhoid clot Injection into hemorrhoid clot Anoscopy, remove fesion Anoscopy, remove lesion Anoscopy, remove lesion Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Repair of anal stricture Repair of anal stricture Repair of anal stricture Repair of anal stricture Repair of anal stricture Repair of anovaginal fistula Construction of absent anus Construction of absent anus Repair of cloacal anomaly Repair of cloacal anomaly Repair of cloacal anomaly Repair of cloacal anomaly Repair of cloacal anomaly Repair of cloacal anomaly Repair of anal sphincter Reconstruction of anus Repair of anal sphincter Implant artificial sphincter Implant artificial sphincter Implant artificial sphincter Destruction, anal lesion(s) Destruction of hemorrhoids Destruction of hemorrhoids Destruction of hemorrhoids Destruction of hemorrhoids Cryotherapy of rectal lesion Cryotherapy of rectal lesion Treatment of anal fissure	Surgery Surger		2.4 × 2.4 ×	8.444.0000.000.000.000.000.000.000.000.0	8.2244-1.000.00044-4.4214.238.228-24.42.42.42.42.42.42.42.42.42.42.42.42.4		
	Modifier	Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of hemorrhoid Injection into hemorrhoid Diagnostic anoscopy Anoscopy, remove lesis Anoscopy, remove lesis Anoscopy, remove lesis Anoscopy, remove lesis Anoscopy, remove lesis Anoscopy, remove lesis Anoscopy, remove lesis Anoscopy, remove lesis Anoscopy, remove lesis Anoscopy, remove lesis Anoscopy, remove lesis Anoscopy, remove lesis Anoscopy, remove lesis Repair of anal stricture Repair of anal stricture Repair of anal stricture Repair of anostruction of absent Construction of absent Repair of cloacal anom Repair of cloacal anom Repair of cloacal anom Repair of anal sphincte Reconstruction of anal sphincte Implant artificial sphincte Destruction of anal lesion Destruction of anal lesion Destruction of hemorrh Destruction of hemorrh Destruction of hemorrh Destruction of hemorrh Destruction of hemorrh Destruction of hemorrh Destruction of hemorrh Destruction of hemorrh Destruction of hemorrh Cryotherapy of rectal le Cryotherapy of rectal le Cryotherapy of rectal lesion Treatment of anal fissu	Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Repair anal fistula Repair anal fistula Repair anal fistula Anoscopy and dilation Anoscopy, remove for body Anoscopy, remove for body Anoscopy, remove fesions Anoscopy, remove lesions Anoscopy, control bleeding Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Repair of anal stricture Repair of anal stricture Repair of anowaginal fistula Repair of anowaginal fistula Repair of anowaginal fistula Repair of anowaginal fistula Repair of anowaginal fistula Construction of absent anus Construction of absent anus Construction of absent anus Construction of absent anus Construction of anomaly Repair of cloacal anomaly Repair of anal sphincter Repair of anal sphincter Repair of anal sphincter Repair of anal sphincter Repair of anal sphincter Repair of anal sphincter Repair of anal sphincter Repair of anal sphincter Repair of anal sphincter Repair of anal sphincter Repair of anal sphincter Repair of anal sphincter Repair of anal sphincter Repair of anal lesion(s) Destruction of hemorrhoids Destruction of hemorrhoids Destruction of hemorrhoids Destruction of hemorrhoids Destruction of hemorrhoids Destruction of hemorrhoids Surgery Treatment of anal fissure Treatment of anal fissure	Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Anoscopy and dilation Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Anoscopy, remove lesions Repair of anal stricture Repair of anal stricture Repair of anal stricture Repair of anal stricture Repair of anal stricture Repair of anoxapinal fistula Construction of absent anus Surgery Repair of anoxapinal fistula Construction of absent anus Surgery Repair of anal sphincter Repair of cloacal anomaly Repair of cloacal anomaly Repair of cloacal anomaly Repair of cloacal anomaly Repair of cloacal anomaly Repair of cloacal anomaly Repair of cloacal anomaly Repair of cloacal anomaly Repair of cloacal anomaly Repair of anal sphincter Repair of anal sph	Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Repair anal fistula Repair anal fistula Repair anal fistula Repair anal fistula Repair anal fistula Repair anal fistula Repair anal fistula Repair anal fistula Repair anal fistula Repair anal fistula Repair anal fistula Repair anal fistula Repair anal fistula Repair anal fistula Repair anal fistula Repair anal structure Repair and anal structure Repair anal structure Repair anal structure Repair anal structure Repair anal structure Repair anal structure Repair anal structure Repair anal structure Repair anal structure Repair ana	Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal fistula Removal of anal sistula Repair of anal sistula Repair of anal sistula Repair of anal sistula Repair of anal sistula Repair of anal sistula Repair of anal sistula Repair of anal sistula Repair of anal sistula Surgery Anoscopy, control bleeding Anoscopy, control bleeding Surgery Repair of anal sistula Surgery S	Removal of anal fistula septimental construction of absent annal septiments and feature sep	CPTHCPCS Cade Description Factor/CAME Usage (Particle Practice Particle

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 75 OF 173

_								
CPT/HCPCS Code	Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
Ligation of hemorrhoids Ligation of hemorrhoids Anus surgery procedure Needle biopsy of liver Needle biopsy, liver add-on Open drainage, liver lesion	hoids hoids edure edure rver er lesion	Surgery Surgery Surgery Surgery Surgery		1.84 2.58 1.90 1.90 16.01	3.93 4.99 8.24 0.67	2.15 2.45 0.65 0.67	1.45	Misc
Percut drain, irrer reston inject/aspirate liver cyst Wedge biopsy of liver Partial removal of liver Partial removal of liver Partial removal of liver Removal of donor liver Partial removal, donor liver Transplantation of liver Transplantation of liver Surgery for liver lesion Repair liver wound	r cyst iver liver I of liver liver nnor liver liver liver liver sision	Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery		25.50 35.50 35.50 35.50 49.19 39.15 39.15 39.15 49.16 49 49.16 49 49 49 49 49 49 49 49 49 49 49 49 49	7.55 23.43 22.34.3 22.84 22.84 22.84 22.84 22.84 23.84 23.84 23.84 23.84 23.84 24.85 24.85 24.85 24.85 24.85 26.85	7.50 7.80 7.80 7.80 7.80 7.80 7.80 7.80 7.8	53.82	PHCS
Repair liver wound Repair liver wound Repair liver wound Laparo ablate liver tumor rf Laparoscope procedure, liver Open ablate liver tumor rf Open ablate liver tumor rf Open ablate liver tumor rf	tumor rf cryosurg edure, liver Jmor rf mmor cryo	Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery		26.92 47.12 18.51 19.69 19.69 23.20 23.27	12:57 19:57 9:54 9:72 9:72 11:01 12:53	15.21 19.57 19.57 10.11 10.11 10.11	39.13	Misc
Percut ablate liver in Liver surgery procedure incision of liver duct incision of bile duct incision of bile duct clinicise bile duct sphincter incision of gallbladder incisi	dure tt tt tt incter der der der duct n n n hru skin hru skin hru skin hru skin	Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery		92.5 92.6 93.6 94.6 95.6	4.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0	4.6 4.6 6.0 6.0 6.0 6.0 6.0 6.0 6.0 6	24.27	Misc

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 76 OF 173

Charge Method- ology	Misc	Misc
Total Expense RVUs	26.92	21.11
Non- Facility Practice Expense RVUs	3.3.9 1.84 5.01 5.01 5.01 6.08 6.08 6.08 7.03 8.45 9.12 9.13 13.06 13.06 13.08 13.08	20.25 20
Facility Practice Expense RVUs	3.39 1.84 5.01 5.01 5.01 5.03 6.08 7.03 7.03 8.45 8.45 9.12 1.30 6.11 1.30 6.11 1.30 6.11 1.30 6.11 1.30 6.11 1.30 6.11 1.30 6.11 1.30 6.11 1.30 6.11 1.30 6.11 1.30 6.11 1.30 6.11 6.11 6.11 6.11 6.11 6.11 6.11 6.1	20.25 20
Work Expense RVUs	88 4 6 11 10 10 10 10 10 10 10 10 10 10 10 10	24,888,24,24,24,24,24,24,24,24,24,24,24,24,24,
Status/ Usage Indicator		
Conversion Factor/GAAF Category	Surgery Surger	Surgery Surger
CPT/HCPCS Code Description	Biliary endoscopy thru skin Laparoscopy wicholangio Laparo wicholangio Laparo wicholangiobiopsy Laparoscopic cholecystectomy Laparo cholecystectomy/expir Laparo cholecystectomy/expir Laparo cholecystectomy/expir Laparo cholecystectomy/expir Laparo cholecystectomy/expir Laparo cholecystectomy/expir Laparo cholecystectomy/expir Removal of gallbladder Removal of gallbladder Removal of gallbladder Removal of gallbladder Removal of gallbladder Removal of gallbladder Removal of gallbladder Removal of gallbladder Expioration of bile duct stone Excision of bile duct tumor Excision of bile duct tumor Excision of bile duct cyst	Fuse upper gi structures Fuse gallbladder & bowel Fuse gallbladder & bowel Fuse gallbladder & bowel Fuse gallbladder & bowel Fuse bile ducts and bowel Fuse bile ducts and bowel Fuse bile ducts and bowel Fuse bile ducts and bowel Fuse bile ducts and bowel Reconstruction of bile ducts Placement, bile duct support Fuse liver duct & intestine Suture bile duct injury Bile tract surgery procedure Drainage of abdomen Drainage of abdomen Placement of drain, pancreas Resect/debride pancreas Resect/debride pancreas Removal of pancreas Partial removal of pancreas Pancreatectomy Removal of pancreas Pancreatectomy Removal of pancreas
Modifier		
CPT/ HCPCS Code	47556 47561 47561 47562 47563 47570 47600 47610 47610 47610 47700 47711 47711 47711	47720 47721 47721 47721 47780

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 77 OF 173

Charge Method- ology	MOR	SAF Misc	Misc
Total Expense RVUs	62.79	25.86 46.42	17.54
Non- Facility Practice Expense RVUs	21.58 20.13 13.48 10.85 0.67 7.29 7.29 7.21 7.21 7.21 8.62 8.62 8.62 8.63	18 60.0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	3.42 4.03 0.80 3.81 0.97
Facility Practice Expense RVUs	21.58 20.13 10.85 10.85 10.72 7.24 7.24 7.21 7.21 8.62 8.62 8.62 8.63	148 60.00 60	3.47 4.03 0.80 3.81 0.97
Work Expense RVUs	47.89 44.10 24.10 44.10 1.95 1.95 1.13 1.13 1.13 1.13 1.13 1.13 1.13 1.1	4.6. 1.00.00	9.48 1.88 6.65 5.54
Status/ Usage Indicator			
Conversion Factor/GAAF Category	Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery	Surgery Surger	Audeins Audein
CPT/HCPCS Code Description	Pancreatectomy Pancreatectomy Removal of pancreas Removal of pancreas Pancreas removal/transplant Fuse pancreas and bowel Injection, intraop add-on Surgery of pancreatic cyst Drain pancreatic pseudocyst Crain pancreatic pseudocyst Fuse pancreas cyst and bowel Fuse pancreas cyst and bowel Pancreatorrhaphy Duodenal exclusion	Donor pancreatectomy Transpl allograft pancreas Removal, allograft pancreas Pancreas surgery procedure Exploration of abdomen Reopening of abdomen Reopening of abdomen Reopening of abdomen Drain abdominal abscess Drain, open, abdom abscess Drain, open, abdom abscess Drain, open, retroper absc Drain, percut, abdom abscess Drain, percut, retroper absc Drain, percut, retroper absc Drain, percut, retroper absc Drain, percut, peritoneal cavity Removal of abdominal fluid Remova abdomen foreign body Biopsy, abdominal lesson Removal of abdominal lesson Removal of abdominal lesson Removal of abdominal lesson Removal of abdominal lesson Removal of abdominal lesson Removal of abdominal lesson Removal of mabilicus Removal of mentum Diag laparo separate proc	Laparoscopy, aspiration Laparo drain lymphocele Laparo proc, abdm/per/oment Air injection into abdomen Insrt abdom cath for chemotx Insert abdom drain, temp Insert abdom drain, perm
Modifier			
CPT/ HCPCS Code	48153 48155 48155 48180 48500 48550 48551 48551 48554 48540	48550 48554 48556 48999 49000 49001 49001 49060 49060 49080	49323 49329 49400 49419 49420

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 78 OF 173

Charge Method- ology		Misc
Total Expense RVUs		12.73
Non- Facility Practice Expense RVUs	20000000000000000000000000000000000000	4.28 6.65 15.98
Facility Practice Expense RVUs	20000000000000000000000000000000000000	6.65 15.98
Work Expense RVUs	625 626 626 626 626 626 626 626	8.24 12.28 20.00
Status/ Usage Indicator		
Conversion Factor/GAAF Category		
	Surgery Surger	Surgery Surgery Surgery Surgery
CPT/HCPCS Code Description	Remove perm cannula/catheter Exchange drainage catheter Assess cyst, contrast inject insert abdomen-venous drain Revise abdomen-venous shunt injection, abdominal shunt Ligation of shunt Removal of shunt Removal of shunt Removal of shunt Removal of shunt Removal of shunt Removal of shunt Removal of shunt Removal of shunt Removal of shunt Removal of shunt Removal of shunt Report ing hernia baby, blocked Rpr ing hernia baby, blocked Rpr ing hernia, init, reduce Rpr ing hernia, init blocked Pro j.hem init block-5 yr Prop lihem init and hernia and Repair ing hernia, sliding Repair ing hernia, sliding Repair ing hernia, init, reduce Rpr fem hernia, init, reduce Rpr fem hernia, init, reduce Rpr ventral hern init, reduce Rpr ventral hern init, reduce Rpr ventral hern init, reduce Rpr ventral hern init, reduce Rpr ventral hern init, reduce Rpr ventral hern init, reduce Rpr ventral hern, reduce Rpr ventral hern, reduce Rpr ventral hern, reduce Rpr ventral hern, reduce Rpr umbil hern, reduce Syr Rpr umbil hern, reduce Syr Rpr umbil hern, reduce Syr Rpr umbil hern, reduce Syr Rpr umbil hern, block > 5 yr Rpr umbil hern, block > 5 yr Rpr umbil lenr, holock > 5 yr Rpr umbil lenr, holock > 5 yr Rpr umbil lenr, block > 5 yr Rpr umbil lenr, block > 5 yr Rpr umbilical lesion Repair umbilical lesion Repair umbilical lesion Repair umbilical lesion Repair umbilical lesion Repair umbilical lesion Repair umbilical lesion Repair umbilical lesion Labaro hernia repair initial	Laparo hernia repair recur Laparo proc, hernia repair Repair of abdominal wall Omental flap, extra-abdom
Modifier	·	
CPT/ HCPCS Code	499422 499423 499426 499426 499426 499426 499491 499501 499501 499572 499572 499582 499583 499583 499583 499583 499583 499583 499583 499590 499600 499600 499600 499600 499600 499600 499600 499600 499600 499600	49651 49659 49900 49904

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 79 OF 173

Charge Method- ology	MDR MDR	
Total Expense RVUs	27.81	
Non- Facility Practice Expense RVUs	4 4 5 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	10.04
Facility Practice Expense RVUs	4. 4. 5. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6. 6.	
Work Expense RVUs	6.6 6.7 6.7 6.7 6.7 6.7 6.7 6.7	17.23
Status/ Usage Indicator		
Conversion Factor/GAAF Category	Surgery Surger	Surgery
CPT/HCPCS Code Description	Omental flap, intra-abdom Abdomen surgery procedure Exploration of kidney Renal abscess, open drain Renal abscess, open drain Renal abscess, open drain Renal abscess, open drain Renal abscess, open drain Renal abscess, open drain Renoval of kidney Removal of kidney stone Removal of kidney stone Removal of kidney stone Removal of kidney stone Removal of kidney stone Removal of kidney stone Exploration of kidney Biopsy of kidney Removal of kidney Biopsy of kidney Biopsy of kidney Removal of kidney Removal of kidney Removal of kidney lesion Removal of kidney lesion Removal of kidney lesion Removal of kidney lesion Removal of kidney lesion Removal of kidney lesion Removal of kidney lesion Removal of kidney lesion Removal of kidney lesion Removal of kidney lesion Removal of kidney lesion Removal of kidney lesion Removal of kidney kemoval of kidney Removal of kidney lesion Removal of kidney Removal of kidney Removal of kidney lesion Insert ureteral tube Injection for kidney veray Create passage to kidney Measure kidney drain Insert ureteral tube Revision of kidney pressure Change kidney tube Revision of kidney wound Repair of kidney wound	Close kidney-skin fistula
Modifier		_
CPT/ HCPCS Code	49905 49999 50010 50021 50040 50040 50040 50070 50070 50070 50220 50220 50220 50220 50230 50230 50330	50520

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 80 OF 173

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 81 OF 173

Charge Method- ology	Misc
Total Expense RVUs	30.98
Non- Facility Practice Expense RVUs	6 9 9 9 9 1 1 1 2 1 2 1 2 1 2 1 2 1 2 1 2
Facility Practice Expense RVUs	9 9 9 9 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Work Expense RVUs	18.45 19.54 19.54 19.54 19.55
Status/ Usage Indicator	
Conversion Factor/GAAF Category	667 667 667 667 667 667 667 667 667 667
	Surgery Surger
CPT/HCPCS Code Description	Fusion of ureters Splicing of ureters Splicing of ureters Reimplant ureter in bladder Reimplant ureter in bladder Reimplant ureter in bladder Reimplant ureter in bladder Reimplant ureter in bladder Reimplant ureter in bladder Implant ureter in bowel Fusion of ureter & bowel Une shunt to intestine Construct bowel bladder Revise urine flow Replace ureter by bowel Apico-vesicostomy Transplant ureter to skin Repair of ureter Closure ureter/bowel fistula Release of ureter Closure ureter/bowel fistula Release of ureter Laparoscopy ureterolithotomy Laparo new ureter/bladder Laparoscope proc., ureter Endoscopy of ureter Chaproscope of ureter Chaproscope of ureter Chaproscopy of ureter Chaproscopy of ureter Chaproscopy of ureter Chaproscopy of ureter Chaproscopy of ureter Chaproscopy of ureter Chaproscopy of ureter Chaproscopy of ureter Chaproscopy of ureter Chaproscopy of ureter Chaproscopy of ureter Chaproscopy of ureter Chaproscopy of ureter Chaproscopy & treatment Ureter endoscopy & treatment
Modifier	
CPT/ HCPCS Code	50760 50770 50770 507780 507780 50782 508810 50811 50825 50826 50826 50826 50845 50845 50840 50940 50946 50947 50947 50947 50953 50953 50953 50953 50976 50976 50976 51000 51000 51000 51040 51040 51040 51040 51040

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 82 OF 173

			2000						
CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
51500 51525 51525 51530 51535 51530 51555 51570 51586 51586 51586 51700	\$2\$5\$5\$5\$5\$5\$5\$5\$5\$5\$5\$5\$	Removal of bladder cyst Removal of bladder lesion Removal of bladder lesion Removal of bladder lesion Repair of ureter lesion Partial removal of bladder Partial removal of bladder Revise bladder & ureter(s) Removal of bladder & ureter Removal of bladder & nodes Removal of bladder & nodes Removal of bladder & nodes Removal of bladder & nodes Removal of bladder & nodes Removal of bladder & nodes Removal of bladder x-ray Injection for bladder x-ray Injection for bladder x-ray Injection for bladder x-ray Injection for bladder cath Insert bladder cath complex Change of bladder tube Change of bladder tube Change of bladder tube Change of bladder tube Change of bladder tube Endoscopic injection/implant Treatment of bladder lesion Simple cystometrogram Complex cystometrogram Complex cystometrogram Complex cystometrogram Urine flow measurement Urine flow measurement Urine flow measurement Electro-uroflowmetry, first Electro-uroflowmetry, first Electro-uroflowmetry, first Electro-uroflowmetry, first Urethra pressure profile Anal/urinary muscle study Anal/urinary muscle study Urinary reflex study	Surgery Surger		0.00 £ £ £ £ £ £ £ £ £ £ £ £ £ £ £ £ £ £	68.6.7.7.7.0.001.4.4.4.6.1.7.4.8.8.1.7.7.7.8.8.8.9.7.7.4.8.8.7.7.4.8.8.7.4.8.8.9.7.7.4.8.8.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9	8.8.2.7.7.7.00 8.8.2.7.7.7.00 9.9.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4		
	_	-							

NOTES: OPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 83 OF 173

Charge Method- ology	∀ ∀
Total Expense RVUs	0.07
Non- Facility Practice Expense RVUs	8.77 8.79 9.70 9.70
Facility Practice Expense RVUs	2.5.0 2.
Work Expense RVUs	7 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Status/ Usage Indicator	a a
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Intraabdominal pressure test Us urine capacity measure Us urine capacity measure Us urine capacity measure Revision of bladder/urethra Attach bladder/urethra Attach bladder/urethra Attach bladder/urethra Attach bladder/urethra Attach bladder/urethra Repair bladder/wagina lesion Close bladder opening Repair bladder/wagina lesion Close bladder opening Construct bladder opening Laparo urethral suspension Construct bladder opening Laparo urethral suspension Construct bladder opening Laparo urethral suspension Cystoscopy Cystoscopy Cystoscopy and treatment
Modifier	10 P P P P P P P P P P P P P P P P P P P
CPT/ HCPCS Code	51797 51798 51798 51798 51798 51800 51840 51841

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 84 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	1.28.1.21.1.22.22.88.8.22.22.22.8.4.8.8.8.8.8.8.8.8
Facility Practice Expense RVUs	6.5.6.4.4.6.6.6.6.6.6.6.6.6.6.6.6.6.6.6.
Work Expense RVUs	2.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Cystoscopy and treatment Remove bladder stone Remove bladder stone Cystoscopy and treatment Cystoscopy, stone removal Cystoscopy, and treatment Cystoscopy and treatment Cystoscopy and treatment Cystoscopy and treatment Cystoscopy and treatment Cystoscopy and treatment Cystoscopy and treatment Create passage to kidney Cystoscopy and treatment Cystoscopy and treatment Cystoscopy and treatment Cystoureter ox by stricture tx Cystoureter ox who stricture Laser surgery of prostate Drainage of urethra Removal of urethra Removal of urethra Removal of urethra Removal of urethra
Modifier	
CPT/ HCPCS Code	52315 52317 52317 52330 52330 52337 52337 52334 52341 52361

NOTES: OPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 85 OF 173

Charge Method- ology		Misc
Total Expense RVUs		2.96
Non- Facility Practice Expense RVUs	6 6	3.30
Facility Practice Expense RVUs	6000 4 4 4 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	38.58
Work Expense RVUs	7.00 8.30	5.24 1.54 2.19
Status/ Usage Indicator		
Conversion Factor/GAAF Category	Sunderly Sun	Surgery Surgery Surgery Surgery
CPT/HCPCS Code Description	Treatment of urethra lesion Removal of urethra lesion Surgery for urethra pouch Removal of urethra gland Treatment of urethra gland Treatment of urethra gland Treatment of urethra gland Removal of urethra gland Repair of urethra stage 1 Revise urethra, stage 2 Reconstruction of urethra Reconstruct urethra, stage 2 Reconstruct urethra, stage 2 Reconstruct urethra, stage 2 Reconstruct urethra, stage 2 Reconstruct urethra, stage 2 Reconstruct urethra, stage 2 Reconstruct urethra, stage 2 Reconstruct urethra, stage 2 Reconstruct urethra, stage 2 Reconstruct urethra, stage 2 Reconstruct urethra, stage 2 Reconstruct urethra, stage 2 Reconstruct urethra, stage 2 Reconstruct urethra, stage 2 Reconstruct urethra, stage 2 Removereblace urethra sing Insert landem cuff Insert uroves nck sphincter Removereblace ur sphincter Removereblace ur sphincter Remover of urethra Repair of urethra injury Repair of urethra injury Repair of urethra injury Repair of urethra injury Repair of urethra injury Repair of urethra stricture Dilate urethra stricture	Prostatic if thermother Prostatic water thermother Urology surgery procedure Slitting of prepuce Slitting of prepuce
Modifier		
CPT/ HCPCS Code	53220 53230 53230 53230 53240 53240 53240 53270	53853 53853 54000 54001

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 86 OF 173

Conversion	Conver	sion	Status/	Work	Facility	Non- Facility	Total	Charge
O	CPT/HCPCS Code Description	Factor/GAAF Category	Usage Indicator	Expense RVUs	Expense RVUs	Practice Expense RVUs	Expense RVUs	Method- ology
Drain (Drain penis lesion	Surgery		5.32	6.51	3.05		
Destru	Destruction, perils resion(s) Destruction, penis lesion(s)	Surgery		1.22	5.59	1.39		
Cryost	irgery, penis lesion(s)	Surgery		1.24	3.12	0.54		
Laser	Laser surg, penis lesion(s)	Surgery		1.24	2.03	1.24		
Destr	ori or perils resion(s)	Surgery		2.42	5.24	2.02		
Biops	Biopsy of penis	Surgery		1.90	3.32	0.76		
Biops	Biopsy of penis	Surgery		3.50	5.55	2.07		
Treat	Treatment of penis lesion	Surgery		10.13	0.80 0.30	0.85		
Treat	Freat penis lesion, graft Treat penis lesion, graft	Surgery		15.86	98	88.86		
Treat	Treatment of penis lesion	Surger		6.15	9.53	90'9		
Parti	Partial removal of penis	Surgery		9.97	7.23	7.23		
Ren	Removal of penis	Surgery		13.53	8.43	8.43		
Rem	Remove penis & nodes	Surgery		20.14	10.94	10.94		
Rem	ove penis & nodes	Surgery		26.36	13.00	13.00		
<u>ರ</u>	Circumcision	Surgery		1.81	5.45	1.88		
ฐ <u>เ</u>	Circumcision	Surgery		2.3	1.05	1.03		
֓֞֝֞֝֓֓֓֓֓֓֓֓֓֓֓֓֟֓֓֓֓֟֓֓֓֓֓֓֓֓֓֓֓֟֝֓֓֓֓֓֓֓֓	Circumcision	Surger		3.27	1.92	1.92		
Lys	Lysis penil circumic lesion	Surgery	-	3.00	2.30	2.30		
Rec	Repair of circumcision	Surgery		3.00	2.07	2.07		
Ē	Frenulotomy of penis	Surgery		1.06	2.80	1.90		
<u> </u>	I reatment of penis lesion	Surgery		7 - 00	2.40 6.47	6.37		
- F	Treatment of penis lesion	Surgery		2.42	1.89	102	····	
<u> </u>	Prepare penis study	Surgery		1.34	0.44	0.44		
ò	Dynamic cavernosometry	Surgery		2.04	2.14	0.81		
Pe-	Penile injection	Surgery		1.19	1.12	0.40		
P.	Penis study	Surgery		1.31	4.5	0.44		
<u>a</u>	Penis study	Surgery	ros	0.00	1.41	1.41		
ב פ	Penis study	Sirano	a	0.00	2.5	2,5		
i d	Perision of penis	Surgery.	3	10 41	80.8	80.8		
9	Revision of penis	Surgery		12.49	9.25	9.25		
Re	Reconstruction of urethra	Surgery		11.83	8.82	8.82		
Sec	Reconstruction of urethra	Surgery		13.57	9.87	9.87		
Rec	Reconstruction of urethra	Surgery		16.82	10.83	10.83		
Ř	Reconstruction of urethra	Surgery	-	11.25	8.64	8.64		
Rec	Reconstruction of urethra	Surgery		13.01	8.56	8.56		
Sec.	Reconstruction of urethra	Surgery		16.31	11.06	11.06	*******	
œ (construction of urethra	Surgery		15.72	10.15	10.15		
ž ć	Revise penis/urethra	Surgery		17.03	10.09	10.03		
é (Revise penis/uremra	Surgery		2000	10.00	2,50		

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 87 OF 173

	Charge Method- ology	MDR	Misc
	Total Expense RVUs	14.97	23.60
	Non- Facility Practice Expense RVUs	7.01.14 7.01.14 7.01.15 7.01.1	3.06 3.26 3.26 3.26 3.326
	Facility Practice Expense RVUs	7.01.14 7.01.14 7.01.12 7.01.02 7.02.03 7.03 7.03 7.03 7.03 7.03 7.03 7.03 7	6.32 6.32 7.02 7.02 8.326 3.33
	Work Expense RVUs	8 627 4 4 1 1 2 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2	10.96 10.96 12.88 3.43 2.33 5.14 5.38
	Status/ Usage Indicator		
2000	Conversion Factor/GAAF Category	Surgery Surger	Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery
	CPT/HCPCS Code Description	Secondary urethral surgery Secondary urethral surgery Secondary urethral surgery Secondary urethral surgery Reconstruct urethralpenis Penis plastic surgery Repair penis Repair penis Repair penis and bladder Insert semi-rigid prosthesis Insert semi-rigid prosthesis Insert semi-rigid prosthesis Insert semi-romp penis pros Remove multi-comp penis pros Remove/replace penis prost Remov/replo penis prost Remov/replo penis prost Removireplo penis comp Revision of penis Revision of penis Revision of penis Revision of penis Revision of penis Revision of penis Revision of penis Revision of penis Revision of penis Revision of penis Revision of penis Revision of penis Removal of testis Excise lesion testis Exploration for testis Exploration for testis Exploration for testis Suspension of testis Suspension of testis Suspension of testis Reduce testis torsion Suspension of testis Revision of testis Reduce testis torsion Suspension of testis Revision of testis Repair restis in liury Revision of testis Repair restis in liury Revision of testis Repair restis in liury Revision of testis	Laparoscopy, orchiectomy Laparoscopy, orchiectomy Laparoscope proc, testis Drainage of scroftum Biopsy of epididymis Exploration of epididymis Remove epididymis lesion
	Modifier		
	CPT/ HCPCS Code	54340 54344 54344 54344 54346 54385 54385 54406 54406 54406 54406 54406 54406 54415 54415 54415 54415 54500 5500 5000 5000 5000 5000 5000 5000 5000 5000 5000 5000 5000 5000	54690 54690 54692 54699 54700 54820 54830

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 88 OF 173

	Charge Method- ology	Wisc Wisc
	Total Expense RVUs	13.57
	Non- Facility Practice Expense RVUs	2.8.8.4.4.8.8.8.9.9.9.9.9.9.9.9.9.9.9.9.9
	Facility Practice Expense RVUs	84448884488844888888888888888888888888
	Work Expense RVUs	6.52 6.53
	Status/ Usage Indicator	
100000	Conversion Factor/GAAF Category	Surgery Surger
	CPT/HCPCS Code Description	Remove epididymis lesion Removal of epididymis Removal of spermatic ducts Fusion of spermatic ducts Drainage of hydrocele Removal of hydrocele Removal of hydrocele Removal of hydrocele Removal of hydrocele Removal of scrotum Revision of scrotum Revision of scrotum Revision of scrotum Revision of scrotum Revision of scrotum Revision of scrotum Revision of scrotum Revision of scrotum Revision of sperm duct Ligation of sperm duct Removal of sperm duct Ligation of sperm duct Removal of sperm duct Revise spermatic cord veins Revise spermatic cord veins Revise spermatic cord veins Revise spermatic cord veins Revise spermatic cord veins Revise spermatic cord veins Revise spermatic cord veins Revise spermatic cord veins Revise spermatic cord veins Revise spermatic cord lesion Revise spermatic cord veins Revise spermatic cord veins Revise spermatic cord veins Revise spermatic ord veins Revise spermatic ord veins Revise spermatic pouch Incise sperm duct pouch Remove sperm duct pouch Remove sperm duct pouch Remove sperm duct pouch Remove sperm duct pouch Remove sperm duct pouch Remove sperm duct pouch Remove sperm duct pouch Remove sperm duct pouch Remove sperm duct pouch Remove sperm duct pouch Remove sperm duct pouch Remove sperm duct pouch Remove sperm duct pouch Remove sperm duct pouch Remove sperm duct pouch Remove sperm duct pouch Remove sperm duct pouch Remove sperm duct pouch Removel of prostate Drainage of prostate Extensive prostate surgery Extensive prost
	Modifier	
	CPT/ HCPCS Code	54840 54840 54860 54861 54861 55000 55040 55040 55110 55110 55110 55110 55110 55120 5520 55

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 89 OF 173

Charge Method- ology	Misc
Total Expense RVUs	26.24
Non- Facility Practice Expense RVUs	9.01 10.50 10.
Facility Practice Expense RVUs	9.01 9.01 9.02 9.02 9.03 9.03 9.03 9.03 9.03 9.03 9.03 9.03
Work Expense RVUs	8223 8223 8224 8224 8224 8224 8224 8224 8225
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Extensive prostate surgery Extensive prostate surgery Laparo radical prostate surgery Laparo radical prostate curgery Laparo radical prostate curgery Laparo radical prostate Gental surgery procedure I & D of vulva/perineum Drainage of gland abscess Surgery for vulva lesion(s) Destroy, vulva lesion's compl Biopsy of vulva/perineum Biopsy of vulva/perineum Partial removal of vulva Complete removal of vulva Extensive vulva surgery Extens
Modifier	
CPT/ HCPCS Code	55862 55865 55865 55865 55870 55873 55870 56440 56440 56440 56644 56625 56605 56631 56631 56631 56630

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 90 OF 173

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense	Non- Facility Practice Expense	Total Expense RVUs	Charge Method- ology
						RVUS	RVUs		
57120		Closure of vagina	Surgery		7.41	4.59	4.59		
57135		Remove vagina lesion	Surgery		2.67	2.87	2.13		
57150 57155		Treat vagina infection Insert uteri tandems/ovoids	Surgery		0.55	3.68	3.68		
57160		Insert pessary/other device	Surgery		0.89	1.10	0,40		
57170		Fitting of diaphragm/cap	Surgery		0.91	1.38	0.34		
57200		Repair of vaginal	Surgery		3.94	3.11	3.1		
57210		Repair vagina/perineum	Surgery		5.17	3.67	3.67		
57220		Revision of urethra	Surgery		4. n	33.34	9. % 4. 7.		
57240		Repair of ureural resion Repair bladder & vagina	Surgery		6.07	3.90	9.8		
57250		Repair rectum & vagina	Surgery		5.53	3.81	3.81		
57260		Repair of vagina	Surgery		8.27	5.14	4 %		
57268		Extensive repair of vagina Repair of bowel bulde	Surgery		6.76	4.48	0.50		
57270		Repair of bowel pouch	Surgery		12.11	6.60	6.60		
57280		Suspension of vagina	Surgery		15.04	7.73	7.73		
57282		Repair of vaginal prolapse	Surgery		8.86	5.58	5.58		
57284		Repair paravaginal defect Revise/remove slind renair	Surgery		10.71	5.60	5.60		
57288		Repair bladder defect	Surgery		13.02	6.05	6.05	-	
57289		Repair bladder & vagina	Surgery		11.58	6.26	6.26		
57291		Construction of vagina	Surgery		7.95	5.29	5.29		
57292		Construct vagina with graft	Surgery		13.03	4.85	7.30		
57305		Repair rectum-vagina fistula	Surgery		13.77	6.49	6.49		
57307		Fistula repair & colostomy	Surgery		15.93	7.55	7.55		
57308		Fistula repair, transperine	Surgery		40.00	5.89	5.89		
57311		Repair urethrovaginal lesion	Surgery		7.98	4.85	4.85		
57320		Repair bladder-vagina lesion	Surgery		8.01	4.95	4.95		
57330		Repair bladder-vagina lesion	Surgery		12.35	6.29	6.29		
57335		Repair vagina	Surgery		18.73	144	8.87		
57400		Diation of vagina	Singery		1.75	2.55	103		
57415		Remove vaginal foreign body	Surgery		2.17	3.21	1.87		
57420		Exam of vagina w/scope	Surgery		1.60	1.68	0.69		
57421		Exam/biopsy of vag w/scope	Surgery		2.20	2.08	0.98		
57452		Exam of cervix w/scope	Surgery		7.50	1.70	0.65		
5/454		EX/curett of cervix w/scope	Surgery		4.33	2.03	200		
57456		Endocery curettage w/scope	Surgery		1.85	1.86	48.0		
57460		Bx of cervix w/scope, leep	Surgery		2.83	5.01	1.25		
57461		Conz of cervix w/scope, leep	Surgery		3.44	5.32	1.50		

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 91 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	0.000000000000000000000000000000000000
Facility Practice Expense RVUs	2018 2018 2018 2018 2018 2018 2018 2018
Work Expense RVUs	2000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surgery
CPT/HCPCS Code Description	Biopsy of cervix Endocervical curettage Cauterization of cervix Laser surgery of cervix Laser surgery of cervix Conization of cervix Conization of cervix Removal of cervix Dilation of cervix Revision of cervix Dilation and curettage Myomectomy abdom method Myomectomy abdom complex Total hysterectomy Partial hysterectomy Partial hysterectomy Removal of pelvis contents Vag hyst will culding to Vag hyst will the very expair Vag hyst will the very expair Vag hyst will the complex Vag hyst will the complex Vag hyst will the complex Vag hyst will the complex Vag hyst will the cepair Complex Vag hyst will the cepair, complex Vag hyst will the cepair, complex Vag hyst will the cepair, complex Vag hyst will the cepair, complex Vag hyst will the device Remove intrauterine device Remove intrauterine device
Modifier	
CPT/ HCPCS Code	57500 57505 57505 57510 57511 57512 57513 57520 57520 57520 57530 57550 57550 57720

NOTES: OPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 92 OF 173

Charge Method- ology		Misc Misc
Total Expense RVUs		13.10
Non- Facility Practice Expense RVUs	0.10 1.33 1.33 1.33 1.33 1.33 1.33 1.33	2.71 2.328 3.129 3.129 3.639 3.639 3.639 6.635 6
Facility Practice Expense RVUs	2.21 2.22 2.22 2.22 2.22 2.22 2.22 2.22	2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2. 2
Work Expense RVUs	00000 00000 00000 00000 00000 00000 0000	5.60 5.60 5.60 5.60 5.60 5.60 5.60 5.60
Status/ Usage Indicator		
Conversion Factor/GAAF Category	Surgery Surger	Surgery Surger
CPT/HCPCS Code Description	Sperm washing Catheter for hysterography Reopen fallopian tube Insert heyman uteri capsule Reopen fallopian tube Endometr ablate, thermal Suspension of uterus Suspension of uterus Repair of ruptured uterus Revision of uterus Laparo-asst vag hysterectomy Laparo-vag hyst, complex Laparo-vag hyst, complex Laparo-vag hyst, complex Laparo-vag hyst, complex Laparo-vag hyst, witto, compl Hysteroscopy, iysis Hysteroscopy, lysis Hysteroscopy, remove myoma Hysteroscopy, remove myoma	Hysteroscopy, ablation Laparo proc, uterus Hysteroscope procedure Division of fallopian tube Ligate oviduct(s) add-on Occlude fallopian tube(s) Laparoscopy, remove adnexa Laparoscopy, remove adnexa Laparoscopy, tubal cautery Laparoscopy, tubal cautery Laparoscopy, tubal block Laparoscopy, furbioplasty Laparoscopy, furbioplasty Laparoscopy, furbioplasty Laparoscopy, sapingostomy Laparoscopy, sapingostomy Removal of fallopian tube Removal of fallopian tube(s) Repair oviduct Revise fallopian tube(s) Repair oviduct Revise ovarian tube(s) Repair oviduct Create new tubal obstruction Create new tubal opening Drainage of ovarian cyst(s)
Modifier		
CPT/ HCPCS Code	58323 58340 58345 58345 58345 58340 58410 58410 58540 58545 5855 5855 585 585 585 585 585 585 585 585 585 585 585 585 585 585 585 585 585 585 585	58563 58563 58579 58600 58605 58615 58615 58670 58672 58673 58673 58673 58673 58673 58673 58673 58673 58673 58673 58673 58770 58770 58770 58770 58770

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/IDFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 93 OF 173

Charge Method- ology	M MDR
Total Expense RVUs	. 4.68 . 5.85
Non- Facility Practice Expense RVUs	25.732 25
Facility Practice Expense RVUs	2.8.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2
Work Expense RVUs	4 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Status/ Usage Indicator	a a
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Drain ovary abscess, open Drain ovary abscess, percut Transposition, ovary(s) Biopsy of ovary(s) Bremoval of ovarian cyst(s) Removal of ovarian cyst(s) Removal of ovarian malignancy Resect ovarian malignancy Resect ovarian malignancy Resect ovarian malignancy Resect ovarian malignancy Resect ovarian malignancy Resect ovarian malignancy Resect ovarian malignancy Resect ovarian malignancy Tan, rad dissect for debulk Tan rad debulklymph remove Exploration of abdomen Retrieval of occyte Transfer of embryo Transfer of embryo Gental surgery procedure Amniocentesis, diagnostic Amniocentesis, therapeutic Fetal contract stress test Fetal contract stress test Fetal contract stress test Fetal contract stress test Fetal non-stress test Fetal non-stress test Fetal contract stress test Fetal contract stress test Fetal contract stress test Fetal contract stress test Transfer of programcy Treat ectopic pregnancy Treat ec
Modifier	26 10 10 10 10 10 10 10 10 10 10 10 10 10
CPT/ HCPCS Code	58822 58822 58822 58822 58822 58823 58820 58920 58943 58943 58951 58951 58951 58970 58970 58970 58970 58970 58970 58970 58970 58970 58970 58970 58970 58970 58970 58970 58970 58970 58970 58974 58970 59970

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 94 OF 173

Charge Method- ology	Misc Misc
Total Expense RVUs	19.62 19.62
Non- Facility Practice Expense RVUs	6.00 6.00
Facility Practice Expense RVUs	0.0004800866886660 0.000480086688666 0.00048668666 0.00048668666 0.0004866866 0.00048666 0.00048666 0.0004866 0.0004866 0.0004866<
Work Expense RVUs	£4.4 £4.4 £7.4 £7.5
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Maternity — Normal Deliveries Maternity — Normal Deliveries Maternity — Normal Deliveries Maternity — Normal Deliveries Maternity — Normal Deliveries Maternity — Normal Deliveries Maternity — Cesarean Deliveries Maternity — Cesarean Deliveries Maternity — Cesarean Deliveries Maternity — Cesarean Deliveries Maternity — Normal Deliveries Maternity — Normal Deliveries Maternity — Normal Deliveries Maternity — Norn-Deliveries Maternity — Nor-Deliveries Maternity — Non-Deliveries Maternity — Non-Selveries
CPT/HCPCS Code Description	Obstetrical care Obstetrical care Antepartum manipulation Deliver placenta Antepartum care only Antepartum care only Antepartum care only Casarean delivery Cesarean delivery Cesarean delivery Cesarean delivery Cesarean delivery Cesarean delivery Wac delivery Vbac care after delivery Vbac care after delivery Attempted vbac delivery Attempted vbac delivery Attempted vbac delivery Attempted vbac delivery Attempted vbac delivery Attempted vbac delivery Attempted vbac delivery Attempted vbac delivery Attempted vbac delivery Attempted vbac delivery Attempted vbac delivery Attempted vbac delivery Attempted vbac delivery Attempted vbac delivery Attempted vbac delivery Attempted vbac delivery Attempted vbac delivery Abortion Aborti
Modifier	
CPT/ HCPCS Code	59409 59410 59410 59414 59416 59416 59416 59416 59514 59617 59618 59618 59618 59618 59618 59618 59810 60000 60000 60020 60020 60020 60020 60020 60020 60020 60020 60020 60020 60020

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 95 OF 173

Charge Method- ology	Misc Misc
Total Expense RVUs	36.12
Non- Facility Practice Expense RVUs	1 2 3 3 3 4 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Facility Practice Expense RVUs	1 0
Work Expense RVUs	20 66 68 68 68 68 68 68 68 68 68
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Alebing Alebin
CPT/HCPCS Code Description	Removal of thyroid Removal of thyroid Remova thyroid duct lesion Remove thyroid duct lesion Remove thyroid duct lesion Explore parathyroid glands Removal of thymus gland Removal of thymus gland Removal of thymus gland Removal of thymus gland Removal of thymus gland Removal of thymus gland Removal of thymus gland Removal of thymus gland Remova adrenal gland Laparoscopy adrenalectomy Laparoscopy adrenalectomy Laparoscopy adrenalectomy Laparoscopy adrenalectomy Laparoscopy adrenalectomy Remove canial cavity fluid Remove cranial cavity fluid Remove cranial cavity fluid Remove brain canal Remove brain canal Remove brain canal Remove brain canal Remove brain canal Remove brain canal Remove brain canal Remove brain canal Remove brain canal Remove brain canal Remove brain canal Remove brain canal Remove canial cavity fluid Remove brain canal Remove canial fluid Injection into brain canal Remove brain canal Remove brain canal Remove brain canal Remove brain canal Remove brain canal Remove brain canal Remove brain canal Remove brain canal Remove brain canal Remove brain fluid for drainage Dien skull for drainage Open skull for drainage Open skull for drainage Open skull for drainage Open skull for drainage Open skull for drainage Open skull for drainage Open skull for drainage Open skull for drainage Open skull for drainage Open skull for drainage Open skull for drainage Open skull for drainage Open skull for drainage Open skull for drainage Open skull for drainage
Modifier	
CPT/ HCPCS Code	60270 60271 60281 60281 60502 60502 60502 60502 60502 60502 60503

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 96 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	\$6.44466611746666666666666666666666666666
Facility Practice Expense RVUs	\$6.4446.601176.65.65.610.012.02.02.02.02.02.02.02.02.02.02.02.02.02
Work Expense RVUs	23.288 23.286 23.386 23
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Open skull for drainage Decompressive craniotomy Decompress eye socket Explore/biopsy eye socket Explore orbit/remove lesion Explore orbit/remove lesion Explore orbit/remove object Subtemporal decompression Incise skull (press relief) Relieve cranial pressure Incise skull for surgery Incise skul
Modifier	
CPT/ HCPCS Code	61322 61323 61323 61323 61323 61323 61324 61324 61324 61510 61510 61526 61526 61526 61536

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 97 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	7.85.20 2.8.35 2
Facility Practice Expense RVUs	7. 84 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
Work Expense RVUs	44.02.02.02.02.02.02.02.02.02.02.02.02.02.
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Alabüns Alabün
CPT/HCPCS Code Description	Release of skull seams Release of skull seams Incise skull/sutures Incise skull/sutures Excision of skull/sutures Excision of skull/sutures Excision of skull tumor Excision of skull tumor Remove foreign body, brain Incise skull for brain wound Skull base/brainstem surgery Skull base/brainstem surgery Craniofacial approach, skull Craniofacial approach, skull Craniofacial approach, skull Craniofacial approach, skull Craniofacial approach, skull Craniofacial approach/skull Infratemporal approach/skull Orbitocranial approach/skull Infratemporal approach/skull Infratemporal approach/skull Infratemporal approach/skull Resect nasopharynx, skull Infratemporal approach/skull Iranspetrosal approach/skull Transpetrosal approach/skull Iranspetrosal approach/skull Iranspetrosal approach/skull Iranspetrosal approach/skull Iranspetrosal approach/skull Iranspetrosal approach/skull Resect/excise cranial lesion Resect/excise cranial lesion Resect/excise cranial lesion Resect/excise cranial lesion Resect/excise cranial lesion Resect/excise cranial lesion Resect/excise cranial lesion Resect/excise cranial lesion Resect/excise cranial lesion Resect/excise cranial lesion Resect/excise cranial lesion Resect/excise cranial lesion Resect/excise cranial lesion Resect/excise cranial lesion Iransect artery, sinus Iransect artery, sinus Resect/excise lesion, skull Resect/excise lesion, skull Repair dura Endovasc tempory vessel occl Iranscanial vessel surgery Intracranial vessel surgery Intracranial vessel surgery Intracranial vessel surgery
Modifier	
CPT/ HCPCS Code	61550 61552 61555 61555 61555 61555 61558 61558 61570 61588 61588 61588 61588 61588 61588 61588 61588 61588 61588 61588 61588 61588 61588 61588 61588 61588 61698 61619 61610 61610 61611

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 98 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	22,882,222,232,242,242,242,242,242,242,242,24
Facility Practice Expense RVUs	23.25 24.25 25.25
Work Expense RVUs	29.84 29.84 29.84 29.84 29.87 20.87
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surgery
CPT/HCPCS Code Description	Intracranial vessel surgery Intracranial vessel surgery Intracranial vessel surgery Intracranial vessel surgery Brain aneurysm rept, comply Brain aneurysm rept, comply Brain aneurysm rept, comply Brain aneurysm rept, simple Inner skull vessel surgery Clamp neck artery Revise circulation to head Revise circulation to head Revise circulation to head Revise circulation to head Revise circulation to head Revise circulation to head Revise circulation to head Revise circulation to head Revise circulation to head Revise circulation to head Revise circulation to head Revise circulation to head Revise circulation to head Revise circulation beam Incise skull/brain surgery Incise skull/brain surgery Incise skull/brain surgery using computer Implant beuroelectrodes Implant neuroelectrodes Implant neurostim one array Implant neurostim arrays Revise/remove neuroelectrodes Implant neurostim arrays Revise/remove neuroelectrodes Implant neurostim arrays Revise/remove neuroelectrodes Implant neurostim arrays Repair of skull ferfect Reduction of skull defect Repair of skull defect Repair of skull defect Repair of skull ledect Repair of skull ledect Repair of skull plate/flap Replair of skull plate/flap Replair of skull plate/flap Replair of skull brain
Modifier	
CPT/ HCPCS Code	61684 61686 61692 61692 61693 61700

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 99 OF 173

		Conversion	Status/	Work	Facility Practice	Non- Facility	Total	Charge
Modifier	CPI/HCPCS Code Description	Faciofyskar Category	Usage	Expense	Expense RVUs	Expense RVUs	RVUs	ology
	Repair of skull with graft	Surgery		16.12	10.40	10.40		
	Repair of skull with grant Retr bone flap to fix skull	Surgery		2.00	0.82	0.82		
	Neuroendoscopy add-on	Surgery		3.00	1.16	1.16		
	Dissect brain w/scope	Surgery		20.00	9.71	9.71		
	Remove colloid cyst w/scope	Surgery		25.25	11.89	11.89		
	Neuroendoscopy w/tb removal	Surgery		15.50	13.12	13.12		
	Domoto pituit tumor w/scope	Surger		22.00	10.12	10.12		
	Fetablish brain cavity shint	Surgery		21.06	12.90	12.90		
	Establish brain cavity shunt	Surgery		11.07	7.73	7.73		
	Establish brain cavity shunt	Surgery		12.25	8.27	8.27		
	Replace/irrigate catheter	Surgery		5.03	2.77	2.77		
	Establish brain cavity shunt	Surgery		18.32	11.59	11.59		
	Brain cavity shunt w/scope	Surgery		14.86	9.77	9.77		
	Establish brain cavity shunt	Surgery		13.00	8.65	8.65		
	Establish brain cavity shunt	Surgery		12.87	8.51	8.51		
	Replace/irrigate catheter	Surgery		5.41	4.81	4.81		
	Replace/revise brain shunt	Surgery		10.54	7.23	7.23		
26	Csf shunt reprogram	Surgery		0.74	0.38	0.38		
ပ	Csf shunt reprogram	Surgery	æ	0.00	1.09	1.09		
	Remove brain cavity shunt	Surgery		0.60	0.40	0.45		
	Replace brain cavity shunt	Surgery		14.54	42.94	4.34		
	Epidural lysis mult sessions	Surgery		0.4	24.0	4.45		
	Epidural lysis on single day	Surgery		4.45	2.71	25.1		
	Mode Figures aring out	Suigery		1 0	23.7	2.7		
	Spinal fluid tan diagnostic	Views Views		1 13	3.78	0.50		
	Drain cerebro spinal fluid	Sirgery		1.35	4.85	0.65		
	Treat epidural spine lesion	Surgery		2.15	2.79	0.58		
	Treat spinal cord lesion	Surgery		2.63	9.34	0.82		
	Treat spinal cord lesion	Surgery		2.66	7.92	0.72		
	Treat spinal canal lesion	Surgery		2.33	11.43	0.73		
	Injection for myelogram	Surgery		1.54	20.9	0.61		
	Percutaneous diskectomy	Surgery		8.08	5.04	5.04		
	Inject for spine disk x-ray	Surgery		3.00	8.54	1.29		
_	Inject for spine disk x-ray	Surgery		2.91	7.28	1.15	-	
	Injection into disk lesion	Surgery		7.86	5.04	5.04		
	Injection into spinal artery	Surgery		11.83	6.68	99.9		
	Inject spine c/t	Surgery		1.91	4.91	0.51		
	Inject spine I/s (cd)	Surgery		1.54	5.02	0.45		
	Inject spine w/cath, c/t	Surgery		2.04	5.53	0.52		
	Inject spine w/cath I/s (cd)	Surgery		1.87	4.90	0.48		
	Implant spinal canal cath	Surgery		6.87	3.64	3.64		
	Implant spinal canal cath	Surgery		10.00	6.72	6.72		
-	Remove spinal canal catheter	Surgery		5.45	2.82	2.82		

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 100 OF 173

Charge Method- ology	SAF MDR MDR
Total Expense RVUs	1.04
Non- Facility Practice Expense RVUs	22.23.24.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.
Facility Practice Expense RVUs	86.50 86.00 86
Work Expense RVUs	2.65 2.65
Status/ Usage Indicator	ൻ ൻ
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Insert spine infusion device Implant spine infusion pump Remove spine infusion pump Analyze spine infusion pump Analyze spine infusion pump Analyze spine infusion pump Analyze spine infusion pump Analyze spine infusion pump Analyze spine infusion pump Analyze spine infusion pump Removal of spinal lamina Removal of spinal lamina Removal of spinal lamina Removal of spinal lamina Removal of spinal lamina Removal of spinal lamina Removal of spinal lamina Removal of spinal lamina Removal of spinal lamina Removal of spinal lamina Removal of spinal lamina and-on Laminotomy, single lumbar Laminotomy, add cervical Laminotomy, add cervical Laminotomy, add cervical Laminotomy, add cervical Laminotomy, add cervical Caminotomy, single lumbar Removal of spinal lamina Removal of spinal lamina Removal of spinal lamina de-on Decompress spinal cord Decompress spinal cord Decompress spinal cord Decompress spinal cord add-on Neck spine disk surgery, thorax Spine disk surgery, thorax Spine disk surgery, thorax Spine disk surgery, thorax Spine disk surgery, thorax Spine disk surgery, thorax Spine disk surgery, thorax Spine disk surgery of vertebral body add-on Removal of vertebral body add-o
Modifier	129 129 129 129
CPT/ HCPCS Code	62360 62361 62362 62363 62364 62367 62368 62368 63001 63001 63001 63004 63045 63046 63046 63046 63046 63046 63046 63046 63046 63066 63066 63066 63067 63068 63068 6308 630

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 101 OF 173

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
63173		Drainage of spinal cyst	Surgery		21.99	15.22	15.22		
63182 63182	•	Revise spinal cord ligaments Revise spinal cord ligaments	Surgery		20.50	12.93	12.93		
63185		Incise spinal column/nerves	Surgery		15.04	9.82	9.82		
63190 63191		Incise spinal column/nerves	Surgery		17.54	12.31	12.31		
63194		Incise spinal column & cord	Surgery		19.19	13.35	13.35		
63195		Incise spinal column & cord	Surgery		22.30	13.65	13.65		
63197		Incise spinal column & cord	Surgery		21.11	13.85	13.85		
63198		Incise spinal column & cord	Surgery		25.38	10.80	10.80		
63200			Surgery		19.18	13.10	13.10		
63250		Revise spinal cord vessels	Surgery		40.76	20.69	20.69		
63251		Revise spinal cord vessels	Surgery		41.20	23.26	23.26		
63252		Kevise spinal cord vessels Excise intraspinal lesion	Surgery		21.56	13.30	13.30		
63266		Excise intraspinal lesion	Surgery		22.30	13.73	13.73		
63267		Excise intraspinal lesion	Surgery		17.95	11.53	11.53		
63268		Excise intraspinal lesion	Surgery		18.52	10.86	10.86		
63270		Excise intraspinal tesion Excise intraspinal tesion	Surgery		26.92	16.20	16.20		
63272		Excise intraspinal lesion	Surgery		25.32	15.27	15.27		
63273		Excise intraspinal lesion	Surgery		24.29	14.89	14.89	•	
63275		Biopsy/excise spinal (umor	Surgery		23.00	14.23	5, 4 2, 23 2, 23		
63277		Biopsy/excise spinal tumor	Surgery		20.83	13.01	13.01		
63278		Biopsy/excise spinal tumor	Surgery		20.56	12.84	12.84		
63280		Biopsy/excise spinal furnor Biopsy/excise spinal furnor	Surgery		28.05	16.64	16.64		
63282		Biopsy/excise spinal tumor	Surgery		26.39	15.77	15.77		
63283		Biopsy/excise spinal tumor	Surgery		25.00	15.09	15.09		
63285		Biopsy/excise spinal tumor	Surgery		36.00	20.53	20.53		
63280		Biopsy/excise spinal fumor	Surgery		36.70	21.04	21.04		
63290		Biopsy/excise spinal tumor	Surgery		37.38	21.18	21.18		
63300		Removal of vertebral body	Surgery		24.43	14.84	14.84		
63301		Removal of vertebral body	Surgery		27.60	15.84	15.84		
63302		Removal of Vertebral body Removal of vertebral body	Surgery		30.50	17.39	17.39		
63304		Removal of vertebral body	Surgery		30.33	17.77	17.77		
63305		Removal of vertebral body	Surgery		32.03	18.30	18.30		
63306		Removal of vertebral body	Surgery		32.22	18.04	18.04		
63307		Removal of Vertebral body	Surgery		5.05	2.53	2.67		
63600		Remove spinal cord lesion	Surgery		14.02	6.03	6.03		

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 102 OF 173

			201 201						
CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
63610 63655 63656 63656 63660 63688 63702 63702 63704 63704 63746 64413 64413 64415 64416 64416 64416 64416 64416 64417 64416 64417 64417 64416 64417 64416 64417 64416 64417 64417 64416 64417 64416 64417 64416 64417 64416 64417 64416 64417 64416 64417 64417 64416 64417 64417 64416 64417 64416 64417 64416 64417 64416 64417 64418 64417 64418 64416 64416 64416 64417 64416 64417 64418 64417 64418 64417 64418 64417 64418 64417 64418 64418 64418 64419 64418 64419		Stimulation of spinal cord Remove lesion of spinal cord Implant neuroelectrodes Implant neuroelectrodes Revise/remove neuroelectrode Implant neuroelectrodes Revise/remove neuroelectrode Implant neuroelectrodes Revise/remove neuroelectrode Repair of spinal herniation Repair of spinal herniation Repair of spinal herniation Repair of spinal herniation Repair of spinal herniation Repair of spinal herniation Repair of spinal herniation Repair of spinal herniation Repair of spinal herniation Repair of spinal herniation Repair of spinal herniation Repair of spinal shunt Revision of spinal shunt Revision of spinal shunt N block ini, trigeminal N block ini, trigeminal N block ini, phrenic N block ini, spinal accessor N block ini, spinal accessor N block ini, spinal accessor N block ini, phrenic N block ini, metroost, mit N block ini, intercost, mit N block ini, intercost, mit N block ini, intercost, mit N block ini, paracervical N block ini, paracervical N block ini, paracervical N block ini, paracervical N block ini, paracervical N block ini, paracervical N block ini, paravertebral (stadd-on ini paravertebral (stadd-on ini paravertebral (stadd-on ini foramen epidural add-on ini foramen epidural add-on ini foramen epidural lis	Surgery Surger		8 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6	88.44.00116.888.44.1.1.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9.9.	889.47.625.888.47.40.000.000.000.000.000.000.000.000.0		

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 103 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	8.4.28.6.000
Facility Practice Expense RVUs	24 - 4 - 4 - 4 - 6 - 6 - 6 - 6 - 6 - 6 -
Work Expense RVUs	25.21 25.21 25.21 25.21 25.21 25.22 25.23 25
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	In foramen epidural add-on N block, spenopalatine gangl N block, stellate ganglion N block istellate ganglion N block in whar/thoracic N block in cellac pelus In block in cellac pelus Apply neurostimulator Implant neuroelectrodes Injection treatment of nerve Destroy nerve, extrem musc Injection treatment of nerve Destroy nerve, extrem musc Injection treatment of nerve Destro paravertebral nedd-on Destro paravertebral nedd-on Injection treatment of nerve Injection treatment of nerve Revise anm/leg nerve Revise anm/leg nerve Revise of arm nerve at elibow Revise ulnar nerve at elibow Revise ulnar nerve at wrist Carpal tunnel surgery Relieve pressure on nerve(s)
Modifier	
CPT/ HCPCS Code	64484 64508 64508 64508 64508 64508 64553 64553 64553 64565 64561 64573 64612 64612 64612 64612 64613 64713 64713

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 104 OF 173

CPT/			Conversion	Status/	Work	Facility	Non- Facility	Total	Charge
HCPCS	Modifier	CPT/HCPCS Code Description	Factor/GAAF Category	Usage Indicator	Expense	Expense	Practice Expense	Expense	Method-
			() () () () () () () () () ()			RVUs	RVUs		66
64727		Internal nerve revision	Surgery		3.10	1.54	1.54		
64/32		Incision of cheek perve	Surgery		4.4	3.64	80.6 40.6		
64736		Incision of chin nerve	Sugar		4 60	2.95	200		
64738		Incision of jaw nerve	Surgery		5.73	3.65	3.65		
64740		Incision of tongue nerve	Surgery		5.59	3.82	3.82		
64742		Incision of facial nerve	Surgery		6.22	4.71	4.71		
64/44		Incise nerve, back of head	Surgery		5.24	00.4	00.4		
64/46		Incise diaphragm nerve	Surgery		5.93 7.06	94.4	4.49		
64755		Incision of stomach nerves	Surgery		13.52	6.17	6.17		
64760		Incision of vagus nerve	Surgery		96.9	4.02	4.02		
64761		Incision of pelvis nerve	Surgery		6.41	3.63	3.63		
64763		Incise hip/thigh nerve	Surgery		6.93	6.07	6.07		
64/66		Incise nip/mign nerve	Surgery		70.07	0.00	0.00		
64772		Decision of spinal nerve	Surgery		7.27	20.02	20.62		
64774		Remove skin nerve lesion	Surgery		5.17	3.78	3.78		
64776		Remove digit nerve lesion	Surgery		5.12	3.84	3.84		
64778		Digit nerve surgery add-on	Surgery		3.11	1.54	1.54		
64782		Remove limb nerve lesion	Surgery		6.23	3.72	3.72		
64783		Limb nerve surgery add-on	Surgery		3.72	1.85	1.89		
64786 64786		Remove nerve lesion Remove sciatic nerve lesion	Surgery		15.46	10.00	10.00		
64787		Implant nerve end	Surgery		4.30	2.18	2.18		
64788		Remove skin nerve lesion	Surgery		4.61	3.48	3.48		
64790		Removal of nerve lesion	Surgery		11.31	7.29	7.29		
64792		Removal of nerve lesion	Surgery		14.92	8.85	8.85		
64/95		Blopsy of nerve	Surgery		3.07	7.80	7.80		
64804		Remove sympatic nerves	Surgery		14.64	7.42	7.42		
64809		Remove sympathetic nerves	Surgery		13.67	6.31	6.31		
64818		Remove sympathetic nerves	Surgery		10.30	5.77	5.77		
64820		Remove sympathetic nerves	Surgery		10.37	7.44	7.44		
64821		Remove sympathestic nerves	Surgery		8.75	9.23	9.23		
64822		Remove sympathetic nerves	Surgery		8.75	9.23	9.23		
64823		Remove sympathetic nerves	Surgery		10.37	10.03	10.03		
64831		Repair of digit nerve	Surgery		44.24	47.7	47.7		
64637		Repair of hand or foot negre	Surgery		10.00	20.02	20.02		
64835		Repair of hand or foot nerve	Surgery		10.94	7.86	7.86		
64836		Repair of hand or foot nerve	Surgery		10.94	7.83	7.83		
64837		Repair nerve add-on	Surgery		6.26	3.31	3.31		
64840		Repair of leg nerve	Surgery		13.02	8.34	8.34		
64856		Repair/transpose nerve	Surgery		13.80	9.40	9.40		
64857		Repair arm/leg nerve	Surgery	_	14.49	9.87	9.87	_	

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 105 OF 173

Charge Method- ology	Misc
Total Expense RVUs	99
Non- Facility Practice Expense RVUs	0.022228
Facility Practice Expense RVUs	0.22228
Work Expense RVUs	64.4 64.4 64.6 65.6 66.6
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Andery Surgery
CPT/HCPCS Code Description	Repair sciatic nerve Nerve surgery Repair of law back nerves Repair of facial nerve Repair of facial nerve Repair of facial nerve Fusion of facial/other nerve Fusion of facial/other nerve Subsequent repair of nerve Subsequent repair of nerve Subsequent repair of nerve Repair of facial/other nerve Subsequent repair of nerve Repair servise nerve add-on Repair servise nerve add-on Repair nerve/shorten bone Nerve graft, hand or foot Nerve graft, hand or foot Nerve graft, hand or foot Nerve graft, hand or foot Nerve graft, hand or foot Nerve graft, arm or leg Nerve graft, arm or leg Nerve graft, arm or leg Nerve graft, arm or leg Nerve graft add-on Nerve graft add-on Nerve pedicle transfer Nervous system surgery Rewise eye with implant Removal of eye Remove eye/frevise socket Remove eye/frevise socket Remove eye/frevise socket Remove eye/frevise socket Remove eye/frevise socket Remove eye/frevise socket Remove ocular implant Insert ocular implant Removal of eve Remove foreign body from eye Remove foreign body from eye Remove foreign body from eye
Modifier	
CPT/ HCPCS Code	64858 64865 64865 64865 64865 64865 64865 64876 64876 64891 64891 64891 64892 64893 65112 65113

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 106 OF 173

Charge Method- ology	M M M M M M M M M M M M M M M M M M M
Total Expense RVUs	32.51 37.71 35.11 19.12
Non- Facility Practice Expense RVUs	8 6 7 1 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2
Facility Practice Expense RVUs	8 6 6 7 7 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8
Work Expense RVUs	72.001 72.001 72.001 72.001 73.001 74.001 75.001
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Remove foreign body from eye Remove foreign body from eye Remove foreign body from eye Repair of eye wound Repair of eye wound Repair of eye wound Repair of eye wound Repair of eye wound Repair of eye wound Repair of eye wound Repair of eye wound Repair of eye wound Repair of eye wound Repair of eye socket wound Repair of eye socket wound Repair of eye elsoin Biopsy of cornea Corneal smear Curette/treat cornea Corneal smear Curette/treat cornea Corneal smear Corneal transplant Corneal transplant Corneal transplant Corneal transplant Corneal transplant Corneal transplant Revision of cornea Revision of cornea Corneal transplant Corneal transplant Corneal transplant Corneal transplant Revision of cornea Revision of cornea Corneal transplant Revision of cornea Corneal transplant Revision of cornea Corneal transplant Revision of cornea Dorinage of eye Drainage of eye Drainage of eye Drainage of eye Drainage of eye Laser surgery of eye Incise inner eye adhesions Incise inner eye adhesions Incise inner eye adhesions Incise inner eye adhesions Incise inner eye adhesions Remove eye lesion Remove implant of eye Remove implant of eye
Modifier	
CPT/ HCPCS Code	65235 65260 65265 65270 65272 65273 65273 65286 65286 65286 65420 65420 65420 65430 65430 65430 65730 65800 65810

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 107 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	26.600000000000000000000000000000000000
Facility Practice Expense RVUs	2.22 \cdot 0.01 \cdot 0.02 \cdot
Work Expense RVUs	6 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Injection treatment of eye Remove eye lesion Glaucoma surgery Glaucoma surgery Glaucoma surgery Glaucoma surgery Glaucoma surgery Glaucoma surgery Glaucoma surgery Glaucoma surgery Glaucoma surgery Glaucoma surgery Hoision of eye Implant eye shunt Revise eye shunt Repair eye lesion Fellow-ub surgery of eye Incision of iris Removal of iris Removal of iris Removal of iris Removal of iris Removal of iris Removal of iris Removal of iris Removal of iris Removal of iris Removal of iris Removal of iris Removal of iris Removal of iris Repair iris & ciliary body Destruction, ciliary body Destruction, ciliary body Destruction, ciliary body Destruction, ciliary body Destruction, ciliary body Destruction, ciliary body Destruction, ciliary body Destruction, ciliary body Destruction, ciliary body Destruction, ciliary body Destruction, ciliary body Destruction, ciliary body Destruction of iris Removal of irens material Removal of lens material
Modifier	
CPT/ HCPCS Code	66020 66030 66130 66150 66150 66150 66160 661172 661180 661180 66220 66220 66220 66220 66220 66220 66220 66220 66220 66220 66220 66220 66220 66220 66220 66220 66220 66220 66220 66230 66230 66630

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 108 OF 173

Charge Method- ology	Misc
Total Expense RVUs	21.82
Non- Facility Practice Expense RVUs	2.05 2.05 2.17
Facility Practice Expense RVUs	22.8 8 2.2 6 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2
Work Expense RVUs	0.30 0.30
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Surgery Surger
CPT/HCPCS Code Description	Eye surgery procedure Partial removal of eye fluid Release of eye fluid Release of eye fluid Release of eye fluid Release of eye fluid Release of the fluid Implant eye drug system Injection eye drug Indise inner eye strands Laser surgery, eye strands Removal of inner eye fluid Strip retinal membrane Laser treatment of retina Repair detached retina Remove eye implant material Treatment of retinal lesion Treatment of retinal lesion Treatment of retinal lesion Treatment of retinal lesion Treatment of retinal lesion Treatment of retinal lesion Reinforce eye wall Reinforce eye wall Reinforce eye muscle Revise e
Modifier	
CPT/ HCPCS Code	66999 67005 67010 67015 67025 67027 67030 67030 67030 67030 67112 67112 67112 67112 67112 67112 67112 67121 67220 67210 67220 67220 67220 67220 67220 67220 67220 67220 67231 67220 67231 67232 67233 67333 67333

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 109 OF 173

Modifier	er CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
	Release eye tissue Destroy nerve of eye muscle Biopsy eye muscle Eye muscle surgery procedure Explore/biopsy eye socket Explore/freat eye socket Explore/freat eye socket	Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery		2.35 2.96 2.87 9.76 7.93 9.50 10.00	7.00 4.33 1.93 12.30 15.45 13.35	7.00 1.34 1.93 12.30 15.45 13.35	4.79	Misc
	Expir/decompress eye socket Aspiration, orbital contents Explore/freat eye socket Explore/freat eye socket Explore/freat eye socket Explore/freat eye socket Inject/freat eyelid fasion Revise of eyelid fasions Remove eyelid lesions Revise eyelashes Revise eyelad defect Repair eyelid defect Repair eyelid defect Repair eyelid defect Repair eyelid defect Repair eyelid defect Repair eyelid defect Repair eyelid defect	Surgery Surgery		6.5.00 6.00	6.00 6.00	0.00 0.00	1.82	Misc
	Repair eyelid defect Repair eyelid defect Repair eyelid defect	Surgery Surgery Surgery		6.26 6.79 5.13	14.38 9.57 9.32	8.10 6.37 6.10		

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 110 OF 173

Charge Method- ology	Misc	Misc
Total Expense RVUs	3.23	1.46
Non- Facility Practice Expense RVUs	6 6 6 6 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	6.79 5.53 5.53 7.82 7.82 7.82 7.13 9.59 10.69 10.69 7.17
Facility Practice Expense RVUs	6 6 9 5 1 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2 1 2	6.79 5.48 14.49 6.58 6.58 11.17 11.50 7.52 9.59 10.69 12.31
Work Expense RVUs	5.40 5.27	8.18 7.19 4.17 7.34 1.69 1.02 1.02 1.03 1.03 1.03 1.03 1.03 1.03 1.03 1.03
Status/ Usage Indicator		
Conversion Factor/GAAF Category	Surgery Surger	Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery
CPT/HCPCS Code Description	Revise eyelid defect Revise eyelid defect Repair eyelid defect Revision of eyelid Revision of eyelid Reconstruction of eyelid Revision of eyelid lining Remove eyelid lining lesion Remove eyelid lining lesion Remove eyelid lining lesion Treat eyelid lining lesion Treat eyelid lining Revise/graft eyelid lining Revise/graft eyelid lining Revise/graft eyelid lining Revise/graft eyelid lining Revise/graft eyelid lining	Revise/graft eyelid lining Revise eyelid lining Revise/graft eyelid lining Separate eyelid athesions Revise eyelid laning Revise eyelid lining Eyelid lining surgery Incise/drain tear gland Incise/drain tear gland Incise tear duct opening Removal of tear gland Partial removal, tear gland Riopsy of tear gland Removal of tear sac
Modifier		
CPT/ HCPCS Code	67909 67914 67914 67915 67916 67922 67922 67923 67923 67923 67923 67923 67923 67938 67944 67973 67973 67973 67973 67973 68110 68115 68115 68115 68135 68320 68325	68328 68330 68335 68340 68362 68362 68369 68400 68440 68400 68500 68500

NOTES: OPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 111 OF 173

Charge Method- ology		Misc		MDR		M.	}
Total Expense RVUs		5.31		0.67		1 43)
Non- Facility Practice Expense RVUs	20.8.9.1 6.00.7.7.0.00 7.1.0.00.7.8.1 7.0.0.00.00 8.0.00.00 8.000 8.000	0.31	2.03	0.41	2.52 2.52 11.17 15.26 0.76 0.24	0.437 9.71 9.71 13.79	0.40 0.35 1.46 0.16
Facility Practice Expense RVUs	2.2.2.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0	14.94	2.53	1.59	3.37 3.37 1.17 1.16 1.56	1.52 2.23 4.37 9.71 13.79	1.51 1.51 1.54 2.36 2.36
Work Expense RVUs	4 & 6 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	0.80	2.11	0.81 0.85 3.44	4.05 7.97 2.62 13.43 20.80 0.77 0.77 0.77	0.83 1.40 6.36 10.79 16.96	0.83 0.63 0.33 1.33
Status/ Usage Indicator			1.				
Conversion Factor/GAAF Category	Surgery Surgery	Surgery Surgery	Surgery Surgery Surgery	Surgery Surgery Surgery Surgery	Surgery Surgery Surgery Surgery Surgery Surgery Surgery	Surgery Surgery Surgery Surgery Surgery	Surgery Surgery Surgery Surgery Surgery
CPT/HCPCS Code Description	Biopsy of tear sac Clearance of tear duct Remove tear gland lesion Remove tear gland lesion Repair tear ducts Revise tear duct opening Create tear sac drain Create tear duct opening Create tear duct opening Close tear duct opening	Injection for tear sac x-ray Tear duct system surgery	Drain external ear resion Drain external ear lesion Drain outer ear canal lesion	Pierce earlobes Biopsy of external ear Biopsy of external ear canal Remove external ear, partial	Removal of external ear Remove ear canal lesion(s) Remove ear canal lesion(s) Extensive ear neal surgery Extensive ear/neck surgery Clear outer ear canal Clear outer ear canal Remove impacted ear wax	Clean out mastoid cavity Clean out mastoid cavity Revise external ear Rebuild outer ear canal Cuter ear canal Outer ear surgenty procedure	Inflate middle ear canal Inflate middle ear canal Catheterize middle ear canal Inset middle ear (baffle) Incision of eardrum
Modifier							
CPT/ HCPCS Code	68525 68530 68540 68550 68700 68720 68720 68750 68750 68770 68770 68811 68811 68811	68850 68899	69005 69020 69020	69090 69100 69105 69110	69120 69140 69145 69150 69205 69205 69210	69220 69222 69300 69310 69320	69400 69401 69405 69410 69420

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 112 OF 173

Charge Method- ology		PHCS
Total Expense RVUs		17.75
Non- Facility Practice Expense RVUs	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	9.03 5.53 9.35
Facility Practice Expense RVUs	0.55	9.35 9.35 11.17
Work Expense RVUs	0.1 - 1. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5. 5.	8.23 10.44 14.00
Status/ Usage Indicator		
Conversion Factor/GAAF Category	Surgery Surger	Surgery Surgery Surgery Surgery
CPT/HCPCS Code Description	Remove ventilating tube Create eardrum opening Create eardrum opening Create eardrum opening Exploration of middle ear Eardrum revision Mastoidectomy Mastoidectomy Remove mastoid surgery Extensive mastoid surgery Extensive mastoid surgery Extensive mastoid surgery Extensive mastoid surgery Extensive mastoid surgery Remove ear lesion Remove ear lesion Remove ear lesion Mastoid surgery revision Repair of eardrum Repair of eardrum Repair eardrum structures Rebuild eardrum structures Rebuild eardrum structures Rebuild eardrum structures Rebuild eardrum structures Rebuild eardrum structures Revise middle ear & mastoid Revise middle ear & mastoid Revise middle ear & mastoid Revise middle ear bone Revise middle ear bone Revise middle ear bone Revise middle ear bone Revise middle ear bone Revise middle ear bone Revise middle ear bone Revise middle ear bone Repair middle ear bone Repair middle ear structures Repair middle ear structures Repair middle ear structures Repair middle ear structures	Remove madae ear nerve Close mastoid fistula Implant/replair hearing aid Remove/repair hearing aid Implant temple bone w/stimul
Modifier		
CPT/ HCPCS Code	69424 69424 69424 69424 69426 69426 69502 69502 69602 69603 69603 69603 69603 69604 69603 69604 69660 69660 69660 69660 69660 69660 69660 69660 69660 69660 69660 69660 69660 69660 69660 69660	69700 69710 69711 69711

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 113 OF 173

Charge Method- ology	Misc Misc	
Total Expense RVUs	33.71	
Non- Facility Practice Expense RVUs	25.00 25	0.06 0.06 0.09 0.78
Facility Practice Expense RVUs	2.5.1 2.	0.74 0.06 0.09 0.78 0.06
Work Expense RVUs	82.44 82.45 82.65 83.66 83.66 83.66 84.66 85.66 86.69 86	0.00 0.26 0.00 0.00
Status/ Usage Indicator		
Conversion Factor/GAAF Category	Surgery Surger	Kadiology Radiology Radiology Radiology Radiology
CPT/HCPCS Code Description	Temple bne implnt w/stimulat Temple bone implant revision Revise temple bone implant Release facial nerve Repair facial nerve Repair facial nerve Repair facial nerve Repair facial nerve Repair facial nerve Middle ear surgery procedure Incise inner ear Explore inner ear Explore inner ear window Revise inner ear window Revise inner ear window Revise inner ear window Revise inner ear reve Incise inner ear inner ear incise inner ear incise inner ear incise inner ear incise inner ear incise inner ear levice Innise inner ear levice Incise inner ear levice Innise inner ear op inain Contrast x-ray of brain	X-ray exam of middle ear X-ray exam of facial bones X-ray exam of facial bones X-ray exam of facial bones X-ray exam of facial bones X-ray exam of nasal bones
Modifier	8578778778778	7 7 7 8 7 9 7 9 7 9 7 9 7 9 7
CPT/ HCPCS Code	69715 69717 69717 69718 69720 69745 69745 69802 69802 69803 69806 69806 69806 69810 69910	70134 70140 70140 70150 70150

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 114 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	0.000000000000000000000000000000000000
Facility Practice Expense RVUs	0.000 0.000
Work Expense RVUs	0.000000000000000000000000000000000000
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Abolic Agolic Ag
	Radiology Radiology
CPT/HCPCS Code Description	X-ray exam of nasal bones X-ray exam of tear duct X-ray exam of tear duct X-ray exam of eye sockets X-ray exam of eye sockets X-ray exam of eye sockets X-ray exam of eye sockets X-ray exam of sinuses X-ray exam of sinuses X-ray exam of sinuses X-ray exam of sinuses X-ray exam of sinuses X-ray exam of sinuses X-ray exam of sinuses X-ray exam of sinuses X-ray exam of skull X-ray exam of skull X-ray exam of skull X-ray exam of skull X-ray exam of skull X-ray exam of teeth X-ray exam of teeth X-ray exam of teeth X-ray exam of teeth X-ray exam of teeth X-ray exam of teeth X-ray exam of internot X-ray exam of internot X-ray exam of internot X-ray exam of internot X-ray exam of internot X-ray exam of internot X-ray exam of internot X-ray exam of internot X-ray exam of internot X-ray exam of internot X-ray exam of internot X-ray exam of internot X-ray exam of internot X-ray exam of internot X-ray exam of internot X-ray exam of exek X-ray
Modifier	58585858585858585858585858585858585858
CPT/ HCPCS Code	70160 70170 70190 70190 70200 70200 70210 70220 70220 70220 70220 70230 70330 70330 70332 70332 70332 70332 70332 70336 70336 70336 70336 70336 70336 70336 70336 70337 70337 70337 70337 70337 70337 70337 70337 70337 70337 70337

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 115 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	7.00 4.00 6.00 6.00 6.00 6.00 6.00 6.00 6
Facility Practice Expense RVUs	7.70 7.70
Work Expense RVUs	0.000 0.000
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Radiology Radiology
CPT/HCPCS Code Description	X-ray exam of salivary duct Ct head/brain w/o dye Ct head/brain w/o dye Ct head/brain w/o dye Ct head/brain w/o dye Ct head/brain w/dye Ct head/brain w/dye Ct head/brain w/dye Ct head/brain w/o&w dye Ct orbit/ear/fossa w/o dye Ct orbit/ear/fossa w/o dye Ct orbit/ear/fossa w/o dye Ct orbit/ear/fossa w/o dye Ct orbit/ear/fossa w/o dye Ct orbit/ear/fossa w/o dye Ct orbit/ear/fossa w/o dye Ct orbit/ear/fossa w/o dye Ct maxillofacial w/o dye Ct maxillofacial w/o dye Ct maxillofacial w/o dye Ct orbit/such orbit/ear/en w/o dye Ct orbit/such orbit/ear/en w/o dye Ct soft tissue neck w/o dye Ct soft tissue neck w/o dye Ct soft tissue neck w/o dye Ct soft tissue neck w/o dye Ct soft tissue neck w/o dye Ct soft tissue neck w/o dye Ct soft tissue neck w/o dye Ct angiography, head Ct angiography, head Ct angiography, neck Mri orbit/face/neck w/o dye Mri orbit/face/neck w/o dye Mri orbit/face/neck w/o dye Mri angiography head w/o dye Mr angiography head w/o dye Mr angiography head w/o dye Mr angiography neck w/o dye
Modifier	58585858585858585858585858585858585858
CPT/ HCPCS Code	70390 70450 70450 70450 70450 70440 70480 70481 70482 70488 70488 70488 70490 70490 70490 70490 70540

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 116 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	22.00.1.1.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.
Facility Practice Expense RVUs	22.0.1.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0
Work Expense RVUs	0.000 0.000
Status/ Usage Indicator	, , , , , , , , , , , , , , , , , , ,
Conversion Factor/GAAF Category	Radiology Radiology
CPT/HCPCS Code Description	Mr angiograph neck w/o&w dye Mri brain w/o dye Mri brain w/o dye Mri brain w/dye Mri brain w/dye Mri brain w/dye Mri brain w/o&w dye Mri brain w/o&w dye Mri brain w/o&w dye Chest x-ray C
Modifier	58
CPT/ HCPCS Code	70549 70551 70552 70553 70553 70053 71010 71010 71020 71020 71020 71020 71020 71030 71101 71111 71111 71111 71111 71120 71120 71130

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 117 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	7.00 7.00
Facility Practice Expense RVUs	7.00 7.00
Work Expense RVUs	7.000000000000000000000000000000000000
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Radiology Radiology
CPT/HCPCS Code Description	Ct thorax w/dye Ct thorax w/dye Ct thorax w/o&w dye Ct thorax w/o&w dye Ct angiography, chest Ct angiography, chest Ct angiography, chest Ct angiography, chest Ct angiography, chest Ct angiography, chest Min chest w/o dye Min chest w/o dye Min chest w/o dye Min chest w/o dye Min angio chest w or w/o dye Min angio chest w or w/o dye X-ray exam of spine X-ray exam of spine X-ray exam of spine X-ray exam of neck spine X-ray exam of neck spine X-ray exam of neck spine X-ray exam of neck spine X-ray exam of neck spine X-ray exam of thoracic spine X-ray exam of thoracic spine X-ray exam of thoracic spine X-ray exam of thoracic spine X-ray exam of thoracic spine X-ray exam of thoracic spine X-ray exam of thoracic spine X-ray exam of thoracic spine X-ray exam of thoracic spine X-ray exam of thoracic spine X-ray exam of thoracic spine X-ray exam of thoracic spine X-ray exam of thoracic spine X-ray exam of thoracic spine X-ray exam of thoracic spine X-ray exam of lower spine
Modifier	287878787878787878787878787878787878787
CPT/ HCPCS Code	71260 71270 71270 71270 71270 71270 71551 71550 71552 71555 71555 72040 72040 72040 72040 72040 72040 72050 72069 72069 72070

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 118 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	7.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
Facility Practice Expense RVUs	7.00 8.00 9.00 9.00 9.00 9.00 9.00 9.00 9
Work Expense RVUs	0.100 0.000 0.000
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Radiology Radiology
CPT/HCPCS Code Description	Ct neck spine w/dye Ct neck spine w/o&w/dye Ct neck spine w/o&w/dye Ct neck spine w/o dye Ct chest spine w/o dye Ct chest spine w/o dye Ct chest spine w/o dye Ct chest spine w/o dye Ct chest spine w/o dye Ct chest spine w/o dye Ct lumbar spine w/o dye Ct lumbar spine w/o dye Ct lumbar spine w/o dye Ct lumbar spine w/o dye Ct lumbar spine w/o dye Ct lumbar spine w/o dye Mri neck spine w/o dye Mri neck spine w/o dye Mri neck spine w/o dye Mri neck spine w/o dye Mri neck spine w/o dye Mri neck spine w/o dye Mri chest spine w/o dye Mri chest spine w/o dye Mri chest spine w/o dye Mri lumbar spine w/o dye Mri lumbar spine w/o dye Mri lumbar spine w/o dye Mri lumbar spine w/o dye Mri lumbar spine w/o dye Mri lumbar spine w/o&w/dye Ct mrigograph pelv w/o&w/dye Ct angiograph pelv w/o&w/dye Ct pelvis w/o dye Ct pelvis w/o dye Ct pelvis w/o dye Ct pelvis w/o&w/dye
Modifier	285858585858585858585858585858585858585
CPT/ HCPCS Code	72126 72127 72128 72128 72129 72129 72130 72130 72131 72132 72133 72144 72144 72144 72144 72144 72145 72149 72150

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 119 OF 173

CPT/			Conversion	Status/	Work	Facility	Non- Facility	Total	Charae
HCPCS	Modifier	CPT/HCPCS Code Description	Factor/GAAF	Usage	Expense	Practice	Practice	Expense	Method-
Code			Category	Indicator	RVUs	Expense B// le	Expense	RVUs	ology
						2	RVUs		
72194	J.	Ct pelvis w/o&w/dve	Radiology	æ	00.00	8.45	8.45		
72195	26	Mri pelvis w/o dye	Radiology		1.46	0.50	0.50		
72195	ပ	Mri pelvis w/o dye	Radiology	a	0.00	11.16	11.16		
72196	56	Mri pelvis w/dye	Radiology		1.73	0.59	0.59		
72196	ပ	Mri pelvis w/dye	Radiology	œ	0.00	13.38	13.38		
72197	26	Mri pelvis w/o & w/dye	Radiology		2.26	0.77	0.77		
72197	2	Mri pelvis w/o & w/dye	Radiology	ro	00.00	24.78	24.78		
72198	56	Mr angio pelvis w/o&w/dye	Radiology		1.80	0.70	0.70		
72198	5	Mr angio pelvis w/o&w/dye	Radiology	æ	0.00	11.16	11.16		
72200	56	X-ray exam sacroiliac joints	Radiology		0.17	90.0	90.0		
72200	ည	X-ray exam sacroiliac joints	Radiology	æ	0.00	0.52	0.52		
72202	56	X-ray exam sacroilíac joints	Radiology		0.19	90.0	90.0		
72202	<u>ე</u>	X-ray exam sacroiliac joints	Radiology	æ	0.00	0.62	0.62	••=n•	
72220	56	X-ray exam of tailbone	Radiology		0.17	0.06	0.06		
72220	ပ	X-ray exam of tailbone	Radiology	æ	0.00	0.57	0.57		
72240	56	Contrast x-ray of neck spine	Radiology		0.91	0.30	0.30		
72240	ပ	Contrast x-ray of neck spine	Radiology	æ	0.00	4.73	4.73		
72255	56	Contrast x-ray, thorax spine	Radiology		0.91	0.28	0.28		
72255	ပ	Contrast x-ray, thorax spine	Radiology	æ	0.00	4.31	4.31		
72265	56	Contrast x-ray, lower spine	Radiology		0.83	0.26	0.26		
72265	<u>ဥ</u>	Contrast x-ray, lower spine	Radiology	m	0.00	4.05	4.05		
72270	56	Contrast x-ray of spine	Radiology		1.33	0.43	0.43		
72270	ပ	Contrast x-ray of spine	Radiology	æ	0.00	6.07	6.07		
72275	56	Epidurography	Radiology		0.76	0.20	0.20		
72275	2	Epidurography	Radiology	æ	0.00	2.09	2.09		
72285	58	X-ray c/t spine disk	Kadiology		1.16	0.37	0.37		
72285	ပ	X-ray c/t spine disk	Radiology	æ	00.0	8.35	8.35		
72295	56	X-ray of lower spine disk	Radiology		0.83	0.28	0.28		
72295	ပ	X-ray of lower spine disk	Kadiology	æ	00.00	7.82	7.82		
73000	56	X-ray exam of collar bone	Kadiology		0.16	0.05	0.05		
73000	2	X-ray exam of collar bone	Kadiology	æ	0.00	0.52	0.52		
73010	2	X-ray exam of shoulder blade	Kadiology		0.17	0.00	90.0		
73010	ပ	X-ray exam of shoulder blade	Radiology	æ	0.00	0.52	0.52		
73020	56	X-ray exam of shoulder	Kadiology		0.15	0.03	60.0		
73020	ပ	X-ray exam of shoulder	Radiology	æ	0.00	0.47	0.47		
73030	56	X-ray exam of shoulder	Radiology		0.18	0.06	90.0		
73030	ပ	X-ray exam of shoulder	Radiology	æ	00.0	0.57	0.57		
73040	56	Contrast x-ray of shoulder	Radiology		0.54	0.18	0.18		
73040	ပ	Contrast x-ray of shoulder	Radiology	æ	00.00	5.09	5.09		
73050	56	X-ray exam of shoulders	Radiology		0.20	0.07	0.07		
73050	2	X-ray exam of shoulders	Radiology	æ	00.00	0.67	0.67		
73060	56	X-ray exam of humerus	Radiology		0.17	90.0	90.0		
73060	ဥ	X-ray exam of humerus	Radiology	rs.	0.00	0.57	0.57		
73070	78	X-ray exam of elbow	Radiology		0.15	0.05	0.05		
73070	ဥ (X-ray exam of elbow	Radiology	æ	0.00	0.52	0.52		
73080	56	X-ray exam of elbow	Radiology		0.17	- qn:o	0.00	-	

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 120 OF 173

Charge Method-	ology																																								
Total	KVUs																																								
Non- Facility Practice	Expense RVUs	0.57	0.19	2.03	0.00	0.05	0.49	90.0	0.49	0.0	0.53	1.57	0.00	0.49	90.0	0.53	0.04	0.42	0.37	40.4	, v	0.00	7.39	0.62	10.92	0.46	0.70	13.38	0.74	24.78	0.46	11.16	0.55	5.50	24.78	0.68	11,16	0.06	0.47	0.07	0.09
Facility Practice Expense	RVUs	0.57	0.19	20.03	0.52	0.05	0.49	90.0	0.49	0.00	0.03	1.57	0.06	0.49	90.0	0.53	40.0	0.42	0.37	4.04	2 2 2	0.00	7.39	0.62	10.92	0.46	0.10	13.38	0.74	24.78	0.46	11.16	0.55	0.50	24.78	0.68	11.16	90.0	0.47	0.07	0.09
Work	KVUS	0.00	4.0	0.0	000	0.16	0.00	0.16	00.0	0.17	000	000	0.16	0.00	0.17	0.00	0.13	00.0	1.09	0.00	0 0	200,0	0.00	1.81	0.00	1.35	6,00	0.00	2.15	0.00	1.35	00.0	7.62	0.00	0.00	1.73	00.0	0.17	0.00	0.21	0.00
Status/ Usage	Indicator	a	¢	5	a	3	æ		๗	•	TO .	æ	ı	æ		æ		m	1	ros	n	3	ю	,	æ	,	ŭ	e e		æ		æ	,	TO.	ď	3	ø	ı	æ		æ
Conversion Factor/GAAF	Category	Radiology	Kadiology	Radiology	Radiology	Radiology	Radiology	Radiology	Radiology	Kadiology	Radiology	Radiology	Radiology	Radiology	Radiology	Radiology	Radiology	Radiology	Kadiology	Kadiology	Radiology	Radiology	Radiology	Radiology	Radiology	Radiology	Radiology	Radiology	Radiology	Radiology	Radiology	Kadiology	Kadiology	Radiology	Radiology	Radiology	Radiology	Radiology	Radiology	Radiology	Kadiology Radiology
CPT/HCPCS Code Description		X-ray exam of elbow	Contrast x-ray of elbow	X-ray exam of forearm	X-ray exam of forearm	X-ray exam of arm, infant	X-ray exam of arm, infant	X-ray exam of wrist	X-ray exam of wrist	X-ray exam of wrist	A-riay exam of wrist	Contrast x-ray of wrist	X-ray exam of hand	X-ray exam of hand	X-ray exam of hand	X-ray exam of hand	X-ray exam of finger(s)	X-ray exam of finger(s)	Ct upper extremity w/o dye	Ct upper extremity w/o dye	Of upper extremity w/dye	Ct uppr extremity w/o&w/dve	Ct uppr extremity w/o&w/dye	Ct angio upr extrm w/o&w/dye	Ct angio upr extrm w/o&w/dye	Mri upper extremity w/o dye	Mri upper extremity w/dve	Mri upper extremity w/dve	Mri uppr extremity w/o&w/dye	Mri uppr extremity w/o&w/dye	Mri joint upr extrem w/o dye	Mr joint upr extrem w/o dye	Mri joint upr extrem w/dye	Mri joint upr extrem w/dye	Mri joint upr extr w/o&w/dye	Mr anglo upr extr w/o&w/dve	Mr angio upr extr w/o&w/dve	X-ray exam of hip	X-ray exam of hip	X-ray exam of hip	X-ray exam of hip X-ray exam of hips
Modifier		J.	9 1	<u> </u>	2	2 %	5	56	ည	9 4	ے ہ	12	56	5	26	ည	5 6	ည	52	ب ا	27	2 %	12	56	ည	2 5) w	22	56	5	78	ပ (97	٢	9 2	2 %	12	28	ည	190	28
CPT/ HCPCS	Code	73080	73085	73090	73090	73092	73092	73100	73100	73110	73110	73115	73120	73120	73130	73130	73140	73140	73200	73200	73201	73202	73202	73206	73206	73218	73210	73219	73220	73220	73221	73221	73222	73772	73223	73225	73225	73500	73500	73510	73510 73520

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 121 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	0.000000000000000000000000000000000000
Facility Practice Expense RVUs	0.000000000000000000000000000000000000
Work Expense RVUs	0.000000000000000000000000000000000000
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Radiology Radiology
CPT/HCPCS Code Description	X-ray exam of hips Contrast x-ray of hip X-ray exam of hip X-ray exam of hip X-ray exam of hip X-ray exam of hip X-ray exam of pelvis & hips X-ray exam of pelvis & hips X-ray exam of high X-ray exam of high X-ray exam of thigh X-ray exam of three, 1 or 2 X-ray exam of knee, 3 X-ray exam of knee, 3 X-ray exam of knee, 3 X-ray exam of knee, 3 X-ray exam of knee iont Contrast x-ray of knee joint Contrast x-ray of knee joint Contrast x-ray of knee joint X-ray exam of lower leg X-ray exam of lower leg X-ray exam of lower leg X-ray exam of lower leg X-ray exam of lower leg X-ray exam of lower leg X-ray exam of lower leg X-ray exam of ankle X-ray exam of ankle X-ray exam of ankle X-ray exam of ankle Contrast x-ray of ankle Contrast x-ray of ankle X-ray exam of foot X-ra
Modifier	58585858585858585858585858585858585858
CPT/ HCPCS Code	73520 73525 73526 73526 73530 73540 73550 73550 73560 73562 73562 73562 73563 73560 73563 73563 73563 73563 73563 73563 73630 73650 7360 7360 7360 7360 7360 7360 7360 736

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 122 OF 173

	Charge Method- ology	
	Total Expense RVUs	
	Non- Facility Practice Expense RVUs	0.0011.0000000000000000000000000000000
	Facility Practice Expense RVUs	0.00
	Work Expense RVUs	0.000 0.000
	Status/ Usage Indicator	
10 TOT 10 110	Conversion Factor/GAAF Category	Radiology Radiology
	CPT/HCPCS Code Description	Ct angio lwr extr w/o&w/dye Mri lower extremity w/o dye Mri lower extremity w/dye Mri lower extremity w/dye Mri lower extremity w/o&w/dye Mri lower extremity w/o&w/dye Mri lower extremity w/o&w/dye Mri int of lwr extr w/o dye Mri int of lwr extr w/o dye Mri joint of lwr extr w/o&w/dye Mri angi lwr ext w or w/o dye K-ray exam of abdomen X-ray exam series, abdomen Ct abdomen w/o dye Ct abdomen w/o dye Ct abdomen w/o dye Ct abdomen w/o dye Ct abdomen w/o dye Ct abdomen w/o dye Mri abdomen w/o dye Mri abdomen w/o dye Mri abdomen w/o dye Mri abdomen w/o dye Mri abdomen w/o dye Mri abdomen w/o dye Mri abdomen w/o dye Mri abdomen w/o dye Mri abdomen w/o dye Mri abdomen w/o dye Mri abdomen w/o dye Mri abdomen w/o dye Mri abdomen w/o dye Mri abdomen w/o dye Mri abdomen w/o dye Mri angio, abdom w or w/o dy
	Modifier	285858585858585858585858585858585858585
	CPT/ HCPCS Code	73706 73718 73719 73719 73720 73721 73722 73722 73722 73722 74000 74000 74000 74000 74000 74150 74150 74160

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 123 OF 173

Charge Method- ology	M MDR A M M M M M M M M M M M M M M M M M M
Total Expense RVUs	0.81
Non- Facility Practice Expense RVUs	10001-0-1
Facility Practice Expense RVUs	+ 0.000 + 0.00
Work Expense RVUs	0.000000000000000000000000000000000000
Status/ Usage Indicator	, , , , , , , , , , , , , , , , , , ,
Conversion Factor/GAAF Category	Radiology Radiology
CPT/HCPCS Code Description	Cinefvid x-ray, throat/esoph Remove esophagus obstruction X-ray exam, upper gi tract X-ray exam, upper gi tract X-ray exam, upper gi tract X-ray exam, upper gi tract X-ray exam, upper gi tract X-ray exam, upper gi tract Confrst x-ray uppr gi tract Confrst x-ray uppr gi tract Confrst x-ray uppr gi tract Confrst x-ray uppr gi tract Confrst x-ray uppr gi tract Confrst x-ray uppr gi tract Confrst x-ray uppr gi tract Confrst x-ray uppr gi tract Confrst x-ray uppr gi tract Confrst x-ray uppr gi tract Confrst x-ray uppr gi tract Confrst x-ray uppr gi tract Confrst x-ray uppr gi tract Confrst x-ray uppr gi tract Confrst x-ray uppr gi tract Confrst x-ray exam of small bowel X-ray exam of small bowel X-ray exam of small bowel X-ray exam of small bowel Confrast x-ray exam of colon Confrast x-ray exam of colon Confrast x-ray exam of colon Confrast x-ray exam of colon Confrast x-ray, gallbladder Confrast x-ray, gallbladder Confrast x-ray, gallbladder Confrast x-ray, gallbladder X-ray bile ducts/pancreas X-ray bile ducts/pancreas X-ray bile ducts/pancreas Confrast x-ray of bile ducts Confrast x-ray of bile ducts Confrast x-ray of bile ducts X-ray bile duct endoscopy X-ray bile stone removal X-ray bile duct endoscopy
Modifier	287878787878787878787878787878787878787
CPT/ HCPCS Code	74230 74235 74235 74240 74241 74241 74245 74246 74246 74249 74249 74250 74250 74280

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 124 OF 173

CPT/			Conversion	Status/	Work	Facility	Non- Facility	Total	Charge
HCPCS	Modifier	CPT/HCPCS Code Description	Factor/GAAF	Usage	Expense	Practice	Practice	Expense	Method-
Code			Category	Indicator	RVUs	RVUs	Expense RVUs	RVUs	ology
74330	75	X-ray bile/panc endoscopy	Radiology	a	0.00	3.13	3,13		
74340	56	X-ray guide for GI tube	Radiology		0.54	0.18	0.18		
74340	ဥ	X-ray guide for GI tube	Radiology	æ	0.00	2.61	2.61		
74350	4 78	X-ray guide, stomach tube	Kadiology	1	0.76	0.26	0.26		
74355	۶,۲	X-ray guide, stomach tube X-ray duide, intestinal tube	Radiology	T T	0.00	0.78	5.73		
74355	12	X-ray guide, intestinal tube	Radiology	ro	00.00	2.61	2.61		
74360	56	X-ray guide, GI dilation	Radiology	ı	0.54	0.19	0.19		
74360	ည	X-ray guide, Gl dilation	Radiology	Ø	0.00	3.13	3.13		
74363	7 Z	X-ray, bile duct dilation	Kadiology	ď	0.88	0.30	0.30		
74400	2 %	Contrat x-ray urinary tract	Radiology	ช	00.0	0.0	0.07		
74400	ပ	Contrst x-ray, urinary tract	Radiology	œ	00.00	1.67	1.67		
74410	56	Contrst x-ray, urinary tract	Radiology		0.49	0.17	0.17		
74410	ည	Contrst x-ray, urinary tract	Radiology	æ	0.00	1.94	1.94		
74415	189	Contrst x-ray, urinary tract	Radiology		0.49	0.17	0.17		
74415	ည	Contrst x-ray, urinary tract	Radiology	Ø	0.00	2.11	2.11		
74420	28	Contrst x-ray, urinary tract	Kadiology	,	0.36	0.12	0.12		
74420	۲۳	Control X-ray, unimary tract	Radiology	U	0.00	7.07	7.01		
74425	25	Control x-ray, unitially liabil	Radiology	α	0000	10.1	1 30 7		
74430	202	Contrast x-ray, bladder	Radiology	3	0.35	0.11	211		
74430	ပ	Contrast x-ray, bladder	Radiology	ro	0.00	1.04	1.04		
74440	56	X-ray, male genital tract	Radiology		0.38	0.13	0.13	-	
74440	ည	X-ray, male genital tract	Radiology	æ	0.00	1.12	1.12		
74445	1 79	X-ray exam of penis	Radiology	į	1.14	0.38	0.38		
74443	٤٤	X-ray exam of penis	Radiology	σ	0000	7.5	1.12		
74450	ရုပ	X-ray, urethra/bladder	Radiology	æ	00.0	1.45	1.45		
74455	56	X-ray, urethra/bladder	Radiology		0.33	0.11	0.11		
74455	ဥ	X-ray, urethra/bladder	Radiology	æ	00:00	1.57	1.57		
74470	۹ ¢	X-ray exam of kidney lesion	Kadiology	,	40.0	0.18	0.18		
74475	2 92	X-ray control cath insert	Radiology	ซ	0.0	0.18	0 18		
74475	2	X-ray control, cath insert	Radiology	ro	00.0	4.05	4.05		
74480	56	X-ray control, cath insert	Radiology		0.54	0.18	0.18		
74480	ည	X-ray control, cath insert	Radiology	æ	0.00	4.05	4,05		
74485	2,6	X-ray guide, GU dilation	Radiology		0.54	0.18	0.18		
74485	ပ န	X-ray guide, GU dilation	Kadiology	æ	00.0	3.13	3.13		
74710	۹ <u>۲</u>	X-ray measurement of pelvis	Kadiology	(46.0	0.12	0.12		
74710	ود	X-ray measurement or peivis	Kadiology	æ	00.00	40.1	40.0		
74740	۵۲ ۲	X-ray, remaie genital tract	Radiology	c	86.0	4.30	4.30		
74742	292	X-ray, ternale genital tract	Radiology	5	0.00	0.50	0.50		
74742	2	X-ray, fallopian tube	Radiology	œ	00.0	3.13	3.13		
74775	56	X-ray exam of perineum	Radiology	ACCESSION A	0.62	0.22	0.22		

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 125 OF 173

CPT/			Conversion	Status/	Work	Facility	Non- Facility	Total	Charge
HCPCS	Modifier	CPT/HCPCS Code Description	Factor/GAAF	Usage	Expense	Fractice	Practice	Expense	Method-
Code			Category	Indicator	RVUs	RVUs	Expense RVUs	RVUs	ology
74775	TC Ac	X-ray exam of perineum	Radiology Radiology	w	0.00	1.45	1.45		
75552	2 2 2	Heart mri for morph w/o dve	Radiology	œ	00.0	11.16	11.16		
75553	56	Heart mri for morph w/dye	Radiology		2.00	0.68	0.68		
75553	ဥ	Heart mri for morph w/dye	Radiology	Ø	0.0	11.16	11.16		
75554	9 6	Cardiac MKI/function	Kadiology	,	2.83	0.67	0.67		
75555	2 %	Cardiac MRI/function	Radiology	æ	1.74	0.10	0.1.0		
75555	2	Cardiac MRI/limited study	Radiology	æ	00.00	11.16	11.16		
75600	56	Contrast x-ray exam of aorta	Radiology		0.49	0.19	0.19		
75600	28	Contrast x-ray exam of aorta	Radiology	æ	0.0	12.55	12.55		
72505	9 5	Contrast x-ray exam of aorta	Kaulology	(4 5	12.0	14.0		
75625	2 %	Contrast x-ray exam of aorta	Radiology	ซ	0.07	0.39	0.39		
75625	12	Contrast x-ray exam of aorta	Radiology	æ	00.00	12.55	12.55		
75630	56	X-ray aorta, leg arteries	Radiology		1.79	0.64	0.64		
75630	ဥ	X-ray aorta, leg arteries	Radiology	O	0.00	13.08	13.08		
75635	56	Ct angio abdominal arteries	Radiology		2.40	0.82	0.82		
75635	ပ္	Ct anglo abdominal arteries	Kadiology	or.	0.00	15.84	15.84		
75650	9 ¢	Affery X-rays, head & neck	Kadiology	¢	94.0	10.51	10.51		
75658	ر د و	5 5 8	Radiology	ס	3.1	0.49	0.49		
75658	2	Artery x-rays, arm	Radiology	œ	0.00	12.55	12.55	***************************************	
75660	56	head & necl	Radiology	ı	1.31	0.46	0.46	***********	
75660	7 2	head & necl	Radiology	æ	0.00	12.55	12.55		
75662	56	head & necl	Radiology		1.66	0.61	0.61		
75662	ပ္	head & neci	Radiology	œ	0.00	12.55	12.55	**********	
75655	9 2	Affery x-rays, flead & fleck	Radiology	п	000	12.55	12.45		
75671	56	head & necl	Radiology	;	1.66	0.57	0.57		
75671	2	Artery x-rays, head & neck	Radiology	æ	0.00	12.55	12.55		
75676	56	Artery x-rays, neck	Radiology		1.31	0.46	0.46		
75690	၁ ဖွ	Artery X-rays, neck	Kadology	æ	0.00	12.55	12.55		
75680	2 4		Badiology	ď		10.01	10.01		
75685	2 %	Artery x-rays, neck	Radiology	g	131	0.45	0.45		
75685	12	Artery x-rays, spine	Radiology	æ	00.0	12.55	12.55		
75705	56	Artery x-rays, spine	Radiology		2.18	0.76	0.76	•	
75705	2		Radiology	Ø	0.00	12.55	12.55		
75710	56		Radiology		1.14	0.40	0.40		
75710	ပ		Radiology	æ	0.00	12.55	12.55		
75716	58		Radiology		1.31	0.45	0.45		
75716	_ ဗ	Artery x-rays, arms/legs	Kadiology	a	0.00	12.55	12.55		
75722	2 5		Radiology	α	2	12.55	10.1		
75724	26		Radiology	3	1.49	0.58	0.58	_	

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 126 OF 173

	Charge Method- ology	
	Total Expense RVUs	
	Non- Facility Practice Expense RVUs	70050050505050505050500500000000000000
	Facility Practice Expense RVUs	70070070070070070070070070070000000000
	Work Expense RVUs	0.1.0.4.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.
	Status/ Usage Indicator	
	Conversion Factor/GAAF Category	Radiology Radiology
	CPT/HCPCS Code Description	Artery x-rays, kidneys Artery x-rays, abdomen Artery x-rays, abdomen Artery x-rays, adrenal gland Artery x-rays, adrenal gland Artery x-rays, adrenal gland Artery x-rays, adrenals Artery x-rays, pelvis Artery x-rays, pelvis Artery x-rays, pelvis Artery x-rays, lung Artery x-rays, lung Artery x-rays, lung Artery x-rays, lung Artery x-rays, lung Artery x-rays, lung Artery x-rays, chest Artery x-rays, chest Artery x-rays, chest Artery x-rays, chest Artery x-rays, chest Artery x-rays, chest Artery x-rays, chest Artery x-ray, arm/leg Lymph vessel x-ray, arm/leg Lymph vessel x-ray, runk Lymph ve
	Modifier	28
Version and the second	CPT/ HCPCS Code	75724 75726 75726 75731 75733 75733 75733 75734 75741 75745 75746 75746 75746 75746 75746 75746 75740 75740 75740 75740 75740 75740 75803

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 127 OF 173

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
75040	JL	Vois v adronal aland	Radiology		00 0	12.55	12.55		***************************************
75842	2 92	Vein X-ray, adrenal glands	Radiology	5	1.49	0.50	0.50		
75842	2	Vein x-ray, adrenal glands	Radiology	m	0.00	12.55	12.55		
75860	78	Vein x-ray, neck	Radiology	1	1.14	0.40	0.40		
75860	ပ္ ဖွ	Vein x-ray, neck	Radiology	TO.	0.00	0.20	0.40		
75870	0 7	Ven X-ray, shuil	Radiology	œ	00.0	12.55	12.55		
75872	28.5	Vein x-ray, skull	Radiology	i	1.14	0.39	0.39		
75872	2	Vein x-ray, skull	Radiology	Ø	0.00	12.55	12.55		
75880	56	Vein x-ray, eye socket	Radiology		0.70	0.24	0.24		
75880	ည္ဖ	Vein x-ray, eye socket	Radiology	æ	0.00	0.95	0.65		
75885	1 Z	Vein x-ray, iiver	Radiology	æ	0.00	12.55	12.55		
75887	7 7 8 9 7	Vein x-ray, liver	Radiology		1.44	0.49	0.49		
75887	5	Vein x-ray, liver	Radiology	Ø	0.00	12.55	12.55		
75889	56	Vein x-ray, liver	Radiology		1.14	0.38	0.38		
75889	ဥ	Vein x-ray, liver	Radiology	æ	0.00	12.55	12.55		
75891	7 28	Vein x-ray, liver	Kadiology	,	4	10.38	0.38		
75891	ည ဗု	Vein x-ray, liver	Kadiology Dadiology	TG.	0.00	0.70	010	***************************************	
75003	۹ ۲	Venous sampling by catheter	Radiology	a	500	12.55	12.55	·····	
75894	2 92	X-rays, transcath therapy	Radiology	3	1.31	0.45	0.45		
75894	2	X-rays, transcath therapy	Radiology	rs ·	0.00	24.03	24.03		
75896	9 1	X-rays, transcath therapy	Radiology	ı	1.31	0.47	0.47		
75896	ဥဗ	X-rays, transcath therapy	Radiology	m	0.00	20.90	20.90	***************************************	
75898	9,5	Follow-up anglography	Radiology	α	00.0	20.0	20.5		
75900	292	Arterial catheter exchange	Radiology	s	0.49	0.17	0.17		
75900	ဥ	Arterial catheter exchange	Radiology	æ	0.00	20.88	20.88		
75901	56	Remove cva device obstruct	Radiology	,	0.49	0.17	0.17		
75901	ပ ဗု	Kemove cva device obstruct	Radiology	70	0000		1.50		
75902	9 6	Remove ova limen obstruct	Radiology	æ	0.00	130	1.30		
75940	792	X-ray placement, vein filter	Radiology		0.54	0.18	0.18		
75940	2	X-ray placement, vein filter	Radiology	æ	0.00	12.55	12.55		
75945	97	Intravascular us	Radiology	,	0.40	0.15	0.15		
75945	၁ ဗ	Intravascular us	Radiology	TO.	0.00	0.40	50.4		
75946	27	Intravascular us add-on	Radiology	æ	0.00	2.28	2.28		
75952	792	Endovasc repair abdom aorta	Radiology		4.50	1.75	1.75		
75952	5	Endovasc repair abdom aorta	Radiology	æ				18.50	MDR
75953	56	Abdom aneurysm endovas rpr	Radiology		1.36	0.53	0.53		
75953	C %	Abdom aneurysm endovas rpr	Radiology	m	1.36	0.48	0.48	20.58	MOK
75954	2 C	liac aneurysin endovas ipi	Radiology	Ø	2	? :	2	16.56	SA
75960	- 5 <u>ê</u>	Transcatheter intro, stent	Radiology		0.82	0.29	0.29	-	i

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 128 OF 173

Charge Method- ology		MDR
Total Expense RVUs		6.77
Non- Facility Practice Expense RVUs	44-10-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-	_
Facility Practice Expense RVUs	444-00-00-00-00-00-00-00-00-00-00-00-00-	_
Work Expense RVUs	0.440 0.000	
Status/ Usage Indicator		æ
Conversion Factor/GAAF Category	Radiology Radiology	Radiology
CPT/HCPCS Code Description	Transcatheter intro, stent Retrieval, broken catheter Retrieval, broken catheter Repair arterial blockage Repair arterial blockage Repair arterial blockage Repair arterial blockage Repair arterial blockage Repair arterial blockage Repair arterial blockage Repair arterial blockage Repair arterial blockage Repair arterial blockage Repair arterial blockage Repair arterial blockage Repair arterial blockage Contrast biopsy Repair venous blockage Contrast xray exam bile duct Contrast xray exam bile duct Contrast xray exam bile duct Contrast xray exam bile duct Contrast xray exam bile duct Contrast xray exam bile duct Contrast xray exam bile duct Contrast xray exam bile duct Contrast xray exam bile duct Contrast xray exam bile duct Ary control catheter change Asscess drainage under x-ray Abscess drainage under x-ray Atherectomy, x-ray exam A	Percut vertebroplasty fluor
Modifier	2528787878787878787878787878787878787878	2
CPT/ HCPCS Code	75960 75961 75962 75964 75964 75964 75964 75966 75968 75968 75980 75980 75981 75992 75992 75992 75993 75994 75994 75996 75996 75996 75996 75996 75996 75996 75996 75996 75996 75996 75996 75997 75996	76012

NOTES: OPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 129 OF 173

Charge Method- ology	M D D D D D D D D D D D D D D D D D D D
Total Expense RVUs	
Non- Facility Practice Expense RVUs	0.000000000000000000000000000000000000
Facility Practice Expense RVUs	0.000000000000000000000000000000000000
Work Expense RVUs	3.3 1.3 1.3 1.3 1.3 1.3 1.3 1.3
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Radiology Radiology
CPT/HCPCS Code Description	Percut vertebroplasty, ct Percut vertebroplasty, ct X-rays for bone age X-rays bone evaluation X-rays, bone evaluation X-rays, bone survey X-rays, bone survey X-rays, bone survey X-rays, bone survey X-rays, bone survey X-rays, bone survey X-rays, bone evaluation X-rays, bone evaluation X-rays, bone evaluation X-rays, bone evaluation X-rays, bone evaluation X-rays, bone evaluation X-rays, bone evaluation X-rays, bone evaluation X-ray, bone density, peripheral Ct bone density
Modifier	\$5.85.85.85.85.85.85.85.85.85.85.85.85.85
CPT/ HCPCS Code	76013 76013 76013 76013 76020 76040 76061 76062 76065 76065 76065 76076 76076 76076 76076 76080

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 130 OF 173

Charge Method- ology	SA SA SA SA SA SA SA SA SA SA SA SA SA S	Misc Misc
Total Expense RVUs	0.78 1.03	0.36
Non- Facility Practice Expense RVUs	0.001.01.01.00 0 0.80.81.80.92.00.00.00.00.00.00.00 0 0.80.81.80.90.00.00.00.00.00.00.00.00.00.00.00.00	7.11. 7.11.
Facility Practice Expense RVUs	0.000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0	25.11.6.0.1.4.4.1.1.6.1.1.6.1.1.1.1.1.1.1.1.1.1.1
Work Expense RVUs	00000000000000000000000000000000000000	20401040 002000 00000 00000 00000 00000 00000 00000
Status/ Usage Indicator	<i>თ თ თ თ თ თ თ თ თ თ</i>	<i>"""""""""""""""""</i>
Conversion Factor/GAAF Category	Radiology Radiology	Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology
CPT/HCPCS Code Description	X-ray exam, breast specimen X-ray exam of body section X-ray exam of body section X-ray exam of body section X-ray exam of body section X-ray exam of body section X-ray exam, body section x-ray Complex body section x-ray Complex body section x-rays Complex body section x-rays Complex body section x-rays Cinelyideo X-rays Cinelyideo X-rays Cinelyideo X-rays add-on Cinelyideo X-rays add-on X-ray consultation X-ray consultation X-ray consultation X-ray exam, dry process Special x-ray contrast study Special x-ray contrast study CAT scan for localization CAT scan for localization CAT scan for localization CAT scan for needle biopsy CAT scan for tissue ablation Cat scan for tissue ablation Cat scan for tissue ablation CAT scan for therapy guide CAT scan for therapy guide CAT scan for therapy guide CAT scan follow-up study Mr spectroscopy Mr spectroscopy	Mri guidance for needle place Mri guidance for needle place Mri for tissue ablation Mri for tissue ablation Mri for tissue ablation Magnetic image, bone marrow Us for tissue ablation Us for tissue ablation Us for tissue ablation Eadiographic procedure Echo exam of head Echo exam of head Echo exam of head Echo exam of eye Echo exam of eye Echo exam of eye Echo exam of eye
Modifier		82828282828282
CPT/ HCPCS Code	76098 76100 76100 76100 76101 76101 76101 76102 76120 76120 76125 76120 76126 76350 76350 76350 76350 76360 76360 76360 76360 76360 76360 76360 76360 76360 76360 76360 76360	76393 76394 76394 76400 76400 76490 76499 76506 76506 76506 76511

NOTES: OPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 131 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	0.400-0-0-400-0-0-0-0-0-0-0-0-0-0-0-0-0-
Facility Practice Expense RVUs	0.400-0.400-0.0-0.0-0.0-0.0-0.0-0.0-0.0-
Work Expense RVUs	0.000000000000000000000000000000000000
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Radiology Radiology
CPT/HCPCS Code Description	Echo exam of eye, water bath Echo exam of eye, water bath Echo exam of eye Echo exam of eye Echo exam of eye Echo exam of eye Echo exam of eye Echo exam of head and neck Us exam of head and neck Us exam of head and neck Us exam, chest, b-scan Us exam, chest, b-scan Us exam, breast(s) Us exam, chest, b-scan Us exam, breast(s) Us exam, chest, b-scan Us exam, abdom, complete Us exam, abdom, complete Echo exam of abdomen Echo exam abdo back wall, imm Us exam abdo back wall, imm Us eam abdo back wall, imm Us eam abdo back wall, imm Us exam kidney transplant Us exam kidney transplant Us exam kidney transplant Us exam kidney transplant Us exam kidney transplant Us exam kidney transplant Us exam kidney transplant Us exam kidney transplant Us exam kidney transplant Us exam kidney transplant Ob us < 14 wks, single fetus Ob us < 14 wks, addl fetus Ob us < 14 wks, addl fetus Ob us < 14 wks, addl fetus Ob us detailed, sngl fetus Ob us, detailed, sngl fetus Ob us, detailed, addl fetus Ob us, imited, fetus(s) Ob us, imited, fetus(s) Ob us, imited, fetus(s) Ob us, imited, fetus(s) Ob us, follow-up, per fetus Transvaginal us, obstetric Fetal biophys profile winst Fetal
Modifier	82
CPT/ HCPCS Code	76513 76513 76514 76515 76519 76529 76529 76529 76529 76529 76529 76700 76801 76801 76801 76801 76801 76801 76801 76801 76801 76801 76801 76801 76801 76801 76801 76801 76801 76801 76811 76811 76811

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 132 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20
Facility Practice Expense RVUs	0.20 0.20 0.20 0.20 0.20 0.20 0.20 0.20
Work Expense RVUs	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Status/ Usage Indicator	
Conversion Factor/GAAF Category	
Co Fact	Radiology Radiology
 CPT/HCPCS Code Description	Fetal biophys profil wo nst Fetal biophys profil wo nst Echo exam of fetal heart Echo exam of fetal heart Echo exam of fetal heart Echo exam of fetal heart Echo exam of fetal heart Echo exam of fetal heart Echo exam of fetal heart Echo exam of fetal heart Echo exam of fetal heart Echo exam of fetal heart Echo exam of fetal heart Echo exam of fetal heart Echo exam, uterus Us exam, pelvic, complete Us exam, pelvic, complete Us exam, pelvic, complete Us exam, pelvic, ilmited Us exam, pelvic, ilmited Us exam, scrotum Us exam, scrotum Us exam, scrotum Us exam, scrotum Us exam, stremity Us exam, extremity Us exam, extremity Us exam, infant hips, dynamic Us exam infant hips, static Echograp trans r. pros study Us exam infant hips, static Echograp trans r. pros study Us exam infant hips, static Echograp trans r. pros study Us exam infant hips, static Echograp trans r. pros study Echograp trans r. pros study Us exam infant hips, static Echograp transfusion Echoguide for arrety repair
Modifier	85
CPT/ HCPCS Code	76819 76825 76825 76826 76826 76827 76828 76830 76831 76831 76831 76831 76831 76831 76832 76832 76835 76836

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 133 OF 173

Charge Method- ology	Misc	Misc	Misc Misc
Total Expense RVUs		3.22	2.62
Non- Facility Practice Expense RVUs	0.20 1.30 0.45 1.04 1.04 1.51 0.02 0.02 0.02	27.00 20.00	23.2 2.2 2.3 2.3 2.3 2.3 2.3 2.3 2.3 2.3
Facility Practice Expense RVUs	0.20 1.30 0.45 5.54 0.14 1.04 1.51 0.02 0.02 0.02	27.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00	23.1 23.1 23.2 20.2 20.3 20.3 20.3 20.3 20.3 20.3
Work Expense RVUs	0.58 0.00 0.00 0.00 0.00 0.00 0.00 0.00	2.139 2.14 3.141 0.00 0.00 0.00 0.00 0.00 0.00 0.00	0000 0000 0000 0000 0000 0000 0000 0000 0000
Status/ Usage Indicator		ற நைற ற	0 0 0 0 0 0 0 0 0 0 0
Conversion Factor/GAAF Category	Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology	Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology	Radiology Radiology
CPT/HCPCS Code Description	Echo guidance radiotherapy Echo guidance radiotherapy Echo guidance radiotherapy Echo guidance radiotherapy Ultrasound exam follow-up Ultrasound exam follow-up Gl endoscopic ultrasound Gl endoscopic ultrasound Gl endoscopic ultrasound Us bone density measure Us bone density measure Ultrasound guide intraoper Ultrasound guide intraoper Echo examination procedure	Echo examination procedue Radiation therapy planning Radiation therapy planning Set radiation therapy planning Set radiation therapy field Set radiation therapy field Set radiation therapy field Set radiation therapy field Set radiation therapy field Set radiation therapy field Set radiation therapy field Set radiation therapy field Set radiation therapy field Set radiation therapy field Set radiation therapy field Set radiation therapy field	Radiation therapy planning Radiation therapy planning Radiation therapy dose plan Radiation therapy dose plan Radiotherapy dose plan Radiotherapy dose plan, imrt Radiotherapy dose plan, imrt Telex isodose plan simple Telex isodose plan simple Telex isodose plan intermed Telex isodose plan intermed Telex isodose plan intermed Telex isodose plan complex Telex isodose plan complex Special telex port plan Special telex port plan Brachytx isodose calc imferm Brachytx isodose calc inferm Brachytx isodose calc inferm Brachytx isodose calc inferm Brachytx isodose plan compl Brachytx isodose plan compl Brachytx isodose plan compl Brachytx isodose plan compl Brachytx isodose plan compl Brachytx isodose plan compl
Modifier	25 25 25 25 25 25 25 25 25 25 25 25 25 2	75 28 75 75 28 76 28 76 28	2828282828282828282828
CPT/ HCPCS Code	76950 76950 76965 76965 76970 76970 76975 76977 76977 76977	76999 77261 77262 77280 77280 77285 77295 77290 77290	77299 77299 77300 77301 77301 77310 77315 77315 77321 77321 77321 77321 77321 77321 77321 77321 77321 77321

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 134 OF 173

Charge Method- ology	Misc Misc	Misc Misc PHCS
Total Expense RVUs	3.70	3.51 22.20 19.70
Non- Facility Practice Expense RVUs	0.50 0.23 0.23 0.23 0.23 0.23 0.23 0.23 0.2	25.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.
Facility Practice Expense RVUs	0.050 0.133	7.2.2.2.0.5.1.0.8.0.1.0.8.0.0.4.0.8.0.0.4.0.8.0.0.4.0.8.0.0.4.0.8.0.0.4.0.8.0.0.4.0.8.0.0.4.0.8.0.0.4.0.8.0.0.4.0.8.0.0.0.4.0.8.0.0.0.4.0.8.0.0.0.0
Work Expense RVUs	0.00000-0000 0.00000-0000 0.00000000000	7.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2
Status/ Usage Indicator	, , , , , , , , , , , , , , , , , , ,	<i></i>
Conversion Factor/GAAF Category	Radiology Radiology	Radiology Radiology
CPT/HCPCS Code Description	Special radiation dosimetry Radiation treatment aid(s) Radiation treatment aid(s) Radiation treatment aid(s) Radiation treatment aid(s) Radiation treatment aid(s) Radiation treatment aid(s) Radiation treatment aid(s) Radiation physics consult External radiation dosimetry External radiation dosimetry External radiation dosimetry Radiation treatment delivery Radiation treatment delivery Radiation treatment delivery Radiation treatment delivery Radiation treatment delivery Radiation treatment delivery Radiation treatment delivery Radiation treatment delivery Radiation treatment delivery Radiation treatment delivery Radiation treatment delivery Radiation treatment delivery Radiation treatment delivery Radiation treatment delivery Radiation treatment delivery Radiation treatment delivery Radiation treatment delivery	Radiation treatment delivery Radiation treatment delivery Radiation treatment delivery Radiation treatment delivery Radiation treatment delivery Radiation by port film(s) Radiation to therapy management Special radiation treatment Special radiation treatment Special radiation treatment Radiation therapy management Radiation therapy management Radiation therapy management Proton trmt, intermediate Hyperthermia treatment
Modifier	70 26 26 26 70 70 70 70	825 855 855 855 855 855 855 855 855 855
CPT/ HCPCS Code	77331 77332 77333 77333 77334 77336 77399 77399 77401 77403 77403 77406 77409 77409	77413 77414 77416 77416 77418 77427 77431 77432 77499 77500 77600 77600 77600 77600 77600 77600 77600 77600 77600 77600 77600 77600 77600 77600 77600 77600 77600

NOTES: OPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 135 OF 173

Charge Method- ology	Misc Misc
Total Expense RVUs	8.25 10.22
Non- Facility Practice Expense RVUs	1.22
Facility Practice Expense RVUs	7.22
Work Expense RVUs	8 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6 6
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Radiology Radiology
CPT/HCPCS Code Description	Apply intraav radiat simple Apply intraav radiat simple Apply intraav radiat interm Apply intraav radiat interm Apply intraav radiat compl Apply intraav radiat compl Apply interstit radiat simpl Apply interstit radiat simpl Apply interstit radiat simpl Apply interstit radiat inter Apply interstit radiat compl Apply interstit radiat compl Apply interstit radiat compl Apply interstit radiat compl High intensity brachytherapy Radiation handling Radiation handling Radiation handling Radiation handling Radiation handling Radiation handling Radiation handling Radiation handling Radiation Apply surface radiation Apply surface radiation Apply surface radiation Apply surface radiation Apply surface radiation Apply surface radiation Apply surface radiation Apply surface
Modifier	82
CPT/ HCPCS Code	77761 77762 77763 77763 77776 77776 77776 77777 77778 77778 77779 77789 77779 7779 7779 77

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 136 OF 173

Charge Method- ology	Misc	MDR
Total. Expense RVUs	0.83	1.12
Non- Facility Practice Expense RVUs	0.029 0.29 0.29 0.20 0.20 0.20 0.20 0.20	2000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Facility Practice Expense RVUs	0.22 0.29 0.29 0.27 0.27 0.27 0.27 0.095 0	0.000000000000000000000000000000000000
Work Expense RVUs	00000000000000000000000000000000000000	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Status/ Usage Indicator		, , , , , , , , , , , , , , , , , , ,
Conversion Factor/GAAF Category	Radiology Radiology	Radiology Radiology
CPT/HCPCS Code Description	Thyroid met uptake Thyroid met uptake Parathyroid nuclear imaging Adrenal nuclear imaging Adrenal nuclear imaging Adrenal nuclear imaging Endocrine nuclear procedure Bone marrow imaging, Itid Bone marrow imaging, Itid Bone marrow imaging, Itid Bone marrow imaging, Itid Bone marrow imaging, Itid Bone marrow imaging, Itid Bone marrow imaging, body Plasma volume, single Plasma volume, single Red cell mass, single Red cell mass, single Red cell mass, multiple Red cell mass, multiple Blood volume Blood volume Blood volume Red cell survival study Red cell survival study Red cell survival kinetics Red cell survival kinetics Red cell survival kinetics Red cell survival kinetics	Red cell sequestration Plasma iron turnover Plasma iron turnover Radioiron absorption exam Radioiron absorption exam Radioiron absorption exam Red cell iron utilization Total body iron estimation Total body iron estimation Spleen imaging Spleen imaging Platelet survival Platelet survival Platelet survival Platelet survival Platelet survival Platelet survival Platelet survival Platelet survival Platelet survival Platelet survival Platelet survival Platelet survival Platelet survival Platelet survival
Modifier	8562858585858585858585858585858585858585	2858585858585858585
CPT/ HCPCS Code	78020 78070 78070 78070 78070 78099 78102 78102 78103 78110 78111 78120 78121 78120 78121 78120 78121 78120 78121 78121 78120 78130 78130	78140 78160 78160 78162 78162 78170 78172 78172 78185 78190 78190 78190 78190

NOTES: OPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 137 OF 173

	Charge Method- ology	Misc C	MDR
-	Total Expense RVUs	8.10	3.32
	Non- Facility Practice Expense RVUs	0.000000000000000000000000000000000000	0.14 0.24 3.04 3.05 3.05
	Facility Practice Expense RVUs	0.000000000000000000000000000000000000	4.86 0.14 0.24 3.04 3.05
	Work Expense RVUs	00000000000000000000000000000000000000	0.00
	Status/ Usage Indicator		<i>თ თ</i> თ
ו אפר ופן פון וופ	Conversion Factor/GAAF Category	Radiology Radiology	Radiology Radiology Radiology Radiology Radiology Radiology
	CPT/HCPCS Code Description	Blood/lymph nuclear exam Blood/lymph nuclear exam Blood/lymph nuclear exam Liver imaging Liver imaging with flow Liver imaging with flow Liver imaging (3D) Liver imaging (3D) Liver imaging (3D) Liver imaging (3D) Liver imaging (3D) Liver imaging (3D) Liver imaging (3D) Liver imaging (3D) Liver and spleen imaging Liver and spleen imaging Liver and spleen imaging Liver and spleen imaging Liver and spleen imaging Liver as spleen imaging Liver function study Liver function study Hepatobiliary imaging Serial salivary gland imaging Salivary gland imaging Salivary gland imaging Salivary gland function exam Salivary gland function exam Salivary gland function exam Salivary gland function exam Salivary gland function exam Salivary gland function exam Salivary gland function exam Gastric mucosa imaging Gastric emptying study Gastric emptying study Vit B-12 absorption exam Vit B-12 absorption exam Vit B-12 absorption exam Vit B-12 absorption exam Vit B-12 absorp. combined Vit B-12 absorp. combined Vit B-12 absorp. combined Vit B-12 absorp. combined Vit B-12 absorp. combined Vit B-12 absorp. combined	Acute GI blood loss imaging GI protein loss exam GI protein loss exam Meckel's divert exam Meckel's divert exam Leveen/shunt patency exam Leveen/shunt patency exam
	Modifier	82828282828282828282828282828282828	78787
	CPT/ HCPCS Code	78199 78199 78201 78201 78202 78202 78205 78206 78216 78216 78220 78231 78231 78232	78278 78282 78282 78290 78290 78291

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 138 OF 173

	Charge Method- ology	Misc Misc NAR	Misc	Misc	S	S DHCS
	Total Expense RVUs	7.30	1.4.1	8.52	7	8. 18.
	Non- Facility Practice Expense RVUs	0.248 0.30 0.30 0.30 0.30 0.36 0.36 0.36 0.37 0.38		0.16	0.30 2.24 0.18 1.85	6.000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	Facility Practice Expense RVUs	0.22 0.248 0.259 0.30 0.30 0.30 0.37 0.37 0.37 0.37 0.37		0.16	0.30 2.24 0.18 1.85	3.937 2.036 2.037 2.037 2.038 2.
	Work Expense RVUs	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0		0.45	0.78 0.00 0.49 0.00	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
	Status/ Usage Indicator		Ø	. co a	טיי טיי ס	
100 CT 110	Conversion Factor/GAAF Category	Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology	Radiology Radiology	Radiology Radiology Radiology	Radiology Radiology Radiology Radiology Radiology	Radiology Radiology
	CPT/HCPCS Code Description	Gl nuclear procedure Gl nuclear procedure Bone imaging, limited area Bone imaging, multiple areas Bone imaging, multiple areas Bone imaging, whole body Bone imaging, whole body Bone imaging, 3 phase Bone imaging, 3 phase Bone imaging (3D) Bone imaging (3D) Bone imaging (3D) Bone mineral, single photon Bone mineral, single photon Bone mineral, single photon	Bone mineral, dual photon Musculoskeletal nuclear exam	Musculoskeletal nuclear exam Non-imaging heart function Non-imaging heart function	Cardiac shunt imaging Cardiac shunt imaging Cardiac shunt imaging Vascular flow imaging Vascular flow imaging Venous thrombosis study	Venous thrombosis study Acute venous thrombus image Acute venous thrombus image Venous thrombosis imaging Venous thrombosis imaging Ven thrombosis images, bilat Ven thrombosis images, bilat Ven thrombosis images, bilat Ven thrombosis images, bilat Ven thrombosis images, bilat Ven thrombosis images, bilat Ven thrombosis images, bilat Ven thrombosis images, bilat Ven thrombosis images, bilat Ven thrombosis images Ven thrombosis images Heart muscle blood, single Heart muscle blood, multiple Heart muscle blood, multiple Heart image (3d), single Heart image (3d), multiple Heart image (3d), multiple Heart infarct image Heart infarct image Heart infarct image (ef)
	Modifier	8787878787878	32 S	128 128 1	287858	7878787878787878787878
	CPT/ HCPCS Code	78299 78299 78300 78300 78305 78306 78315 78315 78320 78350 78350	78351 78399	78399 78414 78414	78428 78428 78445 78445	78456 78456 78456 78457 78457 78458 78459 78460 78461 78464 78464 78465 78465 78465 78465 78465 78465 78465

NOTES: OPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 139 OF 173

CPT/ HCPCS Code	Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
78469	26 TC	Heart infarct image (3D)	Radiology Radiology	α	0.92	0.32	0.32		
78472	2g	Gated heart, planar, single	Radiology	5	0.98	0.35	0.35		
78472	ဥ	Gated heart, planar, single	Radiology	Ø	0.00	5.48	5.48		
78473	7. 1. 1.	Gated heart, multiple	Kadiology	ď	74.7	0.53	0.53		
78478	2 %	Heart wall motion add-on	Radiology	3	0.62	0.23	0.23		
78478	2	Heart wall motion add-on	Radiology	a	00.0	1.55	1.55		
78480	75	Heart function add-on	Radiology	,	0.62	0.23	0.23		
78481	2 %	Heart first pass single	Radiology	U	0.98	0.37	0.37		
78481	22	Heart first pass, single	Radiology	ø	0.00	5.19	5.19		
78483	56	Heart first pass, multiple	Radiology		1.47	0.56	0.56		
78483	ဥႜ	Heart first pass, multiple	Radiology	œ	0.00	7.83	7.83		
78491	0 C	Heart image (pet), single Heart image (pet), single	Radiology	π	200	00.0	0.00	06.7	Ą
78492	292	Heart image (bet), smalled	Radiology	3	1.87	0.75	0.75	2	5
78492	2	Heart image (pet), multiple	Radiology	Ø				14.89	PHCS
78494	56	Heart image, spect	Radiology		1.19	0.43	0.43		
78494	ပ္ ဗ	Heart image, spect	Kadiology	æ	3.6	40.0	40.0		
78496	9 F	Heart first pass add-on	Radiology	ď	900	20.0	7.0		
78499	99	Cardiovascular nuclear exam	Radiology	5	}			1.46	Misc
78499	12	Cardiovascular nuclear exam	Radiology	æ				3.10	Misc
78580	26	Lung perfusion imaging	Radiology		0.74	0.26	0.26		
78580	ဥ္	Lung perfusion imaging	Kadiology	ø	0.00	14.0	2.41		
78584	92	Lung V/O image single preath	Radiology	ro	00.0	3.5	3.78		
78585	56		Radiology		1.09	0.38	0.38		
78585	ည		Radiology	æ	0.00	5.61	5.61		
78586	75	Aerosol lung image, single	Radiology	(0.40	0.14	0.14		
78587	۲ ۲ ۲	Aerosol lung image, single	Radiology	ŭ	0.00	0.70	0.70		
78587	32	Aerosol lung image, multiple	Radiology	Ø	00:00	2.80	2.80		
78588	26	Perfusion lung image	Radiology		1.09	0.38	0.38	- Control	
78588	ပ္		Radiology	Ø	0.00	3.18	3.18		
78591	726		Kadiology	4	0.40	0.14	0.14		
76597	٢	Ventimage, i preatn, i proj	Radiology	T)	0.00	0.04	7.04		
78593	22	Vent image, 1 proj. gas	Radiology	œ	00.0	3.43	3.43	-	
78594	5.2	Vent image, mult proj. gas	Radiology		0.53	0.19	0.19		
78594	2	Vent image, mult proj. gas	Radiology	Ø	0.00	4.96	4.96		
78596	78	Lung differential function	Radiology	ı	1.27	0.44	0.4		
78596	၁ ဗ	Lung differential function	Radiology	ซ	0.00	5 0.	4.	1 87	Adioo
78599	35	Respiratory nuclear exam	Radiology	æ				6.82	Misc

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 140 OF 173

Charge Method- ology	Misc Misc
Total Expense RVUs	28.40 29.38 13.06
Non- Facility Practice Expense RVUs	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Facility Practice Expense RVUs	0.00
Work Expense RVUs	40000000000000000000000000000000000000
Status/ Usage Indicator	, , , , , , , , , , , , , , , , , , ,
Conversion Factor/GAAF Category	Radiology Radiology
CPT/HCPCS Code Description	Brain imaging, Itd static Brain imaging, Itd static Brain imaging, Itd static Brain imaging, complete Brain imaging, complete Brain imaging, complete Brain imaging, complete Brain imaging, complete Brain imaging (3D) Brain imaging (3D) Brain imaging (PET) Brain imaging (PET) Brain imaging (PET) Brain flow imaging only Brain flow imaging only Cerebral vascular flow image Cerebral vascular flow image Cerebral vascular flow image Cerebral vascular flow image Cerebral vascular flow image Cerebral vascular flow image Cerebral vascular flow image Cerebral vascular flow image Cerebral vascular flow image CSF shunt evaluation CSF shunt evaluation CSF shunt evaluation CSF shunt evaluation CSF shut evaluation image Cidney imaging (3D) Cidney imaging cidney coman Cidney imaging cidney C
Modifier	28567857857857857857857857857857857857857857
CPT/ HCPCS Code	78600 78600 78600 78601 78605 78605 78606 78606 78615 78615 78615 78615 78615 78635 78635 78635 78635 78635 78635 78635 78635 78635 78647 78650 78650 78650 78650 78650 78650 78670 78700 78701

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 141 OF 173

Charge Method- ology	Misc Misc	PHCS Misc Misc
Total Expense RVUs	1.64 8.90	28.52 1.89 1.48 5.22
Non- Facility Practice Expense RVUs	0.13 0.13	0.04 0.05 0.05 0.05 0.05 0.05 0.05 0.05
Facility Practice Expense RVUs	0.023 0.	0.04 0.05
Work Expense RVUs	00000000000000000000000000000000000000	1000 1000 1000 1000 1000 1000 1000 100
Status/ Usage Indicator	, , , , , , , , , , , , , , , , , , ,	, , , , , , , , , , , , , , , , , , ,
Conversion Factor/GAAF Category	Radiology Radiology	Radiology Radiology
CPT/HCPCS Code Description	Kidney function study Kidney function study Urinary bladder retention Urinary bladder retention Urinary bladder retention Ureteral reflux study Ureteral reflux study Testicular imaging Testicular imaging/Now Testicular imaging/Now Genitourinary nuclear exam Genitourinary nuclear exam Genitourinary nuclear exam Tumor imaging, limited area Tumor imaging, mult areas Tumor imaging, mult areas Tumor imaging, whole body Tumor imaging, whole body Tumor imaging, whole body Tumor imaging, tid area Abscess imaging, tid area Abscess imaging, whole body Abscess imaging, whole body	Nuclear localization/abscess Nuclear localization/abscess Tumor imaging (PET) Tumor imaging (PET) Nuclear medicine data proc Nuclear medicine data proc Nuclear med data proc Nuclear med data proc Nuclear data proc Provide diag radionuclide(s) Nuclear diagnostic exam Nuclear diagnostic exam Init hyperthyroid therapy Repeat hyperthyroid therapy Repeat hyperthyroid therapy Repeat hyperthyroid therapy Thyroid ablation Thyroid ablation Thyroid ablation, carcinoma Thyroid metastatic therapy Thyroid metastatic therapy Thyroid metastatic therapy Thyroid metastatic therapy Thyroid metastatic therapy Thyroid metastatic therapy Hematopoetic nuclear therapy
Modifier	25	87878787 2878782828
CPT/ HCPCS Code	78725 78725 78730 78730 78740 78740 78760 78761 78761 78799 78800 78800 78801 78802 78802 78802 78803 78803 78803	78807 78810 78810 78810 78890 78891 78999 78999 78999 78900 79000 79001 79001 79030 79030

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 142 OF 173

Charge Method- ology	MDR SAF MISC MISC
Total Expense RVUs	1.88 1.36 3.06 5.22 5.22
Non- Facility Practice Expense RVUs	2.0.22 2.0.22 2.0.23 2.
Facility Practice Expense RVUs	2.61 2.62 2.62 2.63 2.63 2.63 2.63 2.63 2.63
Work Expense RVUs	0.00 0.00
Status/ Usage Indicator	ט ט ט ט ט ט ט ט ט ט ט ט ט ט ט ט ט ט ט
Conversion Factor/GAAF Category	Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Radiology Pathology
CPT/HCPCS Code Description	Hematopoetic nuclear therapy Intracavitary nuclear timt Intracavitary nuclear timt Intracavitary nuclear timt Intracavitary nuclear therapy Interstitial nuclear therapy Nonhemato nuclear therapy Nonhemato nuclear therapy Intravascular nuclear ther nutavascular nuclear therapy Nuclear joint therapy Nuclear joint therapy Nuclear ioint therapy Nuclear medicine therapy Nuclear medicine therapy Lab pathology consultation Lab pathology consultation Lab pathology consultation Hemoglobin electrophoresis Genetic examination Hemoglobin electrophoresis Genetic examination Postein, western blot test Blood smear interpretation Bone marrow interpretation Bone marrow interpretation Fibrinolysins screen Blood batelet aggregation Physician blood bank service Physician blood bank service Physician blood bank service Physician blood bank service Physician blood bank service Physician blood bank service Physician blood bank service Physician blood bank service Iluorescent antibody, titer Serun immunoelectrophoresis immunoelectrophoresis immunoelectrophoresis Immunoelectrophoresis Simmunoffxation procedure Coccidioidomycosis skin test Histoplasmosis skin test Histoplasmosis skin test TB intradermal test TB intradermal test Cytopathology, fluids
Modifier	756 756 756 756 756 756 756 756 756 756
CPT/ HCPCS Code	79100 79200 79200 79300 79300 79400 79400 79440 79440 79440 79440 79490 79999 79999 79999 79999 79999 79999 80500 83020 83020 83020 83020 83020 83020 83020 83020 83032 86078 86078 86078 86078 86078 86334 86334 86334 86334 86334 86334 86334 86334 86334 86336 86337 86336 8636 8

NOTES. CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 143 OF 173

	Charge Method- ology	Misc Misc
	Total Expense RVUs	2.08
	Non- Facility Practice Expense RVUs	0.058 0.076 0.076 0.076 0.076 0.076 0.076 0.076 0.076 0.076 0.076 0.076 0.076 0.076 0.076 0.076 0.076 0.076 0.077 0.076 0.077 0.
	Facility Practice Expense RVUs	0.000 0.000
	Work Expense RVUs	0.000 0.000
	Status/ Usage Indicator	, , , , , , , , , , , , , , , , , , ,
211 10 251 37071	Conversion Factor/GAAF Category	Pathology Pathology
	CPT/HCPCS Code Description	Cytopath, concentrate tech Cytopath, concentrate tech Cytopath, concentrate tech Forensic cytopathology Forensic cytopathology Cytopath, cvv, interpret Cytopath smear, other source Cytopath smear, other source Cytopath smear, other source Cytopath smear, other source Cytopath smear, other source Cytopath smear, other source Cytopath smear, other source Cytopath smear, other source Cytopath eval, fina, report Cytopath eval, fina, report Cytopath eval, fina, report Cytopath eval, fina, report Cytopath eval, fina, report Cytopath eval, fina, report Cytopathology procedure Cytopathology procedure Cytopathology procedure Cytopathology procedure Cytopathology procedure Cytopathology procedure Cytopathology procedure Cytopathology procedure Cytopathology pathologist Tissue exam by pathologist Tissue exam by pathologist Tissue exam by pathologist Tissue exam by pathologist Tissue exam by pathologist Tissue exam by pathologist Decalcify tissue Decalcify tissue Decalcify tissue Decalcify tissue Exam by pathologist Decalcify tissue Exam by pathologist Tissue exam by pa
	Modifier	\$585 \$5858585858585858585858585858585858
	CPT/ HCPCS Code	88108 88125 88125 88125 88160 88160 88161 88161 88162 88162 88162 88172 88172 88172 88173 88300 88300 88300 88300 88301 88311

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 144 OF 173

Charge Method- ology	Misc Misc	Misc Misc
Total Expense RVUs	1.43 2.86	0.71
Non- Facility Practice Expense RVUs	0.058 0.099 0.	0.13 0.07 0.08 0.08 0.08 0.35 0.41
Facility Practice Expense RVUs	0.083 0.047	1.97 1.76 1.77 1.77 2.22 2.80 0.41
Work Expense RVUs	1.33 1.33 1.33 1.33 1.33 1.33 1.33 1.33	0.45 0.19 0.79 0.02 0.08 0.00 0.00
Status/ Usage Indicator	, , , , , , , , , , , , , , , , , , , ,	
Conversion Factor/GAAF Category	Pathology Pathology	Pathology Pathology Pathology Pathology Pathology Pathology Pathology Pathology Pathology Pathology
CPT/HCPCS Code Description	Microslide consultation Microslide consultation Microslide consultation Comprehensive review of data Path consult intraop. 1 bloc Path consult intraop, 1 bloc Path consult intraop, 1 bloc Path consult intraop, 1 bloc Path consult intraop, addi Immunocytochemistry Immunocytochemistry Immunofluorescent study Immunofluo	Sample stomach contents Sample stomach contents Sample stomach contents Sample stomach contents Sample stomach contents Sample stomach contents Sample stomach contents Sample stomach contents Supplier stoering collection Collect sweat for test Surgical pathology procedure Surgical pathology procedure
Modifier	%5 %5%5%5%5%5%5%5%5%5%5%5% %5%5%5%5%5%5%	26 TC
CPT/ HCPCS Code	88323 88323 88323 88323 88323 88333 88331 88332 88334 88334 88345 88346 88346 88346 88346 88346 88346 88355 88355 88355 88355 88356 88356 88356 88362 88362 88362 88362 88362 88363 88363 88362 88365 88365 88365 88365 88365 88365 88365 88365 88365 88365 88366 88366 88366 88366 88366 88366 88366 88366 88366 88366 88366	8 8 8 9 1 3 5 8 9 1 3 5 8 9 1 3 5 9 1 3 5 9 1 3 5 9 1 4 5 9 1 5 9

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 145 OF 173

Total Charge Expense Method- RVUs ology	0.32 PHCS 0.72 PHCS 0.23 PHCS 0.24 PHCS 0.26 PHCS 0.36 PHCS 0.98 MDR 1.18 MDR 4.79 PHCS 0.96 PHCS 0.96 PHCS 0.96 PHCS 0.96 PHCS 0.97 PHCS 0.96 PHCS 0.97 PHCS 0.97 PHCS 0.98 PHCS 0.99 PHC	MDR MDR MDR MDR MDR MDR MDR MDR MDR MDR
Non- Facility To Practice Expe Expense RV	0.20	
Facility Practice Expense RVUs	0.20	<u>t</u> 5
Work Expense RVUs	000	
Status/ Usage Indicator		
Conversion Factor/GAAF Category	Therapeutic Injections Therapeutic Injections	Immunizations Im
CPT/HCPCS Code Description	Human ig. im Human ig. iv Botulinum antitoxin Botulism ig. iv Cmv ig. iv Diphtheria antitoxin Hep b ig, im Rabies ig, im8c Rabies ig, heat treated Rav ig, in, 50mg Rsv ig, iv Rh ig, inidose, im Rh ig, inidose, im Rh ig, inidose, im Rh ig, inidose, im Rh ig, inidose, im Vacicila ig, im Vacicila zoster ig, im Immune globulin Immunization admin	immunization admin, each add immune admin oral/nasal limmune admin oral/nasal Adenovirus vaccine, type 4 Adenovirus vaccine, type 7 Anthrax vaccine, type 7 Anthrax vaccine, percut Bcg vaccine, percut Bcg vaccine, intravesical Hep a vacc, ped/adol, 2 dose Hep a vacc, ped/adol, 3 dose Hep a vacc, ped/adol, 3 dose Hep a vacc, ped/adol, 3 dose Hep a vacc, ped/adol, 1 dose Hey a vaccine, pro-d, im Hib vaccine, pro-d, im Hib vaccine, pro-d, im Hib vaccine, pro-d, im Flu vaccine, pro-d, im Flu vaccine, orasal Lyme disease vaccine, im Pneumocoocaal vacc, ped <5 Rabies vaccine, id Rabies vaccine, id Rabies vaccine, id Rabies vaccine, id Rabies vaccine, id
Modifier		
CPT/ HCPCS Code	90281 90283 90288 90288 90286 90375 90376 90378 90384 90386 90386 90389 90389	90472 90473 90474 90577 90581 90588 90632 90633 90634 90645 90645 90646 90669 90669 90669 90669

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 146 OF 173

Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
	Typhoid vaccine, h-p, sc/id Typhoid vaccine, im Dtp vaccine, im Dtp vaccine, im Dt vaccine, im Ot vaccine, im Mumps vaccine, sc Massles vaccine, sc Massles vaccine, sc Massles vaccine, sc Mmv vaccine, sc Mmv vaccine, sc Mmv vaccine, sc Mmv vaccine, sc Mmv vaccine, sc Oral poliovirus vaccine Poliovirus, ipv, sc Chicken pox vaccine, im Dtp/hib vaccine, im Dtp/hib vaccine, im Dtap-hep b-ipv vaccine, im Cholera vaccine, im Dtap-hep b-ipv vaccine Maningococcal vaccine Meningococcal vaccine, im Pheb vacc, aldol, 2 dose, im Hep b vacc, ill pat 3 dose im Hep b vacc, ill pat 3 dose im Hep b vacc, ill pat 4 dose im Hep b vacc, ill pat 4 dose im Hep b vaccine, im Ni infusion, additional hour Injection, of antibiotic Ther/prophylactic/dx inject Psytx, office, 20-30 min Psytx, off, 45-50 min w/e&m Psytx, off, 45-50 min w/e&m	Immunizations Im		0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	1.10 0.17 0.17 0.07 0.052 0.052 0.052	1.00.00.00 0.00.00.00 0.00.00.00 0.00.00 0.00.0	0.000 0.000	M S S S S S S S S S S S S S S S S S S S
		Typhoid vaccine, h-p. sc/id Typhoid vaccine, and, sc Dtap vaccine, im Dty vaccine, im Dty vaccine im Dty vaccine im Annus vaccine, sc Measles vaccine, sc Measles vaccine, sc Mmv vaccine, sc Mmv vaccine, sc Mmv vaccine, sc Mmv vaccine, sc Mmv vaccine, sc Oral poliovirus, ipv, sc Oral poliovirus vaccine Poliovirus, ipv, sc Tyaccine, sc Tyaccine, sc Tyaccine, sc Tyaccine, sc Tyaccine, sc Tyaccine, im Diphtheria vaccine, im Dtap-hep b-ipv vaccine im Dtap-hep b-ipv vaccine im Dtap-hep b-ipv vaccine, im Hepb vacci ill pat 3 dose im Hepb vacc, ill pat 3 dose im Hepb vacc, ill pat 4 dose im Hepb vacc, ill pat 4 dose im Hepb vacc, ill pat 4 dose im Hepb vacc, ill pat 4 dose im Hepb vacc, ill pat 4 dose im Hepb brinb vaccine, im Hepb vacc scili pat 4 dose im Hepb brinb vaccine, im Hepb vacc ped/adol 3 dose im Hepb brinb vaccine, im Hepb vacc scili pat 4 dose im Hepb vacc scili pat 4 dose im Hepb vacc scili pat 4 dose im Hepb vacc ill pat 4 dose im Hepb vacc ill pat 4 dose im Hepb vacc scili pat 4 dose im Hepb vacc scili pat 4 dose im Hepb vacc scili pat 4 dose im Hepb vacc ill pat 4 dose im Hepb vacc ill pat 4 dose im Hepb vaccine, iv Initacion, sc/im Iniection, iv Iniection	F	F	Immunizations Im	Immunizations Im	Immunizations im	Immunizations im

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 147 OF 173

Charge Method- ology	MDR Misc
Total Expense RVUs	3.03 1.69
Non- Facility Practice Expense RVUs	0.095 0.
Facility Practice Expense RVUs	0.000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.0000
Work Expense RVUs	2.23 2.36 2.36 2.36 2.36 2.36 2.36 2.36
Status/ Usage Indicator	
Conversion Factor/GAAF Category	OP Psych./Alc. & Drug Abuse OP
CPT/HCPCS Code Description	Psytx, office, 75-80 min hate psytx, off, 75-80 min intac psytx, 20-30 will mare psytx, 20-30 will intac psytx, 20-30 will intac psytx, 45-50 min intac psytx, 45-50 min will mare psytx, 45-50 min will mare psytx, 75-80 will will mare psytx, hosp, 20-30 min will will psytx, hosp, 45-50 min will psytx, hosp, 45-50 min will psytx, hosp, 45-50 min will mare psytx, hosp, 75-80 min min a psytx, hosp, 75-80 min min psytx, hosp, 75-80 min min psytx, hosp, 75-80 min min psytx, hosp, 75-80 min intac psytx, hosp, 75-80 min wilded services, month ESRD related services, month ESRD related services, day Estd related services, day
Modifier	
CPT/ HCPCS Code	90808 90810 90811 90811 90813 90814 90815 90819 90829 90828 90828 90828 90828 90828 90829 90829 90849 90849 90887

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 148 OF 173

Charge Method- ology	A A A A MURA MURA MURA MURA MURA MURA MU	SA	ć	Misc
Total Expense RVUs	0.86 1.29 0.86 1.29 2.42	0.38	0	2.15
Non- Facility Practice Expense RVUs	0.00 1 0.00 0.00 0.00 0.00 0.00 0.00 0.	O.18	0.24	edonostrios.
Facility Practice Expense RVUs	0.00 1 0.	<u>s</u>	0.24	
Work Expense RVUs	4 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2	0.52	99:0	
Status/ Usage Indicator		æ	,	70
Conversion Factor/GAAF Category	Miscellaneous Medical Miscellaneous Medical	Miscellaneous Medical Miscellaneous Medical	Miscellaneous Medical	Miscellaneous Medical Miscellaneous Medical
CPT/HCPCS Code Description	Esrd related services, day Esrd related services, day Hemodialysis, one evaluation Hemodialysis study, transcut Hemodialysis study, transcut Hemodialysis study, transcut Hemodialysis study, transcut Hemodialysis study, transcut Hemodialysis access study Dialysis, one evaluation Dialysis, one evaluation Dialysis, repeated eval Dialysis training, incompl Hemoperfusion Esophageal intubation Esophageal intubation Esophagea motility study Esophagus motility study Esophagus motility study Esophagus motility study Esophagus motility study Castric motility Gastric motility Acid perfusion of esophagus Acid perfusion of esophagus Acid perfusion of esophagus Esophagus, acid reflux test Prolonged acid reflux test Prolonged acid reflux test Gastric analysis test Gastric nanlysis test Gastric nanlysis test Gastric nanlysis test Gastric ranlysis test Gastric nanlysis test Gastric nanlysis test Gastric ranlysis test Gastric intubation for smear Gastric saline load test Breath hydrogen test Breath hydrogen test Gastric intubation treatment Anal pressure record	Electrogastrography Electrogastrography		Electrogastrography wrtest Gastroenterology procedure
Modifier	87 28 28 28 28 28 28 28 28 28 28 28 28 28		58	38 28
CPT/ HCPCS Code	90924 90935 90935 90937 90939 90939 90945 90945 90945 90945 90993 90993 90993 91010 91010 91012 91032 91032 91032 91032 91032 91033 91033 91033 91055 91065 91065 91065	91132 91132	91133	91133 91299

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 149 OF 173

Charge Method- ology	Misc C
Total Expense RVUs	4.60
Non- Facility Practice Expense RVUs	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Facility Practice Expense RVUs	90 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Work Expense RVUs	0.00 0.00
Status/ Usage Indicator	, , , , , , , , , , , , , , , , , , ,
Conversion Factor/GAAF Category	Miscellaneous Medical Vision Exams Vision Exams Vision Exams Vision Exams Vision Exams Vision Exams Miscellaneous Medical
CPT/HCPCS Code Description	Gastroenterology procedure Eye exam, new patient Eye exam, new patient Eye exam established pat Eye exam & treatment Eye exam & treatment Refraction New eye exam & treatment Special eye evaluation Special eye evaluation Special eye evaluation Special eye evaluation Special eye evaluation Special eye evaluation Special eye evaluation Special eye evaluation Special eye evaluation Special eye evaluation Special eye evaluation Special eye evaluation Special eye evaluation Special eye evaluation(s) Visual field examination(s) Visual field examination(s) Visual field examination(s) Visual field examination(s) Serial tonometry exam(s) Tonography & eye evaluation Opthalmic dx imaging Opthalmic dx imaging Opthalmic biometry Glaucoma provocative tests Special eye exam, initial Special eye exam, initial Special eye exam, with photos Eye exam with p
Modifier	T
CPT/ HCPCS Code	91299 92002 92002 92004 92014 92015 92016 92019 92081 92082 92083 92136 92136 92136 92136 92136 92136 92226 92226 92236 92226 92226 92226 92226 92226 92236 92226 92236 92236 92236 92236 92236 92236 92236 92236 92236 92236 92236 92236 92236 92236 92236

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 150 OF 173

Charge Method- ology	S SAF Misc Misc Misc Misc Misc Misc Misc Misc
Total Expense RVUs	1.05 2.46 4.39 1.97 5.58
Non- Facility Practice Expense RVUs	0.000000000000000000000000000000000000
Facility Practice Expense RVUs	0.00000
Work Expense RVUs	0.00 0.00
Status/ Usage Indicator	, o o o o
Conversion Factor/GAAF Category	Miscellaneous Medical Miscellaneous Medical
CPT/HCPCS Code Description	Dark adaptation eye exam Dark adaptation eye exam Eye photography Internal eye photography Internal eye photography Internal eye photography Internal eye photography Internal eye photography Internal eye photography Internal eye photography Internal eye photography Internal eye photography Internal eye photography Internal eye photography Internal eye photography Internal eye photography Internal eye photography Internal eye photography Internal eye photography Internal eye photography Internal eye photography Internal eye prostact lens Internal eye fitting Prescription of contact lens Internated en fitting Internated en fitting Internated en fitting Internated en fitting Internated en fitting Internated en fitting Internated en fitting Internated en fitting Internated en fitting Internated en fitting Internated en fitting Internated en format lenses Interna
Modifier	179 179 179 179
CPT/ HCPCS Code	92284 92284 92285 92286 92286 92287 92311 92311 92313 92314 92314 92335 92336 92336 92336 92337 92337 92337 92339 92399

NOTES: OPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 151 OF 173

Charge Method- ology	M M M M M M M M M M M M M M M M M M M	MDR PHCS PHCS
Total Expense RVUs	0.0.0.1.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0	0.42 0.62 0.62
Non- Facility Practice Expense RVUs	0.20 0.20 0.21 0.91 0.91 0.93 0.13 0.14 0.14 0.14 0.17 0.13 0.13 0.13 0.13 0.13 0.13 0.13 0.13	0.045 0.038 0.040 0.040 0.040 0.030 0.030 0.030 0.030 0.030 0.030 0.030 0.030 0.030
Facility Practice Expense RVUs	0.97 0.55 0.50 0.20 0.91 0.94 0.05 0.94 0.13 0.14 0.14 0.17 0.17 0.17 0.17 0.17 0.17 0.17 0.17	0.057 0.038 0.038 0.040 0.052 0.039 0.039 0.039 0.039 0.039 0.039 0.039 0.039 0.039 0.039 0.039
Work Expense RVUs	0.40 0.00 0.00 0.00 0.00 0.00 0.00 0.00	000000 00000000000000000000000000000000
Status/ Usage Indicator		
Conversion Factor/GAAF Category	Miscellaneous Medical Miscellaneous Medical	Hearing/Speech Exams Hearing/Speech Exams
CPT/HCPCS Code Description		Pure tone hearing test, air Pure tone addometry, air Audiometry, air & bone Speech threshold audiometry Speech audiometry complete Comprehensive hearing test Group audiometry, caren Bekesy audiometry, diagnosis Loudness balance test Tone decay hearing test Sisi hearing test Sisi hearing test Sisi hearing test Sisi hearing test Sisi hearing test Sisi hearing test Stanger test, pure tone Tympanometry Acoustic reflex decay test Filtered speech hearing test Stangered spondaic word test Lombard test Sensorineural acuity test Synthetic sentence test Sensorineural acuity test Synthetic sentence test Stanger test, speech Visual audiometry (vra) Conditioning play audiometry
Modifier	85 28 28 28 38 38 38 38 38 38 38 38 38 38 38 38 38	
CPT/ HCPCS Code	92516 92520 92521 92531 92532 92533 92541 92541 92542 92542 92544 92544 92544 92545 92544 92544 92546 92546	92551 92552 92553 92555 92556 92556 92561 92562 92563 92567 92567 92577 92577 92577 92577

NOTES: OPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 152 OF 173

Charge Method- ology	M M M M M M M M M M	& S
Total Expense RVUs	1.60 0.74 1.06 0.77 1.15	3.50
Non- Facility Practice Expense RVUs	0.022484.00.00.00.00.00.00.00.00.00.00.00.00.00	0.000 0.000
Facility Practice Expense RVUs	0.22 0.22 0.22 0.22 0.22 0.22 0.33 0.42 0.53 0.53 0.63	2.0.3.3.4.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8
Work Expense RVUs	000000000000000000000000000000000000000	0000 0000 0000 0000 0000 0000 0000 0000 0000
Status/ Usage Indicator		ס ס
Conversion Factor/GAAF Category	Hearing/Speech Exams Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical	Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Cardiovascular
CPT/HCPCS Code Description	Select picture audiometry Electrocochleography Auditor evoke potent, compre Auditor evoke potent, compre Auditor evoke potent, ilmit Evoked auditory test Evoked auditory test Evoked auditory test Evoked auditory test Evoked auditory test Evoked auditory test Auditory function test(s) Hearing aid exam, one ear Hearing aid check, one ear Hearing aid check, one ear Hearing aid check, one ear Electro hearng aid test, one Electro hearng aid test, one Electro hearng aid test, one Electro cochlear impti fup exam < 7 Cochlear impti fup exam < 7 Cochlear impti fup exam < 7 Reprogram cochlear impti 7 > Ex for speech device x; thr Ex for speech device x; thr Ex for speech device x; thr Ex for speech device x; thr	Use of speech device service Evaluate swallowing function Motion fluoroscopy/swallow Endoscopy swallow tst (fees) Laryngoscopic sensory test Fees wilaryngeal sense test Hear/Uning resuscitation cpr Temporary external pacing Cardioversion, electric, int Cardioversion, electric, int Cardioversion, electric, int Cardioversion, electric, int Cardioassist, internal Cardioassist, external Percut coronary thrombectomy Cath place, cardio brachytx Dissolve clot, heart vessel Dissolve clot, heart vessel Intravasc us, heart add-on Intravasc us, hea
Modifier	26 26 26 70 70	26 75 75 75 76
CPT/ HCPCS Code	92583 92584 92585 92585 92586 92587 92588 92587 92590 92591 92592 92594 92595 92595 92595 92596 92596 92596 92596 92596 92596 92596 92596 92596 92596 92596 92596 92596 92596 92596 92596 92597	92609 92610 92611 92612 92614 92950 92953 92970 92973 92973 92973 92978 92978

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 153 OF 173

Charge Method- ology	MM DDR R	
Total Expense RVUs	39.45 27.64	-
Non- Facility Practice Expense RVUs	4.66 4.66	D. 1.0
Facility Practice Expense RVUs	4.66 4.66	04.0
Work Expense RVUs	4 5 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7 7	- 20.1
Status/ Usage Indicator	ກ ກ	
Conversion Factor/GAAF Category	Surgery Surger	- Cardiovascular
CPT/HCPCS Code Description	Insert intracoronary stent Coronary artery dilation Coronary artery dilation Coronary artery dilation Revision of acutic valve Revision of heart chamber Revision of heart chamber Revision of heart chamber Revision of heart chamber Coronary atherectomy add-on Pul art balloon repr, percut Electrocardiogram, complete Electrocardiogram, racing Electrocardiogram, racing Electrocardiogram report Transmission of ecg Cardiovascular stress test Cardiovascula	ECHO transtrioracic
Modifier	28 17 17 17 17 17	07
CPT/ HCPCS Code	92981 92982 92982 92986 92990 92990 92992 92995 92995 92996 92996 93010 93011 93014 93024 93025 93226 93226 93226 93226 93226 93227 93226 93227 93226 93227 93228	83303

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 154 OF 173

Charge Method- ology	M MDR MDR MDR MDR MDR MDR MDR MDR MDR MD
Total Expense RVUs	. 4.35
Non- Facility Practice Expense RVUs	3.82 3.83
Facility Practice Expense RVUs	8.001.08.08.08.08.09.08.09.09.09.09.09.09.09.09.09.09.09.09.09.
Work Expense RVUs	0.000 0.000
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Cardiovascular Cardio
CPT/HCPCS Code Description	Echo transthoracic Echo transthoracic Echo exam of heart Echo exam of heart Echo exam of heart Echo exam of heart Echo exam of heart Echo exam of heart Echo transesophageal Echo
Modifier	78787878787878787878787878787878787878
CPT/ HCPCS Code	93303 93304 93304 93307 93308 93312 93313 93314 93314 93315 93316 93317

NOTES: OPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 155 OF 173

Charge Method- ology		SA
Total Expense RVUs		5:35
Non- Facility Practice Expense RVUs	8 8 4 8 8 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9	<u>.</u>
Facility Practice Expense RVUs	8. 8. 1. 8. 8. 8. 8. 9. 9. 9. 9. 9. 9. 9. 9. 9. 9. 9. 9. 9.	<u>.</u>
Work Expense RVUs	8 9 9 4 9 4 9 8 9 5 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9	23.5
Status/ Usage Indicator	, , , , , , , , , , , , , , , , , , , ,	70
Conversion Factor/GAAF Category	Surgery Surger	Cardiovascular Cardiovascular
CPT/HCPCS Code Description	Rt & Lt heart catheters Rt & Lt heart catheters Rt & Lt heart catheterization Rt, it heart cath, congenital Rt heart cath, congenital Rt heart cath, congenital R & I heart cath, congenital R & I heart cath, congenital R & I heart cath, congenital R & I heart cath, congenital R & I heart cath, congenital R & I heart cath, congenital R & I heart cath, congenital R & I heart cath, congenital R & I heart cath, congenital R & I heart cath, congenital R & I heart cath, congenital R & I heart cath, congenital Injection, cardiac cath Injection for lung angiogram Injection for heart x-rays Injection for heart x-rays Injection for heart x-rays Injection for heart x-rays Injection for neart x-rays Injection for neart x-rays Injection for eartography Inject for coronary x-rays Injection for eartography Inject for coronary x-rays Injection for neart x-rays Injection for neart x-rays Injection for neart x-rays Injection for neart x-rays Injection for neartography Inject for coronary x-rays Injection for neartography Inject for coronary x-rays Injection for neart x-rays In	Intraventricular pacing Electrophys map 3d, add-on
Modifier	\$1857877877877877877877877878 \$17872877877877877877877877877877877877877	7 2 2 8
CPT/ HCPCS Code	93528 93528 93529 93529 93520 93530 93531 93532 93532 93532 93532 93532 93532 93532 93540 93540 93540 93540 93540 93540 93561 93560 93560 93560 93560 93560 93560 93560 93560 93560 93560 93560 93560 93560 93560 93560 93560 93560 93560 93560	93612 93613

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 156 OF 173

Charge Method- ology	S S S W WDR	MDR MDR	SA
Total Expense RVUs	4.37 13.26 2.41 3.55 3.98	12.96	0.56
Non- Facility Practice Expense RVUs	0.27 0.32 0.32 1.71 1.71 2.39 4.62 1.93 1.94 1.193 1.39 1.39 1.39 1.39 1.39 1.39 1.3	0.07	0.71 0.05 1.96 3.95 0.20 0.18
Facility Practice Expense RVUs	0.27 0.32 0.32 0.32 0.32 0.32 0.32 0.32 0.32	0.07	0.71 0.05 1.96 3.95 0.20 0.18
Work Expense RVUs	99.0 90.0 90.0 90.0 90.0 90.0 90.0 90.0	0.17	0.00 0.17 0.17 0.00 0.52 0.45
Status/ Usage Indicator	, , , , , , , , , , , , , , , , , , ,	as as	, a a a
Conversion Factor/GAAF Category	Cardiovascular Cardio	Cardiovascular Cardiovascular Cardiovascular Cardiovascular	Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular
CPT/HCPCS Code Description	Electrophys map 3d, add-on Esophageal recording Esophageal recording Esophageal recording Esophageal recording Esophageal recording Esophageal recording Heart rhythm pacing Heart rhythm pacing Heart rhythm pacing Heart rhythm pacing Electrophysiology evaluation Ablate heart dysrhythm focus Ablate heart dysrhythm focus Tilt table evaluation Itilt table evaluation Itilt table evaluation Itilt rable evaluation intracardiac ecg (ice)	Intracardiac ecg (ice) Peripheral vascular rehab Bioimpedance, thoracic Rioimpedance, thoracic	Total body plethysmography Total body plethysmography Plethysmography tracing Plethysmography report Analyze pacemaker system Analyze ilr system Analyze pacemaker system Analyze pacemaker system Analyze pacemaker system
Modifier	25 C8 C8 C8 C8 C8 C8 C8 C8 C8 C8 C8 C8 C8	75 26 15	26 75 75 75 75
CPT/ HCPCS Code	93615 93615 93615 93616 93616 93619 93619 93620 93620 93621 93621 93621 93621 93641 93641 93641 93641 93650 93651 93651 93651 93661 93661	93662 93668 93701	93720 93720 93721 93722 93724 93724 93731

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 157 OF 173

Charge Method- ology		0 0 0 0 4 4 4	MDR Misc Misc
Total Expense RVUs		0.29 1.18 0.64 2.61	1.82 1.47 3.40
Non- Facility Practice Expense RVUs	0.36 0.51 0.073 0.035 0.035 0.045 0.063 0.063 0.067 0.067 0.067 0.067	0.003	0.00 0.007 0.01 1.57 0.09 0.08 0.03 0.03 0.03 0.03 0.03 0.03 0.03
 Facility Practice Expense RVUs	0.36 0.51 0.073 0.073 0.025 0.063 0.064 0.057 0.057 0.057 0.057	0.05 0.03 0.98 0.98	0.07 0.39 0.50 0.00 1.57 0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.0
Work Expense RVUs	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	0.00 0.00 0.17 0.00	0.17 0.18 0.18 0.00 0.00 0.00 0.00 0.00 0.00
Status/ Usage Indicator		ט ט ט ט	
Conversion Factor/GAAF Category	Cardiovascular Cardiovascular	Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular	Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Cardiovascular Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical
CPT/HCPCS Code Description	Analyze pacemaker system Analyze pacemaker system Telephone analy, pacemaker Telephone analy, pacemaker Analyze pacemaker system Analyze pacemaker system Analyze pacemaker system Analyze pacemaker system Analyze pacemaker system Telephone analy, pacemaker Telephone analy, pacemaker Temperature gradient studies Temperature gradient studies Analyze it pace device sngl Analyze it pace device sngl Analyze it pace device sngl Analyze it pace device dual Analyze it pace device dual Analyze it pace device dual	Cephalic thermogram Cephalic thermogram Cephalic thermogram Peripheral thermogram Measure venous pressure Measure venous pressure Ambulatory BP monitoring Ambulatory BP recording	Ambulatory BP analysis Review/report BP recording Cardiac rehab/monitor Cardiovascular procedure Cardiovascular procedure Extracranial study Extracranial study Extracranial study Extracranial study Extracranial study Extracranial study Intracranial study Extremity study Extremity study
Modifier	827828282828282828282828282828282828282	75 75 75 75 75 75	28 28 28 28 28 28 28 28 29 29 29
CPT/ HCPCS Code	93732 93732 93733 93733 93734 93735 93736 93740 93741 93741 93742 93742 93742 93742	937.44 937.60 937.62 937.62 937.70 937.84 937.86	93788 93790 93790 93799 93799 93875 93887 93880 93882 93882 93882 93888 93888 93888

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 158 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	0.00
Facility Practice Expense RVUs	0.000 0.000
Work Expense RVUs	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Status/ Usage Indicator	თ თ თ თ თ თ თ თ თ თ თ თ თ თ თ თ
Conversion Factor/GAAF Category	Miscellaneous Medical Miscellaneous Medical
CPT/HCPCS Code Description	Extremity study Extremity study Extremity study Extremity study Lower extremity study Lower extremity study Lower extremity study Lower extremity study Upper extremity study Upper extremity study Upper extremity study Upper extremity study Upper extremity study Extremity study Extremity study Extremity study Extremity study Extremity study Extremity study Extremity study Vascular study Vascula
Modifier	\$7\$7\$7\$7\$7\$7\$7\$7\$7\$7\$7\$7\$7\$7\$7\$7\$7\$7\$7
CPT/ HCPCS Code	93923 93923 93924 93924 93925 93926 93926 93926 93930 93930 93930 93977 93977 93977 93977 939788 93978

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 159 OF 173

Charge Method- ology	A G A
Total Expense RVUs	2.17
Non- Facility Practice Expense RVUs	0.03 0.03 0.03 0.03 0.03 0.03 0.03 0.03
Facility Practice Expense RVUs	0.03 0.04 0.05 0.05 0.05 0.05 0.05 0.05 0.05
Work Expense RVUs	0.000 0.000
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Miscellaneous Medical Miscellaneous Medical
CPT/HCPCS Code Description	Residual lung capacity Expired gas collection Expired gas collection Thoracic gas volume Thoracic gas volume Thoracic gas volume Thoracic gas volume Thoracic gas volume Thoracic gas volume Lung nitrogen washout curve Measure airflow resistance Measure airflow resistance Measure airflow resistance Respiratory flow volume loop Respiratory flow volume loop CO2 breathing response curve Hypoxia response respective Hypoxia response curve Hypoxia response curve Hypoxia response curve Hypoxia response curve Hypoxia response Hypoxi
Modifier	28 128 128 128 128 128 128 128 128 128 1
CPT/ HCPCS Code	94240 94250 94250 94250 94350 94350 94350 94350 94370 944370 944370 944370 94450 94621 94621 94621 94621 94621 94621 94621 94621 94621 94620 94620 94621 94631 94631 94631 94664 94660 94720 94720 94720 94720 94720 94720 94720 94720 94720 94720 94720

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 160 OF 173

Charge Method- ology	PHCS Misc Misc	MMMMMM MDMM MDRARAR MDRAR MDRAR MDRARAR MDRAR MDRARAR MDRARAR MDRARAR MDRARAR MDRARAR MDRARAR MDRARAR MDRARAR	Misc
Total Expense RVUs	3 67 0 42 2 84	0.50 0.70 0.70 1.24 1.82 2.18 2.18	0.28
Non- Facility Practice Expense RVUs	1. 64 0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.	0.0000000000000000000000000000000000000	3.22 0.68 16.43 0.55 3.55 0.54 11.46
Facility Practice Expense RVUs	49 1. 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0 0.0	0.020 0.083 0.083 0.00 0.00 0.00 0.00	3.22 0.68 16.43 0.55 3.55 0.54 11.46
Work Expense RVUs	0 0000000000000000000000000000000000000	2.000000000000000000000000000000000000	0.00 1.66 0.00 1.66 0.00 2.65
Status/ Usage Indicator	ס ס		ס ס ס
Conversion Factor/GAAF Category	Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Allergy Testing	Allergy Immunotherapy Allergy Immunotherapy	Allergy Immunotherapy Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical
CPT/HCPCS Code Description	Exhaled carbon dioxide test Breath recording, infant Pulmonary service/procedure Percut allergy skin tests Percut allergy skin tests Percut allergy titrate-drug/bug Id allergy titrate-drug/bug Id allergy titrate-drug/bug Id allergy titrate-ariborne Id allergy test, drug/bug Id allergy test, drug/bug Id allergy test, drug/bug Id allergy test, drug/bug Id allergy tests Photo patch test Photo patch test Photo sealingy tests Bronchial allergy tests Bronchial allergy tests Ingestion challenge tests Ingestion challenge tests Ingestion challenge tests Immunotherapy, one injection	immunotherapy injection immunotherapy, one injection immunotherapy, many antigens immunotherapy, insect venom immunotherapy, insect venoms immunotherapy, insect venoms immunotherapy, insect venoms immunotherapy, insect venoms immunotherapy, insect venoms immunotherapy, insect venoms immunotherapy, insect venoms Antigen therapy services Antigen therapy services Antigen therapy services Antigen therapy services Antigen therapy services Antigen therapy services Antigen therapy services Antigen therapy services Antigen therapy services Antigen therapy services Antigen therapy services Antigen therapy services	Allergy immunology services Glucose monitoring, cont Glucose monitoring, cont Multiple sleep latency test Multiple sleep latency test Sleep study, unattended Sleep study, attended Sleep study, attended Sleep study, attended Sleep study, attended Sleep study, attended Sleep study, attended
Modifier	7 5 C		75 75 75 75 75 75 75 75
CPT/ HCPCS Code	94770 94772 94799 94799 95004 95010 9502 95027 95028 95044 9505 9505 9506 9506 9507 9507 9507 9507 9507	95117 95120 95120 95132 95133 95134 95144 95145 95146 95148 95149 95149	95199 95250 95805 95805 95806 95806 95807 95807

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 161 OF 173

Charge Method- ology	PHCS
Total Expense RVUs	1.69
Non- Facility Practice Expense RVUs	21.24 21.24 21.24 22.24 23.24 24.24 24.24 25.24 26.25 26.25 26.25 27.26 27
Facility Practice Expense RVUs	21.16.0 21.16.0 21.2.0 21.0
Work Expense RVUs	0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.00
Status/ Usage Indicator	, , , , , , , , , , , , , , , , , , ,
Conversion Factor/GAAF Category	Miscellaneous Medical Miscellaneous Medical
CPT/HCPCS Code Description	Polysomnography, 1-3 Polysomnography, 4-3 Polysomnography, 4 or more Polysomnography, 4 or more Polysomnography wicpap Polysomnography wicpap Eeg, 41-60 minutes Eeg, 41-60 minutes Eeg, over 1 hour Eeg, over 1 hour Eeg, awake and drowsy Eeg, awake and drowsy Eeg, awake and asleep Eeg, a
Modifier	24
CPT/ HCPCS Code	95808 95810 95811 95811 95811 95812 95813 95813 95813 95824 95825 95827 95827 95827 95827 95827 95828 95827 95828 95828 95828 95828 95828 95828 95828 95828 95828 95828 95828 95828 95828 95828 95832 95832 95832 95833 95833 95833 95833 95860 95860 95860 95861 95867 95861 95867 95867 95867 95867 95867 95867 95867 95867 95867 95867 95867 95867 95867 95867 95867 95867 95867 95867 95867 95868

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 162 OF 173

Charge Method- ology	
Total Expense RVUs	
Non- Facility Practice Expense RVUs	0.055 0.056 0.057 0.057 0.058
Facility Practice Expense RVUs	0.055 0.056 0.057
Work Expense RVUs	0.00 0.00
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Miscellaneous Medical Miscellaneous Medical
CPT/HCPCS Code Description	Muscle test, nonparaspinal Muscle test, one fiber Limb exercise test Limb exercise test Limb exercise test Limb exercise test Limb exercise test Limb exercise test Motor nerve conduction test Motor nerve conduction test Motor nerve conduction test Sense nerve conduction test Sense nerve conduction test Intraop nerve test add-on Intraop nerve test add-on Intraop nerve test add-on Intraop nerve test add-on Autonomic nerv function test Autonomic nerv function test Autonomic nerv function test Autonomic nerv function test Autonomic nerv function test Autonomic nerv function test Somatosensory testing Somatosensor
Modifier	2678787878787878787878787878787878787878
CPT/ HCPCS Code	95872 95872 95875 95875 95875 95900 95900 95900 95901 95902 95903 95922 95922 95923 95923 95923 95923 95923 95923 95924 95936 95936 95936 95936 95936 95936 95936 95936 95936 95936 95936 95937 95936 95936 95936 95936 95936 95936 95936 95936 95936 95936 95936 95936 95936 95936 95936 95936 95936 95937 95937 95937 95937 95937 95936 95936 95936 95936 95936 95936 95936 95936 95936 95937 95936 95937 95956 95956 95956 95956 95956

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 163 OF 173

Charge Method- ology	:	Å Å Å	MDR MDR
Total Expense RVUs		44.44 22.20 19.44	2.66
Non- Facility Practice Expense RVUs	14.36 0.87 1.69 1.73 1.35 1.30 1.30 1.30	1.55 1.36 0.15 0.23 0.23 0.35 1.32 0.35 0.35 0.35	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Facility Practice Expense RVUs	14.36 0.87 1.69 1.73 1.73 1.35 1.35 1.30 1.30	1.55 1.36 0.28 0.28 1.32 1.32 1.45	64 0000 0000 0000 0000 0000 0000 0000 0
Work Expense RVUs	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0	3.50 0.45 0.45 0.78 1.50 0.02 0.00 0.00	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Status/ Usage Indicator	, , , , , , , , , , , , , , , , , , ,	ס ס	ە مەمەم
Conversion Factor/GAAF Category	Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical	Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical	Miscellaneous Medical Miscellaneous Medical
CPT/HCPCS Code Description	Eeg monitoring, cable/radio EEG digital analysis EEG digital analysis EEG digital analysis EEG monitoring/function test EEG monitoring/function test Electrode stimulation, brain Electrode stimulation, brain Electrode stim, brain add-on Electrode stim, brain add-on Meg, spontaneous	Meg, spontaneous Meg, evoked, single Meg, evoked, single Meg, evoked, each addl Meg, evoked, each addl Analyze neurostim, no prog Analyze neurostim, complex Analyze neurostim, complex Cranial neurostim, complex	Spin/brain pump reni & main Neurological procedure Motion analysis, video/3d Motion test w/ft press meas Dynamic surface emg Dynamic surface emg Dynamic surface emg Phys review of motion tests Psychological testing Assessment of aphasia Developmental test, lim Developmental test, lim Developmental test, watend Neurobehavior status exam Neuropsych test battery Assess lith/behave, subseq intervene hith/behave, subseq intervene hith/behave, group interv hith/behav, fam w/pt intervene hith/behav
Modifier	26 26 26 26 26 26 26 26 26 26 26 26 26 2	75 25 28 72 72 72	
CPT/ HCPCS Code	96956 95957 95957 95958 95958 95961 95961 95962 95962	95965 95966 95966 95967 95970 95971 95973 95973 95974	95990 95990 96000 96000 96000 96000 96110 96111 96115 96150 96152 96152 96152 96153 96154 96165 96166 96165 96166 96166 96167 96166 96167 96166 96166 96166 96166 96166 96166 96166 96166 96166 96166 96166 96166 96166 96166

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 164 OF 173

Charge Method- ology	SAF SA SA SA SA SA SA SA SA SA SA SA SA SA S
Total Expense RVUs	1.89 0.39 1.56 0.78
Non- Facility Practice Expense RVUs	1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
Facility Practice Expense RVUs	222433 24244444444444444444444444444444
Work Expense RVUs	0.000 0.000
Status/ Usage Indicator	ວວວວວວ
Conversion Factor/GAAF Category	Miscellaneous Medical Miscellaneous Medicine Physical Medicine
CPT/HCPCS Code Description	Chemo, infuse method add-on Chemotherapy, bush technique Chemotherapy, infusion method Chemotherapy, infusion method Chemotherapy, infusion method Chemotherapy, infusion method Chemotherapy, infusion method Chemotherapy, infusion method Chemotherapy, infusion method Chemotherapy, infusion method Chemotherapy, infusion in CNS Port pump refill & main Syst pump refill & main Chemotherapy injection Provide chemotherapy inspecified Photodynamic tx, add I 15 min Ultraviolet light therapy I Trichogram Photodynamic tx, add I 15 min Ultraviolet light therapy I Trichogram Photodynamic tx, add I 15 min Ultraviolet light therapy I Trichogram Photochemotherapy with UV-A or B Laser tx, skin < 250 sq cm Laser tx, skin < 250 sq cm Dermatological procedure Pt evaluation Pt re-evaluation Of re-evaluation Of re-evaluation Of re-evaluation Athletic train reeval Hot or cold packs therapy Warlebotherapy Warlebotherapy Warlebotherapy Warlebotherapy Ultraviolet therapy Ultrav
Modifier	
CPT/ HCPCS Code	96414 96423 96423 96425 96425 96425 96426 96530 96530 96549 96570 96571 96571 96571 96570 96570 96902 96902 96902 96913 96913 96913 96913 96914 96910 97010 97010 97010 97010 97002 97002 97003 97003 97003

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 165 OF 173

	Charge Method- ology	MDR MDR SAF SAF Misc	M M M M M M M M M M M M M M M M M M M
-	Total Expense RVUs	2.52 1.01 0.37 1.18 1.57 0.97	0.22 0.24 0.35 1.22 0.65 0.65
-	Non- Facility Practice Expense RVUs	0.000000000000000000000000000000000000	0.00
	Facility Practice Expense RVUs	0.24 0.27 0.27 0.27 0.27 0.27 0.27 0.27 0.27	0.24
	Work Expense RVUs	0.50 0.45 0.45 0.45 0.65 0.65 0.65 0.65 0.65 0.65 0.65 0.6	0.40
	Status/ Usage Indicator		
	Conversion Factor/GAAF Category	Physical Medicine Chiropractor Chiropractor	Chropractor Chropractor Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical
	CPT/HCPCS Code Description		Chiropractic manipulation Specimen handling Specimen handling Device handling Postop follow-up visit Initial surgical evaluation Medical services at fire firs Medical services at night Medical services unusual his
	Modifier		
	CPT/ HCPCS Code	97039 97112 97112 97113 97116 97124 97139 97150 97530 97535 97535 97535 97535 97545 97535 97546 97601 97703	98943 99000 99000 99024 99025 99050 99052

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 166 OF 173

Charge Method- ology	MDR MDR MDR MDR MDR MDR MDR MDR MDR MDR
Total Expense RVUs	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Non- Facility Practice Expense RVUs	0.039 6.039 7.039 6.000 6.000
Facility Practice Expense RVUs	2.1.2 2.1.2 2.1.3 6.1.1 6.1.1 6.1.3
Work Expense RVUs	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Status/ Usage Indicator	ס ס
Conversion Factor/GAAF Category	Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Miscellaneous Medical Miscellaneous Miscellaneous Miscellaneous Miscellaneous Miscellaneous Miscellaneous Miscellaneous Miscel
CPT/HCPCS Code Description	Non-office medical services Office emergancy care Special supplies Patient education materials Medical testimony Group health education Special reports or forms Unusual physician travel Computer data analysis Collect/review data from pt Special anesthesia service Anesthesia with hypothermia Special anesthesia procedure Emergancy anesthesia Special anesthesia Sedation, iv/im or inhalant Sedation, iv/im or inhalant Sedation, oral/rectal/nasal Anogenial exam, child Ocular function screen Induction of vomiting Hyperbaric oxygen therapy Regional hypothermia Total body hypothermia Total body hypothermia Special pump services Special pump services Special pump services Special pump services Special pump services Special pump services Special pump services Chice/outpatient visit, new Office/outpatient visit, new Office/outpatient visit, est
Modifier	70 70 70 70 70 70 70 70 70 70 70 70 70 7
CPT/ HCPCS Code	99056 99075 99077 99077 99077 99078 99078 99078 99170 99172 99172 99172 99172 99172 99172 99172 99172 99172 99172 99172 99172 99173 99173 99173 99173 99173 99173 99173 99173 99173 99174 99174 99174 99177 99191 99191 99191 99203 99203 99203 99203 99203 99213 99213

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 167 OF 173

Modifier	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Status/ Usage Indicator	Work Expense RVUs	Facility Practice Expense RVUs	Non- Facility Practice Expense RVUs	Total Expense RVUs	Charge Method- ology
	Initial hospital care Initial hospital care	Inpatient Visits Inpatient Visits		2.14	0.75	0.75		
	Subsequent hospital care	Inpatient Visits		0.64	0.23	0.23		
	Subsequent hospital care	Inpatient Visits		3.75	0.53	0.53		
	Observ/hosp same date	Inpatient Visits		2.56	0.89	0.89		
	Observ/hosp same date	Inpatient Visits		3.42	1.16	1.16		
	Observ/hosp same date	Inpatient Visits		4.27	1.45	1.45		
	Hospital discharge day	Inpatient Visits		1.28	0.56	0.56		
	Office consultation	Consults		 	0.73	0.73		
	Office consultation	Consults		1.29	1.02	0.47		
	Office consultation	Consults		1.72	1.35	0.64		
	Office consultation	Consults		2.58	1.80	0.94		
	Office consultation	Consults		3.43	2.26	1.24		
	Initial inpatient consult	Consults		0.66	0.25	0.25		
	Initial inpatient consult	Consults		1.32	0.51	0.51		
	initial inpatient consult	Consuits		1.82	0.70	0.70		
	Initial inpatient consult	Consuits		7, v.	9.6	3.6		
	Follow-up inpatient consult	Consults		0.42	0.16	0.16		
	Follow-up inpatient consult	Consults		0.85	0.31	0.31		
	Follow-up inpatient consult	Consults		1.27	0.46	0.46		
	Confirmatory consultation	Consults		0.45	0.66	0.16		
	Confirmatory consultation	Consults		0.84	0.89	0.32		
	Confirmatory consultation	Consults		173	20.5	0.43		
	Confirmatory consultation	Consults		2.31	1.64	98.0		
	Emergency dept visit	Emergency Room Visits		0.33	60.0	0.09		
	Emergency dept visit	Emergency Room Visits		0.55	0.15	0.15		
	Emergency dept visit	Emergency Room Visits		1.24	0.32	0.32		
	Emergency dept visit	Emergency Room Visits		1.95	0.49	0.49		
	Emergency dept visit	Emergency Room Visits		3.00	0.74	4/.0	1 25	L
	Differt advanced life support	Innergency Room visits		Ca v	1 87	1 87	0.33	L
	Ded crit care transport	Inpatient Visits		0.40	10.1	20.0		
	Critical care, first hour	Inpatient Visits		00.4	1.57	130		
	Critical care, addl 30 min	Inpatient Visits		2.00	0.86	0.65	-	
	Ped critical care, initial	Inpatient Visits		16.00	5.13	5.13		
	Ped critical care, subseq	Inpatient Visits		8.00	2.57	2.57		
	Neonate crit care, initial	Inpatient Visits		18.49	5.48	5.48		
	Neonate critical care subseq	Inpatient Visits		8.00	2.61	2.61		
	le for Ibw infant < 1500 gm	Inpatient Visits		2.75	0.96	0.96		
	Ic, tow inrant 1500-2500 gm	Inpatient Visits		7.50	08.0	0.80		
	יות אווה ומכוונל כמום	Inpatient Viole		3 5	0.00	7 1		

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 168 OF 173

Charge Method- ology	M M M M M M M M M M M M M M M M M M M
Total Expense RVUs	47774017 07474017 07474000
Non- Facility Practice Expense RVUs	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Facility Practice Expense RVUs	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
Work Expense RVUs	2.00 1.10
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Inpatient Visits Inpatient Visits Inpatient Visits Inpatient Visits Inpatient Visits Inpatient Visits Office/Home/Urgent Care Visits Office/Home/Urgent Car
CPT/HCPCS Code Description	Nursing facility care Nursing fac care, subseq Nursing fac care, subseq Nursing fac care, subseq Nursing fac care, subseq Nursing fac discharge day Rest home visit, new patient Rest home visit, new patient Rest home visit, est pat Rest home visit, est pat Home visit, new patient Home visit, new patient Home visit, new patient Home visit, new patient Home visit, new patient Home visit, new patient Home visit, new patient Home visit, new patient Home visit, est patient Home visit, est patient Home visit, or patient Home visit, or patient Home visit, or patient Home visit, or patient Home visit, or patient Home visit, or patient Home visit, or patient Home visit, or patient Home visit, or patient Home visit, or patient Home visit, or patient Home visit, or patient Home visit, or patient Home visit, or patient Home visit, or patient Home visit, or patient Home visit, or patient Home visit, or care supervision Howspican/Home consultation Howe health care supervision Howe health care supervision Nursing fac care supervision Nursing fac care supervision Nursing fac care supervision Nursing fac care supervision Nursing fac care supervision Hospice care supervision Nursing fac care supervision Nursing fac care supervision Nursing fac care supervision Nursing fac care supervision Hospice care supervision Nursing fac wist, new, age 12-17 Prev visit, new, age 12-17 Prev visit, new, age 18-39 Prev visit, new, age 18-4 Prev visit, new, age 18-7 Prev visit, n
Modifier	·
CPT/ HCPCS Code	99303 99312 99313 99315 99315 99332 99332 99333 99344 99344 99346 99346 99346 99346 99356 99356 99377 99377 99377 99377 99377 99377 99377 99377 99377 99377 99377 99377 99377 99377 99377 99377 99377 99377 99377

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 169 OF 173

	Charge Method- ology	SAF SAF SAF SAF SAF SAF SAF SAF SAF SAF	PHCS
	Total Expense RVUs	4.4. 9.4.4.8.9.4.9.4.9.8.9.9.9.9.9.8.4.4.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8.8	2.20
	Non- Facility Practice Expense RVUs	0.00.00.00.00 0.00.00.00.00 0.00.00.00 0.00.0	
	Facility Practice Expense RVUs	20.11.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.1.	
	Work Expense RVUs	1.02 1.136 1	
	Status/ Usage Indicator		
211 22 23 23 2	Conversion Factor/GAAF Category	Well Baby Exams Physical Exams Office/Home/Urgent Care Visits Office/H	Office/Home/Urgent Care Visits Office/Home/Urgent Care Visits
	CPT/HCPCS Code Description	Prev visit, est, infant Prev visit, est, age 144 Prev visit, est, age 12-17 Prev visit, est, age 12-17 Prev visit, est, age 18-39 Prev visit, est, age 18-39 Prev visit, est, age 40-64 Prev visit, est, age 40-64 Prev visit, est, age 40-64 Prev visit, est, age 40-64 Prev visit, est, age 40-64 Preventive counseling, indiv Preventive counseling, indiv Preventive counseling, indiv Preventive counseling, group Preventive cou	Home infuse, each addl tx Home visit nos
	Modifier		
	CPT/ HCPCS Code	993391 993392 993393 993393 993395 993396 994403 994412 994414 994414 994416 994433 994416 994433 994450 994450 994450 994450 994450 994450 994450 99450 99450 99550 99551 99555 99556 99556 99556 99556 99556 99556	99569 99600

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 170 OF 173

Charge Method- ology	M M M M M M M M M M M M M M M M M M M
Total Expense RVUs	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
Non- Facility Practice Expense RVUs	0.052 0.052
Facility Practice Expense RVUs	0.52 0.52 0.52 0.52 0.52 0.52 0.52 0.52
Work Expense RVUs	1.50 1.50 1.50 1.50 1.50 1.50 1.50 1.50
Status/ Usage Indicator	
Conversion Factor/GAAF Category	Immunizations Immunizations Radiology Wiscellaneous Medical Miscellaneous Pedical Miscellaneous Medical Miscellaneous Medical Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Surgery Radiology Radiology Radiology Radiology Radiology
CPT/HCPCS Code Description	Admin influenza virus vac Admin pneumococcal vaccine Admin hepatitis b vaccine PET imaging prev PET single PET imaging prev PET single PET imaging prev PET multiple PET follow SPECT 78464 mult PET follow SPECT 78465 mult PET follow cornry angio sing PET follow cornry angio mult PET follow word perf sing PET follow word perf sing PET follow word perf sing PET follow word perf sing PET follow word perf sing PET follow word perf sing PET follow worthiculogm mult PET follow word perf sing PET follow word perf sing PET follow word perf sing PET follow word perf sing PET follow word perf sing PET follow word perf sing PET follow word perf sing PET follow word perf sing PET follow word perf sing PET follow word perf sing PET follow word perf sing PET follow word perf sing PET follow word perf sing PET follow word perf sing PET follow stress echo mult PET follow stress echo mult PET follow stress ECG singl PET follow stress echo multiple stress Colon ca scrn; barium enema Colon ca scrn; barium enema Colon ca scrn; barium enema Colon ca scrn; barium enema Colon ca scrn; barium enema Colon ca scrn; barium enema Colon ca scrn; barium enema Colon ca scrn; barium enema Colon ca scrn; barium enema Colon ca scrn; barium enema Colon ca scrn; barium enema Colon ca scrn; barium enema Colon ca scrn; barium enema Colon ca scrn; barium enema Colon ca scrn; barium enema
Modifier	78 78 78 78 78 78 78 78 78 78 78 78 78 7
CPT/ HCPCS Code	60008 60003 60003 60003 60003 60003 60003 60003 60004

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 171 OF 173

Charge Method- ology	M M M M M M M M M M M M M M M M M M M
Total Expense RVUs	2.37
Non- Facility Practice Expense RVUs	0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.00000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.00000
Facility Practice Expense RVUs	0.000
Work Expense RVUs	0.00 0.07 0.07 0.09 0.07 0.09
Status/ Usage Indicator	ס ס ס ס
Conversion Factor/GAAF Category	Surgery Miscellaneous Medical Radiology Pathology Office/Home/Urgent Care Visits Miscellaneous Medical Surgery Office/Home/Urgent Care Visits Office/Home/U
CPT/HCPCS Code Description	Trim nail(s) CORF skilled nursing service Single energy x-ray study Scr c/v cyto, autosys and md HHCP-serv of pt, ea 15 min Extrnl counterpulse, per bx Hyperbaric oz tx:no md regrd Wound closure by adhesive MD certification HHA patient Home health care supervision Disprostic mammography film digital Disprostic mammography film digital Disprostic mammography film digital Disprostic mammography film digital Disprostic mammography digital film convert diag ma Digital film convert diag ma
Modifier	28 888888888888888888888888888888888888
CPT/ HCPCS Code	G01127 G01138 G01138 G01141 G01141 G01179 G01179 G0202 G0202 G0201 G0202 G020 G

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 172 OF 173

Charge Method- ology	W W W W W W W W W W W W W W W W W W W
Total Expense RVUs	7.0. 0.22.22.1.4.8.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0
Non- Facility Practice Expense RVUs	0.000448.000000000000000000000000000000
Facility Practice Expense RVUs	0.000.44.8.00.00.00.00.00.00.00.00.00.00.00.00.0
Work Expense RVUs	0.000000000000000000000000000000000000
Status/ Usage Indicator	a a a
Conversion Factor/GAAF Category	Miscellaneous Medical Office/Home/Urgent Care Visits Office/Home/Urgent Care Visits Office/Home/Urgent Care Visits Office/Home/Urgent Care Visits Cardiovascular Cardiovascular Cardiovascular Radiology Radio
CPT/HCPCS Code Description	Therapeutic procd strg endur Initial foot exam pt lops Routine footcare pt ve lops Routine footcare pt ve lops Routine footcare pt ve lops Demonstrate use home in mon Provide test material equipm MD review interpret of test PET image brst dection recur PET image brst dection recur PET image brst dection recur PET image brst dection recur PET image brst dection recur PET image brst dection recur PET image brst dection recur PET image brst dection recur PET image brst dection recur PET image brst dection recur PET image brst dection recur PET image brst dection recur PET image brst dection recur PET image brst dection recur PET image brst dection and Removal of impacted wax md MNT subs tx for change dx Group MNT 2 or more 30 mins Nasoforo gastric tube of MD Pretx planning, non-Hodgkins Radiopharm tx, non-Hodgkins Radiopharm tx, non-Hodgkins Remal angio, cardiac cath liac art angio, cardiac cath liac art angio, cardiac cath Excorp shock tx, other than Ecc stim unattend for press Elec stim other than wound Recon, CTA for surg plan Arthro, loose body + chondro Visit for drug monitoring Prolotherapy V chelationtherapy Screening pap smear by phys Culture bacterial urine Washed red blood cells unit Red blood cells unit Red blood cells unit Alburnin (human), 5%, 50ml Alburnin (human), 5%, 50ml Alburnin (human), 5%, 50ml Alburnin (human), 5%, 50ml Alburnin (human), 5%, 50ml
Modifier	26 26 26 26 26 77 70
CPT/ HCPCS Code	G02245 G02245 G02248 G02248 G02253 G02553 G02554 G02273 G02774 G02774 G02774 G02774 G02774 G02778 G0278 F0278 F02

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply. See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE G. — PHYSICIAN AND OTHER PROFESSIONAL SERVICES RELATIVE VALUE UNITS (RVUS) BY CPT/HCPCS CODE

PAGE 173 OF 173

Total Charge Expense Method- RVUs ology	2.40 SA 0.01 MDR 0.19 MDR
Non- Facility Practice Expense RVUs	0.07 0.39 0.14 0.32
Facility Practice Expense RVUs	0.07 0.39 0.68 0.32
Work Expense RVUs	0.17 0.00 0.37 0.00
Status/ Usage Indicator	æ
Conversion Factor/GAAF Category	Miscellaneous Medical Miscellaneous Medical Miscellaneous Medical Radiology Radiology Pathology Radiology
CPT/HCPCS Code Description	Plasmaprotein fract, 5%, 250ml One-way allow prorated miles One-way allow prorated trip Cardiokymography Cardiokymography Obtaining screen pap smear Set up port xray equipment
Modifier	26 TC
CPT/ HCPCS Code	P9048 P9603 P9604 Q0035 Q0035 Q0091 Q0092

Key to Status/Usage Indicators:

a Cannot be billed by VA Hospital Outpatients and Provider-Based Clinics (because the service is separately priced as outpatient facility charges — see Table F). b Cannot be billed by VA Hospital Outpatients and Provider-Based Clinics (because a different code is used for facility billing).

No entry. Can be billed at all VA locations.

Misc. RVUs obtained using the methodology for unlisted procedures.

No entry: RVUs obtained from the Medicare Physician Fee Schedule.

All other entries: See Supplementary Table 1, Reasonable Charges Data Sources - V2.0. Charge Methodology:

NOTES: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply, See end of table for notes regarding Status/Usage Indicators and Charge Methodology.

TABLE H. — PROFESSIONAL ANESTHESIA NATIONWIDE BASE UNITS BY CPT CODE PAGE 1 OF 4

CPT Code	CPT Code Description	Base Units
00100	Anes-Proc Salivary Glands Incl Bx	5.0
00100	Anes-Proc Plastic Repair Cleft Lip	6.0
00103	Anes-Reconstructive Proc Evelid	5.0
00104	Anes-Electroculvulsive Therapy	4.0
00120	Anes-Ext Mid&Innr Ear W/Bx; Nos	5.0
00124	Anes-Ext Mid&Innr Ear W/Bx; Otscpy	4.0
00126	Anes-Ext Mid&Innr Ear W/Bx; Tympnot	4.0
00140 00142	Anesthesia Procedures On Eye; Nos Anesthesia Proc Eye; Lens Surgery	5.0 4.0
00142	Anes-Proc Eve: Corneal Transplant	6.0
00145	Anes-Proc Eye; Vitreoretinal Surg	6.0
00147	Anesthesia Proc Eye; Iridectomy	4.0
00148	Anesthesia Proc Eye; Ophthalmoscopy	4.0
00160	Anes-Proc Nose&Access Sinuses; Nos	5.0
00162	Anes-Nse&Acss Sinuses; Radl Surg	7.0
00164 00170	Anes-Nse&Acss Sinuses; Bx Sft Tiss Anes-Intraoral Including Bx; Nos	4.0 5.0
00170	Anes-Intraora Michaeling Bx, Nos Anes-Intraori W/Bx; Repr Clt Palate	6.0
00174	Anes-Intraoral W/Bx; Exc Tumor	6.0
00176	Anes-Intraorl Incl Bx; Radi Surgery	7.0
00190	Anes-Proc Facial Bones/Skull; Nos	5.0
00192	Anes-Proc Fce Bns/Skull; Radi Surg	7.0
00210	Anes-Intracran; Nos	11.0
00212 00214	Anes-Intracran; Subdural Taps Anes-Cran; Burr Holes-Ventricgrph	5.0 9.0
00214	Anes-Intracran; Elev Ski Fx-Xtraduri	9.0
00216	Anes-Intracran; Vascular Procedures	15.0
00218	Anes-Intracran; Proc Sitting Pstn	13.0
00220	Anes-Intracran; Cerebrosp FI Shnting	10.0
00222	Anes-Intracran; Elec-Coag Cran Nerv	6.0
00300	Anes-Integ-Musc&Nerv-Head-TrunkNos	5.0
00320	Anes-Esoph Thyrd Trachea; Nos 1 Yr/>	6.0
00322 00326	Anes-Esoph Thyroid Trach; Bx Thyroid Anes-Larynx&Trach Chld < 1 Yr Age	7.0
00350	Anes-Proc Major Vessels Neck; Nos	10.0
00352	Anes-Proc Maj Ves Neck; Simple Lig	5.0
00400	Anes-Integ Extrem Trnk Perin; Nos	3.0
00402	Anes-Integ Extrem Trnk; Brst Recon	5.0
00404	Anes-Integ Trunk; Radl Breast Proc	5.0
00406 00410	Anes-Integ:Radl Brst W/Node Dissect Anes-Integ Extrm Trnk;Convrt Arryth	13.0 4.0
00410	Anes-Proc Clavicle&Scapula Nos	5.0
00452	Anes-Proc Clav&Scapula Radi Surg	6.0
00454	Anes-Proc Clav&Scapula Bx Clav	3.0
00470	Anes-Partial Rib Resection; Nos	6.0
00472	Anes-Part Rib Res: Thoracoplasty	10.0
00474	Anes-Part Rib Resection; Radl Proc	13.0 15.0
00500 00520	Anes-On Esophagus Anes-Closed Chest; Nos	6,0
00520	Anes-Closed Chest; Needle Bx Pleura	4.0
00524	Anes-Closed Chest; Pneumocentesis	4.0
00528	Anes-Closed Chest; Mediastinoscopy	8.0
00530	Anes-Perm Trns Pacemkr Insertion	4.0
00532	Anes-Access Cntrl Venous Circ	4.0
00534 00537	Anes-Trns Insrt/Repl Pacing Defib Anes-Card Eps Incl Radiofreg Ablat	7.0
00537	Anes-Tracheobronchial Reconstruct	18.0
00540	Anes-Thoracot ; Nos	12.0
00541	Anes-Thoracot; Util 1 Lung Vent	15.0
00542	Anes-Thoracot ; Decortication	15.0
00544	Anes-Thoracot Pleurectomy	15.0
00546	Anes-Thoracot Lungs;Thoracoplasty	15.0
00548 00550	Anes-Thoracot Lungs;Intrathor Trach Anesthesia For Sternal Debridement	17.0 10.0
00560	Anes-Hrt Pericard Sac; W/O Oxygntr	15.0
00562	Anes-Hrt Pericard Sac; W/Oxygntr	20.0
00563	Anes-Hrt Pericard Sac;Oxygntr&Arrst	25.0
00566	Anes-Direct Cabg W/O Pump Oxygenatr	25.0
00580	Anes-Hrt Tpint/Hrt/Lung Tpint	20.0
00600	Anesthesia Proc C-Spine&Cord Nos	10.0 13.0
00604	Anes-Cerv Spine&Cord Pt Sit Pstn	1 13.0

NOTE: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

TABLE H. — PROFESSIONAL ANESTHESIA NATIONWIDE BASE UNITS BY CPT CODE PAGE 2 OF 4

CPT Code	CPT Code Description	Base Units
00620	Anesthesia Proc T-Spine&Cord Nos	10.0
00622	Anes-Thoracic:Thoracolum Sympathect	13.0
00630	Anesthesia Proc Lumbar Region: Nos	8.0
00632	Anes-Proc Lumb Rgn; Lumb Sympathect	7.0
00634	Anes-Lumb Rgn; Chemonucleolysis	10.0
00635	Anes-Lumb Rgn; Dx/Tx Lumb Punct	4.0
00640	Anes-Manip Spn/Clos Proc Spn	3.0
00670	Anes-Exten Spine & Spinal Cord	13.0
00700	Anes-Proc Upper Ant Abd Wall; Nos	4.0
00702 00730	Anes-Up Ant Abd Wall; Perg Livr Bx Anes-Proc Upper Posterior Abd Wall	4.0 5.0
00740	Anes-Proc Opper Posterior Abd Wall Anes-Ugi Endoscopy-Intro Prox Duod	5.0
00750	Anes-Hernia Repairs Upper Abd; Nos	4.0
00752	Anes-Hernia Repr Up Abd; &/Dehis	6.0
00754	Anes-Hern Repr Up Abd; Omphalocele	7.0
00756	Anes-Hernia Repr Up Abd;Transabd	7.0
00770	Anes-On Major Abd Blood Vessels	15.0
00790	Anes-Intraper Up Abd W/Lap;Nos	7.0
00792	Anes-Intraper Up Abd W/Lap;Hepatec	13.0
00794	Anes-Intraper Up W/Lap;Pancreatect	8.0
00796	Anes-Intraper Up W/Lap; Liver TpInt	30.0
00797	Anes-Intraper W/Lap; Gastr Restirct Anes-Proc Lower Ant Abd Wall; Nos	8.0 4.0
00800 00802	Anes-Lw Ant Abd Wall; Panniculect	5.0
00810	Anes-Low Intest Endo-Dist To Duod	5.0
00820	Anes-Proc Lower Posterior Abd Wall	5.0
00830	Anes-Hernia Repairs Lower Abd; Nos	4.0
00832	Anes-Hern Rep ; Ventral&Inci Hern S	6.0
00834	Anes-Hern Repr Nos Under 1 Yr Age	5.0
00836	Anes-Hern Nos<37Wk Brth &<50Wk Surg	6.0
00840	Anes-Intraper W/Laparscpy; Nos	6.0
00842	Anes-Intraper W/Laparscpy; Amnio	4.0
00844	Anes-Intraper; Abd-Perinl Resection	7.0
00846	Anes-Intraper Low W/Lap;Radi Hyst	8.0 8.0
00848 00851	Anes-Intraper W/Lap;Pelv Exentratn Anes-Intraper W/Lap; Tubal Lig	6.0
00860	Anes-Xtraper W/Urin Tract; Nos	6.0
00862	Anes-Xtraper;Up 1/3 Ureter/Nephrect	7.0
00864	Anes-Xtraper Low Abd; Tot Cystect	8.0
00865	Anes-Xtraper Low;Radl Prostatect	7.0
00866	Anes-Xtraper Low Abd; Adrenalectomy	10.0
00868	Anes-Xtraper Low Abd;Renal TrspInt	10.0
00870	Anes-Xtraper Low Abd; Cystolithtomy	5.0
00872	Anes-Lith Etracorp;W/Water Bath	7.0 5.0
00873 00880	Anes-Lith Xtracorp;W/O Water Bath Anes-Proc Major Lower Abd Ves; Nos	15.0
00882	Anes-Maj Ves; Inf Vena Cava Lig	10.0
00902	Anesthesia For: Anorectal Procedure	5.0
00904	Anes-For; Radical Perineal Proc	7.0
00906	Anesthesia For, Vulvectomy	4.0
80000	Anes-For; Perineal Prostatectomy	6.0
00910	Anes-Transurethral ; Nos	3.0
00912	Anes-Trnsureth;Resect Bladder Tumor	5.0
00914	Anes-Transurethral; Turp	5.0 5.0
00916 00918	Anes-Trnsureth;Post Resection Bleed Anes-Trnsureth;W/Manip&/Remv Calcu	5.0
00920	Anesthesia Proc Male Genitalia; Nos	3.0
00921	Anes-Male Gnt; Vasect Unilat/Bilat	3.0
00922	Anes-Proc Male Gnt; Seminl Vesicles	6.0
00924	Anes-Male Undescend Testis Uni/Bil	4.0
00926	Anes-Male Gnt; Radl Orchect Ing	4.0
00928	Anes-Male Gnt; Radi Orchect Abd	6.0
00930	Anes-Male Genit;Orchiopexy Uni/Bil	4.0
00932 00934	Anes-Proc Male Gnt; Cmpl Amp Penis Anes-Male;Radl Amp Penis-Ing Lymph	6.0
00934 00936	Anes Male;Radi Amp Penis-Ing Lymph Anes Male;Radi Amp Penis-Ing&lliac	8.0
00938	Anes-Male Genit;Insrt Penile Prosth	4.0
00940	Anes-Vag; Not Otherwise Specified	3.0
00942	Anes-Vag; Colpot Vaginect&Opn Ureth	4.0
00944	Anes-Vag : Vaginal Hysterectomy	6.0
00948	Anes-Vag ; Cervical Cerclage	4.0

NOTE: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

TABLE H. — PROFESSIONAL ANESTHESIA NATIONWIDE BASE UNITS BY CPT CODE PAGE 3 OF 4

CPT Code	CPT Code Description	Base Units
00950	Anes-Vag ; Culdoscopy	5.0
00952	Anes-Vag; Cuidoscopy Anes-Vag; Hysteroscopy&/Salpingraphy	4.0
01112	Anes-Bn Marrow Asp&/Bx Iliac Crest	5.0
01120	Anesthesia Procedures Bony Pelvis	6.0
01130	Anes-Body Cast Application/Rev	3.0
01140	Anesthesia Interpelviabd Amputation	15.0
01150	Anes-Radi Tumor Pelv No Hndgtr Amp	10.0
01160	Anes-Clos Proc Invlv Pubis/Si Jnt	4.0
01170 01180	Anes-Open Proc Invlv Pubis/Si Jnt	8.0 3.0
01190	Anes-Obtur Neurectomy; Extrapelvic Anes-Obtur Neurectomy; Intrapelvic	4.0
01200	Anes-All Clos Proc Invlv Hip Joint	4.0
01202	Anes-Arthroscopic Proc Hip Joint	4.0
01210	Anes-Open Proc Invlv Hip Joint; Nos	6.0
01212	Anes-Open Proc Invlv Hip Disartic	10.0
01214	Anes-Opn Hip Jnt; Tot Hip Arthplsty	8.0
01215	Anes-Open Invlv Hip;Total Hip Rev	10.0
01220	Anes-All Clos Proc Inviv Up 2/3 Fem	4.0
01230	Anes-Open Inviv Upper 2/3 Femur;Nos Anes-Open Inviv Upper 2/3 Femur;Amp	6.0 5.0
01232 01234	Anes-Open Upper 2/3 Femur; Radi Res	8.0
01250	Anes-All Nerv Musc Tend Fasc Up Leg	4.0
01260	Anes-Inviv Vns Upper Leg Incl Expl	3.0
01270	Anes-Inviv Artery Up Leg W/Gft;Nos	8.0
01272	Anes-Invlv Art Up Leg W/Gft;Fem Lig	4.0
01274	Anes-Inviv Art Up Leg W/Gft;Fem Emb	6.0
01320	Anes-Nerv Musc Fasc Burs Knee&/Pop	4.0
01340	Anes-All Clos Proc Lower 1/3 Femur	4.0
01360	Anes-All Open Proc Lower 1/3 Femur	5.0
01380 01382	Anes-All Closed Proc Knee Joint Anes-Dx Arthroscopic Proc Knee Jnt	3.0
01390	Anes-All Clos Up Ends Tib Fib&/Pat	3.0
01392	Anes-All Open Up Ends Tib Fib&/Pat	4.0
01400	Anes-Open/Scope Proc Knee Jnt; Nos	4.0
01402	Anes-Open/Scope Knee Jnt; Tot Plsty	7.0
01404	Anes-Open/Scope Knee Jnt; Disartic	5.0
01420	Anes-All Cast Applic/Repr W/Knee	3.0
01430	Anes-Proc Veins Knee&Pop Area; Nos	3.0
01432 01440	Anes-Vns Knee&Pop Area; Av Fist Anes-Proc Art Knee&Pop Area; Nos	6.0 8.0
01442	Anes-Art Knee;Pop Thrombendartect	8.0
01444	Anes-Art Knee; Pop Exc Occi/Aneur	8.0
01462	Anes-All Clos Proc Low Leg Ank&Foot	3.0
01464	Anes-Arthroscopic Proc Ank ⩔ Foot	3.0
01470	Anes-Nerv Musc Fasc Leg Ank&FtNos	3.0
01472	Anes-Nerv Musc Leg&FtRepr Achilles	5.0
01474	Anes-Nrv Musc Leg&FtGastroc Recess	5.0
01480 01482	Anes-Open Bones Low Leg Ank&FtNos Anes-Open Bones Lw Leg;Radl Res/Amp	3.0 4.0
01484	Anes-Open Bns Lw Leg;Osteot Tib Fib	4.0
01486	Anes-Open Bones Lw Leg; Tot Ank Repl	7.0
01490	Anes-Lw Leg Cast Applic Removl/Repr	3.0
01500	Anes-Art Lw Leg W/Byps Gft; Nos	8.0
01502	Anes-Art Low Leg W/Gft; Embolectomy	6.0
01520	Anes-Proc Veins Lower Leg; Nos	3.0
01522	Anes-Veins Lw Leg;Thrombect Direct Anes-Nery Musc Tend Fasc Burs Shldr	5.0 5.0
01610 01620	Anes-All Clos Hum Sc Ac&Shidr Jnt	4.0
01622	Anes-Dx Arthroscopic Proc Shidr Jnt	4.0
01630	Anes-Open/Scope Hum Sc Ac&ShldrNos	5.0
01632	Anes-Opn/Scope Hum Sc&Shldr,Rad Res	6.0
01634	Anes-Opn/Scope Hum Sc&ShldrDisartc	9.0
01636	Anes-Opn/Scope Hum Sc Ac&Shidr Amp	15.0
01638	Anes-Open/Scope Hum Ac&Shldr Repl	10.0
01650 01652	Anes-Proc Art Shoulder&Axilla Nos Anes-Art Shldr&Ax Ax-Brach Aneur	6.0 10.0
01654	Anes-Proc Art Shidr&Ax Byps Graft	8.0
01656	Anes-Art Shidr&Ax Ax-Fem Byps Gft	10.0
01670	Anes-On Veins Of Shoulder&Axilla	4.0
01680	Anes-Shidr Cast Applc/Remv/Repr;Nos	3.0
01682	Anes-Shldr Cast Applic/Remv;Spica	4.0

NOTE: CPT Codes and descriptions only copyright 2002 American Medical Association. All rights reserved. Applicable FARS/DFARS apply.

TABLE H. — PROFESSIONAL ANESTHESIA NATIONWIDE BASE UNITS BY CPT CODE PAGE 4 OF 4

CPT Code	CPT Code Description	Base Units
01710 01712 01714 01716 01730 01732 01740 01742 01744 01756 01758 01760 01770 01772 01780 01822 01810 01829 01830 01832 01842 01844 01852 01842 01844 01955 01905 01905 01905 01905 01905 01906 01906 01907 01963 01964 01967 01968 01996 01990 01991 01995 01996	Anes-Nrv Musc Burs Up Arm&ElbNos Anes-Nrv Musc Burs Up Arm&ElbTenot Anes-Nrv Musc Up Arm&ElbTenoplasty Anes-Nrv Musc Up Arm&ElbTenoplasty Anes-Nrv Musc Up Arm&ElbTenodesis Anes-All Closed Proc Humerus&Elbow Anes-Open/Scope Proc Elb Joint Anes-Open/Scope Proc Elb;Nos Anes-Open/Scope Proc Elb;Nos Anes-Open/Scope Proc Elb;Rep Non/Mal Hum Anes-Open/Scope Elb;Rep Non/Mal Hum Anes-Open/Scope Elb;Exc Cyst/Tum Hum Anes-Open/Scope Elb;Exc Cyst/Tum Hum Anes-Open/Scope Elb;Exc Cyst/Tum Hum Anes-Open/Scope Elb;Tot Elb Repl Anes-Proc Art Upper Arm&Elb Embo Anes-Proc Art Upper Arm&Elb Nos Anes-Proc Veins Up Arm&Elb Phleborr Anes-All Nerv Musc Forarm Wrst&Hnd Anes-Clos Radius Ulna Wrst/Hnd Bone Anes-Dx Arthroscopic Proc Wrist Anes-Open/Scope/Endo Wrst/Hnd; Nos Anes-Open/Scope/Endo Wrst/Hnd; Nos Anes-Proc Art Forarm Wrst&Hand Nos Anes-Proc Art Forarm Wrst&Hand Nos Anes-Proc Art Forarm Wrst&Hand Nos Anes-Proc Art Forarm Wrst&Hand Nos Anes-Proc Art Forarm Wrst&Hand Nos Anes-Proc Art Forarm Wrst&Hand Nos Anes-Proc Art Forarm Wrst&Hand Nos Anes-Proc Art Forarm Wrst&Hand Nos Anes-Proc Art Forarm Wrst&Hand Nos Anes-Proc Art Forarm Wrst&Hand Nos Anes-Proc Art Forarm Wrst&Hand Nos Anes-Proc Art Forarm Wrst&Hand Nos Anes-Proc Art Forarm Wrst&Hand Nos Anes-Tx Forarm/Hand Cast Applic/Remy Anes-Non-Invasive Imaging/Rad Tx Anes-Tx Intrvn Rad Art; Carotid/Cor Anes-Tx Rad Venus; Intrahep/Portal Anes-Tx Rad Venus; Intrahep/Portal Anes-Tx Rad Venus; Intrahep/Portal Anes-Tx Rad Venus; Intrahep/Portal Anes-Tx Rad Venus; Intrahep/Portal Anes-Tx Rad Venus; Intrahep/Portal Anes-Tx Rad Venus; Intrahep/Portal Anes-C/S Hyst Wo Labr Analg/Anes Anesthesia Vaginal Delivery Only Anesthesia Cesarean Delivery Only Anesthesia Cesarean Delivery Only Anesthesia Cesarean Delivery Only Anesthesia For Abortion Procedures Neurax Labr Anlg/Anes Anes-C/S Hyst Fiw Neurax Labr Analg/Anes Anes-C/S Hyst Fiw Neurax Labr Analg/Anes Anes-C/S Hyst Fiw Neurax Labr Analg/Anes Anes-Dx/Tx Nrv Biks&Ini Not Prone Anes-Dx/Tx Nrv Biks&Ini Prone Pstn Rgn Iv Ad	3.0 5.0 5.0 3.0 3.0 5.0 6.0 6.0 3.0 6.0 3.0 6.0 3.0 6.0 6.0 7.0 6.0 3.0 6.0 7.0 5.0 7.0 5.0 7.0 5.0 7.0 5.0 7.0 5.0 7.0 7.0 5.0 7.0 5.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7.0 7
01999	Unlisted Anesthesia Procedure	5.0

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE PAGE 1 OF 8

	77.02 1010		
HCPCS Code	HCPCS Code Description	Charge	GAAF Category
D0120	Periodic oral evaluation	\$35.86	ı
D0120	Limit oral eval problm focus	\$54.15	1
D0150	Comprehensive oral evaluation	\$59.52	i
D0150	Extensy oral eval prob focus	\$129.76	i
D0170	Re-eval,est pt.problem focus	\$48.63	
D0170	Comp periodontal evaluation	\$57.62	ì
D0100	Intraor complete film series	\$99.08	
D0210	Intraoral periapical first f	\$21.11	i
D0230	Intraoral periapical ea add	\$16.53	i
D0240	Intraoral occlusal film	\$30.14	i
D0250	Extraoral first film	\$42.22	i
D0260	Extraoral ea additional film	\$36.68	i
D0270	Dental bitewing single film	\$20.96	i
D0272	Dental bitewings two films	\$33.05	i
D0274	Dental bitewings four films	\$46.69	i
D0277	Vert bitewings-sev to eight	\$70.11	
D0290	Dental film skull/facial bon	\$110.65	i
D0310	Dental saliography	\$377.27	1
D0320	Dental tmj arthrogram incl i	\$630.54	ı
D0321	Dental other tmj films	\$153.72	1
D0322	Dental tomographic survey	\$412.53	1
D0330	Dental panoramic film	\$86.55	1
D0340	Dental cephalometric film	\$98.57	I
D0350	Oral/facial images	\$49.34	ı
D0415	Bacteriologic study	\$26.58	ı
D0425	Caries susceptibility test	\$22.04	1
D0460	Pulp vitality test	\$38.70	1
D0470	Diagnostic casts	\$77.33	1
D0472	Gross exam, prep & report	\$61.49	1
D0473	Micro exam, prep & report	\$123.90	1
D0474	Micro w exam of surg margins	\$92.99	ı
D0480	Cytopath smear prep & report	\$53.51	1
D0502	Other oral pathology procedu	\$111.18	l
D1110	Dental prophylaxis adult	\$67.18	!
D1120	Dental prophylaxis child	\$48.80	!
D1201	Topical fluor w prophy child	\$72.98	
D1203	Topical fluor w/o prophy chi	\$28.49	!
D1204	Topical fluor w/o prophy adu	\$28.43	!
D1205	Topical fluoride w/ prophy a	\$84.80	!
D1310	Nutri counsel-control caries	\$45.62	!
D1320	Tobacco counseling	\$50.88	!
D1330	Oral hygiene instruction	\$44.27	!
D1351	Dental sealant per tooth	\$39.74	
D1510	Space maintainer fxd unilat	\$255.52	
D1515	Fixed bilat space maintainer Remove unilat space maintain	\$368.47	l ii
D1520 D1525	Remove bilat space maintain	\$315.66 \$439.34	l ii
D1523	Recement space maintainer	\$56.37	11
D2140	Amalgam one surface permanen	\$97.07	l ii
D2150	Amalgam two surfaces permane	\$122.71	l ii
D2160	Amalgam three surfaces perma	\$148.35	l ii
D2161	Amalgam 4 or > surfaces perm	\$177.29	ii
D2330	Resin one surface-anterior	\$111.45	ii ii
D2331	Resin two surfaces-anterior	\$139.53	ll ll
D2332	Resin three surfaces-anterio	\$170.58	
D2335	Resin 4/> surf or w incis an	\$208.20	11
D2390	Ant resin-based cmpst crown	\$367.35	ll II
D2391	Post 1 srfc resinbased cmpst	\$133.77	- 11
D2392	Post 2 srfc resinbased cmpst	\$176.99	II
D2393	Post 3 srfc resinbased cmpst	\$223.29	11
D2394	Post >=4srfc resinbase cmpst	\$261.37	1 !!
D2410	Dental gold foil one surface	\$182.78	!!!
D2420	Dental gold foil two surface	\$410.14	111
D2430	Dental gold foil three surfa	\$696.90	
D2510	Dental inlay metalic 1 surf	\$616.00	
D2520	Dental inlay metallic 2 surf	\$689.11 \$756.12	111
D2530	Dental inlay metallic 2 surf	\$783.11	111
D2542 D2543	Dental onlay metallic 2 surf Dental onlay metallic 3 surf	\$810.69	"
D2543 D2544	Dental onlay meti 4/more sur	\$838.25	
U2044	1 Domai omay mon amore sur	(\$000.20	• ""

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE PAGE 2 OF 8

	FAGE 2 OF 6		*
HCPCS Code	HCPCS Code Description	Charge	GAAF Category
D2610	Inlay porcelain/ceramic 1 su	\$709.63	111
D2620	Inlay porcelain/ceramic 2 su	\$752.51	111
D2630	Dental onlay porc 3/more sur	\$795.38	111
D2642	Dental onlay porcelin 2 surf	\$799.80	Ш
D2643	Dental onlay porcelin 3 surf	\$835.73	Ш
D2644	Dental onlay porc 4/more sur	\$862.59	111
D2650	Inlay composite/resin one su	\$535.30	111
D2651	Inlay composite/resin two su	\$637.68	111
D2652 D2662	Dental inlay resin 3/mre sur Dental onlay resin 2 surface	\$675.37 \$669.36	III III
D2663	Dental onlay resin 3 surface	\$718.96	iii
D2664	Dental onlay resin 4/mre sur	\$743.82	iii
D2710	Crown resin laboratory	\$348.82	111
D2720	Crown resin w/ high noble me	\$824.61	111
D2721	Crown resin w/ base metal	\$745.30	III
D2722	Crown resin w/ noble metal	\$775.02	111
D2740	Crown porcelain/ceramic subs	\$877.95	111
D2750	Crown porcelain w/ h noble m	\$847.10 \$770.51	
D2751 D2752	Crown porcelain fused base m Crown porcelain w/ noble met	\$801.94	111
D2780	Crown 3/4 cast hi noble met	\$844.03	iii
D2781	Crown 3/4 cast base metal	\$813.02	III
D2782	Crown 3/4 cast noble metal	\$809.76	111
D2783	Crown 3/4 porcelain/ceramic	\$877.97	
D2790	Crown full cast high noble m	\$824.22	111
D2791	Crown full cast base metal	\$764.54	111 111
D2792 D2799	Crown full cast noble metal Provisional crown	\$782.22 \$309.49	111
D2910	Dental recement inlay	\$79.83	iii
D2920	Dental recement crown	\$80.19	III
D2930	Prefab stniss steel crwn pri	\$206.29	111
D2931	Prefab stnlss steel crown pe	\$239.79	111
D2932	Prefabricated resin crown	\$262.60	111
D2933 D2940	Prefab stainless steel crown Dental sedative filling	\$284.00 \$82.63	
D2950	Core build-up incl any pins	\$206.97	111
D2951	Tooth pin retention	\$45.45	iii
D2952	Post and core cast + crown	\$326.27	111
D2953	Each addtnl cast post	\$200.12	111
D2954	Prefab post/core + crown	\$262.73	111
D2955 D2957	Post removal Each addtnl prefab post	\$217.78 \$117.74	111 111
D2960	Laminate labial veneer	\$516.20	l iii
D2961	Lab labial veneer resin	\$754.87	l iii
D2962	Lab labial veneer porcelain	\$827.06	111
D2970	Temporary- fractured tooth	\$215.38	111
D2980 D3110	Crown repair	\$203.99	iii
D3110 D3120	Pulp cap direct Pulp cap indirect	\$58.05 \$51.46	II II
D3220	Therapeutic pulpotomy	\$136.74	l ii
D3221	Gross pulpal debridement	\$150.95	ii
D3230	Pulpal therapy anterior prim	\$172.90	- 11
D3240	Pulpal therapy posterior pri	\$188.63	- !!
D3310 D3320	Anterior Rest sens thereby 2 canals	\$551.31	
D3320	Root canal therapy 2 canals Root canal therapy 3 canals	\$660.01 \$839.74	"
D3331	Non-surg tx root canal obs	\$250.28	l ii
D3332	Incomplete endodontic tx	\$365.38	11
D3333	Internal root repair	\$189.01	11
D3346	Retreat root canal anterior	\$712.54	11
D3347 D3348	Retreat root canal bicuspid Retreat root canal molar	\$814.55 \$979.31	
D3346	Apexification/recalc initial	\$282.66	l ii
D3352	Apexification/recalc interim	\$163.67	ii
D3353	Apexification/recalc final	\$428.63	
D3410	Apicoect/perirad surg anter	\$594.74	
D3421	Root surgery bicuspid Root surgery molar	\$651.80 \$737.93	
D3425 D3426	Root surgery ea add root	\$268.39	11
D3430	Retrograde filling	\$195.75	
	•	÷	

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE PAGE 3 OF 8

	17.02.001.0		
HCPCS Code	HCPCS Code Description	Charge	GAAF Category
D3450	Root amputation	\$396.23	11
D3460	Endodontic endosseous implan	\$1.532.94	ii
D3470	Intentional replantation	\$639.49	ii
D3910	Isolation- tooth w rubb dam	\$147.39	ii
D3920	Tooth splitting	\$324.37	ii
D3950	Canal prep/fitting of dowel	\$150.64	ii
D4210	Gingivectomy/plasty per guad	\$494.95	ii
D4211	Gingivectomy/plasty per toot	\$152.77	11
D4240	Gingival flap proc w/ planin	\$581.26	11
D4241	Gngvl flap w rootplan 1-3 th	\$497.01	11
D4245	Apically positioned flap	\$528.09	II
D4249	Crown lengthen hard tissue	\$669.21	11
D4260	Osseous surgery per quadrant	\$904.70	II
D4261	Osseous surgl-3teethperquad	\$671.94	11
D4263	Bone repice graft first site	\$412.60	11
D4264	Bone replice graft each add	\$175.89	H
D4265	Bio mtrls to aid soft/os reg	\$344.72	II.
D4266	Guided tiss regen resorble	\$491.32	11
D4267	Guided tiss regen nonresorb	\$592.32)
D4268 D4270	Surgical revision procedure Pedicle soft tissue graft pr	\$598.80 \$694.05	"
D4270 D4271	Free soft tissue graft proc	\$731.22	11
D4271	Subepithelial tissue graft	\$834.73	"
D4274	Distal/proximal wedge proc	\$270.36	ii
D4275	Soft tissue allograft	\$748.08	ii
D4276	Con tissue w dble ped graft	\$905.52	ii
D4320	Provision spint intracoronal	\$343.87	ii
D4321	Provisional splint extracoro	\$306.96	ii
D4341	Periodontal scaling & root	\$193.17	II
D4342	Periodontal scaling 1-3teeth	\$101.87	11
D4355	Full mouth debridement	\$131.37	11
D4381	Localized chemo delivery	\$127.65	#1
D4910	Periodontal maint procedures	\$107.31	П
D4920	Unscheduled dressing change	\$84.70	II
D5110	Dentures complete maxillary	\$1,133.84	111
D5120	Dentures complete mandible	\$1,126.73	****
D5130 D5140	Dentures immediat maxillary	\$1,225.08	## ###
D5140 D5211	Dentures immediat mandible Dentures maxill part resin	\$1,222.18 \$899.41	111
D5211	Dentures mand part resin	\$981.95	111
D5213	Dentures maxill part metal	\$1,240.52	111
D5214	Dentures mandibl part metal	\$1,237.72	
D5281	Removable partial denture	\$698.03	iii
D5410	Dentures adjust cmplt maxil	\$63.99	III
D5411	Dentures adjust cmplt mand	\$62.21	
D5421	Dentures adjust part maxill	\$65.41	111
D5422	Dentures adjust part mandbl	\$63.99	111
D5510	Dentur repr broken compl bas	\$137.30	111
D5520	Replace denture teeth complt	\$115.45	111
D5610	Dentures repair resin base	\$139.15	111
D5620	Rep part denture cast frame	\$175.61	
D5630	Rep partial denture clasp	\$177.41	111
D5640	Replace part denture teeth	\$122.23	###
D5650 D5660	Add tooth to partial denture Add clasp to partial denture	\$157.10 \$188.69	111
D5670	Replc tth&acric on mtl frmwk	\$501.12	111
D5671	Replc tth&acrlc mandibular	\$501.12	iii
D5710	Dentures rebase cmplt maxil	\$430.05	ı iii
D5711	Dentures rebase cmplt mand	\$422.89	IHI
D5720	Dentures rebase part maxill	\$412.64	111
D5721	Dentures rebase part mandbl	\$414.42	III
D5730	Denture rein cmplt maxil ch	\$261.73	111
D5731	Denture rein cmplt mand chr	\$261.02	111
D5740	Denture rein part maxil chr	\$246.52	
D5741	Denture rein part mand chr	\$248.23 \$340.81	
D5750	Denture rein cmpit max lab Denture rein cmpit mand lab	\$340.81	111
D5751 D5760	Denture rein cripit mand lab Denture rein part maxil lab	\$340.37	iii
D5761	Denture rein part maxilitab	\$340.01	iii
D5810	Denture interm cmplt maxill	\$562.58	

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE PAGE 4 OF 8

	PAGE 4 OF 6		
HCPCS Code	HCPCS Code Description	Charge	GAAF Category
D5811	Denture interm cmplt mandbl	\$584.36	111
D5820	Denture interm part maxill	\$456.16	111
D5821	Denture interm part mandbl	\$471.32	iii
D5850	Denture tiss conditn maxill	\$127.46	111
D5851	Denture tiss condtin mandbl	\$127.82	
D5860	Overdenture complete	\$1,623.06	Ш
D5861	Overdenture partial	\$1,416.27	111
D5862	Precision attachment	\$487.76	111
D5867 D5875	Replacement of precision att Prosthesis modification	\$189.28 \$352.12	
D5911	Facial moulage sectional	\$268.73	111
D5912	Facial moulage complete	\$268.73	iii
D5913	Nasal prosthesis	\$5,658.73	iii
D5914	Auricular prosthesis	\$5,658.73	Ш
D5915	Orbital prosthesis	\$7,657.75	III
D5916	Ocular prosthesis	\$2,042.52	111
D5922	Nasal septal prosthesis	\$415.93	
D5931	Surgical obturator	\$3,046.86 \$4,571.56	
D5932 D5933	Postsurgical obturator Refitting of obturator	\$693.22	111
D5934	Mandibular flange prosthesis	\$5,193.78	iii
D5935	Mandibular denture prosth	\$4,519.06	iii
D5936	Temp obturator prosthesis	\$5,075.85	111
D5937	Trismus appliance	\$617.61	111
D5951	Feeding aid	\$829.38	
D5952	Pediatric speech aid	\$2,693.07	111
D5953 D5954	Adult speech aid Superimposed prosthesis	\$5,114.51 \$4,739.45	
D5955	Palatal lift prosthesis	\$4,383.73	111
D5982	Surgical stent	\$436.71	iii
D5983	Radiation applicator	\$1,275.97	111
D5984	Radiation shield	\$1,275.97	111
D5985	Radiation cone locator	\$1,275.97	111
D5986	Fluoride applicator	\$142.55	111
D5987 D5988	Commissure splint Surgical splint	\$1,914.92 \$508.20	111 111
D6010	Odontics endosteal implant	\$1,731.79	l iii
D6020	Odontics abutment placement	\$283.17	111
D6040	Odontics eposteal implant	\$6,095.67	111
D6050	Odontics transosteal implnt	\$4,923.89	III
D6053	Impint/abtmnt spprt remv dnt	\$1,970.54	!!!
D6054 D6055	Implint/abtmnt sport remyortl Implant connecting bar	\$1,970.54 \$1,081.15	111
D6056	Prefabricated abulment	\$629.25	l iii
D6057	Custom abutment	\$794.60	l iii
D6058	Abutment supported crown	\$1,157.23	111
D6059	Abutment supported mtl crown	\$1,142.08	
D6060	Abutment supported mtl crown	\$1,069.18	!!!
D6061 D6062	Abutment supported mtl crown Abutment supported mtl crown	\$1,092.78 \$1,140.63	
D6063	Abutment supported mil crown Abutment supported mtl crown	\$879.60	l iii
D6064	Abutment supported mtl crown	\$1,062.49	iii
D6065	Implant supported crown	\$1,207.88	111
D6066	Implant supported mtl crown	\$1,181.41	!!!
D6067	Implant supported mtl crown	\$1,171.68	
D6068 D6069	Abutment supported retainer Abutment supported retainer	\$1,066.32 \$1,136.19	
D6070	Abutment supported retainer	\$973.57	"
D6071	Abutment supported retainer	\$1,057.23	iii
D6072	Abutment supported retainer	\$1,218.20	111
D6073	Abutment supported retainer	\$916.75	!!!
D6074	Abutment supported retainer	\$1,079.82 \$1,027.54	
D6075 D6076	Implant supported retainer Implant supported retainer	\$1,027.54	"
D6077	Implant supported retainer	\$1,042.18	l iii
D6078	Implnt/abut suprtd fixd dent	\$4,518.13	111
D6079	Implnt/abut suprtd fixd dent	\$2,054.25	1 111
D6080	Implant maintenance	\$94.97 \$443.98	111
D6090 D6095	Repair implant Odontics repr abutment	\$439.35	
23000	1 accompany accompany	, ,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	•

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE PAGE 5 OF 8

	,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,		
HCPCS Code	HCPCS Code Description	Charge	GAAF Category
D6100	Removal of implant	\$576.87	111
D6210	Prosthodont high noble metal	\$818.33	111
D6211	Bridge base metal cast	\$769.73	iii
D6212	Bridge noble metal cast	\$780.31	III
D6240	Bridge porcelain high noble	\$836.47	iii
D6241	Bridge porcelain base metal	\$749.05	III
D6242	Bridge porcelain nobel metal	\$791.11	111
D6245	Bridge porcelain/ceramic	\$852.73	Ш
D6250	Bridge resin w/high noble	\$830.29	III
D6251	Bridge resin base metal	\$770.39	111
D6252	Bridge resin w/noble metal	\$786.12	
D6253	Provisional pontic	\$762.49	III III
D6545 D6548	Dental retainr cast metl Porcelain/ceramic retainer	\$448.88 \$521.42	111
D6600	Porcelain/ceramic retainer Porcelain/ceramic inlay 2srf	\$900.38	
D6601	Porc/ceram inlay >= 3 surfac	\$1,007.39	111
D6602	Cst high nble mtl inlay 2 srf	\$965.20	iii
D6603	Cst hgh nble mtl inlay >=3sr	\$1,047.52	iii
D6604	Cst bse mtl inlay 2 surfaces	\$877.74	111
D6605	Cst bse mtl inlay >= 3 surfa	\$969.32	111
D6606	Cast noble metal inlay 2 sur	\$926.10	111
D6607	Cst noble mtl inlay >=3 surf	\$1,017.68	III
D6608	Onlay porc/crmc 2 surfaces	\$951.83	111
D6609	Onlay porc/crmc >=3 surfaces	\$1,151.45	111
D6610	Onlay cst hgh nbl mtl 2 srfc	\$1,070.16	
D6611	Onlay cst hgh nbl mtl >=3srf	\$1,211.13	iii
D6612	Onlay cst base mtl 2 surface	\$912.72	111
D6613	Onlay cst base mti >=3 surfa	\$1,102.06	
D6614	Onlay cst nbl mtl 2 surfaces	\$998.13 \$1,174.09	22 8 131
D6615 D6720	Onlay cst nbl mtl >=3 surfac Retain crown resin w hi nble	\$843.38	111
D6720	Crown resin w/hase metal	\$782.99	111
D6722	Crown resin w/noble metal	\$814.53	iii
D6740	Crown porcelain/ceramic	\$903.12	l iii
D6750	Crown porcelain high noble	\$875.56	iii
D6751	Crown porcelain base metal	\$785.74	111
D6752	Crown porcelain noble metal	\$824.07	111
D6780	Crown 3/4 high noble metal	\$831.65	111
D6781	Crown 3/4 cast based metal	\$838.13	III
D6782	Crown 3/4 cast noble metal	\$803.03	!!!
D6783	Crown 3/4 porcelain/ceramic	\$851.86	
D6790	Crown full high noble metal	\$842.70 \$787.59	181 111
D6791 D6792	Crown full base metal cast Crown full noble metal cast	\$815.81	111
D6793	Provisional retainer crown	\$346.77	l iii
D6920	Dental connector bar	\$142.59	iii
D6930	Dental recement bridge	\$113.74	iii
D6940	Stress breaker	\$275.69	III
D6950	Precision attachment	\$473.97	III
D6970	Post & core plus retainer	\$321.52	III
D6971	Cast post bridge retainer	\$307.76	Ш
D6972	Prefab post & core plus reta	\$253.99	!!!
D6973	Core build up for retainer	\$201.00	!!!
D6975	Coping metal	\$543.08 \$169.75	
D6976 D6977	Each addtnl cast post Each addtl prefab post	\$134.69	"
D6980	Bridge repair	\$267.87	l iii
D6985	Pediatric partial denture fx	\$805.71	l iii
D7111	Coronal remnants deciduous t	\$114.22	11
D7140	Extraction erupted tooth/exr	\$118.34	
D7210	Rem imp tooth w mucoper flp	\$203.24	- 11
D7220	Impact tooth remov soft tiss	\$245.14	#
D7230	Impact tooth remov part bony	\$313.41	11
D7240	Impact tooth remov comp bony	\$373.80	11
D7241	Impact tooth rem bony w/comp	\$451.88 \$219.27	11
D7250 D7260	Tooth root removal Oral antral fistula closure	\$1,495.77	1 ::
D7261	Primary closure sinus perf	\$611.23	l ii
D7270	Tooth reimplantation	\$404.59) ii
D7272	Tooth transplantation	\$534.30	11

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE PAGE 6 OF 8

	PAGE 0 OF 6		
HCPCS Code	HCPCS Code Description	Charge	GAAF Category
D7280	Exposure impact tooth orthod	\$435,46	- 1
D7281	Exposure tooth aid eruption	\$366.04	i II
D7282	Mobilize erupted/malpos toot	\$420.86	
D7285	Biopsy of oral tissue hard	\$516.78	ii
D7286	Biopsy of oral tissue soft	\$276.97	11
D7287	Cytology sample collection	\$91.58	II
D7290	Repositioning of teeth	\$350.79	11
D7291	Transseptal fiberotomy	\$171.57	
D7310	Alveoplasty w/ extraction	\$214.70	!!
D7320	Alveoplasty w/o extraction	\$383.08	
D7340 D7350	Vestibuloplasty ridge extens Vestibuloplasty exten graft	\$1,266.27 \$1,777.56	ii ii
D7330	Rad exc lesion up to 1.25 cm	\$395.87	l ii
D7411	Excision benign lesion>1.25c	\$473.34	ii
D7412	Excision benign lesion compl	\$549.49	ii
D7413	Excision malig lesion<=1.25c	\$494.95	- 11
D7414	Excision malig lesion>1.25cm	\$668.85	ll ll
D7415	Excision malig les complicat	\$818.06	II
D7440	Malig tumor exc to 1.25 cm	\$817.04	!!
D7441	Malig tumor > 1.25 cm	\$1,424.15	!!
D7450 D7451	Rem odontogen cyst to 1.25cm Rem odontogen cyst > 1.25 cm	\$508.15 \$791.17	#
D7460	Rem nonodonto cyst to 1.25cm	\$505.56	l ii
D7461	Rem nonodonto cyst to 1.25cm	\$834.77	l ii
D7465	Lesion destruction	\$317.38	l ii
D7471	Rem exostosis any site	\$573.71	ii
D7472	Removal of torus palatinus	\$576.24	II.
D7473	Remove torus mandibularis	\$576.24	H
D7485	Surg reduct osseoustuberosit	\$516.56	!!
D7490	Mandible resection	\$6,417.25	!!
D7510 D7520	1&d absc intraoral soft tiss 1&d abscess extraoral	\$186.88 \$788.27	
D7520	Removal fb skin/areolar tiss	\$286.50	l ii
D7540	Removal of fb reaction	\$439.71	l ii
D7550	Removal of sloughed off bone	\$307.68	I
D7560	Maxillary sinusotomy	\$1,543.57	H.
D7610	Maxilla open reduct simple	\$3,311.00	11
D7620	Clsd reduct simpl maxilla fx	\$2,329.93	II.
D7630	Open red simpl mandible fx	\$3,600.65	II II
D7640 D7650	Clsd red simpl mandible fx Open red simp malar/zygom fx	\$2,490.27 \$2,573.45	
D7660	Clsd red simp malar/zygom fx	\$1,879.93	i
D7670	Closd red simp maianzygom ix Closd rductn splint alveolus	\$1,094.13	l ii
D7671	Alveolus open reduction	\$307.67	ii
D7680	Reduct simple facial bone fx	\$5,630.98	11
D7710	Maxilla open reduct compound	\$3,625.56	II
D7720	Clsd reduct compd maxilla fx	\$2,598.19	!!
D7730	Open reduct compd mandble fx	\$4,968.45	11
D7740 D7750	Clsd reduct compd mandble fx Open red comp malar/zygma fx	\$2,726.57 \$3,345.47	
D7760	Clsd red comp malar/zygma fx	\$2,630.57	l ii
D7770	Open reduc compd alveolus fx	\$1,813.81	l ii
D7771	Alveolus clsd reduc stblz te	\$659.59	ii
D7780	Reduct compnd facial bone fx	\$7,705.36	П
D7810	Tmj open reduct-dislocation	\$3,446.61	ll ll
D7820	Closed tmp manipulation	\$451.14	!!
D7830	Tmj manipulation under anest	\$443.55	
D7840 D7850	Removal of tmj condyle Tmj meniscectomy	\$4,547.27 \$4,260.13	
D7852	Tmi repair of joint disc	\$4,615.49	11
D7854	Tmj excisn of joint membrane	\$4,698.25	l ii
D7856	Tmj cutting of a muscle	\$3,062.83	11
D7858	Tmj reconstruction	\$9,743.55	!!
D7860	Tmj cutting into joint	\$4,153.00	l II
D7865	Tmj reshaping components	\$6,692.50	 }
D7870	Tmj aspiration joint fluid	\$241.45 \$407.80	11
D7871 D7872	Lysis + lavage w catheters Tmj diagnostic arthroscopy	\$2,360.64	11
D7873	Tmj arthroscopy lysis adhesn	\$2,842.39	l ii
D7874	Tmj arthroscopy disc reposit	\$4,077.04	

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE PAGE 7 OF 8

HCPCS Code	HCPCS Code Description	Charge	GAAF Category
D7875	Tmj arthroscopy synovectomy	\$4,466.47	II
D7876	Tmj arthroscopy discectomy	\$4,815.52	ï
D7877	Tmj arthroscopy descectority Tmj arthroscopy debridement	\$4,250.12	11
D7880	Occlusal orthotic appliance	\$666,43	ii
D7910	Dent sutur recent wnd to 5cm	\$255.12	ii
D7911	Dental suture wound to 5 cm	\$571.59	ii
D7912	Suture complicate wnd > 5 cm	\$1,420.55	ii
D7920	Dental skin graft	\$1,766.23	ii
D7940	Reshaping bone orthognathic	\$2,396.87	ii
D7941	Bone cutting ramus closed	\$6,893.52	11
D7943	Cutting ramus open w/graft	\$6,859.06	ii
D7944	Bone cutting segmented	\$5,943.51	11
D7945	Bone cutting body mandible	\$6,090.09	11
D7946	Reconstruction maxilla total	\$7,509.35	11
D7947	Reconstruct maxilla segment	\$6,775.81	II
D7948	Reconstruct midface no graft	\$10,051.04	11
D7949	Reconstruct midface w/graft	\$12,959.53	11
D7950	Mandible graft	\$2,045.32	11
D7955	Repair maxillofacial defects	\$1,972.06	II
D7960	Frenulectomy/frenulotomy	\$396.29	H
D7970	Excision hyperplastic tissue	\$413.24	11
D7971	Excision pericoronal gingiva	\$173.63	П
D7972	Surg redct fibrous tuberosit	\$806.74	11
D7980	Sialolithotomy	\$589.16	11
D7981	Excision of salivary gland	\$2,020.14	11
D7982	Sialodochoplasty	\$1,553.51	11
D7983	Closure of salivary fistula	\$1,392.25	11
D7990	Emergency tracheotomy	\$1,322.12	- 11
D7991	Dental coronoidectomy	\$3,567.74	11
D7995	Synthetic graft facial bones	\$399.93	11
D7996	Implant mandible for augment	\$1,386.43	- 11
D7997	Appliance removal	\$224.98	11
D8010	Limited dental tx primary	\$1,555.85	III
D8020	Limited dental tx transition	\$1,779.14	III
D8030	Limited dental tx adolescent	\$2,043.59	111
D8040	Limited dental tx adult	\$2,058.00	111
D8050	Intercep dental tx primary	\$2,238.08	111
D8060	Intercep dental tx transitn	\$2,540.60	!!!
D8070	Compre dental tx transition	\$4,645.94	!!!
D8080	Compre dental tx adolescent	\$4,733.40	!!!
D8090	Compre dental tx adult	\$4,977.27	111
D8210	Orthodontic rem appliance tx	\$719.27	!!!
D8220	Fixed appliance therapy habt Preorthodontic tx visit	\$823.20	181 811
D8660	Periodic orthodontc tx visit	\$144.68	111
D8670 D8680	Orthodontic retention	\$167.91 \$420.46	111
D8690	Orthodontic freatment	\$179.06	
D8691	Repair ortho appliance	\$125.90	l iii
D8692	Replacement retainer	\$225.56	l iii
D9110	Tx dental pain minor proc	\$87.32	l ii
D9210	Dent anesthesia w/o surgery	\$24.96	l ii
D9211	Regional block anesthesia	\$28.68	l ii
D9212	Trigeminal block anesthesia	\$109.07	11
D9215	Local anesthesia	\$22.29	II
D9220	General anesthesia	\$302.55	11
D9221	General anesthesia ea ad 15m	\$120.40	- 11
D9230	Analgesia	\$46.65	- 11
D9241	Intravenous sedation	\$281.95	- 11
D9242	IV sedation ea ad 30 m	\$106.39	
D9248	Sedation (non-iv)	\$59.85	li li
D9310	Dental consultation	\$115.44	!!
D9410	Dental house call	\$196.75	!
D9420	Hospital call	\$249.97	!
D9430	Office visit during hours	\$55.81	!
D9440	Office visit after hours	\$113.48]]
D9450	Case presentation tx plan	\$98.78 \$67.73	l iii
D9610 D9630	Dent therapeutic drug inject Other drugs/medicaments	\$40.22	1 111
D9910	Dent appl desensitizing med	\$38.81	111
D9911	Appl desensitizing resin	\$53.58	
20011	t white appointmental control	, \$55.00	•

TABLE I. — OUTPATIENT DENTAL PROFESSIONAL NATIONWIDE CHARGES BY HCPCS CODE PAGE 8 OF 8

HCPCS Code	HCPCS Code Description	Charge	GAAF Category
D9920	Behavior management	\$119.41	III
D9930	Treatment of complications	\$94.02	111
D9940	Dental occlusal guard	\$484.86	111
D9941	Fabrication athletic guard	\$152.76	111
D9950	Occlusion analysis	\$233.80	111
D9951	Limited occlusal adjustment	\$108.17	111
D9952	Complete occlusal adjustment	\$532.05	111
D9970	Enamel microabrasion	\$40.27	111
D9971	Odontoplasty 1-2 teeth	\$51.27	Ш
D9972	Extrnl bleaching per arch	\$267.16	111
D9973	Extrnl bleaching per tooth	\$31.74	111
D9974	Intrnl bleaching per tooth	\$217.18	111

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)
PAGE 1 OF 17

CDT		Can		Ch
CPT/		Conversion	Total	Charge
HCPCS	CPT/HCPCS Code Description	Factor/GAAF	RVUs	Method-
Code		Category	11403	ology
70067	Prooffs tot attain/anal a 14	Pathology	0.40	
78267	Breath tst attain/anal c-14	1	0.40	
78268	Breath test analysis, c-14	Pathology	3.46	
80048	Basic metabolic panel	Pathology	0.43	
80050	General health panel	Pathology	1.52	MDR
80051	Electrolyte panel	Pathology	0.36	
80053	Comprehen metabolic panel	Pathology	0.54	
80055	Obstetric panel	. Pathology	1.37	MDR
80061	Lipid panel	Pathology	0.69	
80069	Renal function panel	Pathology	0.45	
80074	Acute hepatitis panel	Pathology	2.44	
80076	Hepatic function panel	Pathology	0.42	
80100	Drug screen, qualitate/multi	Pathology	0.75	
80101	Drug screen, single	Pathology	0.71	
80102	Drug confirmation	Pathology	0.68	
80103	Drug analysis, tissue prep	Pathology	0.49	MDR
80150	Assay of amikacin	Pathology	0.77	****
80152	Assay of amitriptyline	Pathology	0.92	
80154	Assay of benzodiazepines	Pathology	0.95	
80156		Pathology	0.75	
80157	Assay, carbamazepine, total Assay, carbamazepine, free	Pathology	0.73	
			0.93	
80158	Assay of cyclosporine	Pathology	0.88	
80160	Assay of desipramine	Pathology		
80162	Assay of digoxin	Pathology	0.68	
80164	Assay, dipropylacetic acid	Pathology	0.70	
80166	Assay of doxepin	Pathology	0.80	
80168	Assay of ethosuximide	Pathology	0.84	
80170	Assay of gentamicin	Pathology	0.84	1
80172	Assay of gold	Pathology	0.84	
80173	Assay of haloperidol	Pathology	0.75	}
80174	Assay of imipramine	Pathology	0.88	
80176	Assay of lidocaine	Pathology	0.75	
80178	Assay of lithium	Pathology	0.34	
80182	Assay of nortriptyline	Pathology	0.70	
80184	Assay of phenobarbital	Pathology	0.59	
80185	Assay of phenytoin, total	Pathology	0.68	
80186	Assay of phenytoin, free	Pathology	0.71	
80188	Assay of primidone	Pathology	0.85	
80190	Assay of procainamide	Pathology	0.86	
80192	Assay of procainamide	Pathology	0.86	
80194	Assay of guinidine	Pathology	0.75	
80196	Assay of salicylate	Pathology	0.36	
80197	Assay of tacrolimus	Pathology	0.70	
80198	Assay of theophylline	Pathology	0.73	
80200	Assay of tobramycin	Pathology	0.83	1
80201	Assay of topiramate	Pathology	0.61	j
80202	Assay of vancomycin	Pathology	0.70	
80299	Quantitative assay, drug	Pathology	0.70	
80400	Acth stimulation panel	Pathology	1.67	1
80402	Acth stimulation panel	Pathology	4.46	l
80402	Acth stimulation panel	Pathology	4.02	l
80408	Aldosterone suppression eval	Pathology	6.44	l
				l
80410	Calcitonin stimul panel	Pathology	4.12	İ
80412	CRH stimulation panel	Pathology	16.91	l
80414	Testosterone response	Pathology	2.65	1
80415	Estradiol response panel	Pathology	2.87	
80416	Renin stimulation panel	Pathology	6.77	l
80417	Renin stimulation panel	Pathology	2.26	1
80418	Pituitary evaluation panel	Pathology	29.74	1
80420	Dexamethasone panel	Pathology	3.70	l
80422	Glucagon tolerance panel	Pathology	2.36	1
80424	Glucagon tolerance panel	Pathology	2.59	l
80426	Gonadotropin hormone panel	Pathology	7.62	I
80428	Growth hormone panel	Pathology	3.42	1
80430	Growth hormone panel	Pathology	4.03	l
80432	Insulin suppression panel	Pathology	6.93	
80434	Insulin tolerance panel	Pathology	5.19	1
80435	Insulin tolerance panel	Pathology	5.28	1
80436	Metyrapone panel	Pathology	4.68	1
80438	TRH stimulation panel	Pathology	2.59	I

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS) PAGE 2 OF 17

CPT/ HCPCS	CPT/HCPCS Code Description	Conversion Factor/GAAF	Total	Charge Method-
Code	GET/HOPOS Code Description	Category	RVUs	ology
80439	TRH stimulation panel	Pathology	3.45	
80440	TRH stimulation panel	Pathology	2.98 0.16	
81000 81001	Urinalysis, nonauto w/scope Urinalysis, auto w/scope	Pathology Pathology	0.16	
81002	Urinalysis nonauto w/o scope	Pathology	0.13	
81003	Urinalysis, auto, w/o scope	Pathology	0.12	
81005	Urinalysis	Pathology	0.11	
81007	Urine screen for bacteria	Pathology	0.13	
81015	Microscopic exam of urine	Pathology	0.16	
81020	Urinalysis, glass test	Pathology	0.19 0.32	
81025 81050	Urine pregnancy test Urinalysis, volume measure	Pathology Pathology	0.32	
81099	Urinalysis test procedure	Pathology	0.16	
82000	Assay of blood acetaldehyde	Pathology	0.64	
82003	Assay of acetaminophen	Pathology	1.04	
82009	Test for acetone/ketones	Pathology	0.23	
82010	Acetone assay	Pathology	0.42	
82013	Acetylcholinesterase assay	Pathology	0.57	
82016 82017	Acylcarnitines, qual Acylcarnitines, quant	Pathology Pathology	0.71 0.87	
82017 82024	Acylcarnitines, quant Assay of acth	Pathology	1.98	
82030	Assay of adp & amp	Pathology	1.32	
82040	Assay of serum albumin	Pathology	0.25	
82042	Assay of urine albumin	Pathology	0.27	
82043	Microalbumin, quantitative	Pathology	0.30	
82044	Microalbumin, semiquant	Pathology	0.23	
82055	Assay of ethanol	Pathology	0.55 0.62	
82075 82085	Assay of breath ethanol Assay of aldolase	Pathology Pathology	0.52	
82088	Assay of aldosterone	Pathology	2.09	
82101	Assay of urine alkaloids	Pathology	1.54	
82103	Alpha-1-antitrypsin, total	Pathology	0.69	
82104	Alpha-1-antitrypsin, pheno	Pathology	0.74	
82105	Alpha-fetoprotein, serum	Pathology	0.86	
82106	Alpha-fetoprotein, amniotic	Pathology	0.86 1.31	
82108 82120	Assay of aluminum Amines, vaginal fluid qual	Pathology Pathology	0.19	
82127	Amino acid, single qual	Pathology	0.71	
82128	Amino acids, mult qual	Pathology	0.71	
82131	Amino acids, single quant	Pathology	0.87	
82135	Assay, aminolevulinic acid	Pathology	0.84	
82136	Amino acids, quant, 2-5	Pathology	0.87	
82139	Amino acids, quan, 6 or more	Pathology	0.87	
82140 82143	Assay of ammonia Amniotic fluid scan	Pathology Pathology	0.75 0.35]
82145	Assay of amphetamines	Pathology	0.80	
82150	Assay of amplications	Pathology	0.33	
82154	Androstanediol glucuronide	Pathology	1.48	1
82157	Assay of androstenedione	Pathology	1.50	
82160	Assay of androsterone	Pathology	1.28	
82163 82164	Assay of angiotensin II Angiotensin I enzyme test	Pathology Pathology	1.05 0.75	
82164 82172	Assay of apolipoprotein	Pathology	0.75]
82175	Assay of apolipoprotein	Pathology	0.97	
82180	Assay of ascorbic acid	Pathology	0.51	
82190	Atomic absorption	Pathology	0.77	1
82205	Assay of barbiturates	Pathology	0.59	
82232	Assay of beta-2 protein	Pathology	0.83 0.88	
82239 82240	Bile acids, total Bile acids, cholylglycine	Pathology Pathology	1.36	
82240 82247	Bilirubin, total	Pathology	0.26	
82248	Bilirubin, direct	Pathology	0.26	l
82252	Fecal bilirubin test	Pathology	0.23	1
82261	Assay of biotinidase	Pathology	0.87	1
82270	Test for blood, feces	Pathology	0.17	
82273	Test for blood, other source Assay test for blood, fecal	Pathology Pathology	0.17 1.09	SA
82274 82286	Assay test for blood, fecal Assay of bradykinin	Pathology	0.35	5/
	I INDUSTRICE OF DESIGNATIONS	1	, 0.00	1

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)
PAGE 3 OF 17

-	1,100 0 0, 11			
CPT/		Conversion		Charge
HCPCS	CPT/HCPCS Code Description	Factor/GAAF	Total	Method-
Code		Category	RVUs	ology
-		J		
82306	Assay of vitamin D	Pathology	1.52	
82307	Assay of vitamin D	Pathology	1.65	
82308	Assay of calcitonin	Pathology	1.37	
82310	Assay of calcium	Pathology	0.26	
82330 82331	Assay of calcium Calcium infusion test	Pathology Pathology	0.70 0.27	
82340	Assay of calcium in urine	Pathology	0.27	
82355	Calculus analysis, qual	Pathology	0.59	
82360	Calculus assay, quant	Pathology	0.66	
82365	Calculus spectroscopy	Pathology	0.66	
82370 82373	X-ray assay, calculus	Pathology Pathology	0.64 0.93	
82374	Assay, c-d transfer measure Assay, blood carbon dioxide	Pathology	0.93	
82375	Assay, blood carbon monoxide	Pathology	0.63	
82376	Test for carbon monoxide	Pathology	0.31	
82378	Carcinoembryonic antigen	Pathology	0.97	
82379	Assay of carnitine	Pathology	0.87	
82380 82382	Assay of carotene Assay, urine catecholamines	Pathology Pathology	0.47 0.88	
82383	Assay, unne catecholamines Assay, blood catecholamines	Pathology	1.29	
82384	Assay, three catecholamines	Pathology	1.30	
82387	Assay of cathepsin-d	Pathology	1.07	
82390	Assay of ceruloplasmin	Pathology	0.55	
82397	Chemiluminescent assay	Pathology	0.73 0.65	
82415 82435	Assay of chloramphenicol Assay of blood chloride	Pathology Pathology	0.03	
82436	Assay of urine chloride	Pathology	0.26	
82438	Assay, other fluid chlorides	Pathology	0.25	
82441	Test for chlorohydrocarbons	Pathology	0.31	
82465	Assay, bld/serum cholesterol	Pathology	0.22 0.40	
82480 82482	Assay, serum cholinesterase Assay, rbc cholinesterase	Pathology Pathology	0.40	
82485	Assay, chondroitin sulfate	Pathology	1.06	
82486	Gas/liquid chromatography	Pathology	0.93	
82487	Paper chromatography	Pathology	0.82	
82488	Paper chromatography	Pathology	1.10	
82489 82491	Thin layer chromatography Chromotography, quant, sing	Pathology Pathology	0.95 0.93	ŀ
82492	Chromotography, quant, sing Chromotography, quant, mult	Pathology	0.93	
82495	Assay of chromium	Pathology	1.04	
82507	Assay of citrate	Pathology	1.43	1
82520	Assay of cocaine	Pathology	0.78	
82523 82525	Collagen crosslinks	Pathology Pathology	0.96 0.64	ĺ
82528	Assay of copper Assay of corticosterone	Pathology	1.16	
82530	Cortisol, free	Pathology	0.86	
82533	Total cortisol	Pathology	0.84	
82540	Assay of creatine	Pathology	0.24	
82541	Column chromotography, qual	Pathology Pathology	0.93 0.93	
82542 82543	Column chromotography, quant Column chromotograph/isotope	Pathology	0.93	
82544	Column chromotograph/isotope	Pathology	0.93	
82550	Assay of ck (cpk)	Pathology	0.33	
82552	Assay of cpk in blood	Pathology	0.69	1
82553	Creatine, MB fraction	Pathology	0.59	
82554 82565	Creatine, isoforms Assav of creatinine	Pathology Pathology	0.61 0.26]
82570	Assay of creatinine Assay of urine creatinine	Pathology	0.27	1
82575	Creatinine clearance test	Pathology	0.48	
82585	Assay of cryofibrinogen	Pathology	0.44	
82595	Assay of cryoglobulin	Pathology	0.33	
82600 82607	Assay of cyanide Vitamin B-12	Pathology Pathology	1.00 0.77	1
82608	B-12 binding capacity	Pathology	0.73	
82615	Test for urine cystines	Pathology	0.42	1
82626	Dehydroepiandrosterone	Pathology	1.30	
82627 82633	Dehydroepiandrosterone Descriptionsterone	Pathology Pathology	1.14 1.59	
82633 82634	Desoxycorticosterone Deoxycortisol	Pathology	1.50	1
02004	1			•

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)
PAGE 4 OF 17

CPT/ HCPCS	CPT/HCPCS Code Description	Conversion Factor/GAAF	Total	Charge Method-
Code	Ci moi os code bescription	Category	RVUs	ology
82638	Assay of dibucaine number	Pathology	0.63	
82646	Assay of dihydrocodeinone	Pathology	1.06	
82649	Assay of dihydromorphinone	Pathology	1.32	
82651	Assay of dihydrotestosterone	Pathology	1.32	
82652	Assay of dihydroxyvitamin d	Pathology	1.98	
82654	Assay of dimethadione	Pathology	0.71	
82657 82658	Enzyme cell activity Enzyme cell activity, ra	Pathology Pathology	0.93 0.93	
82664	Electrophoretic test	Pathology	1.76	
82666	Assay of epiandrosterone	Pathology	1.10	
82668	Assay of epitalidiosicrone Assay of erythropoietin	Pathology	0.96	
82670	Assay of estradiol	Pathology	1.43	
82671	Assay of estrogens	Pathology	1.66	
82672	Assay of estrogen	Pathology	1.11	
82677	Assay of estriol	Pathology	1.24	
82679	Assay of estrone	Pathology	1.28	
82690	Assay of ethchlorvynol	Pathology	0.89	
82693	Assay of ethylene glycol	Pathology	0.76	
82696	Assay of etiocholanolone	Pathology	1.21	
82705	Fats/lipids, feces, qual	Pathology	0.26	
82710	Fats/lipids, feces, quant	Pathology	0.86	
82715 82725	Assay of fecal fat Assay of blood fatty acids	Pathology	0.88 0.68	
82726	Long chain fatty acids	Pathology Pathology	0.00	
82728	Assay of ferritin	Pathology	0.93	
82731	Assay of fetal fibronectin	Pathology	3.31	
82735	Assay of fluoride	Pathology	0.95	
82742	Assay of flurazepam	Pathology	1.02	
82746	Blood folic acid serum	Pathology	0.75	
82747	Assay of folic acid, rbc	Pathology	0.89	
82757	Assay of semen fructose	Pathology	0.89	
82759	Assay of rbc galactokinase	Pathology	1.10	
82760	Assay of galactose	Pathology	0.57	
82775	Assay galactose transferase	Pathology	1.08	
82776 82784	Galactose transferase test	Pathology	0.43 0.48	
82785	Assay of gammaglobulin igm Assay of gammaglobulin ige	Pathology Pathology	0.46	1
82787	lgg 1, 2, 3 or 4, each	Pathology	0.03	
82800	Blood pH	Pathology	0.43	
82803	Blood gases: pH, pO2 & pCO2	Pathology	0.99	
82805	Blood gases W/02 saturation	Pathology	1.46	
82810	Blood gases, O2 sat only	Pathology	0.45	
82820	Hemoglobin-oxygen affinity	Pathology	0.51	
82926	Assay of gastric acid	Pathology	0.28	
82928	Assay of gastric acid	Pathology	0.34	
82938 82941	Gastrin test Assay of gastrin	Pathology Pathology	0.91 0.90	
82943	Assay of glucagon	Pathology	0.50	
82945	Glucose other fluid	Pathology	0.73	
82946	Glucagon tolerance test	Pathology	0.20	
82947	Assay, glucose, blood quant	Pathology	0.20	
82948	Reagent strip/blood glucose	Pathology	0.16	
82950	Glucose test	Pathology	0.24	
82951	Glucose tolerance test (GTT)	Pathology	0.66	
82952	GTT-added samples	Pathology	0.20	
82953	Glucose-tolbutamide test	Pathology	0.78	
82955	Assay of g6pd enzyme Test for G6PD enzyme	Pathology	0.50 0.31	
82960 82962	Glucose blood test	Pathology Pathology	0.31	1
82963	Assay of glucosidase	Pathology	1.10	1
82965	Assay of gdh enzyme	Pathology	0.40	J
82975	Assay of glutamine	Pathology	0.81	1
82977	Assay of GGT	Pathology	0.37	1
82978	Assay of glutathione	Pathology	0.73	
82979	Assay, rbc glutathione	Pathology	0.35	1
82980	Assay of glutethimide	Pathology	0.94	
82985 83001	Glycated protein Gonadotropin (FSH)	Pathology Pathology	0.77 0.95	
83002	Gonadotropin (LH)	Pathology	0.95	1

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)
PAGE 5 OF 17

CPT/ Conversion	Total	Charge
HCPCS CPT/HCPCS Code Description Factor/GAAF		Method-
Code Category	RVUs	ology
	0.00	
83003 Assay, growth hormone (hgh) Pathology	0.86	
83008 Assay of guanosine Pathology	0.86	
83010 Assay of haptoglobin, quant Pathology	0.65	
83012 Assay of haptoglobins Pathology	0.88	
83013 H pylori analysis Pathology	3.46	
83014 H pylori drug admin/collect Pathology	0.40	
83015 Heavy metal screen Pathology	0.97	
83018 Quantitative screen, metals Pathology	1.13	
83020 Hemoglobin electrophoresis Pathology	0.66	
83021 Hemoglobin chromotography Pathology	0.93	
83026 Hemoglobin, copper sulfate Pathology	0.12	
83030 Fetal hemoglobin, chemical Pathology	0.42	
83033 Fetal hemoglobin assay, qual Pathology	0.31	
83036 Glycated hemoglobin test Pathology	0.50	
83045 Blood methemoglobin test Pathology	0.25	
83050 Blood methemoglobin assay Pathology	0.38	
83051 Assay of plasma hemoglobin Pathology	0.37	
83055 Blood sulfhemoglobin test Pathology	0.25	
83060 Blood sulfhemoglobin assay Pathology	0.42	
83065 Assay of hemoglobin heat Pathology	0.35	
83068 Hemoglobin stability screen Pathology	0.43	
83069 Assay of urine hemoglobin Pathology	0.20	
83070 Assay of hemosiderin, qual Pathology	0.24	
83071 Assay of hemosiderin, quant Pathology	0.35	
83080 Assay of b hexosaminidase Pathology	0.87	
83088 Assay of histamine Pathology	1.52	
83090 Assay of homocystine Pathology	0.87	
83150 Assay of for hva Pathology	0.99	
83491 Assay of corticosteroids Pathology	0.90	
83497 Assay of Controsteroids Pathology	0.66	
83498 Assay of progesterone Pathology	1.39	
83499 Assay of progesterone Pathology	1.29	
83500 Assay, free hydroxyproline Pathology	1.16	
83505 Assay, total hydroxyproline Pathology	1.25	
83516 Immunoassay, nonantibody Pathology	0.59	
83518 Immunoassay, dipstick Pathology	0.44	
83519 Immunoassay, nonantibody Pathology	0.69	
83520 Immunoassay, RIA Pathology	0.66	
83525 Assay of insulin Pathology	0.59	
83527 Assay of insulin Pathology	0.66	
83528 Assay of intrinsic factor Pathology	0.82	
83540 Assay of iron Pathology	0.33	
83550 Iron binding test Pathology	0.45	
83570 Assay of idh enzyme Pathology	0.45	
83582 Assay of ketogenic steroids Pathology	0.73	
83586 Assay 17- ketosteroids Pathology	0.66	
83593 Fractionation, ketosteroids Pathology	1.35	
83605 Assay of lactic acid Pathology	0.55	
83615 Lactate (LD) (LDH) enzyme Pathology	0.31	
83625 Assay of Idh enzymes Pathology	0.66	
83632 Placental lactogen Pathology	1.04	
83633 Test urine for lactose Pathology	0.28	
83634 Assay of urine for lactose Pathology	0.59	
83655 Assay of lead Pathology 83661 L/s ratio, fetal lung Pathology	0.62 1.13	
83662 Foam stability, fetal lung Pathology	0.97	
83663 Fluoro polarize, fetal lung Pathology Patholog	0.49 0.24	
83670 Assay of lap enzyme Pathology	0.47	
83690 Assay of lipase Pathology	0.35	
83715 Assay of blood lipoproteins Pathology	0.58	
83716 Assay of blood lipoproteins Pathology	1.27	
83718 Assay of lipoprotein Pathology	0.42	
83719 Assay of blood lipoprotein Pathology	0.60	
83721 Assay of blood lipoprotein Pathology	0.49	
83727 Assay of Irh hormone Pathology	0.88	
83735 Assay of magnesium Pathology	0.34	
83775 Assay of md enzyme Pathology	0.38	
83785 Assay of manganese Pathology	1.26	l

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS) PAGE 6 OF 17

CPT/		Conversion		Charge
HCPCS	ODT/HODOO O- d- D		Total	
	CPT/HCPCS Code Description	Factor/GAAF	RVUs	Method-
Code		Category		ology
83788	Mass spectrometry qual	Pathology	0.93	
83789	Mass spectrometry quant	Pathology	0.93	
83805	Assay of meprobamate	Pathology	0.90	
83825	Assay of mercury	Pathology	0.83	
83835	Assay of metanephrines	Pathology	0.87	
83840	Assay of methadone	Pathology	0.84	
83857	Assay of methemalbumin	Pathology	0.55	
83858	Assay of methsuximide	Pathology	0.76	
83864	Mucopolysaccharides	Pathology	1.02	
83866	Mucopolysaccharides screen	Pathology	0.51	
83872	Assay synovial fluid mucin	Pathology	0.30	
83873	Assay of csf protein	Pathology	0.88	
83874	Assay of myoglobin	Pathology	0.66	
83880	Natriuretic peptide	Pathology	1.74	
83883	Assay, nephelometry not spec	Pathology	0.70	
83885	Assay of nickel	Pathology	1.26	
83887	Assay of nicotine	Pathology	1.22	
83890	Molecule isolate	Pathology	0.21	
83891	Molecule isolate nucleic	Pathology	0.21	
83892	Molecular diagnostics	Pathology	0.21	
83893	Molecule dot/slot/blot	Pathology	0.21	
83894	Molecule gel electrophor	Pathology	0.21	
83896	Molecular diagnostics	Pathology	0.21	
83897	Molecule nucleic transfer	Pathology	0.21	
83898	Molecule nucleic ampli	Pathology	0.86	
83901	Molecule nucleic ampli	Pathology	0.86	
83902	Molecular diagnostics	Pathology	0.73	
83903	Molecule mutation scan	Pathology	0.86	
83904	Molecule mutation identify	Pathology	0.86	
83905	Molecule mutation identify	Pathology	0.86	
83906	Molecule mutation identify	Pathology	0.86	
83912	Genetic examination	Pathology	0.21	
83915	S Oliganianal handa	Pathology	0.57	
83916	Oligoclonal bands	Pathology	1.03 0.84	
83918	Organic acids, total, quant	Pathology Pathology	0.84	
83919 83921	Organic acids, qual, each Organic acid, single, quant	Pathology	0.84	
83925	Assay of opiates	Pathology	1.00	
83930	Assay of opiales Assay of blood osmolality	Pathology	0.34	
83935	Assay of urine osmolality	Pathology	0.35	
83937	Assay of osteocalcin	Pathology	1.53	
83945	Assay of oxalate	Pathology	0.66	
83950	Oncoprotein, her-2/neu	Pathology	3.31	
83970	Assay of parathormone	Pathology	2.12	
83986	Assay of body fluid acidity	Pathology	0.18	
83992	Assay for phencyclidine	Pathology	0.75	
84022	Assay of phenothiazine	Pathology	0.80	
84030	Assay of blood pku	Pathology	0.28	
84035	Assay of phenylketones	Pathology	0.19	
84060	Assay acid phosphatase	Pathology	0.38	
84061	Phosphatase, forensic exam	Pathology	0.41	
84066	Assay prostate phosphatase	Pathology	0.50	
84075	Assay alkaline phosphatase	Pathology	0.27	
84078	Assay alkaline phosphatase	Pathology	0.37	
84080	Assay alkaline phosphatases	Pathology	0.76	
84081	Amniotic fluid enzyme test	Pathology	0.85	
84085	Assay of rbc pg6d enzyme	Pathology	0.35	
84087	Assay phosphohexose enzymes	Pathology	0.53	
84100	Assay of phosphorus	Pathology	0.24	
84105	Assay of urine phosphorus	Pathology	0.27	
84106	Test for porphobilingen	Pathology	0.22	
84110	Assay of porphobilinogen	Pathology	0.43 0.44	1
84119	Test urine for porphyrins	Pathology Pathology	0.44	
84120 84126	Assay of urine porphyrins Assay of feces porphyrins	Pathology	1.31	
84126 84127	Assay of feces porphyrins Assay of feces porphyrins	Pathology	0.60	Į
84132	Assay of feces porpriyrins Assay of serum potassium	Pathology	0.00	
84133	Assay of urine potassium	Pathology	0.22	
84134	Assay of unite potassium Assay of prealbumin	Pathology	0.75	
27101	1 - manual as because assess	1		•

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS) PAGE 7 OF 17

CPT/		Conversion		Charge
	ORTHODOS O L. D	•	Total	•
HCPCS	CPT/HCPCS Code Description	Factor/GAAF	RVUs	Method-
Code		Category		ology
				·
84135	Assay of pregnanediol	Pathology	0.98	
84138	Assay of pregnanetriol	Pathology	0.97	
84140	Assay of pregnenolone	Pathology	1.06	
84143	Assay of 17-hydroxypregneno	Pathology	1.17	
84144	Assay of progesterone	Pathology	1.07	
84146	Assay of prolactin	Pathology	0.99	
84150	Assay of prostaglandin	Pathology	1.28	
84152	Assay of psa, complexed	Pathology	0.94	
84153	Assay of psa, total	Pathology	0.94	
84154	Assay of psa, free	Pathology	0.94	
84155	Assay of protein	Pathology	0.19	
84160	Assay of serum protein	Pathology	0.27	
84165	Assay of serum proteins	Pathology	0.55	
84181	Western blot test	Pathology	0.87	
84182	Protein, western blot test	Pathology	0.92	
84202	Assay RBC protoporphyrin	Pathology	0.74	
84203	Test RBC protoporphyrin	Pathology	0.44	
84206	Assay of proinsulin	Pathology	0.91	
84207	Assay of profitsum Assay of vitamin b-6	Pathology	1.44	
84210	Assay of vitarilli b-o	Pathology	0.56	
84220	Assay of pyruvate Assay of pyruvate kinase	Pathology	0.38	
84228	Assay of guinine	Pathology	0.40	
84233	Assay of guilline Assay of estrogen	Pathology	3.31	
84234	Assay of estrogen Assay of progesterone	Pathology	3.33	
84235	Assay of progesterone Assay of endocrine hormone	Pathology	2.69	
84238		Pathology	1.88	
84244	Assay, nonendocrine receptor Assay of renin	Pathology	1.13	
			1.04	
84252	Assay of vitamin b-2	Pathology Pathology	1.04	
84255	Assay of selenium	1	1.59	
84260	Assay of serotonin	Pathology Pathology	1.12	
84270	Assay of sex hormone globul			
84275	Assay of sialic acid	Pathology	0.69	
84285	Assay of silica	Pathology	1.21	
84295	Assay of serum sodium	Pathology	0.25	
84300	Assay of urine sodium	Pathology	0.25	
84302	Assay of sweat sodium	Pathology	0.25	
84305	Assay of somatomedin	Pathology	1.09	
84307	Assay of somatostatin	Pathology	0.94	
84311	Spectrophotometry	Pathology	0.36	
84315	Body fluid specific gravity	Pathology	0.13	
84375	Chromatogram assay, sugars	Pathology	1.01	
84376	Sugars, single, qual	Pathology	0.28	
84377	Sugars, multiple, qual	Pathology	0.28	
84378	Sugars single quant	Pathology	0.59	
84379	Sugars multiple quant	Pathology	0.59	
84392	Assay of urine sulfate	Pathology	0.24	ľ
84402	Assay of testosterone	Pathology	1.31	
84403	Assay of total testosterone	Pathology	1.33	
84425	Assay of vitamin b-1	Pathology	1.09	
84430	Assay of thiocyanate	Pathology	0.60	
84432	Assay of thyroglobulin	Pathology	0.82	1
84436	Assay of total thyroxine	Pathology	0.35	
84437	Assay of neonatal thyroxine	Pathology	0.33	
84439	Assay of free thyroxine	Pathology	0.46	
84442	Assay of thyroid activity	Pathology	0.76	
84443	Assay thyroid stim hormone	Pathology	0.86	
84445	Assay of tai	Pathology	2.61	
84446	Assay of transporting	Pathology	0.73	
84449	Assay of transcortin	Pathology	0.92	1
84450	Transferase (AST) (SGOT)	Pathology	0.27 0.27]
84460 84466	Alanine amino (ALT) (SGPT)	Pathology	0.27	1
	Assay of transferrin	Pathology Pathology	0.30	l
84478	Assay of triglycerides		0.30	1
84479	Assay of thyroid (t3 or t4)	Pathology Pathology	0.33	1
84480	Assay, triiodothyronine (t3)	Pathology	0.73	l
84481	Free assay (FT-3)	Pathology	0.81	l
84482	T3 reverse Assay of troponin, quant	Pathology	0.51	Į.
84484 84485	Assay of troponin, quant Assay duodenal fluid trypsin	Pathology	0.39	1
0-1-400	1 Modely adopted and a typolit	1 . 0000091	. 0.00	•

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)
PAGE 8 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Method- ology
84488	Test feces for trypsin	Pathology	0.37	
84490	Assay of feces for trypsin	Pathology	0.39	
84510	Assay of tyrosine	Pathology	0.53	
84512	Assay of troponin, qual	Pathology	0.40	
84520	Assay of urea nitrogen	Pathology	0.20	
84525	Urea nitrogen semi-quant	Pathology	0.19	
84540	Assay of urine/urea-n	Pathology	0.24	
84545	Urea-N clearance test	Pathology	0.34	
84550 84560	Assay of blood/uric acid Assay of urine/uric acid	Pathology Pathology	0.23 0.24	
84577	Assay of difficultic acid Assay of feces/urobilingen	Pathology	0.64	
84578	Test urine urobilinogen	Pathology	0.04	
84580	Assay of urine urobilinogen	Pathology	0.36	
84583	Assay of urine urobilinogen	Pathology	0.26	
84585	Assay of urine vma	Pathology	0.80	
84586	Assay of vip	Pathology	1.81	
84588	Assay of vasopressin	Pathology	1.74	
84590	Assay of vitamin a	Pathology	0.59	
84591	Assay of nos vitamin	Pathology	0.59	
84597	Assay of vitamin k	Pathology	0.70	
84600	Assay of volatiles	Pathology	0.82	
84620	Xylose tolerance test	Pathology	0.61	
84630	Assay of zinc	Pathology	0.58	
84681	Assay of c-peptide	Pathology Pathology	1.07 0.77	
84702 84703	Chorionic gonadotropin test Chorionic gonadotropin assay	Pathology	0.77	
84830	Ovulation tests	Pathology	0.53	
84999	Clinical chemistry test	Pathology	0.27	
85002	Bleeding time test	Pathology	0.23	
85004	Automated diff wbc count	Pathology	0.33	
85007	BI smear w/diff wbc count	Pathology	0.18	
85008	Bl smear w/o diff wbc count	Pathology	0.18	
85009	Manual diff wbc count b-coat	Pathology	0.19	
85013	Spun microhematocrit	Pathology	0.12	
85014	Hematocrit	Pathology	0.12	
85018	Hemoglobin	Pathology	0.12	
85025 85027	Complete cbc w/auto diff wbc Complete cbc, automated	Pathology Pathology	0.40 0.33	
85032	Manual cell count, each	Pathology	0.33	
85041	Automated rbc count	Pathology	0.15	
85044	Manual reticulocyte count	Pathology	0.22	
85045	Automated reticulocyte count	Pathology	0.21	
85046	Reticyte/hgb concentrate	Pathology	0.29	
85048	Automated leukocyte count	Pathology	0.13	
85049	Automated platelet count	Pathology	0.23	ľ
85130	Chromogenic substrate assay	Pathology	0.61	
85170	Blood clot retraction	Pathology	0.19	
85175 85210	Blood clot lysis time Blood clot factor II test	Pathology Pathology	0.23 0.67	
85220	Blood clot factor V test	Pathology	0.07	
85230	Blood clot factor VII test	Pathology	0.92	
85240	Blood clot factor VIII test	Pathology	0.92	
85244	Blood clot factor VIII test	Pathology	1.05	
85245	Blood clot factor VIII test	Pathology	1.18	
85246	Blood clot factor VIII test	Pathology	1.18	
85247	Blood clot factor VIII test	Pathology	1.18	
85250	Blood clot factor IX test	Pathology	0.98	1
85260 85370	Blood clot factor X test	Pathology	0.92	
85270 85280	Blood clot factor XI test Blood clot factor XII test	Pathology Pathology	0.92 0.99	
85290	Blood clot factor XIII test	Pathology	0.84]
85291	Blood clot factor XIII test	Pathology	0.46	
85292	Blood clot factor assay	Pathology	0.97	
85293	Blood clot factor assay	Pathology	0.97	
85300	Antithrombin III test	Pathology	0.61	
85301	Antithrombin III test	Pathology	0.55	
85302 85303	Blood clot inhibitor antigen Blood clot inhibitor test	Pathology Pathology	0.62 0.71	
	Connection and the control of the co	r alliology	. 0./1	

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)
PAGE 9 OF 17

CPT/		Conversion		Charge
HCPCS	CPT/HCPCS Code Description	Factor/GAAF	Total	Method-
Code	OF MICEOS Code Description	1 . 1	RVUs	
Code		Category		ology
05000	DI	D-46-1	0.70	
85306 85307	Blood clot inhibitor test	Pathology	0.79	
85335	Assay activated protein c Factor inhibitor test	Pathology Pathology	0.79 0.66	
85337	Thrombomodulin	Pathology	0.53	
85345	Coagulation time	Pathology	0.22	
85347	Coagulation time	Pathology	0.22	
85348	Coagulation time	Pathology	0.19	
85360	Euglobulin lysis	Pathology	0.43	
85362	Fibrin degradation products	Pathology	0.35	
85366	Fibrinogen test	Pathology Pathology	0.44 0.58	
85370 85378	Fibrinogen test Fibrin degrade, semiquant	Pathology	0.37	
85379	Fibrin degradation, quant	Pathology	0.52	
85380	Fibrin degradation, vte	Pathology	0.52	
85384	Fibrinogen	Pathology	0.44	
85385	Fibrinogen	Pathology	0.44	
85390	Fibrinolysins screen	Pathology	0.27	
85400	Fibrinolytic plasmin	Pathology	0.45 0.40	
85410 85415	Fibrinolytic antiplasmin Fibrinolytic plasminogen	Pathology Pathology	0.40	
85420	Fibrinolytic plasminogen	Pathology	0.34	
85421	Fibrinolytic plasminogen	Pathology	0.52	
85441	Heinz bodies, direct	Pathology	0.22	
85445	Heinz bodies, induced	Pathology	0.35	
85460	Hemoglobin, fetal	Pathology	0.40	
85461	Hemoglobin, fetal	Pathology	0.34	
85475	Hemolysin	Pathology	0.46 0.67	
85520 85525	Heparin assay Heparin neutralization	Pathology Pathology	0.67	
85530	Heparin-protamine tolerance	Pathology	0.73	
85536	Iron stain peripheral blood	Pathology	0.33	
85540	Wbc alkaline phosphatase	Pathology	0.44	
85547	RBC mechanical fragility	Pathology	0.44	
85549	Muramidase	Pathology	0.96	
85555	RBC osmotic fragility	Pathology	0.34	
85557 85576	RBC osmotic fragility Blood platelet aggregation	Pathology Pathology	0.69 1.10	
85597	Platelet neutralization	Pathology	0.92	
85610	Prothrombin time	Pathology	0.20	
85611	Prothrombin test	Pathology	0.20	
85612	Viper venom prothrombin time	Pathology	0.49	
85613	Russell viper venom, diluted	Pathology	0.49	
85635	Reptilase test	Pathology	0.51 0.18	
85651 85652	Rbc sed rate, nonautomated Rbc sed rate, automated	Pathology Pathology	0.16	
85660	RBC sickle cell test	Pathology	0.28	
85670	Thrombin time, plasma	Pathology	0.30	
85675	Thrombin time, titer	Pathology	0.35	
85705	Thromboplastin inhibition	Pathology	0.49	
85730	Thromboplastin time, partial	Pathology	0.31	
85732	Thromboplastin time, partial	Pathology	0.33 0.60	
85810 85000	Blood viscosity examination	Pathology Pathology	0.60	
85999 86000	Hematology procedure Agglutinins, febrile	Pathology	0.20	[
86001	Allergen specific igg	Pathology	0.27	
86003	Allergen specific IgE	Pathology	0.27	
86005	Allergen specific IgE	Pathology	0.41	
86021	WBC antibody identification	Pathology	0.77	
86022	Platelet antibodies	Pathology	0.94	
86023	Immunoglobulin assay Antinuclear antibodies	Pathology Pathology	0.64 0.62	
86038 86039	Antinuclear antibodies Antinuclear antibodies (ANA)	Pathology	0.57	1
86060	Antistreptolysin o, titer	Pathology	0.37	
86063	Antistreptolysin o, screen	Pathology	0.30	
86140	C-reactive protein	Pathology	0.27	1
86141	C-reactive protein, hs	Pathology	0.66	
86146	Glycoprotein antibody	Pathology	1.31 1.31	
86147 86148	Cardiolipin antibody Phospholipid antibody	Pathology Pathology	0.82	1
00140	i nosphonpia ambody	1	, 0.02	•

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS) PAGE 10 OF 17

CPT/ HCPCS Code CPT/HCPCS Code Description Code Chemotaxis assay R81156 R81156 R81157 R81156 R81157 R81156 R81157 R81156 R81157 R81156 R81157 R81157 R81156 R81157 R81156 R81157 R8115		17102 10 07 17			
HCPCS Code Code RVUs RVUs RS155 RS155 RS156 RS158 RS158 RS157 RS157 RS160 Cod aggulutinin screen Cod aggulutinin screen RS1610 Cod aggulutinin, ther RS1610 Complement furthuncion activity RS1610 Complement furthuncion activity RS1610 Complement furthuncion activity RS1610 Complement furthuncion activity RS1610 Complement furthuncion activity RS1610 Complement furthuncion activity RS1610 Complement furthuncion activity RS1610 Complement furthuncion activity RS1610 Complement furthuncion activity RS1610 Complement furthuncion activity RS1610 Complement furthuncion activity RS1610 Complement furthuncion activity RS1610 RS1610 Complement furthuncion activity RS1610 RS1610 Complement furthuncion activity RS1610 RS1610 RS1610 Complement furthuncion activity RS1610 RS	CDT/		Conversion		Chargo
Code Category RVUS clogy		CDT/MCDCS Code December	i i	Total	•
86155 Chemotaxis assay Bathology Cold agglutinin, screen Cold agglutinin, steren B6160 Complement, antigen B6161 Complement/function activity B6162 Complement/function activity B6163 Complement (total (CH50) Pathology B6171 Complement fixation, each B6164 Complement fixation, each B6165 Counterimmunoelectrophoresis B6215 Deoxyriborunclease, antibody B6225 DNA antibody B6225 DNA antibody B6226 DNA antibody B726 Counterimmunoelectrophoresis B6235 Novel antibody B726 Counterimmunoelectrophoresis B6235 Novel antibody B726 Counterimmunoelectrophoresis B6236 PAThology B727 Counterimmunoelectrophoresis B727 PAThology B727 Counterimmunoelectrophoresis B727 PAThology B727 Counterimmunoelectrophoresis B727 PAThology B727 Counterimmunoelectrophoresis B727 PAThology B727 Counterimmunoelectrophoresis B727 PAThology B727 Counterimmunoelectrophoresis B727 PAThology B727 Counterimmunoelectrophoresis B727 PAThology B727 Counterimmunoelectrophoresis B727 PAThology B727 Counterimmunoelectrophoresis B727 PAThology B727 Counterimmunoelectrophoresis B727 PAThology B727 Counterimmunoelectrophoresis B727 PAThology B727 Counterimmunoelectrophoresis B727 PAThology B727		CP1/HCPCS Code Description	1	RVUs	
86156 Cold agglutinin, stereen Pathology 0.34 86160 Cod agglutinin, stere Pathology 0.62 86161 Complement, antigen Pathology 0.62 86162 Complement, total (CH50) Pathology 0.62 86171 Complement fixation, each six Pathology 1.04 86181 Counterimmunoelectrophoresis Pathology 0.61 86223 DNA antibody Pathology 0.62 86224 DNA antibody Pathology 0.62 86225 DNA antibody Pathology 0.62 86226 BOXA Pathology 0.62 86226 For coceptor Pathology 0.62 86256 Fluorescent antibody, screen Pathology 0.62 86276 Fluorescent antibody, screen Pathology 0.62 86280 Hemsglutination inhibition Pathology 0.42 Immunoassay, tumor ca 15-3 Pathology 0.42 Basantia Pathology 1.07 86301	Code		Category		ology
86156 Cold agglutinin, stereen Pathology 0.34 86160 Cod agglutinin, stere Pathology 0.62 86161 Complement, antigen Pathology 0.62 86162 Complement, total (CH50) Pathology 0.62 86171 Complement fixation, each six Pathology 1.04 86181 Counterimmunoelectrophoresis Pathology 0.61 86223 DNA antibody Pathology 0.62 86224 DNA antibody Pathology 0.62 86225 DNA antibody Pathology 0.62 86226 BOXA Pathology 0.62 86226 For coceptor Pathology 0.62 86256 Fluorescent antibody, screen Pathology 0.62 86276 Fluorescent antibody, screen Pathology 0.62 86280 Hemsglutination inhibition Pathology 0.42 Immunoassay, tumor ca 15-3 Pathology 0.42 Basantia Pathology 1.07 86301					
86157 Cold agiplutinin, titer Pathology 0.41 86161 Complement/function activity Pathology 0.62 86161 Complement total (CH50) Pathology 0.62 86171 Complement total (CH50) Pathology 0.51 86185 Counterimmunoelectrophoresis Pathology 0.51 86215 Deoxyribonuclease, antibody Pathology 0.68 86226 DNA antibody, single strand Pathology 0.52 86235 DNA antibody, single strand Pathology 0.52 86245 F. creceptor Pathology 0.52 86255 F. creceptor Pathology 1.02 86280 Growth hormone antibody Pathology 0.62 86294 Hemagulutination inhibition Pathology 0.61 86294 Immunoassay, tumor ca 19-9 Pathology 1.07 86301 Immunoassay, tumor ca 19-9 Pathology 0.27 86303 Heterophile antibodies Pathology 0.27 86301 Heterophile					
86160 Complement, antigen Pathology 0.62 86161 Complement, total (CH50) Pathology 0.62 86171 Complement fixation, each Pathology 0.51 86171 Complement fixation, each Pathology 0.51 86215 Deoxyribonuclease, antibody Pathology 0.68 86225 DNA antibody Pathology 0.62 86235 DNA antibody Pathology 0.62 86235 Nuclear antiped antibody Pathology 0.52 86236 Forecptor Pathology 1.05 86236 Fluorescent antibody, screen Pathology 1.05 86236 Fluorescent antibody, streen Pathology 0.62 86237 Fluorescent antibody, streen Pathology 0.62 86227 Growth hormone antibody Pathology 0.62 86280 Hemagulturation inhibition Pathology 0.42 86294 Immunoassay, tumor cat 15-3 Pathology 0.10 86304 Immunoassay, tumor cat 15-3<					
86161 Complement/function activity Pathology 0.62 86171 Complement fixation, each Pathology 0.51 86185 Counterimmunoelectrophoresis Pathology 0.46 86215 Deoxyribonuclease, antibody Pathology 0.68 86226 DNA antibody single strand Pathology 0.71 86227 DNA antibody Pathology 0.92 86235 For receptor Pathology 0.92 Furorescent antibody, screen Pathology 0.62 Fluorescent antibody, streen Pathology 0.62 Fluorescent antibody, screen Pathology 0.62 Fluorescent antibody, screen Pathology 0.61 Fluorescent antibody screen Pathology 0.61 Fluorescent antibody screen Pathology 0.61 Fluorescent antibody screen					
86162 Complement (rotal (CH50) Pathology 0.51 86181 Counterimmunoelectrophoresis Pathology 0.51 86185 Counterimmunoelectrophoresis Pathology 0.68 86225 DNA antibody Pathology 0.68 86226 DNA antibody Pathology 0.62 86226 Nuclear antiped antibody Pathology 0.62 86236 Nuclear antiped antibody Pathology 0.62 86236 Nuclear antiped of Pathology 0.62 86237 Pathology 0.62 86236 Pluorescent antibody stere Pathology 0.62 86236 Pluorescent antibody stere Pathology 0.62 86237 Pluorescent antibody stere Pathology 0.62 86237 Pluorescent antibody Pathology 0.62 86238 Pluorescent antibody Pathology 0.62 86239 Pluorescent antibody Pathology 0.62 86230 Pluorescent antibody Pathology 0.62 86230 Pluorescent antibody Pathology 0.62 86230 Pluorescent antibody Pathology 0.62 86230 Pluorescent antibody Pathology 0.62 86230 Pluorescent antibody 0.62 86230 Pluorescent antibody 0.62 86230 Pluorescent antibody 0.62 86230 Pluorescent 0.62 86231 Pluorescent 0.62 86231 Pluorescent 0.62 86231 Pluorescent 0.62 86232 Pluorescent 0.62 86233 Pluorescent 0.62 86234 Pluorescent 0.62 86235 Pluorescent 0.62 86230 Pluorescent 0.62 86230 Pluorescent 0.62 86230 Pluorescent 0.62 86230 Pluorescent 0.62 86230 Pluorescent 0.62 86230 Pluorescent 0.62 86231 Pluorescent 0.62 86232 Pluorescent 0.62 86232 Pluorescent 0.62 86233 Pluorescent 0.62 86234 Pluorescent 0.62 86235 Pluorescent					
88171 Complement fixation, each Pathology 0.46 86215 Beoxyribonuclease, antibody Pathology 0.46 86226 Deoxyribonuclease, antibody Pathology 0.71 86226 DNA antibody Pathology 0.71 86235 Secaso Pathology 0.92 86243 F. receptor Pathology 0.62 86256 Fluorescent antibody, screen Pathology 0.62 86277 Fluorescent antibody, titer Pathology 0.62 86280 Hemagglutination inhibition Pathology 0.81 86280 Immunoassay, tumor cal 3 Pathology 1.01 86300 Immunoassay, tumor cal 19-9 Pathology 1.07 86301 Immunoassay, tumor cal 19-9 Pathology 1.07 86302 Heterophile antibodies Pathology 0.27 86303 Heterophile antibodies Pathology 0.33 86316 Immunoassay, infectious agent Pathology 0.07 80317 Serum immunoelectrophore					
86185 Counterimmunoelectrophoresis Pathology 0.68 80215 Deoxyribonuclease, antibody Pathology 0.68 80225 DNA antibody single strand Nuclear antigen antibody Pathology 0.62 Nuclear antigen antibody Pathology 0.62 Nuclear antigen antibody Pathology 0.62 Nuclear antigen antibody Pathology 0.62 Nuclear antigen antibody Pathology 0.62 Pathology 0.62 Filuorescent antibody, screen Pathology 0.62 Filuorescent antibody, titer Pathology 0.62 Growth hormone antibody Pathology 0.62 Hemagglutination inhibition Pathology 0.81 Immunoassay, tumor qual Pathology 0.81 Immunoassay, tumor qual Pathology 1.01 Immunoassay, tumor ca 15-3 Pathology 1.07 Immunoassay, tumor ca 15-3 Pathology 1.07 Immunoassay, tumor ca 15-3 Pathology 1.07 Immunoassay, tumor ca 15-3 Pathology 1.07 Immunoassay, tumor ca 15-3 Pathology 1.07 Immunoassay, tumor ca 15-3 Pathology 0.27 Heterophile antibodies Pathology 0.33 Heterophile antibodies Pathology 0.33 Heterophile antibodies Pathology 0.38 Immunoassay, infectious agent Pathology 0.38 Immunoassay, infectious agent Pathology 0.77 Immunoassay, infectious agent Pathology 0.77 Immunoassay, infectious agent Pathology 0.76 Sa325 Other immunoelectrophoresis Pathology 1.15 Other immunoelectrophoresis Pathology 1.15 Immunoassay, infectious agent Pathology 1.15 Other immunoelectrophoresis Pathology 1.15 Immunocalifusion oucherlory Pathology 0.72 Immunocalifusion oucherlory Pathology 0.72 Immunocalifusion oucherlory Pathology 0.72 Immunocalifusion Pathology 0.75 Immunocalifusion Pathology 0.77 Immunocalifusion oucherlory Pathology 0.75 Immunocalifusion oucherlory Pathology 0.77 Immunocalifusion oucherlory Pathology 0.77 Immunocalifusion oucherlory Pathology 0.77 Immunocalifusion oucherlory Pathology 0.77 Immunocalifusion oucherlory Pathology 0.77 Immunocalifusion oucherlory Pathology 0.77 Immunocalifusion oucherlory 0.77 Pathology 0.77 Immunocalifusion oucherlory 0.77 Pathology 0.77 Immunocalifusion oucherlory 0.77 Pathology 0.78 Pathology 0.78 Pathology 0.78 Pathology 0.78 Pathology 0.78 Pathology 0.79 Pathology 0					
88215 Deoxyribonuclease, antibody Pathology 0.68 88226 DNA antibody Pathology 0.71 88226 Mona antibody, single strand Pathology 0.92 86243 Fc receptor Pathology 0.92 86255 Fluorescent antibody, screen Pathology 0.62 86256 Fluorescent antibody, titer Pathology 0.81 86280 Hemagglutination inhibition Pathology 0.81 186280 Immunoassay, tumor can 15-3 Pathology 1.01 186300 Immunoassay, tumor can 19-9 Pathology 1.07 186304 Immunoassay, tumor can 19-9 Pathology 1.07 186308 Heterophile antibodies Pathology 0.27 186318 Heterophile antibodies Pathology 0.38 185318 Immunoassay, infectious agent Pathology 0.77 185318 Pathology 0.77 185325 Pathology 1.05 185327 Pathology 1.15 185328 <td></td> <td></td> <td></td> <td></td> <td></td>					
88225 DNA antibody, single strand Pathology 0.71 86226 Rec235 Nuclear antigen antibody 0.62 86235 Fluorescent antibody, screen Pathology 1.05 86256 Fluorescent antibody, screen Pathology 0.62 86257 Fluorescent antibody, titer Pathology 0.62 86280 Hemsgalutination inhibition Pathology 0.81 86281 Immunoassay, tumor cat 15-3 Pathology 1.01 86301 Immunoassay, tumor cat 15-9 Pathology 1.07 86308 Heterophile antibodies Pathology 1.07 86309 Heterophile antibodies Pathology 0.27 86310 Immunoassay, intectious agent Pathology 0.33 86311 Immunoassay, intectious agent Pathology 0.33 86312 Immunoassay, infectious agent Pathology 0.77 86318 Immunodiffusion Pathology 0.77 86320 Serum immunodiffusion Pathology 1.16 86327 <td></td> <td></td> <td></td> <td></td> <td></td>					
86226 DNA antibody, single strand Pathology 0.62 86243 Fc receptor Pathology 1.05 86256 Fluorescent antibody, screen Pathology 0.62 86256 Fluorescent antibody, titer Pathology 0.62 86276 Growth hormone antibody Pathology 0.81 86280 Hemagolutination inhibition Pathology 0.42 86280 Immunoassay, tumor cat 15-3 Pathology 1.07 86301 Immunoassay, tumor cat 12-9 Pathology 1.07 86304 Immunoassay, tumor cat 125 Pathology 1.07 86309 Heterophile antibodies Pathology 0.33 86311 Immunoassay, infectious agent Pathology 0.77 86318 Immunoassay, infectious agent Pathology 0.76 86320 Other immunoelectrophoresis Pathology 1.06 86321 Immunodiffusion Pathology 1.07 86318 Immunodiffusion Pathology 1.07 86325 Other					
88235 Nuclear antigen antibody Pathology 0.92 88245 Fc receptor Pathology 1.05 88255 Fluorescent antibody, titer Pathology 0.62 86277 Growth hormone antibody Pathology 0.81 86280 Hemsgollutination inhibition Pathology 0.42 86301 Immunoassay, tumor can 15-3 Pathology 1.01 86301 Immunoassay, tumor can 15-3 Pathology 1.07 86308 Helerophile antibodies Pathology 1.07 86309 Helterophile antibodies Pathology 0.27 86310 Helterophile antibodies Pathology 0.27 86311 Helterophile antibodies Pathology 0.33 86316 Immunoassay, infectious agent Pathology 0.77 86317 Immunoassay, infectious agent Pathology 0.77 86318 Immunodiffusion Pathology 0.77 86320 Serum immunoelectrophoresis Pathology 1.15 86321 Immunof					
88243 Fc receptor Pathology 0.62 86256 Fluorescent antibody, titer Pathology 0.62 862756 Fluorescent antibody, titer Pathology 0.62 86280 Hemmoresay, tumor can 16-3 Pathology 0.42 86280 Immunoassay, tumor can 15-3 Pathology 1.07 86300 Immunoassay, tumor can 19-9 Pathology 1.07 86304 Immunoassay, tumor can 125 Pathology 1.07 86309 Heterophile antibodies Pathology 0.27 86316 Immunoassay, intectious agent Pathology 0.77 86318 Immunoassay, intectious agent Pathology 0.77 86318 Immunoassay, intectious agent Pathology 1.07 86320 Serum immunoelectrophoresis Pathology 1.15 86321 Immunodiffusion Pathology 1.07 86328 Immunoelectrophoresis sasay Pathology 1.15 86329 Immunodiffusion outheriony Pathology 0.72 86331	86235	Nuclear antigen antibody		0.92	
86256 Fluorescent antibody, itler Pathology 0.62 86270 Growth hormone antibody Pathology 0.42 86280 Hemagglutination inhibition Pathology 0.42 86301 Immunoassay, tumor ca 15-3 Pathology 1.07 86302 Immunoassay, tumor ca 15-3 Pathology 1.07 86303 Immunoassay, tumor, ca 125 Pathology 0.27 86304 Heterophile antibodies Pathology 0.27 86305 Heterophile antibodies Pathology 0.33 86310 Heterophile antibodies Pathology 0.33 86311 Immunoassay, infectious agent Pathology 0.77 86317 Immunoassay, infectious agent Pathology 0.77 86327 Immunoalectrophoresis Pathology 1.15 86327 Immunodiffusion Pathology 1.16 86331 Immunodiffusion ouchterlory Pathology 0.62 86332 Immunodiffusion Pathology 0.62 863331 Immunof	86243			1.05	
86277 Growth hormone antibody Pathology 0.81 86284 Hemaguluriation inhibition Pathology 1.01 86301 Immunoassay, tumor ca 15-3 Pathology 1.07 86301 Immunoassay, tumor ca 19-9 Pathology 1.07 86304 Immunoassay, tumor ca 125 Pathology 1.07 86309 Heterophile antibodies Pathology 0.33 86316 Heterophile antibodies Pathology 0.33 86317 Immunoassay, infectious agent Pathology 0.07 86318 Immunoassay, infectious agent Pathology 0.66 86320 Cher immunoelectrophoresis Pathology 0.66 86321 Immunoelectrophoresis Pathology 0.60 86322 Immunoelectrophoresis assay Pathology 0.72 86323 Immunoelectrophoresis assay Pathology 0.72 86331 Immunodiffusion ouchteriony Pathology 0.72 86332 Immunofitisoin ouchteriony Pathology 0.72 86333<	86255	Fluorescent antibody, screen	Pathology	0.62	
86280 Hemagqlutination inhibition Pathology 0.42 86294 Immunoassay, tumor ca 15-3 Pathology 1.07 86301 Immunoassay, tumor ca 19-9 Pathology 1.07 86308 Immunoassay, tumor ca 19-9 Pathology 0.27 86308 Heterophile antibodies Pathology 0.23 86310 Heterophile antibodies Pathology 0.33 86317 Immunoassay, infectious agent Pathology 0.77 86318 Immunoassay, infectious agent Pathology 0.77 86319 Immunoalectrophoresis Pathology 0.77 86310 Immunoalectrophoresis Pathology 0.77 86311 Immunoalectrophoresis Pathology 1.15 86320 Serum immunoelectrophoresis Pathology 1.15 86321 Immunodiffusion Pathology 1.16 86322 Immunodiffusion ouchterlony Pathology 1.16 86323 Immunoffusion ouchterlony Pathology 1.25 86321 I		Fluorescent antibody, titer	Pathology		
86294 Immunoassay, tumor qual Pathology 1.01 86301 Immunoassay, tumor ca 15-3 Pathology 1.07 86308 Immunoassay, tumor ca 19-9 Pathology 1.07 86308 Heterophile antibodies Pathology 0.27 86309 Heterophile antibodies Pathology 0.33 86316 Immunoassay, tumor other Pathology 1.07 86317 Immunoassay, infectious agent Pathology 1.07 86318 Immunoassay, infectious agent Pathology 0.07 86320 Cother immunoelectrophoresis Pathology 0.15 86321 Immunoelectrophoresis assay Pathology 1.15 86322 Immunoelectrophoresis assay Pathology 0.72 86331 Immunoelectrophoresis assay Pathology 0.72 86332 Immunoelectrophoresis assay Pathology 0.72 86333 Immunofiffusion ouchterlony Pathology 0.72 86334 Islanda Pathology 1.25 86335					
86300 Immunoassay, tumor ca 15-3 Pathology 1.07 86304 Immunoassay, tumor, ca 125 Pathology 1.07 86308 Heterophile antibodies Pathology 0.27 86309 Heterophile antibodies Pathology 0.33 86310 Heterophile antibodies Pathology 0.33 86317 Immunoassay, infectious agent Pathology 0.77 86318 Immunoassay, infectious agent Pathology 0.72 86319 Immunoassay, infectious agent Pathology 0.72 86311 Immunoassay, infectious agent Pathology 0.66 86320 Serum immunoelectrophoresis Pathology 1.15 86321 Immunodiffusion Pathology 1.15 86322 Immunodiffusion ouchterlony Pathology 0.62 86331 Immunodiffusion ouchterlony Pathology 0.62 86332 Immunodiffusion ouchterlony Pathology 1.15 863331 Immunofisation procedure Pathology 1.25 86334<					
86301 Immunoassay, tumor ca 19-9 Pathology 1.07 86308 Heterophile antibodies Pathology 0.27 86309 Heterophile antibodies Pathology 0.33 86310 Heterophile antibodies Pathology 0.33 86311 Immunoassay, infectious agent Pathology 0.07 86318 Immunoassay, infectious agent Pathology 0.06 86321 Serum immunoelectrophoresis Pathology 0.06 86325 Other immunoelectrophoresis Pathology 1.15 86327 Immunodiffusion ouchterlony Pathology 1.16 86329 Immunodiffusion ouchterlony Pathology 0.72 86331 Immunodiffusion ouchterlony Pathology 1.15 86332 Immunodiffusion ouchterlony Pathology 1.25 863331 Immunodiffusion ouchterlony Pathology 1.15 86334 Intrinsic factor antibody Pathology 1.17 86341 Islandia antibody Pathology 1.07 86341<					
86304 Immunoassay, tumor, ca 125 Pathology 1.07 86309 Heterophile antibodies Pathology 0.33 86310 Heterophile antibodies Pathology 0.33 86317 Immunoassay, infectious agent Pathology 0.77 86318 Immunoassay, infectious agent Pathology 0.77 86311 Immunoassay, infectious agent Pathology 0.76 86320 Serum immunoelectrophoresis Pathology 1.15 86321 Immunoelectrophoresis Pathology 1.15 86327 Immunoelffusion ouchterlony Pathology 1.16 863287 Immunodiffusion ouchterlony Pathology 0.72 86331 Immunodiffusion ouchterlony Pathology 1.25 863331 Immunofixation procedure Pathology 1.25 863343 Inhibin A Pathology 1.15 86336 Inhibin A Pathology 0.77 86341 Leukocyte histamine release Pathology 0.77 86343 Leukocy					
86308 Heterophile antibodies Pathology 0.27 86310 Heterophile antibodies Pathology 0.33 86316 Immunoassay, tumor other Pathology 0.35 86317 Immunoassay, infectious agent Pathology 0.66 86328 Derum immunoelectrophoresis Pathology 0.66 86329 Serum immunoelectrophoresis Pathology 1.15 86321 Immunodiffusion Pathology 1.16 86322 Immunodiffusion ouchterlony Pathology 0.72 86331 Immunodiffusion ouchterlony Pathology 0.72 86332 Immunodiffusion ouchterlony Pathology 1.25 86333 Immunodiffusion ouchterlony Pathology 1.25 86334 Immunofixation procedure Pathology 1.25 86337 Insilia antibodies Pathology 1.11 86341 Isle toell antibody Pathology 1.02 86342 Leukocyte phagocytosis Pathology 0.41 86359 Toell, a					
86309 Heterophile antibodies Pathology 0.33 86310 Heterophile antibodies Pathology 0.38 86317 Immunoassay, infectious agent Pathology 0.77 86318 Immunoassay, infectious agent Pathology 0.66 86320 Serum immunoelectrophoresis Pathology 1.15 86327 Immunodiffusion Pathology 1.16 86331 Immunodiffusion ouchterlony Pathology 0.72 86331 Immunodiffusion ouchterlony Pathology 0.62 Immunodiffusion Pathology 1.15 Immunodiffusion Pathology 1.15 Immunodiffusion Pathology 1.10					
86310 Heterophile antibodies Pathology 0.38 86316 Immunoassay, tumor other Pathology 0.77 86317 Immunoassay, infectious agent Pathology 0.66 86320 Serum immunoelectrophoresis Pathology 0.66 86325 Other immunoelectrophoresis Pathology 1.15 86327 Immunodiffusion Pathology 1.16 86329 Immunodiffusion Pathology 0.72 86331 Immunodiffusion ouchterlony Pathology 1.25 86332 Immunofixation procedure Pathology 1.25 Immunofixation procedure Pathology 1.25 Immunofixation procedure Pathology 0.80 Intrinsic factor antibody Pathology 0.77 86334 Intrinsic factor antibody Pathology 0.77 86341 Intrinsic factor antibody Pathology 0.77 86342 Leukocyte histamine release Pathology 0.41 86353 Lymphocyte transformation Pathology 2.52 86353 Toell, absolute countration Pathology <td></td> <td></td> <td></td> <td></td> <td></td>					
86316 Immunoassay, tumor other Pathology 1.07 86317 Immunoassay, infectious agent Pathology 0.66 86320 Serum immunoelectrophoresis Pathology 1.15 86327 Other immunoelectrophoresis assay Pathology 1.16 86329 Immunodiffusion Pathology 0.72 86331 Immunodiffusion ouchterlony Pathology 0.62 86332 Immunofixation procedure Pathology 0.62 Immuno complex assay Pathology 1.25 86334 Immunofixation procedure Pathology 1.15 Inibin A Pathology 1.10 86337 Insulin antibodies Pathology 1.10 86340 Intrinsic factor antibody Pathology 0.77 86341 Islet cell antibody Pathology 0.77 86343 Islet cell antibody Pathology 0.77 86343 Leukocyte histamine release Pathology 0.41 46334 Levicocyte histamine release Pathology 0.41 86353 Lymphocyte transformation Pathology <td></td> <td></td> <td></td> <td></td> <td></td>					
Immunoassay_infectious agent					
86318 Immunoassay infectious agent Pathology 0.66 86320 Serum immunoelectrophoresis Pathology 1.15 86327 Immunodiffusion Pathology 1.15 86329 Immunodiffusion ouchteriony Pathology 0.72 86331 Immunodiffusion ouchteriony Pathology 0.62 86332 Immune complex assay Pathology 1.15 863331 Insulin antibodies Pathology 1.15 86334 Inhibin A Pathology 1.15 86337 Insulin antibodies Pathology 1.10 86340 Intrinsic factor antibody Pathology 0.77 86341 Iselt cell antibody Pathology 0.64 86342 Leukocyte phagocytosis Pathology 0.64 86343 Leukocyte phagocytosis Pathology 2.52 86359 T cell, absolute count/ratio Pathology 2.52 86359 T cell, absolute count/ratio Pathology 2.41 86376 Microsomal antibody					
Serum immunoelectrophoresis					
86325 Other immunoelectrophoresis Pathology 1.15 86327 Immunoelectrophoresis assay Pathology 0.72 86331 Immunodiffusion ouchterlony Pathology 0.62 86332 Immunoelectrophoresis assay Pathology 0.62 86331 Immunofixation procedure Pathology 1.25 86334 Inhibin A Pathology 0.80 86337 Insulin antibodies Pathology 0.77 86340 Intrinsic factor antibody Pathology 0.77 86341 Isle cell antibody Pathology 0.64 86342 Leukocyte histamine release Pathology 0.64 86343 Leukocyte phagocytosis Pathology 0.64 86354 Leukocyte phagocytosis Pathology 0.64 86355 Lymphocyte transformation Pathology 0.52 86360 T cell, absolute count/ratio Pathology 1.94 86371 Microsomal antibody Pathology 0.75 86372 Microsomal antibody Pathology 0.75 86381 Nitroblue tetrazollum dye Pathology 0.58 86382 Nautralization test, viral Pathology 0.58 86403					
Immunodiffusion Pathology 0.72 Resiliation Resiliation Pathology 0.62 Resiliation				1.15	
Be331 Immunodiffusion ouchterlony Pathology Description Pathology Description Descript	86327	Immunoelectrophoresis assay	Pathology	1.16	
Immune complex assay Pathology 1.25 86334 Immunofixation procedure Pathology 1.15 86336 Inhibin A Pathology 0.80 86337 Insulin antibodies Pathology 0.80 1.10 Pathology 0.77 86341 Istet cell antibody Pathology 0.77 86341 Istet cell antibody Pathology 0.64 86343 Leukocyte histamine release Pathology 0.64 86344 Leukocyte phagocytosis Pathology 0.64 86355 Lymphocyte transformation Pathology 0.41 86351 Toells, total count Pathology 0.41 86360 Toell, absolute count/ratio Pathology 0.41 86361 Toell, absolute count/ratio Pathology 0.75 86376 Microsomal antibody Pathology 0.75 86378 Migration inhibitory factor Pathology 0.75 86382 Nitroblue tetrazolium dye Pathology 0.58 86403 Particle agglutination test Pathology 0.55 86406 Particle agglutination test Pathology 0.55 86430 Rheumatoid factor (puant Pathology 0.55 86431 Rheumatoid factor (puant Pathology 0.29 86481 Rheumatoid factor (puant Pathology 0.29 86485 Skin test, candida Pathology 0.30 MDR 86590 Streptokinase, antibody Pathology 0.22 86693 Blood serology, qualitative Pathology 0.22 86600 Aspergillus antibody Pathology 0.66 86606 Aspergillus antibody Pathology 0.66 86611 Bartonella antibody Pathology 0.66 86612 Blastomyces antibody Pathology 0.66 86615 Bordetella antibody Pathology 0.68 86616 Bordetella antibody Pathology 0.69 86618 Bordetella antibody Pathology 0.69 86618 Bordetella antibody Pathology 0.69 86618 Bordetella antibody Pathology 0.69 86618 Bordetella antibody Pathology 0.69 86622 Brucella antibody Pathology 0.69 86622 Brucella antibody Pathology 0.69 Pathology 0.69 Pathology 0.69 Pathology 0.69 Pathology 0.69 Pathology 0.69 Pathology 0.69 Pathology 0.69 Pathology 0.69 Pathology 0.69 Pathology 0.69 Pathology 0.69 Pathology 0	86329	Immunodiffusion	Pathology		
Immunofixation procedure					
Be336					
Insulin antibodies					
Second Color			1 _ '''		
Islet cell antibody					
86343Leukocyte histamine releasePathology0.6486344Leukocyte phagocytosisPathology0.4186353Lymphocyte transformationPathology2.5286359T cells, total countPathology1.9486360T cell, absolute count/ratioPathology2.4186361T cell, absolute countPathology0.7586376Microsomal antibodyPathology0.7586378Migration inhibitory factorPathology0.8786382Neutralization test, viralPathology0.5286403Particle agglutination testPathology0.5286406Particle agglutination testPathology0.5586430Rheumatoid factor testPathology0.2986485Skin test, candidaPathology0.2986485Skin test, unlistedPathology0.3086590Streptokinase, antibodyPathology0.2286592Blood serology, quantitativePathology0.2286593Blood serology, quantitativePathology0.2286600Aspergillus antibodyPathology0.5286601Bartonella antibodyPathology0.5286602Blastomyces antibodyPathology0.6686615Bordetella antibodyPathology0.6686616Bordetella antibodyPathology0.6686617Lyme disease antibodyPathology0.6986618Lyme disease antibodyPathology </td <td></td> <td></td> <td></td> <td></td> <td></td>					
Re344 Leukocyte phagocytosis Re353 Lymphocyte transformation Read Section 1 Cells, total count Read Section 2 Cells, absolute count Read Section 3 Cells, absolute count Read Section 3 Cells, absolute count Read Section 3 Cells, absolute count Read Section 3 Cells, absolute count Read Section 3 Cells, absolute count Read Section 3 Cells, absolute count Read Section 3 Cells, absolute count Read Section 3 Cells, absolute count Read Section 3 Cells, absolute count Read Section 4 Cells, absolute count Read Section 4 Cells, absolute count Read Section 4 Cells, absolute count Read Section 4 Cells, absolute count Read Section 4 Cells, absolute count Read Section 4 Cells, absolute count Read Section 4 Cells, absolute count Read Section 4 Cells, absolute count Read Section 4 Cells, absolute count Read Section 4 Cells, absolute count Read Section 4 Cells, absolute count Read Section 4 Cells, absolute count Read Section 4 Cells, absolute count Read Section 4 Cells, absolute count Read Section 4 Cells, absolute count Read Section 4 Cells, absolute count Read Section 4 Cells, absolute 6 Cells, absolute 6 Cells, absolute 6 Cells, absolute 6 Cells, absolute 6 Cells, absolute 6 Cells, absolute 7 Cells, absolute 6 Cells, absolute 7 Ce					
86353Lymphocyte transformationPathology2.5286359T cells, total countPathology1.9486360T cell, absolute countPathology2.4186361T cell, absolute countPathology1.3786376Microsomal antibodyPathology0.7586378Migration inhibitory factorPathology1.0186382Neutralization test, viralPathology0.5786384Nitroblue tetrazolium dyePathology0.5886403Particle agglutination testPathology0.5586406Particle agglutination testPathology0.5586430Rheumatoid factor testPathology0.2986431Rheumatoid factor, quantPathology0.2986485Skin test, candidaPathology0.3086590Streptokinase, antibodyPathology0.5786592Blood serology, qualitativePathology0.2286593Blood serology, qualitativePathology0.2286602Antinomyces antibodyPathology0.5286603Adenovirus antibodyPathology0.5286604Aspergillus antibodyPathology0.6686611Bartonella antibodyPathology0.6686615Bordetella antibodyPathology0.6686616Borrelia antibodyPathology0.6786618Lyme disease antibodyPathology0.6986622Brucella antibodyPathology0.69 <td></td> <td></td> <td></td> <td></td> <td>•</td>					•
86359T cells, total countPathology1.9486360T cell, absolute count/ratioPathology2.4186361T cell, absolute countPathology2.4186376Microsomal antibodyPathology0.7586378Migration inhibitory factorPathology0.7586381Neutralization test, viralPathology0.8786382Nitroblue tetrazolium dyePathology0.5886403Particle agglutination testPathology0.5286404Particle agglutination testPathology0.5586430Rheumatoid factor festPathology0.2986431Rheumatoid factor quantPathology0.2986485Skin test, candidaPathology0.3086586Skin test, unlistedPathology0.3086592Blood serology, qualitativePathology0.5786593Blood serology, quantitativePathology0.2286602Antinomyces antibodyPathology0.5286606Aspergillus antibodyPathology0.5686601Bartonella antibodyPathology0.5686615Bordetella antibodyPathology0.5286618Lyme disease antibodyPathology0.6886619Borrelia antibodyPathology0.6986620Brucella antibodyPathology0.6986622Brucella antibodyPathology0.69					
86360T cell, absolute count/ratioPathology2.4186361T cell, absolute countPathology1.3786376Microsomal antibodyPathology0.7586378Migration inhibitory factorPathology1.0186382Neutralization test, viralPathology0.8786384Nitroblue tetrazolium dyePathology0.5886403Particle agglutination testPathology0.5286406Particle agglutination testPathology0.5586430Rheumatoid factor testPathology0.2986431Rheumatoid factor, quantPathology0.2986485Skin test, candidaPathology0.3086590Streptokinase, antibodyPathology0.5786592Blood serology, qualitativePathology0.2286593Blood serology, quantitativePathology0.2386602Antinomyces antibodyPathology0.5286603Aspergillus antibodyPathology0.6686604Bacterium antibodyPathology0.6686615Bartonella antibodyPathology0.5286616Bordetella antibodyPathology0.6886617Lyme disease antibodyPathology0.7986618Borrelia antibodyPathology0.6986620Brucella antibodyPathology0.6986620Brucella antibodyPathology0.69					
86376Microsomal antibodyPathology0.7586378Migration inhibitory factorPathology1.0186382Neutralization test, viralPathology0.8786384Nitroblue tetrazolium dyePathology0.5886403Particle agglutination testPathology0.5286406Particle agglutination testPathology0.5986431Rheumatoid factor, quantPathology0.2986485Skin test, candidaPathology0.3086586Skin test, unlistedPathology0.3086592Blood serology, qualitativePathology0.2286593Blood serology, qualitativePathology0.2386602Antinomyces antibodyPathology0.5286603Adenovirus antibodyPathology0.5286606Aspergillus antibodyPathology0.6686611Bartonella antibodyPathology0.5286612Blastomyces antibodyPathology0.5286615Bordetella antibodyPathology0.6686617Lyme disease antibodyPathology0.6886619Borrelia antibodyPathology0.6986620Brucella antibodyPathology0.6986622Brucella antibodyPathology0.6986622Brucella antibodyPathology0.69	86360			2.41	
86378Migration inhibitory factorPathology1.0186382Neutralization test, viralPathology0.8786384Nitroblue tetrazolium dyePathology0.5886403Particle agglutination testPathology0.5286406Particle agglutination testPathology0.5586430Rheumatoid factor testPathology0.2986431Rheumatoid factor, quantPathology0.3086586Skin test, candidaPathology0.3086586Skin test, unlistedPathology0.5786592Blood serology, qualitativePathology0.5286593Blood serology, quantitativePathology0.2386602Antinomyces antibodyPathology0.5286603Adenovirus antibodyPathology0.5286604Aspergillus antibodyPathology0.6686611Bartonella antibodyPathology0.5286612Blastomyces antibodyPathology0.5286615Bordetella antibodyPathology0.6686617Lyme disease antibodyPathology0.6886619Borrelia antibodyPathology0.6786619Borrelia antibodyPathology0.6986620Brucella antibodyPathology0.6986621Brucella antibodyPathology0.69	86361	T cell, absolute count	Pathology	1.37	
86382 86384Neutralization test, viral Nitroblue tetrazolium dye Particle agglutination test Particle agglutination test Particle agglutination test Particle agglutination test Particle agglutination test Parthology Parthology Patho		Microsomal antibody	Pathology	0.75	
86384 86403Nitroblue tetrazollum dye Particle agglutination test Particle agglutination test Particle agglutination test Rheumatoid factor test Rheumatoid factor quant Rheumatoid factor, quant Rheumatoid factor, quant Skin test, candida Skin test, candida Skin test, unlisted Streptokinase, antibody Blood serology, qualitative R6592 Blood serology, quantitative Adenovirus antibody R6603 R6606 R6604 R6615 R6615 R6617 R6619 R6619 R6619 R6619 R6619 R6619 R6619 R6619 R6619 R6619 R6619 R6619 R6619 R6619 R6619 R6611 R6619 R6612 R6612 R6612 R6613 R6613 R6614 R6615 R6615 R6616 R6616 R6616 R6617 R6619 R6619 R6619 R6619 R6619 R6619 R6610 R6610 R6611 R6611 R6612 R6612 R6613 R6613 R6614 R6614 R6615 R6615 R6615 R6616 R6616 R6616 R6617 R6619 R6618 R6619 R6619 R6619 R6619 R6610 					
86403 Particle agglutination test Pathology 0.52 86406 Particle agglutination test Pathology 0.55 86430 Rheumatoid factor test Pathology 0.29 86431 Rheumatoid factor, quant Pathology 0.29 86485 Skin test, candida Pathology 0.30 MDR 86586 Skin test, unlisted Pathology 0.30 MDR 86590 Streptokinase, antibody Pathology 0.57 86592 Blood serology, qualitative Pathology 0.22 86593 Blood serology, quantitative Pathology 0.23 86602 Antinomyces antibody Pathology 0.52 86603 Adenovirus antibody Pathology 0.66 86606 Aspergillus antibody Pathology 0.77 86609 Bacterium antibody Pathology 0.52 86611 Bartonella antibody Pathology 0.66 86615 Bordetella antibody Pathology 0.68 86617					
86406 Particle agglutination test Pathology 0.55 86430 Rheumatoid factor test Pathology 0.29 86431 Rheumatoid factor, quant Pathology 0.29 86485 Skin test, candida Pathology 0.30 MDR 86586 Skin test, unlisted Pathology 0.30 MDR 86590 Streptokinase, antibody Pathology 0.57 86592 Blood serology, qualitative Pathology 0.22 86593 Blood serology, quantitative Pathology 0.23 86602 Antinomyces antibody Pathology 0.52 86603 Adenovirus antibody Pathology 0.66 86606 Aspergillus antibody Pathology 0.66 86611 Bartonella antibody Pathology 0.52 86612 Blastomyces antibody Pathology 0.68 86615 Bordetella antibody Pathology 0.68 86617 Lyme disease antibody Pathology 0.68 86619 <					
86430 Rheumatoid factor test Pathology 0.29 86431 Rheumatoid factor, quant Pathology 0.29 86485 Skin test, candida Pathology 0.30 86586 Skin test, unlisted Pathology 0.30 86590 Streptokinase, antibody Pathology 0.57 86592 Blood serology, qualitative Pathology 0.22 86593 Blood serology, quantitative Pathology 0.23 86602 Antinomyces antibody Pathology 0.52 86603 Adenovirus antibody Pathology 0.66 86604 Aspergillus antibody Pathology 0.77 86609 Bacterium antibody Pathology 0.52 86611 Blastomyces antibody Pathology 0.52 86612 Blastomyces antibody Pathology 0.66 86615 Bordetella antibody Pathology 0.68 86617 Lyme disease antibody Pathology 0.79 86619 Borrelia antibody Pathology <td></td> <td></td> <td></td> <td></td> <td></td>					
86431 Rheumatoid factor, quant Pathology 0.29 86485 Skin test, candida Pathology 0.30 86586 Skin test, unlisted Pathology 0.30 86590 Streptokinase, antibody Pathology 0.57 86592 Blood serology, qualitative Pathology 0.22 86593 Blood serology, quantitative Pathology 0.23 86602 Antinomyces antibody Pathology 0.52 86603 Adenovirus antibody Pathology 0.66 86606 Aspergillus antibody Pathology 0.67 86609 Bacterium antibody Pathology 0.66 86611 Bartonella antibody Pathology 0.66 86612 Blastomyces antibody Pathology 0.66 86615 Bordetella antibody Pathology 0.79 86618 Lyme disease antibody Pathology 0.79 86619 Borrelia antibody Pathology 0.69 86622 Brucella antibody Pathology					
86485 Skin test, candida Pathology 0.30 MDR 86586 Skin test, unlisted Pathology 0.30 MDR 86590 Streptokinase, antibody Pathology 0.57 86592 Blood serology, qualitative Pathology 0.22 86593 Blood serology, quantitative Pathology 0.52 86602 Antinomyces antibody Pathology 0.52 86603 Adenovirus antibody Pathology 0.77 86606 Aspergillus antibody Pathology 0.77 86609 Bacterium antibody Pathology 0.66 86611 Bartonella antibody Pathology 0.52 86612 Blastomyces antibody Pathology 0.68 86615 Bordetella antibody Pathology 0.68 86617 Lyme disease antibody Pathology 0.79 86618 Borrelia antibody Pathology 0.69 86622 Brucella antibody Pathology 0.46					
86586 Skin test, unlisted Pathology 0.30 MDR 86590 Streptokinase, antibody Pathology 0.57 86592 Blood serology, qualitative Pathology 0.23 86593 Blood serology, quantitative Pathology 0.23 86602 Antinomyces antibody Pathology 0.52 86603 Aspergillus antibody Pathology 0.66 86604 Aspergillus antibody Pathology 0.66 86611 Bartonella antibody Pathology 0.52 86612 Blastomyces antibody Pathology 0.66 86615 Bordetella antibody Pathology 0.68 86617 Lyme disease antibody Pathology 0.79 86618 Lyme disease antibody Pathology 0.87 86619 Borrelia antibody Pathology 0.69 86622 Brucella antibody Pathology 0.46					MDR
86590 Streptokinase, antibody Pathology 0.57 86592 Blood serology, qualitative Pathology 0.22 86593 Blood serology, quantitative Pathology 0.23 86602 Antinomyces antibody Pathology 0.52 86603 Adenovirus antibody Pathology 0.66 86604 Aspergillus antibody Pathology 0.77 86609 Bacterium antibody Pathology 0.66 86611 Blastomyces antibody Pathology 0.52 86612 Blastomyces antibody Pathology 0.66 86615 Bordetella antibody Pathology 0.68 86617 Lyme disease antibody Pathology 0.79 86618 Borrelia antibody Pathology 0.87 86619 Borrelia antibody Pathology 0.69 86622 Brucella antibody Pathology 0.46					
86592 Blood serology, qualitative Pathology 0.22 86593 Blood serology, quantitative Pathology 0.23 86602 Antinomyces antibody Pathology 0.52 86603 Adenovirus antibody Pathology 0.66 86604 Aspergillus antibody Pathology 0.77 86609 Bacterium antibody Pathology 0.66 86611 Blastomyces antibody Pathology 0.52 86612 Blastomyces antibody Pathology 0.66 86615 Bordetella antibody Pathology 0.68 86617 Lyme disease antibody Pathology 0.79 86618 Borrelia antibody Pathology 0.87 86619 Borrelia antibody Pathology 0.69 86622 Brucella antibody Pathology 0.46					*****
86602 Antinomyces antibody Pathology 0.52 86603 Adenovirus antibody Pathology 0.66 86604 Aspergillus antibody Pathology 0.77 86609 Bacterium antibody Pathology 0.66 86611 Bartonella antibody Pathology 0.52 86612 Blastomyces antibody Pathology 0.66 86615 Bordetella antibody Pathology 0.68 86617 Lyme disease antibody Pathology 0.79 86618 Lyme disease antibody Pathology 0.87 86619 Borrelia antibody Pathology 0.69 86622 Brucella antibody Pathology 0.46				0.22	
86603 Adenovirus antibody 86606 Aspergillus antibody 86609 Bacterium antibody 86611 Bartonella antibody 86612 Blastomyces antibody 86615 Bordetella antibody 86616 Lyme disease antibody 86617 Lyme disease antibody 86618 Borrelia antibody 86619 Borrelia antibody 86622 Brucella antibody 86622 Brucella antibody 86622 Pathology 90.68 91.79 92.79 93.79 94.79 94.79 95.79	86593		Pathology	0.23	
86606 Aspergillus antibody Pathology 0.77 86609 Bacterium antibody Pathology 0.66 86611 Bartonella antibody Pathology 0.52 86612 Blastomyces antibody Pathology 0.66 86615 Bordetella antibody Pathology 0.68 86617 Lyme disease antibody Pathology 0.79 86618 Lyme disease antibody Pathology 0.87 86619 Borrelia antibody Pathology 0.69 86622 Brucella antibody Pathology 0.46					
86609 Bacterium antibody Pathology 0.66 86611 Bartonella antibody Pathology 0.52 86612 Blastomyces antibody Pathology 0.66 86615 Bordetella antibody Pathology 0.68 86617 Lyme disease antibody Pathology 0.79 86618 Lyme disease antibody Pathology 0.87 86619 Borrelia antibody Pathology 0.69 86622 Brucella antibody Pathology 0.46					
86611 Bartonella antibody Pathology 0.52 86612 Blastomyces antibody Pathology 0.66 86615 Bordetella antibody Pathology 0.68 86617 Lyme disease antibody Pathology 0.79 86618 Lyme disease antibody Pathology 0.87 86619 Borrelia antibody Pathology 0.69 86622 Brucella antibody Pathology 0.46					
86612 Blastomyces antibody Pathology 0.66 86615 Bordetella antibody Pathology 0.68 86617 Lyme disease antibody Pathology 0.79 86618 Borrelia antibody Pathology 0.87 86619 Borrelia antibody Pathology 0.69 86622 Brucella antibody Pathology 0.46					
86615 Bordetella antibody Pathology 0.68 86617 Lyme disease antibody Pathology 0.79 86618 Lyme disease antibody Pathology 0.87 86619 Borrelia antibody Pathology 0.69 86622 Brucella antibody Pathology 0.46					
86617 Lyme disease antibody Pathology 0.79 86618 Lyme disease antibody Pathology 0.87 86619 Borrelia antibody Pathology 0.69 86622 Brucella antibody Pathology 0.46					
86618 Lyme disease antibody Pathology 0.87 86619 Borrelia antibody Pathology 0.69 86622 Brucella antibody Pathology 0.46					
86619 Borrelia antibody Pathology 0.69 86622 Brucella antibody Pathology 0.46					
86622 Brucella antibody Pathology 0.46					
86625 Campylobacter antibody Pathology 0.67		Brucella antibody			
	86625	Campylobacter antibody	Pathology	0.67	l

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS) PAGE 11 OF 17

CPT/		0		
		Conversion	Total	Charge
HCPCS	CPT/HCPCS Code Description	Factor/GAAF	1	Method-
Code		Category	RVUs	ology
				o.og,
00000	0 - 11 12 - 1	5	2.22	
86628	Candida antibody	Pathology	0.62	
86631	Chlamydia antibody	Pathology	0.61	
86632	Chlamydia igm antibody	Pathology	0.65	
86635	Coccidioides antibody	Pathology	0.59	
86638	Q fever antibody	Pathology	0.62	
86641	Cryptococcus antibody	Pathology	0.74	
86644	CMV antibody	Pathology	0.74	
86645	CMV antibody, IgM	Pathology	0.86	
86648	Diphtheria antibody	Pathology	0.78	
86651	Encephalitis antibody	Pathology	0.68	
86652	Encephalitis antibody	Pathology	0.68	
86653	Encephalitis antibody	Pathology	0.68	
	Encephalitis antibody			
86654		Pathology	0.68	
86658	Enterovirus antibody	Pathology	0.67	
86663	Epstein-barr antibody	Pathology	0.67	
86664	Epstein-barr antibody	Pathology	0.79	
86665	Epstein-barr antibody	Pathology	0.93	
86666	Ehrlichia antibody	Pathology	0.52	
86668	Francisella tularensis	Pathology	0.53	
86671	Fungus antibody	Pathology	0.63	
86674	Giardia lamblia antibody	Pathology	0.76	
86677	Helicobacter pylori	Pathology	0.74	
86682	Helminth antibody	Pathology	0.67	
86684	Hemophilus influenza	Pathology	0.81	
86687	Htlv-i antibody	Pathology	0.43	
86688	Htlv-ii antibody	Pathology	0.72	
86689			0.99	
	HTLV/HIV confirmatory test	Pathology		
86692	Hepatitis, delta agent	Pathology	0.88	
86694	Herpes simplex test	Pathology	0.74	
86695	Herpes simplex test	Pathology	0.68	
86696	Herpes simplex type 2	Pathology	0.99	
86698	Histoplasma	Pathology	0.64	
86701	HIV-1	Pathology	0.46	
86702	HIV-2	Pathology	0.69	
86703	HIV-1/HIV-2, single assay	Pathology	0.70	
86704	Hep b core antibody, total	Pathology	0.62	
86705	Hep b core antibody, igm	Pathology	0.60	
86706	Hep b surface antibody	Pathology	0.55	
86707	Hep be antibody	Pathology	0.59	
86708	Hep a antibody, total	Pathology	0.64	
86709	Hep a antibody, igm	Pathology	0.58	
86710	Influenza virus antibody	Pathology	0.70	
86713	Legionella antibody	Pathology	0.79	
			0.63	
86717	Leishmania antibody	Pathology	0.68	
86720	Leptospira antibody	Pathology		
86723	Listeria monocytogenes ab	Pathology	0.68	
86727	Lymph choriomeningitis ab	Pathology	0.66	
86729	Lympho venereum antibody	Pathology	0.61	
86732	Mucormycosis antibody	Pathology	0.68	
86735	Mumps antibody	Pathology	0.67	
86738	Mycoplasma antibody	Pathology	0.68	I
86741	Neisseria meningitidis	Pathology	0.68	1
86744	Nocardia antibody	Pathology	0.68	l
86747	Parvovirus antibody	Pathology	0.77	
86750	Malaria antibody	Pathology	0.68	l
86753	Protozoa antibody nos	Pathology	0.64	1
86756	Respiratory virus antibody	Pathology	0.66	
86757	Rickettsia antibody	Pathology	0.99	
86759	Rotavirus antibody	Pathology	0.68	l
86762	Rubella antibody	Pathology	0.74	1
86765	Rubeola antibody	Pathology	0.66	J
86768	Salmonella antibody	Pathology	0.68	1
86771	Shigella antibody	Pathology	0.68	
86774	Tetanus antibody	Pathology	0.76	
86777	Toxoplasma antibody	Pathology	0.74	ļ
86778	Toxoplasma antibody, igm	Pathology	0.74	1
86781	Treponema pallidum, confirm	Pathology	0.68	
86784	Trichinella antibody	Pathology	0.64	l
86787	Varicella-zoster antibody	Pathology	0.66	
00101	ranocia-zostei antibody	, i alliology	, 0.00	•

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)

PAGE 12 OF 17

CPT/ HCPCS	CPT/HCPCS Code Description	Conversion Factor/GAAF	Total	Charge Method-
Code		Category	RVUs	ology
86790	Virus antibody nos	Pathology	0.66	
86793	Yersinia antibody	Pathology	0.68	
86800	Thyroglobulin antibody	Pathology	0.82	
86803	Hepatitis c ab test	Pathology	0.73	
86804	Hep c ab test, confirm	Pathology	0.79	
86805	Lymphocytotoxicity assay	Pathology	2.68	
86806	Lymphocytotoxicity assay	Pathology	2.44	
86807	Cytotoxic antibody screening	Pathology	2.03	
86808	Cytotoxic antibody screening	Pathology	1.52	
86812	HLA typing, A, B, or C	Pathology	1.32	
86813 86816	HLA typing, A, B, or C HLA typing, DR/DQ	Pathology Pathology	2.98 1.43	
86817	HLA typing, DR/DQ HLA typing, DR/DQ	Pathology	3.30	
86821	Lymphocyte culture, mixed	Pathology	2.90	
86822	Lymphocyte culture, primed	Pathology	1.88	
86849	Immunology procedure	Pathology	1.17	SAF
86850	RBC antibody screen	Pathology	0.42	MDR
86860	RBC antibody elution	Pathology	0.42	MDR
86870	RBC antibody identification	Pathology	0.73	MDR
86880	Coombs test, direct	Pathology	0.28	
86885	Coombs test, indirect, qual	Pathology	0.29	
86886	Coombs test, indirect, titer	Pathology	0.27	
86890	Autologous blood process	Pathology	1.68	MDR
86891	Autologous blood, op salvage	Pathology	2.62	MDR
86900	Blood typing, ABO	Pathology	0.15	
86901	Blood typing, Rh (D)	Pathology	0.21	MDR
86903	Blood typing, antigen screen	Pathology	0.48	
86904	Blood typing, patient serum	Pathology	0.49 0.20	
86905 86906	Blood typing, RBC antigens Blood typing, Rh phenotype	Pathology Pathology	0.40	
86910	Blood typing, it is phenotype Blood typing, paternity test	Pathology	0.46	MDR
86911	Blood typing, paternity test Blood typing, antigen system	Pathology	0.36	MDR
86920	Compatibility test	Pathology	0.46	MDR
86921	Compatibility test	Pathology	0.42	MDR
86922	Compatibility test	Pathology	0.25	MDR
86927	Plasma, fresh frozen	Pathology	0.23	MDR
86930	Frozen blood prep	Pathology	1.46	PHCS
86931	Frozen blood thaw	Pathology	2.31	MDR
86932	Frozen blood freeze/thaw	Pathology	2.52	MDR
86940	Hemolysins/agglutinins, auto	Pathology	0.42	
86941	Hemolysins/agglutinins	Pathology	0.62 0.63	MDR
86945 86950	Blood product/irradiation Leukacyte transfusion	Pathology Pathology	1.15	MDR
86965	Pooling blood platelets	Pathology	0.29	MDR
86970	RBC pretreatment	Pathology	0.34	MDR
86971	RBC pretreatment	Pathology	0.34	MDR
86972	RBC pretreatment	Pathology	0.31	MDR
86975	RBC pretreatment, serum	Pathology	0.21	MDR
86976	RBC pretreatment, serum	Pathology	0.17	MDR
86977	RBC pretreatment, serum	Pathology	0.21	MDR
86978	RBC pretreatment, serum	Pathology	0.46	MDR
86985	Split blood or products	Pathology	0.44	MDR
87001	Small animal inoculation	Pathology	0.68	
87003	Small animal inoculation	Pathology	0.86 0.34	
87015 87040	Specimen concentration	Pathology Pathology	0.54	
87040 87045	Blood culture for bacteria Feces culture, bacteria	Pathology	0.33	
87046	Stool cultr, bacteria, each	Pathology	0.12	
87070	Culture, bacteria, other	Pathology	0.44	
87071	Culture bacteri aerobic othr	Pathology	0.24	
87073	Culture bacteria anaerobic	Pathology	0.24	
87075	Culture bacteria anaerobic	Pathology	0.49	
87076	Culture anaerobe ident, each	Pathology	0.41	
87077	Culture aerobic identify	Pathology	0.41	l
87081	Culture screen only	Pathology	0.34	1
87084	Culture of specimen by kit	Pathology	0.44 0.41	
87086	Urine culture/colony count	Pathology Pathology	0.41	
87088 87101	Urine bacteria culture Skin fungi culture	Pathology	0.42	1
07101	1 Own rungi culture	1 , 40,0091	0.10	2

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)
PAGE 13 OF 17

CPT/		Conversion		Charge
HCPCS	CPT/HCPCS Code Description	Factor/GAAF	Total	Method-
Code	or more of odde becompany.	Category	RVUs	ology
0000		Outegory		ology
87102	Fungus isolation culture	Pathology	0.43	
87103	Blood fungus culture	Pathology	0.46	
87106	Fungi identification, yeast	Pathology	0.53	
87107	Fungi identification, mold	Pathology	0.53	
87109	Mycoplasma	Pathology	0.79	
87110	Chlamydia culture	Pathology	1.01	
87116	Mycobacteria culture	Pathology	0.55	
87118	Mycobacteric identification	Pathology	0.56	
87140	Culture type immunofluoresc	Pathology	0.29	
87143	Culture typing, glc/hplc	Pathology	0.64	
87147	Culture type, immunologic	Pathology	0.27	
87149	Culture type, nucleic acid	Pathology	1.03 0.27	
87152 87158	Culture type pulse field gel Culture typing, added method	Pathology Pathology	0.27	
87164	Dark field examination	Pathology	0.55	
87166	Dark field examination	Pathology	0.58	
87168	Macroscopic exam arthropod	Pathology	0.22	
87169	Macroscopic exam parasite	Pathology	0.22	
87172	Pinworm exam	Pathology	0.22	
87176	Tissue homogenization, cultr	Pathology	0.30	
87177	Ova and parasites smears	Pathology	0.46	
87181	Microbe susceptible, diffuse	Pathology	0.24	
87184	Microbe susceptible, disk	Pathology	0.35	
87185	Microbe susceptible, enzyme	Pathology	0.24	
87186	Microbe susceptible, mic	Pathology	0.44	
87187	Microbe susceptible, mlc	Pathology	0.53	
87188	Microbe suscept, macrobroth	Pathology Pathology	0.34 0.29	
87190 87197	Microbe suscept, mycobacteri Bactericidal level, serum	Pathology	0.29	
87205	Smear, gram stain	Pathology	0.22	
87206	Smear, fluorescent/acid stai	Pathology	0.28	
87207	Smear, special stain	Pathology	0.31	
87210	Smear, wet mount, saline/ink	Pathology	0.22	
87220	Tissue exam for fungi	Pathology	0.22	
87230	Assay, toxin or antitoxin	Pathology	1.01	
87250	Virus inoculate, eggs/animal	Pathology	1.00	
87252	Virus inoculation, tissue	Pathology	1.34	
87253	Virus inoculate tissue, addl	Pathology	1.04	
87254	Virus inoculation, shell via	Pathology	0.25	
87255	Genet virus isolate, hsv	Pathology	1.74 0.62	
87260 87265	Adenovirus ag, if Pertussis ag, if	Pathology Pathology	0.62	
87267	Enterovirus antibody, dfa	Pathology	0.62	
87270	Chlamydia trachomatis ag, if	Pathology	0.62	
87271	Cryptosporidum/gardia ag, if	Pathology	0.62	
87272	Cryptosporidum/gardia ag, if	Pathology	0.62	
87273	Herpes simplex 2, ag, if	Pathology	0.62	
87274	Herpes simplex 1, ag, if	Pathology	0.62	
87275	Influenza b, ag, if	Pathology	0.62	
87276	Influenza a, ag, if	Pathology	0.62	
87277	Legionella micdadei, ag, if	Pathology	0.62	
87278 872 7 0	Legion pneumophilia ag, if	Pathology	0.62 0.62	
87279 87280	Parainfluenza, ag, if Respiratory syncytial ag, if	Pathology Pathology	0.62	
87281	Pneumocystis carinii, ag, if	Pathology	0.62	
87283	Rubeola, ag, if	Pathology	0.62	
87285	Treponema pallidum, ag, if	Pathology	0.62	
87290	Varicella zoster, ag, if	Pathology	0.62	
87299	Antibody detection, nos, if	Pathology	0.62	
87300	Ag detection, polyval, if	Pathology	0.31	
87301	Adenovirus ag, eìa	Pathology	0.62	1
87320	Chylmd trach ag, eia	Pathology	0.62	
87324	Clostridium ag, eia	Pathology	0.62	l
87327 87328	Cryptococcus neoform ag, eia Cryptospor ag, eia	Pathology Pathology	0.62 0.62	1
87328 87332	Cytomegalovirus ag, eia	Pathology	0.62	1
87335	E coli 0157 ag, eia	Pathology	0.62	1
87336	Entamoeb hist dispr, ag, eia	Pathology	0.62	
87337	Entamoeb hist group, ag, eia	Pathology	0.62]
	* ***	•		-

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)
PAGE 14 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Method- ology
87338	Hpylori, stool, eia	Pathology	0.74	
87339	H pylori ag, eia	Pathology	0.62	
87340	Hepatitis b surface ag, eia	Pathology	0.53	
87341	Hepatitis b surface, ag, eia	Pathology	0.53	
87350	Hepatitis be ag, eia	Pathology	0.59	
87380	Hepatitis delta ag, eia	Pathology	0.84	
87385	Histoplasma capsul ag, eia	Pathology	0.62	
87390	Hiv-1 ag, eia	Pathology Pathology	0.91	
87391	Hiv-2 ag, eia	1	0.91 0.62	
87400 87420	Influenza a/b, ag, eia Resp syncytial ag, eia	Pathology Pathology	0.62	
87425	Rotavirus ag, eia	Pathology	0.62	
87427	Shiga-like toxin ag, eia	Pathology	0.62	
87430	Strep a ag, eia	Pathology	0.62	
87449	Ag detect nos, eia, mult	Pathology	0.62	
87450	Ag detect nos, eia, single	Pathology	0.49	
87451	Ag detect polyval, eia, mult	Pathology	0.49	
87470	Bartonella, dna, dir probe	Pathology	1.03	
87471	Bartonella, dna, amp probe	Pathology	1.80	
87472	Bartonella, dna, quant	Pathology	2.20	
87475	Lyme dis, dna, dir probe	Pathology	1.03	
87476	Lyme dis, dna, amp probe	Pathology	1.80	
87477	Lyme dis, dna, quant	Pathology	2.20	
87480	Candida, dna, dir probe	Pathology	1.03	
87481	Candida, dna, amp probe	Pathology	1.80	
87482	Candida, dna, quant	Pathology	2.14	
87485	Chylmd pneum, dna, dir probe	Pathology	1.03	
87486	Chylmd pneum, dna, amp probe	Pathology	1.80	
87487	Chylmd pneum, dna, quant	Pathology	2.20	1
87490	Chylmd trach, dna, dir probe	Pathology	1.03	
87491	Chylmd trach, dna, amp probe	Pathology	1.80	
87492	Chylmd trach, dna, quant	Pathology	1.79	
87495	Cytomeg, dna, dir probe	Pathology	1.03 1.80	
87496 87497	Cytomeg, dna, amp probe Cytomeg, dna, guant	Pathology Pathology	2.20	
87510	Gardner vag, dna, dir probe	Pathology	1.03	
87511	Gardner vag, dna, amp probe	Pathology	1.80	1
87512	Gardner vag, dna, quant	Pathology	2.14	
87515	Hepatitis b, dna, dir probe	Pathology	1.03	
87516	Hepatitis b, dna, amp probe	Pathology	1.80	
87517	Hepatitis b, dna, quant	Pathology	2.20	1
87520	Hepatitis c, rna, dir probe	Pathology	1.03	1
87521	Hepatitis c, rna, amp probe	Pathology	1.80	1
87522	Hepatitis c, rna, quant	Pathology	2.20	1
87525	Hepatitis g, dna, dir probe	Pathology	1.03	1
87526	Hepatitis g, dna, amp probe	Pathology	1.80	
87527	Hepatitis g, dna, quant	Pathology	2.14	ł
87528	Hsv, dna, dir probe	Pathology	1.03	
87529 87530	Hsv, dna, amp probe	Pathology	1.80 2.20	1
	Hsv, dna, quant Hhv-6, dna, dir probe	Pathology	1.03	
87531 87532	Hhv-6, dna, amp probe	Pathology Pathology	1.80	l
87533	Hhv-6, dna, quant	Pathology	2.14	
87534	Hiv-1, dna, dir probe	Pathology	1.03	1
87535	Hiv-1, dna, amp probe	Pathology	1.80	l
87536	Hiv-1, dna, quant	Pathology	4.37	1
87537	Hiv-2, dna, dir probe	Pathology	1.03	
87538	Hiv-2, dna, amp probe	Pathology	1.80	
87539	Hiv-2, dna, quant	Pathology	2.20	l
87540	Legion pneumo, dna, dir prob	Pathology	1.03	
87541	Legion pneumo, dna, amp prob	Pathology	1.80	1
87542	Legion pneumo, dna, quant	Pathology	2.14	1
87550	Mycobacteria, dna, dir probe	Pathology	1.03	1
87551	Mycobacteria, dna, amp probe	Pathology	1.80	
87552	Mycobacteria, dna, quant	Pathology	2.20	1
87555 97556	M.tuberculo, dna, dir probe	Pathology Pathology	1.03 1.80	
87556 87557	M.tuberculo, dna, amp probe M.tuberculo, dna, quant	Pathology	2.20	
01001	i w.tubercuio, una, quant	Pathology	1.03	1

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)
PAGE 15 OF 17

CPT/ HCPCS	CPT/HCPCS Code Description	Conversion Factor/GAAF	Total	Charge Method-
Code		Category	11,403	ology
87561 87562 87580 87581 87582 87590 87591 87592 87620 87621 87622 87650 87651 87652	M.avium-intra, dna, amp prob M.avium-intra, dna, quant M.pneumon, dna, di probe M.pneumon, dna, amp probe M.pneumon, dna, quant N.gonorrhoeae, dna, dir prob N.gonorrhoeae, dna, amp prob N.gonorrhoeae, dna, quant Hpv, dna, dir probe Hpv, dna, amp probe Hpv, dna, quant Strep a, dna, dir probe Strep a, dna, amp probe Strep a, dna, quant	Pathology Pathology	1.80 2.20 1.03 1.80 2.14 1.03 1.80 2.14 1.03 1.80 2.14	
87797 87798	Detect agent nos, dna, dir Detect agent nos, dna, amp	Pathology Pathology	1.03 1.80	
87799	Detect agent nos, dna, quant	Pathology	2.20	
87800	Detect agnt mult, dna, direc	Pathology	2.06	
87801 87802	Detect agnt mult, dna, ampli Strep b assay w/optic	Pathology Pathology	3.60 0.62	
87803	Clostridium toxin a w/optic	Pathology	0.62	
87804	Influenza assay w/optic	Pathology	0.62	
87810 87850	Chylmd trach assay w/optic N. gonorrhoeae assay w/optic	Pathology Pathology	0.62 0.62	
87880	Strep a assay w/optic	Pathology	0.62	
87899	Agent nos assay w/optic	Pathology	0.62	
87901	Genotype, dna, hiv reverse t Genotype, dna, hepatitis C	Pathology	13.21 13.21	
87902 87903	Phenotype, dna hiv w/culture	Pathology Pathology	25.08	
87904	Phenotype, dna hiv w/clt add	Pathology	1.34	
87999	Microbiology procedure	Pathology	0.42	
88000 88005	Autopsy (necropsy), gross Autopsy (necropsy), gross	Pathology Pathology	7.21 8.01	MDR MDR
88007	Autopsy (necropsy), gross	Pathology	8.81	MDR
88012	Autopsy (necropsy), gross	Pathology	6.64	MDR
88014	Autopsy (necropsy), gross	Pathology	6.64	MDR
88016 88020	Autopsy (necropsy), gross Autopsy (necropsy), complete	Pathology Pathology	8.07 10.36	MDR MDR
88025	Autopsy (necropsy), complete	Pathology	11.16	MDR
88027	Autopsy (necropsy), complete	Pathology	11.96	MDR
88028	Autopsy (necropsy), complete	Pathology	6.64	MDR
88029 88036	Autopsy (necropsy), complete Limited autopsy	Pathology Pathology	6.64 4.29	MDR MDR
88037	Limited autopsy	Pathology	3.15	MDR
88040	Forensic autopsy (necropsy)	Pathology	17.16	MDR
88045 88099	Coroner's autopsy (necropsy) Necropsy (autopsy) procedure	Pathology Pathology	1.43 11.16	MDR Misc.
88130	Sex chromatin identification	Pathology	0.77	Wilse.
88140	Sex chromatin identification	Pathology	0.41	
88142	Cytopath, c/v, thin layer	Pathology	1.04	
88143 88147	Cytopath c/v thin layer redo Cytopath, c/v, automated	Pathology Pathology	1.04 0.58	
88148	Cytopath, c/v, auto rescreen	Pathology	0.78	
88150	Cytopath, c/v, manual	Pathology	0.54	
88152 88153	Cytopath, c/v, auto redo Cytopath, c/v, redo	Pathology Pathology	0.54 0.54	
88154	Cytopath, c/v, redo	Pathology	0.54	
88155	Cytopath, c/v, index add-on	Pathology	0.31	
88164	Cytopath the c/v rada	Pathology	0.54	
88165 88166	Cytopath tbs, c/v, redo Cytopath tbs, c/v, auto redo	Pathology Pathology	0.54 0.54	
88167	Cytopath tbs, c/v, select	Pathology	0.54	
88174	Cytopath, c/v auto, in fluid	Pathology	1.10	
88175 88230	Cytopath c/v auto fluid redo Tissue culture, lymphocyte	Pathology Pathology	1.36 5.98	
88230 88233	Tissue culture, skin/biopsy	Pathology	7.22	
88235	Tissue culture, placenta	Pathology	7.56	
88237	Tissue culture, bone marrow	Pathology	6.48 7.57	
88239	Tissue culture, tumor	Pathology	1 7.57	,

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS)
PAGE 16 OF 17

	1700 10 01 17			
CPT/		Conversion		Charge
	CRT/UCRCS Code Description	t i	Total	_
HCPCS	CPT/HCPCS Code Description	Factor/GAAF	RVUs	Method-
Code		Category		ology
			0.50	
88240	Cell cryopreserve/storage	Pathology	0.52 0.52	
88241 88245	Frozen cell preparation Chromosome analysis, 20-25	Pathology Pathology	7.64	
88248	Chromosome analysis, 50-100	Pathology	8.89	
88249	Chromosome analysis, 30-100	Pathology	8.89	
88261	Chromosome analysis, 5	Pathology	9.07	
88262	Chromosome analysis, 15-20	Pathology	6.40	
88263	Chromosome analysis, 45	Pathology	7.71	
88264	Chromosome analysis, 20-25	Pathology	6.40	
88267	Chromosome analys, placenta	Pathology	9.23	
88269	Chromosome analys, amniotic	Pathology	8.53	
88271	Cytogenetics, dna probe	Pathology	1.10	
88272	Cytogenetics, 3-5	Pathology	1.37	
88273	Cytogenetics, 10-30	Pathology	1.65	
88274	Cytogenetics, 25-99	Pathology	1.79	
88275	Cytogenetics, 100-300	Pathology	2.06 1.29	
88280 88283	Chromosome karyotype study Chromosome banding study	Pathology Pathology	3.52	
88285	Chromosome count, additional	Pathology	0.97	
88289	Chromosome study, additional	Pathology	1.77	
88299	Cytogenetic study	Pathology	6.40	
88371	Protein, western blot tissue	Pathology	1.14	
88372	Protein analysis w/probe	Pathology	1.17	
88400	Bilirubin total transcut	Pathology	0.13	
89050	Body fluid cell count	Pathology	0.24	
89051	Body fluid cell count	Pathology	0.28	
89055	Leukocyte count, fecal	Pathology	0.22	
89060	Exam, synovial fluid crystals	Pathology	0.37	
89125	Specimen fat stain	Pathology	0.22	
89160	Exam feces for meat fibers	Pathology	0.19	
89190	Nasal smear for eosinophils	Pathology	0.24 14.48	MDR
89250 89251	Fertilization of oocyte Culture oocyte w/embryos	Pathology Pathology	18.44	PHCS
89252	Assist oocyte fertilization	Pathology	27.11	PHCS
89253	Embryo hatching	Pathology	10.85	PHCS
89254	Oocyte identification	Pathology	9.00	PHCS
89255	Prepare embryo for transfer	Pathology	5.42	PHCS
89256	Prepare cryopreserved embryo	Pathology	9.76	PHCS
89257	Sperm identification	Pathology	5.42	PHCS
89258	Cryopreservation, embryo	Pathology	10.85	PHCS
89259	Cryopreservation, sperm	Pathology	2.71	PHCS
89260	Sperm isolation, simple	Pathology	1.63	PHCS
89261	Sperm isolation, complex	Pathology	2.71	PHCS
89264 89300	Identify sperm tissue Semen analysis w/huhner	Pathology Pathology	5.42 0.46	PHCS
89310	Semen analysis w/count	Pathology	0.40	
89320	Semen analysis, complete	Pathology	0.62	
89321	Semen analysis & motility	Pathology	0.62	
89325	Sperm antibody test	Pathology	0.55	
89329	Sperm evaluation test	Pathology	1.08	
89330	Evaluation, cervical mucus	Pathology	0.51	
89355	Exam feces for starch	Pathology	0.17	
89365	Water load test	Pathology	0.28	
G0001	Drawing blood for specimen	Pathology	0.11	
G0103	Psa, total screening	Pathology	0.94	
G0107	CA screen; fecal blood test	Pathology	0.17	
G0123 G0143	Screen cerv/vag thin layer Scr c/v cyto,thinlayer,rescr	Pathology Pathology	1.04 1.04	ĺ
G0144	Scr c/v cyto,thinlayer,rescr	Pathology	1.10	
G0145	Scr c/v cyto,thinlayer,rescr	Pathology	1.36	
G0147	Scr c/v cyto, automated sys	Pathology	0.58	
G0148	Scr c/v cyto, autosys, rescr	Pathology	0.78	
G0265	Cryopresevation Freeze+stora	Pathology	0.52	
G0266	Thawing + expansion froz cel	Pathology	0.52	
P2038	Blood mucoprotein	Pathology	0.26	1
P3000	Screen pap by tech w md supv	Pathology	0.54	
P9612	Catheterize for urine spec	Pathology	0.11	1
P9615 Q0111	Urine specimen collect mult Wet mounts/ w preparations	Pathology Pathology	0.11 0.22	1
QUIII	1	1 autology	, 0.22	,

TABLE J. — PATHOLOGY AND LABORATORY SERVICES RELATIVE VALUE UNITS (RVUS) PAGE 17 OF 17

CPT/ HCPCS Code	CPT/HCPCS Code Description	Conversion Factor/GAAF Category	Total RVUs	Charge Method- ology
Q0112	Potassium hydroxide preps	Pathology	0.22	
Q0113	Pinworm examinations	Pathology	0.28	
Q0114	Fern test	Pathology	0.37	
Q0115	Post-coital mucous exam	Pathology	0.51	

Charge Methodology:

Misc: RVUs obtained using the methodology for unlisted procedures.

No entry: RVUs based on Medicare Clinical Diagnostic Laboratory Fee Schedule.

All other entries: See Supplementary Table 1, Reasonable Charges Data Sources - V2.0.

PAGE 1 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogor
A4206		1 CC sterile syringe&needle		\$0.61	Non-Dru
A4207	1 1	2 CC sterile syringe&needle		\$0.70	Non-Dru
A4208	1 1	3 CC sterile syringe&needle	1 1	\$0.61	Non-Dru
A4209	1 1	5+ CC sterile syringe&needle		\$0.61	Non-Drug
A4210	1 1	Nonneedle injection device	1	\$1,900.89	Non-Dru
A4211	1 1	Supp for self-adm injections	1	\$0.84	Non-Dru
A4212	1 1	Non coring needle or stylet		\$17.52	Non-Dru
A4213	1 1	20+ CC syringe only		\$1.84	Non-Dru
A4214 A4215	1 1	30 CC sterile water/saline Sterile needle	1 1	\$2.50	Non-Dru
A4210		Infusion pump refill kit	1	\$0.35 \$30.87	Non-Dru Non-Dru
A4221	1 1	Maint drug infus cath per wk	1	\$35.84	Non-Dru
A4222	1 1	Drug infusion pump supplies	1	\$72.92	Non-Dru
A4230	1 1	Infus insulin pump non needl		\$21.67	Non-Dru
A4231		Infusion insulin pump needle		\$9.54	Non-Dru
A4232		Syringe w/needle insulin 3cc	1 1	\$7.35	Non-Dru
A4244		Alcohol or peroxide per pint	1 1	\$1.84	Non-Dru
A4245		Alcohol wipes per box		\$5.66	Non-Dru
A4246		Betadine/phisohex solution		\$6.30	Non-Dru
A4247	1 1	Betadine/iodine swabs/wipes	1 1	\$9.49	Non-Dru
A4250	l l	Urine reagent strips/tablets		\$37.92	Non-Dru
A4253	NU	Blood glucose/reagent strips	1	\$59.60	Non-Dru
A4253	l l	Blood glucose/reagent strips		\$65.12 \$12.05	Non-Dru
A4254	NU	Battery for glucose monitor	1 1	\$12.95 \$1.91	Non-Dru Non-Dru
A4254 A4254	RR UE	Battery for glucose monitor Battery for glucose monitor		\$10.61	Non-Dru
A4254	02	Battery for glucose monitor		\$13.69	Non-Dru
A4255	1 1	Glucose monitor platforms	1	\$9.43	Non-Dru
A4256		Calibrator solution/chips		\$17.12	Non-Dru
A4257		Replace Lensshield Cartridge		\$19.18	Non-Dru
A4258	1	Lancet device each		\$27.49	Non-Dru
A4259		Lancets per box	1	\$19.16	Non-Dru
A4260		Levonorgestrel implant		\$815.75	Non-Dru
A4261		Cervical cap contraceptive		\$45.36	Non-Dru
A4262		Temporary tear duct plug		\$1.21	Non-Dru
A4263		Permanent tear duct plug	1	\$86.88	Non-Dru
A4265		Paraffin	1	\$4.91 \$0.61	Non-Dru Non-Dru
A4267 A4269		Male condom Spermicide		\$1.84	Non-Dru
A4209 A4270		Disposable endoscope sheath	1	\$32.95	Non-Dru
A4280		Brst prsths adhsv attchmnt		\$8.66	Non-Dru
A4284		Replomnt breast pump shield		\$38.60	Non-Dru
A4290		Sacral nerve stim test lead	1	\$218.58	Non-Dru
A4300	1 1	Cath impl vasc access portal	1 1	\$17.00	Non-Dru
A4301		Implantable access syst perc	1 1	\$74.87	Non-Dru
A4305		Drug delivery system >=50 ML	1	\$28.40	Non-Dru
A4306		Drug delivery system <=5 ML	1 1	\$38.60	Non-Dru
A4310	1	Insert tray w/o bag/cath		\$11.28 \$22.46	Non-Dru Non-Dru
A4311 A4312		Catheter w/o bag 2-way latex	1	\$27.48	Non-Dru
A4312 A4313		Cath w/o bag 2-way silicone Catheter w/bag 3-way	1	\$28.23	Non-Dru
A4314		Cath w/drainage 2-way latex	1 1	\$38.86	Non-Dru
A4315		Cath w/drainage 2-way silcne	. 1 .	\$40.58	Non-Dru
A4316		Cath w/drainage 3-way	1 1	\$43.74	Non-Dru
A4319		Sterile H2O irrigation solut	1 1	\$9.92	Non-Dru
A4320		Irrigation tray	1 1	\$7.77	Non-Dru
A4321	1	Cath therapeutic irrig agent	1	\$2.51	Non-Dru
A4322		Irrigation syringe		\$4.40	Non-Dru
A4323		Saline irrigation solution		\$12.95 \$5.43	Non-Dru
A4324		Male ext cath w/adh coating Male ext cath w/adh strip		\$5.43 \$5.03	Non-Dru Non-Dru
A4325 A4326	1	Male ext cath wadn strip Male external catheter		\$16.10	Non-Dru
A4327		Fem urinary collect dev cup		\$69.19	Non-Dru
A4328		Fem urinary collect pouch		\$15.57	Non-Dru
A4330	1	Stool collection pouch		\$10.44	Non-Dru
A4331		Extension drainage tubing	. [\$4.61	Non-Dru
A4332	}	Lubricant for cath insertion		\$0.17	Non-Dru
A4333	į į	Urinary cath anchor device	1 1	\$5.46	Non-Dru

PAGE 2 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
A4334		Urinary cath leg strap		\$8.41	Non-Drug
A4335		Incontinence supply		\$1.53	Non-Drug
A4338		Indwelling catheter latex		\$18.41	Non-Drug
A4340		Indwelling catheter special		\$48,99	Non-Drug
A4344		Cath indw foley 2 way silicn		\$24.31	Non-Drug
A4346		Cath indw foley 3 way		\$29.91	Non-Drug
A4347 A4348		Male external catheter Male ext cath extended wear		\$31.10 \$42.84	Non-Drug Non-Drug
A4346 A4351		Straight tip urine catheter		\$42.64 \$2.59	Non-Drug Non-Drug
A4352	1 1	Coude tip urinary catheter		\$9.37	Non-Drug Non-Drug
A4353	1	Intermittent urinary cath		\$10.22	Non-Drug
A4354	1 1	Cath insertion tray w/bag	1 1	\$17.69	Non-Drug
A4355	1 1	Bladder irrigation tubing		\$13.15	Non-Drug
A4356	1 1	Ext ureth clmp or compr dvc		\$70.78	Non-Drug
A4357	1 1	Bedside drainage bag		\$14.39	Non-Drug
A4358	1 1	Urinary leg or abdomen bag		\$9.68	Non-Drug
A4359	1 1	Urinary suspensory w/o leg b	1 1	\$47.24	Non-Drug
A4361	1	Ostomy face plate		\$28.00	Non-Drug
A4362 A4364	1 1	Solid skin barrier]]	\$5.02	Non-Drug
A4365		Adhesive, liquid or equal Adhesive remover wipes		\$6.25 \$16.93	Non-Drug Non-Drug
A4367		Ostomy belt		\$10.74	Non-Drug
A4368	1 1	Ostomy filter	1 1	\$0.36	Non-Drug
A4369		Skin barrier liquid per oz		\$3.49	Non-Drug
A4371		Skin barrier powder per oz	1	\$5.30	Non-Drug
A4372		Skin barrier solid 4x4 equiv		\$6.08	Non-Drug
A4373	1	Skin barrier with flange		\$9.16	Non-Drug
A4375		Drainable plastic pch w fcpl		\$26.13	Non-Drug
A4376 A4377		Drainable rubber pch w fcplt Drainable plstic pch w/o fp	1	\$73.84 \$6.24	Non-Drug Non-Drug
A4378		Drainable rubber pch w/o fp		\$47.43	Non-Drug Non-Drug
A4379		Urinary plastic pouch w fcpl		\$22.74	Non-Drug
A4380	1	Urinary rubber pouch w fcplt		\$57.75	Non-Drug
A4381		Urinary plastic pouch w/o fp		\$6.71	Non-Drug
A4382		Urinary hvy plstc pch w/o fp	1 1	\$37.80	Non-Drug
A4383	1 1	Urinary rubber pouch w/o fp	1 1	\$43.41	Non-Drug
A4384 A4385		Ostomy facepit/silicone ring Ost skn barrier sld ext wear		\$14.26 \$7.43	Non-Drug Non-Drug
A4387	1	Ost clsd pouch w att st barr		\$4.73	Non-Drug
A4388	1	Drainable pch w ex wear barr	1	\$6.34	Non-Drug
A4389	1	Drainable pch w st wear barr	1 1	\$9.08	Non-Drug
A4390		Drainable pch ex wear convex		\$14.25	Non-Drug
A4391		Urinary pouch w ex wear barr		\$11.48	Non-Drug
A4392	1 1	Urinary pouch w st wear barr	1 1	\$12.11	Non-Drug
A4393	1	Urine pch w ex wear bar conv	1	\$14.51	Non-Drug
A4394 A4395	l l	Ostomy pouch liq deodorant Ostomy pouch solid deodorant	.	\$3.72 \$0.07	Non-Drug Non-Drug
A4396		Peristomal hernia supprt blt	1	\$62.69	Non-Drug Non-Drug
A4397		Irrigation supply sleeve		\$6.97	Non-Drug
A4398		Ostomy irrigation bag	1	\$20.84	Non-Drug
A4399	1	Ostomy irrig cone/cath w brs		\$18.41	Non-Drug
A4400		Ostomy irrigation set		\$75.86	Non-Drug
A4402		Lubricant per ounce		\$2.28	Non-Drug
A4404 A4405		Ostomy ring each		\$2.41	Non-Drug
A4405 A4406		Nonpectin based ostomy paste Pectin based ostomy paste		\$4.93 \$8.37	Non-Drug Non-Drug
A4407		Ext wear ost skn barr <=4sq"		\$12.91	Non-Drug
A4408		Ext wear ost skn barr >4sq"		\$14.66	Non-Drug
A4409		Ost skn barr w flng <=4 sq"		\$9.08	Non-Drug
A4410		Ost skn barr w fing >4sq"		\$13.35	Non-Drug
A4413		2 pc drainable ost pouch		\$8.02	Non-Drug
A4414		Ostomy sknbarr w fing <=4sq"		\$7.18 \$9.75	Non-Drug Non-Drug
A4415 A4421		Ostomy skn barr w flng >4sq"		\$8.75	HoneDrug
A4421		Ost pouch absorbent material		\$0.17	Non-Drug
A4450	1	Non-waterproof tape		\$0.13	Non-Drug
A4452		Waterproof tape		\$0.50	Non-Drug
A4455	1	Adhesive remover per ounce	j j	\$2.03	Non-Drug

PAGE 3 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
A4462		Abdmnl drssng holder/binder		\$4,77	Non-Drug
A4465		Non-elastic extremity binder		\$19.56	Non-Drug Non-Drug
A4470	1 :	Gravlee jet washer	1 1	\$12.77	Non-Drug Non-Drug
A4480	1	Vabra aspirator	1 1	\$10.12	Non-Drug
A4481		Tracheostoma filter		\$1.08	Non-Drug
A4490	1	Above knee surgical stocking		\$14.13	Non-Drug
A4495		Thigh length surg stocking	1	\$14.13	Non-Drug
A4500		Below knee surgical stocking	1 1	\$10.12	Non-Drug
A4510		Full length surg stocking		\$25.68	Non-Drug
A4521		Adult size diaper sm each		\$20.91	Non-Drug
A4522		Adult size diaper med each	1	\$37.63	Non-Drug
A4523	1	Adult size diaper lg each	1	\$52.96	Non-Drug
A4524		Adult size diaper xl each		\$16.73	Non-Drug
A4525		Adult size brief sm each	1	\$1.21	Non-Drug
A4526	1	Adult size brief med each		\$2.48	Non-Drug
A4527		Adult size brief lg each	1	\$3.11 \$1.84	Non-Drug Non-Drug
A4528 A4531		Adult size brief xl each Child size brief sm/med each		\$1.21	Non-Drug
A4531 A4532	(Child size brief lg each		\$2.48	Non-Drug
A4534	1	Youth size brief each	1	\$1.21	Non-Drug
A4535		Disp incont liner/shield ea		\$0.61	Non-Drug
A4550	[Surgical trays		\$63.76	Non-Drug
A4554		Disposable underpads	1 1	\$6.30	Non-Drug
A4556		Electrodes, pair	1 1	\$20.88	Non-Drug
A4557	1	Lead wires, pair		\$33.65	Non-Drug
A4558	1	Conductive paste or gel	1	\$11.34	Non-Drug
A4561		Pessary rubber, any type		\$34.87	Non-Drug
A4562	1	Pessary, non rubber, any type		\$87.99	Non-Drug
A4565		Slings	1 1	\$14.81	Non-Drug
A4570		Splint		\$37.24	Non-Drug Non-Drug
A4575		Hyperbaric o2 chamber disps		\$712.76 \$29.77	Non-Drug
A4580 A4590		Cast supplies (plaster) Special casting material		\$84.84	Non-Drug
A4595		TENS suppl 2 lead per month		\$44.63	Non-Drug
A4608	(Transtracheal oxygen cath		\$92.29	Non-Drug
A4609		Trach suction cath clsed sys		\$97.54	Non-Drug
A4610		Trach sctn cath 72h clsedsys		\$2.42	Non-Drug
A4611	NU	Heavy duty battery		\$326.81	Non-Drug
A4611	RR	Heavy duty battery		\$32.60	Non-Drug
A4611	UE	Heavy duty battery		\$243.53	Non-Drug
A4611		Heavy duty battery		\$374.36	Non-Drug
A4612	NU	Battery cables		\$129.22	Non-Drug
A4612	RR	Battery cables		\$15.17 \$97.04	Non-Drug Non-Drug
A4612 A4612	UE	Battery cables Battery cables	1	\$152.24	Non-Drug
A4613	NU	Battery charger		\$238.23	Non-Drug
A4613	RR	Battery charger		\$24.14	Non-Drug
A4613	ÜË	Battery charger	1	\$170.53	Non-Drug
A4614	1	Hand-held PEFR meter	1 1	\$36.49	Non-Drug
A4615	1	Cannula nasal	l l	\$6.46	Non-Drug
A4616	1	Tubing (oxygen) per foot	1	\$2.58	Non-Drug
A4617	1	Mouth piece	1	\$33.60	Non-Drug
A4618	NU	Breathing circuits	l l	\$13.12	Non-Drug
A4618	RR	Breathing circuits	1 1	\$1.43	Non-Drug
A4618 A4618	UE	Breathing circuits Breathing circuits))	\$9.74 \$16.16	Non-Drug Non-Drug
A4619	1	Face tent		\$4.26	Non-Drug
A4620	1	Variable concentration mask		\$11.63	Non-Drug
A4621	1	Tracheotomy mask or collar		\$4.89	Non-Drug
A4622	1	Tracheostomy or larngectomy		\$89.04	Non-Drug
A4623	1	Tracheostomy inner cannula	1	\$9.56	Non-Drug
A4624	NU	Tracheal suction tube		\$7.32	Non-Drug
A4624		Tracheal suction tube	1 1	\$8.07	Non-Drug
A4625	1	Trach care kit for new trach		\$10.12 \$4.62	Non-Drug Non-Drug
A4626	1	Tracheostomy cleaning brush Spacer bag/reservoir	1	\$4.62 \$33.94	Non-Drug Non-Drug
A4627 A4628	NU	Oropharyngeal suction cath		\$5.43	Non-Drug
A4628	1 140	Oropharyngeal suction cath		\$1.21	
74040	1	1 Orophia frigues addition addit	'	¥ · · · · · ·	

PAGE 4 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
A4629		Tracheostomy care kit		\$6.74	Non-Drug
A4630	NU	Repl bat t.e.n.s. own by pt		\$12.48	Non-Drug
A4630 A4631	NU	Repl bat t.e.n.s. own by pt	1 1	\$11.45	Non-Drug
A4631	RR	Wheelchair battery Wheelchair battery		\$165.12 \$18.27	Non-Drug Non-Drug
A4631	ÜÈ	Wheelchair battery		\$120.98	Non-Drug
A4631		Wheelchair battery		\$193.72	Non-Drug
A4635	NU	Underarm crutch pad		\$10.87	Non-Drug
A4635	RR	Underarm crutch pad		\$1.97	Non-Drug
A4635	UE	Underarm crutch pad	1 1	\$8.40	Non-Drug
A4635 A4636	NU	Underarm crutch pad Handgrip for cane etc	1 1	\$10.32 \$9.57	Non-Drug Non-Drug
A4636	RR	Handgrip for cane etc		\$1.23	Non-Drug
A4636	ÜE	Handgrip for cane etc		\$7.95	Non-Drug
A4636		Handgrip for cane etc	1 .	\$9.76	Non-Drug
A4637	NU	Repl tip cane/crutch/walker		\$6.08	Non-Drug
A4637	RR	Repl tip cane/crutch/walker		\$0.86	Non-Drug
A4637 A4637	UE	Repl tip cane/crutch/walker Repl tip cane/crutch/walker	1 1	\$4.60 \$6.76	Non-Drug Non-Drug
A4640	NU	Alternating pressure pad	1	\$101.06	Non-Drug
A4640	RR	Alternating pressure pad		\$12.77	Non-Drug
A4640	UE	Alternating pressure pad	·	\$69.75	Non-Drug
A4640		Alternating pressure pad		\$97.38	Non-Drug
A4641		Diagnostic imaging agent	1 1	\$74.79	Non-Drug
A4642 A4643		Satumomab pendetide per dose High dose contrast MRI		\$5.02 \$189.61	Non-Drug Non-Drug
A4644		Contrast 100-199 MGs iodine		\$1.92	Non-Drug
A4645	1	Contrast 200-299 MGs iodine	1 1	\$2.46	Non-Drug
A4646		Contrast 300-399 MGs iodine	1	\$3.15	Non-Drug
A4647		Supp- paramagnetic contr mat		\$188.73	Non-Drug
A4649		Calibrated microson tuba	1	\$2.00	Non-Drug
A4651 A4652		Calibrated microcap tube Microcapillary tube sealant		\$2.86 \$4.29	Non-Drug
A4656		Needle any size	. 1	\$7.14	Non-Drug
A4660		Sphyg/bp app w cuff and stet	1	\$36.42	Non-Drug
A4663		Dialysis blood pressure cuff	1 1	\$46.26	Non-Drug
A4670 A4680	1	Automatic bp monitor, dial		\$112.14	Non-Drug
A4690	1	Activated carbon filter, ea Dialyzer, each	1	\$80.42 \$1,176.93	Non-Drug Non-Drug
A4707		Bicarbonate conc pow per pac		\$5.71	Non-Drug
A4709		Acid conc sol per gallon		\$14.29	Non-Drug
A4712	1	Sterile water inj per 10 ml		\$6.47	Non-Drug
A4719		"Y set" tubing	j j	\$14.29	Non-Drug
A4721 A4722		Dialysat sol fld vol > 999cc Dialys sol fld vol > 1999cc	1	\$28.57 \$42.86	Non-Drug Non-Drug
A4723		Dialys sol fid vol > 1999cc	1 1	\$38.57	Non-Drug
A4725		Dialys sol fld vol > 4999cc	.	\$41.43	Non-Drug
A4726		Dialys sol fld vol > 5999cc		\$48.57	Non-Drug
A4730		Fistula cannulation set, ea	1 1	\$2.86	Non-Drug
A4740		Shunt accessory		\$1.43	Non-Drug
A4750 A4755	1	Art or venous blood tubing Comb art/venous blood tubing		\$17.15 \$28.00	Non-Drug Non-Drug
A4765		Dialysate conc pow per pack	1 1	\$11.43	Non-Drug
A4766		Dialysate conc sol add 10 ml	1	\$5.71	Non-Drug
A4770		Blood collection tube/vacuum	1	\$27.78	Non-Drug
A4772	1	Blood glucose test strips		\$36.82	Non-Drug
A4773 A4802		Occult blood test strips Protamine sulfate per 50 mg		\$27.65 \$8.82	Non-Drug Non-Drug
A4860	-	Disposable catheter tips		\$6.78	Non-Drug
A4890	1	Repair/maint cont hemo equip		\$150.00	Non-Drug
A4911		Drain bag/bottle		\$17.14	Non-Drug
A4913		Veneue excessive elema		\$1.43	Non-Drug
A4918 A4927	1	Venous pressure clamp Non-sterile gloves		\$1.43 \$6.62	Non-Drug Non-Drug
A4928		Surgical mask		\$0.34	Non-Drug
A4929		Tourniquet for dialysis, ea		\$0.26	Non-Drug
A5051	1	Pouch clsd w barr attached		\$3.11	Non-Drug
A5052	1	Clsd ostomy pouch w/o barr	1 1	\$4.39	Non-Drug

PAGE 5 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogo
A5053		Clsd ostomy pouch faceplate		\$2.49	Non-Dru
A5054		Clsd ostomy pouch w/flange		\$1.84	Non-Dru
A5055		Stoma cap		\$2.05	Non-Dru
A5061	- 1	Pouch drainable w barrier at		\$5.03	Non-Dru
A5062	į.	Drnble ostomy pouch w/o barr	1 1	\$3.19	Non-Dru
A5063	1	Drain ostomy pouch w/flange		\$3.11	Non-Dru
A5071		Urinary pouch w/barrier		\$10.12	Non-Dru
A5072		Urinary pouch w/o barrier	1	\$5.11	Non-Dru
A5073	1	Urinary pouch on barr w/flng		\$6.94	Non-Dru
A5081		Continent stoma plug		\$4.78	Non-Dru
A5082	1	Continent stoma catheter	1 1	\$17.83	Non-Dru
A5093	[Ostomy accessory convex inse		\$2.80	Non-Dru
A5102		Bedside drain btl w/wo tube		\$34.60	Non-Dru
A5105		Urinary suspensory		\$63.13	Non-Dru
A5112	1	Urinary leg bag		\$53.50	Non-Dru
A5113		Latex leg strap		\$6.84	Non-Dru
A5114		Foam/fabric leg strap		\$13.20	Non-Dru
A5119		Skin barrier wipes box pr 50	1 1	\$16.19	Non-Dru
A5121 A5122	Į.	Solid skin barrier 6x6	1 1	\$10.90 \$19.33	Non-Dru Non-Dru
A5122 A5126	1	Solid skin barrier 8x8 Disk/foam pad +or- adhesive		\$1.87	Non-Dru
A5120 A5131		Appliance cleaner		\$24.06	Non-Dru
A5200		Percutaneous catheter anchor		\$16.90	Non-Dru
A5500	ł	Diab shoe for density insert		\$95.12	Non-Dru
A5501		Diabetic custom molded shoe		\$287.15	Non-Dru
A5503		Diabetic shoe w/roller/rockr	1	\$51.13	Non-Dru
A5504		Diabetic shoe with wedge		\$43.41	Non-Dru
A5505		Diab shoe w/metatarsal bar	1 1	\$49.00	Non-Dru
A5506		Diabetic shoe w/off set heel		\$43.05	Non-Dru
A5507		Modification diabetic shoe	1 1	\$90.61	Non-Dru
A5508	l	Diabetic deluxe shoe	1 1	\$43.23	Non-Dru
A5509	1	Direct heat form shoe insert		\$45.18	Non-Dru
A5510	1	Compression form shoe insert		\$42.67	Non-Dru
A5511	- 1	Custom fab molded shoe inser	1 1	\$46.43	Non-Dru
A6000	İ	Wound warming wound cover	1 1	\$32.39	Non-Dru
A6010	- 1	Collagen based wound filler	1 1	\$47.75	Non-Dru
A6011	1	Collagen gel/paste wound fil	1 1	\$3.28	Non-Dru
A6021	1	Collagen dressing <=16 sq in	1 1	\$32.16	Non-Dru
A6022	1	Collagen drsg>6<=48 sq in		\$32.16	Non-Dru
A6023		Collagen dressing >48 sq in	1	\$297.82	Non-Dru
A6024	-	Collagen dsg wound filler	1 1	\$9.03	Non-Dru
A6025	1	Silicone gel sheet, each	1	\$52.88	Non-Dru
A6154	I	Wound pouch each	1	\$21.73	Non-Dru
A6196	- 1	Alginate dressing <=16 sq in	1 1	\$10.74	Non-Dru
A6197	- 1	Alginate drsg >16 <=48 sq in		\$24.97	Non-Dru
A6199]	Alginate drsg wound filler	1	\$7.71	Non-Dru
A6200	1	Compos drsg <=16 no border		\$14.08	Non-Dru
A6201	1	Compos drsg >16<=48 no bdr		\$31.81	Non-Dri
A6202	ļ	Compos drsg >48 no border		\$53.91	Non-Dri
A6203		Composite drsg <= 16 sq in	1	\$4.86	Non-Dru
A6204		Composite drsg >16<=48 sq in	1	\$9.09	Non-Dru
A6205		Composite drsg > 48 sq in	1 1	\$12.80	Non-Dri
A6206	į	Contact layer <= 16 sq in	1 1	\$8.85	Non-Dri
A6207	1	Contact layer >16<= 48 sq in		\$10.72	Non-Dri
A6208		Contact layer > 48 sq in	1 1	\$6.59	Non-Dri
A6209	I	Foam drsg <=16 sq in w/o bdr		\$10.93 \$30.43	Non-Dri Non-Dri
A6210	1	Foam drg > 16<=48 sq in w/o b		\$30.43 \$45.26	Non-Dr
A6211	1	Foam drg > 48 sq in w/o brdr		\$45.26 \$14.39	Non-Dri
A6212		Foam drg <=16 sq in w/border		\$46.08	Non-Dr
A6213	1	Foam drg >16<=48 sq in w/bdr Foam drg > 48 sq in w/border		\$40.00 \$15.32	Non-Dri
A6214 A6216	1	Non-sterile gauze<=16 sq in	1	\$0.07	Non-Dr
A6217	1	Non-sterile gauze<-16 sq m		\$0.61	Non-Dri
A6217 A6218		Non-sterile gauze > 48 sq in		\$0.61	Non-Dri
A6219		Gauze <= 16 sq in w/border		\$1.33	Non-Dr
A6220		Gauze >16 <=48 sq in w/bordr		\$3.72	Non-Dr
A6222		Gauze <=16 in no w/sal w/o b		\$3.06	Non-Dr
A6223	1	Gauze >16<=48 no w/sal w/o b	1 1	\$3.49	

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
A6224		Gauze > 48 in no w/sal w/o b		\$5.24	Non-Drug
A6228		Gauze <= 16 sq in water/sal		\$3.75	Non-Drug
A6229	1	Gauze >16<=48 sq in watr/sal		\$5.24	Non-Drug
A6230		Gauze > 48 sq in water/salne		\$6.30	Non-Drug
A6231 A6232		Hydrogel dsg<=16 sq in Hydrogel dsg>16<=48 sg in	1 1	\$6.81 \$10.05	Non-Drug Non-Drug
A6232 A6233		Hydrogel dressing >48 sq in		\$29.28	Non-Drug
A6234		Hydrocolld drg <=16 w/o bdr		\$9.55	Non-Drug
A6235		Hydrocolld drg >16<=48 w/o b		\$25.56	Non-Drug
A6236		Hydrocolld drg > 48 in w/o b	1	\$41.93	Non-Drug
A6237		Hydrocolld drg <=16 in w/bdr		\$11.58	Non-Drug
A6238	1	Hydrocolld drg >16<=48 w/bdr		\$34.93	Non-Drug
A6239		Hydrocolld drg > 48 in w/bdr	1	\$18.14	Non-Drug
A6240		Hydrocolld drg filler paste	1 1	\$18.38	Non-Drug
A6241 A6242		Hydrocolloid drg filler dry Hydrogel drg <=16 in w/o bdr		\$3.71 \$8.86	Non-Drug Non-Drug
A6243		Hydrogel drg >16<=48 w/o bdr	1 1	\$18.49	Non-Drug
A6244		Hydrogel drg >48 in w/o bdr		\$60.81	Non-Drug
A6245		Hydrogel drg <= 16 in w/bdr		\$10.62	Non-Drug
A6246		Hydrogel drg >16<=48 in w/b		\$14.74	Non-Drug
A6247		Hydrogel drg > 48 sq in w/b		\$36.49	Non-Drug
A6248		Hydrogel drsg gel filler		\$24.65	Non-Drug
A6250		Skin seal protect moisturizr		\$2.47	Non-Drug
A6251		Absorpt drg <=16 sq in w/o b		\$2.85 \$4.71	Non-Drug Non-Drug
A6252 A6253		Absorpt drg >16 <=48 w/o bdr Absorpt drg > 48 sg in w/o b	1 1	\$9.25	Non-Drug
A6254		Absorpt drg <=16 sq in w/bdr		\$1.71	Non-Drug
A6255		Absorpt drg >16<=48 in w/bdr	1 1	\$4.38	Non-Drug
A6257		Transparent film <= 16 sq in		\$2.18	Non-Drug
A6258		Transparent film >16<=48 in		\$6.25	Non-Drug
A6259		Transparent film > 48 sq in		\$16.34	Non-Drug
A6260		Wound cleanser any type/size		\$1.84	Non-Drug
A6261		Wound filler gel/paste /oz		\$8.21 \$1.84	Non-Drug
A6262		Wound filler dry form / gram Impreg gauze no h20/sal/yard		\$2.75	Non-Drug Non-Drug
A6266 A6402		Sterile gauze <= 16 sq in	1	\$0.17	Non-Drug
A6403		Sterile gauze>16 <= 48 sq in		\$0.60	Non-Drug
A6404		Sterile gauze > 48 sq in		\$1.21	Non-Drug
A6410		Sterile eye pad		\$0.55	Non-Drug
A6411		Non-sterile eye pad	1	\$0.61	Non-Drug
A6412		Occlusive eye patch	1 1	\$0.61	Non-Drug
A6440		Zinc paste bdg >=3<5"w /roll		\$17.03 \$17.17	Non-Drug Non-Drug
A7000	NU	Disposable canister for pump	1	\$20.44	Non-Drug Non-Drug
A7000 A7001	NU	Disposable canister for pump Nondisposable pump canister	1	\$50.72	Non-Drug
A7001	110	Nondisposable pump canister	1	\$60.59	Non-Drug
A7002	NU	Tubing used w suction pump		\$9.03	Non-Drug
A7002		Tubing used w suction pump		\$10.32	Non-Drug
A7003	NU	Nebulizer administration set		\$7.48	Non-Drug
A7003		Nebulizer administration set		\$8.07	Non-Drug
A7004	NU	Disposable nebulizer sml vol		\$5.14 \$6.76	Non-Drug Non-Drug
A7004	NU	Disposable nebulizer sml vol Nondisposable nebulizer set		\$6.76 \$47.51	Non-Drug
A7005 A7005	"	Nondisposable nebulizer set Nondisposable nebulizer set		\$57.24	Non-Drug
A7005 A7006	NU	Filtered nebulizer admin set		\$17.17	Non-Drug
A7006	1 ''	Filtered nebulizer admin set		\$19.88	Non-Drug
A7007	NU	Lg vol nebulizer disposable		\$10.14	Non-Drug
A7007	Í	Lg vol nebulizer disposable]]	\$11.45	Non-Drug
A7008	NU	Disposable nebulizer prefill		\$19.25 \$22.69	Non-Drug
A7008		Disposable nebulizer prefill		\$22.69 \$64.97	Non-Drug Non-Drug
A7009 A7009	NU	Nebulizer reservoir bottle Nebulizer reservoir bottle	.	\$79.32	Non-Drug
A7009 A7010	NU	Disposable corrugated tubing		\$37.19	Non-Drug
A7010	1	Disposable corrugated tubing	1	\$44.06	Non-Drug
A7011		Nondispos corrugated tubing		\$63.53	Non-Drug
A7012	NU	Nebulizer water collec devic		\$8.96	Non-Drug
A7012	1	Nebulizer water collec devic		\$10.32 \$2.37	Non-Drug Non-Drug
A7013	NU	Disposable compressor filter	1 1	Ψ2.31	1 HOULDING

PAGE 7 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
A7013		Disposable compressor filter		\$2.25	Non-Drug
A7014	NU	Compressor nondispos filter	1 1	\$9.97	Non-Drug
A7014 A7015	NU	Compressor nondispos filter Aerosol mask used w nebulize	1	\$11.45 \$5.37	Non-Drug Non-Drug
A7015 A7015	140	Aerosol mask used w nebulize Aerosol mask used w nebulize		\$6.76	Non-Drug Non-Drug
A7016	NU	Nebulizer dome & mouthpiece		\$13.91	Non-Drug
A7016		Nebulizer dome & mouthpiece		\$15.94	Non-Drug
A7017	NU	Nebulizer not used w oxygen		\$220.98	Non-Drug
A7017	RR	Nebulizer not used w oxygen		\$22.67	Non-Drug
A7017 A7018	UE	Nebulizer not used w oxygen Water distilled w/nebulizer		\$164.14 \$1.08	Non-Drug Non-Drug
A7019	1	Saline solution dispenser		\$0.48	Non-Drug
A7020		Sterile H2O or NSS w lgv neb		\$7.49	Non-Drug
A7042		Implanted pleural catheter		\$319.47	Non-Drug
A7043		Vacuum drainagebottle/tubing		\$45.02 \$164.00	Non-Drug Non-Drug
A7501 A7502		Tracheostoma valve w diaphra Replacement diaphragm/fplate		\$77.49	Non-Drug Non-Drug
A7503		HMES filter holder or cap		\$16.95	Non-Drug
A7504	1	Tracheostoma HMES filter		\$0.94	Non-Drug
A7505		HMES or trach valve housing		\$6.81	Non-Drug
A7506		HMES/trachvalve adhesivedisk		\$0.46 \$3.59	Non-Drug Non-Drua
A7507 A7508	1	Integrated filter & holder Housing & Integrated Adhesiv		\$4.15	Non-Drug
A7509		Heat & moisture exchange sys		\$2.00	Non-Drug
A9150		, , , , , , , , , , , , , , , , , , , ,		·	••
A9270	1				
A9300		Tachnotium TC 00m contomibi	1	\$175.77	Non-Drug
A9500 A9502	į.	Technetium TC 99m sestamibi Technetium TC99M tetrofosmin		\$175.77 \$191.41	Non-Drug Non-Drug
A9503	1	Technetium TC 99m medronate		\$47.06	Non-Drug
A9504		Technetium to 99m apoitide		\$77.90	Non-Drug
A9505		Thallous chloride TL 201/mci		\$79.83	Non-Drug
A9507		Indium/111 capromab pendetid	a	\$2,699.79	Non-Drug
A9508 A9510		lobenguane sulfate I-131 Technetium TC99m Disofenin	a	\$38.51 \$173.6 7	Non-Drug Non-Drug
A9600	1	Strontium-89 chloride	a	\$1,283.32	Non-Drug
A9605		Samarium sm153 lexidronamm	a	\$609.49	Non-Drug
A9700		Echocardiography Contrast	a	\$261.28	Non-Drug
A9900 A9901		Supply/accessory/service Delivery/set up/dispensing		\$20.90 \$15.28	Non-Drug Non-Drug
B4034		Enter feed supkit syr by day		\$9.37	Non-Drug
B4035		Enteral feed supp pump per d		\$17.87	Non-Drug
B4036		Enteral feed sup kit grav by		\$12.24	Non-Drug
B4081		Enteral ng tubing w/ stylet		\$35.90	Non-Drug
B4082 B4083		Enteral ng tubing w/o stylet Enteral stomach tube levine		\$25.46 \$3.75	Non-Drug Non-Drug
B4086		Gastrostomy/jejunostomy tube		\$62.49	Non-Drug
B4150		Enteral formulae category i		\$1.02	Non-Drug
B4151		Enteral formulae cat1natural		\$2.39	Non-Drug
B4152 B4153		Enteral formulae category ii Enteral formulae categoryIII		\$0.85 \$2.91	Non-Drug Non-Drug
B4154		Enteral formulae category IV		\$1.86	Non-Drug
B4155		Enteral formulae category v	1 1	\$1.45	Non-Drug
B4156		Enteral formulae category vi		\$2.06	Non-Drug
B4164		Parenteral 50% dextrose solu		\$26.19	Non-Drug Non-Drug
B4168 B4172		Parenteral sol amino acid 3. Parenteral sol amino acid 5.		\$40.39 \$35.06	Non-Drug Non-Drug
B4176		Parenteral sol amino acid 7-		\$82.83	Non-Drug
B4178		Parenteral sol amino acid >		\$100.43	Non-Drug
B4180		Parenteral sol carb > 50%		\$39.67	Non-Drug
B4184 B4186		Parenteral sol lipids 10% Parenteral sol lipids 20%		\$141.36 \$190.13	Non-Drug Non-Drug
B4189	1	Parenteral sol amino acid &		\$320.57	Non-Drug
B4193		Parenteral sol 52-73 gm prot		\$415.70	Non-Drug
B4197		Parenteral sol 74-100 gm pro		\$507.16	Non-Drug
B4199 B4216		Parenteral sol > 100gm prote Parenteral nutrition additiv		\$580.25 \$11.48	Non-Drug Non-Drua
D4Z ID	i	Fareiteiai nutition auditiv	1 1	\$11.89	

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
B4222		Parenteral supply kit homemi		\$14.66	Non-Drug
B4224		Parenteral administration ki		\$40.86	Non-Drug
B5000		Parenteral sol renal-amirosy		\$17.66	Non-Drug
B5100		Parenteral sol hepatic-fream	1	\$6.90 \$523.73	Non-Drug
B5200 B9000	NU	Parenteral sol stres-brnch c Enter infusion pump w/o alrm		\$2,311.66	Non-Drug Non-Drug
B9000	RR	Enter infusion pump w/o airm		\$207.92	Non-Drug
B9000	UE	Enter infusion pump w/o alrm	1 1	\$1,732.50	Non-Drug
B9002	NU	Enteral infusion pump w/ ala		\$2,311.66	Non-Drug
B9002	RR	Enteral infusion pump w/ ala		\$219.42	Non-Drug
B9004	NU	Parenteral infus pump portab		\$4,616.04	Non-Drug
B9004	RR UE	Parenteral infus pump portab Parenteral infus pump portab		\$726.60 \$3,460.79	Non-Drug Non-Drug
B9004 B9006	NU	Parenteral infus pump statio		\$4,616.04	Non-Drug
B9006	RR	Parenteral infus pump statio		\$726.60	Non-Drug
B9006	UE	Parenteral infus pump statio		\$3,460.79	Non-Drug
B9998		·			
B9999	I			***	
E0100	NU	Cane adjust/fixed with tip		\$33.60	Non-Drug
E0100	RR UE	Cane adjust/fixed with tip Cane adjust/fixed with tip		\$12.04 \$27.52	Non-Drug Non-Drug
E0100 E0105	NU	Cane adjust/fixed quad/3 pro		\$76.96	Non-Drug
E0105	RR	Cane adjust/fixed quad/3 pro		\$16.20	Non-Drug
E0105	ÜE	Cane adjust/fixed quad/3 pro		\$57.88	Non-Drug
E0110	NU	Crutch forearm pair		\$125.26	Non-Drug
E0110	RR	Crutch forearm pair		\$26.36	Non-Drug
E0110	UE	Crutch forearm pair	 	\$92.34	Non-Drug
E0111	NU	Crutch forearm each Crutch forearm each		\$84.00 \$15.59	Non-Drug Non-Drug
E0111 E0111	RR UE	Crutch forearm each		\$63.38	Non-Drug
E0112	NU	Crutch underarm pair wood		\$56.43	Non-Drug
E0112	RR	Crutch underarm pair wood	1 1	\$17.73	Non-Drug
E0112	UE	Crutch underarm pair wood		\$43.81	Non-Drug
E0113	NU	Crutch underarm each wood		\$33.69	Non-Drug
E0113	RR	Crutch underarm each wood		\$10.91	Non-Drug
E0113 E0114	UE NU	Crutch underarm each wood Crutch underarm pair no wood	1	\$26.18 \$73.70	Non-Drug Non-Drug
E0114	RR	Crutch underarm pair no wood		\$15.79	Non-Drug
E0114	UE	Crutch underarm pair no wood		\$54.41	Non-Drug
E0116	NU	Crutch underarm each no wood		\$43.11	Non-Drug
E0116	RR	Crutch underarm each no wood		\$11.27	Non-Drug
E0116	UE	Crutch underarm each no wood		\$33.33 \$112.77	Non-Drug
E0130 E0130	NU RR	Walker rigid adjust/fixed ht Walker rigid adjust/fixed ht		\$27.55	Non-Drug Non-Drug
E0130	UE	Walker rigid adjust/fixed ht		\$86.49	Non-Dru
E0135	NU	Walker folding adjust/fixed		\$135.85	Non-Dru
E0135	RR	Walker folding adjust/fixed		\$28.17	Non-Dru
E0135	UE	Walker folding adjust/fixed		\$102.75	Non-Dru
E0141	NU	Rigid walker wheeled wo seat		\$189.18 \$35.44	Non-Dru
E0141	RR UE	Rigid walker wheeled we seat		\$35.44 \$140.31	Non-Dru Non-Dru
E0141 E0142	NU	Rigid walker wheeled wo seat Walker rigid wheeled with se		\$285.32	Non-Dru
E0142	RR	Walker rigid wheeled with se	1	\$41.24	Non-Dru
E0142	UE	Walker rigid wheeled with se	1	\$215.79	Non-Dru
E0143	NU	Walker folding wheeled w/o s		\$197.56	Non-Dru
E0143	RR	Walker folding wheeled w/o s		\$34.34 \$146.27	Non-Dru
E0143	UE	Walker folding wheeled w/o s Enclosed walker w rear seat	1	\$146.27 \$533.69	Non-Dru Non-Dru
E0144 E0144	NU RR	Enclosed walker w rear seat Enclosed walker w rear seat		\$48.98	Non-Dru
E0144	UE	Enclosed walker w rear seat		\$398.68	Non-Dru
E0145	NU	Walker whied seat/crutch att		\$229.74	Non-Dru
E0145	RR	Walker whied seat/crutch att		\$33.15	Non-Dru
E0145	UE	Walker whied seat/crutch att		\$184.02	Non-Dru
E0146	NU	Folding walker wheels w seat		\$293.27 \$30.71	Non-Dru Non-Dru
E0146	RR UE	Folding walker wheels w seat Folding walker wheels w seat		\$234.93	Non-Dru
E0146 E0147	NU	Walker variable wheel resist		\$968.41	Non-Dru
E0147	RR	Walker variable wheel resist	l i	\$91.15	Non-Dru

PAGE 9 OF 54

HCPCS Code	Modifier	HCPCS Code Description		Status/ Usage Indicator	Charge	GAAF Cateogory
E0147	UE	Walker variable wheel resist			\$724.77	Non-Drug
E0148	NU	Heavyduty walker no wheels]	\$209.13	Non-Drug
E0148 E0148	RR UE	Heavyduty walker no wheels Heavyduty walker no wheels			\$21.70 \$155.25	Non-Drug Non-Drug
E0148	NU	Heavy duty wheeled walker			\$372.17	Non-Drug
E0149	RR	Heavy duty wheeled walker		1 1	\$35.38	Non-Drug
E0149	UE	Heavy duty wheeled walker			\$277.53	Non-Drug
E0153	NU	Forearm crutch platform atta		1 1	\$111.33	Non-Drug
E0153	RR	Forearm crutch platform atta		1	\$14.75 \$81.91	Non-Drug
E0153 E0154	UE NU	Forearm crutch platform atta Walker platform attachment			\$113.25	Non-Drug Non-Drug
E0154	RR	Walker platform attachment		1	\$15.77	Non-Drug
E0154	UE	Walker platform attachment		1	\$84.52	Non-Drug
E0155	NU	Walker wheel attachment,pair			\$48.55	Non-Drug
E0155	RR	Walker wheel attachment pair			\$9.06	Non-Drug
E0155	UE NU	Walker wheel attachment,pair Walker seat attachment			\$37.85 \$41.24	Non-Drug Non-Drug
E0156 E0156	RR	Walker seat attachment		1	\$8.39	Non-Drug
E0156	ÜE	Walker seat attachment			\$31.86	Non-Drug
E0157	NU	Walker crutch attachment			\$132.60	Non-Drug
E0157	RR	Walker crutch attachment			\$16.39	Non-Drug
E0157	UE	Walker crutch attachment			\$97.89	Non-Drug
E0158 E0158	NU RR	Walker leg extenders set of4 Walker leg extenders set of4			\$49.44 \$8.63	Non-Drug Non-Drug
E0158	UE	Walker leg extenders set of4			\$38.19	Non-Drug Non-Drug
E0159	NU	Brake for wheeled walker			\$29.04	Non-Drug
E0159	RR	Brake for wheeled walker			\$5.28	Non-Drug
E0159	UE	Brake for wheeled walker			\$22.67	Non-Drug
E0159	1	Brake for wheeled walker		1	\$39.56	Non-Drug
E0160 E0160	NU RR	Sitz type bath or equipment Sitz type bath or equipment			\$50.69 \$9.74	Non-Drug Non-Drug
E0160	UE	Sitz type bath or equipment		1	\$38.88	Non-Drug
E0161	NU	Sitz bath/equipment w/faucet		1	\$40.96	Non-Drug
E0161	RR	Sitz bath/equipment w/faucet]	\$8.66	Non-Drug
E0161	UE	Sitz bath/equipment w/faucet		1	\$31.56	Non-Drug
E0162	NU	Sitz bath chair		1	\$240.75 \$25.36	Non-Drug Non-Drug
E0162 E0162	RR UE	Sitz bath chair Sitz bath chair		1	\$185.30	Non-Drug
E0163	NU	Commode chair stationry fxd		1	\$180.71	Non-Drug
E0163	RR	Commode chair stationry fxd		1	\$38.39	Non-Drug
E0163	UE	Commode chair stationry fxd			\$137.91	Non-Drug
E0164	NU	Commode chair mobile fixed a			\$301.29	Non-Drug
E0164 E0164	RR UE	Commode chair mobile fixed a Commode chair mobile fixed a		1	\$41.24 \$224.39	Non-Drug Non-Drug
E0165	NU	Commode chair mobile fixed a	•		\$261.81	Non-Drug
E0165	RR	Commode chair stationry det			\$30.05	Non-Drug
E0165	UE	Commode chair stationry det		1	\$209.22	Non-Drug
E0166	NU	Commode chair mobile detach			\$397.70	Non-Drug
E0166 E0166	RR UE	Commode chair mobile detach Commode chair mobile detach			\$47.95 \$317.14	Non-Drug Non-Drug
E0167	NU	Commode chair mobile detach		1	\$20.68	Non-Drug
E0167	RR	Commode chair pail or pan			\$3.60	Non-Drug
E0167	UE	Commode chair pail or pan			\$16.46	Non-Drug
E0168	NU	Heavyduty/wide commode chair			\$249.60	Non-Drug
E0168	RR UE	Heavyduty/wide commode chair Heavyduty/wide commode chair			\$25.19 \$185.61	Non-Drug Non-Drug
E0168 E0169	NU	Seatlift incorp commodechair		1	\$515.67	Non-Drug
E0169	RR	Seatlift incorp commodechair			\$79.33	Non-Drug
E0169	UE	Seatlift incorp commodechair		1	\$385.42	Non-Drug
E0175	NU	Commode chair foot rest			\$105.99	Non-Drug
E0175	RR	Commode chair foot rest Commode chair foot rest		1	\$13.01 \$76.33	Non-Drug Non-Drug
E0175 E0176	UE NU	Air pressre pad/cushion nonp		1	\$175.31	Non-Drug
E0176	RR	Air pressre pad/cushion nonp		1	\$23.74	Non-Drug
E0176	UE	Air pressre pad/cushion nonp			\$128.70	Non-Drug
E0177 E0177	NU	Water press pad/cushion nonp] [\$173.67 \$20.89	Non-Drug Non-Drug
	RR	Water press pad/cushion nonp		, ,	20.83	i inchi-liftid

PAGE 10 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
E0178	NU	Gel pressre pad/cushion nonp		\$199.44	Non-Drug
E0178	RR	Gel pressre pad/cushion nonp		\$24.97	Non-Drug
E0178	UE NU	Gel pressre pad/cushion nonp		\$147.99 \$20.62	Non-Drug Non-Drug
E0179 E0179	RR	Dry pressre pad/cushion nonp Dry pressre pad/cushion nonp		\$3.54	Non-Drug
E0179	ÜE	Dry pressre pad/cushion nonp		\$16.98	Non-Drug
E0180	NU	Press pad alternating w pump		\$311.55	Non-Drug
E0180	RR	Press pad alternating w pump		\$34.54	Non-Drug
E0180 E0181	UE NU	Press pad alternating w pump Press pad alternating w/ pum		\$195.97 \$415.63	Non-Drug Non-Drug
E0181	RR	Press pad alternating w/ pum		\$37.89	Non-Drug
E0181	UE	Press pad alternating w/ pum		\$331.56	Non-Drug
E0182	NU	Pressure pad alternating pum		\$428.02	Non-Drug
E0182 E0182	RR UE	Pressure pad alternating pum Pressure pad alternating pum		\$40.89 \$352.64	Non-Drug Non-Drug
E0182	NU	Dry pressure mattress		\$323.84	Non-Drug
E0184	RR	Dry pressure mattress		\$38.59	Non-Drug
E0184	UE	Dry pressure mattress		\$246.89	Non-Drug
E0185	NU	Gel pressure mattress pad		\$536.08	Non-Drug
E0185 E0185	RR UE	Gel pressure mattress pad Gel pressure mattress pad		\$69.89 \$409.95	Non-Drug Non-Drug
E0186	NU	Air pressure mattress		\$381.12	Non-Drug
E0186	RR	Air pressure mattress		\$32.51	Non-Drug
E0186	UE	Air pressure mattress		\$189.34 \$363.81	Non-Drug
E0187 E0187	NU RR	Water pressure mattress Water pressure mattress		\$36.65	Non-Drug Non-Drug
E0187	ÜE	Water pressure mattress		\$309.51	Non-Drug
E0188	NU	Synthetic sheepskin pad		\$40.65	Non-Drug
E0188	RR	Synthetic sheepskin pad		\$4.49 \$30.32	Non-Drug Non-Drug
E0188 E0188	UE	Synthetic sheepskin pad Synthetic sheepskin pad		\$73.96	Non-Drug
E0189	NU	Lambswool sheepskin pad		\$80.71	Non-Drug
E0189	RR	Lambswool sheepskin pad		\$8.21	Non-Drug
E0189	UE NU	Lambswool sheepskin pad		\$60.34 \$17.81	Non-Drug Non-Drug
E0191 E0191	RR	Protector heel or elbow Protector heel or elbow		\$2.91	Non-Drug
E0191	UE	Protector heel or elbow		\$14.21	Non-Drug
E0192	NU	Pad wheelchr low press/posit		\$478.15	Non-Drug
E0192 E0192	RR UE	Pad wheelchr low press/posit Pad wheelchr low press/posit		\$53.92 \$360.58	Non-Drug Non-Drug
E0193	RR	Powered air flotation bed		\$1,270.07	Non-Drug
E0194	NU	Air fluidized bed		\$42,822.34	Non-Drug
E0194	RR	Air fluidized bed		\$4,532.83	Non-Drug
E0194 E0196	UE NU	Air fluidized bed Gel pressure mattress		\$32,168.79 \$533.35	Non-Drug Non-Drug
E0196	RR	Gel pressure mattress Gel pressure mattress		\$53.07	Non-Drug
E0196	UE	Gel pressure mattress		\$400.01	Non-Drug
E0197	NU	Air pressure pad for mattres		\$369.42	Non-Drug
E0197 E0197	RR UE	Air pressure pad for mattres Air pressure pad for mattres		\$47.14 \$323.74	Non-Drug Non-Drug
E0198	NU	Water pressure pad for mattr		\$369.42	Non-Drug
E0198	RR	Water pressure pad for mattr	1	\$36.28	Non-Drug
E0198	UE	Water pressure pad for mattr		\$278.80	Non-Drug
E0199 E0199	NU RR	Dry pressure pad for mattres Dry pressure pad for mattres		\$49.25 \$8.12	Non-Drug Non-Drug
E0199	UE	Dry pressure pad for mattres		\$37.84	Non-Drug
E0200	NU	Heat lamp without stand		\$128.12	Non-Drug
E0200	RR	Heat lamp without stand		\$18.91	Non-Drug
E0200 E0202	UE RR	Heat lamp without stand Phototherapy light w/ photom]	\$94.56 \$99.85	Non-Drug Non-Drug
E0205	NU	Heat lamp with stand		\$322.76	Non-Drug
E0205	RR	Heat lamp with stand		\$33.99	Non-Drug
E0205	UE	Heat lamp with stand		\$240.48 \$50.09	Non-Drug Non-Drug
E0210 E0210	NU RR	Electric heat pad standard Electric heat pad standard		\$50.09 \$7.95	Non-Drug Non-Drug
E0210	UE	Electric heat pad standard		\$38.46	Non-Drug
E0215	NU	Electric heat pad moist		\$113.81	Non-Drug
E0215	RR	Electric heat pad moist	1 1	\$14.13	Non-Drug

PAGE 11 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
E0215	UE	Electric heat pad moist		\$83.79	Non-Drug
E0217	NU	Water circ heat pad w pump		\$835.57	Non-Drug
E0217	RR	Water circ heat pad w pump]	\$87.42	Non-Drug
E0217 E0218	UE NU	Water circ heat pad w pump Water circ cold pad w pump		\$625.04 \$599.16	Non-Drug Non-Drug
E0218	RR	Water circ cold pad w pump	1 1	\$63.93	Non-Drug
E0218	UE	Water circ cold pad w pump		\$447.29	Non-Drug
E0218		Water circ cold pad w pump		\$452.85	Non-Drug
E0220	NU	Hot water bottle		\$15.64	Non-Drug
E0220	RR	Hot water bottle		\$2.54	Non-Drug
E0220 E0221	UE NU	Hot water bottle Infrared heating pad system]	\$12.59 \$3,577.56	Non-Drug Non-Drug
E0221	RR	Infrared heating pad system		\$352.06	Non-Drug
E0221	ÜE	Infrared heating pad system	1 1	\$2,681.60	Non-Drug
E0225	NU	Hydrocollator unit	1	\$652.73	Non-Drug
E0225	RR	Hydrocollator unit	1	\$58.65	Non-Drug
E0225	UE	Hydrocollator unit		\$487.96	Non-Drug
E0230 E0230	NU RR	ice cap or collar ice cap or collar		\$15.66 \$2.71	Non-Drug Non-Drug
E0230	UE	ice cap or collar	1 1	\$12.61	Non-Drug Non-Drug
E0235	NU	Paraffin bath unit portable	1	\$282.22	Non-Drug
E0235	RR	Paraffin bath unit portable	1 1	\$28.17	Non-Drug
E0235	UE	Paraffin bath unit portable		\$211.54	Non-Drug
E0236 E0236	NU RR	Pump for water circulating p		\$354.42 \$68.72	Non-Drug
E0236	UE	Pump for water circulating p Pump for water circulating p		\$283.82	Non-Drug Non-Drug
E0238	NU	Heat pad non-electric moist		\$42.10	Non-Drug
E0238	RR	Heat pad non-electric moist	1 1	\$7.45	Non-Drug
E0238	UE	Heat pad non-electric moist		\$31.91	Non-Drug
E0239	NU	Hydrocollator unit portable	.	\$756.48	Non-Drug
E0239 E0239	RR UE	Hydrocollator unit portable Hydrocollator unit portable		\$69.97 \$565.81	Non-Drug Non-Drug
E0239	02	Bath tub wall rail		\$39.00	Non-Drug
E0242		Bath tub rail floor		\$89.36	Non-Drug
E0243		Toilet rail	1 1	\$69.28	Non-Drug
E0244		Toilet seat raised	1 1	\$51.93	Non-Drug
E0245		Tub stool or bench		\$88.02	Non-Drug
E0246 E0249	NU	Transfer tub rail attachment Pad water circulating heat u		\$122.81 \$162.58	Non-Drug Non-Drug
E0249	RR	Pad water circulating heat u	1	\$19.18	Non-Drug
E0249	UE	Pad water circulating heat u	1 1	\$120.35	Non-Drug
E0250	NU	Hosp bed fixed ht w/ mattres	1	\$2,026.33	Non-Drug
E0250	RR	Hosp bed fixed ht w/ mattres	·	\$151.85	Non-Drug
E0250 E0251	UE NU	Hosp bed fixed ht w/ mattres Hosp bed fixd ht w/o mattres	1 1	\$1,312.45 \$1,185.91	Non-Drug Non-Drug
E0251	RR	Hosp bed fixd ht w/o mattres	1 1	\$118.86	Non-Drug
E0251	UE	Hosp bed fixd ht w/o mattres	1	\$948.20	Non-Drug
E0255	NU	Hospital bed var ht w/ mattr		\$2,056.09	Non-Drug
E0255	RR	Hospital bed var ht w/ mattr	1 1	\$179.22	Non-Drug
E0255 E0256	UE NU	Hospital bed var ht w/ mattr Hospital bed var ht w/o matt	1	\$1,539.31 \$1,318.49	Non-Drug Non-Drug
E0256	RR	Hospital bed var ht w/o matt	1 1	\$131.85	Non-Drug
E0256	ÜE	Hospital bed var ht w/o matt	1	\$1,054.79	Non-Drug
E0260	NU	Hosp bed semi-electr w/ matt	1	\$2,024.10	Non-Drug
E0260	RR	Hosp bed semi-electr w/ matt	1 1	\$249.24	Non-Drug
E0260	UE	Hosp bed semi-electr w/ matt		\$1,563.39 \$1,070.77	Non-Drug
E0261 E0261	NU RR	Hosp bed semi-electr w/o mat Hosp bed semi-electr w/o mat		\$1,979.77 \$206.23	Non-Drug Non-Drug
E0261	UE	Hosp bed semi-electr w/o mat		\$1,319.85	Non-Drug
E0265	NU	Hosp bed total electr w/ mat	1	\$2,441.19	Non-Drug
E0265	RR	Hosp bed total electr w/ mat		\$293.58	Non-Drug
E0265	UE	Hosp bed total electr w/ mat		\$1,579.91	Non-Drug
E0266 E0266	NU RR	Hosp bed total elec w/o matt Hosp bed total elec w/o matt		\$2,625.21 \$262.64	Non-Drug Non-Drug
E0266	UE	Hosp bed total elec w/o matt		\$1,804.83	Non-Drug
E0270	NU	Hospital bed institutional t		\$513.52	Non-Drug
E0270	RR	Hospital bed institutional t		\$54.36	Non-Drug
E0270	UE	Hospital bed institutional t	1 1	\$385.76	Non-Drug

PAGE 12 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
=				*****	N 5
E0271	NU	Mattress innerspring		\$324.34	Non-Drug
E0271 E0271	RR UE	Mattress innerspring		\$38.15 \$256.91	Non-Drug Non-Drug
E0271	NU	Mattress innerspring Mattress foam rubber		\$297.04	Non-Drug Non-Drug
E0272	RR	Mattress foam rubber		\$35.10	Non-Drug
E0272	UE	Mattress foam rubber		\$225.81	Non-Drug
E0273	NU	Bed board		\$43.48	Non-Drug
E0273	RR	Bed board		\$18.28	Non-Drug
E0273	UE	Bed board		\$34.87	Non-Drug
E0273	NO.	Bed board	1	\$83.63 \$69.30	Non-Drug Non-Drug
E0274 E0274	NU RR	Over-bed table Over-bed table		\$31.19	Non-Drug Non-Drug
E0274	ÜÈ	Over-bed table		\$55.78	Non-Drug
E0274		Over-bed table		\$33.45	Non-Drug
E0275	NU	Bed pan standard		\$25.39	Non-Drug
E0275	RR	Bed pan standard	1 1	\$4.57	Non-Drug
E0275	UE	Bed pan standard]	\$19.93	Non-Drug
E0276	NU	Bed pan fracture		\$22.53	Non-Drug Non-Drug
E0276 E0276	RR UE	Bed pan fracture Bed pan fracture		\$4.48 \$18.57	Non-Drug Non-Drug
E0277	NU	Powered pres-redu air mattrs		\$10,109.17	Non-Drug
E0277	RR	Powered pres-redu air mattrs		\$1,070.08	Non-Drug
E0277	UE	Powered pres-redu air mattrs		\$7,594.16	Non-Drug
E0280	NU	Bed cradle		\$62.10	Non-Drug
E0280	RR	Bed cradle		\$8.18	Non-Drug
E0280	UE	Bed cradle		\$47.00	Non-Drug
E0290	NU RR	Hosp bed fx ht w/o rails w/m Hosp bed fx ht w/o rails w/m		\$1,235.89 \$119.90	Non-Drug Non-Drug
E0290 E0290	UE	Hosp bed fx ht w/o rails w/m		\$988.84	Non-Drug
E0290	NU	Hosp bed fx ht w/o rail w/o		\$875.68	Non-Drug
E0291	RR	Hosp bed fx ht w/o rail w/o		\$87.57	Non-Drug
E0291	UE	Hosp bed fx ht w/o rail w/o		\$648.26	Non-Drug
E0292	NU	Hosp bed var ht w/o rail w/o		\$1,326.11	Non-Drug
E0292	RR	Hosp bed var ht w/o rail w/o		\$132.81	Non-Drug
E0292	UE	Hosp bed var ht w/o rail w/o		\$1,060.50 \$1,149.22	Non-Drug Non-Drug
E0293 E0293	NU RR	Hosp bed var ht w/o rail w/ Hosp bed var ht w/o rail w/		\$1,149.22	Non-Drug
E0293	UE	Hosp bed var ht w/o rail w/		\$839.82	Non-Drug
E0294	NU	Hosp bed semi-elect w/ mattr		\$1,913.63	Non-Drug
E0294	RR	Hosp bed semi-elect w/ mattr		\$197.50	Non-Drug
E0294	UE	Hosp bed semi-elect w/ mattr		\$1,315.01	Non-Drug
E0295	NU	Hosp bed semi-elect w/o matt		\$1,765.55	Non-Drug
E0295	RR	Hosp bed semi-elect w/o matt	1	\$192.92 \$1,145.29	Non-Drug Non-Drug
E0295 E0296	UE NU	Hosp bed semi-elect w/o matt Hosp bed total elect w/ matt		\$2,438.14	Non-Drug
E0296	RR	Hosp bed total elect w/ matt		\$244.06	Non-Drug
E0296	ÜE	Hosp bed total elect w/ matt		\$1,950.64	Non-Drug
E0297	NU	Hosp bed total elect w/o mat	1	\$2,116.52	Non-Drug
E0297	RR	Hosp bed total elect w/o mat		\$211.40	Non-Drug
E0297	UE	Hosp bed total elect w/o mat		\$1,416.40 \$297.48	Non-Drug Non-Drug
E0305 F0305	NU RR	Rails bed side half length		\$29.82	Non-Drug
E0305	UE	Rails bed side half length Rails bed side half length		\$213.57	Non-Drug
E0310	NU	Rails bed side full length		\$285.61	Non-Drug
E0310	RR	Rails bed side full length		\$37.68	Non-Drug
E0310	UE	Rails bed side full length		\$220.06	Non-Drug
E0315		Bed accessory brd/tbl/supprt		\$55.46	Non-Drug
E0316	RR	Bed safety enclosure		\$309.40 \$17.98	Non-Drug Non-Drug
E0325 E0325	NU RR	Urinal male jug-type Urinal male jug-type		\$4.31	Non-Drug
E0325	UE	Urinal male jug-type	1	\$13.11	Non-Drug
E0326	NU	Urinal female jug-type		\$18.54	Non-Drug
E0326	RR	Urinal female jug-type		\$3.40	Non-Drug
E0326	UE	Urinal female jug-type		\$14.79	Non-Drug Non-Drug
E0352		Disposable pack w/bowel syst	1	\$59.60 \$20.73	Non-Drug Non-Drug
E0370 E0371	RR	Air elevator for heel Nonpower mattress overlay	1	\$747.40	Non-Drug
E0371	RR	Powered air mattress overlay		\$908.26	
20072		1	*		

PAGE 13 OF 54

HODOG			Status/		CAAE
HCPCS	Modifier	HCPCS Code Description	Usage	Charge	GAAF
Code		·	Indicator		Cateogory
	-				
E0373	RR	Nonpowered pressure mattress		\$1,035.66	Non-Drug
E0424	RR	Stationary compressed gas 02		\$504.85	Non-Drug
E0425	NU	Gas system stationary compre	1	\$6,795.38	Non-Drug
E0425	UE	Gas system stationary compre		\$5,131.01	Non-Drug
E0430 E0430	NU	Oxygen system gas portable		\$3,082.00 \$5.50	Non-Drug Non-Drug
E0430	RR UE	Oxygen system gas portable Oxygen system gas portable		\$2,313.52	Non-Drug Non-Drug
E0431	RR	Portable gaseous 02		\$86.86	Non-Drug
E0434	RR	Portable liquid 02		\$86.86	Non-Drug
E0435	NU	Oxygen system liquid portabl		\$2,121.60	Non-Drug
E0435	UE	Oxygen system liquid portabl		\$1,593.62	Non-Drug
E0439	RR	Stationary liquid 02		\$504.85	Non-Drug
E0440 E0440	NU UE	Oxygen system liquid station Oxygen system liquid station		\$4,298.82 \$3,226.14	Non-Drug Non-Drug
E0440	000	Oxygen contents, gaseous		\$362.18	Non-Drug
E0442		Oxygen contents, liquid	1	\$362.18	Non-Drug
E0443	İ	Portable 02 contents, gas		\$57.89	Non-Drug
E0444		Portable 02 contents, liquid		\$57.89	Non-Drug
E0450	NU	Volume vent stationary/porta		\$15,231.61	Non-Drug
E0450	RR	Volume vent stationary/porta		\$1,612.30	Non-Drug
E0450	UE NU	Volume vent stationary/porta Chest shell		\$11,442.22 \$1,035.73	Non-Drug Non-Drug
E0457 E0457	RR	Chest shell		\$1,035.73	Non-Drug Non-Drug
E0457	ÜE	Chest shell		\$775.16	Non-Drug
E0459	NU	Chest wrap		\$799.79	Non-Drug
E0459	RR	Chest wrap		\$79.98	Non-Drug
E0459	UE	Chest wrap		\$600.12	Non-Drug
E0460	NU	Neg press vent portabl/statn		\$11,692.02	Non-Drug
E0460 E0460	RR UE	Neg press vent portabl/statn		\$1,237.62 \$8,783.23	Non-Drug Non-Drug
E0462	NU	Neg press vent portabl/statn Rocking bed w/ or w/o side r		\$4,207.54	Non-Drug
E0462	RR	Rocking bed w/ or w/o side r		\$420.60	Non-Drug
E0462	UE	Rocking bed w/ or w/o side r		\$3,155.78	Non-Drug
E0480	NU	Percussor elect/pneum home m		\$653.76	Non-Drug
E0480	RR	Percussor elect/pneum home m		\$68.19	Non-Drug
E0480	UE	Percussor elect/pneum home m		\$573.73	Non-Drug
E0481 E0482	RR	Intrpulmnry percuss vent sys Cough stimulating device		\$1,036.44 \$722.88	Non-Drug Non-Drug
E0500	NU	Ippb all types		\$1,978.06	Non-Drug Non-Drug
E0500	RR	Ippb all types		\$179.82	Non-Drug
E0500	UE	Ippb all types		\$1,303.72	Non-Drug
E0550	NU	Humidif extens supple w ippb		\$479.82	Non-Drug
E0550	RR	Humidif extens supple w ippb		\$78.69	Non-Drug
E0550 E0555	UE	Humidifier for you will regula		\$383.85 \$24.55	Non-Drug
E0555	NU RR	Humidifier for use w/ regula Humidifier for use w/ regula		\$16.80	Non-Drug Non-Drug
E0555	UE	Humidifier for use w/ regula		\$20.68	Non-Drug Non-Drug
E0555		Humidifier for use w/ regula		\$21.55	Non-Drug
E0560	NU	Humidifier supplemental w/ i		\$284.54	Non-Drug
E0560	RR	Humidifier supplemental w/ i		\$32.22	Non-Drug
E0560	UE	Humidifier supplemental w/ i		\$211.82	Non-Drug
E0565 E0565	RR R	Compressor air power source		\$969.39 \$97.14	Non-Drug Non-Drug
E0565	UE	Compressor air power source Compressor air power source		\$681.99	Non-Drug
E0570	NU	Nebulizer with compression		\$289.20	Non-Drug
E0570	RR	Nebulizer with compression		\$31.69	Non-Drug
E0570	UE	Nebulizer with compression		\$116.21	Non-Drug
E0571	RR	Aerosol compressor for syneb	1 1	\$46.29	Non-Drug
E0572	RR	Aerosol compressor adjust pr		\$91.46 \$96.16	Non-Drug Non-Drug
E0574 E0575	RR NU	Ultrasonic generator w svneb Nebulizer ultrasonic	1 1	\$1,682.63	Non-Drug Non-Drug
E0575	RR	Nebulizer ultrasonic	1	\$167.97	Non-Drug
E0575	UE	Nebulizer ultrasonic	1	\$1,095.46	Non-Drug
E0580	NU	Nebulizer for use w/ regulat	1	\$220.98	Non-Drug
E0580	RR	Nebulizer for use w/ regulat	1	\$22.67	Non-Drug
E0580	UE	Nebulizer for use w/ regulat		\$164.14 \$536.20	Non-Drug Non-Drug
E0585 E0585	NU RR	Nebulizer w/ compressor & he Nebulizer w/ compressor & he		\$53.56	
20000	1 MX	1 Headinger W. Compressor & No.		\$ 00.00	

PAGE 14 OF 54

		1 AOE 14 OF 54			
HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
E0585	UE	Nebulizer w/ compressor & he		\$345.85	Non-Drug
E0590	05	Dispensing fee dme neb drug		\$7.74	Non-Drug
E0600	NU	Suction pump portab hom modl		\$642.61	Non-Drug
E0600	RR	Suction pump portab hom modi	1	\$71.33	Non-Drug
E0600	ÜE	Suction pump portab hom modi		\$385.69	Non-Drug
E0601	NŪ	Cont airway pressure device	1	\$1,686.27	Non-Drug
E0601	RR	Cont airway pressure device	1	\$183.11	Non-Drug
E0601	UE	Cont airway pressure device	1 1	\$1,009.44	Non-Drug
E0602	NU	Manual breast pump		\$45.65	Non-Drug
E0602	RR	Manual breast pump	1	\$7.79	Non-Drug
E0602	UE	Manual breast pump	1 1	\$35.13	Non-Drug
E0602		Manual breast pump		\$38.44	Non-Drug
E0603	NU	Electric breast pump	1 1	\$128.16	Non-Drug
E0603	RR	Electric breast pump	1 1	\$41.25	Non-Drug
E0603	UE	Electric breast pump	1	\$101.40 \$381.05	Non-Drug Non-Drug
E0604	NU	Hosp grade elec breast pump		\$301.05 \$142.21	Non-Drug Non-Drug
E0604 E0604	RR UE	Hosp grade elec breast pump Hosp grade elec breast pump		\$284.04	Non-Drug
E0605	NU	Vaporizer room type	1 1	\$41.24	Non-Drug Non-Drug
E0605	RR	Vaporizer room type		\$7.95	Non-Drug
E0605	I ÜE I	Vaporizer room type		\$34.60	Non-Drug
E0606	NU	Drainage board postural		\$365.51	Non-Drug
E0606	RR	Drainage board postural	l i	\$36.27	Non-Drug
E0606	UE	Drainage board postural	1 1	\$274.27	Non-Drug
E0607	NU	Blood glucose monitor home	1 1	\$79.99	Non-Drug
E0607	RR	Blood glucose monitor home		\$10.88	Non-Drug
E0607	UE	Blood glucose monitor home	1 1	\$71.29	Non-Drug
E0607		Blood glucose monitor home		\$78.60	Non-Drug
E0610	NU	Pacemaker monitr audible/vis	1 1	\$397.03	Non-Drug
E0610	RR	Pacemaker monitr audible/vis	1	\$39.33	Non-Drug
E0610 E0615	UE NU	Pacemaker monitr audible/vis Pacemaker monitr digital/vis	1 1	\$296.24 \$805.64	Non-Drug Non-Drug
E0615	RR	Pacemaker monitr digital/vis		\$92.88	Non-Drug
E0615	UE	Pacemaker monitr digital/vis		\$602.66	Non-Drug
E0617	RR	Automatic ext defibrillator	1 1	\$509.27	Non-Drug
E0618		Apnea monitor		\$483.42	Non-Drug
E0621	NU	Patient lift sling or seat		\$156.46	Non-Drug
E0621	RR	Patient lift sling or seat		\$16.76	Non-Drug
E0621	UE	Patient lift sling or seat		\$116.39	Non-Drug
E0625	NU	Patient lift bathroom or toi	1 1	\$1,091.15	Non-Drug
E0625	RR	Patient lift bathroom or toi		\$115.50	Non-Drug
E0625	UE	Patient lift bathroom or toi		\$819.69	Non-Drug
E0627 E0627	NU RR	Seat lift incorp lift-chair Seat lift incorp lift-chair	1 1	\$565.69 \$51.66	Non-Drug Non-Drug
E0627	UE	Seat lift incorp lift-chair	1 1	\$422.70	Non-Drug
E0628	NU	Seat lift for pt furn-electr	[[\$565.69	Non-Drug
E0628	RR	Seat lift for pt furn-electr		\$51.66	Non-Drug
E0628	UE	Seat lift for pt furn-electr		\$422.70	Non-Drug
E0629	NU	Seat lift for pt furn-non-el		\$554.48	Non-Drug
E0629	RR	Seat lift for pt furn-non-el	j	\$50.72	Non-Drug
E0629	UE	Seat lift for pt furn-non-el		\$414.24	Non-Drug
E0630	NU	Patient lift hydraulic		\$1,784.73	Non-Drug
E0630	RR	Patient lift hydraulic	1	\$166.46	Non-Drug
E0630	UE	Patient lift hydraulic	1	\$1,268.37 \$2,009.71	Non-Drug
E0635 E0635	NU RR	Patient lift electric Patient lift electric] }	\$2,009.71	Non-Drug Non-Drug
E0635	UE	Patient lift electric	1 1	\$1,371.73	Non-Drug Non-Drug
E0650	NU	Pneuma compresor non-segment	1	\$1,214.99	Non-Drug
E0650	RR	Pneuma compresor non-segment		\$144.38	Non-Drug
E0650	UE	Pneuma compresor non-segment		\$909.65	Non-Drug
E0651	NU	Pneum compressor segmental		\$1,551.08	Non-Drug
E0651	RR	Pneum compressor segmental		\$152.78	Non-Drug
E0651	UE	Pneum compressor segmental		\$1,161.74	Non-Drug
E0652	NU	Pneum compres w/cal pressure		\$8,983.55	Non-Drug Non-Drug
E0652	RR UE	Pneum compres w/cal pressure Pneum compres w/cal pressure		\$882.16 \$6,730.05	Non-Drug Non-Drug
E0652 E0655	NU	Pneumatic appliance half arm		\$176.69	Non-Drug
E0655	RR	Pneumatic appliance half arm		\$21.65	Non-Drug
		•	·		

PAGE 15 OF 54

	1				
HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
E0655	UE	Pneumatic appliance half arm		\$131,12	Non-Drug
E0660	NU	Pneumatic appliance full leg	1 1	\$264.58	Non-Drug
E0660	RR	Pneumatic appliance full leg		\$27.27	Non-Drug
E0660	UE	Pneumatic appliance full leg	1 1	\$196.83	Non-Drug
E0665	NU	Pneumatic appliance full arm		\$225.98	Non-Drug
E0665 E0665	RR UE	Pneumatic appliance full arm Pneumatic appliance full arm	1 1	\$23.63 \$168.14	Non-Drug Non-Drug
E0666	NU	Pneumatic appliance half leg	1	\$227.83	Non-Drug
E0666	RR	Pneumatic appliance half leg		\$23.85	Non-Drug
E0666	UE	Pneumatic appliance half leg		\$169.34	Non-Drug
E0667	NU	Seg pneumatic appl full leg		\$542.71	Non-Drug
E0667 E0667	RR UE	Seg pneumatic appl full leg Seg pneumatic appl full leg		\$55.68 \$405.46	Non-Drug Non-Drug
E0668	NU	Seg pneumatic appl full arm		\$743.00	Non-Drug
E0668	RR	Seg pneumatic appl full arm		\$67.63	Non-Drug
E0668	UE	Seg pneumatic appl full arm		\$555.68	Non-Drug
E0669	NU	Seg pneumatic appli half leg		\$304.53	Non-Drug
E0669 E0669	RR UE	Seg pneumatic appli half leg Seg pneumatic appli half leg		\$29.71 \$226.86	Non-Drug Non-Drug
E0671	NU	Pressure pneum appli full leg		\$698.01	Non-Drug
E0671	RR	Pressure pneum appl full leg		\$64.12	Non-Drug
E0671	ŲΕ	Pressure pneum appl full leg		\$521.91	Non-Drug
E0672	NU	Pressure pneum appl full arm		\$540.95	Non-Drug
E0672 E0672	RR UE	Pressure pneum appl full arm		\$49.58	Non-Drug
E0672	NU	Pressure pneum appl full arm Pressure pneum appl half leg		\$404.15 \$448.43	Non-Drug Non-Drug
E0673	RR	Pressure pneum appl half leg		\$41.80	Non-Drug
E0673	UE	Pressure pneum appl half leg		\$334.78	Non-Drug
E0700		Safety equipment		\$41.11	Non-Drug
E0710		Restraints any type		\$401.83 \$617.00	Non-Drug
E0720 E0720	NU RR	Tens two lead Tens two lead	1 1	\$177.48	Non-Drug Non-Drug
E0720	ÜE	Tens two lead		\$338.25	Non-Drug
E0730	NU	Tens four lead		\$622.06	Non-Drug
E0730	RR	Tens four lead		\$211.79	Non-Drug
E0730 E0731	UE NU	Tens four lead	1 1	\$342.74 \$598.54	Non-Drug
E0731	RR	Conductive garment for tens/ Conductive garment for tens/		\$63.36	Non-Drug Non-Drug
E0731	ÜE	Conductive garment for tens/		\$449.63	Non-Drug
E0740	NU	Incontinence treatment systm		\$880.33	Non-Drug
E0740	RR	Incontinence treatment systm		\$82.35	Non-Drug
E0740 E0744	UE NU	Incontinence treatment systm Neuromuscular stim for scoli		\$658.72 \$998.18	Non-Drug Non-Drug
E0744	RR	Neuromuscular stim for scoli		\$148.96	Non-Drug
E0744	UE	Neuromuscular stim for scoli		\$904.91	Non-Drug
E0745	NU	Neuromuscular stim for shock		\$1,374.26	Non-Drug
E0745	RR	Neuromuscular stim for shock		\$145.47	Non-Drug
E0745 E0747	UE NU	Neuromuscular stim for shock Elec osteogen stim not spine		\$1,032.36 \$5,974.90	Non-Drug Non-Drug
E0747	RR	Elec osteogen stim not spine		\$5,974.90	Non-Drug
E0747	UE	Elec osteogen stim not spine		\$4,437.62	Non-Drug
E0748	NU	Elec osteogen stim spinal		\$5,936.14	Non-Drug
E0748	RR	Elec osteogen stim spinal		\$587.92	Non-Drug
E0748 E0749	UE RR	Elec osteogen stim spinal Elec osteogen stim implanted		\$4,450.56 \$428.01	Non-Drug Non-Drug
E0749	KK	Elec osteogen stim implanted		\$5,661.76	Non-Drug
E0752		Neurostimulator electrode		\$508.73	Non-Drug
E0754		Pulsegenerator pt programmer		\$1,370.24	Non-Drug
E0756		Implantable pulse generator		\$9,845.24	Non-Drug
E0757 E0758		Implantable RF receiver External RF transmitter		\$7,024.19 \$6,178.68	Non-Drug Non-Drug
E0759		Replace rdfrquncy transmittr		\$851.93	Non-Drug
E0760	NU	Osteogen ultrasound stimitor		\$4,931.75	Non-Drug
E0760	RR	Osteogen ultrasound stimitor		\$487.50	Non-Drug
E0760	UE NU	Osteogen ultrasound stimitor Nerve stimulator for tx n&v		\$3,697.24 \$136.35	Non-Drug Non-Drug
E0765 E0765	RR	Nerve stimulator for tx n&v		\$15.59	Non-Drug
E0765	ÜE	Nerve stimulator for tx n&v		\$100.72	

PAGE 16 OF 54

	,				
			Status/		
HCPCS	Modifier	HCPCS Code Description	Usage	Charge	GAAF
Code	Widamer	nor do dae Bescription	Indicator	Onargo	Cateogory
			indicator		
F0776		lu noto		C22C 44	Non Drug
E0776	NU RR	lv pole Iv pole		\$236.44 \$30.15	Non-Drug Non-Drug
E0776 E0776	UE	ly pole	1	\$172.29	Non-Drug
E0779	RR	Amb infusion pump mechanical		\$27.42	Non-Drug
E0780	NU	Mech amb infusion pump <8hrs		\$18.35	Non-Drug
E0781	RR	External ambulatory infus pu		\$442.83	Non-Drug
E0782	NU	Non-programble infusion pump		\$6,551.24	Non-Drug
E0782	RR	Non-programble infusion pump		\$649.46	Non-Drug
E0782	UE	Non-programble infusion pump		\$4,911.85	Non-Drug
E0782		Non-programble infusion pump		\$7,627.39	Non-Drug
E0783	NU	Programmable infusion pump		\$12,497.95	Non-Drug
E0783	RR	Programmable infusion pump		\$1,244.12 \$9,371.89	Non-Drug Non-Drua
E0783 E0784	UE RR	Programmable infusion pump Ext amb infusn pump insulin		\$701.77	Non-Drug Non-Drug
E0784	KK	Ext amb infusin pump insulin		\$5,014.13	Non-Drug
E0785	1	Replacement impl pump cathet		\$715.35	Non-Drug
E0786	NU	Implantable pump replacement		\$12,190.83	Non-Drug
E0786	RR	Implantable pump replacement		\$1,213.39	Non-Drug
E0786	UE	Implantable pump replacement		\$9,141.54	Non-Drug
E0791	NU	Parenteral infusion pump sta	1	\$6,053.99	Non-Drug
E0791	RR	Parenteral infusion pump sta		\$640.83	Non-Drug
E0791	UE	Parenteral infusion pump sta		\$4,547.85	Non-Drug
E0830		Ambulatory traction device		\$2,267.22	Non-Drug
E0840	NU	Tract frame attach headboard		\$117.59	Non-Drug
E0840	RR	Tract frame attach headboard		\$27.49	Non-Drug
E0840	UE	Tract frame attach headboard		\$88.56	Non-Drug
E0850	NU	Traction stand free standing		\$161.98 \$24.50	Non-Drug
E0850	RR UE	Traction stand free standing		\$24.50 \$125.53	Non-Drug
E0850 E0855	NU	Traction stand free standing Cervical traction equipment		\$846.01	Non-Drug Non-Drug
E0855	RR	Cervical traction equipment		\$78.91	Non-Drug
E0855	ÜÈ	Cervical traction equipment	1	\$632.91	Non-Drug
E0860	NU	Tract equip cervical tract		\$62.62	Non-Drug
E0860	RR	Tract equip cervical tract		\$11.97	Non-Drug
E0860	UE	Tract equip cervical tract		\$48.36	Non-Drug
E0870	NU	Tract frame attach footboard	1 1	\$177.59	Non-Drug
E0870	RR	Tract frame attach footboard		\$22.87	Non-Drug
E0870	UE	Tract frame attach footboard		\$137.78	Non-Drug
E0880	NU	Trac stand free stand extrem	1 1	\$190.40	Non-Drug
E0880	RR	Trac stand free stand extrem		\$32.85	Non-Drug
E0880	UE	Trac stand free stand extrem		\$148.05	Non-Drug
E0890 E0890	NU	Traction frame attach pelvic	1	\$183.28	Non-Drug
E0890	RR UE	Traction frame attach pelvic Traction frame attach pelvic]	\$53.61 \$150.78	Non-Drug Non-Drug
E0900	NU	Trac stand free stand pelvic		\$193.98	Non-Drug
E0900	RR	Trac stand free stand pelvic		\$45.37	Non-Drug
E0900	ÜE	Trac stand free stand pelvic		\$149.57	Non-Drug
E0910	NU	Trapeze bar attached to bed		\$333.66	Non-Drug
E0910	RR	Trapeze bar attached to bed		\$33.31	Non-Drug
E0910	UE	Trapeze bar attached to bed		\$250.38	Non-Drug
E0920	NU	Fracture frame attached to b		\$745.97	Non-Drug
E0920	RR	Fracture frame attached to b		\$74.66	Non-Drug
E0920	UE	Fracture frame attached to b		\$618.80	Non-Drug
E0930	NU	Fracture frame free standing		\$736.87	Non-Drug
E0930	RR	Fracture frame free standing	1	\$73.95 \$541.85	Non-Drug Non-Drug
E0930 E0935	UE RR	Fracture frame free standing Exercise device passive moti	1	\$35.97	Non-Drug
E0940	NU	Trapeze bar free standing		\$529.98	Non-Drug
E0940	RR	Trapeze bar free standing		\$56.68	Non-Drug
E0940	UE	Trapeze bar free standing	1	\$375.02	Non-Drug
E0941	NU	Gravity assisted traction de		\$702.78	Non-Drug
E0941	RR	Gravity assisted traction de		\$70.34	Non-Drug
E0941	UE	Gravity assisted traction de		\$531.40	Non-Drug
E0942	NU	Cervical head harness/halter		\$33.08	Non-Drug
E0942	RR	Cervical head harness/halter		\$5.38	Non-Drug
E0942	UE	Cervical head harness/halter	1	\$25.21	Non-Drug
E0943	NU	Cervical pillow		\$45.44 \$6.80	Non-Drug Non-Drug
E0943	RR	Cervical pillow	1 1	φυ.ου	, Hon-Ding

PAGE 17 OF 54

HCPCS			Status/		GAAF
Code	Modifier	HCPCS Code Description	Usage Indicator	Charge	Cateogory
E0943	UE	Cervical pillow	1	\$34.48	Non-Drug
E0944	NU	Pelvic belt/harness/boot		\$63.32	Non-Drug
E0944	RR	Pelvic belt/harness/boot		\$7.06	Non-Drug
E0944 E0945	NU NU	Pelvic belt/harness/boot Belt/harness extremity		\$47.68 \$61.20	Non-Drug Non-Drug
E0945	RR	Belt/harness extremity		\$6.84	Non-Drug
E0945	ÜE	Belt/harness extremity		\$47.55	Non-Drug
E0946	NU	Fracture frame dual w cross		\$954.27	Non-Drug
E0946	RR	Fracture frame dual w cross	1	\$95.26	Non-Drug
E0946	UE NU	Fracture frame dual w cross Fracture frame attachmnts pe		\$716.14 \$857.87	Non-Drug Non-Drug
E0947 E0947	RR	Fracture frame attachmnts pe		\$101.16	Non-Drug
E0947	ÜÈ	Fracture frame attachmnts pe	1	\$647.44	Non-Drug
E0948	NU	Fracture frame attachmnts ce		\$830.29	Non-Drug
E0948	RR	Fracture frame attachmnts ce		\$94.43	Non-Drug
E0948 E0950	NU NU	Fracture frame attachmnts ce Trav		\$590.34 \$141.97	Non-Drug Non-Drug
E0950	RR	Tray		\$17.27	Non-Drug
E0950	UE	Tray		\$108.44	Non-Drug
E0950		Tray	1	\$52.12	Non-Drug
E0951	NU	Loop heel	1	\$26.45	Non-Drug
E0951	RR UE	Loop heel Loop heel		\$3.45 \$20.05	Non-Drug Non-Drug
E0951 E0952	NU	Loop fiee		\$32.73	Non-Drug
E0952	RR	Loop tie		\$4.40	Non-Drug
E0952	UE	Loop tie		\$25.00	Non-Drug
E0953	NU	Pneumatic tire	1	\$62.09	Non-Drug
E0953 E0953	RR UE	Pneumatic tire Pneumatic tire		\$6.97 \$46.63	Non-Drug Non-Drug
E0953	00	Pneumatic tire	1	\$26.71	Non-Drug
E0954	NU	Wheelchair semi-pneumatic ca	1	\$63.12	Non-Drug
E0954	RR	Wheelchair semi-pneumatic ca		\$8.52	Non-Drug
E0954	UE	Wheelchair semi-pneumatic ca	1 1	\$36.85	Non-Drug
E0954 E0958	NU	Wheelchair semi-pneumatic ca Whichr att- conv 1 arm drive		\$71.75 \$603.81	Non-Drug Non-Drug
E0958	RR	Whichr att- conv 1 arm drive	1	\$60.26	Non-Drug
E0958	ÜÈ	Whichr att- conv 1 arm drive	1 1	\$453.17	Non-Drug
E0959	NU	Amputee adapter		\$118.55	Non-Drug
E0959	RR	Amputee adapter		\$15.73	Non-Drug
E0959 E0959	UE	Amputee adapter Amputee adapter		\$94.21 \$175.17	Non-Drug Non-Drug
E0961	NU	Wheelchair brake extension	1	\$51.27	Non-Drug
E0961	RR	Wheelchair brake extension		\$6.46	Non-Drug
E0961	UE	Wheelchair brake extension		\$38.91	Non-Drug
E0961		Wheelchair brake extension Wheelchair 1 inch cushion		\$21.09 \$80.16	Non-Drug Non-Drug
E0962 E0962	NU RR	Wheelchair 1 inch cushion		\$8.89	Non-Drug
E0962	ÜE	Wheelchair 1 inch cushion		\$61.59	Non-Drug
E0963	NU	Wheelchair 2 inch cushion		\$94.22	Non-Drug
E0963	RR	Wheelchair 2 inch cushion		\$10.63	Non-Drug
E0963 E0964	NU NU	Wheelchair 2 inch cushion Wheelchair 3 inch cushion]	\$72.78 \$104.21	Non-Drug Non-Drug
E0964	RR	Wheelchair 3 inch cushion		\$11.68	Non-Drug
E0964	ÜE	Wheelchair 3 inch cushion		\$80.16	Non-Drug
E0965	NU	Wheelchair 4 inch cushion		\$110.85	Non-Drug
E0965	RR	Wheelchair 4 inch cushion		\$12.35	Non-Drug
E0965 E0966	NU NU	Wheelchair 4 inch cushion Wheelchair head rest extensi		\$85.13 \$94.21	Non-Drug Non-Drug
E0966	RR	Wheelchair head rest extensi		\$10.58	Non-Drug
E0966	UE	Wheelchair head rest extensi	1	\$67.11	Non-Drug
E0966		Wheelchair head rest extensi		\$75.52	Non-Drug
E0967 E0967	NU RR	Wheelchair hand rims Wheelchair hand rims		\$168.43 \$19.27	Non-Drug Non-Drug
E0967	UE	Wheelchair hand rims Wheelchair hand rims		\$128.33	Non-Drug
E0968	NU	Wheelchair commode seat		\$254.80	Non-Drug
E0968	RR	Wheelchair commode seat		\$25.23	Non-Drug
E0968	UE	Wheelchair parrowing device		\$162.47 \$198.20	Non-Drug Non-Drug
E0969	NU	Wheelchair narrowing device	, ,	₩190.20	, Honebrug

PAGE 18 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
E0969	RR	Wheelchair narrowing device		\$21.93	Non-Drug
E0969	UE	Wheelchair narrowing device		\$150.63	Non-Drug
E0970 E0970	NU	Wheelchair no. 2 footplates		\$69.87 \$6.97	Non-Drug
E0970	RR UE	Wheelchair no. 2 footplates Wheelchair no. 2 footplates		\$53.33	Non-Drug Non-Drug
E0970	"	Wheelchair no. 2 footplates		\$50.44	Non-Drug
E0971	NU	Wheelchair anti-tipping devi		\$87.77	Non-Drug
E0971	RR	Wheelchair anti-tipping devi		\$10.96	Non-Drug
E0971	UE	Wheelchair anti-tipping devi		\$67.79	Non-Drug
E0972 E0972	NU RR	Transfer board or device Transfer board or device		\$97.75 \$12.09	Non-Drug Non-Drug
E0972	ÜÈ	Transfer board or device		\$71.92	Non-Drug
E0972	"	Transfer board or device	1	\$63.42	Non-Drug
E0973	NU	Wheelchair adjustabl height		\$140.59	Non-Drug
E0973	RR	Wheelchair adjustabl height		\$14.70	Non-Drug
E0973 E0973	UE	Wheelchair adjustabl height		\$103.85 \$147.58	Non-Drug Non-Drug
E0973	NU	Wheelchair adjustabl height Wheelchair grade-aid		\$147.36	Non-Drug
E0974	RR	Wheelchair grade-aid		\$12.64	Non-Drug
E0974	UE	Wheelchair grade-aid		\$84.56	Non-Drug
E0974		Wheelchair grade-aid		\$198.42	Non-Drug
E0975	NU	Wheelchair reinforced seat u		\$73.54	Non-Drug
E0975 E0975	RR UE	Wheelchair reinforced seat u Wheelchair reinforced seat u		\$8.00 \$55.91	Non-Drug Non-Drug
E0975	00	Wheelchair reinforced seat u	1	\$68.32	Non-Drug Non-Drug
E0976	NU	Wheelchair reinforced back u		\$63.63	Non-Drug
E0976	RR	Wheelchair reinforced back u		\$8.00	Non-Drug
E0976	UE	Wheelchair reinforced back u		\$55.91	Non-Drug
E0976		Wheelchair reinforced back u		\$68.90	Non-Drug
E0977 E0977	NU RR	Wheelchair wedge cushion Wheelchair wedge cushion		\$87.35 \$9.38	Non-Drug Non-Drug
E0977	ÜE	Wheelchair wedge cushion		\$67.51	Non-Drug
E0978	NU	Wheelchair belt w/airplane b		\$68.03	Non-Drug
E0978	RR	Wheelchair belt w/airplane b		\$7.49	Non-Drug
E0978	UE	Wheelchair belt w/airplane b		\$51.27	Non-Drug
E0978 E0979	NU	Wheelchair belt w/airplane b Wheelchair belt with velcro		\$58.99 \$49.72	Non-Drug Non-Drug
E0979	RR	Wheelchair belt with velcro		\$5.43	Non-Drug Non-Drug
E0979	UE	Wheelchair belt with velcro		\$37.36	Non-Drug
E0979		Wheelchair belt with velcro		\$58.99	Non-Drug
E0980	NU	Wheelchair safety vest		\$45.85	Non-Drug
E0980 E0980	RR UE	Wheelchair safety vest Wheelchair safety vest		\$5.29 \$34.40	Non-Drug Non-Drug
E0990	NU	Whellchair elevating leg res		\$155.75	Non-Drug Non-Drug
E0990	RR	Whellchair elevating leg res		\$20.36	Non-Drug
E0990	UE	Whellchair elevating leg res		\$124.98	Non-Drug
E0990	1	Whellchair elevating leg res		\$150.57	Non-Drug
E0991	NU	Wheelchair upholstry seat		\$67.11	Non-Drug
E0991 E0991	RR UE	Wheelchair upholstry seat Wheelchair upholstry seat		\$8.52 \$50.24	Non-Drug Non-Drug
E0991	\ \frac{1}{2}	Wheelchair upholstry seat		\$63.32	Non-Drug
E0992	NU	Wheelchair solid seat insert		\$130.95	Non-Drug
E0992	RR	Wheelchair solid seat insert		\$14.70	Non-Drug
E0992	UE	Wheelchair solid seat insert		\$86.86	Non-Drug
E0992 E0993	NU	Wheelchair solid seat insert Wheelchair back upholstery		\$123.49 \$63.12	Non-Drug Non-Drug
E0993	RR	Wheelchair back upholstery		\$7.49	Non-Drug Non-Drug
E0993	ÜE	Wheelchair back upholstery		\$47.66	Non-Drug
E0993		Wheelchair back upholstery		\$64.17	Non-Drug
E0994	NU	Wheelchair arm rest		\$24.82	Non-Drug
E0994 E0994	RR UE	Wheelchair arm rest Wheelchair arm rest		\$3.22 \$18.82	Non-Drug Non-Drug
E0994 E0995	NU	Wheelchair calf rest		\$45.09	Non-Drug Non-Drug
E0995	RR	Wheelchair calf rest] [\$5.94	Non-Drug
E0995	UE	Wheelchair calf rest		\$39.42	Non-Drug
E0995	,	Wheelchair calf rest	1	\$42.22	Non-Drug
E0996	NU	Wheelchair tire solid	1 1	\$42.00	Non-Drug

PAGE 19 OF 54

<u> </u>			<u> </u>		
HCPCS	Modifier	HCPCS Code Description	Status/ Usage	Charge	GAAF
Code	Wiodiller	rior od dode bescription	Indicator	Charge	Cateogory
		——————————————————————————————————————			
E0996	UE	Wheelchair tire solid		\$32.73	Non-Drug
E0996	l	Wheelchair tire solid		\$39.66 \$88.69	Non-Drug
E0997 E0997	NU RR	Wheelchair caster w/ a fork Wheelchair caster w/ a fork	1 1	\$10.51	Non-Drug Non-Drug
E0997	UE	Wheelchair caster w/ a fork	1 1	\$68.49	Non-Drug Non-Drug
E0998	NU	Wheelchair caster w/o a fork		\$52.96	Non-Drug
E0998	RR	Wheelchair caster w/o a fork		\$6.19	Non-Drug
E0998	UE	Wheelchair caster w/o a fork		\$39.95	Non-Drug
E0999	NU	Wheelchr pneumatic tire w/wh		\$147.58	Non-Drug
E0999	RR	Wheelchr pneumatic tire w/wh	1 1	\$16.48	Non-Drug
E0999	UE	Wheelchr pneumatic tire w/wh	j j	\$112.65	Non-Drug
E1000 E1000	NU RR	Wheelchair tire pneumatic ca		\$53.33 \$7.49	Non-Drug Non-Drug
E1000	UE	Wheelchair tire pneumatic ca Wheelchair tire pneumatic ca		\$39.94	Non-Drug Non-Drug
E1000	00	Wheelchair tire pneumatic ca	1 1	\$49.86	Non-Drug
E1001	NU	Wheelchair wheel		\$127.03	Non-Drug
E1001	RR	Wheelchair wheel		\$14.82	Non-Drug
E1001	UE	Wheelchair wheel		\$97.25	Non-Drug
E1031	NU	Rollabout chair with casters		\$692.48	Non-Drug
E1031	RR	Rollabout chair with casters	[[\$69.25	Non-Drug
E1031	UE	Rollabout chair with casters		\$519.36 \$366.99	Non-Drug
E1035 E1050	NU	Patient transfer system Whelchr fxd full length arms		\$366.99 \$1,477.68	Non-Drug Non-Drug
E1050	RR	Whelchr fxd full length arms		\$1,477.00	Non-Drug Non-Drug
E1050	ÜÈ	Whelchr fxd full length arms		\$1,108.70	Non-Drug Non-Drug
E1060	NÜ	Wheelchair detachable arms		\$1,906.99	Non-Drug
E1060	RR	Wheelchair detachable arms	1 1	\$161.07	Non-Drug
E1060	UE	Wheelchair detachable arms	1 1	\$1,430.11	Non-Drug
E1065	NU	Wheelchair power attachment		\$3,540.64	Non-Drug
E1065	RR	Wheelchair power attachment	1 1	\$329.05	Non-Drug
E1065	UE	Wheelchair power attachment		\$2,657.45	Non-Drug
E1066 E1066	NU RR	Wheelchair battery charger Wheelchair battery charger		\$352.30 \$39.42	Non-Drug Non-Drug
E1066	UE	Wheelchair battery charger	1 1	\$248.05	Non-Drug
E1066	"-	Wheelchair battery charger		\$328.21	Non-Drug
E1069	NU	Wheelchair deep cycle batter	1 1	\$134.16	Non-Drug
E1069	RR	Wheelchair deep cycle batter		\$20.36	Non-Drug
E1069	UE	Wheelchair deep cycle batter	1 1	\$118.55	Non-Drug
E1069		Wheelchair deep cycle batter	1	\$144.38	Non-Drug
E1070	NU	Wheelchair detachable foot r		\$1,731.26	Non-Drug
E1070 E1070	RR UE	Wheelchair detachable foot r Wheelchair detachable foot r		\$140.97 \$1,298.33	Non-Drug Non-Drug
E1070	NU	Hemi-wheelchair fixed arms	1 1	\$1,036.41	Non-Drug
E1083	RR	Hemi-wheelchair fixed arms	1 1	\$103.55	Non-Drug
E1083	UE	Hemi-wheelchair fixed arms	1 1	\$756.42	Non-Drug
E1084	NU	Hemi-wheelchair detachable a		\$1,554.76	Non-Drug
E1084	RR	Hemi-wheelchair detachable a		\$127.08	Non-Drug
E1084	UE	Hemi-wheelchair detachable a		\$1,110.54	Non-Drug
E1085	NU	Hemi-wheelchair fixed arms		\$967.69	Non-Drug
E1085	RR UE	Hemi-wheelchair fixed arms		\$103.85 \$697.20	Non-Drug Non-Drug
E1085	UE	Hemi-wheelchair fixed arms Hemi-wheelchair fixed arms]]	\$849.98	Non-Drug Non-Drug
E1085 E1086	NU	Hemi-wheelchair detachable a	1 1	\$1,177.11	Non-Drug
E1086	RR	Hemi-wheelchair detachable a	1 1	\$114.41	Non-Drug
E1086	UE	Hemi-wheelchair detachable a	1 1	\$857.01	Non-Drug
E1086		Hemi-wheelchair detachable a		\$849.98	Non-Drug
E1087	NU	Wheelchair lightwt fixed arm		\$1,613.99	Non-Drug
E1087	RR	Wheelchair lightwt fixed arm		\$161.60	Non-Drug
E1087	UE	Wheelchair lightwoight det a		\$1,176.87 \$1,916.99	Non-Drug Non-Drug
E1088 E1088	NU RR	Wheelchair lightweight det a Wheelchair lightweight det a		\$1,910.99	Non-Drug Non-Drug
E1088	UE	Wheelchair lightweight det a		\$1,314.83	Non-Drug
E1089	NU	Wheelchair lightwt fixed arm		\$1,559.66	Non-Drug
E1089	RR	Wheelchair lightwt fixed arm		\$163.09	Non-Drug
E1089	UE	Wheelchair lightwt fixed arm		\$1,172.05	Non-Drug
E1089		Wheelchair lightwt fixed arm		\$2,024.06	Non-Drug
E1090	NU RR	Wheelchair lightweight det a		\$1,607.88 \$163.09	Non-Drug Non-Drug
E1090	1 1/1/1	Wheelchair lightweight det a	, ,	\$105.0 3	Hombing

PAGE 20 OF 54

	·				
			Status/		
HCPCS	Mandisina	UCDCC Code Deposition	1 1	Chaus	GAAF
Code	Modifier	HCPCS Code Description	Usage	Charge	Cateogory
			Indicator		,
	 				
E1090	UE	Wheelchair lightweight det a	1 [\$1,177.11	Non-Drug
E1090	j	Wheelchair lightweight det a	1 1	\$2,024.06	Non-Drug
E1091	RR	Wheelchair youth		\$109.18	Non-Drug
E1092	NU	Wheelchair wide w/ leg rests		\$1,808.49	Non-Drug
E1092	RR	Wheelchair wide w/ leg rests	1 1	\$164.03	Non-Drug
E1092	UE	Wheelchair wide w/ leg rests		\$1,321.59	Non-Drug
E1093	NU	Wheelchair wide w/ foot rest	i j	\$1,388.44	Non-Drug
E1093	RR	Wheelchair wide w/ foot rest Wheelchair wide w/ foot rest	1 1	\$142.17	Non-Drug
E1093 E1100	UE NU		1	\$1,033.26 \$1,339.73	Non-Drug
E1100	RR	Whchr s-recl fxd arm leg res Whchr s-recl fxd arm leg res		\$1,339.73	Non-Drug Non-Drug
E1100	UE	Which s-recified arm legites Which s-recified arm legites		\$1,005.12	Non-Drug
E1110	NU	Wheelchair semi-recl detach	1	\$1,315.52	Non-Drug
E1110	RR	Wheelchair semi-recl detach		\$131.40	Non-Drug
E1110	ÜE	Wheelchair semi-recl detach	1 1	\$957.01	Non-Drug
E1130	NU	Whichr stand fxd arm ft rest	1 1	\$623.26	Non-Drug
E1130	RR	Whichr stand fxd arm ft rest		\$69.41	Non-Drug
E1130	UE	Whichr stand fxd arm ft rest	1	\$475.38	Non-Drug
E1130		Whichr stand fxd arm ft rest	1 1	\$739.55	Non-Drug
E1140	NU	Wheelchair standard detach a		\$894.21	Non-Drug
E1140	RR	Wheelchair standard detach a	1 1	\$96.50	Non-Drug
E1140	UE	Wheelchair standard detach a		\$635.66	Non-Drug
E1140		Wheelchair standard detach a	1 1	\$739.55	Non-Drug
E1150	NU	Wheelchair standard w/ leg r	1 1	\$1,104.42	Non-Drug
E1150	RR	Wheelchair standard w/ leg r	1 1	\$107.00	Non-Drug
E1150	UE	Wheelchair standard w/ leg r	1 1	\$731.55	Non-Drug
E1160	NU	Wheelchair fixed arms		\$918.73	Non-Drug
E1160	RR	Wheelchair fixed arms	1 1	\$83.82	Non-Drug
E1160	NU NU	Wheelchair fixed arms	1 1	\$641.69 \$1,164.42	Non-Drug
E1170 E1170	RR	Whichr ampu fxd arm leg rest Whichr ampu fxd arm leg rest	1 1	\$1,104.42	Non-Drug Non-Drug
E1170	ÜE	Which ampu fxd arm leg rest	1 1	\$873.20	Non-Drug
E1171	NU	Wheelchair amputee w/o leg r	1 1	\$1,053.05	Non-Drug
E1171	RR	Wheelchair amputee w/o leg r	1	\$105.27	Non-Drug
E1171	ÜE	Wheelchair amputee w/o leg r	1 1	\$790.08	Non-Drug
E1172	NU	Wheelchair amputee detach ar	1 1	\$1,268.56	Non-Drug
E1172	RR	Wheelchair amputee detach ar		\$126.89	Non-Drug
E1172	UE	Wheelchair amputee detach ar		\$951.32	Non-Drug
E1180	NU	Wheelchair amputee w/ foot r		\$1,309.68	Non-Drug
E1180	RR	Wheelchair amputee w/ foot r	1 1	\$131.01	Non-Drug
E1180	UE	Wheelchair amputee w/ foot r	1 1	\$982.38	Non-Drug
E1190	NU	Wheelchair amputee w/ leg re	1	\$1,502.26	Non-Drug
E1190	RR	Wheelchair amputee w/ leg re		\$150.13	Non-Drug
E1190	UE	Wheelchair amputee w/ leg re	1 1	\$1,097.21	Non-Drug
E1195	NU	Wheelchair amputee heavy dut	1 1	\$1,603.63	Non-Drug
E1195	RR UE	Wheelchair amputee heavy dut		\$160.53 ¹	Non-Drug
E1195 E1200	NU	Wheelchair amputee heavy dut Wheelchair amputee fixed arm	j 1	\$1,202.93 \$1,133.55	Non-Drug Non-Drug
E1200	RR	Wheelchair amputee fixed arm		\$1,133.55 \$113.60	Non-Drug Non-Drug
E1200	UE	Wheelchair amputee fixed arm		\$850.16	Non-Drug Non-Drug
E1210	NU	Whichr moto ful arm leg rest		\$5,071.30	Non-Drug
E1210	RR	Which moto ful arm leg rest	1	\$507.13	Non-Drug
E1210	ÜE	Whichr moto ful arm leg rest		\$3,804.13	Non-Drug
E1211	NU	Wheelchair motorized w/ det		\$5,159.87	Non-Drug
E1211	RR	Wheelchair motorized w/ det		\$516.43	Non-Drug
E1211	UE	Wheelchair motorized w/ det	1 1	\$3,872.10	Non-Drug
E1212	NU	Wheelchair motorized w full		\$5,243.25	Non-Drug
E1212	RR	Wheelchair motorized w full	1	\$531.41	Non-Drug
E1212	UE	Wheelchair motorized w full	1	\$3,935.78	Non-Drug
E1212	,	Wheelchair motorized w full		\$5,255.16	Non-Drug
E1213	NU	Wheelchair motorized w/ det	1 1	\$5,638.20 \$570.90	Non-Drug Non-Drug
E1213 E1213	RR UE	Wheelchair motorized w/ det Wheelchair motorized w/ det		\$4,232.00	Non-Drug Non-Drug
E1213 E1213	"	Wheelchair motorized w/ det Wheelchair motorized w/ det		\$5,255.16	Non-Drug
E1213		Whichr special size/constrc		\$3,302.56	Non-Drug Non-Drug
E1221	NU	Wheelchair special size w foot		\$658.40	Non-Drug
E1221	RR	Wheelchair spec size w foot		\$65.54	Non-Drug
E1221	UE	Wheelchair spec size w foot		\$493.80	
	-	•	•		

PAGE 21 OF 54

E1222 NU Wheelchair spec size w/ leg \$900.45 E1222 RR Wheelchair spec size w/ leg \$90.25 E1223 UE Wheelchair spec size w foot \$978.16 E1223 RR Wheelchair spec size w foot \$978.26 E1223 UE Wheelchair spec size w foot \$699.41 E1224 NU Wheelchair spec size w leg \$1,119.83 E1224 RR Wheelchair spec size w/ leg \$106.48 E1224 UE Wheelchair spec size w/ leg \$750.97 E1225 NU Wheelchair spec size w/ leg \$750.97 E1225 UE Wheelchair spec size w/ leg \$62.40 E1225 NU Wheelchair spec size w/ leg \$62.40 E1225 UE Wheelchair spec sz semi-recl \$62.40 E1225 UE Wheelchair spec sz semi-recl \$684.80 E1226 RR Wheelchair spec sz full-recl \$75.38 E1226 UE Wheelchair spec sz full-recl \$487.78 E1227 NU	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
E1222 UE Wheelchair spec size w foot \$647.76 E1223 RR Wheelchair spec size w foot \$978.16 E1223 RR Wheelchair spec size w foot \$699.41 E1224 UE Wheelchair spec size w leg \$1,119.83 E1224 RR Wheelchair spec size w leg \$106.48 E1224 UE Wheelchair spec size w leg \$750.97 E1225 NU Wheelchair spec size w leg \$750.97 E1225 UE Wheelchair spec size w leg \$622.11 E1225 UE Wheelchair spec size w leg \$622.11 E1226 UE Wheelchair spec size w leg \$75.38 E1226 UE Wheelchair spec size w leg \$670.92 E1227 NU Wheelchair spec size w leg \$345.08	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
E1223 NU Wheelchair spec size w foot \$978.16 E1223 RR Wheelchair spec size w foot \$97.82 E1223 UE Wheelchair spec size w foot \$699.41 E1224 NU Wheelchair spec size w / leg \$1.119.83 E1224 UE Wheelchair spec size w / leg \$106.48 E1224 UE Wheelchair spec size w / leg \$750.97 E1225 NU Wheelchair spec size w / leg \$622.11 E1225 RR Wheelchair spec size w / leg \$622.11 E1225 UE Wheelchair spec size w / leg \$622.11 E1225 UE Wheelchair spec size w / leg \$622.11 E1226 UE Wheelchair spec size w / leg \$622.11 E1226 NU Wheelchair spec size w / leg \$622.11 E1226 RR Wheelchair spec size w / leg \$684.80 E1226 UE Wheelchair spec size w / leg \$670.92 E1227 NU Wheelchair spec size w / leg \$345.08	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
E1223 RR Wheelchair spec size w foot \$97.82 E1223 UE Wheelchair spec size w foot \$699.41 E1224 NU Wheelchair spec size w leg \$1,119.83 E1224 RR Wheelchair spec size w leg \$106.48 E1224 UE Wheelchair spec size w leg \$750.97 E1225 NU Wheelchair spec sz semi-recl \$622.11 E1225 RR Wheelchair spec sz semi-recl \$66.81 E1225 UE Wheelchair spec sz semi-recl \$466.81 E1226 NU Wheelchair spec sz full-recl \$684.80 E1226 UE Wheelchair spec sz full-recl \$75.38 E1226 UE Wheelchair spec sz full-recl \$670.92 E1227 NU Wheelchair spec sz semi-recl \$345.08	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
E1223 UE Wheelchair spec size w foot \$699.41 E1224 NU Wheelchair spec size w leg \$1,119.83 E1224 RR Wheelchair spec size w leg \$106.48 E1224 UE Wheelchair spec size w leg \$750.97 E1225 NU Wheelchair spec sz semi-recl \$62.41 E1225 UE Wheelchair spec sz semi-recl \$466.81 E1226 NU Wheelchair spec sz full-recl \$684.80 E1226 RR Wheelchair spec sz full-recl \$75.38 E1226 UE Wheelchair spec sz full-recl \$47.78 E1226 UE Wheelchair spec sz full-recl \$670.92 E1227 NU Wheelchair spec sz spec ht a \$345.08	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
E1224 NU Wheelchair spec size w/ leg \$1,119.83 E1224 RR Wheelchair spec size w/ leg \$106.48 E1224 UE Wheelchair spec size w/ leg \$750.97 E1225 NU Wheelchair spec sz semi-recl \$622.11 E1225 RR Wheelchair spec sz semi-recl \$62.40 E1225 UE Wheelchair spec sz semi-recl \$466.81 E1226 NU Wheelchair spec sz full-recl \$684.80 E1226 UE Wheelchair spec sz full-recl \$75.38 E1226 UE Wheelchair spec sz full-recl \$487.78 E1226 UE Wheelchair spec sz full-recl \$670.92 E1227 NU Wheelchair spec sz spec ht a \$345.08	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
E1224 RR Wheelchair spec size w/ leg \$106.48 E1224 UE Wheelchair spec size w/ leg \$750.97 E1225 NU Wheelchair spec sz semi-recl \$622.11 E1225 RR Wheelchair spec sz semi-recl \$622.40 E1225 UE Wheelchair spec sz semi-recl \$466.81 E1226 NU Wheelchair spec sz full-recl \$684.80 E1226 RR Wheelchair spec sz full-recl \$75.38 E1226 UE Wheelchair spec sz full-recl \$487.78 E1226 Wheelchair spec sz full-recl \$670.92 E1227 NU Wheelchair spec sz spec ht a \$345.08	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
E1224 UE Wheelchair spec size w/ leg \$750.97 E1225 NU Wheelchair spec sz semi-recl \$622.11 E1225 RR Wheelchair spec sz semi-recl \$62.40 E1225 UE Wheelchair spec sz semi-recl \$466.81 E1226 NU Wheelchair spec sz full-recl \$684.80 E1226 RR Wheelchair spec sz full-recl \$75.38 E1226 UE Wheelchair spec sz full-recl \$487.78 E1226 Wheelchair spec sz full-recl \$670.92 E1227 NU Wheelchair spec sz sz spec ht a \$345.08	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
E1225 RR Wheelchair spec sz semi-recl \$62.40 E1225 UE Wheelchair spec sz semi-recl \$466.81 E1226 NU Wheelchair spec sz full-recl \$584.80 E1226 RR Wheelchair spec sz full-recl \$75.38 E1226 UE Wheelchair spec sz full-recl \$487.78 E1226 Wheelchair spec sz full-recl \$670.92 E1227 NU Wheelchair spec sz spec ht a \$345.08	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
E1225 UE E1226 Wheelchair spec sz semi-recl \$466.81 E1226 NU Wheelchair spec sz full-recl \$684.80 E1226 RR Wheelchair spec sz full-recl \$75.38 E1226 UE Wheelchair spec sz full-recl \$487.78 E1226 Wheelchair spec sz full-recl \$670.92 E1227 NU Wheelchair spec sz spec ht a \$345.08	Non-Drug Non-Drug Non-Drug Non-Drug
E1226 NU Wheelchair spec sz full-recl \$684.80 E1226 RR Wheelchair spec sz full-recl \$75.38 E1226 UE Wheelchair spec sz full-recl \$487.78 E1226 Wheelchair spec sz full-recl \$670.92 E1227 NU Wheelchair spec sz spec ht a \$345.08	Non-Drug Non-Drug Non-Drug
E1226 RR Wheelchair spec sz full-recl \$75.38 E1226 UE Wheelchair spec sz full-recl \$487.78 E1226 Wheelchair spec sz full-recl \$670.92 E1227 NU Wheelchair spec sz spec ht a \$345.08	Non-Drug Non-Drug
E1226 UE Wheelchair spec sz full-recl \$487.78 E1226 Wheelchair spec sz full-recl \$670.92 E1227 NU Wheelchair spec sz spec ht a \$345.08	Non-Drug
E1226 Wheelchair spec sz full-recl \$670.92 E1227 NU Wheelchair spec sz spec ht a \$345.08	
E1227 NU Wheelchair spec sz spec ht a \$345.08	Non-Drug
	Non-Drug
E1227 RR Wheelchair spec sz spec ht a \$38.61	Non-Drug
E1227 UE Wheelchair spec sz spec ht a \$260.81	Non-Drug
E1228 NU Wheelchair spec sz spec ht b \$391.18	Non-Drug
E1228 RR Wheelchair spec sz spec ht b	Non-Drug
E1228 UE Wheelchair spec sz spec ht b \$293.50 E1230 NU Power operated vehicle \$2,756.30	Non-Drug Non-Drug
E1230 NU Power operated vehicle \$2,756.30 E1230 RR Power operated vehicle \$278.18	Non-Drug
E1230 UE Power operated vehicle \$2,181.56	Non-Drug
E1240 NU Whoth litwt det arm leg rest \$1,328.47	Non-Drug
E1240 RR Whichr litwt det arm leg rest \$133.06	Non-Drug
E1240 UE Whchr litwt det arm leg rest \$950.70	Non-Drug
E1250 NU Wheelchair lightwt fixed arm \$955.75	Non-Drug
E1250 RR Wheelchair lightwt fixed arm \$94.21	Non-Drug
E1250 UE Wheelchair lightwt fixed arm \$758.73 E1250 Wheelchair lightwt fixed arm \$95.20	Non-Drug Non-Drug
E1260 NU Wheelchair lightwt foot rest \$1,115.57	Non-Drug
E1260 RR Wheelchair lightwr foot rest \$118.55	Non-Drug
E1260 UE Wheelchair lightwt foot rest \$881.81	Non-Drug
E1260 Wheelchair lightwt foot rest \$108.53	Non-Drug
E1270 NU Wheelchair lightweight leg r \$1,036.48	Non-Drug
E1270 RR Wheelchair lightweight leg r	Non-Drug
E1270 UE Wheelchair lightweight leg r \$760.84 E1280 NU Whohr h-duty det arm leg res \$1,671.64	Non-Drug Non-Drug
E1280 RR Which h-duty det arm leg res \$167.37	Non-Drug
E1280 UE Whohr h-duty det arm leg res \$1,198.11	Non-Drug
E1285 NU Wheelchair heavy duty fixed \$1,435.66	Non-Drug
E1285 RR Wheelchair heavy duty fixed \$150.70	Non-Drug
E1285 UE Wheelchair heavy duty fixed \$1,054.03	Non-Drug
E1285 Wheelchair heavy duty fixed \$1,326.22	Non-Drug Non-Drug
E1290 NU Wheelchair hvy duty detach a \$1,484.80 \$1,484.80 E1290 RR Wheelchair hvy duty detach a \$155.75	Non-Drug
E1290 UE Wheelchair hvy duty detach a \$1,084.80	Non-Drug Non-Drug
E1290 Wheelchair hvy duty detach a \$1,326.22	Non-Drug
E1295 NU Wheelchair heavy duty fixed \$1,552.77	Non-Drug
E1295 RR Wheelchair heavy duty fixed \$155.48	Non-Drug
E1295 UE Wheelchair heavy duty fixed \$1,127.94	Non-Drug
E1296 NU Wheelchair special seat heig \$605.33 E1296 RR Wheelchair special seat heig \$68.56	Non-Drug
E1296 RR Wheelchair special seat heig \$68.56 E1296 UE Wheelchair special seat heig \$455.96	Non-Drug Non-Drug
E1297 NU Wheelchair special seat dept \$134.99	Non-Drug
E1297 RR Wheelchair special seat dept \$16.63	Non-Drug
E1297 UE Wheelchair special seat dept \$103.20	Non-Drug
E1298 NU Wheelchair spec seat depth/w \$522.67	Non-Drug
E1298 RR Wheelchair spec seat depth/w \$59.87	Non-Drug
E1298 UE Wheelchair spec seat depth/w \$393.96 F1300 NU Whirlpool portable \$1,461.95	Non-Drug Non-Drug
E1300 NU Whirlpool portable \$1,461.95 \$1,461.95 \$1,461.95	Non-Drug Non-Drug
E1310 NU Whirlpool non-portable \$3,635.11	Non-Drug
E1310 RR Whirlpool non-portable \$305.14	Non-Drug
E1310 UE Whirlpool non-portable \$2,724.75	Non-Drug
E1340 Repair for DME, per 15 min \$16.97	Non-Drug

PAGE 22 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
E1353	NU	Oxygen supplies regulator		\$168.96	Non-Drug
E1353	RR	Oxygen supplies regulator		\$14.22	Non-Drug
E1353	UE	Oxygen supplies regulator		\$137.10 \$33.38	Non-Drug Non-Drug
E1353 E1355	NU	Oxygen supplies regulator Oxygen supplies stand/rack		\$117.99	Non-Drug
E1355	RR	Oxygen supplies stand/rack		\$20.68	Non-Drug
E1355	UE	Oxygen supplies stand/rack		\$96.49	Non-Drug
E1372	NU	Oxy suppl heater for nebuliz		\$270.14	Non-Drug
E1372	RR	Oxy suppl heater for nebuliz		\$37.34 \$198.32	Non-Drug Non-Drug
E1372 E1390	UE NU	Oxy suppl heater for nebuliz Oxygen concentrator		\$3.835.79	Non-Drug Non-Drug
E1390	RR	Oxygen concentrator		\$504.85	Non-Drug
E1399	'''`	Durable medical equipment mi		\$2.76	Non-Drug
E1405	NU	O2/water vapor enrich w/heat		\$4,921.42	Non-Drug
E1405	RR	O2/water vapor enrich w/heat	1	\$520.94	Non-Drug
E1405	UE NU	O2/water vapor enrich w/heat O2/water vapor enrich w/o he		\$3,697.05 \$2,100.21	Non-Drug Non-Drug
E1406 E1406	RR	O2/water vapor enrich w/o he		\$222.31	Non-Drug
E1406	UE	O2/water vapor enrich w/o he]	\$1,577.71	Non-Drug
E1510	RR	Kidney dialysate delivry sys		\$631.46	Non-Drug
E1510	l	Kidney dialysate delivry sys	1	\$1,403.10	Non-Drug
E1590	RR RR	Hemodialysis machine		\$1,107.71 \$544.78	Non-Drug Non-Drug
E1594 E1610	RR	Cycler dialysis machine Reverse osmosis h2o puri sys		\$499.99	Non-Drug
E1700	NU	Jaw motion rehab system		\$578.44	Non-Drug
E1700	RR	Jaw motion rehab system		\$51.77	Non-Drug
E1700	UE	Jaw motion rehab system		\$432.25	Non-Drug
E1701		Repl cushions for jaw motion		\$18.69 \$35.74	Non-Drug Non-Drug
E1702 E1800	RR	Repl measr scales jaw motion Adjust elbow ext/flex device		\$201.41	Non-Drug
E1801	RR	SPS elbow device		\$212.43	Non-Drug
E1805	RR	Adjust wrist ext/flex device		\$207.92	Non-Drug
E1806	RR	SPS wrist device		\$173.28	Non-Drug
E1810	RR	Adjust knee ext/flex device		\$204.94 \$221.12	Non-Drug Non-Drug
E1811 E1815	RR	SPS knee device Adjust ankle ext/flex device	1	\$207.92	Non-Drug
E1816	RR	SPS ankle device		\$224.71	Non-Drug
E1818	RR	SPS forearm device		\$229.54	Non-Drug
E1820	NU	Soft interface material		\$132.29	Non-Drug
E1820	RR	Soft interface material		\$15.22 \$97.65	Non-Drug Non-Drug
E1820 E1821	UE NU	Soft interface material Replacement interface SPSD		\$172.16	Non-Drug
E1821	RR	Replacement interface SPSD		\$18.55	Non-Drug
E1821	UE	Replacement interface SPSD		\$127.56	Non-Drug
E1825	RR	Adjust finger ext/flex devc		\$207.92	Non-Drug
E1830	RR	Adjust toe ext/flex device Adj shoulder ext/flex device	1 1	\$207.92 \$642.66	Non-Drug Non-Drug
E1840 E2000	RR RR	Gastric suction pump hme mdl		\$81.57	Non-Drug
E2100	NU	Bld glucose monitor w voice		\$1,084.36	Non-Drug
E2100	RR	Bld glucose monitor w voice		\$102.75	Non-Drug
E2100	UE	Bld glucose monitor w voice		\$811.71	Non-Drug
E2101	NU	Bld glucose monitor w lance		\$313.43 \$30.45	Non-Drug Non-Drug
E2101 E2101	RR UE	Bld glucose monitor w lance Bld glucose monitor w lance		\$233.49	Non-Drug
J0120	0.2	Tetracyclin injection		\$221.44	Drug
J0130	1	Abciximab injection	a	\$858.69	Drug
J0150	-	Injection adenosine 6 MG		\$72.13	Drug
J0151		Adenosine injection Adrenalin epinephrin inject	a	\$378.97 \$3.36	Drug Drug
J0170 J0200	1	Alatrofloxacin mesylate		\$41.22	Drug
J0205	1	Alglucerase injection	1	\$71.56	Drug
J0207	1	Amifostine	a	\$704.16	Drug
J0210	1	Methyldopate hcl injection		\$25.54 \$3.36	Drug Drug
J0256	1	Alpha 1 proteinase inhibitor Alprostadil for injection		\$3.30 \$7.12	Drug
J0270 J0275	1	Alprostadii urethral suppos		\$41.26	Drug
J0280	1	Aminophyllin 250 MG inj	1	\$1.68	Drug
J0282	1	Amiodarone HCI		\$42.94	Drug

PAGE 23 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
J0285		Amphotericin B		\$23.94	Drug
J0287	1	Amphotericin b lipid complex	a	\$45.80	Drug
J0288	İ	Ampho b cholesteryl sulfate	1 1	\$33.55	Drug
J0289	1	Amphotericin b liposome inj	[[\$68.70	Drug
J0290 J0295	1	Ampicillin 500 MG inj	-	\$2.80 \$15.13	Drug Drug
J0295 J0300	1	Ampicillin sodium per 1.5 gm Amobarbital 125 MG inj	1	\$3.92	Drug
J0330	1	Succinvcholine chloride ini	1 1	\$0.56	Drug
J0360	i	Hydralazine hcl injection		\$38.93	Drug
J0380		Ini metaraminol bitartrate	1	\$2.24	Drug
J0390		Chloroquine injection	1 1	\$42.36	Drug
J0395		Arbutamine HCI injection		\$311.42	Drug
J0456		Azithromycin		\$50.38	Drug
J0460		Atropine sulfate injection		\$1.12	Drug
J0470 J0475		Dimecaprol injection Baclofen 10 MG injection	1 1	\$48.66 \$366.37	Drug Drug
J0475	1	Baclofen intrathecal trial		\$141.97	Drug
J0500		Dicyclomine injection	.	\$35.15	Drug
J0515		Inj benztropine mesylate	1	\$7.12	Drug
J0520	1	Bethanechol chloride inject	1 1	\$10.32	Drug
J0530		Penicillin g benzathine inj	1 1	\$23.14	Drug
J0540		Penicillin g benzathine inj	1	\$44.08	Drug
J0550		Penicillin g benzathine ini	1	\$83.58	Drug
J0560	1	Penicillin g benzathine inj	1	\$11.12	Drug
J0570		Penicillin g benzathine ini		\$11.12	Drug
J0580 J0585		Penicillin g benzathine ini Botulinum toxin a per unit	a	\$24.74 \$8.72	Drug Drug
J0587		Botulinum toxin type B	a	\$18.33	Drug
J0592		Buprenorphine hydrochloride	"	\$1.68	Drug
J0600	1	Edetate calcium disodium ini	1	\$76.14	Drug
J0610	1	Calcium gluconate injection	· 1	\$1.68	Drug
J0620		Calcium glycer & lact/10 ML		\$11.93	Drug
J0630		Calcitonin salmon injection		\$73.28	Drug
J0636	1	Inj calcitriol per 0.1 mcg		\$2,296.70	Drug
J0637 J0640		Caspofungin acetate Leucovorin calcium injection	a	\$61.83 \$38.93	Drug Drug
J0670	1	Inj mepivacaine HCL/10 ml		\$3.36	Drug
J0690		Cefazolin sodium injection	1	\$2.80	Drug
J0692	1	Cefepime HCl for injection		\$17.53	Drug
J0694		Cefoxitin sodium injection	1	\$23.14	Drug
J0696		Ceftriaxone sodium injection	1	\$32.75	Drug
J0697		Sterile cefuroxime injection		\$13.53	Drug
J0698	1	Cefotaxime sodium injection	.	\$22.34	Drug
J0702 J0704	1	Betamethasone acet&sod phosp Betamethasone sod phosp/4 MG	i i	\$7.12 \$3.92	Drug Drug
J0704 J0706		Caffeine citrate injection	1	\$5.52 \$5.52	Drug
J0710		Cephapirin sodium injection		\$15.77	Drug
J0713		Inj ceftazidime per 500 mg		\$14.33	Drug
J0715	1	Ceftizoxime sodium / 500 MG		\$9.52	Drug
J0720		Chloramphenicol sodium injec		\$14.33	Drug
J0725		Chorionic gonadotropin/1000u		\$2.80	Drug
J0735	1	Clonidine hydrochloride	1 1	\$100.75	Drug
J0740	1	Cidofovir injection	1	\$1,339.55	Drug
J0743		Cilastatin sodium injection		\$35.15 \$32.75	Drug Drug
J0744 J0745	1	Ciprofloxacin iv Inj codeine phosphate /30 MG		\$0.56	Drug
J0743		Colchicine injection		\$14.33	Drug
J0770		Colistimethate sodium inj		\$99.61	Drug
J0780		Prochlorperazine injection		\$3.92	Drug
J0800		Corticotropin injection	l l	\$185.48	Drug
J0835	1	Inj cosyntropin per 0.25 MG		\$36.75	Drug
J0850		Cytomegalovirus imm IV /vial	a	\$1,171.82	Drug
J0880		Darbepoetin alfa injection		\$48.66 \$32.75	Drug Drug
J0895		Deferoxamine mesylate inj Testosterone enanthate inj		\$2,75	Drug
J0900 J0945		Brompheniramine maleate inj		\$2.60 \$1.68	Drug
J0970		Estradiol valerate injection		\$2.80	Drug
J1000	1	Depo-estradiol cypionate inj	1	\$1.12	

PAGE 24 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
J1020		Methylprednisolone 20 MG inj		\$3.92	Drug
J1030		Methylprednisolone 40 MG ini	1	\$10.32	Drug
J1040		Methylprednisolone 80 MG inj		\$21.54	Drug
J1051 J1055		Medroxyprogesterone inj Medrxyprogester acetate inj		\$9.52 \$112.78	Drug Drug
J1055		MA/EC contraceptiveinjection		\$52.10	Drug
J1060		Testosterone cypionate 1 ML		\$8.72	Drug
J1070		Testosterone cypionat 100 MG	1 1	\$10.32	Drug
J1080		Testosterone cypionat 200 MG		\$19.13	Drug
J1094		Ini dexamethasone acetate		\$0.56	Drug
J1100		Dexamethasone sodium phos Inj dihydroergotamine mesylt		\$1.12 \$60.11	Drug Drug
J1110 J1120		Acetazolamid sodium injectio		\$58.96	Drug
J1160		Digoxin injection	1	\$2.80	Drug
J1165		Phenytoin sodium injection	1	\$1.12	Drug
J1170		Hydromorphone injection		\$2.24	Drug
J1180		Dyphylline injection	1	\$19.13	Drug
J1190		Dexrazoxane HCI injection	a	\$384.12	Drug
J1200 J1205		Diphenhydramine hcl injectio Chlorothiazide sodium inj		\$2.80 \$22.34	Drug Drug
J1212	1	Dimethyl sulfoxide 50% 50 ML		\$79.00	Drug
J1230		Methadone injection	-	\$1.12	Drug
J1240		Dimenhydrinate injection		\$0.56	Drug
J1245	1	Dipyridamole injection		\$45.80	Drug
J1250		Ini dobutamine HCL/250 mg		\$7.12	Drug
J1260	1	Dolasetron mesylate Injection, doxercalciferol		\$29.90 \$8.72	Drug Drug
J1270 J1320		Amitriptyline injection		\$3.92	Drug
J1325		Epoprostenol injection		\$39.50	Drug
J1327	1	Eptifibatide injection	a	\$27.94	Drug
J1364		Erythro lactobionate /500 MG		\$6.32	Drug
J1380		Estradiol valerate 10 MG inj		\$0.56 \$1.68	Drug
J1390 J1410		Estradiol valerate 20 MG inj Inj estrogen conjugate 25 MG	1	\$1.00	Drug Drug
J1435		Injection estrone per 1 MG		\$0.56	Drug
J1436		Etidronate disodium ini	1	\$125.94	Drug
J1438		Etanercept injection		\$254.75	Drug
J1440		Filgrastim 300 mcg injection	а	\$317.14	Drug
J1441		Filgrastim 480 mcg injection	a	\$529.53 \$163.15	Drug Drug
J1450 J1452		Fluconazole Intraocular Fomivirsen na		\$1,581.70	Drug
J1455		Foscarnet sodium injection		\$26.34	Drug
J1460		Gamma globulin 1 CC inj		\$24.74	Drug
J1470		Gamma globulin 2 CC inj		\$47.52	Drug
J1480		Gamma globulin 3 CC inj		\$66.41	Drug
J1490	1	Gamma globulin 4 CC inj		\$85.30 \$104.19	Drug Drug
J1500 J1510		Gamma globulin 5 CC inj Gamma globulin 6 CC inj		\$123.08	Drug
J1520		Gamma globulin 7 CC inj		\$141.97	Drug
J1530		Gamma globulin 8 CC inj		\$160.86	Drug
J1540		Gamma globulin 9 CC inj		\$179.75	Drug
J1550		Gamma globulin 10 CC inj		\$198.64	Drug
J1560		Gamma globulin > 10 CC inj	a	\$19.26 \$101.33	Drug Drug
J1563 J1564	1	IV immune globulin Immune globulin 10 mg	a	\$1.12	Drug
J1565	1	RSV-ivig	a	\$36.75	Drug
J1570	1	Ganciclovir sodium injection	1	\$68.12	Drug
J1580	ł	Garamycin gentamicin ini	1	\$3.36	Drug
J1590	1	Gatifloxacin injection		\$1.68 \$29.55	Drug Drug
J1600		Gold sodium thiomaleate ini Glucagon hydrochloride/1 MG		\$29.55 \$81.29	Drug
J1610 J1620	1	Gonadorelin hydroch/ 100 mcg		\$344.05	Drug
J1626		Granisetron HCI injection		\$40.65	Drug
J1630	1	Haloperidol injection		\$15.13	Drug
J1631	1	Haloperidol decanoate inj	1	\$50.95 \$1.12	Drug Drug
J1642	1	Inj heparin sodium per 10 u Inj heparin sodium per 1000u		\$0.56	Drug
J1644 J1645	1	Dalteparin sodium	1 1	\$34.35	

PAGE 25 OF 54

		1 AOE 23 OF 3	T		
HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
J1650		Inj enoxaparin sodium		\$11.12	Drug
J1652		Fondaparinux sodium	1	\$17.53	Drug
J1655		Tinzaparin sodium injection		\$7.12	Drug
J1670	1	Tetanus immune globulin inj	1	\$198.64	Drug
J1700		Hydrocortisone acetate inj		\$0.56	Drug
J1710		Hydrocortisone sodium ph ini	1 1	\$11.12	Drug
J1720		Hydrocortisone sodium succ i	1	\$2.80	Drug
J1730 J1742		Diazoxide injection Ibutilide fumarate injection	1	\$212.96 \$443.08	Drug Drug
J1745		Infliximab injection	a	\$118.50	Drug
J1750		Iron dextran	1 - 1	\$39.50	Drug
J1756		fron sucrose injection	1	\$1.12	Drug
J1785		Injection imiglucerase /unit	1	\$7.12	Drug
J1790		Droperidol injection		\$2.80	Drug
J1800 J1810		Propranolol injection Droperidol/fentanyl inj		\$25.54 \$19.93	Drug Drug
J1815		Insulin injection	1	\$0.56	Drug
J1825		Interferon beta-1a	a	\$396.72	Drug
J1830		Interferon beta-1b / .25 MG	a	\$103.14	Drug
J1835	1	Itraconazole injection		\$1,463.20	Drug
J1840		Kanamycin sulfate 500 MG ini	1	\$6.32	Drug
J1850 J1885		Kanamycin sulfate 75 MG inj Ketorolac tromethamine inj	1	\$0.56 \$11.93	Drug Drug
J1890		Cephalothin sodium injection		\$22.34	Drug
J1910	1	Kutapressin injection		\$32.75	Drug
J1940		Furosemide injection		\$1.68	Drug
J1950		Leuprolide acetate /3.75 MG	a	\$851.25	Drug
J1955		Inj levocarnitine per 1 gm		\$66.41	Drug
J1956 J1960		Levofloxacin injection Levorphanol tartrate inj		\$42.36 \$7.12	Drug Drug
J1980		Hyoscyamine sulfate inj		\$17.53	Drug
J1990		Chlordiazepoxide injection		\$50.95	Drug
J2000	1	Lidocaine injection		\$7.92	Drug
J2010		Lincomycin injection		\$6.32	Drug
J2020		Linezolid injection	1	\$73.28	Drug
J2060 J2150		Lorazepam injection Mannitol injection		\$5.52 \$10.32	Drug Drug
J2175		Meperidine hydrochl /100 MG	·	\$1.12	Drug
J2180		Meperidine/promethazine inj		\$8.72	Drug
J2210		Methylergonovin maleate inj		\$7.12	Drug
J2250		Ini midazolam hydrochloride		\$2.24	Drug
J2260		Inj milrinone lactate / 5 ML		\$95.03 \$1.12	Drug
J2270 J2271		Morphine sulfate injection Morphine so4 injection 100mg		\$30.35	Drug Drug
J2275		Morphine sulfate injection		\$3.92	Drug
J2300		Inj nalbuphine hydrochloride		\$2.24	Drug
J2310		Inj naloxone hydrochloride		\$3.92	Drug
J2320	1	Nandrolone decanoate 50 MG		\$10.32	Drug
J2321 J2322	1	Nandrolone decanoate 100 MG Nandrolone decanoate 200 MG		\$22.3 4 \$27.94	Drug Drug
J2324		Nesiritide	a	\$248.45	Drug
J2352	1	Octreotide acetate injection	a	\$156.28	Drug
J2355	1	Oprelvekin injection	a	\$434.50	Drug
J2360	İ	Orphenadrine injection		\$11.12	Drug
J2370		Phenylephrine hal injection		\$3.36	Drug
J2400 J2405		Chloroprocaine hol injection Ondansetron hol injection		\$12.73 \$12.73	Drug Drug
J2410	1	Oxymorphone hcl injection		\$4.72	Drug
J2430		Pamidronate disodium /30 MG	a	\$465.41	Drug
J2440		Papaverin hcl injection	1	\$11.93	Drug
J2460		Oxytetracycline injection		\$1.68	Drug
J2501		Paricalcitol Penicillin g procaine inj		\$10.32 \$19.13	Drug Drug
J2510 J2515		Pentobarbital sodium inj		\$1.12	Drug
J2540		Penicillin g potassium inj		\$7.12	Drug
J2543	1	Piperacillin/tazobactam		\$9.52	Drug
J2545		Pentamidine isethionte/300mg		\$164.87	Drug
J2550	ł	Promethazine hcl injection	j j	\$3,36	Drug

PAGE 26 OF 54

Pherobarbital sodium in	HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
12597			Phenobarbital sodium inj			
26560 Prednisolone acetate inj S0.56 Drug 26770 2675 Drug 2676 S7.12 Drug 2676 S7.12 Drug 2676 S7.12 Drug 2788 Drug 2770 S7.12 Drug 2770 S7.12 Drug 2770 Drug 2770 Drug 2770 Drug 2770 Drug 2770 Drug 27720 Inj profamine sulfate/10 MG S1.12 Drug 27720 Inj profamine sulfate/10 MG S1.12 Drug 27720 Inj profamine sulfate/10 MG S1.12 Drug 27720 Inj profamine sulfate/10 MG S1.12 Drug 27730 Drug 27730 Drug 27730 Drug 27730 Drug 27730 Drug 27730 Drug Drug 27730 Drug Drug Drug 27730 Drug Drug Drug 27730 Drug Drug Drug 27730 Drug Drug Drug 27730 Drug Drug Drug 27730 Drug Drug Drug 27730 Drug 27730 Drug Drug Drug 27730 Drug Drug 27730 Drug 27730 Drug Drug Drug 27730 Drug 27730 Drug 27730 Drug 27730 Drug 27730 Drug 27730 Drug 27730 Drug 27730 Drug Drug 27730 Drug 27730 Drug 27730 Drug 27730 Drug Drug Drug 27730 Drug 27730 Drug Drug Drug 27730 Drug Drug Drug 27730 Drug 27730 Drug Drug Drug Drug 27730 Drug Drug Drug 27730 Drug Drug Drug 27730 Drug Drug Drug 27730 Drug Drug Drug Drug 27730 Drug Drug Drug Drug 27730 Drug						
2877]		
1,2875						
2880 Fluphenazine decanoate 25 MG 2690 Procainamide hat injection \$23.34 Drug 2700 2700 Oxacilin sodium injection \$1.12 Drug 2710 Oxacilin sodium injection \$1.12 Drug 2710 Oxacilin sodium injection \$1.12 Drug 2710 Oxacilin sodium injection \$1.12 Drug 2710 Oxacilin sodium injection \$1.12 Drug 2710 Oxacilin sodium injection \$1.12 Drug 2710 Oxacilin sodium injection \$1.12 Drug 2710 Oxacilin sodium injection \$1.00 Oxacilin sodium injection \$1.00 Oxacilin sodium injection \$1.00 Oxacilin sodium injection \$2.00 Drug 2710 Oxacilin sodium injection \$2.00 Drug 2710 Oxacilin sodium injection \$1.00 Oxacilin sodiu						
22690				1		
32710 Neositjamine methyis/lite inj 33.92 Drug 32725 Inj protamine sulfate/10 MG 51.12 Drug 32726 Inj protamine sulfate/10 MG 51.12 Drug 32730 Pralidoxime chioride inj 580.38 Drug 32730 Pralidoxime chioride inj 580.54 Drug 32785 Metoclopramide het injection 22.80 Drug 32					\$23.94	
19720						
James Jame				1	7	
J27360]]		
J2766						
J27760				1		
J2788 Rantidine hydrochloride inj J2788 Rho d immune globulin 50 mcg a \$9.9.27 Drug J2792 Rho (Drumune globulin inj sile4, 33 Drug J2792 Rho (Drumune globulin inj sile4, 33 Drug J2792 Rho (Drumune globulin inj sile4, 33 Drug J2795 Rho (Drumune globulin inj sile4, 33 Drug J2796 Rho (Drumune globulin inj sile4, 33 Drug J2810 J2810 Methocarbamol injection sile5, 35 Drug J2810 J2810 J2810 Aurothioglucose injection sile5, 35 Drug J2912 Sodium chloride injection sile5, 35 Drug J2912 Sodium chloride injection sile5, 35 Drug J2912 Sodium chloride injection sile5, 35 Drug J2914 Somatrie injection sile5, 35 Drug J2930 Methylpredrisolone injection sile5, 35 Drug J2930 Methylpredrisolone injection sile5, 35 Drug J2940 Somatriem injection sile5, 35 Drug J2941 Somatriem injection sile5, 35 Drug J2941 Somatriem injection sile5, 35 Drug J2941 Somatriem injection sile5, 35 Drug J2945 Alteria (Somothio Sout						
J2789				1		
J2790				,		
J2795 Rho(D) immune globulin h, sd s s43,51 Drug J2795 Ropivacaine HCI injection S0,21 Drug J2810 Unit theophylline per 40 MG \$1,36 Drug J2810 Unit theophylline per 40 MG \$1,36 Drug J2810 Aurothioglucose injection \$35,51 Drug J2810 Aurothioglucose injection \$35,51 Drug J28110 Aurothioglucose injection \$35,51 Drug J2816 Na ferric gluconate complex \$17,53 Drug J2816 Na ferric gluconate complex \$17,53 Drug J2820 Methylprednisolone injection \$2,80 Drug J2830 Methylprednisolone injection \$3,36 Drug J2840 Somatomin injection \$3,36 Drug J2841 Somatomin injection \$3,36 Drug J2841 Somatomin injection \$3,36 Drug J2895 Injection \$3,55 Drug J2895 Injection \$3,27 J2895 Injection \$3,27 J2895 Injection \$3,27 J2895 Injection \$3,27 J2895 Injection \$3,27 J2895 Injection \$3,27 J2895 Injection \$3,27 J2895 Injection \$3,27 J2895 Injection \$3,27 J2895 J2897 J				1 "		
J2810				a		
Jasto			Ropivacaine HCl injection			
1,2820		1				
James						
2916 Sodium chloride injection \$0.56 Drug		1		1		
1,2916 Na ferric gluconate complex \$17.53 Drug 1,2920 Methylprednisolone injection \$2.80 Drug 1,2930 Methylprednisolone injection \$3.36 Drug 1,2940 Somatrem injection \$3.36 Drug 1,2941 Somatropin injection \$3.36 Drug 1,2950 Promazine hel injection \$0.56 Drug 1,2993 Reteplase injection \$0.56 Drug 1,2995 Injection \$2.17.133 Drug 1,2997 Alteplase recombinant \$219.25 Drug 1,3000 Streptomycin injection \$12.73 Drug 1,3000 Streptomycin injection \$12.73 Drug 1,3000 Streptomycin injection \$12.73 Drug 1,3000 Streptomycin injection \$1.273 Drug 1,3000 Streptomycin injection \$1.273 Drug 1,3000 Sumatriptan succinate / 6 MG \$5.381 Drug 1,3100 Tencteplase injection \$3.36 Drug 1,3100 Tencteplase injection \$3.32 Drug 3,3100 Tencerelase injection \$3.83.99 Drug 3,3100 Tencerelase injection \$3.83.99 Drug 3,3100 Tencerelase injection \$3.83.90 Drug 3,3100 Tencerelase injection \$3.83.90 Drug 3,3100 Tencerelase injection \$3.83.90 Drug 3,3110 Testosterone enanthate inj \$3.59.50 Drug 3,3120 Testosterone suspension inj \$3.59.50 Drug 3,3130 Testosterone propionate inj \$1.68 Drug 3,3230 Chlorpromazine hcl injection \$1.68 Drug 3,3240 Thyotropin injection \$1.68 Drug 3,3250 Timethobenzamide hcl inj \$2.24 Drug 3,3301 Timetinolone diacetate inj \$0.56 Drug 3,3301 Timetinolone diacetate inj \$0.56 Drug 3,3301 Timetinolone diacetate inj \$0.56 Drug 3,3302 Timetinolone hexacetoni inj \$0.56 Drug 3,3303 Timetinolone hexacetoni inj \$0.56 Drug 3,3304 Urokinase 5000 IU injection \$1.68 Drug 3,3305 Urokinase 5000 IU injection \$1.69 Drug 3,3306 Urokinase 5000 IU injection \$1.60 Drug 3,3307 Vancomycin hcl injection \$1.51 Drug 3,3308 Drug Drug 3,3309 Drug Drug 3,3300 Drug Drug						
12930 Methylprednisolone injection Samatrem injection Somatrem injection Samatrem i			Na ferric gluconate complex	1		
1,2940 Somatrem injection Somatropin in				1		
J2941 Somatropin injection a \$85.30 Drug J2993 Reteplase injection a \$2,171.33 Drug J2995 Inj streptokinase /25000 IU \$219.25 Drug J3000 Streptomycin injection \$12.73 Drug J3000 Streptomycin injection \$12.73 Drug J3001 Fentanyl citrate injection \$3.36 Drug J3030 Sumatriptan succinate / 6 MG \$53.81 Drug J3070 Pentazocine injection \$3.36 Drug J3100 Tenecteplase injection a \$44,332.94 Drug J3120 Testosterone enanthate inj \$58.99 Drug J3120 Testosterone enanthate inj \$1.12 Drug J3130 Testosterone enanthate inj \$35.95 Drug J3140 Testosterone enanthate inj \$35.95 Drug J3240 Thyotropin injection a \$947.42 Drug J3240 Thyotropin injection a \$947.42 Drug J3240 Thyotropin injection a \$947.42 Drug J3260 Tirofiban hydrochloride a \$774.54 Drug J3260 Tirofiban hydrochloride a \$774.54 Drug J3280 Triamcinolone diacetate inj \$2.24 Drug J3300 Triamcinolone dacetate inj \$2.24 Drug J3300 Triamcinolone dacetate inj \$2.24 Drug J3300 Triamcinolone dacetate inj \$2.24 Drug J3300						
1995				_		
J2993			1	"		
Jacob				a		
3000 Streptomycin injection \$12,73 Drug 3300 Streptomycin injection \$3.36 Drug 33030 Sumatriptan succinate / 6 MG \$53.81 Drug 33070 Pentazocine injection \$10.32 Drug 3100 Tenecleplase injection \$4,332,94 Drug 3105 Tenecleplase injection \$58.39 Drug 31105 Testosterone enanthate inj \$58.39 Drug 31100 Testosterone enanthate inj \$1.12 Drug 31140 Testosterone enanthate inj \$35.95 Drug 31140 Testosterone suspension inj \$0.56 Drug 31150 Testosterone propionate inj \$1.68 Drug 31230 Chlorpromazine hcl injection \$7.12 Drug 313240 Thyrotropin injection \$3.244 Drug 313245 Tirofiban hydrochloride \$3.474, \$4 Drug 313250 Trimethobenzamide hcl inj \$2.24 Drug 313280 Tobramycin sulfate injection \$1.273 Drug 313280 Thiethylperazine maleate inj \$2.24 Drug 313280 Triamcinolone acteonide inj \$2.24 Drug 313301 Triamcinolone diacetate inj \$2.24 Drug 313302 Triamcinolone diacetate inj \$1.68 Drug 313305 Inj trimetrexate glucoronate \$3.872 Drug 31310 Perphenazine injection \$1.83 Drug 31310 Perphenazine injection \$1.83 Drug 313280 Drug Spectinomych di-hcl inj \$5.381 Drug 313360 Drazepam injection \$1.68 Drug 313360 Drazepam injection \$1.68 Drug 313360 Drazepam injection \$1.68 Drug 313360 Drazepam injection \$1.68 Drug 313360 Drazepam injection \$1.68 Drug 313360 Drazepam injection \$1.68 Drug 313360 Drazepam injection \$1.68 Drug 313360 Drazepam injection \$1.68 Drug 313360 Drazepam injection \$1.68 Drug 313360 Drazepam injection \$1.68 Drug 313360 Drazepam injection \$1.61 Drug 313360 Drazepam injection \$1.61 Drug 313360 Drazepam injection \$1.61 Drug 313360 Drazepam injection \$1.61 Drug 313360 Drazepam injection \$1.61 Drug 313360 Drazepam injection \$1.61 Drug 313360 Drazepam injection \$1.61 Drug 313360 Drazepam injecti						
Jan						
Jacob Sumatriptan succinate / 6 MG \$53.81 Drug Jacob Pentazocine injection \$10.32 Drug Jacob Pentazocine injection a \$4,332.94 Drug Jacob Tenecteplase injection a \$4,332.94 Drug Jacob Terbutaline sulfate inj \$58.39 Drug Jacob Testosterone enanthate inj \$58.39 Drug Jacob Drug Drug Drug Drug Drug Drug Drug Drug Dr				1 1		
Jan		1				
J3105						
January Janu				a		
January Janu				1		
January				1		
J3150				1		
Thyrotropin injection a \$947.42 Drug						
J3245			1	1		
33250						
3260				a		
Jacob				1		
3301			Injection torsemide 10 mg/ml	1		
3302		1		1		
J3303						
J3305				1		
J3310				a		
J3320 Spectinomycn di-hcl inj \$53.81 Drug J3350 Urea injection \$176.32 Drug J3360 Diazepam injection \$173.32 Drug J3364 Urokinase 5000 IU injection \$103.62 Drug J3365 Urokinase 250,000 IU inj \$856.40 Drug J3370 Vancomycin hcl injection \$15.13 Drug J3395 Verteporfin injection a \$2,423.22 Drug J3400 Triflupromazine hcl inj \$74.27 Drug	J3310			1		
J3350				1		
Diazepam injection \$7.12 Drug						
J3364 Urokinase 5000 IU injection \$103.62 Drug J3365 Urokinase 250,000 IU inj \$856.40 Drug J3370 Vancomycin hol injection \$15.13 Drug J3395 Verteporfin injection a \$2,423.22 Drug J3400 Triflupromazine hol inje				1		
J3365 Urokinase 250,000 IU inj \$856.40 Drug J3370 Vancomycin hcl injection \$15.13 Drug J3395 Verteporfin injection a \$2,423.22 Drug J3400 Triflupromazine hcl inj \$74.27 Drug					\$103.62	Drug
J3395 Verteporfin injection a \$2,423.22 Drug J3400 Triflupromazine hcl inj \$74.27 Drug	J3365		Urokinase 250,000 IU inj			
J3400 Triflupromazine hcl inj \$74.27 Drug		İ		_		
				a		
DUTTO 1 I HYDIOAYZHIC HOLHICOHOH 1 1 1 01.121 DIOG	J3410		Hydroxyzine hol injection		\$1.12	Drug
J3420 Vitamin b12 injection \$2.24 Drug						

PAGE 27 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogo
J3430		Vitamin k phytonadione inj		\$3.92	Drug
J3470	- 1	Hyaluronidase injection	1 1	\$50.95	Drug
J3475	1	Inj magnesium sulfate		\$0.56	Drug
J3480	- 1	Ini potassium chloride		\$0.56	Drug
J3485		Zidovudine		\$1.68	Drug
J3487	1	Zoledronic acid	a	\$369.81	Drug
	ŀ	Zoledi Offic acid	1 ª 1	\$303.01	Drug
J3490	1	F1.4.1 P. P		64.40	
J3520		Edetate disodium per 150 mg		\$1.12	Drug
J3535	I	Metered dose inhaler drug		\$2.99	Drug
J3570		Laetrile amygdalin vit B17	1	\$35.76	Drug
J3590	l			_	_
J7030	I	Normal saline solution infus	1 1	\$23.14	Drug
J7040		Normal saline solution infus		\$11.12	Drug
J7042		5% dextrose/normal saline	1	\$19.93	Drug
J7050		Normal saline solution infus	1	\$4.72	Drug
J7051	1	Sterile saline/water	1	\$1.12	Drug
J7060	l	5% dextrose/water	1 1	\$15.93	Drug
J7070	l	D5w infusion	1	\$24.74	Drug
J7100	l	Dextran 40 infusion	1 1	\$51.52	Drug
J7110	j	Dextran 75 infusion	1 1	\$31.15	Drug
J7110	l	Ringers lactate infusion		\$27.14	Drug
	l		1 1		
J7130		Hypertonic saline solution	1 _ (\$1.12	Drug
J7190	l	Factor viii	a	\$1.68	Drug
J7191	1	Factor VIII (porcine)	a	\$3.36	Drug
J7192		Factor viii recombinant	a	\$2.24	Drug
J7193	1	Factor IX non-recombinant	a	\$1.68	Drug
J7194	1	Factor ix complex	a	\$0.56	Drug
J7195	ì	Factor IX recombinant	a	\$1.68	Drug
J7197	1	Antithrombin iii injection	a	\$1.68	Drug
J7198	1	Anti-inhibitor	a	\$2.24	Drug
J7300	1	Intraut copper contraceptive	1 1	\$461.84	Drug
J7302	1	Levonorgestrel iu contracept		\$751.64	Drug
J7308	I	Aminolevulinic acid hcl top	1 1	\$176.89	Drug
J7310		Ganciclovir long act implant		\$7,869.58	Drug
J7317	- 1	Sodium hyaluronate injection	1 1	\$245.01	Drug
	J		1 - 1	\$378.97	Drug
J7320		Hylan G-F 20 injection	a		
J7330	1	Cultured chondrocytes implnt	а	\$25,100.57	Drug
J7340		Metabolic active D/E tissue	1 1	\$58.39	Drug
J7342		Metabolically active tissue	1 1	\$28.40	Non-Dri
J7500	- 1	Azathioprine oral 50mg	1 1	\$2.24	Drug
J7501	l	Azathioprine parenteral	1 1	\$108.77	Drug
J7502	1	Cyclosporine oral 100 mg	a	\$16.73	Drug
J7504	- 1	Lymphocyte immune globulin	a	\$490.03	Drug
J7505	- 1	Monoclonal antibodies	a	\$1,563.38	Drug
J7506	- 1	Prednisone oral		\$0.09	Drug
J7507	1	Tacrolimus oral per 1 MG	a	\$7.12	Drug
J7508		Tacrolimus oral per 5 MG		\$40.07	Drug
J7509		Methylprednisolone oral	1 1	\$1.12	Drug
J7510		Prednisolone oral per 5 mg	1	\$0.18	Drug
J7511	- 1	Antithymocyte globuln rabbit	lal	\$547.84	Drug
J7513		Daclizumab, parenteral	a	\$713.28	Drug
J7515		Cyclosporine oral 25 mg	1 - 1	\$2.80	Drug
J7516		Cyclosporin parenteral 250mg	1	\$60.11	Drug
J7517		Mycophenolate mofetil oral	a	\$4.72	Drug
J7520		Sirolimus, oral	a	\$16.73	Drug
J7525	- 1	Tacrolimus injection		\$239.86	Drug
		racionina injection	1	\$200.00	Drug
J7599		Acetylcysteine inh sol u d		\$13.07	Drug
J7608		Acetylcysteine inn sol u d Albuterol inh sol con		\$0.23	Drug
J7618		Albuterol inh sol u d	l l	\$0.75	Drug
J7619	- 1		į l	\$6.88	Drug
J7622		Beclomethasone inhalatn sol	1		
J7626		Budesonide inhalation sol	Į l	\$10.32	Drug
J7628	-	Bitolterol mes inhal sol con		\$0.40	Drug
J7629		Bitolterol mes inh sol u d		\$1.12	Drug
J7631		Cromolyn sodium inh sol u d		\$0.56	Drug
J7633		Budesonide concentrated sol		\$11.93	Drug
J7636		Atropine inhal sol unit dose		\$0.51	Drug
J7637		Dexamethasone inhal sol con	1 1	\$0.21	Drug

PAGE 28 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
J7638		Dexamethasone inhal sol u d		\$0.50	Drug
J7639		Dornase alpha inhal sol u d		\$89.31	Drug
J7642		Glycopyrrolate inhal sol con		\$9.63	Drug
J7643		Glycopyrrolate inhal sol u d	1 1	\$12.38	Drug
J7644		Ipratropium brom inh sol u d		\$5.79	Drug
J7649	1	Isoetharine hol inh sol u d		\$1.38	Drug
J7668 J7669		Metaproterenol inh sol con Metaproterenol inh sol u d	1	\$0.50 \$2.44	Drug Drug
J7680		Terbutaline so4 inh sol con		\$6.88	Drug
J7681		Terbutaline so4 inh sol u d		\$2.77	Drug
J7682		Tobramycin inhalation sol	1 1	\$102.47	Drug
J7683		Triamcinolone inh sol con	1 1	\$0.10	Drug
J7684		Triamcinolone inh sol u d		\$0.30	Drug
J7699			1		
J7799			1 1		
J8499		Could be 15 or	· 1	65.44	D
J8510		Oral busulfan		\$5.11 \$6.56	Drug Drug
J8520 J8521	1	Capecitabine, oral, 150 mg Capecitabine, oral, 500 mg	а	\$22.61	Drug
J8530	1	Cyclophosphamide oral 25 MG]]	\$5.83	Drug
J8560	1	Etoposide oral 50 MG	a	\$137.05	Drug
J8600		Melphalan oral 2 MG		\$5.83	Drug
J8610		Methotrexate oral 2.5 MG		\$8.02	Drug
J8700		Temozolmide	a	\$16.05	Drug
J8999		, , , , , , , , , , , , , , , , , , , ,	1		_
J9000		Doxorubic hcl 10 MG vl chemo	1 1	\$103.76	Drug
J9001		Doxorubicin hel liposome inj	a	\$636.00 \$855.83	Drug
J9010 J9015	1	Alemtuzumab injection Aldesleukin/single use vial	a	\$1,084.35	Drug Drug
J9013	1	Arsenic trioxide	a	\$64.91	Drug
J9020		Asparaginase injection	1 " 1	\$127.34	Drug
J9031		Bcg live intravesical vac	1	\$351.05	Drug
J9040		Bleomycin sulfate injection	a	\$511.64	Drug
J9045		Carboplatin injection	a	\$274.40	Drug
J9050		Carmus bischl nitro ini	а	\$257.06	Drug
J9060	1	Cisplatin 10 MG injection	a	\$87.80	Drug
J9062		Cisplatin 50 MG injection	1 _ 1	\$405.71	Drug
J9065		Inj cladribine per 1 MG	a	\$108.61 \$12.40	Drug Drug
J9070 J9080		Cyclophosphamide 100 MG inj Cyclophosphamide 200 MG inj	1	\$12.40 \$24.07	Drug
J9090		Cyclophosphamide 500 MG inj		\$49.65	Drug
J9091		Cyclophosphamide 1.0 grm inj		\$97.51	Drug
J9092		Cyclophosphamide 2.0 grm inj	1	\$192.55	Drug
J9093	1	Cyclophosphamide lyophilized	1 1	\$12.40	Drug
J9094		Cyclophosphamide lyophilized		\$24.80	Drug
J9095		Cyclophosphamide lyophilized		\$51.03	Drug
J9096		Cyclophosphamide lyophilized	1	\$99.59	Drug
J9097		Cyclophosphamide lyophilized		\$198.10 \$12.40	Drug Drug
J9100 J9110	1	Cytarabine hcl 100 MG inj Cytarabine hcl 500 MG inj		\$49.65	Drug
J9120		Dactinomycin actinomycin d	1 1	\$29.17	Drug
J9130		Dacarbazine 10 MG inj]	\$26.99	Drug
J9140		Dacarbazine 200 MG inj		\$46.87	Drug
J9150	1	Daunorubicin	. a	\$162.03	Drug
J9151		Daunorubicin citrate liposom	а	\$131.50	Drug
J9160	1	Denileukin diftitox, 300 mcg	а	\$2,012.76	Drug
J9165		Diethylstilbestrol injection	а	\$30.63 \$565.82	Drug
J9170	1	Docetaxel Epirubicin HCl injection	а	\$565.82 \$1,113.38	Drug Drug
J9180 J9181		Etoposide 10 MG ini		\$21.88	Drug
J9182	1	Etoposide 10 MG inj	1	\$211.28	Drug
J9185	1	Fludarabine phosphate inj	a	\$563.40	Drug
J9190		Fluorouracil injection		\$5.83	Drug
J9200	1	Floxuridine injection	a	\$261.92	Drug
J9201		Gemcitabine HCI	a	\$244.58	Drug
J9202	1	Goserelin acetate implant	a	\$731.24	Drug
J9206		Irinotecan injection	lal	\$306.31	Drug

PAGE 29 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
J9209		Mesna injection	а	\$74.62	Drug
J9211		Idarubicin hel injection	а	\$759.30	Drug
J9212		Interferon alfacon-1		\$7.92	Drug
J9213		Interferon alfa-2a ini		\$71.85	Drug
J9214		Interferon alfa-2b inj		\$28.44	Drug
J9215		Interferon alfa-n3 inj		\$16.77	Drug
J9216		Interferon gamma 1-b inj	a	\$393.13	Drug
J9217	1 1	Leuprolide acetate suspnsion	a	\$961.97	Drug
J9218		Leuprolide acetate injeciton Leuprolide acetate implant	a	\$51.73 \$7.657.49	Drug Drug
J9219 J9230		Mechlorethamine hol inj	a	\$25.53	Drug
J9245	1	Inj melphalan hydrochl 50 MG	a	\$689.65	Drug
J9250	1	Methotrexate sodium inj	"	\$0.73	Drug
J9260		Methotrexate sodium inj	 	\$11.67	Drug
J9265		Paclitaxel injection	a	\$327.13	Drug
J9266		Pegaspargase/singl dose vial	a	\$2,102.56	Drug
J9268	1	Pentostatin injection	a	\$2,800.56	Drug
J9270		Plicamycin (mithramycin) inj	1 1	\$189.77	Drug
J9280		Mitomycin 5 MG inj	a	\$196.02	Drug
J9290		Mitomycin 20 MG inj		\$685.29	Drug
J9291		Mitomycin 40 MG inj		\$1,322.34	Drug
J9293	1	Mitoxantrone hydrochl / 5 MG	a	\$478.75	Drug
J9300		Gemtuzumab ozogamicin		\$3,045.80	Drug
J9310	1	Rituximab cancer treatment	a	\$770.91	Drug
J9320		Streptozocin injection		\$275.79	Drug
J9340		Thiotepa injection		\$236.25	Drug
J9350	1	Topotecan	a	\$1,127.40 \$100.75	Drug Drug
J9355 J9357		Trastuzumab Valrubicin, 200 mg	a	\$881.59	Drug
J9360		Vandbicin, 200 mg Vinblastine sulfate ini	a	\$8.75	Drug
J9370		Vincristine sulfate 1 MG ini	1	\$69.76	Drug
J9375		Vincristine sulfate 2 MG inj	1 1	\$106.53	Drug
J9380	l	Vincristine sulfate 5 MG ini		\$323.66	Drug
J9390	1	Vinorelbine tartrate/10 mg	a	\$200.87	Drug
J9600	l	Porfimer sodium	a	\$3,747.66	Drug
J9999					
K0001	NU	Standard wheelchair	1	\$739.55	Non-Drug
K0001	RR	Standard wheelchair	1 1	\$74.24	Non-Drug
K0001	UE	Standard wheelchair	1	\$554.66	Non-Drug
K0002	NU	Stnd hemi (low seat) whichr	1 1	\$849.98	Non-Drug
K0002	RR	Stnd hemi (low seat) whichr		\$107.31	Non-Drug
K0002	UE	Stnd hemi (low seat) whichr	1 1	\$667.37 \$1,326.22	Non-Drug Non-Drug
K0003 K0003	NU RR	Lightweight wheelchair Lightweight wheelchair	1	\$1,320.22	Non-Drug
K0003	UE	Lightweight wheelchair	1	\$994.78	Non-Drug
K0003	NU	High strength Itwt whichr	1 1	\$2,024.06	Non-Drug
K0004	RR	High strength ltwt whichr		\$170.26	Non-Drug
K0004	ÜE	High strength Itwt whichr		\$1,517.77	Non-Drug
K0005	NU	Ultralightweight wheelchair		\$2,254.41	Non-Drug
K0005	RR	Ultralightweight wheelchair	1	\$232.50	Non-Drug
K0005	UE	Ultralightweight wheelchair		\$1,692.75	Non-Drug
K0006	NU	Heavy duty wheelchair		\$1,461.95	Non-Drug
K0006	RR	Heavy duty wheelchair	1 1	\$160.26	Non-Dru
K0006	UE	Heavy duty wheelchair	1	\$1,101.81	Non-Dru
K0007	NU	Extra heavy duty wheelchair	1	\$2,247.76	Non-Dru
K0007	RR	Extra heavy duty wheelchair		\$224.78 \$2.201.16	Non-Dru Non-Dru
K0007	UE	Extra heavy duty wheelchair		\$2,201.16 \$545.20	Non-Dru
K0009 K0010	NU	Other manual wheelchair/base Stnd wt frame power whichr		\$5,255.16	Non-Drug
K0010	RR	Stnd wt frame power which		\$525.52	Non-Drug
K0010	UE	Stnd wt frame power which		\$3,942.05	Non-Dru
K0010	NU	Stnd wt name power which	1	\$8,819.59	Non-Dru
K0011	RR	Stnd wt pwr whichr w control		\$651.48	Non-Dru
K0012	RR	Ltwt portbl power whichr		\$402.70	Non-Dru
K0012	''''	Ltwt portbl power whichr		\$3,760.35	Non-Dru
K0014		Other power whichr base		\$1,445.57	Non-Dru
K0015	NU	Detach non-adjus hight armrst		\$228.66	Non-Dru
K0015	RR	Detach non-adjus hight armrst	1 1	\$25.57	Non-Dru

PAGE 30 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
K0015	UE	Detach non-adjus hight armrst		\$173.46	Non-Drug
K0016	NU	Detach adjust armrst cmplete		\$147.58	Non-Drug
K0016	RR	Detach adjust armrst cmplete		\$15.71	Non-Drug
K0016	UE NU	Detach adjust armrest complete		\$112.65	Non-Drug
K0017 K0017	RR	Detach adjust armrest base Detach adjust armrest base		\$69.98 \$7.75	Non-Drug Non-Drug
K0017	ÜÈ	Detach adjust armrest base		\$53.03	Non-Drug
K0018	NU	Detach adjust armrst upper		\$39.70	Non-Drug
K0018	RR	Detach adjust armrst upper		\$4.66	Non-Drug
K0018	UE	Detach adjust armrst upper		\$30.00	Non-Drug
K0019	NU	Arm pad each		\$24.29	Non-Drug
K0019 K0019	RR UE	Arm pad each Arm pad each		\$3.13 \$18.41	Non-Drug Non-Drug
K0020	NU	Fixed adjust armrest pair		\$64.11	Non-Drug
K0020	RR	Fixed adjust armrest pair		\$7.13	Non-Drug
K0020	UE	Fixed adjust armrest pair		\$48.26	Non-Drug
K0022	NU	Reinforced back upholstery	1 1	\$68.90	Non-Drug
K0022	RR	Reinforced back upholstery		\$7.61	Non-Drug
K0022	UE	Reinforced back upholstery		\$52.12	Non-Drug
K0023 K0023	NU RR	Planr back insrt foam w/strp Planr back insrt foam w/strp		\$122.20 \$13.60	Non-Drug Non-Drug
K0023	UE	Planr back insrt foam w/strp		\$93.64	Non-Drug
K0024	NU	Plnr back insrt foam w/hrdwr		\$143.23	Non-Drug
K0024	RR	Plnr back insrt foam w/hrdwr		\$15.99	Non-Drug
K0024	UE	Plnr back insrt foam w/hrdwr		\$109.41	Non-Drug
K0025	NU	Hook-on headrest extension		\$94.60	Non-Drug
K0025	RR	Hook-on headrest extension		\$10.39 \$72.91	Non-Drug
K0025 K0026	UE NU	Hook-on headrest extension Back upholst igtwt whichr		\$64.17	Non-Drug Non-Drug
K0026	RR	Back uphoist igtwt which		\$7.10	Non-Drug
K0026	ÜÈ	Back uphoist igtwt whichr		\$48.53	Non-Drug
K0027	NU	Back uphoist other whichr		\$64.17	Non-Drug
K0027	RR	Back upholst other whichr		\$7.10	Non-Drug
K0027	UE	Back uphoist other whichr		\$48.53	Non-Drug
K0028	NU RR	Manual fully reclining back		\$670.92 \$76.11	Non-Drug Non-Drug
K0028 K0028	UE	Manual fully reclining back Manual fully reclining back		\$505.11	Non-Drug
K0029	NU	Reinforced seat upholstery		\$68.32	Non-Drug
K0029	RR	Reinforced seat upholstery		\$7.52	Non-Drug
K0029	UE	Reinforced seat upholstery		\$51.67	Non-Drug
K0030	NU	Solid plnr seat sngl dnsfoam		\$123.49	Non-Drug
K0030	RR UE	Solid plnr seat snal dosfoam		\$13.40 \$94.60	Non-Drug Non-Drug
K0030 K0030	0-	Solid plnr seat sngl dnsfoam Solid plnr seat sngl dnsfoam		\$175.04	Non-Drug
K0030	NU	Safety belt/pelvic strap	1 1	\$58.99	Non-Drug
K0031	RR	Safety belt/pelvic strap		\$6.62	Non-Drug
K0031	UE	Safety belt/pelvic strap		\$43.94	Non-Drug
K0032	NU	Seat uphols igtwt whichr] [\$63.32 \$6.79	Non-Drug Non-Drug
K0032 K0032	RR UE	Seat uphols igtwt whichr Seat uphols igtwt whichr		\$47.93	Non-Drug
K0032	NU	Seat uphoisigtwit which	1	\$63.32	Non-Drug
K0033	RR	Seat upholstery other whichr		\$6.79	Non-Drug
K0033	UE	Seat upholstery other whichr		\$47.93	Non-Drug
K0035	NU	Heel loop with ankle strap		\$36.09	Non-Drug
K0035	RR	Heel loop with ankle strap	l	\$4.33	Non-Drug
K0035	UE NU	Heel loop with ankle strap		\$27.30 \$26.45	Non-Drug Non-Drug
K0036 K0036	RR	Toe loop each Toe loop each		\$3.46	Non-Drug
K0036	ÜE	Toe loop each		\$20.05	Non-Drug
K0037	NU	High mount flip-up footrest		\$66.39	Non-Drug
K0037	RR	High mount flip-up footrest		\$6.65	Non-Drug
K0037	UE	High mount flip-up footrest		\$50.03 \$33.86	Non-Drug Non-Drug
K0038	NU RR	Leg strap each Leg strap each		\$4.10	Non-Drug Non-Drug
K0038 K0038	UE	Leg strap each		\$25.60	Non-Drug
K0030	NU	Leg strap each		\$73.34	Non-Drug
K0039	RR	Leg strap h style each		\$8.15	Non-Drug
K0039	UE	Leg strap h style each	1 1	\$55.87	Non-Drug

PAGE 31 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
V0040	NILL	Adiustable and factalets		f00 64	Non Dave
K0040	NU	Adjustable angle footplate	1	\$98.61	Non-Drug
K0040	RR	Adjustable angle footplate		\$10.94	Non-Drug
K0040	UE	Adjustable angle footplate		\$75.91	Non-Drug
K0041	NU	Large size footplate each		\$72.18	Non-Drug
K0041	RR	Large size footplate each	1 1	\$8.03	Non-Drug
K0041	UE	Large size footplate each	1 1	\$54.89	Non-Drug
K0042	NU	Standard size footplate each		\$50.44	Non-Drug
K0042	RR	Standard size footplate each		\$5.74	Non-Drug
K0042	UE	Standard size footplate each	1 [\$38.03	Non-Drug
K0043	NU	Ftrst lower extension tube	1	\$27.41	Non-Drug
K0043	RR	Ftrst lower extension tube		\$3.45	Non-Drug Non-Drug
K0043	UE	Ftrst lower extension tube		\$20.77	
K0044	NU	Ftrst upper hanger bracket	1 1	\$23.47	Non-Drug
K0044	RR	Ftrst upper hanger bracket	1	\$3.07	Non-Drug
K0044	UE NU	Ftrst upper hanger bracket	1 1	\$17.80	Non-Drug
K0045 K0045	RR	Footrest complete assembly		\$76.67 \$8.75	Non-Drug Non-Drug
K0045 K0045	UE	Footrest complete assembly	1 1	\$58.67	Non-Drug Non-Drug
K0045 K0046	NU	Footrest complete assembly Elevat legrst low extension		\$27.41	Non-Drug
K0046	RR	Elevat legist low extension	1 1	\$3.45	Non-Drug
K0046	UE	Elevat legist low extension		\$20.77	Non-Drug
K0040 K0047	NU	Elevat legist low extension Elevat legist up hangr brack	1 1	\$100.81	Non-Drug
K0047	RR	Elevat legist up hangr brack		\$11.24	Non-Drug Non-Drug
K0047	ÜÈ	Elevat legist up hangr brack	1	\$77.55	Non-Drug
K0047	NU	Elevate legrest complete		\$150.57	Non-Drug
K0048	RR	Elevate legrest complete	1	\$18.81	Non-Drug
K0048	UE	Elevate legrest complete		\$119.36	Non-Drug
K0049	NU	Calf pad each]]	\$42.22	Non-Drug
K0049	RR	Calf pad each		\$4.95	Non-Drug
K0049	UE	Calf pad each	1	\$31.84	Non-Drug
K0050	NU	Ratchet assembly		\$45.09	Non-Drug
K0050	RR	Ratchet assembly		\$5.21	Non-Drug
K0050	UE	Ratchet assembly		\$34.03	Non-Drug
K0051	NU	Cam relese assem ftrst/igrst		\$71.80	Non-Drug
K0051	RR	Cam relese assem ftrst/lgrst		\$8.00	Non-Drug
K0051	UE	Cam relese assem ftrst/lgrst	1	\$54.55	Non-Drug
K0052	NU	Swingaway detach footrest		\$120.20	Non-Drug
K0052	RR	Swingaway detach footrest		\$13.38	Non-Drug
K0052	UE	Swingaway detach footrest		\$92.11	Non-Drug
K0053	NU	Elevate footrest articulate		\$131.83	Non-Drug
K0053	RR	Elevate footrest articulate		\$14.68	Non-Drug
K0053	UE	Elevate footrest articulate		\$100.84	Non-Drug
K0054	NU	Seat wdth 10-12/15/17/20 wc		\$135.02	Non-Drug
K0054	RR	Seat wdth 10-12/15/17/20 wc	1 1	\$15.05	Non-Drug
K0054	UE	Seat wdth 10-12/15/17/20 wc		\$103.22	Non-Drug
K0055	NU	Seat dpth 15/17/18 ltwt wc		\$123.43	Non-Drug
K0055	RR	Seat dpth 15/17/18 ltwt wc		\$13.75	Non-Drug
K0055	UE	Seat dpth 15/17/18 ltwt wc		\$94.56	Non-Drug
K0056	NU	Seat ht <17 or >=21 ltwt wc		\$123.43	Non-Drug
K0056	RR	Seat ht <17 or >=21 ltwt wc		\$13.75	Non-Drug
K0056	UE	Seat ht <17 or >=21 ltwt wc		\$94.56	Non-Drug
K0057	NU	Seat wdth 19/20 hvy dty wc	1 1	\$158.79	Non-Drug
K0057	RR	Seat wdth 19/20 hvy dty wc	1	\$17.73 \$121.05	Non-Drug
K0057	UE	Seat wdth 19/20 hvy dty wc		\$81.23	Non-Drug Non-Drug
K0058	NU	Seat dpth 17/18 power wc	1 1	\$9.02	Non-Drug Non-Drug
K0058 K0058	RR UE	Seat dpth 17/18 power wc Seat dpth 17/18 power wc		\$62.49	Non-Drug Non-Drug
K0058 K0059	NU	Plastic coated handrim each		\$44.02	Non-Drug
K0059 K0059	RR	Plastic coated handrim each		\$5.10	Non-Drug Non-Drug
K0059	UE	Plastic coated handrim each]	\$33.21	Non-Drug
K0060	NU	Steel handrim each		\$38.61	Non-Drug
K0060	RR	Steel handrim each		\$4.58	Non-Drug
K0060	ÜÈ	Steel handrim each		\$29.14	Non-Drug
K0061	NU	Aluminum handrim each		\$54.45	Non-Drug
K0061	RR	Aluminum handrim each		\$6.16	Non-Drug
K0061	UE	Aluminum handrim each		\$41.05	Non-Drug
K0062	NU	Handrim 8-10 vert/obliq proj		\$82.01	Non-Drug
K0062	RR	Handrim 8-10 vert/obliq proj	1 1	\$9.13	Non-Drug

PAGE 32 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
K0062	UE	Handrim 8-10 vert/obliq proj		\$63.15	Non-Drug
K0063	NU	Hndrm 12-16 vert/obliq proj		\$106.86	Non-Drug
K0063	RR	Hndrm 12-16 vert/oblig proj		\$11.90	Non-Drug
K0063	UE	Hndrm 12-16 vert/oblig proj		\$82.09	Non-Drug
K0064 K0064	NU RR	Zero pressure tube flat free Zero pressure tube flat free		\$42.24 \$4.95	Non-Drug Non-Drug
K0064	UE	Zero pressure tube flat free		\$31.85	Non-Drug
K0065	NU	Spoke protectors		\$61.39	Non-Drug
K0065	RR	Spoke protectors		\$6.86	Non-Drug
K0065	UE	Spoke protectors		\$46.23	Non-Drug
K0066	NU	Solid tire any size each		\$39.66	Non-Drug
K0066	RR	Solid tire any size each		\$4.54	Non-Drug
K0066	UE	Solid tire any size each		\$30.52 \$56.55	Non-Drug
K0067 K0067	NU RR	Pneumatic tire any size each Pneumatic tire any size each		\$6.26	Non-Drug Non-Drua
K0067	UE	Pneumatic tire any size each		\$40.72	Non-Drug
K0068	NU	Pneumatic tire tube each		\$8.80	Non-Drug
K0068	RR	Pneumatic tire tube each		\$1.62	Non-Drug
K0068	UE	Pneumatic tire tube each	1 1	\$6.81	Non-Drug
K0069	NU	Rear whi complete solid tire	1	\$129.29	Non-Drug
K0069	RR	Rear whi complete solid tire		\$14.98	Non-Drug
K0069	UE NU	Rear whi complete solid tire Rear whi complipheum tire	1	\$98.93 \$230.44	Non-Drug Non-Drug
K0070 K0070	RR	Rear whi complipheum tire		\$25.77	Non-Drug
K0070	ÜE	Rear whi complipheum tire	[[\$174.80	Non-Drug
K0071	NU	Front castr compl pneum tire	1	\$140.63	Non-Drug
K0071	RR	Front castr compl pneum tire		\$15.69	Non-Drug
K0071	UE	Front castr compl pneum tire		\$107.42	Non-Drug
K0072	NU	Frnt cstr cmpl sem-pneum tir		\$87.78	Non-Drug
K0072	RR	Frnt cstr cmpl sem-pneum tir	1	\$9.74	Non-Drug
K0072 K0073	UE NU	Frnt cstr cmpl sem-pneum tir	1 1	\$67.80 \$48.22	Non-Drug Non-Drug
K0073 K0073	RR	Caster pin lock each Caster pin lock each	1 1	\$5.53	Non-Drug
K0073	UE	Caster pin lock each		\$36.36	Non-Drug
K0074	NU	Pneumatic caster tire each	1	\$49.86	Non-Drug
K0074	RR	Pneumatic caster tire each	1	\$6.19	Non-Drug
K0074	UE	Pneumatic caster tire each		\$37.58	Non-Drug
K0075	NU	Semi-pneumatic caster tire		\$57.83	Non-Drug
K0075 K0075	RR	Semi-pneumatic caster tire Semi-pneumatic caster tire	1	\$7.22 \$43.57	Non-Drug Non-Drug
K0075 K0076	NU	Solid caster tire each		\$35.61	Non-Drug Non-Drug
K0076	RR	Solid caster tire each		\$4.31	Non-Drug
K0076	UE	Solid caster tire each		\$26.93	Non-Drug
K0077	NU	Front caster assem complete		\$79.38	Non-Drug
K0077	RR	Front caster assem complete	1	\$8.80	Non-Drug
K0077	UE	Front caster assem complete	1	\$60.94 \$13.87	Non-Drug Non-Drug
K0078 K0078	NU RR	Pneumatic caster tire tube Pneumatic caster tire tube		\$2.09	Non-Drug
K0078	UE	Pneumatic caster tire tube		\$10.58	Non-Drug
K0079	NÜ	Wheel lock extension pair		\$80.20	Non-Drug
K0079	RR	Wheel lock extension pair	1	\$9.27	Non-Drug
K0079	UE	Wheel lock extension pair		\$41.30	Non-Drug
K0080	NU	Anti-rollback device pair		\$198.42	Non-Drug
K0080	RR	Anti-rollback device pair	1 [\$23.47 \$151.85	Non-Drug Non-Drug
K0080 K0081	UE NU	Anti-rollback device pair Wheel lock assembly complete		\$56.24	Non-Drug Non-Drug
K0081	RR	Wheel lock assembly complete		\$6.32	Non-Drug
K0081	ÜE	Wheel lock assembly complete		\$42.36	Non-Drug
K0082	NU	22 nf nonsealed leadacid		\$144.38	Non-Drug
K0082	RR	22 nf nonsealed leadacid		\$16.18	Non-Drug
K0082	UE	22 nf nonsealed leadacid		\$110.26 \$137.38	Non-Drug Non-Drug
K0082	N11.1	22 nf nonsealed leadacid		\$137.38 \$177.35	Non-Drug Non-Drug
K0083 K0083	NU RR	22nf sealed leadacid battery 22nf sealed leadacid battery		\$177.33	Non-Drug
K0083	UE	22nf sealed leadacid battery		\$135.00	Non-Drug
K0083	"	22nf sealed leadacid battery	1	\$169.06	Non-Drug
K0084	NU	Gr24 nonsealed leadacid		\$119.64	Non-Drug
K0084	RR	Gr24 nonsealed leadacid		\$13.33	Non-Drug

PAGE 33 OF 54

		PAGE 33 OF 54			
HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
K0084	UE	Gr24 nonsealed leadacid		\$91.69	Non-Drug
K0084	"	Gr24 nonsealed leadacid		\$126.81	Non-Drug
K0085	NU	Gr24 sealed leadacid battery		\$233.89	Non-Drug
K0085	RR	Gr24 sealed leadacid battery		\$26.15	Non-Drug
K0085	UE	Gr24 sealed leadacid battery		\$177.38	Non-Drug
K0085		Gr24 sealed leadacid battery	1	\$222.80	Non-Drug
K0086	NU	U1nonsealed leadacid battery U1nonsealed leadacid battery		\$144.38 \$16.18	Non-Drug Non-Drua
K0086 K0086	RR UE	U1nonsealed leadacid battery		\$10.16	Non-Drug
K0086	0	U1nonsealed leadacid battery		\$137.38	Non-Drug
K0087	NU	U1 sealed leadacid battery		\$144.17	Non-Drug
K0087	RR	U1 sealed leadacid battery	1 1	\$16.08	Non-Drug
K0087	UE	U1 sealed leadacid battery		\$110.13	Non-Drug
K0087	NIL I	U1 sealed leadacid battery		\$137.38	Non-Drug
K0088 K0088	NU RR	Battery charger, single mode Battery charger, single mode		\$328.21 \$36.81	Non-Drug Non-Drug
K0088	UE	Battery charger, single mode		\$248.13	Non-Drug
K0088	"-	Battery charger, single mode	·	\$311.43	Non-Drug
K0089	NU	Battery charger, dual mode	1	\$517.12	Non-Drug
K0089	RR	Battery charger, dual mode	1 1	\$57.91	Non-Drug
K0089	UE	Battery charger, dual mode		\$389.81	Non-Drug
K0090	NU RR	Rear tire power wheelchair	1 1	\$100.44 \$11.19	Non-Drug Non-Drug
K0090 K0090	UE	Rear tire power wheelchair Rear tire power wheelchair	1 1	\$77.30	Non-Drug Non-Drug
K0090	NU	Rear tire tube power whichr	1	\$29.10	Non-Drug
K0091	RR	Rear tire tube power whichr		\$3.61	Non-Drug
K0091	UE	Rear tire tube power whichr		\$22.01	Non-Drug
K0092	NU	Rear assem cmplt powr whichr	1	\$303.31	Non-Drug
K0092	RR	Rear assem cmplt powr whichr		\$33.91	Non-Drug
K0092 K0093	UE NU	Rear assem cmplt powr whichr Rear zero pressure tire tube	.	\$229.45 \$192.43	Non-Drug Non-Drua
K0093	RR	Rear zero pressure tire tube		\$21.49	Non-Drug Non-Drug
K0093	ÜE	Rear zero pressure tire tube		\$146.29	Non-Drug
K0094	NU	Wheel tire for power base		\$68.02	Non-Drug
K0094	RR	Wheel tire for power base		\$7.55	Non-Drug
K0094	UE	Wheel tire for power base	1 1	\$51.37	Non-Drug
K0095 K0095	NU RR	Wheel tire tube each base Wheel tire tube each base	1 1	\$68.02 \$7.55	Non-Drug Non-Drug
K0095	UE	Wheel tire tube each base		\$51.37	Non-Drug
K0096	NU	Wheel assem powr base complt		\$341.18	Non-Drug
K0096	RR	Wheel assem powr base compit	1 1	\$38.16	Non-Drug
K0096	UE	Wheel assem powr base complt		\$257.85	Non-Drug
K0097	NU	Wheel zero presure tire tube		\$84.53	Non-Drug
K0097 K0097	RR UE	Wheel zero presure tire tube Wheel zero presure tire tube	1 (\$9.39 \$65.27	Non-Drug Non-Drug
K0097	NU	Drive belt power wheelchair	1 1	\$37.88	Non-Drug
K0098	RR	Drive belt power wheelchair		\$4.50	Non-Drug
K0098	UE	Drive belt power wheelchair		\$28.58	Non-Drug
K0099	NU	Pwr wheelchair front caster	1	\$106.19	Non-Drug
K0099	RR	Pwr wheelchair front caster		\$11.84 \$81.61	Non-Drug Non-Drug
K0099 K0100	NU NU	Pwr wheelchair front caster Amputee adapter pair		\$115.31	Non-Drug Non-Drug
K0100	RR	Amputee adapter pair Amputee adapter pair		\$12.89	Non-Drug
K0100	UE	Amputee adapter pair		\$89.19	Non-Drug
K0102	NU	Crutch and cane holder	. 1	\$59.87	Non-Drug
K0102	RR	Crutch and cane holder		\$6.71	Non-Drug
K0102	UE	Crutch and cane holder		\$45.10 \$74.85	Non-Drug Non-Drug
K0103 K0103	NU RR	Transfer board < 25" Transfer board < 25"	Į l	\$8.44	Non-Drug
K0103	UE	Transfer board < 25"		\$55.80	Non-Drug
K0104	NU	Cylinder tank carrier		\$152.21	Non-Drug
K0104	RR	Cylinder tank carrier		\$16.97	Non-Drug
K0104	UE	Cylinder tank carrier		\$116.13 \$128.69	Non-Drug Non-Drug
K0105	NU	ly hanger	l l	\$120.09	Non-Drug
K0105 K0105	RR UE	I tv hanger Iv hanger		\$98.48	Non-Drug
K0106	NU	Arm trough each		\$138.09	Non-Drug
K0106	RR	Arm trough each	.	\$15.43	Non-Drug
	•				

PAGE 34 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
K0106	UE	Arm trough each		\$105.54	Non-Drug
K0107	NU	Wheelchair tray	1	\$134.19	Non-Drug
K0107	RR	Wheelchair tray		\$14.98	Non-Drug
K0107 K0108	UE	Wheelchair tray W/c component-accessory NOS		\$102.62 \$84.19	Non-Drug Non-Drug
K0112		Trunk vest supprt innr frame		\$476.66	Non-Drug Non-Drug
K0113		Trunk vest suprt w/o inr frm	ļ	\$288.28	Non-Drug
K0114	NU	Whichr back suprt inr frame	1	\$929.20	Non-Drug
K0114	RR	Whichr back suprt inr frame		\$100.03	Non-Drug
K0114 K0115	UE NU	Whichr back suprt inr frame Back module orthotic system	1	\$698.87 \$1,467.92	Non-Drug Non-Drug
K0115	RR	Back module orthotic system	1	\$141.14	Non-Drug
K0115	UE	Back module orthotic system	1 1	\$1,099.37	Non-Drug
K0116	NU	Back & seat modul orthot sys	1	\$3,070.77	Non-Drug
K0116	RR	Back & seat modul orthot sys	1	\$301.39	Non-Drug
K0116 K0195	UE RR	Back & seat modul orthot sys Elevating whichair leg rests	1	\$2,301.53 \$29.51	Non-Drug Non-Drug
K0195	'''	Elevating whichair leg rests	1	\$143.35	Non-Drug
K0268	NU	Humidifier nonheated w PAP	1	\$240.83	Non-Drug
K0268	RR	Humidifier nonheated w PAP		\$36.55	Non-Drug
K0268 K0415	UE	Humidifier nonheated w PAP	1	\$182.82	Non-Drug
K0416					
K0452	NU	Wheelchair bearings	1	\$9.72	Non-Drug
K0452	RR	Wheelchair bearings	1	\$1.69	Non-Drug
K0452	UE	Wheelchair bearings		\$7.50	Non-Drug
K0455 K0460	RR RR	Pump uninterrupted infusion WC power add-on joystick	1	\$442.83 \$311.57	Non-Drug Non-Drug
K0460 K0461	NU	WC power add-on tiller cntrl		\$2,329.53	Non-Drug
K0461	RR	WC power add-on tiller cntrl		\$223.67	Non-Drug
K0461	UE	WC power add-on tiller cntrl		\$1,799.34	Non-Drug
K0462	, NII I	Temporary replacement eqpmnt		\$40.18 \$504.47	Non-Drug Non-Drug
K0531 K0531	NU RR	Heated humidifier used w pap Heated humidifier used w pap		\$46.49	Non-Drug
K0531	ÜE	Heated humidifier used w pap		\$376.77	Non-Drug
K0532	RR	Noninvasive assist wo backup		\$428.81	Non-Drug
K0533	RR	Noninvasive assist w backup		\$1,082.63	Non-Drug
K0534 K0538	RR RR	Invasive assist w backup Neg pressure wnd thrpy pump		\$1,082.63 \$2,904.35	Non-Drug Non-Drug
K0539	''''	Neg pres wnd thrpy dsg set	1	\$42.20	Non-Drug
K0540	İ	Neg pres wnd thrp canister	1	\$37.66	Non-Drug
K0541	NU	SGD prerecorded msg <= 8 min		\$656.82	Non-Drug
K0541 K0541	RR UE	SGD prerecorded msg <= 8 min SGD prerecorded msg <= 8 min		\$60.00 \$491.03	Non-Drug Non-Drug
K0542	NU	SGD prerecorded msg > 8 min]	\$2,556.81	Non-Drug
K0542	RR	SGD prerecorded msg > 8 min		\$249.98	Non-Drug
K0542	UE	SGD prerecorded msg > 8 min	1	\$1,916.02	Non-Drug Non-Drug
K0543 K0543	NU RR	SGD msg formed by spelling SGD msg formed by spelling		\$6,058.67 \$600.20	Non-Drug Non-Drug
K0543	ÜÈ	SGD msg formed by spelling		\$4,542.45	Non-Drug
K0544	NU	SGD w multi methods msg/accs	1	\$11,470.86	Non-Drug
K0544	RR	SGD w multi methods msg/accs		\$1,141.39	Non-Drug
K0544	UE	SGD w multi methods msg/accs		\$8,601.55 \$259.11	Non-Drug Non-Drug
K0547 K0548		SGD accessory NOC Insulin lispro		\$3.11	Drug
K0549	NU	Hosp bed hvy dty xtra wide		\$4,382.11	Non-Drug
K0549	RR	Hosp bed hvy dty xtra wide	1	\$438.06	Non-Drug
K0549	UE	Hosp bed hvy dty xtra wide		\$3,285.44 \$10,257.46	Non-Drug Non-Drug
K0550 K0550	NU RR	Hosp bed xtra hvy dty x wide Hosp bed xtra hvy dty x wide		\$1,085.77	Non-Drug
K0550	UE	Hosp bed xtra hvy dty x wide		\$7,705.56	Non-Drug
K0556		Socket insert w lock mech		\$835.33	Non-Drug
K0557		Socket insert w/o lock mech		\$690.23 \$1,504.95	Non-Drug Non-Drug
K0558 K0559		Intl custm cong/atyp insert Initial custom socket insert	1	\$1,504.95	Non-Drug
K0581		Ost pch clsd w barrier/filtr		\$3.97	Non-Drug
K0582		Ost pch w bar/bitinconv/fitr	1	\$5.40	Non-Drug
K0583	l	Ost pch clsd w/o bar w filtr	1 1	\$2.59	Non-Drug

PAGE 35 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
K0584		Ost pch for bar w flange/fit		\$2.49	Non-Drug
K0587		Ost pch drain w bar & filter	1 1	\$6.91	Non-Drug
K0588		Ost pch drain for barrier fl		\$5.19	Non-Drug
K0589		Ost pch drain 2 piece system		\$3.40 \$9.50	Non-Drug
K0591 K0592		Urine ost pouch w faucet/tap Urine ost pouch w bltinconv	1	\$10.99	Non-Drug Non-Drug
K0592		Ost urine pch w b/bltin conv		\$12.54	Non-Drug
K0594		Ost pch urine w barrier/tapy		\$7.40	Non-Drug
K0595		Os pch urine w bar/fange/tap	1	\$5.21	Non-Drug
K0596		Urine ost pch bar w lock fln		\$4.84	Non-Drug
K0597		Ost pch urine w lock flng/ft	1	\$5.46	Non-Drug
L0100		Cranial orthosis/helmet mold	1	\$668.86	Non-Drug
L0110 L0120		Cranial orthosis/helmet nonm Cerv flexible non-adjustable		\$158.59 \$31.81	Non-Drug Non-Drug
L0130		Flex thermoplastic collar mo	1	\$179.68	Non-Drug Non-Drug
L0140		Cervical semi-rigid adjustab	1 1	\$72.38	Non-Drug
L0150		Cerv semi-rig adj molded chn	1	\$120.06	Non-Drug
L0160		Cerv semi-rig wire occ/mand		\$172.61	Non-Drug
L0170		Cervical collar molded to pt	1	\$753.42	Non-Drug
L0172		Cerv col thermplas foam 2 pi	1 1	\$140.52 \$300.73	Non-Drug
L0174 L0180	1	Cerv col foam 2 piece w thor Cer post col occ/man sup adi	1 1	\$300.73 \$417.90	Non-Drug Non-Drug
L0190		Cerv collar supp adj cerv ba	1 1	\$570.55	Non-Drug
L0200	1	Cerv col supp adi bar & thor		\$596.28	Non-Drug
L0210		Thoracic rib belt		\$51.01	Non-Drug
L0220		Thor rib belt custom fabrica	1 1	\$135.65	Non-Drug
L0450	1	TLSO flex prefab thoracic		\$191.21	Non-Drug
L0452	1	tlso flex custom fab thoraci		\$367.89	Non-Drug
L0454		TLSO flex prefab sacrococ-T9	1	\$411.73 \$411.73	Non-Drug Non-Drug
L0456 L0458		TLSO flex prefab TLSO 2Mod symphis-xipho pre		\$853.60	Non-Drug
L0450	1	TLSO2Mod symphysis-stern pre	1	\$853.60	Non-Drug
L0462		TLSO 3Mod sacro-scap pre	1	\$853.60	Non-Drug
L0464	1	TLSO 4Mod sacro-scap pre	1 1	\$853.60	Non-Drug
L0466		TLSO rigid frame pre soft ap	l 1	\$421.67	Non-Drug
L0468	1	TLSO rigid frame prefab pelv	1 1	\$525,32	Non-Drug
L0470	1	TLSO rigid frame pre subclav		\$744.43 \$459.25	Non-Drug Non-Drug
L0472 L0476		TLSO rigid frame hyperex pre TLSO flexion compres jac pre	1	\$1,135.31	Non-Drug
L0478		TLSO flexion compres jac cus		\$1,697.58	Non-Drug
L0480		TLSO rigid plastic custom fa		\$1,706.07	Non-Drug
L0482	1	TLSO rigid lined custom fab		\$1,861.08	Non-Drug
L0484		TLSO rigid plastic cust fab		\$2,137.96	Non-Drug
L0486		TLSO rigidlined cust fab two	1	\$2,270.41	Non-Drug
L0488 L0490		TLSO rigid lined pre one pie TLSO rigid plastic pre one		\$1,603.34 \$1,334.77	Non-Drug Non-Drug
L0500		Lso flex surgical support		\$149.88	Non-Drug
L0510		Lso flexible custom fabricat		\$301.85	Non-Drug
L0515		Lso flex elas w/ rig post pa	1 1	\$320.76	Non-Drug
L0520		Lso a-p-I control with apron		\$468.70	Non-Drug
L0530	1	Lso ant-pos control w apron		\$471.41	Non-Drug
L0540	1	Lso lumbar flexion a-p-l	1 1	\$510.43 \$1,582.23	Non-Drug
L0550 L0560		Lso a-p-I control molded Lso a-p-I w interface		\$1,731.87	Non-Drug Non-Drug
L0561		Prefab Iso		\$368.09	Non-Drug
L0565		Lso a-p-I control custom	1 1	\$1,336.07	Non-Drug
L0600		Sacroiliac flex surg support		\$102.90	Non-Drug
L0610		Sacroiliac flexible custm fa		\$282.72	Non-Drug
L0620		Sacroiliac semi-rig w apron		\$482.53 \$2,437.03	Non-Drug Non-Drug
L0700 L0710		Ctlso a-p-I control molded Ctlso a-p-I control w/ inter		\$2,437.03	Non-Drug
L0710 L0810	1	Halo cervical into jckt vest	1	\$3,119.03	Non-Drug
L0820		Halo cervical into body jack		\$2,606.25	Non-Drug
L0830	1	Halo cerv into milwaukee typ		\$3,799.39	Non-Drug
L0860		Magnetic resonanc image comp		\$1,454.51	Non-Drug
L0960		Post surgical support pads		\$77.86 \$126.80	Non-Drug Non-Drug
L0970	1	Tiso corset front	1 1	\$126.60	

PAGE 36 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
L0974		Tiso full corset		\$196.89	Non-Drug
L0976	1 1	Lso full corset	1 1	\$176.16	Non-Drug
L0978	1 1	Axillary crutch extension	1 1	\$211.44	Non-Drug
L0980		Peroneal straps pair	. [\$21.99	Non-Drug
L0982		Stocking supp grips set of f		\$20.71 \$67.88	Non-Drug
L0984 L0999	1	Protective body sock each	1 1	\$07.00	Non-Drug
L1000		Ctlso milwauke initial model	1 1	\$2,447,47	Non-Drug
L1005		Tension based scoliosis orth		\$3,704.11	Non-Drug
L1010	1	Ctlso axilla sling		\$75.73	Non-Drug
L1020		Kyphosis pad	1	\$96.64	Non-Drug
L1025	1 1	Kyphosis pad floating		\$138.07	Non-Drug
L1030	1	Lumbar bolster pad		\$71.95	Non-Drug
L1040		Lumbar or lumbar rib pad		\$87.53	Non-Drug
L1050		Sternal pad		\$93.20 \$106.61	Non-Drug Non-Drug
L1060 L1070		Thoracic pad Trapezius sling		\$100.01	Non-Drug
L1070		Outrigger	·	\$62.99	Non-Drug
L1085		Outrigger bil w/ vert extens		\$169.70	Non-Drug
L1090	1 1	Lumbar sling	1	\$102.31	Non-Drug
L1100		Ring flange plastic/leather	1	\$175.22	Non-Drug
L1110		Ring flange plas/leather mol		\$279.53	Non-Drug
L1120		Covers for upright each		\$46.08	Non-Drug
L1200	1	Furnsh initial orthosis only		\$1,880.78	Non-Drug
L1210		Lateral thoracic extension	1	\$286.31 \$242.88	Non-Drug Non-Drug
L1220		Anterior thoracic extension Milwaukee type superstructur	1 1	\$659.93	Non-Drug
L1230 L1240	}	Lumbar derotation pad	1 1	\$87.13	Non-Drug
L1250		Anterior asis pad	1	\$81.29	Non-Drug
L1260		Anterior thoracic derotation	.	\$84.98	Non-Drug
L1270	1	Abdominal pad		\$86.95	Non-Drug
L1280]	Rib gusset (elastic) each	1 [\$96.46	Non-Drug
L1290		Lateral trochanteric pad		\$88.17	Non-Drug
L1300		Body jacket mold to patient		\$2,007.48	Non-Drug
L1310		Post-operative body jacket	1 1	\$2,066.72 \$281.56	Non-Drug Non-Drug
L1499 L1500		Spinal orthosis NOS Thkao mobility frame		\$2,287.56	Non-Drug
L1510		Thkao standing frame	1	\$1,434.27	Non-Drug
L1520		Thkao swivel walker	1 1	\$2,754.56	Non-Drug
L1600		Abduct hip flex frejka w cvr	1	\$142.58	Non-Drug
L1610		Abduct hip flex frejka covr		\$50.61	Non-Drug
L1620		Abduct hip flex pavlik harne	<u> </u>	\$148.11	Non-Drug
L1630		Abduct control hip semi-flex	.	\$186.51	Non-Drug
L1640	(Pelv band/spread bar thigh c	1 1	\$529.06 \$253.70	Non-Drug Non-Drug
L1650		HO abduction hip adjustable HO bi thighcuffs w sprdr bar		\$253.76 \$381.26	Non-Drug
L1652 L1660		HO abduction static plastic	1	\$188.32	Non-Drug
L1680	1	Pelvic & hip control thigh c]	\$1,454.74	Non-Drug
L1685	ı	Post-op hip abduct custom fa	1	\$1,419.35	Non-Drug
L1686		HO post-op hip abduction	1 1	\$1,080.28	Non-Drug
L1690	1	Combination bilateral HO	1	\$2,223.99	Non-Drug
L1700	1	Leg perthes orth toronto typ	1 1	\$1,832.22	Non-Drug
L1710	l	Legg perthes orth newington	1 1	\$2,150.82	Non-Drug
L1720	1	Legg perthes orthosis trilat	1	\$1,576.17 \$1,348.81	Non-Drug Non-Drug
L1730		Legg perthes orth scottish r	- 1	\$216.05	Non-Drug
L1750 L1755		Legg perthes sling Legg perthes patten bottom t		\$1,900.86	Non-Drug
L1755		Knee orthoses elas w stays		\$75.10	Non-Dru
L1810	1	Ko elastic with joints		\$109.68	Non-Drug
L1815	1	Elastic with condylar pads		\$107.95	Non-Dru
L1820	1	Ko elas w/ condyle pads & jo		\$143.43	Non-Dru
L1825	1	Ko elastic knee cap		\$62.61	Non-Dru
L1830	1	Ko immobilizer canvas longit]	\$97.78	Non-Dru
L1832		KO adj int pos rigid support	1 1	\$708.25 \$914.04	Non-Dru Non-Dru
L1834	1	Ko w/0 joint rigid molded to		\$914.04 \$141.07	Non-Dru Non-Dru
L1836	1	Rigid KO wo joints Ko derot ant cruciate custom		\$1,089.18	Non-Dru
L1840	1	KO single upright custom fit		\$1,013.07	

PAGE 37 OF 54

		PAGE 37 OF 54			
HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
L1844		Ko w/adj it rot cntrl molded		\$1,909.21	Non-Drug
L1845		Ko w/ adj flex/ext rotat cus		\$964.30	Non-Drug
L1846		Ko w adi flex/ext rotat mold		\$1,263.09	Non-Drug
L1847		KO adjustable w air chambers		\$636.76	Non-Drug
L1850		Ko swedish type		\$316.78	Non-Drug
L1855		Ko plas doub upright int mol		\$1,308.56	Non-Drug
L1858	1	Ko polycentric pneumatic pad		\$1,430.08 \$1,276.98	Non-Drug Non-Drug
L1860 L1870		Ko supracondylar socket mold Ko doub upright lacers molde		\$1,276.96	Non-Drug Non-Drug
L1880		Ko doub upright cuffs/lacers		\$830.33	Non-Drug
L1885		Knee upright w/resistance		\$1,181.50	Non-Drug
L1900		Afo sprng wir drsflx calf bd	1	\$295.10	Non-Drug
L1901	1	Prefab ankle orthosis		\$21.38	Non-Drug
L1902	1	Afo ankle gauntlet		\$89.49	Non-Drug
L1904		Afo molded ankle gauntlet		\$539.84	Non-Drug
L1906	1	Afo multiligamentus ankle su	1	\$133.26 \$292.55	Non-Drug Non-Drug
L1910 L1920	1	Afo sing bar clasp attach sh Afo sing upright w/ adjust s		\$392.30	Non-Drug Non-Drug
L1920	1	Afo plastic		\$259.16	Non-Drug
L1940	İ	Afo molded to patient plasti		\$569.56	Non-Drug
L1945	1	Afo molded plas rig ant tib	1 1	\$1,096.79	Non-Drug
L1950		Afo spiral molded to pt plas		\$875.63	Non-Drug
L1960		Afo pos solid ank plastic mo		\$642.61	Non-Drug
L1970	1	Afo plastic molded w/ankle i	1 1	\$834.93	Non-Drug
L1980	1	Afo sing solid stirrup calf	1 1	\$413.60	Non-Drug
L1990		Afo doub solid stirrup calf		\$509.88	Non-Drug
L2000 L2010	-	Kafo sing fre stirr thi/calf Kafo sng solid stirrup w/o j		\$1,205.11 \$1,095.46	Non-Drug Non-Drug
L2010 L2020	1	Kafo dbl solid stirrup band/		\$1,392.65	Non-Drug
L2020		Kafo dbl solid stirrup w/o j		\$1,203.60	Non-Drug
L2035		KAFO plastic pediatric size	1	\$183.36	Non-Drug
L2036		Kafo plas doub free knee mol		\$2,233.58	Non-Drug
L2037		Kafo plas sing free knee mol		\$2,001.57	Non-Drug
L2038	1	Kafo w/o joint multi-axis an		\$1,713.15	Non-Drug
L2039		KAFO,plstic,mediat rotat con		\$2,561.21	Non-Drug
L2040 L2050	1	Hkafo torsion bil rot straps Hkafo torsion cable hip pelv	1 1	\$195.27 \$547.31	Non-Drug Non-Drug
L2050	1	Hkafo torsion ball bearing i	1 1	\$674.77	Non-Drug
L2070		Hkafo torsion unilat rot str	1 1	\$148.66	Non-Drug
L2080	1	Hkafo unilat torsion cable	1 1	\$404.63	Non-Drug
L2090		Hkafo unilat torsion ball br	1	\$501.00	Non-Drug
L2102	1	Afo tibial fx cast plstr mol		\$571.57	Non-Drug
L2104		Afo tib fx cast synthetic mo		\$608.54	Non-Drug
L2106	1	Afo tib fx cast plaster mold	1	\$796.23 \$1,271.35	Non-Drug
L2108 L2112		Afo tib fx cast molded to pt Afo tibial fracture soft	1 1	\$535.32	Non-Drug Non-Drug
L2114		Afo tib fx semi-rigid		\$674.58	Non-Drug
L2116		Afo tibial fracture rigid		\$835.35	Non-Drug
L2122	1	Kafo fem fx cast plaster mol	1	\$1,034.91	Non-Drug
L2124	1	Kafo fem fx cast synthet mol		\$1,242.77	Non-Drug
L2126		Kafo fem fx cast thermoplas		\$1,429.11	Non-Drug
L2128	1	Kafo fem fx cast molded to p		\$2,061.65	Non-Drug
L2132		Kafo femoral fx cast soft	1 1	\$951.24 \$1.47.51	Non-Drug
L2134		Kafo fem fx cast semi-rigid		\$1,147.51 \$1,410.94	Non-Drug Non-Drug
L2136 L2180		Kafo femoral fx cast rigid Plas shoe insert w ank joint		\$1,410.94	Non-Drug
L2182		Drop lock knee		\$102.30	Non-Drug
L2184		Limited motion knee joint		\$137.17	Non-Drug
L2186		Adj motion knee jnt lerman t		\$166.04	Non-Drug
L2188		Quadrilateral brim		\$331.03	Non-Drug
L2190		Waist belt		\$97.61	Non-Drug
L2192		Pelvic band & belt thigh fla Limited ankle motion ea int		\$400.81 \$54.55	Non-Drug Non-Drug
L2200 L2210		Dorsiflexion assist each joi		\$75.85	Non-Drug
L2210 L2220	-	Dorsinexion assist each joi Dorsi & plantar flex ass/res		\$91.73	Non-Drug
L2230	1	Split flat caliper stirr & p		\$86.14	Non-Drug
			1 1	000.00	
L2240	ł	Round caliper and plate atta Foot plate molded stirrup at	l l	\$93.60 \$399.32	Non-Drug Non-Drug

PAGE 38 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogo
L2260		Reinforced solid stirrup		\$220.07	Non-Dru
L2265	1 1	Long tongue stirrup	i i	\$130.56	Non-Dru
L2270	1	Varus/valgus strap padded/li	1	\$61.22	Non-Dru
L2275	1	Plastic mod low ext pad/line		\$138.84	Non-Dru
L2280		Molded inner boot	1	\$518.52	Non-Dru
L2300		Abduction bar jointed adjust		\$294.52	Non-Dru
L2310		Abduction bar-straight		\$136.24	Non-Dru
L2320		Non-molded lacer	1 [\$225.79	Non-Dru
L2330	1 1	Lacer molded to patient mode	1	\$444.96	Non-Dru
L2335		Anterior swing band	1 1	\$248.99	Non-Dru
L2340		Pre-tibial shell molded to p	1	\$511.33 \$1.054.41	Non-Dru
L2350	1 1	Prosthetic type socket molde	1	\$1,054.41	Non-Dru Non-Dru
L2360	1 1	Extended steel shank	1 1	\$280.95	Non-Dru
L2370		Patten bottom Torsion ank & half solid sti	1 1	\$125.40	Non-Dru
L2375 L2380	1 1	Torsion straight knee joint	1	\$136.34	Non-Dru
L2385		Straight knee joint heavy du	1	\$148.06	Non-Dru
L2390		Offset knee joint each	1	\$121.57	Non-Dru
L2395	1 1	Offset knee joint heavy duty	1	\$172.44	Non-Dru
L2397		Suspension sleeve lower ext	1	\$124.74	Non-Dru
L2405	1 1	Knee joint drop lock ea int	1	\$93.25	Non-Dru
L2415	1 1	Knee joint cam lock each joi		\$128.71	Non-Dru
L2425		Knee disc/dial lock/adj flex	1	\$151.32	Non-Dru
L2430	1 1	Knee int ratchet lock ea int	1	\$151.32	Non-Dru
L2435		Knee joint polycentric joint	1	\$182.22	Non-Dru
L2492		Knee lift loop drop lock rin		\$113.47	Non-Dru
L2500	1 1	Thi/glut/ischia wgt bearing	1	\$350.57	Non-Dru
L2510	1 1	Th/wght bear quad-lat brim m		\$853.05	Non-Dru
L2520	1 1	Th/wght bear quad-lat brim c	1	\$528.13	Non-Dru
L2525		Th/wght bear nar m-l brim mo	1	\$1,455.44	Non-Dru
L2526	1 1	Th/wght bear nar m-l brim cu	1	\$802.38	Non-Dru
L2530		Thigh/wght bear lacer non-mo		\$257.41	Non-Dru
L2540		Thigh/wght bear lacer molded	1	\$481.80 \$316.00	Non-Dru Non-Dru
L2550 L2570	1	Thigh/wght bear high roll cu Hip clevis type 2 posit int	1	\$547.25	Non-Dru
L2570		Pelvic control pelvic sling		\$532.33	Non-Dru
L2600		Hip clevis/thrust bearing fr]	\$225.39	Non-Dru
L2610	1	Hip clevis/thrust bearing lo		\$265.95	Non-Dru
L2620	1	Pelvic control hip heavy dut		\$292.50	Non-Dru
L2622	1	Hip joint adjustable flexion]	\$339.80	Non-Dru
L2624	1	Hip adj flex ext abduct cont	1	\$369.73	Non-Dru
L2627	1	Plastic mold recipro hip & c		\$2,061.11	Non-Dru
L2628		Metal frame recipro hip & ca		\$2,013.54	Non-Dru
L2630		Pelvic control band & belt u		\$271.12	Non-Dri
L2640		Pelvic control band & belt b	1	\$375.74	Non-Dru
L2650		Pelv & thor control gluteal	1	\$132.99	Non-Dru
L2660		Thoracic control thoracic ba		\$204.82	Non-Dru
L2670		Thorac cont paraspinal uprig	l 1	\$187.73 \$172.47	Non-Dri Non-Dri
L2680		Thorac cont lat support upri	1	\$93.56	Non-Dri
L2750	1	Plating chrome/nickel pr bar		\$138.21	Non-Dru
L2755 L2760		Carbon graphite lamination Extension per extension per	l 1	\$68.85	Non-Dru
L2768		Ortho sidebar disconnect		\$137.83	Non-Dri
L2770		Low ext orthosis per bar/int		\$69.92	Non-Dri
L2780		Non-corrosive finish	1	\$76.34	Non-Dri
L2785		Drop lock retainer each	1 1	\$37.39	Non-Dr
L2795		Knee control full kneecap		\$95.06	Non-Dri
L2800		Knee cap medial or lateral p]	\$118.55	Non-Dru
L2810		Knee control condylar pad	1	\$87.63	Non-Dru
L2820		Soft interface below knee se	1	\$97.09	Non-Dr
L2830		Soft interface above knee se]	\$104.79	Non-Dri
L2840		Tibial length sock fx or equ]	\$50.38 \$70.44	Non-Dru
L2850		Femoral loth sock fx or equa		\$70.11 \$414.14	Non-Dri
L2860	1	Torsion mechanism knee/ankle		\$414.14	Non-Dri
L2999		Falling and make beneficial entre to all	1	\$264.94	Non-Dri
L3000		Ft insert ucb berkeley shell	1	\$264.94 \$157.32	Non-Dri
L3001	i	Foot insert remov molded spe	1 [\$130.54	Non-Dr

PAGE 39 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
L3003		Foot insert silicone gel eac		\$159.80	Non-Drug
L3010	1	Foot longitudinal arch suppo	j j	\$206.42	Non-Drug
L3020		Foot longitud/metatarsal sup		\$260.97	Non-Drug
L3030		Foot arch support remov prem		\$260.97	Non-Drug
L3040 L3050		Ft arch suprt premold longit Foot arch supp premold metat	1	\$48.71 \$45.74	Non-Drug Non-Drug
L3060		Foot arch supp longitud/meta		\$85.41	Non-Drug
L3070	1	Arch suprt att to sho longit	1 .	\$28.38	Non-Drug
L3080		Arch supp att to shoe metata	1 1	\$13.50	Non-Drug
L3090		Arch supp att to shoe long/m		\$18.96	Non-Drug
L3100		Hallus-valgus nght dynamic s	•	\$29.87 \$79.96	Non-Drug Non-Drug
L3140 L3150		Abduction rotation bar shoe Abduct rotation bar w/o shoe		\$67.56	Non-Drug
L3160		Shoe styled positioning dev	[[\$22.93	Non-Drug
L3170		Foot plastic heel stabilizer] [\$36.81	Non-Drug
L3201		Oxford w supinat/pronat inf		\$79.46	Non-Drug
L3202		Oxford w/ supinat/pronator c		\$77.97	Non-Drug
L3203 L3204		Oxford w/ supinator/pronator Hightop w/ supp/pronator inf	1	\$75.99 \$75.99	Non-Drug Non-Drug
L3206		Hightop w/ supp/pronator chi		\$78.97	Non-Drug
L3207	1	Hightop w/ supp/pronator jun		\$80.45	Non-Drug
L3208		Surgical boot each infant	1 1	\$43.75	Non-Drug
L3209		Surgical boot each child	1 1	\$60.62	Non-Drug
L3211		Surgical boot each junior		\$64.09 \$88.39	Non-Drug Non-Drug
L3212 L3213		Benesch boot pair infant Benesch boot pair child		\$106.24	Non-Drug Non-Drug
L3214		Benesch boot pair junior		\$112.69	Non-Drug
L3215		Orthopedic ftwear ladies oxf	1	\$142.44	Non-Drug
L3216		Orthoped ladies shoes dpth i		\$171.70	Non-Drug
L3217		Ladies shoes hightop depth i		\$186.08	Non-Drug
L3219 L3221		Orthopedic mens shoes oxford Orthopedic mens shoes dpth i		\$159.80 \$191.04	Non-Drug Non-Drug
L3222		Mens shoes hightop depth inl	1	\$210.88	Non-Drug
L3224		Woman's shoe oxford brace		\$66.74	Non-Drug
L3225		Man's shoe oxford brace		\$76.30	Non-Drug
L3230		Custom shoes depth inlay		\$247.58	Non-Drug
L3250 L3251		Custom mold shoe remov prost Shoe molded to pt silicone s		\$502.09 \$68.55	Non-Drug Non-Drug
L3252		Shoe molded plastazote cust		\$263.45	Non-Drug
L3253		Shoe molded plastazote cust	1	\$68.05	Non-Drug
L3254		Orth foot non-stndard size/w		\$22.59	Non-Drug
L3255		Orth foot non-standard size/		\$25.10	Non-Drug
L3257 L3260		Orth foot add charge split s Ambulatory surgical boot eac		\$50.20 \$29.87	Non-Drug Non-Drug
L3265		Plastazote sandal each	1	\$31.85	Non-Drug
L3300		Sho lift taper to metatarsal		\$36.32	Non-Drug
L3310		Shoe lift elev heel/sole neo		\$69.54	Non-Drug
L3320		Shoe lift elev heel/sole cor		\$179.14	Non-Drug
L3330 L3332		Lifts elevation metal extens Shoe lifts tapered to one-ha		\$287.75 ¹ \$22.93	Non-Drug Non-Drug
L3334		Shoe lifts elevation heel /i		\$22.93	Non-Drug
L3340		Shoe wedge sach		\$50.70	Non-Drug
L3350		Shoe heel wedge		\$33.34	Non-Drug
L3360		Shoe sole wedge outside sole	1	\$25.90	Non-Drug
L3370		Shoe sole wedge between sole Shoe clubfoot wedge		\$30.36 \$49.71	Non-Drug Non-Drug
L3380 L3390		Shoe outflare wedge		\$68.05	Non-Drug Non-Drug
L3400	1	Shoe metatarsal bar wedge ro		\$65.58	Non-Drug
L3410	1	Shoe metatarsal bar between		\$108.72	Non-Drug
L3420		Full sole/heel wedge btween		\$36.81 \$88.30	Non-Drug
L3430		Sho heel count plast reinfor Heel leather reinforced	1	\$88.39 \$60.12	Non-Drug Non-Drug
L3440 L3450		Shoe heel sach cushion type		\$49.71	Non-Drug
L3455		Shoe heel new leather standa		\$22.43	Non-Drug
L3460	1	Shoe heel new rubber standar		\$36.81	Non-Drug
L3465		Shoe heel thomas with wedge		\$26.89 \$61.61	Non-Drug Non-Drug
L3470	1	Shoe heel thomas extend to b	1	10.10¢	NUITUIU

PAGE 40 OF 54

		FAGE 40 OF 54			
HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
L3485		Shoe heel pad removable for		\$29.87	Non-Drug
L3500		Ortho shoe add leather insol	1	\$32.35	Non-Drug
L3510	1	Orthopedic shoe add rub insl	1 1	\$30.36	Non-Drug
L3520		O shoe add felt w leath insl		\$47.72	Non-Drug
L3530		Ortho shoe add half sole		\$16.48	Non-Drug
L3540		Ortho shoe add full sole		\$52.19	Non-Drug
L3550		O shoe add standard toe tap		\$11.02	Non-Drug
L3560		O shoe add horseshoe toe tap	1 1	\$13.50	Non-Drug
L3570		O shoe add instep extension	1	\$46.73	Non-Drug
L3580		O shoe add instep velcro clo		\$68.05	Non-Drug
L3590		O shoe convert to sof counte	1 1	\$53.67	Non-Drug
L3595		Ortho shoe add march bar		\$17.47	Non-Drug
L3600	1	Trans shoe calip plate exist	1 1	\$85.41	Non-Drug
L3610		Trans shoe caliper plate new		\$136.00	Non-Drug
L3620	1	Trans shoe solid stirrup exi	1	\$85.41	Non-Drug
L3630		Trans shoe solid stirrup new		\$104.26	Non-Drug
L3640		Shoe dennis browne splint bo	1	\$36.32	Non-Drug
L3649	1	Chidan fin 9 abdunt restrain	1 1	¢65.01	Non Drug
L3650	1	Shider fig 8 abduct restrain		\$65.91 \$65.06	Non-Drug Non-Drug
L3651 L3652	1	Prefab shoulder orthosis Prefab dbl shoulder orthosis	1 1	\$189.84	Non-Drug
L3652 L3660	1	Abduct restrainer canvas&web		\$111.96	Non-Drug
L3670		Acromio/clavicular canvas&web	1 1	\$122.86	Non-Drug
L3675	1	Canvas vest SO		\$168.25	Non-Drug Non-Drug
L3677	1	SO hard plastic stabilizer		\$196.00	Non-Drug
L3700		Elbow orthoses elas w stavs	1 1	\$77.02	Non-Drug
L3701		Prefab elbow orthosis		\$22.25	Non-Drug
L3710		Elbow elastic with metal joi		\$134.02	Non-Drug
L3720	1	Forearm/arm cuffs free motio	}	\$747.48	Non-Drug
L3730	1	Forearm/arm cuffs ext/flex a		\$1,043.49	Non-Drug
L3740		Cuffs adj lock w/ active con		\$1,243.68	Non-Drug
L3760		EO withjoint, Prefabricated	1 1	\$496.53	Non-Drug
L3762	1	Rigid EO wo joints		\$104.29	Non-Drug
L3800	j	Whfo short opponen no attach]]	\$214.88	Non-Drug
L3805		Whfo long opponens no attach		\$347.65	Non-Drug
L3807	1	WHFO,no joint, prefabricated		\$238.42	Non-Drug
L3810	1	White accord man characters a		\$71.73 \$66.81	Non-Drug Non-Drug
L3815 L3820		Whfo second m.p. abduction a Whfo ip ext asst w/ mp ext s		\$112.54	Non-Drug
L3825]	White the extrassit with prexits White m.p. extension stop]]	\$71.78	Non-Drug
L3830		Whfo m.p. extension assist		\$92.75	Non-Drug
L3835	1	Whfo m.p. spring extension a	1	\$100.30	Non-Drug
L3840	1	Whfo spring swivel thumb	1	\$69.67	Non-Drug
L3845	1	Whfo thumb ip ext ass w/ mp		\$89.07	Non-Drug
L3850		Action wrist w/ dorsiflex as	1 1	\$125.91	Non-Drug
L3855	\	Whfo adj m.p. flexion contro	1	\$126.89	Non-Drug
L3860		Whfo adj m.p. flex ctrl & i.		\$172.56	Non-Drug
L3890	į	Torsion mechanism wrist/elbo		\$303.18	Non-Drug
L3900		Hinge extension/flex wrist/f		\$1,513.16	Non-Drug
L3901	1	Hinge ext/flex wrist finger	l l	\$1,887.79	Non-Drug
L3902		White all power compress gas		\$2,879.60	Non-Drug
L3904	1	Whfo electric custom fitted		\$3,469.03 \$437.62	Non-Drug Non-Drug
L3906		Wrist gauntlet molded to pt Whfo wrst gauntlt thmb spica	1 1	\$572.64	Non-Drug
L3907 L3908	1	Wrist cock-up non-molded		\$66.56	Non-Drug
L3909	į.	Prefab wrist orthosis		\$16.39	Non-Drug
L3910	1	Whfo swanson design	[]	\$413.64	Non-Drug
L3912	1	Flex glove w/elastic finger		\$103.54	Non-Drug
L3914	1	WHO wrist extension cock-up	1	\$93.88	Non-Drug
L3916	1	Whfo wrist extens w/ outrigg		\$137.61	Non-Drug
L3918)	HFO knuckle bender	1	\$86.10	Non-Drug
L3920	1	Knuckle bender with outrigge		\$106.82	Non-Drug
L3922	1	Knuckle bend 2 seg to flex i		\$106.66	Non-Drug
L3923	1	HFO, no joint, prefabricated		\$39.71	Non-Drug
L3924	1	Oppenheimer		\$116.03	Non-Drug Non-Drua
L3926		Thomas suspension		\$101.42 \$64.73	Non-Drug Non-Drug
L3928		Finger extension w/ clock sp Finger extension with wrist		\$68.26	
L3930	1	I HIRE EXICUSION MILL MILLS	, 1	Ψ00.20	

PAGE 41 OF 54

	T .				
HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
L3932		Safety pin spring wire		\$52.87	Non-Drug
L3934	1 1	Safety pin modified		\$54.12	Non-Drug
L3936		Palmer	1 1	\$97.44	Non-Drug
L3938		Dorsal wrist	. 1	\$101.89	Non-Drug
L3940	1	Dorsal wrist w/ outrigger at	1	\$116.95	Non-Drug
L3942		Reverse knuckle bender	1 1	\$81.85	Non-Drug
L3944 L3946		Reverse knuckle bend w/ outr HFO composite elastic	1 1	\$107.12 \$96.96	Non-Drug Non-Drug
L3948		Finger knuckle bender	1	\$61.45	Non-Drug
L3950		Oppenheimer w/ knuckle bend		\$161.92	Non-Drug
L3952		Oppenheimer w/ rev knuckle 2	1	\$179.37	Non-Drug
L3954		Spreading hand	1	\$120.06	Non-Drug
L3956	1	Add joint upper ext orthosis	1 1	\$45.18	Non-Drug
L3960	1	Sewho airplan desig abdu pos	1	\$844.23	Non-Drug
L3962	1 !	Sewho erbs palsey design abd	1	\$823.36 \$1,961.14	Non-Drug
L3963 L3964	NU	Molded w/ articulating elbow Seo mobile arm sup att to wc	1 1	\$721.54	Non-Drug Non-Drug
L3964	RR	Seo mobile arm sup att to wo	·	\$70.06	Non-Drug
L3964	UE	Seo mobile arm sup att to wc	1 1	\$532.31	Non-Drug
L3964		Seo mobile arm sup att to wc	1 1	\$933.50	Non-Drug
L3965	NU	Arm supp att to we rancho ty	1 1	\$1,172.34	Non-Drug
L3965	RR	Arm supp att to we rancho ty	1	\$110.00	Non-Drug
L3965	UE	Arm supp att to we rancho ty		\$870.45	Non-Drug
L3965 L3966	NU	Arm supp att to we rancho ty Mobile arm supports reclinin	1	\$1,511.14 \$874.48	Non-Drug Non-Drug
L3966	RR	Mobile arm supports reclinin		\$83.62	Non-Drug
L3966	ÜE	Mobile arm supports reclinin		\$647.06	Non-Drug
L3966		Mobile arm supports reclinin	1 1	\$1,191.78	Non-Drug
L3968	NU	Friction dampening arm supp	1	\$1,115.99	Non-Drug
L3968	RR	Friction dampening arm supp	· 1	\$104.98	Non-Drug
L3968	UE	Friction dampening arm supp		\$828.20	Non-Drug
L3968 L3969	NU	Friction dampening arm supp Monosuspension arm/hand supp	1	\$1,324.01 \$769.82	Non-Drug Non-Drug
L3969	RR	Monosuspension arm/hand supp		\$74.35	Non-Drug
L3969	ÜE	Monosuspension arm/hand supp		\$568.55	Non-Drug
L3969		Monosuspension arm/hand supp		\$957.03	Non-Drug
L3970	NU	Elevat proximal arm support		\$288.13	Non-Drug
L3970	RR	Elevat proximal arm support	1	\$31.59	Non-Drug
L3970	UE	Elevat proximal arm support		\$216.87 \$348.02	Non-Drug Non-Drug
L3970 L3972	NU	Elevat proximal arm support Offset/lat rocker arm w/ ela		\$184.34	Non-Drug
L3972	RR	Offset/lat rocker arm w/ ela	1	\$21.22	Non-Drug
L3972	ÜÈ	Offset/lat rocker arm w/ ela		\$139.03	Non-Drug
L3972		Offset/lat rocker arm w/ ela		\$322.25	Non-Drug
L3974	NU	Mobile arm support supinator		\$156.82	Non-Drug
L3974	RR	Mobile arm support supinator		\$18.48	Non-Drug
L3974 L3974	UE	Mobile arm support supinator Mobile arm support supinator		\$118.39 \$198.48	Non-Drug Non-Drug
L3980		Upp ext fx orthosis humeral		\$334.73	Non-Drug
L3982	1	Upper ext fx orthosis rad/ul		\$411.51	Non-Drug
L3984	1	Upper ext fx orthosis wrist		\$376.67	Non-Drug
L3985	1	Forearm hand fx orth w/ wr h		\$664.19	Non-Drug
L3986		Humeral rad/ulna wrist fx or	1	\$635.51	Non-Drug
L3995		Sock fracture or equal each		\$37.73	Non-Drug
L3999 L4000	1	Upper limb orthosis NOS Repl girdle milwaukee orth	. [\$36.07 \$1,523.98	Non-Drug Non-Drug
L4000		Replace trilateral socket br		\$785.48	Non-Drug
L4020	1	Replace quadlat socket brim		\$1,018.07	Non-Drug
L4030		Replace socket brim cust fit	1 1	\$582.19	Non-Drug
L4040		Replace molded thigh lacer		\$463.96	Non-Drug
L4045		Replace non-molded thigh lac	1	\$365.93 \$460.64	Non-Drug
L4050		Replace molded calf lacer Replace non-molded calf lace		\$469.64 \$292.45	Non-Drug Non-Drug
L4055 L4060		Replace front-molded call face Replace high roll cuff	1	\$353.42	Non-Drug
L4070		Replace prox & dist upright		\$308.94	Non-Drug
L4080		Repl met band kafo-afo prox	1	\$112.57	Non-Drug
L4090	1	Repl met band kafo-afo calf/	1 1	\$100.83	Non-Drug
L4100		Repl leath cuff kafo prox th	. 1	\$115.99	Non-Drug

PAGE 42 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
L4110		Repl leath cuff kafo-afo cal		\$94.88	Non-Drug
L4130		Replace pretibial shell	1 1	\$571.50	Non-Drug
L4205		Ortho dvc repair per 15 min	1 1	\$31.44	Non-Drug
L4210		Orth dev repair/repl minor p		\$40.79	Non-Drug
L4350		Pneumatic ankle cntrl splint	1	\$99.85	Non-Drug
L4360]	Pneumatic walking splint Pneumatic full leg splint		\$303.38 \$207.43	Non-Drug Non-Drug
L4370 L4380	1 1	Pneumatic knee splint		\$119.36	Non-Drug
L4386		Non-pneumatic walking splint	1 1	\$167.06	Non-Drug
L4392		Replace AFO soft interface		\$27.39	Non-Drug
L4394		Replace foot drop spint	1	\$20.82	Non-Drug
L4396		Static AFO	1	\$176.32	Non-Drug
L4398		Foot drop splint recumbent	1	\$82.83	Non-Drug
L5000		Sho insert w arch toe filler	1	\$623.05	Non-Drug
L5010		Mold socket ank hgt w/ toe f		\$1,550.87	Non-Drug
L5020		Tibial tubercle hgt w/ toe f		\$2,546.61	Non-Drug
L5050		Ank symes mold sckt sach ft	1	\$2,954.66 \$3,563.12	Non-Drug Non-Drug
L5060 L5100	1 1	Symes met fr leath socket ar Molded socket shin sach foot	1 1	\$2,992.69	Non-Drug
L5105		Plast socket its/thgh lacer	1	\$4,490.63	Non-Drug
L5150	1	Mold sckt ext knee shin sach		\$4,539.81	Non-Drug
L5160		Mold socket bent knee shin s	1 1	\$4,940.94	Non-Drug
L5200		Kne sing axis fric shin sach		\$4,268.55	Non-Drug
L5210		No knee/ankle joints w/ ft b	1 1	\$3,126.13	Non-Drug
L5220		No knee joint with artic ali	1	\$3,558.23	Non-Drug
L5230		Fem focal defic constant fri		\$4,920.85	Non-Drug
L5250		Hip canad sing axi cons fric	1	\$6,724.41 \$6,665.20	Non-Drug Non-Drug
L5270 L5280		Tilt table locking hip sing Hemipelvect canad sing axis	1 1	\$6,598.19	Non-Drug
L5301		BK mold socket SACH ft endo	1 (\$2,956.06	Non-Drug
L5311		Knee disart, SACH ft, endo	1 1	\$4,262.05	Non-Drug
L5321		AK open end SACH	l I	\$4,246.69	Non-Drug
L5331		Hip disart canadian SACH ft	1	\$6,023.84	Non-Drug
L5341		Hemipelvectomy canadian SACH]]	\$6,549.06	Non-Drug
L5400		Postop dress & 1 cast chg bk		\$1,532.77	Non-Drug
L5410		Postop dsg bk ea add cast ch		\$509.13 \$1,945.06	Non-Drug Non-Drug
L5420		Postop dsg & 1 cast chg ak/d Postop dsg ak ea add cast ch	l I	\$620.38	Non-Drug
L5430 L5450		Postop dsg ak ea add cast ch	1	\$495.57	Non-Drug
L5460	1	Postop app non-wgt bear dsg	1 1	\$675.18	Non-Drug
L5500		Init bk ptb plaster direct	. 1	\$1,638.01	Non-Drug
L5505		Init ak ischal pistr direct		\$2,230.77	Non-Drug
L5510		Prep BK ptb plaster molded	1 (\$1,861.50	Non-Drug
L5520		Perp BK ptb thermopls direct		\$1,838.29	Non-Drug
L5530		Prep BK ptb thermopis molded	1	\$2,215.03 \$2,174.08	Non-Drug Non-Drug
L5535 L5540		Prep BK ptb open end socket Prep BK ptb laminated socket	1	\$2,322.81	Non-Drug Non-Drug
L5560		Prep AK ischial plast molded		\$2,496.89	Non-Drug
L5570		Prep AK ischial direct form	1	\$2,597.27	Non-Drug
L5580		Prep AK ischial thermo mold	1 1	\$3,038.03	Non-Drug
L5585		Prep AK ischial open end	1 (\$3,298.08	Non-Drug
L5590		Prep AK ischial laminated	1	\$3,096.63	Non-Drug
L5595		Hip disartic sach thermopls	1	\$5,210.50	Non-Drug
L5600		Hip disart sach laminat mold	·	\$5,757.62	Non-Drug Non-Drug
L5610		Above knee hydracadence	1	\$2,662.09 \$2,063.83	Non-Drug
L5611		Ak 4 bar link w/fric swing Ak 4 bar ling w/hydraul swig	1 1	\$3,157.55	Non-Drug
L5613 L5614		4-bar link above knee w/swng		\$1,940.09	Non-Drug
L5616		Ak univ multiplex sys frict		\$1,734.20	Non-Drug
L5617	1	AK/BK self-aligning unit ea		\$623.95	Non-Drug
L5618	1	Test socket symes	1 1	\$331.18	Non-Drug
L5620		Test socket below knee		\$326.99	Non-Drug
L5622		Test socket knee disarticula	1 1	\$437.09 \$438.44	Non-Drug Non-Drug
L5624	1	Test socket above knee	l l	\$438.44 \$585.95	Non-Drug Non-Drug
L5626		Test socket hip disarticulat Test socket hemipelyectomy		\$593.80	Non-Drug
L5628 L5629	1	Below knee acrylic socket		\$378.82	Non-Drug
L5630	1	Syme typ expandabl wall sckt	ı	\$549.48	

PAGE 43 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
L5631		Ak/knee disartic acrylic soc		\$537.21	Non-Drug
L5632]]	Symes type ptb brim design s		\$259.14	Non-Drug
L5634		Symes type poster opening so		\$361.08	Non-Drug
L5636		Symes type medial opening so	1 1	\$296.92	Non-Drug
L5637 L5638		Below knee total contact Below knee leather socket	1 1	\$341.16 \$598.82	Non-Drug Non-Drug
L5639		Below knee wood socket		\$1,425.47	Non-Drug
L5640	1 1	Knee disarticulat leather so		\$797.85	Non-Drug
L5642		Above knee leather socket	1 1	\$771.97	Non-Drug
L5643		Hip flex inner socket ext fr		\$1,992.52	Non-Drug
L5644		Above knee wood socket	1 1	\$734.28	Non-Drug
L5645		Bk flex inner socket ext fra	1 1	\$1,004.29 \$678.62	Non-Drug
L5646 L5647	1 1	Below knee air cushion socke Below knee suction socket	1 1	\$1,001.12	Non-Drug Non-Drug
L5648		Above knee air cushion socke		\$822.52	Non-Drug
L5649	1	Isch containmt/narrow m-l so	1 1	\$2,445.23	Non-Drug
L5650		Tot contact ak/knee disart s		\$600.80	Non-Drug
L5651		Ak flex inner socket ext fra	1 1	\$1,529.34	Non-Drug
L5652		Suction susp ak/knee disart		\$532.79	Non-Drug
L5653		Knee disart expand wall sock		\$723.01	Non-Drug
L5654		Socket insert symes	1 1	\$396.86	Non-Drug
L5655 L5656	1 1	Socket insert below knee Socket insert knee articulat	1	\$310.35 \$448.08	Non-Drug Non-Drug
L5658]]	Socket insert above knee]]	\$438.49	Non-Drug Non-Drug
L5661		Multi-durometer symes		\$757.60	Non-Drug
L5665		Multi-durometer below knee	1	\$631.87	Non-Drug
L5666		Below knee cuff suspension		\$83.81	Non-Drug
L5668		Socket insert w/o lock lower	1	\$119.54	Non-Drug
L5670	1	Bk molded supracondylar susp	1 1	\$318.31	Non-Drug
L5671		BK/AK locking mechanism		\$612.81	Non-Drug
L5672 L5674		Bk removable medial brim sus Bk suspension sleeve	1	\$353.27 \$76.79	Non-Drug Non-Drug
L5675		Bk heavy duty susp sleeve	1 1	\$102.99	Non-Drug
L5676		Bk knee joints single axis p		\$436.89	Non-Drug
L5677		Bk knee joints polycentric p	1 1	\$607.15	Non-Drug
L5678	1	Bk joint covers pair	1 1	\$48.88	Non-Drug
L5680		Bk thigh lacer non-molded		\$361.33	Non-Drug
L5682		Bk thigh lacer glut/ischia m	1 1	\$779.56	Non-Drug
L5684	1	Bk fork strap Bk back check		\$58.59 \$61.99	Non-Drug Non-Drug
L5686 L5688		Bk waist belt webbing		\$73.52	Non-Drug
L5690		Bk waist belt padded and lin	1 (\$115.93	Non-Drug
L5692		Ak pelvic control belt light		\$156.31	Non-Drug
L5694	1	Ak pelvic control belt pad/l	1 1	\$212.29	Non-Drug
L5695		Ak sleeve susp neoprene/equa]	\$191.15	Non-Drug
L5696	1	Ak/knee disartic pelvic join		\$216.45	Non-Drug
L5697		Ak/knee disartic pelvic band		\$95.66 \$123.38	Non-Drug Non-Drug
L5698 L5699		Ak/knee disartic silesian ba Shoulder harness	1 1	\$218.10	Non-Drug
L5700		Replace socket below knee	1	\$3,532.55	Non-Drug
L5701	1	Replace socket above knee	1	\$4,394.46	Non-Drug
L5702		Replace socket hip	1	\$5,624.99	Non-Drug
L5704		Custom shape cover BK	1	\$650.79	Non-Drug
L5705		Custom shape cover AK		\$1,174.99	Non-Drug
L5706		Custom shape cvr knee disart		\$1,152.09	Non-Drug
L5707		Custom shape cvr hip disart		\$1,576.41 \$433.36	Non-Drug Non-Drug
L5710		Kne-shin exo sng axi mnl loc Knee-shin exo mnl lock ultra	.	\$433.36 \$645.06	Non-Drug
L5711 L5712		Knee-shin exo frict swg & st		\$526.16	Non-Drug
L5714		Knee-shin exo variable frict		\$509.73	Non-Drug
L5716		Knee-shin exo mech stance ph		\$914.32	Non-Drug
L5718		Knee-shin exo frct swg & sta		\$1,151.60	Non-Drug
L5722		Knee-shin pneum swg frct exo		\$1,141.06	Non-Drug
L5724		Knee-shin exo fluid swing ph		\$1,931.25 \$2,231.10	Non-Drug Non-Drug
L5726	1	Knee-shin ext ints fld swg e Knee-shin fluid swg & stance		\$3,064.79	Non-Drug
L5728 L5780	1	Knee-shin bneum/hydra pneum		\$1,456.38	Non-Drug
L5781	1	Lower limb pros vacuum pump	1 1	\$4,648.50	Non-Drug

PAGE 44 OF 54

		17/02 44 01 04			
HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
L5785		Exoskeletal bk ultralt mater		\$641.66	Non-Drug
L5790		Exoskeletal ak ultra-light m		\$901.54	Non-Drug
L5795	i i	Exoskel hip ultra-light mate	1 1	\$1,363.60	Non-Drug
L5810		Endoskel knee-shin mnl lock		\$599.08	Non-Drug
L5811		Endo knee-shin mnl lck ultra	1	\$914.94	Non-Drug
L5812		Endo knee-shin frct swg & st	1 1	\$701.25	Non-Drug
L5814		Endo knee-shin hydral swg ph		\$4,312.18	Non-Drug
L5816	1	Endo knee-shin polyc mch sta	1 1	\$1,072.75	Non-Drug
L5818		Endo knee-shin frct swg & st	1 1	\$1,215.91	Non-Drug
L5822	1	Endo knee-shin pneum swg fro	1 1	\$2,183.33	Non-Drug
L5824		Endo knee-shin fluid swing p	1 1	\$1,962.71	Non-Drug
L5826		Miniature knee joint		\$3,643.33	Non-Drug
L5828	1	Endo knee-shin fluid swg/sta	1 1	\$3,643.80 \$2,436.88	Non-Drug
L5830 L5840		Endo knee-shin pneum/swg pha Multi-axial knee/shin system	·	\$4,380.49	Non-Drug Non-Drug
L5845		Knee-shin sys stance flexion		\$2,062.91	Non-Drug
L5846		Knee-shin sys microprocessor		\$6,350.78	Non-Drug
L5847		Microprocessor cntrl feature	1	\$18,094.38	Non-Drug
L5848	1	Knee-shin sys hydraul stance		\$1,223.54	Non-Drug
L5850	1	Endo ak/hip knee extens assi		\$150.61	Non-Drug
L5855		Mech hip extension assist		\$367.14	Non-Drug
L5910	1	Endo below knee alignable sy		\$436.63	Non-Drug
L5920		Endo ak/hip alignable system		\$656.04	Non-Drug
L5925 L5930		Above knee manual lock		\$402.54 \$3,930.12	Non-Drug Non-Drug
L5940		High activity knee frame Endo bk ultra-light material		\$618.29	Non-Drug
L5950		Endo ak ultra-light material		\$978.38	Non-Drug
L5960		Endo hip ultra-light materia		\$1,220.74	Non-Drug
L5962		Below knee flex cover system		\$730.57	Non-Drug
L5964		Above knee flex cover system		\$1,184.90	Non-Drug
L5966		Hip flexible cover system		\$1,519.50	Non-Drug
L5968		Multiaxial ankle w dorsiflex		\$4,218.60	Non-Drug
L5970 L5972		Foot external keel sach foot Flexible keel foot		\$237.29 \$423.94	Non-Drug Non-Drug
L5974	1	Foot single axis ankle/foot	1 1	\$271.81	Non-Drug
L5975		Combo ankle/foot prosthesis		\$507.47	Non-Drug
L5976		Energy storing foot	1	\$694.39	Non-Drug
L5978		Ft prosth multiaxial ankl/ft		\$344.99	Non-Drug
L5979		Multi-axial ankle/ft prosth		\$2,937,45	Non-Drug
L5980		Flex foot system		\$4,795.18 \$3,717.06	Non-Drug Non-Drug
L5981 L5982		Flex-walk sys low ext prosth Exoskeletal axial rotation u	1	\$717.96	Non-Drug
L5984		Endoskeletal axial rotation		\$706.97	Non-Drug
L5985		Lwr ext dynamic prosth pylon		\$297.55	Non-Drug
L5986	1	Multi-axial rotation unit	1 1	\$790.35	Non-Drug
L5987	1	Shank ft w vert load pylon	1	\$8,385.66	Non-Drug
L5988		Vertical shock reducing pylo	1	\$2,303.27	Non-Drug
L5989	ļ	Pylon w elctrnc force sensor	1	\$3,590.71	Non-Drug
L5990		User adjustable heel height	l i	\$2,088.47	Non-Drug
L5999 L6000	1	Par hand robin-aids thum rem	1 1	\$1,695.81	Non-Drug
L6010		Hand robin-aids little/ring	1	\$1,891.13	Non-Drug
L6020		Part hand robin-aids no fing		\$1,760.80	Non-Drug
L6025		Part hand disart myoelectric		\$9,332.24	Non-Drug
L6050		Wrst MLd sck flx hng tri pad		\$2,439.61	Non-Drug
L6055		Wrst mold sock w/exp interfa	1 1	\$3,414.06	Non-Drug
L6100		Elb mold sock flex hinge pad Elbow mold sock suspension t		\$2,472.17 \$2,624.28	Non-Drug Non-Drug
L6110 L6120	1	Elbow mold doub splt soc ste	1 1	\$3,064.05	Non-Drug
L6130	1	Elbow stump activated lock h	1 1	\$3,337.36	Non-Drug
L6200	1	Elbow mold outsid lock hinge	1	\$3,518.93	Non-Drug
L6205	1	Elbow molded w/ expand inter		\$4,709.00	Non-Drug
L6250	1	Elbow inter loc elbow forarm	1	\$3,463.25	Non-Drug
L6300	1	Shider disart int lock elbow		\$4,818.52	Non-Drug Non-Drug
L6310	1	Shoulder passive restor comp	.	\$3,918.25 \$2,191.19	Non-Drug Non-Drug
L6320 L6350		Shoulder passive restor cap Thoracic intern lock elbow	ļ	\$5,067.74	Non-Drug
L6360	1	Thoracic passive restor comp		\$4,114.42	
20000	•	1a.mana hamaania mannia aaniih			- "

PAGE 45 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
L6370		Thoracic passive restor cap		\$2,610.87	Non-Drug
L6380		Postop dsg cast chg wrst/elb		\$1,463.36	Non-Drug
L6382		Postop dsg cast chg elb dis/		\$1,893.81	Non-Drug
L6384		Postop dsg cast chg shider/t		\$2,448.72	Non-Drug
L6386 L6388		Postop ea cast chg & realign Postop applicat rigid dsg on	1	\$487.98 \$537.53	Non-Drug Non-Drug
L6400	1	Below elbow prosth tiss shap	1 1	\$2,987.80	Non-Drug
L6450		Elb disart prosth tiss shap		\$3,981.43	Non-Drug
L6500		Above elbow prosth tiss shap	1	\$3,984.72	Non-Drug
L6550		Shidr disar prosth tiss shap	1	\$4,932.67	Non-Drug
L6570		Scap thorac prosth tiss shap		\$5,666.96	Non-Drug
L6580		Wrist/elbow bowden cable mol Wrist/elbow bowden cbl dir f		\$2,001.27 \$1,757.84	Non-Drug Non-Drug
L6582 L6584	1	Elbow fair lead cable molded	1 1	\$2,631.36	Non-Drug Non-Drug
L6586		Elbow fair lead cable dir fo		\$2,418.51	Non-Drug
L6588		Shdr fair lead cable molded	1	\$3,647.17	Non-Drug
L6590		Shdr fair lead cable direct		\$3,392.33	Non-Drug
L6600		Polycentric hinge pair		\$219.39	Non-Drug
L6605		Single pivot hinge pair		\$216.68	Non-Drug
L6610 L6615		Flexible metal hinge pair Disconnect locking wrist uni		\$195.07 \$203.41	Non-Drug Non-Drug
L6616		Disconnect insert locking wr		\$77.88	Non-Drug Non-Drug
L6620		Flexion-friction wrist unit		\$359.82	Non-Drug
L6623		Spring-ass rot wrst w/ latch		\$800.49	Non-Drug
L6625		Rotation wrst w/ cable lock		\$657.70	Non-Drug
L6628		Quick disconn hook adapter o		\$588.89	Non-Drug
L6629		Lamination collar w/ couplin		\$171.80	Non-Drug
L6630 L6632		Stainless steel any wrist Latex suspension sleeve each		\$251.62 \$78.01	Non-Drug Non-Drug
L6635		Lift assist for elbow		\$206.19	Non-Drug
L6637		Nudge control elbow lock		\$443.17	Non-Drug
L6638		Elec lock on manual pw elbow		\$2,892.11	Non-Drug
L6640		Shoulder abduction joint pai		\$329.72	Non-Drug
L6641	1	Excursion amplifier pulley t		\$188.09	Non-Drug
L6642 L6645		Excursion amplifier lever ty Shoulder flexion-abduction j		\$253.84 \$380.69	Non-Drug Non-Drug
L6646		Multipo locking shoulder int		\$3,656.79	Non-Drug
L6647	1	Shoulder lock actuator		\$572.62	Non-Drug
L6648		Ext pwrd shider lock/unlock		\$3,772.57	Non-Drug
L6650	-	Shoulder universal joint	1 1	\$405.77	Non-Drug
L6655		Standard control cable extra		\$89.71 \$108.94	Non-Drug Non-Drug
L6660 L6665		Heavy duty control cable Teflon or equal cable lining		\$56.20	Non-Drug
L6670		Hook to hand cable adapter		\$58.39	Non-Drug
L6672		Harness chest/shider saddle		\$197.53	Non-Drug
L6675		Harness figure of 8 sing con		\$141.57	Non-Drug
L6676		Harness figure of 8 dual con		\$142.94	Non-Drug
L6680 L6682	1	Test sock wrist disart/bel e Test sock elbw disart/above		\$270.64 \$298.98	Non-Drug Non-Drug
L6684		Test sock elbw disart/above Test socket shidr disart/tho		\$418.92	Non-Drug
L6686		Suction socket		\$733.92	Non-Drug
L6687	1	Frame typ socket bel elbow/w		\$716.26	Non-Drug
L6688	1	Frame typ sock above elb/dis	1	\$654.94	Non-Drug
L6689		Frame typ socket shoulder di		\$842.62	Non-Drug
L6690		Frame typ sock interscap-tho Removable insert each		\$860.62 \$414.51	Non-Drug Non-Drug
L6691 L6692	1	Silicone gel insert each		\$693.36	Non-Drug
L6693	1	Lockingelbow forearm cntrbal		\$3,288.08	Non-Drug
L6700	1	Terminal device model #3		\$640.60	Non-Drug
L6705	1	Terminal device model #5		\$361.55	Non-Drug
L6710	1	Terminal device model #5x]]	\$414.44 \$411.43	Non-Drug Non-Drug
L6715 L6720	1	Terminal device model #5xa Terminal device model #6	1	\$1,076.22	Non-Drug Non-Drug
L6725	1	Terminal device model #7		\$502.89	Non-Drug
L6730		Terminal device model #7lo		\$797.30	Non-Drug
L6735		Terminal device model #8		\$352.99	Non-Drug
L6740		Terminal device model #8x	1	\$470.91	Non-Drug
L6745	1	Terminal device model #88x	1 I	\$427.87	Non-Drug

PAGE 46 OF 54

L6750 L6755 L6765 L6765 L6770 L6775 L6780 L6790 L6795 L6800 L6805 L6806 L6807 L6808 L6809 L6810 L6825 L6830 L6835 L6840 L6845 L6855 L6860 L6868 L6870 L6855 L6860 L6865 L6869 L6870 L6872 L6873 L6890 L6895 L6900 L6905 L6900	Terminal device model #10p Terminal device model #10x Terminal device model #9x Terminal device model #99x Terminal device model #955 Terminal device model #555 Terminal device model #555 Hooks-accu hook or equal Hooks-2 load or equal Hooks-2 load or equal Modifier wrist flexion unit Trs grip vc or equal Term device grip1/2 or equal Term device grip1/2 or equal Term device infant or child Trs super sport passive Pincher tool otto bock or eq Hands dorrance vo Hand seirra vo Hand seirra vo Hand becker lock grip Term dvc-hand becker plylite Hand robin-aids vo soft Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand child mitt Hand myu child hand Hand mech inf steeper or equ			\$422.53 \$421.22 \$441.65 \$424.50 \$509.48 \$547.02 \$553.49 \$1,577.15 \$1,284.80 \$408.05 \$1,858.00 \$1,681.54 \$1,430.72 \$448.20 \$218.20 \$1,308.93 \$1,729.02 \$1,501.61 \$1,032.46 \$955.92 \$862.43 \$1,106.48 \$830.67 \$389.02 \$1,216.42	Non-Drug Non-Drug
L6765 L6770 L6775 L6775 L6780 L6790 L6795 L6800 L6805 L6806 L6807 L6808 L6810 L6825 L6830 L6835 L6840 L6845 L6855 L6860 L6865 L6868 L6870 L6872 L6872 L6875 L6880 L6865 L6870 L6875 L6890 L6865 L6870 L6875 L6890 L6895 L6900 L6905 L6900	Terminal device model #12p Terminal device model #99x Terminal device model #555 Terminal device model #555 Terminal device model #555 Hooks-accu hook or equal Hooks-2 load or equal Hooks-2 load or equal Modifier wrist flexion unit Trs grip vc or equal Term device grip1/2 or equal Term device infant or child Trs super sport passive Pincher tool otto bock or eq Hands dorrance vo Hand sierra vo Hand sierra vo Hand becker imperial Hand becker lock grip Term dvc-hand becker plylite Hand robin-aids vo Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand child mitt Hand nyu child hand Hand mech inf steeper or equ			\$441.65 \$424.50 \$509.48 \$547.02 \$553.49 \$1,577.15 \$1,284.80 \$408.05 \$1,858.00 \$1,681.54 \$1,430.72 \$448.20 \$218.20 \$1,308.93 \$1,729.02 \$1,501.61 \$1,032.46 \$955.92 \$862.43 \$1,106.48 \$830.67 \$389.02 \$1,216.42	Non-Drug Non-Drug
L6770 L6775 L6780 L6795 L6800 L6805 L6806 L6807 L6808 L6809 L6810 L6825 L6830 L6835 L6840 L6845 L6860 L6867 L6868 L6870 L6865 L6860 L6865 L6860 L6865 L6970 L6915 L6920 L6935 L6930 L6935 L6930 L6935 L6940 L6945 L6950 L6955 L6960 L6965 L6970 L6975 L7010 L7015 L7010	Terminal device model #99x Terminal device model #555 Terminal device model #s555 Hooks-accu hook or equal Hooks-2 load or equal Hooks-aprl vc or equal Modifier wrist flexion unit Trs grip vc or equal Term device grip1/2 or equal Term device infant or child Trs super sport passive Pincher tool otto bock or eq Hands dorrance vo Hand sierra vo Hand sierra vo Hand becker imperial Hand becker lock grip Term dvc-hand becker plylite Hand robin-aids vo Hand robin-aids vo Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand child mitt Hand nyu child hand Hand mech inf steeper or equ			\$424.50 \$509.48 \$547.02 \$553.49 \$1,577.15 \$1,284.80 \$408.05 \$1,858.00 \$1,681.54 \$1,430.72 \$448.20 \$218.20 \$1,308.93 \$1,729.02 \$1,501.61 \$1,032.46 \$955.92 \$862.43 \$1,106.48 \$339.02 \$1,216.42	Non-Drug Non-Drug
L6775 L6780 L6790 L6795 L6800 L6805 L6805 L6807 L6808 L6809 L6810 L6825 L6830 L6835 L6845 L6845 L6845 L6850 L6855 L6860 L6865 L6867 L6868 L6872 L6872 L6873 L6888 L6890 L6915 L6920 L6925 L6900 L6905 L6915 L6900 L6905 L6915 L6900 L6905 L6905 L6900 L6905 L6905 L6900 L6905 L6900 L6905 L6905 L6905 L6900 L6905	Terminal device model #555 Terminal device model #ss555 Hooks-accu hook or equal Hooks-2 load or equal Hooks-aprl vc or equal Modifier wrist flexion unit Trs grip vc or equal Term device grip 1/2 or equal Term device infant or child Trs super sport passive Pincher tool otto bock or eq Hands dorrance vo Hand aprl vc Hand sierra vo Hand becker imperial Hand becker lock grip Term dvc-hand becker plylite Hand robin-aids vo Hand robin-aids vo Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand child mitt Hand nyu child hand Hand mech inf steeper or equ			\$509.48 \$547.02 \$553.49 \$1,577.15 \$1,284.80 \$408.05 \$1,858.00 \$1,681.54 \$1,430.72 \$448.20 \$11,20 \$1,308.93 \$1,729.02 \$1,501.61 \$1,032.46 \$955.92 \$862.43 \$1,106.48 \$339.07 \$389.02 \$1,216.42	Non-Drug Non-Drug
L6780 L6790 L6795 L6800 L6805 L6806 L6807 L6808 L6809 L6810 L6825 L6830 L6835 L6840 L6845 L6850 L6855 L6860 L6867 L6868 L6870 L6872 L6873 L6872 L6873 L6870 L6872 L6970 L6995 L6900 L6905 L6900	Terminal device model #ss555 Hooks-accu hook or equal Hooks-2 load or equal Hooks-aprl vc or equal Modifier wrist flexion unit Trs grip vc or equal Term device grip1/2 or equal Term device infant or child Trs super sport passive Pincher tool otto bock or eq Hands dorrance vo Hand aprl vc Hand sierra vo Hand becker imperial Hand becker imperial Hand becker lock grip Term dvc-hand becker plylite Hand robin-aids vo Hand robin-aids vo Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand nyu child hand Hand mech inf steeper or equ			\$547.02 \$553.49 \$1,577.15 \$1,284.80 \$408.05 \$1,858.00 \$1,681.54 \$1,430.72 \$448.20 \$218.20 \$1,308.93 \$1,729.02 \$1,501.61 \$1,032.46 \$955.92 \$862.43 \$1,106.48 \$330.67 \$389.02 \$1,216.42	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
L6790 L6795 L6806 L6805 L6806 L6807 L6808 L6810 L6825 L6830 L6835 L6840 L6845 L6855 L6860 L6865 L6867 L6868 L6870 L6872 L6872 L6873 L6872 L6873 L6872 L6873 L6875 L6890 L6865 L6870 L6875 L6890 L6865 L6970 L6975 L6900 L6915 L6900 L6915 L6900 L6915 L6900 L6905 L6900	Hooks-accu hook or equal Hooks-accu hook or equal Hooks-accu hook or equal Modifier wrist flexion unit Trs grip vc or equal Term device grip1/2 or equal Term device infant or child Trs super sport passive Pincher tool otto bock or eq Hands dorrance vo Hand apri vc Hand sierra vo Hand sierra vo Hand becker imperial Hand becker lock grip Term dvc-hand becker plylite Hand robin-aids vo Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand child mitt Hand nyu child hand Hand Hand mech inf steeper or equ			\$553.49 \$1,577.15 \$1,284.80 \$408.05 \$1,858.00 \$1,681.54 \$1,430.72 \$4448.20 \$218.20 \$1,308.93 \$1,729.02 \$1,501.61 \$1,032.46 \$955.92 \$862.43 \$1,106.48 \$830.67 \$389.02 \$1,216.42	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
L6795 L6800 L6805 L6806 L6807 L6808 L6809 L6810 L6825 L6830 L6835 L6840 L6840 L6845 L6850 L6866 L6867 L6868 L6867 L6868 L6872 L6873 L6872 L6873 L6872 L6873 L6875 L6890 L6915 L6920 L6925 L6900 L6905 L6905 L6905 L6900	Hooks-2 load or equal Hooks-aprl vc or equal Modifier wrist flexion unit Trs grip vc or equal Term device grip1/2 or equal Term device infant or child Trs super sport passive Pincher tool otto bock or eq Hands dorrance vo Hand sierra vo Hand sierra vo Hand becker imperial Hand becker lock grip Term dvc-hand becker plylite Hand robin-aids vo Hand robin-aids vo Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand nyu child hand Hand meth inf steeper or equ			\$1,577.15 \$1,284.80 \$408.05 \$1,858.00 \$1,681.54 \$1,430.72 \$448.20 \$218.20 \$1,308.93 \$1,729.02 \$1,501.61 \$1,032.46 \$955.92 \$862.43 \$1,106.48 \$330.67 \$389.02 \$1,216.42	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
L6800 L6805 L6806 L6807 L6808 L6809 L6810 L6825 L6830 L6835 L6845 L6850 L6865 L6867 L6868 L6867 L6868 L6872 L6872 L6873 L6872 L6873 L6875 L6920 L6925 L6900 L6905 L6905 L6900	Hooks-aprl vc or equal Modifier wrist flexion unit Trs grip vc or equal Term device grip1/2 or equal Term device infant or child Trs super sport passive Pincher tool otto bock or eq Hands dorrance vo Hand sierra vo Hand sierra vo Hand becker imperial Hand becker lock grip Term dvc-hand becker plylite Hand robin-aids vo Hand robin-aids vo Hand passive hand Passive inf hand steeper/hos Hand child mitt Hand nyu child hand Hand Hand Hand Hand Hand Hand Hand H			\$1,284.80 \$408.05 \$1,858.00 \$1,681.54 \$1,430.72 \$448.20 \$218.20 \$1,308.93 \$1,729.02 \$1,501.61 \$1,032.46 \$955.92 \$862.43 \$1,106.48 \$330.67 \$389.02 \$1,216.42	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
L6805 L6806 L6807 L6808 L6809 L6810 L6825 L6830 L6835 L6840 L6855 L6860 L6865 L6867 L6868 L6872 L6873 L6872 L6873 L6890 L6895 L6900 L6905 L6905 L6905 L6905 L6900	Modifier wrist flexion unit Trs grip vc or equal Term device grip1/2 or equal Term device infant or child Trs super sport passive Pincher tool otto bock or eq Hands dorrance vo Hand aprl vc Hand sierra vo Hand becker imperial Hand becker lock grip Term dvc-hand becker plylite Hand robin-aids vo Hand robin-aids vo Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand nyu child hand Hand mech inf steeper or equ			\$408.05 \$1,858.00 \$1,681.54 \$1,430.72 \$448.20 \$218.20 \$1,308.93 \$1,729.02 \$1,501.61 \$1,032.46 \$955.92 \$862.43 \$1,106.48 \$830.67 \$389.02 \$1,216.42	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
L6806 L6807 L6808 L6809 L6810 L6825 L6830 L6835 L6840 L6845 L6855 L6860 L6865 L6867 L6868 L6872 L6872 L6873 L6872 L6873 L6872 L6873 L6875 L6890 L6895 L6900 L6905 L6900	Trs grip vc or equal Term device grip1/2 or equal Term device infant or child Trs super sport passive Pincher tool otto bock or eq Hands dorrance vo Hand aprl vc Hand sierra vo Hand becker imperial Hand becker lock grip Term dvc-hand becker plylite Hand robin-aids vo Hand robin-aids vo soft Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand child mitt Hand nyu child hand Hand mech inf steeper or equ			\$1,858.00 \$1,681.54 \$1,430.72 \$448.20 \$218.20 \$1,308.93 \$1,729.02 \$1,501.61 \$1,032.46 \$955.92 \$862.43 \$1,106.48 \$830.67 \$389.02 \$1,216.42	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
L6807 L6808 L6809 L6810 L6825 L6830 L6835 L6840 L6845 L6850 L6855 L6860 L6867 L6867 L6867 L6872 L6873 L6872 L6873 L6890 L6915 L6900 L6905 L6905 L6905 L6905 L6905 L6900	Term device grip1/2 or equal Term device infant or child Trs super sport passive Pincher tool otto bock or eq Hands dorrance vo Hand aprl vc Hand sierra vo Hand becker imperial Hand becker lock grip Term dvc-hand becker plylite Hand robin-aids vo Hand robin-aids vo soft Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand nyu child hand Hand Hand Hand Hand Hand Hand Hand H			\$1,430.72 \$448.20 \$218.20 \$1,308.93 \$1,729.02 \$1,501.61 \$1,032.46 \$955.92 \$862.43 \$1,106.48 \$830.67 \$389.02 \$1,216.42	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
L6809 L6810 L6825 L6830 L6835 L6840 L6845 L6855 L6860 L6865 L6867 L6868 L6871 L6872 L6873 L6872 L6873 L6875 L6880 L6895 L6900 L6915 L6925 L6930 L6925 L6930 L6935 L6940 L6945 L6950 L6945 L6950 L6955 L6970 L6975 L7010 L7015 L7020	Trs super sport passive Pincher tool otto bock or eq Hands dorrance vo Hand aprl vc Hand sierra vo Hand becker imperial Hand becker lock grip Term dvc-hand becker plylite Hand robin-aids vo Hand robin-aids vo Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand nyu child hand Hand mech inf steeper or equ			\$448.20 \$218.20 \$1,308.93 \$1,729.02 \$1,501.61 \$1,032.46 \$955.92 \$862.43 \$1,106.48 \$830.67 \$389.02 \$1,216.42	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
L6810 L6825 L6830 L6835 L6840 L6845 L6850 L6865 L6860 L6865 L6867 L6868 L6870 L6872 L6873 L6872 L6873 L6875 L6880 L6881 L6890 L6895 L6990 L6995 L6900 L6900 L6905 L6900 L6905 L6900 L6905 L6900 L6905 L6900 L6905 L6900 L6905 L6900 L6905 L6900 L6905 L6900 L6905 L6900 L6905 L6900 L6905 L6900 L6905 L6900 L6905 L6900 L6905 L6900 L6905 L6900	Pincher tool otto bock or eq Hands dorrance vo Hand apri vc Hand sierra vo Hand becker imperial Hand becker lock grip Term dvc-hand becker plylite Hand robin-aids vo Hand robin-aids vo soft Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand child mitt Hand nyu child hand Hand mech inf steeper or equ			\$218.20 \$1,308.93 \$1,729.02 \$1,501.61 \$1,032.46 \$955.92 \$862.43 \$1,106.48 \$830.67 \$389.02 \$1,216.42	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
L6825 L6830 L6835 L6840 L6845 L6845 L6850 L6866 L6867 L6867 L6867 L6872 L6873 L6873 L6880 L6881 L6882 L6890 L6995 L6905 L6915 L6920 L6925 L6930 L6935 L6940 L6945 L6950 L6955 L6960 L6965 L6970 L6975 L7010 L7015 L7020	Hands dorrance vo Hand aprl vc Hand sierra vo Hand becker imperial Hand becker lock grip Term dvc-hand becker plylite Hand robin-aids vo Hand robin-aids vo soft Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand child mitt Hand nyu child hand Hand mech inf steeper or equ			\$1,308.93 \$1,729.02 \$1,501.61 \$1,032.46 \$955.92 \$862.43 \$1,106.48 \$830.67 \$389.02 \$1,216.42	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
L6830 L6835 L6840 L6845 L6850 L6855 L6867 L6868 L6867 L6868 L6872 L6873 L6875 L6880 L6881 L6882 L6890 L6905 L6905 L6905 L6905 L6906 L6905 L6915 L6920 L6925 L6920 L6925 L6930 L6935 L6940 L6945 L6940 L6945 L6940 L6945 L6940 L6955 L6940 L6955 L6940 L6955 L69600 L6965 L6970 L6975 L7010 L7015 L7010	Hand apri vo Hand sierra vo Hand becker imperial Hand becker lock grip Term dvc-hand becker plylite Hand robin-aids vo Hand robin-aids vo soft Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand child mitt Hand nyu child hand Hand mech inf steeper or equ			\$1,729.02 \$1,501.61 \$1,032.46 \$955.92 \$862.43 \$1,106.48 \$830.67 \$389.02 \$1,216.42	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
L6835 L6840 L6845 L6845 L6855 L6860 L6865 L6867 L6868 L6872 L6873 L6872 L6873 L6875 L6880 L6881 L6890 L6895 L69905 L6915 L6925 L6930 L6935 L6945 L6950 L6945 L6950 L6955 L6970 L6975 L7010 L7015 L7010	Hand sierra vo Hand becker imperial Hand becker lock grip Term dvc-hand becker plylite Hand robin-aids vo Hand robin-aids vo soft Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand child mitt Hand nyu child hand Hand mech inf steeper or equ			\$1,501.61 \$1,032.46 \$955.92 \$862.43 \$1,106.48 \$830.67 \$389.02 \$1,216.42	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
L6840 L6845 L6850 L6865 L6860 L6865 L6867 L6868 L6870 L6872 L6873 L6873 L6880 L6881 L6882 L6890 L6895 L6990 L6905 L6905 L6915 L6920 L6925 L6930 L6935 L6940 L6945 L6950 L6955 L6960 L6965 L6970 L6975 L7010 L7015 L7020	Hand becker imperial Hand becker lock grip Term dvc-hand becker plylite Hand robin-aids vo Hand robin-aids vo soft Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand child mitt Hand nyu child hand Hand mech inf steeper or equ			\$1,032.46 \$955.92 \$862.43 \$1,106.48 \$830.67 \$389.02 \$1,216.42	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
L6845 L6850 L6850 L6860 L6865 L6867 L6867 L6872 L6873 L6873 L6875 L6880 L6881 L6882 L6890 L6995 L6990 L6995 L6905 L6915 L6925 L6930 L6935 L6940 L6945 L6950 L6955 L6960 L6955 L6960 L6965 L6970 L6975 L7010 L7015 L7020	Hand becker lock grip Term dvc-hand becker plylite Hand robin-aids vo Hand robin-aids vo soft Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand child mitt Hand nyu child hand Hand mech inf steeper or equ			\$955.92 \$862.43 \$1,106.48 \$830.67 \$389.02 \$1,216.42	Non-Drug Non-Drug Non-Drug Non-Drug Non-Drug
L6850 L6855 L6860 L6865 L6867 L6868 L6870 L6872 L6873 L6875 L6880 L6890 L6895 L6900 L6905 L6910 L6915 L6920 L6925 L6930 L6935 L6940 L6945 L6950 L6955 L6960 L6955 L6970 L6975 L7010 L7015 L7020	Term dvc-hand becker plylite Hand robin-aids vo Hand robin-aids vo soft Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand child mitt Hand nyu child hand Hand mech inf steeper or equ			\$862.43 \$1,106.48 \$830.67 \$389.02 \$1,216.42	Non-Drug Non-Drug Non-Drug Non-Drug
L6855 L6860 L6865 L6867 L6868 L6870 L6872 L6873 L6875 L6880 L6881 L6882 L6890 L6895 L69905 L6910 L6915 L6925 L6930 L6935 L6940 L6945 L6950 L6955 L6960 L6965 L6970 L6975 L7010	Hand robin-aids vo Hand robin-aids vo soft Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand child mitt Hand nyu child hand Hand mech inf steeper or equ			\$1,106.48 \$830.67 \$389.02 \$1,216.42	Non-Drug Non-Drug Non-Drug
L6860 L6865 L6867 L6868 L6870 L6872 L6873 L6875 L6880 L6881 L6882 L6890 L6995 L6990 L6995 L6990 L6915 L6920 L6925 L6940 L6945 L6940 L6945 L6950 L6955 L6960 L6965 L6970 L6975 L7010 L7015	Hand robin-aids vo soft Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand child mitt Hand nyu child hand Hand mech inf steeper or equ			\$830.67 \$389.02 \$1,216.42	Non-Drug Non-Drug
L6865 L6867 L6868 L6870 L6872 L6872 L6875 L6875 L6880 L6881 L6882 L6890 L6995 L6905 L6915 L6920 L6915 L6920 L6925 L6935 L6940 L6945 L6940 L6945 L6955 L6960 L6965 L6970 L6975 L7010 L7015	Hand passive hand Hand detroit infant hand Passive inf hand steeper/hos Hand child mitt Hand nyu child hand Hand mech inf steeper or equ			\$1,216.42	Non-Drug
L6868 L6870 L6872 L6873 L6875 L6880 L6881 L6881 L6889 L6895 L6990 L6995 L6910 L6915 L6925 L6930 L6935 L6940 L6945 L6950 L6955 L6960 L6965 L6970 L6975 L7010 L7015	Passive inf hand steeper/hos Hand child mitt Hand nyu child hand Hand mech inf steeper or equ				Man -
L6870 L6872 L6873 L6875 L6880 L6881 L6882 L6890 L6895 L6900 L6905 L6915 L6920 L6925 L6930 L6935 L6940 L6945 L6950 L6955 L6960 L6965 L6970 L6975 L7010 L7015	Hand child mitt Hand nyu child hand Hand mech inf steeper or equ			ውስማስ ድለ i	Non-Drug
L6872 L6873 L6875 L6880 L6881 L6882 L6890 L6995 L6905 L6915 L6920 L6915 L6925 L6935 L6940 L6945 L6945 L6945 L6945 L6940 L6955 L6960 L6955 L6960 L6975 L7010 L7015 L7010	Hand nyu child hand Hand mech inf steeper or equ		1 1	\$279.56	Non-Drug
L6873 L6875 L6880 L6881 L6882 L6890 L6995 L6910 L6915 L6920 L6925 L6930 L6935 L6940 L6945 L6950 L6955 L6960 L6965 L6970 L6975 L7010 L7015	Hand mech inf steeper or equ		1 1	\$277.19	Non-Drug
L6875 L6880 L6881 L6882 L6890 L6895 L6900 L6910 L6915 L6925 L6930 L6935 L6940 L6945 L6950 L6955 L6960 L6965 L6970 L6975 L7010 L7015 L7020				\$1,191.78	Non-Drug Non-Drug
L6880 L6881 L6882 L6890 L6895 L6905 L6915 L6915 L6925 L6930 L6935 L6940 L6945 L6950 L6955 L6960 L6965 L6970 L6975 L7010 L7015 L7010				\$574.24 \$977.40	Non-Drug Non-Drug
L6881 L6882 L6890 L6900 L6905 L6910 L6915 L6920 L6925 L6930 L6935 L6940 L6945 L6950 L6965 L6960 L6965 L6970 L6975 L7010 L7015 L7015	Hand bock vo		1	\$621.73	Non-Drug
L6882 L6890 L6905 L6910 L6915 L6920 L6925 L6930 L6935 L6940 L6945 L6950 L6955 L6960 L6965 L6970 L6975 L7010 L7015 L7010	Autograsp feature ul term dv			\$4,750.41	Non-Drug
L6890 L6895 L6900 L6910 L6915 L6920 L6925 L6930 L6935 L6940 L6945 L6950 L6960 L6965 L6970 L6975 L7010 L7015 L7010	Microprocessor control uplmb			\$3,594.92	Non-Drug
L6900 L6905 L6910 L6915 L6920 L6925 L6935 L6940 L6945 L6950 L6955 L6960 L6965 L6970 L6975 L7010 L7015 L7010	Production glove			\$199.23	Non-Drug
L6905 L6910 L6915 L6920 L6925 L6930 L6935 L6945 L6950 L6955 L6960 L6965 L6970 L6975 L7010	Custom glove			\$692.26	Non-Drug
L6910 L6915 L6920 L6925 L6930 L6935 L6940 L6945 L6950 L6965 L6960 L6965 L6970 L6975 L7015 L7015	Hand restorat thumb/1 finger		1	\$1,932.61	Non-Drug
L6915 L6920 L6925 L6930 L6935 L6940 L6945 L6950 L6955 L6960 L6965 L6970 L6975 L7010 L7015	Hand restoration multiple fi			\$1,877.57	Non-Drug
L6920 L6925 L6935 L6935 L6940 L6945 L6950 L6955 L6960 L6965 L6970 L6975 L7010 L7015 L7010	Hand restoration no fingers			\$1,828.23	Non-Drug
L6925 L6930 L6935 L6940 L6945 L6950 L6955 L6960 L6965 L6970 L6975 L7010	Hand restoration replacmnt g		1	\$780.37 \$8,659.29	Non-Drug Non-Drug
L6930 L6935 L6940 L6945 L6950 L6955 L6960 L6965 L6970 L6975 L7010 L7015	Wrist disarticul switch ctrl Wrist disart myoelectronic c			\$10,002.46	Non-Drug
L6935 L6940 L6945 L6950 L6955 L6960 L6965 L6970 L6975 L7010 L7015	Below elbow switch control			\$8,713,21	Non-Drug
L6940 L6945 L6955 L6955 L6960 L6965 L6970 L6975 L7010 L7015 L7020	Below elbow myoelectronic ct			\$10,190.37	Non-Drug
L6945 L6955 L6955 L6960 L6965 L6970 L6975 L7010 L7015 L7020	Elbow disarticulation switch			\$11,395.16	Non-Drug
L6955 L6960 L6965 L6970 L6975 L7010 L7015 L7020	Elbow disart myoelectronic c		1	\$13,262.69	Non-Drug
L6960 L6965 L6970 L6975 L7010 L7015 L7020	Above elbow switch control		1	\$12,957.01	Non-Drug
L6965 L6970 L6975 L7010 L7015 L7020	Above elbow myoelectronic ct			\$15,524.75	Non-Drug
L6970 L6975 L7010 L7015 L7020	Shidr disartic switch contro		1	\$15,658.18	Non-Drug
L6975 L7010 L7015 L7020	Shidr disartic myoelectronic			\$18,428.81 \$18,965.96	Non-Drug Non-Drug
L7010 L7015 L7020	Interscapular-thor switch ct			\$20,784.04	Non-Drug
L7015 L7020	Interscap-thor myoelectronic Hand otto back steeper/eg sw			\$4,723.06	Non-Drug
L7020	Hand sys teknik village swit			\$7,526.04	Non-Drug
	Electronic greifer switch ct			\$4,398.09	Non-Drug
L7025	Electron hand myoelectronic	•		\$4,438.65	Non-Drug
L7030	Hand sys teknik vill myoelec			\$6,806.00	Non-Drug
L7035	Electron greifer myoelectro			\$4,546.53	Non-Drug
L7040	Prehensile actuator hosmer s			\$3,637.60	Non-Drug Non-Drug
L7045	Electron hook child michigan		1	\$2,070.54 \$7,603.74	Non-Drug Non-Drug
L7170	Electronic elbow hosmer swit Electronic elbow utah myoele		1	\$7,603.74 \$42,523.31	Non-Drug
L7180 L7185			1	\$7,700.25	Non-Drug
L7186			1	\$11,488.73	Non-Drug
L7190	Electron elbow adolescent sw			\$9,806.70	Non-Drug
L7191			1	\$12,006.64	Non-Drug
L7260	Electron elbow adolescent sw Electron elbow child switch		1	\$2,528.73	Non-Drug
L7261 L7266	Electron elbow adolescent sw Electron elbow child switch Elbow adolescent myoelectron		{ I	\$4,632.14	Non-Drug Non-Drug

PAGE 47 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
L7272		Analogue control unb or equa		\$2,594.82	Non-Drug
L7274	1	Proportional ctl 12 volt uta		\$7,447.51	Non-Drug
L7360		Six volt bat otto bock/eq ea		\$265.32	Non-Drug
L7362		Battery chrgr six volt otto		\$292.00	Non-Drug
L7364 L7366		Twelve volt battery utah/equ Battery chrgr 12 volt utah/e	,	\$483.93 \$664.08	Non-Drug Non-Drug
L7367		Replacemnt lithium ionbatter	1	\$420.53	Non-Drug Non-Drug
L7368	1	Lithium ion battery charger	1 1	\$555.58	Non-Drug
L7500		Prosthetic dvc repair hourly		\$100.40	Non-Drug
L7510		Prosthetic device repair rep		\$28.32	Non-Drug
L7520		Repair prosthesis per 15 min	1 1	\$32.52	Non-Drug
L7900		Vacuum erection system		\$592.57 \$45.19	Non-Drug Non-Drug
L8000 L8001		Mastectomy bra Breast prosthesis bra & form	1	\$133.04	Non-Drug
L8002		Brst prostnesis bla a form	1	\$174.03	Non-Drug
L8010		Mastectomy sleeve		\$63.10	Non-Drug
L8015		Ext breastprosthesis garment		\$65.34	Non-Drug
L8020		Mastectomy form	}	\$234.43	Non-Drug
L8030		Breast prosthesis silicone/e		\$375.80	Non-Drug
L8035 L8040	км	Custom breast prosthesis Nasal prosthesis		\$4,253.37 \$2,719.08	Non-Drug Non-Drug
L8040	KN	Nasal prosthesis	1	\$1,124.49	Non-Drug
L8040	1 ''''	Nasal prosthesis		\$2,864.05	Non-Drug
L8041	KM	Midfacial prosthesis		\$3,284.63	Non-Drug
L8041	KN	Midfacial prosthesis		\$1,362.62	Non-Drug
L8041		Midfacial prosthesis		\$3,459.37	Non-Drug
L8042 L8042	KM KN	Orbital prosthesis Orbital prosthesis		\$3,694.95 \$1,535.39	Non-Drug Non-Drug
L8042	1	Orbital prosthesis	1 1	\$3,891.28	Non-Drug
L8043	KM	Upper facial prosthesis		\$4,142.57	Non-Drug
L8043	KN	Upper facial prosthesis	1	\$1,723.86	Non-Drug
L8043		Upper facial prosthesis	1 1	\$4,362.46	Non-Drug
L8044	KM	Hemi-facial prosthesis		\$4,590.20 \$1,912.33	Non-Drug Non-Drug
L8044 L8044	KN	Hemi-facial prosthesis Hemi-facial prosthesis		\$4,833.63	Non-Drug Non-Drug
L8045	KM	Auricular prosthesis	1	\$3,008.31	Non-Drug
L8045	KN	Auricular prosthesis	1	\$1,246.28	Non-Drug
L8045		Auricular prosthesis	. 1 1	\$3,168.51	Non-Drug
L8046	KM	Partial facial prosthesis		\$2,948.92	Non-Drug
L8046	KN	Partial facial prosthesis Partial facial prosthesis	1 1	\$1,221.27 \$3,105.98	Non-Drug Non-Drug
L8046 L8047	KM	Nasal septal prosthesis	1	\$1,494.17	Non-Drug
L8047	KN	Nasal septal prosthesis		\$608.74	Non-Drug
L8047		Nasal septal prosthesis	1	\$1,574.66	Non-Drug
L8100		Compression stocking BK18-30		\$28.38	Non-Drug
L8110		Compression stocking BK30-40	1 1	\$28.88 \$29.87	Non-Drug Non-Drug
L8120 L8130		Compression stocking BK40-50 Gc stocking thighIngth 18-30		\$42.76	Non-Drug
L8140		Gc stocking thighingth 10-30 Gc stocking thighlight 30-40	1	\$42.76	Non-Drug
L8150		Gc stocking thighIngth 40-50		\$37.80	Non-Drug
L8160		Gc stocking full Ingth 18-30		\$47.72	Non-Drug
L8170		Gc stocking full Ingth 30-40		\$47.72	Non-Drug
L8180		Gc stocking full Ingth 40-50		\$47.72	Non-Drug
L8190 L8195	1	Gc stocking waistIngth 18-30 Gc stocking waistIngth 30-40		\$182.61 \$159.38	Non-Drug Non-Drug
L8200	1	Gc stocking waistingth 30-40 Gc stocking waistingth 40-50		\$182.61	Non-Drug
L8210		Gc stocking custom made		\$92.85	Non-Drug
L8220		Gc stocking lymphedema		\$29.87	Non-Drug
L8230		Gc stocking garter belt		\$30.86	Non-Drug
L8239		Truce single w/ standard sed		\$100.36	Non-Drug
L8300 L8310	1	Truss single w/ standard pad Truss double w/ standard pad		\$156.67	Non-Drug
L8320		Truss addition to std pad wa		\$64.73	Non-Drug
L8330		Truss add to std pad scrotal	.	\$60.02	Non-Drug
L8400	1	Sheath below knee		\$21.24	Non-Drug
L8410		Sheath above knee Sheath upper limb		\$26.98 \$27.81	Non-Drug Non-Drug
L8415	1	Pros sheath/sock w gel cushn	1 1	\$80.97	

PAGE 48 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
L8420		Prosthetic sock multi ply BK		\$25.52	Non-Drug
L8430		Prosthetic sock multi ply AK		\$28.62	Non-Drug
L8435	[[Pros sock multi ply upper Im		\$27.33	Non-Drug
L8440		Shrinker below knee	1 1	\$51.32	Non-Drug
L8460		Shrinker above knee	1 1	\$79.95	Non-Drug
L8465		Shrinker upper limb		\$59.34	Non-Drug
L8470 L8480		Pros sock single ply BK Pros sock single ply AK		\$10.79 \$13.70	Non-Drug Non-Drug
L8485		Pros sock single ply upper I	1	\$15.70	Non-Drug
L8490		Air seal suction reten systm	1 1	\$156.31	Non-Drug
L8499		7 iii Oodi Odolio ii 70tan oyottii		*	
L8500		Artificial larynx	1	\$824.59	Non-Drug
L8501	, ,	Tracheostomy speaking valve]	\$142.39	Non-Drug
L8505		Artificial larynx, accessory		\$26.35	Non-Drug
L8507		Trach-esoph voice pros pt in		\$46.50	Non-Drug
L8509		Trach-esoph voice pros md in		\$116.24	Non-Drug
L8510	1	Voice amplifier		\$264.91	Non-Drug
L8600]]	Implant breast silicone/eq		\$778.33	Non-Drug
L8603		Collagen imp urinary 2.5 ml	1 1	\$660.89	Non-Drug
L8606 L8610	۱ ۱	Synthetic implnt urinary 1ml Ocular implant		\$330.99 \$727.34	Non-Drug Non-Drug
L8612		Aqueous shunt prosthesis		\$756.94	Non-Drug
L8613		Ossicular implant		\$299.79	Non-Drug
L8614	, ,	Cochlear device/system]]	\$22,606.58	Non-Drug
L8619		Replace cochlear processor		\$9,683.53	Non-Drug
L8630		Metacarpophalangeal implant		\$403.71	Non-Drug
L8641		Metatarsal joint implant		\$420.83	Non-Drug
L8642		Hallux implant	1 1	\$334.69	Non-Drug
L8658		Interphalangeal joint implint	1 1	\$362.41	Non-Drug
L8670		Vascular graft, synthetic	1 1	\$617.47	Non-Drug
L8699					
Q0081		Infusion ther other than che	a	\$99.11	Non-Drug
Q0083		Chemo by other than infusion	a	\$189.77	Drug
Q0084	1	Chemotherapy by infusion	a	\$322.96	Drug
Q0085		Chemo by both infusion and o	a	\$404.96 \$75.05	Drug Non-Drug
Q0086 Q0136		Physical therapy evaluation/ Non esrd epoetin alpha inj	a	\$27.94	Drug
Q0130 Q0144		Azithromycin dihydrate, oral	"	\$29.55	Drug
Q0163		Diphenhydramine HCI 50mg	1 1	\$1.46	Drug
Q0164	1	Prochlorperazine maleate 5mg	1 1	\$0.73	Drug
Q0165		Prochlorperazine maleate10mg	1 1	\$1.46	Drug
Q0166		Granisetron HCl 1 mg oral		\$90.58	Drug
Q0167		Dronabinol 2.5mg oral	1	\$7.29	Drug
Q0168		Dronabinol 5mg oral		\$16.77	Drug
Q0169		Promethazine HCI 12.5mg oral		\$0.73	Drug
Q0170		Promethazine HCl 25 mg oral	1	\$0.25 \$0.73	Drug Drug
Q0171		Chlorpromazine HCl 10mg oral		\$0.73	Drug
Q0172 Q0173		Chlorpromazine HCl 25mg oral Trimethobenzamide HCl 250mg	1 1	\$0.73	Drug
		Thirethopenzamide not 250mg Thiethylperazine maleate10mg		\$1.46	Drug
Q0174 Q0175		Perphenazine 4mg oral]]	\$1.46	Drug
Q0176		Perphenazine 8mg oral	1	\$1.46	Drug
Q0177		Hydroxyzine pamoate 25mg		\$0.25	Drug
Q0178		Hydroxyzine pamoate 50mg	1 1	\$0.73	Drug
Q0179		Ondansetron HCI 8mg oral	1 1	\$113.47	Drug
Q0180		Dolasetron mesylate oral	1 1	\$143.30	Drug
Q0181		Unspecified oral anti-emetic	1 1	\$0.29	Drug
Q0183	1	Nonmetabolic active tissue		\$28.40	Non-Dru
Q0187		Factor viia recombinant	a	\$2,651.05	Drug Non Drug
Q1001		Ntiol category 1		\$70.64 \$70.64	Non-Dru Non-Dru
Q1002	1	Ntiol category 2]	\$70.64 \$58.39	Drug
Q2001	1	Oral cabergoline 0.5 mg Elliotts b solution per ml	1 1	\$31.15	Drug
Q2002 Q2003		Aprotinin, 10,000 kiu	.	\$3.36	Drug
Q2003 Q2004	l	Bladder calculi irrig sol	1	\$50.38	Drug
Q2004 Q2005		Corticorelin ovine triflutat	a	\$611.39	Drug
Q2006	1	Digoxin immune fab (ovine)	a	\$911.93	Drug
	ł	Ethanolamine oleate 100 mg	1 1	\$103.04	Drug

PAGE 49 OF 54

		1705 49 01 04			
HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
Q2009 Q2010 Q2011		Fosphenytoin, 50 mg Glatiramer acetate, per dose Hemin, per 1 mg	a	\$34.38 \$60.68 \$35.76	Drug Drug Drug
Q2012 Q2014		Pegademase bovine, 25 iu Sermorelin acetate, 0.5 mg		\$237.57 \$34.35	Drug Drug
Q2017 Q2018 Q2019		Teniposide, 50 mg Urofollitropin, 75 iu Basiliximab	a	\$435.21 \$163.15 \$2,332.77	Drug Drug Drug
Q2019 Q2021 Q2022		Lepirudin VonWillebrandFactrCmplxperIU	a l	\$222.69 \$1.38	Drug Drug
Q3002 Q3004		Gallium ga 67 Xenon xe 133		\$60.28 \$58.61	Non-Drug Non-Drug
Q3005 Q3008 Q3009		Technetium tc99m mertiatide Indium 111-in pentetreotide Technetium tc99m oxidronate	а	\$261.21 \$2,427.93 \$23.93	Non-Drug Non-Drug Non-Drug
Q3010 Q3014		Technetium tc99mlabeledrbcs Telehealth facility fee		\$18.88 \$45.34	Non-Drug Non-Drug
Q3021 Q3022 Q3023		Ped hepatitis b vaccine ini Hepatitis b vaccine adult ds Injection hepatitis Byaccine	a a a	\$79.57 \$168.30 \$506.05	Drug Drug Drug
Q3025 Q3025 Q4001		IM inj interferon beta 1-a Cast sup body cast plaster	a	\$138.54 \$305.13	Drug Non-Drug
Q4002 Q4003 Q4004		Cast sup body cast fiberglas Cast sup shoulder cast pistr		\$649.17 \$165.07 \$351.36	Non-Drug Non-Drug Non-Drug
Q4004 Q4005 Q4006		Cast sup shoulder cast fbrgl Cast sup long arm adult plst Cast sup long arm adult fbrg		\$90.28 \$192.94	Non-Drug Non-Drug
Q4007 Q4008		Cast sup long arm ped plster Cast sup long arm ped fbrgls Cast sup obtains adult bets		\$44.72 \$95.72 \$69.20	Non-Drug Non-Drug Non-Drua
Q4009 Q4010 Q4011		Cast sup sht arm adult plstr Cast sup sht arm adult fbrgl Cast sup sht arm ped plaster		\$149.43 \$34.52	Non-Drug Non-Drug
Q4012 Q4013		Cast sup sht arm ped fbrglas Cast sup gauntlet plaster		\$73.96 \$65.12 \$140.59	Non-Drug Non-Drug Non-Drug
Q4014 Q4015 Q4016		Cast sup gauntlet fiberglass Cast sup gauntlet ped pister Cast sup gauntlet ped forgis		\$32.48 \$69.88	Non-Drug Non-Drug Non-Drug
Q4017 Q4018 Q4019		Cast sup Ing arm splint plst Cast sup Ing arm splint forg		\$56.96 \$122.23 \$28.40	Non-Drug Non-Drug Non-Drug
Q4079 Q4020 Q4021		Cast sup Ing arm spint ped p Cast sup Ing arm spint ped f Cast sup sht arm splint pist		\$61.04 \$56.96	Non-Drug Non-Drug Non-Drug
Q4022 Q4023		Cast sup sht arm splint fbrg Cast sup sht arm splnt ped p Cast sup sht arm splnt ped f		\$122.23 \$28.40 \$61.04	Non-Drug Non-Drug Non-Drug
Q4024 Q4025 Q4026		Cast sup hip spica plaster Cast sup hip spica plaster Cast sup hip spica fiberglas		\$256.18 \$545.82	Non-Drug Non-Drug Non-Drug
Q4027 Q4028 Q4029		Cast sup hip spica ped plstr Cast sup hip spica ped fbrgl Cast sup long leg plaster		\$127.67 \$272.49 \$125.63	Non-Drug Non-Drug Non-Drug
Q4029 Q4030 Q4031		Cast sup long leg fiberglass Cast sup long leg fiberglass Cast sup lng leg ped plaster		\$268.41 \$62.40	Non-Drug Non-Drug
Q4032 Q4033 Q4034		Cast sup Ing leg ped fbrgls Cast sup Ing leg cylinder pl Cast sup Ing leg cylinder fb		\$133.79 \$107.27 \$228.30	Non-Drug Non-Drug Non-Drug
Q4035 Q4036		Cast sup ingleg cylindr ped p Cast sup ingleg cylindr ped f		\$52.88 \$113.39	Non-Drug Non-Drug
Q4037 Q4038 Q4039		Cast sup shrt leg plaster Cast sup shrt leg fiberglass Cast sup shrt leg ped plster		\$143,99 \$307,85 \$71,24	Non-Drug Non-Drug Non-Drug
Q4040 Q4041		Cast sup shrt leg ped fbrgls Cast sup ing leg spint pistr		\$153.51 \$82.12	Non-Drug Non-Drug Non-Drug
Q4042 Q4043 Q4044		Cast sup ing leg spint forgi Cast sup ing leg spint ped p Cast sup ing leg spint ped f		\$175.27 \$40.64 \$87.56	Non-Drug Non-Drug
Q4045 Q4046 Q4047		Cast sup sht leg spint pistr Cast sup sht leg spint fbrgl Cast sup sht leg spint ped p		\$52.88 \$113.39 \$25.68	Non-Drug Non-Drug Non-Drug
Q4047	1	Cast sup sht leg spint ped p	ı i	\$25.08	Non-Drug

PAGE 50 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
Q4048 Q4049 Q4050		Cast sup sht leg spint ped f Finger splint, static		\$56.28 \$69.88	Non-Drug Non-Drug
Q4051		Splint supplies misc		\$28.14	Non-Drug
Q9920		Epoetin with hct <= 20	1 1	\$25.54	Drug
Q9921		Epoetin with hct = 21	1	\$25.54	Drug
Q9922		Epoetin with hct = 22	1	\$25.54 \$25.54	Drug
Q9923 Q9924		Epoetin with hct = 23 Epoetin with hct = 24	[[\$25.54 \$25.54	Drug Drug
Q9925		Epoetin with hct = 25		\$25.54	Drug
Q9926		Epoetin with hct = 26		\$25.54	Drug
Q9927		Epoetin with hct = 27	1	\$25.54	Drug
Q9928		Epoetin with hct = 28		\$25.54	Drug
Q9929		Epoetin with hct = 29 Epoetin with hct = 30		\$25.54 \$25.54	Drug Drug
Q9930 Q9931		Epoetin with hct = 30		\$25.54	Drug
Q9932		Epoetin with hct = 32		\$25.54	Drug
Q9933		Epoetin with hct = 33	1	\$25.54	Drug
Q9934		Epoetin with hct = 34	(\$25.54	Drug
Q9935		Epoetin with hot = 35	1 1	\$25.54 \$25.54	Drug Drug
Q9936 Q9937		Epoetin with hct = 36 Epoetin with hct = 37	1	\$25.54	Drug
Q9938		Epoetin with hct = 38		\$25.54	Drug
Q9939		Epoetin with hct = 39		\$25.54	Drug
Q9940		Epoetin with hct >= 40		\$25.54	Drug
R0070		Transport portable x-ray		\$141.79	Non-Drug
R0075		Transport port x-ray multipl		\$74.62 \$138.30	Non-Drug Non-Drug
R0076 S0009		Transport portable EKG Injection, butorphanol tartr		\$16.02	Non-Drug
S0012		Butorphanol tartrate, nasal		\$161.88	Non-Drug
50014		Tacrine hydrochloride, 10 mg		\$2.27	Non-Drug
S0016	1	Injection, amikacin sulfate	1	\$55.47	Non-Drug
S0017		Injection, aminocaproic acid	1	\$4.01 \$6.59	Non-Drug Non-Drug
S0020 S0023	}	Injection, bupivicaine hydro Injection, cimetidine hydroc		\$8.79	Non-Drug
S0023		Injection, famotidine, 20 mg		\$9.57	Non-Drug
S0030		Injection, metronidazole		\$26.81	Non-Drug
S0032		Injection, nafcillin sodium	1 1	\$10.26	Non-Drug
S0039		Injection, sulfamethoxazole		\$19.90 \$28.85	Non-Drug Non-Drug
S0040 S0071	İ	Injection, ticarcillin disod Injection, acyclovir sodium		\$4.10	Non-Drug
S0071	ļ	Injection, anikacin sulfate		\$213.03	Non-Drug
S0073		Injection, aztreonam, 500 mg		\$27.56	Non-Drug
S0074		Injection, cefotetan disodiu		\$13.36	Non-Drug
S0077		Injection, clindamycin phosp	1	\$19.06 \$29.41	Non-Drug Non-Drug
S0079 S0080		Octreotide 100 mcg Injection, pentamidine iseth		\$29.41 \$162.68	Non-Drug Non-Drug
S0080 S0081	1	Injection, piperacillin sodi		\$68.22	Non-Drug
50090	1	Sildenafil citrate, 25 mg		\$16.70	Non-Drug
S0091		Granisetron 1mg		\$367.81	Non-Drug
S0092	1	Hydromorphone 250 mg		\$167.29 \$19.93	Non-Drug Non-Drug
S0093 S0106		Morphine 500 mg Bupropion HCL SR 60 tablets		\$198.96	Non-Drug
S0108		Mercaptopurine 50 mg		\$6.87	Non-Drug
S0122		Inj menotropins 75 iu		\$120.71	Non-Drug
S0126		Ini follitropin alfa 75 iu		\$159.97	Non-Drug
S0128		Ini follitropin beta 75 iu		\$156.05 \$32.99	Non-Drug Non-Drug
S0130 S0155		Inj c gonadotropin 5000 iu Epoprostenol dilutant		\$21.73	Non-Drug
S0155 S0156		Exemestane, 25 mg]	\$13.47	Non-Drug
S0170		Anastrozole 1 mg		\$12.19	Non-Drug
S0171		Burnetanide 0.5 mg		\$2.71	Non-Drug
S0172	1	Chlorambucil 2 mg		\$3.12 \$1.82	Non-Drug Non-Drug
S0173 S0174		Dexamethasone 4 mg Dolasetron 50 mg		\$121.16	Non-Drug
JU1/4	ı			\$3.70	Non-Drug
	1	Flutamide 125 mg	1 1		
S0175 S0176	1	Hydroxyurea 500 mg		\$2.40 \$11.98	Non-Drug

PAGE 51 OF 54

					·
HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
S0178		Lomustine 10 mg		\$12.04	Non-Drug
S0179		Megestrol 20 mg		\$1.26	Non-Drug
50181		Ondansetron 4 mg		\$31.45	Non-Drug
S0182		Procarbazine 5 mg		\$1.30	Non-Drug
S0183		Prochlorperazine 5 mg		\$1.06	Non-Drug
S0187		Tamoxifen 10 mg		\$4.16 \$158.38	Non-Drug Non-Drug
S0190 S0191		Mifepristone, oral, 200 mg Misoprostol, oral, 200 mcg		\$1.88	Non-Drug Non-Drug
S0209		WC van mileage per mi		\$1.36	Non-Drug
S0215		Nonemerg transp mileage		\$1.36	Non-Drug
S0302	l	Completed EPSDT	1 1	\$64.13	Non-Drug
S0395		Impression casting ft	1 1	\$68.22	Non-Drug
S0500		Dispos cont lens		\$122.80 \$34.11	Non-Drug Non-Drug
S0580 S0605	1	Polycarb lens Digital rectal examination,		\$20.47	Non-Drug Non-Drug
S0610		Annual gynecological examina	1 1	\$143.27	Non-Drug
\$0612		Annual gynecological examina		\$109.16	Non-Drug
S0620		Routine ophthalmological exa	1	\$75.05	Non-Drug
S0621	1	Routine ophthalmological exa		\$83.23	Non-Drug
S0630		Removal of sutures		\$51.85	Non-Drug
S0800		Laser in situ keratomileusis	1 1	\$1,562.32 \$110.52	Non-Drug Non-Drug
S0820 S1016	1	Computerized corneal topogra Non-pyc intravenous administ		\$21.83	Non-Drug
\$3620		Newborn metabolic screening		\$40.93	Non-Drug
\$4993	1	Contraceptive pills for bc		\$32.75	Non-Drug
\$5000		Prescription drug, generic		\$15.01	Non-Drug
S5001	1	Prescription drug,brand name		\$64.13	Non-Drug
S5010		5% dextrose and 0.45% saline		\$10.92	Non-Drug
S5199		HIT simple cath care		\$20.47	Non-Drug
S5498 S5501		HIT complex cath care		\$27.29	Non-Drug
S5502		HIT interim cath care		\$12.28	Non-Drug
\$8085		Fluorine-18 fluorodeoxygluco		\$701.34	Non-Drug
S8092		Electron beam computed tomog		\$538.97	Non-Drug
S8095		Wig (for medically-induced h		\$409.34 \$27.29	Non-Drug Non-Drug
S8096		Portable peak flow meter Peak expiratory flow rate (p		\$25.92	Non-Drug
S8110 S8181		Trach tube holder		\$8.19	Non-Drug
S8186		Swivel adaptor		\$46.39	Non-Drug
S8189	1	Trach supply noc		\$24.56	Non-Drug
S8260		Oral orthotic for treatment		\$1,289.43	Non-Drug
S8420		Custom gradient sleev/glov		\$1.36 \$9.55	Non-Drug Non-Drug
S8450 S8451		Splint digit Splint wrist or ankle		\$38.21	Non-Drug
S9001		Home uterine monitor with or		\$100.97	Non-Drug
S9015		Automated EEG monitoring		\$120.07	Non-Drug
\$9075		Smoking cessation treatment		\$238.78	Non-Drug
S9088	1	Services provided in urgent		\$122.80 \$88.69	Non-Drug Non-Drug
S9090		Vertebral axial decompressio Home health aide or certifie		\$58.73	Non-Drug Non-Drug
S9122 S9123	}	Nursing care, in the home; b]	\$100.15	Non-Drug
S9124		Nursing care, in the home; b		\$53.21	Non-Drug
S9126	1	Hospice care, in the home, p		\$272.89	Non-Drug
S9127	1	Social work visit, in the ho	1	\$210.60	Non-Drug
S9129		Occupational therapy, in the		\$178.61 \$174.65	Non-Drug Non-Drug
S9131	1	PT in the home per diem Diabetic Management Program,		\$86.20	Non-Drug
S9140 S9208	1	Home mgmt preterm labor	1	\$8,671.22	Non-Drug
S9325	1	HIT pain mgmt per diem		\$320.65	Non-Drug
S9326		HIT cont pain per diem		\$129.62	Non-Drug
\$9330		HIT cont chem diem	}	\$122.80 \$341.12	Non-Drug Non-Drug
S9331		HIT intermit chemo diem HIT immunotherapy diem		\$341.12 \$163.74	Non-Drug Non-Drug
S9338 S9340		HIT enteral per diem		\$170.56	Non-Drug
S9342		HIT enteral pump diem		\$62.77	Non-Drug
S9347		HIT longterm infusion diem		\$88.69	Non-Drug
S9348	1	HIT sympathomim diem		\$12.28 \$272.89	Non-Drug Non-Drug
S9349	1	HIT tocolysis diem	1	\$212.09	i Morribrug

PAGE 52 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
S9364		HIT ton total diem		\$927.84	Non-Drug
S9366		HIT tpn 2 liter diem	1 [\$573.08	Non-Drug
S9367		HIT tpn 3 liter diem		\$477.57	Non-Drug
S9373		HIT hydra total diem]	\$498.03	Non-Drug
S9374		HIT hydra 1 liter diem	. [\$122.80 \$17.74	Non-Drug Non-Drug
S9375 S9435		HIT hydra 2 liter diem Medical foods for inborn err	1 1	\$13.64	Non-Drug Non-Drug
S9455		Diabetic Management Program,	1 1	\$68.22	Non-Drug
S9460		Diabetic Management Program,	1 1	\$95.51	Non-Drug
S9465		Diabetic Management Program,	1 1	\$84.83	Non-Drug
S9470		Nutritional counseling, diet	1 1	\$76.33	Non-Drug
S9494		HIT antibiotic total diem	1	\$4.09 \$143.27	Non-Drug Non-Drug
S9500 S9501		HIT antibiotic q24h diem HIT antibiotic q12h diem		\$221.04	Non-Drug
S9502		HIT antibiotic q8h diem	1 1	\$238.78	Non-Drug
S9503		HIT antibiotic g6h diem		\$204.67	Non-Drug
S9504		HIT antibiotic q4h diem	1	\$343.85	Non-Drug
S9524		Nursing services related to		\$168.22	Non-Drug
S9537		HT hem horm inj diem	1	\$68.22	Non-Drug
S9558 V2020		HT inj growth horm diem Vision svcs frames purchases	1	\$5.46 \$82.55	Non-Drug Non-Drug
V2025		Eyeglasses delux frames	1	\$114.03	Non-Drug
V2100		Lens spher single plano 4.00	1	\$47.76	Non-Drug
V2101		Single visn sphere 4.12-7.00	1	\$50.29	Non-Drug
V2102		Singl visn sphere 7.12-20.00		\$70.47	Non-Drug
V2103		Spherocylindr 4.00d/12-2.00d	1	\$41.57	Non-Drug
V2104	1	Spherocylindr 4.00d/2.12-4d	1	\$45.96 \$49.98	Non-Drug Non-Drug
V2105 V2106		Spherocylinder 4.00d/4.25-6d Spherocylinder 4.00d/>6.00d		\$55.38	Non-Drug
V2100 V2107		Spherocylinder 4.25d/12-2d	1 1	\$52.71	Non-Drug
V2108		Spherocylinder 4.25d/2.12-4d		\$54.55	Non-Drug
V2109		Spherocylinder 4.25d/4.25-6d	1	\$60.27	Non-Drug
V2110]	Spherocylinder 4.25d/over 6d		\$59.49 \$61.99	Non-Drug Non-Drug
V2111 V2112		Spherocylindr 7.25d/.25-2.25 Spherocylindr 7.25d/2.25-4d		\$67.60	Non-Drug
V2112 V2113		Spherocylindr 7.25d/4.25-6d	1	\$75.48	Non-Drug
V2114		Spherocylinder over 12.00d		\$80.84	Non-Drug
V2115		Lens lenticular bifocal		\$87.01	Non-Drug
V2116		Nonaspheric lens bifocal		\$78.58	Non-Drug
V2117	1	Aspheric lens bifocal		\$89.55 \$86.35	Non-Drug Non-Drug
V2118 V2199		Lens aniseikonic single Lens single vision not oth c	1	\$95.05	Non-Drug
V2133 V2200		Lens spher bifoc plano 4.00d		\$62.30	Non-Drug
V2201		Lens sphere bifocal 4.12-7.0	1 1	\$67.84	Non-Drug
V2202		Lens sphere bifocal 7.12-20.		\$78.57	Non-Drug
V2203		Lens sphcyl bifocal 4.00d/.1	1 1	\$62.84	Non-Drug Non-Drug
V2204		Lens sphcy bifocal 4.00d/2.1 Lens sphcy bifocal 4.00d/4.2	1 1	\$65.68 \$70.96	Non-Drug
V2205 V2206		Lens sphcy bifocal 4.00d/4.2		\$75.54	Non-Drug
V2207		Lens sphcy bifocal 4.25-7d/.	1 1	\$69.36	Non-Drug
V2208		Lens sphcy bifocal 4.25-7/2.	1 1	\$72.62	Non-Drug
V2209		Lens sphcy bifocal 4.25-7/4.		\$77.35	Non-Drug
V2210		Lens sphcy bifocal 4.25-7/ov		\$84.18 \$86.88	Non-Drug Non-Drug
V2211 V2212		Lens sphcy bifo 7.25-12/.25- Lens sphcyl bifo 7.25-12/2.2		\$89.35	Non-Drug Non-Drug
V2212 V2213		Lens sphcyl bifo 7.25-12/2.2 Lens sphcyl bifo 7.25-12/4.2		\$90.15	Non-Drug
V2213 V2214		Lens sphcyl bifocal over 12.	1	\$97.03	Non-Drug
V2215	1	Lens lenticular bifocal		\$98.33	Non-Drug
V2216	1	Lens lenticular nonaspheric		\$105.57 \$100.37	Non-Drug
V2217	1	Lens lenticular aspheric bif Lens aniseikonic bifocal		\$100.37 \$114.91	Non-Drug Non-Drug
V2218 V2219	1	Lens bifocal seg width over		\$54.20	Non-Drug
V2219 V2220	1	Lens bifocal add over 3.25d		\$44.09	Non-Drug
V2299	1	Lens bifocal speciality		\$64.82	Non-Drug
V2300	1	Lens sphere trifocal 4.00d		\$78.06	Non-Drug
V2301	(Lens sphere trifocal 4.12-7.		\$90.04 \$95.26	Non-Drug Non-Drug
V2302	1	Lens sphere trifocal 7.12-20 Lens sphcy trifocal 4.0/.12-	. 1	\$76.99	

PAGE 53 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
V2304		Lens sphcy trifocal 4.0/2.25		\$80.05	Non-Drug
V2305		Lens sphcy trifocal 4.0/4.25	1 1	\$90.99	Non-Drug
V2306		Lens sphcyl trifocal 4.00/>6	1 1	\$93.36	Non-Drug
V2307	1 1	Lens sphcy trifocal 4.25-7/.	1 1	\$88.99	Non-Drug
V2308		Lens sphc trifocal 4.25-7/2.	1 .	\$92.73 \$100.03	Non-Drug Non-Drug
V2309 V2310	1	Lens sphc trifocal 4.25-7/4. Lens sphc trifocal 4.25-7/>6		\$98.97	Non-Drug
V2311	1 1	Lens sphc trifo 7.25-12/.25-	1 1	\$102.53	Non-Drug
V2312		Lens sphc trifo 7.25-12/2.25	1 1	\$103.06	Non-Drug
V2313		Lens sphc trifo 7.25-12/4.25		\$113.81	Non-Drug
V2314		Lens sphcyl trifocal over 12	1	\$121.40	Non-Drug
V2315		Lens lenticular trifocal	1	\$133.57 \$125.91	Non-Drug Non-Drug
V2316 V2317	i '	Lens lenticular nonaspheric Lens lenticular aspheric tri		\$134.67	Non-Drug
V2318	- (Lens aniseikonic trifocal		\$161.66	Non-Drug
V2319		Lens trifocal seg width > 28		\$60.37	Non-Drug
V2320	1	Lens trifocal add over 3.25d		\$63.65	Non-Drug
V2399		Lens trifocal speciality	1	\$49.52	Non-Drug
V2410	l	Lens variab asphericity sing		\$103.12	Non-Drug
V2430	1	Lens variable asphericity bi	1 1	\$122.01 \$37.13	Non-Drug Non-Drug
V2499 V2500		Variable asphericity lens Contact lens pmma spherical	1	\$94.51	Non-Drug
V2500 V2501	1	Cntct lens pmma-toric/prism	1 1	\$138.18	Non-Drug
V2502	\	Contact lens pmma bifocal	1 1	\$167.64	Non-Drug
V2503	ļ	Cntct lens pmma color vision	, ,	\$155.28	Non-Drug
V2510	1	Cntct gas permeable sphericl		\$124.97	Non-Drug
V2511		Cntct toric prism ballast		\$174.74	Non-Drug
V2512	1	Cntct lens gas permbl bifocl	((\$204.47	Non-Drug
V2513		Contact lens extended wear		\$173.44 \$118.14	Non-Drug Non-Drug
V2520 V2521	1	Contact lens hydrophilic Cntct lens hydrophilic toric	1 1	\$197.48	Non-Drug
V2522	1	Cntct lens hydrophil bifocl	1 1	\$192.48	Non-Drug
V2523	1	Cntct lens hydrophil extend		\$165.67	Non-Drug
V2530		Contact lens gas impermeable	1	\$240.05	Non-Drug
V2531		Contact lens gas permeable		\$513.76	Non-Drug
V2599	1	Contact lens/es other type	1	\$85.78 \$68.37	Non-Drug Non-Drug
V2600 V2610		Hand held low vision aids Single lens spectacle mount	1 1	\$305.64	Non-Drug
V2623	1	Plastic eye prosth custom		\$2,172.80	Non-Drug
V2624	1	Polishing artifical eye	1	\$78.58	Non-Drug
V2625		Enlargemnt of eye prosthesis		\$779.92	Non-Drug
V2626	1	Reduction of eye prosthesis		\$379.00	Non-Drug
V2627		Scleral cover shell	1 1	\$3,204.93 \$605.98	Non-Drug Non-Drug
V2628 V2629		Fabrication & fitting Prosthetic eye other type	1	\$694.63	Non-Drug
V2630	1	Anter chamber intraocul lens	1 1	\$275.82	Non-Drug
V2632	- 1	Post chmbr intraocular lens	1 1	\$356.48	Non-Drug
V2700		Balance lens		\$53.35	Non-Drug
V2710	1	Glass/plastic slab off prism) !	\$76.89	Non-Drug
V2715	1	Prism lens/es		\$14.66	Non-Drug
V2718		Fresnell prism press-on lens	1	\$35.01 \$26.04	Non-Drug Non-Drug
V2730	1	Special base curve Rose tint plastic	1	\$13.30	Non-Drug
V2740 V2741		Non-rose tint plastic		\$12.79	Non-Drug
V2742	1	Rose tint glass	1	\$12.73	Non-Drug
V2743	1	Non-rose tint glass		\$16.09	Non-Drug
V2744		Tint photochromatic lens/es]]	\$20.41 \$23.63	Non-Drug Non-Drug
V2750		Anti-reflective coating		\$23.63 \$20.65	Non-Drug
V2755	1	UV lens/es Scratch resistant coating		\$20.65 \$19.95	Non-Drug
V2760 V2770	(Occluder lens/es		\$24.15	Non-Drug
V2770 V2780		Oversize lens/es		\$15.75	Non-Drug
V2781	1	Progressive lens per lens	1	\$145.84	Non-Drug
V2785		Corneal tissue processing]]	\$2,702.35	Non-Drug
V2790	}	Amniotic membrane]	\$48.62	Non-Dru
V2799	-	Housing percepting		\$91.45	Non-Dru
V5008	1	Hearing screening Assessment for hearing aid	1 1	\$116.41	

PAGE 54 OF 54

HCPCS Code	Modifier	HCPCS Code Description	Status/ Usage Indicator	Charge	GAAF Cateogory
V5011		Hearing aid fitting/checking		\$176.17	Non-Drug
V5014		Hearing aid repair/modifying	1	\$210.32	Non-Drug
V5020		Conformity evaluation	1	\$103.28	Non-Drug
V5030	1	Body-worn hearing aid air		\$1,936.98	Non-Drug
V5040		Body-worn hearing aid bone	1	\$1,401.20	Non-Drug
V5050		Hearing aid monaural in ear	1	\$1,666.60	Non-Drug
V5060		Behind ear hearing aid		\$1,343.55	Non-Drug
V5070		Glasses air conduction]]	\$614.94	Non-Drug
V5080		Glasses bone conduction		\$1,994.63	Non-Drug
V5090		Hearing aid dispensing fee	1	\$548.53	Non-Drug
V5100)	Body-worn bilat hearing aid		\$3,378.30	Non-Drug
V5110		Hearing aid dispensing fee	1	\$557.07	Non-Drug
V5120		Body-worn binaur hearing aid		\$2,915.09	Non-Drug
V5130	1	In ear binaural hearing aid	1	\$3,120.85	Non-Drug
V5140	1	Behind ear binaur hearing ai		\$3,257.03	Non-Drug
V5150		Glasses binaural hearing aid	1	\$3,497.58	Non-Drug
V5160		Dispensing fee binaural		\$695.45	Non-Drug
V5170	1	Within ear cros hearing aid		\$2,342.54	Non-Drug
V5180	1	Behind ear cros hearing aid	1	\$1,936.98	Non-Drug
V5190	1	Glasses cros hearing aid	1	\$2,313.71	Non-Drug
V5200	l	Cros hearing aid dispens fee	1 1	\$552.48	Non-Drug
V5210	1	In ear bicros hearing aid		\$2,571.16	Non-Drug
V5220		Behind ear bicros hearing ai	1	\$2,458.84	Non-Drug
V5230		Glasses bicros hearing aid)	\$2,552.27	Non-Drug
V5240	l	Dispensing fee bicros		\$571.52	Non-Drug
V5241		Dispensing fee, monaural]]	\$112.38	Non-Drug
V5243		Hearing aid, monaural, itc		\$1,364.61	Non-Drug
V5245	1	Hearing aid, prog, mon, itc		\$2,408.13	Non-Drug
V5249	1	Hearing aid, binaural, itc		\$2,083.83	Non-Drug
V5251	1	Hearing aid, prog, bin, itc		\$5,442.37	Non-Drug
V5252	1	Hearing aid, prog, bin, ite		\$5,137.34	Non-Drug
V5258	1	Hearing aid, digit, bin, cic		\$5,456.82	Non-Drug
V5264	1	Ear mold/insert	}	\$78.67	Non-Drug
V5266	1	Battery for hearing device		\$1.61	Non-Drug
V5267	(Hearing aid supply/accessory		\$24.08	Non-Drug
V5275	1	Ear impression		\$48.16	Non-Drug
V5299	1	Hearing service	1	\$1,553.98	Non-Drug

Key to Status/Usage Indicators:

No entry: Can be billed at all VA locations.

a Cannot be billed by VA Hospital Outpatient and Provider-Based Clinics (because the service is separately priced as outpatient facility charges — see Table F).

TABLE L. — PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE PAGE 1 OF 15

	Non- Deliv- eries	1.00	$\begin{smallmatrix} 0.1&1&1&1&1&1&1&1&1&1&1&1&1&1&1&1&1&1&1&$
	Cesar- ean Deliv- eries	1.00	$\begin{smallmatrix} 0 & -1 & -1 & -1 & -1 & -1 & -1 & -1 & $
	Normal Deliv- eries	1.00	8 6 1 1 1 1 1 2 2 2 2 2 2 2 2 2 2 2 2 2 2
	Anes- thesia	1.00	7.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4.4
	Path- ology	1.00	00000 000000
	Radi- ology	1.00	0.000 0.000
	Sur- gery	1.00	4
	Psych./ Alcohol & Drug Abuse	1.00	0.011100000000000000000000000000000000
	Chiro- practor	1.00	4.4.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0
tegory	Phys- ical Exams	1.00	2
By Ca	Hear- ing/ Speech Exams	1.00	1.58 1.58
Conversion Factor GAAFs By Category	Vision Exams	1.00	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
actor (Well Baby Exams	1.00	0.00 0.00
ersion F	Immun- izations	1.00	7.000000000000000000000000000000000000
Conve	Cardio- vas- cular	1.00	0001-1-0-1-0-0-0-0-0-0-0-0-0-0-0-0-0-0-
	Phys- ical Med- icine	1.00	0.00 0.00
	Con- sulfs	1.00	0.00
	ER Visits	1.00	0.096 0.096 0.096 0.096 0.097 0.096
	Misc. Med- ical	1.00	0.00
	Allergy Immuno- therapy	1.00	244444
	Altergy Test- ing	1.00	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
	Thera- peutic Injec- tions	1.00	0.055 1.102 1.104 1.104 1.105
	Office/ Home/ Urgent Care Visits	1.00	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	Inpa- tient Visits	1.00	744111100000000000000000000000000000000
s	Total Unit Value	1.000	1,100 0,20 0,20 0,20 0,20 0,20 0,20 0,20
RVU GAAFs	Practice Expense	1.000	1.030 0.712
RVL	Work P Expense E	1.000	0.0986 0.0986 0.0000 0.0000 0.0
	Zip Code	Nationwide Average	000 000 000 000 000 000 000 000 000 00

TABLE L. — PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE PAGE 2 OF 15

	Non- Deliv- eries	10000000000000000000000000000000000000
	Cesar- ean Deliv- eries	444 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
	Normal Deliv- eries	1128 1128 1128 1128 1128 1128 1132 1132
	Anes- thesia	444-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1
	Path-	0.000000000000000000000000000000000000
	Radi-	0.097 0.097 0.098
	Sur- gery	103 103 103 103 103 103 103 103 103 103
	Psych./ Alcohol & Drug Abuse	0.00 0.00
	Chiro- practor	2001 2001 2001 2001 2001 2001 2001 2001
egory	Phys- ical Exams	2221 2221 2221 2221 2221 2222 2222 222
Conversion Factor GAAFs By Category	Hear- ing/ Speech Exams	0.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
SAAFs	Vision Exams	800 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
actor G	Well Baby Exams	2221 2421
rsion F	lmmun- izations	8 8 8 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9
Conve	Cardio- vas- cular	0 0 8 8 8 9 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	Phys- ical Med- icine	0.93 0.93 0.93 0.93 0.99 0.99 0.99 0.99
	Con-	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	ER Visits	0.76 0.82 0.82 0.82 0.82 0.82 0.82 0.82 0.83 0.83 0.84 0.85 0.85 0.85 0.85 0.85 0.85 0.85 0.85
	Misc. Med- ical	0.087 0.087 0.087 0.087 0.087 0.087 0.087 0.097 0.
	Allergy fmmuno- therapy	100 100 100 100 100 100 100 100 100 100
	Allergy Test- ing	0.097 0.097
	Thera- peutic Injec- tions	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
	Office/ Home/ Urgent Care Visits	0.099 0.
	Inpa- tient Visits	$\begin{array}{c} 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 \\ 0 $
s	Total Unit Value	1110 1110 110 110
RVU GAAFs	Practice Expense	1156 1156 1156 1156 1116 11193 1193
R.	Work	1050 1050 1050 1050 1050 1058 1058 1058
	Zip Code	065 968 968 968 968 968 968 968 968 968 968

TABLE L. — PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 3 OF 15

	Non- Deliv- eries	$\begin{array}{c} 1\\ 0\\ 0\\ 0\\ 0\\ 0\\ 0\\ 0\\ 0\\ 0\\ 0\\ 0\\ 0\\ 0\\$
	Cesar- ean Deliv- eries	7.1.1.1.0.0.0.0.1.1.1.0.0.0.0.0.0.0.0.0.
	Normal Deliv- eries	0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0
	Anes- thesia	0.001111000000000000000000000000000000
	Path- ology	000000000000000000000000000000000000000
	Radi- ology	88888888888888888888888888888888888888
	Sur- gery	20020202020202020202020202020202020202
	Psych./ Alcohol & Drug Abuse	
	Chiro- practor	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
legory	Phys- ical Exams	1.08
By Category	Hear- ing/ Speech Exams	88888888888888888888888888888888888888
Conversion Factor GAAFs	Vision Exams	40.000
actor (Well Baby Exams	11111111111111111111111111111111111111
rsion F	Immun- izations	22222 22222 22222 22222 22222 22222 2222
Conve	Cardio- vas- cular	0.096 0.096
	Phys- ical Med- icine	0.0888 0.0833 0.070 0.070 0.070 0.083 0.083 0.09
	Con- sults	0000 0000 0000 0000 0000 0000 0000 0000 0000
	ER Visits	44401 44
	Misc. Med- ical	44449
	Allergy fmmuno- therapy	1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-
	Allergy Test- ing	88 88 88 88 88 88 88 88 88 88 88 88 88
	Thera- peutic Injec- tions	00824 00824 00824 00824 00825 00
	Office/ Home/ Urgent Care Visits	00001010000000000000000000000000000000
	Inpa- tient Visits	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
s	Total Unit Value	0.977 0.977 0.977 0.977 0.977 0.977 0.977 0.977 0.977 0.977 0.977 0.977 0.977 0.967
RVU GAAFs	Practice Expense	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
R.	Work	0.09988 0.099888 0.099888 0.09988 0.09988 0.09988 0.09988 0.09988 0.09988 0.09988 0.09
	Zip Code	\$2550 \$254 \$444 \$444 \$445 \$550 \$550 \$550 \$550 \$5

TABLE L. — PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE PAGE 4 OF 15

	Non- Deliv- eries	24-1-25-1-4-1-4-1-4-1-4-1-4-1-4-1-4-1-4-1-4-1-
	Cesar- ean Deliv- eries	0.00 0.00
	Normal Deliv- eries	0.00 0.00
	Anes- thesia	8 6 7 7 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
	Fath-	01100010000000000000000000000000000000
	Radi- ology	00000000000000000000000000000000000000
	Sur- gery	91111111111111111111111111111111111111
	Psych./ Alcohoi & Drug Abuse	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
	Chiro- practor	0.000 0.000
egory	Phys- ical Exams	2.4.4.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2.2
By Cat	Hear- ing/ Speech Exams	14444 14
SAAFs	Vision Exams	0.000
actor (Well Baby Exams	00000000000000000000000000000000000000
Conversion Factor GAAFs By Category	Immun- izations	88 88 88 88 88 88 88 88 88 88 88 88 88
Conve	Cardio- vas- cular	00000000000000000000000000000000000000
	Phys- ical Med- icine	0.89 0.89 0.99 0.99 0.99 0.99 0.99 0.99
	Con- sults	0.00 0.00
	ER Visits	8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
	Misc. Med- ical	0.86 0.87 0.87 0.87 0.87 0.87 0.87 0.87 0.88 0.88
	Allergy Immuno- therapy	0.088 0.088 0.088 0.088 0.097 0.097 0.097 0.098
	Allergy Test- ing	0.085 0.078 0.085 0.095
	Thera- peutic Injec- tions	0.000 0.0000 0.0000
	Office/ Home/ Urgent Care Visits	0.00 1.00
	Inpa- tient Visits	0.09 0.09
,øs	Total Unit Value	0.960 0.960
RVU GAAFs	Practice Expense	0.929 1.035 1.035 1.035 1.036 1.166
RVL	Work Expense	0.989 1.050 1.
Zip Code 196		200 200 200 200 200 200 200 200 200 200

TABLE L. — PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 5 OF 15

	Non- Deliv- eries	10000000000000000000000000000000000000
	Cesar- ean Deliv- eries	00000000000000000000000000000000000000
	Normal Deliv- eries	7.00 9.00
	Anes-	0.098 0.098 0.098 0.098 0.098 0.099
	Path-	%1444444444444444444444444444444444444
	Radi-	28.23.21.21.21.21.21.21.21.21.21.21.21.21.21.
	Sur-	1000 1000 1000 1000 1000 1000 1000 100
	Psych./ Alcohol & Drug Abuse	44444444444444444444444444444444444444
	Chiro- practor	00000000000000000000000000000000000000
egory	Phys- ical Exams	2 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
By Cat	Hear- ing/ Speech Exams	1288 1288 1288 1288 1288 1288 1288 1288
AAFs	Vision Exams	1077 1107 1107 1107 1107 1107 1107 1108 1108
actor G	Well Baby Exams	1133 1133 1133 1133 1133 1133 1133 113
Conversion Factor GAAFs By Category	Immun- izations	00999999999999999999999999999999999999
Conve	Cardio- vas- cular	2000 2000 2000 2000 2000 2000 2000 200
	Phys- ical Med- icine	1338 1338 1338 1338 1338 1338 1338 1338
	Con-	2000 2000 2000 2000 2000 2000 2000 200
	ER Visits	0.098 0.098
	Misc. Med- ical	0.09 0.09
	Allergy fmmuno- therapy	1112 1112 1112 1112 1112 1112 1112 111
	Atlergy Test-	24444444444444444444444444444444444444
	Thera- peutic Injec- tions	0.00 0.00
	Office/ Home/ Urgent Care Visits	2011 1011 1011 1011 1011 1011 1011 1011
	Inpa- tient Visits	0.0988888888888888888888888888888888888
S	Total Unit Value	0.0000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.000000
RVU GAAFs	Practice Expense	0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.850 0.851 0.831 0.831 0.892
8	Work Expense	0.0963 0.0963 0.0963 0.0963 0.0963 0.0963 0.0970 0.
	Zip Code	2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2 2

TABLE L. — PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE PAGE 6 OF 15

	Non- Deliv- eries	0.089 0.089 0.090 0.090 0.090 0.0000 0.0000
	Cesar- ean Deliv- eries	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
	Normal Deliv- eries	4 7 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8 7 8
	Anes- thesia	$\begin{array}{c} 0.11 \\ 0.$
	Path- olegy	0.000000000000000000000000000000000000
	Radi- ology	### ### ##############################
	Sur- gery	0.000000000000000000000000000000000000
	Psych./ Alcohol & Drug Abuse	0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.
	Chiro- practor	0.0988999999999999999999999999999999999
egory	Phys- ical Exams	44444444444444444444444444444444444444
Conversion Factor GAAFs By Category	Hear- ing/ Speech Exams	1000 11000 11000 11000 1111 1111 1111
SAAFs	Vision Exams	0.0933333333333333333333333333333333333
actor G	Welf Baby Exams	1220 1220 1220 1220 1220 1220 1220 1220
rsion F.	Immun- izations	0.000000000000000000000000000000000000
Conve	Cardio- vas- cular	48888888888888888888888888888888888888
	Phys- ical Med- icine	0.00 0.00
	Con- sults	0.097 0.
	ER Visits	0.00 0.00
	Misc. Med- ical	0.093 0.093
	Allergy Immuno- therapy	00000000000000000000000000000000000000
	Allergy Test- ing	0.097 0.
	Thera- peutic Injec- tions	0.09 0.09
	Office/ Home/ Urgent Care Visits	0.0989000000000000000000000000000000000
	Inpa- tient Visits	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
8	Totai Unit Value	0.9960 0.
RVU GAAFs	Practice Expense	0.946 0.946
RVU	Work Pr Expense Ex	0.975 0.975
Zp		222 222 222 223 223 223 223 233 233 233

TABLE L. — PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE PAGE 7 OF 15

	Non- Deliv- eries	00999999999999999999999999999999999999
	Cesar- ean Deliv- eries	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	Normal Deliv- eries	0.088
	Anes- thesia	0.091 0.091 0.091 0.093
	Path-	5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5 5
	Radi-	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
	Sur- gery	0001 1000 1000 1000 1000 1000 1000 100
	Psych./ Alcohoi & Drug Abuse	0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.00000 0
	Chiro- practor	74444444444444444444444444444444444444
egory	Phys- ical Exams	0.73 0.73 0.73 0.73 0.73 0.73 0.95 0.95 0.95 0.95 0.95 0.95 0.95 0.95
Conversion Factor GAAFs By Category	Hear- ing/ Speech Exams	11088
SAAFs	Vision Exams	0.09444600000000000000000000000000000000
actor (Well Baby Exams	0.072 0.072 0.072 0.072 0.072 0.072 0.072 0.072 0.082
rsion F	Immun- izations	0.099 0.099
Conve	Cardio- vas- cular	1119 1119 1119 1119 1119 1119 1119 111
	Phys- ical Med- icine	1000 1000 1000 1000 1000 1000 1000 100
	Con- sults	0.0988888888888888888888888888888888888
	ER Visits	0.096 0.096 0.096 0.096 0.096 0.098
	Misc. Med- ical	0.01 0.01
	Allergy Immuno- therapy	10.00
	Altergy Test- ing	00000000000000000000000000000000000000
	Thera- peutic Injec- tions	0.00 0.00
	Office/ Home/ Urgent Care Visits	96 96 96 96 96 96 96 96 96 96 96 96 96 9
	Inpa- tient Visits	0.000000000000000000000000000000000000
s	Total Unit Value	0.890 0.890 0.890 0.890 0.890 0.900 0.900
RVU GAAFs	Practice Expense	0.0837 0.0837 0.0837 0.0837 0.0837 0.0837 0.0866 0.
RVU	Work P Expense E)	0.957 0.957
	Zip Code	989 989 989 989 989 989 989 989 989 989

TABLE L. — PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE PAGE 8 OF 15

	Non- Deliv- eries	101 101 102 103 103 103 103 103 103 103 103 103 103
	Cesar- ean Deliv- eries	0.078 0.089
	Normal Deliv- eries	0.082 0.082 0.082 0.082 0.082 0.082 0.082 0.083 0.083 0.093
	Anes-	0.084 0.092 0.092 0.092 0.092 0.093
	Path-	0.09 0.09
	Radi-	0.094 0.094 0.094 0.094 0.098 0.
	Sur-	0.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	Psych./ Alcohol & Drug Abuse	00000000000000000000000000000000000000
	Chiro- practor	00000000000000000000000000000000000000
egony	Phys- ical Exams	00000000000000000000000000000000000000
Conversion Factor GAAFs By Category	Hear- ing/ Speech Exams	0000 0000 0000 0000 0000 0000 0000 0000 0000
SAAFs	Vision Exams	00000000000000000000000000000000000000
actor G	Well Baby Exams	00.00 00
rsion F	Immun- ízations	00.099 17.28 1
Conve	Cardio- vas- cular	0.096 0.096
	Phys- ical Med- icine	0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.00
	Con-	0.090 0.000 0.000
	ER Visits	0.088 0.088 0.098
	Misc. Med- ícal	0.088 0.098
	Altergy Immuno- therapy	0.084 0.087 0.097 0.097 0.098
	Allergy Test- ing	0.089 0.089 0.089 0.089 0.088
	Thera- peutic Injec- tions	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
	Office/ Home/ Urgent Care Visits	00 88 80 00 00 00 00 00 00 00 00 00 00 0
	Inpa- tient Visits	0088880 00880 00880 00880 008880 008880 008880 008880 00880 008880 008880 008880 008880 008880 008880 008880 00880
s	Total Unit Value	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
RVU GAAFs	Practice Expense	0 944 4 0 0 944 4 0 0 944 4 0 0 944 4 0 0 944 4 0 0 944 4 0 0 944 4 0 0 942 0 0 922
RV	Work Expense	0 988 0 0 988
	Ztp Code	\$64 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4

TABLE L. — PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE PAGE 9 OF 15

	Non- Deliv- eries	0.889 0.089 0.089 0.089 0.089 0.089 0.089 0.099
	Cesar- ean Deliv- eries	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4
	Normal Deliv- eries	1089 1089 1089 1089 1089 1089 1089 1089
	Anes- thesia	0.03 0.03
	Path.	0.86 0.086 0.086 0.086 0.086 0.086 0.086 0.086 0.086 0.086 0.097 0.097 0.097 0.097 0.098 0
	Radi- ology	1000 10000 1
	Sur-	0.088 0.098
	Psych./ Alcohol & Drug Abuse	2001 2001 2001 2001 2001 2001 2001 2001
	Chiro- practor	44444444444444444444444444444444444444
egory	Phys- ical Exams	0.099999999999999999999999999999999999
Conversion Factor GAAFs By Category	Hear- ing/ Speech Exams	1022 1022 1022 1022 1022 1022 1022 1022
SAAFs	Vision Exams	00000000000000000000000000000000000000
actor G	Well Baby Exams	7001 7001
rsion F	Immun-	0.00 0.00
Conve	Cardio- vas- cular	2001 2001 2001 2001 2001 2001 2001 2001
	Phys- ical Med- icine	0.092 0.093
	Con- sults	1122 1122 1222 1222 1222 1222 1222 122
	ER Visits	0 0 8 2 2 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
	Misc. Med- ical	0.099 0.097 0.097 0.097 0.097 0.097 0.097 0.098 0.
	Allergy Immuno- therapy	1221 1221 1221 1221 1221 1222 1223 1223
	Allergy Test- ing	1128 1128 1128 1128 1128 1128 1128 1128
	Thera- peutic Injec- tions	747.00 747.00
	Office/ Home/ Urgent Care Visits	0.00 0.00
	Inpa- tient Visits	2000 2000
s	Total Unit Value	0.0910 0.
RVU GAAFs	Practice Expense	0.876 0.876 0.876 0.876 0.876 0.876 0.876 0.929
₽ S	Work Expense	0.0959 0.0959
	Zip Code	\$22.20 \$2.20

TABLE I. — PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE PAGE 10 OF 15

	Non- Deliv- eries	0.098
	Cesar. ean Deliv- eries	1007 1007 1107 1107 1107 1107 1107 1107
	Normal Deliv- eries	0 0 8 8 0 0 0 8 8 0 0 0 8 8 0 0 0 8 8 0 0 0 8 8 0 0 0 8 8 0 0 0 8 8 0 0 0 8 8 0 0 0 0 8 8 0 0 0 0 8 8 0
	Anes-	0.084 0.087 0.087 0.087
	Path-	8 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	Radi-	00000000000000000000000000000000000000
	Sur-	88888888888888888888888888888888888888
	Psych./ Alcohol & Drug Abuse	8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8
	Chiro- practor	C. 88 88 88 88 88 88 88 88 88 88 88 88 88
tegory	Phys- ical Exams	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
By Category	Hear- ing/ Speech Exams	
Conversion Factor GAAFs	Vision	0.000 0.0000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.00000 0.000000
actor (Well Baby Exams	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
rsion F	Immun- izations	0.000000000000000000000000000000000000
Conve	Cardio- vas-	4.10 9.80
	Phys- ical Med- icine	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
	Con-	71.00 90.01 10.00 10
	ER Visits	0.00 0.00
	Misc. Med- ical	0.90 0.90 0.90 0.90 0.90 0.90 0.90 0.90
	Allergy Immuno- therapy	0.089 0.089 0.099
	Allergy Test- ing	0.00 0.00
	Thera- peutic Injec- tions	0 0 93 3 0 0 93 3 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1 1
	Office/ Home/ Urgent Care Visits	1004 1004 1004 1004 1004 1006 1006 1006
	Inpa- tient Visits	11.13 0.097 0.097 0.097 0.097 0.098
ş	Total Unit Value	0.910 0.910 0.910 0.910 0.910 0.910 0.910 0.920
RVU GAAFs	Practice Expense	0 876 0 876 0 876 0 876 0 876 0 876 0 876 0 876 0 876 0 876 0 8876 0 8889 0 8888
	Work F Expense E	
Zip Code		551 552 553 554 555 555 555 555 555 555

TABLE L. — PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 11 OF 15

1	Non- Deliv- eries	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	Cesar- ean Deliv- eries	0.088 0.089 0.089 0.089 0.089 0.090 0.0000 0.0000
	Normal Deliv- eries	0.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	Anes- thesia	0.0883 0.
	Path-	1121 1121 1121 1121 1122 1123 1123 1123
	Radi- ology	112 100 100 100 100 100 100 100 100 100
	Sur- gery	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
	Psych./ Alcohol & Drug Abuse	0000 0000 0000 0000 0000 0000 0000 0000 0000
	Chiro- practor	44600 4600
egory	Phys- ical Exams	4 7 7 9 8 9 9 9 9 8 9 9 9 8 9 9 9 9 9 9 9
By Cat	Hear- ing/ Speech Exams	100 100 100 100 100 100 100 100
Conversion Factor GAAFs By Category	Vision Exams	0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.000 0.0000 0.000 0.00000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0000 0.0
actor G	Well Baby Exams	0.75 1.00 0.00
sion F	fmmun- izations	0.05
Conve	Cardio- vas- cular	0.94 1.09 1.09 1.09 1.09 1.09 1.09 1.09 1.09
	Phys- ical Med- icine	0.05 0.07 0.07 0.08
	Con- sults	0.00
	ER Visits	0.00 0.00
	Misc. Med-	0.097 0.098 0.
	Allergy Immuno- therapy	0.00 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	Allergy Test-	1.16 1.05 1.05 1.05 1.05 1.05 1.05 1.05 1.05
	Thera- peutic Injec- tions	0.00
	Office/ Home/ Urgent Care Visits	9.000 9.0000 9.000 9.000 9.000 9.000 9.000 9.000 9.000 9.000 9.00000 9.0000 9.0000 9.0000 9.0000 9.0000 9.0000 9.0000 9.
	Inpa- tient Visits	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
s	Total Unit Value	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
RVU GAAFs	Practice Expense	0 825 8 9 9 9 8 9 8 9 8 9 8 9 8 9 8 9 8 9 8
₽.	Work Expense	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	Zip Code	669 669 669 669 669 669 669 669 673 673 673 674 675 675 677 677 677 677 677 677 677 677

TABLE L. — PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 12 OF 15

	Non- Deliv- eries	0.099999999999999999999999999999999999
	Cesar- ean Deliv- I	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	Normal Deliv- eries	0.000 0.000
	Anes- thesia	0.093 8.893 8.993 8.
	Path-	1000 1000 1000 1000 1000 1000 1000 100
	Radi- ology	100 100 100 100 100 100 100 100 100 100
	Sur- gery	00000000000000000000000000000000000000
	Psych./ Alcohol & Drug Abuse	0.0989 0.
}	Chiro- practor	0.000 0.0000 0.000
tegory	Phys- ical Exams	0.099 0.
Conversion Factor GAAFs By Category	Hear- ing/ Speech Exams	0.032 0.
SAAFs	Vision Exams	0.088 0.088 0.088 0.088 0.098
actor (Well Baby Exams	1.00 0.00 0.00 0.00 0.00 0.00 0.00 0.00
rsion F	Immun- izations	0.00 0.00
Conve	Cardio- vas- cular	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
	Phys- ical Med- icine	1223 1223 1238 1238 1238 1238 1238 1238 1238 1238 1338
	Con- sufts	105 105 105 105 105 105 105 105
	ER Visits	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
	Misc. Med- ical	5.4.4.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.0.
	Allergy Immuno- therapy	0.05 0.05
	Allergy Test- ing	0.0988880000000000000000000000000000000
	Thera- peutic Injec- tions	1000 1000 1000 1000 1000 1000 1000 100
	Office/ Home/ Urgent Care Visits	100 100 100 100 100 100 100 100
	Inpa- tient Visits	0.09 0.09
S	Total Unit Value	0.920 0.920
RVU GAAFs	Practice Expense	0.876 0.876 0.876 0.876 0.876 0.876 0.876 0.876 0.876 0.876 0.876 0.886
RVL	Work F Expense E	0.0988888888888888888888888888888888888
	Zp Code	733 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3 3

TABLE L. — PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 13 OF 15

	Non- Deliv- eries	100 000 000 000 000 000 000 000 000 000
	Cesar- ean Deliv- eries	11034 1037 1037 1037 1037 1037 1037 1037 1037
	Normal Deliv- eries	00000000000000000000000000000000000000
	Anes-	0.990 0.900 0.900
	Path-	1.18 1.16 1.16 1.16 1.16 1.08 1.08 1.08 1.08 1.08 1.08 1.08 1.08
	Radi-	1.13 1.13 1.13 1.13 1.13 1.13 1.13 1.13
	Sur- gery	1.07 1.07 1.07 1.07 1.07 1.07 1.07 1.07
	Psych./ Alcohol & Drug Abuse	7-1-1-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-0-
	Chiro- practor	00001-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1
egory	Phys- ical Exams	0.00 0.00
Conversion Factor GAAFs By Category	Hear- ing/ Speech Exams	7.00 7.00
AAFs	Vision Exams	0.00 0.00 0.00 0.00 0.00 0.00 0.00 0.0
actor G	Well Baby Exams	0.000 0.0000 0.
rsion F	fmmun- tzations	444444 44444 44444 44444 44444 44444 4444
Conve	Cardio- vas- cutar	14444 14
	Phys- ical Med- icine	0.092 0.092 0.092 0.092 0.092 0.093
	Con-	1000 1000 1000 1000 1000 1000 1000 100
	ER	7.7.4 0.01 0.01 0.02 0.03
	Misc. Med- ical	128 128 128 128 128 128 128 128
	Altergy Immuno- therapy	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	Allengy Test- I	0.88 0.088 0.095 0.095 0.095 0.095 0.072 0
	Thera- peutic Injec- tions	128 128 128 128 128 138 141 144 144 143 143 143 143 143 143 143
	Office/ Home/ Urgent Care Visits	1.02 1.02 1.02 1.03 1.03 1.03 1.03 1.03 1.03 1.03 1.03
	Inpa- tient Visits	1.07 1.07 1.07 1.07 1.07 1.07 1.07 1.07
s	Total Unit Value	0.000 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
RVU GAAFs	Practice Expense	0.880 0.892 0.993 0.993
N.	Work Expense	0.996 0.996
	Zip Code	749 749 749 749 749 749 749 749 749 749

TABLE L. — PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 14 OF 15

	Non- Deliv- eries	0.833
	Cesar- ean Deliv- eries	0.088
	Normal Deliv- eries	0.088
	Anes- thesia	0.086 0.086 0.093
	Path-	0.088 0.088 0.098
	Radi-	1000 1000 1000 1000 1000 1000 1000 100
	Sur- gery	0.000000000000000000000000000000000000
	Psych./ Alcohol & Drug Abuse	44488888888888888888888888888888888888
	Chiro- practor	0.000 0.000
egory	Phys- ical Exams	2711 2711
Conversion Factor GAAFs By Category	Hear- ing/ Speech Exams	889 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
SAAFs	Vision	1011 1010 1010 1010 1010 1010 1010 101
actor C	Welf Baby Exams	25.000000000000000000000000000000000000
rsion F	Immun- izations	0 0 8 8 9 0 0 0 0 0 8 8 9 0 0 0 0 8 8 9 0 0 0 8 8 9 0 0 0 8 8 9 0 0 0 8 9 8 9
Conve	Cardio- vas- cular	129 129 129 129 129 129 129 129 129 129
	Phys- ical Med- icine	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	Con- sults	1001
	ER Visits	0.000 0.000
	Misc. Med- ical	1115 1116 1119 1119 1119 1119 1119 1119
	Altergy Immuno- therapy	1.06 0.91 0.91 0.91 0.91 1.06 0.91 1.02 0.93 0.93 0.93 0.93 0.93 0.93 0.93 0.93
	Allergy Test-	0.777 0.777 0.777 0.778 0.788 0.788 0.788 0.877 0.873 0.833
	Thera- peutic Injec- tions	120 120 120 120 120 120 120 120 120 120
	Office/ Home/ Urgent Care Visits	1005 1005 1006 1006 1006 1006 1006 1006
	Inpa- tient Visits	0.0988999999999999999999999999999999999
s	Total Unit Value	0.930 0.930
RVU GAAFs	Practice Expense	0.0900 0.09000 0.0900 0.0900 0.0900 0.0900 0.0900 0.0900 0.0900 0.0900 0.09000 0.0900 0.0900 0.0900 0.0900 0.0900 0.0900 0.0900 0.0900 0.09000 0.0900 0.0900 0.0900 0.0900 0.0900 0.0900 0.0900 0.0900 0.09000 0.0900 0.0900 0.0900 0.0900 0.0900 0.0900 0.0900 0.0900 0.09000 0.0900 0.0900 0.0900 0.0900 0.0900 0.0900 0.0900 0.0900 0.09000 0.09000 0.0900 0.0900 0.0900 0.0900 0.0900 0.0900 0.0900 0.0900 0.09000 0.09000 0.09000 0.09000 0.09000 0.09000 0.09000 0.09000 0.090000 0.09000 0.09000 0.09000 0.09000 0.09000 0.09000 0.09000 0.09000 0.09000 0.09000 0.09000 0.090000 0.090000 0.09000 0.09000 0.090000 0.090000 0.09000 0.09000 0.00000 0.00000000
Ŋ.	Work	0.973 0.973
	Zip Code	8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8 8

TABLE L. — PROFESSIONAL SERVICES RELATIVE VALUE UNIT (RVU) AND CONVERSION FACTOR GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE PAGE 15 OF 15

	Non- Deliv- eries	0.85 0.81 0.81 0.81 0.82 0.83 0.83 0.83 0.83 0.83 0.83 0.83 0.83
	Cesar- ean Deliv- eries	0.098 0.098
	Normal Deliv- eries	0.000000000000000000000000000000000000
	Anes- thesia	71-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-1-
	Path-	00022 00020 00
	Radi-	00000000000000000000000000000000000000
	Sur- gery	0.00
	Psych./ Alcohol & Drug Abuse	0 0 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9 9
	Chiro- practor	0.099 0.099
egory	Phys- ical Exams	0.000
By Cate	Hear- ing/ Speech Exams	0.088888888888888888888888888888888888
AAFs	Vision Exams	0.099999999999999999999999999999999999
Conversion Factor GAAFs By Category	Well Baby Exams	0.000000000000000000000000000000000000
rsion F	lmmun- izations	00000000000000000000000000000000000000
Conve	Cardio- vas- cular	00 00 00 00 00 00 00 00 00 00 00 00 00
	Phys- ical Med- icine	0.0944444444444444444444444444444444444
	Con- sults	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	ER Visits	0.086 0.098
	Misc. Med- ical	0.097 0.098 0.098 0.098 0.098 0.098 0.098 0.098 0.098 0.088 0.088 0.088 0.088 0.088 0.088 0.088 0.088 0.098
	Altergy Immuno- therapy	0.089 0.087 0.087 0.087 0.087 0.087 0.087 0.088 0.
	Allergy Test-	0.052 0.072 0.073 0.073 0.073 0.073 0.073 0.093 0.094 0.097
	Thera- peutic Injec- tions	0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0 0
	Office/ Home/ Urgent Care Visits	00000000000000000000000000000000000000
	Inpa- tient Visits	00000000000000000000000000000000000000
s	Total Unit Value	1.260 1.150 1.150 1.150 1.020
RVU GAAFs	Practice Expense	1,228 1,228 1,228 1,238 1,238 1,034
RVU	Work P	1004 1004 1004 1004 1004 1006 1006 1006
	Zip Code V Exp	4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4 4

TABLE M. — CHARGE ADJUSTMENT FACTORS FOR PROFESSIONAL SERVICES CHARGE MODIFIERS

CPT/ HCPCS Code Modifier	Description	Charge Factor
22 50 51 52 53 62 80	Unusual Procedure Bilateral Procedure Multiple Procedures Reduced Services Discontinued Procedure Two Surgeons Assistant Surgeon	1.20 1.54 0.94 0.70 0.97 0.92 0.31

PAGE 1 OF 7

ZIP	1	r Surgical RGs	1	or Non- II DRGs	•	ZIP		r Surgical Gs		or Non- I DRGs
Code	Room & Board	Ancillary	Room & Board	Ancillary		Code	Room & Board	Ancillary	Room & Board 1.22 1.22 2.65 2.53 2.54 3.10 2.26 2.13 2.34 1.87 1.94 2.23 2.37 2.25 2.75 2.75 2.75 2.53 3.22 2.17 2.17 1.71 2.31 1.43 1.01 0.89 0.89 1.19 2.12 1.89 1.89 1.89 1.93 1.53 1.48 1.48 1.26 1.26 0.72 0.72 0.65 0.81 0.90 0.77	Ancillary
Nationwide Average	1.00	1.00	1.00	1.00		068 069 070	1.10 1.10 2.77	0.90 0.90 0.68	1.22	0,99 0.99 0.73
002 005 006 007 008 009 010 011 012 013 014 015 016 017 018 019 020 021 022 023 024 025 026 027 028 029 030 031 032 033 034 035 036 047 048 049 050 051 048 049 050 051 052 053 054 055 056 057 058 059 050 050 051 052 053 054 055 056 057 058 059 050 050 050 050 050 050 050	0.84 1.22 0.26 0.25 0.63 0.43 0.69 0.92 0.77 0.80 0.80 0.92 1.10 0.81 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75	1.01 0.51 0.30 0.30 0.34 0.40 0.59 0.89 0.77 0.68 0.71 0.58 0.71 0.73 0.73 0.73 0.73 0.73 0.73 0.73 0.73	0.93 1.48 0.25 0.51 0.73 0.47 0.78 1.14 0.90 1.02 0.84 1.29 0.80 1.26 1.14 1.14 1.14 0.67 1.06 1.34 0.86 0.89 0.79 0.86 0.80 1.04 1.04 1.11 1.01 1.01 1.01 0.83 0.83 0.83 0.82 0.81 0.79 0.88 1.25 1.104 1.11 1.06 1.06 1.06 1.06 1.06 1.06 1.06	0.90 0.50 0.38 0.33 0.39 0.42 0.58 0.74 0.70 0.67 0.94 0.92 0.68 0.68 0.68 0.68 0.68 0.68 0.68 0.75 0.87 0.75 0.87 0.75 0.87 0.75 0.87 0.75 0.87 0.75 0.87 0.75 0.87 0.75 0.87 0.75 0.87 0.75 0.87 0.75 0.87 0.75 0.87 0.75 0.87 0.75 0.87 0.75 0.87 0.75 0.87 0.75 0.81 0.73 0.81 0.81 0.81 0.81 0.82 0.83 0.84 0.85 0.85 0.86 0.87 0.75 0.87 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.70 0.80 0.70 0.70 0.70 0.70 0.80 0.70 0.80 0.70 0.80 0.70 0.80		070 071 072 073 074 075 076 077 078 079 080 081 082 083 084 085 086 087 088 089 100 101 102 103 104 105 106 107 108 109 110 111 112 113 114 115 116 117 118 119 120 121 122 123 124 125 126 127 128 130 131 134 135 136 137 138 139 140 141 142	2.77 2.54 2.80 2.80 2.08 1.97 2.54 3.52 2.13 2.19 2.27 2.27 3.68 2.19 2.27 2.27 2.27 2.27 2.27 2.27 2.27 2.2	0.68 0.79 0.86 0.56 0.59 0.74 0.75 0.74 0.79 1.03 0.82 0.82 1.07 0.79 0.89 0.58 0.58 0.58 0.46 0.36 0.36 0.36 0.36 0.36 0.36 0.35 0.46 0.35 0.55 0.55 0.55 0.55 0.55 0.56 0.56 0.5	2.53 2.54 3.10 2.26 2.13 2.53 3.81 2.53 3.81 2.37 2.25 2.37 2.75 2.75 2.75 2.75 2.75 2.75 2.75 2.17 2.17 2.17 1.43 1.01 0.89 1.93 1.53 1.48 1.26 1.26 0.72 0.65 0.81 0.90 1.14 0.90 0.90 0.90	0.73 0.84 1.01 0.72 0.60 0.71 0.84 0.85 0.67 0.97 0.87 1.01 0.84 0.98 0.52 0.52 0.52 0.52 0.57 0.33 0.46 0.46 0.76 0.31 0.38 0.39 0.50 0.58 0.58 0.58 0.58 0.58 0.58 0.58

PAGE 2 OF 7

ZIP		r Surgical !Gs		For Non- al DRGs	ZIP	GAAF For Surgical DRGs		GAAF For Non- Surgical DRGs	
Code	Room & Board	Ancillary	Room & Board	Ancillary	 Code	Room & Board	Ancillary	Room & Board	Ancillary
145 146 147 148 149 150 151 152 153 154 155 156 157 158 159 160 161 162 163 164 165 166 167 168 169 170 171 172 173 174 175 177 178 179 180 181 182 183 184 185 186 187 188 189 190 191 192 193 194 195 196 197 198 199 200 201 202	0.64 0.75 0.53 0.61 0.61 0.70 0.71 1.34 1.00 0.57 0.60 0.65 0.65 0.65 0.65 0.65 0.65 0.65	0.37 0.45 0.50 0.50 0.50 0.83 0.72 1.40 0.88 0.45 0.99 0.71 0.62 0.99 0.75 0.61 1.07 1.07 0.73 0.70 0.73 0.70 0.74 0.99 0.75 0.61 1.07 1.07 0.73 0.76 0.76 0.76 0.77 0.76 0.77 0.77 0.77 0.78 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.70 0.70 0.70 0.71 0.71 0.72 0.73 0.76 0.76 0.77 0.77 0.77 0.77 0.77 0.77 0.77 0.78 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.70 0.70 0.71 0.71 0.72 0.73 0.76 0.76 0.77 0.77 0.77 0.77 0.77 0.77 0.77 0.78 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.70 0.50	0.68 0.76 0.60 0.61 0.61 0.83 0.83 1.21 1.00 0.67 0.75 0.86 0.64 0.70 0.75 0.71 0.59 1.01 1.01 0.80 0.64 0.72 0.64 0.77 1.09 1.12 0.60 0.73 0.73 0.71 0.82 0.56 0.95 1.01 0.70 0.70 0.70 0.70 0.70 0.70 0.70	0.36 0.42 0.55 0.51 0.51 0.90 0.85 1.33 0.87 0.52 0.93 0.73 0.68 0.74 0.68 0.59 1.06 1.06 0.67 0.65 0.79 0.65 0.83 1.03 0.71 0.71 0.83 0.73 0.71 0.71 0.83 1.05 0.79 0.65 0.89 1.06 0.69 1.73 1.73 0.86 0.69 1.59 0.86 0.69 1.73 1.73 1.73 0.86 0.69 1.59 0.86 0.69 1.73 1.73 0.86 0.69 1.59 0.86 0.69 1.73 1.73 0.86 0.69 1.73 1.73 0.86 1.10 0.87	212 214 215 216 2217 2218 2219 2221 2222 2234 2225 2226 2227 2230 2312 2332 2342 2235 2337 2343 2345 2340 2441 2445 2445 2447 2445 2447 2448 245 247 247 248 249 251 251 251 251 251 251 251 251 251 251	0.85 0.69 0.44 0.66 0.62 0.52 0.66 0.62 0.52 0.66 0.62 0.58 0.77 0.55 0.87 0.49 0.61 0.86 0.49 0.67 0.62 0.58 0.77 0.70 0.41 0.38 0.32 0.32 0.38 0.66 0.66 0.66 0.40 0.43 0.43 0.43 0.43 0.43 0.43 0.43	0.56 0.51 0.43 0.39 0.41 0.39 0.96 0.96 1.07 0.74 0.76 0.68 0.68 0.69 1.05 1.05 1.05 1.05 1.05 1.05 1.05 1.07 0.74 0.94 0.89 0.74 0.97 0.91 0.92 0.88 1.02 0.79 1.13 0.73 0.81 0.73 0.73 0.81 0.79 0.79 0.68 0.65 0.75 0.65 0.75 0.63 0.70 0.81 0.81 0.81 0.81 0.81 0.81 0.81 0.8	0.87 0.76 0.46 0.74 0.75 0.75 0.75 1.00 0.75 0.69 0.49 0.76 0.62 0.80 0.65 0.65 0.65 0.81 0.81 0.81 0.53 0.53 0.53 0.53 0.53 0.66 0.66 0.66 0.65 0.65 0.65 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.7	0.50 0.45 0.37 0.41 0.38 0.39 0.41 1.07 1.107 1.101 0.98 0.83 0.78 0.78 0.79 0.79 0.79 0.79 0.79 0.79 0.86 0.79 1.10 1.10 1.01 1.05 0.92 1.37 0.79 0.79 0.86 0.79 1.10 1.10 0.98 0.80 0.80 0.80 0.80 0.80 0.80 0.8
203 204 205 206 207 208 209 210 211	1.01 1.01 1.01 0.61 0.71 0.58 0.59 0.69	1.09 1.09 1.09 0.45 0.45 0.57 0.42 0.51	1.03 1.03 1.03 0.73 0.77 0.69 0.64 0.76	1.20 1.20 1.20 0.48 0.46 0.48 0.44 0.45 0.45	272 273 274 275 276 277 278 279 280	0.30 0.60 0.36 0.69 0.60 1.01 0.34 0.46 0.39	0.72 1.12 0.50 0.82 0.91 0.92 0.77 0.82 0.85	0.51 0.64 0.43 0.57 0.75 0.87 0.52 0.58 0.63	0.78 1.19 0.54 0.79 0.81 1.01 0.82 0.84 0.92

PAGE 3 OF 7

ZIP	l .	r Surgical Gs	i .	For Non- II DRGs	ZIP	1	r Surgical Gs	GAAF Fo Surgical Room & Board 1.06 0.75 0.65 0.59 0.83 0.67 0.64 0.83 0.65 0.62 0.49 0.36 0.47 0.64	
Code	Room & Board	Ancillary	Room & Board	Ancillary	Code	Room & Board	Ancillary		Ancillary
281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 3331 332 3331 332 3331 332 3333 334 335 336 337 338 339 341 342 346 347 349 340 350 351	0.43 0.84 0.62 0.50 0.29 0.51 0.62 0.62 0.63 0.63 0.65 0.67 0.67 0.67 0.68 0.63 0.69 0.69 0.69 0.69 0.69 0.69 0.69 0.69 0.70 0.69 0.69 0.77 0.69 0.77 0.69 0.77 0.69 0.77 0.77 0.69 0.77 0.69 0.77 0.77 0.69 0.77 0.77 0.69 0.77 0.77 0.69 0.77	0.92 0.91 0.99 1.04 0.81 1.39 0.80 1.00 0.86 1.19 0.99 1.17 1.08 1.09 1.107 1.09 1.17 1.08 1.09 1.17 1.08 1.09 1.17 1.08 1.09 1.17 1.08 1.18 1.19 1.19 1.19 1.11 1.11 1.11 1.12 1.13 1.13 1.14 1.13 1.14 1.15 1.15 1.15 1.15 1.15 1.15 1.16 1.17 1.17 1.18 1.18 1.19 1.19 1.19 1.19 1.19 1.19 1.19 1.19 1.19 1.19 1.19 1.19 1.11 1.11 1.11 1.12 1.13 1.14 1.15	0.53 0.86 0.73 0.86 0.57 0.68 0.57 0.68 0.67 0.79 0.68 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79	1.09 0.95 0.94 1.12 0.78 1.09 0.82 0.83 0.82 0.93 0.75 1.31 1.06 1.29 0.92 1.78 0.96 1.35 1.20 1.12 1.07 0.93 1.40 1.14 1.14 1.126 0.97 0.97 0.85 0.93 1.25 1.01 1.01 1.02 0.93 0.93 0.78 0.95 1.54 1.27 1.30 1.40 1.18 1.58 1.46 1.20 1.42 1.22 1.70 1.45 1.20 1.42 1.22 1.70 1.45 1.70 1.88 1.46 1.20 1.42 1.22 1.70 1.45 1.70 1.88 1.40 1.41 1.44 1.44 1.58 1.46 1.20 1.42 1.22 1.70 1.45 1.70 1.88 1.40 1.41 1.52 1.44 1.58 1.40 1.41 1.52 1.44 1.55 1.25 1.25 1.25	352 354 355 356 357 358 359 360 361 362 363 364 365 366 367 373 374 375 377 378 379 380 381 382 383 384 385 386 387 377 378 379 380 381 382 383 384 385 386 387 377 378 379 380 381 382 383 384 385 386 387 377 378 379 380 381 382 383 384 385 386 387 387 378 379 380 381 382 383 384 385 386 387 387 399 390 391 392 393 394 405 406 407 408 409 410 411 412 413 414 415 416 417 418 420 421	0.92 0.82 0.67 0.69 0.69 0.69 0.69 0.69 0.69 0.60	1.56 1.11 1.26 1.09 1.22 1.26 1.09 1.22 1.36 1.57 1.14 1.05 1.18 0.90 0.92 0.90 1.21 0.81 1.02 1.09 0.95 0.72 1.04 1.07 1.09 0.89 0.72 1.04 1.07 1.09 0.89 0.75 0.73 0.87 0.65 1.04 1.25 0.88 1.00 0.77 1.35 0.93 0.92 0.98 0.98 0.98 0.98 0.98 0.98 0.98 0.98	0.75 0.65 0.59 0.83 0.67 0.64 0.83 0.65 0.62 0.49 0.36 0.47	1.64 1.11 1.30 1.07 1.30 1.30 1.30 1.30 1.30 1.30 1.30 1.30

PAGE 4 OF 7

ZIP	1	r Surgical RGs	ŧ.	or Non- al DRGs		ZIP		r Surgical IGs	i .	or Non-
Code	Room & Board	Ancillary	Room & Board	Ancillary	-	Code	Room & Board	Ancillary	Room & Board	Ancillary
422 423 424 425 426 427 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 459 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 470 471 472 473 474 475 476 477 478 479 470 471 472 473 474 475 476 477 478 479 470 471 472 473 474 475 476 477 478 479 470 471 472 473 474 475 476 477 478 479 470 471 472 473 474 475 476 477 478 479 470 471 472 473 474 475 476 477 478 479 470 471 472 473 474 475 476 477 478 479 470 471 472 473 474 475 476 477 478 478 479 479 470 471 471 472 473 474 475 476 477 478 478 478 478 478 478 478 478 478	0.57 0.57 0.57 0.63 0.72 0.48 0.51 0.57 0.49 0.51 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75	1.00 0.78 0.82 1.23 1.23 0.75 0.87 0.89 0.87 1.00 1.07 0.78 0.78 0.75 0.68 0.84 0.85 0.84 1.11 0.59 0.85 0.78 1.01 0.83 0.87 0.81 0.81 0.81 0.81 0.81 0.81 0.81 0.81	0.59 0.62 0.61 0.80 0.80 0.58 0.64 0.62 0.66 0.50 0.91 1.01 0.66 0.73 0.75 1.06 0.89 1.03 0.62 0.79 0.54 0.70 0.71 0.68 0.64 0.81 0.83 0.72 0.82 0.64 0.72 0.80 0.80 0.66 0.63 0.99 1.07 0.88 0.64 0.71 0.72 0.73 0.74 0.78 0.78 0.79 0.71 0.78 0.79 0.71 0.71 0.71 0.72 0.72 0.73 0.74 0.75 0.78 0.78 0.79 0.79 0.79 0.79 0.71 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79	0.87 0.78 0.77 1.07 1.07 1.07 0.72 0.93 0.83 0.83 1.13 0.74 0.81 0.67 0.85 0.96 1.09 0.59 0.59 0.59 0.77 0.83 0.77 0.85 0.96 1.09 0.59 0.80 0.77 0.81 0.83 0.83 0.83 0.83 0.83 0.83 0.83 0.83		491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 508 509 510 512 513 514 515 520 521 522 523 524 525 527 528 529 531 532 533 534 535 536 537 538 538 539 539 539 539 539 539 539 539 539 539	0.58 0.68 0.46 0.72 0.76 0.74 0.69 0.54 0.54 0.66 0.52 0.71 0.72 0.74 0.74 0.74 0.75	0.89 0.66 0.77 0.77 0.77 0.79 0.68 0.67 0.77 0.72 0.72 0.72 0.72 0.72 0.73 0.79 0.79 0.79 0.83 0.83 0.83 0.83 0.83 0.83 0.83 0.81 0.65 0.65 0.65 0.65 0.65 0.65 0.65 0.65	0.68 0.81 0.60 0.60 0.83 0.81 0.78 0.62 0.62 0.62 0.62 0.62 0.62 0.64 0.67 0.64 0.67 0.68 0.68 0.68 0.69 0.78 1.04 0.59 0.70 0.64 0.69 0.61 0.69 0.61 0.69 0.61 0.69 0.61 0.69 0.61 0.69 0.61 0.69 0.61 0.69 0.69 0.61 0.69 0.61 0.69 0.69 0.69 0.69 0.69 0.69 0.70 0.69 0.69 0.69 0.69 0.69 0.69 0.69 0.70 0.69 0.69 0.69 0.69 0.69 0.69 0.69 0.69 0.69 0.70 0.69 0.70 0.69 0.69 0.69 0.70 0.69 0.69 0.69 0.69 0.70 0.69 0.70 0.69 0.70 0.69 0.69 0.70 0.69 0.69 0.70 0.69 0.70 0.70 0.69 0.70	0.91 0.80 0.83 0.83 0.83 0.71 0.80 0.75 0.83 0.70 0.70 0.70 0.70 0.77 0.77 0.77 0.7
470 471 472 473 474 475 476 477 478 479 480 481 482 483 484 485	0.61 0.62 0.61 0.64 0.70 0.71 0.57 0.60 0.78 1.08 1.01 1.13 0.93 0.73 0.90 0.71	0.75 0.90 0.75 0.85 0.76 0.77 0.92 0.92 0.99 0.86 0.88 0.89 1.08 0.62 0.80	0.73 0.72 0.73 0.64 0.81 0.75 0.78 0.78 0.80 0.75 1.12 0.93 1.12 0.93 0.80	0.81 1.03 0.81 0.82 0.80 0.71 0.91 0.96 0.81 1.04 0.79 0.93 0.99 0.74 0.76 0.86		543 544 545 546 547 548 549 550 551 553 554 555 556 557 558 559 560	0.67 0.43 0.72 0.24 0.38 0.72 0.45 0.76 1.25 1.09 0.55 0.55 0.87 0.97	0.76 0.85 0.80 1.11 0.96 0.84 0.84 0.93 1.12 0.93 0.80 0.80 0.90 0.78	0.77 0.60 0.65 0.45 0.50 0.65 0.57 0.95 1.32 1.03 1.46 1.03 0.70 0.70 0.99 1.05 0.60	

PAGE 5 OF 7

ZIP	GAAF For Surgical DRGs		GAAF For Non- Surgical DRGs		ZIP	GAAF For Surgical DRGs		GAAF For Non- Surgical DRGs	
Code	Room & Board	Ancillary	Room & Board	Ancillary	Code	Room & Board	Ancillary	Room & Board	Ancillary
565 566 567 570 571 572 573 574 575 576 577 580 581 582 583 584 585 586 587 588 590 591 592 593 594 595 596 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 620 622 623 624 625 626 627 628 629 630 631 633 634 635 636 637 638	0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75	0.63 0.63 0.63 0.63 0.63 0.63 0.81 0.94 0.88 0.89 0.79 0.79 0.79 0.87 0.95 0.54 0.81 0.81 0.91 1.02 0.66 1.02 0.66 0.80 0.91 1.20 1.28 1.15 1.29 1.29 1.07 0.95 1.06 0.80 0.72 1.23 1.18 1.09 1.29 1.09 1.21 1.09 1.29 1.09 1.20 1.21 1.29 1.29 1.29 1.29 1.29 1.29 1.29	0.81 0.81 0.81 0.86 0.56 0.56 0.68 0.68 0.68 0.75 0.75 0.75 0.75 0.80 0.87 0.77 0.71 0.71 0.90 0.82 0.72 0.82 0.72 0.81 0.79 1.24 1.27 1.27 1.27 1.27 1.27 1.27 1.27 1.27	0.65 0.65 0.65 0.65 1.18 0.78 0.78 0.78 0.78 0.78 0.78 0.79 0.74 0.74 0.74 0.77 0.77 0.81 0.67 0.67 0.67 0.67 0.67 0.77 1.32 1.41 1.41 1.35 1.19 1.47 1.35 1.35 1.35 1.35 1.19 1.47 1.35 1.35 1.35 1.19 1.47 1.35 1.35 1.35 1.19 1.41 1.41 1.41 1.35 1.19 1.42 0.98 0.75 0.92 0.84 1.21 1.08 1.06 1.06 1.02 0.81 0.98 0.85 1.02 1.04 0.96 0.92 1.13 1.40 0.96 0.92 1.13 1.40 0.91 0.91 0.91 0.91 0.92 0.81 0.92 0.81 0.96 0.92 1.13 1.40 0.96 0.92 1.13 1.40 0.96 0.92 1.11 1.11	639 640 641 644 645 646 647 648 650 651 653 6554 6556 666 667 667 678 670 671 672 677 678 679 680 681 683 684 685 687 688 689 691 701 703 704 705 706 707 711 713 714 716 718 719	0.48 0.77 0.92 0.72 0.62 0.61 0.72 0.72 0.72 0.74 0.75 0.74 0.74 0.75 0.74 0.75 0.71 0.73 0.73 0.73 0.73 0.73 0.73 0.66 0.57 0.65 0.73 0.73 0.66 0.57 0.67 0.73 0.73 0.73 0.74 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.77	0.98 1.09 1.33 1.05 1.24 1.04 1.14 1.33 0.96 0.96 0.79 0.97 0.87 0.97 0.97 0.97 0.97 0.97 0.97 1.19 1.39 0.79 1.01 0.75 0.64 0.98 0.79 0.97 0.98 1.23 0.98 1.23 0.98 0.89 0.89 0.89 0.89 0.89 0.89 0.89	0.58 0.89 1.01 0.80 0.72 0.85 1.01 0.80 0.72 0.85 1.01 0.80 0.75 0.71 0.80 0.85 0.75 0.71 0.80 0.85 0.75 0.71 0.80 0.80 0.75 0.71 0.80 0.80 0.75 0.75 0.71 0.80 0.61 0.80 0.75 0.75 0.75 0.75 0.77 0.62 0.62 0.67 0.67 0.67 0.67 0.67 0.67 0.69 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.77 0.62 0.73 0.73 0.73 0.73 0.73 0.73 0.73 0.73 0.75 0.67 0.67 0.67 0.67 0.67 0.67 0.67 0.67 0.67 0.67 0.67 0.67 0.69 0.75 0.67 0.67 0.67 0.67 0.67 0.69 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.67 0.67 0.67 0.67 0.67 0.67 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.75 0.67 0.67 0.67 0.75 0.77 0.75 0.76 0.77 0.75 0.75 0.76 0.77 0.76 0.77 0.77 0.76 0.89 0.70	1.11 1.21 1.41 0.98 0.98 0.99 1.05 1.17 1.41 0.94 0.86 0.86 1.02 1.02 0.83 0.98 1.36 1.48 0.74 0.77 0.80 0.85 0.85 0.85 0.85 1.42 1.42 0.99 0.99 0.99 0.99 0.99 0.99 0.99 0.9

PAGE 6 OF 7

ZIP		r Surgical Gs		or Non-		ZIP		r Surgical Gs		or Non-
Code	Room & Board	Ancillary	Room & Board	Ancillary	•	Code	Room & Board	Ancillary	Room & Board	Ancillary
720 721 722 723 724 725 726 727 728 729 730 731 733 734 735 736 737 738 739 740 741 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 772 773 774 775 776 777 778 779 780 781 782 783	0.49 0.49 0.48 0.38 0.37 0.48 0.58 0.30 0.47 0.63 0.57 0.68 0.57 0.69 0.47 0.43 0.84 0.59 0.47 0.43 0.84 0.59 0.49 0.47 0.49 0.49 0.47 0.49 0.49 0.49 0.49 0.49 0.49 0.49 0.49	0.79 1.03 1.05 0.52 0.70 0.78 0.86 1.22 0.93 1.03 1.27 0.92 1.19 1.13 1.12 1.05 1.12 1.05 1.12 1.19 1.13 1.11 0.79 0.89 0.65 0.83 1.05 1.19 0.64 0.83 1.24 1.11 1.11 0.79 0.91 0.89 1.44 1.20 1.06 1.09 1.45 0.78 1.06 0.98 1.11 1.11 1.11 0.79 0.91 0.81 1.10 1.12 1.19 1.13 1.16 1.19 1.18 1.33 1.24 1.51 0.92 0.81 1.09 1.123	0.74 0.64 0.63 0.61 0.65 0.61 0.80 0.55 0.48 0.66 0.51 0.57 0.77 0.77 0.77 0.77 0.77 0.78 0.63 0.44 0.71 0.68 0.71 0.70 0.63 0.44 0.71 0.70 0.68 0.71 0.74 0.74 0.74 0.74 0.74 0.74 0.74 0.74	0.91 1.06 1.26 0.77 0.75 0.75 0.75 0.75 1.16 1.02 0.88 1.31 1.05 1.16 1.05 0.85 0.81 1.05 0.85 0.81 1.05 1.16 1.05 1.16 1.05 1.16 1.05 1.16 1.05 1.16 1.05 1.16 1.05 1.16 1.05 1.16 1.17 1.17 1.18 1.18 1.18 1.18 1.18 1.18		790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 816 820 821 822 823 824 825 827 828 829 830 831 832 834 835 836 837 838 840 841 842 843 844 845 846 847 850 852 853 855 856 857 859	0.53 0.57 0.53 0.84 0.84 0.40 0.58 0.52 1.11 1.27 1.27 1.09 1.27 1.01 1.01 1.00 1.00 1.00 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.74 0.86 1.10 1.10 1.10 1.10 1.10 1.20 1.24 0.87 1.24 0.87	1.02 1.15 1.02 1.43 0.94 0.95 0.94 1.98 1.31 1.48 1.31 1.02 1.02 1.02 1.02 1.31 1.31 1.00 1.00 0.93 0.93 0.93 0.93 1.05 1.05 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0	0.79 0.64 0.79 0.82 0.82 0.42 0.64 1.16 1.29 1.09 1.09 1.09 1.09 0.87 0.84 0.84 0.84 1.11 1.11 0.85 0.85 0.77 0.77 0.77 0.77 0.77 0.77 0.77 0.7	0.93 1.35 0.93 1.98 1.98 0.77 1.46 0.98 2.50 2.50 1.35 1.35 1.35 1.10 1.10 1.10 1.10 1.10 1.10 1.10 1.1
784 785 786 787 788 789	0.60 0.83 0.51 0.68 0.42 0.51	1.23 1.36 0.92 1.04 0.71 0.92	0.88 0.97 0.51 0.79 0.48 0.51	1.53 1.71 1.05 1.19 0.86 1.05		860 863 864 865 870 871	0.92 0.92 0.92 0.92 0.86 0.86	1.18 1.18 1.18 1.18 1.03 1.03	0.91 0.91 0.91 0.91 1.00	1.12 1.12 1.12 1.12 1.12 0.94 0.94

PAGE 7 OF 7

ZIP	1	r Surgical	i	For Non- al DRGs	-	ZIP		r Surgical RGs	ľ	For Non- al DRGs
Code	Room & Board	Ancillary	Room & Board	Ancillary	•	Code	Room & Board	Ancillary	Room & Board	Ancillary
872	0,86	1.03	1.00	0.94	_	938	1.01	1.30	1.07	1.17
873	0.81	0.67	0.85	0.74		939	1.57	1.41	2.19	1.53
874	0.81	0.67	0.85	0.74		940	2.68	1.58	2.76	1.59
875	0.77	0.97	0.76	0.97		941	2.61	1.57	2.61	1.65
877	0.77	0.97	0.76	0.97		942	2.03	2.07	2.06	2.21
878	0.65	1.01	0.67	1.24		943	3.03	1.65	2.59	1.71
879	0.65	1.01	0.67	1.24		944	3.03	1.65	2.59	1.71
880	0.65	1.01	0.67	1.24		945	2.27	1.79	2.11	1.55
881	0.84	1.18	0.87	1.32		946	2.64	1.87	2.65	1.76
882	0.84	1.18	0.87	1.32		947	2.64	1.87	2.65	1.76 1.76
883 884	0.84	1.18	0.87 0.76	1.32 0.97		948 949	2.64 2.99	1.87 1.41	2.65 2.80	1.76
885	0.77 1.11	0.97 1.98	1,16	2.50		950	1.97	1.98	2.00	1.81
889	0.65	1.76	0.78	1.99		951	2.18	1.55	2.13	1.53
890	0.86	1.81	1.01	1.98		952	2.25	1.54	2.03	1.23
891	0.65	1.76	0.78	1.99		953	2.65	3.63	2.13	3.03
893	0.89	1.41	1.19	1.42		954	1.38	1.39	1.40	1.10
894	0.89	1.41	1.19	1.42		955	1.02	1.35	1.08	1.22
895	0.82	1.61	1.03	1.49		956	2.03	2.07	2.06	2.21
897	0.89	1.41	1.19	1.42		957	2.03	2.07	2.06	2.21
898	0.89	1.41	1.19	1.42		958	3.01	2.34	2.49	1.98
900	2.07	1.90	2.09	1.89		959	1.37	1.18	1.26	1.41
901 902	2.07 1.99	1.90 1.84	2.09 1.68	1.89 2.00		960 961	1.87 1.27	3.22 1.55	1.55 1.13	2.62 1.40
903	2.24	2.08	2.41	2.36		967	0.97	0.77	0.99	0.85
904	2.24	2.08	2.41	2.36		968	1.07	0.97	1.22	1.11
905	2.70	1.48	2.78	1.46		969	0.57	0.33	0.54	0.36
906	1.35	1.37	1.39	1.65		970	1.02	0.76	1.06	1.42
907	1.32	1.61	1.43	1.98		971	0.74	1.05	0.96	1.00
908	1.32	1.61	1.43	1.98		972	0.91	1.00	1.03	1.09
910	1.42	1.47	1.53	1.62		973	0.92	0.75	0.94	0.78
911	1.42	1.47	1.53	1.62		974	0.74	0.91	0.95	0.87
912	1.42	1.47 1.75	1.53 1.78	1.62 1.82		975 976	1,14 0.87	0.90 0.72	1.06 0.81	0.95 0.86
913 914	1.74 1.64	1.75	1.70	1.53		977	0.87	0.72	0.81	0.86
915	1.64	1.41	1.64	1.53		978	0.87	0.72	0.81	0.86
916	1.64	1.41	1.64	1.53		979	0.87	0.72	0.81	0.86
917	1.80	1.80	1.61	1.83		980	0.94	0.79	1.10	0.76
918	1.80	1.80	1.61	1.83		981	1.22	1.04	1.19	0.95
919	1.65	1.47	1.43	1.22		982	0.91	1.06	1.10	0.88
920	1.79	1.35	1.76	1.35		983	0.80	0.79	0.92	0.75
921	1.94	1.85	1.76	1.73		984	0.72	1.20	0.67	0.79
922	1.74	2.11	2.06	2.32 1.42		985	1.10	1.08	1.18	0.85
923 924	1.52 1.33	1.42 1.35	1.32 1.37	1.42		986 988	0.82 0.83	0.81 0.89	0.94 1.05	0.83 0.72
925	1.33	1.35	1.37	1.44		989	0.83	0.89	1.05	0.72
926	1.39	1.81	1.47	1.88		990	0.80	0.92	0.74	0.83
927	1.86	2.65	1.88	2.62		991	0.80	0.92	0.74	0.83
928	1.38	1.90	1.46	1.98		992	0.80	0.92	0.74	0.83
930	1.16	1.58	1.23	1.52		993	0.94	0.94	1.01	0.91
931	1.53	2.16	1.50	2.15		994	0.94	0.94	1.01	0.91
932	0.84	1.17	0.97	1.19		995	1.33	1.01	1.38	1.02
933	1.06	1.20	1.23	1.15		996	1.33	1.01	1.38	1.02
934	1.85	2.36	1.85	2.78		997	1.33	1.01	1.38	1.02
935 936	1.18	1.51	1.22	1.64		998	0.93	0.96	1.35	0.72
	1.01	1.30	1.07	1.17		999	0.93	0.96	1.35	0.72

TABLE O. — SKILLED NURSING FACILITY/SUB-ACUTE INPATIENT FACILITY CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 1 OF 4

ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF	ZIP . Code	GAAF
Nationwide Average	1.00	070 071	1.04 0.86	149 150	0.81 1.03	219 220	0.89 0.92
002 005	0.95 0.88	072 073 074	0.67 0.86 0.96	151 152 153	1.02 1.25 1.13	221 222 223	0.87 0.87 1.06
006	0.00	075	0.50	154	1.05	224	0.73
007	0.67	076	1.00	155	0.90	225	0.73
008	0.67	077	0.94	156	1.20	226	0.72
009	0.88	078	0.77	157	0.95	227	0.63
010	0.92	079	1.11	158	0.69	228	0.76
011	0.69	080	0.94	159	1.16	229	0.91
012	0.96	081	1.22	160	0.94	230	0.70
013	0.85	082	0.98	161	1.18	231 232	0.82 0.83
014 015	1.06 1.02	083 084	0.67 0.59	162 163	0.97 1.13	232	0.64
016	0.97	085	1.05	164	0.72	234	0.86
017	1.14	086	0.88	165	1.14	235	0.83
018	1.06	087	0.89	166	1.08	236	0.82
019	1.00	088	0.90	167	0.64	237	0.72
020	1.05	089	1.85	168	1.08	238	0.72
021 022	1.11 2.20	100 101	0.99 0.99	169 170	0.68 0.95	239 240	0.68 0.83
023	0.91	102	0.99	171	0.92	241	0.00
024	1.04	103	0.95	172	0.83	242	0.72
025	0.95	104	0.92	173	0.88	243	1.04
026	1.03	105	0.88	174	0.74	244	0.61
027	1.03	106	0.86	175	0.71	245 246	0.85
028 029	0.81 0.82	107 108	0.74 0.96	176 177	0.96 0.77	246 247	1.41 1.77
030	0.99	109	0.70	178	0.75	248	0.61
031	0.87	110	1.19	179	0.78	249	1.09
032	0.73	111	0.66	180	0.96	250	0.68
033	0.82	112	0.89	181	1.12	251	0.89
034 035	0.77 0.79	113 114	0.91 0.90	182 183	0.87 0.73	252 253	0.93 1.04
036	0.79	115	0.88	184	0.75	253 254	1.04
037	0.92	116	0.75	185	1.24	255	0,80
038	0.95	117	0.93	186	0.72	256	1.12
039	1.53	118	1.07	187	0.96	257	1.03
040	0.95	119	0.87	188	1.56	258	0.71
041 042	0.85 0.81	120 121	0.85 0.68	189 190	1.07	259 260	0.83 0.96
043	0.75	122	0.70	191	1.49	261	1.06
044	0.96	123	0.81	192	1.49	262	0.77
045	0.70	124	0.90	193	1.02	263	1.01
046	0.77	125	0.77	194	1.24	264	0.56
047	1.05	126	0.85	195	0.69	265	0.96
048 049	0.90 0.94	127 128	0.67 0.68	196 197	0.83 0.67	266 267	0.83 0.63
050	1.00	129	0.75	198	0.83	268	0.78
051	0.63	130	0.76	199	0.74	270	0.58
052	0.74	131	0.72	200	1.23	271	0.90
053	0.68	132	0.76	201	1.06	272	0.70
054 055	1.06	133 134	0.55 0.64	202 203	1.23	273 274	1.03
056	0.55	135	0.66	204	1.23	275	0.68
057	0.78	136	0.60	205	1.23	276	0.77
058	0.55	137	0.69	206	1.02	277	0.91
059	0.79	138	0.66	207	0.84	278	0.68
060 061	0.93	139 140	0.66 0.81	208 209	1.01 1.14	279 280	0.71 0.68
061 062	1.00 0.91	140	0.81	209	1.02	281	0.88
063	0.89	142	0.76	211	0.85	282	0.91
064	1.00	143	0.68	212	0.98	283	0.62
065	1.10	144	0.65	214	1.09	284	0.80
066	1.10	145	0.71	215 216	0.61	285 286	0.75 0.92
067 068	0.91 1.01	146 147	0.76 0.59	217	0.70	287	0.92
069	1.14	148	0.66	218	0.81	288	0.82
- • •			•		•		-

TABLE O. — SKILLED NURSING FACILITY/SUB-ACUTE INPATIENT FACILITY CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE PAGE 2 OF 4

ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF
289	0.47	363	0.70	436	1.16	505	0.68
290	0.47	364	0.70	437	0.93	506	0.70
291	0.68	365	0.84	437 438	0.75	507	1.38
292	1.06	366	0.78	439	1.15	508	0.62
293	0.68	367	0.67	440	1.02	509	1.15
294	1.03	368	0.84	441	1.40	510	0.64
295	0.83	369	0.72	442	0.86	511	1.33
296	0.81	370	1.01	443	1.03	512	0.51
297	0.97	371	0.76	444	1.03 0.98	513	0.51 0.88
297 298	0.57	372	1.26	445	1.14 0.87	514	0.60
299	1.09	373	0.69	446	0.87	515	1.15
300	0.81	374	0.82	447	1.04	516	0.62
301 302	0.76	375	1.05	448 449	0.97 0.75	520	1.17 0.56
303	0.72 0.99	376 377	1.14 0.74	450	0.73	521 522	0.83
304	0.48	378	0.74	451	0.81	523	0.85
305	0.84	379	1.21	452 453	1.07	524	1.07
306	0.84	380	0.61	453	0.83	525	1.07 0.93
307	0.92	381	1.05	454	0.97 0.99	526	1.13
308	0.57	382	1.15	455	0.99	527	0.97
309	0.76	383	0.86	456	0.85	528	1.28
310	0.62	384	0.67	457 458	0.92 0.84	530 531	0.88 0.80
311 312	0.99 0.72	385 386	0.87 1.20	458 459	1.07	532	0.80
313	0.72	387	1.07	460	0.98	534	0.91 0.74
314	1.14	388	0.99	461	0.95	535	0.81
315	0.71	389	1.02	462	0.95 0.99	535 537	0.78
316	0.71	390	0.66	463	1.10	538	0.77
317 318	0.56	391	0.84	464	1.30	539	0.66
318	0.50	392	0.87	465	1.02	540	0.66
319	0.63	393	0.52	466	0.94	541 542	0.69 0.71
320	0.82 0.84	394 395	0.84 1.34	467 468	0.86	542 543	0.71
321	0.04	396	0.68	469	0.91 0.96	544	0.69
322 323	0.89	397	0.95	470	0.81	545	0.69
324	0.76	399	0.99	471	0.88	546	0.64
324 325 326	1.06	400	0.85	472	1 1 1 0	547	0.75
326	1.14	401	0.55	473	0.91 0.76	548	0.71
327	0.87	402	1.07	474	0.76	549	0.77
328	1.24	403	0.91	475	0.79 0.68	550	0.66 0.84
329 330	1.07 1.08	404 405	0.90 0.92	476 477	1.17	551 553	0.84
331	1.29	406	0.64	478	1.03	554	0.72
332	1.08	407	0.81	479	1.03 0.82	555	0.72
333	1.17	408	1.10	480	1.01	556	0.67
334	0.98	409	0.69	481	0.83	557	0.66
333 334 335	1.19	410	1.15	482	0.89	558	0.63
336 337	1.08	411	0.89	483	1.03 0.82	559 560	0.63 0.58 0.55 0.52
337	1.07	412	0.54	484	1.05	560	0.55
338 339 341	0.90 1.11	413 414	0.55 0.85	485 486	0.91	561 562	0.52
341	0.93	415	0.83	487	0.65	563	0.63
342	1.14	416	1.33	488	0.88	564	0.66
344	0.90	417	0.41	489	0.77	565	0.60
346	0.97	418	0.61	490	0.72	566	0.62
347	0.90	420	0.89	491	0.95	567	0.65
349	1.29	421	0.66	492	0.85	570 571	0.55
350 351	0.79 0.90	422 423	0.56 0.90	493 494	0.83 0.71	571 572	0.64 0.62
351 352	1.05	423 424	0.96	494 495	0.89	572 573	0.62
354	0.80	425	1.28	496	0.86	574	0.55
355	0.83	426	0.48	497	0.82	575	0.69
356	0.76	427	0.63	498	0.56	576	0.56
357	0.94	430	0.82	499	0.61	577	0.55
358	0.95	431	0.81	500	1.00	580 581	0.63 1.16
359 360	0.77 0.89	432 433	1.01	501 502	0.81 0.69	581 582	0.76
361	0.87	434	0.77	503	1.15	583	0.76
362	0.75	435	0.95	504	0.95	584	0.61
	•		-		-		-

TABLE O. — SKILLED NURSING FACILITY/SUB-ACUTE INPATIENT FACILITY CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE PAGE 3 OF 4

ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF
585 586 587 589 591 592 594 595 596 602 603 604 605 606 607 608 601 611 612 613 614 615 617 618 619 622 623 624 625 627 628 631 633 634 645 646 647 649 650 651 653 654 655 655 655 655 655 655 655	1.21 0.59 0.61 0.93 0.62 1.12 0.45 0.57 0.77 0.71 1.03 0.79 0.76 0.73 1.16 1.39 1.73 1.76 1.17 1.12 1.48 0.98 1.44 0.91 1.03 0.86 1.18 1.08 0.87 0.92 1.27 0.89 1.00 0.90 1.09 0.81 1.30 0.87 0.82 1.04 1.42 1.35 0.79 1.35 1.00 0.90 1.09 0.81 1.30 0.87 0.82 1.27 0.89 1.00 0.90 1.09 0.81 1.35 0.79 1.35 1.00 0.90 1.09 0.81 1.35 0.79 1.35 1.00 0.92 1.27 0.89 1.01 1.35 1.01 1.35 1.101 1.35 1.101 1.35 1.101 1.35 1.101 1.35 1.101 1.35 1.101 1.35 1.101 1.35 1.101 1.35 1.101 1.35 1.101 1.35 1.101 1.35 1.101 1.35 1.101 1.35 1.101 1.35 1.101 1.35 1.101 1.35 1.311 1.33	660 661 662 664 665 666 667 668 669 670 671 672 673 674 675 676 680 681 683 684 685 686 687 688 689 690 691 700 701 703 704 705 706 707 707 708 710 711 712 713 714 716 717 718 719 720 721 722 723 724 725 726 737 738 739 730 731 738 739 730 731 738 739 739 739 739 739 739 739 739 739 739	1.12 1.48 1.04 0.66 0.78 0.72 1.16 0.77 0.99 0.81 0.96 1.84 1.07 0.96 1.58 0.52 0.90 1.31 0.87 1.48 0.64 0.59 1.13 0.52 0.62 0.87 0.91 0.49 0.54 0.73 0.76 1.98 2.26 1.09 1.70 1.78 1.52 1.09 1.70 1.78 1.52 1.09 1.70 1.78 1.52 1.09 1.70 1.78 1.52 1.09 1.70 1.78 1.52 1.09 1.70 1.78 1.52 1.09 1.70 1.78 1.52 1.09 1.70 1.78 1.52 1.09 1.70 1.78 1.52 1.09 1.70 1.70 1.78 1.51 1.31 0.69 0.84 0.89 0.85 0.88 0.96 0.87 0.91 0.90 0.92 1.51 1.13 0.69 0.84 0.89 0.75 1.36 0.77 0.80 1.34 0.85 0.88 0.98 1.04 0.98 1.07 1.38 0.95 1.34 0.77 1.38 0.998 1.07 1.38 0.998 1.070 1.70 0.704 1.31 1.31 0.998	741 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 769 761 762 763 764 765 766 767 768 769 770 772 773 774 775 778 779 780 781 782 783 784 785 786 787 788 789 790 781 782 783 784 785 786 787 788 789 790 781 782 783 784 785 786 787 788 789 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 800 801 802 803 804 806 807 808 809 810 811	1.64 0.89 0.89 0.83 1.11 0.91 1.05 0.88 1.22 0.92 1.45 1.45 0.82 0.95 1.79 1.18 0.58 0.71 0.58 0.71 0.58 0.91 1.09 0.88 0.71 1.09 0.88 0.71 1.10 1.30 1.53 1.53 1.44 1.01 1.30 1.52 1.36 1.23 1.03 1.25 0.71 1.16 0.69 0.85 0.77 1.16 0.69 0.85 0.77 1.16 0.69 0.85 0.77 1.16 0.69 0.85 0.77 1.16 0.69 0.85 0.77 1.16 0.69 0.85 0.77 1.16 0.69 0.85 0.77 1.16 0.69 0.85 0.77 1.16 0.69 0.85 0.77 1.16 0.69 0.85 0.77 1.16 0.69 0.85 0.77 1.16 0.69 0.85 0.77 1.16 0.69 0.85 0.77 1.16 0.69 0.85 0.77 1.16 0.69 0.85 0.77 1.16 0.69 0.85 0.77 1.17 0.78 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0.79	812 813 814 815 820 821 822 823 824 825 826 827 828 830 831 832 833 834 844 845 840 841 842 843 844 845 850 852 853 856 857 850 857 850 851 852 853 854 855 856 857 856 857 856 857 857 858 869 869 869 869 869 869 869 869 869 86	0.83 1.09 0.88 1.31 0.73 0.94 0.94 0.94 0.59 0.67 0.83 0.67 0.69 0.71 0.91 0.71 0.91 0.71 0.91 1.18 1.28 0.80 1.65 1.23 1.31 0.88 1.194 0.57 1.25 1.25 0.61 0.89 1.194 0.57 1.25 1.25 0.61 0.89 1.18 0.77 0.77 0.89 1.94 0.57 1.25 1.25 0.61 0.89 1.135 1.26 1.35 1.39 1.39 1.39 1.39 1.39 1.39 1.39

TABLE O. — SKILLED NURSING FACILITY/SUB-ACUTE INPATIENT FACILITY CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE PAGE 4 OF 4

ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF
903	1.41	927	1.67	951	1.50	979	0.86
904	1.23	928	1.18	952	1.35	980	0.90
905	1.82	930	1.39	953	1.43	981	1.21
906	1.19	931	1.73	954	1.42	982	0.79
907	1.01	932	1.20	955	0.60	983	0.81
908	1.24	933	1.28	956	0.97	984	0.81
910	1.16	934	1.31	957	0.97	985	0.96
911	0.79	935	1.66	958	1.77	986	0.82
912	1.58	936	0.72	959	1.11	988	0.89
913	1.53	937	1.05	960	1.40	989	0.91
914	1.24	938	1.05	961	1.19	990	0.62
915	1.55	939	1.02	967	1.06	991	0.67
916	0.69	940	2.00	968	1.03	992	0.82
917	1.22	941	2.13	969	1.43	993	1.00
918	0.56	942	0.97	970	0.80	994	1.08
919	1.06	943	1.05	971	0.99	995	2.24
920	1.32	944	2.00	972	0.97	996	0.82
921	1.63	945	1.55	973	0.82	997	1.15
922	1.49	946	1.32	974	0.80	998	1.23
923	1.12	947	1.36	975	0.81	999	1.23
924	1.53	948	0.87	976	1.18		
925	1.11	949	1.31	977	1.01		
926	1.78	950	1.42	978	1.11		

TABLE P. — OUTPATIENT FACILITY CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE PAGE 1 OF 4

ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF
Nationwide Average	1.00	071 072 073	0.90 0.89 0.90	151 152 153	1.00 1.00 0.84	222 223 224	0.90 0.90 0.92
002	0.94	074	0.88				
				154	0.84	225	0.92
005	0.80	075	0.88	155	0.81	226	0.72
006	0.40	076	0.88	156	0.87	227	0.72
007	0.40	077	1.12	157	0.80	228	0.72
800	0.40	078	0.87	158	0.75	229	0.72
009	0.40	079	0.87	159	0.81	230	0.92
010	0.81	080	1.11	160	0.87	231	0.92
011	0.81	081	1,11	161	0.87	232	0.92
012	0.70	082	1.11	162	0.87	233	0.82
013	0.91	083	1.11	163	0.75	234	0.82
014	0.91	084	1.11	164	0.84	235	0.82
015	1.00	085	1.12	165	0.84	236	0.82
016	0.90	086	1.12	166	0.85	237	0.82
017	1.03	087	1.01	167	0.75	238	0.92
018	0.80	088	0.98	168	0.80	239	0.74
019	0.80	089	1,12	169	0.73	240	0.74
020	0.87	100	0.86	170	0.79	241	
021	0.91	101	0.86	170	0.79	241	0.76
022	1.08	102	0.86	172			0.76
023					0.77	243	0.76
023	0.87	103	0.89	173	0.77	244	0.72
	0.91	104	0.89	174	0.77	245	0.74
025	0.77	105	0.85	175	0.77	246	0.76
026	0.77	106	0.85	176	0.65	247	0.67
027	0.87	107	0.85	177	0.73	248	0.67
028	0.83	108	0.85	178	0.73	249	0.67
029	0.83	109	1.00	179	0.67	250	0.67
030	0.91	110	0.89	180	0.77	251	0.67
031	0.91	111	0.89	181	0.77	252	0.67
032	0.79	112	0.90	182	0.83	253	0.67
033	0.79	113	0.90	183	0.86	254	0.74
034	0.79	114	0.90	184	0.83	255	0.67
035	0.79	115	0.80	185	0.83	256	0.67
036	0.79	116	0.80	186	0.83	257	0.67
037	0.79	117	0.80	187	0.83	258	0.67
038	0.94	118	0.80	188	0.83	259	0.67
039	0.78	119	0.80	189	1.24	260	0.67
040	0.75	120	0.68	190	1.48	261	0.74
041	0.64	121	0.68	191	1.27	262	0.74
042	0.75	122	0.68	192	1.27	263	0.74
043	0.78	123	0.68	193	1.24	264	0.74
044	0.80	124	0.68	194	1.24	265	0.67
045	0.80	125	0.75	195	0.67	266	0.67
046	0.80	126	0.75	196	0.67	267	0.74
047	0.78	127	0.75	197	0.67	268	0.74
048	0.80	128	0.66	198	0.67	270	0.63
049	0.78	129	0.66	199	0.76	271	0.60
050	0.73	130	0.60	200	0.91	272	0.63
051	0.73	131	0.60	201	0.86	273	0.63
052	0.73	132	0.60	202	0.91	274	0.63
053	0.73	133	0.67	203	0.91	275	0.72
054	0.69	134	0.67	204	0.91	276	0.72
055	0.80	135	0.67	205	0.91	277	0.77
056	0.73	136	0.67	206	0.65	278	0.72
057	0.73	137	0.64	207	0.66	279	0.72
058	0.73	138	0.64	208	0.72	280	0.72
059	0.73	139	0.64	209	0.72	281	0.72
060	0.88	140	0.54	210	0.54	282	0.73
061	0.83	141	0.54	211	0.54	283	0.72
062	0.88	142	0.54	212	0.54	284	0.72
063	0.88	143	0.54	214	0.54	285	0.72
064	0.91	144	0.56	215	0.49	286	0.75
065	0.88	145	0.56	216	0.50	287	0.75
066	0.88	146	0.56	217	0.49	288	0.75
067	0.91	147	0.54	218	0.50	289	0.75
068	0.94	148	0.56	219	0.54	290	0.82
069	0.94	149	0.56	220	0.86	291	0.82
070	0.89	150	1.00	221	0.86	292	0.76

TABLE P. — OUTPATIENT FACILITY CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE PAGE 2 OF 4

ZIP		ZIP		ZIP		ZIP	
Code	GAAF	Code	GAAF	Code	GAAF		GAAF
Code		Code		Code		Code	
293	0.87	368	1.01	442	0.84	512	0.72
294	0.89	369	1.01	443	0.84	513	0.72
295 296 297	0.89	370	0.83	444	0.80	514	0.72
296	0.78	371	0.83	445	0.80	515	0.72
297	0.87	372	0.85	446	0.76	516	0.72
298	0.88	373	0.79	447	0.64	520	0.71
299	0.88	374	0.79	448	0.76	521	0.71
300	0.88	375	0.81	449	0.78	522	0.71
301 302	0.86	376	0.79	450	0.77 0.77	523	0.71
302	0.86	377	0.79	451	0.77	524	0.71
303 304	0.86	378	0.79	452	0.73	525	0.71
304	0.90	379	0.81	453	0.81	526	0.71
305	0.83	380	0.82	454	0.86	527	0.71
306	0.83	381	0.81	455	0.81	528	0.71
307	0.83	382	0.72	456	0.77	530	0.91
308 309 310	0.83	383	0.72	457	0.76	531	1.00
309	0.83	384	0.83	458	0.72	532	0.97
310	0.86	385	0.79	459	0.73	534	0.90
311	0.86	386	0.76	460	0.76	535	0.82
311 312	0.86	387	0.73	461	0.76	537	0.80
313	0.90	388	0.73	462	0.72	538	0.82
314	0.90	389	0.73	463	0.82	539	0.84
315	0.90	390	0.70	464	0.82	540	0.93
316	0.82	391	0.70	465	0.84	541	0.74
317	0.82	392	0.70	466	0.84	542	0.74
318	0.82	393	0.70	467	0.73	543	0.66
319	0.82	394	0.75	468	0.73	544	0.75
320 321	1.17	395	0.75	469	0.77	545	0.93
321	1.02	396	0.75	470	0.76	546	0.82
322 323	1.15	397	0.73	471	0.76	547	0.80
323	1.10	399	0.86	472	0.76	548	0.93
324 325 326 327	1.10	400	0.96	473	0.76	549	0.67
325	1.10	401	0.96	474	0.76	550	0.98
326	0.98	402	0.90	475	0.77	551	1.00
327	1.19	403	0.75	476	0.77	553	1.06
328	1.13	404	0.75	477	0.77	554	0.95
329	1.26	405	0.79	478	0.76	555	1.06
330	1.28	406	0.79	479	0.77	556	0.83
330 331 332 333 334 335	1.11	407	0.83	480	0.97	557	0.83
332	1.11	408	0.83	481	0.96	558	0.79
333	1.42	409	0.83	482	0.97 0.99	559	0.76
334	1.14	410	0.75	483	0.99	560	0.74
335	1.19	411	0.83	484	0.89	561	0.79
336	1.18	412	0.83	485	0.89	562	0.79
337	1.19	413	0.83	486	0.81	563	0.76
338	1.02	414	0.83	487	0.81	5 64	0.76 0.83
339	1.12	415	0.83	488	0.79	565	0.83
341 342 344 346	1.34	416	0.83	489	0.79	566	0.83
342	1.06	417	0.83	490	0.79	567	0.83
344	0.92	418	0.83	491	0.79	570	0,65
346	1.06	420	0.74	492	0.79	571	0.68
347	1.19	421	0.94	493	0.70	572	0.65
349	1.23	422	0.74	494	0.70	573	0.65
350	1.00	423	0.74	495	0.70	574	0.65
351	1.00	424	0.74	496	0.70	575	0.65
352	1.11	425	0.74	497	0.70	576	0.65
354	1.00	426	0.74	498	0.82	577	0.65
355	1.00	427	0.74	499	0.82	580	0.74
356	0.94	430	0.79	500	0.74	581	0.86
357	0.94	431	0.79	501	0.74	582	0.74
358	0.94	432	0.74	502	0.74	583	0.74
359	1.09	433	0.72	503	0.74	584	0.74
360	1.01	434	0.82	504	0.71	585	0.74
361	1.01	435	0.82	505	0.72	586	0.74
362	1.09	436	0.82	506	0.71	587	0.74
363	1.01	437	0.76	507	0.71	588 500	0.74
364	1.01	438	0.76	508	0.72	590	0.68
365 366	0.81	439	0.76	509 510	0.74 0.72	591 592	0.84 0.68
366	0.81	440	0.83	510 511		592 593	
367	1.01	441	0.80	511	0.75	593	0.68

TABLE P. — OUTPATIENT FACILITY CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE PAGE 3 OF 4

	 -						
ZIP	GAAF	ZIP	GAAF	ZIP	GAAF	ZIP	GAAF
Code	0.0	Code	0,4,1	Code		Code	
594	0.68	670	0.94	752	1.08	826	0.92
595	0.68	671	0.94	753	1.08	827	0.92
596	0.68	672	1.11	754	1.10	828	0.92
597	0.68	673	0.83	755	1.10 1.10	829	0.92
598 599	0.68 0.68	674 675	0.80 0.80	756 757	1.10	830 831	0.92 0.92
600	1.22	676	0.80	758	1.10	832	0.87
601	1.25	677	0.80	758 759	1.10 1.10	833	0.88
602	1.15	678	0.80	760	1.18	834	0.87
603	1.15 1.28	679 680	0.80 0.92	761 762	1.18 1.08	835 836	0.88 0.88
604 605	1.33	681	0.92	763	1.08	837	0.82
606	1.18	683	0.79	764	0.92	838	0.88
607	1.18	684	0.79	765	1.07 0.92	840	0.98
608 609	1.18 1.10	685 686	0.90 0.79	766 767	0.92	841 842	0.95 0.95
610	0.92	687	0.79	767 768	0.97	843	0.95
611 612	1.04	688	0.79	769	0.97	844	0.95
612	0.92	689	0.79	770	1.12	845	0.82
613 614	1.04 1.04	690 691	0.79 0.79	772 773	1.12 1.12	846 847	0.82 0.82
615	1.04	692	0.79	774	1 12	850	1.27
616	1.17	693	0.79	775	1.12 1.32	852	1.29
617	1.13	700	1.06	776	1.32	853	1.29
618 619	1.04 0.95	701 703	1.14 0.94	777 778	1.32 1.07	855 856	1.20 1.10
620	1.20	704	1.06	779	0.97	857	1.10
622	0.99	705	0.94	780	1.04	859	1.20
623	0.84	706	0.94	781	0.97	860	1.04
624 625	0.92 0.84	707 708	0.97 0.97	782 783	1.04 1.28	863 864	1.20 1.20
626	0.84	710	1.07	784	1.28	865	1.04
627	0.94	711	1.07	785	1.28	870	0.96
628	0.92	712	1.07 1.07	786 787	1.06 1.06	871 872	0.88 0.96
629 630	0.99 1.07	713 714	1.07	788	0.97	873	0.96
631	1.07	716	0.92	789	1.06	874	0.96
633	1.07	717	0.92	790	1.01	875	0.96
634	1.07	718	0.92	791 792	1.01 1.01	877 878	0.96 1.08
635 636	0.95 0.92	719 720	0.92 1.01	792 793	1.22	879	1.08
637	0.92	721	1.01	794	1.22	880	1.08
638	0.91	722	1.01	795	1.22	881	1.08
639 640	0.91 1.09	723 724	0.92 0.85	796 797	1.22 0.97	882 883	1.08 1.08
641	1.09	725	0.85	798	0.97	884	0.96
644	0.95	726	0.85	798 799	1.82	885	1.82
645	0.95	727	0.85	800	1.06	889	1.54
646 647	0.95 0.91	728 729	0.92 0.86	801 802	1.28 1.07	890 891	1.54 1.54
647 648	0.91	730	0.95	803	1.06	893	1.33
649	1.09	731	0.95	804	1.06	894	1.33
650	0.90	733	1.06	805	0.91	895	1.33
651 652	0.90	734 735	1.02	806 807	0.91	897 898	1.33 1.33
652 653	0.91	736	0.95	808	1.02	900	1.45
654	0.91	737	0.95	809	1.02	901	1.45
655	0.91	738	0.95	810	1.02	902	1.73
656 657	0.91 0.91	739 740	0.95 0.80	811 812	0.90 0.90	903 904	1.73 1.73
658	0.79	741	0.80	813	0.90	905	1.61
660	1.08	743	0.88	814	0.90	906	1.61
661	1.08	744	0.88	815	0.90	907 908	1.61 1.61
662 664	1.26 0.93	745 746	1.02 0.95	816 820	0.98 0.92	908 910	1.46
665	0.93	747	1.02	821	0.92	911	1.69
666	0.97	748	0.88	822	0.92	912	1.46
667	0.83	749	1.02	823 824	0.92	913 914	1.47 1.56
668 669	0.83 0.80	750 751	1.18 1.18	824 825	0.92 0.92	914 915	1.55
009	1 0.00	7.51	1 (.10	320	, 0.02	3.0	•

TABLE P. — OUTPATIENT FACILITY CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE PAGE 4 OF 4

ZIP Code GA	AF ZIP Code	GAAF	ZIP Code	GAAF	ZIP Code	GAAF
917 1. 918 1. 919 1. 920 1. 921 1. 922 1. 923 1. 924 1. 925 1. 926 1. 927 1. 928 1. 930 1. 931 1. 932 1. 933 1. 931 1. 932 1. 933 1. 933 1.	56 937 69 938 69 939 40 940 40 941 40 942 38 943 38 944 38 945 38 946 44 947 44 948 44 949 21 950 67 951 20 952 20 953 66 954 20 955 28 956	1.28 1.28 1.39 1.60 1.54 1.81 1.43 1.48 1.60 1.60 1.60 1.60 1.60 1.60 1.60 1.62 1.72 1.72 1.68 1.68 1.23 1.88	957 958 959 960 961 967 968 969 970 971 972 973 974 975 976 977 978 979 980	1.88 1.81 1.23 1.23 1.23 1.05 1.05 1.05 1.01 1.01 0.92 0.84 0.81 0.81 0.81 0.99 0.99 0.99 0.99 0.98	982 983 984 985 986 988 989 990 991 992 993 994 995 996 997 998	0.95 1.02 1.02 0.92 0.89 0.90 0.90 1.03 1.03 1.03 0.90 0.90 1.13 1.07 1.13 1.07

TABLE Q. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 1 OF 5

Nationwide		GAAF			GAAF				GAAF		
Average	1		Drug		1	Drug			1	Drug	
OOZ 1.12 0.71 071 1.06 1.00 147 0.94 0.94 OOS 0.95 0.67 072 0.97 1.05 1.48 1.05 1.09 OOR 1.16 0.68 073 1.06 1.00 1.49 1.05 1.05 1.05 1.05 1.05 1.05 1.05 1.05 1.05 1.05 0.00 1.00 1.00 1.00 1.00 1.00 1.00 1.00 0.00 1.00 0.00 1.00 1.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00		1.00	1.00	069	1.12	0.75	•	145	1.05	1.09	
006				071	1.06	1.00		147	0.94	0.90	
007 1.16 0.88 0.74 0.98 0.80 150 1.05 0.59 008 1.16 0.68 0.76 0.98 0.80 151 1.05 0.59 010 0.81 0.73 0.77 1.07 0.76 153 1.02 1.28 011 0.81 0.73 0.78 0.93 0.76 154 1.02 1.28 012 0.95 0.98 0.79 0.93 0.76 154 1.02 1.28 013 1.00 1.04 0.80 1.17 1.18 156 1.00 0.80 014 1.00 1.04 0.80 1.17 1.18 156 1.00 1.00 015 0.93 0.76 1.54 1.02 1.02 1.00 016 0.93 0.76 1.15 1.02 1.03 0.00 1.00 0.00 1.00 0.00 1.00 0.00 1.00 0.00 1.00											
00B 1.16 0.68 0.75 0.98 0.80 151 1.05 0.59 009 1.16 0.68 0.75 0.98 0.80 152 1.05 0.59 010 0.81 0.73 0.77 1.07 0.76 153 1.02 1.28 011 0.81 0.73 0.77 0.77 0.76 153 1.02 1.28 012 0.95 0.98 0.79 0.93 0.76 155 1.06 0.93 0.76 155 1.06 0.93 0.76 155 1.06 0.93 0.76 1.17 1.18 155 1.06 0.93 0.96 0.81 1.17 1.18 157 1.09 0.05 0.81 1.07 0.18 1.05 0.02 0.81 1.07 1.08 1.05 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.02 0.0											
COO 1.16 0.88 0.76 0.98 0.80 152 1.05 0.59 010 0.81 0.73 0.78 0.93 0.76 154 1.02 1.28 011 0.81 0.73 0.78 0.93 0.76 154 1.02 1.28 012 0.95 0.98 0.79 0.93 0.76 154 1.02 1.28 013 1.00 1.04 0.80 1.17 1.18 156 1.00 0.68 014 1.00 1.04 0.81 1.17 1.18 158 1.02 1.10 015 1.07 0.62 0.82 1.17 1.18 158 1.02 1.10 016 0.93 0.96 0.83 1.17 1.18 150 1.06 0.91 1.00 0.68 018 0.90 0.80 0.86 1.07 0.76 162 1.00 0.68 019 0.90 0											
010									1.05	0.59	
012	010				1.07						
013 100 1.04 080 1.17 1.18 156 1.09 0.08 014 1 00 1.04 081 1.17 1.18 157 1.09 1.05 015 1 07 0.92 082 1.17 1.18 158 1.02 1.10 016 0.93 0.96 0.83 1.17 1.18 159 1.06 0.91 017 0.86 1.07 0.84 1.17 1.18 160 1.00 0.68 018 0.90 0.80 0.85 1.07 0.76 162 1.00 0.68 019 0.90 0.80 0.86 1.07 0.76 162 1.00 0.68 020 0.85 1.08 0.07 0.76 162 1.00 0.68 021 0.92 0.89 0.92 0.89 1.03 1.03 1.03 1.03 1.03 1.03 1.03 1.03 1.03 1.03											
014 100 1.04 081 1.17 1.18 157 1.09 1.05 015 1.07 0.92 082 1.17 1.18 158 1.02 1.10 016 0.93 0.96 083 1.17 1.18 159 1.06 0.91 0.01 0.01 0.068 0.91 0.90 0.80 0.85 1.07 0.76 161 1.00 0.68 0.99 0.80 0.85 1.07 0.76 161 1.00 0.68 0.99 0.80 0.85 1.07 0.76 161 1.00 0.68 0.99 0.80 0.85 1.07 0.76 162 1.00 0.68 0.99 0.80 0.85 1.08 0.87 1.15 0.77 163 1.02 1.10 0.22 0.89 0.92 0.89 0.76 0.63 165 1.13 0.95 0.22 0.89 0.92 0.89 0.76 0.63 165 1.13 0.95 0.22 0.89 0.92 0.89 0.76 0.63 165 1.13 0.95 0.22 0.89 0.92 0.89 0.76 0.63 165 1.13 0.95 0.23 0.85 1.08 100 1.16 0.75 166 0.99 1.04 0.24 0.92 1.03 101 1.16 0.75 168 0.99 1.04 0.24 0.92 1.03 101 1.16 0.75 168 1.09 0.90 0.26 0.95 0.93 102 1.16 0.75 168 1.09 0.90 0.26 0.95 0.93 103 1.08 0.69 169 0.78 0.97 0.27 0.85 1.08 104 1.08 0.69 169 0.78 0.97 0.27 0.85 1.08 104 1.08 0.69 169 0.78 0.97 0.28 0.88 1.31 105 1.14 0.67 171 0.96 0.93 0.29 0.88 1.31 105 1.14 0.67 171 0.96 0.93 0.30 0.73 1.19 107 1.14 0.67 174 0.96 0.93 0.30 0.73 1.19 107 1.14 0.67 174 1.06 0.90 0.33 1.04 0.74 109 0.94 0.74 175 1.06 0.90 0.33 1.04 0.74 110 1.08 0.69 177 0.78 0.97 0.34 1.04 0.74 110 1.08 0.69 177 0.78 0.97 0.34 1.04 0.74 111 1.08 0.69 177 0.78 0.97 0.35 1.04 0.74 113 1.05 1.14 1.067 174 1.06 0.90 0.33 1.04 0.74 113 1.05 1.14 1.067 175 1.06 0.90 0.33 1.04 0.74 113 1.05 0.89 0.77 1.14 0.69 0.90 0.33 1.04 0.74 113 1.05 0.90 0.77 1.14 0.67 175 1.06 0.90 0.33 1.04 0.74 113 1.05 0.90 0.77 1.18 0.77 0.78 0.97 0.35 1.04 0.74 113 1.05 0.90 0.77 1.18 0.77 0.78 0.97 0.97 0.98 0.97 0.98 0.97 0.98 0.99 0.98 0.98 0.98 0.99 0.98 0.99 0.98 0.99 0.98 0.99 0.98 0.99 0.98 0.99 0.98 0.99 0.99											
016											
016									1.02	1.10	
018	016										
019											
1.02											
021											
023											
103											
1.02											
026 0.95 0.93 103 1.08 0.69 169 0.78 0.97 027 0.28 0.88 1.31 105 1.14 0.67 171 0.96 0.93 029 0.88 1.31 106 1.03 0.86 172 1.06 0.90 030 0.73 1.19 107 1.14 0.67 173 1.06 0.90 031 0.73 1.19 108 1.14 0.67 174 1.06 0.90 032 1.04 0.74 110 9.94 0.74 175 1.06 0.90 033 1.04 0.74 110 1.08 0.69 176 1.11 1.02 034 1.04 0.74 111 1.08 0.69 176 1.11 1.02 035 1.04 0.74 112 1.05 1.14 178 0.78 0.97 035 1.04 0.74 111											
027 0.85 1.08 104 1.08 0.69 170 0.96 0.93 028 0.88 1.31 105 1.14 0.67 171 0.96 0.93 029 0.88 1.31 106 1.03 0.86 172 1.06 0.90 030 0.73 1.19 107 1.14 0.67 173 1.06 0.90 031 0.73 1.19 108 1.14 0.67 174 1.06 0.90 033 1.04 0.74 110 1.08 0.69 176 1.11 1.02 033 1.04 0.74 111 1.08 0.69 177 0.78 0.97 035 1.04 0.74 112 1.05 1.14 178 0.78 0.97 035 1.04 0.74 112 1.05 1.14 179 1.07 0.76 037 1.04 0.74 113 1.05					1.08	0.69			0.78	0.97	
029	027	0.85	1.08	104							
0.50											
1.14											
032 1.04 0.74 109 0.94 0.74 175 1.06 0.90 033 1.04 0.74 110 1.08 0.69 176 1.11 1.02 034 1.04 0.74 111 1.08 0.69 177 0.78 0.97 035 1.04 0.74 112 1.05 1.14 178 0.78 0.97 036 1.04 0.74 113 1.05 1.14 179 1.07 0.76 037 1.04 0.74 114 1.05 1.14 180 1.07 1.00 038 1.12 0.71 115 0.95 0.67 182 0.96 0.85 040 1.09 0.57 117 0.95 0.67 182 0.96 0.85 040 1.09 0.57 117 0.95 0.67 183 1.16 0.79 0.41 1.16 0.61 118 0.95 0.67 <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td> <td></td>											
1.04	032							175			
035 1.04 0.74 112 1.05 1.14 178 0.78 0.97 036 1.04 0.74 113 1.05 1.14 179 1.07 0.76 037 1.04 0.74 114 1.05 1.14 180 1.07 0.76 038 1.12 0.71 115 0.95 0.67 181 1.07 1.00 039 0.90 0.85 116 0.95 0.67 182 0.96 0.85 040 1.09 0.57 117 0.95 0.67 182 0.96 0.85 040 1.09 0.57 117 0.95 0.67 183 1.16 0.79 041 1.16 0.61 118 0.95 0.67 184 0.96 0.85 042 1.09 0.57 119 0.95 0.67 184 0.96 0.85 043 0.90 0.85 120 1.00											
036 1.04 0.74 113 1.05 1.14 179 1.07 0.76 037 1.04 0.74 114 1.05 1.14 180 1.07 1.00 038 1.12 0.71 115 0.95 0.67 181 1.07 1.00 039 0.90 0.85 116 0.95 0.67 182 0.96 0.85 040 1.09 0.57 117 0.95 0.67 183 1.16 0.79 041 1.16 0.61 118 0.95 0.67 183 1.16 0.79 041 1.16 0.61 118 0.95 0.67 184 0.96 0.85 042 1.09 0.57 119 0.95 0.67 184 0.96 0.85 043 0.90 0.85 120 1.00 1.10 186 0.96 0.85 044 0.85 0.84 121 1.00											
037 1.04 0.74 114 1.05 1.14 180 1.07 1.00 038 1.12 0.71 115 0.95 0.67 181 1.07 1.00 039 0.90 0.85 116 0.95 0.67 182 0.96 0.85 040 1.09 0.57 117 0.95 0.67 183 1.16 0.79 041 1.16 0.61 118 0.95 0.67 184 0.96 0.85 042 1.09 0.57 119 0.95 0.67 184 0.96 0.85 043 0.90 0.85 120 1.00 1.10 186 0.96 0.85 043 0.90 0.85 122 1.00 1.10 186 0.96 0.85 044 0.85 0.84 121 1.00 1.10 188 0.96 0.85 046 0.85 0.84 122 1.00											
039 0.90 0.85 116 0.95 0.67 182 0.96 0.85 040 1.09 0.57 117 0.95 0.67 183 1.16 0.79 041 1.16 0.61 118 0.95 0.67 184 0.96 0.85 042 1.09 0.57 119 0.95 0.67 185 0.96 0.85 043 0.90 0.85 120 1.00 1.10 186 0.96 0.85 044 0.85 0.84 121 1.00 1.10 187 0.96 0.85 045 0.85 0.84 122 1.00 1.10 187 0.96 0.85 046 0.85 0.84 122 1.00 1.10 188 0.96 0.85 046 0.85 0.84 123 1.00 1.10 189 1.12 0.88 047 0.90 0.85 126 0.72	037										
040 1.09 0.57 117 0.95 0.67 183 1.16 0.79 041 1.16 0.61 118 0.95 0.67 184 0.96 0.85 042 1.09 0.57 119 0.95 0.67 185 0.96 0.85 043 0.90 0.85 120 1.00 1.10 186 0.96 0.85 044 0.85 0.84 121 1.00 1.10 187 0.96 0.85 045 0.85 0.84 122 1.00 1.10 188 0.96 0.85 046 0.85 0.84 122 1.00 1.10 188 0.96 0.85 046 0.85 0.84 123 1.00 1.10 188 0.96 0.85 048 0.85 0.84 123 1.00 1.10 190 1.05 0.78 048 0.82 0.90 0.85 124											
041 1.16 0.61 118 0.95 0.67 184 0.96 0.85 042 1.09 0.57 119 0.95 0.67 185 0.96 0.85 043 0.90 0.85 120 1.00 1.10 186 0.96 0.85 044 0.85 0.84 121 1.00 1.10 187 0.96 0.85 045 0.85 0.84 122 1.00 1.10 188 0.96 0.85 046 0.85 0.84 122 1.00 1.10 188 0.96 0.85 046 0.85 0.84 123 1.00 1.10 189 1.12 0.88 047 0.90 0.85 124 1.00 1.10 190 1.05 0.78 048 0.85 0.84 125 0.72 0.56 191 0.84 0.82 049 0.90 0.85 126 0.72	039										
042 1.09 0.57 119 0.95 0.67 185 0.96 0.85 043 0.90 0.85 120 1.00 1.10 186 0.96 0.85 044 0.85 0.84 121 1.00 1.10 187 0.96 0.85 045 0.85 0.84 122 1.00 1.10 188 0.96 0.85 046 0.85 0.84 123 1.00 1.10 189 1.12 0.88 047 0.90 0.85 124 1.00 1.10 190 1.05 0.78 048 0.85 0.84 125 0.72 0.56 191 0.84 0.82 049 0.90 0.85 126 0.72 0.56 192 0.84 0.82 049 0.90 0.85 126 0.72 0.56 193 1.12 0.88 050 1.14 0.78 128 0.97											
044 0.85 0.84 121 1.00 1.10 187 0.96 0.85 045 0.85 0.84 122 1.00 1.10 188 0.96 0.85 046 0.85 0.84 123 1.00 1.10 189 1.12 0.88 047 0.90 0.85 124 1.00 1.10 189 1.12 0.88 047 0.90 0.85 124 1.00 1.10 189 1.12 0.78 048 0.85 0.84 125 0.72 0.56 191 0.84 0.82 049 0.90 0.85 126 0.72 0.56 192 0.84 0.82 050 1.14 0.78 127 0.72 0.56 193 1.12 0.88 051 1.14 0.78 128 0.97 0.72 194 1.12 0.88 051 1.14 0.78 130 0.85	042	1.09	0.57	119				185			
045 0.85 0.84 122 1.00 1.10 188 0.96 0.85 046 0.85 0.84 123 1.00 1.10 189 1.12 0.88 047 0.90 0.85 124 1.00 1.10 190 1.05 0.78 048 0.85 0.84 125 0.72 0.56 191 0.84 0.82 049 0.90 0.85 126 0.72 0.56 192 0.84 0.82 050 1.14 0.78 128 0.97 0.72 0.56 193 1.12 0.88 051 1.14 0.78 128 0.97 0.72 194 1.12 0.88 051 1.14 0.78 129 0.97 0.72 194 1.12 0.88 052 1.14 0.78 130 0.85 1.16 196 1.07 0.76 053 1.14 0.78 130											
046 0.85 0.84 123 1.00 1.10 189 1.12 0.88 047 0.90 0.85 124 1.00 1.10 190 1.05 0.78 048 0.85 0.84 125 0.72 0.56 191 0.84 0.82 049 0.90 0.85 126 0.72 0.56 192 0.84 0.82 050 1.14 0.78 127 0.72 0.56 192 0.84 0.82 050 1.14 0.78 128 0.97 0.72 194 1.12 0.88 051 1.14 0.78 129 0.97 0.72 195 1.07 0.76 053 1.14 0.78 130 0.85 1.16 196 1.07 0.76 054 1.07 0.60 131 0.85 1.16 197 0.83 0.88 055 0.90 0.80 132 0.85											
047 0.90 0.85 124 1.00 1.10 190 1.05 0.78 048 0.85 0.84 125 0.72 0.56 191 0.84 0.82 049 0.90 0.85 126 0.72 0.56 192 0.84 0.82 050 1.14 0.78 127 0.72 0.56 193 1.12 0.88 051 1.14 0.78 128 0.97 0.72 194 1.12 0.88 052 1.14 0.78 129 0.97 0.72 195 1.07 0.76 053 1.14 0.78 130 0.85 1.16 196 1.07 0.76 054 1.07 0.60 131 0.85 1.16 197 0.83 0.88 055 0.90 0.80 132 0.85 1.16 198 0.83 0.88 056 1.14 0.78 133 1.07											
049 0.90 0.85 126 0.72 0.56 192 0.84 0.82 050 1.14 0.78 127 0.72 0.56 193 1.12 0.88 051 1.14 0.78 128 0.97 0.72 194 1.12 0.88 052 1.14 0.78 129 0.97 0.72 195 1.07 0.76 053 1.14 0.78 130 0.85 1.16 196 1.07 0.76 054 1.07 0.60 131 0.85 1.16 197 0.83 0.88 055 0.90 0.80 132 0.85 1.16 197 0.83 0.88 055 0.90 0.80 132 0.85 1.16 198 0.83 0.88 055 1.14 0.78 133 1.07 0.98 199 1.07 0.82 057 1.14 0.78 135 1.07	047		0.85	124							
050 1.14 0.78 127 0.72 0.56 193 1.12 0.88 051 1.14 0.78 128 0.97 0.72 194 1.12 0.88 052 1.14 0.78 129 0.97 0.72 195 1.07 0.76 053 1.14 0.78 130 0.85 1.16 196 1.07 0.76 054 1.07 0.60 131 0.85 1.16 197 0.83 0.88 055 0.90 0.80 132 0.85 1.16 198 0.83 0.88 056 1.14 0.78 133 1.07 0.98 199 1.07 0.82 057 1.14 0.78 134 1.07 0.98 199 1.07 0.82 057 1.14 0.78 135 1.07 0.98 200 1.11 1.39 058 1.14 0.78 135 1.07											
051 1.14 0.78 128 0.97 0.72 194 1.12 0.88 052 1.14 0.78 129 0.97 0.72 195 1.07 0.76 053 1.14 0.78 130 0.85 1.16 196 1.07 0.76 054 1.07 0.60 131 0.85 1.16 197 0.83 0.88 055 0.90 0.80 132 0.85 1.16 198 0.83 0.88 056 1.14 0.78 133 1.07 0.98 199 1.07 0.82 057 1.14 0.78 134 1.07 0.98 200 1.11 1.39 058 1.14 0.78 135 1.07 0.98 201 1.22 0.97 059 1.14 0.78 136 1.07 0.98 202 1.11 1.39 060 0.81 0.77 137 1.15											
052 1.14 0.78 129 0.97 0.72 195 1.07 0.76 053 1.14 0.78 130 0.85 1.16 196 1.07 0.76 054 1.07 0.60 131 0.85 1.16 197 0.83 0.88 055 0.90 0.80 132 0.85 1.16 198 0.83 0.88 056 1.14 0.78 133 1.07 0.98 199 1.07 0.82 057 1.14 0.78 134 1.07 0.98 200 1.11 1.39 058 1.14 0.78 135 1.07 0.98 201 1.22 0.97 059 1.14 0.78 135 1.07 0.98 201 1.22 0.97 059 1.14 0.77 137 1.15 0.57 203 1.11 1.39 060 0.81 0.77 137 1.15					0.97	0.72			1.12	0.88	
054 1.07 0.60 131 0.85 1.16 197 0.83 0.88 055 0.90 0.80 132 0.85 1.16 198 0.83 0.88 056 1.14 0.78 133 1.07 0.98 199 1.07 0.82 057 1.14 0.78 134 1.07 0.98 200 1.11 1.39 058 1.14 0.78 135 1.07 0.98 201 1.22 0.97 059 1.14 0.78 136 1.07 0.98 202 1.11 1.39 060 0.81 0.77 137 1.15 0.57 203 1.11 1.39 061 0.77 0.70 138 1.15 0.57 204 1.11 1.39 062 0.81 0.77 139 1.15 0.57 205 1.11 1.39 063 0.81 0.77 140 0.94		1	1	129							
055 0.90 0.80 132 0.85 1.16 198 0.83 0.88 056 1.14 0.78 133 1.07 0.98 199 1.07 0.82 057 1.14 0.78 134 1.07 0.98 200 1.11 1.39 058 1.14 0.78 135 1.07 0.98 201 1.22 0.97 059 1.14 0.78 136 1.07 0.98 202 1.11 1.39 060 0.81 0.77 137 1.15 0.57 203 1.11 1.39 061 0.77 0.70 138 1.15 0.57 204 1.11 1.39 062 0.81 0.77 139 1.15 0.57 205 1.11 1.39 063 0.81 0.77 140 0.94 0.90 206 1.09 0.84 064 1.04 0.66 141 0.94											
056 1.14 0.78 133 1.07 0.98 199 1.07 0.82 057 1.14 0.78 134 1.07 0.98 200 1.11 1.39 058 1.14 0.78 135 1.07 0.98 201 1.22 0.97 059 1.14 0.78 136 1.07 0.98 202 1.11 1.39 060 0.81 0.77 137 1.15 0.57 203 1.11 1.39 061 0.77 0.70 138 1.15 0.57 204 1.11 1.39 062 0.81 0.77 139 1.15 0.57 205 1.11 1.39 063 0.81 0.77 140 0.94 0.90 206 1.09 0.84 064 1.04 0.66 141 0.94 0.90 207 1.12 0.92 065 1.00 0.61 142 0.94	054 055			131							
057 1.14 0.78 134 1.07 0.98 200 1.11 1.39 058 1.14 0.78 135 1.07 0.98 201 1.22 0.97 059 1.14 0.78 136 1.07 0.98 202 1.11 1.39 060 0.81 0.77 137 1.15 0.57 203 1.11 1.39 061 0.77 0.70 138 1.15 0.57 204 1.11 1.39 062 0.81 0.77 139 1.15 0.57 205 1.11 1.39 063 0.81 0.77 140 0.94 0.90 206 1.09 0.84 064 1.04 0.66 141 0.94 0.90 207 1.12 0.92 065 1.00 0.61 142 0.94 0.90 208 1.00 0.74 066 1.00 0.61 143 0.94					1.07	0.98			1.07	0.82	
059 1.14 0.78 136 1.07 0.98 202 1.11 1.39 060 0.81 0.77 137 1.15 0.57 203 1.11 1.39 061 0.77 0.70 138 1.15 0.57 204 1.11 1.39 062 0.81 0.77 139 1.15 0.57 205 1.11 1.39 063 0.81 0.77 140 0.90 206 1.09 0.84 064 1.04 0.66 141 0.94 0.90 207 1.12 0.92 065 1.00 0.61 142 0.94 0.90 208 1.00 0.74 066 1.00 0.61 143 0.94 0.90 209 1.00 0.74	057	1.14	0.78	134							
060 0.81 0.77 137 1.15 0.57 203 1.11 1.39 061 0.77 0.70 138 1.15 0.57 204 1.11 1.39 062 0.81 0.77 139 1.15 0.57 205 1.11 1.39 063 0.81 0.77 140 0.94 0.90 206 1.09 0.84 064 1.04 0.66 141 0.94 0.90 207 1.12 0.92 065 1.00 0.61 142 0.94 0.90 208 1.00 0.74 066 1.00 0.61 143 0.94 0.90 209 1.00 0.74											
061 0.77 0.70 138 1.15 0.57 204 1.11 1.39 062 0.81 0.77 139 1.15 0.57 205 1.11 1.39 063 0.81 0.77 140 0.94 0.90 206 1.09 0.84 064 1.04 0.66 141 0.94 0.90 207 1.12 0.92 065 1.00 0.61 142 0.94 0.90 208 1.00 0.74 066 1.00 0.61 143 0.94 0.90 209 1.00 0.74											
062 0.81 0.77 139 1.15 0.57 205 1.11 1.39 063 0.81 0.77 140 0.94 0.90 206 1.09 0.84 064 1.04 0.66 141 0.94 0.90 207 1.12 0.92 065 1.00 0.61 142 0.94 0.90 208 1.00 0.74 066 1.00 0.61 143 0.94 0.90 209 1.00 0.74 067 0.90 0.90 209 1.00 0.74 0.97						0.57			1.11	1.39	
063 0.81 0.77 140 0.94 0.90 206 1.09 0.84 064 1.04 0.66 141 0.94 0.90 207 1.12 0.92 065 1.00 0.61 142 0.94 0.90 208 1.00 0.74 066 1.00 0.61 143 0.94 0.90 209 1.00 0.74	062	0.81	0.77	139	1.15	0.57		205			
065 1.00 0.61 142 0.94 0.90 208 1.00 0.74 0.66 1.00 0.61 143 0.94 0.90 209 1.00 0.74	063										
066 1.00 0.61 143 0.94 0.90 209 1.00 0.74											
4.00 4.00 0.00 1.007									1.00	0.74	
067 7.04 0.66 144 1.05 1.09 210 0.69 0.61	067	1.04	0.66	144	1.05	1.09		210	0.89	0.97	

TABLE Q. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 2 OF 5

ZIP	GA	VAF	ZIP	G/	NAF	ZIP	G/	4AF
Code	Non- Drug	Drug	Code	Non- Drug	Drug	Code	Non- Drug	Drug
211 212 214 215 216 217 218 219 220 221 222 223 224 225 226 227 228 229 230 231 232 233 234 235 236 237 238 239 240 241 242 243 244 245 246 247 248 249 250 251 252 253 254 255 256 257 258 259 260 261 262 263 264 265 266 267 268 270 271 272 273 274 275 276 277 278 279	0.89 0.95 0.89 1.04 0.72 1.04 0.72 1.04 0.72 1.09 1.01 1.01 1.01 1.01 1.01 1.01 1.01	0.97 1.07 0.97 0.97 0.73 0.97 0.73 0.97 0.97 0.97 0.97 0.92 0.92 1.10 1.10 1.10 1.10 1.10 1.10 1.10 1.1	280 281 282 283 284 285 286 287 288 289 290 291 292 293 294 295 296 297 298 299 300 301 302 303 304 305 306 307 308 309 310 311 312 313 314 315 316 317 318 319 320 321 322 323 324 325 326 327 328 329 330 331 332 333 334 335 336 337 338 339 341 342 344 346 347 349 350	1.07 1.07 1.08 1.11 1.11 1.27 1.27 1.27 1.27 1.01 1.13 1.09 1.09 0.94 0.94 0.94 0.94 0.94 1.02 1.12 0.100 0.75 0.75 0.75 0.75 0.75 0.75 1.05 0.94 1.00 1.11 1.11 1.11 1.11 1.11 1.11 1.1	0.98 0.98 1.27 0.96 0.96 0.96 1.10 1.10 1.10 1.10 1.10 1.11 1.10 1.15 1.35 0.97 1.01 1.35 0.86 0.86 1.09 1.20 1.09 1.10 1.04 1.04 1.04 1.04 1.04 1.09 1.09 1.10 1.09 1.09 1.09 1.09 1.09	351 352 354 355 356 357 358 360 361 362 363 364 365 366 367 368 369 370 371 372 373 374 375 376 377 378 379 380 381 382 383 384 385 386 387 379 380 381 382 383 384 385 386 387 379 389 390 391 392 393 394 395 396 397 397 398 399 390 391 392 393 394 395 396 397 397 398 399 390 391 392 393 394 395 396 397 397 398 399 390 391 392 393 394 395 396 397 397 398 399 390 391 392 393 394 395 396 397 397 398 399 390 391 392 393 394 395 396 397 397 398 399 390 391 392 393 394 395 396 397 397 398 399 390 391 392 393 394 405 406 407 408 408 409 401 401 402 403 404 405 406 407 408 409 410 411 412 413 414 415 416 417 418 420	0.89 0.99 0.89 0.89 0.89 0.89 0.92 0.92 1.08 1.04 1.04 1.08 1.04 1.04 1.04 1.04 1.04 1.07 1.07 1.07 1.07 1.07 1.07 1.07 1.07	1.01 0.89 1.01 0.90 0.90 0.90 0.90 1.21 0.85 0.85 1.21 0.85 0.85 1.01 1.01 1.00 0.88 1.32 1.32 1.32 1.32 1.32 1.32 1.32 1.32

TABLE Q. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 3 OF 5

	C.				 VAF		G/	 WF
ZIP	- GA		ZIP			ZIP	G,	VAF
Code	Non- Drug	Drug	Code	Non- Drug	Drug	Code	Non- Drug	Drug
421 422 423 424 425 426 427 430 431 432 433 434 435 436 437 438 439 440 441 442 443 444 445 446 447 448 449 450 451 452 453 454 455 456 457 458 460 461 462 463 464 465 466 467 468 469 470 471 472 473 474 475 476 477 478 479 479 479 479 479 479 479 479 471 471 472 473 474 475 476 477 478 479 470 471 472 473 474 475 476 477 478 479 470 471 471 472 473 474 475 476 477 478 479 470 471 471 472 473 474 475 476 477 478 479 470 471 471 472 473 474 475 476 477 478 479 470 471 471 472 473 474 475 476 477 478 479 479 470 471 471 471 471 471 472 473 474 477 478 479 479 479 479 479 479 479 479 479 479	0.95 1.01 1.01 1.01 1.01 1.05 1.05 1.05 1.0	0.80 0.95 0.95 0.95 1.13 1.13 1.13 0.53 0.53 1.21 0.76 0.68 0.68 0.68 0.85 0.85 0.85 0.85 0.95 0.77 0.98 0.98 0.95 0.71 0.72 0.81 1.01 0.99 1.01 0.72 0.81 1.21 1.21 1.21 1.21 1.21 1.21 1.21 1	490 491 492 493 494 495 496 497 498 499 500 501 502 503 504 505 506 507 508 509 510 511 512 513 514 515 516 520 521 522 523 524 525 526 527 528 529 531 532 531 532 531 532 533 534 535 537 538 539 531 532 533 534 535 537 538 539 531 532 533 534 535 537 538 539 531 532 533 534 535 537 538 539 531 532 533 534 535 537 538 539 531 532 533 534 535 536 537 538 539 531 532 533 534 535 537 538 539 531 532 533 534 535 537 538 539 531 532 533 534 535 537 538 539 539 539 531 532 533 534 535 537 538 538 539 539 539 539 539 539 539 539 539 539	0.84 0.84 0.84 0.94 0.94 0.94 0.94 0.94 0.93 0.93 0.93 0.93 0.76 0.92 0.76 0.92 0.92 0.92 0.92 0.92 0.92 0.92 0.92	0.73 0.73 0.73 0.73 0.72 0.72 0.72 0.72 0.72 0.65 0.65 0.67 0.67 0.67 0.75 0.76 0.75 0.76 0.76 0.76 0.76 0.76 0.76 0.76 0.76	564 565 565 566 567 570 571 572 573 574 575 576 577 580 581 582 583 584 585 586 587 588 590 591 592 593 594 595 596 600 601 602 603 604 605 606 607 608 609 610 611 612 613 614 615 616 617 618 619 622 622 623 624 625 626 627 628	1.03 0.87 0.87 0.87 0.97 0.97 0.97 0.97 0.97 0.97 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.97 0.97 0.97 0.97 0.97 0.97 0.97 0.97 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.97 0.97 0.97 0.97 0.97 0.97 0.97 0.97 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.97 0.97 0.97 0.97 0.97 0.97 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.96 0.97 0.99	0.84 0.74 0.74 0.74 0.73 0.82 0.73 0.73 0.73 0.73 0.73 0.73 0.73 0.58 0.58 0.58 0.58 0.58 0.58 0.58 0.58
481 482 483 484 485 486 487 488 489	1.07 0.95 1.04 1.05 1.05 1.10 1.10 0.85 0.85	0.93 1.03 1.07 0.76 0.76 0.93 0.93 0.78	555 556 557 558 559 560 561 562 563	0.72 0.87 0.87 0.85 0.96 0.98 0.71 0.71 1.03	0.64 0.74 0.74 0.90 0.65 0.80 0.58 0.58	628 629 630 631 633 634 635 636	0.87 0.79 0.80 1.07 0.80 0.80 0.92 0.99 0.99	1.02 0.77 0.98 0.77 0.77 1.17 1.00

TABLE Q. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 4 OF 5

-	GAAF		GAAF						 \AF	
ZIP Code	Non- Drug	Drug	ZII Cod		Non- Drug	Drug		ZIP Code	Non- Drug	Drug
638 639 640 641 644 645 646 647 648 649 650 651 652 653 654 655 666 667 668 667 668 667 672 673 674 675 676 677 678 679 680 681 683 684 685 687 688 687 688 689 690 691 692 693 700 701 703 704 705 706 707 708 707 708 707 708 710 707 708 711 712 713 714 715 716 717 718	1.11 1.11 0.97 0.92 0.92 0.92 1.11 1.11 0.97 0.93 0.93 1.11 1.11 1.11 1.11 1.11 1.11 1.11 1	1.04 1.04 1.01 1.17 1.17 1.17 1.17 1.17 1.04 1.01 1.01 1.01 1.01 1.01 1.01 1.04 1.04	71 72 72 72 72 72 72 72 72 73 73 73 73 73 73 73 73 73 74 74 74 74 74 74 74 75 75 75 75 75 75 75 75 75 75 75 75 75	01234567890134567890134567890112345678901234567890012345678902345678901234567	1.07 0.99 0.99 0.99 1.07 1.13 1.13 1.13 1.07 0.98 1.03 1.04 1.06 1.06 0.90 0.90 0.90 1.08 1.08 1.08 1.08 1.06 1.01 1.01 1.01 1.04 1.04 0.97 0.97 0.97 0.97 0.97 0.97 0.97 0.97	0.95 0.92 0.92 0.92 0.92 0.95 0.80 0.80 0.80 0.80 0.80 0.95 1.09 1.33 1.33 1.08 1.41 1.17 1.17 1.17 1.17 1.17 1.17 1.17		789 790 791 792 793 794 795 796 797 798 800 801 802 803 804 805 806 807 808 809 810 811 812 813 814 815 820 821 822 823 824 825 827 828 829 831 832 833 834 835 836 837 838 840 841 842 843 844 845 847 850 851 860 863 865 870	1.04 1.21 1.21 1.21 1.02 1.02 1.02 1.02 1.02	1.08 1.05 1.05 1.05 1.05 1.05 1.28 1.28 1.28 1.28 1.28 1.28 1.28 1.28

TABLE Q. — DURABLE MEDICAL EQUIPMENT, SUPPLIES, VISION AND HEARING HARDWARE CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 5 OF 5

710	GAAF ZIP		ZIP	G/	NAF.	710	G/	4AF
Code	Non- Drug	Drug	Code	Non- Drug	Drug	ZIP Code	Non- Drug	Drug
871 872 873 874 875 877 878 879 880 881 882 883 884 885 890 891 893 894 895 897 898 900 901 902 903 904 905 906 907 908 911 912 913 914	0.93 1.01 1.01 1.01 1.01 1.01 1.01 0.90 0.90	0.86 0.99 0.99 0.99 0.99 0.95 0.95 0.95 0.95	917 918 919 920 921 922 923 924 925 926 927 928 930 931 932 933 934 935 936 937 938 939 940 941 942 943 944 945 946 947 948 949 950 951 952	1.12 1.12 1.12 0.91 0.84 0.87 0.87 0.87 1.20 1.20 1.20 1.20 1.21 1.07 1.07 1.07 1.07 1.07 1.07 1.07 1.0	1.17 1.17 0.80 0.80 0.84 0.95 0.95 0.95 0.95 1.04 1.04 1.04 1.04 0.64 1.04 1.04 0.70 0.70 0.70 0.70 0.70 0.71 1.06 0.61 0.69 0.89 0.89 0.89 0.89 0.89 0.89 0.89 0.8	956 957 958 959 960 961 967 968 969 970 971 972 973 974 975 976 977 978 979 980 981 982 983 984 985 986 988 989 990 991 992 993 994 995 998	1.26 1.26 1.26 1.02 1.00 1.00 1.00 1.00 1.04 1.04 1.04 1.08 1.08 0.98 0.91 0.92 0.92 0.92 0.92 1.03 1.03 1.11 0.87 0.93 1.04 1.04 1.09 0.96 0.96 0.91 0.96 0.91 0.991 0.991 0.991 0.991 0.991 0.991 0.991 0.991 0.991 0.991 0.991 0.991 0.991 0.991 0.991 0.91 0.	1.03 1.03 0.60 0.91 0.91 0.91 1.10 1.10 1.10 0.89 0.76 0.52 0.95 0.95 0.95 0.95 0.95 0.95 0.95 0.95
915 916	0.96	0.81	955	1.00	0.91	999	0.80	1.08

TABLE R. — OUTPATIENT DENTAL PROFESSIONAL CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 1 OF 5

ZIP		GAAF		ZIP		GAAF		-	ZIP		GAAF	
Code	Class I	Class II	Class III	Code	Class I	Class II	Class III	_	Code	Class I	Class II	Class III
Nationwide Average	1.00	1.00	1.00	070 071 072	1.16 1.16 1.16	1.13 1.04 1.13	1.16 1.10 1.16		149 150 151	0.77 0.84 0.84	0.82 0.82 0.82	0.94 0.89 0.89
002	0.96	1.02	1.08	073	1.16	1.04	1.10		152	0.84	0.82	0.89
005	1.23	1.11	1.15	074	1.16	1.18	1.18		153	0.82	0.80	0.88
006 007	0.80 0.80	0.64 0.64	0.74 0.74	075 076	1.16 1.16	1,18. 1,18	1.18 1.18		154 155	0.82 0.71	0.80 0.69	0.88 0.76
008	0.80	0.64	0.74	077	1.03	1.07	1.07		156	0.71	0.09	0.76
009	0.80	0.64	0.74	078	1.16	1.20	1.18		157	0.76	0.74	0.82
010	0.93	0.98	1.04	079	1.16	1.20	1.18		158	0.73	0.70	0.79
011 012	0.93	0.98 0.94	1.04 1.02	080	0.98	1.03	1.01 1.01		159 160	0.71	0.69	0.76 0.84
012	0.87 0.98	1.04	1.02	081 082	0.98 0.98	1.03 1.03	1.01		161	0.80 0.80	0.77 0.77	0.84
014	0.98	1.04	1.07	083	0.98	1.03	1,01		162	0.80	0.77	0.84
015	1.00	1.03	1.12	084	0.98	1.03	1.01		163	0.73	0.70	0.79
016 017	1.04 1.06	1.07 1.10	1.12 1.20	085 086	1.03 1.03	1.07 1.07	1.07 1.07		164 165	0.78	0.79	0.85 0.85
017	1.00	1.08	1.20	087	1.03	1.07	1.04		166	0.78 0.82	0.79 0.77	0.89
019	1.07	1.08	1.16	088	1.15	1.16	1.16		167	0.73	0.70	0.79
020	1.04	1.06	1.12	089	1.17	1.19	1.16		168	0.76	0.74	0.82
021 022	1.12 1.10	1.11 1.10	1.24 1.30	100 101	1.73 1.73	1.62 1.62	1.58 1.58		169 170	0.75 0.86	0.73 0.83	0.82 0.89
023	1.04	1.06	1.12	102	1.73	1.62	1.58		171	0.86	0.83	0.89
024	1.12	1.11	1.24	103	1.35	1.12	1.17		172	0.80	0.80	0.89
025	1.06	1.08	1.15	104	1.35	1.12	1.17		173	0.80	0.80	0.89
026 027	1.06 1.04	1.08 1.06	1.15 1.12	105 106	1.24 1.28	1.19 1.24	1,24 1,31		174 175	0.80 0.80	0.80 0.80	0.89 0.89
028	1.08	0.97	1.05	107	1.24	1.19	1.24		176	0.84	0.88	0.96
029	1.08	0.97	1.05	108	1.24	1.19	1.24		177	0.75	0.73	0.82
030 031	0.98	1.05	1.09 1.09	109	1.13	1.10	1.15		178 179	0.75	0.73	0.82 0.89
031	0.98 0.96	1.05 1.00	1.09	110 111	1.35 1.35	1.12 1.12	1.17 1.17		180	0.83 0.92	0.83 0.92	0.89
033	0.96	1.00	1.08	112	1.43	1.14	1.17		181	0.92	0.92	0.96
034	0.96	1.00	1.08	113	1.43	1.14	1.17		182	0.79	0.79	0.86
035 036	0.96 0.96	1.00 1.00	1.08 1.08	114 115	1.43 1.23	1.14 1.11	1.17 1.15		183 184	0.90 0.79	0.89 0.79	0.94 0.86
037	0.96	1.00	1.08	116	1.23	1.11	1.15		185	0.79	0.79	0.86
038	0.96	1.02	1.08	117	1.23	1.11	1.15		186	0.79	0.79	0.86
039 040	0.88 0.93	0.90 0.98	1.01 1.08	118 119	1,23 1,23	1.11	1.15 1.15		187 188	0.79 0.79	0.79 0.79	0.86 0.86
041	0.93	1.04	1.00	120	0.91	0.91	0.96		189	1.03	1.02	1.07
042	0.93	0.98	1.08	121	0.91	0.91	0.96		190	1.06	1.02	1.07
043	0.88	0.90	1.01	122	0.91	0.91	0.96		191	1.04	0.98	1.04
044 045	0.89 0.89	0.93 0.93	1.01 1.01	123 124	0.91	0.91 0.91	0.96 0.96		192 193	1.04 1.03	0.98 1.02	1.04 1.07
046	0.89	0.93	1.01	125	0.91	0.90	0.98		194	1.03	1.02	1.07
047	0.88	0.90	1.01	126	0.91	0.90	0.98		195	0.83	0.83	0.89
048 049	0.89	0.93 0.90	1.01	127 128	0.91	0.90	0.98 0.94		196 197	0.83	0.83	0.89 1.19
050	0.88 0.87	0.90	1.01 0.99	129	0.90	0.88 0.88	0.94		198	1.13 1.13	1.12 1.12	1.19
051	0.87	0.94	0.99	130	0.82	0.88	0.90		199	1.02	1.02	1.10
052	0.87	0.94	0.99	131	0.82	0.88	0.90		200	1.18	1.24	1.27
053 054	0.87 0.87	0.94 0.97	0.99 0.99	132 133	0.82 0.74	0.88 0.82	0.90 0.84		201 202	1.07 1.18	1.12 1.24	1.09 1.27
055	1.07	1.08	1.16	134	0.74	0.82	0.84		203	1.18	1.24	1.27
056	0.87	0.94	0.99	135	0.74	0.82	0.84		204	1.18	1.24	1.27
057 058	0.87 0.87	0.94 0.94	0.99 0.99	136 137	0.74 0.81	0.82 0.82	0.84 0.91		205 206	1.18 0.99	1.24 0.97	1.27 1.01
059	0.87	0.94	0.99	138	0.81	0.82	0.91		207	1.05	1.02	1.04
060	1.08	1.08	1.12	139	0.81	0.82	0.91		208	1.07	1.09	1.10
061	1.12	1.09	1.14	140	0.81	0.80	0.91		209	1.07	1.09	1.10 1.05
062 063	1.08 1.08	1.08 1.08	1.12 1.12	141 142	0.81 0.81	0.80 0.80	0.91 0.91		210 211	1.00 1.00	1.00 1.00	1.05
064	1.10	1.09	1.13	143	0.81	0.80	0.91		212	1.02	0.96	1.03
065	1.16	1.10	1.15	144	0.77	0.82	0.94		214	1.00	1.00	1.05
066 067	1.16 1.10	1.10 1.09	1.15 1.13	145 146	0.77 0.77	0.82 0.82	0.94 0.94		215 216	0.93 0.87	0.93 0.92	0.99 0.92
068	1.17	1.24	1.29	147	0.81	0.80	0.91		217	0.93	0.93	0.99
069	1.17	1.24	1.29	148	0.77	0.82	0.94		218	0.87	0.92	0.92

TABLE R. — OUTPATIENT DENTAL PROFESSIONAL CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE PAGE 2 OF 5

ZIP		GAAF		ZIP		GAAF		ZIP		GAAF	
Code	Class I	Class II	Class III	Code	Class I	Class II	Class III	Code	Class I	Class II	Class III
219	1.00	1.00	1.05	289	0.83	0.92-	0.92	363	0.72	0.78	0.78
220	1.07	1.12	1.09	290	0.81	0.87	0.92	364	0.72	0.78	0.78
221	1.07	1.12	1.09	291	0.81	0.87	0.92	365	0.75	0.81	0.83
222	1.09	1,14	1.12	292	0.83	0.91	0.95	366	0.75	0.81	0.83
223	1.09	1.14	1.12	293	0.82	0.86	0.90	367	0.72	0.78	0.78
224	0.90	0.89	0.95	294	0.83	0.87	0.92	368	0.72	0.78	0.78
225	0.90	0.89	0.95	295	0.83	0.87	0.92	369	0.72	0.78	0.78
226	0.82	0.87	0.92	296	0.84	0.85 0.86	0.93 0.90	370 371	0.84	0.86 0.86	0.88 0.88
227 228	0.82 0.82	0.87 0.87	0.92 0.92	297 298	0.82 0.83	0.88	0.93	371	0.84 0.90	0.86	0.00
229	0.82	0.87	0.92	299	0.83	0.88	0.93	373	0.78	0.81	0.82
230	0.90	0.89	0.95	300	0.96	1.04	1.04	374	0.78	0.81	0.82
231	0.90	0.89	0.95	301	0.91	0.99	0.98	375	0.85	0.85	0.90
232	0.90	0.89	0.95	302	0.91	0.99	0.98	376	0.78	0.81	0.82
233	0.93	0.94	0.98	303	1.01	1.11	1,11	377	0.78	0.81	0.82
234	0.93	0.94	0.98	304	0.82	0.89	0.94	378	0.78	0.81	0.82
235	0.93	0.94	0.98	305	0.82	0.93	0.92	379	0.80	0.82	0.84
236	0.93	0.94	0.98	306	0.82	0.93	0.92	380	0.80	0.79	0.83
237	0.93 0.90	0.94	0.98	307 308	0.82 0.82	0.93 0.93	0.92 0.92	381	0.85 0.76	0.85 0.76	0.90
238 239	0.90	0.89 0.77	0.95 0.82	309	0.82	0.93	0.92	381 382 383	0.76	0.76	0.77 0.77
240	0.78	0.79	0.83	310	0.80	0.87	0.88	384	0.84	0.86	0.88
241	0.78	0.79	0.83	311	1.01	1.11	1.11	385	0.78	0.81	0.82
242	0.78	0.79	0.83	312	0.80	0.87	0.88	386	0.79	0.76	0.78
243	0.78	0.79	0.83	313	0.85	0.88	0.95	387	0.77	0.78	0.78
244	0.82	0.87	0.92	314	0.85	0.88	0.95	388	0.77	0.78	0.78
245	0.77	0.77	0.82	315	0.82	0.89	0.94	389 390	0.77	0.78	0.78
246	0.78	0.79	0.83	316	0.80	0.87	0.90 0.90	390	0.81	0.81 0.81	0.84 0.84
247 248	0.76 0.76	0.73 0.73	0.82 0.82	317 318	0.80 0.80	0.87 0.87	0.90	391 392	0.81	0.81	0.84
249	0.76	0.73	0.82	319	0.80	0.87	0.90	393	0.81	0.81	0.84
250	0.76	0.73	0.82	320	0.84	0.91	0.94	394	0.80	0.80	0.82
251	0.76	0.73	0.82	321	0.78	0.88	0.90	395	0.80	0.80	0.82
252	0.76	0.73	0.82	322	0.90	0.96	0.98	396	0.80	0.80	0.82
253	0.76	0.73	0.82	323	0.81	0.89	0.89	397	0.77	0.78	0.78
254	0.76	0.74	0.80	324	0.81	0.89	0.89 0.89	399 400	1.01	1.11	1.11
255 256	0.76 0.76	0.73 0.73	0.82 0.82	325 326	0.81 0.82	0.89 0.93	0.09	400	0.79 0.79	0.78 0.78	0.83 0.83
257	0.76	0.73	0.82	327	0.86	0.93	0.94	402	0.81	0.81	0.86
258	0.76	0.73	0.82	328	0.87	0.93	0.94	403	0.79	0.77	0.82
259	0.76	0.73	0.82	329	0.91	1.02	0.97	404	0.79	0.77	0.82
260	0.74	0.74	0.80	330	1.09	1.09	1.04	405	0.81	0.83	0.86
261	0.76	0.74	0.80	331	1.38	1.30	1.19	406	0.81	0.83	0.86
262	0.76	0.74	0.80	332	1.38	1.30	1.19	407	0.78	0.73	0.77
263	0.76	0.74	0.80	333 334	1.10 0.99	1.15 1.08	1.04 1.08	408 409	0.78 0.78	0.73 0.73	0.77 0.77
264 265	0.76 0.74	0.74 0.74	0.80 0.80	335	0.85	0.97	0.95	410	0.79	0.73	0.82
266	0.76	0.73	0.82	336	0.89	1.01	0.95	411	0.78	0.73	0.77
267	0.76	0.74	0.80	337	0.85	0.97	0.95	412	0.78	0.73	0.77
268	0.76	0.74	0.80	338	0.84	0.89	0.92	413	0.78	0.73	0.77
270	0.86	0.93	0.93	339	0.89	1.00	0.98	414	0.78	0.73	0.77
271	0.94	0.99	0.93	341	0.93	1.06	1.02	415	0.78	0.73 0.73	0.77 0.77
272	0.86	0.93 0.93	0.93	342 344	0.85 0.77	0.97 0.89	0.95 0.87	416 417	0.78 0.78	0.73	0.77
273 274	0.86 0.86	0.93	0.93	346	0.85	0.03	0.95	418	0.78	0.73	0.77
275	0.93	0.98	0.97	347	0.86	0.93	0.94	420	0.76	0.77	0.81
276	0.93	0.98	0.97	349	0.88	0.98	0.97	421	0.77	0.76	0.79
277	0.94	0.97	0.95	350	0.74	0.76	0.77	422	0.76	0.77	0.81
278	0.86	0.90	0.89	351	0.74	0.76	0.77	423	0.76	0.77	0.81
279	0.86	0.90	0.89	352	0.77	0.81	0.80	424 425	0.76 0.72	0.77	0.81 0.73
280 281	0.89 0.89	0.92 0.92	0.92 0.92	354 355	0.74	0.76 0.76	0.77	425 426	0.72	0.71	0.73
282	0.09	1.01	1.02	356	0.79	0.80	0.80	427	0.72	0.71	0.73
283	0.86	0.90	0.89	357	0.79	0.80	0.80	430	0.87	0.91	0.93
284	0.86	0.90	0.89	358	0.79	0.80	0.80	431	0.87	0.91	0.93
285	0.86	0.90	0.89	359	0.74	0.75	0.76	432	0.90	0.95	0.99
286	0.83	0.92	0.92	360 361	0.72	0.78 0.78	0.78 0.78	433 434	0.76	0.80	0.86
287 288	0.83 0.83	0.92 0.92	0.92 0.92	361 362	0.72 0.74	0.75	0.76	435	0.85	0.87	0.93
200	0.00	1 0.02	1 0.02			,	,				•

TABLE R. — OUTPATIENT DENTAL PROFESSIONAL CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

PAGE 3 OF 5

ZIP		GAAF		ZIP		GAAF		ZIP		GAAF	
Code	Class I	Class II	Class III	Code	Class I	Class II	Class III	Code	Class I	Class II	Class III
436	0.85	0.87	0.93	505	0.69	0.73	0.75	585	0.78	0.75	0.81
437	0.76	0.79	0.86	506	0.73	0.75	0.78	586	0.78	0.75	0.81
438	0.76	0.79	0.86	507	0.73	0.75	0.78	587	0.78	0.75	0.81
439	0.76	0.79	0.86	508	0.69	0.73	0.75	588	0.78	0.75	0.81 0.88 0.92 0.88
440	0.87	0.90	0.95	509	0.83	0.84	0.85	590	0.89	0.86	0.88
441	0.92	0.95	1.01	510	0.69	0.73	0.75	591	0.90	0.92	0.92
442	0.87	0.90	0.95	511	0.84	0.86	0.87	591 592	0.89	0.86	0.88
443	0.87	0.90	0.95	512	0.69	0.73	0.75	593	0.89	0.86	0.88
444	0.82	0.81	0.88	513	0.69	0.73	0.75	594	0.89	0.86	0.88
445	0.82	0.81	0.88	514	0.69	0.73	0.75	595	0.89	0.86	0.88
446	0.76	0.79	0.86	515	0.69	0.73	0.75	596	0.89	0.86	0.88
447	0.85	0.88	0.93	516	0.69	0.73	0.75 0.80	597 598	0.89	0.86	0.88 0.88
448 449	0.77 0.78	0.80 0.81	0.86 0.88	520 521	0.75 0.73	0.78 0.75	0.78	599	0.89 0.89	0.86 0.86	0.00
450	0.78	0.84	0.90	521 522	0.75	0.78	0.76	600	1.01	1.05	1.06
451	0.82	0.84	0.90	523	0.75	0.78	0.80	601	0.97	1.01	0.88 1.06 1.02
452	0.87	0.92	0.95	524	0.75	0.78	0.80	602	1.01	1.06	1.05
453	0.80	0.80	0.88	525	0.75	0.78	0.80	603	1.01	1.06	1.05
454	0.83	0.87	0.90	526	0.75	0.78	0.80	604	0.94	0.96	0.98
455	0.80	0.80	0.88	527	0.75	0.78	0.80	605	0.98	1.01	1.03
456	0.82	0.84	0.90	528	0.75	0.78	0.80	606	1.07	1.05	1.06
457	0.76	0.79	0.86	530	0.88	0.89	0.93	607	1.07	1.05	1.06
458	0.76	0.80	0.86	531	0.90	0.90	0.91	608	1.07	1.05	1.06
459	0.87	0.92	0.95	532	0.91	0.91	0.92	609	0.80	0.83	0.85 0.87
460	0.82	0.86	0.89	534	0.92	0.94	0.93	610	0.82	0.82	0.87
461	0.82	0.86	0.89	535	0.80	0.82	0.85	611	0.88	0.93	0.95
462	0.86	0.93	0.93	537	0.93	0.96	0.96 0.85	612 613	0.82	0.82 0.81	0.87 0.85
463	0.90	0.91 0.91	0.95 0.95	538 539	0.80 0.84	0.82 0.87	0.89	614	0.80 0.80	0.81	0.85
464 465	0.90 0.81	0.91	0.89	540	0.79	0.87	0.84	615	0.80	0.81	0.85
466	0.81	0.87	0.89	541	0.82	0.82	0.89	616	0.86	0.88	0.84
467	0.76	0.82	0.85	542	0.82	0.82	0.89	617	0.83	0.81	0.87
468	0.76	0.82	0.85	543	0.89	0.94	0.97	618	0.83	0.83	0.87
469	0.82	0.87	0.89	544	0.84	0.85	0.89	619	0.78	0.79	0.85
470	0.79	0.79	0.85	545	0.79	0.81	0.84	620	0.78	0.83	0.83
471	0.79	0.79	0.85	546	0.80	0.81	0.85	622	0.79	0.82	0.84
472	0.79	0.79	0.85	547	0.83	0.83	0.88	623	0.74	0.76	0.81
473	0.82	0.86	0.89	548	0.79	0.81	0.84	624	0.73	0.73	0.79
474	0.79	0.79	0.85	549	0.85	0.88	0.90	625	0.74	0.76	0.81 0.81
475	0.74	0.78	0.85	550 551	0.92	0.95 0.98	0.94 1.01	626 627	0.74 0.83	0.76 0.87	0.01
476 477	0.74 0.74	0.78 0.78	0.85 0.85	551 553	0.98 0.95	0.99	0.98	628	0.03	0.73	0.91 0.79
478	0.74	0.79	0.85	554	1.04	1.04	1.03	629	0.79	0.82	0.73
479	0.82	0.87	0.89	555	0.95	0.99	0.98	630	0.89	0.91	0.84 0.92
480	1.05	0.94	0.94	556	0.84	0.80	0.84	631	0.90	0.92	0.95
481	1.06	0.95	0.94	557	0.84	0.80	0.84	633	0.89	0.91	0.95 0.92
482	1.06	0.93	0.94	558	0.83	0.83	0.87	634	0.89	0.91	0.92
483	1.07	0.96	0.96	559	0.85	0.83	0.89	635	0.71	0.69	0.74
484	1.01	0.89	0.88	560	0.80	0.79	0.85	636	0.75	0.76	0.77
485	1.01	0.89	0.88	561	0.78	0.76	0.81	637	0.75	0.76	0.77 0.75
486	0.91	0.87	0.86	562	0.78	0.76	0.81	638 639	0.73 0.73	0.74 0.74	0.75
487 488	0.91 0.94	0.87 0.89	0.86 0.89	563 564	0.83 0.83	0.82	0.86 0.86	640	0.73	0.89	0.75
489	0.94	0.89	0.89	565	0.84	0.80	0.84	641	0.86	0.89	0.89
490	0.88	0.85	0.89	566	0.84	0.80	0.84	644	0.71	0.69	0.74
491	0.88	0.85	0.89	567	0.84	0.80	0.84	645	0.71	0.69	0.74
492	0.88	0.85	0.89	570	0.81	0.77	0.80	646	0.71	0.69	0.74
493	0.86	0.86	0.90	571	0.80	0.79	0.80	647	0.73	0.74	0.75
494	0.86	0.86	0.90	572	0.81	0.77	0.80	648	0.73	0.74	0.75
495	0.86	0.86	0.90	573	0.81	0.77	0.80	649	0.86	0.89	0.89
496	0.86	0.86	0.90	574	0.81	0.77	0.80	650	0.78	0.83	0.85
497	0.86	0.86	0.90	575	0.81	0.77	0.80	651 652	0.78 0.78	0.83	0.85 0.85
498	0.83	0.82	0.87 0.87	576 577	0.81	0.77 0.77	0.80	653	0.78	0.74	0.85
499 500	0.83	0.82 0.84	0.87	577 580	0.61	0.75	0.80	654	0.73	0.74	0.75
501	0.83	0.84	0.85	581	0.83	0.80	0.85	655	0.73	0.74	0.75
502	0.83	0.84	0.85	582	0.78	0.75	0.81	656	0.73	0.74	0.75
503	0.83	0.84	0.85	583	0.78	0.75	0.81	657	0.73	0.74	0.75
504	0.73	0.75	0.78	584	0.78	0.75	0.81	658	0.81	0.82	0.86

TABLE R. — OUTPATIENT DENTAL PROFESSIONAL CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE PAGE 4 OF 5

ZIP	GAAF		ZIP		GAAF		ZIP		GAAF	
Code Clas	S I Class II	Class III	Code	Class I	Class II	Class III	Code	Class I	Class II	Class III
660 0.8 661 0.8 662 0.9 664 0.8 665 0.8 666 0.7 668 0.7 669 0.7 671 0.8 671 0.8 672 0.8 671 0.7 678 0.7 678 0.7 678 0.7 678 0.7 680 0.7 681 0.7 683 0.7 684 0.7 685 0.7 686 0.7 687 0.7 688 0.7 686 0.7 687 0.7 689 0.7 689 0.7 689 0.7 689 0.7 689 0.7 689 0.7 689 0.7 689 0.7 689 0.7 689 0.7 689 0.7	0.86 0.86 0.97 0.80 0.80 0.85 0.76 0.76 0.77 0.78 0.77 0.77 0.77 0.77 0.77 0.77	0.85 0.85 0.88 0.83 0.83 0.87 0.78 0.80 0.81 0.81 0.89 0.78 0.80 0.80 0.80 0.80 0.80 0.80 0.80	741 743 744 745 746 747 748 749 750 751 752 753 754 755 756 757 758 759 760 761 762 763 764 765 766 767 768 769 770 772 773	0.83 0.77 0.77 0.79 0.81 0.79 0.77 0.79 0.95 0.96 0.77 0.77 0.77 0.77 0.77 0.89 0.89 0.85 0.84 0.78 0.79 0.79 0.89	Class II 0.85 0.73 0.73 0.76 0.79 0.76 0.73 0.76 1.07 1.07 1.09 1.09 0.83 0.83 0.83 0.83 0.83 0.83 0.83 0.83	0.88 0.77 0.77 0.79 0.83 0.79 0.77 0.79 1.03 1.09 1.09 0.88 0.88 0.88 0.88 0.88 0.88 0.88 0	812 813 814 815 816 820 821 822 823 824 825 826 827 828 830 831 832 833 834 835 836 837 838 840 841 842 843 844 845 846	0.85 0.85 0.85 0.85 0.97 0.80 0.80 0.80 0.80 0.80 0.80 0.80 0.8	Class II 0.89 0.89 0.89 0.89 0.76 0.76 0.76 0.76 0.76 0.76 0.76 0.76	0.91 0.91 0.91 1.07 0.79 0.79 0.79 0.79 0.79 0.79 0.79 0
691	0.75 0.75 0.75 0.75 0.88 0.89 0.84 0.88 0.84 0.86 0.86 0.83 0.83 0.83 0.83 0.83 0.83 0.83 0.83		772 773 774 775 776 777 778 779 780 781 782 783 784 785 786 787 788 789 790 791 792 793 794 795 796 797 798 799 800 801 802 803 804 805 806 807 808 809 810				845 846 847 850 852 853 855 856 857 859 860 863 864 865 870 871 872 873 874 875 877 878 879 880 881 882 883 884 885 889 890 891 895 896 897 896 897 897 898 899			0.81 0.81 0.99 0.99 0.99 0.99 0.92 0.96 0.96 0.92 0.95 0.92 0.95 0.97 0.97 0.97 0.97 0.97 0.97 0.97 0.97 0.97 0.93 0.93 0.93 0.93 0.93 0.93 0.93 0.93 0.93 0.93 0.96 1.06 1.06 1.06 1.06 1.06 1.06 1.06 1.13 1.17

TABLE R. — OUTPATIENT DENTAL PROFESSIONAL CHARGES GEOGRAPHIC AREA ADJUSTMENT FACTORS (GAAFS) BY ZIP CODE

		 _	_
$\neg \land$	GF		⊏

ZIP		GAAF		ZIP		GAAF		ZIP		GAAF	
Code	Class I	Class II	Class III	Code	Class I	Class II	Class III	Code	Class 1	Class II	Class III
903	1.32	1.29	1.17	935	1.10	1.06	0.98	970	1.14	1.01	0.98
904	1.32	1.29	1.17	936	1.06	1.04	0.94	971	1.14	1.01	0.98
905	1,22	1.15	1.07	937	1.06	1.04	0.94	972	1.15	1.01	0.95
906	1.22	1.15	1.07	938	1.06	1.04	0.94	973	1.07	0.97	0.96
907	1.22	1.15	1.07	939	1.15	1.20	1.07	974	1.09	0.96	0.94
908	1.22	1.15	1.07	940	1.27	1.31	1.17	975	1.09	0.96	0.94
910	1.15	1.12	1.07	941	1.25	1.31	1.19	976	1.09	0.96	0.94
911	1.19	1.15	1.10	942	1.12	1.12	0.99	977	1.09	0.96	0.94
912	1.15	1.12	1.07	943	1.36	1.41	1.30	978	1.03	0.90	0.91
913	1.18	1.21	1.09	944	1.25	1.29	1.18	979	1.03	0.90	0.91
914	1.23	1.21	1.10	945	1.22	1.26	1.11	980	1.32	1.22	1.13
915	1.18	1.21	1.09	946	1.22	1.26	1.11	981	1.30	1.24	1.15
916	1.23	1.21	1.10	947	1.22	1.26	1.11	982	1.23	1.12	1.08
917	1.23	1.08	1.03	948	1.22	1.26	1.11	983	1.26	1.17	1.10
918	1.23	1.08	1.03	949	1.22	1.26	1.11	984	1.26	1.17	1.10
919	1.11	1.16	1.05	950	1.30	1.28	1.13	985	1.20	1.09	1.04
920	1.11	1.16	1.05	951	1.30	1.28	1.13	986	1.18	1.09	1.03
921	1.11	1.15	1.04	952	1.09	1.08	0.97	988	1.17	1.10	1.03
922	1.15	1.07	1.01	953	1.09	1.08	0.97	989	1.17	1.10	1.03
923	1.15	1.07	1.01	954	1.06	1.15	1.01	990	1.15	1.07	1.00
924	1.15	1.07	1.01	955	1.06	1.15	1.01	991	1.15	1.07	1.00
925	1.15	1.07	1.01	956	1.11	1.10	0.99	992	1.15	1.07	1.00
926	1.24	1.22	1.11	957	1.11	1.10	0.99	993	1.17	1.10	1.03
927	1.24	1.22	1.11	958	1.12	1.12	0.99	994	1.17	1.10	1.03
928	1.24	1.22	1.11	959	1.06	1.15	1.01	995	1.51	1.39	1.21
930	1.17	1.16	1.04	960	1.06	1.15	1.01	996	1.52	1.37	1.20
931	1.18	1.29	1.13	961	1.06	1.15	1.01	997	1.51	1.39	1.21
932	1.10	1.06	0.98	967	1.12	1.01	1.01	998	1.52	1.37	1.20
933	1.10	1.06	0.98	968	1.12	1.01	1.01	999	1.47	1.38	1.17
934	1.08	1.10	0.99	969	1.12	1.01	1.01				

 ${\sf TABLE~S.-PROFESSIONAL~SERVICES~CONVERSION~FACTORS}$

Category	Conversion Factor
Allergy Immunotherapy	\$50.29
Allergy Testing	\$66.19
Anesthesia	\$80.29
Cardiovascular	\$113.14
Chiropractor	\$63.89
Consults	\$62.53
Emergency Room Visits	\$105.87
Hearing/Speech Exams	\$68.85
Immunizations	\$113.64
Inpatient Visits	\$78.48
Maternity — Cesarean Deliveries	\$79.59
Maternity — Non-Deliveries	\$128.86
Maternity — Normal Deliveries	\$73.22
Miscellaneous Medical	\$87.24
Office/Home/Urgent Care Visits	\$55.05
OP Psych./Alc. & Drug Abuse	\$54.93
Pathology	\$98.38
Physical Exams	\$52.61
Physical Medicine	\$70.01
Radiology	\$112.74
Surgery	\$132.82
Therapeutic Injections	\$167.00
Vision Exams	\$42.51
Well Baby Exams	\$46.12

Page 1 of 6

Supplementary Table 1 Reasonable Charges Data Sources - V2.0

V2p0 PR Data Sources.xls - By Charge Type

Charge	Deregreenh	to iti	Data Cource	Edition
246.	r alaylapii			0000 1-11
Inpt	(b)(2)	per diem charges	CPI-U, inpatient hospital services component, seasonally adjusted	Jan 2003, as of Feb 2003
Inpt	(b)(2)	per diem charges	MedPAR file	FY 2001
Inpt	(b)(2)	per diem charges	MedStat claims database	1999
Inpt	(b)(2)(i)	charge component percentages: R&B, ancillary	MedPAR file	FY 2001
Inpt	(b)(2)(ii)	charge ratios: standard R&B, ICU R&B	MedPAR file	FY 2001
lubt	(b)(2)(iii)	80th percentile	MedPAR file	FY 2001
Inpt	(b)(2)(iv)	trending forward	CPI-U, inpatient hospital services component, seasonally adjusted	Jan 2003, as of Feb 2003
lupt	(p)(3)	GAAFS	MedPAR file	FY 2001
Inpt	(p)(3)	GAAFs	MedStat claims database	1999
Inpt	(b)(a)	GAAFs	VA nationwide discharges	FY 2002
SNF	(c)(2)	per diem charge	MedPAR skilled nursing facility file	FY 2000
SNF	(c)(2)(i)	80th percentile adjustment factor	MedPAR skilled nursing facility file	
SNF	(c)(2)(ii)	trending forward	CPI-U, inpatient hospital services component, seasonally adjusted	Jan 2003, as of Feb 2003
SNF	(c)(3)	GAAFs	MedPAR skilled nursing facility file	FY 2000
Ē	(0)(1)	and the second s	Madiana OAF FOL Cample and selections food the commences	OC 2004
ב כ	(a)(z)	per dierricularye	Medicare SAF 5% Sample, outpatient facility component	121 0000 121 121 0000
Ľ	(a)(z)(li)	trending lorward	CPI-U, outpatient nospital services component, seasonally adjusted	Jan Zuus, as oi Feb zuus
ţ	(1)/(2)/(1)	80th nercentile charges codes with APCs	Madinara APC navment amount	2003
	(1)(0)(0)	ooth percentile charges, codes with ADCs	Medical O. O. Daylielle anions	2004
5 6	(e)(e)(ii)	Sour percentile charges, codes with APCs	Medicare SAF 5% Sarripie, outpatient lacinty component	1.45.000
E C	(e)(a)(II)	Soun percentile charges, codes with no APC	MID'R database, outpatient raciility component	July 2002
Opt	(e)(3)(jj)	80th percentile charges, codes with no APC	Medicare SAF 5% Sample, outpatient facility component	CY 2001
Opt	(e)(3)(ii)	80th percentile charges, codes with no APC	MedStat claims database	1999
Opt	(e)(3)(iii)	trending forward	CPI-U, outpatient hospital services component, seasonally adjusted	Jan 2003, as of Feb 2003
Opt	(e)(4)	GAAFs	MDR database	July 2002
Ö	(e)(4)	GAAFs	Milliman USA, Inc., Health Cost Guidelines	2002
		to the date of the	оосноволенного и подпинання для да да надажения в надажения для надажения в надажения для да да да да да да да да да да да да да	
Phys	(f)(2)(i)(A)	RVUs, codes with Medicare RVUs, work expense	Medicare Geographic Practice Cost Index, work expense	2003
Phys	(f)(2)(l)(A)	RVUs, codes with Medicare RVUs, work expense	Medicare Physician Fee Schedule RVUs, work expense	2003
Phys	(f)(2)(i)(B)		Medicare Geographic Practice Cost Index, practice expense	2003
Phys	(f)(2)(i)(B)	RVUs, codes with Medicare RVUs, practice expense	Medicare Physician Fee Schedule RVUs, practice expense	2003
Phys	(f)(2)(ii)	RVUs, codes with no Medicare RVUs	Ingenix/St. Anthony's RBRVS	2003
Phys	(f)(2)(ii)	RVUs, codes with no Medicare RVUs	MDR database	Aug 2001
Phys	(f)(2)(ii)	RVUs, codes with no Medicare RVUs	Medicare SAF 5% Sample, Part B component	CY 2001
Phys	(f)(2)(ii)	RVUs, codes with no Medicare RVUs	Prevailing Healthcare Charges System	May 2002
Phys	(f)(2)(iii)	RVUs, unlisted procedures	VA nationwide distribution of procedures and services	FY 2002
Phys	(f)(2)(iv)	RVU GAAFs, codes with no Medicare RVUs	Medicare Geographic Practice Cost Index, practice expense	2003
Phys	(f)(2)(iv)	RVU GAAFs, codes with no Medicare RVUs	Medicare Geographic Practice Cost Index, work expense	2003
Phys	(t)(3)	conversion factors, 80th percentile, geographically adjusted	MDR database	Aug 2001
Phys	(t)(3)	conversion factors, 80th percentile, geographically adjusted	Milliman USA, Inc., Health Cost Guidelines fee survey	2002
Phys	(f)(3)(ii)	trending forward	CPI-U, physicians' services component, seasonally adjusted	Jan 2003, as of Feb 2003
Phys	(f)(4)	modifiers: charge adjustment factors	Medicare SAF 5% Sample, Part B component	CY 2001
Anes	(a)(2)	RVUs	CMS anesthesia base units	2003
Anes	(a)(b)	RVUs for unlisted procedures	VA nationwide distribution of procedures and services	FY 2002
2010	/ 3 //6/	TO CO TOL STITLES TO COCCUTION	VALIGIOLIVIA GIOGINATION DISCOSSIONI CONTRACTORIO DE LA CONTRACTORIO D	

Page 2 of 6

V2p0 PR Data Sources.xls - By Charge Type

Charge	Paragraph	foiding	Data Source	Edition
246.	idaidai i	-		
Anes	(g)(3)(l)	conversion factor, nationwide	CMS anesthesia base units	2003
Anes,	(g)(g)(i)	conversion factor, nationwide	MDR database	Sept 2001
Anes	(g)(g)	conversion factor, nationwide	Medicare SAF 5% Sample, Part B component	CY 2001
Anes	(g)(g)(j)	conversion factor, nationwide	Milliman USA, Inc., Health Cost Guidelines	2002
Anes	(g)(g)(ii)	trending forward	CPI-U, physicians' services component, seasonally adjusted	Jan 2003, as of Feb 2003
Dent	(h)(2)	charges, 80th percentile, nationwide	CPI-U, dental services component, seasonally adjusted	
Dent	(h)(2)	charges, 80th percentile, nationwide	Ingenix Comprehensive Healthcare Payment System, Dental UCR Module	Sept 2002
Dent	(h)(2)	charges, 80th percentile, nationwide	National Dental Advisory Service nationwide pricing index	
Dent	(h)(2)	charges, 80th percentile, nationwide	Prevailing Healthcare Charges System	May 2002
Dent	(h)(2)(ii)	charges, 80th percentile, nationwide, for unlisted procedures Prevailing Healthcare Charges System	Prevailing Healthcare Charges System	May 2002
Dent	(h)(2)(iii)	trending forward	CPI-U, dental services component, seasonally adjusted	Jan 2003, as of Feb 2003
Dent	(h)(3)	GAAFs	Ingenix Comprehensive Healthcare Payment System, Dental UCR Module	Sept 2002
Dent	(h)(3)	GAAFS	Milliman USA, Inc., Dental Health Cost Guidelines	2002
Lab	(i)(2)(i)	RVUs, codes with Medicare-based RVUs	MDR database	Aug 2001
Lab	(i)(2)(i)	RVUs, codes with Medicare-based RVUs	Medicare Clinical Diagnostic Laboratory Fee Schedule	2003
Lab	(i)(2)(i)	RVUs, codes with Medicare-based RVUs	Medicare conversion factor	2003
Lab	(i)(2)(i)	RVUs, codes with Medicare-based RVUs	Medicare Physician Fee Schedule payment levels	2003
Lab	(ii)(2)(ii)	RVUs, codes with no Medicare-based RVUs	Ingenix/St. Anthony's RBRVS	2003
Lab	(I)(2)(II)	RVUs, codes with no Medicare-based RVUs	MDR database	Aug 2001
Lab	(i)(2)(ii)	RVUs, codes with no Medicare-based RVUs	Medicare SAF 5% Sample, Part B component	CY 2001
Lab	(i)(2)(ii)	RVUs, codes with no Medicare-based RVUs	Prevailing Healthcare Charges System	May 2002
Lab	(I)(2)(III)	RVUs, unlisted procedures	VA nationwide distribution of procedures and services	FY 2002
Lab	(i)(2)(iv)	RVU GAAFs, codes with no Medicare-based RVUs	Medicare Geographic Practice Cost Index, practice expense	2003
Lab	(i)(2)(iv)	RVU GAAFs, codes with no Medicare-based RVUs	Medicare Geographic Practice Cost Index, work expense	2003
Lab	(i)(3)	conversion factors, 80th percentile, geographically adjusted	MDR database	Aug 2001
Lab	(i)(3)	conversion factors, 80th percentile, geographically adjusted	Milliman USA, Inc., Health Cost Guidelines fee survey	2002
Lab	(i)(3)(ii)	trending forward	CPI-U, physicians' services component, seasonally adjusted	Jan 2003, as of Feb 2003
			A CALL AND A CALL AND	
sqo	(1)(2)(1)	charges, 80th percentile, nationwide	Medicare SAF 5% Sample, outpatient facility component	CY 2001
sqo	(1)(2)(11)	trending forward	CPI-U, outpatient hospital services component, seasonally adjusted	Jan 2003, as of Feb 2003
Amb	(k)(2)(i)	base charge. 80th percentile, nationwide	Medicare SAF 5% Sample, outpatient facility component	CY 2001
Amb	(k)(2)(ii)		Medicare SAF 5% Sample, outpatient facility component	CY 2001
Amb	(k)(2)(iii)		CPI-U, outpatient hospital services component, seasonally adjusted	Jan 2003, as of Feb 2003
DME	(I)(2)(I)	PVUS	Ingenix/St. Anthony's RBRVS, practice expense RVUs	2003
DME	(1)(2)(1)	RVUs	Medicare DME Fee Schedule	2003
DME	(1)(2)(1)	RVUs	Medicare Parenteral and Enteral Nutrition Fee Schedule	2003
DME	(I)(2)(II)	charge amounts	Medicare SAF 5% Sample, DME component	CY 2001
DME	(I)(2)(ii)	charge amounts	Medicare SAF 5% Sample, Part B component	CY 2001
DME	(1)(2)(iii)	charge ratios, 80th percentile to median	MDR database	Sept 2002
DME	(1)(2)(iii)	charge ratios, 80th percentile to median	Medicare SAF 5% Sample, DME component	CY 2001
DME	(I)(2)(II)	charge ratios, 80th percentile to median	Medicare SAF 5% Sample, Part B component	CY 2001
DME	(I)(2)(iv)	trending forward	CPI-U, medical care commodities component, seasonally adjusted	Jan 2003, as of Feb 2003

Page 3 of 6

V2p0 PR Data Sources.xis - By Charge Type

Type	Paragraph	Subject	Data Source	Edition
DME	(1)(3)	charges for codes with no RVUs	MDR database	Sept 2002
DME ((1)(3)	charges for codes with no RVUs	Medicare SAF 5% Sample, DME component	CY 2001
DME	(E)(I)	charges for codes with no RVUs	Medicare SAF 5% Sample, Part B component	CY 2001
	(E)(I)	charges for codes with no RVUs	Milliman USA, Inc., Optimized HMO Data Sets	2000
DME	(I)(3)(I)	trending forward	CPI-U, medical care commodities component, seasonally adjusted	Jan 2003, as of Feb 2003
	(1)(4)	charges for unlisted procedures	VA nationwide distribution of procedures, services, items, and supplies	FY 2002
DME	(I)(5)(II)	charges, weighted average, area-specific	MDR database	Sept 2002
DME	(I)(5)(II)	charges, weighted average, area-specific	Medicare SAF 5% Sample, DME component	CY 2001
DME ((i)(5)(ii)	charges, weighted average, area-specific	Medicare SAF 5% Sample, Part B component	CY 2001
DME	(I)(5)(III)	charges, weighted average, nationwide	Milliman USA, Inc., Health Cost Guidelines	2002
T. Charles	Civical A Am		Other Apparit	
Cliarde	Jiaige 1 ype Appleviations		Office Applications	
Amb = An	= Ambulance		APC = Ambulatory Payment Classification	
Anes = An	= Anesthesia		CMS = Centers for Medicare and Medicaid Services	
Dent = De	 Dental HCPCS Level II 	S Level II	CPI-U = Consumer Price Index - All Urban Consumers	
DME = DN	VE and other	 DME and other HCPCS Level II 	CY = Calendar Year (January - December)	
Inpt = Ac	sute inpatient	Acute inpatient facility charges	DME = Durable Medical Equipment	
Lab = Pa	 Pathology and laboratory 	laboratory	FY = Fiscal Year (October - September)	
ops = Op	Observation care	ıre	GAAF = Geographic Area Adjustment Factor	
	 Outpatient facility charges 	lity charges	HMO = Health Maintenance Organizations	
PH = Pa	Partial hospitalization	Ization	ICU = Intensive Care Unit	
Phys = Ph	nysician and	Physician and other professional charges	MDR = Medical Data Research	
SNF = Sk	killed nursing	Skilled nursing facility / sub-acute inpatient facility charges	MedPAR = Medicare Provider Analysis and Review	
			R&B = Room and Board	
ţ*.			RBRVS = Resource-Based Relative Value Scale	-
			RVU = Relative Value Unit	
			SAF = Standard Analytical File	
			UCR = Usual, Customary, or Reasonable	
			VA = Department of Veterans Affairs	

Page 4 of 6

V2p0 PR Data Sources.xls - By Data Source

Charge				
Type	Paragraph	Subject	Data Source	Edition
Anes	(d)(5)		CMS anesthesia base units	2003
Anes	(j)(j)	conversion factor, nationwide	CMS anesthesia base units	2003
Dent	(h)(2)	charges, 80th percentile, nationwide	CPI-U, dental services component, seasonally adjusted	Jan 2003, as of Feb 2003
Dent	(h)(2)(iii)	trending forward	CPI-U, dental services component, seasonally adjusted	Jan 2003, as of Feb 2003
Inpt	(b)(2)	per diem charges	CPI-U, inpatient hospital services component, seasonally adjusted	Jan 2003, as of Feb 2003
Inpt	(b)(2)(iv)	trending forward	CPI-U, inpatient hospital services component, seasonally adjusted	Jan 2003, as of Feb 2003
SNF	(c)(2)(ii)	trending forward	CPI-U, inpatient hospital services component, seasonally adjusted	Jan 2003, as of Feb 2003
DME	(I)(2)(iv)	trending forward	CPI-U, medical care commodities component, seasonally adjusted	Jan 2003, as of Feb 2003
DME	(I)(3)(i)	trending forward	CPI-U, medical care commodities component, seasonally adjusted	Jan 2003, as of Feb 2003
Ŧ	(d)(2)(ii)	trending forward	CPI-U, outpatient hospital services component, seasonally adjusted	Jan 2003, as of Feb 2003
ă O	(e)(3)(iii)	trending forward	CPI-U, outpatient hospital services component, seasonally adjusted	Jan 2003, as of Feb 2003
Ops	(1)(2)(ii)	trending forward	CPI-U, outpatient hospital services component, seasonally adjusted	Jan 2003, as of Feb 2003
Amb	(k)(2)(iii)	trending forward	CPI-U, outpatient hospital services component, seasonally adjusted	Jan 2003, as of Feb 2003
Phys	(f)(3)(ii)	trending forward	CPI-U, physicians' services component, seasonally adjusted	Jan 2003, as of Feb 2003
Anes	(i)(s)(ii)	trending forward	CPI-U, physicians' services component, seasonally adjusted	Jan 2003, as of Feb 2003
Lab	(i)(3)(ii)	trending forward	CPI-U, physicians' services component, seasonally adjusted	Jan 2003, as of Feb 2003
Dent	(h)(2)	charges, 80th percentile, nationwide	Ingenix Comprehensive Healthcare Payment System, Dental UCR Module	Sept 2002
Dent	(h)(3)	GAAFs	Ingenix Comprehensive Healthcare Payment System, Dental UCR Module	Sept 2002
Phys	(f)(2)(ii)	RVUs, codes with no Medicare RVUs	Ingenix/St. Anthony's RBRVS	2003
Lab	(i)(2)(ii)	RVUs, codes with no Medicare-based RVUs	Ingenix/St. Anthony's RBRVS	2003
DME	(I)(2)(i)	RVUs	Ingenix/St. Anthony's RBRVS, practice expense RVUs	2003
Opt	(e)(4)	GAAFs	MDR database	July 2002
Phys	(f)(2)(ii)	RVUs, codes with no Medicare RVUs	MDR database	Aug 2001
Phys	(f)(3)	conversion factors, 80th percentile, geographically adjusted	MDR database	Aug 2001
Anes	(a)(a)(i)	conversion factor, nationwide	MDR database	Sept 2001
Lab	(1)(2)(1)	RVUs, codes with Medicare-based RVUs	MDR database	Aug 2001
Lab	(i)(2)(ii)	RVUs, codes with no Medicare-based RVUs	MDR database	Aug 2001
Lab	(i)(3)	conversion factors, 80th percentile, geographically adjusted	MDR database	Aug 2001
DME	(I)(2)(iii)	charge ratios, 80th percentile to median	MDR database	Sept 2002
DME	(1)(3)	charges for codes with no RVUs	MDR database	Sept 2002
DME	(I)(5)(ii)	charges, weighted average, area-specific	MDR database	Sept 2002
Opt	(e)(3)(ii)	80th percentile charges, codes with no APC	MDR database, outpatient facility component	July 2002
Obt	(e)(3)(i)	80th percentile charges, codes with APCs	Medicare APC payment amount	2003
Lab	(i)(2)(i)	RVUs, codes with Medicare-based RVUs	Medicare Clinical Diagnostic Laboratory Fee Schedule	2003
Lab	(i)(2)(i)	RVUs, codes with Medicare-based RVUs	Medicare conversion factor	2003
DME	(1)(2)(i)		Medicare DME Fee Schedule	2003
Phys	(f)(2)(l)(B)	RVUs, codes with Medicare RVUs, practice expense	Medicare Geographic Practice Cost Index, practice expense	2003
Phys	(f)(2)(iv)	RVU GAAFs, codes with no Medicare RVUs	Medicare Geographic Practice Cost Index, practice expense	2003
Lab	(i)(2)(iv)	RVU GAAFs, codes with no Medicare-based RVUs	Medicare Geographic Practice Cost Index, practice expense	2003
Phys	(f)(2)(i)(A)	RVUs, codes with Medicare RVUs, work expense	Medicare Geographic Practice Cost Index, work expense	2003
Phys	(f)(2)(iv)	RVU GAAFs, codes with no Medicare RVUs	Medicare Geographic Practice Cost Index, work expense	2003
Lab	(i)(2)(iv)	RVU GAAFs, codes with no Medicare-based RVUs	Medicare Geographic Practice Cost Index, work expense	2003
DME	(1)(2)(1)	RVUs	Medicare Parenteral and Enteral Nutrition Fee Schedule	2003
Lab	(i)(2)(i)		Medicare Physician Fee Schedule payment levels	2003
Phys	(f)(2)(i)(B)		Medicare Physician Fee Schedule RVUs, practice expense	2003
Phys	(f)(2)(i)(A)	RVUs, codes with Medicare RVUs, work expense	Medicare Physician Fee Schedule RVUs, work expense	2003

Charge				
Type	Paragraph	Subject	Data Source	Edition
DME	(1)(2)(ii)	charge amounts	Medicare SAF 5% Sample, DME component	CY 2001
DME	(1)(2)(111)	charge ratios, 80th percentile to median	Medicare SAF 5% Sample, DME component	CY 2001
DME	(E)(I)	charges for codes with no RVUs	Medicare SAF 5% Sample, DME component	CY 2001
DME	(I)(5)(II)	charges, weighted average, area-specific	Medicare SAF 5% Sample, DME component	CY 2001
H H	(d)(2)	per diem charge	Medicare SAF 5% Sample, outpatient facility component	CY 2001
Opt	(e)(3)(i)	80th percentile charges, codes with APCs	Medicare SAF 5% Sample, outpatient facility component	CY 2001
Opt	(e)(3)(ii)	80th percentile charges, codes with no APC	Medicare SAF 5% Sample, outpatient facility component	CY 2001
SqO	(1)(2)(1)	charges, 80th percentile, nationwide	Medicare SAF 5% Sample, outpatient facility component	CY 2001
Amb	(k)(2)(i)	base charge, 80th percentile, nationwide	Medicare SAF 5% Sample, outpatient facility component	CY 2001
Amb	(k)(2)(ii)	mileage charge, 80th percentile, nationwide	Medicare SAF 5% Sample, outpatient facility component	CY 2001
Phys	(f)(2)(ii)	RVUs, codes with no Medicare RVUs	Medicare SAF 5% Sample, Part B component	CY 2001
Phys	(f)(4)	modifiers: charge adjustment factors	Medicare SAF 5% Sample, Part B component	CY 2001
Anes	(a)(s)(i)	conversion factor, nationwide	Medicare SAF 5% Sample, Part B component	CY 2001
Lab	(i)(2)(ii)	RVUs, codes with no Medicare-based RVUs	Medicare SAF 5% Sample, Part B component	CY 2001
DME	(I)(2)(ii)	charge amounts	Medicare SAF 5% Sample, Part B component	CY 2001
DME	(1)(2)(11)	charge ratios, 80th percentile to median	Medicare SAF 5% Sample, Part B component	CY 2001
DME	(1)(3)	charges for codes with no RVUs	Medicare SAF 5% Sample, Part B component	CY 2001
DME	(I)(5)(II)	charges, weighted average, area-specific	Medicare SAF 5% Sample, Part B component	CY 2001
Inpt	(b)(2)	per diem charges	MedPAR file	FY 2001
	(b)(2)(i)	charge component percentages: R&B, ancillary	MedPAR file	FY 2001
Inpt	(b)(2)(ii)	charge ratios: standard R&B, ICU R&B	MedPAR file	FY 2001
Inpt	(b)(2)(iii)	80th percentile	MedPAR file	FY 2001
Inpt	(c)(q)	GAAFs	MedPAR file	FY 2001
SNF	(c)(2)	per diem charge	MedPAR skilled nursing facility file	FY 2000
SNF	(c)(2)(i)	80th percentile adjustment factor	MedPAR skilled nursing facility file	FY 2000
SNF	(c)(3)	GAAFs	MedPAR skilled nursing facility file	FY 2000
Inpt	(b)(2)	per diem charges	MedStat claims database	1999
Inpt	(p)(3)	GAAFS	MedStat claims database	1999
o O	(e)(3)(ii)	80th percentile charges, codes with no APC	MedStat claims database	1999
Dent	(h)(3)	GAAFs	Milliman USA, Inc., Dental Health Cost Guidelines	2002
Opt	(e)(4)	GAAFs	Milliman USA, Inc., Health Cost Guidelines	2002
Anes	(g)(g)(j)	conversion factor, nationwide	Milliman USA, Inc., Health Cost Guidelines	2002
DME	(I)(5)(III)	charges, weighted average, nationwide	Milliman USA, Inc., Health Cost Guidelines	2002
Phys	(t)(3)	conversion factors, 80th percentile, geographically adjusted	Milliman USA, Inc., Health Cost Guidelines fee survey	2002
Lab	(E)(J)	conversion factors, 80th percentile, geographically adjusted	Milliman USA, Inc., Health Cost Guidelines fee survey	2002
DME	(1)(3)	charges for codes with no RVUs	Milliman USA, Inc., Optimized HMO Data Sets	2000
Dent	(h)(2)	charges, 80th percentile, nationwide	National Dental Advisory Service nationwide pricing index	2003
Phys	(f)(2)(ii)	RVUs, codes with no Medicare RVUs	Prevailing Healthcare Charges System	May 2002
Dent	(h)(2)	charges, 80th percentile, nationwide	Prevailing Healthcare Charges System	May 2002
Dent	(h)(2)(ii)	charges, 80th percentile, nationwide, for unlisted procedures Prevailing Healthcare Charges System	Prevailing Healthcare Charges System	May 2002
Lab	(i)(2)(ii)	RVUs, codes with no Medicare-based RVUs	Prevailing Healthcare Charges System	May 2002
Inpt	(p)(g)	GAAFs	VA nationwide discharges	FY 2002
Phys	(f)(2)(iii)	RVUs, unlisted procedures	VA nationwide distribution of procedures and services	FY 2002
Anes	(g)(z)	RVUs for unlisted procedures	VA nationwide distribution of procedures and services	FY 2002
Lab	(1)(2)(iii)	RVUs, unlisted procedures	VA nationwide distribution of procedures and services	
DME	(i)(4)	charges for unlisted procedures	VA nationwide distribution of procedures, services, items, and supplies	es FY 2002

Supplementary Table 1 Reasonable Charges Data Sources - V2.0

V2p0 PR Data Sources.xls - By Data Source

Page 6 of 6

Charge	9			
Type	Paragraph Subject	Subject	Data Source	Edition
Charge	Charge Type Abbreviations	ations	Other Abbreviations	
Amb =	Amb = Ambulance		APC = Ambulatory Payment Classification	
Anes =	Anes = Anesthesia		CMS = Centers for Medicare and Medicaid Services	
Dent =	Dent = Dental HCPCS Level II	S Level II	CPI-U = Consumer Price Index - All Urban Consumers	
DME =	DME and other	DME = DME and other HCPCS Level II	CY = Calendar Year (January - December)	
Inpt	Acute inpatient	= Acute inpatient facility charges	DME = Durable Medical Equipment	
Lab =	 Pathology and laboratory 	laboratory	FY = Fiscal Year (October - September)	
= sqo	Observation care	ıre	GAAF = Geographic Area Adjustment Factor	
= Obt	 Outpatient facility charges 	lity charges	HMO = Health Maintenance Organizations	
PH	Partial hospitalization	lization	ICU = Intensive Care Unit	
Phys =	Physician and	Physician and other professional charges	MDR = Medical Data Research	
SNF =		Skilled nursing facility / sub-acute inpatient facility charges	MedPAR = Medicare Provider Analysis and Review	
			R&B = Room and Board	
			RBRVS = Resource-Based Relative Value Scale	
			RVU = Relative Value Unit	
			SAF = Standard Analytical File	
			UCR = Usual, Customary, or Reasonable	
			VA = Department of Veterans Affairs	

Page 1 of 1

Supplementary Table 2 Reasonable Charges Data Sources - V2.0 - Where To Obtain

V2p0 PR Data Sources.xls - Obtain

CMS anesthesia base units	Centers for Medicare and Medicaid Services
CPI-11 various components, seasonally adjusted	Bureau of Labor Statistics Internet site. CPI section. http://www.bls.gov/cpi/
Ingenix Comprehensive Healthcare Payment System. Dental UCR Module	-
Indenix/St Anthony's RRBVS	
MCR database	Ingenix Inc. 2525 Lake Park Blvd., Salt Lake City. UT 84120
MDR database, outpatient facility component	Indenix: Inc. 2525 Lake Park Blvd. Salt Lake City. UT 84120
Medicare APC payment amount	CMS Internet site, http://www.cms.gov/regulations/hopps/changecy2003.asp
Medicare Clinical Diagnostic Laboratory Fee Schedule	CMS Internet site, files-for-download section, http://www.cms.gov/providers/pufdownload/
Medicare conversion factor	Federal Register, Vol. 68, No. 40, February 28, 2003, pages 9567-9568
Medicare DME Fee Schedule	CMS Internet site, files-for-download section, http://www.cms.gov/providers/pufdownload/
Medicare Geographic Practice Cost Index, practice expense	Federal Register, Vol. 67, No. 251, December 31, 2002, pages 80170-80172
Medicare Geographic Practice Cost Index, work expense	Federal Register, Vol. 67, No. 251, December 31, 2002, pages 80170-80172
Medicare Parenteral and Enteral Nutrition Fee Schedule	CMS Internet site, files-for-download section, http://www.cms.gov/providers/pufdownload/
	(included as part of DME Fee Schedule download)
Medicare Physician Fee Schedule payment levels	CMS Internet site, files-for-download section, http://www.cms.gov/providers/pufdownload/
Medicare Physician Fee Schedule RVUs, practice expense	CMS Internet site, files-for-download section, http://www.cms.gov/providers/pufdownload/
Medicare Physician Fee Schedule RVUs, work expense	CMS Internet site, files-for-download section, http://www.cms.gov/providers/pufdownload/
Medicare SAF 5% Sample, DME component	CMS Internet site, Files for Purchase Directory, at http://cms.hhs.gov/data/purchase/default.asp
Medicare SAF 5% Sample, outpatient facility component	CMS Internet site, Files for Purchase Directory, at http://cms.hhs.gov/data/purchase/default.asp
Medicare SAF 5% Sample, Part B component	CMS Internet site, Files for Purchase Directory, at http://cms.hhs.gov/data/purchase/default.asp
MedPAR file	CMS Internet site, Files for Purchase Directory, at http://cms.hhs.gov/data/purchase/default.asp
MedPAR skilled nursing facility file	CMS Internet site, Files for Purchase Directory, at http://cms.hhs.gov/data/purchase/default.asp
MedStat claims database	MedStat Group, 777 E. Eisenhower Parkway, Ann Arbor, MI 48108
Milliman USA, Inc., Dental Health Cost Guidelines	Milliman USA, Inc., 1301 5th Avenue, Suite 3800, Seattle, WA 98101-2605
Milliman USA, Inc., Health Cost Guidelines	Milliman USA, Inc., 1301 5th Avenue, Suite 3800, Seattle, WA 98101-2605
Milliman USA, Inc., Health Cost Guidelines fee survey	Milliman USA, Inc., 1301 5th Avenue, Suite 3800, Seattle, WA 98101-2605
Milliman USA, Inc., Optimized HMO Data Sets	Milliman USA, Inc., 1301 5th Avenue, Suite 3800, Seattle, WA 98101-2605
National Dental Advisory Service nationwide pricing index	Wasserman Medical Publishers, Ltd., PO. Box 510949, Milwaukee, WI 53203
Prevailing Healthcare Charges System	Ingenix, Inc., 2525 Lake Park Blvd., Salt Lake City, UT 84120
VA nationwide discharges	Veterans Health Administration
VA nationwide distribution of procedures and services	Veterans Health Administration
VA nationwide distribution of procedures, services, items, and supplies	Veterans Health Administration
Abbreviations	
APC = Ambulatory Payment Classification	
CMS = Centers for Medicare and Medicaid Services	
CPI-U = Consumer Price Index - All Urban Consumers	
DME = Durable Medical Equipment	
HMO = Health Maintenance Organizations	
MDR = Medical Data Research	
MedPAR = Medicare Provider Analysis and Review	
RBRVS = Resource-Based Relative Value Scale	
RVU = Relative Value Unit	
SAF = Standard Analytical File	
UCR = Usual, Customary, or Reasonable	
VA = Department of Veterans Affairs	

RC V2p0 Station List 02-11-05.xls

Page 1 of 18

Fac #	VA Facility Location	ST	ZIP 3	VN	Type
463	ANCHORAGE, AK	AK	995		IOC
463GA	FAIRBANKS, AK	AK	997	20	СВОС
463HA	FORT WAINWRIGHT, AK	AK	997	20	CBOC
463GB	KENAI, AK	AK	996	20	СВОС
521GE	ANNISTON, AL	AL	362	7	CBOC
521	BIRMINGHAM, AL	AL	352	7	VAMC
521GB	DECATUR, AL	AL	356	7	CBOC
619GB	DOTHAN, AL	AL	363	7	CBOC
521GC	FLORENCE, AL	AL	356	7	CBOC
521GD	GADSDEN, AL	AL	359	7	CBOC
521GA	HUNTSVILLE, AL	AL	358	7	CBOC
521GF	JASPER, AL	AL	355	7	CBOC
520GA	MOBILE, AL	AL	366	16	CBOC
619	MONTGOMERY, AL	AL	361	7	VAMC
679	TUSCALOOSA, AL	AL	354	7	VAMC
619A4	TUSKEGEE, AL	AL	360	7	VAMC
598GB	EL DORADO, AR	AR	717	16	CBOC
564HK	FAYETTEVILLE MOC, AR	AR	727	16	CBOC
564	FAYETTEVILLE, AR	AR	727	16	VAMC
564GB	FORT SMITH, AR	AR	729	16	CBOC
564GA	HARRISON, AR	AR	726	16	CBOC
598GC	HOT SPRINGS, AR	AR	719	16	CBOC
614GB	JONESBORO, AR	AR	724	9	CBOC
598	LITTLE ROCK, AR	AR	722	16	VAMC
598GA	MOUNTAIN HOME, AR	AR	726	16	CBOC
598A0	NORTH LITTLE ROCK, AR	AR	721	16	VAMC
657GG	PARAGOULD, AR	AR	724	15	CBOC
649GB	BELLEMONT, AZ	AZ	860	18	CBOC
649GD	BLACK CANYON CITY, AZ	AZ	853	18	CBOC
644GC	BUCKEYE, AZ	AZ	853	18	CBOC
678GC	CASA GRANDE, AZ	AZ	852	18	CBOC
649GE	COTTONWOOD, AZ	AZ	863	18	CBOC
678GE	GREEN VALLEY, AZ	AZ	856	18	CBOC
649GF	HOLBROOK, AZ	AZ	860	18	CBOC
649GA	KINGMAN, AZ	AZ	864	18	CBOC
649GC	LAKE HAVASU CITY, AZ	AZ	864	18	CBOC
644BY	MESA/WILLIAMS AFB, AZ	AZ	852	18	CBOC
644GD	PAYSON, AZ	AZ	855	18	CBOC
644	PHOENIX, AZ	AZ	850	18	VAMC
649HK	PRESCOTT MOC, AZ	AZ	863	18	CBOC
649	PRESCOTT, AZ	AZ	863	18	VAMC
678GD	SAFFORD, AZ	AZ	855	18	CBOC
644GB	SHOW LOW, AZ	AZ	859	18	CBOC
678GA	SIERRA VISTA, AZ	AZ	856	18	CBOC
644GA	SUN CITY, AZ	AZ	853	18	СВОС
678	TUCSON, AZ	AZ	857	18	VAMC
678GB	YUMA, AZ	AZ	853	18	CBOC
600GA	ANAHEIM, CA	CA	928	22	CBOC
570GA	ATWATER, CA	CA	953	21	CBOC

RC V2p0 Station List 02-11-05.xls

Page 2 of 18

Fac #	VA Facility Location	ST	ZIP 3	VN	Type
654GA	AUBURN, CA	CA	956	21	CBOC
691GD	BAKERSFIELD, CA	CA	933	22	CBOC
640GA	CAPITOLA, CA	CA	950	21	СВОС
612GG	CHICO, CA	CA	959	21	СВОС
664GC	CHULA VISTA, CA	CA	919	22	СВОС
605GD	CORONA, CA	CA	928	22	CBOC
691GI	CULVER CITY, CA	CA	902	22	СВОС
691GF	EAST LOS ANGELES, CA	CA	900	22	CBOC
664GA	EL CENTRO, CA	CA	922	22	CBOC
664GD	ESCONDIDO, CA	CA	920	22	CBOC
662GC	EUREKA, CA	CA	955	21	СВОС
612GD	FAIRFIELD, CA	CA	945	21	CBOC
570	FRESNO, CA	CA	937	21	VAMC
691GC	GARDENA, CA	CA	902	22	CBOC
691GG	LANCASTER/ANTELOPE VALLEY, CA	CA	935	22	СВОС
640A4	LIVERMORE, CA	CA	945	21	VAMC
605	LOMA LINDA, CA	CA	923	22	VAMC
691GL	LOMPOC, CA	CA	934	22	СВОС
600GC	LONG BEACH CBOC, CA	CA	908	22	CBOC
600	LONG BEACH, CA	CA	908	22	VAMC
691GE	LOS ANGELES CBOC, CA	CA	900	22	CBOC
612GE	MARE ISLAND, CA	CA	945	21	CBOC
612GF	MARTINEZ CBOC, CA	CA	945	21	CBOC
612	MARTINEZ, CA	CA	945	21	VAMC
612GH	MCCLELLAN AFB, CA	CA	956	21	CBOC
640A0	MENLO PARK, CA	CA	940	21	VAMC
640HB	MODESTO, CA	CA	953	21	CBOC
640HC	MONTEREY/FORT ORD, CA	CA	939	21	CBOC
612BY	OAKLAND, CA	CA	946	21	CBOC
605GC	PALM DESERT, CA	CA	922	22	CBOC
640	PALO ALTO, CA	CA	943	21	VAMC
691GO	PASADENA, CA	CA	911	22	CBOC
691GM	PORT HUENEME/OXNARD, CA	CA	930	22	CBOC
612B4	REDDING, CA	CA	960	21	CBOC
612A4	SACRAMENTO/MATHER AFB, CA	CA	958	21	VAMC
664BY	SAN DIEGO CBOC, CA	CA	921	22	CBOC
664	SAN DIEGO, CA	CA	921	22	VAMC
662BU	SAN FRANCISCO HOMELESS CTR, CA	CA	941	21	CBOC
662	SAN FRANCISCO, CA	CA	941	21	VAMC
640BY	SAN JOSE, CA	CA	951	21	CBOC
691GK	SAN LUIS OBISPO, CA	CA	934	22	CBOC
600GB	SANTA ANA, CA	CA	927	22	CBOC
691GB	SANTA BARBARA, CA	CA	931	22	CBOC
600GD	SANTA FE SPRINGS, CA	CA	906	22	CBOC
662GA	SANTA ROSA, CA	CA	954	21	CBOC
691A4	SEPULVEDA, CA	CA	913	22	CBOC
640GB	SONORA, CA	CA	953	21	CBOC
640HA	STOCKTON, CA	CA	952	21	CBOC
605GB	SUN CITY, CA	CA	923	22	CBOC

RC V2p0 Station List 02-11-05.xls

Page 3 of 18

Fac #	VA Facility Location	ST	ZIP 3	VN	Type
612CZ	TRAVIS AFB, CA	CA	945	21	CBOC
570GB	TULARE, CA	CA	932	21	CBOC
662GD	UKIAH, CA	CA	954	21	CBOC
605GE	UPLAND, CA	CA	917	22	CBOC
662GB	VALLEJO, CA	CA	945	21	CBOC
605GA	VICTORVILLE, CA	CA	923	22	CBOC
664GB	VISTA, CA	CA	920	22	CBOC
691GJ	WEST HOLLYWOOD, CA	CA	900	22	CBOC
691GH	WEST LA/PATRIOTIC HALL, CA	CA	900	22	CBOC
691GA	WEST LOS ANGELES CBOC, CA	CA	900	22	СВОС
691	WEST LOS ANGELES, CA	CA	900	22	VAMC
662GU	YOUNTVILLE HOMELESS CTR, CA	CA	945	21	СВОС
662HA	YOUNTVILLE, CA	CA	945	21	CBOC
554GF	ALAMOSA, CO	· CO	811	19	CBOC
554GB	AURORA, CO	CO	800	19	CBOC
554GE	COLORADO SPRINGS, CO	СО	809	19	CBOC
554	DENVER, CO	CO	802	19	VAMC
501GJ	DURANGO, CO	СО	813	18	СВОС
442GC	FORT COLLINS, CO	CO	805	19	CBOC
554A4	FORT LYON, CO	СО	810	19	VAMC
554HB	FORT MORGAN, CO	CO	807	19	CBOC
575	GRAND JUNCTION, CO	СО	815	19	VAMC
442GD	GREELEY, CO	СО	806	19	СВОС
554GG	LA JUNTA, CO	CO	810	19	CBOC
554GC	LAKEWOOD, CO	СО	802	19	CBOC
554GH	LAMAR, CO	СО	810	19	CBOC
575GA	MONTROSE, CO	CO	814	19	CBOC
554GD	PUEBLO, CO	СО	810	19	CBOC
689GE	DANBURY, CT	СТ	068	1	CBOC
689HC	NEW LONDON, CT	CT	063	1	CBOC
689A4	NEWINGTON, CT	CT	061	1	CBOC
689HB	NORWICH, CT	CT	063	1	CBOC
689GB	STAMFORD, CT	CT	069	1	CBOC
689GA	WATERBURY, CT	СТ	067	1	CBOC
689	WEST HAVEN, CT	CT	065	1	VAMC
689HA	WILLIMANTIC, CT	CT	062	1	CBOC
689GC	WINDHAM, CT	CT	062	1	CBOC
689GD	WINSTED, CT	CT	060	1	CBOC
688HK	WASHINGTON MOC, DC	DC	204	5	CBOC
688GB	WASHINGTON SE, DC	DC	200	- 5	CBOC
688	WASHINGTON, DC	DC	204	5	VAMC
460HA	DOVER AFB, DE	DE	199	4	СВОС
460HB	GEORGETOWN, DE	DE	199	4	СВОС
460GA	MILLSBORO, DE	DE	199	4	CBOC
460HK	NEW CASTLE, DE	DE	197	4	СВОС
460HC	OCEAN VIEW, DE	DE	199	4	CBOC
460HD	REHOBOTH, DE	DE	199	4	СВОС
460HL	SMYRNA, DE	DE	199	4	CBOC
460	WILMINGTON, DE	DE	198	4	VAMC

RC V2p0 Station List 02-11-05.xls

Page 4 of 18

Fac#	VA Facility Location	ST	<u>ZIP 3</u>	<u>VN</u>	<u>Type</u>
516GH	AVON PARK, FL	FL	338	8	CBOC
516	BAY PINES, FL	FL	337	8	VAMC
548GD	BOCA RATON, FL	FL	334	8	CBOC
673GC	BROOKSVILLE, FL	FL	346	8	CBOC
516GC	CLEARWATER, FL	FL	346	8	CBOC
546GG	CORAL SPRINGS, FL	FL	330	8	CBOC
573BZ	DAYTONA BEACH, FL	FL	321	8	СВОС
546GH	DEERFIELD BEACH, FL	FL	334	8	CBOC
548GB	DELRAY BEACH, FL	FL	334	8	CBOC
516GD	ELLENTON, FL	FL	342	8	СВОС
516BZ	FORT MYERS, FL	FL	339	8	CBOC
548GA	FORT PIERCE, FL	FL	349	8	СВОС
573	GAINESVILLE, FL	FL	326	8	VAMC
546GF	HALLANDALE, FL	FL	330	8	CBOC
546GC	HOMESTEAD, FL	FL	330	8	CBOC
573GG	INVERNESS, FL	FL	344	8	CBOC
573BY	JACKSONVILLE, FL	FL	322	8	СВОС
546GE	KEY LARGO, FL	FL	330	8	СВОС
546GB	KEY WEST, FL	FL	330	8	CBOC
		FL			
673GE	KISSIMMEE, FL		347	8	CBOC
573A4	LAKE CITY, FL	FL	320	8	VAMC
673GB	LAKELAND, FL	FL	338	8	CBOC
573GH	LEESBURG, FL	FL	347	8	CBOC
546GA	MIAMI CBOC, FL	FL	331	8	CBOC
546	MIAMI, FL	FL	331	8	VAMC
516GF	NAPLES, FL	FL -	341	8	CBOC
546BZ	OAKLAND PARK, FL	FL	333	8	CBOC
573GD	OCALA, FL	FL	344	8	CBOC
548GF	OKEECHOBEE, FL	FL	349	8	CBOC
673BY	ORLANDO, FL	FL	328	8	CBOC
520GB	PANAMA CITY, FL	FL	324	16	CBOC
546GD	PEMBROKE PINES, FL	FL	330	8	CBOC
520BZ	PENSACOLA, FL	FL	325	16	CBOC
516GE	PORT CHARLOTTE, FL	FL	339	8	CBOC
673BZ	PORT RICHEY, FL	FL	346	8	CBOC
573GE	SAINT AUGUSTINE, FL	FL	320	8	CBOC
516GB	SAINT PETERSBURG, FL	FL	337	8	CBOC
673GD	SANFORD, FL	FL	327	8	CBOC
516GA	SARASOTA, FL	FL	342	8	CBOC
548GC	STUART, FL	FL	349	8	СВОС
573GF	TALLAHASSEE, FL	FL	323	8	CBOC
673	TAMPA, FL	FL	336	8	VAMC
548GE	VERO BEACH, FL	FL	329	8	CBOC
673GA	VIERA/MELBOURNE, FL	FL	329	8	CBOC
548	WEST PALM BEACH, FL	FL	334	8	VAMC
673GF	ZEPHYRHILLS, FL	FL	335	8	CBOC
557GB	ALBANY, GA	GA	317	7	CBOC
508		GA	300	7	
	ATLANTA/MIDTOWN CA		<u> </u>		VAMC
508GA	ATLANTA/MIDTOWN, GA	GA	303	7	CBOC

RC V2p0 Station List 02-11-05.xls

Page 5 of 18

Fac #	VA Facility Location	ST	ZIP 3	VN	Type
509	AUGUSTA DOWNTOWN, GA	GA	309	7	VAMC
509A0	AUGUSTA UPTOWN, GA	GA	309	7	VAMC
619GA	COLUMBUS, GA	GA	319	7	CBOC
557	DUBLIN, GA	GA	310	7	VAMC
508GB	GAINESVILLE/NE CORRIDOR, GA	GA	305	7	CBOC
508GH	LAWRENCEVILLE, GA	GA	300	7	CBOC
557GA	MACON, GA	GA	312	7	CBOC
508GF	MARIETTA, GA	GA	300	7	CBOC
508GE	OAKWOOD/NE CORRIDOR, GA	GA	305	7	СВОС
534BY	SAVANNAH, GA	GA	314	7	CBOC
573GA	VALDOSTA, GA	GA	316	8	CBOC
459GE	GUAM, GU	GU	969	21	CBOC
459GB	HILO, HI	HI	967	21	CBOC
459	HONOLULU, HI	HI	968	21	VAMC
459GA	KAHULUI, HI	HI	967	21	CBOC
459GC	KAILUA KONA, HI	н	967	21	CBOC
459GD	LIHUE, HI	HI	967	21	CBOC
636GF	BETTENDORF, IA	IA	527	23	CBOC
636A6	DES MOINES, IA	IA	503	23	VAMC
636GJ	DUBUQUE, IA	IA	520	23	СВОС
636GK	FORT DODGE, IA	IA	505	23	CBOC
636A8	IOWA CITY, IA	IA	522	23	VAMC
636A7	KNOXVILLE, IA	IA	501	23	VAMC
636GD	MARSHALLTOWN, IA	IA	501	23	CBOC
636GC	MASON CITY, IA	IA	504	23	СВОС
636GE	OTTUMWA, IA	IA	525	23	CBOC
438GC	SIOUX CITY, IA	IA	511	23	CBOC
636GH	WATERLOO, IA	IA	507	23	CBOC
531	BOISE, ID	ID	837	20	VAMC
687GB	LEWISTON, ID	ID	835	20	CBOC
660GA	POCATELLO, ID	ID	832	19	CBOC
531GE	TWIN FALLS, ID	ID	833	20	CBOC
578GD		IL ID	605	12	CBOC
	AURORA, IL BELLEVILLE, IL	IL IL	622	15	CBOC
657GA	CHICAGO HEIGHTS, IL	IL	604	12	CBOC
537GA 537A4	CHICAGO LAKESIDE, IL	IL	606	12	VAMC
537A4 537	CHICAGO WEST SIDE, IL	IL	606	12	VAMC
AND THE PERSON NAMED IN COLUMN TWO IS NOT THE OWNER.					
537HA 550	CHICAGO/WOODLAWN, IL	IL	606	12	
	DANVILLE, IL	IL	618	11	VAMC CBOC
550GA	DECATUR, IL	IL	625	11	
550GE	EFFINGHAM, IL	IL	624	11	CBOC
657GC	EFFINGHAM, IL	IL	624	15	CBOC
657GM	EFFINGHAM, IL	IL TT	624	15	CBOC
578GE	ELGIN, IL	IL	601	12	CBOC
556GA	EVANSTON, IL	IL	602	12	CBOC
636GI	GALESBURG, IL	IL	614	23	CBOC
578	HINES, IL	IL	601	12	VAMC
578GA	JOLIET, IL	IL	604	12	CBOC
578GF	LA SALLE, IL	IL .	613	12	CBOC

RC V2p0 Station List 02-11-05.xls

Page 6 of 18

578GC MANTENO, IL IL 669 12 CBOC 657AS MARION, IL IL 669 12 VAMC 556GC MCHENRY, IL IL 600 12 CBOC 657GK MOUNT VERNON, IL IL 600 12 VAMC 556 NORTH CHICAGO, IL IL 604 12 VAMC 578GB OAK PARK, IL IL 604 12 CBOC 578GB OAK PARK, IL IL 611 CBOC CBOC 636GG QUINCY, IL IL 623 23 CBOC 697HA ROCKFORD, IL IL 621 CBOC 697HA ROCKFORD, IL IL 627 15 CBOC 697GE SPRINGFIELD, IL IL 627 15 CBOC 583GB BLOOMINGTON, IN IN 474 II CBOC 687GJ EVANSVILLE, IN IN 477 15 CBOC 6104A	Fac #	VA Facility Location	ST	ZIP 3	VN	Type
657A5 MARION, IL IL 629 15 VAMC 556GC MCHENRY, IL IL 600 12 CBOC 657GK MOUNT VERNON, IL IL 600 12 VAMC 556 NORTH CHICAGO, IL IL 600 12 VAMC 578GB OAK LAWN, IL IL 604 12 CBOC 578GB OAK PARK, IL IL 606 12 CBOC 550BY PEORIA, IL IL 616 11 CBOC 636GG QUINCY, IL IL 623 23 CBOC 667GB SPRINGFIELD, IL IL 627 11 CBOC 550GD SPRINGFIELD, IL IL 627 11 CBOC 537BY CROWN POINT, IN IN 443 11 CBOC 657GJ EVANSVILLE, IN IN 447 11 CBOC 657GJ EVANSVILLE, IN IN 446 11 VAMC						
S56GC MCHENRY, IL IL 600 12 CBOC 687GK MOUNT VERNON, IL IL 628 15 CBOC 687GK MOUNT VERNON, IL IIL 604 12 CBOC 578GG OAK LAWN, IL IIL 604 12 CBOC 578GG OAK LAWN, IL IIL 603 12 CBOC 578GB OAK PARK, IL IIL 603 12 CBOC	<u> </u>					
657GK MOUNT VERNON, IL IL 600 12 VAMC	<u> </u>		~~~~			
556 NORTH CHICAGO, IL IL 600 12 VAMC 578GG OAK LAWN, IL IL 604 12 CBOC 578GB OAK PARK, IL IL 603 12 CBOC 550BY PEORIA, IL IL 616 11 CBOC 636GG QUINCY, IL IL 623 23 CBOC 677BA ROCKFORD, IL IL 611 12 CBOC 657GE SPRINGFIELD, IL IL 627 15 CBOC 657GE SPRINGFIELD, IL IL 627 15 CBOC 657GJ SPRINGFIELD, II IL 627 15 CBOC 657GJ EVANSVILLE, IN IN 474 11 CBOC 657GJ EVANSVILLE, IN IN 477 15 CBOC 657GJ EVANSVILLE, IN IN 477 11 CBOC 651GL LAFAYETTE, IN IN 470 11 CBOC	<u> </u>					
578GG OAK LAWN, IL IL 604 12 CBOC 578GB OAK PARK, IL IL 603 12 CBOC 578GB PEORIA, IL IL 616 11 CBOC 636GG QUINCY, IL IL 623 23 CBOC 607HA ROCKFORD, IL IL 611 12 CBOC 550GD SPRINGFIELD, II IL 627 15 CBOC 687GE SPRINGFIELD, II IL 627 15 CBOC 583GB BLOOMINGTON, IN IN 474 11 CBOC 583GB BLOOMINGTON, IN IN 463 12 CBOC 610A4 FORT WAYNE, IN IN 463 11 VAMC 583GB BLOOMINGTON, IN IN 479 11 CBOC 610A4 FORT WAYNE, IN IN 479 11 CBOC 539GC LAWRENCEBURG, IN IN 479 11 CBOC						
578GB OAK PARK, IL IL 603 12 CBOC 550BY PEORIA, IL IL 616 11 CBOC 636GG QUINCY, IL IL 612 32 32 CBOC 607HA ROCKFORD, IL IL 611 12 CBOC 550GD SPRINGFIELD, IL IL 627 15 CBOC 583GB BLOOMINGTON, IN IN 474 11 CBOC 537BY CROWN POINT, IN IN 463 12 CBOC 657GJ EVANSVILLE, IN IN 474 11 CBOC 657GJ EVANSVILLE, IN IN 475 15 CBOC 657GJ EVANSVILLE, IN IN 477 15 CBOC 657GJ EVANSVILLE, IN IN 479 11 CBOC 657GJ EVANSVILLE, IN IN 479 11 CBOC 539GC LAFAYETTE, IN IN 479 11 CBOC			···			
S50BY PEORIA, IL IL 616 11 CBOC						
636GG QUINCY, IL IL 623 23 CBOC 607HA ROCKFORD, IL IL 611 12 CBOC 550GD SPRINGFIELD, IL IIL 627 11 CBOC 657GE SPRINGFIELD, IL IIL 627 15 CBOC 583GB BLOOMINGTON, IN IN 474 11 CBOC 537BY CROWN POINT, IN IN 474 11 CBOC 657GJ EVANSVILLE, IN IN 463 12 CBOC 657GJ EVANSVILLE, IN IN 463 12 CBOC 657GJ EVANSVILLE, IN IN 468 11 VAMC 583 INDIANAPOLIS, IN IN 468 11 VAMC 583 INDIANAPOLIS, IN IN 462 11 VAMC 550GC LAFAYETTE, IN IN 479 11 CBOC 539GC LAWRENCEBURG, IN IN 479 11 CBOC 610GB MUNCIE, IN IN 469 11 VAMC 610GB MUNCIE, IN IN 479 11 CBOC 610GB MUNCIE, IN IN 473 11 CBOC 610GB MUNCIE, IN IN 473 11 CBOC 559GC RICHMOND, IN IN 473 10 CBOC 610GA SOUTH BEND, IN IN 473 10 CBOC 610GA SOUTH BEND, IN IN 478 11 CBOC 589GK ABILENE, KS KS 674 15 CBOC 589GK ABILENE, KS KS 667 15 CBOC 589GM CHANUTE, KS KS 667 15 CBOC 589GM CHANUTE, KS KS 666 15 CBOC 589GN FORT RILEY, KS KS 666 15 CBOC 589GP GARNETT, KS KS 666 15 CBOC 589GP GARNET, KS KS 666 15 CBOC 589GP GARNET, KS KS 666 15 CBOC 589GP GARNET, KS KS 666 15 CBOC 589GP GARNET, KS KS 666 15 CBOC 589GP GARNET, KS KS 666 15 CBOC 589GP GARNET, KS KS 666 15 CBOC 589GP GARNET, KS KS 666 15 CBOC 589GP GARNET, KS KS 666 15 CBOC 589GP GARNET, KS KS 666 15 CBOC 589GP GARNET, KS KS 666 15 CBOC 589GP GARNET, KS KS 666 15 CBOC 589GP GARNET, KS KS 666 15 CBOC 589GP GARNET, KS KS 666 15 CBOC 589GP GARNET, KS KS 666 15 CBOC 5						
607HA ROCKFORD, IL IL 611 12 CBOC 550GD SPRINGFIELD, IL IL 627 11 CBOC 657GE SPRINGFIELD, IL IL 627 11 CBOC 533GB BLOOMINGTON, IN IN 474 11 CBOC 537BY CROWN POINT, IN IN 463 12 CBOC 657GJ EVANSVILLE, IN IN 477 15 CBOC 657GJ EVANSVILLE, IN IN 477 15 CBOC 657GJ EVANSVILLE, IN IN 468 11 VAMC 553 INDIANAPOLIS, IN IN 468 11 VAMC 553 INDIANAPOLIS, IN IN 462 11 VAMC 550GC LAFAYETTE, IN IN 479 11 CBOC 610 MARION, IN IN 479 11 CBOC 610 MARION, IN IN 479 11 CBOC 610 MARION, IN IN 479 11 CBOC 610 MARION, IN IN 479 11 CBOC 603GB NEW ALBANY, IN IN 471 19 CBOC 603GB NEW ALBANY, IN IN 471 19 CBOC 610GA SOUTH BEND, IN IN 473 10 CBOC 559GC RICHMOND, IN IN 473 11 CBOC 558GK ABILENE, KS KS 674 15 CBOC 5589GK ABILENE, KS KS 674 15 CBOC 5589GK ABILENE, KS KS 674 15 CBOC 5589GM CHANUTE, KS KS 678 15 CBOC 5589GD DODGE CITY, KS KS 666 15 CBOC 5589GD FORT RILEY, KS KS 666 15 CBOC 5589GP GARNETT, KS KS 666 15 CBOC 5589GP GARNETT, KS KS 666 15 CBOC 5589GP GARNETT, KS KS 660 15 CBOC 5589GP GARNETT, KS KS 660 15 CBOC 5589GP JUNCTION CITY, KS KS 660 15 CBOC 5589GP JUNCTION CITY, KS KS 660 15 CBOC 5589GP LAWRENCE, KS KS 660 15 CBOC 5589GP JUNCTION CITY, KS KS 660 15 CBOC 5589GP JUNCTION CITY, KS KS 660 15 CBOC 5589GP JUNCTION CITY, KS KS 660 15 CBOC 5589GP JUNCTION CITY, KS KS 660 15 CBOC 5589GP JUNCTION CITY, KS KS 660 15 CBOC 5589GP JUNCTION CITY, KS KS 660 15 CBOC 5589GP JUNCTION CITY, KS KS 660 15 CBOC 5589GP JUNCTION CITY, KS KS 660 15 CBOC 5589GP JUNCTION CITY, KS KS 660 15 CBOC 5589GP JUNCTION CITY, KS KS 660 15 CBOC 5589GP JUNCTION CITY, KS KS 660 15 CBOC 5589GP JUNCTION CITY, KS KS 660 15 CBOC 5589GP JUNCTION CITY, KS KS 660 15 CBOC 5589GP JUNCTION CITY, KS KS 660 15 CBOC 5589GP JUNCTION CITY, KS KS 660 15 CBOC 5589GF SALINA, KS KS 674 15 CBOC 5589GF SALINA, KS KS 674 15 CBOC 5589GF SALINA, KS KS 674 15 CBOC 5589GF SALINA, KS KS 674 15 CBOC 5589GF SALINA, KS KS 674 15 CBOC 5589GF SALINA, KS KS 674 15 CBOC 5589GF SALINA, KS KS 674 15 CBOC 5589GF SALINA, KS KS 674 15 CBOC 5589GF SALINA, KS KS 674 15 CBOC 5589GF SALINA, KS KS 666 15 VA						
550GD SPRINGFIELD, IL IL 627 11 CBOC 657GE SPRINGFIELD, IL IL 627 15 CBOC 657GE SPRINGFIELD, IL IL 627 15 CBOC 537BY CROWN POINT, IN IN 474 11 CBOC 657GJ EVANSVILLE, IN IN 468 11 VAMC 61044 FORT WAYNE, IN IN 468 11 VAMC 583 INDIANAPOLIS, IN IN 462 11 VAMC 559GC LAFAYETTE, IN IN 470 10 CBOC 539GC LAWRENCEBURG, IN IN 470 10 CBOC 610GB MURICIE, IN IN 473 11 CBOC 610GB MURICIE, IN IN 473 11 CBOC 52GC RICHMOND, IN IN 473 11 CBOC 589GR RICHMOND, IN IN 478 11 CBOC						
657GE SPRINGFIELD, IL IL 627 15 CBOC 583GB BLOOMINGTON, IN IN 474 11 CBOC 583GB CROWN POINT, IN IN 463 12 CBOC 657GJ EVANSVILLE, IN IN 463 12 CBOC 661044 FORT WAYNE, IN IN 468 11 VAMC 583 INDIANAPOLIS, IN IN 462 11 VAMC 583GC LAFYETTE, IN IN 479 11 CBOC 610 MARION, IN IN 479 11 CBOC 610 MARION, IN IN 473 11 CBOC 603GB MUNCIE, IN IN 473 11 CBOC 603GB NEW ALBANY, IN IN 471 9 CBOC 610GA SOUTH BEND, IN IN 478 11 CBOC 589GA ABILENE, KS KS 674 15 CBOC						
583GB BLOOMINGTON, IN IN 474 11 CBOC 537BY CROWN POINT, IN IN 463 12 CBOC 657GJ EVANSVILLE, IN IN 477 15 CBOC 610A4 FORT WAYNE, IN IN 462 11 VAMC 583 INDIANAPOLIS, IN IN 462 11 VAMC 59GC LAFAYETTE, IN IN 479 11 CBOC 539GC LAWENCEBURG, IN IN 470 10 CBOC 610GB MUNCIE, IN IN 473 11 CBOC 603GB NEW ALBANY, IN IN 473 11 CBOC 610GA SOUTH BEND, IN IN 473 10 CBOC 582GC RICHMOND, IN IN 476 11 CBOC 589GK ABILENE, KS KS 674 15 CBOC 589GW CHANUTE, KS KS 667 15 CBOC						
537BY CROWN POINT, IN IN 463 12 CBOC 657GJ EVANSVILLE, IN IN 477 15 CBOC 610A4 FORT WAYNE, IN IN 468 11 VAMC 583 INDIANAPOLIS, IN IN 462 11 VAMC 559GC LAFAYETTE, IN IN 470 10 CBOC 539GC LAWRENCEBURG, IN IN 470 10 CBOC 610 MARION, IN IN 473 11 CBOC 610GB MUNCIE, IN IN 473 11 CBOC 610GB NEW ALBANY, IN IN 473 11 CBOC 552GC RICHMOND, IN IN 473 10 CBOC 610GA SOUTH BEND, IN IN 478 11 CBOC 589GK ABILENE, KS KS 667 15 CBOC 589GA TERNER HAUTE, IN IN 478 11 CBOC						
657GJ EVANSVILLE, IN IN 477 15 CBOC 61044 FORT WAYNE, IN IN 468 11 VAMC 583 INDIANAPOLIS, IN IN 462 11 VAMC 550GC LAFAYETTE, IN IN 470 10 CBOC 550GC LAWRENCEBURG, IN IN 470 10 CBOC 610 MARION, IN IN 469 11 VAMC 610GB MUNCIE, IN IN 473 11 CBOC 610GB MUNCIE, IN IN 473 11 CBOC 610GA SOUTH BEND, IN IN 473 10 CBOC 610GA SOUTH BEND, IN IN 473 10 CBOC 610GA SOUTH BEND, IN IN 478 11 CBOC 610GA SOUTH BEND, IN 478 11 CBOC 610GA SOUTH BEND, IN IN 478 11 CBOC 610GA SOUTH BEND, IN IN 478 11 CBOC 610GA SOUTH BEND, IN IN 478 11 CBOC 610GA SOUTH BEND, IN IN 478 11 CBOC 610GA SOUTH BEND, IN IN 478 11 CBOC 610GA SOUTH BEND, IN IN 478 11 CBOC 610GA SOUTH BEND, IN IN 478 11 CBOC 610GA SOUTH BEND, IN IN 478 11 CBOC 610GA SOUTH BEND, IN 471 10 CBOC 610GA SOUTH BEND, IN IN 478 11 CBOC 610GA SOUTH BEND, IN A 666 15 CBOC 610GA SOUTH BEND, IN A 666 15 CBOC 610GA SOUTH SOUTH, KS KS 660 15 CBOC 610GA SOUTH SOUTH, KS KS 660 15 CBOC 610GA SOUTH SOUTH, KS KS 660 15 CBOC 610GA SOUTH SOUTH, KS KS 660 15 CBOC 610GA SOUTH SOUTH, KS KS 660 15 CBOC 610GA SOUTH SOUT						
610A4 FORT WAYNE, IN IN 468 11 VAMC 583 INDIANAPOLIS, IN IN 462 11 VAMC 550GC LAFAYETTE, IN IN 479 11 CBOC 539GC LAWRENCEBURG, IN IN 479 11 CBOC 610 MARION, IN IN 469 11 VAMC 610GB MUNCIE, IN IN 473 11 CBOC 603GB NEW ALBANY, IN IN 471 9 CBOC 610GA SOUTH BEND, IN IN 473 10 CBOC 610GA SOUTH BEND, IN IN 473 10 CBOC 589GK ABILENE, KS KS 674 15 CBOC 589GD PARSONS, KS 666 15 CBOC 589GL HUTON, KS KS 667 15 CBOC 589GL HUTON, KS KS 667 15 CBOC 589GL HUTON, KS KS 667 15 CBOC 589GL HUTON, KS KS 664 15 CBOC 589GL HUTON, KS KS 660 15 CBOC 589GL HUTON, KS KS 660 15 CBOC 589GL HUTON, KS KS 660 15 CBOC 589GL HUTON, KS KS 660 15 CBOC 589GL HUTON, KS KS 660 15 CBOC 589GL HUTON, KS KS 660 15 CBOC 589GL HUTON, KS KS 661 15 CBOC 589GL HUTON, KS KS 661 15 CBOC 589GL HUTON, KS KS 661 15 CBOC 589GL HUTON, KS KS 661 15 CBOC 589GL HUTON, KS KS 661 15 CBOC 589GL HUTON, KS KS 661 15 CBOC 589GS PARSONS, KS KS 673 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15						
583 INDIANAPOLIS, IN IN 462 11 VAMC 559GC LAFAYETTE, IN IN 479 11 CBOC 539GC LAWRENCEBURG, IN IN 470 10 CBOC 610G MARION, IN IN 469 11 VAMC 610GB MUNCIE, IN IN 473 11 CBOC 603GB NEW ALBANY, IN IN 473 10 CBOC 552GC RICHMOND, IN IN 473 10 CBOC 552GC RICHMOND, IN IN 473 10 CBOC 610GA SOUTH BEND, IN IN 478 11 CBOC 583GA TERRE HAUTE, IN IN 478 11 CBOC 589GK ABILENE, KS KS 667 15 CBOC 589GM CHANUTE, KS KS 667 15 CBOC 589GD FORT RILEY, KS KS 668 15 CBOC <td< td=""><td>Annual Control of the</td><td></td><td></td><td></td><td></td><td></td></td<>	Annual Control of the					
550GC LAFAYETTE, IN IN 479 11 CBOC 539GC LAWRENCEBURG, IN IN 470 10 CBOC 610 MARION, IN IN 469 11 VAMC 610GB MUNCIE, IN IN 473 19 CBOC 603GB NEW ALBANY, IN IN 471 19 CBOC 552GC RICHMOND, IN IN 473 10 CBOC 583GA SOUTH BEND, IN IN 466 11 CBOC 589GK ABILENE, KS KS 674 15 CBOC 589GM CHANUTE, KS KS 667 15 CBOC 589GM CHANUTE, KS KS 667 15 CBOC 589GM CHANUTE, KS KS 668 15 CBOC 589GW CHANUTE, KS KS 668 15 CBOC 589GW EMPORIA, KS KS 668 15 CBOC 589GP	<u></u>					
539GC LAWRENCEBURG, IN IN 470 10 CBOC 610 MARION, IN IN 469 11 VAMC 610GB MUNCIE, IN IN 473 11 CBOC 603GB NEW ALBANY, IN IN 471 9 CBOC 603GB NEW ALBANY, IN IN 473 10 CBOC 610GA SOUTH BEND, IN IN 478 11 CBOC 583GA TERRE HAUTE, IN IN 478 11 CBOC 589GK ABILENE, KS KS 667 15 CBOC 589GM CHANUTE, KS KS 667 15 CBOC 589GD EMPORIA, KS KS 668 15 CBOC 589GD FORT RILEY, KS KS 664 15 CBOC 589GD FORT RILEY, KS KS 660 15 CBOC 589GP GARNETT, KS KS 660 15 CBOC 58			WATER THE PROPERTY OF THE PROP			
610 MARION, IN IN 469 11 VAMC 610GB MUNCIE, IN IN 473 11 CBOC 603GB NEW ALBANY, IN IN 471 9 CBOC 552GC RICHMOND, IN IN 473 10 CBOC 610GA SOUTH BEND, IN IN 476 11 CBOC 589GK ABILENE, KS KS 674 15 CBOC 589GN CHANUTE, KS KS 667 15 CBOC 589GN EMPORIA, KS KS 668 15 CBOC 589GV FORT SCOTT, KS KS 666 15 CBOC 589GV FORT SCOTT, KS KS 667 15 CBOC 589GV FORT SCOTT, KS KS 667 15 CBOC 589GV HAYS, KS KS 667 15 CBOC 589GV HAYS, KS KS 666 15 CBOC 589GV HOLTON, KS KS 664 15 CBOC 589GV HOLTON, KS KS 664 15 CBOC 589GV LAWRENCE, KS KS 660 15 CBOC 589GV LAWRENCE, KS KS 660 15 CBOC 589GV LAWRENCE, KS KS 660 15 CBOC 589GV LAWRENCE, KS KS 660 15 CBOC 589GV LAWRENCE, KS KS 660 15 CBOC 589GV LAWRENCE, KS KS 660 15 CBOC 589GC BLEAVENWORTH, KS KS 660 15 CBOC 589GC PAOLA, KS KS 660 15 CBOC 589GS LIBERAL, KS KS 660 15 CBOC 589GS PARSONS, KS KS 676 15 CBOC 589GS PARSONS, KS KS 676 15 CBOC 589GS PARSONS, KS KS 676 15 CBOC 589GS PARSONS, KS KS 676 15 CBOC 589GS PARSONS, KS KS 676 15 CBOC 589GS PARSONS, KS KS 676 15 CBOC 589GS PARSONS, KS KS 676 15 CBOC 589GS PARSONS, KS KS 676 15 CBOC 589GS PARSONS, KS KS 676 15 CBOC 589GS PARSONS, KS KS 676 15 CBOC 589GS PARSONS, KS KS 676 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GS PARSONS, KS KS 674 15 CBOC 589GT SENECA, KS KS 674 15 CBOC 589GT SENECA, KS KS 674 15 CBOC 589GT SENECA, KS KS 674 15 CBOC 589GT SENECA, KS KS 674 15 CBOC 589GT SENECA, KS KS 674 15 CBOC 589GT SENECA, KS KS 674 15 CBOC 589GT SENECA, KS KS 674 15 CBOC 589GT SENECA, KS KS 674 15 CBOC 589GT SENECA, KS KS 674 15 CBOC 589GT SENECA, KS KS 674 15 CBOC 589GT SENECA, KS KS 674 15 CBOC 589GT SENECA, KS KS 674 15 CBOC	L	1				
610GB MUNCIE, IN IN 473 11 CBOC 603GB NEW ALBANY, IN IN 471 9 CBOC 552GC RICHMOND, IN IN 473 10 CBOC 610GA SOUTH BEND, IN IN 473 10 CBOC 583GA TERRE HAUTE, IN IN 478 11 CBOC 589GK ABILENE, KS KS 674 15 CBOC 589GC CHANUTE, KS KS 667 15 CBOC 589GD CHANUTE, KS KS 667 15 CBOC 589GN EMPORIA, KS KS 668 15 CBOC 589GV FORT RILEY, KS KS 668 15 CBOC 589GV FORT SCOTT, KS KS 666 15 CBOC 589GP GARNETT, KS KS 666 15 CBOC 589GQ HOLTON, KS KS 664 15 CBOC 589GQ HOLTON, KS KS 664 15 CBOC 589GQ HOLTON, KS KS 664 15 CBOC 589GQ HOLTON, KS KS 664 15 CBOC 589GD LAWRENCE, KS KS 666 15 CBOC 589GU LAWRENCE, KS KS 660 15 CBOC 589GU LAWRENCE, KS KS 660 15 CBOC 589GU LAWRENCE, KS KS 660 15 CBOC 589GB LIBERAL, KS KS 660 15 CBOC 589GS LIBERAL, KS KS 660 15 CBOC 589GS PARSONS, KS KS 660 15 CBOC 589GS PARSONS, KS KS 660 15 CBOC 589GS RUSSELL, KS KS 660 15 CBOC 589GS RUSSELL, KS KS 679 18 CBOC 589GS RUSSELL, KS KS 670 15 CBOC 589GS RUSSELL, KS			· · · · · · · · · · · · · · · · · · ·			
603GB NEW ALBANY, IN IN 471 9 CBOC 552GC RICHMOND, IN IN 473 10 CBOC 610GA SOUTH BEND, IN IN 466 11 CBOC 583GA TERRE HAUTE, IN IN 478 11 CBOC 589GK ABILENE, KS KS 674 15 CBOC 589GM CHANUTE, KS KS 667 15 CBOC 589GM CHANUTE, KS KS 667 15 CBOC 589GD DODGE CITY, KS KS 668 15 CBOC 589GD FORT RILEY, KS KS 664 15 CBOC 589GV FORT SCOTT, KS KS 660 15 CBOC 589GP GARNETT, KS KS 660 15 CBOC 589GA HAYS, KS KS 664 15 CBOC 589GA HOLTON, KS KS 664 15 CBOC 589GB<	<u> </u>					
552GC RICHMOND, IN IN 473 10 CBOC 610GA SOUTH BEND, IN IN 466 11 CBOC 583GA TERRE HAUTE, IN IN 478 11 CBOC 589GK ABILENE, KS KS 674 15 CBOC 589GM CHANUTE, KS KS 667 15 CBOC 589G2 DODGE CITY, KS KS 667 15 CBOC 589GN EMPORIA, KS KS 668 15 CBOC 589GV FORT RILEY, KS KS 664 15 CBOC 589GV FORT SCOTT, KS KS 664 15 CBOC 589GV FORT SCOTT, KS KS 660 15 CBOC 589GV FORT SCOTT, KS KS 660 15 CBOC 589GV FORT SCOTT, KS KS 660 15 CBOC 589GQ HOLTON, KS KS 664 15 CBOC	Carrow Company of the	-4				
610GA SOUTH BEND, IN IN 466 11 CBOC 583GA TERRE HAUTE, IN IN 478 11 CBOC 589GK ABILENE, KS KS 674 15 CBOC 589GK CHANUTE, KS KS 667 15 CBOC 589GD CHANUTE, KS KS 667 15 CBOC 589GD EMPORIA, KS KS 668 15 CBOC 589GO FORT RILEY, KS KS 664 15 CBOC 589GV FORT SCOTT, KS KS 666 15 CBOC 589GP GARNETT, KS KS 660 15 CBOC 589GQ HOLTON, KS KS 664 15 CBOC 589GD HAYS, KS KS 664 15 CBOC 589GD KANSAS CITY/WYANDOTTE, KS KS 661 15 CBOC 589GU LAWRENCE, KS KS 660 15 CBOC 589GU LAWRENCE, KS KS 660 15 CBOC 589GU LAWRENCE, KS KS 669 15 CBOC 589GB LIBERAL, KS KS 669 15 CBOC 589GS LIBERAL, KS KS 669 15 CBOC 589GS PARSONS, KS KS 660 15 CBOC 589GS PARSONS, KS KS 660 15 CBOC 589GS PARSONS, KS KS 660 15 CBOC 589GS PARSONS, KS KS 661 15 CBOC 589GS RUSSELL, KS KS 661 15 CBOC 589GS RUSSELL, KS KS 674 15 CBOC 589GW SALINA, KS KS 674 15 CBOC 589GT SENECA, KS KS 675 15 CBOC 589GT SENECA, KS KS 675 15 CBOC 589GT SENECA, KS KS 675 15 CBOC 589GT SENECA, KS KS 675 15 CBOC 589GT SENECA, KS KS 675 15 CBOC 589GT SENECA, KS KS 675 15 CBOC 589GT SENECA, KS KS 675 15 CBOC 589GT SENECA 570 THE TRUST THE TRUST THE TRUS						
583GA TERRE HAUTE, IN IN 478 11 CBOC 589GK ABILENE, KS KS 674 15 CBOC 589GM CHANUTE, KS KS 667 15 CBOC 589G2 DODGE CITY, KS KS 668 15 CBOC 589GN EMPORIA, KS KS 664 15 CBOC 589GO FORT RILEY, KS KS 664 15 CBOC 589GV FORT SCOTT, KS KS 667 15 CBOC 589GP GARNETT, KS KS 660 15 CBOC 589GP GARNETT, KS KS 660 15 CBOC 589GP GARNETT, KS KS 660 15 CBOC 589GP GARNETT, KS KS 660 15 CBOC 589GP HOLTON, KS KS 664 15 CBOC 589GR JUNCTION CITY, KS KS 664 15 CBOC 589						
589GK ABILENE, KS KS 674 15 CBOC 589GM CHANUTE, KS KS 667 15 CBOC 589G2 DODGE CITY, KS KS 678 15 CBOC 589GN EMPORIA, KS KS 668 15 CBOC 589GO FORT RILEY, KS KS 664 15 CBOC 589GV FORT SCOTT, KS KS 667 15 CBOC 589GP GARNETT, KS KS 660 15 CBOC 589G4 HAYS, KS KS 660 15 CBOC 589GQ HOLTON, KS KS 664 15 CBOC 589GR JUNCTION CITY, KS KS 664 15 CBOC 589GB JUNCTION CITY, KS KS 661 15 CBOC 589GU LAWRENCE, KS KS 661 15 CBOC 589GU LEAVENWORTH, KS KS 679 18 CBOC <td< td=""><td></td><td></td><td>····</td><td></td><td></td><td></td></td<>			····			
589GM CHANUTE, KS KS 667 15 CBOC 589G2 DODGE CITY, KS KS 678 15 CBOC 589GN EMPORIA, KS KS 668 15 CBOC 589GO FORT RILEY, KS KS 664 15 CBOC 589GV FORT SCOTT, KS KS 667 15 CBOC 589GP GARNETT, KS KS 660 15 CBOC 589G4 HAYS, KS KS 660 15 CBOC 589GQ HOLTON, KS KS 664 15 CBOC 589GR JUNCTION CITY, KS KS 664 15 CBOC 589GJ KANSAS CITY/WYANDOTTE, KS KS 661 15 CBOC 589GU LAWRENCE, KS KS 660 15 CBOC 589GU LAWRENCE, KS KS 660 15 VAMC 589GB LIBERAL, KS KS 679 18 CBOC						
589G2 DODGE CITY, KS KS 668 15 CBOC 589GN EMPORIA, KS KS 668 15 CBOC 589GO FORT RILEY, KS KS 664 15 CBOC 589GV FORT SCOTT, KS KS 667 15 CBOC 589GP GARNETT, KS KS 660 15 CBOC 589GH HAYS, KS KS 676 15 CBOC 589GQ HOLTON, KS KS 664 15 CBOC 589GR JUNCTION CITY, KS KS 664 15 CBOC 589GJ KANSAS CITY/WYANDOTTE, KS KS 661 15 CBOC 589GU LAWRENCE, KS KS 660 15 CBOC 589GU LAWRENCE, KS KS 660 15 VAMC 504GB LIBERAL, KS KS 679 18 CBOC 589G3 LIBERAL, KS KS 679 15 CBOC		The state of the s	·····			
589GN EMPORIA, KS KS 668 15 CBOC 589GO FORT RILEY, KS KS 664 15 CBOC 589GV FORT SCOTT, KS KS 667 15 CBOC 589GP GARNETT, KS KS 660 15 CBOC 589G4 HAYS, KS KS 664 15 CBOC 589GQ HOLTON, KS KS 664 15 CBOC 589GR JUNCTION CITY, KS KS 664 15 CBOC 589GJ KANSAS CITY/WYANDOTTE, KS KS 660 15 CBOC 589GU LAWRENCE, KS KS 660 15 CBOC 589GU LAWRENCE, KS KS 660 15 VAMC 504GB LIBERAL, KS KS 679 18 CBOC 589G3 LIBERAL, KS KS 679 15 CBOC 589G5 PARSONS, KS KS 676 15 CBOC <						
589GO FORT RILEY, KS KS 664 15 CBOC 589GV FORT SCOTT, KS KS 667 15 CBOC 589GP GARNETT, KS KS 660 15 CBOC 589G4 HAYS, KS KS 664 15 CBOC 589GQ HOLTON, KS KS 664 15 CBOC 589GR JUNCTION CITY, KS KS 664 15 CBOC 589GJ KANSAS CITY/WYANDOTTE, KS KS 661 15 CBOC 589GU LAWRENCE, KS KS 660 15 CBOC 589GU LAWRENCE, KS KS 660 15 VAMC 589GB LIBERAL, KS KS 660 15 VAMC 589G3 LIBERAL, KS KS 679 15 CBOC 589G5 PARSONS, KS KS 676 15 CBOC 589GS RUSSELL, KS KS 674 15 CBOC <						
589GV FORT SCOTT, KS KS 667 15 CBOC 589GP GARNETT, KS KS 660 15 CBOC 589G4 HAYS, KS KS 676 15 CBOC 589GQ HOLTON, KS KS 664 15 CBOC 589GR JUNCTION CITY, KS KS 664 15 CBOC 589GJ KANSAS CITY/WYANDOTTE, KS KS 661 15 CBOC 589GU LAWRENCE, KS KS 660 15 CBOC 589A6 LEAVENWORTH, KS KS 660 15 VAMC 504GB LIBERAL, KS KS 679 18 CBOC 589G3 LIBERAL, KS KS 679 15 CBOC 589G5 PARSONS, KS KS 660 15 CBOC 589G5 PARSONS, KS KS 674 15 CBOC 589G6 SALINA, KS KS 674 15 CBOC <t< td=""><td></td><td></td><td></td><td></td><td></td><td></td></t<>						
589GP GARNETT, KS KS 660 15 CBOC 589G4 HAYS, KS KS 676 15 CBOC 589GQ HOLTON, KS KS 664 15 CBOC 589GR JUNCTION CITY, KS KS 664 15 CBOC 589GJ KANSAS CITY/WYANDOTTE, KS KS 661 15 CBOC 589GU LAWRENCE, KS KS 660 15 CBOC 589A6 LEAVENWORTH, KS KS 660 15 VAMC 504GB LIBERAL, KS KS 679 18 CBOC 589G3 LIBERAL, KS KS 679 15 CBOC 589GC PAOLA, KS KS 660 15 CBOC 589GS RUSSELL, KS KS 673 15 CBOC 589GS RUSSELL, KS KS 674 15 CBOC 589GW SALINA, KS KS 674 15 CBOC 589GW SALINA, KS KS 665 15 CBOC 589GT					15	
589G4 HAYS, KS KS 676 15 CBOC 589GQ HOLTON, KS KS 664 15 CBOC 589GR JUNCTION CITY, KS KS 664 15 CBOC 589GJ KANSAS CITY/WYANDOTTE, KS KS 661 15 CBOC 589GU LAWRENCE, KS KS 660 15 CBOC 589A6 LEAVENWORTH, KS KS 660 15 VAMC 504GB LIBERAL, KS KS 679 18 CBOC 589G3 LIBERAL, KS KS 679 15 CBOC 589GC PAOLA, KS KS 660 15 CBOC 589GS RUSSELL, KS KS 673 15 CBOC 589GS RUSSELL, KS KS 674 15 CBOC 589GW SALINA, KS KS 674 15 CBOC 589GW SALINA, KS KS 665 15 CBOC 589GT SENECA, KS KS 665 15 CBOC 589A5	589GV			667	15	CBOC
589GQ HOLTON, KS KS 664 15 CBOC 589GR JUNCTION CITY, KS KS 664 15 CBOC 589GJ KANSAS CITY/WYANDOTTE, KS KS 661 15 CBOC 589GU LAWRENCE, KS KS 660 15 CBOC 589A6 LEAVENWORTH, KS KS 660 15 VAMC 504GB LIBERAL, KS KS 679 18 CBOC 589G3 LIBERAL, KS KS 679 15 CBOC 589GC PAOLA, KS KS 660 15 CBOC 589GS PARSONS, KS KS 673 15 CBOC 589GS RUSSELL, KS KS 676 15 CBOC 589GS SALINA, KS KS 674 15 CBOC 589GW SALINA, KS KS 674 15 CBOC 589GT SENECA, KS KS 665 15 VAMC 58				660		
589GR JUNCTION CITY, KS KS 664 15 CBOC 589GJ KANSAS CITY/WYANDOTTE, KS KS 661 15 CBOC 589GU LAWRENCE, KS KS 660 15 CBOC 589A6 LEAVENWORTH, KS KS 660 15 VAMC 504GB LIBERAL, KS KS 679 18 CBOC 589G3 LIBERAL, KS KS 679 15 CBOC 589GC PAOLA, KS KS 660 15 CBOC 589G5 PARSONS, KS KS 673 15 CBOC 589GS RUSSELL, KS KS 676 15 CBOC 589G6 SALINA, KS KS 674 15 CBOC 589GW SALINA, KS KS 674 15 CBOC 589GT SENECA, KS KS 665 15 CBOC 589A5 TOPEKA, KS KS 666 15 VAMC 58	Lawrence Control Control			676		
589GJ KANSAS CITY/WYANDOTTE, KS KS 661 15 CBOC 589GU LAWRENCE, KS KS 660 15 CBOC 589A6 LEAVENWORTH, KS KS 660 15 VAMC 504GB LIBERAL, KS KS 679 18 CBOC 589G3 LIBERAL, KS KS 679 15 CBOC 589GC PAOLA, KS KS 660 15 CBOC 589G5 PARSONS, KS KS 673 15 CBOC 589GS RUSSELL, KS KS 676 15 CBOC 589G6 SALINA, KS KS 674 15 CBOC 589GW SALINA, KS KS 674 15 CBOC 589GT SENECA, KS KS 665 15 CBOC 589A5 TOPEKA, KS KS 666 15 VAMC 589A7 WICHITA, KS KS 672 15 VAMC	589GQ			664	15	CBOC
589GU LAWRENCE, KS KS 660 15 CBOC 589A6 LEAVENWORTH, KS KS 660 15 VAMC 504GB LIBERAL, KS KS 679 18 CBOC 589G3 LIBERAL, KS KS 679 15 CBOC 589GC PAOLA, KS KS 660 15 CBOC 589G5 PARSONS, KS KS 673 15 CBOC 589GS RUSSELL, KS KS 676 15 CBOC 589G6 SALINA, KS KS 674 15 CBOC 589GW SALINA, KS KS 674 15 CBOC 589GT SENECA, KS KS 665 15 CBOC 589A5 TOPEKA, KS KS 666 15 VAMC 589A7 WICHITA, KS KS 672 15 VAMC	589GR	JUNCTION CITY, KS	KS	664	15	СВОС
589A6 LEAVENWORTH, KS KS 660 15 VAMC 504GB LIBERAL, KS KS 679 18 CBOC 589G3 LIBERAL, KS KS 679 15 CBOC 589GC PAOLA, KS KS 660 15 CBOC 589G5 PARSONS, KS KS 673 15 CBOC 589GS RUSSELL, KS KS 676 15 CBOC 589G6 SALINA, KS KS 674 15 CBOC 589GW SALINA, KS KS 674 15 CBOC 589GT SENECA, KS KS 665 15 CBOC 589A5 TOPEKA, KS KS 666 15 VAMC 589A7 WICHITA, KS KS 672 15 VAMC	589GJ	KANSAS CITY/WYANDOTTE, KS	KS	661	15	CBOC
504GB LIBERAL, KS KS 679 18 CBOC 589G3 LIBERAL, KS KS 679 15 CBOC 589GC PAOLA, KS KS 660 15 CBOC 589G5 PARSONS, KS KS 673 15 CBOC 589GS RUSSELL, KS KS 676 15 CBOC 589G6 SALINA, KS KS 674 15 CBOC 589GW SALINA, KS KS 674 15 CBOC 589GT SENECA, KS KS 665 15 CBOC 589A5 TOPEKA, KS KS 666 15 VAMC 589A7 WICHITA, KS KS 672 15 VAMC	589GU	LAWRENCE, KS	KS	660	15	CBOC
504GB LIBERAL, KS KS 679 18 CBOC 589G3 LIBERAL, KS KS 679 15 CBOC 589GC PAOLA, KS KS 660 15 CBOC 589G5 PARSONS, KS KS 673 15 CBOC 589GS RUSSELL, KS KS 676 15 CBOC 589G6 SALINA, KS KS 674 15 CBOC 589GW SALINA, KS KS 674 15 CBOC 589GT SENECA, KS KS 665 15 CBOC 589A5 TOPEKA, KS KS 666 15 VAMC 589A7 WICHITA, KS KS 672 15 VAMC	589A6	LEAVENWORTH, KS	KS	660	15	VAMC
589GC PAOLA, KS KS 660 15 CBOC 589G5 PARSONS, KS KS 673 15 CBOC 589GS RUSSELL, KS KS 676 15 CBOC 589G6 SALINA, KS KS 674 15 CBOC 589GW SALINA, KS KS 674 15 CBOC 589GT SENECA, KS KS 665 15 CBOC 589A5 TOPEKA, KS KS 666 15 VAMC 589A7 WICHITA, KS KS 672 15 VAMC	504GB	LIBERAL, KS	KS	679	-	CBOC
589GC PAOLA, KS KS 660 15 CBOC 589G5 PARSONS, KS KS 673 15 CBOC 589GS RUSSELL, KS KS 676 15 CBOC 589G6 SALINA, KS KS 674 15 CBOC 589GW SALINA, KS KS 674 15 CBOC 589GT SENECA, KS KS 665 15 CBOC 589A5 TOPEKA, KS KS 666 15 VAMC 589A7 WICHITA, KS KS 672 15 VAMC	589G3	LIBERAL, KS	KS	679	15	CBOC
589G5 PARSONS, KS KS 673 15 CBOC 589GS RUSSELL, KS KS 676 15 CBOC 589G6 SALINA, KS KS 674 15 CBOC 589GW SALINA, KS KS 674 15 CBOC 589GT SENECA, KS KS 665 15 CBOC 589A5 TOPEKA, KS KS 666 15 VAMC 589A7 WICHITA, KS KS 672 15 VAMC	589GC				15	
589GS RUSSELL, KS KS 676 15 CBOC 589G6 SALINA, KS KS 674 15 CBOC 589GW SALINA, KS KS 674 15 CBOC 589GT SENECA, KS KS 665 15 CBOC 589A5 TOPEKA, KS KS 666 15 VAMC 589A7 WICHITA, KS KS 672 15 VAMC		PARSONS, KS			15	
589G6 SALINA, KS KS 674 15 CBOC 589GW SALINA, KS KS 674 15 CBOC 589GT SENECA, KS KS 665 15 CBOC 589A5 TOPEKA, KS KS 666 15 VAMC 589A7 WICHITA, KS KS 672 15 VAMC	589GS	RUSSELL, KS				
589GW SALINA, KS KS 674 15 CBOC 589GT SENECA, KS KS 665 15 CBOC 589A5 TOPEKA, KS KS 666 15 VAMC 589A7 WICHITA, KS KS 672 15 VAMC					15	
589GT SENECA, KS KS 665 15 CBOC 589A5 TOPEKA, KS KS 666 15 VAMC 589A7 WICHITA, KS KS 672 15 VAMC						
589A5 TOPEKA, KS KS 666 15 VAMC 589A7 WICHITA, KS KS 672 15 VAMC						
589A7 WICHITA, KS KS 672 15 VAMC						

	539GA	BELLEVUE, KY	KY	410		CBOC

RC V2p0 Station List 02-11-05.xls

Page 7 of 18

Fac #	VA Facility Location	ST	ZIP 3	VN	Type
626GC	BOWLING GREEN, KY	KY	421	9	CBOC
603GA	FORT KNOX, KY	KY	401	9	СВОС
626GD	HOPKINSVILLE, KY	KY	422	9	CBOC
596A0	LEXINGTON COOPER DRIVE, KY	KY	405	9	VAMC
596A4	LEXINGTON COOPER DRIVE, KY	KY	405	9	VAMC
596	LEXINGTON LEESTOWN, KY	KY	405	9	VAMC
596HA	LEXINGTON ORC, KY	KY	405	9	CBOC
603GC	LOUISVILLE CBOC, KY	KY	402	9	CBOC
603	LOUISVILLE, KY	KY	402	9	VAMC
657GL	PADUCAH, KY	KY	420	15	CBOC
581GA	PRESTONSBURG, KY	KY	416	9	CBOC
596GA	SOMERSET, KY	KY	425	9	CBOC
581GC	WHITESBURG, KY	KY	418	9	CBOC
502	ALEXANDRIA, LA	LA	713	16	VAMC
629BY	BATON ROUGE, LA	LA	708	16	CBOC
502GA	JENNINGS, LA	LA	705	16	СВОС
502GB	LAFAYETTE, LA	LA	705	16	CBOC
667GB	MONROE, LA	LA	712	16	СВОС
629	NEW ORLEANS, LA	LA	701	16	VAMC
667	SHREVEPORT, LA	LA	711	16	VAMC
518	BEDFORD, MA	MA	017	1	VAMC
523BZ	BOSTON CBOC, MA	MA	021	1	CBOC
523BZ	BOSTON, MA	MA	021	1	VAMC
523A5	BROCKTON, MA	MA	021	1	VAMC
523GE	DORCHESTER, MA	MA	024	1	CBOC
518GG	FITCHBURG, MA	MA	014	1	CBOC
523GA	FRAMINGHAM, MA	MA	017	1	CBOC
518GE	GLOUCESTER, MA	MA	 		
631GD	GREENFIELD, MA	MA	019 013	1	CBOC CBOC
518GB	· · · · · · · · · · · · · · · · · · ·	MA		$\frac{1}{1}$	ļ
	HAVERHILL, MA		018		CBOC
650GB 518GD	HYANNIS, MA	MA	026	1	CBOC
	LOWELL, MA	MA	018	1	CBOC
518GA	LYNN, MA	MA	019	1	CBOC
650GE	NANTUCKET, MA	MA	025	1	CBOC
650GA	NEW BEDFORD, MA	MA	027	1	CBOC
631GA	NORTHAMPTON CBOC, MA	MA	010	1	CBOC
631	NORTHAMPTON, MA	MA	010	1	VAMC
650GC	OAK BLUFFS, MA	MA	025		CBOC
631GC	PITTSFIELD, MA	MA	012	1	CBOC
523GD	PLYMOUTH, MA	MA	023	1	CBOC
523GC	QUINCY, MA	MA	021	1	CBOC
631GB	SPRINGFIELD CBOC, MA	MA	011	1	CBOC
631BY	SPRINGFIELD SOC, MA	MA	011	1	CBOC
523A4	WEST ROXBURY, MA	MA	021	1	VAMC
518GC	WINCHINDON, MA	MA	014	1	CBOC
523GB	WORCESTER, MA	MA	016	1	CBOC
512HK	BALTIMORE MOC, MD	MD	212	5	CBOC
512	BALTIMORE, MD	MD	212	5	VAMC
512GD	BALTIMORE/LOCH RAVEN, MD	MD	212	5	CBOC

RC V2p0 Station List 02-11-05.xls

Page 8 of 18

Fac #	VA Facility Location	ST	ZIP 3	VN	Type
512GA	CAMBRIDGE, MD	MD	216	5	CBOC
512GB	CHARLOTTE HALL, MD	MD	206	5	CBOC
613GA	CUMBERLAND, MD	MD	215	5	СВОС
512GF	FORT HOWARD CBOC, MD	MD	210	5	CBOC
512A4	FORT HOWARD, MD	MD	210	5	VAMC
512GC	GLEN BURNIE, MD	MD	210	5	CBOC
613GB	HAGERSTOWN, MD	MD	217	5	СВОС
688GC	LANDOVER, MD	MD	207	5	CBOC
460HM	MILLINGTON, MD	MD	216	4	CBOC
512A5	PERRY POINT, MD	MD	219	5	VAMC
512GE	POCOMOKE CITY, MD	MD	218	5	CBOC
402HB	BANGOR, ME	ME	044	1	CBOC
402GB	CALAIS MOC, ME	ME	046	$-\hat{1}$	CBOC
402GA	CARIBOU, ME	ME	047	1	CBOC
402HK	MACHIAS MOC, ME	ME	046	- <u></u>	CBOC
402HC	PORTLAND, ME	ME	041	1	CBOC
402GC	RUMFORD MOC, ME	ME	042	1	СВОС
402GD	SACO, ME	ME	040	1	CBOC
402	TOGUS, ME	ME	043	1	VAMC
506	ANN ARBOR, MI	MI	481	11	VAMC
515	BATTLE CREEK, MI	MI	490	11	VAMC
515GC	BENTON HARBOR, MI	MI	490	$\frac{11}{11}$	CBOC
553	DETROIT, MI	MI	482	11	VAMC
506GB	FLINT, MI	MI	485	11	CBOC
655GA	GAYLORD, MI	MI	497	11	СВОС
515BY	GRAND RAPIDS, MI	MI	495	11	CBOC
585GA	HANCOCK/PORTAGE, MI	MI	499	12	CBOC
585		MI	499	12	VAMC
	IRON MOUNTAIN, MI	MI	499		
585GD	IRONWOOD, MI			12	CBOC
506GC	JACKSON, MI	MI	492	11	CBOC
515GB	LANSING, MI	MI	489	11	CBOC
585HA	MARQUETTE, MI	MI MI	498	12	CBOC
585GC 515GA	MENOMINEE, MI	MI	498	12	CBOC CBOC
	MUSKEGON, MI		494	11	
655GC 553GB	OSCODA, MI	MI	487	11	CBOC
553GB 655	PONTIAC, MI SAGINAW, MI	MI MI	483	11 11	CBOC VAMC
		· · · · · · · · · · · · · · · · · · ·	486		
585HB	SAULT SAINTE MARIE, MI	MI	497	12	L
655GB	TRAVERSE CITY, MI	MI	496	11	CBOC
553GA	YALE, MI	MI	480	11	CBOC
656GA	BRAINERD, MN	MN	564	23	CBOC
437GC	FERGUS FALLS, MN	MN	565	23	CBOC
618GB	HIBBING, MN	MN	557	23	CBOC
618GA	MANKATO, MN	MN	560	23	CBOC
618	MINNEAPOLIS, MN	MN	554	23	VAMC
656GB	MONTEVIDEO, MN	MN	562	23	CBOC
618GG	ROCHESTER, MN	MN	559	23	CBOC
656	SAINT CLOUD, MN	MN	563	23	VAMC
618GD	SAINT PAUL, MN	MN	551	23	CBOC

RC V2p0 Station List 02-11-05.xls

Page 9 of 18

Fac #	VA Facility Location	ST	ZIP 3	<u>VN</u>	Type
656HA	VIRGINIA, MN	MN	557	23	CBOC
589GB	BELTON, MO	MO	640	15	CBOC
589GZ	CAMERON, MO	MO	644	15	CBOC
657GH	CAPE GIRARDEAU, MO	MO	637	15	CBOC
589A4	COLUMBIA, MO	МО	652	15	VAMC
657GI	FARMINGTON, MO	MO	636	15	CBOC
589GF	FORT LEONARD WOOD, MO	MO	654	15	CBOC
589	KANSAS CITY, MO	MO	641	15	VAMC
589GE	KIRKSVILLE, MO	МО	635	15	CBOC
589GX	MEXICO, MO	MO	652	15	CBOC
564BY	MOUNT VERNON, MO	МО	657	16	CBOC
589GD	NEVADA, MO	MO	647	15	CBOC
589GH	OSAGE BEACH, MO	MO	650	15	CBOC
657A4	POPLAR BLUFF, MO	MO	639	15	VAMC
657GD	SAINT CHARLES, MO	MO	633	15	CBOC
589GY	SAINT JAMES, MO	MO	655	15	CBOC
589GI	SAINT JOSEPH, MO	МО	645	15	CBOC
657GB	SAINT LOUIS CBOC, MO	MO	631	15	CBOC
657A0	SAINT LOUIS JEFF BARRACKS, MO	МО	631	15	VAMC
657	SAINT LOUIS JOHN COCHRAN, MO	МО	631	15	VAMC
657HK	SALEM, MO	МО	655	15	CBOC
589G1	WARRENSBURG, MO	МО	640	15	СВОС
657GF	WEST PLAINS, MO	МО	657	15	СВОС
589GG	WHITEMAN AFB/KNOB NOSTER, MO	MO	653	15	СВОС
520	BILOXI, MS	MS	395	16	VAMC
614GC	BYHALIA, MS	MS	386	9	СВОС
586GC	GREENVILLE, MS	MS	387	16	CBOC
520A0	GULFPORT, MS	MS	395	16	VAMC
586GD	HATTIESBURG, MS	MS	394	16	CBOC
586	JACKSON, MS	MS	392	16	VAMC
586GA	KOSCIUSKO, MS	MS	390	16	CBOC
586GB	MERIDIAN, MS	MS	393	16	CBOC
586GE	NATCHEZ, MS	MS	391	16	CBOC
614GA	SMITHVILLE, MS	MS	388	9	CBOC
436GA	ANACONDA, MT	MT	597	19	CBOC
436GH	BILLINGS, MT	MT	591	19	CBOC
436GD	BOZEMAN, MT	MT	597	19	CBOC
436	FORT HARRISON, MT	MT	596	19	VAMC
436GI	GLASGOW, MT	MT	592	19	CBOC
436GB	GREAT FALLS, MT	MT	594	19	СВОС
436GF	KALISPELL, MT	MT	599	19	CBOC
568HN	LAME DEER, MT	MT	590	23	СВОС
436GJ	MILES CITY, MT	MT	593	19	СВОС
436GC	MISSOULA, MT	MT	598	19	СВОС
436GK	SIDNEY, MT	MT	592	19	CBOC
637	ASHEVILLE, NC	NC	288	6	VAMC
659GA	CHARLOTTE, NC	NC	282	6	СВОС
558	DURHAM, NC	NC	277	6	VAMC
565	FAYETTEVILLE, NC	NC	283	6	VAMC

RC V2p0 Station List 02-11-05.xls

Page 10 of 18

Fac #	VA Facility Location	ST	ZIP 3	VN	Type
558GA	GREENVILLE, NC	NC	278	6	CBOC
565GA	JACKSONVILLE UCJ, NC	NC	285	6	CBOC
558GB	RALEIGH, NC	NC	276	6	CBOC
659	SALISBURY, NC	NC	281	6	VAMC
565GC	WILMINGTON, NC	NC	284	6	CBOC
659BY	WINSTON-SALEM, NC	NC	271	6	CBOC
437GB	BISMARCK, ND	ND	585	23	CBOC
437	FARGO, ND	ND	581	23	VAMC
437GA	GRAFTON, ND	ND	582	23	CBOC
437GD	MINOT, ND	ND	587	23	CBOC
568HC	ALLIANCE, NE	NE	693	23	CBOC
568HH	GERING, NE	NE	693	23	CBOC
636A4	GRAND ISLAND, NE	NE	688	23	VAMC
636A5	LINCOLN, NE	NE	685	23	VAMC
636GA	NORFOLK, NE	NE	687	23	CBOC
636GB	NORTH PLATTE, NE	NE	691	23	CBOC
636	OMAHA, NE	NE	681	23	VAMC
568HB	RUSHVILLE, NE	NE	693	23	CBOC
442GB	SIDNEY, NE	NE	691	19	CBOC
608GD	CONWAY, NH	NH	038	1	CBOC
405HE	KEENE, NH	NH	034	1	CBOC
608	MANCHESTER, NH	NH	031	1	VAMC
608GA	PORTSMOUTH, NH	NH	038	1	CBOC
608HA	TILTON, NH	NH	032	1	CBOC
608GC	WOLFEBORO, NH	NH	038	1	CBOC
460HF	BLACKWOOD, NJ	NJ	080	4	CBOC
561BZ	BRICK, NJ	NJ	087	3	CBOC
642GB	CAPE MAY, NJ	NJ	082	4	CBOC
561	EAST ORANGE, NJ	NJ	070	3	VAMC
561GB	ELIZABETH, NJ	NJ	072	3	CBOC
642GA	FORT DIX, NJ	NJ	086	4	CBOC
561GD	HACKENSACK, NJ	NJ	076	3	CBOC
561HB	JAMESBURG, NJ	NJ	088	3	CBOC
561GE	JERSEY CITY, NJ	NJ	073	3	CBOC
561A4	LYONS, NJ	NJ	079	3	VAMC
561GH	MORRISTOWN, NJ	NJ	079	3	CBOC
561GF	NEW BRUNSWICK, NJ	NJ	089	3	CBOC
561GG	NEWARK CBOC, NJ	NJ	071	3	CBOC
561BY	NEWARK SAC, NJ	NJ	071	3	СВОС
561GA	TRENTON, NJ	NJ	086	3	CBOC
460HE	VENTNOR CITY, NJ	NJ	084	4	CBOC
542GI	VENTNOR CITY, NJ	NJ	084	4	CBOC
460HG	VINELAND, NJ	NJ	083	4	СВОС
542GF	VINELAND, NJ	NJ	083	4	CBOC
501GI	ALAMOGORDO, NM	NM	883	18	CBOC
501	ALBUQUERQUE, NM	NM	871	18	VAMC
501GA	ARTESIA, NM	NM	882	18	CBOC
504GC	CLAYTON, NM	NM	884	18	CBOC
504BZ	CLOVIS, NM	NM	881	18	CBOC

RC V2p0 Station List 02-11-05.xls

Page 11 of 18

Fac #	VA Facility Location	ST	ZIP 3	VN	Type
501GE	ESPANOLA, NM	NM	884	18	CBOC
501GB	FARMINGTON, NM	NM	874	18	СВОС
501GD	GALLUP, NM	NM	873	18	CBOC
519GB	HOBBS, NM	NM	882	18	CBOC
756GA	LAS CRUCES, NM	NM	880	18	CBOC
501G2	LAS VEGAS, NM	NM	875	18	СВОС
501HB	RATON, NM	NM	877	18	CBOC
501GK	SANTA FE, NM	NM	875	18	CBOC
501GF	SANTA ROSA, NM	NM	884	18	CBOC
501GC	SILVER CITY, NM	NM	880	18	CBOC
501GH	TRUTH OR CONSEQUENCES, NM	NM	879	18	CBOC
660GC	ELY, NV	NV	893	19	CBOC
593GB	HENDERSON, NV	NV	890	22	СВОС
593GA	LAS VEGAS CBOC, NV	NV	891	22	CBOC
593	LAS VEGAS, NV	NV	891	22	VAMC
654GB	MINDEN, NV	NV	894	21	CBOC
593GC	PAHRUMP, NV	NV	890	22	CBOC
654	RENO, NV	NV	895	21	VAMC
528A8	ALBANY, NY	NY	122	2	VAMC
528G5	AUBURN, NY	NY	130	2	CBOC
528G3	BAINBRIDGE, NY	NY	137	2	CBOC
528A4	BATAVIA, NY	NY	140	2	VAMC
528A6	BATH, NÝ	NY	148	2	VAMC
528GN	BINGHAMTON, NY	NY	139	2	СВОС
526	BRONX, NY	NY	104	3	VAMC
630GD	BROOKLYN BEDFORD-STUYVESANT, NY	NY	112	3	СВОС
630GE	BROOKLYN CBOC, NY	NY	112	3	CBOC
630GC	BROOKLYN CHAPEL STREET, NY	NY	112	3	CBOC
630CG	BROOKLYN HOMELESS CTR, NY	NY	112	3	CBOC
630A4	BROOKLYN, NY	NY	112	3	VAMC
528	BUFFALO, NY	NY	142	2	VAMC
528A5	CANANDAIGUA, NY	NY	144	2	VAMC
620GB	CARMEL, NY	NY	105	3	CBOC
620A4	CASTLE POINT, NY	NY	125	3	VAMC
528G7	CATSKILL, NY	NY	124	2	CBOC
528GY	CLIFTON PARK, NY	NY	120	2	CBOC
528G9	CORTLAND, NY	NY	130	2	CBOC
528GC	DUNKIRK, NY	NY	140	2	CBOC
528G2	ELIZABETHTOWN, NY	NY	129	2	CBOC
528G4	ELMIRA, NY	NY	149	2	CBOC
630GF	FAR ROCKAWAY, NY	NY	116	3	CBOC
528G6	FONDA, NY	NY	120	2	CBOC
528GT	GLENS FALLS, NY	NY	128	2	CBOC
630GA	HARLEM, NY	NY	100	3	CBOC
620GF	HARRIS, NY	NY	127	3	CBOC
632HG	HICKSVILLE, NY	NY	118	3	CBOC
632HC	ISLIP, NY	NY	117	3	CBOC
528GB	JAMESTOWN, NY	NY	147	2	CBOC
528GZ	KINGSTON, NY	NY	124	2	CBOC

RC V2p0 Station List 02-11-05.xls

Page 12 of 18

Fac #	VA Facility Location	ST	ZIP 3	VN	Type
620GC	KINGSTON, NY	NY	124	3	CBOC
528GQ	LACKAWANNA, NY	NY	142	2	CBOC
632HF	LINDENHURST, NY	NY	117	3	CBOC
528GK	LOCKPORT, NY	NY	140	2	CBOC
632HA	LYNBROOK, NY	NY	115	3	CBOC
528G1	MALONE, NY	NY	129	2	CBOC
528GL	MASSENA, NY	NY	136	2	CBOC
620	MONTROSE, NY	NY	105	3	VAMC
528GI	MOUNT MORRIS, NY	NY	145	2	CBOC
632HE	MOUNT SINAI, NY	NY	117	3	CBOC
620GA	NEW CITY, NY	NY	109	3	CBOC
630BZ	NEW YORK METHADONE, NY	NY	100	3	CBOC
630B2	NEW YORK SOHO C&P UNIT, NY	NY	100	3	CBOC
630	NEW YORK, NY	NY	100	3	VAMC
528GD	NIAGARA FALLS, NY	NY	143	2	CBOC
632	NORTHPORT/LONG ISLAND, NY	NY	117	3	VAMC
528GR	OLEAN, NY	NY	147	2	СВОС
528GP	OSWEGO, NY	NY	131	2	CBOC
632HD	PATCHOGUE, NY	NY	117	3	СВОС
528GJ	PENN YAN, NY	NY	145	2	СВОС
632GA	PLAINVIEW, NY	NY	118	3	СВОС
528GV	PLATTSBURGH, NY	NY	129	2	СВОС
620GE	PORT JERVIS, NY	NY	127	3	CBOC
620GG	POUGHKEEPSIE, NY	NY	126	3	СВОС
526GD	QUEENS, NY	NY	111	3	CBOC
632HB	RIVERHEAD, NY	NY	119	3	CBOC
528GE	ROCHESTER, NY	NY	146	2	CBOC
528GM	ROME, NY	NY	134	2	СВОС
630A5	SAINT ALBANS, NY	NY	114	3	VAMC
632HH	SAYVILLE, NY	NY	117	3	СВОС
528GW	SCHENECTADY, NY	NY	123	2	СВОС
526GC	SOUTH BRONX, NY	NY	104	3	СВОС
630GB	STATEN ISLAND, NY	NY	103	3	СВОС
528A7	SYRACUSE, NY	NY	132	2	VAMC
528GX	TROY, NY	NY	121	2	CBOC
620GD	WALLKILL, NY	NY	125	3	CBOC
528GO	WATERTOWN/FORT DRUM, NY	NY	136	2	CBOC
528G8	WELLSVILLE, NY	NY	148	2	CBOC
526GA	WHITE PLAINS/BRONX, NY	NY	106	3	СВОС
526GB	YONKERS, NY	NY	107	3	CBOC
541GG	AKRON, OH	ОН	443	10	CBOC
562GB	ASHTABULA, OH	ОН	440	4	CBOC
538GA	ATHENS, OH	ОН	457	10	CBOC
541BY	CANTON, OH	ОН	447	10	СВОС
538	CHILLICOTHE, OH	ОН	456	10	VAMC
539GB	CINCINNATI CBOC, OH	ОН	452	10	CBOC
539	CINCINNATI, OH	ОН	452	10	VAMC
	CLEVELAND BRECKSVILLE, OH	OH	441	10	VAMC
541A0					

RC V2p0 Station List 02-11-05.xls

Page 13 of 18

Fac #	VA Facility Location	ST	ZIP 3	VN	Type
541	CLEVELAND WADE PARK, OH	OH	441	10	VAMC
757	COLUMBUS, OH	OH	432		IOC
552	DAYTON, OH	ОН	454		VAMC
541GH	EAST LIVERPOOL, OH	ОН	439	10	CBOC
757GB	GROVE CITY, OH	ОН	431	10	CBOC
538GD	LANCASTER, OH	ОН	431	10	CBOC
552GB	LIMA, OH	ОН	458	10	CBOC
541GB	LORAIN, OH	ОН	440	10	CBOC
541GD	MANSFIELD, OH	ОН	449	10	CBOC
538GC	MARIETTA, OH	ОН	457	10	СВОС
552GA	MIDDLETOWN, OH	ОН	450	10	CBOC
541GF	PAINESVILLE, OH	ОН	440	10	CBOC
538GB	PORTSMOUTH, OH	ОН	456	10	CBOC
646GA	SAINT CLAIRSVILLE, OH	ОН	439	4	CBOC
541GC	SANDUSKY, OH	ОН	448	10	СВОС
552GD	SPRINGFIELD, OH	ОН	455	10	CBOC
506GA	TOLEDO, OH	ОН	436	11	CBOC
541GI	WARREN, OH	ОН	444	10	СВОС
538HF	WASHINGTON COURT HOUSE, OH	ОН	431	10	CBOC
538HA	WELLSTON, OH	ОН	456	10	СВОС
541BZ	YOUNGSTOWN, OH	ОН	445	10	CBOC
757GA	ZANESVILLE, OH	ОН	437	10	СВОС
635HB	ARDMORE, OK	ОК	734	16	CBOC
635HA	CLINTON, OK	ОК	736	16	CBOC
635GD	KONAWA, OK	ОК	748	16	CBOC
635GA	LAWTON/FORT SILL, OK	ОК	735	16	CBOC
623GA	MCALESTER, OK	ОК	745	16	CBOC
623	MUSKOGEE, OK	OK	744	16	VAMC
635	OKLAHOMA CITY, OK	OK	731	16	VAMC
635GC	PONCA CITY, OK	OK	746	16	CBOC
623HA	TALIHINA, OK	OK	745	16	CBOC
623BY	TULSA, OK	OK	741	16	CBOC
653GA	BANDON, OR	OR	974	20	CBOC
648GA	BEND, OR	OR	977	20	CBOC
653GB	BROOKINGS, OR	OR	974	20	CBOC
653BY	EUGENE, OR	OR	974	20	CBOC
692GA	KLAMATH FALLS, OR	OR	976	20	CBOC
648GD	NORTH COAST, OR	OR	971	20	CBOC
531GD	ONTARIO, OR	OR	979	20	CBOC
648	PORTLAND, OR	OR	972	20	VAMC
653	ROSEBURG, OR	OR	974	20	VAMC
648GB	SALEM, OR	OR	973	20	CBOC
692	WHITE CITY, OR	OR	975	20	DOM
646GC	ALIQUIPPA, PA	PA	150	4	CBOC
693B4	ALLENTOWN, PA	PA	181	4	CBOC
503	ALTOONA, PA	PA	166	4	VAMC
693GF	BERWICK, PA	PA	186	4	CBOC
529	BUTLER, PA	PA	160	4	VAMC
595GA	CAMP HILL, PA	PA	170	4	CBOC

RC V2p0 Station List 02-11-05.xls

Page 14 of 18

Fac #	VA Facility Location	ST	ZIP 3	VN	Type
542GH	COATESVILLE CBOC, PA	PA	193	4	CBOC
542GG	COATESVILLE MSCEC, PA	PA	193	4	CBOC
542	COATESVILLE, PA	PA	193	4	VAMC
503GB	DU BOIS, PA	PA	158	4	СВОС
562	ERIE, PA	PA	165	4	VAMC
646GB	GREENSBURG, PA	PA	156	4	CBOC
503GA	JOHNSTOWN, PA	PA	159	4	CBOC
529GC	KITTANNING, PA	PA	162	4	CBOC
529GD	KNOX, PA	PA	162	4	CBOC
542GD	LANCASTER, PA	PA	176	4	СВОС
595GC	LANCASTER, PA	PA	176	4	CBOC
595	LEBANON, PA	PA	170	4	VAMC
562GA	MEADVILLE, PA	PA	163	4	СВОС
529GA	MERCER, PA	PA	161	4	CBOC
529GB	NEW CASTLE, PA	PA	161	4	CBOC
542GB	PHILADELPHIA CBOC, PA	PA	191	4	CBOC
642	PHILADELPHIA, PA	PA	191	4	VAMC
646A0	PITTSBURGH ASPINWALL, PA	PA	152	4	VAMC
646A4	PITTSBURGH ASPINWALL, PA	PA	152	4	VAMC
646A5	PITTSBURGH HIGHLAND DR, PA	PA	152	4	VAMC
646	PITTSBURGH UNIV DR, PA	PA	152	4	VAMC
595GB	POTTSVILLE/SCHUYLKILL/SHENANDOAH, PA	PA	179	4	СВОС
693GE	POTTSVILLE/SCHUYLKILL/SHENANDOAH, PA	PA	179	4	CBOC
542GC	READING, PA	PA	196	4	CBOC
595GD	READING, PA	PA	196	4	CBOC
693GA	SAYRE, PA	PA	188	4	CBOC
693GD	SCRANTON, PA	PA	185	4	CBOC
562GC	SMETHPORT, PA	PA	167	4	CBOC
542GE	SPRING CITY, PA	PA	194	4	CBOC
542GA	SPRINGFIELD, PA	PA	190	4	CBOC
503GC	STATE COLLEGE, PA	PA	168	4	CBOC
693GC	TOBYHANNA, PA	PA	184	4	CBOC
646GD	WASHINGTON, PA	PA	153	4	CBOC
693HK	WILKES-BARRE MOC, PA	PA	187	4	CBOC
693	WILKES-BARRE, PA	PA	187	4	VAMC
693GB	WILLIAMSPORT, PA	PA	177	4	СВОС
642GC	WILLOW GROVE, PA	PA	190	4	CBOC
595GE	YORK, PA	PA	174	4	СВОС
672GC	ARECIBO, PR	PR	006	8	CBOC
672BZ	MAYAGUEZ, PR	PR	006	8	CBOC
672B0	PONCE, PR	PR	007	8	CBOC
672	SAN JUAN, PR	PR	009	8	VAMC
650GD	MIDDLETOWN, RI	RI	028	1	CBOC
650	PROVIDENCE, RI	RI	029	1	VAMC
544GD	ANDERSON, SC	SC	296	7	CBOC
534GC	BEAUFORT, SC	SC	299	7	CBOC
AND ADDRESS OF THE PARTY OF THE	CHARLESTON, SC	SC	294	7	VAMC
1534					
534 544	COLUMBIA, SC	SC	292	7	VAMC

RC V2p0 Station List 02-11-05.xls

Page 15 of 18

Fac#	VA Facility Location	ST	ZIP 3	<u>VN</u>	Type
544BZ	GREENVILLE, SC	SC	296	7	CBOC
534GB	MYRTLE BEACH, SC	SC	295	7	CBOC
544GE	ORANGEBURG, SC	SC	291	7	CBOC
544GC	ROCK HILL, SC	SC	297	7	CBOC
544GF	SUMTER, SC	SC	291	7	CBOC
438GD	ABERDEEN, SD	SD	574	23	CBOC
568HM	EAGLE BUTTE, SD	SD	576	23	CBOC
568HD	ELLSWORTH AFB, SD	SD	577	23	CBOC
568	FORT MEADE, SD	SD	577	23	VAMC
568A4	HOT SPRINGS, SD	SD	577	23	VAMC
568HE	KYLE, SD	SD	577	23	CBOC
568HK	MCLAUGHLIN, SD	SD	576	23	CBOC
568GB	PIERRE, SD	SD	575	23	CBOC
568HF	PINE RIDGE, SD	SD	577	23	CBOC
568GA	RAPID CITY, SD	SD	577	23	CBOC
568HJ	ROSEBUD, SD	SD	575	23	CBOC
438	SIOUX FALLS, SD	SD	571	23	VAMC
568HP	WINNER, SD	SD	575	23	CBOC
438GA	WORTHING, SD	SD	570	23	CBOC
626GF	CHATTANOOGA, TN	TN	374	9	CBOC
626GE	CLARKSVILLE, TN	TN	370	9	CBOC
626GH	COOKEVILLE, TN	TN	385	9	CBOC
626GA	DOVER, TN	TN	370	9	CBOC
	The state of the s	TN	379	9	CBOC
626BY	KNOXVILLE, TN	TN		9	СВОС
626GB	MADISON, TN		371	9	
614	MEMPHIS, TN	TN	381	<u> </u>	VAMC
621GB	MOUNTAIN CITY, TN	TN	376	9	CBOC
621	MOUNTAIN HOME, TN	TN	376	9	VAMC
626A4	MURFREESBORO, TN	TN	371	9	VAMC
626	NASHVILLE, TN	TN	372	9	VAMC
621GA	ROGERSVILLE, TN	TN	378	9	CBOC
614GD	SAVANNAH, TN	TN	383	9	CBOC
626GG	TULLAHOMA/ARNOLD AFB, TN	TN	373	9	CBOC
519HC	ABILENE, TX	TX	796	18	CBOC
671GG	ALICE, TX	TX	783	17	CBOC
504	AMARILLO, TX	TX	791	18	VAMC
674BY	AUSTIN, TX	TX	787	17	CBOC
580BY	BEAUMONT, TX	TX	777		CBOC
671GH	BEEVILLE, TX	TX	781	17	CBOC
519	BIG SPRING, TX	TX	797	18	VAMC
549GC	BONHAM CBOC, TX	TX	754	17	CBOC
549A4	BONHAM, TX	TX	754	17	VAMC
671GA	BROWNSVILLE, TX	TX	785	17	CBOC
674GB	BROWNWOOD, TX	TX	768	17	CBOC
674GC	BRYAN/COLLEGE STATION, TX	TX	778	17	CBOC
674GD	CEDAR PARK, TX	. TX	786	17	CBOC
504GA	CHILDRESS, TX	TX	792	18	CBOC
549GI	CLEBURNE, TX	TX	760	17	CBOC
671BZ	CORPUS CHRISTI, TX	TX	784	17	CBOC

RC V2p0 Station List 02-11-05.xls

Page 16 of 18

Fac #	VA Facility Location	ST	ZIP 3	VN	Type
549	DALLAS, TX	TX	752	17	VAMC
549GB	DALLAS/PLEASANT GROVE, TX	TX	752	17	CBOC
549GE	DECATUR, TX	TX	762	17	СВОС
671GC	DEL RIO, TX	TX	788	17	СВОС
549GD	DENTON, TX	TX	762	17	СВОС
671GD	EAGLE PASS, TX	TX	788	17	CBOC
549GF	EASTLAND, TX	TX	764	17	CBOC
756	EL PASO, TX	TX	799	18	IOC
519GD	FORT STOCKTON, TX	TX	797	18	CBOC
549BY	FORT WORTH SOC, TX	TX	761	17	СВОС
549HA	FORT WORTH/DIAMOND HILL, TX	TX	761	17	CBOC
549GH	GREENVILLE, TX	TX	754	17	CBOC
674HA	HAMILTON, TX	TX	765	17	CBOC
580GB	HOUSTON CBOC, TX	TX	770	16	CBOC
580	HOUSTON, TX	TX	770	16	VAMC
671A4	KERRVILLE, TX	TX	780	17	VAMC
671GI	KINGSVILLE, TX	TX	783	17	СВОС
671GE	LAREDO, TX	TX	780	17	CBOC
667GC	LONGVIEW, TX	TX	756	16	CBOC
504BY	LUBBOCK, TX	TX	794	18	СВОС
580BZ	LUFKIN, TX	TX	759	16	СВОС
674A5	MARLIN, TX	TX	766	17	VAMC
671B0	MCALLEN, TX	TX	785	17	СВОС
549GG	MCKINNEY, TX	TX	750	17	CBOC
519GE	MONAHANS, TX	TX	797	18	СВОС
671GL	NEW BRAUNFELS, TX	TX	781	17	СВОС
519GA	ODESSA, TX	TX	797	18	CBOC
674GA	PALESTINE, TX	TX	758	17	СВОС
519HF	SAN ANGELO, TX	TX	769	18	CBOC
671BY	SAN ANTONIO CBOC, TX	TX	782	17	CBOC
671GK	SAN ANTONIO CBOC, TX	TX	782	17	CBOC
671	SAN ANTONIO, TX	TX	782	17	VAMC
671GM	SAN MARCOS, TX	TX	786	17	CBOC
671GN	SEGUIN, TX	TX	781	17	CBOC
671GF	SOUTH BEXAR COUNTY, TX	TX	782	17	CBOC
519HD	STAMFORD, TX	TX	795	18	CBOC
504HB	STRATFORD, TX	TX	790	18	CBOC
674	TEMPLE, TX	TX	765	17	VAMC
667GA	TEXARKANA, TX	TX	755	16	CBOC
549GA	TYLER, TX	TX	757	17	CBOC
671GJ	UVALDE, TX	TX	788	17	CBOC
671GB	VICTORIA, TX	TX	779	17	CBOC
674A4	WACO, TX	TX	767	17	VAMC
635GB	WICHITA FALLS, TX	TX	763	16	CBOC
660GI	NEPHI, UT	UT	846	19	CBOC
660GB	OGDEN, UT	UT	844	19	CBOC
660GE	OREM, UT	UT	840	19	CBOC
660GD	ROOSEVELT, UT	UT	840	19	CBOC
660GG	SAINT GEORGE, UT	UT	847	19	CBOC

RC V2p0 Station List 02-11-05.xls

Page 17 of 18

Fac #	VA Facility Location	ST	ZIP 3	<u>VN</u>	Type
660	SALT LAKE CITY, UT	UT	841	19	VAMC
688GA	ALEXANDRIA, VA	VA	223	5	CBOC
658HG	COVINGTON, VA	VA	244	6	CBOC
658GB	DANVILLE, VA	VA	245	6	CBOC
652GA	FREDERICKSBURG, VA	VA	224	6	CBOC
590	HAMPTON, VA	VA	236	6	VAMC
613GF	HARRISONBURG, VA	VA	228	5	CBOC
658HD	HILLSVILLE, VA	VA	243	6	CBOC
658HC	LYNCHBURG, VA	VA	245	6	CBOC
658HH	MARION, VA	VA	243	6	CBOC
658HE	MARTINSVILLE, VA	VA	241	6	CBOC
590GA	NORFOLK, VA	VA	235	6	CBOC
621GC	NORTON, VA	VA	242	9	СВОС
658HB	PULASKI, VA	VA	243	6	CBOC
652	RICHMOND, VA	VA	232	6	VAMC
621GD	SAINT CHARLES, VA	VA	242	9	CBOC
658	SALEM, VA	VA	241	6	VAMC
613GC	STEPHENS CITY, VA	VA	226	5	CBOC
658HA	STUARTS DRAFT, VA	VA	244	6	CBOC
658GA	TAZEWELL, VA	VA	246	6	СВОС
672GD	KINGSHILL, VI	VI	008	8	CBOC
672GA	SAINT CROIX, VI	VI	008	8	СВОС
672GB	SAINT THOMAS, VI	VI	008	8	CBOC
405GA	BENNINGTON, VT	VT	052	1	СВОС
405HA	BURLINGTON, VT	VT	054	1	CBOC
405HB	MONTPELIER, VT	VT	056	1	CBOC
405HD	NEWPORT, VT	VT	058	1	CBOC
405HF	RUTLAND, VT	VT	057	1	CBOC
405HC	SAINT JOHNSBURY, VT	VT	058	1	CBOC
405	WHITE RIVER JCT, VT	VT	050	1	VAMC
405HG	WILDER, VT	VT	050	1	CBOC
663A4	AMERICAN LAKE/TACOMA, WA	WA	984	20	VAMC
663GB	BREMERTON, WA	WA	983	20	CBOC
648GC	LONGVIEW, WA	WA	986	20	СВОС
663GA	LYNNWOOD/NORTHGATE, WA	WA	980	20	CBOC
687GA	RICHLAND, WA	WA	993	20	CBOC
663	SEATTLE, WA	WA	981	20	VAMC
668HK	SPOKANÉ MOC, WA	WA	992	20	CBOC
668	SPOKANE, WA	WA	992	20	VAMC
648A4	VANCOUVER, WA	WA	986	20	VAMC
687	WALLA WALLA, WA	WA	993	20	VAMC
687HA	YAKIMA, WA	WA	989	20	CBOC
695BY	APPLETON, WI	WI	549	12	CBOC
607GD	BARABOO, WI	WI	539	12	СВОС
607GE	BEAVER DAM, WI	WI	539	12	CBOC
618GE		Company and substitute water and substitute and sub	547	23	CBOC
	CHIPPEWA FALLS, WI	VV 1	1 341		
	CHIPPEWA FALLS, WI CLEVELAND, WI	WI			- unwerver
695GC 607GC	CHIPPEWA FALLS, WI CLEVELAND, WI EDGERTON, WI	WI WI	530 535	12 12	CBOC CBOC

RC V2p0 Station List 02-11-05.xls

Page 18 of 18

Fac #	VA Facility Location	ST	ZIP 3	VN	Type
676GC	LA CROSSE, WI	WI	546	12	CBOC
676GE	LOYAL, WI	WI	544	12	CBOC
607	MADISON, WI	WI	537	12	VAMC
695HK	MILWAUKEE MOC, WI	WI	532	12	CBOC
695	MILWAUKEE, WI	WI	532	12	VAMC
585GB	RHINELANDER, WI	WI	545	12	CBOC
618BY	SUPERIOR, WI	WI	548	23	CBOC
676	TOMAH, WI	WI	546	12	VAMC
695GA	UNION GROVE, WI	WI	531	12	CBOC
676GA	WAUSAU, WI	WI	544	12	CBOC
676HB	WAUTOMA, WI	WI	549	12	CBOC
676GD	WISCONSIN RAPIDS, WI	WI	544	12	CBOC
517	BECKLEY, WV	WV	258	6	VAMC
581GB	CHARLESTON, WV	WV	253	9	CBOC
540	CLARKSBURG, WV	WV	263	4	VAMC
613GD	FRANKLIN, WV	WV	268	5	CBOC
517GA	GASSAWAY, WV	WV	266	6	CBOC
540GC	GASSAWAY, WV	WV	266	4	CBOC
581	HUNTINGTON, WV	WV	257	9	VAMC
581GE	LOGAN, WV	wv	256	9	CBOC
613HK	MARTINSBURG MOC, WV	WV	254	5	CBOC
613	MARTINSBURG, WV	WV	254	5	VAMC
540GB	PARKERSBURG, WV	WV	261	4	CBOC
540GA	PARSONS, WV	WV	262	4	CBOC
613GE	PETERSBURG, WV	WV	268	5	CBOC
581GD	WILLIAMSON, WV	WV	256	9	CBOC
666GB	CASPER, WY	WY	826	19	CBOC
442	CHEYENNE, WY	WY	820	19	VAMC
666GE	GILLETTE, WY	WY	827	19	CBOC
660GF	GREEN RIVER, WY	WY	829	19	CBOC
568HA	NEWCASTLE, WY	WY	827	23	CBOC
666GD	POWELL, WY	WY	824		CBOC
666GC	RIVERTON, WY	WY	825		CBOC
666	SHERIDAN, WY	WY	828	19	VAMC
Abbrevia	ations				
CBOC =	Community-Based Outpatient Clinic				
	Independent Domiciliary				
Fac # =	VA Facility Number				
	Independent Outpatient Clinic				
MOC =	Mobile Outreach Clinic				
SOC =	Satellite Outpatient Clinic				
ST = St	ate				
VAMC	= VA Medical Center				
VN = V	eterans Integrated Service Network				
	First three digits of ZIP Code		T		Ī



Thursday, October 2, 2003

Part III

Department of Transportation

Federal Transit Administration Over-the-Road Bus Accessibility Program Announcement of Project Selections; Notice

DEPARTMENT OF TRANSPORTATION

Federal Transit Administration

Over-the-Road Bus Accessibility Program Announcement of Project Selections

AGENCY: Federal Transit Administration,

DOT.

ACTION: Notice.

SUMMARY: The U.S. Department of Transportation (DOT) Federal Transit Administration (FTA) announces the selection of projects to be funded under Fiscal Year 2003 appropriations for the Over-the-Road Bus (OTRB) Accessibility Program, authorized by Section 3038 of the Transportation Equity Act for the 21st Century (TEA-21). The OTRB Accessibility Program makes funds

available to private operators of overthe-road buses to help finance the incremental capital and training costs of complying with DOT's over-the-road bus accessibility rule, published in the **Federal Register** on September 24, 1998.

FOR FURTHER INFORMATION CONTACT: The appropriate FTA Regional Administrator for grant-specific issues; or Blenda Younger, Office of Program Management, 202–366–2053, for general information about the OTRB Program.

SUPPLEMENTARY INFORMATION: A total of \$6.9 million was made available for the program in FY 2003: \$5.2 million for intercity fixed-route providers and \$1.7 million for all other providers, such as commuter, charter, and tour operators. A total of 84 applicants requested \$17.6 million: \$10.5 million was requested by

intercity fixed-route providers, and \$7.1 million was requested by all other providers. Project selections were made on a discretionary basis, based on each applicant's responsiveness to statutory project selection criteria, fleet size, and level of funding received in previous years. Because of the high demand for the funds available, most applicants received less funding than they requested, but all qualified applicants received some funding. The selected projects will provide funding for the incremental cost of adding lifts to 128 new vehicles, retrofitting 80 vehicles, and \$335,546 for training. Each of the following 74 awardees, as well as the 10 applicants who were not selected for funding, will receive a letter that explains how funding decisions were made.

			Award amounts	
Operator	City/State	Intercity fixed- route	Other	Total
Region I:				
Bonanza Bus Lines	Providence, RI	\$109,935		\$109.935
Bristol Tours, Inc		, , , , , , , , , , , , , , , , , , , ,	39.547	39,547
Concord Coach Lines, Inc		48.800		48.800
Entertainment Tours		63,000		63,000
Peter Pan Bus Lines	*	157,859		157,859
Vermont Transit Co		107,000	33.151	33,151
Region II:	Barmigton, v.		00,101	00,101
Adirondack Trailways	Hurley, NY	187.500		187,500
Blue Bird Coach Lines, Inc			87,030	87,030
Hampton Jitney, Inc	•		28,800	28,800
Shortline (Hudson Transit)		180.000	,	180.000
	Green Port, NY		39,384	39,384
Surrise Coach Lines, Inc	Green Fort, NY		,	,
Syracuse and Oswego Motor Lines			43,481	43,481
Trans Express, Inc	1	70.000	33,750	33,750
Trolley Tours, Inc		72,000	22,950	94,950
Utica Rome Bus Company	Clinton, NY		41,990	41,990
Region III:				
Abbott Bus Lines, Inc			91,482	91,482
Angelic Luxury Coach, Inc		35,000		35,000
Brown Bus Company			28,710	28,710
Butler Motor Transit			37,800	37,800
Capitol Bus Company		50,400		50,400
Elegance Bus Tours, Inc	Suitland, MD	35,000		35,000
Eyre Bus Service, Inc			63,142	63,142
First Priority Tours, Inc	District Hgts. MD		20,965	20,965
Hagey Coach, Inc			50,400	50,400
Krapf's Coaches, Inc			25,200	25,200
Lenzer Tour and Travel			37,800	37,800
Penn Highway Transit Co			33,712	33,712
Perkiomen Tours	*		33,300	33,300
Susquehanna Transit Co		100,596		100,596
Thomas Tours			12.617	12,617
Trans-Bridge Lines		154,101		154,101
Region IV:	Botherion, 17t	101,101		101,101
Americoach Tours	Memphis, TN		38,250	38,250
Blue Grass Tours, Inc			28,507	28,507
Carolina Trailways	1 5 .		33,151	33,151
Champion Coach			27.000	27,000
•			,	,
Escot Bus Lines, Inc	1 '		39,368	39,368 2.700
Good Time Tours			2,700	,
Lancaster Tours and Travel			35,000	35,000
North Mississippi Services	Tupelo, MS		45,814	45,814
Region V:				
Alpha Bus Leasing			54,871	54,871
B&W Charters, Inc			36,961	36,961
Brecksville Road Transit, Inc	Brecksville, OH	l	37,104	37,104

			Award amounts	
Operator	City/State	Intercity fixed- route	Other	Total
Cavallo Bus Lines, Inc	Gillespie, IL		35,000	35,000
Colonial Coach Lines	Des Plaines, IL	112,274		112,274
Dixon Meyers Bus Transportation	Mt. Morris, IL		35,946	35,946
Jefferson Lines	Minneapolis, MN	133,250		133,250
Peoria Charter Coach Co	Peoria, IL	35,910		35,910
Pioneer Coach Lines, Inc	Chicago, IL		27,000	27,000
Red River Trails	Moorhead, MN		27,239	27,239
Robinson Coach	Evanston, IL		35,500	35,500
Trobec Bus Service, Inc	St. Stephen, MN		27,000	27,000
Vandalia Bus Lines, Inc	Caseyville, II		52,332	52,332
Wisconsin Coach	Waukesha, WI	108.000	·	108,000
Region VI:	,	·		•
Cowtown Bus Charters, Inc	Fort Worth, TX		28,474	28,474
El Expresso	Houston, TX	76,050		76,050
Fun Time Tours	Corpus Christi, TX		38,554	38,554
Gotta Go Express Trailways	Fort Worth, TX		25,626	25,626
Greyhound	Dallas, TX	2,588,544		2,588,544
Gulf Coast Transit	Houston, TX	_,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,,	38,250	38,250
Kerrville Bus Co	San Antonio, TX	176,670	33,233	176,670
TNM&O	Lubbock,TX	165,755		165,755
Valley Transit	Harlingen, TX	99,453		99,453
Region VII:		00,.00		00,.00
Burlington Trailways	W. Burlington, IA	85,488		85,488
Tiger Air Express, Inc	Columbia, MO	45,022		45.022
Region VIII:		.0,022		.0,022
Express Charters, Inc	Fort Collins, CO		27.000	27.000
Utah Trailways	Salt Lake City, UT	28,135	2.,000	28,135
Region IX:	Can Land Only, O'l	20,100		20,100
Marin Airporter	San Rafael, CA	112,365		112,365
Pacific Coachways	Garden Grove, CA		25.200	25,200
Quest Transportation, Inc	San Luis Obispo, CA	74,160	20,200	74,160
RDH Transportation Services	Honolulu, Hawaii	7 - 7, 100	55.576	55.576
Silverado Stages, Inc	San Luis Obispo, CA	74,160	00,070	74,160
Region X:	Can 2010 Obiopo, O/	7 , 100		7-4,100
Central Washington Airporter	Ferndale, WA	44,305		44,305
Northwestern Stage Lines	Spokane, WA	29,250		29,250
Premier Alaska Tours, Inc	Anchorage, AK	25,250	26,316	26,316
Tomor Adona Todio, Ino	/ III o i o i o i o i o i o i o i o i o i		20,010	20,010
Total		5,182,982	1,688,950	6,871,932

Eligible project costs may be incurred by awardees prior to final grant approval. The incremental capital cost for adding wheelchair lift equipment to any new vehicles delivered on or after June 9, 1998, the effective date of TEA– 21, is eligible for funding under the OTRB Accessibility Program.

Applicants selected for funding may be contacted by FTA regional offices if additional information is needed before grants are made. The grant applications will be sent to the U.S. Department of Labor (DOL) for certification under labor protection requirements pursuant to 49 U.S.C. 5333(b). After referring applications to affected employees represented by a labor organization, DOL will issue a certification to FTA. Terms and conditions of the certification will be incorporated in the FTA grant agreement under the new guidelines replacing those in 29 CFR

Part 215. Please see Amendment to Section 5333(b), Guidelines to Carry Out New Programs Authorized by the Transportation Equity Act for the 21st Century (TEA-21); Final Rule (64 FR 40990, July 28, 1999).

Issued on: September 26, 2003.

Jennifer L. Dorn,

Administrator.

[FR Doc. 03–24965 Filed 10–1–03; 8:45 am] BILLING CODE 4910–57–P



Thursday, October 2, 2003

Part IV

Department of the Interior

Fish and Wildlife Service

50 CFR Part 32 2003–2004 Refuge-Specific Hunting and Sport Fishing Regulations; Final Rule

DEPARTMENT OF THE INTERIOR

Fish and Wildlife Service

50 CFR Part 32 RIN 1018-AI63

2003–2004 Refuge-Specific Hunting and Sport Fishing Regulations

AGENCY: Fish and Wildlife Service,

Interior.

ACTION: Final rule.

SUMMARY: The Fish and Wildlife Service adds seven additional refuges to the list of areas open for hunting and/or sport fishing activities and increases the activities available at three other refuges for 2003–2004.

DATES: This rule is effective October 2, 2003

FOR FURTHER INFORMATION CONTACT: Leslie A. Marler, (703) 358–2397; Fax (703) 358–2248.

SUPPLEMENTARY INFORMATION: The National Wildlife Refuge System Administration Act of 1966 (Administration Act) closes national wildlife refuges to all uses until opened. The Secretary of the Interior (Secretary) may open refuge areas to any use, including hunting and/or fishing, upon a determination that such uses are compatible with the purposes of the refuge and National Wildlife Refuge System mission. The action also must be in accordance with provisions of all laws applicable to the areas, developed in coordination with the appropriate State fish and wildlife agency(ies), and consistent with the principles of sound fish and wildlife management and administration. These requirements ensure that we maintain the biological integrity, diversity, and environmental health of the National Wildlife Refuge System (System or we) for the benefit of present and future generations of Americans.

We annually review refuge hunting and fishing programs to determine whether to include additional refuges.

Provisions governing hunting and fishing on national wildlife refuges are in Title 50 of the Code of Federal Regulations in part 32 (50 CFR part 32). We regulate hunting and fishing on refuges to:

- Ensure compatibility with refuge purpose(s);
- Properly manage the fish and wildlife resource(s);
 - Protect other refuge values;
 - Ensure refuge visitor safety; and
- Provide opportunities for quality recreational and educational experiences.

On many refuges where we decide to allow hunting and fishing, our general policy of adopting regulations identical to State hunting and fishing regulations is adequate in meeting these objectives. On other refuges, we must supplement State regulations with more-restrictive Federal regulations to ensure that we meet our management responsibilities, as outlined in the "Statutory Authority" section. We issue refuge-specific hunting and sport fishing regulations when we open wildlife refuges to either migratory game bird hunting, upland game hunting, big game hunting, or sport fishing. These regulations list the wildlife species that you may hunt or those species subject to sport fishing, seasons, bag limits, methods of hunting or fishing, descriptions of areas open to hunting or fishing, and other provisions as appropriate. You may find previously issued refuge-specific regulations for hunting and fishing in 50 CFR part 32.

Statutory Authority

The National Wildlife Refuge System Administration Act (Administration Act) of 1966 (16 U.S.C. 668dd–668ee, as amended) and the Refuge Recreation Act (Recreation Act) of 1962 (16 U.S.C. 460k–460k–4) govern the administration and public use of national wildlife refuges.

Amendments enacted by the National Wildlife Refuge System Improvement Act of 1997 (Improvement Act) build upon the Administration Act in a manner that provides an "Organic Act" for the System similar to those that exist for other public Federal lands. The Improvement Act serves to ensure that we effectively manage the System as a national network of lands, waters, and interests for the protection and conservation of our Nation's wildlife resources. The Administration Act states first and foremost that we focus the mission of the System on conservation of fish, wildlife, and plant resources and their habitats. The Improvement Act requires the Secretary, before allowing a new use of a refuge, or before expanding, renewing, or extending an existing use of a refuge, to determine that the use is compatible. The Improvement Act established as the policy of the United States that wildlifedependent recreation, when compatible, is a legitimate and appropriate public use of the System, through which the American public can develop an appreciation for fish and wildlife. The Act established six wildlife-dependent recreational uses, when compatible, as the priority general public uses of the System. These uses are: hunting, fishing, wildlife observation and

photography, and environmental education and interpretation.

The Recreation Act authorizes the Secretary to administer areas within the System for public recreation as an appropriate incidental or secondary use only to the extent that doing so is practicable and not inconsistent with the primary purpose(s) for which Congress and the Service established the areas. The Recreation Act requires that any recreational use of refuge lands be compatible with the primary purpose(s) for which we established the refuge and not inconsistent with other previously authorized operations.

The Administration Act and Recreation Act also authorize the Secretary to issue regulations to carry out the purposes of the Acts and regulate uses.

We develop specific management plans for each refuge prior to opening it to hunting or fishing. In many cases, we develop refuge-specific regulations to ensure the compatibility of the programs with the purpose(s) for which we established the refuge and the mission of the System. We ensure initial compliance with the Administration Act and the Recreation Act for hunting and sport fishing on newly acquired refuges through an interim determination of compatibility made at or near the time of acquisition. These regulations ensure that we make the determinations required by these acts prior to adding refuges to the lists of areas open to hunting and fishing in 50 CFR part 32. We ensure continued compliance by the development of comprehensive conservation plans, specific plans, and by annual review of hunting and sport fishing programs and regulations.

Response to Comments Received

In the August 14, 2003, **Federal Register** (68 FR 48583), we published a proposed rulemaking identifying the refuges and their proposed hunting and/or fishing programs and invited public comments. We reviewed and considered all comments following a 30-day comment period.

We received 1,541 comments on the proposed rule: 570 in support and 482 in opposition to the openings and 489 comments that were either considered to be anonymous (did not provide a full mailing address as stipulated in the proposed rule) or were received after the comment close date. Of the 1,052 comments considered, 1,031 came from individuals (558 in support and 473 in opposition), 15 represented nongovernment organizations (7 in support and 8 in opposition), 5 comments from States (all in support)

and 1 comment from academia (in opposition).

We also received numerous comments unrelated to the content of the proposed rule (e.g., those dealing with such issues as trapping and general refuge management). We reviewed and analyzed the specific substantive comments and broke them into 12 general comments as follows:

Comment #1: A commenter suggested that the circumstances surrounding the possibility of opening these refuges to hunting dictate that, according to the National Environmental Policy Act (NEPA), the Service should have prepared an Environmental Impact Statement (EIS).

Response: We disagree with the statement that the Service should have prepared an EIS for the opening of these seven refuges to hunting and/or fishing. Each individual refuge, when making a determination as to whether or not to allow hunting and/or fishing, complies with NEPA (Categorical Exclusion, Environmental Assessment, or an Environmental Impact Statement) as appropriate when preparing an 'opening package." For each of the refuges included in this rulemaking, we prepared Environmental Assessments and determined that EISs were unnecessary. No changes were made as a result of this comment.

Comment #2: A commenter suggested the Service should have conducted biological assessments and inventories of flora and fauna as required by the (National Wildlife Refuge System Improvement Act of 1997) Improvement

Response: The Improvement Act does not require a biological assessment of flora and fauna. However, the Improvement Act does require the Service to "monitor the status and trends of fish, wildlife, and plants in each refuge." Before we establish a hunting or fishing program, the law requires we first determine compatibility with refuge purposes. All seven refuges at which hunting or fishing programs were proposed met this requirement. No changes were made as a result of this comment.

Comment #3: Many commenters said the Service should have considered public opinion polls containing statistics on public opposition to recreational and commercial killing of wildlife on national wildlife refuges. Many also felt that a trend is developing within the System placing the interests of sport hunters ahead of those of both the wildlife and nonhunting refuge visitors.

Response: The System has a long history of support by recreational

hunters, including the creation of over 300 units through the use of Migratory Bird Conservation Act of 1919 (16 U.S.C. 715a-715r) using "Duck Stamp" funds. This traditional support has been recognized in subsequent statutory authority for the System, including most recently the Improvement Act amendment to the Administration Act. This law, which also provides the System its mission, clearly states that six wildlife-dependent recreational uses, including both hunting and fishing as well as wildlife observation and photography and environmental education and interpretation, when compatible, are the priority general public uses of the System. Furthermore, these uses are to receive "enhanced consideration over other general public uses in planning and management within the System * * *." The Improvement Act also directs the Service to provide "increased opportunities for families to experience compatible wildlife-dependent recreation, particularly opportunities for parents and their children to safely engage in traditional outdoor activities, such as fishing and hunting * * *.' From this statutory language, Congress' intent is clear that the Service provide opportunities for compatible hunting and fishing on the System. Thus, while we carefully consider public comment and opinion in our rulemaking, we find this statutory direction unequivocal.

Commercial hunting and fishing are generally prohibited within the System. This rulemaking does not include commercial hunting and fishing. No changes were made as a result of this comment.

Comment #4: A commenter said the Service should have determined the detrimental effects of current predator management strategies to protect sensitive, threatened, and endangered species.

Response: This comment appears to be directed at refuge management generally and endangered species management specifically and not at the proposed rule. Specific to Endangered Species Act Section 7 Consultation, each refuge reviews its opening package to determine the impact of allowing hunting and/or fishing on any threatened or endangered species. We also comply with section 7 of the ESA when developing comprehensive conservation plans (CCPs) and stepdown management plans for public use of refuges, such as hunting and fishing, and prior to implementing any new or revised public recreation program on a refuge as identified in 50 CFR 26.32. We made no changes as a result of this comment.

Comment #5: Many commenters stated that the majority of people who visit refuges do so to observe wildlife and enjoy nature, and not to hunt, fish, or trap.

Response: Within the System as a whole, this information is correct. However, in some locations, such as North Dakota, South Dakota, and Minnesota, more visitors participate in consumptive uses (hunting, fishing, and trapping) than nonconsumptive forms of wildlife-dependent recreation. However, as explained in response to comment #3 above, the Improvement Act clearly indicates that six forms of wildlifedependent recreation, when compatible, are the priority general public uses of the System. The Act and associated House Report 105-106 also indicate there are no priorities between these six uses (again, when compatible), and does not indicate usage should be allocated based on the relative proportion of individuals participating in the activity. No changes were made as a result of this comment.

Comment #6: Several commenters suggested that the Service must conduct rigorous biological analyses of wildlife populations...before making any compatibility determinations about the commercial and/or recreational killing of wildlife on the refuges listed in the Notice. On a related topic, several commenters believe, in the past, the Service relied too heavily on lethal predator control as the primary method of addressing recovery of threatened and endangered species on refuges and has failed to address more serious threats to these species, including habitat degradation, pollution, and human impact.

Response: In addition to the information provided above in response to comment #2, many of the suggested biological analyses are conducted at the flyway level for migratory waterfowl and other game birds, with survey data going back decades. These population surveys detect trends in population numbers. If there is not sufficient information for a refuge manager, using his/her sound professional judgment to make an affirmative determination of compatibility, the manager cannot allow the use. Similar to the response to comment #4, some of this comment appears to be directed at endangered and threatened species conservation, not these regulations. No changes were made as a result of these comments.

Comment #7: Concern was expressed that Service has strayed far from its own policy, which directs that "wildlife comes first" in the System. A related comment said a thorough discussion of

programs.

proposed refuge habitat management practices is needed.

Response: The Administration Act authorizes the Service to allow uses of any refuge area as long as those uses are compatible; in fact, the Act specifically references hunting and fishing. Recent amendments to the Administration Act made by the Improvement Act establish wildlife-dependent recreational uses as priority general public uses and include hunting and fishing in the definition of those priority uses.

The principal focus of the Improvement Act was to clearly establish a wildlife conservation mission for the System and provide managers clear direction to make determinations regarding wildlife conservation and public uses within the units of the System. The Service manages national wildlife refuges primarily for wildlife conservation, habitat protection, and biological integrity, and allows uses only when compatible with the refuge purpose(s). In passing the Improvement Act, Congress reaffirmed the System was created to conserve fish, wildlife, plants, and their habitats and would facilitate opportunities for Americans to participate in compatible wildlifedependent recreation, including hunting and/or fishing on System lands. The Service has adopted policies and regulations implementing the requirements of the Improvement Act with which refuge managers comply when considering hunting and fishing

When lands and waters are under consideration for addition to the System, the refuge manager will make an interim compatibility determination on any existing wildlife-dependent recreational uses. The record of decision establishing the refuge must document the completion of such determinations. The results of these determinations are in effect until the completion of a CCP. During the development of the CCP and implementation of the NEPA process, we accept and incorporate public comments into the hunting and/or fishing decision on the refuge. When considering opening an existing refuge, the refuge manager similarly must make a determination that the proposal is compatible and complies with NEPA before taking any action. Refuge managers plan efforts well in advance of any proposed changes in order to obtain as much involvement from stakeholders as possible. This may include public meetings, workshops, news releases, and mailings to interested groups. The refuge manager consults with affected Service Regional Office, State fish and wildlife agencies, tribes, and the public

before opening a refuge to hunting or fishing. This decision must also be consistent with the principles of sound wildlife management, applicable wildlife objectives, and otherwise be in the public interest. The refuge manager must submit a hunting and/or fishing plan that has undergone a public input process to the Regional Office for approval. The $\bar{\text{Regional}}$ Director approves the plan before the rulemaking process begins. These hunting and/or fishing plans contain:

1. Step-down hunting/fishing plans containing compatibility determinations. The plan is usually an appendix to the overall plan for providing visitor services on refuges, providing documentation of the hunting and/or fishing allowed on a refuge, including the relationship of hunting and/or fishing to other priority general public uses, refuge purpose(s), goals, objectives, and the System mission;

2. Appropriate NEPA documentation; 3. Appropriate decision documentation;

4. Section 7 ESA evaluation;

5. Copies of letters requesting State and, where appropriate, tribal involvement and the results of the request;

6. Draft news release; and

7. Outreach plan.

One of the elements of the CCP, specific to the habitat management practices comment, requires that each refuge develop goals for significant wildlife species or groups of species, habitat (including land protection needs), compatible wildlife-dependent recreation, other mandates (such as refuge-specific legislation, Executive orders, special area designations), and fish, wildlife and plant populations, as appropriate.

Comment #8: A commenter felt the Service should use the Improvement Act to restore this public land system to its original purpose of providing an inviolate sanctuary for wildlife.

Response: The term "inviolate sanctuary" is something of a misnomer. The Migratory Bird Conservation Act of 1929 authorized acquisition of refuges as "inviolate sanctuaries" where the birds could rest and reproduce in total security. In 1949, the "inviolate sanctuary" concept was modified by an amendment to the Migratory Bird Hunting and Conservation Stamp Act which permitted hunting on up to 25 percent of each inviolate refuge. Another amendment to the Migratory Bird Hunting and Conservation Stamp Act in 1958 increased the total area of an inviolate refuge that could be opened for hunting up to 40 percent. These parameters were enacted as part of the

Administration Act. Whether an area is an "inviolate sanctuary" is a function of the mechanism of its creation. If a refuge was acquired as an inviolate sanctuary, only 40 percent of the refuge area may be opened at one time for hunting of migratory game birds. However, if the refuge was not acquired as an inviolate sanctuary, 100 percent of the refuge may be opened for hunting. The Fish and Wildlife Improvement Act of 1978 amended section 6 of the Administration Act to provide for the opening of all or any portion of an inviolate sanctuary to the taking of migratory birds if taking is determined to be "beneficial" to the species. Such opening of more than 40 percent to hunting is determined on a species-byspecies basis. This amendment refers to inviolate sanctuaries created in the past or to be created in the future. It has no application to areas acquired for other management purposes. No changes were made as a result of this comment.

Comment #9: A commenter believes the Service needs to consider the need for assessment and mitigation of the impacts of recreational activities on native flora and fauna.

Response: See the response to the comment #7 above concerning "straying from the FWS policy." No changes were made as a result of this comment.

Comment #10: One commenter asked us to clarify/change Coldwater National Wildlife Refuge relative to the prohibition of "any weapon" while fishing on the refuge. Does that include a fishing knife?

Response: With respect to knives, the legal definition of a weapon in the State of Mississippi is a knife longer than 3 inches (7.5 cm). We will modify the condition listed under Coldwater National Wildlife Refuge to read: D.4. We prohibit possession of any weapon while fishing on the refuge. This does not include fishing knives unless they are longer than 3 inches (7.5 cm).

Comment #11: One commenter asked if we could allow lead shot no larger than #6 shot with a maximum of 25 shells carried in the field at one time on Northern Tallgrass Prairie National Wildlife Refuge under Upland Game

Response: 50 CFR 32.2(k) prohibits possession of lead shot unless hunting for turkey and deer (where we allow those activities). The refuge in question, Northern Tallgrass Prairie in the States of Minnesota and Iowa, under Upland Game Hunting, does not have turkey hunting; therefore, we already prohibit lead shot.

Comment #12: One commenter questioned the economic analysis. "It is estimated that the consumer surplus

from the proposed expansion in hunting and sport fishing opportunities is \$199,614. However, this estimate is seriously flawed, since it includes only the gains from increased hunting and fishing opportunities, but excludes the losses in consumer surplus of nonconsumptive users due to a decline in wildlife watching opportunities. Before any rule changes are considered, the U.S. Fish and Wildlife Service should conduct a new economic analysis of changes to the consumer surplus, which takes all relevant factors, including changes in non-consumptive uses, into consideration"

Response: Increased hunting and fishing opportunities may impact wildlife watching opportunities in two ways. First, increased hunting would decrease the wildlife population that is being hunted (e.g., deer, migratory birds, etc.). As such, the quality of a wildlife watching activity may slightly decline because a visitor may be less likely to view wildlife. However, we would expect this impact to only be a small decrease to consumer surplus. Second, some wildlife watching visitors may choose not to visit during hunting season. Instead, they may choose to visit before or after the hunting season or choose to visit a different area for their wildlife watching activities. Again, we would expect this impact to be a small decrease to consumer surplus because the quality of the visit may be impacted. If the visitor chooses to no longer view wildlife at all, then there would be a loss of consumer surplus and visitor expenditures to the region. While these are valid impacts to wildlife watching

opportunities, we do not have the data to properly quantify them. For example, we do not know how a slight change to wildlife populations will influence wildlife watching behavior. Because this information is not available, and we believe these shifts in visitation to be small, we are unable to conduct an economic analysis that addresses this concern.

Other changes from the proposed rule were as follows: We clarified the issue of only allowing specific breeds of dogs on Grand Cote National Wildlife Refuge and Big Branch Marsh National Wildlife Refuge (§ 32.37), in the State of Louisiana. We also made several administrative changes for clarity under North Platte and Boyer Chute National Wildlife Refuges (§ 32.46) in the State of Nebraska.

Effective Date

This rule is effective upon publication in the **Federal Register**. We have determined that any further delay in implementing these refuge-specific hunting and sport fishing regulations would not be in the public interest, in that a delay would hinder the effective planning and administration of the hunting and fishing programs. We provided a 30-day comment period for the August 14, 2003, proposed rule. An additional delay would jeopardize holding the hunting and/or fishing programs this year or shorten their duration and thereby lessen the management effectiveness of this regulation. This rule does not impact the public generally in terms of requiring lead time for compliance.

Rather it relieves restrictions in that it allow activities on refuges that we would otherwise prohibit. Therefore, we find good cause under 5 U.S.C. 553(d)(3) to make this rule effective upon publication.

New Hunting and Fishing Programs

In preparation for opening additional refuges to hunting and fishing, or to initiating new hunting or fishing programs on refuges already open, we document appropriate compliance with the National Environmental Policy Act (NEPA) through an Environmental Assessment with a finding of No Significant Impact, an Environmental Impact Statement with a Record of Decision, or determine and document that the action qualifies for a Categorical Exclusion. We also conduct and document internal consultations under section 7 of the Endangered Species Act, and coordinate with the State(s), and if appropriate, Tribe(s) in or near the refuge.

Upon review of these documents, we have determined that the opening of these National Wildlife Refuges to hunting and/or fishing is compatible with the purpose of the refuge and the mission of the system, and not inconsistent with applicable State laws. A copy of the compatibility determinations for each respective refuge is available upon request from the Regional Office noted under the heading "Available Information for Specific Refuges."

We allow the following wildlifedependent recreational activities:

Refuge	State	Migratory bird hunting	Upland game hunt- ing	Big game hunting	Sport fishing
Wapanocca	Arkansas Louisiana	X X X	X	X X	
Northern Tallgrass Prairie Boyer Chute DeSoto	Minnesota/lowa Nebraska Iowa	x	X	x	
Big Branch Marsh	Louisiana		X X	X	
Coldwater Bandon Marsh Rappahannock River Valley	Mississippi Oregon Virginia				X X X

Lands acquired as "waterfowl production areas," which we generally manage as part of Wetland Management Districts, are open to the hunting of migratory game birds, upland game, big game, and sport fishing subject to the provisions of State law and regulations (see 50 CFR 32.1 and 32.4). This year we are adding Detroit Lakes Wetland Management District in Minnesota to

the list of refuges open for all four of these activities.

We are correcting an administrative error in 50 CFR part 32 that occurred with regard to Bandon Marsh National Wildlife Refuge in Oregon. It has come to our attention that the CFR does not indicate that the refuge is open to sport fishing. We opened the refuge to sport fishing in 1986 (55 FR 30655, 30663; August 28, 1986). It appears that a

clerical error was made when the rules adopted in 1986 were being published in the subsequent edition of the CFR. We are correcting that error and part 32 will now reflect that the refuge is open to sport fishing. Coldwater National Wildlife Refuge was part of Tallahatchie National Wildlife Refuge (both in Mississippi) and is an area of the System that we opened by reason of its having been included in Tallahatchie's

fishing plan (61 FR 45364, August 29, 1996). It has become a separate unit this year, thus we are including a separate listing that Coldwater National Wildlife Refuge is open to fishing only.

Upon publication of this document, the 2003–2004 hunting and fishing season will result in a net of three national wildlife refuges added to fishing and four national wildlife refuges added to hunting. This will bring our cumulative total of national wildlife refuges open to hunting to 315 and refuges open to fishing to 274.

We incorporate this regulation into 50 CFR part 32. Part 32 contains general provisions and refuge-specific regulations for hunting and sport fishing on national wildlife refuges.

Regulatory Planning and Review

In accordance with the criteria in Executive Order 12866, the Service asserts that this rule is not a significant regulatory action. The Office of Management and Budget (OMB) makes the final determination under Executive Order 12866.

a. This rule will not have an annual economic effect of \$100 million or adversely affect an economic sector, productivity, jobs, the environment, or other units of the government. A costbenefit and full economic analysis is not required. The purpose of this rule is to add seven refuges to the list of refuges that have hunting and/or fishing activities and to increase the type of activities at three other refuges. The refuges are located in the States of Arkansas, Iowa, Louisiana, Minnesota,

Mississippi, Nebraska, Oregon, and Virginia. Fishing and hunting are two of the wildlife-dependent uses of national wildlife refuges that Congress recognized as legitimate and appropriate and directed us to facilitate, subject to such restrictions or regulations as may be necessary to ensure their compatibility with the purpose(s) and mission of each refuge. Many of the 542 existing national wildlife refuges already have programs where we allow fishing and hunting. Not all refuges have the necessary resources and landscape that would make fishing and hunting opportunities available to the public. By opening these refuges to new activities, we have determined that we can make quality experiences available to the public. This rule establishes hunting and/or fishing programs at the following refuges: Wapanocca National Wildlife Refuge in Arkansas, Grand Cote National Wildlife Refuge in Louisiana, Northern Tallgrass Prairie National Wildlife Refuge in Minnesota and Iowa, Boyer Chute and North Platte National Wildlife Refuges in Nebraska, DeSoto National Wildlife Refuge in Iowa, Big Branch Marsh National Wildlife Refuge in Louisiana, Coldwater National Wildlife Refuge in Mississippi, Bandon Marsh National Wildlife Refuge in Oregon, and Rappahannock River Valley National Wildlife Refuge in Virginia. We present impacts in 2002 real dollars.

For this analysis, we do not expect changes to recreational visits at the Detroit Lakes Wetland Management District, Bandon Marsh National Wildlife Refuge, or Coldwater National

Wildlife Refuge. All Wetland Management Districts are open to hunting and fishing activities until closed, and this rulemaking reflects that Detroit Lakes Wetland Management District is open to hunting of migratory game birds, upland game, big game, and sport fishing. However, we do not expect any change in visitation rates at this management district because recreationists currently have the option to participate in these activities at Detroit Lakes. We expect no visitation changes at Bandon Marsh National Wildlife Refuge. The rule corrects an administrative error, but does not change current activities at the refuge since the refuge has been open to fishing since 1986. Also, we expect no visitation changes at Coldwater National Wildlife Refuge. Coldwater was part of Tallahatchie National Wildlife Refuge (also in the State of Mississippi) and covered by its fishing plan. Therefore, we would expect any previous fishing activity in the Coldwater section of Tallahatchie to continue without change.

Following a best-case scenario, if the refuges establishing new fishing and hunting programs were a pure addition to the current supply of such activities, it would mean a consumer surplus of approximately \$200,000 annually and an estimated increase of 1,000 user days of hunting and 2,082 user days of fishing (Table 1). Consequently, this rule will have a small, measurable, beneficial economic impact on the U.S. economy.

TABLE 1.—ESTIMATED CHANGES IN CONSUMER SURPLUS FROM ADDITIONAL FISHING AND HUNTING OPPORTUNITIES IN 2003
[In days]

Refuge	Current visitation (FY02)	Additional fishing	Additional hunting	Additional fishing and hunting combined
Wapanocca	844		70	70
Northern Tallgrass Prairie	2,500		1,000 300	1,000
Boyer Chute	3,147		175	175
DeSoto	14,967		25	25
Big Branch Marsh	5,975		500	500
North Platte			12	12
Bandon Marsh	100			0
Coldwater				0
Rappahannock River	45	1,000		1,000
Total Days per Year	27,578	1,000	2,082	3,082
Consumer Surplus per Day		\$62.16	\$66.02	
Change in Total Consumer Surplus		\$62,160	\$137,454	\$199,614

Note: All estimates are stated in 2002 real dollars.

b. This rule will not create inconsistencies with other agencies' actions. This action pertains solely to the management of the System. The fishing and hunting activities located on national wildlife refuges account for approximately 1 percent of the available supply in the United States. Any small, incremental change in the supply of fishing and hunting opportunities will not measurably impact any other agency's existing programs.

c. This rule will not materially affect entitlements, grants, user fees, loan programs, or the rights and obligations of their recipients. This rule does not affect entitlement programs. There are no grants or other Federal assistance programs associated with public use of

national wildlife refuges.

d. This rule will not raise novel legal or policy issues. This rule opens seven additional refuges for fishing and hunting activities and increases the activities available at three other refuges. This rule continues the practice of allowing recreational public use of national wildlife refuges. Many refuges in the System currently have opportunities for the public to hunt and fish on refuge lands.

Regulatory Flexibility Act

We certify that this rule will not have a significant economic effect on a substantial number of small entities as defined under the Regulatory Flexibility Act (5 U.S.C. 601 *et seq.*). A Regulatory Flexibility Analysis is not required. Accordingly, a Small Entity Compliance Guide is not required.

This rule does not increase the number of recreation types allowed in the System but establishes new or additional hunting and/or fishing programs on 10 refuges. As a result, opportunities for wildlife-dependent recreation on national wildlife refuges will increase. The changes in the amount of permitted use are likely to increase visitor activity on these national wildlife refuges.

For purposes of analysis, we will assume that any increase in refuge

visitation is a pure addition to the supply of the available activity. This will result in a best-case scenario, and we expect to overstate the benefits to local businesses. The latest information on the distances traveled for fishing and hunting activities indicates that more than 80 percent of the participants travel less than 100 miles from home to engage in the activity. This indicates that participants will spend travelrelated expenditures in their local economies. Since participation is scattered across the country, many small businesses benefit. The 2001 National Survey of Fishing, Hunting, and Wildlife Associated Recreation identifies expenditures for food and lodging, transportation, and other incidental expenses. Using the average expenditures for these categories with the expected maximum additional participation on the System as a result of this rule yields the following estimates (Table 2) compared to total business activity for these sectors.

TABLE 2.—ESTIMATION OF THE ADDITIONAL EXPENDITURES WITH AN INCREASE OF ACTIVITIES IN THREE REFUGES AND THE OPENING OF SEVEN REFUGES TO FISHING AND/OR HUNTING FOR 2003–2004

	U.S. total expenditures in 2001 (in billions)	Average ex- penditures per day	Current refuge expenditures w/o duplication (FY2002) (in millions)	Possible additional refuge expenditures
Anglers:				
Total Days Spent (in millions)	\$557		\$5.9	\$1,000
Total Expenditures	36.2	\$465	386.3	64,937
Trip Related	14.9	27	158.9	26,710
Food and Lodging	6.0	11	63.8	10,718
Transportation	3.6	6	38.1	6,407
Other	5.3	10	57.0	9,585
Hunters:				
Total Days Spent (in millions)	228		2.0	2,082
Total Expenditures	20.6	92	181.0	190,878
Trip Related	5.3	23	46.1	48,642
Food and Lodging	2.4	11	21.5	22,689
Transportation	1.8	8	15.7	16,571
Other	1.0	5	8.9	9,383

Note: All estimates are in 2002 real dollars.

Using a national impact multiplier for hunting activities (2.73) derived from the report "Economic Importance of Hunting in America" and a national impact multiplier for sportfishing activities (2.79) from the report "Sportfishing in America" for the estimated increase in direct

expenditures yields a total economic impact of approximately 257,000 (Southwick Associates, Inc., 2003).

A large percentage of the retail trade establishments in the majority of affected counties qualifies as small businesses. With the small increase in overall spending anticipated from this rule, it is unlikely that a substantial number of small entities will have more than a small benefit from the increased recreationist spending near the affected refuges; none are likely to have any adverse impact.

Refuge/county(ies)	Retail trade in 1997 (2002 dollars) (in millions)	Estimated maximum ad- dition from new refuge	Addition as a % of total	Total number retail establish	Establish. with <10 emp.
Wapannocca, Crittenden, AR	\$24,260	\$6,440	0.00003	262	171
Grand Cote, Avoyelles, LA	238	92,000	0.39	169	129
Northern Tallgrass Prairie, Rock, MN	96	27,600	.029	62	39
Boyer Chute, Washington, NE	262	16,100	.006	99	64
DeSoto, Washington, NE	262	1,150	.0004	99	64
Harrison, IA	187	1,150	.0006	101	76
Big Branch Marsh, St. Tammany, LA	1,694	46,000	.003	1068	713
North Platte, Scotts Bluff, NE	439	1,104	.0003	312	220
Rappahannock River, Northumberland, VA	5,492	65,000	.001	54	45

Table 3.—Comparative Expenditures for Retail Trade Associated With Additional Refuge Visitation for 2003

Many small businesses may benefit from some increased wildlife refuge visitation. We expect that the incremental recreational opportunities will be scattered, and so we do not expect that the rule will have a significant economic effect (benefit) on a substantial number of small entities in any region or nationally.

Small Business Regulatory Enforcement Fairness Act

The rule is not a major rule under 5 U.S.C. 804(2), the Small Business Regulatory Enforcement Fairness Act. We anticipate no significant employment or small business effects. This rule:

a. Does not have an annual effect on the economy of \$100 million or more. The additional fishing and hunting opportunities at the 10 refuges would generate angler and hunter expenditures with an economic impact estimated at \$257,000 per year (2002 dollars). Consequently, the maximum benefit of this rule for businesses, both small and large, would not be sufficient to make this a major rule. The impact would be scattered across the country and would most likely not be significant in any local area.

b. Will not cause a major increase in costs or prices for consumers, individual industries, Federal, State, or local government agencies, or geographic regions. This rule will have only a slight effect on the costs of hunting and fishing opportunities for Americans. Under the assumption that any additional hunting and fishing opportunities would be quality opportunities, we would attract participants to the refuge. If the refuge were closer to the participants' residences, then a reduction in travel costs would occur and benefit the participants. The Service does not have information to quantify this reduction in travel cost but assumes that, since most people travel less than 100 miles to hunt and fish, the reduced travel cost would be small for the additional days of hunting and fishing generated by this rule. We do not expect this rule to affect the supply or demand for fishing and hunting opportunities in the United States and; therefore, it should not affect prices for fishing and hunting equipment and supplies, or the retailers that sell equipment.

c. Does not have significant adverse effects on competition, employment, investment, productivity, innovation, or the ability of United States-based enterprises to compete with foreign-based enterprises. Refuges that establish hunting and fishing programs may hire additional staff from the local community to assist with the programs, but this would not be a significant increase, because only seven refuges are adding new programs and only three refuges are increasing programs by this rule.

Unfunded Mandates Reform Act

Since this rule applies to public use of federally owned and managed refuges, it does not impose an unfunded mandate on State, local, or Tribal governments or the private sector of more than \$100 million per year. The rule does not have a significant or unique effect on State, local, or Tribal governments or the private sector. A statement containing the information required by the Unfunded Mandates Reform Act (2 U.S.C. 1531 et seq.) is not required.

Takings (Executive Order 12630)

In accordance with Executive Order 12630, the rule does not have significant takings implications. This regulation will affect only visitors at national wildlife refuges and describe what they can do while they are on a refuge.

Federalism (Executive Order 13132)

As discussed in the Regulatory Planning and Review and Unfunded Mandates Reform Act sections above, this rule does not have sufficient Federalism implications to warrant the preparation of a Federalism Assessment under Executive Order 13132. In preparing this rule, we worked with State governments, and our programs are consistent to the State regulations to the degree practicable.

Civil Justice Reform (Executive Order 12988)

In accordance with Executive Order 12988, the Office of the Solicitor has determined that the rule does not unduly burden the judicial system and that it meets the requirements of sections 3(a) and 3(b)(2) of the Order. The regulation will clarify established regulations and result in better understanding of the regulations by refuge visitors.

Energy Supply, Distribution or Use (Executive Order 13211)

On May 18, 2001, the President issued Executive Order 13211 on regulations that significantly affect energy supply, distribution, and use. Executive Order 13211 requires agencies to prepare Statements of Energy Effects when undertaking certain actions. Because this rule opens seven refuges to hunting and/or sport fishing programs and increases activities at three others, it is not a significant regulatory action under Executive Order 12866 and is not expected to significantly affect energy supplies, distribution, and use. Therefore, this action is a not a significant energy action and no Statement of Energy Effects is required.

Consultation and Coordination With Indian Tribal Governments (Executive Order 13175)

In accordance with Executive Order 13175, we have evaluated possible effects on federally recognized Indian tribes and have determined that there are no effects. We coordinate recreational use on national wildlife refuges with Tribal governments having adjoining or overlapping jurisdiction before we propose the regulations. This regulation is consistent with and not less restrictive than Tribal reservation

Paperwork Reduction Act

This regulation does not contain any information collection requirements other than those already approved by the OMB under the Paperwork Reduction Act (44 U.S.C. 3501 et seq.) (OMB Control Number is 1018–0102). See 50 CFR 25.23 for information concerning that approval. An agency may not conduct or sponsor and a person is not required to respond to a collection of information unless it displays a currently valid OMB control number.

Endangered Species Act Section 7 Consultation

We reviewed the changes in hunting and fishing regulations herein with regard to section 7 of the Endangered Species Act of 1973 (16 U.S.C. 1531-1544, as amended) (ESA). For the national wildlife refuges opening for hunting and/or fishing we have determined that DeSoto National Wildlife Refuge, Wapanocca National Wildlife Refuge, Northern Tallgrass Prairie National Wildlife Refuge, and Grand Cote National Wildlife Refuge (for Louisiana black bear) will not likely adversely affect any endangered or threatened species or designated critical habitat, and Grand Cote National Wildlife Refuge (for bald eagle), North Platte National Wildlife Refuge, Big Branch Marsh National Wildlife Refuge, Rappahannock River Valley National Wildlife Refuge, and Boyer Chute National Wildlife Refuge will not affect any endangered or threatened species or designated critical habitat.

We also comply with section 7 of the ESA when developing CCPs and stepdown management plans for public use of refuges, and prior to implementing any new or revised public recreation program on a refuge as identified in 50 CFR 26.32. We also make determinations when required by the ESA before the addition of a refuge to the lists of areas open to hunting or fishing as contained in 50 CFR 32.7.

National Environmental Policy Act

Prior to submitting these openings for publication in this rule, the Service complied with the National Environmental Policy Act of 1969 (42 U.S.C. 4332(C)) and 516 DM 6, Appendix 1 for each of the openings or program additions during the preparation of individual refuge hunting or fishing decision documents.

We analyzed this rule in accordance with the criteria of the NEPA. A categorical exclusion from NEPA documentation applies to this amendment of refuge-specific hunting and fishing regulations since it is technical and procedural in nature and we otherwise comply with NEPA at the specific refuge units.

Prior to the addition of a refuge to the list of areas open to hunting and fishing in 50 CFR part 32, we develop specific management plans for the affected refuges. We incorporate these refuge hunting and fishing activities in refuge CCPs and/or other step-down management plans, pursuant to our refuge planning guidance in 602 FW 1, 3, and 4. We prepare CCPs and stepdown plans in compliance with section 102(2)(C) of NEPA, and the Council on Environmental Quality's regulations for implementing NEPA in 40 CFR parts 1500-1508. We invite the affected public to participate in the review, development, and implementation of these plans.

Available Information for Specific Refuges

Individual refuge headquarters retain information regarding public use programs and the conditions that apply to their specific programs and maps of their respective areas. You may also obtain information from the Regional Offices at the addresses listed below:

Region 1—California, Hawaii, Idaho, Nevada, Oregon, and Washington. Regional Chief, National Wildlife Refuge System, U.S. Fish and Wildlife Service, Eastside Federal Complex, 911 N.E. 11th Avenue, Portland, Oregon 97232-4181; Telephone (503) 231-6214.

Region 2—Arizona, New Mexico, Oklahoma, and Texas. Regional Chief, National Wildlife Refuge System, U.S. Fish and Wildlife Service, PO Box 1306, 500 Gold Avenue, Albuquerque, New Mexico 87103; Telephone (505) 248-6804.

Region 3—Illinois, Indiana, Iowa, Michigan, Minnesota, Missouri, Ohio, and Wisconsin. Regional Chief, National Wildlife Refuge System, U.S. Fish and Wildlife Service, 1 Federal Drive, Federal Building, Fort Snelling, Minnesota 55111; Telephone (612)-713-5400.

Region 4—Alabama, Arkansas, Florida, Georgia, Kentucky, Louisiana, Mississippi, North Carolina, South Carolina, Tennessee, Puerto Rico, and the Virgin Islands. Regional Chief, National Wildlife Refuge System, U.S. Fish and Wildlife Service, 1875 Century Boulevard, Atlanta, Georgia 30345; Telephone (404) 679-7154.

Region 5—Connecticut, Delaware, Maine, Maryland, Massachusetts, New Hampshire, New Jersey, New York, Pennsylvania, Rhode Island, Vermont, Virginia, and West Virginia. Regional Chief, National Wildlife Refuge System, U.S. Fish and Wildlife Service, 300 Westgate Center Drive, Hadley, Massachusetts 01035–9589; Telephone (413) 253-8302.

Region 6—Colorado, Kansas, Montana, Nebraska, North Dakota, South Dakota, Utah, and Wyoming. Regional Chief, National Wildlife Refuge System, U.S. Fish and Wildlife Service, 134 Union Blvd., Lakewood, Colorado 80228; Telephone (303) 236-8145.

Region 7—Alaska. Regional Chief, National Wildlife Refuge System, U.S. Fish and Wildlife Service, 1011 E. Tudor Rd., Anchorage, Alaska 99503; Telephone (907) 786-3354.

Primary Author

Leslie A. Marler, Management Analyst, Division of Conservation Planning and Policy, National Wildlife Refuge System, U.S. Fish and Wildlife Service, Arlington, Virginia 22203, is the primary author of this rulemaking document.

List of Subjects in 50 CFR Part 32

Fishing, Hunting, Reporting and recordkeeping requirements, Wildlife, Wildlife refuges.

■ For the reasons set forth in the preamble, we amend Title 50, Chapter I, subchapter C of the Code of Federal Regulations as follows:

PART 32—[AMENDED]

■ 1. The authority citation for part 32 continues to read as follows:

Authority: 5 U.S.C. 301: 16 U.S.C. 460k. 664, 668dd-668ee, and 715i.

- 2. In § 32.7 "What refuge units are open to hunting and/or fishing?" by:
- a. Alphabetically adding Detroit Lakes Wetland Management District in the State of Minnesota;
- b. Alphabetically adding Northern Tallgrass Prairie National Wildlife Refuge in the States of Minnesota and
- c. Alphabetically adding Coldwater National Wildlife Refuge in the State of Mississippi;

■ 3. In § 32.23 Arkansas by adding the text of paragraphs A. and C. of Wapanocca National Wildlife Refuge to read as follows:

§ 32.23 Arkansas.

* * * * *

Wapanocca National Wildlife Refuge

- A. Hunting of Migratory Game Birds. We allow hunting of snow geese on designated areas of the refuge in accordance with State regulations subject to the following conditions:
- 1. We require refuge hunting permits. The permits are nontransferable and anyone on refuge land in possession of hunting equipment must sign and carry them at all times.
- 2. We provide annual season dates on the hunt brochure/permit.
- 3. You must sign in prior to the hunt and sign out after the hunt at the Hunter Information Station.
- 4. You must adhere to all public use special conditions and regulations on the annual hunt brochure/permit.

* * * * *

- C. Big Game Hunting. We allow hunting of white-tailed deer on designated areas of the refuge in accordance with State regulations subject to the following conditions:
 - 1. Conditions A1 and A4 apply.
- 2. We prohibit hunting from or within 50 yards (45 m) of graveled roads and within 150 yards (135 m) of refuge buildings.
- We allow archery/crossbow hunting for deer. We specify annual season dates and bag limits on the hunting permits.
- 4. Immediately record the deer zone 640 on the hunter's license and later on official check station records upon harvest of a deer.
- 5. You must sign in prior to the hunt and sign out after the hunt at the Hunter Information Station. You must check harvested deer at this location.
 - 6. We prohibit dogs.
- 7. We allow only single-person portable tree stands. You may place tree stands on the refuge 2 days before the hunt but must remove them within 2 days after the hunt. You must permanently affix the owner's name and address on stands left on the refuge.
- 8. We prohibit possession of or marking trails with materials other than biodegradable paper/flagging or reflective tape/tacks.

9. We prohibit ATVs.

- 4. In § 32.34 Iowa by:
- a. Adding the text of paragraph B. of DeSoto National Wildlife Refuge; and
- b. Adding Northern Tallgrass Prairie National Wildlife Refuge to read as follows:

§ 32.34 lowa.

* * * * *

DeSoto National Wildlife Refuge

B. Upland Game Hunting. We allow hunting of ring-necked pheasant and turkey on designated areas of the refuge in accordance with the States of Iowa and Nebraska regulations subject to the following condition: We require a refuge permit.

Northern Tallgrass Prairie National Wildlife

Refer to $\S\,32.42$ Minnesota for regulations.

- 5. In § 32.37 Louisiana by:
- a. Adding the text of paragraph B. of Big Branch Marsh National Wildlife Refuge: and
- b. Adding the text of paragraphs A., B., and C. of Grand Cote National Wildlife Refuge to read as follows:

§ 32.37 Louisiana.

* * * * *

Big Branch Marsh National Wildlife Refuge

- B. Upland Game Hunting. We allow hunting of squirrel, rabbit, snipe, woodcock, quail, gallinule, rail, and nutria subject to the following conditions:
- 1. We allow hunting during the open State season using only approved nontoxic shot size #4 or smaller.
- You may use dogs for squirrel and rabbit after the close of the State gun deer season only.
- 3. You may only use dogs to locate, point, and retrieve when hunting for snipe, woodcock, and quail.
- 4. You must possess and carry a valid refuge hunt permit.
- 5. We prohibit air-thrust boats, motorized pirogues, mud boats, and air-cooled propulsion engines on the refuge.
- 6. Youth hunters 15 years of age and under must successfully complete a State-approved hunter education course. While hunting, each youth must possess and carry a card or certificate of completion. One adult 21 years of age or older must supervise each youth hunter. For upland game hunts, one adult may supervise two youths.
- 7. You must unload and encase or dismantle firearms carried in vehicles or hoats.
- 8. We open the refuge during daylight hours only.
- 9. We prohibit possession of buckshot, slugs, rifles, or rifle ammunition.
- 10. We prohibit hunting within 200 feet (60 m) of any road (including refuge roads), residence, or designated public facilities.
- 11. We prohibit possession of lead shot during all refuge hunts.

Grand Cote National Wildlife Refuge

- A. Hunting of Migratory Game Birds. We allow hunting of ducks, geese, coots, mourning dove, and woodcock on designated areas of the refuge, as shown on refuge hunting brochure map, subject to the following conditions:
- 1. We require hunters 16 years of age and older to purchase and carry a signed \$12.50 refuge hunt/fish/ATV permit.
- 2. We allow public access from 5 a.m. to 1 hour after legal sunset.

- 3. An adult 21 years of age or older must accompany (within sight of and in normal voice contact with) youth hunters 15 years of age and under. We require youth hunters to possess and carry proof of completion of an approved Hunter Safety Course. Each adult can supervise one youth hunter during deer hunts and not more that two youths during all other hunts.
- 4. We require hunters to enter and exit the refuge from designated parking lots only.
- 5. We require hunters to check in/out at a designated check station.
- 6. We prohibit camping or parking overnight on the refuge.
- 7. We prohibit discharge of firearms except when hunting.

when hunting.
8. We prohibit marking of trails with nonbiodegradable flagging tape.

- 9. We allow use of ATVs on designated trails from the third Saturday in September to the last day of the State rabbit season. An ATV is an off-road vehicle with factory specifications not to exceed the following: weight—750 lbs. (337.5 kg), length—85 inches (212.5 cm), and width—48 inches (120 cm). We restrict ATV tires to those no larger than 25 x 12 with a maximum 1-inch (2.5 cm) lug height and a maximum allowable tire pressure of 7 psi as indicated on the tire by the manufacturer.
 - 10. We prohibit horses and mules.
- 11. We prohibit saws, saw blades, and/or machetes while on the refuge.
- 12. We prohibit hunting within 100 feet (30 m) of any designated road, ATV or hiking trail, or refuge facility.
- 13. We prohibit transportation of loaded weapons on an ATV.
- 14. We prohibit blocking of gates or trails with vehicles or ATVs.
- 15. We prohibit ATVs on trails/roads not specifically designated by signs for ATV use.
 - 16. We allow only nonmotorized boats.
- 17. You may take raccoon, feral hog, beaver, nutria, and coyote incidental to migratory bird hunting, upland game hunting, and big game hunting with weapons legal for that hunt.
- 18. We allow waterfowl (ducks, geese, coots) hunting on Wednesdays and Saturdays until 12 a.m. (noon) only during the Statewide duck season.
- 19. We allow use of shotguns during designated hunts only.
- 20. We prohibit the construction or use of permanent blinds.
- 21. You must remove all decoys, portable blinds, and boats daily.
- 22. We have a youth waterfowl hunt in the Crawfish Pond Unit during the Statewide duck season. This will be a quota-type hunt, and hunters will apply on an index or post card with their name, address, phone number, and dates of the hunt for which they are applying. When the State sets the duck season, we will set the dates of the hunt.
- 23. We allow hunting of mourning doves incidentally by waterfowl hunters only on days open to waterfowl hunting.
- 24. We only allow dogs to locate, point, and retrieve when hunting for migratory game birds.
 - 25. We prohibit frogging.
- B. Upland Game Hunting. We allow hunting of rabbit, raccoon, feral hog, beaver,

nutria, and coyote on designated areas of the refuge, as shown on refuge hunting brochure map, subject to the following conditions:

1. Conditions A1 through A17 and A25 apply.

- 2. We allow rabbit hunting from December 1 until the end of the Statewide season.
- 3. We allow use of shotguns during designated hunts only.
- 4. We allow rabbit dogs only after the close of the State deer rifle season.
- 5. We require you to collar all dogs with owner's name and phone number.
- C. Big Game Hunting. We allow hunting of white-tailed deer on designated areas of the refuge as shown on refuge hunting brochure map subject to the following conditions:

1. Conditions A1 through A17 and A25 apply.

- 2. We allow archery-only deer hunting on the refuge from October 1 through October 31 in the Gremillion Unit, Island of the Owls Unit, and Concrete Bridge Unit.
- 3. You must have hunter's name, address, and phone number permanently attached to all deer stands. We allow only portable deer stands that hunters must take down daily.
- 4. We prohibit hunters to drive deer or use pursuit dogs. We prohibit use of dogs to trail wounded deer.
- 5. We allow only archery equipment during designated seasons.
- 6. We require hunters to complete and possess and carry proof of completion of the International Bowhunters' Safety Course.
- 7. You may kill one deer of either sex per day during the deer season.

* * * * *

- 6. In § 32.42 Minnesota by:
- a. Adding Detroit Lakes Wetland Management District; and
- b. Adding Northern Tallgrass Prairie National Wildlife Refuge to read as follows:

§ 32.42 Minnesota.

* * * *

Detroit Lakes Wetland Management District

- A. Hunting of Migratory Game Birds. We allow hunting of migratory game birds throughout the district in accordance with State regulations, except that we prohibit hunting on the Headquarters Waterfowl Production Area (WPA) in Becker County, the Hitterdal WPA in Clay County, and the McIntosh WPA in Polk County. The following conditions apply:
- 1. We prohibit the use of motorized boats.
- 2. You must remove boats, decoys, blinds, and blind materials brought onto WPAs following each day's hunt.
- 3. We allow the use of hunting dogs, provided the dog is under the immediate control of the hunter at all times.
- B. Upland Game Hunting. We allow upland game hunting in accordance with State regulations throughout the district, except that we allow no hunting on the Headquarters Waterfowl Production Area (WPA) in Becker county, the Hitterdal WPA in Clay county, and the McIntosh WPA in Polk county. The following condition applies: We allow the use of hunting dogs,

provided the dog is under the immediate control of the hunter at all times.

C. Big Game Hunting. We allow big game hunting in accordance with State regulations throughout the district, except that we allow no hunting on the Headquarters Waterfowl Production Area (WPA) in Becker county, the Hitterdal WPA in Clay county, and the McIntosh WPA in Polk county. The following conditions apply:

1. We prohibit the construction or use of permanent blinds, platforms, or ladders.

- 2. You must remove all portable hunting stands from the area at the end of each day's hunt.
- D. Sport Fishing. We allow fishing in accordance with State regulations throughout the district subject to the following condition: We prohibit the use of motorized boats.

Northern Tallgrass Prairie National Wildlife Refuge

- A. Hunting of Migratory Game Birds. We allow hunting of migratory game birds on designated areas in accordance with State regulations subject to the following conditions:
- 1. You must remove boats, decoys, portable or temporary blinds, materials brought onto the refuge, and other personal property at the end of each day's hunt.
- 2. We prohibit the construction or use of permanent blinds, stands, or scaffolds.
- 3. We prohibit the use of motorized watercraft.
- B. Upland Game Hunting. We allow hunting of upland game on designated areas in accordance with State regulations subject to the following conditions:
- 1. Hunters may possess only approved nontoxic shot while in the field.
- 2. We prohibit the use of dogs for hunting furbearers.
- 3. Hunters may take weasel, coyote, gopher, crow, and all other species for which there is no closed season only during a State-designated open season for other upland game species.
- C. Big Game Hunting. We allow hunting of big game in accordance with State regulations subject to the following conditions:
- 1. We prohibit the construction or use of permanent blinds, stands, or scaffolds.
- 2. You must remove all temporary blinds, stands, and scaffolds at the end of each day's hunt.
- 3. We prohibit the use of motorized watercraft.
- 7. In § 32.43 Mississippi by adding Coldwater National Wildlife Refuge to read as follows:

§ 32.43 Mississippi.

* * * * *

Coldwater National Wildlife Refuge

- A. Hunting of Migratory Game Birds. [Reserved]
 - B. Upland Game Hunting. [Reserved]
 C. Big Game Hunting. [Reserved]

- D. Sport Fishing. We allow fishing on designated areas of the refuge in accordance with State regulations subject to the following conditions:
- 1. All persons fishing who are 16 years of age and older must carry a State license on the refuge. You must have a signed refuge fishing permit in your possession when fishing on the refuge. You may obtain permits at North Mississippi Refuges Complex Headquarters, 2776 Sunset Drive, Grenada, Mississippi 38901, or at the Dahomey National Wildlife Refuge Office, Box 381, Highway 446, Boyle, Mississippi 38730, or by mail from the above addresses.

2. We close the refuge to fishing from October 1 through February 28.

- 3. We allow fishing in bar pits along the Corps of Engineers levee only.
- 4. We prohibit possession of any weapon while fishing on the refuge. This does not include fishing knives unless they are longer than 3 inches (7.5 cm).
- 5. We prohibit possession or use of jugs, seines, nets, hand-grab baskets, slat traps/baskets, or any other similar devices and commercial fishing of any kind.
- 6. We allow trotlines, yo-yos, limb lines, crawfish traps, or any other similar devices for recreational use only, and you must tag or mark them with waterproof ink, legibly inscribed or legibly stamped on the tag with your full name and full residence address, including zip code. You must attend these devices a minimum of once daily. If you are not going to attend these devices, you must remove them from the refuge.
- 7. We prohibit snagging or attempting to snag fish.
 - 8. We allow crawfishing.
- 9. We allow taking of frogs by Special Use Permit only.

* * * * *

- 8. In § 32.46 Nebraska by:
- a. Adding the text of paragraph A. and the text of paragraph C. of Boyer Chute National Wildlife Refuge; and
- b. Adding the text of paragraphs B. and C. of North Platte National Wildlife Refuge to read as follows:

§ 32.46 Nebraska.

* * * * *

Boyer Chute National Wildlife Refuge

- A. Hunting of Migratory Game Birds. We allow hunting of ducks, geese, and coots on designated areas of the refuge subject to the following conditions:
- 1. You may access the refuge from 1½ hours before legal sunrise to 1 hour after legal sunset along the immediate shoreline and including the high bank of the Missouri River. You may access the hunting area by water or, if by land, only within the public use area of the Island Unit and only with shotgun cased and unloaded.
- 2. You must remove all blinds and decoys at the conclusion of each day's hunt.
- 3. You must adhere to all applicable State hunting regulations.

C. Big Game Hunting. We allow hunting of white-tailed deer subject to the following

condition: We allow a mentored youth hunt on designated areas of the refuge subject to the guidelines set forth and administered by the State.

* * * * *

North Platte National Wildlife Refuge

- B. Upland Game Hunting. We allow hunting of squirrel, rabbit, pheasant, Statedefined furbearers, and coyote on designated areas of the refuge in accordance with State regulations subject to the following conditions:
- 1. We close the Lake Alice Unit to all public entry from October 15 through January
- 2. Hunters must be 15 years of age or younger. A licensed hunter 19 years of age or older must accompany youth hunters. We prohibit adults accompanying youth hunters to hunt or carry firearms. The accompanying adult is responsible for ensuring that the hunter does not engage in conduct that would constitute a violation of refuge or State regulations.
- 3. We close the refuge to public use from legal sunset to legal sunrise. However, youth hunters and their adult guides may enter the designated hunting area 1 hour prior to legal sunrise.
- 4. We only allow dogs for pheasanthunting on the refuge.
- C. Big Game Hunting. We allow archery hunting of mule deer and white-tailed deer on designated areas of the refuge in accordance with State regulations subject to the following conditions:
- 1. We close the Lake Alice Unit to all public entry from October 15 through January 14.

2. We close the refuge to public use from legal sunset to legal sunrise. However, archery deer hunters may enter the designated hunting area 1 hour prior to legal sunrise and remain until 1 hour after legal sunset.

* * * * *

■ 9. In § 32.56 Oregon by adding the text of paragraph D. of Bandon Marsh National Wildlife Refuge to read as follows:

§ 32.56 Oregon.

* * * * *

Bandon Marsh National Wildlife Refuge * * * * * *

D. Sport Fishing. We allow sport fishing in accordance with State regulations, on that portion of the refuge west of U.S. Highway 101.

* * * * * *

■ 10. In § 32.66 Virginia by adding the text of paragraph D. of Rappahannock River Valley National Wildlife Refuge to read as follows:

§ 32.66 Virginia.

* * * * * *

Rappahannock River Valley National Wildlife Refuge

* * * * *

- D. Sport Fishing. We allow fishing on designated areas of Wilna Pond in Richmond County subject to the following conditions:
- 1. As we implement the new fishing program at Wilna Pond, we intend to be open

on a daily basis, legal sunrise to legal sunset. If unexpected law enforcement issues arise, we may restrict hours of access for fishing.

- 2. From March 15 through June 30, we allow fishing from the Wilna Pond pier only (no boat or bank fishing).
- 3. During the period when we open the Wilna Tract for deer hunting, we will close it to all other uses, including fishing.
- 4. We prohibit fishing by any means other than by use of one or more attended poles with hook and line attached.
- 5. We prohibit the use of lead fishing tackle.
- 6. We require catch and release fishing only for largemouth bass. Anglers may take other finfish species in accordance with State regulations.
- 7. We prohibit the take of any reptile, amphibian, or invertebrate species for use as bait or for any other purpose.
- 8. We prohibit the use of live minnows as bait.
- 9. We prohibit use of boats propelled by gasoline motors, sail, or mechanically operated paddle wheel. We only permit cartop boats; and we prohibit trailers.
- 10. Prescheduled environmental education field trips will have priority over other uses, including sport fishing, on the Wilna Pond pier at all times.

* * * * *

Dated: September 29, 2003.

Julie MacDonald,

Assistant Secretary for Fish and Wildlife and Parks.

[FR Doc. 03–25193 Filed 9–30–03; 3:56 pm] $\tt BILLING$ CODE 4310–55–P

Reader Aids

Federal Register

Vol. 68, No. 191

Thursday, October 2, 2003

CUSTOMER SERVICE AND INFORMATION

Federal Register/Code of Federal Regulations	
General Information, indexes and other finding aids	202–741–6000
Laws	741–6000
Presidential Documents	
Executive orders and proclamations	741-6000
The United States Government Manual	741–6000
Other Services	
Electronic and on-line services (voice)	741-6020
Privacy Act Compilation	741–6064
Public Laws Update Service (numbers, dates, etc.)	741–6043
TTY for the deaf-and-hard-of-hearing	741–6086

ELECTRONIC RESEARCH

World Wide Web

Full text of the daily Federal Register, CFR and other publications is located at: http://www.access.gpo.gov/nara

Federal Register information and research tools, including Public Inspection List, indexes, and links to GPO Access are located at: http://www.archives.gov/federal register/

E-mail

FEDREGTOC-L (Federal Register Table of Contents LISTSERV) is an open e-mail service that provides subscribers with a digital form of the Federal Register Table of Contents. The digital form of the Federal Register Table of Contents includes HTML and PDF links to the full text of each document.

To join or leave, go to http://listserv.access.gpo.gov and select Online mailing list archives, FEDREGTOC-L, Join or leave the list (or change settings); then follow the instructions.

PENS (Public Law Electronic Notification Service) is an e-mail service that notifies subscribers of recently enacted laws.

To subscribe, go to http://listserv.gsa.gov/archives/publaws-l.html and select *Join or leave the list* (or change settings); then follow the instructions.

FEDREGTOC-L and **PENS** are mailing lists only. We cannot respond to specific inquiries.

Reference questions. Send questions and comments about the Federal Register system to: info@fedreg.nara.gov

The Federal Register staff cannot interpret specific documents or regulations.

FEDERAL REGISTER PAGES AND DATE, SEPTEMBER

56521-56764	1
56765-57318	2

CFR PARTS AFFECTED DURING OCTOBER

At the end of each month, the Office of the Federal Register publishes separately a List of CFR Sections Affected (LSA), which lists parts and sections affected by documents published since the revision date of each title.

the revision date of each title.	
3 CFR	37 CFR
Proclamations:	256556
771056521	38 CFR
5 CFR	
57556665	Proposed Rules: 1756876
89056523	17
89256523, 56525	39 CFR
•	11156557
7 CFR	22456557
30156529	26156557
12 CFR	26256557
356530	26356557
20856530	26456557 26556557
22556530	26656557
32556530	26756557
56756530	26856557
70256537	
70456537	40 CFR
71256537 72356537	8056776
74256537	Proposed Rules:
Proposed Rules:	8056805
356568	8256809 26156603
20856568	20150003
22556568	41 CFR
32556568	101–656560
56756568	
70156586	47 CFR
708a56589 74156586	5256781
74150580	6456764
13 CFR	Proposed Rules:
	Proposed Rules: 73 (2 documents)56810,
13 CFR 12056553	Proposed Rules: 73 (2 documents)56810, 56811
13 CFR 12056553 14 CFR	Proposed Rules: 73 (2 documents)56810,
13 CFR 12056553 14 CFR Proposed Rules:	Proposed Rules: 73 (2 documents)56810, 56811
13 CFR 12056553 14 CFR	Proposed Rules: 73 (2 documents)56810, 56811 48 CFR Ch. 156668, 56689 156669
13 CFR 12056553 14 CFR Proposed Rules: 3956591, 56594, 56596,	Proposed Rules: 73 (2 documents)56810, 56811 48 CFR Ch. 156668, 56689 156669 256669, 56676, 56681
13 CFR 12056553 14 CFR Proposed Rules: 3956591, 56594, 56596, 56598, 56792, 56794, 56796, 56799, 56801	Proposed Rules: 73 (2 documents)56810, 56811 48 CFR Ch. 156668, 56689 156669, 56676, 56681 456669, 56676, 56679
13 CFR 12056553 14 CFR Proposed Rules: 3956591, 56594, 56596, 56598, 56792, 56794, 56796, 56799, 56801 15 CFR	Proposed Rules: 73 (2 documents)56810, 56811 48 CFR Ch. 156668, 56689 156669 256669, 56676, 56681 456669, 56676, 56679 556676
13 CFR 12056553 14 CFR Proposed Rules: 3956591, 56594, 56596, 56598, 56792, 56794, 56796, 56799, 56801	Proposed Rules: 73 (2 documents)56810, 56811 48 CFR Ch. 156668, 56689 156669, 56676, 56681 456669, 56676, 56679
13 CFR 12056553 14 CFR Proposed Rules: 3956591, 56594, 56596, 56598, 56792, 56794, 56796, 56799, 56801 15 CFR	Proposed Rules: 73 (2 documents)
13 CFR 120	Proposed Rules: 73 (2 documents)
13 CFR 120	Proposed Rules: 73 (2 documents)
13 CFR 120	Proposed Rules: 73 (2 documents)56810, 56811 48 CFR Ch. 156668, 56689 156669, 56676, 56681 456669, 56676, 56676 556676 656676 756676 856676 1056676, 56681 1256676, 56681, 56682
13 CFR 120	Proposed Rules: 73 (2 documents)56810, 56811 48 CFR Ch. 156668, 56689 156669, 56676, 56681 456669, 56676, 56679 556676 656676 756676 856676 1056676, 56681 1256676, 56681 1356669, 56681
13 CFR 120	Proposed Rules: 73 (2 documents)56810, 56811 48 CFR Ch. 156668, 56689 156669, 56676, 56681 456669, 56676, 56679 556676 656676 756676 856676 1056676, 56681 1256676, 56681 1256676, 56681 1356676, 56681 1456676
13 CFR 120	Proposed Rules: 73 (2 documents)56810, 56811 48 CFR Ch. 156668, 56689 156669, 56676, 56681 456669, 56676, 56679 556676 656676 756676 856676 1056676, 56681 1256676, 56681 1356669, 56681
13 CFR 120	Proposed Rules: 73 (2 documents)56810, 56811 48 CFR Ch. 156668, 56689 156669, 56676, 56681 456669, 56676, 56679 556676 656676 756676 856676 1056676, 56681 1256676, 56681 1256676, 56681 1456676 1956676, 56681 2456676
13 CFR 120	Proposed Rules: 73 (2 documents)56810, 56811 48 CFR Ch. 156668, 56689 156669, 56676, 56681 456669, 56676, 56679 556676 656676 756676 856688 956676 1056676, 56681 1256676, 56681 1256676, 56681 1456676 1956676, 56681 2456676 2456688 2556688, 56688
13 CFR 120	Proposed Rules: 73 (2 documents)56810, 56811 48 CFR Ch. 156668, 56689 156669, 56676, 56681 456669, 56676, 56679 556676 656676 756676 856676 1056676, 56681 1256676, 56681 1256676, 56681 1456679 1956676, 56681 2256676 2456688 2556676, 56681, 56684, 56685
13 CFR 120	Proposed Rules: 73 (2 documents)56810,
13 CFR 120	Proposed Rules: 73 (2 documents)56810, 56811 48 CFR Ch. 156668, 56689 156669, 56676, 56681 456669, 56676, 56679 556676 656676 756676 856676 1056676, 56681 1256676, 56681 1256676, 56681 1456676 1956676, 56681 2256676 2456688 2556676, 56681, 56684, 56685 3156686 3256669, 56682
13 CFR 120	Proposed Rules: 73 (2 documents)56810,
13 CFR 120	Proposed Rules: 73 (2 documents)
13 CFR 120	Proposed Rules: 73 (2 documents)
13 CFR 120	Proposed Rules: 73 (2 documents)

213 226 237	
16	56613
39	56613
50 CFR	
	56564
17	56564
17 32	
17 32 635	57308
17 32 635 679	57308 56783
17 32 635 679	57308 56783 56788 56789
17	57308 56783 56788 56789

REMINDERS

The items in this list were editorially compiled as an aid to Federal Register users. Inclusion or exclusion from this list has no legal significance.

RULES GOING INTO EFFECT OCTOBER 2, 2003

COMMERCE DEPARTMENT National Oceanic and Atmospheric Administration

Fishery conservation and management:

Alaska; fisheries of Exclusive Economic Zone—

Pollock; published 10-3-03 Rock sole and yellowfish sole; published 9-2-03

Marine mammals:

Taking and importation—

San Nicolas Island, CA; marine mammals incidental to missile launch operations; published 9-2-03

ENERGY DEPARTMENT

Acquisition regulations:

Motor vehicle fleet fuel efficiency; published 9-2-

FEDERAL COMMUNICATIONS COMMISSION

Common carrier services:

Telecommunications Act of 1996; implementation—

Wireline services offering advanced telecommunications capability; deployment; published 9-2-03

HEALTH AND HUMAN SERVICES DEPARTMENT

Food and Drug Administration

Animal drugs, feeds, and related products:

Dexamethasone injection; published 10-2-03

INTERIOR DEPARTMENT Fish and Wildlife Service

Hunting and fishing:

Refuge-specific regulations; published 10-2-03

TRANSPORTATION DEPARTMENT

Federal Aviation Administration

8-28-03

Airworthiness directives: Rolls-Royce plc; published

COMMENTS DUE NEXT WEEK

AGRICULTURE DEPARTMENT

Agricultural Marketing Service

Fresh fruits, vegetables, and other products; inspection and certification:

Fees and charges increase; comments due by 10-8-03; published 9-8-03 [FR 03-22682]

Oranges, grapefruit, tangerines, and tangelos grown in—

Florida; comments due by 10-9-03; published 9-9-03 [FR 03-23045]

Prunes (dried) produced in— California; comments due by 10-6-03; published 8-6-03 [FR 03-19969]

AGRICULTURE DEPARTMENT

Animal and Plant Health Inspection Service

Gentically engineered organisms and products: Introductions of plants genetically engineered to encode compounds for industrial use; permit requirements; comments due by 10-6-03; published 8-6-03 [FR 03-19877]

AGRICULTURE DEPARTMENT

Farm Service Agency

Special programs:

Tree Assistance Program; comments due by 10-10-03; published 8-11-03 [FR 03-20345]

AGRICULTURE DEPARTMENT

Rural Business-Cooperative Service

Guaranteed loanmaking:

Secondary market sales; fiscal and transfer agent; comments due by 10-6-03; published 8-6-03 [FR 03-19987]

COMMERCE DEPARTMENT National Oceanic and Atmospheric Administration

Fishery conservation and management:

Northeastern United States fisheries—

Summer flounder, scup, and black sea bass; comments due by 10-9-03; published 9-24-03 [FR 03-24249]

West Coast States and Western Pacific fisheriesPacific Coast groundfish; comments due by 10-6-03; published 9-5-03 [FR 03-22571]

Pacific Coast groundfish; Groundfish Observer Program; comments due by 10-10-03; published 9-10-03 [FR 03-22570]

DEFENSE DEPARTMENT

Civilian health and medical program of uniformed services (CHAMPUS):

TRICARE program—

Individual Case
Management Program
withdrawn, Persons with
Disabilities Program
renamed Extended Care
Option Program, and
other administrative
amendments; comments
due by 10-6-03;
published 8-6-03 [FR
03-19822]

DEFENSE DEPARTMENT Engineers Corps

Enforcement:

Permit regulations; Class I administrative civil penalties; inflation adjustment; comments due by 10-6-03; published 8-20-03 [FR 03-21331]

ENVIRONMENTAL PROTECTION AGENCY

Air pollution control:

State operating permit programs—-

Nebraska; comments due by 10-6-03; published 9-5-03 [FR 03-22540]

State operating permit programs—

Nebraska; comments due by 10-6-03; published 9-5-03 [FR 03-22539]

Air quality implementation plans; approval and promulgation; various States:

California; comments due by 10-6-03; published 9-4-03 [FR 03-22445]

Nevada; comments due by 10-8-03; published 9-8-03 [FR 03-22646]

Pesticides; tolerances in food, animal feeds, and raw agricultural commodities:

2,6-Diisopropylnaphthalene; comments due by 10-7-03; published 8-8-03 [FR 03-20307]

Spinosad; comments due by 10-6-03; published 8-6-03 [FR 03-20017]

Radiation protection programs: Transuranic radioactive

waste for disposal at

Waste Isolation Pilot Plant; waste characterization program documents availability— Hanford Site, WA; comments due by 10-6-03; published 9-5-03 [FR 03-22638]

Water pollution; effluent guidelines for point source categories:

Centralized waste treatment industry; comments due by 10-10-03; published 9-10-03 [FR 03-22930]

FARM CREDIT ADMINISTRATION

Farm credit system:

Loan policies and operations, etc.-

Other financial institutions and investments in Farmers' notes; comments due by 10-10-03; published 8-11-03 [FR 03-20360]

FEDERAL COMMUNICATIONS COMMISSION

Radio broadcasting:

Definition of radio markets for areas not located in an arbitron survey area; comments due by 10-6-03; published 8-25-03 [FR 03-21652]

HEALTH AND HUMAN SERVICES DEPARTMENT

Centers for Medicare & Medicaid Services

Medicare:

Hospital outpatient prospective payment system and 2004 CY payment rates; comments due by 10-6-03; published 8-12-03 [FR 03-20280]

Physician fee schedule (2004 CY); payment policies and relative value unit adjustments; comments due by 10-7-03; published 8-15-03 [FR 03-20662]

Correction; comments due by 10-7-03; published 9-26-03 [FR 03-24548]

HEALTH AND HUMAN SERVICES DEPARTMENT Food and Drug Administration

Food for human consumption: Food labeling—

Trans fatty acids in nutrition labeling, nutrient content claims, and health claims; footnote or disclosure statements; comments due by 10-9-03; published 7-11-03 [FR 03-17526]

HOMELAND SECURITY DEPARTMENT

Customs and Border Protection Bureau

Freedom of Information Act; implementation:

Confidential commercial information; comments due by 10-10-03; published 8-11-03 [FR 03-20328]

HOMELAND SECURITY DEPARTMENT Coast Guard

Drawbridge operations:

Florida; comments due by 10-6-03; published 8-5-03 [FR 03-19900]

Ports and waterways safety: Charleston Harbor, Cooper River, SC; regulated navigation area; comments due by 10-7-03; published 8-8-03 [FR 03-20196]

HOMELAND SECURITY DEPARTMENT

Federal Emergency Management Agency

National Flood Insurance Program:

Private sector property insurers; assistance; comments due by 10-6-03; published 9-5-03 [FR 03-22659]

HOMELAND SECURITY DEPARTMENT

Immigration:

Orphan petitions; advance processing application; validity period; discretionary extension; comments due by 10-6-03; published 8-7-03 [FR 03-20173]

INTERIOR DEPARTMENT Fish and Wildlife Service

Endangered and threatened species:

Critical habitat designations— Peirson's milk-vetch; comments due by 10-6-03; published 8-5-03 [FR 03-19670]

Migratory bird permits:
Application fee schedule;
revision; comments due
by 10-10-03; published 826-03 [FR 03-21489]
Wild Bird Conservation Act:

Wild Bird Conservation Act:
Non-captive-bred species;
approved list; additions—
Blue-fronted Amazon
parrots from Argentina;
comments due by 10-603; published 8-6-03
[FR 03-19945]

INTERIOR DEPARTMENT Minerals Management Service

Outer Continental Shelf; oil, gas, and sulfur operations:

Incident reporting requirements; comments due by 10-6-03; published 7-8-03 [FR 03-16782]

INTERIOR DEPARTMENT

National Park Service

Special regulations:

Canyonlands National Park, Salt Creek Canyon, UT; motor vehicle prohibition; comments due by 10-10-03; published 8-11-03 [FR 03-19964]

JUSTICE DEPARTMENT Drug Enforcement Administration

Schedules of controlled substances:

2,5-Dimethoxy-4-(n)propylthiophenethylamine, etc.; placement into Schedule I; comments due by 10-8-03; published 9-8-03 [FR 03-22684]

JUSTICE DEPARTMENT Prisons Bureau

Inmate control, custody, care, etc.:

D.C. Code; civil contempt of court commitments; comments due by 10-6-03; published 8-5-03 [FR 03-19853]

ARTS AND HUMANITIES, NATIONAL FOUNDATION National Foundation on the Arts and the Humanities

√1√Supplemental standards of ethical conduct for National Endowment for the Arts employees; comments due by 10-6-03; published 9-5-03 [FR 03-22653]

√2√Supplemental standards of ethical conduct for National Endowment for the Humanities employees; comments due by 10-6-03; published 9-5-03 [FR 03-22654]

Conflicts of interest; cross reference provision; comments due by 10-6-03; published 9-5-03 [FR 03-22655]

NUCLEAR REGULATORY COMMISSION

Production and utilization facilities; domestic licensing: Emergency planning and preparedness; comments due by 10-7-03; published 7-24-03 [FR 03-18845]

PERSONNEL MANAGEMENT OFFICE

Federal computer systems; security awareness and training for employees responsible for management or use; comments due by 10-6-03; published 9-4-03 [FR 03-22487]

TRANSPORTATION DEPARTMENT

Federal Aviation Administration

Airworthiness directives:

Airbus; comments due by 10-8-03; published 9-8-03 [FR 03-22704]

Cessna; comments due by 10-6-03; published 7-28-03 [FR 03-19059]

Honeywell International Inc.; comments due by 10-7-03; published 8-8-03 [FR 03-20231]

McDonnell Douglas; comments due by 10-6-03; published 8-21-03 [FR 03-21414]

MD Helicopters Inc.; comments due by 10-7-03; published 8-8-03 [FR 03-19976]

Airworthiness standards:

Special conditions-

Gulfstream Aerospace LP 1125 Westwind Astra airplanes; comments due by 10-9-03; published 9-9-03 [FR 03-22797]

Sabreliner Model NA-265 Series airplanes; comments due by 10-9-03; published 9-9-03 [FR 03-22798]

Class E airspace; comments due by 10-5-03; published 8-21-03 [FR 03-21459]

TRANSPORTATION DEPARTMENT

National Highway Traffic Safety Administration

Motor vehicle safety standards:

Occupant crash protection— Belted frontal barrier crash test; maximum test speed and phase-in schedule; comments due by 10-6-03; published 8-6-03 [FR 03-20054]

Integral lap/shoulder safety belts; rear seats requirement; comments due by 10-6-03; published 8-6-03 [FR 03-20024]

TREASURY DEPARTMENT Comptroller of the Currency

Bank activities and operations and real estate lending and appraisals:

National banks; State law applicability; comments due by 10-6-03; published 8-5-03 [FR 03-19906]

TREASURY DEPARTMENT Internal Revenue Service

Income taxes:

At-risk limitations; interest other than that of creditor; comments due by 10-6-03; published 7-8-03 [FR 03-17090]

Defined contribution plans; distribution forms elimination; comments due by 10-6-03; published 7-8-03 [FR 03-17089]

Multi-step transactions; effect of elections; crossreference; comments due by 10-7-03; published 7-9-03 [FR 03-17227]

Notarized statements of purchase; comments due by 10-8-03; published 7-10-03 [FR 03-17088]

Stock basis after group structure change; comments due by 10-6-03; published 7-8-03 [FR 03-17091]

Vans and light trucks; depreciation; crossreference; comments due by 10-6-03; published 7-7-03 [FR 03-17086]

Procedure and administration:

Fees for copies of exempt organizations' material open to public inspection; authorization; crossreference; comments due by 10-7-03; published 7-9-03 [FR 03-17228]

Information reporting penalties waiver; prompt correction determination; comments due by 10-7-03; published 7-9-03 [FR 03-17229]

Return information disclosure by officers and employees for investigative purposes; cross-reference; comments due by 10-8-03; published 7-10-03 [FR 03-17385]

Testimony or production of records in court or other proceeding; comments due by 10-7-03; published 7-9-03 [FR 03-17230]

LIST OF PUBLIC LAWS

This is a continuing list of public bills from the current session of Congress which have become Federal laws. It may be used in conjunction with "PLUS" (Public Laws Update Service) on 202–741–6043. This list is also available online at http://www.nara.gov/fedreg/plawcurr.html.

The text of laws is not published in the Federal

Register but may be ordered in "slip law" (individual pamphlet) form from the Superintendent of Documents, U.S. Government Printing Office, Washington, DC 20402 (phone, 202–512–1808). The text will also be made available on the Internet from GPO Access at http://www.access.gpo.gov/nara/nara005.html. Some laws may not yet be available.

H.R. 2658/P.L. 108–87 Department of Defense Appropriations Act, 2004 (Sept. 30, 2003; 117 Stat. 1054) H.R. 3087/P.L. 108–88

Surface Transportation Extension Act of 2003 (Sept. 30, 2003; 117 Stat. 1110) H.R. 3146/P.L. 108–89 To extend the Temporary Assistance for Needy Families block grant program, and certain tax and trade programs, and for other purposes. (Oct. 1, 2003; 117 Stat. 1131) Last List October 1, 2003

Public Laws Electronic Notification Service (PENS)

PENS is a free electronic mail notification service of newly

enacted public laws. To subscribe, go to http:// listserv.gsa.gov/archives/ publaws-l.html

Note: This service is strictly for E-mail notification of new laws. The text of laws is not available through this service. **PENS** cannot respond to specific inquiries sent to this address.